

APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

40th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY**

2020

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2019.

40th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2020

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

CONTENTS

	<i>PAGE</i>
PREFACE TO FORTIETH EDITION.....	iv
1.0 INTRODUCTION.....	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms.....	vii
1.3 Further Guidance on Bioequivalence.....	ix
1.4 Reference Listed Drug and Reference Standard.....	x
1.5 General Policies and Legal Status.....	xi
1.6 Practitioner/User Responsibilities.....	xi
1.7 Therapeutic Equivalence Evaluations Codes.....	xii
1.8 Description of Certain Special Situations.....	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity.....	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiv
1.11 Discontinued Section.....	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition.....	xxv
2.0 HOW TO USE THE DRUG PRODUCTS LISTS.....	2-1
2.1 Key Sections for Using the Drug Product Lists.....	2-1
2.2 Drug Product Illustration.....	2-3
2.3 Therapeutic Equivalence Evaluations Illustration.....	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	3-1
OTC Drug Product List.....	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List.....	5-1
Discontinued Drug Product List.....	6-1
Orphan Products Designations and Approvals List.....	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution.....	8-1
APPENDICES	
A. Product Name Index.....	A-1
B. Product Name Index Listed by Applicant.....	B-1
C. Uniform Terms.....	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM.....	AD1
A. Patent and Exclusivity Lists.....	ADA1
B. Patent and Exclusivity Terms.....	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

PREFACE TO FORTIETH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under section 505(b) of the FD&C Act or an abbreviated new drug application (ANDA) under section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or *United States Adopted Names* (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. The Agency will list the drug product in the Orange Book and the date of approval as determined under Section 505(x).

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

¹ Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication. See Section 1.12.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.² They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).³ Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.⁴ Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.⁵

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug

² 21 CFR 314.3(b).

³ See 21 CFR 314.3(b).

⁴ 21 CFR 314.3(b).

⁵ 21 CFR 314.3(b).

product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1) (a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1) (a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).⁶ Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.⁷

⁶ 21 CFR 314.3(b).

⁷ 21 CFR 314.3(b).

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.⁸ Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (see Section 1.4) shall be considered bioequivalent:

- (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
- (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.⁹

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.¹⁰

⁸ 21 CFR 314.3(b).

⁹ 21 CFR 320.24.

¹⁰ We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs> and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at <https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development>.

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug¹¹ identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.¹² Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.¹³

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.¹⁴ FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale FDA may select an ANDA as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated,

¹¹ A "listed drug" is a new drug product that has been approved under section 505(c) of the FD&C Act for safety and effectiveness or under section 505(j) of the FD&C Act, which has not been withdrawn or suspended under section 505(e) (1) through (5) or section 505(j) (6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

¹² 21 CFR 314.3(b).

¹³ 21 CFR 314.94(a) (3) (i).

¹⁴ 21 CFR 314.3(b).

e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different

characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory¹⁵ and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly

¹⁵ <https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory>.

whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or

- (2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered

therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms*, the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.¹⁶ In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book displays the strength of all new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g. 50 mg/mL. For example, if this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1 gm/20 mL (50 mg/mL) and 3 gm/60 mL (50 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

¹⁶ The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.¹⁷ Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.¹⁸

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS

¹⁷ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

¹⁸ The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at <https://www.fda.gov/media/72973/download>. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ¹⁹	MYLAN	0.3MG	A076187	-	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.²⁰ (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity.²¹ If the listed drug is also protected by one or more

¹⁹ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levotheroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

²⁰ If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

²¹ See Patent and Exclusivity Information Addendum in the Orange Book.

patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its exclusivity, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.²² Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180

²² See, e.g., Section 506I(d) of the FD&C Act.

days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, the FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the [Orange Book](#) home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, <https://www.gpo.gov/>.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>					
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION					
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>					
REFERENCE LISTED DRUG* (+)	→	<u>AP</u> +!	PAGE PHARMA	<u>25MG/ML</u>	<u>N013111</u>	<u>001</u>	AUG 22, 1983
REFERENCE STANDARD * (!)	→	<u>AP</u> +!		<u>50MG/ML</u>	<u>N013111</u>	<u>002</u>	AUG 22, 1983
		<u>AP</u> +!		<u>75MG/ML</u>	<u>N013111</u>	<u>003</u>	AUG 22, 1983
		<u>AP</u> +!		<u>100MG/ML</u>	<u>N013111</u>	<u>004</u>	JAN 04, 1989
		<u>MEPERIDINE HCL</u>					
THERAPEUTIC EQUIVALENCE (TE)	→	<u>AP</u>	GREENBERG PHARM	<u>25MG/ML</u>	<u>A064890</u>	001	FEB 29, 1987
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u>		<u>50MG/ML</u>	<u>A064890</u>	002	FEB 29, 1987
		<u>AP</u>		<u>75MG/ML</u>	<u>A064890</u>	003	FEB 29, 1987
		<u>AP</u>		<u>100MG/ML</u>	<u>A064890</u>	004	MAR 08, 1992
SINGLE SOURCE PRODUCT (NO TE CODE)			! TIMOKIM LLC	10MG/ML	A099225	001	DEC 12, 1995
		<u>AP</u>	JOHNSON MED	<u>25MG/ML</u>	<u>A099226</u>	<u>001</u>	NOV 27, 1993
			! KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999
APPLICANT	→						
AVAILABLE STRENGTH(S) OF A PRODUCT	→						
APPLICATION NUMBER AND PRODUCT NUMBER	→						
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→						
APPROVAL DATE	→						

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4


MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>					
PRODUCT INFORMATION	→	TABLET; ORAL					
		HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL					
		REINWALD LABS 25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982					

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A077950 001	Mar 14, 2018
AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107 001	Sep 26, 2016

ZIAGEN

AA	+! VIIV HLHCARE	EQ 20MG BASE/ML	N020978 001	Dec 17, 1998
-----------	-----------------	------------------------	--------------------	--------------

TABLET;ORAL

ABACAVIR SULFATE

AB	APOTEX INC	EQ 300MG BASE	A201570 001	Dec 17, 2012
AB	AUROBINDO PHARMA LTD	EQ 300MG BASE	A077844 001	Dec 17, 2012
AB	CIPLA	EQ 300MG BASE	A078119 001	Nov 21, 2017
AB	HETERO LABS LTD III	EQ 300MG BASE	A091560 001	Sep 13, 2013
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012
AB	STRIDES PHARMA	EQ 300MG BASE	A091050 001	Oct 28, 2016

ZIAGEN

AB	+! VIIV HLHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998
-----------	-----------------	----------------------	--------------------	--------------

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+!	VIIV HLHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551 001	Aug 22, 2014
----	--------------	---	--------------------	--------------

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A090159 001	Nov 15, 2018
AB		EQ 600MG BASE;300MG	A206151 001	Mar 28, 2017
AB	CIPLA	EQ 600MG BASE;300MG	A091144 001	Mar 28, 2017
AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990 001	Mar 28, 2017
AB	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246 001	Sep 29, 2016

EPZICOM

AB	+! VIIV HLHCARE	EQ 600MG BASE;300MG	N021652 001	Aug 02, 2004
-----------	-----------------	----------------------------	--------------------	--------------

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912 001	Dec 05, 2013
-----------	-----------	----------------------------------	--------------------	--------------

TRIZIVIR

AB	+! VIIV HLHCARE	EQ 300MG BASE;150MG;300MG	N021205 001	Nov 14, 2000
-----------	-----------------	----------------------------------	--------------------	--------------

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743 001	Apr 28, 2017
----	-------------------	-------------------------------	--------------------	--------------

ABEMACICLIB

TABLET;ORAL

VERZENIO

+	ELI LILLY AND CO	50MG	N208716 001	Sep 28, 2017
+		100MG	N208716 002	Sep 28, 2017
+		150MG	N208716 003	Sep 28, 2017
+!		200MG	N208716 004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	AMNEAL PHARMS	250MG	A208327 001	Jan 07, 2019
AB	APOTEX	250MG	A208453 001	Oct 31, 2018
AB	GLENMARK PHARMS	250MG	A209227 001	Oct 16, 2019
AB	HIKMA PHARMS	250MG	A208339 001	Oct 31, 2018
AB	MSN	250MG	A210686 001	Jul 10, 2019
AB	MYLAN	250MG	A208446 001	Oct 31, 2018
AB	QILU	250MG	A212462 001	Sep 27, 2019
AB	RISING	250MG	A208371 001	Feb 25, 2019
AB	TEVA PHARMS USA	250MG	A208432 001	Oct 31, 2018
AB	WOCKHARDT BIO AG	250MG	A208380 001	Feb 27, 2019

ZYTIGA

AB	+ JANSSEN BIOTECH	250MG	N202379 001	Apr 28, 2011
-----------	-------------------	--------------	--------------------	--------------

YONSA

+!	SUN PHARMA GLOBAL	125MG	N210308 001	May 22, 2018
----	-------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+! JANSSEN BIOTECH 500MG N202379 002 Apr 14, 2017

ACALABRUTINIB

CAPSULE; ORAL

CALQUENCE

+! ASTRAZENECA 100MG N210259 001 Oct 31, 2017

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

<u>AB</u>	!	GLENMARK GENERICS	<u>333MG</u>	<u>A202229</u>	<u>001</u>	Jul 16, 2013
<u>AB</u>		MYLAN	<u>333MG</u>	<u>A200142</u>	<u>001</u>	Mar 11, 2014
<u>AB</u>		ZYDUS PHARMS	<u>333MG</u>	<u>A205995</u>	<u>001</u>	May 26, 2017

ACARBOSE

TABLET; ORAL

ACARBOSE

<u>AB</u>		EMCURE PHARMS LTD	<u>25MG</u>	<u>A202271</u>	<u>001</u>	Feb 07, 2012
<u>AB</u>			<u>50MG</u>	<u>A202271</u>	<u>002</u>	Feb 07, 2012
<u>AB</u>			<u>100MG</u>	<u>A202271</u>	<u>003</u>	Feb 07, 2012
<u>AB</u>		HIKMA	<u>25MG</u>	<u>A078470</u>	<u>001</u>	May 07, 2008
<u>AB</u>			<u>50MG</u>	<u>A078470</u>	<u>002</u>	May 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A078470</u>	<u>003</u>	May 07, 2008
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A078441</u>	<u>001</u>	May 14, 2009
<u>AB</u>			<u>50MG</u>	<u>A078441</u>	<u>002</u>	May 14, 2009
<u>AB</u>			<u>100MG</u>	<u>A078441</u>	<u>003</u>	May 14, 2009
<u>AB</u>	!	STRIDES PHARMA	<u>25MG</u>	<u>A090912</u>	<u>001</u>	Jul 27, 2011
<u>AB</u>			<u>50MG</u>	<u>A090912</u>	<u>002</u>	Jul 27, 2011
<u>AB</u>			<u>100MG</u>	<u>A090912</u>	<u>003</u>	Jul 27, 2011
<u>AB</u>		VIRTUS PHARM	<u>25MG</u>	<u>A091343</u>	<u>001</u>	Oct 17, 2013
<u>AB</u>			<u>50MG</u>	<u>A091343</u>	<u>002</u>	Oct 17, 2013
<u>AB</u>			<u>100MG</u>	<u>A091343</u>	<u>003</u>	Oct 17, 2013
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A077532</u>	<u>001</u>	May 07, 2008
<u>AB</u>			<u>50MG</u>	<u>A077532</u>	<u>002</u>	May 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A077532</u>	<u>003</u>	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	!	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047</u>	<u>001</u>	Dec 30, 1999
<u>AB</u>	!		<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u>	Dec 30, 1999
<u>AB</u>		MYLAN	<u>EQ 200MG BASE</u>	<u>A074288</u>	<u>001</u>	Apr 24, 1995
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A074288</u>	<u>002</u>	Apr 24, 1995

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

<u>AP</u>		CUSTOPHARM INC	<u>1GM/100ML (10MG/ML)</u>	<u>A202605</u>	<u>001</u>	Jun 13, 2016
<u>AP</u>		SANDOZ INC	<u>1GM/100ML (10MG/ML)</u>	<u>A204052</u>	<u>001</u>	Mar 22, 2016
<u>OFIRMEV</u>						
<u>AP</u>	+	MALLINCKRODT HOSP	<u>1GM/100ML (10MG/ML)</u>	<u>N022450</u>	<u>001</u>	Nov 02, 2010
<u>ACETAMINOPHEN</u>						
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL

APADAZ

+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019
+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018
+	!	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BUTALBITAL AND ACETAMINOPHEN

<u>AA</u>		GRANULES PHARMS	<u>300MG;50MG</u>	<u>A213115</u>	<u>001</u>	Nov 22, 2019
<u>AA</u>	!	MAYNE PHARMA INC	<u>300MG;50MG</u>	<u>A207313</u>	<u>001</u>	Dec 27, 2017

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

<u>AA</u>		CNTY LINE PHARMS	<u>300MG;50MG</u>	<u>A207635</u>	<u>001</u>	Jun 05, 2017
<u>AA</u>			<u>325MG;50MG</u>	<u>A205120</u>	<u>001</u>	Oct 30, 2015
<u>AA</u>		LARKEN LABS INC	<u>325MG;50MG</u>	<u>A203484</u>	<u>002</u>	Dec 04, 2015
<u>AA</u>		MIKART	<u>300MG;50MG</u>	<u>A207386</u>	<u>001</u>	Nov 15, 2016
<u>AA</u>	!	NEXGEN PHARMA	<u>300MG;50MG</u>	<u>A090956</u>	<u>001</u>	Aug 23, 2011

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTAPAP

AA	!	MIKART	325MG;50MG	A089987 001	Oct 26, 1992
		ALLZITAL			
	!	LARKEN LABS INC	325MG;25MG	A203484 001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	325MG;50MG;40MG	A204733 001	Sep 26, 2018
AA		LANNETT CO INC	300MG;50MG;40MG	A212082 001	Dec 17, 2019
AA			325MG;50MG;40MG	A212083 001	Dec 17, 2019
AA		MAYNE PHARMA INC	300MG;50MG;40MG	A210817 001	Dec 17, 2019
AA	!		325MG;50MG;40MG	A089007 001	Mar 17, 1986
AA	!	NEXGEN PHARMA	300MG;50MG;40MG	A040885 001	Nov 16, 2009
AA		NUVO PHARMS INC	300MG;50MG;40MG	A207118 001	Oct 28, 2016
AA		WRASER PHARMS LLC	300MG;50MG;40MG	A206615 001	Aug 04, 2017

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

!	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387 001	Jan 31, 2003
---	--------	--------------------------------	-------------	--------------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	325MG;50MG;40MG	A211106 001	Sep 26, 2018
AA		ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616 001	Nov 09, 1984
AA		CNTY LINE PHARMS	325MG;50MG;40MG	A204984 001	Jan 10, 2017
AA		HIKMA PHARMS	325MG;50MG;40MG	A089718 001	Jun 12, 1995
AA		LANNETT CO INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012
AA		MIKART	325MG;50MG;40MG	A089175 001	Jan 21, 1987
AA		NEXGEN PHARMA INC	325MG;50MG;40MG	A209587 001	Oct 31, 2018
AA		SPECGX LLC	325MG;50MG;40MG	A087804 001	Jan 24, 1985
AA	!	VINTAGE PHARMS	325MG;50MG;40MG	A040511 001	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		NEXGEN PHARMA INC	325MG;50MG;40MG;30MG	A076560 001	Jun 10, 2004
AB		VINTAGE PHARMS	325MG;50MG;40MG;30MG	A075929 001	Apr 22, 2002
		FIORICET W/ CODEINE			
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232 001	Jul 30, 1992
		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE			
		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		WRASER PHARMS LLC	320.5MG;30MG;16MG	A204785 001	Nov 26, 2014
--	--	-------------------	-------------------	-------------	--------------

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG;30MG;16MG	A204209 001	Sep 30, 2016
--	--	-----------------	-----------------	-------------	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		ANDA REPOSITORY	120MG/5ML;12MG/5ML	A089450 001	Oct 27, 1992
AA		HI TECH PHARMA	120MG/5ML;12MG/5ML	A040119 001	Apr 26, 1996
AA	!	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001	
AA		WOCKHARDT BIO AG	120MG/5ML;12MG/5ML	A087006 001	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	300MG;30MG	A040779 001	May 29, 2008
AA		AUROLIFE PHARMA LLC	300MG;15MG	A202800 001	Apr 15, 2013
AA			300MG;30MG	A202800 002	Apr 15, 2013
AA			300MG;60MG	A202800 003	Apr 15, 2013
AA		ELITE LABS INC	300MG;15MG	A212418 001	Sep 10, 2019
AA			300MG;30MG	A212418 002	Sep 10, 2019
AA			300MG;60MG	A212418 003	Sep 10, 2019
AA		EYWA	300MG;15MG	A211610 001	Jun 27, 2019
AA			300MG;30MG	A211610 002	Jun 27, 2019
AA			300MG;60MG	A211610 003	Jun 27, 2019
AA	!	SPECGX LLC	300MG;15MG	A040419 001	May 31, 2001
AA			300MG;30MG	A040419 002	May 31, 2001
AA			300MG;60MG	A040419 003	May 31, 2001
AA		SUN PHARM INDS LTD	300MG;30MG	A085868 001	

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	!	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988

TYLENOL W/ CODEINE NO. 3

<u>AA</u>	!	JANSSEN PHARMS	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>
<u>AA</u>		JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>

TYLENOL W/ CODEINE NO. 4ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	!	ANDA REPOSITORY	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>		GENUS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>		PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013
<u>AA</u>		VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>		WES PHARMA INC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A211023</u>	<u>001</u>	Mar 08, 2019
<u>AA</u>	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
<u>AA</u>	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

<u>AA</u>		SPECGX LLC	<u>325MG;5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
-----------	--	------------	------------------	----------------	------------	--------------

ANEXSIA 7.5/325

<u>AA</u>		SPECGX LLC	<u>325MG;7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
-----------	--	------------	--------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		ABHAI LLC	<u>300MG;5MG</u>	<u>A209036</u>	<u>001</u>	Jun 21, 2017
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A209036</u>	<u>002</u>	Jun 21, 2017
<u>AA</u>			<u>300MG;10MG</u>	<u>A209036</u>	<u>003</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;5MG</u>	<u>A209037</u>	<u>001</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A209037</u>	<u>002</u>	Jun 21, 2017
<u>AA</u>			<u>325MG;10MG</u>	<u>A209037</u>	<u>003</u>	Jun 21, 2017
<u>AA</u>		ACTAVIS LABS FL INC	<u>300MG;5MG</u>	<u>A206470</u>	<u>001</u>	Jun 02, 2016
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A206470</u>	<u>002</u>	Jun 02, 2016
<u>AA</u>			<u>300MG;10MG</u>	<u>A206470</u>	<u>003</u>	Jun 02, 2016
<u>AA</u>		AMNEAL PHARMS	<u>300MG;10MG</u>	<u>A207137</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>		AMNEAL PHARMS NY	<u>300MG;5MG</u>	<u>A206869</u>	<u>001</u>	Jun 23, 2017
<u>AA</u>			<u>325MG;5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A040746</u>	<u>002</u>	May 10, 2016
<u>AA</u>			<u>325MG;10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>	!	ANDA REPOSITORY	<u>325MG;2.5MG</u>	<u>A040846</u>	<u>001</u>	Jun 09, 2010
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>		ASCENT PHARMS INC	<u>325MG;2.5MG</u>	<u>A211487</u>	<u>001</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;5MG</u>	<u>A211487</u>	<u>002</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A211487</u>	<u>003</u>	Nov 07, 2018
<u>AA</u>			<u>325MG;10MG</u>	<u>A211487</u>	<u>004</u>	Nov 07, 2018
<u>AA</u>		AUROLIFE PHARMA LLC	<u>300MG;5MG</u>	<u>A207709</u>	<u>001</u>	Sep 13, 2018
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A207709</u>	<u>002</u>	Sep 13, 2018
<u>AA</u>			<u>300MG;10MG</u>	<u>A207709</u>	<u>003</u>	Sep 13, 2018
<u>AA</u>			<u>325MG;5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A201013</u>	<u>002</u>	Apr 11, 2012
<u>AA</u>			<u>325MG;10MG</u>	<u>A201013</u>	<u>003</u>	Apr 11, 2012
<u>AA</u>		EPIC PHARMA LLC	<u>325MG;5MG</u>	<u>A203863</u>	<u>001</u>	Mar 30, 2018
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A203863</u>	<u>002</u>	Mar 30, 2018
<u>AA</u>			<u>325MG;10MG</u>	<u>A203863</u>	<u>003</u>	Mar 30, 2018
<u>AA</u>		GRANULES PHARMS	<u>325MG;5MG</u>	<u>A211729</u>	<u>001</u>	Jan 03, 2020
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A211729</u>	<u>002</u>	Jan 03, 2020
<u>AA</u>			<u>325MG;10MG</u>	<u>A211729</u>	<u>003</u>	Jan 03, 2020
<u>AA</u>	!	MIKART	<u>300MG;5MG</u>	<u>A040658</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>	!		<u>300MG;7.5MG</u>	<u>A040658</u>	<u>002</u>	Mar 24, 2006
<u>AA</u>	!		<u>300MG;10MG</u>	<u>A040658</u>	<u>003</u>	Jun 23, 2004
<u>AA</u>		NOVEL LABS INC	<u>300MG;5MG</u>	<u>A206142</u>	<u>001</u>	Nov 14, 2016
<u>AA</u>			<u>300MG;7.5MG</u>	<u>A206142</u>	<u>002</u>	Nov 14, 2016
<u>AA</u>			<u>300MG;10MG</u>	<u>A206142</u>	<u>003</u>	Nov 14, 2016
<u>AA</u>			<u>325MG;5MG</u>	<u>A206245</u>	<u>001</u>	Dec 01, 2016
<u>AA</u>			<u>325MG;7.5MG</u>	<u>A206245</u>	<u>002</u>	Dec 01, 2016
<u>AA</u>			<u>325MG;10MG</u>	<u>A206245</u>	<u>003</u>	Dec 01, 2016
<u>AA</u>		PAR PHARM	<u>300MG;5MG</u>	<u>A205001</u>	<u>001</u>	Jul 05, 2016

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A205001 002</u>	Jul 05, 2016
<u>AA</u>		<u>300MG; 10MG</u>	<u>A205001 003</u>	Jul 05, 2016
<u>AA</u>		<u>325MG; 5MG</u>	<u>A202935 002</u>	Jun 15, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202935 003</u>	Jun 15, 2016
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202935 004</u>	Jun 15, 2016
<u>AA</u>	RHODES PHARMS	<u>300MG; 5MG</u>	<u>A207808 001</u>	Mar 30, 2018
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A207808 002</u>	Mar 30, 2018
<u>AA</u>		<u>300MG; 10MG</u>	<u>A207808 003</u>	Mar 30, 2018
<u>AA</u>		<u>325MG; 5MG</u>	<u>A202991 001</u>	Apr 12, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202991 002</u>	Apr 12, 2016
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202991 003</u>	Apr 12, 2016
<u>AA</u>	SPECGX LLC	<u>300MG; 5MG</u>	<u>A206718 001</u>	Mar 31, 2017
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A206718 002</u>	Mar 31, 2017
<u>AA</u>		<u>300MG; 10MG</u>	<u>A206718 003</u>	Mar 31, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040400 001</u>	Jul 26, 2000
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 5MG</u>	<u>A090118 001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118 002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118 003</u>	Dec 23, 2008
<u>AA</u>	TRIS PHARMA INC	<u>300MG; 5MG</u>	<u>A202214 004</u>	Mar 15, 2016
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A202214 005</u>	Mar 15, 2016
<u>AA</u>		<u>300MG; 10MG</u>	<u>A202214 006</u>	Mar 15, 2016
<u>AA</u>		<u>325MG; 5MG</u>	<u>A202214 001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202214 002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202214 003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>300MG; 5MG</u>	<u>A090415 001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A090415 002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 10MG</u>	<u>A090415 003</u>	Jan 24, 2011
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040655 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355 001</u>	May 31, 2000
<u>AA</u>	WES PHARMA INC	<u>300MG; 5MG</u>	<u>A207509 001</u>	Oct 29, 2018
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A207509 002</u>	Oct 29, 2018
<u>AA</u>		<u>300MG; 10MG</u>	<u>A207509 003</u>	Oct 29, 2018
<u>AA</u>		<u>325MG; 5MG</u>	<u>A210211 001</u>	Oct 30, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210211 002</u>	Oct 30, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210211 003</u>	Oct 30, 2017
<u>NORCO</u>				
<u>AA</u>	APIL	<u>325MG; 2.5MG</u>	<u>A040148 004</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG; 5MG</u>	<u>A040099 001</u>	Jun 25, 1997
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040148 005</u>	Jul 07, 2014
<u>AA</u>	!	<u>325MG; 7.5MG</u>	<u>A040148 003</u>	Sep 12, 2000
<u>AA</u>	!	<u>325MG; 10MG</u>	<u>A040148 001</u>	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

! ABHAI LLC

325MG/5ML; 5MG/5ML

A211499 001 Dec 31, 2018

TABLET; ORAL

OXYCET

<u>AA</u>	SPECGX LLC	<u>325MG; 5MG</u>	<u>A087463 001</u>	Dec 07, 1983
<u>OXYCODONE AND ACETAMINOPHEN</u>				
<u>AA</u>	ABHAI LLC	<u>325MG; 2.5MG</u>	<u>A210644 001</u>	Feb 09, 2018
<u>AA</u>		<u>325MG; 5MG</u>	<u>A210644 002</u>	Feb 09, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210644 003</u>	Feb 09, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210644 004</u>	Feb 09, 2018
<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<u>A201447 001</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201447 002</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201447 003</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201447 004</u>	Apr 12, 2013
<u>AA</u>	ALVOGEN	<u>325MG; 5MG</u>	<u>A202677 003</u>	Mar 08, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202677 001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677 002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS	<u>325MG; 5MG</u>	<u>A040777 001</u>	Nov 27, 2007
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 7.5MG</u>	<u>A040778 002</u>	Jun 27, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778 001</u>	Nov 27, 2007
<u>AA</u>	ANDA REPOSITORY	<u>325MG; 5MG</u>	<u>A207834 001</u>	Aug 15, 2019
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207834 002</u>	Aug 15, 2019
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207834 003</u>	Aug 15, 2019
<u>AA</u>	ASCENT PHARMS INC	<u>325MG; 2.5MG</u>	<u>A207419 001</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A207419 002</u>	Mar 22, 2017

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207419 003</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207419 004</u>	Mar 22, 2017
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972 001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201972 002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201972 003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201972 004</u>	Jul 15, 2013
<u>AA</u>	EPIC PHARMA LLC	<u>325MG; 5MG</u>	<u>A203864 001</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A203864 002</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A203864 003</u>	Jul 02, 2018
<u>AA</u>	GRANULES PHARMS	<u>325MG; 2.5MG</u>	<u>A211708 001</u>	Oct 31, 2019
<u>AA</u>		<u>325MG; 5MG</u>	<u>A211708 002</u>	Oct 31, 2019
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A211708 003</u>	Oct 31, 2019
<u>AA</u>		<u>325MG; 10MG</u>	<u>A211708 004</u>	Oct 31, 2019
<u>AA</u>	LANNETT CO INC	<u>325MG; 5MG</u>	<u>A207333 001</u>	Sep 25, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207333 002</u>	Sep 25, 2017
<u>AA</u>	MAYNE PHARMA INC	<u>325MG; 2.5MG</u>	<u>A090177 001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177 002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177 003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177 004</u>	Oct 20, 2008
<u>AA</u>	NESHER PHARMS	<u>325MG; 2.5MG</u>	<u>A210079 001</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A210079 002</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A210079 003</u>	Dec 28, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A210079 004</u>	Dec 28, 2017
<u>AA</u>	NOSTRUM LABS INC	<u>325MG; 5MG</u>	<u>A209385 001</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A209385 002</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A209385 003</u>	Jul 02, 2018
<u>AA</u>	NOVEL LABS INC	<u>325MG; 2.5MG</u>	<u>A204407 001</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A204407 002</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A204407 003</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A204407 004</u>	Feb 24, 2017
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278 001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278 002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278 003</u>	Aug 28, 2014
<u>AA</u>	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040545 001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545 002</u>	Jun 30, 2004
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535 001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535 002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535 003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535 004</u>	Dec 26, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105 001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734 002</u>	Jul 11, 2013
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171 001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535 001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535 002</u>	Sep 05, 2003
<u>AA</u>	WES PHARMA INC	<u>325MG; 5MG</u>	<u>A207510 001</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207510 002</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207510 003</u>	Mar 21, 2018
<u>AA</u>	XIROMED	<u>325MG; 5MG</u>	<u>A207574 001</u>	Dec 13, 2016

PERCOCET

<u>AA</u>	!	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330 001</u>	Jun 25, 1999
<u>AA</u>	!		<u>325MG; 5MG</u>	<u>A040330 002</u>	Jun 25, 1999
<u>AA</u>	!		<u>325MG; 7.5MG</u>	<u>A040330 003</u>	Nov 23, 2001
<u>AA</u>	!		<u>325MG; 10MG</u>	<u>A040330 004</u>	Nov 23, 2001

ROXICET

<u>AA</u>		HIKMA	<u>325MG; 5MG</u>	<u>A087003 001</u>	
		OXYCODONE AND ACETAMINOPHEN			
	!	MIKART	300MG; 2.5MG	A040608 001	Dec 30, 2005
	!		300MG; 5MG	A040608 002	Dec 30, 2005
	!		300MG; 7.5MG	A040608 003	Dec 30, 2005
	!		300MG; 10MG	A040608 004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALKEM LABS LTD	<u>325MG; 37.5MG</u>	<u>A202076 001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485 001</u>	Dec 09, 2009
<u>AB</u>	APOTEX	<u>325MG; 37.5MG</u>	<u>A078778 001</u>	Apr 07, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>325MG; 37.5MG</u>	<u>A207152 001</u>	Mar 22, 2017

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

LTD

<u>AB</u>	MACLEODS PHARMS LTD	<u>325MG; 37.5MG</u>	<u>A206885 001</u>	May 02, 2017
<u>AB</u>	MICRO LABS LTD	<u>325MG; 37.5MG</u>	<u>A201952 001</u>	Dec 14, 2012
	INDIA			
<u>AB</u>	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858 001</u>	Sep 26, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184 001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>325MG; 37.5MG</u>	<u>A090460 001</u>	Sep 06, 2012
	INC			
	<u>ULTRACET</u>			
<u>AB</u>	+! JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123 001</u>	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	ALEM BIC PHARMS LTD	<u>500MG</u>	<u>A210423 001</u>	Feb 19, 2019
<u>AB</u>	CADILA	<u>500MG</u>	<u>A205301 001</u>	Jan 16, 2019
<u>AB</u>	HERITAGE PHARMA	<u>500MG</u>	<u>A040904 001</u>	Dec 10, 2008
<u>AB</u>	! HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779 001</u>	Jul 14, 2011
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A204691 001</u>	Mar 29, 2016
<u>AB</u>	NOVAST LABS	<u>500MG</u>	<u>A203434 001</u>	Sep 30, 2016

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	EYWA PHARMA	<u>125MG</u>	<u>A211556 001</u>	Oct 18, 2019
<u>AB</u>		<u>250MG</u>	<u>A211556 002</u>	Oct 18, 2019
<u>AB</u>	HERITAGE PHARMA	<u>125MG</u>	<u>A205530 001</u>	Oct 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A205530 002</u>	Oct 27, 2016
<u>AB</u>	LANNETT	<u>250MG</u>	<u>A084840 001</u>	
<u>AB</u>	NOVITIUM PHARMA	<u>125MG</u>	<u>A210588 001</u>	Oct 17, 2019
<u>AB</u>		<u>250MG</u>	<u>A210588 002</u>	Oct 17, 2019
<u>AB</u>	STRIDES PHARMA	<u>125MG</u>	<u>A209734 001</u>	Nov 20, 2017
<u>AB</u>		<u>250MG</u>	<u>A209734 002</u>	Nov 20, 2017
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195 001</u>	May 28, 1997
<u>AB</u>	!	<u>250MG</u>	<u>A040195 002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	MYLAN ASI	<u>EQ 500MG BASE/VIAL</u>	<u>A200880 001</u>	May 09, 2012
<u>AP</u>	WEST-WARD PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040089 001</u>	Feb 28, 1995
	INT			
<u>AP</u>	! X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784 001</u>	Dec 10, 2008
<u>AP</u>	ZYDUS PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A206533 001</u>	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523 001</u>	Feb 19, 1982
<u>AT</u>	+! ICU MEDICAL INC	<u>250MG/100ML</u>	<u>N017656 001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

<u>AT</u>	MLV	<u>2%</u>	<u>A040607 001</u>	Feb 24, 2005
<u>AT</u>	RISING	<u>2%</u>	<u>A207280 001</u>	Mar 09, 2018
<u>AT</u>	TARO	<u>2%</u>	<u>A088638 001</u>	Sep 06, 1984
<u>AT</u>	! WOCKHARDT BIO AG	<u>2%</u>	<u>A040166 001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179 001</u>	
-----------	----------------	-----------	--------------------	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	TARO PHARM INDS LTD	<u>2%; 1%</u>	<u>A088759 001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%; 1%</u>	<u>A040609 001</u>	Feb 06, 2006
	<u>VOSOL HC</u>			
<u>AT</u>	+! HI TECH PHARMA	<u>2%; 1%</u>	<u>N012770 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+! MISSION PHARMA 250MG N018749 001 May 31, 1983

ACETYLCOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+! BAUSCH AND LOMB 20MG/VIAL N020213 001 Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE**AP** +! CUMBERLAND PHARMS **6GM/30ML (200MG/ML)** **N021539 001** Jan 23, 2004ACETYLCYSTEINE**AP** AKORN INC **6GM/30ML (200MG/ML)** **A203173 001** Mar 24, 2015**AP** AUROBINDO PHARMA **6GM/30ML (200MG/ML)** **A207358 001** Feb 29, 2016

LTD

AP FRESENIUS KABI USA **6GM/30ML (200MG/ML)** **A200644 001** Nov 07, 2012**AP** SAGENT PHARMS INC **6GM/30ML (200MG/ML)** **A091684 001** Oct 31, 2017**AP** ZYDUS PHARMS **6GM/30ML (200MG/ML)** **A208166 001** Jul 20, 2018

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE**AN** ALVOGEN INC **10%** **A204674 001** Feb 11, 2014**AN** **20%** **A203853 001** Jun 21, 2012**AN** HOSPIRA **10%** **A073664 001** Aug 30, 1994**AN** **20%** **A074037 001** Aug 30, 1994**AN** ! LUITPOLD **10%** **A072489 001** Jul 28, 1995**AN** ! **20%** **A072547 001** Jul 28, 1995ACITRETIN

CAPSULE; ORAL

ACITRETIN**AB** BARR LABS INC **10MG** **A091455 001** Apr 04, 2013**AB** **25MG** **A091455 002** Apr 04, 2013**AB** IMPAX LABS INC **10MG** **A202552 001** Dec 23, 2015**AB** **17.5MG** **A202552 002** Dec 23, 2015**AB** **22.5MG** **A202552 003** Dec 23, 2015**AB** **25MG** **A202552 004** Dec 23, 2015**AB** MYLAN **10MG** **A202148 001** Sep 10, 2015**AB** **25MG** **A202148 002** Sep 10, 2015**AB** SIGMAPHARM LABS LLC **10MG** **A204633 001** May 22, 2015**AB** **17.5MG** **A204633 002** May 22, 2015**AB** **22.5MG** **A204633 003** May 22, 2015**AB** **25MG** **A204633 004** May 22, 2015**AB** TEVA PHARMS USA **17.5MG** **A202897 001** Apr 04, 2013**AB** **22.5MG** **A202897 002** Apr 04, 2013SORIATANE**AB** + STIEFEL LABS INC **10MG** **N019821 001** Oct 28, 1996**AB** +! **25MG** **N019821 002** Oct 28, 1996ACOLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+! CIRCASSIA 0.4MG/INH N202450 001 Jul 23, 2012

ACOLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR

CIRCASSIA 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG; 60MG N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR**AB** ! APOTEX **200MG** **A075677 001** Sep 28, 2005**AB** CADILA **200MG** **A204313 001** Mar 25, 2016**AB** CADILA PHARMS LTD **200MG** **A201445 001** Mar 06, 2014**AB** CARLSBAD TECHNOLOGY **200MG** **A206261 001** Aug 16, 2017**AB** DAVA PHARMS INC **200MG** **A074833 001** Apr 22, 1997**AB** HERITAGE PHARMS INC **200MG** **A074889 001** Oct 31, 1997**AB** KENTON **200MG** **A075090 001** Jan 26, 1999

PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	TEVA	200MG	A074578 001	Apr 22, 1997
-----------	------	--------------	--------------------	--------------

CREAM; TOPICAL

ACYCLOVIR

AB	PERRIGO UK FINCO	5%	A208702 001	Feb 04, 2019
-----------	------------------	-----------	--------------------	--------------

ZOVIRAX

AB	+! BAUSCH	5%	N021478 001	Dec 30, 2002
-----------	-----------	-----------	--------------------	--------------

OINTMENT; TOPICAL

ACYCLOVIR

AB	ACP NIMBLE	5%	A205591 001	Nov 13, 2017
-----------	------------	-----------	--------------------	--------------

AB	ALEMBIC PHARMS LTD	5%	A209000 001	Apr 06, 2018
-----------	--------------------	-----------	--------------------	--------------

AB	AMNEAL PHARMS	5%	A204605 001	Jun 18, 2014
-----------	---------------	-----------	--------------------	--------------

AB	APOTEX	5%	A210774 001	Sep 06, 2019
-----------	--------	-----------	--------------------	--------------

AB	CADILA	5%	A205974 001	Mar 15, 2019
-----------	--------	-----------	--------------------	--------------

AB	CIPLA	5%	A211794 001	Jan 18, 2019
-----------	-------	-----------	--------------------	--------------

AB	FOUGERA PHARMS INC	5%	A206633 001	May 11, 2016
-----------	--------------------	-----------	--------------------	--------------

AB	GLENMARK PHARMS SA	5%	A205510 001	Jul 31, 2017
-----------	--------------------	-----------	--------------------	--------------

AB	MYLAN PHARMS INC	5%	A202459 001	Apr 03, 2013
-----------	------------------	-----------	--------------------	--------------

AB	TARO	5%	A205469 001	Dec 21, 2016
-----------	------	-----------	--------------------	--------------

AB	TOLMAR	5%	A206437 001	Jul 31, 2017
-----------	--------	-----------	--------------------	--------------

AB	TORRENT	5%	A209971 001	Jan 11, 2019
-----------	---------	-----------	--------------------	--------------

ZOVIRAX

AB	+! BAUSCH	5%	N018604 001	Mar 29, 1982
-----------	-----------	-----------	--------------------	--------------

SUSPENSION; ORAL

ACYCLOVIR

AB	ACTAVIS MID	200MG/5ML	A074738 001	Apr 28, 1997
-----------	-------------	------------------	--------------------	--------------

ATLANTIC

AB	HI TECH PHARMA	200MG/5ML	A077026 001	Jun 07, 2005
-----------	----------------	------------------	--------------------	--------------

ZOVIRAX

AB	+! MYLAN	200MG/5ML	N019909 001	Dec 22, 1989
-----------	----------	------------------	--------------------	--------------

TABLET; BUCCAL

SITAVIG

+!	EPI HLTH	50MG	N203791 001	Apr 12, 2013
----	----------	------	-------------	--------------

TABLET; ORAL

ACYCLOVIR

AB	APOTEX INC	400MG	A077309 001	Sep 29, 2005
-----------	------------	--------------	--------------------	--------------

AB		800MG	A077309 002	Sep 29, 2005
-----------	--	--------------	--------------------	--------------

AB	CADILA PHARMS LTD	400MG	A202168 001	Nov 15, 2013
-----------	-------------------	--------------	--------------------	--------------

AB		800MG	A202168 002	Nov 15, 2013
-----------	--	--------------	--------------------	--------------

AB	CARLSBAD	400MG	A075382 001	Apr 30, 1999
-----------	----------	--------------	--------------------	--------------

AB		800MG	A075382 002	Apr 30, 1999
-----------	--	--------------	--------------------	--------------

AB	DAVA PHARMS INC	400MG	A074946 001	Nov 19, 1997
-----------	-----------------	--------------	--------------------	--------------

AB		800MG	A074946 002	Nov 19, 1997
-----------	--	--------------	--------------------	--------------

AB	HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997
-----------	---------------------	--------------	--------------------	--------------

AB		800MG	A074891 002	Oct 31, 1997
-----------	--	--------------	--------------------	--------------

AB	HETERO LABS LTD V	400MG	A203834 001	Oct 29, 2013
-----------	-------------------	--------------	--------------------	--------------

AB		800MG	A203834 002	Oct 29, 2013
-----------	--	--------------	--------------------	--------------

AB	SQUARE PHARMS LTD	400MG	A209366 001	Oct 07, 2019
-----------	-------------------	--------------	--------------------	--------------

AB		800MG	A209366 002	Oct 07, 2019
-----------	--	--------------	--------------------	--------------

AB	TEVA	400MG	A074556 002	Apr 22, 1997
-----------	------	--------------	--------------------	--------------

AB		800MG	A074556 003	Apr 22, 1997
-----------	--	--------------	--------------------	--------------

AB	YILING PHARM LTD	400MG	A210401 001	Mar 07, 2018
-----------	------------------	--------------	--------------------	--------------

AB		800MG	A210401 002	Mar 07, 2018
-----------	--	--------------	--------------------	--------------

AB	ZYDUS PHARMS	400MG	A204314 001	Aug 19, 2014
-----------	--------------	--------------	--------------------	--------------

AB		800MG	A204314 002	Aug 19, 2014
-----------	--	--------------	--------------------	--------------

ZOVIRAX

AB	+ MYLAN	400MG	N020089 001	Apr 30, 1991
-----------	---------	--------------	--------------------	--------------

AB	+!	800MG	N020089 002	Apr 30, 1991
-----------	----	--------------	--------------------	--------------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701 001	Oct 11, 2013
-----------	----------------------	------------------------	--------------------	--------------

AP	! FRESENIUS KABI USA	EQ 50MG BASE/ML	A074930 001	May 13, 1998
-----------	----------------------	------------------------	--------------------	--------------

!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535 001	Aug 31, 2018
---	--------------	--------------------	-------------	--------------

!		EQ 1GM BASE/VIAL	A206535 002	Aug 31, 2018
---	--	------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+! BAUSCH

5%;1%

N022436 001 Jul 31, 2009

ADAPALENE

CREAM; TOPICAL

ADAPALENEAB FOUGERA PHARMS 0.1%A090824 001 Jun 30, 2010DIFFERINAB +! GALDERMA LABS LP 0.1%N020748 001 May 26, 2000

GEL; TOPICAL

ADAPALENEAB ACTAVIS MID 0.3%A201000 001 Oct 27, 2014

ATLANTIC

AB GLENMARK GENERICS 0.1%A091314 001 Jul 01, 2010AB P AND L 0.1%A090962 001 Jun 02, 2010AB TARO 0.3%A208322 001 Jun 23, 2016AB TOLMAR 0.3%A200298 001 Jun 14, 2012DIFFERINAB +! GALDERMA LABS LP 0.3%N021753 001 Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

+! GALDERMA LABS LP

0.1%

N022502 001 Mar 17, 2010

SOLUTION; TOPICAL

ADAPALENEAB CALL INC 0.1%A203981 001 Sep 23, 2016AB 0.1%A204593 001 Jan 05, 2016ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDEAB ACTAVIS MID 0.1%;2.5%A203790 001 Sep 30, 2015

ATLANTIC

AB GLENMARK PHARMS LTD 0.1%;2.5%A208108 001 Nov 08, 2019AB PERRIGO UK FINCO 0.1%;2.5%A205033 001 Jan 23, 2018AB TARO 0.1%;2.5%A206959 001 Jan 24, 2018AB TOLMAR 0.1%;2.5%A206164 001 May 23, 2018EPIDUOAB +! GALDERMA LABS LP 0.1%;2.5%N022320 001 Dec 08, 2008EPIDUO FORTEAB +! GALDERMA LABS 0.3%;2.5%N207917 001 Jul 15, 2015ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXILAB APOTEX 10MGA205459 001 Jul 06, 2018AB SIGMAPHARM LABS LLC 10MGA202051 001 Aug 29, 2013HEPSERAAB +! GILEAD 10MGN021449 001 Sep 20, 2002ADENOSINE

INJECTABLE; INJECTION

ADENOSINEAP ! AKORN 3MG/MLA078076 001 Oct 31, 2008AP FRESENIUS KABI USA 3MG/MLA077133 001 Apr 27, 2005AP 3MG/MLA205568 001 Apr 16, 2018AP GLAND PHARMA LTD 3MG/MLA077283 001 Jun 14, 2007AP 3MG/MLA206778 001 Feb 16, 2018AP MYLAN LABS LTD 3MG/MLA078640 001 Mar 21, 2014AP 3MG/MLA078686 001 May 13, 2009AP WEST-WARD PHARMS 3MG/MLA076404 001 Jun 16, 2004

INT

AP 3MG/MLA076500 001 Jun 16, 2004

SOLUTION; INTRAVENOUS

ADENOSINEAP AKORN 60MG/20ML (3MG/ML)A090450 001 Oct 02, 2014AP 90MG/30ML (3MG/ML)A090450 002 Oct 02, 2014AP AUROBINDO PHARMA 60MG/20ML (3MG/ML)A205331 001 Nov 02, 2017

LTD

AP 90MG/30ML (3MG/ML)A205331 002 Nov 02, 2017AP FRESENIUS KABI USA 60MG/20ML (3MG/ML)A077897 001 Nov 27, 2017AP 90MG/30ML (3MG/ML)A077897 002 Nov 27, 2017AP HOSPIRA INC 60MG/20ML (3MG/ML)A203883 001 Mar 24, 2014AP 90MG/30ML (3MG/ML)A203883 002 Mar 24, 2014

PRESCRIPTION DRUG PRODUCT LIST

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

<u>AP</u>	MYLAN ASI	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	! TEVA PHARMS USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>	!	<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFAMELANOTIDEIMPLANT; SUBCUTANEOUS
SCENESSE

+	CLIVUNEL INC	16MG	N210797 001	Oct 08, 2019
---	--------------	------	-------------	--------------

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
+		EQ 30MG BASE	N201292 002	Jul 12, 2013
+	!	EQ 40MG BASE	N201292 003	Jul 12, 2013

AIR POLYMER-TYPE AFOAM; INTRAUTERINE
EXEM FOAM KIT

+	GISKIT	10ML	N212279 001	Nov 07, 2019
---	--------	------	-------------	--------------

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

<u>AB</u>	ACTAVIS ELIZABETH	<u>200MG</u>	<u>A208094 001</u>	May 20, 2019
<u>AB</u>	CIPLA LTD	<u>200MG</u>	<u>A210434 001</u>	Sep 21, 2018
<u>AB</u>	EDENBRIDGE PHARMS	<u>200MG</u>	<u>A211117 001</u>	May 14, 2019
<u>AB</u>	STRIDES PHARMA	<u>200MG</u>	<u>A210011 001</u>	Dec 07, 2018
<u>AB</u>	ZYDUS PHARMS	<u>200MG</u>	<u>A208979 001</u>	Dec 14, 2018

ALBENZA

<u>AB</u>	+	IMPAX LABS INC	<u>200MG</u>	<u>N020666 001</u>	Jun 11, 1996
-----------	---	----------------	--------------	--------------------	--------------

ALBUMIN HUMANINJECTABLE; INJECTION
OPTISON

+	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
---	---------------	---------	-------------	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

+	ISO TEX	100uCi/10ML (10uCi/ML)	N017836 003	Jun 08, 2004
+		500uCi/0.5ML	N017836 001	
+	!	1,000uCi/ML	N017836 002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837 001	
+	!	1mCi/VIAL	N017837 002	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004
----	---	--------------------	--------------------	-------------	--------------

PROVENTIL-HFA

BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503 001	Aug 15, 1996
----	---	------------------	--------------------	-------------	--------------

VENTOLIN HFA

BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001
----	---	-----------------	--------------------	-------------	--------------

POWDER, METERED; INHALATION

PROAIR DIGIHALER

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636 002	Dec 21, 2018
---	--------------------	--------------------	-------------	--------------

PROAIR RESPICLICK

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636 001	Mar 31, 2015
---	--------------------	--------------------	-------------	--------------

SOLUTION; INHALATION

ACCUNEB

<u>AN</u>	+	MYLAN SPECIALITY LP	<u>EQ 0.021% BASE</u>	<u>N020949 002</u>	Apr 30, 2001
<u>AN</u>	+		<u>EQ 0.042% BASE</u>	<u>N020949 001</u>	Apr 30, 2001

ALBUTEROL SULFATE

<u>AN</u>		AUROBINDO PHARMA LTD	<u>EQ 0.083% BASE</u>	<u>A206224 001</u>	Oct 17, 2017
<u>AN</u>	!	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050 001</u>	Jun 18, 1998
<u>AN</u>		HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A074543 001</u>	Jan 15, 1998

PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

<u>AN</u>	NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355 002</u>	Mar 31, 2010
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A076355 001</u>	Jun 28, 2004
<u>AN</u>	!	<u>EQ 0.083% BASE</u>	<u>A074880 001</u>	Sep 17, 1997
<u>AN</u>		<u>EQ 0.5% BASE</u>	<u>A075664 001</u>	Jun 26, 2001
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839 001</u>	Dec 16, 2008
<u>AN</u>	SUN PHARM	<u>EQ 0.083% BASE</u>	<u>A207857 001</u>	Jul 21, 2017
<u>AN</u>	WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772 001</u>	Sep 25, 2007
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077772 002</u>	Sep 25, 2007

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241 001</u>	May 12, 2010
<u>AA</u>	COSETTE	<u>EQ 2MG BASE/5ML</u>	<u>A074454 001</u>	Sep 25, 1995
<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749 001</u>	Jan 30, 1998
<u>AA</u>	LANNETT CO INC	<u>EQ 2MG BASE/5ML</u>	<u>A078105 001</u>	Dec 27, 2006
<u>AA</u>	QUAGEN	<u>EQ 2MG BASE/5ML</u>	<u>A212197 001</u>	Sep 06, 2019
<u>AA</u>	! TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419 001</u>	Mar 30, 1992
<u>AA</u>	VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788 001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>	AMNEAL PHARMS CO	<u>EQ 2MG BASE</u>	<u>A208804 001</u>	May 21, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208804 002</u>	May 21, 2018
<u>AB</u>	APPCO	<u>EQ 2MG BASE</u>	<u>A207046 001</u>	Jun 29, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A207046 002</u>	Jun 29, 2018
<u>AB</u>	ARISE	<u>EQ 2MG BASE</u>	<u>A210948 001</u>	Mar 15, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A210948 002</u>	Mar 15, 2019
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A072894 002</u>	Jan 17, 1991
<u>AB</u>	! SUN PHARM	<u>EQ 4MG BASE</u>	<u>A072894 001</u>	Jan 17, 1991
<u>AB</u>	INDUSTRIES	<u>EQ 2MG BASE</u>	<u>A072637 002</u>	Dec 05, 1989
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A072637 001</u>	Dec 05, 1989
<u>AB</u>	VIRTUS PHARM	<u>EQ 2MG BASE</u>	<u>A211397 001</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A211397 002</u>	Oct 26, 2018

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A078092 002</u>	Jan 29, 2007
<u>AB</u>	<u>VOSPIRE ER</u>			
<u>AB</u>	DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130 002</u>	Sep 26, 2002
	ALBUTEROL SULFATE			
	! MYLAN	EQ 8MG BASE	A078092 001	Jan 29, 2007

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	CIPLA	<u>EQ 0.083% BASE;0.017%</u>	<u>A077559 001</u>	Dec 31, 2007
<u>AN</u>	NEPHRON	<u>EQ 0.083% BASE;0.017%</u>	<u>A076749 001</u>	Dec 31, 2007
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE;0.017%</u>	<u>A202496 001</u>	Oct 01, 2012
<u>AN</u>	SUN PHARM	<u>EQ 0.083% BASE;0.017%</u>	<u>A207875 001</u>	Aug 07, 2017
<u>AN</u>	WATSON LABS TEVA	<u>EQ 0.083% BASE;0.017%</u>	<u>A077063 001</u>	Dec 31, 2007

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	! BOEHRINGER	EQ 0.1MG BASE/INH;0.02MG/INH	N021747 001	Oct 07, 2011
	INGELHEIM			

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACAPT

+	! ALLERGAN	0.25%	N022134 001	Jul 28, 2010
---	------------	-------	-------------	--------------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	! FOUGERA PHARMS	<u>0.05%</u>	<u>A076973 001</u>	Jul 12, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079061 001</u>	Jun 23, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076587 001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	! FOUGERA PHARMS	<u>0.05%</u>	<u>A076884 001</u>	Jul 18, 2005
<u>AB</u>	GLENMARK GENERICS	<u>0.05%</u>	<u>A079227 001</u>	Jul 30, 2009
<u>AB</u>	TARO	<u>0.05%</u>	<u>A076730 001</u>	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

+	BELCHER PHARMS LLC	99% (1ML)	N207987	001	Jun 21, 2018
+	!	99% (5ML)	N207987	002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE; ORAL

ALECENSA

+	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015
---	-------------------	---------------	---------	-----	--------------

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013
---	-------	-------------------	---------	-----	--------------

TABLET; ORAL

ALENDRONATE SODIUM

AB	APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008
AB		EQ 10MG BASE	A077982	002	Aug 04, 2008
AB		EQ 35MG BASE	A077982	003	Aug 04, 2008
AB		EQ 70MG BASE	A077982	004	Aug 04, 2008
AB	AUROBINDO PHARMA	EQ 10MG BASE	A090124	001	Aug 04, 2008
AB		EQ 35MG BASE	A090124	002	Aug 04, 2008
AB		EQ 70MG BASE	A090124	003	Aug 04, 2008
AB	CIPLA	EQ 5MG BASE	A076768	001	Aug 04, 2008
AB		EQ 10MG BASE	A076768	002	Aug 04, 2008
AB		EQ 35MG BASE	A076768	003	Aug 04, 2008
AB		EQ 40MG BASE	A076768	004	Aug 04, 2008
AB		EQ 70MG BASE	A076768	005	Aug 04, 2008
AB	HANGZHOU BINJIANG	EQ 5MG BASE	A090258	001	Sep 24, 2009
AB		EQ 10MG BASE	A090258	002	Sep 24, 2009
AB		EQ 35MG BASE	A090258	003	Sep 24, 2009
AB		EQ 70MG BASE	A090258	004	Sep 24, 2009
AB	IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008
AB		EQ 10MG BASE	A075710	002	Feb 06, 2008
AB		EQ 35MG BASE	A075710	003	Feb 06, 2008
AB		EQ 40MG BASE	A075710	004	Feb 06, 2008
AB		EQ 70MG BASE	A075710	005	Feb 06, 2008
AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010
AB		EQ 10MG BASE	A090557	002	Feb 18, 2010
AB		EQ 35MG BASE	A090557	003	Feb 18, 2010
AB		EQ 70MG BASE	A090557	004	Feb 18, 2010
AB	NEOPHARMA	EQ 5MG BASE	A079049	003	Aug 04, 2008
AB		EQ 10MG BASE	A079049	004	Aug 04, 2008
AB		EQ 35MG BASE	A079049	001	Aug 04, 2008
AB		EQ 70MG BASE	A079049	002	Aug 04, 2008
AB	SUN PHARM	EQ 5MG BASE	A090022	001	Sep 10, 2008
AB		EQ 10MG BASE	A090022	002	Sep 10, 2008
AB		EQ 35MG BASE	A090022	003	Sep 10, 2008
AB		EQ 70MG BASE	A090022	004	Sep 10, 2008
AB	WATSON LABS	EQ 35MG BASE	A076984	001	Aug 04, 2008
AB		EQ 40MG BASE	A076984	002	Aug 04, 2008
AB		EQ 70MG BASE	A076984	003	Aug 04, 2008

FOSAMAX

AB	+	MERCK AND CO INC	EQ 70MG BASE	N020560	005	Oct 20, 2000
-----------	---	------------------	---------------------	----------------	------------	--------------

TABLET, EFFERVESCENT; ORAL

BINOSTO

+	ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012
---	-------------------	--------------	---------	-----	--------------

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

+	MERCK	EQ 70MG BASE; 2,800 IU	N021762	001	Apr 07, 2005
+	!	EQ 70MG BASE; 5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP	+	AKORN	EQ 0.5MG BASE/ML	N019353	001	Dec 29, 1986
-----------	---	-------	-------------------------	----------------	------------	--------------

ALFENTANIL

AP		HOSPIRA	EQ 0.5MG BASE/ML	A075221	001	Oct 28, 1999
-----------	--	---------	-------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060</u>	<u>001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284</u>	<u>001</u>	Jan 17, 2012
<u>AB</u>	SUN PHARM	<u>10MG</u>	<u>A079057</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	UNICHEM LABS LTD	<u>10MG</u>	<u>A203192</u>	<u>001</u>	Jan 28, 2016

UROXATRAL

<u>AB</u>	+! CONCORDIA	<u>10MG</u>	<u>N021287</u>	<u>001</u>	Jun 12, 2003
-----------	--------------	-------------	----------------	------------	--------------

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A206665</u>	<u>001</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206665</u>	<u>002</u>	Mar 22, 2019
<u>TEKTURNA</u>					
<u>AB</u>	+ NODEN PHARMA	<u>EQ 150MG BASE</u>	<u>N021985</u>	<u>001</u>	Mar 05, 2007
<u>AB</u>	+!	<u>EQ 300MG BASE</u>	<u>N021985</u>	<u>002</u>	Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

	+ NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008
	+!	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
	+!	EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008

ALITRETINOIN

GEL;TOPICAL

PANRETIN

	+! CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999
--	--------------	--------------	---------	-----	--------------

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154</u>	<u>001</u>	May 06, 2013
<u>AB</u>		<u>300MG</u>	<u>A203154</u>	<u>002</u>	May 06, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	INDOCO REMEDIES	<u>100MG</u>	<u>A204467</u>	<u>001</u>	Jul 28, 2016
<u>AB</u>		<u>300MG</u>	<u>A204467</u>	<u>002</u>	Jul 28, 2016
<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637</u>	<u>002</u>	Mar 16, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDUSTRIES	<u>100MG</u>	<u>A071450</u>	<u>002</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	UNICHEM LABS LTD	<u>100MG</u>	<u>A211820</u>	<u>001</u>	Mar 12, 2019
<u>AB</u>		<u>300MG</u>	<u>A211820</u>	<u>002</u>	Mar 12, 2019
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A210117</u>	<u>001</u>	Oct 12, 2017
<u>AB</u>		<u>300MG</u>	<u>A210117</u>	<u>002</u>	Oct 12, 2017
<u>LOPURIN</u>					
<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987
<u>ZYLOPRIM</u>					
<u>AB</u>	+ CASPER PHARMA LLC	<u>100MG</u>	<u>N016084</u>	<u>001</u>	
<u>AB</u>	+!	<u>300MG</u>	<u>N016084</u>	<u>002</u>	

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004
-----------	----------------------	---------------------------	----------------	------------	--------------

ALOPRIM

<u>AP</u>	+! MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u>	May 17, 1996
-----------	------------------------	---------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523 001	Mar 03, 2016
AB	!	EQ 12.5MG BASE	A205523 002	Mar 03, 2016
AB	MYLAN	EQ 6.25MG BASE	A205171 001	Nov 09, 2015
AB		EQ 12.5MG BASE	A205171 002	Nov 09, 2015
AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027 001	Jul 07, 2015
AB		EQ 12.5MG BASE	A078027 002	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271 002	Jan 25, 2013
+	!	EQ 25MG BASE	N022271 003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013
+	!	EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013
+	!	EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 0.5MG BASE	A206647 001	Dec 22, 2016
AB		EQ 1MG BASE	A206647 002	Dec 22, 2016
AB	EYWA PHARMA	EQ 0.5MG BASE	A211621 001	Sep 16, 2019
AB		EQ 1MG BASE	A211621 002	Sep 16, 2019
AB	HIKMA	EQ 0.5MG BASE	A200652 001	May 04, 2015
AB		EQ 1MG BASE	A200652 002	May 04, 2015
AB	PAR PHARM INC	EQ 0.5MG BASE	A206113 001	Feb 23, 2018
AB		EQ 1MG BASE	A206113 002	Feb 23, 2018
AB	RISING	EQ 0.5MG BASE	A209180 001	Jan 14, 2019
AB		EQ 1MG BASE	A209180 002	Jan 14, 2019

LOTRONEX

AB	+	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107 002	Dec 23, 2003
AB	+	!	EQ 1MG BASE	N021107 001	Feb 09, 2000

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526 001	May 24, 2019
+		150MG	N212526 002	May 24, 2019
+	!	200MG	N212526 003	May 24, 2019

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163 001	May 18, 2000
+	!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163 002	Jun 16, 2003

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

! HIKMA

1MG/ML

A074312 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342 001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342 002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342 003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342 004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741 001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741 002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741 003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741 004</u>	Jan 19, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.25MG</u>	<u>A203346 001</u>	Jul 31, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A203346 002</u>	Jul 31, 2015
<u>AB</u>		<u>1MG</u>	<u>A203346 003</u>	Jul 31, 2015
<u>AB</u>		<u>2MG</u>	<u>A203346 004</u>	Jul 31, 2015
<u>AB</u>	BRECKENRIDGE	<u>0.25MG</u>	<u>A207507 001</u>	Jul 09, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A207507 002</u>	Jul 09, 2018
<u>AB</u>		<u>1MG</u>	<u>A207507 003</u>	Jul 09, 2018
<u>AB</u>		<u>2MG</u>	<u>A207507 004</u>	Jul 09, 2018
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174 001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174 002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174 003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174 004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215 001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215 002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215 003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215 004</u>	Jan 27, 1994
<u>AB</u>	NATCO PHARMA LTD	<u>0.25MG</u>	<u>A200739 001</u>	Apr 15, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A200739 002</u>	Apr 15, 2015
<u>AB</u>		<u>1MG</u>	<u>A200739 003</u>	Apr 15, 2015
<u>AB</u>		<u>2MG</u>	<u>A200739 004</u>	Apr 15, 2015
<u>AB</u>	OXFORD PHARMS	<u>0.25MG</u>	<u>A078491 001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491 002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491 003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491 004</u>	Dec 12, 2008
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112 001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112 002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112 003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909 001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARM	<u>0.25MG</u>	<u>A090082 001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082 002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082 003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082 004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248 001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248 002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248 003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248 004</u>	Sep 17, 2010

XANAX

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276 001</u>	
<u>AB</u>	+	<u>0.5MG</u>	<u>N018276 002</u>	
<u>AB</u>	+!	<u>1MG</u>	<u>N018276 003</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N018276 004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056 001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056 002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056 003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056 004</u>	Feb 13, 2007
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387 001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387 002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387 003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387 004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469 001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469 002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469 003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469 004</u>	Sep 29, 2011
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449 001</u>	Nov 12, 2008
<u>AB</u>		<u>1MG</u>	<u>A078449 004</u>	Dec 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A078449 002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449 003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A090871 001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871 002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871 003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871 004</u>	Jun 07, 2011

XANAX XR

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434 001</u>	Jan 17, 2003
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>1MG</u>	<u>N021434 002</u>	Jan 17, 2003
<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>2MG</u>	<u>N021434 003</u>	Jan 17, 2003
<u>AB</u>	+! PHARMACIA AND UPJOHN	<u>3MG</u>	<u>N021434 004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561 001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561 002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561 003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561 004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088 001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088 002</u>	Jan 09, 2009
<u>AB</u>	!	<u>1MG</u>	<u>A078088 003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088 004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196 001</u>	Apr 30, 1999
<u>AP</u>	WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>A074815 001</u>	Jan 20, 1998

CAVERJECT

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379 001</u>	Jul 06, 1995
<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>0.02MG/VIAL</u>	<u>N020379 002</u>	Jul 06, 1995
<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>0.04MG/VIAL</u>	<u>N020379 004</u>	May 19, 1997

EDEX

<u>AP</u>	+ AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649 002</u>	Jun 12, 1997
<u>AP</u>	+ AUXILIUM PHARMS LLC	<u>0.02MG/VIAL</u>	<u>N020649 003</u>	Jun 12, 1997
<u>AP</u>	+! AUXILIUM PHARMS LLC	<u>0.04MG/VIAL</u>	<u>N020649 004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484 001</u>	
	CAVERJECT IMPULSE			
	PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212 001	Jun 11, 2002
		0.02MG/VIAL	N021212 002	Jun 11, 2002
	EDEX			
	+! AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649 005	Jul 30, 1998
	+! AUXILIUM PHARMS LLC	0.02MG/VIAL	N020649 006	Jul 30, 1998
	+! AUXILIUM PHARMS LLC	0.04MG/VIAL	N020649 007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

	+! MYLAN SPECIALITY LP	0.125MG	N020700 001	Nov 19, 1996
	+! MYLAN SPECIALITY LP	0.25MG	N020700 002	Nov 19, 1996
	+! MYLAN SPECIALITY LP	0.5MG	N020700 003	Nov 19, 1996
	+! MYLAN SPECIALITY LP	1MG	N020700 004	Nov 19, 1996

ALVIMOPAN

CAPSULE; ORAL

ALVIMOPAN

<u>AB</u>	WATSON LABS TEVA	<u>12MG</u>	<u>A208295 001</u>	Dec 19, 2019
<u>AB</u>	+! CUBIST PHARMS	<u>12MG</u>	<u>N021775 001</u>	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A208966 001</u>	Jun 21, 2017
<u>AB</u>	BIONPHARMA INC	<u>100MG</u>	<u>A078720 001</u>	May 29, 2008
<u>AB</u>	HERITAGE PHARMA	<u>100MG</u>	<u>A209171 001</u>	Jun 12, 2017
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A207570 001</u>	Sep 30, 2016
<u>AB</u>	! SANDOZ	<u>100MG</u>	<u>A071293 001</u>	Feb 18, 1987

PRESCRIPTION DRUG PRODUCT LIST

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	STRIDES PHARMA	<u>100MG</u>	<u>A209047</u>	<u>001</u>	Jun 07, 2017
<u>AB</u>	UPSHER SMITH LABS	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986
<u>AB</u>	WATSON LABS INC	<u>100MG</u>	<u>A208107</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A208278</u>	<u>001</u>	May 31, 2016

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
+	!	EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	!	ANDA REPOSITORY	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993
<u>AA</u>	!	CMP PHARMA INC	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002
<u>AA</u>	!	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	!	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995
<u>AA</u>	!	WOCKHARDT BIO AG	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A207571</u>	<u>001</u>	Jan 31, 2017
<u>AB</u>		JUBILANT GENERICS	<u>100MG</u>	<u>A210403</u>	<u>001</u>	Feb 07, 2018
<u>AB</u>		STRIDES PHARMA	<u>100MG</u>	<u>A209035</u>	<u>001</u>	Jun 09, 2017
<u>AB</u>	!	UPSHER SMITH LABS	<u>100MG</u>	<u>A076186</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		WATSON LABS INC	<u>100MG</u>	<u>A208096</u>	<u>001</u>	Dec 15, 2016

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+	OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018
+		EQ 193MG BASE	N209410	002	Feb 16, 2018
+	!	EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

<u>AB</u>		CIPLA	<u>5MG</u>	<u>A210715</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>10MG</u>	<u>A210715</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A208441</u>	<u>001</u>	Mar 28, 2019
<u>AB</u>			<u>10MG</u>	<u>A208441</u>	<u>002</u>	Mar 28, 2019
<u>AB</u>		PAR PHARM INC	<u>5MG</u>	<u>A209509</u>	<u>001</u>	Apr 10, 2019
<u>AB</u>			<u>10MG</u>	<u>A209509</u>	<u>002</u>	Apr 10, 2019
<u>AB</u>		SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A208354</u>	<u>001</u>	Apr 10, 2019
<u>AB</u>			<u>10MG</u>	<u>A208354</u>	<u>002</u>	Apr 10, 2019
<u>AB</u>		SUN PHARM	<u>5MG</u>	<u>A210784</u>	<u>001</u>	Mar 28, 2019
<u>AB</u>			<u>10MG</u>	<u>A210784</u>	<u>002</u>	Mar 28, 2019
<u>AB</u>		WATSON LABS INC	<u>5MG</u>	<u>A208252</u>	<u>001</u>	Mar 28, 2019
<u>AB</u>			<u>10MG</u>	<u>A208252</u>	<u>002</u>	Mar 28, 2019
<u>AB</u>		ZYDUS PHARMS	<u>5MG</u>	<u>A210058</u>	<u>001</u>	Mar 28, 2019
<u>AB</u>			<u>10MG</u>	<u>A210058</u>	<u>002</u>	Mar 28, 2019

LETAIRIS

<u>AB</u>	+	GILEAD	<u>5MG</u>	<u>N022081</u>	<u>001</u>	Jun 15, 2007
<u>AB</u>	+	!	<u>10MG</u>	<u>N022081</u>	<u>002</u>	Jun 15, 2007

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.1%</u>	<u>A076065</u>	<u>001</u>	May 15, 2003
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076229</u>	<u>001</u>	May 31, 2002

LOTION;TOPICAL

AMCINONIDE

!	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002
---	----------------	------	---------	-----	--------------

OINTMENT;TOPICAL

AMCINONIDE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.1%</u>	<u>A076096</u>	<u>001</u>	Nov 19, 2002
<u>AB</u>		TARO PHARM INDS	<u>0.1%</u>	<u>A076367</u>	<u>001</u>	Mar 19, 2003

AMIFAMPRIDINE

TABLET;ORAL

RUZURGI

+	!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019
---	---	-------------------------	------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMIFAMPRIDINE PHOSPHATE

TABLET; ORAL

FIRDAPSE

+! CATALYST PHARMS EQ 10MG BASE N208078 001 Nov 28, 2018

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINEAP ! MYLAN LABS LTD 500MG/VIAL A204363 001 Jul 17, 2017AP SUN PHARM 500MG/VIAL A077126 001 Mar 14, 2008ETHYOLAP +! CLINIGEN 500MG/VIAL N020221 001 Dec 08, 1995AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATEAP ! EMCURE PHARMS LTD EQ 250MG BASE/ML A204040 001 Dec 12, 2013AP FRESENIUS KABI USA EQ 50MG BASE/ML A205605 001 Dec 09, 2015AP EQ 250MG BASE/ML A205604 001 Dec 09, 2015AP SAGENT PHARMS INC EQ 250MG BASE/ML A203323 001 May 12, 2016AP ! WEST-WARD PHARMS EQ 50MG BASE/ML A063313 001 Apr 11, 1994

INT

AP EQ 250MG BASE/ML A063315 001 Apr 11, 1994

SUSPENSION, LIPOSOMAL; INHALATION

ARIKAYCE KIT

+! INSMED INC EQ 590MG BASE/8.4ML N207356 001 Sep 28, 2018

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDEAB ! PAR PHARM 5MG A070346 001 Jan 22, 1986AB SIGMAPHARM LABS LLC 5MG A079133 001 Jan 30, 2009AB WINDLAS HLTHCARE 5MG A204180 001 Aug 07, 2015MIDAMORAB + PADDOCK LLC 5MG N018200 001AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEAB BARR EQ 5MG ANHYDROUS; 50MG A071111 001 May 10, 1988AB ! MYLAN EQ 5MG ANHYDROUS; 50MG A073209 001 Oct 31, 1991AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN 15% (150GM/1000ML) A091112 001 Apr 13, 2012

15% (300GM/2000ML) A091112 002 Apr 13, 2012

AMINOSYN II 10% IN PLASTIC CONTAINER

ICU MEDICAL INC 10% (10GM/100ML) N020015 001 Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU MEDICAL INC 15% (15GM/100ML) N020041 001 Dec 19, 1991

AMINOSYN-PF 10%

ICU MEDICAL INC 10% (10GM/100ML) N019492 002 Oct 17, 1986

AMINOSYN-PF 7%

ICU MEDICAL INC 7% (7GM/100ML) N019398 001 Sep 06, 1985

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE 15% (15GM/100ML) A020512 001 Aug 30, 1996

FREAMINE HBC 6.9%

B BRAUN 6.9% (6.9GM/100ML) N016822 006 May 17, 1983

FREAMINE III 10%

B BRAUN 10% (10GM/100ML) N016822 005

FREAMINE III 8.5%

B BRAUN 8.5% (8.5GM/100ML) N016822 004

HEPATAMINE 8%

B BRAUN 8% (8GM/100ML) N018676 001 Aug 03, 1982

NEPHRAMINE 5.4%

B BRAUN 5.4% (5.4GM/100ML) N017766 001

PREMASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10% (10GM/100ML) A075880 002 Jun 19, 2003

PREMASOL 6% IN PLASTIC CONTAINER

BAXTER HLTHCARE 6% (6GM/100ML) A075880 001 Jun 19, 2003

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 20% (20GM/100ML) N020849 001 Aug 26, 1998

TRAVASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10% (10MG/100ML) N018931 003 Aug 23, 1984

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

INJECTABLE; INJECTION

TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE			
+! B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+! B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE			
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER			
+! BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER			
+ FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656 004	Aug 25, 2014
+ FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656 005	Aug 25, 2014
+ FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656 006	Aug 25, 2014
+! FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656 007	Aug 25, 2014
PERIKABIVEN IN PLASTIC CONTAINER			
+ FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656 003	Aug 25, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656 001	Aug 25, 2014
+	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656 002	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;10GM/100ML	N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;25GM/100ML	N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;5GM/100ML	N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988
--	---	-------------	--------------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822 003	
--	--	-------------	--

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AP	AMINOCAPROIC ACID LUITPOLD	250MG/ML	A071192 001	Dec 01, 1987
AP	AMINOCAPROIC ACID IN PLASTIC CONTAINER ! HOSPIRA	250MG/ML	A070010 001	Mar 09, 1987
AA	AMICAR +! CLOVER PHARMS	1.25GM/5ML	N015230 002	
AA	AMINOCAPROIC ACID AMNEAL PHARMS LLC	1.25GM/5ML	A212780 001	Aug 23, 2019
AB	AMICAR + CLOVER PHARMS	500MG	N015197 001	
AB	AMINOCAPROIC ACID + CLOVER PHARMS	1GM	N015197 002	Jun 24, 2004
AB	AMICAR AMNEAL	500MG	A212492 001	Nov 26, 2019
AB	AMINOCAPROIC ACID SUNNY PHARMTECH INC	500MG	A209060 001	Nov 27, 2018
AB	AMINOCAPROIC ACID !	1GM	A209060 002	Nov 27, 2018

PRESCRIPTION DRUG PRODUCT LIST

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN					
+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017
GEL;TOPICAL					
AMELUZ					
+!	BIOFRONTERA	10%	N208081	001	May 10, 2016
SOLUTION;TOPICAL					
LEVULAN					
+!	DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE					
!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER					
!	JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	50MG/ML	A204550	001	Oct 25, 2017	
AP	!	FRESENIUS KABI USA	50MG/ML	A075761	001	Oct 15, 2002
AP	!	GLAND PHARMA LTD	50MG/ML	A077161	001	Apr 20, 2005
AP		HIKMA FARMACEUTICA	50MG/ML	A077234	001	Feb 25, 2008
AP	!	HOSPIRA	50MG/ML	A075955	001	Oct 18, 2002
AP		HOSPIRA INC	50MG/ML	A203884	001	Nov 25, 2013
AP			50MG/ML	A203885	001	Nov 25, 2013
AP	!	MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002
AP		WOCKHARDT	50MG/ML	A077610	001	Oct 30, 2008
AP			50MG/ML	A077834	001	Oct 30, 2008
NEXTERONE						
+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010	
+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010	

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	
AB		100MG	A075389	002	Dec 28, 2017	
AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	
AB		400MG	A075389	003	Dec 28, 2017	
AB	MURTY PHARMS	100MG	A077069	003	Oct 04, 2016	
AB		200MG	A077069	001	Apr 08, 2005	
AB		400MG	A077069	002	Apr 08, 2005	
AB	RUBICON	200MG	A078578	001	Nov 06, 2008	
AB	!	SANDOZ	200MG	A075315	001	Dec 23, 1998
AB		400MG	A075315	002	Jun 30, 2000	
AB	TARO	100MG	A075424	002	Dec 18, 2002	
AB		200MG	A075424	001	Mar 30, 2001	
AB		400MG	A076362	001	Nov 29, 2002	
AB	TEVA PHARMS	200MG	A074739	001	Nov 30, 1998	
AB	ZYDUS PHARMS USA INC	200MG	A079029	001	Sep 16, 2008	

PACERONE

AB	UPSHER SMITH LABS	100MG	A075135	002	Apr 12, 2005
AB		200MG	A075135	001	Apr 30, 1998
AMIODARONE HYDROCHLORIDE					
	TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014
AB		25MG	A202446	002	Jun 04, 2014
AB		50MG	A202446	003	Jun 04, 2014
AB		75MG	A202446	004	Jun 04, 2014
AB		100MG	A202446	005	Jun 04, 2014
AB		150MG	A202446	006	Jun 04, 2014
AB	MYLAN	10MG	A086009	002	
AB		25MG	A086009	003	
AB		50MG	A086009	001	

PRESCRIPTION DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>75MG</u>	<u>A086009</u>	<u>004</u>	
<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	!	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A089399</u>	<u>002</u>	Jul 14, 1987
<u>AB</u>		<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>		<u>50MG</u>	<u>A089399</u>	<u>003</u>	Jul 14, 1987
<u>AB</u>		<u>75MG</u>	<u>A089399</u>	<u>004</u>	Jul 14, 1987
<u>AB</u>		<u>100MG</u>	<u>A089399</u>	<u>005</u>	Jul 14, 1987
<u>AB</u>		<u>150MG</u>	<u>A089399</u>	<u>006</u>	Jul 14, 1987
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997
<u>AB</u>	ZYDUS PHARMS	<u>10MG</u>	<u>A210086</u>	<u>001</u>	Oct 06, 2017
<u>AB</u>		<u>25MG</u>	<u>A210086</u>	<u>002</u>	Oct 06, 2017
<u>AB</u>		<u>50MG</u>	<u>A210086</u>	<u>003</u>	Oct 06, 2017
<u>AB</u>		<u>75MG</u>	<u>A210086</u>	<u>004</u>	Oct 06, 2017
<u>AB</u>		<u>100MG</u>	<u>A210086</u>	<u>005</u>	Oct 06, 2017
<u>AB</u>		<u>150MG</u>	<u>A210086</u>	<u>006</u>	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
	!	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
	!	25MG;2MG	A071443	004	Nov 10, 1988
	!	25MG;4MG	A071443	005	Nov 10, 1988
	!	50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

	+!	SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019
--	----	-------------------	----------------	---------	-----	--------------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CHINA RESOURCES	<u>EQ 2.5MG BASE</u>	<u>A090752</u>	<u>003</u>	May 16, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090752</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>	CIPLA	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	HEBEI CHANGSHAN	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	HIKMA	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771</u>	<u>003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A206367</u>	<u>001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206367</u>	<u>002</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206367</u>	<u>003</u>	Dec 10, 2015
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380</u>	<u>001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380</u>	<u>002</u>	Apr 13, 2012
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	OXFORD PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	POLYGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207821</u>	<u>001</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207821</u>	<u>002</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207821</u>	<u>003</u>	Jul 11, 2016
<u>AB</u>	STRIDES PHARMA	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245</u>	<u>001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245</u>	<u>002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245</u>	<u>003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
<u>NORVASC</u>					
<u>AB</u>	+ PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+!	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A205199</u>	<u>001</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A205199</u>	<u>002</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A205199</u>	<u>003</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A205199</u>	<u>004</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A205199</u>	<u>005</u>	Nov 18, 2019

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A205199 006</u>	Nov 18, 2019
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A205199 007</u>	Nov 18, 2019
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A205199 008</u>	Nov 18, 2019
AB	DR REDDYS	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874 001</u>	Mar 07, 2014
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874 002</u>	Mar 07, 2014
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874 003</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874 004</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874 005</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874 006</u>	Mar 07, 2014
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874 007</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874 008</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874 009</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874 010</u>	Mar 07, 2014
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874 011</u>	Mar 07, 2014
AB	MYLAN	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465 001</u>	Nov 29, 2013
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013

CADUET

AB	+	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
AB	+		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
AB	+		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
AB	+		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
AB	+		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
AB	+		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
AB	+		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
AB	+		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
AB	+		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
AB	+		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
AB	+		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431 001</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;10MG</u>	<u>A091431 002</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;20MG</u>	<u>A091431 003</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;40MG</u>	<u>A091431 004</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;20MG</u>	<u>A091431 005</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;40MG</u>	<u>A091431 006</u>	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239 001</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;10MG</u>	<u>A202239 002</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;20MG</u>	<u>A202239 003</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;40MG</u>	<u>A202239 004</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;20MG</u>	<u>A202239 005</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202239 006</u>	Sep 05, 2012
AB	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183 001</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077183 002</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077183 003</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A090149 001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077183 004</u>	Apr 15, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A090149 002</u>	Jul 05, 2011
AB	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466 001</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078466 002</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A078466 003</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A078466 005</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A078466 004</u>	Feb 05, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A078466 006</u>	Jul 05, 2011
AB	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381 001</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078381 002</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A078381 003</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A078381 005</u>	Jul 29, 2010

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078381 004</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381 006</u>	Jul 29, 2010
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890 001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890 002</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890 003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890 004</u>	Oct 14, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364 002</u>	Jul 05, 2011

LOTREL

<u>AB</u>	+	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364 002</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;10MG</u>	<u>N020364 003</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;20MG</u>	<u>N020364 004</u>	Mar 03, 1995
<u>AB</u>	+		<u>EQ 5MG BASE;40MG</u>	<u>N020364 007</u>	Apr 11, 2006
<u>AB</u>	+		<u>EQ 10MG BASE;20MG</u>	<u>N020364 005</u>	Jun 20, 2002
<u>AB</u>	+		<u>EQ 10MG BASE;40MG</u>	<u>N020364 006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

	+	COEPTIS	EQ 2.5MG BASE;200MG	N210045 001	May 31, 2018
	+		EQ 5MG BASE;200MG	N210045 002	May 31, 2018
	+		EQ 10MG BASE;200MG	N210045 003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		PAR PHARM INC	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A206137 001</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A206137 002</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 5MG BASE;25MG;40MG</u>	<u>A206137 003</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A206137 004</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 10MG BASE;25MG;40MG</u>	<u>A206137 005</u>	Oct 26, 2016
<u>AB</u>		TORRENT	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>A203580 001</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A203580 002</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 5MG BASE;25MG;40MG</u>	<u>A203580 003</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A203580 004</u>	Oct 26, 2016
<u>AB</u>			<u>EQ 10MG BASE;25MG;40MG</u>	<u>A203580 005</u>	Oct 26, 2016
<u>TRIBENZOR</u>					
<u>AB</u>	+	DAIICHI SANKYO	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>N200175 001</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>N200175 002</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 5MG BASE;25MG;40MG</u>	<u>N200175 003</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>N200175 004</u>	Jul 23, 2010
<u>AB</u>	+		<u>EQ 10MG BASE;25MG;40MG</u>	<u>N200175 005</u>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG;12.5MG;160MG</u>	<u>A206180 001</u>	Dec 19, 2017
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A206180 002</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A206180 003</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A206180 004</u>	Dec 19, 2017
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A206180 005</u>	Dec 19, 2017
<u>AB</u>		LUPIN LTD	<u>5MG;12.5MG;160MG</u>	<u>A200797 001</u>	Jun 03, 2015
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A200797 002</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A200797 003</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A200797 004</u>	Jun 03, 2015
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A200797 005</u>	Jun 03, 2015
<u>AB</u>		PAR PHARM	<u>5MG;12.5MG;160MG</u>	<u>A201087 001</u>	Jun 01, 2015
<u>AB</u>			<u>5MG;25MG;160MG</u>	<u>A201087 002</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;12.5MG;160MG</u>	<u>A201087 003</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;25MG;160MG</u>	<u>A201087 004</u>	Jun 01, 2015
<u>AB</u>			<u>10MG;25MG;320MG</u>	<u>A201087 005</u>	Jun 01, 2015
<u>EXFORGE HCT</u>					
<u>AB</u>	+	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314 001</u>	Apr 30, 2009
<u>AB</u>	+		<u>5MG;25MG;160MG</u>	<u>N022314 002</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;12.5MG;160MG</u>	<u>N022314 003</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;25MG;160MG</u>	<u>N022314 004</u>	Apr 30, 2009
<u>AB</u>	+		<u>10MG;25MG;320MG</u>	<u>N022314 005</u>	Apr 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207216 001</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207216 002</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207216 003</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207216 004</u>	Oct 28, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207073 001</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207073 002</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207073 003</u>	Jul 17, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207073 004</u>	Jul 17, 2017
<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A209042 001</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A209042 002</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A209042 003</u>	Aug 14, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A209042 004</u>	Aug 14, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206906 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A206906 002</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A206906 003</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A206906 004</u>	May 15, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207807 001</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207807 002</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207807 003</u>	Jul 05, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207807 004</u>	Jul 05, 2017
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE;20MG</u>	<u>A207450 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207450 002</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207450 003</u>	May 15, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207450 004</u>	May 15, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206884 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A206884 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A206884 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A206884 004</u>	Oct 26, 2016
<u>AB</u>	MICRO LABS	<u>EQ 5MG BASE;20MG</u>	<u>A207435 001</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207435 002</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207435 003</u>	Nov 02, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207435 004</u>	Nov 02, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 5MG BASE;20MG</u>	<u>A209010 001</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A209010 002</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A209010 003</u>	Dec 03, 2018
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A209010 004</u>	Dec 03, 2018
<u>AB</u>	TORRENT	<u>EQ 5MG BASE;20MG</u>	<u>A202933 001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202933 002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202933 003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202933 004</u>	Nov 25, 2016
<u>AB</u>	ZYDUS PHARMS	<u>EQ 5MG BASE;20MG</u>	<u>A207771 001</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207771 002</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207771 003</u>	Sep 22, 2017
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207771 004</u>	Sep 22, 2017
<u>AZOR</u>				
<u>AB</u>	+ DAIICHI SANKYO	<u>EQ 5MG BASE;20MG</u>	<u>N022100 001</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 5MG BASE;40MG</u>	<u>N022100 002</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;20MG</u>	<u>N022100 003</u>	Sep 26, 2007
<u>AB</u>	+!	<u>EQ 10MG BASE;40MG</u>	<u>N022100 004</u>	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003 001	Jan 21, 2015
+		EQ 5MG BASE;7MG	N205003 002	Jan 21, 2015
+	!	EQ 10MG BASE;14MG	N205003 003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A205234 001</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A205234 003</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A205234 002</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A205234 004</u>	Nov 17, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A201586 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A201586 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A201586 004</u>	Jan 08, 2014
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;40MG</u>	<u>A202516 001</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202516 003</u>	Aug 26, 2014

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202516 002</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202516 004</u>	Aug 26, 2014
<u>AB</u>	TORRENT	<u>EQ 5MG BASE;40MG</u>	<u>A202517 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202517 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202517 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202517 004</u>	Jan 08, 2014
<u>TWYNSTA</u>				
<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401 001</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 5MG BASE;80MG</u>	<u>N022401 003</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 10MG BASE;40MG</u>	<u>N022401 002</u> Oct 16, 2009
<u>AB</u>	+		<u>EQ 10MG BASE;80MG</u>	<u>N022401 004</u> Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202713 001</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202713 003</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202713 002</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202713 004</u>	Apr 03, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;160MG</u>	<u>A206512 001</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A206512 002</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A206512 003</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A206512 004</u>	Apr 22, 2016
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE;160MG</u>	<u>A205137 001</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A205137 003</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A205137 002</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A205137 004</u>	Sep 16, 2016
<u>AB</u>	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090245 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090245 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090245 004</u>	Mar 30, 2015
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;160MG</u>	<u>A090483 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090483 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090483 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090483 004</u>	Mar 30, 2015
<u>AB</u>	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829 001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202829 003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202829 002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202829 004</u>	Mar 30, 2015
<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011 001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090011 003</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090011 002</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090011 004</u>	Mar 28, 2013
<u>EXFORGE</u>				
<u>AB</u>	+	NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990 002</u> Jun 20, 2007
<u>AB</u>	+		<u>EQ 5MG BASE;320MG</u>	<u>N021990 004</u> Jun 20, 2007
<u>AB</u>	+		<u>EQ 10MG BASE;160MG</u>	<u>N021990 003</u> Jun 20, 2007
<u>AB</u>	+		<u>EQ 10MG BASE;320MG</u>	<u>N021990 005</u> Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779 001</u>	Oct 19, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)</u>	<u>A204352 001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<u>AP</u>	DECATUR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465 001</u>	Oct 23, 2014
<u>AP</u>	+	FEINSTEIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119 001</u> Aug 23, 2007
<u>AP</u>	GEN HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A207025 001</u>	Feb 03, 2016
<u>AP</u>	IONETIX	<u>22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)</u>	<u>A210524 001</u>	Dec 21, 2018
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514 001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938 001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321 001</u>	Feb 25, 2013
<u>AP</u>	MIDWEST MEDCL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204457 001</u>	Nov 18, 2015
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535 001</u>	Nov 20, 2014
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510 001</u>	Nov 02, 2015
<u>AP</u>	SOFIE	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667 001</u>	Apr 22, 2015
<u>AP</u>	SPECTRON MRC LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455 001</u>	Apr 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812 001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496 001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX SW MEDCTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A209507 001</u>	Nov 01, 2019
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506 001</u>	Feb 07, 2014
	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687 001	Dec 17, 2015
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515 001	Feb 04, 2015
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547 001	Aug 14, 2015
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366 001	Sep 19, 2014
	SOFIE	3.75-260mCi/ML	A203543 001	Dec 14, 2012
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356 001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

! HOSPIRA

5MEQ/ML

A088366 001 Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	! PERRIGO ISRAEL	<u>EQ 12% BASE</u>	<u>A075774 001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883 001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829 001</u>	Feb 07, 2006

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	! PERRIGO ISRAEL	<u>EQ 12% BASE</u>	<u>A075570 001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216 001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575 001</u>	Jun 11, 2002

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS

25MG

A072691 002 Aug 28, 1992

50MG

A072691 003 Aug 28, 1992

100MG

A072691 004 Aug 28, 1992

!

150MG

A072691 001 Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTIBIOTICS	<u>250MG</u>	<u>A062058 001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058 002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271 001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271 002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884 001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881 001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291 001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291 002</u>	Feb 05, 2007
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076 001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076 002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926 001</u>	
<u>AB</u>	!	<u>500MG</u>	<u>A061926 003</u>	

AMOXIL

<u>AB</u>	NEOPHARMA	<u>250MG</u>	<u>A062216 001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216 004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334 001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334 002</u>	Dec 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030 001</u>	Sep 15, 2014
<u>AB</u>		<u>250MG/5ML</u>	<u>A204030 002</u>	Sep 15, 2014
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927 001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927 002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322 002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325 002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322 001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325 001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387 001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378 001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387 002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378 002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>200MG/5ML</u>	<u>A065119 001</u>	Dec 04, 2002

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

AB	!		<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
AB	!		<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
AB		WOCKHARDT BIO AG	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

AB		TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	--	------	----------------	----------------	------------	--------------

AMOXIL

AB		NEOPHARMA	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
AB			<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
AB			<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	

LAROTID

AB		NEOPHARMA	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
AB			<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET;ORAL

AMOXICILLIN

AB		AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
AB			<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
AB		HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
AB		SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
AB			<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
AB		TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
AB	!		<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995
	!		250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	!	RISING	<u>500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG</u>	<u>A206006</u>	<u>001</u>	Oct 07, 2016
AB		SANDOZ INC	<u>500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011
--	----------	-------------------	--	---------	-----	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>A209371</u>	<u>001</u>	Apr 19, 2019
AB			<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
AB			<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A209371</u>	<u>002</u>	Apr 19, 2019
AB			<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
AB			<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011
AB		HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
AB			<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
AB			<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
AB		SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
AB			<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
AB		SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
AB			<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
AB			<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
AB		TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
AB	!		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
AB	!		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
AB		WOCKHARDT BIO AG	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
AB			<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

AB	+	NEOPHARMA	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984
-----------	----------	-----------	--------------------------------------	----------------	------------	--------------

AUGMENTIN '250'

AB	+	NEOPHARMA	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984
-----------	----------	-----------	-------------------------------------	----------------	------------	--------------

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	<u>250MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012
AB			<u>500MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012
AB			<u>875MG;EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	HIKMA PHARMS	875MG;EQ 125MG BASE	A203824 001	Aug 23, 2016
AB	MICRO LABS LTD INDIA	250MG;EQ 125MG BASE	A205707 001	Dec 30, 2016
AB		500MG;EQ 125MG BASE	A205707 002	Dec 30, 2016
AB		875MG;EQ 125MG BASE	A204755 003	Dec 30, 2016
AB	! SANDOZ	250MG;EQ 125MG BASE	A065189 001	Aug 23, 2005
AB		500MG;EQ 125MG BASE	A065064 001	Mar 15, 2002
AB	!	875MG;EQ 125MG BASE	A065063 001	Mar 14, 2002
AB	! SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002
AB	TEVA	500MG;EQ 125MG BASE	A065101 001	Oct 30, 2002
AB	TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096 001	Oct 29, 2002

AUGMENTIN '875'

AB	+ NEOPHARMA	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996
-----------	-------------	----------------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE

A065205 001 Feb 09, 2005

!

400MG;EQ 57MG BASE

A065205 002 Feb 09, 2005

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ	1GM;EQ 62.5MG BASE	A090227 001	Apr 21, 2010
-----------	--------	---------------------------	--------------------	--------------

AUGMENTIN XR

AB	+! NEOPHARMA	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002
-----------	--------------	---------------------------	--------------------	--------------

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE; ORAL

TALICIA

+!

REDHILL

250MG;EQ 10MG BASE;12.5MG

N213004 001 Nov 01, 2019

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE; ORAL

ADZENYS ER

+!

NEOS THERAPS INC

EQ 1.25MG BASE/ML

N204325 001 Sep 15, 2017

DYANAVEL XR

+!

TRIS PHARMA INC

EQ 2.5MG BASE/ML

N208147 001 Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

+

NEOS THERAPS

EQ 3.1MG BASE

N204326 001 Jan 27, 2016

+

EQ 6.3MG BASE

N204326 002 Jan 27, 2016

+

EQ 9.4MG BASE

N204326 003 Jan 27, 2016

+

EQ 12.5MG BASE

N204326 004 Jan 27, 2016

+

EQ 15.7MG BASE

N204326 005 Jan 27, 2016

+!

EQ 18.8MG BASE

N204326 006 Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	+ SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001
-----------	---------	--------------------------------	--------------------	--------------

ADDERALL XR 15

AB	+ SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002
-----------	---------	------------------------------------	--------------------	--------------

ADDERALL XR 20

AB	+ SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001
-----------	---------	------------------------	--------------------	--------------

ADDERALL XR 25

AB	+ SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002
-----------	---------	------------------------------------	--------------------	--------------

ADDERALL XR 30

AB	+! SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001
-----------	----------	--------------------------------	--------------------	--------------

ADDERALL XR 5

AB	+ SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002
-----------	---------	------------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012
-----------	--	------------------------	--------------------	--------------

AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

AB	AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401 001	Jan 22, 2019
-----------	---------------------	------------------------------------	--------------------	--------------

AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401 002	Jan 22, 2019
-----------	--	--------------------------------	--------------------	--------------

AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401 003	Jan 22, 2019
-----------	--	------------------------------------	--------------------	--------------

AB		5MG;5MG;5MG;5MG	A205401 004	Jan 22, 2019
-----------	--	------------------------	--------------------	--------------

AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401 005	Jan 22, 2019
-----------	--	------------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019
AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019
AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019
AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019
AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019
AB		5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013
AB		5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013
	MYDAYIS				
+	SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+	!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB	ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
AB		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003
AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003
AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**AB** 7.5MG;7.5MG;7.5MG;7.5MG **A211352 007** Dec 07, 2018AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	AMNEAL PHARMS	<u>5MG</u>	A211139 001	Sep 26, 2018
AA		<u>10MG</u>	A211139 002	Sep 26, 2018
AA	AUROLIFE PHARMA LLC	<u>5MG</u>	A211639 001	Apr 17, 2019
AA		<u>10MG</u>	A211639 002	Apr 17, 2019
AA	BIONPHARMA INC	<u>5MG</u>	A212919 001	Nov 22, 2019
AA		<u>10MG</u>	A212919 002	Nov 22, 2019
AA	GRANULES PHARMS	<u>5MG</u>	A212619 001	Aug 05, 2019
AA		<u>10MG</u>	A212619 002	Aug 05, 2019

EVEKEO

AA	ARBOR PHARMS LLC	<u>5MG</u>	A200166 001	Aug 09, 2012
AA	!	<u>10MG</u>	A200166 002	Aug 09, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905 001	Jan 30, 2019
+		10MG	N209905 002	Jan 30, 2019
+		15MG	N209905 003	Jan 30, 2019
+		20MG	N209905 004	Jan 30, 2019

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

! X GEN PHARMS 50MG/VIAL A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+! LEADIANT BIOSCI INC 5MG/ML N050724 001 Nov 20, 1995

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+! ASTELLAS 50MG/VIAL N050740 001 Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	<u>EQ 10GM BASE/VIAL</u>	A090889 001	Apr 03, 2013
AP	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	A090354 001	Dec 28, 2009
AP		<u>EQ 500MG BASE/VIAL</u>	A090354 002	Dec 28, 2009
AP		<u>EQ 1GM BASE/VIAL</u>	A090354 003	Dec 28, 2009
AP		<u>EQ 2GM BASE/VIAL</u>	A090354 004	Dec 28, 2009
AP	AUROBINDO PHARMA	<u>EQ 250MG BASE/VIAL</u>	A065499 002	Aug 17, 2010
AP		<u>EQ 500MG BASE/VIAL</u>	A065499 003	Aug 17, 2010
AP		<u>EQ 1GM BASE/VIAL</u>	A065499 004	Aug 17, 2010
AP		<u>EQ 2GM BASE/VIAL</u>	A065499 005	Aug 17, 2010
AP		<u>EQ 10GM BASE/VIAL</u>	A065493 001	Aug 17, 2010
AP	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	A062772 006	Apr 15, 1993
AP		<u>EQ 500MG BASE/VIAL</u>	A062772 007	Apr 15, 1993
AP		<u>EQ 1GM BASE/VIAL</u>	A062772 001	Apr 15, 1993
AP		<u>EQ 2GM BASE/VIAL</u>	A062772 003	Apr 15, 1993
AP		<u>EQ 10GM BASE/VIAL</u>	A063142 001	Apr 15, 1993
AP	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	A201404 001	Dec 20, 2013
AP		<u>EQ 250MG BASE/VIAL</u>	A062719 001	May 12, 1987
AP		<u>EQ 500MG BASE/VIAL</u>	A062719 003	May 12, 1987
AP		<u>EQ 1GM BASE/VIAL</u>	A062719 002	May 12, 1987
AP		<u>EQ 2GM BASE/VIAL</u>	A062797 002	Jul 12, 1993
AP	MYLAN LABS LTD	<u>EQ 250MG BASE/VIAL</u>	A201025 001	Apr 09, 2014
AP		<u>EQ 500MG BASE/VIAL</u>	A201025 002	Apr 09, 2014
AP		<u>EQ 1GM BASE/VIAL</u>	A201025 003	Apr 09, 2014
AP		<u>EQ 2GM BASE/VIAL</u>	A201025 004	Apr 09, 2014
AP		<u>EQ 10GM BASE/VIAL</u>	A202198 001	Apr 07, 2014
AP	SAGENT PHARMS INC	<u>EQ 125MG BASE/VIAL</u>	A090583 001	Nov 27, 2015
AP		<u>EQ 250MG BASE/VIAL</u>	A090583 002	Nov 27, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	A090583 003	Nov 27, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	A090583 004	Nov 27, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	A090583 005	Nov 27, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	A090581 001	Oct 20, 2015
AP	!	<u>EQ 125MG BASE/VIAL</u>	A061395 001	

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	!		<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

<u>AP</u>	!	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>		ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 50MG BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		ANTIBIOTICE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406</u>	<u>001</u>	Dec 07, 2015
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406</u>	<u>002</u>	Dec 07, 2015
<u>AP</u>		ASTRAL	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579</u>	<u>001</u>	Jan 08, 2016
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579</u>	<u>002</u>	Jan 08, 2016
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578</u>	<u>001</u>	Jan 11, 2016
<u>AP</u>		AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>			<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
<u>AP</u>		ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>		MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024</u>	<u>002</u>	Apr 07, 2014
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>		SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>			<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
<u>AP</u>			<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002

UNASYN

<u>AP</u>	!	PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901</u>	<u>002</u>	Feb 27, 1992
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>		DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	!		<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

DAVA PHARMS INC

!

			<u>EQ 125MG BASE/5ML</u>	<u>A062982</u>	<u>001</u>	Feb 10, 1989
			<u>EQ 250MG BASE/5ML</u>	<u>A062982</u>	<u>002</u>	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

<u>AB</u>		SHIRE LLC	<u>EQ 0.5MG BASE</u>	<u>N020333</u>	<u>001</u>	Mar 14, 1997
-----------	--	-----------	----------------------	----------------	------------	--------------

<u>AB</u>		BARR	<u>EQ 0.5MG BASE</u>	<u>A076530</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A076530</u>	<u>002</u>	Apr 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

AB	IMPAX LABS	EQ 0.5MG BASE	A076910 001	Apr 18, 2005
AB		EQ 1MG BASE	A076910 002	Apr 18, 2005
AB	IVAX SUB TEVA PHARMS	EQ 0.5MG BASE	A076468 001	Apr 18, 2005
AB	!	EQ 1MG BASE	A076468 002	Apr 18, 2005
AB	TORRENT	EQ 0.5MG BASE	A209151 001	Jun 30, 2017
AB		EQ 1MG BASE	A209151 002	Jun 30, 2017

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010
AB	APOTEX INC	1MG	A200654 001	May 11, 2012
AB	BEIJING YILING	1MG	A206037 001	Nov 09, 2018
AB	CIPLA	1MG	A091164 001	Jun 28, 2010
AB	FRESENIUS KABI USA	1MG	A090088 001	Jun 28, 2010
AB	HIKMA	1MG	A078485 001	Jun 28, 2010
AB	KENTON	1MG	A078944 001	Jun 28, 2010
AB	MYLAN	1MG	A091051 001	Jun 28, 2010
AB	NATCO PHARMA LTD	1MG	A079220 001	Jun 28, 2010
AB	NEOPHARMA	1MG	A090732 001	Jun 28, 2010
AB	TEVA PHARMS	1MG	A078058 001	Jun 28, 2010
AB	ZYDUS PHARMS USA INC	1MG	A078921 001	Jun 28, 2010

ARIMIDEX

AB	+!	ANI PHARMS INC	1MG	N020541 001	Dec 27, 1995
-----------	----	----------------	------------	--------------------	--------------

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

GIAPREZA

	+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360 001	Dec 21, 2017
--	----	-----------------	--	--------------------	--------------

ANIDULAFUNGIN

POWDER; INTRAVENOUS

ERAXIS

	+!	VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
	+!		100MG/VIAL	N021632 002	Nov 14, 2006

APALUTAMIDE

TABLET; ORAL

ERLEADA

	+!	JANSSEN BIOTECH	60MG	N210951 001	Feb 14, 2018
--	----	-----------------	-------------	--------------------	--------------

APIXABAN

TABLET; ORAL

APIXABAN

AB		MICRO LABS	2.5MG	A210013 001	Dec 23, 2019
AB			5MG	A210013 002	Dec 23, 2019
AB		MYLAN	2.5MG	A210128 001	Dec 23, 2019
AB			5MG	A210128 002	Dec 23, 2019

ELIQUIS

AB	+	BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
AB	+!		5MG	N202155 002	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	+!	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004
--	----	--------------	---------------------------	--------------------	--------------

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT		AKORN INC	EQ 0.5% BASE	A077764 001	Mar 12, 2009
AT	+!	NOVARTIS	EQ 0.5% BASE	N020258 001	Jul 30, 1993
	+!		EQ 1% BASE	N019779 001	Dec 31, 1987

PRESCRIPTION DRUG PRODUCT LIST

APREMILAST

TABLET; ORAL

OTEZLA

+	AMGEN INC	10MG	N205437 001	Mar 21, 2014
+		20MG	N205437 002	Mar 21, 2014
+	!	30MG	N205437 003	Mar 21, 2014

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	GLENMARK PHARMS SA	40MG	A207777 001	Oct 12, 2017
AB		80MG	A207777 002	Oct 12, 2017
AB		125MG	A207777 003	Oct 12, 2017
AB	SANDOZ	40MG	A090999 001	Sep 24, 2012
AB		80MG	A090999 002	Sep 24, 2012
AB		125MG	A090999 003	Sep 24, 2012
EMEND				
AB	+	MERCK	80MG	N021549 001 Mar 26, 2003
AB	+	!	125MG	N021549 002 Mar 26, 2003

EMULSION; INTRAVENOUS

CINVANTI

+	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296 001	Nov 09, 2017
---	-------------------	-----------------------	-------------	--------------

FOR SUSPENSION; ORAL

EMEND

+	MSD MERCK CO	125MG/KIT	N207865 001	Dec 17, 2015
---	--------------	-----------	-------------	--------------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+	SUNOVION	EQ 0.015MG BASE/2ML	N021912 001	Oct 06, 2006
---	----------	---------------------	-------------	--------------

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698 001	Jan 26, 2018
AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811 001	Mar 23, 2015
AP	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012
AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120 001	Sep 21, 2016
AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626 001	Jun 30, 2014
AP	+	NOVARTIS	250MG/2.5ML (100MG/ML)	N020883 001 Jun 30, 2000
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665 001	Jun 30, 2014
+	!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049 002 Sep 30, 2016

INJECTABLE; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570 001	May 22, 2017
AP	+	SANDOZ	125MG/125ML (1MG/ML)	N022485 001 May 09, 2011
ARGATROBAN IN 0.9% SODIUM CHLORIDE				
	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769 001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE				
+	!	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434 001 Jun 29, 2011
SOLUTION; INTRAVENOUS				
ARGATROBAN IN SODIUM CHLORIDE				
	AUROBINDO PHARMA LTD	50MG/50ML (1MG/ML)	N209552 001	Nov 27, 2018

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+	!	PHARMACIA AND UPJOHN	10GM/100ML	N016931 001
---	---	----------------------	------------	-------------

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013
+		300MG	N202971 003	Sep 29, 2014
+	!	400MG/VIAL	N202971 002	Feb 28, 2013
+		400MG	N202971 004	Sep 29, 2014

SOLUTION; ORAL

ARIPIPRAZOLE

AA	!	AMNEAL PHARMS	1MG/ML	A203906 001 Aug 14, 2015
AA		APOTEX INC	1MG/ML	A204094 001 Sep 30, 2015
AA		AUROBINDO PHARMA LTD	1MG/ML	A210479 001 Jan 29, 2019
AA		LANNETT CO INC	1MG/ML	A204171 001 Aug 14, 2015

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

<u>AA</u>	VISTAPHARM	<u>1MG/ML</u>	<u>A212870 001</u>	Dec 26, 2019
	TABLET; ORAL			
	<u>ABILIFY</u>			
<u>AB</u>	+ OTSUKA	<u>2MG</u>	<u>N021436 006</u>	Nov 15, 2002
<u>AB</u>	+!	<u>5MG</u>	<u>N021436 005</u>	Nov 15, 2002
<u>AB</u>	+!	<u>10MG</u>	<u>N021436 001</u>	Nov 15, 2002
<u>AB</u>	+	<u>15MG</u>	<u>N021436 002</u>	Nov 15, 2002
<u>AB</u>	+	<u>20MG</u>	<u>N021436 003</u>	Nov 15, 2002
<u>AB</u>	+	<u>30MG</u>	<u>N021436 004</u>	Nov 15, 2002
	<u>ARIPIPIRAZOLE</u>			
<u>AB</u>	ACCORD HLTHCARE	<u>2MG</u>	<u>A206251 001</u>	Dec 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A206251 002</u>	Dec 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A206251 003</u>	Dec 07, 2016
<u>AB</u>		<u>15MG</u>	<u>A206251 004</u>	Dec 07, 2016
<u>AB</u>		<u>20MG</u>	<u>A206251 005</u>	Dec 07, 2016
<u>AB</u>		<u>30MG</u>	<u>A206251 006</u>	Dec 07, 2016
<u>AB</u>	AJANTA PHARMA LTD	<u>2MG</u>	<u>A206174 001</u>	Sep 12, 2016
<u>AB</u>		<u>5MG</u>	<u>A206174 002</u>	Sep 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A206174 003</u>	Sep 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A206174 004</u>	Sep 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A206174 005</u>	Sep 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A206174 006</u>	Sep 12, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>2MG</u>	<u>A202101 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A202101 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A202101 003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A202101 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A202101 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A202101 006</u>	Apr 28, 2015
<u>AB</u>	ALKEM LABS LTD	<u>2MG</u>	<u>A207105 001</u>	Feb 21, 2019
<u>AB</u>		<u>5MG</u>	<u>A207105 002</u>	Feb 21, 2019
<u>AB</u>		<u>10MG</u>	<u>A207105 003</u>	Feb 21, 2019
<u>AB</u>		<u>15MG</u>	<u>A207105 004</u>	Feb 21, 2019
<u>AB</u>		<u>20MG</u>	<u>A207105 005</u>	Feb 21, 2019
<u>AB</u>		<u>30MG</u>	<u>A207105 006</u>	Feb 21, 2019
<u>AB</u>	AMNEAL PHARMS	<u>2MG</u>	<u>A204838 001</u>	Jun 17, 2016
<u>AB</u>		<u>5MG</u>	<u>A204838 002</u>	Jun 17, 2016
<u>AB</u>		<u>10MG</u>	<u>A204838 003</u>	Jun 17, 2016
<u>AB</u>		<u>15MG</u>	<u>A204838 004</u>	Jun 17, 2016
<u>AB</u>		<u>20MG</u>	<u>A204838 005</u>	Jun 17, 2016
<u>AB</u>		<u>30MG</u>	<u>A204838 006</u>	Jun 17, 2016
<u>AB</u>	APOTEX INC	<u>2MG</u>	<u>A078583 001</u>	Jul 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A078583 002</u>	Jul 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A078583 003</u>	Jul 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A078583 004</u>	Jul 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A078583 005</u>	Jul 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A078583 006</u>	Jul 24, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2MG</u>	<u>A203908 001</u>	Oct 08, 2015
<u>AB</u>		<u>5MG</u>	<u>A203908 002</u>	Oct 08, 2015
<u>AB</u>		<u>10MG</u>	<u>A203908 003</u>	Oct 08, 2015
<u>AB</u>		<u>15MG</u>	<u>A203908 004</u>	Oct 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203908 005</u>	Oct 08, 2015
<u>AB</u>		<u>30MG</u>	<u>A203908 006</u>	Oct 08, 2015
<u>AB</u>	BOSCOGEN	<u>2MG</u>	<u>A091279 001</u>	Jan 09, 2017
<u>AB</u>		<u>5MG</u>	<u>A091279 002</u>	Jan 09, 2017
<u>AB</u>		<u>10MG</u>	<u>A091279 003</u>	Jan 09, 2017
<u>AB</u>		<u>15MG</u>	<u>A091279 004</u>	Jan 09, 2017
<u>AB</u>		<u>20MG</u>	<u>A091279 005</u>	Jan 09, 2017
<u>AB</u>		<u>30MG</u>	<u>A091279 006</u>	Jan 09, 2017
<u>AB</u>	HETERO LABS LTD V	<u>2MG</u>	<u>A205064 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A205064 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A205064 003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A205064 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A205064 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A205064 006</u>	Apr 28, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2MG</u>	<u>A204111 001</u>	Oct 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A204111 002</u>	Oct 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A204111 003</u>	Oct 07, 2016
<u>AB</u>		<u>15MG</u>	<u>A204111 004</u>	Oct 07, 2016
<u>AB</u>		<u>20MG</u>	<u>A204111 005</u>	Oct 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

<u>AB</u>		<u>30MG</u>	<u>A204111</u>	<u>006</u>	Oct 07, 2016
<u>AB</u>	ORCHID HLTHCARE	<u>2MG</u>	<u>A202683</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>5MG</u>	<u>A202683</u>	<u>002</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202683</u>	<u>003</u>	May 23, 2017
<u>AB</u>		<u>15MG</u>	<u>A202683</u>	<u>004</u>	May 23, 2017
<u>AB</u>		<u>20MG</u>	<u>A202683</u>	<u>005</u>	May 23, 2017
<u>AB</u>		<u>30MG</u>	<u>A202683</u>	<u>006</u>	May 23, 2017
<u>AB</u>	PRINSTON INC	<u>2MG</u>	<u>A205363</u>	<u>001</u>	Dec 04, 2017
<u>AB</u>		<u>5MG</u>	<u>A205363</u>	<u>002</u>	Dec 04, 2017
<u>AB</u>		<u>10MG</u>	<u>A205363</u>	<u>003</u>	Dec 04, 2017
<u>AB</u>		<u>15MG</u>	<u>A205363</u>	<u>004</u>	Dec 04, 2017
<u>AB</u>		<u>20MG</u>	<u>A205363</u>	<u>005</u>	Dec 04, 2017
<u>AB</u>		<u>30MG</u>	<u>A205363</u>	<u>006</u>	Dec 04, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>2MG</u>	<u>A206383</u>	<u>001</u>	Sep 29, 2016
<u>AB</u>		<u>5MG</u>	<u>A206383</u>	<u>002</u>	Sep 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A206383</u>	<u>003</u>	Sep 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A206383</u>	<u>004</u>	Sep 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A206383</u>	<u>005</u>	Sep 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A206383</u>	<u>006</u>	Sep 29, 2016
<u>AB</u>	TORRENT	<u>2MG</u>	<u>A201519</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519</u>	<u>006</u>	Apr 28, 2015

ABILIFY MYCITE KIT

+	OTSUKA PHARM CO LTD	2MG	N207202	001	Nov 13, 2017
+	!	5MG	N207202	002	Nov 13, 2017
+		10MG	N207202	003	Nov 13, 2017
+		15MG	N207202	004	Nov 13, 2017
+		20MG	N207202	005	Nov 13, 2017
+		30MG	N207202	006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

ARIPIPIRAZOLE

<u>AB</u>	!	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A202102</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>			<u>15MG</u>	<u>A202102</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		ORCHID HLTHCARE	<u>10MG</u>	<u>A202547</u>	<u>001</u>	Dec 11, 2017
<u>AB</u>			<u>15MG</u>	<u>A202547</u>	<u>002</u>	Dec 11, 2017
<u>AB</u>		SCIEGEN PHARMS INC	<u>10MG</u>	<u>A207240</u>	<u>001</u>	Apr 18, 2018
<u>AB</u>			<u>15MG</u>	<u>A207240</u>	<u>002</u>	Apr 18, 2018
<u>AB</u>		ZYDUS PHARMS	<u>10MG</u>	<u>A090165</u>	<u>001</u>	Aug 28, 2018
<u>AB</u>			<u>15MG</u>	<u>A090165</u>	<u>002</u>	Aug 28, 2018
			20MG	A090165	003	Aug 28, 2018
			30MG	A090165	004	Aug 28, 2018

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+	!	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018
---	--------------	-------------	---------	-----	--------------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206069</u>	<u>001</u>	Mar 06, 2018
<u>AB</u>		<u>150MG</u>	<u>A206069</u>	<u>002</u>	Mar 06, 2018
<u>AB</u>		<u>200MG</u>	<u>A206069</u>	<u>004</u>	Dec 07, 2018
<u>AB</u>		<u>250MG</u>	<u>A206069</u>	<u>003</u>	Mar 06, 2018
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A200751</u>	<u>001</u>	Nov 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A200751</u>	<u>003</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A200751</u>	<u>004</u>	Nov 28, 2016
<u>AB</u>		<u>250MG</u>	<u>A200751</u>	<u>005</u>	Nov 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A200043</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>100MG</u>	<u>A200043</u>	<u>004</u>	May 09, 2019
<u>AB</u>		<u>150MG</u>	<u>A200043</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A200043</u>	<u>005</u>	May 09, 2019

PRESCRIPTION DRUG PRODUCT LIST

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>		<u>250MG</u>	<u>A200043 003</u>	Jun 01, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>50MG</u>	<u>A202768 001</u>	Nov 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A202768 004</u>	Sep 28, 2017
<u>AB</u>		<u>150MG</u>	<u>A202768 002</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A202768 005</u>	Sep 28, 2017
<u>AB</u>		<u>250MG</u>	<u>A202768 003</u>	Nov 28, 2016

NUVIGIL

<u>AB</u>	+ CEPHALON	<u>50MG</u>	<u>N021875 001</u>	Jun 15, 2007
<u>AB</u>	+	<u>150MG</u>	<u>N021875 003</u>	Jun 15, 2007
<u>AB</u>	+	<u>200MG</u>	<u>N021875 005</u>	Mar 26, 2009
<u>AB</u>	+!	<u>250MG</u>	<u>N021875 004</u>	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

<u>AP</u>	AMRING PHARMS	<u>1MG/ML</u>	<u>A210802 001</u>	Nov 13, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A208231 001</u>	Aug 31, 2018
<u>AP</u>	INGENUS PHARMS LLC	<u>1MG/ML</u>	<u>A209315 001</u>	Nov 15, 2018
<u>AP</u>	NEXUS PHARMS	<u>1MG/ML</u>	<u>A209780 001</u>	Nov 15, 2018
<u>AP</u>	STI PHARMA LLC	<u>1MG/ML</u>	<u>A209873 001</u>	May 06, 2019
<u>AP</u>	ZYDUS PHARMS	<u>1MG/ML</u>	<u>A206228 001</u>	Nov 13, 2018
<u>AP</u>		<u>2MG/ML</u>	<u>A206228 002</u>	Aug 30, 2019

TRISENOX

<u>AP</u>	+! CEPHALON	<u>2MG/ML</u>	<u>N021248 002</u>	Oct 13, 2017
-----------	-------------	---------------	--------------------	--------------

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

	+! NOVARTIS	20MG; 120MG	N022268 001	Apr 07, 2009
--	-------------	-------------	-------------	--------------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

<u>AP</u>	+! DEPROCO	<u>4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)</u>	<u>N022010 001</u>	Mar 30, 2006
<u>AP</u>	+!	<u>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</u>	<u>N020971 001</u>	Apr 03, 2000

ULTACAN

<u>AP</u>	HANSAMED INC	<u>4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)</u>	<u>A201751 001</u>	Jul 11, 2017
-----------	--------------	---	--------------------	--------------

ULTACAN FORTE

<u>AP</u>	HANSAMED INC	<u>4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)</u>	<u>A201750 001</u>	Jul 11, 2017
-----------	--------------	---	--------------------	--------------

ORABLOC

	+ PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466 001	Feb 26, 2010
--	-----------	---	-------------	--------------

	+!	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466 002	Feb 26, 2010
--	----	--	-------------	--------------

ASCORBIC ACID

SOLUTION; INTRAVENOUS

ASCOR

	+! MCGUFF	25,000MG/50ML (500MG/ML)	N209112 001	Oct 02, 2017
--	-----------	--------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC

	+! SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265 001	Feb 21, 2001
--	----------------------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

	+! SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265 002	Jan 29, 2004
--	----------------------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; INTRAVENOUS

M.V.I. PEDIATRIC

+	!	HOSPIRA	80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL	N018920 001	Sep 21, 2000
---	---	---------	---	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

+	!	HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL	N021625 001	Jan 30, 2004
---	---	---------	---	-------------	--------------

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	!	HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML	N021643 001	Feb 18, 2004
---	---	---------	--	-------------	--------------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

AA	+	!	SALIX PHARMS	4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM	N021881 001	Aug 02, 2006
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC						
AA			NOVEL LABS INC	4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM	A090145 001	Jan 25, 2012
			PLENVU			
	+	!	SALIX	7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9GM	N209381 001	May 04, 2018

ASENAPINE

SYSTEM; TRANSDERMAL

SECUADO

+			HISAMITSU	3.8MG/24HR	N212268 001	Oct 11, 2019
+				5.7MG/24HR	N212268 002	Oct 11, 2019
+	!			7.6MG/24HR	N212268 003	Oct 11, 2019

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+			ALLERGAN	EQ 2.5 BASE	N022117 003	Mar 12, 2015
+				EQ 5MG BASE	N022117 001	Aug 13, 2009
+	!			EQ 10MG BASE	N022117 002	Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+	!	ESPERO	162.5MG	N200671 001	Sep 04, 2015
---	---	--------	---------	-------------	--------------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	!	ALLERGAN	325MG; 50MG; 40MG	N017534 005	Apr 16, 1986
LANORINAL						
AA			LANNETT	325MG; 50MG; 40MG	A086996 002	Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	!		HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162 002	Feb 16, 1984
AA			PII	325MG; 50MG; 40MG	A204195 001	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB			MAYNE PHARMA INC	325MG; 50MG; 40MG; 30MG	A203335 001	Oct 30, 2015
AB			NEXGEN PHARMA INC	325MG; 50MG; 40MG; 30MG	A075231 001	Nov 30, 2001
AB			STEVENS J	325MG; 50MG; 40MG; 30MG	A074951 001	Aug 31, 1998
FIORINAL W/CODEINE						
AB	+	!	ALLERGAN	325MG; 50MG; 40MG; 30MG	N019429 003	Oct 26, 1990

PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	!	HERITAGE PHARMS INC	325MG;200MG	A089594 001	Mar 31, 1989
AB		NOVAST LABS	325MG;200MG	A040832 001	Jan 07, 2010
AB		SANDOZ	325MG;200MG	A040116 001	Apr 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	325MG;200MG;16MG	A040860 001	Jan 07, 2010
AB	!	SANDOZ	325MG;200MG;16MG	A040118 001	Apr 16, 1996

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOL

AB	+	BOEHRINGER INGELHEIM	25MG;200MG	N020884 001	Nov 22, 1999
-----------	----------	-------------------------	-------------------	--------------------	--------------

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	25MG;200MG	A206392 001	Mar 08, 2016
AB		BARR	25MG;200MG	A078804 001	Aug 14, 2009
AB		DR REDDYS	25MG;200MG	A209048 001	Oct 10, 2018
AB		GLENMARK PHARMS SA	25MG;200MG	A210318 001	May 24, 2019
AB		LANNETT CO INC	25MG;200MG	A204552 001	Mar 20, 2019
AB		PAR PHARM INC	25MG;200MG	A207944 001	Jan 18, 2017
AB		SANDOZ INC	25MG;200MG	A206739 001	Jan 18, 2017
AB		SUN PHARM	25MG;200MG	A208572 001	Aug 21, 2018
AB		ZYDUS PHARMS	25MG;200MG	A206753 001	Aug 29, 2017

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

!		STEVENS J	325MG;400MG	A081145 001	Jan 31, 1995
----------	--	-----------	--------------------	--------------------	--------------

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

YOSPRALA

+		GENUS LIFESCIENCES	81MG;40MG	N205103 001	Sep 14, 2016
+	!		325MG;40MG	N205103 002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084 001	Mar 22, 2011
AA		MAYNE PHARMA INC	325MG;4.8355MG	A091670 001	Mar 16, 2011

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005
-----------	----------	-------------	-----------------------	--------------------	--------------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB		AUROBINDO PHARMA LTD	EQ 100MG BASE	A204806 001	Jun 25, 2018
AB			EQ 150MG BASE	A204806 002	Jun 25, 2018
AB			EQ 200MG BASE	A204806 003	Jun 25, 2018
AB			EQ 300MG BASE	A204806 004	Jun 25, 2018
AB		CIPLA	EQ 100MG BASE	A200626 001	Aug 09, 2018
AB			EQ 150MG BASE	A200626 002	Aug 09, 2018
AB			EQ 200MG BASE	A200626 003	Aug 09, 2018
AB			EQ 300MG BASE	A200626 004	Aug 09, 2018
AB		MYLAN	EQ 150MG BASE	A208177 001	Sep 24, 2018
AB			EQ 200MG BASE	A208177 002	Sep 24, 2018
AB			EQ 300MG BASE	A208177 003	Sep 24, 2018
AB		TEVA PHARMS USA	EQ 100MG BASE	A091673 001	Apr 22, 2014
AB			EQ 150MG BASE	A091673 002	Apr 22, 2014
AB			EQ 200MG BASE	A091673 003	Apr 22, 2014
AB			EQ 300MG BASE	A091673 004	Apr 22, 2014

REYATAZ

AB	+	BRISTOL MYERS SQUIBB	EQ 150MG BASE	N021567 002	Jun 20, 2003
AB	+		EQ 200MG BASE	N021567 003	Jun 20, 2003
AB	+		EQ 300MG BASE	N021567 004	Oct 16, 2006

POWDER; ORAL

REYATAZ

+	!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352 001	Jun 02, 2014
----------	----------	-------------------------	----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

+!	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353 001	Jan 29, 2015
----	-------------------------	---------------------	-------------	--------------

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>A072304 002</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072304 003</u>	Jul 18, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304 001</u>	Jul 15, 1988
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512 001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512 002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512 003</u>	Oct 31, 2007
<u>AB</u>	DAVA PHARMS INC	<u>50MG</u>	<u>A073542 001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543 001</u>	Dec 19, 1991
<u>AB</u>	HLTHCARE	<u>25MG</u>	<u>A074052 001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025 001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026 001</u>	Sep 17, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877 001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877 002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877 003</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457 002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073457 003</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457 001</u>	Jan 24, 1992
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056 003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056 001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056 002</u>	Jan 18, 1995
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A213136 001</u>	Nov 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A213136 002</u>	Nov 21, 2019
<u>AB</u>		<u>100MG</u>	<u>A213136 003</u>	Nov 21, 2019
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443 001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443 002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443 003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900 001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900 002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900 003</u>	Jan 28, 2005
<u>TENORMIN</u>				
<u>AB</u>	+ ALVOGEN	<u>25MG</u>	<u>N018240 004</u>	Apr 09, 1990
<u>AB</u>	+	<u>50MG</u>	<u>N018240 001</u>	
<u>AB</u>	+!	<u>100MG</u>	<u>N018240 002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	ALVOGEN	<u>50MG;25MG</u>	<u>A072302 002</u>	May 31, 1990
<u>AB</u>		<u>100MG;25MG</u>	<u>A072302 001</u>	May 31, 1990
<u>AB</u>	MYLAN	<u>50MG;25MG</u>	<u>A074203 001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG;25MG</u>	<u>A074203 002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG;25MG</u>	<u>A073665 001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG;25MG</u>	<u>A073665 002</u>	Jul 02, 1992
<u>AB</u>	ZYDUS PHARMS	<u>50MG;25MG</u>	<u>A210028 001</u>	Mar 08, 2019
<u>AB</u>		<u>100MG;25MG</u>	<u>A210028 002</u>	Mar 08, 2019
<u>TENORETIC 100</u>				
<u>AB</u>	+! ALVOGEN	<u>100MG;25MG</u>	<u>N018760 001</u>	Jun 08, 1984
<u>TENORETIC 50</u>				
<u>AB</u>	+ ALVOGEN	<u>50MG;25MG</u>	<u>N018760 002</u>	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A078983 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A078983 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A078983 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A078983 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A078983 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A078983 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A078983 007</u>	May 30, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079016 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079016 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079016 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079016 004</u>	May 30, 2017

PRESCRIPTION DRUG PRODUCT LIST

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

<u>AB</u>		<u>60MG</u>	<u>A079016 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079016 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079016 007</u>	May 30, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090609 001</u>	Feb 23, 2018
<u>AB</u>		<u>18MG</u>	<u>A090609 002</u>	Feb 23, 2018
<u>AB</u>		<u>25MG</u>	<u>A090609 003</u>	Feb 23, 2018
<u>AB</u>		<u>40MG</u>	<u>A090609 004</u>	Feb 23, 2018
<u>AB</u>		<u>60MG</u>	<u>A090609 005</u>	Feb 23, 2018
<u>AB</u>		<u>80MG</u>	<u>A090609 006</u>	Feb 23, 2018
<u>AB</u>		<u>100MG</u>	<u>A090609 007</u>	Feb 23, 2018
<u>AB</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A079019 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079019 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079019 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079019 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079019 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079019 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079019 007</u>	May 30, 2017
<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A079022 001</u>	May 30, 2017
<u>AB</u>		<u>18MG</u>	<u>A079022 002</u>	May 30, 2017
<u>AB</u>		<u>25MG</u>	<u>A079022 003</u>	May 30, 2017
<u>AB</u>		<u>40MG</u>	<u>A079022 004</u>	May 30, 2017
<u>AB</u>		<u>60MG</u>	<u>A079022 005</u>	May 30, 2017
<u>AB</u>		<u>80MG</u>	<u>A079022 006</u>	May 30, 2017
<u>AB</u>		<u>100MG</u>	<u>A079022 007</u>	May 30, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>18MG</u>	<u>A079017 001</u>	Sep 17, 2010
<u>AB</u>		<u>25MG</u>	<u>A079017 002</u>	Sep 17, 2010
<u>AB</u>		<u>40MG</u>	<u>A079017 003</u>	Sep 17, 2010
<u>AB</u>		<u>60MG</u>	<u>A079017 004</u>	Sep 17, 2010
<u>AB</u>		<u>80MG</u>	<u>A079017 005</u>	Sep 17, 2010
<u>AB</u>		<u>100MG</u>	<u>A079017 006</u>	Sep 17, 2010
<u>STRATTERA</u>				
<u>AB</u>	+ LILLY	<u>10MG</u>	<u>N021411 002</u>	Nov 26, 2002
<u>AB</u>	+	<u>18MG</u>	<u>N021411 003</u>	Nov 26, 2002
<u>AB</u>	+	<u>25MG</u>	<u>N021411 004</u>	Nov 26, 2002
<u>AB</u>	+	<u>40MG</u>	<u>N021411 005</u>	Nov 26, 2002
<u>AB</u>	+!	<u>60MG</u>	<u>N021411 006</u>	Nov 26, 2002
<u>AB</u>	+	<u>80MG</u>	<u>N021411 007</u>	Feb 14, 2005
<u>AB</u>	+	<u>100MG</u>	<u>N021411 008</u>	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A207687 001</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207687 002</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207687 003</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A207687 004</u>	Mar 30, 2018
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548 004</u>	May 29, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650 001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650 002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650 003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357 001</u>	Jul 17, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 10MG BASE</u>	<u>A209912 001</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209912 002</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209912 003</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209912 004</u>	Jun 18, 2018
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A204846 001</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204846 002</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204846 003</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204846 004</u>	Jan 09, 2017
<u>AB</u>	LANNETT CO INC	<u>EQ 10MG BASE</u>	<u>A091624 001</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624 002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624 003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624 004</u>	Apr 05, 2013
<u>AB</u>	MICRO LABS LTD INDIA	<u>EQ 10MG BASE</u>	<u>A205945 001</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205945 002</u>	Nov 07, 2019

PRESCRIPTION DRUG PRODUCT LIST

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205945 003</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205945 004</u>	Nov 07, 2019
<u>AB</u>	MSN	<u>EQ 10MG BASE</u>	<u>A211933 001</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211933 002</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A211933 003</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A211933 004</u>	Feb 08, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226 004</u>	May 29, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575 004</u>	May 29, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A205519 001</u>	May 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205519 002</u>	May 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205519 003</u>	May 19, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205519 004</u>	May 19, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477 004</u>	Nov 30, 2011
<u>AB</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A205300 001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205300 002</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205300 003</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205300 004</u>	Mar 27, 2017
<u>AB</u>	THEPHARMANETWORK LLC	<u>EQ 10MG BASE</u>	<u>A209288 001</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209288 002</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209288 003</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209288 004</u>	Dec 21, 2018
<u>AB</u>	ZYDUS PHARMS	<u>EQ 10MG BASE</u>	<u>A206536 001</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206536 002</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206536 003</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A206536 004</u>	Nov 20, 2018
<u>LIPITOR</u>				
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020702 001</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020702 002</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020702 003</u>	Dec 17, 1996
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N020702 004</u>	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	<u>EQ 10MG BASE;10MG</u>	<u>A206084 001</u>	Apr 26, 2017
		<u>EQ 20MG BASE;10MG</u>	<u>A206084 002</u>	Apr 26, 2017
		<u>EQ 40MG BASE;10MG</u>	<u>A206084 003</u>	Apr 26, 2017
	!	<u>EQ 80MG BASE;10MG</u>	<u>A206084 004</u>	Apr 26, 2017

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>	ABHAI LLC	<u>750MG/5ML</u>	<u>A210510 001</u>	May 31, 2019
<u>AB</u>	AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960 001</u>	Mar 18, 2014
<u>AB</u>	APOTEX	<u>750MG/5ML</u>	<u>A209750 001</u>	Oct 11, 2017
<u>AB</u>	GLENMARK PHARMS	<u>750MG/5ML</u>	<u>A209685 001</u>	Nov 21, 2018
<u>AB</u>	HETERO LABS LTD III	<u>750MG/5ML</u>	<u>A210692 001</u>	Oct 11, 2018
<u>AB</u>	LUPIN LTD	<u>750MG/5ML</u>	<u>A209105 001</u>	Sep 11, 2018
<u>AB</u>	PADDOCK LLC	<u>750MG/5ML</u>	<u>A207833 001</u>	Apr 28, 2017
<u>MEPRON</u>				
<u>AB</u>	+	<u>GLAXOSMITHKLINE LLC 750MG/5ML</u>	<u>N020500 001</u>	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>62.5MG;25MG</u>	<u>A091211 002</u>	Apr 06, 2015
<u>AB</u>		<u>250MG;100MG</u>	<u>A091211 001</u>	Jan 12, 2011
<u>AB</u>	MYLAN	<u>62.5MG;25MG</u>	<u>A202362 001</u>	May 27, 2014
<u>AB</u>		<u>250MG;100MG</u>	<u>A202362 002</u>	May 27, 2014
<u>MALARONE</u>				
<u>AB</u>	+	<u>GLAXOSMITHKLINE 250MG;100MG</u>	<u>N021078 001</u>	Jul 14, 2000

PRESCRIPTION DRUG PRODUCT LIST

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE PEDIATRIC

AB	+	GLAXOSMITHKLINE	62.5MG;25MG	N021078 002	Jul 14, 2000
-----------	----------	-----------------	--------------------	--------------------	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		MEITHEAL	10MG/ML	A091489 001	Feb 17, 2012
-----------	--	----------	----------------	--------------------	--------------

AP	!	WEST-WARD PHARMS INT	10MG/ML	A074901 001	Jul 18, 1997
-----------	----------	----------------------	----------------	--------------------	--------------

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206010 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		MEITHEAL	10MG/ML	A091488 001	Feb 17, 2012
-----------	--	----------	----------------	--------------------	--------------

AP	!	WEST-WARD PHARMS INT	10MG/ML	A074900 001	Jul 18, 1997
-----------	----------	----------------------	----------------	--------------------	--------------

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
----------	----------	----------------------	-------------------------	-------------	--------------

+	!		EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
----------	----------	--	------------------------	-------------	--------------

+	!		EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
----------	----------	--	----------------------	-------------	--------------

+	!		EQ 2MG SULFATE/0.7ML	N017106 001	
----------	----------	--	----------------------	-------------	--

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146 004	Aug 17, 2017
----------	----------	---------	----------------------	-------------	--------------

+	!		1MG/10ML (0.1MG/ML)	N021146 005	Aug 17, 2017
----------	----------	--	---------------------	-------------	--------------

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146 002	Jul 09, 2001
----------	----------	---------	------------------------	-------------	--------------

+	!		1MG/10ML (0.1MG/ML)	N021146 003	Jul 09, 2001
----------	----------	--	---------------------	-------------	--------------

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260 001	Jan 26, 2018
----------	----------	--------------------	---------------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	!	AKORN	1%	N206289 001	Jul 18, 2014
----------	----------	-------	----	-------------	--------------

ISOPTO ATROPINE

		ALCON LABS INC	1%	N208151 001	Dec 01, 2016
--	--	----------------	----	-------------	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	!	SEBELA IRELAND LTD	0.025MG;1MG	N017744 002	
----------	----------	--------------------	-------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982
----------	----------	-------	-----------------------	-------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS INC	0.025MG;2.5MG	A086727 001	
-----------	--	----------------	----------------------	--------------------	--

AA		BAYSHORE PHARMS LLC	0.025MG;2.5MG	A210819 001	Nov 13, 2018
-----------	--	---------------------	----------------------	--------------------	--------------

AA		LANNETT	0.025MG;2.5MG	A085372 001	
-----------	--	---------	----------------------	--------------------	--

AA		MYLAN	0.025MG;2.5MG	A085762 001	
-----------	--	-------	----------------------	--------------------	--

AA		PAR PHARM	0.025MG;2.5MG	A040357 001	May 02, 2000
-----------	--	-----------	----------------------	--------------------	--------------

AA		UPSHER SMITH LABS	0.025MG;2.5MG	A210571 001	Aug 31, 2018
-----------	--	-------------------	----------------------	--------------------	--------------

LOMOTIL

AA	+	GD SEARLE LLC	0.025MG;2.5MG	N012462 001	
-----------	----------	---------------	----------------------	--------------------	--

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	!	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983 001	Sep 28, 2006
----------	----------	----------------	-----------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AURANOFIN

CAPSULE; ORAL

RIDAURA

+! SEBELA IRELAND LTD 3MG N018689 001 May 24, 1985

AVANAFIL

TABLET; ORAL

STENDRA

+ METUCHEN PHARMS 50MG N202276 001 Apr 27, 2012

+ 100MG N202276 002 Apr 27, 2012

+! 200MG N202276 003 Apr 27, 2012

AVATROMBOPAG MALEATE

TABLET; ORAL

DOPTELET

+! AKARX INC EQ 20MG BASE N210238 001 May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+! ALLERGAN EQ 0.5GM BASE; 2GM/VIAL N206494 001 Feb 25, 2015

AXITINIB

TABLET; ORAL

INLYTA

+ PF PRISM CV 1MG N202324 001 Jan 27, 2012

+! 5MG N202324 002 Jan 27, 2012

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINEAP ACCORD HLTHCARE 100MG/VIAL A207475 001 Jul 02, 2018AP ACTAVIS LLC 100MG/VIAL N208216 001 Apr 29, 2016AP CIPLA 100MG/VIAL A209540 001 May 04, 2018AP DR REDDYS 100MG/VIAL A201537 001 Sep 16, 2013AP MYLAN INSTITUTIONAL 100MG/VIAL A204949 001 Apr 28, 2016AP NATCO PHARMA LTD 100MG/VIAL A207234 001 Jun 23, 2017AP SHILPA MEDICARE 100MG/VIAL A207518 001 Sep 29, 2016VIDAZAAP +! CELGENE 100MG/VIAL N050794 001 May 19, 2004AZATHIOPRINE

TABLET; ORAL

AZASANAB AAIPHARMA LLC 25MG A075252 002 Feb 03, 2003AB 50MG A075252 001 Jun 07, 1999AB 75MG A075252 003 Feb 03, 2003AB 100MG A075252 004 Feb 03, 2003AZATHIOPRINEAB AMNEAL PHARMS LLC 50MG A074069 001 Feb 16, 1996AB MYLAN 50MG A075568 001 Dec 13, 1999AB ZYDUS PHARMS USA 25MG A077621 002 Sep 05, 2008AB 50MG A077621 001 Mar 15, 2007AB 75MG A077621 003 Sep 05, 2008AB 100MG A077621 004 Sep 05, 2008IMURANAB +! SEBELA IRELAND LTD 50MG N016324 001AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

! WEST-WARD PHARMS EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995

INT

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+! LEO PHARMA AS 15% N207071 001 Jul 29, 2015

CREAM; TOPICAL

AZELEX

+! ALMIRALL 20% N020428 001 Sep 13, 1995

GEL; TOPICAL

AZELAIC ACIDAB ACTAVIS LABS UT INC 15% A208011 001 Nov 19, 2018AB GLENMARK PHARMS 15% A204637 001 Nov 19, 2018AB TARO 15% A210549 001 Aug 23, 2019AB TOLMAR 15% A208724 001 Nov 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

AZELAIC ACID

GEL;TOPICAL

FINACEA

AB	+ !	LEO PHARMA AS	15%	N021470	001	Dec 24, 2002
-----------	------------	---------------	------------	----------------	------------	--------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		AKORN	0.05%	A203660	001	Nov 08, 2016
AT		ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019
AT		APOTEX INC	0.05%	A078621	001	Aug 03, 2009
AT	!	SANDOZ INC	0.05%	A202305	001	May 31, 2012
AT		SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019
AT		SUN PHARM	0.05%	A078738	001	Jun 21, 2010

SPRAY, METERED;NASAL

ASTEELIN

AB	+ !	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996
-----------	------------	---------------------	------------------------------	----------------	------------	--------------

ASTEPRO

AB	+ !	MYLAN SPECIALITY LP	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009
-----------	------------	---------------------	-------------------------------	----------------	------------	--------------

AZELASTINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017
AB		AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017
AB			EQ 0.1876MG BASE/SPRAY	A208199	001	Dec 15, 2017
AB		APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954	001	Apr 30, 2009
AB			EQ 0.1876MG BASE/SPRAY	A201846	001	Aug 31, 2012
AB		BRECKENRIDGE	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015
AB		HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019
AB			EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019
AB		HIKMA	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014
AB			EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017
AB		PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014
AB		SUN PHARM	EQ 0.125MG BASE/SPRAY	A090423	001	May 23, 2012
AB		UPSHER SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017
AB		ZYDUS PHARMS	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017
-----------	--	--------	---	----------------	------------	--------------

DYMISTA

AB	+ !	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012
-----------	------------	---------------------	---	----------------	------------	--------------

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

+		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
+ !			EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

+		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011
+ !			EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		AMNEAL PHARMS LLC	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018
AB			EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018
AB		AUROBINDO PHARMA LTD	EQ 100MG BASE/5ML	A209201	001	Oct 09, 2018
AB			EQ 200MG BASE/5ML	A209201	002	Oct 09, 2018
AB		EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018
AB			EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018
AB		PLIVA	EQ 100MG BASE/5ML	A065246	002	Jul 05, 2006
AB			EQ 200MG BASE/5ML	A065246	001	Jul 05, 2006
AB		TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019
AB		TEVA PHARMS	EQ 100MG BASE/5ML	A065419	001	Jun 24, 2008
AB			EQ 200MG BASE/5ML	A065419	002	Jun 24, 2008
AB		ZYDUS	EQ 100MG BASE/5ML	A211147	001	Jul 31, 2018
AB			EQ 200MG BASE/5ML	A211147	002	Jul 31, 2018

ZITHROMAX

AB	+	PFIZER	EQ 100MG BASE/5ML	N050710	001	Oct 19, 1995
AB	+ !		EQ 200MG BASE/5ML	N050710	002	Oct 19, 1995

PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

FOR SUSPENSION;ORAL

ZITHROMAX

+!

EQ 1GM BASE/PACKET

N050693 001 Sep 28, 1994

INJECTABLE; INJECTION

AZITHROMYCIN

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A203294 001</u>	Jun 19, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179 001</u>	Dec 13, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501 001</u>	Nov 09, 2009
<u>AP</u>	HAINAN POLY PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A203412 001</u>	Oct 09, 2018
<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500 001</u>	Jun 26, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511 001</u>	Jun 26, 2009
<u>AP</u>	MYLAN ASI	<u>EQ 500MG BASE/VIAL</u>	<u>A065506 001</u>	Mar 24, 2009
<u>AP</u>	MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A204732 001</u>	Jan 26, 2017
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923 001</u>	Apr 02, 2013

ZITHROMAX

<u>AP</u>	+! PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733 001</u>	Jan 30, 1997
	SOLUTION/DROPS;OPHTHALMIC			
	AZASITE			
	+! OAK PHARMS INC	1%	N050810 001	Apr 27, 2007
	TABLET;ORAL			

AZITHROMYCIN

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A207370 001</u>	Jul 05, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A207398 001</u>	Jul 05, 2018
<u>AB</u>	BIONPHARMA INC	<u>EQ 250MG BASE</u>	<u>A210000 001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A210001 001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209999 001</u>	Dec 26, 2018
<u>AB</u>	CSEPC OUYI	<u>EQ 250MG BASE</u>	<u>A208250 001</u>	Apr 17, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A208249 001</u>	Oct 25, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A207566 001</u>	Sep 24, 2018
<u>AB</u>	LUPIN LTD	<u>EQ 250MG BASE</u>	<u>A065398 001</u>	May 15, 2015
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065399 001</u>	May 15, 2015
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065400 001</u>	May 15, 2015
<u>AB</u>	MYLAN	<u>EQ 600MG BASE</u>	<u>A065360 001</u>	Jan 08, 2007
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223 001</u>	Nov 14, 2005
<u>AB</u>	!	<u>EQ 600MG BASE</u>	<u>A065218 001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209 001</u>	Nov 14, 2005
<u>AB</u>	SUNSHINE LAKE	<u>EQ 250MG BASE</u>	<u>A209045 001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A209044 001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209043 001</u>	Dec 06, 2018
<u>AB</u>	TEVA	<u>EQ 500MG BASE</u>	<u>A065193 001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	+ PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002

AZTREONAM

FOR SOLUTION;INHALATION

CAYSTON

+! GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+! BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
<u>AP</u>	+!	<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986
	<u>AZTREONAM</u>			
<u>AP</u>	FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010
		500MG/VIAL	A065439 001	Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>	X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153 001</u>	May 09, 1997
	<u>BACITRACIN</u>			
<u>AP</u>	AKORN	<u>50,000 UNITS/VIAL</u>	<u>A206719 001</u>	Oct 20, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116 001</u>	Dec 03, 2002

PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

AP	!	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733</u>	<u>002</u>	
AP		XELLIA PHARMS APS	<u>50,000 UNITS/VIAL</u>	<u>A203177</u>	<u>001</u>	Aug 25, 2014

OINTMENT; OPHTHALMIC

BACITRACIN

!	PERRIGO CO	500 UNITS/GM		A061212	001	
	TENNESSEE					

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

!	PERRIGO CO	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A062166	002	
	TENNESSEE					

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213</u>	<u>001</u>	Jul 25, 2012
AT	!	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068</u>	<u>001</u>	Oct 30, 1995

OINTMENT; TOPICAL

+	!	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984
---	---	----------------	---	---------	-----	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088</u>	<u>001</u>	Feb 06, 2004
AT	!	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064</u>	<u>001</u>	Oct 30, 1995
AT		PERRIGO CO	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A060764</u>	<u>002</u>	
		TENNESSEE				

NEOSPORIN

AT	+	CASPER PHARMA LLC	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050417</u>	<u>001</u>	
-----------	---	-------------------	--	----------------	------------	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028</u>	<u>001</u>	Jan 30, 1995
AT	!	BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046</u>	<u>001</u>	Jan 26, 1995
AT		PERRIGO CO	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022</u>	<u>001</u>	Feb 27, 2002
		TENNESSEE				

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP		EMERALD INTL LTD	<u>0.05MG/ML</u>	<u>A091193</u>	<u>001</u>	May 03, 2016
AP			<u>0.5MG/ML</u>	<u>A091193</u>	<u>002</u>	May 03, 2016
AP			<u>2MG/ML</u>	<u>A091193</u>	<u>003</u>	May 03, 2016
AP		MAIA PHARMS INC	<u>0.5MG/ML</u>	<u>A210048</u>	<u>001</u>	Sep 11, 2019
AP			<u>1MG/ML</u>	<u>A210315</u>	<u>001</u>	Jul 30, 2019
AP			<u>2MG/ML</u>	<u>A210048</u>	<u>002</u>	Sep 11, 2019
AP		MYLAN LABS LTD	<u>0.5MG/ML</u>	<u>A209592</u>	<u>001</u>	Mar 21, 2018
AP			<u>1MG/ML</u>	<u>A209594</u>	<u>001</u>	Mar 06, 2018
AP			<u>2MG/ML</u>	<u>A209592</u>	<u>002</u>	Mar 21, 2018

GABLOFEN

AP		PIRAMAL CRITICAL	<u>0.05MG/ML</u>	<u>N022462</u>	<u>001</u>	Nov 19, 2010
AP			<u>0.5MG/ML</u>	<u>N022462</u>	<u>002</u>	Nov 19, 2010
AP	+		<u>1MG/ML</u>	<u>N022462</u>	<u>004</u>	Jun 22, 2012
AP			<u>2MG/ML</u>	<u>N022462</u>	<u>003</u>	Nov 19, 2010

LIORESAL

AP	+	SAOL THERAPS RES LTD	<u>0.05MG/ML</u>	<u>N020075</u>	<u>003</u>	Nov 07, 1996
AP	+		<u>0.5MG/ML</u>	<u>N020075</u>	<u>001</u>	Jun 17, 1992
AP	+		<u>2MG/ML</u>	<u>N020075</u>	<u>002</u>	Jun 17, 1992

SOLUTION; ORAL

OZOBAX

+	!	METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019
---	---	--------------------	---------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

BACLOFEN

TABLET;ORAL

BACLOFEN

<u>AB</u>	EYWA PHARMA	<u>10MG</u>	<u>A211555</u>	<u>001</u>	Feb 01, 2019
<u>AB</u>		<u>20MG</u>	<u>A211555</u>	<u>002</u>	Feb 01, 2019
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A077971</u>	<u>001</u>	Oct 26, 2007
<u>AB</u>		<u>20MG</u>	<u>A077971</u>	<u>002</u>	Oct 26, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	!	<u>20MG</u>	<u>A072235</u>	<u>001</u>	Jul 21, 1988
<u>AB</u>	LANNETT CO INC	<u>10MG</u>	<u>A077241</u>	<u>002</u>	Jul 06, 2007
<u>AB</u>		<u>20MG</u>	<u>A077241</u>	<u>001</u>	Dec 20, 2005
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A077121</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A090334</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090334</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078401</u>	<u>002</u>	Sep 18, 2009
<u>AB</u>		<u>20MG</u>	<u>A078401</u>	<u>001</u>	Sep 18, 2009
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A077088</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>	RUBICON	<u>10MG</u>	<u>A209102</u>	<u>002</u>	Nov 28, 2017
<u>AB</u>		<u>20MG</u>	<u>A209102</u>	<u>003</u>	Nov 28, 2017
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A074584</u>	<u>001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584</u>	<u>002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077068</u>	<u>002</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068</u>	<u>001</u>	Aug 30, 2005
<u>AB</u>	ZYDUS	<u>10MG</u>	<u>A211659</u>	<u>001</u>	Nov 23, 2018
<u>AB</u>		<u>20MG</u>	<u>A211659</u>	<u>002</u>	Nov 23, 2018
	RUBICON	5MG	A209102	001	Nov 28, 2017

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+	GENENTECH INC	20MG	N210854	001	Oct 24, 2018
+	!	40MG	N210854	002	Oct 24, 2018

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	HIKMA	<u>750MG</u>	<u>A077806</u>	<u>001</u>	Dec 28, 2007

COLAZAL

<u>AB</u>	+!	VALEANT PHARMS INTL	<u>750MG</u>	<u>N020610</u>	<u>001</u>	Jul 18, 2000
-----------	----	---------------------	--------------	----------------	------------	--------------

BARICITINIB

TABLET;ORAL

OLUMIANT

+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019
+	!	2MG	N207924	001	May 31, 2018

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+	!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016
---	---	--------	-----------------	---------	-----	--------------

E-Z-PAQUE

+	!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017
---	---	--------	-----------------	---------	-----	--------------

VARIBAR THIN LIQUID

+	!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019
---	---	--------	-----------------	---------	-----	--------------

PASTE;ORAL

VARIBAR PUDDING

		BRACCO	40%	N208844	001	Oct 14, 2016
--	--	--------	-----	---------	-----	--------------

SUSPENSION;ORAL

LIQUID E-Z-PAQUE

+	!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017
---	---	--------	-----------------	---------	-----	--------------

READI-CAT 2

+	!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016
---	---	--------	--------------	---------	-----	--------------

READI-CAT 2 SMOOTHIE

+	!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016
---	---	--------	--------------	---------	-----	--------------

TAGITOL V

+	!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017
---	---	--------	---------------	---------	-----	--------------

VARIBAR HONEY

+	!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018
---	---	--------	-------------------	---------	-----	--------------

VARIBAR NECTAR

+	!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017
---	---	--------	------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LISTBARIUM SULFATE

SUSPENSION;ORAL

VARIBAR THIN HONEY

+! BRACCO 40% (100GM/250ML) N208143 006 Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+! WYETH PHARMS EQ 20MG BASE;0.45MG N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

+ NORTON WATERFORD 0.04MG/INH N207921 001 Aug 03, 2017

+ 0.08MG/INH N207921 002 Aug 03, 2017

AEROSOL, METERED;NASAL

QNASL

+ TEVA BRANDED PHARM 0.04MG/ACTUATION N202813 002 Dec 17, 2014

+! 0.08MG/ACTUATION N202813 001 Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

BECONASE AQ

+! GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+! JANSSEN THERAP EQ 100MG BASE N204384 001 Dec 28, 2012

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

+! ACROTECH 500MG/VIAL N206256 001 Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS	5MG	A076820 001	Feb 03, 2006
AB		10MG	A076820 002	Feb 03, 2006
AB		20MG	A076820 003	Feb 03, 2006
AB		40MG	A076820 004	Feb 03, 2006
AB	APOTEX	5MG	A077128 001	Mar 08, 2006
AB		10MG	A077128 002	Mar 08, 2006
AB		20MG	A077128 003	Mar 08, 2006
AB		40MG	A077128 004	Mar 08, 2006
AB	AUROBINDO PHARMA	10MG	A078212 001	May 22, 2008
AB		20MG	A078212 002	May 22, 2008
AB		40MG	A078212 003	May 22, 2008
AB	CASI PHARMS INC	5MG	A076402 001	Feb 11, 2004
AB		10MG	A076402 002	Feb 11, 2004
AB		20MG	A076402 003	Feb 11, 2004
AB		40MG	A076402 004	Feb 11, 2004
AB	MYLAN	5MG	A076430 001	Feb 11, 2004
AB		10MG	A076430 002	Feb 11, 2004
AB		20MG	A076430 003	Feb 11, 2004
AB		40MG	A076430 004	Feb 11, 2004
AB	PRINSTON INC	5MG	A076118 001	Feb 11, 2004
AB		10MG	A076118 002	Feb 11, 2004
AB		20MG	A076118 003	Feb 11, 2004
AB		40MG	A076118 004	Feb 11, 2004
AB	SUN PHARM INDS LTD	5MG	A076344 001	Feb 11, 2004
AB		10MG	A076344 002	Feb 11, 2004
AB		20MG	A076344 003	Feb 11, 2004
AB		40MG	A076344 004	Feb 11, 2004
AB	TEVA	5MG	A076211 001	Feb 11, 2004
AB		10MG	A076211 002	Feb 11, 2004
AB		20MG	A076211 003	Feb 11, 2004
AB		40MG	A076211 004	Feb 11, 2004
AB	ZYDUS PHARMS USA	5MG	A078848 001	May 23, 2008
AB		10MG	A078848 002	May 23, 2008
AB		20MG	A078848 003	May 23, 2008
AB		40MG	A078848 004	May 23, 2008

LOTENSIN

AB	+ US PHARMS HOLDINGS	5MG	N019851 001	Jun 25, 1991
-----------	----------------------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

I

<u>AB</u>	+		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991
<u>AB</u>	+		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	!	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX	<u>5MG; 6.25MG</u>	<u>A078794</u>	<u>001</u>	Aug 21, 2014
<u>AB</u>			<u>10MG; 12.5MG</u>	<u>A078794</u>	<u>002</u>	Aug 21, 2014
<u>AB</u>			<u>20MG; 12.5MG</u>	<u>A078794</u>	<u>003</u>	Aug 21, 2014
<u>AB</u>			<u>20MG; 25MG</u>	<u>A078794</u>	<u>004</u>	Aug 21, 2014
<u>AB</u>		MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>			<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>			<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>			<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>		SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>			<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>			<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>			<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>						
<u>AB</u>	+	US PHARMS HOLDINGS	<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
		I				
<u>AB</u>	+		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	!	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+	!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+	!		100MG/VIAL	N022249	001	Mar 20, 2008

SOLUTION; IV (INFUSION)

BELRAPZO

+	!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018
---	---	--------------	---------------------	---------	-----	--------------

BENDEKA

+	!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015
---	---	--------------	---------------------	---------	-----	--------------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	+	KING PHARMS LLC	<u>5MG; 40MG</u>	<u>N018647</u>	<u>001</u>	May 25, 1983
<u>AB</u>	+	!	<u>5MG; 80MG</u>	<u>N018647</u>	<u>002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>		IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833</u>	<u>001</u>	Mar 30, 2007
<u>AB</u>			<u>5MG; 80MG</u>	<u>A077833</u>	<u>002</u>	Mar 30, 2007

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALTAFLUOR BENOX

+	!	ALTAIRE PHARMS INC	0.4%; 0.25%	N208582	001	Dec 14, 2017
---	---	--------------------	-------------	---------	-----	--------------

BENZNIDAZOLE

TABLET; ORAL

BENZNIDAZOLE

+		CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
+	!		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>		APOTEX INC	<u>100MG</u>	<u>A091310</u>	<u>001</u>	Jan 16, 2015
<u>AA</u>			<u>200MG</u>	<u>A091310</u>	<u>002</u>	Jan 16, 2015
<u>AA</u>		ASCENT PHARMS INC	<u>100MG</u>	<u>A211518</u>	<u>001</u>	Feb 22, 2019
<u>AA</u>			<u>150MG</u>	<u>A211518</u>	<u>002</u>	Feb 22, 2019
<u>AA</u>			<u>200MG</u>	<u>A211518</u>	<u>003</u>	Feb 22, 2019
<u>AA</u>		BIONPHARMA INC	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
<u>AA</u>			<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
<u>AA</u>		CSPC OUYI	<u>100MG</u>	<u>A202765</u>	<u>002</u>	Aug 25, 2017
<u>AA</u>			<u>200MG</u>	<u>A202765</u>	<u>001</u>	Jul 31, 2015
<u>AA</u>		MIKART	<u>100MG</u>	<u>A040851</u>	<u>001</u>	Nov 09, 2009
<u>AA</u>			<u>150MG</u>	<u>A040851</u>	<u>002</u>	Nov 09, 2009
<u>AA</u>			<u>200MG</u>	<u>A040851</u>	<u>003</u>	Nov 09, 2009
<u>AA</u>		ORIT LABS LLC	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
<u>AA</u>	PURACAP PHARM LLC	<u>100MG</u>	<u>A206948</u>	<u>001</u>	Dec 19, 2018
<u>AA</u>		<u>200MG</u>	<u>A206948</u>	<u>002</u>	Dec 19, 2018
<u>AA</u>	QINGDAO BAHEAL PHARM	<u>100MG</u>	<u>A210562</u>	<u>001</u>	Nov 09, 2018
<u>AA</u>		<u>150MG</u>	<u>A210562</u>	<u>002</u>	Nov 09, 2018
<u>AA</u>		<u>200MG</u>	<u>A210562</u>	<u>003</u>	Nov 09, 2018
<u>AA</u>	STRIDES PHARMA	<u>100MG</u>	<u>A091133</u>	<u>001</u>	Jul 30, 2015
<u>AA</u>		<u>200MG</u>	<u>A091133</u>	<u>002</u>	Jul 30, 2015
<u>AA</u>	! THEPHARMANETWORK LLC	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>	!	<u>150MG</u>	<u>A201209</u>	<u>001</u>	Sep 24, 2014
<u>AA</u>	!	<u>200MG</u>	<u>A040749</u>	<u>001</u>	Jul 25, 2007
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+ PFIZER	<u>100MG</u>	<u>N011210</u>	<u>001</u>	
-----------	----------	--------------	----------------	------------	--

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

<u>AB</u>	+! BAUSCH	<u>2.5%;EQ 1.2% BASE</u>	<u>N050819</u>	<u>001</u>	Oct 23, 2008
-----------	-----------	--------------------------	----------------	------------	--------------

BENZACLIN

<u>AB</u>	+! BAUSCH	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000
-----------	-----------	----------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

<u>AB</u>	ACTAVIS LABS UT INC	<u>2.5%;EQ 1.2% BASE</u>	<u>A205128</u>	<u>001</u>	Jun 19, 2015
<u>AB</u>	GLENMARK PHARMS	<u>5%;EQ 1% BASE</u>	<u>A209252</u>	<u>001</u>	Mar 14, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
<u>AB</u>	PERRIGO ISRAEL	<u>2.5%;EQ 1.2% BASE</u>	<u>A205397</u>	<u>001</u>	Sep 09, 2019
<u>AB</u>		<u>5%;1.2%</u>	<u>A090979</u>	<u>001</u>	Jun 26, 2012
<u>AB</u>	PERRIGO UK FINCO	<u>5%;EQ 1% BASE</u>	<u>A202440</u>	<u>001</u>	Sep 21, 2015
<u>AB</u>	TARO	<u>2.5%;EQ 1.2% BASE</u>	<u>A206575</u>	<u>001</u>	Aug 19, 2019
<u>AB</u>		<u>5%;EQ 1% BASE</u>	<u>A208776</u>	<u>001</u>	May 25, 2018
<u>AB</u>	TARO PHARMS	<u>5%;1.2%</u>	<u>A206218</u>	<u>001</u>	Dec 15, 2017
<u>AB</u>	TOLMAR	<u>5%;EQ 1% BASE</u>	<u>A204087</u>	<u>001</u>	Jun 27, 2017
<u>AB</u>		<u>5%;1.2%</u>	<u>A203688</u>	<u>001</u>	Aug 25, 2016
<u>AB</u>	ZYDUS PHARMS	<u>5%;1.2%</u>	<u>A210794</u>	<u>001</u>	Dec 28, 2018

DUAC

<u>AB</u>	+! STIEFEL	<u>5%;1.2%</u>	<u>N050741</u>	<u>001</u>	Aug 26, 2002
	ONEXTON				
	+! BAUSCH	<u>3.75%;EQ 1.2% BASE</u>	<u>N050819</u>	<u>002</u>	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+! VALEANT INTL	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984
-----------	-----------------	--------------	----------------	------------	--------------

ERYTHROMYCIN AND BENZOYL PEROXIDE

<u>AB</u>	LYNE	<u>5%;3%</u>	<u>A065385</u>	<u>001</u>	Sep 18, 2015
<u>AB</u>	TOLMAR	<u>5%;3%</u>	<u>A065112</u>	<u>001</u>	Mar 29, 2004

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	ANDA REPOSITORY	<u>50MG</u>	<u>A090473</u>	<u>002</u>	Sep 15, 2010
<u>AA</u>	EMCURE PHARMS LTD	<u>50MG</u>	<u>A202061</u>	<u>001</u>	Jan 27, 2012
<u>AA</u>	EPIC PHARMA LLC	<u>50MG</u>	<u>A090346</u>	<u>001</u>	Dec 15, 2015
<u>AA</u>	! KVK TECH	<u>50MG</u>	<u>A090968</u>	<u>001</u>	Jul 20, 2010
<u>AA</u>	SPECGX LLC	<u>50MG</u>	<u>A040773</u>	<u>001</u>	Apr 25, 2007
<u>AA</u>	TWI PHARMS	<u>50MG</u>	<u>A040578</u>	<u>001</u>	Apr 17, 2006
	ANDA REPOSITORY	<u>25MG</u>	<u>A090473</u>	<u>001</u>	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>	NAVINTA LLC	<u>1MG/ML</u>	<u>A091525</u>	<u>001</u>	Feb 05, 2013

COGENTIN

<u>AP</u>	+! OAK PHARMS AKORN	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	
-----------	---------------------	---------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>	!	ASPEN GLOBAL INC	<u>0.5MG</u>	<u>A204713</u>	<u>001</u>	Apr 14, 2015
<u>AA</u>	!		<u>1MG</u>	<u>A204713</u>	<u>002</u>	Apr 14, 2015
<u>AA</u>	!		<u>2MG</u>	<u>A204713</u>	<u>003</u>	Apr 14, 2015
<u>AA</u>		EPIC PHARMA LLC	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>			<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>			<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>		LEADING PHARMA LLC	<u>0.5MG</u>	<u>A090168</u>	<u>001</u>	Nov 28, 2012
<u>AA</u>			<u>1MG</u>	<u>A090168</u>	<u>002</u>	Nov 28, 2012
<u>AA</u>			<u>2MG</u>	<u>A090168</u>	<u>003</u>	Nov 28, 2012
<u>AA</u>		PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		VINTAGE	<u>0.5MG</u>	<u>A040715</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>1MG</u>	<u>A040715</u>	<u>002</u>	Aug 27, 2007
<u>AA</u>			<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+! ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

<u>AT</u>		MYLAN	<u>1.5%</u>	<u>A206220</u>	<u>001</u>	Mar 18, 2019
<u>AT</u>	+!	BAUSCH AND LOMB INC	<u>1.5%</u>	<u>N022288</u>	<u>001</u>	Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+! ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+! BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE

FOR SOLUTION; ORAL

CYSTADANE

+! ORPHAN EUROPE

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>		LUITPOLD	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>	+!	MERCK SHARP DOHME	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACP NIMBLE	<u>EQ 0.05% BASE</u>	<u>A210217</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>	+!	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>N019137</u>	<u>001</u>	Jun 26, 1984
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A073552</u>	<u>001</u>	Apr 30, 1992
<u>AB</u>		ZYDUS PHARMS	<u>EQ 0.05% BASE</u>	<u>A208885</u>	<u>001</u>	Jan 11, 2019

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ANDA REPOSITORY	<u>EQ 0.05% BASE</u>	<u>A076603</u>	<u>001</u>	Jan 23, 2004
<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A076215</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>		GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930</u>	<u>001</u>	Sep 23, 2008
<u>AB</u>		PERRIGO ISRAEL	<u>EQ 0.05% BASE</u>	<u>A076592</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A076543</u>	<u>001</u>	Dec 09, 2003

DIPROLENE AF

<u>AB</u>	+!	MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N019555</u>	<u>001</u>	Apr 27, 1987
-----------	----	-------------------	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075276 001</u>	May 13, 2003
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A076508 001</u>	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACP NIMBLE	<u>EQ 0.05% BASE</u>	<u>A071467 001</u>	Aug 10, 1987
<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070281 001</u>	Jul 31, 1985
<u>AB</u>	!	FOUGERA PHARMS INC	<u>EQ 0.05% BASE</u>	<u>A070275 001</u>	Aug 12, 1985
<u>AB</u>		HI TECH	<u>EQ 0.05% BASE</u>	<u>A209896 001</u>	Feb 06, 2018
<u>AB</u>		PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A072538 001</u>	Jan 31, 1990

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A077111 001</u>	May 21, 2007
<u>AB</u>		HI TECH	<u>EQ 0.05% BASE</u>	<u>A208849 001</u>	Oct 11, 2019
<u>AB</u>	!	TARO	<u>EQ 0.05% BASE</u>	<u>A077477 001</u>	May 21, 2007
<u>AB</u>		TELIGENT PHARMA INC	<u>EQ 0.05% BASE</u>	<u>A206389 001</u>	Feb 13, 2018

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A071012 001</u>	Feb 03, 1987
<u>AB</u>	+	FOUGERA PHARMS INC	<u>EQ 0.05% BASE</u>	<u>N019141 001</u>	Sep 04, 1984
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A074271 001</u>	Sep 15, 1994

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A074304 001</u>	Aug 31, 1995
<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075373 001</u>	Jun 22, 1999
<u>AB</u>		LUPIN LTD	<u>EQ 0.05% BASE</u>	<u>A209106 001</u>	Dec 18, 2019
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A076753 001</u>	Oct 12, 2004
<u>AB</u>		TELIGENT PHARMA INC	<u>EQ 0.05% BASE</u>	<u>A206118 001</u>	Nov 09, 2017

DIPROLENE

<u>AB</u>	+	MERCK SHARP DOHME	<u>EQ 0.05% BASE</u>	<u>N018741 001</u>	Jul 27, 1983
-----------	---	-------------------	----------------------	--------------------	--------------

SPRAY;TOPICAL

SERNIVO

+	!	ENCORE DERMAT	<u>EQ 0.05% BASE/SPRAY</u>	<u>N208079 001</u>	Feb 05, 2016
---	---	---------------	----------------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

+	!	LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N207589 001</u>	Oct 16, 2015
---	---	---------------	----------------------	--------------------	--------------

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>		PERRIGO UK FINCO	<u>0.064%;0.005%</u>	<u>A200174 001</u>	Dec 12, 2014
<u>AB</u>		TOLMAR	<u>0.064%;0.005%</u>	<u>A201615 001</u>	Jan 14, 2013

TACLONEX

<u>AB</u>	+	!	LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N021852 001</u>	Jan 09, 2006
-----------	---	---	---------------	----------------------	--------------------	--------------

SUSPENSION;TOPICAL

TACLONEX

+	!	LEO PHARMA AS	<u>0.064%;0.005%</u>	<u>N022185 001</u>	May 09, 2008
---	---	---------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE;1%</u>	<u>A076002 001</u>	Aug 02, 2002
<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A075502 001</u>	Jun 05, 2001
<u>AB</u>		GLENMARK PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A202894 001</u>	Oct 30, 2015
<u>AB</u>		TARO	<u>EQ 0.05% BASE;1%</u>	<u>A075673 001</u>	May 29, 2001

LOTRISONE

<u>AB</u>	+	!	MERCK SHARP DOHME	<u>EQ 0.05% BASE;1%</u>	<u>N018827 001</u>	Jul 10, 1984
-----------	---	---	-------------------	-------------------------	--------------------	--------------

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE;1%</u>	<u>A076516 001</u>	Jun 16, 2005
<u>AB</u>		TARO	<u>EQ 0.05% BASE;1%</u>	<u>A076493 001</u>	Jul 28, 2004

LOTRISONE

<u>AB</u>	+	!	MERCK SHARP DOHME	<u>EQ 0.05% BASE;1%</u>	<u>N020010 001</u>	Dec 08, 2000
-----------	---	---	-------------------	-------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	PERRIGO UK FINCO	<u>0.12%</u>	<u>A078337 001</u>	Nov 26, 2012
<u>AB</u>	RICONPHARMA LLC	<u>0.12%</u>	<u>A207144 001</u>	May 24, 2017
<u>AB</u>	TARO	<u>0.12%</u>	<u>A208204 001</u>	May 24, 2017

LUXIQ

<u>AB</u>	+! MYLAN	<u>0.12%</u>	<u>N020934 001</u>	Feb 28, 1999
-----------	----------	--------------	--------------------	--------------

CREAM;TOPICAL

BETA-VAL

<u>AB</u>	ACP NIMBLE	<u>EQ 0.1% BASE</u>	<u>N018642 001</u>	Mar 24, 1983
-----------	------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<u>AB</u>	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018861 001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	--------------------	--------------

DERMABET

<u>AB</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A072041 001</u>	Jan 06, 1988
-----------	------	---------------------	--------------------	--------------

VALNAC

<u>AB</u>	ACTAVIS MID	<u>EQ 0.1% BASE</u>	<u>A070050 001</u>	Oct 10, 1984
-----------	-------------	---------------------	--------------------	--------------

ATLANTIC

LOTION;TOPICAL

BETAMETHASONE VALERATE

<u>AB</u>	ANIMA	<u>EQ 0.1% BASE</u>	<u>A070052 001</u>	Jul 31, 1985
-----------	-------	---------------------	--------------------	--------------

<u>AB</u>	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018866 001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	--------------------	--------------

OINTMENT;TOPICAL

BETA-VAL

<u>AB</u>	ACP NIMBLE	<u>EQ 0.1% BASE</u>	<u>A070069 001</u>	Dec 19, 1985
-----------	------------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

<u>AB</u>	ACTAVIS MID	<u>EQ 0.1% BASE</u>	<u>A070051 001</u>	Oct 10, 1984
-----------	-------------	---------------------	--------------------	--------------

ATLANTIC

<u>AB</u>	+! FOUGERA PHARMS INC	<u>EQ 0.1% BASE</u>	<u>N018865 001</u>	Aug 31, 1983
-----------	-----------------------	---------------------	--------------------	--------------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A075386 001</u>	Jun 30, 2000
-----------	-------	---------------------	--------------------	--------------

<u>AT</u>	MEDIMETRIKS PHARMS	<u>EQ 0.5% BASE</u>	<u>A075630 001</u>	Apr 12, 2001
-----------	--------------------	---------------------	--------------------	--------------

<u>AT</u>	WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078694 001</u>	Nov 16, 2009
-----------	-----------	---------------------	--------------------	--------------

BETOPTIC

<u>AT</u>	+! SANDOZ INC	<u>EQ 0.5% BASE</u>	<u>N019270 001</u>	Aug 30, 1985
-----------	---------------	---------------------	--------------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

	+! NOVARTIS	<u>EQ 0.25% BASE</u>	<u>N019845 001</u>	Dec 29, 1989
--	-------------	----------------------	--------------------	--------------

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>10MG</u>	<u>A075541 001</u>	Oct 22, 1999
-----------	-------------	-------------	--------------------	--------------

<u>AB</u>	!	<u>20MG</u>	<u>A075541 002</u>	Oct 22, 1999
-----------	---	-------------	--------------------	--------------

<u>AB</u>	KVK TECH	<u>10MG</u>	<u>A078962 001</u>	Jun 27, 2008
-----------	----------	-------------	--------------------	--------------

<u>AB</u>		<u>20MG</u>	<u>A078962 002</u>	Jun 27, 2008
-----------	--	-------------	--------------------	--------------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

<u>AA</u>	AMNEAL PHARM	<u>5MG</u>	<u>A040855 001</u>	Nov 21, 2007
-----------	--------------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A040855 002</u>	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A040855 003</u>	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>50MG</u>	<u>A040855 004</u>	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>	ECI PHARMS LLC	<u>5MG</u>	<u>A040728 002</u>	Oct 26, 2007
-----------	----------------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A040728 003</u>	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A040728 004</u>	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>50MG</u>	<u>A040728 001</u>	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

<u>AA</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A091256 001</u>	May 04, 2010
-----------	-----------------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A091256 002</u>	May 04, 2010
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A091256 003</u>	May 04, 2010
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>50MG</u>	<u>A091256 004</u>	May 04, 2010
-----------	--	-------------	--------------------	--------------

<u>AA</u>	LANNETT CO INC	<u>5MG</u>	<u>A040677 002</u>	Mar 27, 2008
-----------	----------------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A040677 003</u>	Mar 27, 2008
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A040677 004</u>	Mar 27, 2008
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>50MG</u>	<u>A040677 001</u>	Mar 27, 2008
-----------	--	-------------	--------------------	--------------

<u>AA</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A040633 001</u>	Jun 01, 2005
-----------	-------------------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A040634 001</u>	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A040635 001</u>	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>50MG</u>	<u>A040636 001</u>	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

<u>AA</u>	WOCKHARDT	<u>5MG</u>	<u>A040532 001</u>	Sep 29, 2003
-----------	-----------	------------	--------------------	--------------

<u>AA</u>		<u>10MG</u>	<u>A040533 001</u>	Sep 29, 2003
-----------	--	-------------	--------------------	--------------

<u>AA</u>		<u>25MG</u>	<u>A040534 001</u>	Sep 29, 2003
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA		50MG	A040518 001	Sep 29, 2003
	DUVOID			
AA	CHARTWELL RX	10MG	A086262 001	
AA		25MG	A086263 001	
AA		50MG	A085882 003	
	URECHOLINE			
AA	! ODYSSEY PHARMS	5MG	A089095 001	Dec 19, 1985
AA	!	10MG	A088440 001	May 29, 1984
AA	!	25MG	A088441 001	May 29, 1984
AA	!	50MG	A089096 001	Dec 19, 1985

BETRIXABAN

CAPSULE; ORAL

BEVYXXA

+	PORTOLA PHARMS INC	40MG	N208383 001	Jun 23, 2017
+	!	80MG	N208383 002	Jun 23, 2017

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	AMERIGEN PHARMS LTD	75MG	A209861 001	May 08, 2018
AB	AMNEAL PHARMS NY	75MG	A210105 001	Sep 04, 2018
AB	BIONPHARMA INC	75MG	A203174 001	Aug 12, 2014
AB	UPSHER SMITH LABS	75MG	A209886 001	Jul 25, 2018
	TARGRETIN			
AB	+! VALEANT LUXEMBOURG	75MG	N021055 001	Dec 29, 1999
	GEL; TOPICAL			
	TARGRETIN			
	+! BAUSCH	1%	N021056 001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE	50MG	A078917 001	Jul 06, 2009
AB	APOTEX INC	50MG	A200274 001	May 21, 2015
AB	KENTON	50MG	A091011 001	Jun 10, 2015
AB	MYLAN	50MG	A079185 001	Jul 06, 2009
AB	SANDOZ	50MG	A078575 001	Jul 06, 2009
AB	SUN PHARM	50MG	A079110 001	Jul 06, 2009
AB	WATSON LABS TEVA	50MG	A078634 001	Aug 28, 2009
AB	ZYDUS PHARMS USA INC	50MG	A079089 001	Jul 06, 2009
	CASODEX			
AB	+! ANI PHARMS INC	50MG	N020498 001	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

BIKTARVY

+	GILEAD SCIENCES INC	EQ 50MG BASE; 200MG; EQ 25MG BASE	N210251 001	Feb 07, 2018
---	---------------------	-----------------------------------	-------------	--------------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A210263 001	Apr 12, 2019
AT	APOTEX INC	0.03%	A090449 001	Jul 20, 2015
AT	GLAND PHARMA LTD	0.03%	A210126 001	Mar 22, 2019
AT	! LUPIN LTD	0.03%	A203991 001	Feb 20, 2015
AT	SANDOZ INC	0.03%	A202565 001	May 05, 2015
AT	SOMERSET THERAPS LLC	0.03%	A207601 001	Jun 19, 2019
	LUMIGAN			
	+! ALLERGAN	0.01%	N022184 001	Aug 31, 2010
	SOLUTION/DROPS; TOPICAL			
	BIMATOPROST			
AT	APOTEX INC	0.03%	A201894 001	Dec 01, 2014
AT	HI TECH	0.03%	A203051 001	Oct 09, 2018
AT	SANDOZ INC	0.03%	A202719 001	Apr 19, 2016
	LATISSE			
AT	+! ALLERGAN	0.03%	N022369 001	Dec 24, 2008

PRESCRIPTION DRUG PRODUCT LIST

BINIMETINIB

TABLET;ORAL

MEKTOVI

+! ARRAY BIOPHARMA INC 15MG N210498 001 Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

PYLERA

+! ALLERGAN 140MG;125MG;125MG N050786 001 Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

! AILEX PHARMS LLC 262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG A202584 001 Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910 001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910 002</u>	Dec 27, 2006
<u>AB</u>	CASI PHARMS INC	<u>5MG</u>	<u>A075643 001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643 002</u>	Nov 16, 2000
<u>AB</u>	FRONTIDA BIOPHARM	<u>5MG</u>	<u>A075474 001</u>	Oct 25, 2002
<u>AB</u>		<u>10MG</u>	<u>A075474 002</u>	Oct 25, 2002
<u>AB</u>	ORIT LABS LLC	<u>5MG</u>	<u>A204891 001</u>	Jan 11, 2017
<u>AB</u>		<u>10MG</u>	<u>A204891 002</u>	Jan 11, 2017
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644 001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644 002</u>	Jun 26, 2001
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635 001</u>	Aug 18, 2009
<u>AB</u>	!	<u>10MG</u>	<u>A078635 002</u>	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	SANDOZ	<u>2.5MG;6.25MG</u>	<u>A075579 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A075579 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A075579 003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG;6.25MG</u>	<u>A079106 001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG;6.25MG</u>	<u>A079106 002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG;6.25MG</u>	<u>A079106 003</u>	Jul 28, 2010
<u>ZIAC</u>				
<u>AB</u>	+ TEVA BRANDED PHARM	<u>2.5MG;6.25MG</u>	<u>N020186 003</u>	Mar 26, 1993
<u>AB</u>	+	<u>5MG;6.25MG</u>	<u>N020186 001</u>	Mar 26, 1993
<u>AB</u>	+!	<u>10MG;6.25MG</u>	<u>N020186 002</u>	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAXAP +! SANDOZ INC 250MG/VIAL N020873 001 Dec 15, 2000BIVALIRUDIN

<u>AP</u>	ACCORD HLTHCARE	<u>250MG/VIAL</u>	<u>A206551 001</u>	Nov 22, 2017
<u>AP</u>	APOTEX	<u>250MG/VIAL</u>	<u>A204876 001</u>	Jul 06, 2017
<u>AP</u>	AUROBINDO PHARMA LTD	<u>250MG/VIAL</u>	<u>A205962 001</u>	Jul 27, 2018
<u>AP</u>	CIPLA	<u>250MG/VIAL</u>	<u>A091602 001</u>	Jul 16, 2018
<u>AP</u>	DR REDDYS LABS LTD	<u>250MG/VIAL</u>	<u>A201577 001</u>	May 26, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>250MG/VIAL</u>	<u>A090189 001</u>	Oct 28, 2016
<u>AP</u>	HOSPIRA INC	<u>250MG/VIAL</u>	<u>A090811 001</u>	Jul 14, 2015
<u>AP</u>		<u>250MG/VIAL</u>	<u>A090816 001</u>	Jul 14, 2015
<u>AP</u>	MYLAN INSTITUTIONAL	<u>250MG/VIAL</u>	<u>A202471 001</u>	Jun 01, 2018
<u>AP</u>	SHUANGCHENG	<u>250MG/VIAL</u>	<u>A210031 001</u>	Oct 23, 2019

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

+! MAIA PHARMS INC 250MG/50ML (5MG/ML) N211215 001 Jul 25, 2019

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017

+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017

PRESCRIPTION DRUG PRODUCT LIST

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	CIPLA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A209439 001</u>	Mar 11, 2019
<u>AP</u>	! FRESenius KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185 001</u>	Jan 28, 2008
<u>AP</u>	!	<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185 002</u>	Jan 28, 2008
<u>AP</u>	HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031 001</u>	Mar 10, 2000
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031 002</u>	Mar 10, 2000
<u>AP</u>	MEITHEAL	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A205030 001</u>	Apr 20, 2018
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A205030 002</u>	Apr 20, 2018
<u>AP</u>	TEVA PHARMS USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033 001</u>	Jun 27, 2000
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033 002</u>	Jun 27, 2000
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042 002</u>	Oct 17, 2001
<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042 001</u>	Oct 17, 2001

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+! MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003

POWDER; INTRAVENOUS

BORTEZOMIB

DR REDDYS LABS LTD 3.5MG/VIAL N206927 001 Oct 04, 2019

FRESenius KABI USA 3.5MG/VIAL N205004 001 Nov 06, 2017

BOSENTAN

TABLET; ORAL

BOSENTAN

<u>AB</u>	AMNEAL PHARMS CO	<u>62.5MG</u>	<u>A209742 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A209742 002</u>	Apr 26, 2019
<u>AB</u>	CIPLA	<u>62.5MG</u>	<u>A210342 001</u>	Jan 03, 2020
<u>AB</u>		<u>125MG</u>	<u>A210342 002</u>	Jan 03, 2020
<u>AB</u>	HIKMA	<u>62.5MG</u>	<u>A208695 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A208695 002</u>	Apr 26, 2019
<u>AB</u>	MYLAN	<u>62.5MG</u>	<u>A205173 001</u>	Jan 15, 2020
<u>AB</u>		<u>125MG</u>	<u>A205173 002</u>	Jan 15, 2020
<u>AB</u>	NATCO PHARMA LTD	<u>62.5MG</u>	<u>A206987 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A206987 002</u>	Apr 26, 2019
<u>AB</u>	PAR PHARM INC	<u>62.5MG</u>	<u>A205699 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A205699 002</u>	Apr 26, 2019
<u>AB</u>	SUN PHARM	<u>62.5MG</u>	<u>A209324 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A209324 002</u>	Apr 26, 2019
<u>AB</u>	WATSON LABS INC	<u>62.5MG</u>	<u>A207110 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A207110 002</u>	Apr 26, 2019
<u>AB</u>	ZYDUS PHARMS	<u>62.5MG</u>	<u>A207760 001</u>	Apr 26, 2019
<u>AB</u>		<u>125MG</u>	<u>A207760 002</u>	Apr 26, 2019

TRACLEER

<u>AB</u>	+ ACTELION PHARMS LTD	<u>62.5MG</u>	<u>N021290 001</u>	Nov 20, 2001
<u>AB</u>	+!	<u>125MG</u>	<u>N021290 002</u>	Nov 20, 2001

TABLET, FOR SUSPENSION; ORAL

TRACLEER

+! ACTELION PHARMS 32MG N209279 001 Sep 05, 2017

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+! PF PRISM CV EQ 100MG BASE N203341 001 Sep 04, 2012

+ EQ 400MG BASE N203341 003 Oct 27, 2017

+ EQ 500MG BASE N203341 002 Sep 04, 2012

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+! AMAG PHARMS INC EQ 1.75MG BASE/0.3ML (EQ 1.75MG
BASE/0.3 ML) N210557 001 Jun 21, 2019BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

! BRECKENRIDGE 50MG/ML A204386 001 Dec 21, 2018

PRESCRIPTION DRUG PRODUCT LIST

BREXANOLONE

SOLUTION; INTRAVENOUS

ZULRESSO

+! SAGE THERAP 100MG/20ML (5MG/ML) N211371 001 Jun 17, 2019

BREXPIPIRAZOLE

TABLET; ORAL

REXULTI

+ OTSUKA PHARM CO LTD 0.25MG N205422 001 Jul 10, 2015

+ 0.5MG N205422 002 Jul 10, 2015

+ 1MG N205422 003 Jul 10, 2015

+! 2MG N205422 004 Jul 10, 2015

+ 3MG N205422 005 Jul 10, 2015

+ 4MG N205422 006 Jul 10, 2015

BRIGATINIB

TABLET; ORAL

ALUNBRIG

+ ARIAD 30MG N208772 001 Apr 28, 2017

+ 90MG N208772 002 Apr 28, 2017

+! 180MG N208772 003 Oct 02, 2017

BRILLIANT BLUE G

SOLUTION; OPHTHALMIC

TISSUEBLUE

+! DUTCH OPHTHALMIC 0.025% N209569 001 Dec 20, 2019

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+! GALDERMA LABS LP EQ 0.33% BASE N204708 001 Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P**AT +! ALLERGAN 0.15% N021262 001 Mar 16, 2001****BRIMONIDINE TARTRATE****AT AKORN 0.2% A076439 001 Mar 14, 2006****AT ! BAUSCH AND LOMB 0.2% A076260 001 May 28, 2003****AT INDOCO REMEDIES 0.2% A091691 001 Nov 18, 2014****AT SANDOZ INC 0.2% A076254 001 Sep 16, 2003****AT 0.2% A078075 001 Jan 30, 2008****AT SOMERSET THERAPS 0.2% A208992 001 Mar 11, 2019**

LLC

QOLIANA**AT SANDOZ INC 0.15% N021764 001 May 22, 2006**

ALPHAGAN P

+! ALLERGAN 0.1% N021770 001 Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+! NOVARTIS 0.2%; 1% N204251 001 Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+! ALLERGAN 0.2%; EQ 0.5% BASE N021398 001 Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+! NOVARTIS 1% N020816 001 Apr 01, 1998

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+! UCB INC 50MG/5ML (10MG/ML) N205837 001 May 12, 2016

SOLUTION; ORAL

BRIVIACT

+! UCB INC 10MG/ML N205838 001 May 12, 2016

TABLET; ORAL

BRIVIACT

+ UCB INC 10MG N205836 001 May 12, 2016

+ 25MG N205836 002 May 12, 2016

+ 50MG N205836 003 May 12, 2016

+ 75MG N205836 004 May 12, 2016

+! 100MG N205836 005 May 12, 2016

PRESCRIPTION DRUG PRODUCT LIST

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2	!	ALEMBIC PHARMS LTD	<u>EQ 0.09% ACID</u>	<u>A210560</u>	<u>001</u>	Jun 21, 2019
AT2	!	HI TECH	<u>EQ 0.09% ACID</u>	<u>A203395</u>	<u>001</u>	Jan 22, 2014
AT2		MYLAN	<u>EQ 0.09% ACID</u>	<u>A203368</u>	<u>001</u>	Jun 03, 2019
		BROMSITE				
	+	!	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001 Apr 08, 2016
		PROLENSA				
	+	!	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	!	MYLAN	<u>EQ 5MG BASE</u>	<u>A077226</u>	<u>001</u>	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A078899</u>	<u>001</u>	Jul 30, 2008

PARLODEL

AB	+	US PHARMS HOLDINGS I	<u>EQ 5MG BASE</u>	<u>N017962</u>	<u>002</u>	Mar 01, 1982
-----------	---	-------------------------	--------------------	----------------	------------	--------------

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076962</u>	<u>001</u>	Sep 24, 2004
AB	!	PADDOCK LLC	<u>EQ 2.5MG BASE</u>	<u>A077646</u>	<u>001</u>	Oct 01, 2008
AB		SANDOZ INC	<u>EQ 2.5MG BASE</u>	<u>A074631</u>	<u>001</u>	Jan 13, 1998

PARLODEL

AB	+	US PHARMS HOLDINGS I	<u>EQ 2.5MG BASE</u>	<u>N017962</u>	<u>001</u>	
		CYCLOSET				
	+	!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001 May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	!	WOCKHARDT BIO AG	<u>2MG/5ML;10MG/5ML;30MG/5ML</u>	<u>A088811</u>	<u>001</u>	Jun 07, 1985
-----------	---	------------------	----------------------------------	----------------	------------	--------------

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA	<u>2MG/5ML;10MG/5ML;30MG/5ML</u>	<u>A203375</u>	<u>001</u>	Sep 20, 2016
AA		MAYNE PHARMA INC	<u>2MG/5ML;10MG/5ML;30MG/5ML</u>	<u>A207676</u>	<u>001</u>	Dec 04, 2018
AA		PADDOCK LLC	<u>2MG/5ML;10MG/5ML;30MG/5ML</u>	<u>A205292</u>	<u>001</u>	Jul 15, 2014
AA		TARO	<u>2MG/5ML;10MG/5ML;30MG/5ML</u>	<u>A205112</u>	<u>001</u>	Feb 27, 2017

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+	!	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001 Oct 07, 2014
--	---	---	---------------------	---------------	---------	------------------

CAPSULE;ORAL

BUDESONIDE

AB		ALVOGEN	<u>3MG</u>	<u>A206724</u>	<u>001</u>	Nov 23, 2016
AB		AMNEAL PHARMS	<u>3MG</u>	<u>A206200</u>	<u>001</u>	Jul 31, 2017
AB		APPCO	<u>3MG</u>	<u>A207367</u>	<u>001</u>	Apr 07, 2017
AB		BARR LABS DIV TEVA	<u>3MG</u>	<u>A090379</u>	<u>001</u>	Apr 02, 2014
AB		MAYNE PHARMA	<u>3MG</u>	<u>A206623</u>	<u>001</u>	Apr 08, 2016
AB		MYLAN	<u>3MG</u>	<u>A090410</u>	<u>001</u>	May 16, 2011
AB		SCIECURE PHARMA INC	<u>3MG</u>	<u>A209041</u>	<u>001</u>	Sep 28, 2017
AB		ZYDUS PHARMS	<u>3MG</u>	<u>A206134</u>	<u>001</u>	May 04, 2017

ENTOCORT EC

AB	+	!	PERRIGO PHARMA INTL	<u>3MG</u>	<u>N021324</u>	<u>001</u>	Oct 02, 2001
-----------	---	---	---------------------	------------	----------------	------------	--------------

CAPSULE, EXTENDED RELEASE;ORAL

ORTIKOS

	+		SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019
--	---	--	-------------------	-----	---------	-----	--------------

	+	!		9MG	N211929	002	Jun 13, 2019
--	---	---	--	-----	---------	-----	--------------

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+		ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
--	---	--	-------------	------------	---------	-----	--------------

	+	!		0.16MG/INH	N021949	002	Jul 12, 2006
--	---	---	--	------------	---------	-----	--------------

SUSPENSION;INHALATION

BUDESONIDE

AN		CIPLA	<u>0.25MG/2ML</u>	<u>A205710</u>	<u>001</u>	Nov 16, 2017
AN			<u>0.5MG/2ML</u>	<u>A205710</u>	<u>002</u>	Nov 16, 2017
AN			<u>1MG/2ML</u>	<u>A205710</u>	<u>003</u>	Nov 16, 2017
AN		IMPAX LABS INC	<u>0.25MG/2ML</u>	<u>A078404</u>	<u>001</u>	Jul 31, 2012
AN			<u>0.5MG/2ML</u>	<u>A078404</u>	<u>002</u>	Jul 31, 2012
AN		LUPIN ATLANTIS	<u>0.5MG/2ML</u>	<u>A210897</u>	<u>001</u>	Nov 09, 2018
AN		NEPHRON	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078202 002</u>	Mar 30, 2009
<u>AN</u>	SANDOZ INC	<u>0.25MG/2ML</u>	<u>A201966 003</u>	Sep 27, 2013
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A201966 002</u>	Sep 27, 2013
<u>AN</u>		<u>1MG/2ML</u>	<u>A201966 001</u>	Sep 27, 2013
<u>AN</u>	TEVA PHARMS	<u>0.25MG/2ML</u>	<u>A077519 001</u>	Nov 18, 2008
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519 002</u>	Nov 18, 2008
<u>AN</u>	TEVA PHARMS USA	<u>1MG/2ML</u>	<u>A204548 001</u>	Mar 08, 2016

PULMICORT RESPULES

<u>AN</u>	+	ASTRAZENECA PHARMS	<u>0.25MG/2ML</u>	<u>N020929 001</u>	Aug 08, 2000
<u>AN</u>	+		<u>0.5MG/2ML</u>	<u>N020929 002</u>	Aug 08, 2000
<u>AN</u>	+	!	<u>1MG/2ML</u>	<u>N020929 003</u>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

BUDESONIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>9MG</u>	<u>A205457 001</u>	Jul 03, 2018
-----------	---------------------	------------	--------------------	--------------

UCERIS

<u>AB</u>	+	SALIX	<u>9MG</u>	<u>N203634 001</u>	Jan 14, 2013
-----------	---	-------	------------	--------------------	--------------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+	!	ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929 001	Jul 21, 2006
+	!		0.16MG/INH; 0.0045MG/INH	N021929 002	Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>		HOSPIRA	<u>0.25MG/ML</u>	<u>A074332 001</u>	Oct 31, 1994
<u>AP</u>	!	WEST-WARD PHARMS	<u>0.25MG/ML</u>	<u>A079196 001</u>	Apr 30, 2008

TABLET; ORAL

BUMETANIDE

<u>AB</u>		AMNEAL PHARMS CO	<u>0.5MG</u>	<u>A209724 001</u>	Oct 18, 2017
<u>AB</u>			<u>1MG</u>	<u>A209724 002</u>	Oct 18, 2017
<u>AB</u>			<u>2MG</u>	<u>A209724 003</u>	Oct 18, 2017
<u>AB</u>		CEYONE	<u>0.5MG</u>	<u>A212019 001</u>	Dec 12, 2019
<u>AB</u>			<u>1MG</u>	<u>A212019 002</u>	Dec 12, 2019
<u>AB</u>			<u>2MG</u>	<u>A212019 003</u>	Dec 12, 2019
<u>AB</u>		HERITAGE PHARMA	<u>0.5MG</u>	<u>A074225 001</u>	Apr 24, 1995
<u>AB</u>			<u>1MG</u>	<u>A074225 002</u>	Apr 24, 1995
<u>AB</u>			<u>2MG</u>	<u>A074225 003</u>	Apr 24, 1995
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A074700 001</u>	Nov 21, 1996
<u>AB</u>			<u>1MG</u>	<u>A074700 002</u>	Nov 21, 1996
<u>AB</u>	!		<u>2MG</u>	<u>A074700 003</u>	Nov 21, 1996
<u>AB</u>		UPSHER SMITH LABS	<u>0.5MG</u>	<u>A209916 001</u>	Jan 23, 2018
<u>AB</u>			<u>1MG</u>	<u>A209916 002</u>	Jan 23, 2018
<u>AB</u>			<u>2MG</u>	<u>A209916 003</u>	Jan 23, 2018
<u>AB</u>		ZYDUS PHARMS	<u>0.5MG</u>	<u>A202900 001</u>	Apr 30, 2018
<u>AB</u>			<u>1MG</u>	<u>A202900 002</u>	Apr 30, 2018
<u>AB</u>			<u>2MG</u>	<u>A202900 003</u>	Apr 30, 2018

BUMEX

<u>AB</u>	+	VALIDUS PHARMS	<u>0.5MG</u>	<u>N018225 002</u>	Feb 28, 1983
<u>AB</u>	+		<u>1MG</u>	<u>N018225 001</u>	Feb 28, 1983
<u>AB</u>	+		<u>2MG</u>	<u>N018225 003</u>	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011
+	!		266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A207183 001</u>	May 13, 2016
<u>AP</u>			<u>0.5%</u>	<u>A207183 002</u>	May 13, 2016
<u>AP</u>		HOSPIRA	<u>0.25%</u>	<u>A070583 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070586 001</u>	Mar 03, 1987
<u>AP</u>			<u>0.25%</u>	<u>A070590 001</u>	Feb 17, 1987
<u>AP</u>			<u>0.25%</u>	<u>N018053 002</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070584 001</u>	Feb 17, 1986
<u>AP</u>			<u>0.5%</u>	<u>A070597 001</u>	Mar 03, 1987

PRESCRIPTION DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>0.5%</u>	<u>A070609 001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>N018053 001</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070585 001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>N018053 003</u>	

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895 001</u>	Nov 05, 2013
<u>AP</u>		<u>0.5%</u>	<u>A203895 002</u>	Nov 05, 2013
<u>AP</u>		<u>0.75%</u>	<u>A203895 003</u>	Nov 05, 2013

MARCAINE HYDROCHLORIDE

<u>AP</u>	+! HOSPIRA	<u>0.25%</u>	<u>N016964 001</u>	
<u>AP</u>	+!	<u>0.5%</u>	<u>N016964 006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+! HOSPIRA	<u>0.25%</u>	<u>N016964 012</u>	
<u>AP</u>	+!	<u>0.5%</u>	<u>N016964 005</u>	
<u>AP</u>	+!	<u>0.75%</u>	<u>N016964 009</u>	

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552 001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304 001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553 001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304 002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554 001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304 003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	B BRAUN MEDICAL INC	<u>0.75%</u>	<u>A209087 001</u>	Apr 02, 2019
<u>AP</u>	BAXTER HLTHCARE CORP	<u>0.75%</u>	<u>A207266 001</u>	Jul 25, 2016
<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810 001</u>	Dec 11, 1987
<u>AP</u>	HUONS	<u>0.75%</u>	<u>A212822 001</u>	Dec 30, 2019

MARCAINE

<u>AP</u>	+! HOSPIRA	<u>0.75%</u>	<u>N018692 001</u>	May 04, 1984
-----------	------------	--------------	--------------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	! HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168 001</u>	Jun 16, 1988
<u>AP</u>		<u>0.5%;0.005MG/ML</u>	<u>A071170 001</u>	Jun 16, 1988
	!	0.25%;0.005MG/ML	A071165 001	Jun 16, 1988
		0.25%;0.005MG/ML	A071167 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+! HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 004</u>	
<u>AP</u>	+!	<u>0.5%;0.0091MG/ML</u>	<u>N016964 008</u>	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	+! HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 013</u>	
<u>AP</u>	+!	<u>0.5%;0.0091MG/ML</u>	<u>N016964 007</u>	
<u>AP</u>	+!	<u>0.75%;0.0091MG/ML</u>	<u>N016964 010</u>	

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.25%;0.0091MG/ML</u>	<u>A070967 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>A070968 001</u>	Oct 13, 1987
<u>AP</u>		<u>0.5%;0.0091MG/ML</u>	<u>N018304 004</u>	Sep 02, 1983
<u>AP</u>		<u>0.75%;0.0091MG/ML</u>	<u>N018304 005</u>	Sep 02, 1983
	BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE			
	! SEPTODONT	0.5%;0.0091MG/ML	A077250 001	Sep 27, 2006

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

<u>AB</u>	WATSON LABS TEVA	<u>5MCG/HR</u>	<u>A204937 001</u>	Nov 20, 2018
<u>AB</u>		<u>10MCG/HR</u>	<u>A204937 002</u>	Nov 20, 2018
<u>AB</u>		<u>15MCG/HR</u>	<u>A204937 003</u>	Nov 20, 2018
<u>AB</u>		<u>20MCG/HR</u>	<u>A204937 004</u>	Nov 20, 2018

BUTRANS

<u>AB</u>	+ PURDUE PHARMA LP	<u>5MCG/HR</u>	<u>N021306 001</u>	Jun 30, 2010
<u>AB</u>	+	<u>10MCG/HR</u>	<u>N021306 002</u>	Jun 30, 2010
<u>AB</u>	+	<u>15MCG/HR</u>	<u>N021306 004</u>	Jul 25, 2013
<u>AB</u>	+!	<u>20MCG/HR</u>	<u>N021306 003</u>	Jun 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

+

7.5MCG/HR

N021306 005 Jun 30, 2014

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE

+ INDIVIOR INC

100MG/0.5ML (100MG/0.5ML)

N209819 001 Nov 30, 2017

+!

300MG/1.5ML (200MG/ML)

N209819 002 Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+ BDSI

EQ 0.075MG BASE

N207932 001 Oct 23, 2015

+

EQ 0.15MG BASE

N207932 002 Oct 23, 2015

+

EQ 0.3MG BASE

N207932 003 Oct 23, 2015

+

EQ 0.45MG BASE

N207932 004 Oct 23, 2015

+

EQ 0.6MG BASE

N207932 005 Oct 23, 2015

+

EQ 0.75MG BASE

N207932 006 Oct 23, 2015

+!

EQ 0.9MG BASE

N207932 007 Oct 23, 2015

IMPLANT;IMPLANTATION

PROBUPHINE

+! TITAN PHARMS

EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016

INJECTABLE;INJECTION

BUPRENEXAP +! INDIVIOR INCEQ 0.3MG BASE/MLN018401 001BUPRENORPHINE HYDROCHLORIDEAP AM REGENTEQ 0.3MG BASE/MLA078331 001 Mar 27, 2007AP HOSPIRAEQ 0.3MG BASE/MLA074137 001 Jun 03, 1996AP PAR STERILEEQ 0.3MG BASE/MLA206586 001 Jul 28, 2015

PRODUCTS

AP WEST-WARD PHARMSEQ 0.3MG BASE/MLA076931 001 Mar 02, 2005

INT

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDEAB ACTAVIS ELIZABETHEQ 2MG BASEA090819 001 Feb 19, 2015ABEQ 8MG BASEA090819 002 Feb 19, 2015AB CASI PHARMS INCEQ 2MG BASEA090279 001 Jun 10, 2015ABEQ 8MG BASEA090279 002 Jun 10, 2015AB ETHYPHARMEQ 2MG BASEA090622 001 Sep 24, 2010ABEQ 8MG BASEA090622 002 Sep 24, 2010AB HIKMAEQ 2MG BASEA078633 001 Oct 08, 2009AB !EQ 8MG BASEA078633 002 Oct 08, 2009AB RHODES PHARMSEQ 2MG BASEA207276 001 Mar 27, 2017ABEQ 8MG BASEA207276 002 Mar 27, 2017AB SUN PHARMEQ 2MG BASEA201760 001 Jan 29, 2016ABEQ 8MG BASEA201760 002 Jan 29, 2016BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

+ BDSI

EQ 2.1MG BASE;EQ 0.3MG BASE

N205637 001 Jun 06, 2014

+

EQ 4.2MG BASE;EQ 0.7MG BASE

N205637 002 Jun 06, 2014

+!

EQ 6.3MG BASE;EQ 1MG BASE

N205637 003 Jun 06, 2014

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDEAB ALVOGEN PINE BROOKEQ 2MG BASE;EQ 0.5MG BASEA205954 001 Jan 24, 2019ABEQ 4MG BASE;EQ 1MG BASEA205954 002 Jan 24, 2019ABEQ 8MG BASE;EQ 2MG BASEA205954 003 Jan 24, 2019ABEQ 12MG BASE;EQ 3MG BASEA205954 004 Jan 24, 2019AB DR REDDYS LABS SAEQ 2MG BASE;EQ 0.5MG BASEA205299 001 Jun 14, 2018ABEQ 4MG BASE;EQ 1MG BASEA205806 001 Jun 14, 2018ABEQ 8MG BASE;EQ 2MG BASEA205299 002 Jun 14, 2018ABEQ 12MG BASE;EQ 3MG BASEA205806 002 Jun 14, 2018AB MYLAN TECHNOLOGIESEQ 8MG BASE;EQ 2MG BASEA207607 001 Jun 14, 2018ABEQ 12MG BASE;EQ 3MG BASEA207607 002 Jun 14, 2018SUBOXONEAB + INDIVIOR INCEQ 2MG BASE;EQ 0.5MG BASEN022410 001 Aug 30, 2010AB +EQ 4MG BASE;EQ 1MG BASEN022410 003 Aug 10, 2012AB +EQ 8MG BASE;EQ 2MG BASEN022410 002 Aug 30, 2010AB +!EQ 12MG BASE;EQ 3MG BASEN022410 004 Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDEAB ACTAVIS ELIZABETHEQ 2MG BASE;EQ 0.5MG BASEA091422 001 Feb 22, 2013AB !EQ 8MG BASE;EQ 2MG BASEA091422 002 Feb 22, 2013

PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A203136 001	Feb 22, 2013
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A203136 002	Feb 22, 2013
AB	ETHYPHARM USA CORP	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A204431 001	Oct 16, 2015
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A204431 002	Oct 16, 2015
AB	HIKMA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A203326 001	Jun 27, 2014
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A203326 002	Jun 27, 2014
AB	LANNETT CO INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A205022 001	Sep 19, 2016
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A205022 002	Sep 19, 2016
AB	SPECGX LLC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A207000 001	Dec 13, 2017
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A207000 002	Dec 13, 2017
AB	SUN PHARM	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	A201633 001	Aug 05, 2016
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	A201633 002	Aug 05, 2016
ZUBSOLV				
+	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242 006	Oct 04, 2016
+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242 005	Jun 04, 2015
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	VALEANT PHARMS	174MG	N022108 001	Apr 23, 2008
	NORTH			
+		348MG	N022108 002	Apr 23, 2008
+	!	522MG	N022108 003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	75MG	A203013 001	Jun 08, 2018
AB		100MG	A203013 002	Jun 08, 2018
AB	APNAR PHARMA LP	75MG	A075584 001	Feb 07, 2000
AB		100MG	A075584 002	Feb 07, 2000
AB	APOTEX INC	75MG	A076143 001	Jan 17, 2006
AB	!	100MG	A076143 002	Jan 17, 2006
AB	HERITAGE PHARMA	75MG	A206975 001	Aug 19, 2016
AB		100MG	A206975 002	Aug 19, 2016
AB	INVAGEN PHARMS	75MG	A207389 001	Sep 18, 2017
AB		100MG	A207389 002	Sep 18, 2017
AB	MYLAN	75MG	A075491 001	Apr 17, 2000
AB		100MG	A075491 002	Apr 17, 2000

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	100MG	A079095 001	Mar 24, 2009
AB1		150MG	A079095 002	Mar 24, 2009
AB1		200MG	A079095 003	Mar 24, 2009
AB1	ANCHEN PHARMS	100MG	A091459 001	Jun 09, 2011
AB1		150MG	A091459 002	Jun 09, 2011
AB1		200MG	A091459 003	Jun 09, 2011
AB1	IMPAX LABS	100MG	A075913 001	Jan 28, 2004
AB1		150MG	A075913 002	Mar 22, 2004
AB1		200MG	A076711 001	Dec 03, 2004
AB1	INVAGEN PHARMS	100MG	A206674 001	Feb 09, 2016
AB1		150MG	A206674 002	Feb 09, 2016
AB1		200MG	A206674 003	Feb 09, 2016
AB1	JUBILANT GENERICS	100MG	A202774 001	Oct 11, 2013
AB1		150MG	A202774 002	Oct 11, 2013
AB1		200MG	A202774 003	Oct 11, 2013
AB1	PRINSTON INC	100MG	A202304 001	May 26, 2015
AB1		150MG	A202304 002	May 26, 2015
AB1		200MG	A202304 003	May 26, 2015
AB1	SANDOZ	100MG	A075932 001	Nov 25, 2003
AB1		150MG	A075932 002	Mar 22, 2004
AB1		200MG	A075932 003	Jun 22, 2005
AB1	SCIEGEN PHARMS INC	100MG	A205794 001	Mar 01, 2016
AB1		150MG	A205794 002	Mar 01, 2016
AB1		200MG	A205794 003	Mar 01, 2016
AB1	SUN PHARM	100MG	A078866 001	Apr 06, 2010
AB1		150MG	A078866 002	Apr 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT	<u>100MG</u>	<u>A203969</u>	<u>001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969</u>	<u>002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969</u>	<u>003</u>	Oct 31, 2014
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010

WELLBUTRIN SR

<u>AB1</u>	+	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>	+		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	!	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	!	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>AB2</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>		IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>		JUBILANT GENERICS	<u>150MG</u>	<u>A202775</u>	<u>001</u>	Oct 11, 2013
<u>AB2</u>		SANDOZ INC	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>		SCIEGEN PHARMS INC	<u>150MG</u>	<u>A206122</u>	<u>001</u>	Aug 17, 2016
<u>AB3</u>		ACCORD HLTHCARE	<u>150MG</u>	<u>A210497</u>	<u>001</u>	Oct 31, 2018
<u>AB3</u>			<u>300MG</u>	<u>A210497</u>	<u>002</u>	Oct 31, 2018
<u>AB3</u>		ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		ANBISON LAB	<u>150MG</u>	<u>A207224</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207224</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>			<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>		GRAVITI PHARMS	<u>150MG</u>	<u>A211020</u>	<u>001</u>	Jan 28, 2019
<u>AB3</u>			<u>300MG</u>	<u>A211020</u>	<u>002</u>	Jan 28, 2019
<u>AB3</u>		IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		INVAGEN PHARMS	<u>150MG</u>	<u>A206556</u>	<u>001</u>	Aug 26, 2016
<u>AB3</u>			<u>300MG</u>	<u>A206556</u>	<u>002</u>	Aug 26, 2016
<u>AB3</u>		JUBILANT GENERICS	<u>150MG</u>	<u>A207459</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207459</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>		LUPIN LTD	<u>150MG</u>	<u>A090693</u>	<u>001</u>	Apr 06, 2017
<u>AB3</u>			<u>300MG</u>	<u>A090693</u>	<u>002</u>	Apr 06, 2017
<u>AB3</u>		SCIEGEN PHARMS INC	<u>150MG</u>	<u>A207479</u>	<u>001</u>	Apr 12, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207479</u>	<u>002</u>	Apr 12, 2017
<u>AB3</u>		SINOTHERAPEUTICS INC	<u>150MG</u>	<u>A208652</u>	<u>001</u>	Aug 21, 2017
<u>AB3</u>			<u>300MG</u>	<u>A208652</u>	<u>002</u>	Aug 21, 2017
<u>AB3</u>		TWI PHARMS	<u>150MG</u>	<u>A210081</u>	<u>001</u>	Nov 03, 2017
<u>AB3</u>			<u>300MG</u>	<u>A210081</u>	<u>002</u>	Nov 03, 2017
<u>AB3</u>		WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>			<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>		WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>		YICHANG HUMANWELL	<u>150MG</u>	<u>A210015</u>	<u>001</u>	Jun 14, 2018
<u>AB3</u>			<u>300MG</u>	<u>A210015</u>	<u>002</u>	Jun 14, 2018
<u>AB3</u>		ZHEJIANG JUTAI PHARM	<u>300MG</u>	<u>A211200</u>	<u>001</u>	Sep 05, 2019
<u>AB3</u>		ZYDUS PHARMS	<u>150MG</u>	<u>A201567</u>	<u>002</u>	Jul 23, 2018
<u>AB3</u>			<u>300MG</u>	<u>A201567</u>	<u>001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	+	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>	+	!	<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
		FORFIVO XL				
	+	ALVOGEN	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	!	NALPROPION	90MG; 8MG	N200063	001	Sep 10, 2014
---	---	------------	-----------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A202557</u>	<u>001</u>	Dec 30, 2014
<u>AB</u>			<u>7.5MG</u>	<u>A202557</u>	<u>002</u>	Dec 30, 2014
<u>AB</u>			<u>10MG</u>	<u>A202557</u>	<u>003</u>	Dec 30, 2014
<u>AB</u>			<u>15MG</u>	<u>A202557</u>	<u>004</u>	Dec 30, 2014
<u>AB</u>			<u>30MG</u>	<u>A202557</u>	<u>005</u>	Dec 30, 2014
<u>AB</u>		AMNEAL PHARMS CO	<u>5MG</u>	<u>A208829</u>	<u>001</u>	May 24, 2017
<u>AB</u>			<u>7.5MG</u>	<u>A208829</u>	<u>002</u>	May 24, 2017

PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A208829</u>	<u>003</u>	May 24, 2017
<u>AB</u>		<u>15MG</u>	<u>A208829</u>	<u>004</u>	May 24, 2017
<u>AB</u>		<u>30MG</u>	<u>A208829</u>	<u>005</u>	May 24, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A208972</u>	<u>001</u>	Apr 16, 2019
<u>AB</u>		<u>7.5MG</u>	<u>A208972</u>	<u>002</u>	Apr 16, 2019
<u>AB</u>		<u>10MG</u>	<u>A208972</u>	<u>003</u>	Apr 16, 2019
<u>AB</u>		<u>15MG</u>	<u>A208972</u>	<u>004</u>	Apr 16, 2019
<u>AB</u>		<u>30MG</u>	<u>A208972</u>	<u>005</u>	Apr 16, 2019
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A204582</u>	<u>001</u>	Sep 18, 2015
<u>AB</u>		<u>10MG</u>	<u>A204582</u>	<u>002</u>	Sep 18, 2015
<u>AB</u>		<u>15MG</u>	<u>A204582</u>	<u>003</u>	Sep 18, 2015
<u>AB</u>		<u>30MG</u>	<u>A204582</u>	<u>004</u>	Sep 18, 2015
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	INVENTIA HLTHCARE	<u>5MG</u>	<u>A209696</u>	<u>001</u>	May 03, 2018
<u>AB</u>		<u>7.5MG</u>	<u>A209696</u>	<u>002</u>	May 03, 2018
<u>AB</u>		<u>10MG</u>	<u>A209696</u>	<u>003</u>	May 03, 2018
<u>AB</u>		<u>15MG</u>	<u>A209696</u>	<u>004</u>	May 03, 2018
<u>AB</u>		<u>30MG</u>	<u>A209696</u>	<u>005</u>	May 03, 2018
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076008</u>	<u>003</u>	Mar 01, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>7.5MG</u>	<u>A076008</u>	<u>002</u>	Jul 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A076008</u>	<u>004</u>	Mar 01, 2002
<u>AB</u>		<u>15MG</u>	<u>A076008</u>	<u>005</u>	Mar 28, 2001
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	OXFORD PHARMS	<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202330</u>	<u>001</u>	Aug 25, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202330</u>	<u>005</u>	Feb 17, 2017
<u>AB</u>		<u>10MG</u>	<u>A202330</u>	<u>002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330</u>	<u>003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330</u>	<u>004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>	!	<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A210907</u>	<u>001</u>	Nov 14, 2019
<u>AB</u>		<u>10MG</u>	<u>A210907</u>	<u>002</u>	Nov 14, 2019
<u>AB</u>		<u>15MG</u>	<u>A210907</u>	<u>003</u>	Nov 14, 2019
<u>AB</u>		<u>30MG</u>	<u>A210907</u>	<u>004</u>	Nov 14, 2019
<u>AB</u>	YILING PHARM LTD	<u>5MG</u>	<u>A202087</u>	<u>001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087</u>	<u>002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A202087</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A078888</u>	<u>001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888</u>	<u>002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888</u>	<u>003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888</u>	<u>004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	ACCORD HLTHCARE INC	<u>6MG/ML</u>	<u>A210148</u>	<u>001</u>	Feb 22, 2019
<u>AP</u>	ACTAVIS LLC	<u>6MG/ML</u>	<u>A205139</u>	<u>001</u>	Dec 08, 2017
<u>AP</u>	AMNEAL	<u>6MG/ML</u>	<u>A209580</u>	<u>001</u>	Dec 18, 2017
<u>AP</u>	APOTEX	<u>6MG/ML</u>	<u>A210448</u>	<u>001</u>	May 07, 2019
<u>AP</u>	ATHENEX INC	<u>6MG/ML</u>	<u>A205106</u>	<u>001</u>	Sep 21, 2018
<u>AP</u>	HOSPIRA INC	<u>6MG/ML</u>	<u>A205672</u>	<u>001</u>	Jul 31, 2018
<u>AP</u>	LUITPOLD	<u>6MG/ML</u>	<u>A202259</u>	<u>001</u>	Dec 22, 2015
<u>AP</u>	MYLAN LABS LTD	<u>6MG/ML</u>	<u>A205184</u>	<u>001</u>	Jul 13, 2018
<u>AP</u>	NEXUS PHARMS	<u>6MG/ML</u>	<u>A207794</u>	<u>001</u>	Jan 14, 2019
<u>AP</u>	PHARMASCIENCE INC	<u>6MG/ML</u>	<u>A207050</u>	<u>001</u>	Mar 24, 2017
<u>AP</u>	SHILPA MEDICARE LTD	<u>6MG/ML</u>	<u>A210931</u>	<u>001</u>	Apr 18, 2019
<u>AP</u>	<u>BUSULFEX</u>				
<u>AP</u>	+!	<u>6MG/ML</u>	<u>N020954</u>	<u>001</u>	Feb 04, 1999

PRESCRIPTION DRUG PRODUCT LIST

BUSULFAN

INJECTABLE; INJECTION

MYLERAN

AP	MYLAN INSTITUTIONAL	6MG/ML	A208536 001	Nov 20, 2017
	TABLET; ORAL			
	MYLERAN			
	+! ASPEN GLOBAL	2MG	N009386 001	

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

+!	MYLAN SPECIALITY LP	30MG	N000793 004	
----	---------------------	------	-------------	--

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+!	MYLAN	1%	N020524 001	Oct 18, 1996
----	-------	----	-------------	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

!	PERRIGO ISRAEL	2%	A200923 001	May 18, 2012
---	----------------	----	-------------	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HIKMA FARMACEUTICA	1MG/ML	A078400 001	May 01, 2009
AP		2MG/ML	A078400 002	May 01, 2009
AP	WEST-WARD PHARMS	2MG/ML	A075046 001	Aug 12, 1998
	INT			

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	!	HOSPIRA	1MG/ML	A074626 001	Jan 23, 1997
AP	!		2MG/ML	A074626 002	Jan 23, 1997
AP		WEST-WARD PHARMS	1MG/ML	A075045 001	Aug 12, 1998
		INT			
AP			2MG/ML	A075045 002	Aug 12, 1998

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	APOTEX INC	1MG/SPRAY	A075499 001	Dec 04, 2002	
AB	HIKMA	1MG/SPRAY	A075824 001	Mar 12, 2002	
AB	!	MYLAN	1MG/SPRAY	A075759 001	Aug 08, 2001

CABAZITAXEL

SOLUTION; INTRAVENOUS

JEVTANA KIT

+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023 001	Jun 17, 2010
----	-------------------	----------------------	-------------	--------------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	INGENUS PHARMS LLC	0.5MG	A204735 001	Aug 01, 2018	
AB	IVAX SUB TEVA	0.5MG	A077750 001	Mar 07, 2007	
	PHARMS				
AB	MYLAN	0.5MG	A202947 001	Dec 02, 2013	
AB	!	PAR PHARM	0.5MG	A076310 001	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

+!	EXELIXIS	EQ 20MG BASE	N203756 001	Nov 29, 2012
+		EQ 80MG BASE	N203756 002	Nov 29, 2012

TABLET; ORAL

CABOMETYX

+	EXELIXIS INC	EQ 20MG BASE	N208692 001	Apr 25, 2016
+		EQ 40MG BASE	N208692 002	Apr 25, 2016
+!		EQ 60MG BASE	N208692 003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAF CIT

AP	+!	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999
-----------	----	-------	---	--------------------	--------------

CAFFEINE CITRATE

AP	AUROBINDO PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013 001	Sep 22, 2015
	LTD			
AP	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233 001	Sep 21, 2006
	SCIENCE			
AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077997 001	Jul 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

AP	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906 001</u>	May 15, 2007
AP	MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A207400 001</u>	Dec 14, 2017
AP	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827 001</u>	Aug 29, 2012
AP	SUN PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077 001</u>	Sep 30, 2009

SOLUTION; ORAL

CAFCTT

AA	+ ! HIKMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793 002</u>	Apr 12, 2000
-----------	------------------	---	--------------------	--------------

CAFFEINE CITRATE

AA	EXELA PHARMA SCS LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304 001</u>	Sep 21, 2006
AA	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002 001</u>	Jan 31, 2008
AA	MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A213202 001</u>	Dec 16, 2019
AA	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102 001</u>	Aug 29, 2012
AA	SUN PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357 001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

! COSETTE

100MG; 2MG

A086557 001 Oct 04, 1983

TABLET; ORAL

CAFERGOT

AA	! SANDOZ	<u>100MG; 1MG</u>	<u>A084294 001</u>	
-----------	-----------------	-------------------	--------------------	--

ERGOTAMINE TARTRATE AND CAFFEINE

AA	HIKMA INTL PHARMS	<u>100MG; 1MG</u>	<u>A040510 001</u>	Sep 17, 2004
AA	MIKART	<u>100MG; 1MG</u>	<u>A040590 001</u>	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+! OPKO IRELAND GLOBAL 0.03MG

N208010 001 Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+! MAYNE PHARMA 0.005%

N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENE

AB	GLENMARK PHARMS	<u>0.005%</u>	<u>A205772 001</u>	Jun 09, 2015
AB	TOLMAR	<u>0.005%</u>	<u>A200935 001</u>	May 30, 2012

DOVONEX

AB	+ ! LEO PHARMA AS	<u>0.005%</u>	<u>N020554 001</u>	Jul 22, 1996
-----------	--------------------------	---------------	--------------------	--------------

OINTMENT; TOPICAL

CALCIPOTRIENE

! GLENMARK PHARMS INC 0.005%

A090633 001 Mar 24, 2010

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	ACP NIMBLE	<u>0.005%</u>	<u>A078468 001</u>	Mar 24, 2011
AT	FOUGERA PHARMS	<u>0.005%</u>	<u>A078305 001</u>	May 06, 2008
AT	HI TECH PHARMA	<u>0.005%</u>	<u>A077579 001</u>	Nov 19, 2009
AT	NOVEL LABS INC	<u>0.005%</u>	<u>A207163 001</u>	Dec 26, 2017
AT	! TOLMAR	<u>0.005%</u>	<u>A077029 001</u>	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+! MYLAN IRELAND LTD 200 IU/ML

N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON

AB	! APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396 001</u>	Nov 17, 2008
AB	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979 001</u>	Jun 08, 2009

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB	AMNEAL PHARMS	<u>0.25MCG</u>	<u>A203289 002</u>	Jun 14, 2017
AB		<u>0.5MCG</u>	<u>A203289 001</u>	Jun 14, 2017
AB	BIONPHARMA INC	<u>0.25MCG</u>	<u>A091174 001</u>	May 24, 2013
AB		<u>0.5MCG</u>	<u>A091174 002</u>	May 24, 2013
AB	HIKMA	<u>0.25MCG</u>	<u>A076917 001</u>	Mar 27, 2006
AB	STRIDES PHARMA	<u>0.25MCG</u>	<u>A091356 001</u>	Dec 12, 2014
AB		<u>0.5MCG</u>	<u>A091356 002</u>	Dec 12, 2014
AB	TEVA	<u>0.25MCG</u>	<u>A075765 001</u>	Oct 12, 2001

PRESCRIPTION DRUG PRODUCT LIST

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB		0.5MCG	A075765 002	Oct 12, 2001
-----------	--	---------------	--------------------	--------------

ROCALTRON

AB	+	VALIDUS PHARMS	0.25MCG	N018044 001
-----------	---	----------------	----------------	--------------------

AB	+	!	0.5MCG	N018044 002
-----------	---	---	---------------	--------------------

INJECTABLE; INJECTION

CALCITRIOL

!

AKORN

0.001MG/ML

A078066 001 Jan 29, 2008

OINTMENT; TOPICAL

VECTICAL

+

GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL

AA		ELYSIUM	1MCG/ML	A209798 001	Nov 21, 2018
-----------	--	---------	----------------	--------------------	--------------

AA		HIKMA	1MCG/ML	A076242 001	Jul 18, 2003
-----------	--	-------	----------------	--------------------	--------------

ROCALTRON

AA	+	!	VALIDUS PHARMS	1MCG/ML	N021068 001	Nov 20, 1998
-----------	---	---	----------------	----------------	--------------------	--------------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB		AMNEAL PHARMS	667MG	A201658 001	Oct 06, 2014
-----------	--	---------------	--------------	--------------------	--------------

AB		CHARTWELL RX	667MG	A091312 001	Jun 01, 2012
-----------	--	--------------	--------------	--------------------	--------------

AB		HERITAGE PHARMS INC	667MG	A202315 001	Jun 29, 2015
-----------	--	---------------------	--------------	--------------------	--------------

AB		HIKMA	667MG	A077728 001	Feb 26, 2008
-----------	--	-------	--------------	--------------------	--------------

AB		INVAGEN PHARMS	667MG	A203135 001	Feb 07, 2013
-----------	--	----------------	--------------	--------------------	--------------

AB		LOTUS PHARM CO LTD	667MG	A203298 001	Jul 26, 2016
-----------	--	--------------------	--------------	--------------------	--------------

AB		LUPIN LTD	667MG	A202127 001	Jul 09, 2015
-----------	--	-----------	--------------	--------------------	--------------

AB		NOSTRUM LABS INC	667MG	A203179 001	Oct 26, 2015
-----------	--	------------------	--------------	--------------------	--------------

PHOSLO GELCAPS

AB	+	!	FRESENIUS MEDCL	667MG	N021160 003	Apr 02, 2001
-----------	---	---	-----------------	--------------	--------------------	--------------

SOLUTION; ORAL

PHOSLYRA

+

FRESENIUS MEDCL

667MG/5ML

N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATE

AB		CHARTWELL MOLECULAR	667MG	A202420 001	Feb 05, 2013
-----------	--	---------------------	--------------	--------------------	--------------

AB		HERITAGE PHARMS INC	667MG	A202885 001	Jan 22, 2015
-----------	--	---------------------	--------------	--------------------	--------------

AB	!	PADDOCK LLC	667MG	A091561 001	Apr 13, 2011
-----------	---	-------------	--------------	--------------------	--------------

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	100MG/ML	A209088 001	Jul 27, 2017
-----------	--	-----------	-----------------	--------------------	--------------

AP		INTL MEDICATION SYS	100MG/ML	A203477 001	May 09, 2018
-----------	--	---------------------	-----------------	--------------------	--------------

AP		MEDEFIL INC	100MG/ML	A211553 001	May 01, 2019
-----------	--	-------------	-----------------	--------------------	--------------

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	+	!	HOSPIRA	100MG/ML	N021117 001	Jan 28, 2000
-----------	---	---	---------	-----------------	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

+

ALCON

0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML

N018469 001

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+

BAXTER HLTHCARE

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

N021703 011 Oct 10, 2008

CORP

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+

BAXTER HLTHCARE

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 006 Oct 25, 2006

CORP

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+

BAXTER HLTHCARE

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 002 Oct 25, 2006

CORP

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 003	Oct 25, 2006
----	----------------------	--	-------------	--------------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 015	Oct 10, 2008
----	----------------------	---	-------------	--------------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 004	Oct 25, 2006
----	----------------------	--	-------------	--------------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 014	Oct 10, 2008
----	----------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML</u>	N018883 001	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N018883 004	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020171 001	Aug 19, 1992
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML</u>	N018883 002	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N018883 005	Nov 30, 1984
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020171 002	Aug 19, 1992
-----------	-----------------	---	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML</u>	N018883 003	Nov 30, 1984
-----------	-----------------	--	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N018883 006	Nov 30, 1984
-----------	-----------------	--	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	<u>18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020171 003	Aug 19, 1992
-----------	-----------------	--	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020183 001	Dec 04, 1992
-----------	-------------------	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020183 002	Dec 04, 1992
-----------	-------------------	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020183 004	Dec 04, 1992
-----------	-------------------	--	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 012	Jan 10, 1989
-----------	-------------------	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 013	Jul 11, 1990
-----------	-------------------	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 014	Jul 11, 1990
-----------	-------------------	---	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 015	Jul 11, 1990
-----------	-------------------	--	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+ BAXTER HLTHCARE	<u>25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 004	
-----------	-------------------	---	--------------------	--

AT	+	<u>25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N020163 001	Dec 04, 1992
-----------	---	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	N017512 005	
-----------	---	---	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+		<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML</u>	<u>N020163 002</u>	Dec 04, 1992
-----------	---	--	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N017512 006</u>	
-----------	---	-----------------	---	--------------------	--

AT	+		<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N020163 003</u>	Dec 04, 1992
-----------	---	--	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTT'S B SOLUTION

+	!	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577 001	Sep 27, 1996
---	---	--------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017608 001</u>	
-----------	---	-----------------	--	--------------------	--

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019634 003</u>	Feb 24, 1988
-----------	--	---------	--	--------------------	--------------

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016679 001</u>	
-----------	--	-----------------	--	--------------------	--

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985
-----------	--	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985
-----------	--	-----------------	---	--------------------	--------------

AP			<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985
-----------	--	--	---	--------------------	--------------

AP	+	ICU MEDICAL INC	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988
-----------	---	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985
-----------	--	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985
-----------	--	-----------------	---	--------------------	--------------

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

		B BRAUN	10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML	N019634 001	Feb 24, 1988
--	--	---------	---	-------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 002	Apr 05, 1985
--	--	-----------------	--	-------------	--------------

			20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019367 003	Apr 05, 1985
--	--	--	--	-------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 001	Apr 05, 1985
--	--	-----------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+	!	HOSPIRA	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N018895 001	Jul 20, 1984
---	---	---------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

AT		AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006
-----------	--	-------	---	--------------------	--------------

AT		B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010
-----------	--	---------	---	--------------------	--------------

BSS

AT	+	ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997
-----------	---	-------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B2K 4/0 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026 002	Jan 13, 2015
----	----------------------	--	-------------	--------------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML	N207026 001	Jan 13, 2015
----	----------------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A075323 001</u>	Apr 21, 2000
-----------	-----------------	---	---------------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

AT	+! HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>N018608 001</u>	Feb 26, 1982
-----------	------------	---	---------------------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992
AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	
AP	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156 001</u>	
AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495 001</u>	Feb 19, 1982
AT	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635 001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632 001</u>	Feb 29, 1988
AP	+! BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682 001</u>	
AP	FRESENIUS KABI USA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>A209338 001</u>	Jan 28, 2019
AP	ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641 001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681 001</u>	Dec 27, 1982
AT	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494 001</u>	Feb 19, 1982
AT	+!	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921 001</u>	Apr 03, 1984
AT	+! ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416 001</u>	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418 001	Jun 15, 2017
+!		5GM/50ML (100MG/ML)	N208418 002	Jun 15, 2017
+!		10GM/100ML (100MG/ML)	N208418 003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906 001	Oct 29, 2018
+!		2GM/100ML (20MG/ML)	N210906 002	Oct 29, 2018

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+!	ONY	35MG/ML	N020521 001	Jul 01, 1998
----	-----	---------	-------------	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013
+!		300MG	N204042 002	Mar 29, 2013

PRESCRIPTION DRUG PRODUCT LIST

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG; 500MG	N204353	001	Aug 08, 2014
+		50MG; 1GM	N204353	002	Aug 08, 2014
+		150MG; 500MG	N204353	003	Aug 08, 2014
+	!	150MG; 1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG; 500MG	N205879	001	Sep 20, 2016
+		50MG; 1GM	N205879	002	Sep 20, 2016
+		150MG; 500MG	N205879	003	Sep 20, 2016
+	!	150MG; 1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

<u>AB</u>	+	ANI PHARMS INC	<u>4MG</u>	<u>N020838</u>	<u>001</u>	Jun 04, 1998
<u>AB</u>	+		<u>8MG</u>	<u>N020838</u>	<u>002</u>	Jun 04, 1998
<u>AB</u>	+		<u>16MG</u>	<u>N020838</u>	<u>003</u>	Jun 04, 1998
<u>AB</u>	+	!	<u>32MG</u>	<u>N020838</u>	<u>004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

<u>AB</u>		ALEMBIC PHARMS LTD	<u>4MG</u>	<u>A210302</u>	<u>001</u>	Dec 04, 2018
<u>AB</u>			<u>8MG</u>	<u>A210302</u>	<u>002</u>	Dec 04, 2018
<u>AB</u>			<u>16MG</u>	<u>A210302</u>	<u>003</u>	Dec 04, 2018
<u>AB</u>			<u>32MG</u>	<u>A209119</u>	<u>001</u>	Jun 20, 2017
<u>AB</u>		MACLEODS PHARMS LTD	<u>4MG</u>	<u>A203813</u>	<u>001</u>	Dec 05, 2016
<u>AB</u>			<u>8MG</u>	<u>A203813</u>	<u>002</u>	Dec 05, 2016
<u>AB</u>			<u>16MG</u>	<u>A203813</u>	<u>003</u>	Dec 05, 2016
<u>AB</u>			<u>32MG</u>	<u>A203813</u>	<u>004</u>	Dec 05, 2016
<u>AB</u>		MYLAN	<u>4MG</u>	<u>A078702</u>	<u>001</u>	May 03, 2013
<u>AB</u>			<u>8MG</u>	<u>A078702</u>	<u>002</u>	May 03, 2013
<u>AB</u>			<u>16MG</u>	<u>A078702</u>	<u>003</u>	May 03, 2013
<u>AB</u>			<u>32MG</u>	<u>A078702</u>	<u>004</u>	May 03, 2013
<u>AB</u>		ZYDUS PHARMS	<u>4MG</u>	<u>A091390</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>			<u>8MG</u>	<u>A091390</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>			<u>16MG</u>	<u>A091390</u>	<u>003</u>	Aug 23, 2017
<u>AB</u>			<u>32MG</u>	<u>A091390</u>	<u>004</u>	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	+	ANI PHARMS INC	<u>16MG; 12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>	+		<u>32MG; 12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	!	<u>32MG; 25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>16MG; 12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>			<u>32MG; 12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>			<u>32MG; 25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>16MG; 12.5MG</u>	<u>A204100</u>	<u>001</u>	Feb 27, 2015
<u>AB</u>			<u>32MG; 12.5MG</u>	<u>A204100</u>	<u>002</u>	Feb 27, 2015
<u>AB</u>			<u>32MG; 25MG</u>	<u>A204100</u>	<u>003</u>	Feb 27, 2015
<u>AB</u>		MYLAN	<u>16MG; 12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>			<u>32MG; 12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>			<u>32MG; 25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012
<u>AB</u>		PRINSTON INC	<u>16MG; 12.5MG</u>	<u>A207455</u>	<u>001</u>	Apr 11, 2018
<u>AB</u>			<u>32MG; 12.5MG</u>	<u>A207455</u>	<u>002</u>	Apr 11, 2018
<u>AB</u>			<u>32MG; 25MG</u>	<u>A207455</u>	<u>003</u>	Apr 11, 2018
<u>AB</u>		ZYDUS PHARMS	<u>16MG; 12.5MG</u>	<u>A203466</u>	<u>001</u>	Nov 27, 2017
<u>AB</u>			<u>32MG; 12.5MG</u>	<u>A203466</u>	<u>002</u>	Nov 27, 2017
<u>AB</u>			<u>32MG; 25MG</u>	<u>A203466</u>	<u>003</u>	Nov 27, 2017

CANGRELOR

POWDER; INTRAVENOUS

KENGREAL

+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015
---	----------------	-----------	---------	-----	--------------

CANNABIDIOL

SOLUTION; ORAL

EPIDIOLEX

+	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018
---	------------	----------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	ACCORD HLTHCARE	<u>150MG</u>	<u>A202593 001</u>	Apr 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A202593 002</u>	Apr 23, 2015
<u>AB</u>	ALKEM LABS LTD	<u>150MG</u>	<u>A207652 001</u>	Nov 24, 2017
<u>AB</u>		<u>500MG</u>	<u>A207652 002</u>	Nov 24, 2017
<u>AB</u>	AMNEAL PHARMS	<u>150MG</u>	<u>A204741 001</u>	Feb 28, 2017
<u>AB</u>		<u>500MG</u>	<u>A204741 002</u>	Feb 28, 2017
<u>AB</u>	EUGIA PHARMA	<u>150MG</u>	<u>A210604 001</u>	Apr 17, 2018
<u>AB</u>		<u>500MG</u>	<u>A210604 002</u>	Apr 17, 2018
<u>AB</u>	HIKMA	<u>150MG</u>	<u>A200483 001</u>	Jul 14, 2016
<u>AB</u>		<u>500MG</u>	<u>A200483 002</u>	Jul 14, 2016
<u>AB</u>	MSN	<u>150MG</u>	<u>A209365 001</u>	Jul 02, 2018
<u>AB</u>		<u>500MG</u>	<u>A209365 002</u>	Jul 02, 2018
<u>AB</u>	MYLAN	<u>150MG</u>	<u>A090943 001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943 002</u>	Aug 08, 2014
<u>AB</u>	SHILPA MEDICARE LTD	<u>150MG</u>	<u>A207456 001</u>	Dec 12, 2016
<u>AB</u>		<u>500MG</u>	<u>A207456 002</u>	Dec 12, 2016
<u>AB</u>	SUN PHARM	<u>150MG</u>	<u>A204668 001</u>	Jun 21, 2019
<u>AB</u>		<u>500MG</u>	<u>A204668 002</u>	Jun 21, 2019
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649 001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649 002</u>	Sep 16, 2013

XELODA

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896 001</u>	Apr 30, 1998
<u>AB</u>	+!	<u>500MG</u>	<u>N020896 002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

<u>AP</u>	+! AKORN	<u>EQ 1GM BASE/VIAL</u>	<u>N050095 001</u>	
<u>AP</u>	HISUN PHARM	<u>EQ 1GM BASE/VIAL</u>	<u>A204796 001</u>	Oct 18, 2018
	HANGZHOU			
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202634 001</u>	Nov 27, 2017

CAPSAICIN

PATCH; TOPICAL

QUTENZA

	+! AVERITAS	8%	<u>N022395 001</u>	Nov 16, 2009
--	-------------	----	--------------------	--------------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	AJANTA PHARMA LTD	<u>12.5MG</u>	<u>A212809 001</u>	Dec 13, 2019
<u>AB</u>		<u>25MG</u>	<u>A212809 002</u>	Dec 13, 2019
<u>AB</u>		<u>50MG</u>	<u>A212809 003</u>	Dec 13, 2019
<u>AB</u>		<u>100MG</u>	<u>A212809 004</u>	Dec 13, 2019
<u>AB</u>	BOSCOGEN	<u>12.5MG</u>	<u>A074677 004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677 002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677 001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677 003</u>	May 30, 1997
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG</u>	<u>A074505 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505 004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434 003</u>	Feb 13, 1996
<u>AB</u>	!	<u>100MG</u>	<u>A074434 004</u>	Feb 13, 1996
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A074477 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074477 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074477 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074477 004</u>	Feb 13, 1996
<u>AB</u>	SETON PHARMS	<u>12.5MG</u>	<u>A212223 001</u>	Oct 30, 2019
<u>AB</u>		<u>25MG</u>	<u>A212223 002</u>	Oct 30, 2019
<u>AB</u>		<u>50MG</u>	<u>A212223 003</u>	Oct 30, 2019
<u>AB</u>		<u>100MG</u>	<u>A212223 004</u>	Oct 30, 2019
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322 004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386 001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386 002</u>	May 23, 1996

PRESCRIPTION DRUG PRODUCT LIST

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>		<u>50MG</u>	<u>A074386</u>	<u>003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386</u>	<u>004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT LTD	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	MYLAN	25MG; 15MG	A074896	001	Dec 29, 1997
!		25MG; 25MG	A074896	002	Dec 29, 1997
!		50MG; 15MG	A074896	004	Dec 29, 1997
		50MG; 25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+	ALCON	0.01%	N016968	001	
---	-------	-------	---------	-----	--

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986</u>	<u>001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986</u>	<u>002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986</u>	<u>003</u>	Nov 25, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106</u>	<u>001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106</u>	<u>002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106</u>	<u>003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592</u>	<u>003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	+	SHIRE DEV LLC	<u>100MG</u>	<u>N020712</u>	<u>003</u>	Sep 30, 1997
<u>AB</u>	+		<u>200MG</u>	<u>N020712</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+	!	<u>300MG</u>	<u>N020712</u>	<u>002</u>	Sep 30, 1997
		EQUETRO				
	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+	!	300MG	N021710	003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT BIO AG	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002	
		<u>TEGRETOL</u>				
<u>AB</u>	+	NOVARTIS	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987
		<u>TERIL</u>				
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004	

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005

EPITOL

<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986
-----------	------	--------------	----------------	------------	--------------

TEGRETOL

<u>AB</u>	+	NOVARTIS	<u>200MG</u>	<u>N016608</u>	<u>001</u>
-----------	---	----------	--------------	----------------	------------

CARBAMAZEPINE

	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712</u>	<u>001</u>	Jul 05, 2001
		<u>EPITOL</u>			
<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524</u>	<u>001</u>	Jul 29, 1992
		<u>TEGRETOL</u>			
<u>AB</u>	+	NOVARTIS	<u>100MG</u>	<u>N018281</u>	<u>001</u>
		CARBAMAZEPINE			
!	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

<u>AB</u>	TARO	<u>100MG</u>	<u>A078115 001</u>	Mar 31, 2009
<u>AB</u>		<u>200MG</u>	<u>A078115 002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115 003</u>	Mar 31, 2009
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A205571 001</u>	Feb 07, 2019
<u>AB</u>		<u>200MG</u>	<u>A205571 002</u>	Feb 07, 2019
<u>AB</u>		<u>400MG</u>	<u>A205571 003</u>	Feb 07, 2019
<u>TEGRETOL-XR</u>				
<u>AB</u>	+ NOVARTIS	<u>100MG</u>	<u>N020234 001</u>	Mar 25, 1996
<u>AB</u>	+	<u>200MG</u>	<u>N020234 002</u>	Mar 25, 1996
<u>AB</u>	+!	<u>400MG</u>	<u>N020234 003</u>	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>A204291 001</u>	Jan 08, 2016
<u>AB</u>	AMERIGEN PHARMS LTD	<u>25MG</u>	<u>A203261 001</u>	Mar 10, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A211055 001</u>	Oct 21, 2019
<u>AB</u>	EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205304 001</u>	Feb 17, 2016
<u>AB</u>	NOVEL LABS INC	<u>25MG</u>	<u>A204763 001</u>	Oct 20, 2017
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A209910 001</u>	May 07, 2018
<u>LODOSYN</u>				
<u>AB</u>	+! ATON	<u>25MG</u>	<u>N017830 001</u>	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	SUN PHARM	<u>25MG;200MG;100MG</u>	<u>A079085 001</u>	May 10, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085 002</u>	May 10, 2012
<u>STALEVO 100</u>				
<u>AB</u>	+ ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485 002</u>	Jun 11, 2003
<u>STALEVO 150</u>				
<u>AB</u>	+ ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485 003</u>	Jun 11, 2003
	STALEVO 125			
	+ ORION PHARMA	31.25MG;200MG;125MG	N021485 006	Aug 29, 2008
	STALEVO 200			
	+! ORION PHARMA	50MG;200MG;200MG	N021485 004	Aug 02, 2007
	STALEVO 50			
	+! ORION PHARMA	12.5MG;200MG;50MG	N021485 001	Jun 11, 2003
	STALEVO 75			
	+ ORION PHARMA	18.75MG;200MG;75MG	N021485 005	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

	+ IMPAX LABS INC	23.75MG;95MG	N203312 001	Jan 07, 2015
	+	36.25MG;145MG	N203312 002	Jan 07, 2015
	+	48.75MG;195MG	N203312 003	Jan 07, 2015
	+!	61.25MG;245MG	N203312 004	Jan 07, 2015

SUSPENSION;ENTERAL

DUOPA

	+! ABBVIE INC	4.63MG/ML;20MG/ML	N203952 001	Jan 09, 2015
--	---------------	-------------------	-------------	--------------

TABLET;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260 001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260 002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260 003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120 001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120 002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120 003</u>	Jun 02, 2008
<u>AB</u>	MAYNE PHARMA	<u>10MG;100MG</u>	<u>A073618 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607 001</u>	Aug 28, 1992
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324 001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324 002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324 003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536 001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536 002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536 003</u>	Oct 28, 2008
<u>SINEMET</u>				
<u>AB</u>	+ MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

<u>AB</u>	+	<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+!	<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323</u>	<u>001</u>	Feb 08, 2013
<u>AB</u>		<u>50MG;200MG</u>	<u>A202323</u>	<u>002</u>	Feb 08, 2013
<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG;100MG</u>	<u>A210341</u>	<u>001</u>	Jun 05, 2019
<u>AB</u>		<u>50MG;200MG</u>	<u>A210341</u>	<u>002</u>	Jun 05, 2019
<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>	!	<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>	+	MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992
-----------	---	-------------------	-------------------	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008
<u>AB</u>	!	<u>25MG;250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARM	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003
---	--------	---------	---------	-----	--------------

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013
---	---	------	---------	---------	-----	--------------

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010	
<u>AA</u>	!	MIKART	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003
<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011	
	!	MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>50MG/5ML (10MG/ML)</u>	<u>A206775</u>	<u>001</u>	Feb 09, 2017
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A206775</u>	<u>002</u>	Feb 09, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A206775</u>	<u>003</u>	Feb 09, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A206775</u>	<u>004</u>	Feb 09, 2017
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
<u>AP</u>	EUGIA PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A205487</u>	<u>001</u>	Mar 28, 2016
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A205487</u>	<u>002</u>	Mar 28, 2016
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A205487</u>	<u>003</u>	Mar 28, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>150MG/15ML (10MG/ML)</u>	<u>A207324</u>	<u>002</u>	Feb 15, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A207324</u>	<u>003</u>	Feb 15, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A207324</u>	<u>004</u>	Feb 15, 2017
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	INGENUS PHARMS LLC	<u>50MG/5ML (10MG/ML)</u>	<u>A208487</u>	<u>001</u>	Apr 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A208487 002</u>	Apr 26, 2017
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A208487 003</u>	Apr 26, 2017
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A208487 004</u>	Apr 26, 2017
<u>AP</u>	MEITHEAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077096 001</u>	Jun 14, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077096 002</u>	Jun 14, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077096 003</u>	Jun 14, 2005
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077096 004</u>	Jun 03, 2013
<u>AP</u>	! PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269 001</u>	Oct 14, 2004
<u>AP</u>	!	<u>150MG/15ML (10MG/ML)</u>	<u>A077269 002</u>	Oct 14, 2004
<u>AP</u>	!	<u>450MG/45ML (10MG/ML)</u>	<u>A077269 003</u>	Oct 14, 2004
<u>AP</u>	!	<u>600MG/60ML (10MG/ML)</u>	<u>A077269 004</u>	Dec 28, 2007
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631 001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631 002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631 003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631 004</u>	Dec 02, 2008
<u>AP</u>	SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A078280 001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280 002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280 003</u>	May 08, 2008
<u>AP</u>	SUN PHARM	<u>50MG/5ML (10MG/ML)</u>	<u>A077926 001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926 002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926 003</u>	Sep 19, 2008
<u>AP</u>	! TEVA PHARMS USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077139 001</u>	Sep 21, 2005
<u>AP</u>	!	<u>150MG/15ML (10MG/ML)</u>	<u>A077139 002</u>	Sep 21, 2005
<u>AP</u>	!	<u>450MG/45ML (10MG/ML)</u>	<u>A077139 003</u>	Sep 21, 2005
<u>AP</u>	!	<u>600MG/60ML (10MG/ML)</u>	<u>A077139 004</u>	Sep 21, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/5ML (10MG/ML)</u>	<u>A077244 001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244 002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244 003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244 004</u>	Jan 20, 2006

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A207324 001</u>	Feb 15, 2017
-----------	------------------	---------------------------	--------------------	--------------

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 0.25MG BASE/ML</u>	<u>A211941 001</u>	Jul 02, 2019
<u>AP</u>	! PHARMACIA AND UPJOHN	<u>EQ 0.25MG BASE/ML</u>	<u>N017989 001</u>	

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

<u>AP</u>	DR REDDYS	<u>60MG/VIAL</u>	<u>A209422 001</u>	Sep 09, 2019
<u>AP</u>	! ONYX THERAP	<u>60MG/VIAL</u>	<u>N202714 001</u>	Jul 20, 2012
	+	10MG/VIAL	N202714 003	Jun 07, 2018
	+	30MG/VIAL	N202714 002	Jun 03, 2016

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+	! RECORDATI RARE	200MG	N022562 001	Mar 18, 2010
---	------------------	-------	-------------	--------------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

+	ALLERGAN	EQ 1.5MG BASE	N204370 001	Sep 17, 2015
+		EQ 3MG BASE	N204370 002	Sep 17, 2015
+		EQ 4.5MG BASE	N204370 003	Sep 17, 2015
+	!	EQ 6MG BASE	N204370 004	Sep 17, 2015

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACCELRX LABS	<u>350MG</u>	<u>A040576 001</u>	Jun 07, 2005
<u>AA</u>	ALLIED	<u>350MG</u>	<u>A040245 001</u>	Sep 08, 1997
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792 001</u>	Aug 06, 2009
<u>AA</u>	HIKMA INTL PHARMS	<u>350MG</u>	<u>A040124 001</u>	Jan 24, 1996
<u>AA</u>	NATCO PHARMA LTD	<u>350MG</u>	<u>A090988 001</u>	Oct 28, 2014

PRESCRIPTION DRUG PRODUCT LIST

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	NOVAST LABS	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085</u>	<u>001</u>	Oct 28, 2014
<u>AA</u>	SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>	STRIDES PHARMA	<u>350MG</u>	<u>A205513</u>	<u>002</u>	Nov 12, 2015
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
<u>AA</u>	WILSHIRE PHARMS INC	<u>350MG</u>	<u>A205126</u>	<u>002</u>	Jul 08, 2015

SOMA

<u>AA</u>	+ MYLAN SPECIALITY LP	<u>350MG</u>	<u>N011792</u>	<u>001</u>	
-----------	-----------------------	--------------	----------------	------------	--

CARISOPRODOL

<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A040792</u>	<u>002</u>	Nov 08, 2016
<u>AB</u>	NOSTRUM LABS INC	<u>250MG</u>	<u>A207237</u>	<u>001</u>	May 11, 2017
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A205513</u>	<u>001</u>	Nov 12, 2015
<u>AB</u>	WILSHIRE PHARMS INC	<u>250MG</u>	<u>A205126</u>	<u>001</u>	Jul 08, 2015

SOMA

<u>AB</u>	+! MYLAN SPECIALITY LP	<u>250MG</u>	<u>N011792</u>	<u>004</u>	Sep 13, 2007
-----------	------------------------	--------------	----------------	------------	--------------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+!	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996
----	------------------	-------	---------	-----	--------------

INJECTABLE; INJECTION

BICNU

<u>AP</u>	+! EMCURE PHARMS LTD	<u>100MG/VIAL</u>	<u>N017422</u>	<u>001</u>	
-----------	----------------------	-------------------	----------------	------------	--

CARMUSTINE

<u>AP</u>	AMNEAL	<u>100MG/VIAL</u>	<u>A211229</u>	<u>001</u>	Oct 16, 2018
<u>AP</u>	NAVINTA LLC	<u>100MG/VIAL</u>	<u>A210179</u>	<u>001</u>	Sep 11, 2018
<u>AP</u>	STI PHARMA LLC	<u>100MG/VIAL</u>	<u>A209278</u>	<u>001</u>	Apr 02, 2019

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

!	SANDOZ INC	1%	A075476	001	Jan 03, 2000
---	------------	----	---------	-----	--------------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	CHARTWELL MOLECULAR	<u>3.125MG</u>	<u>A077474</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	RUBICON	<u>3.125MG</u>	<u>A078165</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007

PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>		<u>12.5MG</u>	<u>A078227 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227 004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>3.125MG</u>	<u>A076989 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007

COREG

<u>AB</u>	+	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>	+		<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+		<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>	+		<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

CARVEDILOL PHOSPHATE

<u>AB</u>		IMPAX LABS INC	<u>10MG</u>	<u>A204717 001</u>	May 07, 2018
<u>AB</u>			<u>20MG</u>	<u>A204717 002</u>	May 07, 2018
<u>AB</u>			<u>40MG</u>	<u>A204717 003</u>	May 07, 2018
<u>AB</u>			<u>80MG</u>	<u>A204717 004</u>	May 07, 2018
<u>AB</u>		SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A090132 001</u>	Oct 25, 2017
<u>AB</u>			<u>20MG</u>	<u>A090132 002</u>	Oct 25, 2017
<u>AB</u>			<u>40MG</u>	<u>A090132 003</u>	Oct 25, 2017
<u>AB</u>			<u>80MG</u>	<u>A090132 004</u>	Oct 25, 2017

COREG CR

<u>AB</u>	+	SMITHKLINE BEECHAM	<u>10MG</u>	<u>N022012 001</u>	Oct 20, 2006
<u>AB</u>	+		<u>20MG</u>	<u>N022012 002</u>	Oct 20, 2006
<u>AB</u>	+		<u>40MG</u>	<u>N022012 003</u>	Oct 20, 2006
<u>AB</u>	+		<u>80MG</u>	<u>N022012 004</u>	Oct 20, 2006

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CANCIDAS

<u>AP</u>	+	MERCK	<u>50MG/VIAL</u>	<u>N021227 001</u>	Jan 26, 2001
<u>AP</u>	+		<u>70MG/VIAL</u>	<u>N021227 002</u>	Jan 26, 2001

CASPOFUNGIN ACETATE

<u>AP</u>		FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N206110 001</u>	Dec 30, 2016
<u>AP</u>			<u>70MG/VIAL</u>	<u>N206110 002</u>	Dec 30, 2016
<u>AP</u>		GLAND PHARMA LTD	<u>50MG/VIAL</u>	<u>A207092 001</u>	Sep 29, 2017
<u>AP</u>			<u>70MG/VIAL</u>	<u>A207092 002</u>	Sep 29, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>50MG/VIAL</u>	<u>A200833 001</u>	Jun 28, 2018
<u>AP</u>			<u>70MG/VIAL</u>	<u>A200833 002</u>	Jun 28, 2018
<u>AP</u>		MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A207650 001</u>	Sep 29, 2017
<u>AP</u>			<u>70MG/VIAL</u>	<u>A207650 002</u>	Sep 29, 2017
<u>AP</u>		XELLIA PHARMS APS	<u>50MG/VIAL</u>	<u>A205923 001</u>	Jul 02, 2018
<u>AP</u>			<u>70MG/VIAL</u>	<u>A205923 002</u>	Jul 02, 2018

CEFACLOR

CAPSULE; ORAL

CEFACLOR

<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A065350 001</u>	Apr 03, 2007
<u>AB</u>	!		<u>EQ 500MG BASE</u>	<u>A065350 002</u>	Apr 03, 2007
<u>AB</u>		YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146 001</u>	Jan 22, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065146 002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOR

		YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412 001</u>	Feb 17, 2012
			<u>EQ 187MG BASE/5ML</u>	<u>A065412 002</u>	Feb 17, 2012

PRESCRIPTION DRUG PRODUCT LIST

CEFACLOR

FOR SUSPENSION;ORAL

CEFACLOR

EQ 250MG BASE/5ML

A065412 003 Feb 17, 2012

!

EQ 375MG BASE/5ML

A065412 004 Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

TEVA

EQ 375MG BASE

A065058 001 Sep 04, 2002

!

EQ 500MG BASE

A065058 002 Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXILAB AUROBINDO PHARMAEQ 500MG BASEA065352 001 Jan 25, 2007AB HIKMAEQ 500MG BASEA065311 001 Feb 07, 2006AB LUPINEQ 500MG BASEA065392 001 May 29, 2007AB ORCHID HLTHCAREEQ 500MG BASEA065309 001 Sep 18, 2006AB ! TEVA PHARMSEQ 500MG BASEA065282 001 Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXILAB AUROBINDOEQ 250MG BASE/5MLA065349 001 Apr 25, 2013ABEQ 500MG BASE/5MLA065349 002 Apr 25, 2013AB HIKMA PHARMSEQ 250MG BASE/5MLA091036 001 Nov 28, 2012ABEQ 500MG BASE/5MLA091036 002 Nov 28, 2012AB LUPINEQ 250MG BASE/5MLA065396 001 Feb 21, 2008AB !EQ 500MG BASE/5MLA065396 002 Feb 21, 2008AB ORCHID HLTHCAREEQ 250MG BASE/5MLA065307 002 Oct 16, 2006ABEQ 500MG BASE/5MLA065307 003 Oct 16, 2006

TABLET;ORAL

CEFADROXILAB HIKMAEQ 1GM BASEA065260 001 Mar 30, 2006AB ORCHID HLTHCAREEQ 1GM BASEA065301 001 Sep 18, 2006

!

TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUMAP ACS DOBFAREQ 500MG BASE/VIALA065303 001 Oct 22, 2008APEQ 1GM BASE/VIALA065303 002 Oct 22, 2008APEQ 10GM BASE/VIALA065306 001 Oct 22, 2008AP ! HIKMA FARMACEUTICAEQ 500MG BASE/VIALA065047 001 Sep 18, 2001AP !EQ 1GM BASE/VIALA065047 002 Sep 18, 2001APEQ 10GM BASE/VIALA065143 001 Oct 18, 2004AP QILUEQ 1GM BASE/VIALA203661 001 Dec 28, 2015AP !EQ 10GM BASE/VIALA209217 001 Oct 17, 2018AP SANDOZEQ 500MG BASE/VIALA062831 001 Dec 09, 1988APEQ 1GM BASE/VIALA062831 002 Dec 09, 1988APEQ 1GM BASE/VIALA065345 001 May 09, 2007APEQ 10GM BASE/VIALA062831 003 Sep 25, 1992

ANCEF IN PLASTIC CONTAINER

! BAXTER HLTHCARE

EQ 20MG BASE/ML

A063002 002 Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+! B BRAUN

EQ 1GM BASE/VIAL

N050779 002 Jul 27, 2000

+

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012

CEFAZOLIN SODIUM

! ACS DOBFAR

EQ 20GM BASE/VIAL

A065306 002 Aug 18, 2014

! SAMSON MEDCL

EQ 100GM BASE/VIAL

A065141 001 Nov 29, 2006

!

EQ 300GM BASE/VIAL

A065141 002 Nov 29, 2006

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 2GM BASE/100ML (EQ 20MG BASE/ML)

N207131 001 Aug 07, 2015

CORP

CEFDINIR

CAPSULE;ORAL

CEFDINIRAB AUROBINDO PHARMA300MGA065434 001 Jan 07, 2008AB LUPIN300MGA065264 001 May 19, 2006AB ORCHID HLTHCARE300MGA065418 001 Jul 18, 2007AB ! SANDOZ300MGA065330 001 Apr 06, 2007AB TEVA PHARMS300MGA065368 001 May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIRAB AUROBINDO PHARMA125MG/5MLA065473 001 Dec 14, 2007

PRESCRIPTION DRUG PRODUCT LIST

CEFDINIR

FOR SUSPENSION;ORAL

CEFDINIR

<u>AB</u>		<u>250MG/5ML</u>	<u>A065473 002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259 001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259 002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429 001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429 002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337 001</u>	Apr 06, 2007
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065337 002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332 001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332 002</u>	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441 001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441 002</u>	Mar 20, 2008
<u>AP</u>	QILU	<u>EQ 500MG BASE/VIAL</u>	<u>A203704 001</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203704 002</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203704 003</u>	Feb 01, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 1GM BASE/VIAL</u>	<u>A091048 001</u>	Jan 04, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091048 002</u>	Jan 04, 2017

MAXIPIME

<u>AP</u>	! HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679 001</u>	Jan 18, 1996
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>N050679 002</u>	Jan 18, 1996
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>N050679 003</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

EQ 1GM BASE/VIAL

N050821 001 May 06, 2010

EQ 2GM BASE/VIAL

N050821 002 May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 1GM BASE/50ML (EQ 20MG BASE/ML)

N050817 001 Aug 05, 2008

+!

EQ 2GM BASE/100ML (EQ 20MG BASE/ML)

N050817 002 Aug 05, 2008

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

SAMSON MEDCL

EQ 100GM BASE

A209408 001 Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER; INTRAVENOUS

FETROJA

+! SHIONOGI INC

EQ 1GM BASE/VIAL

N209445 001 Nov 14, 2019

CEFIXIME

CAPSULE; ORAL

CEFIXIME

<u>AB</u>	ALKEM LABS LTD	<u>400MG</u>	<u>A210574 001</u>	Oct 09, 2018
-----------	----------------	--------------	--------------------	--------------

SUPRAX

<u>AB</u>	! LUPIN LTD	<u>400MG</u>	<u>N203195 001</u>	Jun 01, 2012
-----------	-------------	--------------	--------------------	--------------

FOR SUSPENSION; ORAL

CEFIXIME

<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG/5ML</u>	<u>A204835 001</u>	Apr 14, 2015
<u>AB</u>		<u>200MG/5ML</u>	<u>A204835 002</u>	Apr 14, 2015
<u>AB</u>	BELCHER PHARMS LLC	<u>100MG/5ML</u>	<u>A206938 001</u>	Feb 06, 2017
<u>AB</u>		<u>200MG/5ML</u>	<u>A206938 002</u>	Feb 06, 2017
<u>AB</u>		<u>500MG/5ML</u>	<u>A206939 001</u>	Feb 06, 2017

SUPRAX

<u>AB</u>	! LUPIN LTD	<u>500MG/5ML</u>	<u>N202091 001</u>	Feb 20, 2013
-----------	-------------	------------------	--------------------	--------------

<u>AB</u>	LUPIN PHARMS	<u>100MG/5ML</u>	<u>A065129 001</u>	Feb 23, 2004
-----------	--------------	------------------	--------------------	--------------

<u>AB</u>	!	<u>200MG/5ML</u>	<u>A065355 001</u>	Apr 10, 2007
-----------	---	------------------	--------------------	--------------

TABLET; ORAL

SUPRAX

! LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

200MG

A065380 003 Oct 25, 2010

!

PRESCRIPTION DRUG PRODUCT LIST

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

!	HIKMA	EQ 500MG BASE/VIAL	A065072 001	Nov 20, 2002
!		EQ 1GM BASE/VIAL	A065072 002	Nov 20, 2002
!		EQ 2GM BASE/VIAL	A065072 003	Nov 20, 2002
!		EQ 10GM BASE/VIAL	A065071 001	Nov 20, 2002

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

<u>AP</u>	+	TELIGENT	<u>EQ 1GM BASE/VIAL</u>	<u>N050588 001</u>	Dec 27, 1985
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050588 002</u>	Dec 27, 1985

CEFOTETAN

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374 001</u>	Aug 09, 2007	
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065374 002</u>	Aug 09, 2007	
<u>AP</u>		HIKMA	<u>EQ 1GM BASE/VIAL</u>	<u>A091031 001</u>	Oct 26, 2011	
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091031 002</u>	Oct 26, 2011	
		CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER				
	+	!	B BRAUN	EQ 1GM BASE/VIAL	N065430 001	Aug 09, 2007
	+	!		EQ 2GM BASE/VIAL	N065430 002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	!	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414 001</u>	Jun 12, 2009
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065414 002</u>	Jun 12, 2009
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A065415 001</u>	May 19, 2010
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238 001</u>	Mar 12, 2010
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065238 002</u>	Mar 12, 2010
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065239 001</u>	Mar 02, 2010
<u>AP</u>		WEST-WARD PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A065051 001</u>	Sep 11, 2000
		INT			
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065051 002</u>	Sep 11, 2000
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065050 001</u>	Sep 11, 2000

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	!	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N065214 001</u>	Mar 10, 2006
<u>AP</u>	+	!		<u>EQ 2GM BASE/VIAL</u>	<u>N065214 002</u>	Mar 10, 2006

MEFOXIN IN PLASTIC CONTAINER

!	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001	Jan 25, 1993
!		EQ 40MG BASE/ML	A063182 002	Jan 25, 1993

POWDER; INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A200938 001	Nov 16, 2015
--	--------------	---------------	-------------	--------------

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

	AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409 001	Jun 08, 2007
!		EQ 100MG BASE/5ML	A065409 002	Jun 08, 2007

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370 001</u>	Jun 11, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065370 002</u>	Jun 11, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388 001</u>	Nov 14, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065388 002</u>	Nov 14, 2007
<u>AB</u>		SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462 001</u>	May 28, 2008
<u>AB</u>	!		<u>EQ 200MG BASE</u>	<u>A065462 002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>		APOTEX INC	<u>125MG/5ML</u>	<u>A065351 001</u>	Feb 29, 2012
<u>AB</u>			<u>250MG/5ML</u>	<u>A065351 002</u>	Feb 29, 2012
<u>AB</u>		AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381 001</u>	Jan 30, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065381 002</u>	Jan 30, 2007
<u>AB</u>		LUPIN	<u>125MG/5ML</u>	<u>A065261 001</u>	Dec 19, 2005
<u>AB</u>	!		<u>250MG/5ML</u>	<u>A065261 002</u>	Dec 19, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284 002</u>	Dec 30, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065284 001</u>	Dec 30, 2005
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065257 001</u>	Dec 08, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065257 002</u>	Dec 08, 2005
<u>AB</u>		TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236 001</u>	Dec 08, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065236 002</u>	Dec 08, 2005

PRESCRIPTION DRUG PRODUCT LIST

CEFPROZIL

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	CASI PHARMS INC	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	!	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010
+	!	600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>	WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008

FORTAZ

<u>AP</u>	+	TELIGENT	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+	!	<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+	!	<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+	!	<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986	
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986	
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993	
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986	
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993	
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986	
	CEFTAZIDIME IN DEXTROSE CONTAINER					
	+	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+	!	EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

ZERBAXA

+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014
---	-------------------	-------------------------------------	---------	-----	--------------

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008	
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065232</u>	<u>001</u>	Aug 02, 2005	
<u>AP</u>	QILU	<u>EQ 10GM BASE/VIAL</u>	<u>A209218</u>	<u>001</u>	Oct 17, 2018	
<u>AP</u>	!	SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	!	SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006	

CEFTRIAZONE AND DEXTROSE IN DUPLIX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	+	!	<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

CEFTRIAZONE SODIUM

<u>AP</u>	ASTRAL	<u>EQ 10GM BASE/VIAL</u>	<u>A091117</u>	<u>001</u>	Jan 20, 2017
<u>AP</u>	HIKMA	<u>EQ 10GM BASE/VIAL</u>	<u>A090701</u>	<u>001</u>	Oct 04, 2017
	CEFTRIAZONE				
	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

PRESCRIPTION DRUG PRODUCT LIST

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>	AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>	ASTRAL	<u>EQ 250MG BASE/VIAL</u>	<u>A091049</u>	<u>001</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A091049</u>	<u>002</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091049</u>	<u>003</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091049</u>	<u>004</u>	Jun 11, 2018
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065342</u>	<u>002</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065342</u>	<u>003</u>	Jan 10, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065342</u>	<u>004</u>	Jan 10, 2008
<u>AP</u>	LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125</u>	<u>001</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065125</u>	<u>002</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065125</u>	<u>003</u>	Sep 30, 2003
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065125</u>	<u>004</u>	Sep 30, 2003
<u>AP</u>	QILU	<u>EQ 250MG BASE/VIAL</u>	<u>A203702</u>	<u>001</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A203702</u>	<u>002</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203702</u>	<u>003</u>	Jun 29, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203702</u>	<u>004</u>	Jun 29, 2016
<u>AP</u>	! SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169</u>	<u>001</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 500MG BASE/VIAL</u>	<u>A065169</u>	<u>002</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A065169</u>	<u>003</u>	May 09, 2005
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A065169</u>	<u>004</u>	May 09, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065391</u>	<u>002</u>	Apr 12, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065391</u>	<u>003</u>	Apr 12, 2007

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065496</u>	<u>002</u>	Jun 07, 2010
<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069</u>	<u>001</u>	Oct 02, 2002
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065069</u>	<u>002</u>	Oct 02, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065308</u>	<u>002</u>	Mar 29, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065308</u>	<u>003</u>	Mar 29, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135</u>	<u>001</u>	Jul 25, 2003
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A065135</u>	<u>002</u>	Jul 25, 2003
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359</u>	<u>001</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065359</u>	<u>002</u>	Feb 15, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065359</u>	<u>003</u>	Feb 15, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166</u>	<u>001</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065166</u>	<u>002</u>	Jul 29, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065166</u>	<u>003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+! B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001
<u>AP</u>	+!	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004

ZINACEF

<u>AP</u>	+! TELIGENT	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+!	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>	ACS DOBFAR SPA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997
<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004

PRESCRIPTION DRUG PRODUCT LIST

CEFUROXIME SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

<u>AB</u>	<u>+!</u>	<u>TELIGENT</u>	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983
-----------	-----------	-----------------	---------------------------	----------------	------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>	<u>+</u>	<u>GD SEARLE</u>	<u>50MG</u>	<u>N020998</u>	<u>004</u>	Dec 15, 2006
<u>AB</u>	<u>+</u>		<u>100MG</u>	<u>N020998</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>	<u>+</u>		<u>200MG</u>	<u>N020998</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>	<u>+!</u>		<u>400MG</u>	<u>N020998</u>	<u>003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>		<u>ALEMBIC PHARMS LTD</u>	<u>50MG</u>	<u>A204519</u>	<u>001</u>	Aug 21, 2015
<u>AB</u>			<u>100MG</u>	<u>A204519</u>	<u>002</u>	Aug 21, 2015
<u>AB</u>			<u>200MG</u>	<u>A204519</u>	<u>003</u>	Aug 21, 2015
<u>AB</u>			<u>400MG</u>	<u>A204519</u>	<u>004</u>	Aug 21, 2015
<u>AB</u>		<u>AMNEAL PHARMS</u>	<u>50MG</u>	<u>A208833</u>	<u>001</u>	May 31, 2018
<u>AB</u>			<u>100MG</u>	<u>A208833</u>	<u>002</u>	May 31, 2018
<u>AB</u>			<u>200MG</u>	<u>A208833</u>	<u>003</u>	May 31, 2018
<u>AB</u>			<u>400MG</u>	<u>A208833</u>	<u>004</u>	May 31, 2018
<u>AB</u>		<u>APOTEX INC</u>	<u>50MG</u>	<u>A204197</u>	<u>001</u>	Jun 02, 2015
<u>AB</u>			<u>100MG</u>	<u>A204197</u>	<u>002</u>	Jun 02, 2015
<u>AB</u>			<u>200MG</u>	<u>A204197</u>	<u>003</u>	Jun 02, 2015
<u>AB</u>		<u>AUROBINDO PHARMA LTD</u>	<u>50MG</u>	<u>A206827</u>	<u>001</u>	Feb 01, 2016
<u>AB</u>			<u>100MG</u>	<u>A206827</u>	<u>002</u>	Feb 01, 2016
<u>AB</u>			<u>200MG</u>	<u>A206827</u>	<u>003</u>	Feb 01, 2016
<u>AB</u>			<u>400MG</u>	<u>A206827</u>	<u>004</u>	Feb 01, 2016
<u>AB</u>		<u>CADILA PHARMS LTD</u>	<u>50MG</u>	<u>A208701</u>	<u>001</u>	Nov 14, 2019
<u>AB</u>			<u>100MG</u>	<u>A208701</u>	<u>002</u>	Nov 14, 2019
<u>AB</u>			<u>200MG</u>	<u>A208701</u>	<u>003</u>	Nov 14, 2019
<u>AB</u>			<u>400MG</u>	<u>A208701</u>	<u>004</u>	Nov 14, 2019
<u>AB</u>		<u>CIPLA</u>	<u>50MG</u>	<u>A207446</u>	<u>001</u>	Sep 23, 2015
<u>AB</u>			<u>100MG</u>	<u>A207446</u>	<u>002</u>	Sep 23, 2015
<u>AB</u>			<u>200MG</u>	<u>A207446</u>	<u>003</u>	Sep 23, 2015
<u>AB</u>			<u>400MG</u>	<u>A207446</u>	<u>004</u>	Sep 23, 2015
<u>AB</u>		<u>CSPC OUYI</u>	<u>50MG</u>	<u>A210071</u>	<u>001</u>	Jan 23, 2018
<u>AB</u>			<u>100MG</u>	<u>A210071</u>	<u>002</u>	Jan 23, 2018
<u>AB</u>			<u>200MG</u>	<u>A210071</u>	<u>003</u>	Jan 23, 2018
<u>AB</u>		<u>JUBILANT GENERICS</u>	<u>50MG</u>	<u>A207061</u>	<u>001</u>	Apr 04, 2017
<u>AB</u>			<u>100MG</u>	<u>A207061</u>	<u>002</u>	Apr 04, 2017
<u>AB</u>			<u>200MG</u>	<u>A207061</u>	<u>003</u>	Apr 04, 2017
<u>AB</u>			<u>400MG</u>	<u>A207061</u>	<u>004</u>	Apr 04, 2017
<u>AB</u>		<u>LUPIN LTD</u>	<u>50MG</u>	<u>A202240</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>			<u>100MG</u>	<u>A202240</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>			<u>200MG</u>	<u>A202240</u>	<u>003</u>	Jun 09, 2015
<u>AB</u>			<u>400MG</u>	<u>A202240</u>	<u>004</u>	Jun 09, 2015
<u>AB</u>		<u>MACLEODS PHARMS LTD</u>	<u>50MG</u>	<u>A204590</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>			<u>100MG</u>	<u>A204590</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>			<u>200MG</u>	<u>A204590</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>			<u>400MG</u>	<u>A204590</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>		<u>MICRO LABS</u>	<u>50MG</u>	<u>A204776</u>	<u>001</u>	Apr 30, 2018
<u>AB</u>			<u>100MG</u>	<u>A204776</u>	<u>002</u>	Apr 30, 2018
<u>AB</u>			<u>200MG</u>	<u>A204776</u>	<u>003</u>	Apr 30, 2018
<u>AB</u>			<u>400MG</u>	<u>A204776</u>	<u>004</u>	Apr 30, 2018
<u>AB</u>		<u>MYLAN</u>	<u>50MG</u>	<u>A078857</u>	<u>001</u>	May 30, 2014
<u>AB</u>			<u>100MG</u>	<u>A078857</u>	<u>002</u>	Feb 11, 2015
<u>AB</u>			<u>200MG</u>	<u>A078857</u>	<u>003</u>	Feb 11, 2015
<u>AB</u>			<u>400MG</u>	<u>A078857</u>	<u>004</u>	Feb 11, 2015
<u>AB</u>		<u>QINGDAO BAHEAL PHARM</u>	<u>50MG</u>	<u>A208856</u>	<u>001</u>	Aug 07, 2019
<u>AB</u>			<u>100MG</u>	<u>A208856</u>	<u>002</u>	Aug 07, 2019
<u>AB</u>			<u>200MG</u>	<u>A208856</u>	<u>003</u>	Aug 07, 2019
<u>AB</u>			<u>400MG</u>	<u>A208856</u>	<u>004</u>	Aug 07, 2019
<u>AB</u>		<u>TEVA</u>	<u>50MG</u>	<u>A076898</u>	<u>001</u>	May 30, 2014
<u>AB</u>			<u>100MG</u>	<u>A076898</u>	<u>002</u>	May 30, 2014
<u>AB</u>			<u>200MG</u>	<u>A076898</u>	<u>003</u>	May 30, 2014
<u>AB</u>			<u>400MG</u>	<u>A076898</u>	<u>004</u>	May 30, 2014
<u>AB</u>		<u>TORRENT</u>	<u>50MG</u>	<u>A207677</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>			<u>100MG</u>	<u>A207677</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>			<u>200MG</u>	<u>A207677</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>			<u>400MG</u>	<u>A207677</u>	<u>004</u>	Dec 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

CELECOXIB

CAPSULE;ORAL

CELECOXIB

<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562</u>	<u>001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562</u>	<u>002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562</u>	<u>003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562</u>	<u>004</u>	Feb 11, 2015

TABLET;ORAL

CELECOXIB

<u>AB</u>	UMEDICA LABS PVT LTD	<u>50MG</u>	<u>A210628</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		<u>100MG</u>	<u>A210628</u>	<u>002</u>	Nov 27, 2019
<u>AB</u>		<u>200MG</u>	<u>A210628</u>	<u>003</u>	Nov 27, 2019
<u>AB</u>		<u>400MG</u>	<u>A210628</u>	<u>004</u>	Nov 27, 2019

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836</u>	<u>001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836</u>	<u>002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836</u>	<u>004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253</u>	<u>001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253</u>	<u>002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713</u>	<u>002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215</u>	<u>002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229</u>	<u>001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229</u>	<u>002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152</u>	<u>002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	+ PRAGMA	<u>EQ 250MG BASE</u>	<u>N050405</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050405</u>	<u>003</u>	
<u>AB</u>	+!	<u>EQ 750MG BASE</u>	<u>N050405</u>	<u>005</u>	May 12, 2006

CEPHALEXIN

ALKEM LABS LTD
FOR SUSPENSION;ORAL

EQ 333MG BASE

A090836 003 Mar 29, 2013

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 125MG BASE/5ML</u>	<u>A210221</u>	<u>001</u>	Mar 26, 2019
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A210221</u>	<u>002</u>	Mar 26, 2019
<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234</u>	<u>001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234</u>	<u>002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326</u>	<u>001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326</u>	<u>002</u>	Jul 10, 2006
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>	!	<u>EQ 250MG BASE/5ML</u>	<u>A062703</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065336</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065336</u>	<u>002</u>	Jul 25, 2007

TABLET;ORAL

CEPHALEXIN

TEVA

EQ 250MG BASE

A063023 001 Jan 12, 1989

!

EQ 500MG BASE

A063024 001 Jan 12, 1989

CERITINIB

TABLET;ORAL

ZYKADIA

+! NOVARTIS

150MG

N211225 001 Mar 18, 2019

CETIRIZINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

QUZYTIR

+! JDP

10MG/ML (10MG/ML)

N211415 001 Oct 04, 2019

SOLUTION/DROPS;OPHTHALMIC

ZERVIAE

+! EYEVANCE

EQ 0.24% BASE

N208694 001 May 30, 2017

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766</u>	<u>001</u>	Oct 07, 2009
-----------	---------------	----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	BRECKENRIDGE	5MG/5ML	A078488 001	Oct 06, 2008
AA	LANNETT CO INC	5MG/5ML	A078876 001	May 11, 2012
AA	MLV	5MG/5ML	A090191 001	Nov 12, 2009
AA	! PERRIGO PHARMS CO	5MG/5ML	A078398 001	Jun 17, 2008
AA	TARO	5MG/5ML	A076601 001	Jun 20, 2008
AA	TEVA PHARMS	5MG/5ML	A077279 001	May 27, 2008

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+	!	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000
---	---	----------------	-------------------	-------------	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB	HIKMA	30MG	A091591 001	Jul 08, 2013		
AB	NOVEL LABS INC	30MG	A204746 001	Dec 30, 2016		
AB	RISING	30MG	A203775 001	Jun 04, 2014		
EVOXAC						
AB	+	!	DAIICHI SANKYO INC	30MG	N020989 002	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

!	NEXGEN PHARMA	250MG	A091019 001	Oct 22, 2009
---	---------------	-------	-------------	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	!	ASPEN GLOBAL INC	2MG	N010669 002
---	---	------------------	-----	-------------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982
---	--------------------	------------------	-------------	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	BARR	5MG	A084768 001		
AB		10MG	A083116 001		
AB		25MG	A084769 001		
LIBRIUM					
AB	VALEANT PHARM INTL	5MG	A085461 001		
AB		10MG	A085472 001		
AB	!	25MG	A085475 001		

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

LIBRAX

+	!	VALEANT PHARMS	5MG; 2.5MG	N012750 001
---	---	----------------	------------	-------------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	0.12%	A074356 001	May 07, 1996		
AT	LYNE	0.12%	A074291 001	Dec 28, 1995		
AT	PHARM ASSOC	0.12%	A074522 001	Dec 15, 1995		
AT	WOCKHARDT BIO AG	0.12%	A075006 001	Mar 03, 2004		
AT	XTRIUM	0.12%	A077789 001	Jun 18, 2009		
PAROEX						
AT	SUNSTAR AMERICAS	0.12%	A076434 001	Nov 29, 2005		
PERIDEX						
AT	+	!	3M	0.12%	N019028 001	Aug 13, 1986
PERIOGARD						
AT	COLGATE PALMOLIVE CO	0.12%	A073695 001	Jan 14, 1994		
AT	COLGATE-PALMOLIVE CO	0.12%	A203212 001	Jan 28, 2016		
TABLET; DENTAL						
PERIOCHIP						
+	!	DEXCEL PHARMA	2.5MG	N020774 001	May 15, 1998	

PRESCRIPTION DRUG PRODUCT LIST

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP	HOSPIRA	<u>2%</u>	<u>A087447 001</u>	Apr 16, 1982
AP		<u>3%</u>	<u>A087446 001</u>	Apr 16, 1982
AP	WEST-WARD PHARMS INT	<u>2%</u>	<u>A040273 001</u>	Sep 09, 1998
AP		<u>3%</u>	<u>A040273 002</u>	Sep 09, 1998
<u>NESACAINE</u>				
AP	+ FRESENIUS KABI USA	<u>2%</u>	<u>N009435 002</u>	
<u>NESACAINE-MPF</u>				
AP	+! FRESENIUS KABI USA	<u>2%</u>	<u>N009435 006</u>	May 02, 1996
AP	+!	<u>3%</u>	<u>N009435 007</u>	May 02, 1996
NESACAINE				
	+! FRESENIUS KABI USA	1%	N009435 001	
SOLUTION; INTRATHECAL				
CLOROTEKAL				
	+ B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791 001	Sep 26, 2017

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	!	HIKMA PHARMS	<u>EQ 150MG BASE</u>	<u>A083082 001</u>
AA			<u>EQ 300MG BASE</u>	<u>A083082 002</u>
				Sep 17, 1999
AA		IPCA LABS LTD	<u>EQ 150MG BASE</u>	<u>A090610 001</u>
			<u>EQ 300MG BASE</u>	<u>A090249 001</u>
				Dec 03, 2009
AA		NATCO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A091621 001</u>
			<u>EQ 300MG BASE</u>	<u>A090612 001</u>
				Jan 21, 2011
AA	!			Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+! SALIX PHARMS

250MG/5ML

N011870 001

TABLET; ORAL

CHLOROTHIAZIDE

! MYLAN

250MG

A084217 002

500MG

A084217 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP		AM REGENT	<u>EQ 500MG BASE/VIAL</u>	<u>A202561 001</u>	Apr 22, 2013
AP		FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090896 001</u>	Oct 16, 2009
AP		MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>A202493 001</u>	Jun 18, 2014
AP		SAGENT PHARMS INC	<u>EQ 500MG BASE/VIAL</u>	<u>A202462 001</u>	May 29, 2015
AP		SUN PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A091546 001</u>	Jul 26, 2011
<u>DIURIL</u>					
AP	+!	OAK PHARMS AKORN	<u>EQ 500MG BASE/VIAL</u>	<u>N011145 005</u>	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

TUXARIN ER

MAINPOINTE

8MG; 54.3MG

N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

! PADDOCK LLC

4MG/5ML; 5MG/5ML; 60MG/5ML

A204627 001 Apr 29, 2014

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

+! AYTU

EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML

N207768 001 Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE; EQ 5MG BITARTRATE

A077273 002 Sep 24, 2007

! EQ 8MG MALEATE; EQ 10MG BITARTRATE

A077273 001 Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB		TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091632 001</u>	Oct 01, 2010
-----------	--	-----------------	---	--------------------	--------------

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	!	NEOS THERAP INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091671 001</u>	Jun 29, 2012
-----------	---	-----------------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

! WEST-WARD PHARMS 25MG/ML
INT

A083329 001

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A209755 001	Sep 10, 2018
AB		25MG	A209755 002	Sep 10, 2018
AB		50MG	A209755 003	Sep 10, 2018
AB		100MG	A209755 004	Sep 10, 2018
AB		200MG	A209755 005	Sep 10, 2018
AB	UPSHER SMITH LABS	10MG	A083386 001	
AB	!	25MG	A084112 001	
AB		50MG	A084113 001	
AB	!	100MG	A084114 001	
AB		200MG	A084115 001	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	AMNEAL PHARMS CO	25MG	A207204 001	Jul 01, 2019
AB		50MG	A207204 002	Jul 01, 2019
AB	ARISE	25MG	A210742 001	Oct 12, 2018
AB		50MG	A210742 002	Oct 12, 2018
AB	ATHEM	25MG	A211063 001	Feb 26, 2019
AB		50MG	A211063 002	Feb 26, 2019
AB	MYLAN	25MG	A086831 002	
AB	!	50MG	A086831 001	
AB	RICONPHARMA LLC	25MG	A206904 001	Mar 30, 2017
AB		50MG	A206904 002	Mar 30, 2017
AB	SUN PHARM INDUSTRIES	25MG	A089286 002	Jul 21, 1986
AB		50MG	A089286 001	Jul 21, 1986
AB	UMEDICA LABS PVT LTD	25MG	A207222 001	May 24, 2018
AB		50MG	A207222 002	May 24, 2018
AB	UNICHEM LABS LTD	25MG	A211627 001	Aug 06, 2019
AB		50MG	A211627 002	Aug 06, 2019
AB	ZYDUS PHARMS	25MG	A207813 001	May 10, 2019
AB		50MG	A207813 002	May 10, 2019

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	NOVITIUM PHARMA	500MG	A212254 001	Sep 12, 2019
AA	!	500MG	A089859 001	May 04, 1988
AB	!	375MG	A040861 001	Jun 01, 2010
AB	!	750MG	A040861 002	Jun 01, 2010
AB	NOVITIUM PHARMA	375MG	A212253 001	Nov 27, 2019
AB		750MG	A212253 002	Nov 27, 2019
AB	!	250MG	A207483 001	Jun 24, 2016

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554 001	Oct 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A074554 002	Oct 02, 1996
AB	PAR PHARM	EQ 4GM RESIN/PACKET	A077204 001	Aug 26, 2005
AB		EQ 4GM RESIN/SCOOPFUL	A077204 002	Aug 26, 2005
AB	!	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A074557 002	Aug 15, 1996
AB	ZYDUS PHARMS	EQ 4GM RESIN/SCOOPFUL	A202901 001	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB	PAR PHARM	EQ 4GM RESIN/PACKET	A077203 001	Aug 26, 2005
AB		EQ 4GM RESIN/SCOOPFUL	A077203 002	Aug 26, 2005
AB	!	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A074558 002	Aug 15, 1996
AB	ZYDUS PHARMS	EQ 4GM RESIN/SCOOPFUL	A202902 001	Apr 25, 2017

PREVALITE

AB	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A073263 001	Feb 22, 1996
AB		EQ 4GM RESIN/SCOOPFUL	A073263 002	Oct 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

+ RTRX

50MG

N205750 001 Mar 17, 2015

+!

250MG

N205750 002 Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11AP DECATUR4-33.1mCi/MLA206319 001 Nov 13, 2015AP +! MCRPF4-33.1mCi/MLN203155 001 Sep 12, 2012AP UCSF RODIOPHARM4-33.1mCi/MLA208444 001 Nov 20, 2017AP WA UNIV SCH MED4-33.1mCi/MLA208413 001 Jan 10, 2017

UNIV TX MD ANDERSON 4-100mCi/ML

A205690 001 Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACIDAB ACTAVIS ELIZABETHEQ 45MG FENOFIBRIC ACIDA200920 001 Oct 07, 2015AB EQ 135MG FENOFIBRIC ACIDA200920 002 Oct 07, 2015AB ALEMBIC PHARMS LTDEQ 45MG FENOFIBRIC ACIDA208705 001 May 12, 2017AB EQ 135MG FENOFIBRIC ACIDA208705 002 May 12, 2017AB ANCHEN PHARMSEQ 45MG FENOFIBRIC ACIDA201573 002 Jul 18, 2013AB EQ 135MG FENOFIBRIC ACIDA201573 001 Jul 18, 2013AB AUROBINDO PHARMAEQ 45MG FENOFIBRIC ACIDA212598 001 Jul 25, 2019

LTD

AB EQ 135MG FENOFIBRIC ACIDA212598 002 Jul 25, 2019AB GRAVITI PHARMSEQ 45MG FENOFIBRIC ACIDA211626 001 Jul 18, 2019AB EQ 135MG FENOFIBRIC ACIDA211626 002 Jul 18, 2019AB IMPAX LABS INCEQ 45MG FENOFIBRIC ACIDA200264 001 Sep 07, 2016AB EQ 135MG FENOFIBRIC ACIDA200264 002 Sep 07, 2016AB LUPIN LTDEQ 45MG FENOFIBRIC ACIDA200750 001 Dec 04, 2013AB EQ 135MG FENOFIBRIC ACIDA200750 002 Dec 04, 2013TRILIPIXAB + ABBVIEEQ 45MG FENOFIBRIC ACIDN022224 001 Dec 15, 2008AB +!EQ 135MG FENOFIBRIC ACIDN022224 002 Dec 15, 2008CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+! EMD SERONO

EQ 0.25MG /0.5ML

N021149 002 Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA

EQ 0.004MG CHROMIUM/ML

N018961 001 Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+! COVIS PHARMA BV

0.08MG/INH

N021658 002 Jan 10, 2008

+!

0.16MG/INH

N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+! COVIS PHARMA BV

0.037MG/INH

N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+! COVIS PHARMA BV

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROXAB ACP NIMBLE0.77%A078463 001 Dec 20, 2010AB FOUGERA PHARMS0.77%A076435 001 Dec 29, 2004AB GLENMARK PHARMS0.77%A090273 001 Nov 10, 2009AB PERRIGO ISRAEL0.77%A077364 001 Mar 03, 2006AB TARO0.77%A076790 001 Apr 12, 2005LOPROXAB +! MEDIMETRIKS PHARMS0.77%N018748 001 Dec 30, 1982

GEL; TOPICAL

CICLOPIROXAB +! CNTY LINE PHARMS0.77%N020519 001 Jul 21, 1997AB FOUGERA PHARMS0.77%A077896 001 Jun 10, 2008AB GLENMARK GENERICS0.77%A091595 001 Feb 29, 2012AB PADDOCK LLC0.77%A078266 001 Jan 07, 2009

PRESCRIPTION DRUG PRODUCT LIST

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A090490 001</u>	Nov 24, 2009
<u>AT</u>	FOUGERA PHARMS	<u>1%</u>	<u>A090146 001</u>	May 25, 2010
<u>AT</u>	PERRIGO CO	<u>1%</u>	<u>A078594 001</u>	Feb 16, 2010
<u>AT</u>	TARO	<u>1%</u>	<u>A090269 001</u>	Feb 23, 2011
<u>AT</u>	TEGENT PHARMA INC	<u>1%</u>	<u>A209975 001</u>	Apr 05, 2018

LOPROX

<u>AT</u>	+! BAUSCH	<u>1%</u>	<u>N021159 001</u>	Feb 28, 2003
-----------	-----------	-----------	--------------------	--------------

SOLUTION; TOPICAL

CICLOPIROX

<u>AT</u>	ACELLA	<u>8%</u>	<u>A078172 001</u>	Sep 18, 2007
<u>AT</u>	ACP NIMBLE	<u>8%</u>	<u>A078233 001</u>	Sep 18, 2007
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>8%</u>	<u>A078046 001</u>	Sep 18, 2007
<u>AT</u>	AKORN	<u>8%</u>	<u>A078975 001</u>	Feb 17, 2010
<u>AT</u>	ANDA REPOSITORY	<u>8%</u>	<u>A077687 001</u>	Sep 18, 2007
<u>AT</u>	HI TECH PHARMA	<u>8%</u>	<u>A078270 001</u>	Sep 18, 2007
<u>AT</u>	NOVAST LABS	<u>8%</u>	<u>A078124 001</u>	Sep 18, 2007
<u>AT</u>	PERRIGO NEW YORK	<u>8%</u>	<u>A077623 001</u>	Sep 18, 2007
<u>AT</u>	TARO PHARM INDS	<u>8%</u>	<u>A078144 001</u>	Sep 18, 2007

PENLAC

<u>AT</u>	+! VALEANT BERMUDA	<u>8%</u>	<u>N021022 001</u>	Dec 17, 1999
-----------	--------------------	-----------	--------------------	--------------

SUSPENSION; TOPICAL

CICLOPIROX

<u>AB</u>	FOUGERA PHARMS	<u>0.77%</u>	<u>A076422 001</u>	Aug 06, 2004
<u>AB</u>	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676 001</u>	Dec 15, 2006
<u>AB</u>	TARO	<u>0.77%</u>	<u>A077092 001</u>	Aug 10, 2005

LOPROX

<u>AB</u>	+! MEDIMETRIKS PHARMS	<u>0.77%</u>	<u>N019824 001</u>	Dec 30, 1988
-----------	-----------------------	--------------	--------------------	--------------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 75MG BASE/ML</u>	<u>A202501 001</u>	Jul 26, 2012
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>EQ 75MG BASE/ML</u>	<u>A201276 001</u>	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A090577 002</u>	Dec 21, 2011
<u>AP</u>	HQ SPCLT PHARMA	<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A207594 001</u>	Dec 12, 2019
<u>AP</u>	+! MERCK	<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>N050587 002</u>	Nov 26, 1985
	IMIPENEM AND CILASTATIN			
	! ACS DOBFAR	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A090577 001</u>	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER; INTRAVENOUS

RECARBRIO

	+! MSD MERCK CO	<u>EQ 500MG BASE/VIAL; 500MG/VIAL; 250MG/VIAL</u>	<u>N212819 001</u>	Jul 16, 2019
--	-----------------	---	--------------------	--------------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A077030 001</u>	Dec 10, 2004
<u>AB</u>		<u>100MG</u>	<u>A077030 002</u>	Dec 10, 2004
<u>AB</u>	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708 001</u>	Sep 28, 2009
<u>AB</u>		<u>100MG</u>	<u>A077708 002</u>	Sep 28, 2009
<u>AB</u>	CASI PHARMS INC	<u>50MG</u>	<u>A077310 001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021 001</u>	Nov 23, 2004
<u>AB</u>	CHARTWELL RX	<u>50MG</u>	<u>A077722 001</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A077831 001</u>	Sep 24, 2012
<u>AB</u>	HIKMA	<u>50MG</u>	<u>A077024 001</u>	May 17, 2005
<u>AB</u>		<u>100MG</u>	<u>A077024 002</u>	May 17, 2005
<u>AB</u>	SLATE	<u>50MG</u>	<u>A077208 002</u>	Mar 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A077208 001</u>	Mar 29, 2006
<u>AB</u>	! TEVA	<u>50MG</u>	<u>A077027 001</u>	Nov 24, 2004
<u>AB</u>	!	<u>100MG</u>	<u>A077027 002</u>	Nov 24, 2004

PRESCRIPTION DRUG PRODUCT LIST

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	HIKMA	<u>200MG</u>	<u>A074890 001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890 002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890 003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890 004</u>	Dec 18, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246 003</u>	May 17, 1994
<u>AB</u>	!	<u>800MG</u>	<u>A074246 004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566 001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151 001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151 002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151 003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463 001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC

EQ 300MG BASE/2ML

A074428 001 Apr 25, 1996

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>	!	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664 001</u>	Oct 28, 1997
<u>AA</u>		PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553 001</u>	Jan 27, 1997
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 300MG BASE/5ML</u>	<u>A074757 001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

<u>AB</u>		ALKEM LABS LTD	<u>EQ 30MG BASE</u>	<u>A210570 001</u>	May 17, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A210570 002</u>	May 17, 2019
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A210570 003</u>	May 17, 2019
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A206125 001</u>	Mar 08, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A206125 002</u>	Mar 08, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A206125 003</u>	Mar 08, 2018
<u>AB</u>		CIPLA	<u>EQ 30MG BASE</u>	<u>A208915 001</u>	Mar 08, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A208915 002</u>	Mar 08, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A208915 003</u>	Mar 08, 2018
<u>AB</u>		LUPIN LTD	<u>EQ 30MG BASE</u>	<u>A210548 001</u>	Jun 28, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A210548 002</u>	Jun 28, 2019
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A210548 003</u>	Jun 28, 2019
<u>AB</u>		MYLAN	<u>EQ 30MG BASE</u>	<u>A203422 001</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203422 002</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A203422 003</u>	Oct 16, 2018
<u>AB</u>		PIRAMAL HLTHCARE UK	<u>EQ 30MG BASE</u>	<u>A210207 001</u>	Aug 01, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A210207 002</u>	Aug 01, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A210207 003</u>	Aug 01, 2018
<u>AB</u>		STRIDES PHARMA	<u>EQ 30MG BASE</u>	<u>A209226 001</u>	Apr 30, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A209226 002</u>	Apr 30, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A209226 003</u>	Apr 30, 2018
<u>AB</u>		SUN PHARM	<u>EQ 30MG BASE</u>	<u>A207008 001</u>	Oct 11, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A207008 002</u>	Oct 11, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A207008 003</u>	Oct 11, 2018
<u>AB</u>		WATSON LABS TEVA	<u>EQ 30MG BASE</u>	<u>A204377 001</u>	Dec 27, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204377 002</u>	Dec 27, 2018
<u>AB</u>			<u>EQ 90MG BASE</u>	<u>A204377 003</u>	Dec 27, 2018

SENSIPAR

<u>AB</u>	+	AMGEN	<u>EQ 30MG BASE</u>	<u>N021688 001</u>	Mar 08, 2004
<u>AB</u>	+		<u>EQ 60MG BASE</u>	<u>N021688 002</u>	Mar 08, 2004
<u>AB</u>	+	!	<u>EQ 90MG BASE</u>	<u>N021688 003</u>	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

+ BAYER HLTHCARE

250MG/5ML

N020780 001 Sep 26, 1997

+!

500MG/5ML

N020780 002 Sep 26, 1997

INJECTABLE; INJECTION

CIPROFLOXACIN

<u>AP</u>	!	BAXTER HLTHCARE CORP	<u>200MG/20ML (10MG/ML)</u>	<u>A078062 001</u>	Apr 29, 2008
<u>AP</u>	!		<u>400MG/40ML (10MG/ML)</u>	<u>A078062 002</u>	Apr 29, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717 001</u>	Dec 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717 002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245 001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245 002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE CORP	<u>200MG/100ML</u>	<u>A078024 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024 002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431 001</u>	Nov 18, 2009
<u>AP</u>	! HOSPIRA	<u>200MG/100ML</u>	<u>A077753 001</u>	Mar 18, 2008
<u>AP</u>	!	<u>400MG/200ML</u>	<u>A077753 002</u>	Mar 18, 2008
<u>AP</u>	INFORLIFE	<u>200MG/100ML</u>	<u>A078252 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252 002</u>	Mar 18, 2008

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+!	OTONOMY INC	6% (60MG/ML)	N207986 001	Dec 10, 2015
----	-------------	--------------	-------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+!	NOVARTIS	EQ 0.3% BASE	N020369 001	Mar 30, 1998
----	----------	--------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+!	NOVARTIS	<u>EQ 0.3% BASE</u>	<u>N019992 001</u>	Dec 31, 1990
-----------	----	----------	---------------------	--------------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555 001</u>	Dec 11, 2008
<u>AT</u>		ALTAIRE PHARMS INC	<u>EQ 0.3% BASE</u>	<u>A204613 001</u>	May 03, 2018
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568 001</u>	Jun 30, 2008
<u>AT</u>		RISING	<u>EQ 0.3% BASE</u>	<u>A077689 001</u>	Dec 13, 2006
<u>AT</u>		TELIGENT	<u>EQ 0.3% BASE</u>	<u>A076754 001</u>	Jun 09, 2004
<u>AT</u>		WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673 001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRAXAL

+!	WRASER PHARMS	EQ 0.2% BASE	N021918 001	May 01, 2009
----	---------------	--------------	-------------	--------------

TABLET; ORAL

CIPRO

<u>AB</u>	+	BAYER HLTHCARE	<u>EQ 250MG BASE</u>	<u>N019537 002</u>	Oct 22, 1987
<u>AB</u>	+!		<u>EQ 500MG BASE</u>	<u>N019537 003</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859 001</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A077859 002</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A077859 003</u>	Apr 26, 2007
<u>AB</u>		CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076126 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076126 004</u>	Jun 09, 2004
<u>AB</u>		CHARTWELL	<u>EQ 250MG BASE</u>	<u>A076896 001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896 002</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076896 003</u>	Nov 04, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075593 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075593 004</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075593 001</u>	Jun 09, 2004
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A076558 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076558 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076558 004</u>	Jun 09, 2004
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076089 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076089 004</u>	Jun 09, 2004
<u>AB</u>		MYLAN	<u>EQ 500MG BASE</u>	<u>A075817 003</u>	Jun 09, 2004
<u>AB</u>		TARO	<u>EQ 100MG BASE</u>	<u>A076912 001</u>	Feb 18, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A076912 002</u>	Oct 06, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076912 003</u>	Oct 06, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076912 004</u>	Oct 06, 2004
<u>AB</u>		UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639 001</u>	Sep 10, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076639 002</u>	Sep 10, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076639 003</u>	Sep 10, 2004
<u>AB</u>		WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794 001</u>	Feb 10, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A076794 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076794 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076794 004</u>	Jun 09, 2004

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	YILING PHARM LTD	EQ 250MG BASE	A208921 001	Jun 22, 2018
AB		EQ 500MG BASE	A208921 002	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

+	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251 001	Apr 29, 2016
---	---------------------	---------------------	-------------	--------------

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+	NOVARTIS	EQ 0.2% BASE;1%	N020805 001	Feb 10, 1998
---	----------	-----------------	-------------	--------------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	!	ANCHEN PHARMS	425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007
AB		DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701 001	Mar 26, 2007
	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

+	NOVARTIS	0.3%;0.1%	N021537 001	Jul 18, 2003
---	----------	-----------	-------------	--------------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183 001	Feb 26, 2015
AP		HOSPIRA INC	EQ 2MG BASE/ML	A203236 001	Mar 30, 2018
AP			EQ 10MG BASE/ML	A203236 002	Mar 30, 2018
AP		JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A209334 001	Aug 30, 2017
AP		MEITHEAL	EQ 2MG BASE/ML	A211668 001	Apr 25, 2019
AP			EQ 2MG BASE/ML	A211669 001	Apr 25, 2019
AP			EQ 10MG BASE/ML	A211668 002	Apr 25, 2019
AP		SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012
AP		SOMERSET	EQ 2MG BASE/ML	A209132 001	Apr 24, 2019
AP		ZYDUS PHARMS	EQ 2MG BASE/ML	A212171 001	Nov 04, 2019
AP			EQ 10MG BASE/ML	A212171 002	Nov 04, 2019

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182 001	Feb 26, 2015
AP			EQ 10MG BASE/ML	A203182 002	Feb 26, 2015
AP		JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960 001	Jan 27, 2017
AP			EQ 10MG BASE/ML	A204960 002	Sep 19, 2017
AP		SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012
AP			EQ 10MG BASE/ML	A200154 002	Feb 03, 2012
AP		SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791 001	Feb 20, 2019
AP			EQ 10MG BASE/ML	A206791 002	Feb 20, 2019

NIMBEX

AP	+	ABBVIE	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995
-----------	---	--------	-----------------------	--------------------	--------------

NIMBEX PRESERVATIVE FREE

AP	+	ABBVIE	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995
AP	+		EQ 10MG BASE/ML	N020551 002	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		ACCORD HLTHCARE	1MG/ML	A206774 001	Aug 18, 2015
AP	!	FRESENIUS KABI USA	1MG/ML	A074735 001	Jul 16, 1999
AP		GLAND PHARMA LTD	1MG/ML	A207323 001	Mar 17, 2017
AP	+	HQ SPCLT PHARMA	1MG/ML	N018057 004	Nov 08, 1988
AP		PHARMACHEMIE BV	1MG/ML	A074656 001	May 16, 2000
AP		WEST-WARD PHARMS INT	1MG/ML	A075036 001	Nov 07, 2000

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812 001	Aug 28, 2006
AA		HETERO LABS LTD III	EQ 10MG BASE/5ML	A201450 001	Dec 15, 2015
AA	!	HIKMA	EQ 10MG BASE/5ML	A077043 001	Dec 13, 2004

PRESCRIPTION DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA LANNETT CO INC **EQ 10MG BASE/5ML** **A077629 001** Jun 15, 2006
 TABLET;ORAL

CELEXA

AB + ALLERGAN **EQ 10MG BASE** **N020822 001** Apr 27, 2000
AB + **EQ 20MG BASE** **N020822 002** Jul 17, 1998
AB +! **EQ 40MG BASE** **N020822 003** Jul 17, 1998

CITALOPRAM HYDROBROMIDE

AB ACP NIMBLE **EQ 10MG BASE** **A077048 001** Nov 16, 2004
AB **EQ 20MG BASE** **A077048 002** Nov 16, 2004
AB **EQ 40MG BASE** **A077048 003** Nov 16, 2004
AB AMNEAL PHARMS NY **EQ 10MG BASE** **A077289 001** Nov 30, 2006
AB **EQ 20MG BASE** **A077289 002** Nov 30, 2006
AB **EQ 40MG BASE** **A077289 003** Nov 30, 2006
AB APOTEX INC **EQ 10MG BASE** **A077046 001** Nov 24, 2004
AB AUROBINDO **EQ 10MG BASE** **A077031 001** Oct 28, 2004
AB **EQ 20MG BASE** **A077031 002** Oct 28, 2004
AB **EQ 40MG BASE** **A077031 003** Oct 28, 2004
AB CHARTWELL MOLECULAR **EQ 10MG BASE** **A077044 001** Nov 05, 2004
AB **EQ 20MG BASE** **A077044 002** Nov 05, 2004
AB **EQ 40MG BASE** **A077044 003** Nov 05, 2004
AB DR REDDYS LABS LTD **EQ 10MG BASE** **A077038 001** Oct 28, 2004
AB **EQ 20MG BASE** **A077038 002** Oct 28, 2004
AB **EQ 40MG BASE** **A077038 003** Oct 28, 2004
AB EPIC PHARMA **EQ 10MG BASE** **A077045 003** Apr 29, 2005
AB **EQ 20MG BASE** **A077045 002** Apr 29, 2005
AB **EQ 40MG BASE** **A077045 001** Apr 29, 2005
AB GLENMARK GENERICS **EQ 10MG BASE** **A077654 001** Feb 27, 2009
AB **EQ 20MG BASE** **A077654 002** Feb 27, 2009
AB **EQ 40MG BASE** **A077654 003** Feb 27, 2009
AB INVAGEN PHARMS **EQ 10MG BASE** **A077534 001** Oct 03, 2006
AB **EQ 20MG BASE** **A077534 002** Oct 03, 2006
AB **EQ 40MG BASE** **A077534 003** Oct 03, 2006
AB JUBILANT GENERICS **EQ 10MG BASE** **A205407 001** Dec 23, 2015
AB **EQ 20MG BASE** **A205407 002** Dec 23, 2015
AB **EQ 40MG BASE** **A205407 003** Dec 23, 2015
AB MYLAN **EQ 10MG BASE** **A077042 001** Nov 05, 2004
AB **EQ 20MG BASE** **A077042 002** Nov 05, 2004
AB **EQ 40MG BASE** **A077042 003** Nov 05, 2004
AB TORPHARM **EQ 20MG BASE** **A077046 002** Nov 24, 2004
AB **EQ 40MG BASE** **A077046 003** Nov 24, 2004
AB TORRENT PHARMS **EQ 10MG BASE** **A078216 001** Mar 27, 2007
AB **EQ 20MG BASE** **A078216 002** Mar 27, 2007
AB **EQ 40MG BASE** **A078216 003** Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+! UNITED GUARDIAN 6.602GM/100ML;198MG/100ML;3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

+! FERRING PHARMS INC 12GM/BOT;3.5GM/BOT;10MG/BOT N209589 001 Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+! EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP ! FRESENIUS KABI USA **1MG/ML** **A076571 001** Apr 22, 2004
AP HISUN PHARM **1MG/ML** **A210856 001** Nov 25, 2019
 HANGZHOU
AP MYLAN LABS LTD **1MG/ML** **A200510 001** Oct 06, 2011
AP WEST-WARD PHARMS **1MG/ML** **A075405 001** Feb 28, 2000
 INT
 TABLET;ORAL
 MAVENCLAD
 +! EMD SERONO INC 10MG N022561 001 Mar 29, 2019

PRESCRIPTION DRUG PRODUCT LIST

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065283</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	!	<u>250MG/5ML</u>	<u>A065283</u>	<u>003</u>	Sep 04, 2007

TABLET;ORAL

CLARITHROMYCIN

<u>AB</u>	!	AUROBINDO	<u>250MG</u>	<u>A065489</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>	!		<u>500MG</u>	<u>A065489</u>	<u>002</u>	Jul 25, 2012
<u>AB</u>		CHARTWELL	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>			<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>		HEC PHARM	<u>250MG</u>	<u>A203584</u>	<u>001</u>	Sep 28, 2015
<u>AB</u>			<u>500MG</u>	<u>A203584</u>	<u>002</u>	Sep 28, 2015
<u>AB</u>		HIKMA	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>			<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>			<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>		STRIDES PHARMA	<u>250MG</u>	<u>A202710</u>	<u>001</u>	Jun 10, 2013
<u>AB</u>			<u>500MG</u>	<u>A202710</u>	<u>002</u>	Jun 10, 2013
<u>AB</u>		TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>			<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>		WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>			<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

<u>AB</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004
<u>AB</u>	!	MAYNE PHARMA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005
<u>AB</u>		NOSTRUM LABS INC	<u>500MG</u>	<u>A203243</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>		SUNSHINE LAKE	<u>500MG</u>	<u>A208987</u>	<u>001</u>	Jul 09, 2018

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994
---	------	-------------------	---------	-----	--------------

TABLET;ORAL

CLEMASTINE FUMARATE

!	TEVA	2.68MG	A073283	001	Jan 31, 1992
---	------	--------	---------	-----	--------------

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

+	!	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
---	---	----------------	----------------------	---------	-----	--------------

+	!		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
---	---	--	-----------------------	---------	-----	--------------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+	!	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>		ACP NIMBLE	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		EPIC PHARMA LLC	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>		LANNETT CO INC	<u>EQ 75MG BASE</u>	<u>A065243</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065243</u>	<u>003</u>	Aug 12, 2005
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>		MICRO LABS	<u>EQ 75MG BASE</u>	<u>A207402</u>	<u>001</u>	Nov 05, 2018
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A207402</u>	<u>002</u>	Nov 05, 2018
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A207402</u>	<u>003</u>	Nov 05, 2018
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>		WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

AA	!	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A062644 001	Apr 07, 1986
-----------	----------	-------------------------	-------------------------	--------------------	--------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513 001	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409 001	Apr 30, 2013
AA		HERITAGE PHARMS INC	EQ 75MG BASE/5ML	A207047 001	May 11, 2018
AA		LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012
AA		ORIT LABS LLC	EQ 75MG BASE/5ML	A206958 001	May 05, 2017
AA		PADDOCK LLC	EQ 75MG BASE/5ML	A090902 001	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PERRIGO UK FINCO	1%	A090785 001	Mar 31, 2010
-----------	--	------------------	-----------	--------------------	--------------

EVOCLIN

AT	+	MYLAN	1%	N050801 001	Oct 22, 2004
-----------	----------	-------	-----------	--------------------	--------------

CREAM;VAGINAL

CLEOCIN

AB	+	PHARMACIA AND UPJOHN	EQ 2% BASE	N050680 002	Mar 02, 1998
-----------	----------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004
-----------	--	----------------	-------------------	--------------------	--------------

CLINDESSE

+		PERRIGO PHARMA INTL	EQ 2% BASE	N050793 001	Nov 30, 2004
----------	--	---------------------	-------------------	--------------------	--------------

GEL;TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N050615 001	Jan 07, 1987
-----------	----------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000
-----------	--	----------------	-------------------	--------------------	--------------

CLINDAGEL

BT	+	BAUSCH	EQ 1% BASE	N050782 001	Nov 27, 2000
-----------	----------	--------	-------------------	--------------------	--------------

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A062803 001	Oct 16, 1987
-----------	--	-------------------------	-------------------------	--------------------	--------------

AP	+		EQ 150MG BASE/ML	N050441 001	
-----------	----------	--	-------------------------	--------------------	--

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989
-----------	----------	-------------------------	-----------------------	--------------------	--------------

AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989
-----------	----------	--	------------------------	--------------------	--------------

AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991
-----------	----------	--	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AP		ALVOGEN INC	EQ 150MG BASE/ML	A062800 001	Jul 24, 1987
-----------	--	-------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A062801 001	Jul 24, 1987
-----------	--	--	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A062943 001	Sep 29, 1988
-----------	--	--	-------------------------	--------------------	--------------

AP		FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346 001	Mar 29, 2007
-----------	--	--------------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A065347 001	May 09, 2007
-----------	--	--	-------------------------	--------------------	--------------

AP		MYLAN LABS LTD	EQ 150MG BASE/ML	A204748 001	Oct 10, 2017
-----------	--	----------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A204749 001	Oct 10, 2017
-----------	--	--	-------------------------	--------------------	--------------

AP		SAGENT PHARMS INC	EQ 150MG BASE/ML	A090108 001	Sep 30, 2011
-----------	--	-------------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A090109 001	Sep 30, 2011
-----------	--	--	-------------------------	--------------------	--------------

AP		WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062889 001	Apr 25, 1988
-----------	--	-------------------------	-------------------------	--------------------	--------------

AP			EQ 150MG BASE/ML	A065206 001	Sep 24, 2004
-----------	--	--	-------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		AKORN INC	EQ 6MG BASE/ML	A203048 001	Apr 04, 2013
-----------	--	-----------	-----------------------	--------------------	--------------

AP			EQ 12MG BASE/ML	A203048 002	Apr 04, 2013
-----------	--	--	------------------------	--------------------	--------------

AP			EQ 18MG BASE/ML	A203048 003	Apr 04, 2013
-----------	--	--	------------------------	--------------------	--------------

AP		BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084 001	Jun 28, 2017
-----------	--	-------------------------	-----------------------	--------------------	--------------

AP			EQ 12MG BASE/ML	A208084 002	Jun 28, 2017
-----------	--	--	------------------------	--------------------	--------------

AP			EQ 18MG BASE/ML	A208084 003	Jun 28, 2017
-----------	--	--	------------------------	--------------------	--------------

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012
-----------	--	------------	-----------------------	--------------------	--------------

AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012
-----------	--	--	------------------------	--------------------	--------------

AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012
-----------	--	--	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+		ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635 001	Dec 22, 1989
----------	--	---------------	----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL

CLEOCIN T

AB	+ !	PHARMACIA AND UPJOHN	EQ 1% BASE	N050600 001	May 31, 1989
-----------	------------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002
-----------	--	----------------	-------------------	--------------------	--------------

SOLUTION; INTRAVENOUS

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

	+ !	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083 001	Apr 20, 2017
--	------------	-------------------------	-------------------------------------	-------------	--------------

	+ !		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083 002	Apr 20, 2017
--	------------	--	--------------------------------------	-------------	--------------

	+ !		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083 003	Apr 20, 2017
--	------------	--	--------------------------------------	-------------	--------------

SOLUTION; TOPICAL

CLEOCIN T

AT	+ !	PHARMACIA AND UPJOHN	EQ 1% BASE	N050537 001	
-----------	------------	-------------------------	-------------------	--------------------	--

CLINDA-DERM

AT		PADDOCK LLC	EQ 1% BASE	A063329 001	Sep 30, 1992
-----------	--	-------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT		CADILA	EQ 1% BASE	A208767 001	Jul 16, 2018
-----------	--	--------	-------------------	--------------------	--------------

AT		ENCUBE ETHICALS	EQ 1% BASE	A209914 001	Jan 28, 2019
-----------	--	-----------------	-------------------	--------------------	--------------

AT		FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006
-----------	--	----------------	-------------------	--------------------	--------------

AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159 001	Jun 05, 1997
-----------	--	--------------------	-------------------	--------------------	--------------

AT		G AND W LABS INC	EQ 1% BASE	A062811 001	Sep 01, 1988
-----------	--	------------------	-------------------	--------------------	--------------

AT		GLASSHOUSE PHARMS	EQ 1% BASE	A209846 001	Feb 08, 2018
-----------	--	-------------------	-------------------	--------------------	--------------

AT		PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995
-----------	--	------------------	-------------------	--------------------	--------------

AT		TARO PHARM INDS	EQ 1% BASE	A065184 001	Mar 31, 2004
-----------	--	-----------------	-------------------	--------------------	--------------

AT		TELIGENT PHARMA INC	EQ 1% BASE	A206945 001	Dec 30, 2016
-----------	--	---------------------	-------------------	--------------------	--------------

AT		VINTAGE PHARMS	EQ 1% BASE	A203343 001	May 29, 2015
-----------	--	----------------	-------------------	--------------------	--------------

SUPPOSITORY; VAGINAL

CLEOCIN

	+ !	PHARMACIA AND UPJOHN	100MG	N050767 001	Aug 13, 1999
--	------------	-------------------------	-------	-------------	--------------

SWAB; TOPICAL

CLEOCIN

AT	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N050537 002	Feb 22, 1994
-----------	----------	-------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT		AKORN	EQ 1% BASE	A065513 001	Jun 17, 2010
-----------	--	-------	-------------------	--------------------	--------------

AT		PERRIGO NEW YORK	EQ 1% BASE	A065049 001	May 25, 2000
-----------	--	------------------	-------------------	--------------------	--------------

CLINDETS

AT		PERRIGO CO	EQ 1% BASE	A064136 001	Sep 30, 1996
-----------	--	------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564 001	Jun 12, 2015
-----------	--	-------------------------	--------------------	--------------------	--------------

ZIANA

AB	+ !	MEDICIS VELTIN	1.2%;0.025%	N050802 001	Nov 07, 2006
-----------	------------	-------------------	--------------------	--------------------	--------------

BX	+ !	ALMIRALL	1.2%;0.025%	N050803 001	Jul 16, 2010
-----------	------------	----------	-------------	-------------	--------------

CLOBAZAM

FILM; ORAL

SYMPAZAN

	+	AQUESTIVE THERAP	5MG	N210833 001	Nov 01, 2018
--	----------	------------------	-----	-------------	--------------

	+		10MG	N210833 002	Nov 01, 2018
--	----------	--	------	-------------	--------------

	+ !		20MG	N210833 003	Nov 01, 2018
--	------------	--	------	-------------	--------------

SUSPENSION; ORAL

CLOBAZAM

AB		AMNEAL PHARMS LLC	2.5MG/ML	A210039 001	Oct 22, 2018
-----------	--	-------------------	-----------------	--------------------	--------------

AB		BIONPHARMA INC	2.5MG/ML	A208819 001	Oct 22, 2018
-----------	--	----------------	-----------------	--------------------	--------------

AB		HIKMA	2.5MG/ML	A209715 001	Oct 22, 2018
-----------	--	-------	-----------------	--------------------	--------------

AB		LUPIN LTD	2.5MG/ML	A210546 001	Dec 28, 2018
-----------	--	-----------	-----------------	--------------------	--------------

AB		MYLAN	2.5MG/ML	A211259 001	Oct 22, 2018
-----------	--	-------	-----------------	--------------------	--------------

AB		UPSHER SMITH LABS	2.5MG/ML	A210569 001	Oct 22, 2018
-----------	--	-------------------	-----------------	--------------------	--------------

AB		VISTAPHARM	2.5MG/ML	A210746 001	Jul 10, 2019
-----------	--	------------	-----------------	--------------------	--------------

ONFI

AB	+ !	LUNDBECK PHARMS LLC	2.5MG/ML	N203993 001	Dec 14, 2012
-----------	------------	---------------------	-----------------	--------------------	--------------

TABLET; ORAL

CLOBAZAM

AB		ALKEM LABS LTD	10MG	A212714 001	Sep 06, 2019
-----------	--	----------------	-------------	--------------------	--------------

AB			20MG	A212714 002	Sep 06, 2019
-----------	--	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLOBAZAM

TABLET; ORAL

CLOBAZAM

<u>AB</u>	AMNEAL PHARMS CO	<u>10MG</u>	<u>A209718</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209718</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	BIONPHARMA INC	<u>10MG</u>	<u>A208825</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A208825</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	BRECKENRIDGE	<u>10MG</u>	<u>A209308</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209308</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A209795</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209795</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	HIKMA	<u>10MG</u>	<u>A208785</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A208785</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	LANNETT CO INC	<u>10MG</u>	<u>A212092</u>	<u>001</u>	Oct 30, 2019
<u>AB</u>		<u>20MG</u>	<u>A212092</u>	<u>002</u>	Oct 30, 2019
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A210545</u>	<u>001</u>	Dec 14, 2018
<u>AB</u>		<u>20MG</u>	<u>A210545</u>	<u>002</u>	Dec 14, 2018
<u>AB</u>	MICRO LABS	<u>10MG</u>	<u>A211711</u>	<u>001</u>	Jan 30, 2019
<u>AB</u>		<u>20MG</u>	<u>A211711</u>	<u>002</u>	Jan 30, 2019
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>10MG</u>	<u>A209808</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209808</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A209687</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209687</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	ZYDUS PHARMS	<u>10MG</u>	<u>A211449</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A211449</u>	<u>002</u>	Oct 22, 2018
<u>ONFI</u>					
<u>AB</u>	+ LUNDBECK PHARMS LLC	<u>10MG</u>	<u>N202067</u>	<u>002</u>	Oct 21, 2011
<u>AB</u>	+!	<u>20MG</u>	<u>N202067</u>	<u>003</u>	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB1</u>	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A210809</u>	<u>001</u>	Feb 15, 2019
<u>AB1</u>	INGENUS PHARMS LLC	<u>0.05%</u>	<u>A206805</u>	<u>001</u>	Jul 31, 2017
<u>AB1</u>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077763</u>	<u>001</u>	Mar 10, 2008
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A208779</u>	<u>001</u>	Oct 04, 2018
<u>OLUX</u>					
<u>AB1</u>	+! MYLAN	<u>0.05%</u>	<u>N021142</u>	<u>001</u>	May 26, 2000
<u>CLOBETASOL PROPIONATE</u>					
<u>AB2</u>	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A211450</u>	<u>001</u>	Sep 09, 2019
<u>AB2</u>	PERRIGO UK FINCO	<u>0.05%</u>	<u>A201402</u>	<u>001</u>	Aug 14, 2012
<u>OLUX E</u>					
<u>AB2</u>	+! MYLAN	<u>0.05%</u>	<u>N022013</u>	<u>001</u>	Jan 12, 2007

CREAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB1</u>	ACP NIMBLE	<u>0.05%</u>	<u>A074139</u>	<u>001</u>	Aug 03, 1994
<u>AB1</u>	AMNEAL PHARMS LLC	<u>0.05%</u>	<u>A211256</u>	<u>001</u>	Dec 26, 2018
<u>AB1</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
<u>AB1</u>	GLENMARK PHARMS	<u>0.05%</u>	<u>A209095</u>	<u>001</u>	May 10, 2018
<u>AB1</u>	LUPIN LTD	<u>0.05%</u>	<u>A210208</u>	<u>001</u>	Jan 30, 2018
<u>AB1</u>	MYLAN	<u>0.05%</u>	<u>A075338</u>	<u>001</u>	Feb 09, 2001
<u>AB1</u>	RISING	<u>0.05%</u>	<u>A211401</u>	<u>001</u>	Jan 11, 2019
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A074249</u>	<u>001</u>	Jul 08, 1996
<u>AB1</u>	TELIGENT PHARMA INC	<u>0.05%</u>	<u>A209974</u>	<u>001</u>	Apr 17, 2018
<u>AB1</u>	TORRENT	<u>0.05%</u>	<u>A211836</u>	<u>001</u>	Dec 30, 2019
<u>AB1</u>	XIROMED	<u>0.05%</u>	<u>A210034</u>	<u>001</u>	Jun 15, 2018
<u>AB1</u>	ZYDUS PHARMS	<u>0.05%</u>	<u>A211074</u>	<u>001</u>	Oct 15, 2018

CORMAX

<u>AB1</u>	! HI TECH PHARMA	<u>0.05%</u>	<u>A074220</u>	<u>001</u>	May 16, 1997
<u>CLOBETASOL PROPIONATE (EMOLLIENT)</u>					
<u>AB2</u>	! FOUGERA PHARMS	<u>0.05%</u>	<u>A075430</u>	<u>001</u>	May 26, 1999
<u>AB2</u>	NOVAST LABS	<u>0.05%</u>	<u>A075733</u>	<u>001</u>	Aug 22, 2001
<u>AB2</u>	TARO	<u>0.05%</u>	<u>A075633</u>	<u>001</u>	May 17, 2000
<u>AB2</u>	TELIGENT PHARMA INC	<u>0.05%</u>	<u>A209411</u>	<u>001</u>	Aug 21, 2017

EMBELINE E

<u>AB2</u>	HI TECH PHARMA	<u>0.05%</u>	<u>A075325</u>	<u>001</u>	Dec 24, 1998
<u>IMPOYZ</u>					
	+! ENCORE DERMAT	<u>0.025%</u>	<u>N209483</u>	<u>001</u>	Nov 28, 2017

GEL; TOPICAL

CLOBETASOL PROPIONATE

<u>AB</u>	! FOUGERA PHARMS	<u>0.05%</u>	<u>A075368</u>	<u>001</u>	Feb 15, 2000
<u>AB</u>	PERRIGO CO	<u>0.05%</u>	<u>A075027</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	TARO	<u>0.05%</u>	<u>A075279</u>	<u>001</u>	May 28, 1999

PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

GEL;TOPICAL

CLOBETASOL PROPIONATE**AB** TELIGENT PHARMA INC **0.05%** **A208881 001** Mar 06, 2017EMBELINE**AB** HI TECH PHARMA **0.05%** **A076141 001** Apr 12, 2002

LOTION;TOPICAL

CLOBETASOL PROPIONATE**AB** ACTAVIS MID **0.05%** **A078223 001** Dec 04, 2008

ATLANTIC

AB CADILA **0.05%** **A205249 001** Sep 24, 2019**AB** LUPIN LTD **0.05%** **A209147 001** Sep 22, 2017**AB** TARO **0.05%** **A200302 001** Jul 02, 2012**AB** TELIGENT PHARMA INC **0.05%** **A208667 001** Nov 29, 2016CLOBEX**AB** +! GALDERMA LABS LP **0.05%** **N021535 001** Jul 24, 2003

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE**AB** ACP NIMBLE **0.05%** **A074089 001** Feb 16, 1994**AB** ALEOR **0.05%** **A211800 001** Mar 04, 2019

DERMACEUTICALS

AB ENCUBE **0.05%** **A211295 001** Nov 15, 2019**AB** ! FOUGERA PHARMS **0.05%** **A074407 001** Feb 23, 1996**AB** GLENMARK PHARMS **0.05%** **A208933 001** Mar 20, 2017**AB** MYLAN **0.05%** **A075057 001** Aug 12, 1998**AB** NOVEL LABS INC **0.05%** **A208841 001** May 04, 2018**AB** TARO **0.05%** **A074248 001** Jul 12, 1996**AB** TELIGENT PHARMA INC **0.05%** **A208589 001** Jan 23, 2019**AB** TORRENT **0.05%** **A212926 001** Oct 25, 2019**AB** XIROMED **0.05%** **A209701 001** Apr 17, 2018**AB** ZYDUS PHARMS **0.05%** **A210199 001** Oct 27, 2017EMBELINE**AB** HI TECH PHARMA **0.05%** **A074221 001** Mar 31, 1995

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE**AB** ACTAVIS MID **0.05%** **A078854 001** Jun 07, 2011

ATLANTIC

AB HI TECH **0.05%** **A209871 001** Oct 27, 2017**AB** PERRIGO ISRAEL **0.05%** **A090974 001** Aug 09, 2012CLOBEX**AB** +! GALDERMA LABS **0.05%** **N021644 001** Feb 05, 2004

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE**AT** ACP NIMBLE **0.05%** **A074331 001** Dec 15, 1995**AT** ALEOR **0.05%** **A212881 001** Oct 21, 2019

DERMACEUTICALS

AT FOUGERA PHARMS **0.05%** **A075391 001** Feb 08, 1999**AT** GLENMARK PHARMS LTD **0.05%** **A210190 001** Apr 18, 2018**AT** MACLEODS PHARMS LTD **0.05%** **A209361 001** Oct 25, 2017**AT** NOVEL LABS INC **0.05%** **A206075 001** Nov 23, 2015**AT** SAPTALIS PHARMS **0.05%** **A211494 001** Oct 02, 2019**AT** TARO **0.05%** **A075224 001** Nov 16, 1998**AT** **0.05%** **A075363 001** Dec 29, 2000**AT** TOLMAR **0.05%** **A076977 001** Aug 05, 2005**AT** WOCKHARDT BIO AG **0.05%** **A075205 001** Nov 13, 1998EMBELINE**AT** ! HI TECH PHARMA **0.05%** **A074222 001** Dec 06, 1995

SPRAY;TOPICAL

CLOBETASOL PROPIONATE**AT** AKORN **0.05%** **A207218 001** Apr 28, 2017**AT** ALEOR **0.05%** **A211191 001** Oct 02, 2019

DERMACEUTICALS

AT GLENMARK PHARMS **0.05%** **A209004 001** Mar 26, 2018**AT** LUPIN LTD **0.05%** **A208125 001** Mar 26, 2018**AT** PADDOCK LLC **0.05%** **A090898 001** Jun 16, 2011**AT** TARO **0.05%** **A208842 001** Mar 26, 2018**AT** ZYDUS PHARMS **0.05%** **A206378 001** Feb 16, 2017CLOBEX**AT** +! GALDERMA LABS LP **0.05%** **N021835 001** Oct 27, 2005

PRESCRIPTION DRUG PRODUCT LIST

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+! EPI HLTH

0.1%

N017765 001

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

<u>AP</u>	ABON PHARMS LLC	<u>20MG/20ML (1MG/ML)</u>	<u>A204029 001</u>	May 09, 2017
<u>AP</u>	ACCORD HLTHCARE	<u>20MG/20ML (1MG/ML)</u>	<u>A212034 001</u>	Feb 22, 2019
<u>AP</u>	AMNEAL	<u>20MG/20ML (1MG/ML)</u>	<u>A208857 001</u>	Nov 06, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>20MG/20ML (1MG/ML)</u>	<u>A205375 001</u>	Nov 06, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>20MG/20ML (1MG/ML)</u>	<u>A207831 001</u>	Oct 31, 2018
<u>AP</u>	INGENUS PHARMS LLC	<u>20MG/20ML (1MG/ML)</u>	<u>A210270 001</u>	Sep 14, 2018
<u>AP</u>	MSN	<u>20MG/20ML (1MG/ML)</u>	<u>A209775 001</u>	Dec 06, 2017
<u>AP</u>	MYLAN LABS LTD	<u>20MG/20ML (1MG/ML)</u>	<u>A208860 001</u>	Nov 06, 2017

CLOLAR

<u>AP</u>	+! GENZYME	<u>20MG/20ML (1MG/ML)</u>	<u>N021673 001</u>	Dec 28, 2004
-----------	------------	---------------------------	--------------------	--------------

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIPHENE CITRATE

! PAR PHARM

50MG

A075528 001 Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

<u>AB</u>	+! SPECGX LLC	<u>25MG</u>	<u>N019906 001</u>	Dec 29, 1989
<u>AB</u>	+	<u>50MG</u>	<u>N019906 002</u>	Dec 29, 1989
<u>AB</u>	+	<u>75MG</u>	<u>N019906 003</u>	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A208632 001</u>	Oct 31, 2018
<u>AB</u>		<u>50MG</u>	<u>A208632 002</u>	Oct 31, 2018
<u>AB</u>		<u>75MG</u>	<u>A208632 003</u>	Oct 31, 2018
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A212218 001</u>	Oct 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A212218 002</u>	Oct 21, 2019
<u>AB</u>		<u>75MG</u>	<u>A212218 003</u>	Oct 21, 2019
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A209294 001</u>	Nov 21, 2018
<u>AB</u>		<u>50MG</u>	<u>A209294 002</u>	Nov 21, 2018
<u>AB</u>		<u>75MG</u>	<u>A209294 003</u>	Nov 21, 2018
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A074947 001</u>	Apr 30, 1998
<u>AB</u>		<u>50MG</u>	<u>A074947 002</u>	Apr 30, 1998
<u>AB</u>		<u>75MG</u>	<u>A074947 003</u>	Apr 30, 1998
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074364 001</u>	Mar 29, 1996
<u>AB</u>		<u>25MG</u>	<u>A074953 001</u>	Jun 25, 1997
<u>AB</u>		<u>50MG</u>	<u>A074364 002</u>	Mar 29, 1996
<u>AB</u>		<u>50MG</u>	<u>A074953 002</u>	Jun 25, 1997
<u>AB</u>		<u>75MG</u>	<u>A074364 003</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074953 003</u>	Jun 25, 1997
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694 001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694 002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694 003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074958 001</u>	Aug 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074958 002</u>	Aug 26, 1997
<u>AB</u>		<u>75MG</u>	<u>A074958 003</u>	Aug 26, 1997
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A208961 001</u>	Dec 27, 2017
<u>AB</u>		<u>50MG</u>	<u>A208961 002</u>	Dec 27, 2017
<u>AB</u>		<u>75MG</u>	<u>A208961 003</u>	Dec 27, 2017

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147 001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147 002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147 003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869 001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869 002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869 003</u>	Oct 31, 1996
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150 001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150 002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150 003</u>	Oct 05, 1998
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A077856 001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856 002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856 003</u>	Jun 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979 001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979 002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979 003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569 001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569 002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569 003</u>	Sep 10, 1996
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964 001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964 002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964 003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	+ ROCHE	<u>0.5MG</u>	<u>N017533 001</u>	
<u>AB</u>	+!	<u>1MG</u>	<u>N017533 002</u>	
<u>AB</u>	+	<u>2MG</u>	<u>N017533 003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.125MG</u>	<u>A211033 001</u>	Jun 28, 2019
<u>AB</u>		<u>0.25MG</u>	<u>A211033 002</u>	Jun 28, 2019
<u>AB</u>		<u>0.5MG</u>	<u>A211033 003</u>	Jun 28, 2019
<u>AB</u>		<u>1MG</u>	<u>A211033 004</u>	Jun 28, 2019
<u>AB</u>		<u>2MG</u>	<u>A211033 005</u>	Jun 28, 2019
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194 001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194 002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194 003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194 004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194 005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171 001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171 002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171 003</u>	Aug 03, 2005
<u>AB</u>	!	<u>1MG</u>	<u>A077171 004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171 005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654 001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654 002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654 003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654 004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654 005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891 001</u>	Oct 10, 1984
-----------	---------------------------	-------------------	--------------------	--------------

CATAPRES-TTS-2

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891 002</u>	Oct 10, 1984
-----------	---------------------------	-------------------	--------------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+! BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891 003</u>	Oct 10, 1984
-----------	----------------------------	-------------------	--------------------	--------------

CLONIDINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873 001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873 002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873 003</u>	May 06, 2014
<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157 001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157 002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157 003</u>	Aug 18, 2009
<u>AB</u>	MAYNE PHARMA	<u>0.1MG/24HR</u>	<u>A079090 001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090 002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>	X-GEN PHARMS INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>	ZYDUS PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014

PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601</u>	<u>002</u>	Feb 20, 2014
-----------	--	----------------------------	----------------	------------	--------------

DURACLON

<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
-----------	---	---------------------	----------------------------	----------------	------------	--------------

<u>AP</u>	+	!	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999
-----------	---	---	----------------------------	----------------	------------	--------------

TABLET; ORAL

CATAPRES

<u>AB</u>	+	BOEHRINGER	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
-----------	---	------------	--------------	----------------	------------	--

<u>AB</u>	+	INGELHEIM	<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
-----------	---	-----------	--------------	----------------	------------	--

<u>AB</u>	+	!	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	
-----------	---	---	--------------	----------------	------------	--

CLONIDINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
-----------	--	-------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368</u>	<u>001</u>	Dec 06, 2011
-----------	--	--------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A091368</u>	<u>002</u>	Dec 06, 2011
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A091368</u>	<u>003</u>	Dec 06, 2011
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		FRONTIDA BIOPHARM	<u>0.1MG</u>	<u>A070923</u>	<u>003</u>	Sep 04, 1987
-----------	--	-------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A070923</u>	<u>002</u>	Sep 04, 1987
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
-----------	--	------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		PRINSTON INC	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
-----------	--	--------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
-----------	--	---------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		YUNG SHIN PHARM	<u>0.1MG</u>	<u>A202297</u>	<u>001</u>	Jun 13, 2013
-----------	--	-----------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.2MG</u>	<u>A202297</u>	<u>002</u>	Jun 13, 2013
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>0.3MG</u>	<u>A202297</u>	<u>003</u>	Jun 13, 2013
-----------	--	--	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>		ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320</u>	<u>001</u>	May 15, 2015
------------	--	-------------------	--------------	----------------	------------	--------------

<u>AB1</u>		AJANTA PHARMA LTD	<u>0.1MG</u>	<u>A209686</u>	<u>001</u>	Nov 20, 2017
------------	--	-------------------	--------------	----------------	------------	--------------

<u>AB1</u>		AMNEAL PHARMS NY	<u>0.1MG</u>	<u>A210052</u>	<u>001</u>	Nov 20, 2017
------------	--	------------------	--------------	----------------	------------	--------------

<u>AB1</u>		ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984</u>	<u>001</u>	Sep 30, 2013
------------	--	---------------	--------------	----------------	------------	--------------

<u>AB1</u>		JUBILANT GENERICS	<u>0.1MG</u>	<u>A210338</u>	<u>001</u>	Jan 29, 2018
------------	--	-------------------	--------------	----------------	------------	--------------

<u>AB1</u>		LUPIN LTD	<u>0.1MG</u>	<u>A209285</u>	<u>001</u>	Oct 23, 2017
------------	--	-----------	--------------	----------------	------------	--------------

<u>AB1</u>		MAYNE PHARMA INC	<u>0.1MG</u>	<u>A210680</u>	<u>001</u>	Apr 30, 2018
------------	--	------------------	--------------	----------------	------------	--------------

<u>AB1</u>		NOVAST LABS	<u>0.1MG</u>	<u>A209675</u>	<u>001</u>	Mar 05, 2019
------------	--	-------------	--------------	----------------	------------	--------------

<u>AB1</u>		XIAMEN LP PHARM CO	<u>0.1MG</u>	<u>A209757</u>	<u>001</u>	Nov 20, 2017
------------	--	--------------------	--------------	----------------	------------	--------------

KAPVAY

<u>AB1</u>	+	CONCORDIA PHARMS	<u>0.1MG</u>	<u>N022331</u>	<u>003</u>	Sep 28, 2010
------------	---	------------------	--------------	----------------	------------	--------------

		INC				
--	--	-----	--	--	--	--

CLONIDINE HYDROCHLORIDE

<u>AB2</u>		ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A202792</u>	<u>001</u>	May 15, 2015
------------	--	-------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206376 002</u>	May 07, 2018
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165 001</u>	Sep 15, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204165 002</u>	Sep 15, 2014
<u>AB</u>	SUN PHARM	<u>EQ 75MG BASE</u>	<u>A090494 001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999 001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844 001</u>	May 17, 2012
<u>PLAVIX</u>				
<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839 001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839 002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858 002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858 003</u>	Jul 17, 1987
<u>AB</u>	!	<u>15MG</u>	<u>A071858 001</u>	Jul 17, 1987
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731 003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731 002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731 001</u>	Apr 27, 2000
<u>GEN-XENE</u>				
<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787 001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788 001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789 001</u>	Apr 26, 1988
<u>TRANXENE</u>				
<u>AB</u>	+ RECORDATI RARE	<u>7.5MG</u>	<u>N017105 007</u>	

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>1%</u>	<u>A078338 001</u>	Sep 02, 2008
<u>AB</u>	GLENMARK PHARMS	<u>1%</u>	<u>A090219 001</u>	Aug 03, 2010
<u>AB</u>	! TARO	<u>1%</u>	<u>A072640 001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTRIMAZOLE

<u>AT</u>	NOVITIUM PHARMA	<u>1%</u>	<u>A209815 001</u>	Feb 14, 2019
<u>AT</u>	! TARO	<u>1%</u>	<u>A074580 001</u>	Jul 29, 1996
<u>AT</u>	TASMAN PHARMA	<u>1%</u>	<u>A212281 001</u>	Jul 25, 2019
<u>AT</u>	TEVA	<u>1%</u>	<u>A073306 001</u>	Feb 28, 1995

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

<u>AB</u>	! HIKMA	<u>10MG</u>	<u>A076387 001</u>	Jul 29, 2004
<u>AB</u>	PADDOCK LLC	<u>10MG</u>	<u>A076763 001</u>	Oct 28, 2005

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

	+! TASMAN PHARMA	50MG/ML	N203479 001	Feb 06, 2013
--	------------------	---------	-------------	--------------

TABLET; ORAL

CLOZAPINE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A202873 001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A202873 002</u>	Nov 25, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A206433 001</u>	Nov 29, 2016
<u>AB</u>		<u>50MG</u>	<u>A206433 002</u>	Nov 29, 2016
<u>AB</u>		<u>100MG</u>	<u>A206433 003</u>	Nov 29, 2016
<u>AB</u>		<u>200MG</u>	<u>A206433 004</u>	Nov 29, 2016
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A074949 001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949 004</u>	Apr 25, 2005
<u>AB</u>		<u>50MG</u>	<u>A076809 003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949 002</u>	Nov 26, 1997
<u>AB</u>		<u>100MG</u>	<u>A076809 002</u>	Dec 16, 2005
<u>AB</u>		<u>200MG</u>	<u>A076809 001</u>	Dec 16, 2005
<u>AB</u>	MAYNE PHARMA	<u>25MG</u>	<u>A203807 001</u>	Sep 17, 2015
<u>AB</u>		<u>50MG</u>	<u>A203807 003</u>	Aug 22, 2017
<u>AB</u>		<u>100MG</u>	<u>A203807 002</u>	Sep 17, 2015
<u>AB</u>		<u>200MG</u>	<u>A203807 004</u>	Aug 22, 2017
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075417 001</u>	May 27, 1999
<u>AB</u>		<u>50MG</u>	<u>A075417 004</u>	Apr 15, 2010
<u>AB</u>		<u>100MG</u>	<u>A075417 002</u>	May 27, 1999
<u>AB</u>		<u>200MG</u>	<u>A075417 005</u>	Apr 15, 2010

PRESCRIPTION DRUG PRODUCT LIST

CLOZAPINE

TABLET;ORAL

CLOZAPINE

<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002
<u>AB</u>		<u>200MG</u>	<u>A075713</u>	<u>004</u>	Nov 07, 2017

CLOZARIL

<u>AB</u>	+	HERITAGE LIFE	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+		<u>50MG</u>	<u>N019758</u>	<u>003</u>	May 20, 2019
<u>AB</u>	+	!	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989
<u>AB</u>	+		<u>200MG</u>	<u>N019758</u>	<u>004</u>	May 20, 2019

CLOZAPINE

IVAX SUB TEVA
PHARMS

A074949 003 Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

<u>AB</u>	BARR LABS INC	<u>25MG</u>	<u>A090308</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>	!	<u>100MG</u>	<u>A090308</u>	<u>002</u>	Nov 25, 2015
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A201824</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>100MG</u>	<u>A201824</u>	<u>003</u>	Sep 15, 2015
	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018
	TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015
		200MG	A203039	002	Nov 25, 2015

COBICISTAT

TABLET;ORAL

TYBOST

+! GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

+! JANSSEN PRODS 150MG;800MG N205395 001 Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYM TUZA

+! JANSSEN PRODS 150MG;800MG;200MG;EQ 10MG BASE N210455 001 Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

+! GILEAD SCIENCES INC 150MG;150MG;200MG;EQ 10MG BASE N207561 001 Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

+! GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

+! GENENTECH INC EQ 20MG BASE N206192 001 Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+! GENUS LIFESCIENCES 4% N209963 001 Dec 14, 2017

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	VINTAGE	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A040660</u>	<u>001</u>	Dec 07, 2006
-----------	---------	--------------------------------------	----------------	------------	--------------

PROMETH VC W/ CODEINE

<u>AA</u>	!	ACTAVIS MID ATLANTIC	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A088764</u>	<u>001</u>	Oct 31, 1984
-----------	---	----------------------	--------------------------------------	----------------	------------	--------------

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	HI-TECH PHARMA CO	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A040674</u>	<u>001</u>	Dec 23, 2014
-----------	-------------------	--------------------------------------	----------------	------------	--------------

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS	<u>10MG/5ML; 5MG/5ML; 6.25MG/5ML</u>	<u>A200963</u>	<u>001</u>	Aug 26, 2015
-----------	---------------	--------------------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	!	ACTAVIS MID ATLANTIC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088763</u>	<u>001</u>	Oct 31, 1984
AA		AMNEAL PHARMS	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A200894</u>	<u>001</u>	Apr 24, 2013
AA		HI TECH PHARMA	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040151</u>	<u>001</u>	Aug 26, 1997
AA		NOSTRUM LABS INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A090180</u>	<u>001</u>	Mar 17, 2010
AA		TRIS PHARMA INC	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A200386</u>	<u>001</u>	Jun 29, 2012
AA		WOCKHARDT BIO AG	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A088875</u>	<u>001</u>	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA		VINTAGE	<u>10MG/5ML; 6.25MG/5ML</u>	<u>A040650</u>	<u>001</u>	Jan 31, 2006
-----------	--	---------	-----------------------------	----------------	------------	--------------

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

!	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985
---	----------------	------------------------------	---------	-----	--------------

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB	+	HIKMA	<u>15MG</u>	<u>N022402</u>	<u>001</u>	Jul 16, 2009
AB	+		<u>30MG</u>	<u>N022402</u>	<u>002</u>	Jul 16, 2009
AB	+		<u>60MG</u>	<u>N022402</u>	<u>003</u>	Jul 16, 2009
AB		LANNETT CO INC	<u>15MG</u>	<u>A203046</u>	<u>001</u>	Jun 13, 2014
AB			<u>30MG</u>	<u>A203046</u>	<u>002</u>	Jun 13, 2014
AB			<u>60MG</u>	<u>A203046</u>	<u>003</u>	Jun 13, 2014

COLCHICINE

CAPSULE;ORAL

MITIGARE

+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014
---	-------------------	-------	---------	-----	--------------

SOLUTION;ORAL

GLOPERBA

+	AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019
---	--------------	-----------	---------	-----	--------------

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	<u>0.6MG</u>	<u>A211250</u>	<u>001</u>	Feb 08, 2019
AB		DR REDDYS	<u>0.6MG</u>	<u>A209876</u>	<u>001</u>	Sep 06, 2019
AB		MYLAN	<u>0.6MG</u>	<u>A209470</u>	<u>001</u>	Sep 16, 2019
AB		WATSON LABS INC	<u>0.6MG</u>	<u>A204461</u>	<u>001</u>	Jul 31, 2019

COLCRYS

AB	+	TAKEDA PHARMS USA	<u>0.6MG</u>	<u>N022352</u>	<u>001</u>	Jul 29, 2009
-----------	---	-------------------	--------------	----------------	------------	--------------

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	!	WATSON LABS	<u>0.5MG;500MG</u>	<u>A084279</u>	<u>001</u>	
AB		NOVAST LABS	<u>0.5MG;500MG</u>	<u>A040618</u>	<u>001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

+	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019
---	--------------------	--------	---------	-----	--------------

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	<u>3.75GM/PACKET</u>	<u>A210316</u>	<u>001</u>	May 06, 2019
AB		GLENMARK PHARMS LTD	<u>3.75GM/PACKET</u>	<u>A202190</u>	<u>002</u>	Jul 16, 2018

WELCHOL

AB	+	DAIICHI SANKYO	<u>3.75GM/PACKET</u>	<u>N022362</u>	<u>002</u>	Oct 02, 2009
AB		COLESEVELAM HYDROCHLORIDE				
		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	<u>625MG</u>	<u>A209038</u>	<u>001</u>	Oct 05, 2018
AB		BIONPHARMA INC	<u>625MG</u>	<u>A208670</u>	<u>001</u>	Sep 13, 2019
AB		DR REDDYS	<u>625MG</u>	<u>A210889</u>	<u>001</u>	Oct 05, 2018
AB		GLENMARK PHARMS LTD	<u>625MG</u>	<u>A203480</u>	<u>001</u>	May 18, 2018
AB		IMPAX LABS INC	<u>625MG</u>	<u>A091600</u>	<u>001</u>	May 16, 2018
AB		ZYDUS PHARMS	<u>625MG</u>	<u>A207765</u>	<u>001</u>	Oct 07, 2019

WELCHOL

AB	+	DAIICHI SANKYO	<u>625MG</u>	<u>N021176</u>	<u>001</u>	May 26, 2000
-----------	---	----------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	+	PHARMACIA UPJOHN	5GM/SCOOPFUL	N017563 003	Sep 22, 1995
AB	+	!	5GM/PACKET	N017563 004	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	5GM/SCOOPFUL	A077277 001	May 02, 2006
AB			5GM/PACKET	A077277 002	May 02, 2006

FLAVORED COLESTID

	+	PHARMACIA UPJOHN	5GM/PACKET	N017563 001	
	+		5GM/SCOOPFUL	N017563 002	

TABLET; ORAL

COLESTID

AB	+	PHARMACIA UPJOHN	1GM	N020222 001	Jul 19, 1994
-----------	----------	------------------	------------	--------------------	--------------

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	1GM	A077510 001	Oct 24, 2006
-----------	--	------------	------------	--------------------	--------------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP		EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359 001	Sep 28, 2012
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A065364 001	Apr 17, 2008
AP		NEXUS PHARMS	EQ 150MG BASE/VIAL	A065177 001	Mar 19, 2004
AP		SAGENT PHARMS INC	EQ 150MG BASE/VIAL	A201365 001	Feb 19, 2014
AP		X GEN PHARMS	EQ 150MG BASE/VIAL	A064216 001	Feb 26, 1999
AP		XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356 001	May 29, 2015

COLY-MYCIN M

AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108 002	
-----------	----------	----------------------	---------------------------	--------------------	--

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

	+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356 001	
--	----------	-----------------	---	-------------	--

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697 002	Oct 08, 2008
--	----------	-------------------	-----------------------	-------------	--------------

COPANLISIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

ALIQOPA

	+	BAYER HEALTHCARE	60MG/VIAL	N209936 001	Sep 14, 2017
--	----------	------------------	-----------	-------------	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

	+	COOPERSURGICAL	309MG/COPPER	N018680 001	Nov 15, 1984
--	----------	----------------	--------------	-------------	--------------

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

	+	FERRING	EQ 0.1MG BASE/VIAL	N020162 001	May 23, 1996
--	----------	---------	--------------------	-------------	--------------

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

	+	MALLINCKRODT ARD	80 UNITS/ML	N008372 008	
--	----------	------------------	-------------	-------------	--

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

	!	HIKMA INTL PHARMS	25MG	A080776 002	
--	----------	-------------------	------	-------------	--

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750 001	
-----------	----------	----------------------	--------------------	--------------------	--

COSYNTROPIN

AP		MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574 001	Dec 17, 2009
AP		SANDOZ	0.25MG/VIAL	A202147 001	Jun 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

CRISABOROLE

OINTMENT; TOPICAL

EUCRISA

+! ANACOR PHARMS INC 2% N207695 001 Dec 14, 2016

CRIZOTINIB

CAPSULE; ORAL

XALKORI

+ PF PRISM CV 200MG N202570 001 Aug 26, 2011

+! 250MG N202570 002 Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

+! NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM**AA** AILEX PHARMS LLC **100MG/5ML** **A209264 001** Oct 16, 2017**AA** MICRO LABS LTD **100MG/5ML** **A202745 001** Apr 04, 2013

INDIA

AA RISING **100MG/5ML** **A202583 001** Oct 27, 2011GASTROCROM**AA** +! MYLAN SPECIALITY LP **100MG/5ML** **N020479 001** Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUM**AN** AILEX PHARMS LLC **10MG/ML** **A209453 001** Oct 16, 2017**AN** ! TEVA PHARMS **10MG/ML** **A075271 001** Jan 18, 2000**AN** WOCKHARDT BIO AG **10MG/ML** **A075346 001** Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM**AT** ! AKORN **4%** **A074706 001** Apr 29, 1998**AT** SANDOZ INC **4%** **A075282 001** Jun 16, 1999CROTAMITON

LOTION; TOPICAL

CROTAN**AT** MARNEL PHARMS **10%** **A087204 001**EURAX**AT** +! SUN PHARM INDS INC **10%** **N009112 003**CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA EQ 0.4MG COPPER/ML N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN**AP** +! AM REGENT **1MG/ML** **A080737 001****AP** MYLAN LABS LTD **1MG/ML** **A204829 001** Jun 05, 2017**AP** SOMERSET THERAPS **1MG/ML** **A206503 001** Dec 11, 2015

LLC

AP **1MG/ML** **A209429 001** Dec 18, 2018**AP** VITRUVIAS THERAP **1MG/ML** **A209255 001** Dec 18, 2018**AP** WEST-WARD PHARMS **1MG/ML** **A080515 002**

INT

VIBISONE**AP** ! FRESENIUS KABI USA **1MG/ML** **A080557 003**

SPRAY, METERED; NASAL

NASCOBAL

+! ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX**AB** + TEVA PHARMS INTL **15MG** **N021777 001** Feb 01, 2007**AB** +! **30MG** **N021777 002** Feb 01, 2007CYCLOBENZAPRINE HYDROCHLORIDE**AB** APOTEX **15MG** **A206703 001** Jul 24, 2018**AB** **30MG** **A206703 002** Jul 24, 2018**AB** TWI PHARMS INC **15MG** **A091281 001** Jan 31, 2013**AB** **30MG** **A091281 002** Jan 31, 2013

PRESCRIPTION DRUG PRODUCT LIST

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG	A071611 002	Feb 03, 2006
AB		7.5MG	A071611 003	Feb 03, 2006
AB		10MG	A071611 001	May 03, 1989
AB	ANDA REPOSITORY	5MG	A073541 002	Apr 06, 2006
AB		10MG	A073541 001	May 23, 1995
AB	AUROBINDO PHARMA	5MG	A078643 001	Sep 26, 2008
AB		10MG	A078643 002	Sep 26, 2008
AB	INVAGEN PHARMS	5MG	A090478 001	Jul 23, 2010
AB		10MG	A090478 002	Jul 23, 2010
AB	JUBILANT CADISTA	5MG	A077563 001	Apr 19, 2006
AB		7.5MG	A077563 003	Aug 25, 2017
AB		10MG	A077563 002	Apr 19, 2006
AB	KVK TECH	5MG	A078048 001	Feb 28, 2011
AB		10MG	A078048 002	Feb 28, 2011
AB	MYLAN PHARMS INC	5MG	A073144 002	Feb 03, 2006
AB		7.5MG	A073144 003	Mar 25, 2013
AB	!	10MG	A073144 001	May 30, 1991
AB	ORIT LABS LLC	5MG	A078218 002	Jun 19, 2015
AB		10MG	A078218 001	Apr 18, 2008
AB	OXFORD PHARMS	5MG	A077209 002	Feb 03, 2006
AB		10MG	A077209 001	Oct 04, 2005
AB	PLIVA	10MG	A074421 001	Sep 29, 1995
AB	PRINSTON INC	5MG	A077797 001	Feb 28, 2007
AB		10MG	A077797 002	Feb 28, 2007
AB	RUBICON	5MG	A208170 001	May 31, 2017
AB		7.5MG	A208170 002	May 31, 2017
AB		10MG	A208170 003	May 31, 2017
AB	SUN PHARM INDS LTD	5MG	A078722 001	May 12, 2008
AB		7.5MG	A078722 002	May 12, 2008
AB		10MG	A078722 003	May 12, 2008

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT	AKORN	1%	A040164 001	Jan 13, 1997
-----------	-------	-----------	--------------------	--------------

CYCLOGYL

AT	!	ALCON LABS INC	0.5%	A084109 001
AT	!		1%	A084110 001

CYCLOPENTOLATE HYDROCHLORIDE

AT	AKORN INC	0.5%	A205937 001	Dec 09, 2015
-----------	-----------	-------------	--------------------	--------------

PENTOLAIR

AT	BAUSCH AND LOMB	1%	A040075 001	Apr 29, 1994
-----------	-----------------	-----------	--------------------	--------------

CYCLOGYL

!	ALCON LABS INC	2%	A084108 001	
---	----------------	-----------	--------------------	--

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!	ALCON LABS INC	0.2%; 1%	A084300 001	
---	----------------	-----------------	--------------------	--

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	AMERIGEN PHARMS LTD	25MG	A207014 001	Mar 19, 2018	
AB		50MG	A207014 002	Mar 19, 2018	
AB	CIPLA	25MG	A211608 001	Jan 18, 2019	
AB		50MG	A211608 002	Jan 18, 2019	
AB	+	HIKMA	25MG	N203856 001	Sep 16, 2013
AB	+	!	50MG	N203856 002	Sep 16, 2013
AB	STI PHARMA LLC	25MG	A209872 001	May 07, 2018	
AB		50MG	A209872 002	May 07, 2018	

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	AMNEAL	500MG/VIAL	A210046 001	May 25, 2018	
AP		1GM/VIAL	A210046 002	May 25, 2018	
AP		2GM/VIAL	A210046 003	May 25, 2018	
AP	!	BAXTER HLTHCARE	500MG/VIAL	A040745 001	May 21, 2008
AP	!		1GM/VIAL	A040745 002	May 21, 2008
AP	!		2GM/VIAL	A040745 003	May 21, 2008
AP	JIANGSU HENGRUI MED	500MG/VIAL	A204555 001	Oct 31, 2014	
AP		1GM/VIAL	A204555 002	Oct 31, 2014	

PRESCRIPTION DRUG PRODUCT LIST

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP		2GM/VIAL	A204555 003	Oct 31, 2014
-----------	--	-----------------	--------------------	--------------

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

!

PURDUE

250MG

A060593 001

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	APOTEX	25MG	A210721 001	Jul 10, 2019
AB1		50MG	A210721 002	Jul 10, 2019
AB1		100MG	A210721 003	Jul 10, 2019
AB1	IVAX SUB TEVA PHARMS	25MG	A065110 003	Mar 29, 2005
AB1		50MG	A065110 001	Mar 29, 2005
AB1		100MG	A065110 002	Mar 29, 2005
AB1	MAYNE PHARMA	25MG	A065044 002	Dec 20, 2000
AB1		100MG	A065044 001	Dec 20, 2000
AB1	SANDOZ	25MG	A065017 002	Jan 13, 2000
AB1		100MG	A065017 001	Jan 13, 2000

GENGRAF

AB1	ABEVIE	25MG	A065003 001	May 12, 2000
AB1		100MG	A065003 003	May 12, 2000

NEORAL

AB1	+	NOVARTIS	25MG	N050715 001	Jul 14, 1995
AB1	+	!	100MG	N050715 002	Jul 14, 1995

CYCLOSPORINE

AB2	APOTEX	25MG	A065040 001	May 09, 2002
AB2		100MG	A065040 002	May 09, 2002

SANDIMMUNE

AB2	+	NOVARTIS	25MG	N050625 001	Mar 02, 1990
AB2	+	!	100MG	N050625 002	Mar 02, 1990
BX	+		50MG	N050625 003	Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+! ALLERGAN

0.05%

N050790 001 Dec 23, 2002

RESTASIS MULTIDOSE

+! ALLERGAN

0.05%

N050790 002 Oct 27, 2016

INJECTABLE; INJECTION

CYCLOSPORINE

AP	AM REGENT	50MG/ML	A065151 001	Oct 07, 2003
AP	WEST-WARD PHARMS INT	50MG/ML	A065004 001	Oct 29, 1999

SANDIMMUNE

AP	+	NOVARTIS	50MG/ML	N050573 001	Nov 14, 1983
SOLUTION; OPHTHALMIC					
CEQUA					
	+	SUN PHARMA GLOBAL	0.09%	N210913 001	Aug 14, 2018

SOLUTION; ORAL

CYCLOSPORINE

AB1	ABEVIE	100MG/ML	A065025 001	Mar 03, 2000
AB1	IVAX SUB TEVA PHARMS	100MG/ML	A065078 001	Mar 25, 2005
AB1	MAYNE PHARMA	100MG/ML	A065054 001	Dec 18, 2001

NEORAL

AB1	+	NOVARTIS	100MG/ML	N050716 001	Jul 14, 1995
------------	---	----------	-----------------	--------------------	--------------

CYCLOSPORINE

AB2	WOCKHARDT BIO AG	100MG/ML	A065133 001	Sep 17, 2004
------------	------------------	-----------------	--------------------	--------------

SANDIMMUNE

AB2	+	NOVARTIS	100MG/ML	N050574 001	Nov 14, 1983
------------	---	----------	-----------------	--------------------	--------------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	ANDA REPOSITORY	2MG/5ML	A204823 001	Dec 27, 2016	
AA	ELYSIUM	2MG/5ML	A209108 001	Oct 16, 2018	
AA	LANNETT CO INC	2MG/5ML	A203191 001	Jul 13, 2017	
AA	!	LYNE	2MG/5ML	A040668 001	Jun 28, 2006
AA	PHARM ASSOC	2MG/5ML	A091295 001	Mar 28, 2013	
AA	QUAGEN	2MG/5ML	A212423 001	May 22, 2019	

PRESCRIPTION DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	APEX PHARMS INC	<u>4MG</u>	<u>A207783</u>	<u>001</u>	Dec 29, 2016
<u>AA</u>	BEXIMCO PHARMS USA	<u>4MG</u>	<u>A206676</u>	<u>001</u>	Apr 12, 2019
<u>AA</u>	BOSCOGEN	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006
<u>AA</u>	ELYSIUM	<u>4MG</u>	<u>A207555</u>	<u>001</u>	Jan 31, 2017
<u>AA</u>	! HERITAGE PHARMA	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>	MOUNTAIN	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	NOVAST LABS	<u>4MG</u>	<u>A205087</u>	<u>001</u>	Sep 23, 2015
<u>AA</u>	PAR PHARM	<u>4MG</u>	<u>A087129</u>	<u>001</u>	
<u>AA</u>	STRIDES PHARMA	<u>4MG</u>	<u>A209172</u>	<u>001</u>	Apr 11, 2018
<u>AA</u>	TWI PHARMS	<u>4MG</u>	<u>A206553</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A208938</u>	<u>001</u>	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+	!	EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012
---	---	---------------------	---------------	---------	-----	--------------

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

+	!	EXELA PHARMA SCS	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019
		LLC				

NOURESS

		AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019
--	--	---------------	----------------------	---------	-----	--------------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>	!	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
<u>AP</u>		GLAND PHARMA LTD	<u>100MG/VIAL</u>	<u>A211937</u>	<u>001</u>	Dec 23, 2019
<u>AP</u>			<u>2GM/VIAL</u>	<u>A211938</u>	<u>001</u>	Dec 23, 2019
<u>AP</u>	!	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
<u>AP</u>	!		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>	!		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
<u>AP</u>			<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
<u>AP</u>		MEITHEAL	<u>20MG/ML</u>	<u>A206190</u>	<u>001</u>	Nov 09, 2017
<u>AP</u>			<u>100MG/ML</u>	<u>A205696</u>	<u>001</u>	Jul 17, 2018
<u>AP</u>		MYLAN LABS LTD	<u>20MG/ML</u>	<u>A200914</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		WEST-WARD PHARMS	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
		INT				
<u>AP</u>	!		<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
	!		500MG/VIAL	A071472	001	Aug 02, 1989
	!		1GM/VIAL	A074245	001	Aug 31, 1994

CYTARABINE; DAUNORUBICIN

POWDER; INTRAVENOUS

VYXEOS

+	!	CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017
---	---	----------------	-------------	---------	-----	--------------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

+		BOEHRINGER	EQ 75MG BASE	N022512	001	Oct 19, 2010
		INGELHEIM				
+			EQ 110MG BASE	N022512	003	Nov 20, 2015
+	!		EQ 150MG BASE	N022512	002	Oct 19, 2010

PRESCRIPTION DRUG PRODUCT LIST

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

+ NOVARTIS

EQ 50MG BASE

N202806 001 May 29, 2013

+!

EQ 75MG BASE

N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE**AP** ! FRESENIUS KABI USA**200MG/VIAL****A075371 002** Aug 27, 1999**AP** HOSPIRA**200MG/VIAL****A075940 001** Oct 18, 2001**AP** TEVA PHARMS USA**200MG/VIAL****A075259 002** Aug 27, 1998**AP** !**500MG/VIAL****A075259 001** Sep 22, 2000**AP** WEST-WARD PHARMS**200MG/VIAL****A075812 001** Jun 15, 2001

INT

AP**500MG/VIAL****A075812 002** Oct 31, 2002

! FRESENIUS KABI USA

100MG/VIAL

A075371 001 Aug 27, 1999

DACOMITINIB

TABLET; ORAL

VIZIMPRO

+ PFIZER INC

15MG

N211288 001 Sep 27, 2018

+

30MG

N211288 002 Sep 27, 2018

+!

45MG

N211288 003 Sep 27, 2018

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN**AP** +! RECORDATI RARE**0.5MG/VIAL****N050682 001**DACTINOMYCIN**AP** HISUN PHARM**0.5MG/VIAL****A207232 001** Jul 16, 2019

HANGZHOU

AP MYLAN LABS LTD**0.5MG/VIAL****A203385 001** Nov 09, 2017**AP** X-GEN PHARMS INC**0.5MG/VIAL****A203999 001** May 20, 2019DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALVANCE

+! ALLERGAN

EQ 500MG BASE/VIAL

N021883 001 May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA**AB** +! ACORDA**10MG****N022250 001** Jan 22, 2010DALFAMPRIDINE**AB** ACCORD HLTHCARE**10MG****A206863 001** Jul 11, 2018**AB** ACTAVIS LABS FL INC**10MG****A206836 001** Jan 23, 2017**AB** ALKEM LABS LTD**10MG****A206765 001** Jul 30, 2018**AB** AUROBINDO PHARMA**10MG****A206811 001** Jan 23, 2017

LTD

AB HIKMA**10MG****A206646 001** Oct 24, 2018**AB** MICRO LABS**10MG****A210158 001** Mar 11, 2019**AB** SUN PHARM**10MG****A208292 001** May 21, 2019DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

+! KING PHARMS

350MG/VIAL; 150MG/VIAL

N050748 001 Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

+ PFIZER INC

2,500IU/0.2ML (12,500IU/ML)

N020287 001 Dec 22, 1994

+

5,000IU/0.2ML (25,000IU/ML)

N020287 003 Mar 18, 1996

+

7,500IU/0.3ML (25,000IU/ML)

N020287 005 Apr 04, 2002

+

10,000IU/ML (10,000IU/ML)

N020287 004 Jan 30, 1998

+

12,500IU/0.5ML (25,000IU/ML)

N020287 009 May 01, 2007

+

15,000IU/0.6ML (25,000IU/ML)

N020287 010 May 01, 2007

+

18,000IU/0.72ML (25,000IU/ML)

N020287 011 May 01, 2007

+!

95,000IU/3.8ML (25,000IU/ML)

N020287 006 Apr 04, 2002

PRESCRIPTION DRUG PRODUCT LIST

DANAZOL

CAPSULE;ORAL

DANAZOL

<u>AB</u>	BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>		<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	!	<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>	LANNETT CO INC	<u>50MG</u>	<u>A077246</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>100MG</u>	<u>A077246</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

<u>AB</u>	+ PAR STERILE PRODUCTS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N017443</u>	<u>002</u>	

DANTROLENE SODIUM

<u>AB</u>	ELITE LABS INC	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>	IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX

+! EAGLE PHARMS 250MG/VIAL N205579 001 Jul 22, 2014

INJECTABLE;INJECTION

DANTRIUM

<u>AP</u>	+	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	
-----------	---	------------------	----------------	------------	--

DANTROLENE SODIUM

<u>AP</u>	HIKMA PHARMS	<u>20MG/VIAL</u>	<u>A204762</u>	<u>001</u>	Jun 19, 2017
-----------	--------------	------------------	----------------	------------	--------------

REVONTO

<u>AP</u>	US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007
-----------	--------------	------------------	----------------	------------	--------------

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

+ ASTRAZENECA AB 5MG N202293 001 Jan 08, 2014

+! 10MG N202293 002 Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

+ ASTRAZENECA AB 2.5MG;1GM N205649 005 Jul 28, 2017

+ 5MG;500MG N205649 001 Oct 29, 2014

+ 5MG;1GM N205649 002 Oct 29, 2014

+ 10MG;500MG N205649 003 Oct 29, 2014

+! 10MG;1GM N205649 004 Oct 29, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

QTERNMET XR

+ ASTRAZENECA AB 2.5MG;1GM;EQ 2.5MG BASE N210874 001 May 02, 2019

+ 5MG;1GM;EQ 2.5MG BASE N210874 002 May 02, 2019

+ 5MG;1GM;EQ 5MG BASE N210874 003 May 02, 2019

+! 10MG;1GM;EQ 5MG BASE N210874 004 May 02, 2019

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+ ASTRAZENECA AB 5MG;EQ 5MG BASE N209091 002 May 02, 2019

+! 10MG;EQ 5MG BASE N209091 001 Feb 27, 2017

DAPSONE

GEL;TOPICAL

ACZONE

<u>AB</u>	+	<u>5%</u>	<u>N021794</u>	<u>001</u>	Jul 07, 2005
-----------	---	-----------	----------------	------------	--------------

DAPSONE

<u>AB</u>	TARO	<u>5%</u>	<u>A209506</u>	<u>001</u>	Oct 16, 2017
-----------	------	-----------	----------------	------------	--------------

ACZONE

+! ALMIRALL 7.5% N207154 001 Feb 24, 2016

PRESCRIPTION DRUG PRODUCT LIST

DAPSONE

TABLET; ORAL

DAPSONE

<u>AB</u>	ACTAVIS LLC	<u>25MG</u>	<u>A204380</u>	<u>001</u>	Mar 23, 2017
<u>AB</u>		<u>100MG</u>	<u>A204380</u>	<u>002</u>	Mar 23, 2017
<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>A205429</u>	<u>001</u>	Jan 07, 2016
<u>AB</u>		<u>100MG</u>	<u>A205429</u>	<u>002</u>	Jan 07, 2016
<u>AB</u>	JACOBUS	<u>25MG</u>	<u>A086841</u>	<u>001</u>	
<u>AB</u>	!	<u>100MG</u>	<u>A086842</u>	<u>001</u>	
<u>AB</u>	NOSTRUM LABS INC	<u>25MG</u>	<u>A203887</u>	<u>001</u>	May 06, 2016
<u>AB</u>		<u>100MG</u>	<u>A203887</u>	<u>002</u>	May 06, 2016
<u>AB</u>	NOVITIUM PHARMA	<u>25MG</u>	<u>A206505</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		<u>100MG</u>	<u>A206505</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>	SAI LIFE SCIENCES	<u>100MG</u>	<u>A207165</u>	<u>001</u>	May 08, 2019
<u>AB</u>	VIRTUS PHARMS	<u>25MG</u>	<u>A204074</u>	<u>001</u>	May 10, 2016
<u>AB</u>		<u>100MG</u>	<u>A204074</u>	<u>002</u>	May 10, 2016

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

<u>AP</u>	+!	CUBIST PHARMS LLC	<u>500MG/VIAL</u>	<u>N021572</u>	<u>002</u>	Sep 12, 2003
-----------	----	-------------------	-------------------	----------------	------------	--------------

DAPTOMYCIN

<u>AP</u>		ACCORD HLTHCARE	<u>500MG/VIAL</u>	<u>A211961</u>	<u>001</u>	Jun 24, 2019
<u>AP</u>		BE PHARMS	<u>500MG/VIAL</u>	<u>A212513</u>	<u>001</u>	Jun 26, 2019
<u>AP</u>		DR REDDYS	<u>500MG/VIAL</u>	<u>A208375</u>	<u>001</u>	May 01, 2019
<u>AP</u>		FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A206077</u>	<u>001</u>	Apr 11, 2018
<u>AP</u>		HOSPIRA INC	<u>500MG/VIAL</u>	<u>A202857</u>	<u>001</u>	Sep 12, 2014
<u>AP</u>		JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A212022</u>	<u>001</u>	Aug 22, 2019
<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A205037</u>	<u>001</u>	Jun 05, 2018
<u>AP</u>		SAGENT PHARMS INC	<u>500MG/VIAL</u>	<u>A207104</u>	<u>001</u>	Nov 15, 2019
<u>AP</u>		TEVA PHARMS USA	<u>500MG/VIAL</u>	<u>A091039</u>	<u>001</u>	Mar 25, 2016
<u>AP</u>		XELLIA PHARMS APS	<u>500MG/VIAL</u>	<u>A206005</u>	<u>001</u>	Jun 15, 2016

CUBICIN RF

	+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016
--	----	-------------------	------------	---------	-----	--------------

POWDER; IV (INFUSION)

DAPTOMYCIN

<u>AP</u>		ACCORD HLTHCARE	<u>350MG/VIAL</u>	<u>A212667</u>	<u>001</u>	Jul 12, 2019
<u>AP</u>	+!	SAGENT PHARMS INC	<u>350MG/VIAL</u>	<u>N208385</u>	<u>001</u>	Sep 12, 2017
	+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN

<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207302</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207302</u>	<u>002</u>	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

<u>AB</u>		ALAN LABS INC	<u>EQ 7.5MG BASE</u>	<u>A209571</u>	<u>002</u>	Oct 22, 2019
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A209571</u>	<u>001</u>	Oct 22, 2019
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207681</u>	<u>001</u>	Dec 08, 2017
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207681</u>	<u>002</u>	Dec 08, 2017
<u>AB</u>		ANCHEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A091190</u>	<u>001</u>	Mar 13, 2015
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A091190</u>	<u>002</u>	Mar 13, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 7.5MG BASE</u>	<u>A206743</u>	<u>001</u>	Sep 19, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A206743</u>	<u>002</u>	Sep 19, 2016
<u>AB</u>		CIPLA	<u>EQ 7.5MG BASE</u>	<u>A207664</u>	<u>001</u>	Sep 01, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A207664</u>	<u>002</u>	Sep 01, 2016
<u>AB</u>		JUBILANT GENERICS	<u>EQ 7.5MG BASE</u>	<u>A205550</u>	<u>001</u>	Oct 12, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A205550</u>	<u>002</u>	Oct 12, 2016
<u>AB</u>		POLYGEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A211045</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A211045</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>		TORRENT	<u>EQ 7.5MG BASE</u>	<u>A205209</u>	<u>001</u>	Nov 17, 2016
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A205209</u>	<u>002</u>	Nov 17, 2016

ENABLEX

<u>AB</u>	+	APIL	<u>EQ 7.5MG BASE</u>	<u>N021513</u>	<u>001</u>	Dec 22, 2004
<u>AB</u>	+!		<u>EQ 15MG BASE</u>	<u>N021513</u>	<u>002</u>	Dec 22, 2004

DAROLUTAMIDE

TABLET; ORAL

NUBEQA

	+!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019
--	----	------------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

DARUNAVIR

SUSPENSION; ORAL

PREZISTA

+! JANSSEN PRODS 100MG/ML N202895 001 Dec 16, 2011

TABLET; ORAL

DARUNAVIR**AB** TEVA PHARMS USA **600MG** **A202118 001** Nov 21, 2017PREZISTA**AB** + JANSSEN PRODS **600MG** **N021976 002** Feb 25, 2008

+ 75MG N021976 004 Dec 18, 2008

+ 150MG N021976 005 Dec 18, 2008

+! 800MG N021976 006 Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+! ABBVIE INC EQ 250MG BASE, N/A, N/A, N/A; N/A, 12.5MG, 75MG, 50MG N206619 001 Dec 19, 2014

DASATINIB

TABLET; ORAL

SPRYCEL

+ BRISTOL MYERS 20MG N021986 001 Jun 28, 2006

+ SQUIBB 50MG N021986 002 Jun 28, 2006

+ 70MG N021986 003 Jun 28, 2006

+ 80MG N021986 005 Oct 28, 2010

+! 100MG N021986 004 May 30, 2008

+ 140MG N021986 006 Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE**AP** ! WEST-WARD PHARMS **EQ 20MG BASE/VIAL** **A064103 001** Feb 03, 1995
INTDAUNORUBICIN HYDROCHLORIDE**AP** FRESENIUS KABI USA **EQ 20MG BASE/VIAL** **A065000 001** May 25, 1999**AP** HISUN PHARM **EQ 5MG BASE/ML** **A208759 001** Apr 12, 2019

HANGZHOU

AP TEVA PHARMS USA **EQ 5MG BASE/ML** **A065035 001** Jan 24, 2000**AP** +! WEST-WARD PHARMS **EQ 5MG BASE/ML** **N050731 001** Jan 30, 1998

INT

FRESENIUS KABI USA EQ 5MG BASE/VIAL A065034 001 Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN**AP** +! OTSUKA PHARM CO LTD **50MG/VIAL** **N021790 001** May 02, 2006DECITABINE**AP** ACCORD HLTHCARE **50MG/VIAL** **A203475 001** Feb 27, 2017**AP** CHEMI SPA **50MG/VIAL** **A206033 001** Sep 22, 2017**AP** CIPLA **50MG/VIAL** **A208601 001** Nov 16, 2017**AP** DR REDDYS **50MG/VIAL** **A203131 001** Jul 11, 2013**AP** INGENUS PHARMS LLC **50MG/VIAL** **A210984 001** Sep 16, 2019**AP** LUPIN LTD **50MG/VIAL** **A210756 001** Nov 09, 2018**AP** MSN **50MG/VIAL** **A212265 001** Aug 28, 2019**AP** PHARMASCIENCE INC **50MG/VIAL** **A204607 001** May 31, 2017**AP** SAGENT PHARMS INC **50MG/VIAL** **A207100 001** Mar 16, 2018**AP** SANDOZ INC **50MG/VIAL** **A202969 001** Aug 28, 2014**AP** WOCHKHARDT BIO AG **50MG/VIAL** **A209056 001** Apr 09, 2019

POWDER; INTRAVENOUS

DECITABINE

+! SUN PHARMA GLOBAL 50MG/VIAL N205582 001 Jan 28, 2014

DEFERASIROX

GRANULE; ORAL

JADENU SPRINKLE

+ NOVARTIS 90MG N207968 001 May 18, 2017

+ 180MG N207968 002 May 18, 2017

+! 360MG N207968 003 May 18, 2017

TABLET; ORAL

DEFERASIROX**AB** ACTAVIS ELIZABETH **90MG** **A208697 001** Dec 13, 2019**AB** **180MG** **A208697 002** Dec 13, 2019**AB** **360MG** **A208697 003** Dec 13, 2019**AB** ALEMBIC PHARMS LTD **90MG** **A211824 001** Nov 20, 2019

PRESCRIPTION DRUG PRODUCT LIST

DEFERASIROX

TABLET;ORAL

DEFERASIROX

<u>AB</u>		<u>360MG</u>	<u>A211824</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>90MG</u>	<u>A210727</u>	<u>001</u>	Dec 27, 2019
<u>AB</u>		<u>360MG</u>	<u>A210727</u>	<u>002</u>	Dec 27, 2019
<u>AB</u>	MSN	<u>90MG</u>	<u>A210945</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>360MG</u>	<u>A210945</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>90MG</u>	<u>A212995</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>360MG</u>	<u>A212995</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	SUN PHARM	<u>90MG</u>	<u>A211641</u>	<u>001</u>	Jan 02, 2020
<u>AB</u>		<u>360MG</u>	<u>A211641</u>	<u>002</u>	Jan 02, 2020
<u>AB</u>	TEVA PHARMS USA	<u>90MG</u>	<u>A209223</u>	<u>001</u>	Nov 25, 2019
<u>AB</u>		<u>360MG</u>	<u>A209223</u>	<u>002</u>	Nov 25, 2019
<u>AB</u>	ZYDUS PHARMS	<u>90MG</u>	<u>A211383</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>360MG</u>	<u>A211383</u>	<u>002</u>	Nov 20, 2019

JADENU

<u>AB</u>	+	NOVARTIS PHARMS CORP	<u>90MG</u>	<u>N206910</u>	<u>001</u>	Mar 30, 2015
<u>AB</u>	+		<u>180MG</u>	<u>N206910</u>	<u>002</u>	Mar 30, 2015
<u>AB</u>	+		<u>360MG</u>	<u>N206910</u>	<u>003</u>	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

<u>AB</u>	ACTAVIS ELIZABETH	<u>125MG</u>	<u>A203560</u>	<u>001</u>	Jan 26, 2016
<u>AB</u>		<u>250MG</u>	<u>A203560</u>	<u>002</u>	Jan 26, 2016
<u>AB</u>		<u>500MG</u>	<u>A203560</u>	<u>003</u>	Jan 26, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>125MG</u>	<u>A210060</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210060</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210060</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	ALKEM LABS LTD	<u>125MG</u>	<u>A210519</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210519</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210519</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	BIONPHARMA INC	<u>125MG</u>	<u>A210920</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210920</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210920</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	ICHNOS	<u>125MG</u>	<u>A209433</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>		<u>250MG</u>	<u>A209433</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>		<u>500MG</u>	<u>A209433</u>	<u>003</u>	Jan 06, 2020
<u>AB</u>	MSN	<u>125MG</u>	<u>A209878</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209878</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209878</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	SUN PHARM	<u>125MG</u>	<u>A209782</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209782</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209782</u>	<u>003</u>	Nov 20, 2019

EXJADE

<u>AB</u>	+	NOVARTIS	<u>125MG</u>	<u>N021882</u>	<u>001</u>	Nov 02, 2005
<u>AB</u>	+		<u>250MG</u>	<u>N021882</u>	<u>002</u>	Nov 02, 2005
<u>AB</u>	+		<u>500MG</u>	<u>N021882</u>	<u>003</u>	Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+	APOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018
+		100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

FERRIPROX

+	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011
+		1GM	N021825	002	Jul 25, 2019

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A078718</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078718</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/VIAL</u>	<u>A207384</u>	<u>001</u>	Sep 29, 2017
<u>AP</u>		<u>2GM/VIAL</u>	<u>A207384</u>	<u>002</u>	Sep 29, 2017
<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A076019</u>	<u>001</u>	Mar 17, 2004
<u>AP</u>		<u>2GM/VIAL</u>	<u>A076019</u>	<u>002</u>	Mar 17, 2004
<u>AP</u>	WEST-WARD PHARMS INT	<u>500MG/VIAL</u>	<u>A078086</u>	<u>001</u>	May 30, 2007
<u>AP</u>		<u>2GM/VIAL</u>	<u>A078086</u>	<u>002</u>	May 30, 2007

DESFERAL

<u>AP</u>	+	NOVARTIS	<u>500MG/VIAL</u>	<u>N016267</u>	<u>001</u>	
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N016267</u>	<u>002</u>	May 25, 2000

PRESCRIPTION DRUG PRODUCT LIST

DEFIBROTIDE SODIUM

SOLUTION; INTRAVENOUS

DEFITELIO

+! JAZZ PHARMS INC 200MG/2.5ML (80MG/ML) N208114 001 Mar 30, 2016

DEFLAZACORT

SUSPENSION; ORAL

EMFLAZA

+! PTC THERAP 22.75MG/ML N208685 001 Feb 09, 2017

TABLET; ORAL

EMFLAZA

+ PTC THERAP 6MG N208684 001 Feb 09, 2017

+ 18MG N208684 002 Feb 09, 2017

+ 30MG N208684 003 Feb 09, 2017

+! 36MG N208684 004 Feb 09, 2017

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

+ FERRING EQ 80MG BASE/VIAL N022201 001 Dec 24, 2008

+! EQ 120MG BASE/VIAL N022201 002 Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER; INTRAVENOUS

BAXDELA

+! MELINTA EQ 300MG BASE/VIAL N208611 001 Jun 19, 2017

TABLET; ORAL

BAXDELA

+! MELINTA EQ 450MG BASE N208610 001 Jun 19, 2017

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+! VIIV HLTHCARE 200MG N020705 002 Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	AKORN	150MG	A065389 001	Dec 01, 2008
AB		300MG	A065389 002	Dec 01, 2008
AB	AMNEAL PHARM	150MG	A065425 001	Feb 27, 2008
AB	!	300MG	A065425 002	Feb 27, 2008
AB	BARR	150MG	A065171 001	Dec 13, 2004
AB		300MG	A065171 002	Dec 13, 2004
AB	EPIC PHARMA LLC	150MG	A065447 001	Aug 18, 2015
AB		300MG	A065447 002	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

KYBELLA

+! KYTHERA BIOPHARMS 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015

DESFLURANE

LIQUID; INHALATION

DESFLURANE

AN	SHANGHAI HENGRUI	100%	A208234 001	Feb 26, 2018
AN	+	100%	N020118 001	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	10MG	A074430 001	Feb 09, 1996
AB		25MG	A071601 001	Jun 05, 1987
AB		50MG	A071588 001	Jun 05, 1987
AB		75MG	A071602 001	Oct 05, 1987
AB		100MG	A071766 001	Oct 05, 1987
AB		150MG	A074430 002	Feb 09, 1996
AB	AMNEAL PHARMS CO	10MG	A208105 001	Mar 17, 2016
AB		25MG	A208105 002	Mar 17, 2016
AB		50MG	A208105 003	Mar 17, 2016
AB		75MG	A208105 004	Mar 17, 2016
AB		100MG	A208105 005	Mar 17, 2016
AB		150MG	A208105 006	Mar 17, 2016
AB	ANI PHARMS INC	10MG	A205153 001	Oct 28, 2016
AB		25MG	A205153 002	Oct 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A205153 003</u>	Oct 28, 2016	
<u>AB</u>		<u>75MG</u>	<u>A205153 004</u>	Oct 28, 2016	
<u>AB</u>		<u>100MG</u>	<u>A205153 005</u>	Oct 28, 2016	
<u>AB</u>		<u>150MG</u>	<u>A205153 006</u>	Oct 28, 2016	
<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A207433 001</u>	May 05, 2016	
<u>AB</u>		<u>25MG</u>	<u>A207433 002</u>	May 05, 2016	
<u>AB</u>		<u>50MG</u>	<u>A207433 003</u>	May 05, 2016	
<u>AB</u>		<u>75MG</u>	<u>A207433 004</u>	May 05, 2016	
<u>AB</u>		<u>100MG</u>	<u>A207433 005</u>	May 05, 2016	
<u>AB</u>		<u>150MG</u>	<u>A207433 006</u>	May 05, 2016	
<u>AB</u>	NOVAST LABS	<u>10MG</u>	<u>A204963 001</u>	Dec 26, 2017	
<u>AB</u>		<u>25MG</u>	<u>A204963 002</u>	Dec 26, 2017	
<u>AB</u>		<u>50MG</u>	<u>A204963 003</u>	Dec 26, 2017	
<u>AB</u>		<u>75MG</u>	<u>A204963 004</u>	Dec 26, 2017	
<u>AB</u>		<u>100MG</u>	<u>A204963 005</u>	Dec 26, 2017	
<u>AB</u>		<u>150MG</u>	<u>A204963 006</u>	Dec 26, 2017	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099 001</u>	May 24, 1988	
<u>AB</u>		<u>25MG</u>	<u>A072100 001</u>	May 24, 1988	
<u>AB</u>		<u>50MG</u>	<u>A072101 001</u>	May 24, 1988	
<u>AB</u>		<u>75MG</u>	<u>A072102 001</u>	Jun 20, 1988	
<u>AB</u>		<u>100MG</u>	<u>A072103 001</u>	Jun 20, 1988	
<u>AB</u>		<u>150MG</u>	<u>A072104 001</u>	Jun 20, 1988	
<u>NORPRAMIN</u>					
<u>AB</u>	+	US PHARM HOLDINGS	<u>10MG</u>	<u>N014399 007</u>	Feb 11, 1982
<u>AB</u>	+		<u>25MG</u>	<u>N014399 001</u>	
<u>AB</u>	+		<u>50MG</u>	<u>N014399 003</u>	
<u>AB</u>	+		<u>75MG</u>	<u>N014399 004</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N014399 005</u>	
<u>AB</u>	+		<u>150MG</u>	<u>N014399 006</u>	

DESLORATADINE

SOLUTION; ORAL

CLARINEX

<u>AA</u>	+	MERCK SHARP DOHME	<u>0.5MG/ML</u>	<u>N021300 001</u>	Sep 01, 2004
<u>DESLORATADINE</u>					
<u>AA</u>		TARO	<u>0.5MG/ML</u>	<u>A202936 001</u>	May 26, 2016
<u>AA</u>		TARO PHARM INDS LTD	<u>0.5MG/ML</u>	<u>A202592 001</u>	Jun 30, 2015

TABLET; ORAL

CLARINEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021165 001</u>	Dec 21, 2001
<u>DESLORATADINE</u>					
<u>AB</u>		BELCHER PHARMS	<u>5MG</u>	<u>A078355 001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365 001</u>	Mar 08, 2011
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352 001</u>	Oct 25, 2010
<u>AB</u>		ORCHID HLTHCARE	<u>5MG</u>	<u>A078357 001</u>	Feb 19, 2010
<u>AB</u>		PERRIGO	<u>5MG</u>	<u>A078361 001</u>	Dec 22, 2011
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A078364 001</u>	Dec 03, 2010
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A078359 001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312 002</u>	Jul 14, 2005
<u>AB</u>	+		<u>5MG</u>	<u>N021312 001</u>	Jun 26, 2002

DESLORATADINE

<u>AB</u>		REDDYS	<u>2.5MG</u>	<u>A078367 001</u>	Jul 12, 2010
<u>AB</u>			<u>5MG</u>	<u>A078367 002</u>	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG;240MG</u>	<u>N021605 001</u>	Mar 03, 2005
<u>DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR</u>					
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG;240MG</u>	<u>A078366 001</u>	Apr 26, 2011
<u>CLARINEX-D 12 HOUR</u>					
	+	MERCK SHARP DOHME	<u>2.5MG;120MG</u>	<u>N021313 001</u>	Feb 01, 2006

PRESCRIPTION DRUG PRODUCT LIST

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

AP	+ !	FERRING PHARMS INC	0.004MG/ML	N018938	001	Mar 30, 1984
-----------	------------	--------------------	-------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

AP		AM REGENT	0.004MG/ML	A091374	001	Feb 14, 2019
AP		SAGENT PHARMS INC	0.004MG/ML	A204695	001	Aug 22, 2017
AP			0.004MG/ML	A204751	001	Aug 22, 2017
AP		SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013
AP		TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997

SOLUTION; NASAL

DDAVP

+ !	FERRING PHARMS INC	0.01%	N017922	001		
------------	--------------------	-------	---------	-----	--	--

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

AB	+ !	FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996
-----------	------------	--------------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

AB	!	BAUSCH AND LOMB	0.01MG/SPRAY	A074830	001	Jan 25, 1999
-----------	----------	-----------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		APOTEX INC	0.01MG/SPRAY	A076703	001	Jan 27, 2005
AB		SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013
AB		ZYDUS PHARMS	0.01MG/SPRAY	A091345	001	Oct 03, 2017

MINIRIN

AB	+ !	FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
-----------	------------	---------	---------------------	----------------	------------	--------------

STIMATE (NEEDS NO REFRIGERATION)

+ !	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	
------------	--------------------	--------------	---------	-----	--------------	--

TABLET; ORAL

DDAVP

AB	+	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995
AB	+ !		0.2MG	N019955	002	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019
AB			0.2MG	A210371	002	Jan 28, 2019
AB		ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005
AB			0.2MG	A076470	002	Jul 01, 2005
AB		APOTEX INC	0.1MG	A077414	001	Mar 07, 2006
AB			0.2MG	A077414	002	Mar 07, 2006
AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015
AB			0.2MG	A201831	002	May 28, 2015
AB		HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017
AB			0.2MG	A207880	002	May 26, 2017
AB		IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006
AB			0.2MG	A077122	002	Jan 25, 2006
AB		MYLAN	0.1MG	A200653	001	Jun 27, 2014
AB			0.2MG	A200653	002	Jun 27, 2014
AB		NOVAST LABS	0.1MG	A208357	001	Jun 06, 2019
AB			0.2MG	A208357	002	Jun 06, 2019

TABLET; SUBLINGUAL

NOCDURNA

+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018	
+ !		0.0553MG	N022517	002	Jun 21, 2018	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

AB		LUPIN LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202226	001	Aug 12, 2015
-----------	--	-----------	------------------------------------	----------------	------------	--------------

CYCLESSA

AB	+ !	ASPEN GLOBAL INC	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N021090	001	Dec 20, 2000
-----------	------------	------------------	--	----------------	------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	0.15MG, N/A; 0.02MG, 0.01MG	A209170	001	Jun 05, 2017
AB		AUROBINDO PHARMA LTD	0.15MG, N/A; 0.02MG, 0.01MG	A206853	001	Mar 22, 2017
AB	!	DURAMED PHARMS BARR	0.15MG; 0.03MG	A075256	002	Aug 12, 1999
AB		MAYNE PHARMA	0.15MG, N/A; 0.02MG, 0.01MG	A076916	001	Dec 29, 2008
AB			0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	A077182	001	Jan 24, 2006
AB		MYLAN LABS LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202296	001	Aug 30, 2013
AB			0.15MG; 0.03MG	A202085	001	May 20, 2015
AB		NOVAST LABS	0.15MG; 0.03MG	A091234	001	Jul 12, 2013
AB		WATSON LABS	0.15MG; 0.03MG	A076915	001	Jul 29, 2005

EMOQUETTE

AB		VINTAGE PHARMS LLC	0.15MG; 0.03MG	A076675	001	Feb 25, 2011
-----------	--	--------------------	-----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

ENSKYCE

AB	LUPIN LTD	<u>0.15MG;0.03MG</u>	<u>A201887</u>	<u>001</u>	Mar 07, 2013
-----------	-----------	----------------------	----------------	------------	--------------

ISIBLOOM

AB	XIROMED	<u>0.15MG;0.03MG</u>	<u>A202789</u>	<u>001</u>	Aug 12, 2015
-----------	---------	----------------------	----------------	------------	--------------

KALLIGA

AB	AUROBINDO PHARMA LTD	<u>0.15MG;0.03MG</u>	<u>A207081</u>	<u>001</u>	May 17, 2017
-----------	----------------------	----------------------	----------------	------------	--------------

KARIVA

AB	! BARR	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002
-----------	--------	---------------------------------	----------------	------------	--------------

KIMIDESS

AB	VINTAGE PHARMS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A076681</u>	<u>001</u>	Apr 30, 2015
-----------	----------------	---------------------------------	----------------	------------	--------------

PIMTREA

AB	NOVAST LABS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091247</u>	<u>001</u>	Aug 01, 2013
-----------	-------------	---------------------------------	----------------	------------	--------------

VELIVET

AB	DURAMED PHARMS BARR	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004
-----------	---------------------	---	----------------	------------	--------------

VIORELE

AB	GLENMARK GENERICS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091346</u>	<u>001</u>	Apr 02, 2012
-----------	-------------------	---------------------------------	----------------	------------	--------------

VOLNEA

AB	XIROMED	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202689</u>	<u>001</u>	Sep 09, 2016
-----------	---------	---------------------------------	----------------	------------	--------------

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+! ALMIRALL

0.05%

N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDE

AB	ACP NIMBLE	<u>0.05%</u>	<u>A074027</u>	<u>001</u>	Sep 28, 1992
-----------	------------	--------------	----------------	------------	--------------

AB	CADILA	<u>0.05%</u>	<u>A210198</u>	<u>001</u>	Nov 20, 2019
-----------	--------	--------------	----------------	------------	--------------

AB	GLENMARK PHARMS	<u>0.05%</u>	<u>A209729</u>	<u>001</u>	Jul 24, 2017
-----------	-----------------	--------------	----------------	------------	--------------

AB	+! PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
-----------	---------------------	--------------	----------------	------------	--

AB	TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992
-----------	------	--------------	----------------	------------	--------------

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984
-----------	------------------	--------------	----------------	------------	--------------

GEL; TOPICAL

DESONATE

+! LEO PHARMA AS

0.05%

N021844 001 Oct 20, 2006

LOTION; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
-----------	----------------	--------------	----------------	------------	--------------

AB	GLENMARK PHARMS	<u>0.05%</u>	<u>A209494</u>	<u>001</u>	Sep 26, 2017
-----------	-----------------	--------------	----------------	------------	--------------

AB	TARO	<u>0.05%</u>	<u>A202161</u>	<u>001</u>	Oct 31, 2014
-----------	------	--------------	----------------	------------	--------------

AB	TELLIGENT PHARMA INC	<u>0.05%</u>	<u>A207855</u>	<u>001</u>	Sep 28, 2017
-----------	----------------------	--------------	----------------	------------	--------------

DESOWEN

AB	! GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992
-----------	--------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESONIDE

AB	ALEOR	<u>0.05%</u>	<u>A212473</u>	<u>001</u>	Oct 23, 2019
-----------	-------	--------------	----------------	------------	--------------

DERMACEUTICALS

AB	ENCUBE ETHICALS	<u>0.05%</u>	<u>A210998</u>	<u>001</u>	Jan 30, 2019
-----------	-----------------	--------------	----------------	------------	--------------

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
-----------	----------------	--------------	----------------	------------	--------------

AB	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A209996</u>	<u>001</u>	Sep 15, 2017
-----------	---------------------	--------------	----------------	------------	--------------

AB	HI TECH	<u>0.05%</u>	<u>A208836</u>	<u>001</u>	Mar 27, 2017
-----------	---------	--------------	----------------	------------	--------------

AB	+! PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
-----------	---------------------	--------------	----------------	------------	--

AB	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994
-----------	------	--------------	----------------	------------	--------------

AB	TELLIGENT PHARMA INC	<u>0.05%</u>	<u>A212002</u>	<u>001</u>	Mar 12, 2019
-----------	----------------------	--------------	----------------	------------	--------------

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988
-----------	------------------	--------------	----------------	------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A205082</u>	<u>001</u>	Sep 04, 2015
-----------	----------------------	--------------	----------------	------------	--------------

AB	AKORN	<u>0.05%</u>	<u>A203787</u>	<u>001</u>	Jan 06, 2017
-----------	-------	--------------	----------------	------------	--------------

AB		<u>0.25%</u>	<u>A203234</u>	<u>001</u>	Jun 12, 2015
-----------	--	--------------	----------------	------------	--------------

AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369</u>	<u>001</u>	Jun 29, 2010
-----------	----------------	--------------	----------------	------------	--------------

AB	LUPIN ATLANTIS	<u>0.05%</u>	<u>A208163</u>	<u>001</u>	Jan 10, 2017
-----------	----------------	--------------	----------------	------------	--------------

AB		<u>0.25%</u>	<u>A208164</u>	<u>001</u>	Jan 09, 2017
-----------	--	--------------	----------------	------------	--------------

AB	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003
-----------	------------------	--------------	----------------	------------	--------------

AB	RISING	<u>0.05%</u>	<u>A210980</u>	<u>001</u>	Dec 21, 2018
-----------	--------	--------------	----------------	------------	--------------

AB		<u>0.25%</u>	<u>A205594</u>	<u>001</u>	Jul 02, 2018
-----------	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

<u>AB</u>	!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>A073210</u>	<u>001</u>	Nov 30, 1990
<u>AB</u>	!		<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

<u>AB</u>		AKORN	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011
<u>AB</u>		PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
<u>AB</u>		RISING	<u>0.05%</u>	<u>A204675</u>	<u>001</u>	Aug 12, 2016

TOPICORT

<u>AB</u>	!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	---	---------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

<u>AB</u>		ACP NIMBLE	<u>0.25%</u>	<u>A206740</u>	<u>001</u>	Dec 23, 2016
<u>AB</u>		ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A204965</u>	<u>001</u>	Nov 07, 2016
<u>AB</u>		AKORN	<u>0.25%</u>	<u>A201005</u>	<u>001</u>	Apr 24, 2014
<u>AB</u>		FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		GLENMARK GENERICS	<u>0.25%</u>	<u>A202838</u>	<u>001</u>	Sep 20, 2013
<u>AB</u>		LUPIN ATLANTIS	<u>0.05%</u>	<u>A208044</u>	<u>001</u>	Dec 12, 2016
<u>AB</u>			<u>0.25%</u>	<u>A208104</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		NOVEL LABS INC	<u>0.25%</u>	<u>A206792</u>	<u>001</u>	May 10, 2016
<u>AB</u>		PERRIGO ISRAEL	<u>0.25%</u>	<u>A077770</u>	<u>001</u>	Apr 20, 2015
<u>AB</u>		RISING	<u>0.25%</u>	<u>A204272</u>	<u>001</u>	Nov 30, 2016
<u>AB</u>		TELIGENT PHARMA INC	<u>0.05%</u>	<u>A209973</u>	<u>001</u>	Oct 23, 2018
<u>AB</u>			<u>0.25%</u>	<u>A208101</u>	<u>001</u>	Feb 25, 2016
<u>AB</u>		ZYDUS PHARMS	<u>0.25%</u>	<u>A205206</u>	<u>001</u>	Sep 19, 2017

TOPICORT

<u>AB</u>	+!	TARO PHARM INDS LTD	<u>0.05%</u>	<u>N018594</u>	<u>001</u>	Jan 17, 1985
<u>AB</u>	!		<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996

SPRAY; TOPICAL

DESOXIMETASONE

<u>AT</u>		LUPIN ATLANTIS	<u>0.25%</u>	<u>A208124</u>	<u>001</u>	Mar 16, 2018
<u>AT</u>		PERRIGO ISRAEL	<u>0.25%</u>	<u>A206441</u>	<u>001</u>	Jan 20, 2017

TOPICORT

<u>AT</u>	+!	TARO PHARMS	<u>0.25%</u>	<u>N204141</u>	<u>001</u>	Apr 11, 2013
-----------	----	-------------	--------------	----------------	------------	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

	+	!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
	+	!		100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

<u>AB</u>		ACTAVIS LABS FL	<u>EQ 25MG BASE</u>	<u>A204065</u>	<u>001</u>	Jul 29, 2016
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204065</u>	<u>002</u>	Jul 29, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204065</u>	<u>003</u>	Jul 29, 2016
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A204003</u>	<u>003</u>	Sep 14, 2018
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204003</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204003</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		CASI PHARMS INC	<u>EQ 50MG BASE</u>	<u>A204028</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204028</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		HIKMA	<u>EQ 25MG BASE</u>	<u>A204082</u>	<u>002</u>	Aug 28, 2017
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A204082</u>	<u>001</u>	Feb 16, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204083</u>	<u>001</u>	Feb 16, 2016
<u>AB</u>		INTELLIPHARMACEUTIC S	<u>EQ 50MG BASE</u>	<u>A204805</u>	<u>001</u>	May 07, 2019
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204805</u>	<u>002</u>	May 07, 2019
<u>AB</u>		LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204172</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204172</u>	<u>002</u>	Jun 29, 2015
<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A204095</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>		ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A204020</u>	<u>001</u>	Oct 11, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204020</u>	<u>002</u>	Oct 11, 2017

PRISTIQ

<u>AB</u>	+	PF PRISM CV	<u>EQ 25MG BASE</u>	<u>N021992</u>	<u>003</u>	Aug 20, 2014
<u>AB</u>	+!		<u>EQ 50MG BASE</u>	<u>N021992</u>	<u>001</u>	Feb 29, 2008
<u>AB</u>	+!		<u>EQ 100MG BASE</u>	<u>N021992</u>	<u>002</u>	Feb 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+	!	12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983
---	-------	--------	---------	-----	--------------

ELIXIR; ORAL

DEXAMETHASONE

AA	!	ANIMA	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
AA		LANNETT CO INC	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
AA		LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011
AA		WOCKHARDT BIO AG	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
---	----------	-------	---------	-----	--------------

INSERT; OPHTHALMIC

DEXTENZA

+	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018
---	--------------------	-------	---------	-----	--------------

SOLUTION; ORAL

DEXAMETHASONE

!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983
---	-------	-----------	---------	-----	--------------

SUSPENSION; INTRAOCULAR

DEXYCU KIT

+	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018
---	-----------------	----	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

+	NOVARTIS	0.1%	N013422	001	
---	----------	------	---------	-----	--

TABLET; ORAL

DEXAMETHASONE

AB		ECR	<u>1.5MG</u>	<u>A040700</u>	<u>001</u>	Aug 15, 2008
AB		HIKMA	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	
AB		LARKEN LABS INC	<u>1.5MG</u>	<u>A201270</u>	<u>001</u>	Jul 17, 2017
BP		FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP			4MG	A088481	004	Apr 28, 1983
BP			6MG	A088481	001	Nov 28, 1983
BP		HIKMA	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	!		6MG	A088316	001	Sep 15, 1983
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983
		HEMADY				
	+	DEXCEL PHARMA	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A208689</u>	<u>001</u>	Aug 22, 2018
AP		AUROBINDO PHARMA LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A206781</u>	<u>001</u>	Dec 01, 2015
AP	!	FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
AP			<u>EQ 4MG PHOSPHATE/ML</u>	<u>A203129</u>	<u>001</u>	Sep 30, 2015
AP	!		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A209192</u>	<u>001</u>	Jul 06, 2018
AP		MYLAN LABS LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
AP			<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008
AP		SOMERSET	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A207521</u>	<u>001</u>	Jun 08, 2018
AP		SOMERSET THERAPS LLC	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A211036</u>	<u>001</u>	May 10, 2019
AP		WEST-WARD PHARMS INT	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084282</u>	<u>001</u>	
AP	!		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A208690</u>	<u>001</u>	Aug 22, 2018
AP	!	FRESENIUS KABI USA	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003
AP		SOMERSET THERAPS LLC	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A207442</u>	<u>001</u>	Apr 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

! BAUSCH AND LOMB EQ 0.1% PHOSPHATE

A040069 001 Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROLAT +! NOVARTIS 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GMN050065 002NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONEAT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GMA064063 001 Jul 25, 1994AT PERRIGO CO 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GMA062938 001 Jul 31, 1989

TENNESSEE

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORINAT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA064135 001 Sep 13, 1995MAXITROLAT +! NOVARTIS 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLN050023 002AT SANDOZ INC 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062341 001 May 22, 1984DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+! NOVARTIS 0.1%;0.3%

N050616 001 Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEXAB +! NOVARTIS 0.1%;0.3%N050592 001 Aug 18, 1988TOBRAMYCIN AND DEXAMETHASONEAB BAUSCH AND LOMB 0.1%;0.3%A064134 001 Oct 27, 1999

TOBRADEX ST

+! NOVARTIS 0.05%;0.3%

N050818 001 Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATEAA ! WOCKHARDT BIO AG 2MG/5MLA088251 001 Mar 23, 1984POLMONAA CAPELLON PHARMS LLC 2MG/5MLA202520 001 Jul 16, 2018DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANTAB +! TAKEDA PHARMS USA 60MGN022287 002 Jan 30, 2009DEXLANSOPRAZOLEAB PAR PHARM INC 60MGA202294 001 Apr 19, 2017

DEXILANT

+ TAKEDA PHARMS USA 30MG

N022287 001 Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDEAP ACCORD HLTHCARE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A204023 001 Feb 09, 2016AP ACTAVIS INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A204686 001 Oct 17, 2016AP AKORN INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A202585 001 Nov 24, 2014AP AUROBINDO PHARMA EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A205867 001 Mar 17, 2016AP LTDAP BAXTER HLTHCARE EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)A208532 001 Aug 21, 2018

CORP

AP EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)A208532 002 Aug 21, 2018AP FRESENIUS KABI USA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)A208129 001 Nov 29, 2018AP EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A201072 001 Sep 18, 2015AP EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)A208129 002 Nov 29, 2018AP EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)A208129 003 Nov 29, 2018AP JIANGSU HENGRUI MED EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A209065 001 Sep 19, 2017AP MYLAN INSTITUTIONAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A202881 001 Aug 18, 2014AP PAR STERILE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A203972 001 Aug 18, 2014

PRODUCTS

AP SANDOZ INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A091465 001 Jun 14, 2016AP SLAYBACK PHARMA LLC EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)A212791 001 Dec 04, 2019AP EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)A212791 002 Dec 04, 2019AP SUN PHARM INDS INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A202126 001 Aug 20, 2015AP TEVA PHARMS USA EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A205272 001 Nov 28, 2017AP WEST-WARD PHARMS EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A205046 001 Apr 26, 2017

INT

AP ZYDUS PHARMS EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)A206798 001 Feb 27, 2018

PRESCRIPTION DRUG PRODUCT LIST

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRECEDEX

<u>AP</u>	+	HOSPIRA	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>N021038 004</u>	Nov 14, 2014
<u>AP</u>	+		<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038 001</u>	Dec 17, 1999
<u>AP</u>	+		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>N021038 002</u>	Mar 13, 2013
<u>AP</u>	+		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>N021038 003</u>	Mar 13, 2013

SOLUTION; INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

	+	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628 002	Oct 21, 2015
	+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628 003	Jun 22, 2018
	+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628 001	Oct 21, 2015
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628 004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ADARE PHARMS INC	<u>5MG</u>	<u>A210279 001</u>	Oct 09, 2018
<u>AB</u>			<u>10MG</u>	<u>A210279 002</u>	Oct 09, 2018
<u>AB</u>			<u>15MG</u>	<u>A210279 003</u>	Oct 09, 2018
<u>AB</u>			<u>20MG</u>	<u>A210279 004</u>	Oct 09, 2018
<u>AB</u>			<u>25MG</u>	<u>A210279 005</u>	Oct 09, 2018
<u>AB</u>			<u>30MG</u>	<u>A210279 006</u>	Oct 09, 2018
<u>AB</u>			<u>35MG</u>	<u>A210279 007</u>	Oct 09, 2018
<u>AB</u>			<u>40MG</u>	<u>A210279 008</u>	Oct 09, 2018
<u>AB</u>		IMPAX LABS INC	<u>5MG</u>	<u>A079108 001</u>	Aug 05, 2015
<u>AB</u>			<u>10MG</u>	<u>A079108 002</u>	Aug 05, 2015
<u>AB</u>			<u>15MG</u>	<u>A079108 003</u>	May 19, 2014
<u>AB</u>			<u>20MG</u>	<u>A079108 004</u>	Dec 21, 2015
<u>AB</u>			<u>25MG</u>	<u>A203614 001</u>	Jul 05, 2017
<u>AB</u>			<u>30MG</u>	<u>A079108 005</u>	Nov 21, 2013
<u>AB</u>			<u>35MG</u>	<u>A203614 002</u>	Jul 05, 2017
<u>AB</u>		INTELLIPHARMACEUTIC S	<u>15MG</u>	<u>A078992 003</u>	Nov 18, 2013
<u>AB</u>			<u>30MG</u>	<u>A078992 004</u>	Nov 18, 2013
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A204266 001</u>	Aug 25, 2015
<u>AB</u>			<u>10MG</u>	<u>A204266 002</u>	Aug 25, 2015
<u>AB</u>			<u>15MG</u>	<u>A204266 003</u>	Aug 25, 2015
<u>AB</u>			<u>20MG</u>	<u>A204266 004</u>	Dec 21, 2015
<u>AB</u>			<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>			<u>40MG</u>	<u>A204266 007</u>	Aug 25, 2015
<u>AB</u>		PAR PHARM INC	<u>5MG</u>	<u>A202842 001</u>	Nov 30, 2016
<u>AB</u>			<u>10MG</u>	<u>A202842 002</u>	Nov 30, 2016
<u>AB</u>			<u>15MG</u>	<u>A202842 003</u>	Nov 30, 2016
<u>AB</u>			<u>20MG</u>	<u>A202842 004</u>	Nov 30, 2016
<u>AB</u>			<u>25MG</u>	<u>A202842 005</u>	Nov 30, 2016
<u>AB</u>			<u>30MG</u>	<u>A202842 006</u>	Nov 30, 2016
<u>AB</u>			<u>35MG</u>	<u>A202842 007</u>	Nov 30, 2016
<u>AB</u>			<u>40MG</u>	<u>A202842 008</u>	Nov 30, 2016
<u>AB</u>		TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013
<u>AB</u>			<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013
<u>AB</u>			<u>15MG</u>	<u>A078908 004</u>	May 19, 2014
<u>AB</u>			<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013
<u>AB</u>			<u>25MG</u>	<u>A202731 001</u>	Jul 05, 2017
<u>AB</u>			<u>30MG</u>	<u>A202731 003</u>	May 19, 2014
<u>AB</u>			<u>35MG</u>	<u>A202731 004</u>	Jul 05, 2017
<u>AB</u>			<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013

FOCALIN XR

<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>	+		<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>	+		<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>	+		<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>	+		<u>25MG</u>	<u>N021802 008</u>	Apr 21, 2011
<u>AB</u>	+		<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>	+		<u>35MG</u>	<u>N021802 007</u>	Apr 21, 2011
<u>AB</u>	+		<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ABHAI INC	<u>2.5MG</u>	<u>A206931 001</u>	Dec 04, 2015
<u>AB</u>			<u>5MG</u>	<u>A206931 002</u>	Dec 04, 2015
<u>AB</u>			<u>10MG</u>	<u>A206931 003</u>	Dec 04, 2015
<u>AB</u>		ALKEM LABS LTD	<u>2.5MG</u>	<u>A212631 001</u>	Jul 19, 2019
<u>AB</u>			<u>5MG</u>	<u>A212631 002</u>	Jul 19, 2019

PRESCRIPTION DRUG PRODUCT LIST

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A212631 003</u>	Jul 19, 2019
<u>AB</u>	CEDIPROF INC	<u>5MG</u>	<u>A209211 001</u>	Sep 19, 2018
<u>AB</u>		<u>10MG</u>	<u>A209211 002</u>	Sep 19, 2018
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A204534 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A204534 003</u>	Dec 04, 2015
<u>AB</u>	RHODES PHARMS	<u>2.5MG</u>	<u>A208756 001</u>	Nov 20, 2017
<u>AB</u>		<u>5MG</u>	<u>A208756 002</u>	Nov 20, 2017
<u>AB</u>		<u>10MG</u>	<u>A208756 003</u>	Nov 20, 2017
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A201231 001</u>	Sep 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A201231 002</u>	Sep 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A201231 003</u>	Sep 24, 2015
<u>AB</u>	TRIS PHARMA INC	<u>2.5MG</u>	<u>A207901 001</u>	Aug 26, 2016
<u>AB</u>		<u>5MG</u>	<u>A207901 002</u>	Aug 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A207901 003</u>	Aug 26, 2016
<u>FOCALIN</u>				
<u>AB</u>	+ NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>	+	<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+!	<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A207321 002</u>	Dec 16, 2019
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A207321 001</u>	Nov 28, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004
<u>ZINECARD</u>				
<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995
<u>AP</u>	+!	<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995
TOTECT				
	+! CLINIGEN	<u>EQ 500MG BASE/VIAL</u>	<u>N022025 001</u>	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	+ IMPAX LABS INC	<u>5MG</u>	<u>N017078 001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017078 002</u>	
<u>AB</u>	+!	<u>15MG</u>	<u>N017078 003</u>	
<u>DEXTROAMPHETAMINE SULFATE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901 001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901 002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901 003</u>	Nov 30, 2012
<u>AB</u>	MAYNE PHARMA	<u>5MG</u>	<u>A076137 001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137 002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137 003</u>	Jan 18, 2002
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A209111 001</u>	Jun 27, 2017
<u>AB</u>		<u>10MG</u>	<u>A209111 002</u>	Jun 27, 2017
<u>AB</u>		<u>15MG</u>	<u>A209111 003</u>	Jun 27, 2017
<u>AB</u>	PII	<u>5MG</u>	<u>A205077 001</u>	Jun 21, 2019
<u>AB</u>		<u>10MG</u>	<u>A205077 002</u>	Jun 21, 2019
<u>AB</u>		<u>15MG</u>	<u>A205077 003</u>	Jun 21, 2019
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076353 001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353 002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353 003</u>	May 06, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A205673 001</u>	Oct 31, 2017
<u>AB</u>		<u>10MG</u>	<u>A205673 002</u>	Oct 31, 2017
<u>AB</u>		<u>15MG</u>	<u>A205673 003</u>	Oct 31, 2017

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	! OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776 001</u>	Jan 29, 2008
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644 001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	ARBOR PHARMS LLC	<u>5MG</u>	<u>A090533 002</u>	Oct 25, 2011
<u>AA</u>		<u>10MG</u>	<u>A090533 004</u>	Oct 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893 001</u>	Jul 31, 2013
<u>AA</u>		<u>10MG</u>	<u>A202893 002</u>	Jul 31, 2013
<u>AA</u>	AVANTHI INC	<u>5MG</u>	<u>A203548 001</u>	Nov 23, 2015
<u>AA</u>		<u>10MG</u>	<u>A203548 002</u>	Nov 23, 2015
<u>AA</u>	BARR	<u>5MG</u>	<u>A040361 001</u>	Jan 31, 2001
<u>AA</u>	!	<u>10MG</u>	<u>A040361 002</u>	Jan 31, 2001
<u>AA</u>	NESHER PHARMS	<u>5MG</u>	<u>A206588 001</u>	Mar 28, 2016
<u>AA</u>		<u>10MG</u>	<u>A206588 002</u>	Mar 28, 2016
<u>AA</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204330 001</u>	Mar 16, 2016
<u>AA</u>		<u>10MG</u>	<u>A204330 002</u>	Mar 16, 2016
<u>AA</u>	NUVO PHARM	<u>5MG</u>	<u>A210059 001</u>	Oct 18, 2017
<u>AA</u>		<u>10MG</u>	<u>A210059 002</u>	Oct 18, 2017
<u>AA</u>	SPECGX LLC	<u>5MG</u>	<u>A040436 001</u>	Jan 29, 2002
<u>AA</u>		<u>10MG</u>	<u>A040436 002</u>	Jan 29, 2002
	ARBOR PHARMS LLC	2.5MG	A090533 001	Oct 25, 2011
		7.5MG	A090533 003	Oct 25, 2011
		15MG	A090533 005	Oct 25, 2011
		20MG	A090533 006	Oct 25, 2011
		30MG	A090533 007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

<u>AA</u>	HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027 001</u>	Jul 31, 1996
<u>AA</u>	WOCKHARDT BIO AG	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864 001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>20MG; 10MG</u>	<u>A202934 001</u>	Oct 10, 2017
<u>AB</u>	+! AVANIR PHARMS	<u>20MG; 10MG</u>	<u>N021879 001</u>	Oct 29, 2010

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>10GM/100ML</u>	<u>N019626 004</u>	Feb 02, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694 001</u>	
<u>AP</u>	FRESENIUS KABI USA	<u>10GM/100ML</u>	<u>A209448 001</u>	Jul 16, 2018
<u>AP</u>	+! ICU MEDICAL INC	<u>10GM/100ML</u>	<u>N018080 001</u>	

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>50MG/ML</u>	<u>N016730 002</u>	
<u>AP</u>	+!	<u>5GM/100ML</u>	<u>N016730 001</u>	
<u>AP</u>	+!	<u>5GM/100ML</u>	<u>N019626 002</u>	Feb 02, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673 003</u>	Oct 30, 1985
<u>AP</u>	+!	<u>50MG/ML</u>	<u>N020179 002</u>	Dec 07, 1992
<u>AP</u>	+!	<u>5GM/100ML</u>	<u>N016673 001</u>	
<u>AP</u>	+!	<u>5GM/100ML</u>	<u>N020179 001</u>	Dec 07, 1992
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A207449 001</u>	Oct 21, 2016
<u>AP</u>	+! HOSPIRA	<u>5GM/100ML</u>	<u>N019466 001</u>	Jul 15, 1985
<u>AP</u>	+!	<u>5GM/100ML</u>	<u>N019479 001</u>	Sep 17, 1985
<u>AP</u>	+! ICU MEDICAL INC	<u>50MG/ML</u>	<u>N016367 002</u>	

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+! BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N020047 001</u>	Jul 02, 1991
<u>AP</u>	+! ICU MEDICAL INC	<u>50GM/100ML</u>	<u>N018563 001</u>	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>70GM/100ML</u>	<u>N019626 005</u>	Feb 18, 2015
<u>AP</u>	+! BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N020047 003</u>	Jul 02, 1991
<u>AP</u>	+! ICU MEDICAL INC	<u>70GM/100ML</u>	<u>N018561 001</u>	Mar 23, 1982
<u>AP</u>	+!	<u>70GM/100ML</u>	<u>N019893 001</u>	Dec 26, 1989

DEXTROSE 20% IN PLASTIC CONTAINER

	+! ICU MEDICAL INC	20GM/100ML	N018564 001	Mar 23, 1982
--	--------------------	------------	-------------	--------------

DEXTROSE 25%

	+! HOSPIRA	250MG/ML	N019445 002	Nov 23, 1998
--	------------	----------	-------------	--------------

DEXTROSE 30% IN PLASTIC CONTAINER

	+! ICU MEDICAL INC	30GM/100ML	N019345 001	Jan 26, 1985
--	--------------------	------------	-------------	--------------

DEXTROSE 40% IN PLASTIC CONTAINER

	+! ICU MEDICAL INC	40GM/100ML	N018562 001	Mar 23, 1982
--	--------------------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50%

+ HOSPIRA

500MG/ML

N019445 003 Sep 03, 2014

DEXTROSE 50% IN PLASTIC CONTAINER

+ HOSPIRA

500MG/ML

N019445 001 Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML

N017610 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML

N019873 001 Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE

5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML

N017484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML

N019513 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017609 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINERAP + BAXTER HLTHCARE 5GM/100ML; 150MG/100ML N017634 001DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINERAP + BAXTER HLTHCARE 5GM/100ML; 224MG/100ML N017634 003DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINERAP + BAXTER HLTHCARE 5GM/100ML; 300MG/100ML N017634 002POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINERAP B BRAUN 5GM/100ML; 150MG/100ML N019699 004 Sep 29, 1989POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINERAP B BRAUN 5GM/100ML; 300MG/100ML N019699 006 Sep 29, 1989

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5GM/100ML; 75MG/100ML

N017634 004

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 149MG/100ML

N018371 001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQAP BAXTER HLTHCARE 5GM/100ML; 75MG/100ML; 200MG/100ML N018037 006 Apr 13, 1982AP BAXTER HLTHCARE 5GM/100ML; 150MG/100ML; 200MG/100ML N018037 007 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)AP BAXTER HLTHCARE 5GM/100ML; 224MG/100ML; 200MG/100ML N018037 004DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQAP BAXTER HLTHCARE 5GM/100ML; 150MG/100ML; 200MG/100ML N018037 008 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)AP BAXTER HLTHCARE 5GM/100ML; 300MG/100ML; 200MG/100ML N018037 001DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQAP BAXTER HLTHCARE 5GM/100ML; 224MG/100ML; 200MG/100ML N018037 005 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQAP BAXTER HLTHCARE 5GM/100ML; 300MG/100ML; 200MG/100ML N018037 009 Apr 13, 1982DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQAP BAXTER HLTHCARE 5GM/100ML; 75MG/100ML; 200MG/100ML N018037 002DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)AP BAXTER HLTHCARE 5GM/100ML; 150MG/100ML; 200MG/100ML N018037 003

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 005	Mar 23, 1982
----	-----------------	----------------------------------	-------------	--------------

AP		5GM/100ML;150MG/100ML;330MG/100ML	N018629 002	Mar 23, 1982
----	--	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 003	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 004	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

AP		5GM/100ML;300MG/100ML;330MG/100ML	N018629 006	Mar 23, 1982
----	--	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 007	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 008	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 001	Mar 23, 1982
----	-----------------	----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 010	
----	-----------------	-----------------------------------	-------------	--

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630 008	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630 014	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630 020	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630 026	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630 010	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005	Apr 28, 1982
----	-----------------	----------------------------------	-------------	--------------

AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006	Apr 28, 1982
----	--	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009	Jul 05, 1983
----	----	-----------------	------------------------------------	-------------	--------------

AP	+!		5GM/100ML;149MG/100ML;450MG/100ML	N018362 005	Mar 28, 1988
----	----	--	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007	Apr 28, 1982
----	-----------------	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010	Jul 05, 1983
----	----	-----------------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005	Apr 05, 1985
----	-----------------	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005	Mar 24, 1988
----	----	-----------------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008	Apr 28, 1982
----	-----------------	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002	
----	----	-----------------	-----------------------------------	-------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009	Apr 28, 1982
----	-----------------	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003	
----	----	-----------------	-----------------------------------	-------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 007	Apr 05, 1985
----	-----------------	-----------------------------------	-------------	--------------

AP	+!	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691 009	Mar 24, 1988
----	----	-----------------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988
--	---------	-----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988
--	---------	----------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004	Apr 05, 1985
	5GM/100ML;150MG/100ML;900MG/100ML	N019308 002	Apr 05, 1985
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365 001	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 003	Apr 05, 1985
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006	Apr 05, 1985
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001	Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	2.5GM/100ML;450MG/100ML	N019631 004	Feb 24, 1988
AP	+! BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N016697 001	
AP	FRESENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190 001	Dec 20, 2019
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML;200MG/100ML	N019631 007	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML;330MG/100ML	N019631 008	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML;450MG/100ML	N019631 009	Feb 24, 1988
AP	+ ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607 001	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML;900MG/100ML	N019631 010	Feb 24, 1988
AP	+! ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585 001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N016689 001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N016687 001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N016683 001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N016678 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;110MG/100ML	N019631 011	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;200MG/100ML	N019631 012	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;330MG/100ML	N019631 013	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;450MG/100ML	N019631 014	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;900MG/100ML	N019631 015	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631 001	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631 002	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631 003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631 005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631 016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N019631 006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	+! ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799 001	

PRESCRIPTION DRUG PRODUCT LIST

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

+ BRACCO

30%

N010040 018

CYSTOGRAFIN DILUTE

+ BRACCO

18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL

GASTROGRAFIN**AA** +! BRACCO**66%;10%****N011245 003**MD-GASTROVIEW**AA** LIEBEL-FLARSHEIM**66%;10%****A087388 001**DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM**AA** LANNETT CO INC**5MG/ML****A204433 001** Apr 14, 2014DIAZEPAM INTENSOL**AA** ! HIKMA**5MG/ML****A071415 001** Apr 03, 1987

GEL; RECTAL

DIASTAT

+ BAUSCH

2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

DIASTAT ACUDIAL

+ BAUSCH

10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

+!

20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM**AP** BELOTECA INC**10MG/2ML (5MG/ML)****A210363 001** Mar 18, 2019**AP****50MG/10ML (5MG/ML)****A211998 001** Dec 26, 2019**AP** ! HOSPIRA**10MG/2ML (5MG/ML)****A072079 001** Dec 20, 1988**AP** !**50MG/10ML (5MG/ML)****A071583 001** Oct 13, 1987

SOLUTION; ORAL

DIAZEPAM**AA** ! HIKMA**5MG/5ML****A070928 001** Apr 03, 1987**AA** LANNETT CO INC**5MG/5ML****A206477 001** Jun 24, 2016

TABLET; ORAL

DIAZEPAM**AB** BARR**2MG****A070152 001** Nov 01, 1985**AB****10MG****A070154 001** Nov 01, 1985**AB** IVAX SUB TEVA**2MG****A071307 001** Dec 10, 1986

PHARMS

AB**5MG****A071321 001** Dec 10, 1986**AB****10MG****A071322 001** Dec 10, 1986**AB** MAYNE PHARMA**2MG****A071134 001** Feb 03, 1987**AB****5MG****A071135 001** Feb 03, 1987**AB****10MG****A071136 001** Feb 03, 1987**AB** MYLAN**2MG****A070325 002** Sep 04, 1985**AB****5MG****A070325 003** Sep 04, 1985**AB****10MG****A070325 001** Sep 04, 1985**AB** VINTAGE PHARMS**2MG****A077749 001** Mar 31, 2006**AB****5MG****A077749 002** Mar 31, 2006**AB****10MG****A077749 003** Mar 31, 2006VALIUM**AB** + ROCHE**2MG****N013263 002****AB** +**5MG****N013263 004****AB** +!**10MG****N013263 006**DIAZOXIDE

SUSPENSION; ORAL

DIAZOXIDE**AB** E5 PHARMA INC**50MG/ML****A211050 001** Dec 20, 2019PROGLYCEM**AB** +! TEVA BRANDED PHARM**50MG/ML****N017453 001**DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

+! STRONGBRIDGE US

50MG

N011366 002 Aug 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC

CAPSULE;ORAL

ZORVOLEX

+ ZYLA

18MG

N204592 001 Oct 18, 2013

+!

35MG

N204592 002 Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH;TOPICAL

FLECTOR

+! INST BIOCHEM

1.3%

N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUMAB BIONPHARMA INC25MGA204648 001 Feb 23, 2016AB STRIDES PHARMA25MGA210078 001 Dec 03, 2019ZIPSORAB +! ASSERTIO25MGN022202 001 Jun 16, 2009

FOR SOLUTION;ORAL

CAMBIAAB +! ASSERTIO50MGN022165 001 Jun 17, 2009DICLOFENAC POTASSIUMAB PAR FORM50MGA202964 001 May 02, 2016

TABLET;ORAL

DICLOFENAC POTASSIUMAB AMICI50MGA076561 001 Mar 18, 2004AB CASI PHARMS INC50MGA075229 001 Nov 20, 1998AB ! MYLAN50MGA075463 001 Jul 26, 1999AB TEVA50MGA075219 001 Aug 06, 1998DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUMAB ACTAVIS MID3%A206493 001 Dec 02, 2015

ATLANTIC

AB AMNEAL PHARMS1%A208077 001 Mar 18, 2016AB CIPLA1%A209903 001 Aug 03, 2018AB GLENMARK PHARMS LTD3%A208301 001 Sep 13, 2016AB HI TECH1%A209484 001 Nov 21, 2018AB MYLAN1%A204306 001 May 06, 2019AB PERRIGO UK FINCO1%A211253 001 May 16, 2019AB TARO3%A210893 001 Jul 27, 2018AB TOLMAR3%A200936 001 Oct 28, 2013SOLARAZEAB +! FOUGERA PHARMS3%N021005 001 Oct 16, 2000VOLTARENAB +! GLAXOSMITHKLINE1%N022122 001 Oct 17, 2007

CONS

SOLUTION;TOPICAL

DICLOFENAC SODIUMAT AMNEAL PHARMS1.5%A206116 001 Sep 02, 2016AT ! APOTEX INC1.5%A202027 001 May 27, 2014AT CADILA1.5%A206411 001 Apr 17, 2018AT LUPIN LTD1.5%A204132 001 Aug 20, 2015AT NOVEL LABS INC1.5%A205878 001 Dec 09, 2015AT TARO1.5%A203818 001 Nov 26, 2014AT TELIGENT PHARMA INC1.5%A202769 001 Jul 08, 2015AT TWI PHARMS1.5%A202393 001 Nov 24, 2014AT WATSON LABS INC1.5%A202852 001 Nov 24, 2014

PENNSAID

+! HORIZON

2%

N204623 001 Jan 16, 2014

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUMAT AKORN0.1%A077845 001 Apr 17, 2008AT ALTAIRE PHARMS INC0.1%A203383 001 Nov 16, 2015AT BAUSCH AND LOMB0.1%A078792 001 Dec 28, 2007AT RISING0.1%A078553 001 Dec 28, 2007AT SANDOZ INC0.1%A078031 001 Feb 06, 2008VOLTARENAT +! NOVARTIS0.1%N020037 001 Mar 28, 1991

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUMAB ACTAVIS ELIZABETH50MGA074514 001 Mar 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>		<u>75MG</u>	<u>A074514</u>	<u>002</u>	Mar 26, 1996
<u>AB</u>	CARLSBAD	<u>25MG</u>	<u>A075185</u>	<u>002</u>	Nov 13, 1998
<u>AB</u>		<u>50MG</u>	<u>A075185</u>	<u>003</u>	Nov 13, 1998
<u>AB</u>		<u>75MG</u>	<u>A075185</u>	<u>001</u>	Nov 13, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075281</u>	<u>002</u>	Feb 12, 2002
<u>AB</u>		<u>75MG</u>	<u>A075281</u>	<u>003</u>	Feb 12, 2002
<u>AB</u>	! UNIQUE PHARM LABS	<u>25MG</u>	<u>A090066</u>	<u>001</u>	Dec 01, 2010
<u>AB</u>	!	<u>50MG</u>	<u>A090066</u>	<u>002</u>	Dec 01, 2010
<u>AB</u>	!	<u>75MG</u>	<u>A077863</u>	<u>003</u>	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>	! DEXCEL LTD	<u>100MG</u>	<u>A076201</u>	<u>001</u>	Nov 06, 2002
<u>AB</u>	VPNA	<u>100MG</u>	<u>A075492</u>	<u>001</u>	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

<u>AB</u>	+ GD SEARLE LLC	<u>50MG;0.2MG</u>	<u>N020607</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	+	<u>75MG;0.2MG</u>	<u>N020607</u>	<u>002</u>	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG;0.2MG</u>	<u>A201089</u>	<u>001</u>	Jul 09, 2012
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A201089</u>	<u>002</u>	Jul 09, 2012
<u>AB</u>	AMNEAL PHARMS	<u>50MG;0.2MG</u>	<u>A203995</u>	<u>001</u>	Nov 25, 2016
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A203995</u>	<u>002</u>	Nov 25, 2016
<u>AB</u>	SANDOZ	<u>50MG;0.2MG</u>	<u>A200158</u>	<u>001</u>	May 09, 2013
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A200158</u>	<u>002</u>	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	! LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>	WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE;INJECTION

BENTYL

<u>AP</u>	! ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
	<u>BENTYL PRESERVATIVE FREE</u>				
<u>AP</u>	! ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>10MG/ML</u>	<u>A207084</u>	<u>001</u>	May 04, 2018
<u>AP</u>	AM REGENT	<u>10MG/ML</u>	<u>A208353</u>	<u>001</u>	Feb 17, 2017
<u>AP</u>	CUSTOPHARM INC	<u>10MG/ML</u>	<u>A210788</u>	<u>001</u>	Feb 11, 2019
<u>AP</u>	FOSUN PHARMA	<u>10MG/ML</u>	<u>A210979</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A210257</u>	<u>001</u>	Jan 25, 2019
<u>AP</u>	NEXUS PHARMS	<u>10MG/ML</u>	<u>A206468</u>	<u>001</u>	Feb 01, 2019
<u>AP</u>	SLATE	<u>10MG/ML</u>	<u>A207076</u>	<u>001</u>	Nov 02, 2018
<u>AP</u>	SUNGEN PHARMA	<u>10MG/ML</u>	<u>A212058</u>	<u>001</u>	Apr 26, 2019

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

<u>AP</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003
-----------	----------------------	----------------	----------------	------------	--------------

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

! GENERICS

10MG/5ML

A040169 001 Mar 24, 2005

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	HIKMA PHARMS	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996
<u>AB</u>	LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	! WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

PRESCRIPTION DRUG PRODUCT LIST

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AB	AUROBINDO PHARMA	125MG	A090094 001	Sep 24, 2008
AB		200MG	A090094 002	Sep 24, 2008
AB		250MG	A090094 003	Sep 24, 2008
AB		400MG	A090094 004	Sep 24, 2008

VIDEX EC

AB	+ BRISTOL MYERS SQUIBB	125MG	N021183 001	Oct 31, 2000
AB	+	200MG	N021183 002	Oct 31, 2000
AB	+	250MG	N021183 003	Oct 31, 2000
AB	+	400MG	N021183 004	Oct 31, 2000

FOR SOLUTION;ORAL

VIDEX

	+! BRISTOL-MYERS SQUIBB	10MG/ML	N020156 001	Oct 09, 1991
--	----------------------------	---------	-------------	--------------

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+! BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A	N022252 001	May 06, 2010
--	-------------------	--	-------------	--------------

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA	AVANTHI INC	25MG	A201212 001	Dec 22, 2010
AA	! LANNETT CO INC	25MG	A200177 001	Jul 18, 2011

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

AB	! LANNETT CO INC	75MG	A091680 001	Oct 24, 2011
-----------	------------------	-------------	--------------------	--------------

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	! FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002
BX	! TARO	0.05%	A075508 001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB	AKORN	0.05%	A206572 001	Jul 24, 2015
AB	FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999
AB	RISING	0.05%	A207440 001	Feb 27, 2017
AB	! TARO	0.05%	A075331 001	May 14, 1999
AB	TELGENT PHARMA INC	0.05%	A210753 001	Jun 12, 2018

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB	HERITAGE PHARMA	500MG	A202845 001	Mar 08, 2012
AB	! TEVA	500MG	A073673 001	Jul 31, 1992
AB	ZYDUS PHARMS	500MG	A203547 001	Jun 16, 2017

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

	+! NOVARTIS	0.05%	N022212 001	Jun 23, 2008
--	-------------	-------	-------------	--------------

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA	+! HIKMA	0.05MG/ML	N021648 001	Aug 26, 2004
AA	VISTAPHARM	0.05MG/ML	A213000 001	Oct 04, 2019

INJECTABLE;INJECTION

DIGOXIN

AP	SANDOZ INC	0.25MG/ML	A040481 001	Aug 21, 2003
AP	WEST-WARD PHARMS INT	0.25MG/ML	A083391 001	

LANOXIN

AP	+! COVIS PHARMA BV	0.25MG/ML	N009330 002	
	LANOXIN PEDIATRIC			
	+! COVIS PHARMA BV	0.1MG/ML	N009330 004	

TABLET;ORAL

DIGOXIN

AB	HIKMA INTL PHARMS	0.125MG	A077002 002	Oct 30, 2007
AB		0.25MG	A077002 001	Oct 30, 2007
AB	IMPAX LABS	0.125MG	A078556 001	Jul 20, 2009

PRESCRIPTION DRUG PRODUCT LIST

DIGOXIN

TABLET; ORAL

DIGOXIN

<u>AB</u>		<u>0.25MG</u>	<u>A078556</u>	<u>002</u>	Jul 20, 2009
<u>AB</u>	MYLAN PHARMS INC	<u>0.125MG</u>	<u>A040282</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>0.25MG</u>	<u>A040282</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	STEVENS J	<u>0.125MG</u>	<u>A076268</u>	<u>001</u>	Jul 26, 2002
<u>AB</u>		<u>0.25MG</u>	<u>A076268</u>	<u>002</u>	Jul 26, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A076363</u>	<u>001</u>	Jan 31, 2003
<u>AB</u>		<u>0.25MG</u>	<u>A076363</u>	<u>002</u>	Jan 31, 2003

LANOXIN

<u>AB</u>	+	CONCORDIA	<u>0.125MG</u>	<u>N020405</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	!	<u>0.25MG</u>	<u>N020405</u>	<u>004</u>	Sep 30, 1997
	+		0.0625MG	N020405	001	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

<u>AP</u>	+	!	BAUSCH	<u>1MG/ML</u>	<u>N005929</u>	<u>001</u>
-----------	---	---	--------	---------------	----------------	------------

DIHYDROERGOTAMINE MESYLATE

<u>AP</u>		APOLLO	<u>1MG/ML</u>	<u>A212046</u>	<u>001</u>	Jan 07, 2020
<u>AP</u>		HIKMA PHARMS	<u>1MG/ML</u>	<u>A206621</u>	<u>001</u>	Sep 15, 2017
<u>AP</u>		PADDOCK LLC	<u>1MG/ML</u>	<u>A040475</u>	<u>001</u>	Apr 28, 2003
<u>AP</u>		SAGENT PHARMS INC	<u>1MG/ML</u>	<u>A207264</u>	<u>001</u>	Jul 11, 2018
<u>AP</u>		WEST-WARD PHARMS	<u>1MG/ML</u>	<u>A040453</u>	<u>001</u>	Jun 09, 2003

SPRAY, METERED; NASAL

MIGRANAL

	+	!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997
--	---	---	--------	-------------	---------	-----	--------------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB2</u>		APOTEX	<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>		!	<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998

CARDIZEM CD

<u>AB3</u>	+	BAUSCH	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>	+		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>	+		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>	+		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	!	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999

CARTIA XT

<u>AB3</u>		ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>			<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>			<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>			<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>		ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>		NOVAST LABS	<u>120MG</u>	<u>A208783</u>	<u>001</u>	Jun 14, 2019
<u>AB3</u>			<u>180MG</u>	<u>A208783</u>	<u>002</u>	Jun 14, 2019
<u>AB3</u>			<u>240MG</u>	<u>A208783</u>	<u>003</u>	Jun 14, 2019
<u>AB3</u>			<u>300MG</u>	<u>A208783</u>	<u>004</u>	Jun 14, 2019
<u>AB3</u>			<u>360MG</u>	<u>A208783</u>	<u>005</u>	Jun 14, 2019
<u>AB3</u>		PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>			<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>			<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>			<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>		SUN PHARM	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>			<u>120MG</u>	<u>A203023</u>	<u>001</u>	Jun 08, 2017
<u>AB3</u>			<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>			<u>180MG</u>	<u>A203023</u>	<u>002</u>	Jun 08, 2017
<u>AB3</u>			<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>			<u>240MG</u>	<u>A203023</u>	<u>003</u>	Jun 08, 2017
<u>AB3</u>			<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>			<u>300MG</u>	<u>A203023</u>	<u>004</u>	Jun 08, 2017
<u>AB3</u>			<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>			<u>360MG</u>	<u>A203023</u>	<u>005</u>	Jun 08, 2017
<u>AB3</u>		TWI PHARMS	<u>120MG</u>	<u>A205231</u>	<u>001</u>	Aug 30, 2018
<u>AB3</u>			<u>180MG</u>	<u>A205231</u>	<u>002</u>	Aug 30, 2018
<u>AB3</u>			<u>240MG</u>	<u>A205231</u>	<u>003</u>	Aug 30, 2018
<u>AB3</u>			<u>300MG</u>	<u>A205231</u>	<u>004</u>	Aug 30, 2018
<u>AB3</u>			<u>360MG</u>	<u>A205231</u>	<u>005</u>	Aug 30, 2018
<u>AB3</u>		VALEANT PHARMS	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
		NORTH				

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>		<u>180MG</u>	<u>A075116 002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116 003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116 004</u>	Dec 23, 1999
<u>AB3</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206534 001</u>	Aug 08, 2017
<u>AB3</u>		<u>180MG</u>	<u>A206534 002</u>	Aug 08, 2017
<u>AB3</u>		<u>240MG</u>	<u>A206534 003</u>	Aug 08, 2017
<u>AB3</u>		<u>300MG</u>	<u>A206534 004</u>	Aug 08, 2017
<u>AB3</u>		<u>360MG</u>	<u>A206534 005</u>	Aug 08, 2017
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022 001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022 002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022 003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022 004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022 005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022 006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARM	<u>120MG</u>	<u>A090421 001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421 002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421 003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421 004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421 005</u>	Nov 15, 2010
<u>AB4</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206641 001</u>	Aug 11, 2017
<u>AB4</u>		<u>180MG</u>	<u>A206641 002</u>	Aug 11, 2017
<u>AB4</u>		<u>240MG</u>	<u>A206641 003</u>	Aug 11, 2017
<u>AB4</u>		<u>300MG</u>	<u>A206641 004</u>	Aug 11, 2017
<u>AB4</u>		<u>360MG</u>	<u>A206641 005</u>	Aug 11, 2017
<u>AB4</u>		<u>420MG</u>	<u>A206641 006</u>	Aug 11, 2017

DILTIZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395 001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395 002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395 003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395 004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395 005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401 001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401 002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401 003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401 004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401 005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	+	BAUSCH	<u>120MG</u>	<u>N020401 001</u>	Sep 11, 1995
<u>AB4</u>	+		<u>180MG</u>	<u>N020401 002</u>	Sep 11, 1995
<u>AB4</u>	+		<u>240MG</u>	<u>N020401 003</u>	Sep 11, 1995
<u>AB4</u>	+		<u>300MG</u>	<u>N020401 004</u>	Sep 11, 1995
<u>AB4</u>	+		<u>360MG</u>	<u>N020401 005</u>	Sep 11, 1995
<u>AB4</u>	+	!	<u>420MG</u>	<u>N020401 006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	!	MYLAN	120MG	A074910 003	May 02, 1997
		APOTEX	120MG	A074943 003	Dec 19, 2000
		MYLAN	60MG	A074910 001	May 02, 1997
			90MG	A074910 002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>5MG/ML</u>	<u>A075086 001</u>	Apr 09, 1998
<u>AP</u>	!	ATHENEX INC	<u>5MG/ML</u>	<u>A074617 001</u>	Feb 28, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651 001</u>	Aug 09, 2012
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941 001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749 001</u>	Nov 21, 2001
<u>AP</u>		WEST-WARD PHARMS	<u>5MG/ML</u>	<u>A078538 001</u>	Dec 17, 2008
		INT			
	!	HOSPIRA	100MG/VIAL	A075853 001	Dec 17, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	+	BAUSCH	<u>30MG</u>	<u>N018602 001</u>	Nov 05, 1982
<u>AB</u>	+		<u>60MG</u>	<u>N018602 002</u>	Nov 05, 1982
<u>AB</u>	+		<u>90MG</u>	<u>N018602 003</u>	Dec 08, 1986
<u>AB</u>	+	!	<u>120MG</u>	<u>N018602 004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		EDENBRIDGE PHARMS	<u>30MG</u>	<u>A211596 001</u>	Nov 18, 2019
<u>AB</u>			<u>60MG</u>	<u>A211596 002</u>	Nov 18, 2019
<u>AB</u>			<u>90MG</u>	<u>A211596 003</u>	Nov 18, 2019
<u>AB</u>			<u>120MG</u>	<u>A211596 004</u>	Nov 18, 2019

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	+	BAUSCH	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>	+		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>	+		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>	+		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>	+		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	!	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>			<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>			<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>			<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>			<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>			<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
---	--------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	!	AKORN	10%	N005939	001
---	---	-------	-----	---------	-----

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

+		BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
+	!		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

+	!	MYLAN INSTITUTIONAL	50%	N017788	001
---	---	---------------------	-----	---------	-----

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+	!	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
---	---	----------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995
---	---	--------------------	------	---------	-----	--------------

SUPPOSITORY; VAGINAL

PROSTIN E2

+	!	PHARMACIA AND UPJOHN	20MG	N017810	001
---	---	----------------------	------	---------	-----

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

!		PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982
---	--	-------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>		APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002
<u>AP</u>		HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998
<u>AP</u>		MICRO LABS	<u>50MG/ML</u>	<u>A205723</u>	<u>001</u>	Aug 22, 2018
<u>AP</u>		MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005
<u>AP</u>	!	WEST-WARD PHARMS	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A091526</u>	<u>001</u>	Mar 26, 2013
-----------	--	--------------------	----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	!	ATHENEX INC	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998
<u>AP</u>		FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		WEST-WARD PHARMS	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996

INT

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>		BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>			<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>			<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>		MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>			<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>			<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		ZYDUS PHARMS USA	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
		INC				
<u>AB</u>			<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>			<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008

PERSANTINE

<u>AB</u>	+	BOEHRINGER	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
		INGELHEIM				
<u>AB</u>	+		<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+	!	<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

VUMERITY

+	!	BIOGEN	231MG	N211855	001	Oct 29, 2019
---	---	--------	-------	---------	-----	--------------

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>		MAYNE PHARMA	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070173</u>	<u>002</u>	May 31, 1985
<u>AB</u>		TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985

NORPACE

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+	!	<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

+		GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982
+	!		EQ 150MG BASE	N018655	002	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>		ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	!		<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>		ALVOGEN	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013
<u>AB</u>		CHARTWELL MOLECULES	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		HIKMA	<u>250MG</u>	<u>A202652</u>	<u>001</u>	Feb 05, 2014
<u>AB</u>			<u>500MG</u>	<u>A202652</u>	<u>002</u>	Feb 05, 2014
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	!	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
-----------	---	---	--------	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		ZYDUS PHARMS USA	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009
		INC				

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>	+		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983

PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

<u>AB</u>	<u>+</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983
-----------	----------	--	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>		ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008
<u>AB</u>		APOTEX	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554</u>	<u>001</u>	Apr 21, 2011
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090554</u>	<u>002</u>	Apr 21, 2011
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090554</u>	<u>003</u>	Apr 21, 2011
<u>AB</u>		CELLTRION	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		INVATECH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>		PRINSTON INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>		SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163</u>	<u>001</u>	Apr 05, 2011
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A079163</u>	<u>002</u>	Apr 05, 2011
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A079163</u>	<u>003</u>	Apr 05, 2011
<u>AB</u>		UPSHER SMITH LABS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	<u>+</u>	ABEVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	<u>+</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>		AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730</u>	<u>001</u>	May 29, 2015
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A203730</u>	<u>002</u>	May 29, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419</u>	<u>001</u>	Jun 02, 2014
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A202419</u>	<u>002</u>	Jun 02, 2014
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>		IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>		LUPIN LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A209286</u>	<u>001</u>	Oct 18, 2019
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A209286</u>	<u>002</u>	Oct 18, 2019
<u>AB</u>		MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>		REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

PRESCRIPTION DRUG PRODUCT LIST

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>	!		<u>EQ 12.5MG BASE/ML</u>	<u>A074292 001</u>	Feb 16, 1995
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	+	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012
<u>AP</u>		ACTAVIS LLC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>N203551 004</u>	Sep 21, 2015
<u>AP</u>		AMNEAL	<u>20MG/ML (20MG/ML)</u>	<u>A209640 001</u>	Jan 19, 2018
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A209640 002</u>	Jan 19, 2018
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>A209640 003</u>	Jan 19, 2018
<u>AP</u>		DFB ONCOLOGY LTD	<u>20MG/ML (20MG/ML)</u>	<u>A206177 001</u>	Jan 20, 2017
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A206177 002</u>	Jan 20, 2017
<u>AP</u>		DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014
<u>AP</u>	+	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+		<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+		<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>		INGENUS PHARMS LLC	<u>20MG/2ML (10MG/ML)</u>	<u>A207563 001</u>	Aug 31, 2017
<u>AP</u>			<u>80MG/8ML (10MG/ML)</u>	<u>A207563 002</u>	Aug 31, 2017
<u>AP</u>			<u>160MG/16ML (10MG/ML)</u>	<u>A207563 003</u>	Aug 31, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>20MG/ML (20MG/ML)</u>	<u>A207252 001</u>	Aug 09, 2017
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>A207252 002</u>	Aug 09, 2017
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>A207252 003</u>	Aug 09, 2017
<u>AP</u>		MYLAN LABS LTD	<u>20MG/2ML (10MG/ML)</u>	<u>A210072 001</u>	Jul 02, 2018
<u>AP</u>			<u>80MG/8ML (10MG/ML)</u>	<u>A210848 001</u>	Jul 06, 2018
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>A208137 001</u>	Apr 01, 2019
<u>AP</u>		SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011
<u>AP</u>			<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011
<u>AP</u>			<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011
<u>AP</u>		TEIKOKU PHARMA	<u>20MG/ML (20MG/ML)</u>	<u>N205934 001</u>	Dec 22, 2015
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>N205934 002</u>	Dec 22, 2015
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>N205934 003</u>	Dec 22, 2015

TAXOTERE

<u>AP</u>	+	SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

DOCETAXEL

		ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
		DFB ONCOLOGY LTD	200MG/10ML (20MG/ML)	A206177 003	Jan 20, 2017
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234 004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234 005	Jun 23, 2016
	+		160MG/8ML (20MG/ML)	N022234 007	Jan 24, 2017
	!	JIANGSU HENGRUI MED	40MG/ML	A203170 001	Feb 15, 2017

SOLUTION; INTRAVENOUS

DOCETAXEL

<u>AP</u>		SUN PHARMA GLOBAL	<u>20MG/ML (20MG/ML)</u>	<u>N022534 003</u>	Jan 08, 2019
<u>AP</u>			<u>80MG/4ML (20MG/ML)</u>	<u>N022534 004</u>	Jan 08, 2019
<u>AP</u>			<u>160MG/8ML (20MG/ML)</u>	<u>N022534 005</u>	Jan 08, 2019

PRESCRIPTION DRUG PRODUCT LIST

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	MYLAN LABS LTD	160MG/16ML (10MG/ML)	A208859 001	Apr 30, 2018
-----------	----------------	-----------------------------	--------------------	--------------

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB	AUROBINDO PHARMA LTD	0.125MG	A210740 001	Jan 22, 2019
-----------	----------------------	----------------	--------------------	--------------

AB		0.25MG	A210740 002	Jan 22, 2019
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A210740 003	Jan 22, 2019
-----------	--	--------------	--------------------	--------------

DOFETILIDE

AB	BIONPHARMA INC	0.125MG	A208625 001	Apr 10, 2018
-----------	----------------	----------------	--------------------	--------------

AB		0.25MG	A208625 002	Apr 10, 2018
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A208625 003	Apr 10, 2018
-----------	--	--------------	--------------------	--------------

AB	MAYNE PHARMA INC	0.125MG	A207058 001	Jun 06, 2016
-----------	------------------	----------------	--------------------	--------------

AB		0.25MG	A207058 002	Jun 06, 2016
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A207058 003	Jun 06, 2016
-----------	--	--------------	--------------------	--------------

AB	PAR PHARM INC	0.125MG	A208519 001	Oct 09, 2018
-----------	---------------	----------------	--------------------	--------------

AB		0.25MG	A208519 002	Oct 09, 2018
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A208519 003	Oct 09, 2018
-----------	--	--------------	--------------------	--------------

AB	PRINSTON INC	0.125MG	A211223 001	Dec 17, 2019
-----------	--------------	----------------	--------------------	--------------

AB		0.25MG	A211223 002	Dec 17, 2019
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A211223 003	Dec 17, 2019
-----------	--	--------------	--------------------	--------------

AB	RICONPHARMA LLC	0.125MG	A212410 001	Dec 27, 2019
-----------	-----------------	----------------	--------------------	--------------

AB		0.25MG	A212410 002	Dec 27, 2019
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A212410 003	Dec 27, 2019
-----------	--	--------------	--------------------	--------------

AB	SIGMAPHARM LABS LLC	0.125MG	A207746 001	Mar 26, 2018
-----------	---------------------	----------------	--------------------	--------------

AB		0.25MG	A207746 002	Mar 26, 2018
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A207746 003	Mar 26, 2018
-----------	--	--------------	--------------------	--------------

AB	SUN PHARM	0.125MG	A210466 001	Oct 09, 2018
-----------	-----------	----------------	--------------------	--------------

AB		0.25MG	A210466 002	Oct 09, 2018
-----------	--	---------------	--------------------	--------------

AB		0.5MG	A210466 003	Oct 09, 2018
-----------	--	--------------	--------------------	--------------

TIKOSYN

AB	+ PFIZER	0.125MG	N020931 001	Oct 01, 1999
-----------	----------	----------------	--------------------	--------------

AB	+	0.25MG	N020931 002	Oct 01, 1999
-----------	---	---------------	--------------------	--------------

AB	+!	0.5MG	N020931 003	Oct 01, 1999
-----------	----	--------------	--------------------	--------------

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

	+ VIIV HLTHCARE	EQ 10MG BASE	N204790 002	Jun 09, 2016
--	-----------------	--------------	-------------	--------------

	+	EQ 25MG BASE	N204790 003	Jun 09, 2016
--	---	--------------	-------------	--------------

	+!	EQ 50MG BASE	N204790 001	Aug 12, 2013
--	----	--------------	-------------	--------------

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

DOVATO

	+! VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994 001	Apr 08, 2019
--	------------------	--------------------	-------------	--------------

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

JULUCA

	+! VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192 001	Nov 21, 2017
--	------------------	---------------------------	-------------	--------------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

AB	+ EISAI INC	5MG	N020690 002	Nov 25, 1996
-----------	-------------	------------	--------------------	--------------

AB	+!	10MG	N020690 001	Nov 25, 1996
-----------	----	-------------	--------------------	--------------

AB	+!	23MG	N022568 001	Jul 23, 2010
-----------	----	-------------	--------------------	--------------

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662 001	May 31, 2011
-----------	--------------------	------------	--------------------	--------------

AB		10MG	A078662 002	May 31, 2011
-----------	--	-------------	--------------------	--------------

AB	ACTAVIS ELIZABETH	23MG	A202415 001	Dec 17, 2015
-----------	-------------------	-------------	--------------------	--------------

AB	ALEMBIC PHARMS LTD	5MG	A201724 001	Feb 25, 2013
-----------	--------------------	------------	--------------------	--------------

AB		10MG	A201724 002	Feb 25, 2013
-----------	--	-------------	--------------------	--------------

AB	AUROBINDO	5MG	A090056 001	May 31, 2011
-----------	-----------	------------	--------------------	--------------

AB		10MG	A090056 002	May 31, 2011
-----------	--	-------------	--------------------	--------------

AB	CADILA	5MG	A090100 001	Oct 24, 2012
-----------	--------	------------	--------------------	--------------

AB		10MG	A090100 002	Oct 24, 2012
-----------	--	-------------	--------------------	--------------

AB	CADILA PHARMS LTD	5MG	A204609 001	Sep 19, 2017
-----------	-------------------	------------	--------------------	--------------

AB		10MG	A204609 002	Sep 19, 2017
-----------	--	-------------	--------------------	--------------

AB	CIPLA LTD	5MG	A077518 001	May 31, 2011
-----------	-----------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CSPC OUYI	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>	DEXCEL PHARMA	<u>23MG</u>	<u>A203713</u>	<u>001</u>	Feb 19, 2016
<u>AB</u>	DR REDDYS	<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A203034</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A203034</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>	HISUN PHARM HANGZHOU	<u>23MG</u>	<u>A202410</u>	<u>001</u>	Mar 24, 2017
<u>AB</u>	INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>		<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u>		<u>23MG</u>	<u>A203419</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u>	LUPIN LTD	<u>23MG</u>	<u>A202782</u>	<u>001</u>	Oct 30, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>23MG</u>	<u>A202631</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>	MYLAN	<u>23MG</u>	<u>A202656</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A203656</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A203656</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>	ZYDUS PHARMS	<u>23MG</u>	<u>A203162</u>	<u>001</u>	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	HISUN PHARM HANGZHOU	<u>5MG</u>	<u>A205269</u>	<u>001</u>	Jul 27, 2018
<u>AB</u>		<u>10MG</u>	<u>A205269</u>	<u>002</u>	Jul 27, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>	!	<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A204831</u>	<u>001</u>	Nov 10, 2016
<u>AB</u>		<u>10MG</u>	<u>A204831</u>	<u>002</u>	Nov 10, 2016

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

+	ALLERGAN	10MG; 7MG	N206439	003	Jul 18, 2016
+		10MG; 14MG	N206439	001	Dec 23, 2014
+		10MG; 21MG	N206439	004	Jul 18, 2016
+	!	10MG; 28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	HIKMA INTL PHARMS	<u>40MG/ML</u>	<u>A207707</u>	<u>001</u>	Apr 11, 2018
<u>AP</u>		<u>80MG/ML</u>	<u>A207707</u>	<u>002</u>	Apr 11, 2018
<u>AP</u>	+	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+	<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+	<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982

PRESCRIPTION DRUG PRODUCT LIST

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

AP	+ !		160MG/100ML	N018132 003	Feb 04, 1982
		<u>DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%</u>			
AP	+ !	B BRAUN	80MG/100ML	N019099 002	Oct 15, 1986
AP	+ !		320MG/100ML	N019099 004	Oct 15, 1986
		<u>DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	+ !	B BRAUN	160MG/100ML	N019099 003	Oct 15, 1986
		<u>DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	+ !	BAXTER HLTHCARE	80MG/100ML	N019615 001	Mar 27, 1987
AP	+ !		160MG/100ML	N019615 002	Mar 27, 1987
AP	+ !		320MG/100ML	N019615 003	Mar 27, 1987
AP	+ !	HOSPIRA	80MG/100ML	N018826 001	Sep 30, 1983
AP	+ !		160MG/100ML	N018826 002	Sep 30, 1983
AP	+ !		320MG/100ML	N018826 003	Sep 30, 1983
		<u>DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER</u>			
	+ !	B BRAUN	40MG/100ML	N019099 001	Oct 15, 1986
		<u>DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
	+ !	BAXTER HLTHCARE	640MG/100ML	N019615 004	Mar 27, 1987

DORAVIRINE

TABLET; ORAL

PIFELTRO

+ !	MSD MERCK CO	100MG	N210806 001	Aug 30, 2018
------------	--------------	-------	-------------	--------------

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

DELSTRIGO

+ !	MSD MERCK CO	100MG; 300MG; 300MG	N210807 001	Aug 30, 2018
------------	--------------	---------------------	-------------	--------------

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639 001	Aug 09, 2019	
AT	BAUSCH AND LOMB	EQ 2% BASE	A090143 001	Jun 25, 2009	
AT	FDC LTD	EQ 2% BASE	A205294 001	Jan 24, 2019	
AT	HI TECH PHARMA	EQ 2% BASE	A077846 001	Oct 28, 2008	
AT	MICRO LABS	EQ 2% BASE	A204778 001	Nov 08, 2019	
AT	SANDOZ INC	EQ 2% BASE	A078748 001	Nov 06, 2008	
AT		EQ 2% BASE	A078981 001	Apr 13, 2009	
	<u>TRUSOPT</u>				
AT	+ !	MERCK	EQ 2% BASE	N020408 001	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

AT	+ !	OAK PHARMS INC	EQ 2% BASE; EQ 0.5% BASE	N020869 001	Apr 07, 1998
		<u>COSOPT PF</u>			
AT	+ !	OAK PHARMS INC	EQ 2% BASE; EQ 0.5% BASE	N202667 001	Feb 01, 2012
		<u>DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE</u>			
AT		AKORN INC	EQ 2% BASE; EQ 0.5% BASE	A203058 001	Sep 22, 2014
AT		AUROBINDO PHARMA LTD	EQ 2% BASE; EQ 0.5% BASE	A207630 001	Jul 24, 2018
AT		BAUSCH AND LOMB	EQ 2% BASE; EQ 0.5% BASE	A090037 001	Jul 14, 2009
AT		HI TECH PHARMA	EQ 2% BASE; EQ 0.5% BASE	A077847 001	Oct 28, 2008
AT		SANDOZ	EQ 2% BASE; EQ 0.5% BASE	A078749 001	Nov 06, 2008
AT		SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604 001	Nov 18, 2009
AT		SOMERSET	EQ 2% BASE; EQ 0.5% BASE	A207523 001	Jun 25, 2019
AT		TEVA PHARMS	EQ 2% BASE; EQ 0.5% BASE	A078704 001	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+ !	HIKMA	20MG/ML	N014879 001	
		<u>DOXAPRAM HYDROCHLORIDE</u>			
AP		ATHENEX INC	20MG/ML	A076266 001	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB	+ !	PFIZER	EQ 1MG BASE	N019668 001	Nov 02, 1990
AB	+		EQ 2MG BASE	N019668 002	Nov 02, 1990
AB	+		EQ 4MG BASE	N019668 003	Nov 02, 1990
AB	+		EQ 8MG BASE	N019668 004	Nov 02, 1990

PRESCRIPTION DRUG PRODUCT LIST

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824 001</u>	Jun 11, 2014
AB		<u>EQ 2MG BASE</u>	<u>A202824 002</u>	Jun 11, 2014
AB		<u>EQ 4MG BASE</u>	<u>A202824 003</u>	Jun 11, 2014
AB		<u>EQ 8MG BASE</u>	<u>A202824 004</u>	Jun 11, 2014
AB	ANI PHARMS INC	<u>EQ 1MG BASE</u>	<u>A075432 001</u>	Oct 18, 2000
AB		<u>EQ 2MG BASE</u>	<u>A075432 002</u>	Oct 18, 2000
AB		<u>EQ 4MG BASE</u>	<u>A075432 003</u>	Oct 18, 2000
AB		<u>EQ 8MG BASE</u>	<u>A075432 004</u>	Oct 18, 2000
AB	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580 001</u>	Oct 18, 2000
AB		<u>EQ 2MG BASE</u>	<u>A075580 002</u>	Oct 18, 2000
AB		<u>EQ 4MG BASE</u>	<u>A075580 003</u>	Oct 18, 2000
AB		<u>EQ 8MG BASE</u>	<u>A075580 004</u>	Oct 18, 2000
AB	DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161 001</u>	Jun 10, 2004
AB		<u>EQ 2MG BASE</u>	<u>A076161 002</u>	Jun 10, 2004
AB		<u>EQ 4MG BASE</u>	<u>A076161 003</u>	Jun 10, 2004
AB		<u>EQ 8MG BASE</u>	<u>A076161 004</u>	Jun 10, 2004
AB	HERITAGE PHARMA	<u>EQ 1MG BASE</u>	<u>A205210 001</u>	Feb 13, 2018
AB		<u>EQ 2MG BASE</u>	<u>A205210 002</u>	Feb 13, 2018
AB		<u>EQ 4MG BASE</u>	<u>A205210 003</u>	Feb 13, 2018
AB		<u>EQ 8MG BASE</u>	<u>A205210 004</u>	Feb 13, 2018
AB	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509 001</u>	Oct 19, 2000
AB		<u>EQ 2MG BASE</u>	<u>A075509 002</u>	Oct 19, 2000
AB		<u>EQ 4MG BASE</u>	<u>A075509 003</u>	Oct 19, 2000
AB		<u>EQ 8MG BASE</u>	<u>A075509 004</u>	Oct 19, 2000
AB	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750 001</u>	Jun 08, 2001
AB		<u>EQ 2MG BASE</u>	<u>A075750 002</u>	Jun 08, 2001
AB		<u>EQ 4MG BASE</u>	<u>A075750 003</u>	Jun 08, 2001
AB		<u>EQ 8MG BASE</u>	<u>A075750 004</u>	Jun 08, 2001
AB	TEVA	<u>EQ 1MG BASE</u>	<u>A075536 001</u>	Oct 18, 2000
AB		<u>EQ 2MG BASE</u>	<u>A075536 002</u>	Oct 18, 2000
AB		<u>EQ 4MG BASE</u>	<u>A075536 003</u>	Oct 18, 2000
AB		<u>EQ 8MG BASE</u>	<u>A075536 004</u>	Oct 18, 2000
AB	UPSHER SMITH LABS	<u>EQ 1MG BASE</u>	<u>A209013 001</u>	Apr 17, 2018
AB		<u>EQ 2MG BASE</u>	<u>A209013 002</u>	Apr 17, 2018
AB		<u>EQ 4MG BASE</u>	<u>A209013 003</u>	Apr 17, 2018
AB		<u>EQ 8MG BASE</u>	<u>A209013 004</u>	Apr 17, 2018
AB	ZYDUS PHARMS	<u>EQ 1MG BASE</u>	<u>A208719 001</u>	Jul 07, 2017
AB		<u>EQ 2MG BASE</u>	<u>A208719 002</u>	Jul 07, 2017
AB		<u>EQ 4MG BASE</u>	<u>A208719 003</u>	Jul 07, 2017
AB		<u>EQ 8MG BASE</u>	<u>A208719 004</u>	Jul 07, 2017

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+ PFIZER

+!

EQ 4MG BASE

EQ 8MG BASE

N021269 001 Feb 22, 2005

N021269 002 Feb 22, 2005

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A212624 001</u>	Sep 13, 2019
AB		<u>EQ 25MG BASE</u>	<u>A212624 002</u>	Sep 13, 2019
AB		<u>EQ 50MG BASE</u>	<u>A212624 003</u>	Sep 13, 2019
AB		<u>EQ 75MG BASE</u>	<u>A212624 004</u>	Sep 13, 2019
AB		<u>EQ 100MG BASE</u>	<u>A212624 005</u>	Sep 13, 2019
AB	AMNEAL PHARMS CO	<u>EQ 10MG BASE</u>	<u>A207482 001</u>	Jun 28, 2017
AB		<u>EQ 25MG BASE</u>	<u>A207482 002</u>	Jun 28, 2017
AB		<u>EQ 50MG BASE</u>	<u>A207482 003</u>	Jun 28, 2017
AB		<u>EQ 75MG BASE</u>	<u>A207482 004</u>	Jun 28, 2017
AB		<u>EQ 100MG BASE</u>	<u>A207482 005</u>	Jun 28, 2017
AB	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A211603 001</u>	Mar 27, 2019
AB		<u>EQ 25MG BASE</u>	<u>A211603 002</u>	Mar 27, 2019
AB		<u>EQ 50MG BASE</u>	<u>A211603 003</u>	Mar 27, 2019
AB		<u>EQ 75MG BASE</u>	<u>A211603 004</u>	Mar 27, 2019
AB		<u>EQ 100MG BASE</u>	<u>A211603 005</u>	Mar 27, 2019
AB	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
AB	!	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
AB		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
AB		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
AB	!	<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
AB	PAR PHARM	<u>EQ 10MG BASE</u>	<u>A071422 002</u>	Nov 09, 1987

PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071422 003</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A071422 004</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A071422 005</u>	Nov 09, 1987
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A071422 001</u>	Nov 09, 1987
!		EQ 150MG BASE	A071422 006	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	LANNETT CO INC	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>	! TEVA PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A071609 001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT BIO AG	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+! MYLAN

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013
	<u>SILENOR</u>			
<u>AB</u>	+ CURRAX	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+!	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	HIKMA	<u>0.5MCG</u>	<u>A091433 001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433 002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433 003</u>	Jan 14, 2014
<u>AB</u>	RISING	<u>0.5MCG</u>	<u>A201518 001</u>	Sep 09, 2016
<u>AB</u>		<u>1MCG</u>	<u>A201518 002</u>	Sep 09, 2016
<u>AB</u>		<u>2.5MCG</u>	<u>A201518 003</u>	Sep 09, 2016

HECTOROL

<u>AB</u>	+ SANOFI	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>	+	<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+!	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AKORN INC	<u>2MCG/ML (2MCG/ML)</u>	<u>A203929 002</u>	Mar 28, 2016
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203929 001</u>	May 07, 2015
<u>AP</u>	AMNEAL	<u>2MCG/ML (2MCG/ML)</u>	<u>A208974 001</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208974 002</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208975 001</u>	May 24, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210452 001</u>	Sep 26, 2019
<u>AP</u>	HIKMA PHARMS	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
<u>AP</u>	+ HOSPIRA INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>N208614 001</u>	Jul 24, 2018
<u>AP</u>	LUPIN LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210801 001</u>	Nov 01, 2018
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333 001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926 001</u>	Feb 04, 2014
<u>AP</u>	SUN PHARM	<u>2MCG/ML (2MCG/ML)</u>	<u>A203875 001</u>	Nov 14, 2019
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203875 002</u>	Nov 14, 2019

HECTOROL

<u>AP</u>	+ SANOFI	<u>2MCG/ML (2MCG/ML)</u>	<u>N021027 002</u>	Apr 06, 2000
<u>AP</u>	+!	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622 001</u>	Jun 27, 2014
<u>AP</u>		<u>200MG/100ML</u>	<u>A203622 002</u>	Jun 27, 2014
<u>AP</u>	AMNEAL	<u>20MG/VIAL</u>	<u>A208888 001</u>	Feb 17, 2017
<u>AP</u>		<u>50MG/VIAL</u>	<u>A208888 002</u>	Feb 17, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209825 001</u>	Aug 11, 2017
<u>AP</u>	MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>2MG/ML</u>	<u>N050629 001</u>	Dec 23, 1987
<u>AP</u>	+!	<u>200MG/100ML</u>	<u>N050629 002</u>	May 03, 1988

PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	!	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	!	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>		<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
	+ PHARMACIA AND UPJOHN	150MG/75ML	N050629 003	Mar 28, 2011

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	+ BAXTER HLTHCARE CORP	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995
<u>AB</u>	+	<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000
		<u>DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)</u>		
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG/10ML (2MG/ML)</u>	<u>A208657 001</u>	May 15, 2017
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A208657 002</u>	May 15, 2017
<u>AB</u>	!	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>	Feb 04, 2013
<u>AB</u>	!	<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	ACP NIMBLE	<u>EQ 50MG BASE</u>	<u>A204446 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204446 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204446 003</u>	May 28, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A209165 001</u>	Jul 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209165 002</u>	Jul 28, 2017
<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065 001</u>	Feb 17, 2011
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234 001</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234 002</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234 003</u>	Mar 05, 2014
<u>AB</u>	MAYNE PHARMA INC	<u>EQ 50MG BASE</u>	<u>A209396 001</u>	Sep 29, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A209396 002</u>	Sep 29, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209396 003</u>	Sep 29, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778 001</u>	Jun 08, 2012
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055 001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055 002</u>	Dec 01, 2000
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A065055 003</u>	Jul 15, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053 001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053 003</u>	Sep 10, 2003
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A065053 002</u>	Nov 22, 2000
<u>AB</u>	ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A205115 001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A205115 002</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A205115 003</u>	Feb 18, 2016
	ORACEA			
	+! GALDERMA LABS LP	40MG	N050805 001	May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+! PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>	
-----------	-----------	-------------------------	--------------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011
<u>AB</u>	LANNETT CO INC	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065356 004</u>	Jul 29, 2010

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A209582 001</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A209582 002</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209582 003</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209582 004</u>	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+! PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 50MG BASE</u>	<u>A210527 001</u>	Jun 13, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210527 002</u>	Jun 13, 2018
<u>AB</u>	AMNEAL PHARMS	<u>EQ 100MG BASE</u>	<u>A207289 001</u>	Jun 27, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>EQ 100MG BASE</u>	<u>A209402 001</u>	Oct 07, 2019
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 50MG BASE</u>	<u>A062676 002</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986
<u>AB</u>	ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A207774 001</u>	May 31, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207774 002</u>	May 31, 2018

VIBRAMYCINAB +! PFIZEREQ 100MG BASEN050007 002

INJECTABLE; INJECTION

DOXY 100AP ! FRESENIUS KABI USAEQ 100MG BASE/VIALA062475 001

Dec 09, 1983

DOXY 200AP ! FRESENIUS KABI USAEQ 200MG BASE/VIALA062475 002

Dec 09, 1983

DOXYCYCLINEAP MYLAN LABS LTDEQ 100MG BASE/VIALA091406 001

Aug 21, 2012

AP ! WEST-WARD PHARMS INTEQ 100MG BASE/VIALA062569 001

Mar 09, 1988

AP ZYDUS PHARMSEQ 100MG BASE/VIALA207757 001

Sep 28, 2017

APEQ 200MG BASE/VIALA207757 002

Sep 28, 2017

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+! TOLMAR

50MG

N050751 001

Sep 03, 1998

TABLET; ORAL

ACTICLATEAB + ALMIRALLEQ 75MG BASEN205931 001

Jul 25, 2014

AB +!EQ 150MG BASEN205931 002

Jul 25, 2014

DOXYCYCLINE HYCLATEAB ACTAVIS LABS FL INCEQ 100MG BASEA062421 001

Feb 02, 1983

AB AMNEAL PHARMS COEQ 75MG BASEA209372 001

Oct 06, 2017

ABEQ 150MG BASEA209372 002

Oct 06, 2017

AB APOTEXEQ 75MG BASEA209243 001

Apr 15, 2019

ABEQ 150MG BASEA209243 002

Apr 15, 2019

AB CADILAEQ 100MG BASEA207773 001

Oct 30, 2017

AB CARIBE HOLDINGSEQ 100MG BASEA062269 002

Nov 08, 1982

AB CHANGZHOU PHARMEQ 100MG BASEA211343 001

Oct 09, 2019

AB CHARTWELL LIFE SCIEQ 100MG BASEA062505 001

Sep 11, 1984

AB EMCURE PHARMS LTDEQ 100MG BASEA209969 001

Nov 09, 2018

AB EPIC PHARMA LLCEQ 20MG BASEA065182 001

May 13, 2005

AB HERITAGE PHARMAEQ 20MG BASEA065163 001

May 13, 2005

AB ! HIKMA INTL PHARMSEQ 100MG BASEA065095 001

Jul 02, 2003

AB ! LANNETT CO INCEQ 20MG BASEA065277 001

Nov 10, 2005

AB LARKEN LABSEQ 20MG BASEA065287 001

Feb 28, 2006

AB LUPIN LTDEQ 75MG BASEA208818 001

Sep 27, 2017

ABEQ 150MG BASEA208818 002

Sep 27, 2017

AB MAYNE PHARMA INCEQ 75MG BASEA208765 001

Jun 14, 2017

ABEQ 150MG BASEA208765 002

Jun 14, 2017

AB MYLANEQ 100MG BASEA062432 001

Feb 15, 1983

AB NOVEL LABS INCEQ 100MG BASEA207558 001

Sep 06, 2017

AB SUN PHARMEQ 20MG BASEA065134 001

May 13, 2005

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

INDUSTRIES

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062677 001</u>	Jul 10, 1986
	CARIBE HOLDINGS	EQ 50MG BASE	A062269 003	Oct 05, 1983

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>	+	MAYNE PHARMA	<u>EQ 50MG BASE</u>	<u>N050795 006</u>	Dec 19, 2014
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>N050795 005</u>	Apr 11, 2013

DOXYCYCLINE HYCLATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 50MG BASE</u>	<u>A090134 003</u>	May 22, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A090134 004</u>	May 22, 2018
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A200856 004</u>	Nov 13, 2018
<u>AB</u>		MYLAN	<u>EQ 50MG BASE</u>	<u>A090431 003</u>	May 23, 2016
<u>AB</u>		PRINSTON INC	<u>EQ 150MG BASE</u>	<u>A207494 001</u>	Nov 15, 2016
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A207494 002</u>	Nov 15, 2016

DORYX MPC
+! MAYNE PHARMA EQ 120MG BASE N050795 008 May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

<u>AB</u>	+	DUCHESNAY	<u>10MG;10MG</u>	<u>N021876 001</u>	Apr 08, 2013
-----------	---	-----------	------------------	--------------------	--------------

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>10MG;10MG</u>	<u>A205811 001</u>	Aug 19, 2016
<u>AB</u>		PAR PHARM INC	<u>10MG;10MG</u>	<u>A208518 001</u>	Dec 06, 2017

TABLET, EXTENDED RELEASE; ORAL
BONJESTA
+! DUCHESNAY 20MG;20MG N209661 001 Nov 07, 2016

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>		AKORN INC	<u>2.5MG</u>	<u>A079217 001</u>	Jun 20, 2014
<u>AB</u>			<u>5MG</u>	<u>A079217 002</u>	Jun 20, 2014
<u>AB</u>			<u>10MG</u>	<u>A079217 003</u>	Jun 20, 2014
<u>AB</u>		LANNETT CO INC	<u>2.5MG</u>	<u>A201463 001</u>	May 18, 2018
<u>AB</u>			<u>5MG</u>	<u>A201463 002</u>	May 18, 2018
<u>AB</u>			<u>10MG</u>	<u>A201463 003</u>	May 18, 2018
<u>AB</u>		SVC PHARMA	<u>2.5MG</u>	<u>A078292 001</u>	Jun 27, 2008
<u>AB</u>			<u>5MG</u>	<u>A078292 002</u>	Jun 27, 2008
<u>AB</u>			<u>10MG</u>	<u>A078292 003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	+	ABBVIE	<u>2.5MG</u>	<u>N018651 001</u>	May 31, 1985
<u>AB</u>	+		<u>5MG</u>	<u>N018651 002</u>	May 31, 1985
<u>AB</u>	+		<u>10MG</u>	<u>N018651 003</u>	May 31, 1985

SOLUTION; ORAL

SYNDROS

	+	INSYS DEV CO INC	5MG/ML	N205525 001	Mar 23, 2017
--	---	------------------	--------	-------------	--------------

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

	+	SANOFI AVENTIS US	EQ 400MG BASE	N022425 001	Jul 01, 2009
--	---	-------------------	---------------	-------------	--------------

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>		EUROHLTH INTL SARL	<u>2.5MG/ML</u>	<u>A208197 001</u>	Dec 14, 2017
<u>AP</u>		HOSPIRA	<u>2.5MG/ML</u>	<u>A071981 001</u>	Feb 29, 1988
<u>AP</u>		LUITPOLD	<u>2.5MG/ML</u>	<u>A072123 001</u>	Oct 24, 1988

INAPSINE

<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796 001</u>	
-----------	---	-----------	-----------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

DROSPIRENONE

TABLET;ORAL

SLYND

+! EXELTIS USA INC 4MG

N211367 001 May 23, 2019

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

+ BAYER HLTHCARE 0.25MG;0.5MG

N021355 001 Feb 29, 2012

+! 0.5MG;1MG

N021355 002 Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL**AB** ANDA REPOSITORY 3MG;0.02MG**A203291 001** Jul 18, 2017**AB** BARR 3MG;0.02MG**A078515 001** Mar 30, 2009**AB** GLENMARK PHARMS LTD 3MG;0.02MG**A204296 001** Aug 17, 2015**AB** HETERO LABS LTD 3MG;0.02MG**A211944 001** Mar 22, 2019**AB** JUBILANT CADISTA 3MG;0.02MG**A209423 001** Dec 22, 2017**AB** MYLAN LABS LTD 3MG;0.02MG**A202594 001** Oct 22, 2015**AB** WATSON LABS 3MG;0.02MG**A078833 001** Nov 28, 2011KYRA**AB** SUN PHARM 3MG;0.02MG**A202318 001** Jul 23, 2019LO-ZUMANDIMINE**AB** AUROBINDO PHARMA LTD 3MG;0.02MG**A209632 001** Feb 27, 2018LORYNA**AB** XIROMED 3MG;0.02MG**A079221 001** Mar 28, 2011MELAMISA**AB** NOVAST LABS 3MG;0.02MG**A202016 001** Jan 26, 2016NIKKI**AB** LUPIN LTD 3MG;0.02MG**A201661 001** May 27, 2014YAZ**AB** +! BAYER HLTHCARE 3MG;0.02MG**N021676 001** Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL**AB** ACCORD HLTHCARE 3MG;0.03MG**A207245 001** Nov 22, 2016**AB** APOTEX 3MG;0.03MG**A205876 001** Sep 21, 2016**AB** BARR 3MG;0.03MG**A077527 001** May 09, 2008**AB** GLENMARK PHARMS LTD 3MG;0.03MG**A204848 001** Mar 25, 2016**AB** JUBILANT CADISTA 3MG;0.03MG**A210017 001** Sep 10, 2018**AB** LUPIN LTD 3MG;0.03MG**A201663 001** Dec 18, 2012**AB** MAYNE PHARMA 3MG;0.03MG**A090081 001** Sep 07, 2010**AB** MYLAN LABS LTD 3MG;0.03MG**A202131 001** May 04, 2015KEMEYA**AB** SUN PHARM 3MG;0.03MG**A202138 001** Mar 13, 2019SYEDA**AB** XIROMED 3MG;0.03MG**A090114 001** Mar 28, 2011YAELA**AB** NOVAST LABS 3MG;0.03MG**A202015 001** Nov 19, 2014YASMIN**AB** +! BAYER HLTHCARE 3MG;0.03MG**N021098 001** May 11, 2001ZUMANDIMINE**AB** AUROBINDO PHARMA LTD 3MG;0.03MG**A209407 001** Mar 26, 2018DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ**AB** BAYER HLTHCARE 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**N022532 001** Sep 24, 2010DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM**AB** LUPIN LTD 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**A205947 001** Jun 13, 2018**AB** WATSON LABS INC 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**A203593 001** Oct 11, 2016**AB** 3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**A203594 001** Oct 11, 2016SAFYRAL**AB** +! BAYER HLTHCARE 3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**N022574 001** Dec 16, 2010TYDEMY**AB** LUPIN LTD 3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**A205948 001** Dec 12, 2017

PRESCRIPTION DRUG PRODUCT LIST

DROXIDOPA

CAPSULE;ORAL

NORTHERA

+	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014
+		200MG	N203202	002	Feb 18, 2014
+		300MG	N203202	003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

<u>AB</u>	+	LILLY	<u>EQ 20MG BASE</u>	<u>N021427</u>	<u>001</u>	Aug 03, 2004
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N021427</u>	<u>002</u>	Aug 03, 2004
<u>AB</u>	+		<u>EQ 60MG BASE</u>	<u>N021427</u>	<u>004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776</u>	<u>001</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090776</u>	<u>002</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090776</u>	<u>003</u>	Dec 17, 2013
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A208706</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A208706</u>	<u>002</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A208706</u>	<u>004</u>	Mar 11, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A208706</u>	<u>003</u>	Jan 06, 2017
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A202949</u>	<u>001</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202949</u>	<u>002</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202949</u>	<u>003</u>	Jun 09, 2014
<u>AB</u>		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197</u>	<u>001</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203197</u>	<u>002</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203197</u>	<u>003</u>	Aug 26, 2015
<u>AB</u>		ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090780</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090780</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>		APOTEX	<u>EQ 20MG BASE</u>	<u>A202045</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202045</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202045</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090778</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090778</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>		BRECKENRIDGE	<u>EQ 20MG BASE</u>	<u>A203088</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203088</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A203088</u>	<u>004</u>	May 18, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203088</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>		CSPC OUYI	<u>EQ 20MG BASE</u>	<u>A211310</u>	<u>001</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A211310</u>	<u>002</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A211310</u>	<u>003</u>	Oct 16, 2018
<u>AB</u>		HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A204343</u>	<u>001</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204343</u>	<u>002</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204343</u>	<u>003</u>	Aug 03, 2016
<u>AB</u>		INVENTIA	<u>EQ 20MG BASE</u>	<u>A202336</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202336</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202336</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>		LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090694</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090694</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090694</u>	<u>004</u>	Dec 11, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204815</u>	<u>001</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204815</u>	<u>002</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204815</u>	<u>003</u>	Mar 23, 2017
<u>AB</u>		MARKSANS PHARMA	<u>EQ 20MG BASE</u>	<u>A090723</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090723</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090723</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>		PRINSTON INC	<u>EQ 20MG BASE</u>	<u>A206653</u>	<u>001</u>	May 18, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A206653</u>	<u>002</u>	May 18, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A206653</u>	<u>003</u>	May 18, 2017
<u>AB</u>		QINGDAO BAHEAL PHARM	<u>EQ 20MG BASE</u>	<u>A210599</u>	<u>001</u>	Apr 17, 2019
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A210599</u>	<u>002</u>	Apr 17, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A210599</u>	<u>003</u>	Apr 17, 2019
<u>AB</u>		SUN PHARM	<u>EQ 20MG BASE</u>	<u>A090745</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090745</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090745</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>		TORRENT	<u>EQ 20MG BASE</u>	<u>A090774</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090774</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090774</u>	<u>003</u>	Dec 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219 001	Aug 16, 2019
AB		EQ 30MG BASE	A207219 002	Aug 16, 2019
AB		EQ 60MG BASE	A207219 003	Aug 16, 2019
AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739 001	Jan 08, 2014
AB		EQ 30MG BASE	A090739 002	Jan 08, 2014
AB		EQ 60MG BASE	A090739 003	Jan 08, 2014
AB	ZYDUS PHARMS	EQ 20MG BASE	A090728 001	Jan 08, 2014
AB		EQ 30MG BASE	A090728 002	Jan 08, 2014
AB		EQ 60MG BASE	A090728 003	Jan 08, 2014

CAPSULE, DELAYED RELEASE;ORAL

DRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516 001	Jul 19, 2019
+		EQ 30MG BASE	N212516 002	Jul 19, 2019
+		EQ 40MG BASE	N212516 003	Jul 19, 2019
+	!	EQ 60MG BASE	N212516 004	Jul 19, 2019

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	+	GLAXOSMITHKLINE	0.5MG	N021319 001	Nov 20, 2001
-----------	---	-----------------	--------------	--------------------	--------------

DUTASTERIDE

AB		ACTAVIS LABS FL INC	0.5MG	A202808 001	Nov 20, 2015
AB		AMNEAL PHARMS	0.5MG	A203118 001	Nov 20, 2015
AB		APOTEX INC	0.5MG	A204292 001	Nov 24, 2015
AB		ASCENT PHARMS INC	0.5MG	A206574 001	Oct 21, 2016
AB		AUROLIFE PHARMA LLC	0.5MG	A202660 001	Nov 20, 2015
AB		BARR	0.5MG	A090095 001	Dec 21, 2010
AB		BIONPHARMA INC	0.5MG	A200899 001	Nov 20, 2015
AB		CADILA	0.5MG	A204373 001	Oct 04, 2017
AB		HERITAGE PHARMS INC	0.5MG	A207935 001	Oct 13, 2017
AB		HIKMA	0.5MG	A202204 001	Nov 23, 2015
AB		HUMANWELL PURACAP	0.5MG	A209909 001	Nov 21, 2017
AB		INTERGEL PHARMS INC	0.5MG	A206373 001	Mar 17, 2016
AB		MARKSANS PHARMA	0.5MG	A204376 001	Apr 07, 2017
AB		STRIDES PHARMA	0.5MG	A204262 001	Nov 20, 2015
AB		VINTAGE PHARMS LLC	0.5MG	A202421 001	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	0.5MG; 0.4MG	A202975 001	Nov 20, 2015
AB		ANCHEN PHARMS	0.5MG; 0.4MG	A202509 001	Feb 26, 2014
AB		ZYDUS PHARMS	0.5MG; 0.4MG	A207769 001	May 24, 2018
AB	+	GLAXOSMITHKLINE	0.5MG; 0.4MG	N022460 001	Jun 14, 2010

DUVELISIB

CAPSULE;ORAL

COPIKTRA

+	VERASTEM INC	15MG	N211155 001	Sep 24, 2018
+	!	25MG	N211155 002	Sep 24, 2018

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLOPRO

!	NOVOCOL INC	0.5%	A200480 001	Nov 20, 2018
!		1%	A200480 002	Nov 20, 2018

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

+	WYETH PHARMS	0.125%	N011963 001	
---	--------------	--------	-------------	--

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+	GLENMARK	1%	N205175 001	Oct 24, 2013
---	----------	----	-------------	--------------

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		MYLAN	1%	A210364 001	Apr 18, 2018
AB	!	PERRIGO ISRAEL	1%	A076479 001	Jun 23, 2004
AB		TARO	1%	A076005 001	Nov 26, 2002

PRESCRIPTION DRUG PRODUCT LIST

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE**AB** TELIGENT PHARMA INC **1%** **A076574 001** Dec 17, 2004SPECTAZOLE**AB** + ALVOGEN **1%** **N018751 001** Dec 23, 1982EDARAVONE

SOLUTION; INTRAVENOUS

RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML) N209176 001 May 05, 2017

+! 60MG/100ML (0.6MG/ML) N209176 002 Nov 15, 2018

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+! MEDICIS 200MG/ML N008922 001

EDOXYBAN TOSYLATE

TABLET; ORAL

SAVAYSA

+ DAIICHI SANKYO INC EQ 15MG BASE N206316 001 Jan 08, 2015

+ EQ 30MG BASE N206316 002 Jan 08, 2015

+! EQ 60MG BASE N206316 003 Jan 08, 2015

EFAVIRENZ

CAPSULE; ORAL

EFAVIRENZ**AB** AUROBINDO PHARMA LTD **50MG** **A078064 001** Dec 15, 2017**AB** **200MG** **A078064 003** Dec 15, 2017SUSTIVA**AB** + BRISTOL MYERS SQUIBB **50MG** **N020972 001** Sep 17, 1998**AB** +! **200MG** **N020972 003** Sep 17, 1998

EFAVIRENZ

AUROBINDO PHARMA LTD 100MG A078064 002 Dec 15, 2017

LTD

TABLET; ORAL

EFAVIRENZ**AB** AUROBINDO PHARMA LTD **600MG** **A077673 001** Sep 21, 2018**AB** **600MG** **A205322 001** Aug 30, 2018**AB** CIPLA **600MG** **A204766 001** Jun 15, 2018**AB** HETERO LABS LTD III **600MG** **A078886 001** Apr 27, 2018**AB** MYLAN **600MG** **A091471 001** Feb 17, 2016**AB** STRIDES PHARMA **600MG** **A204869 001** Mar 12, 2018SUSTIVA**AB** +! BRISTOL MYERS SQUIBB **600MG** **N021360 002** Feb 01, 2002EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA**AB** +! GILEAD SCIENCES **600MG; 200MG; 300MG** **N021937 001** Jul 12, 2006EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE**AB** AUROBINDO PHARMA LTD **600MG; 200MG; 300MG** **A203041 001** Sep 04, 2018**AB** CIPLA **600MG; 200MG; 300MG** **A206894 001** Jun 03, 2019EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

SYMFI

+! MYLAN LABS LTD 600MG; 300MG; 300MG N022142 001 Mar 22, 2018

SYMFI LO

+! MYLAN 400MG; 300MG; 300MG N208255 001 Feb 05, 2018

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+! BAUSCH 10% N203567 001 Jun 06, 2014

PRESCRIPTION DRUG PRODUCT LIST

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+! SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

ELAGOLIX SODIUM

TABLET; ORAL

ORILISSA

+ ABEVIE INC

EQ 150MG BASE

N210450 001 Jul 23, 2018

+!

EQ 200MG BASE

N210450 002 Jul 23, 2018

ELBASVIR; GRAZOPREVRIL

TABLET; ORAL

ZEPATIER

+! MERCK SHARP DOHME

50MG; 100MG

N208261 001 Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE**AB** AJANTA PHARMA LTD**EQ 20MG BASE****A205186 001** Aug 29, 2017**AB****EQ 40MG BASE****A205186 002** Aug 29, 2017**AB** AMNEAL PHARMS CO**EQ 20MG BASE****A206787 001** May 25, 2018**AB****EQ 40MG BASE****A206787 002** May 25, 2018**AB** AUROBINDO PHARMA**EQ 20MG BASE****A210708 001** Jan 15, 2019

LTD

AB**EQ 40MG BASE****A210708 002** Jan 15, 2019**AB** MYLAN**EQ 20MG BASE****A205152 001** Aug 11, 2017**AB****EQ 40MG BASE****A205152 002** Aug 11, 2017**AB** TEVA PHARMS USA**EQ 20MG BASE****A202040 001** Jun 27, 2017**AB****EQ 40MG BASE****A202040 002** Jun 27, 2017**AB** ZYDUS PHARMS**EQ 20MG BASE****A206409 001** Jun 16, 2017**AB****EQ 40MG BASE****A206409 002** Jun 16, 2017RELPAK**AB** + PFIZER IRELAND**EQ 20MG BASE****N021016 001** Dec 26, 2002**AB** +!**EQ 40MG BASE****N021016 002** Dec 26, 2002ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET, TABLET; ORAL

TRIKAFTA (COPACKAGED)

+! VERTEX PHARMS INC

100MG, 75MG, 50MG; N/A, 150MG, N/A

N212273 001 Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+! GENZYME CORP

EQ 84MG BASE

N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA KIT

+ NOVARTIS

EQ 12.5MG ACID/PACKET

N207027 002 Sep 27, 2018

+!

EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015

TABLET; ORAL

PROMACTA

+ NOVARTIS

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

+

EQ 25MG ACID

N022291 001 Nov 20, 2008

+

EQ 50MG ACID

N022291 002 Nov 20, 2008

+!

EQ 75MG ACID

N022291 003 Sep 08, 2009

ELUXADOLINE

TABLET; ORAL

VIBERZI

+ ALLERGAN HOLDINGS

75MG

N206940 001 May 27, 2015

+!

100MG

N206940 002 May 27, 2015

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

+ BOEHRINGER

10MG

N204629 001 Aug 01, 2014

INGELHEIM

+!

25MG

N204629 002 Aug 01, 2014

PRESCRIPTION DRUG PRODUCT LIST

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

+	BOEHRINGER INGELHEIM	10MG; 5MG	N206073 001	Jan 30, 2015
+	!	25MG; 5MG	N206073 002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

+	BOEHRINGER INGELHEIM	5MG; 500MG	N206111 001	Aug 26, 2015
+		5MG; 1GM	N206111 002	Aug 26, 2015
+		12.5MG; 500MG	N206111 003	Aug 26, 2015
+	!	12.5MG; 1GM	N206111 004	Aug 26, 2015

TABLET, EXTENDED RELEASE; ORAL

SYNJARDY XR

+	BOEHRINGER INGELHEIM	5MG; 1GM	N208658 001	Dec 09, 2016
+		10MG; 1GM	N208658 002	Dec 09, 2016
+		12.5MG; 1GM	N208658 003	Dec 09, 2016
+	!	25MG; 1GM	N208658 004	Dec 09, 2016

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB	CIPLA	200MG	A091168 001	Jul 02, 2018
-----------	-------	--------------	--------------------	--------------

EMTRIVA

AB	+	GILEAD	200MG	N021500 001	Jul 02, 2003
-----------	---	--------	--------------	--------------------	--------------

SOLUTION; ORAL

EMTRIVA

+	!	GILEAD	10MG/ML	N021896 001	Sep 28, 2005
---	---	--------	---------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351 001	Mar 01, 2016
---	---	---------------------	-----------------------------------	-------------	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; 300MG	N202123 001	Aug 10, 2011
---	---	---------------------	----------------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE	N208215 001	Apr 04, 2016
---	---	---------------------	---------------------	-------------	--------------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	200MG; 300MG	A090513 001	Jan 26, 2018
-----------	-------------------------	---------------------	--------------------	--------------

AB	MYLAN	200MG; 300MG	A206436 001	Apr 09, 2018
-----------	-------	---------------------	--------------------	--------------

AB	TEVA PHARMS USA	200MG; 300MG	A090894 001	Jun 08, 2017
-----------	-----------------	---------------------	--------------------	--------------

TRUVADA

AB	+	!	GILEAD	200MG; 300MG	N021752 001	Aug 02, 2004
-----------	---	---	--------	---------------------	--------------------	--------------

+				100MG; 150MG	N021752 002	Mar 10, 2016
---	--	--	--	--------------	-------------	--------------

+				133MG; 200MG	N021752 003	Mar 10, 2016
---	--	--	--	--------------	-------------	--------------

+				167MG; 250MG	N021752 004	Mar 10, 2016
---	--	--	--	--------------	-------------	--------------

ENALAPRIL MALEATE

SOLUTION; ORAL

EPANED

+	!	SILVERGATE PHARMS	1MG/ML	N208686 001	Sep 20, 2016
---	---	-------------------	--------	-------------	--------------

TABLET; ORAL

ENALAPRIL MALEATE

AB	HERITAGE PHARMA	2.5MG	A075479 001	Aug 22, 2000
-----------	-----------------	--------------	--------------------	--------------

AB		5MG	A075479 002	Aug 22, 2000
-----------	--	------------	--------------------	--------------

AB		10MG	A075479 003	Aug 22, 2000
-----------	--	-------------	--------------------	--------------

AB		20MG	A075479 004	Aug 22, 2000
-----------	--	-------------	--------------------	--------------

AB	NOSTRUM LABS INC	2.5MG	A075178 002	Mar 23, 2001
-----------	------------------	--------------	--------------------	--------------

AB		5MG	A075178 001	Mar 23, 2001
-----------	--	------------	--------------------	--------------

AB		10MG	A075178 003	Mar 23, 2001
-----------	--	-------------	--------------------	--------------

AB		20MG	A075178 004	Mar 23, 2001
-----------	--	-------------	--------------------	--------------

AB	SANDOZ INC	2.5MG	A075496 001	Aug 22, 2000
-----------	------------	--------------	--------------------	--------------

AB		5MG	A075496 002	Aug 22, 2000
-----------	--	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>		<u>10MG</u>	<u>A075459 001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459 002</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657 001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657 002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657 003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657 004</u>	Jan 23, 2001
<u>AB</u>	WOCKHARDT LTD	<u>2.5MG</u>	<u>A075483 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483 004</u>	Aug 22, 2000
<u>VASOTEC</u>				
<u>AB</u>	+ BAUSCH	<u>2.5MG</u>	<u>N018998 005</u>	Jul 26, 1988
<u>AB</u>	+	<u>5MG</u>	<u>N018998 001</u>	Dec 24, 1985
<u>AB</u>	+	<u>10MG</u>	<u>N018998 002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998 003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACP NIMBLE	<u>5MG;12.5MG</u>	<u>A075727 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727 002</u>	Sep 18, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909 001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909 002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624 002</u>	Sep 18, 2001
<u>AB</u>	NOSTRUM LABS INC	<u>5MG;12.5MG</u>	<u>A076486 001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486 002</u>	Oct 27, 2004
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788 002</u>	Sep 18, 2001
<u>VASERETIC</u>				
<u>AB</u>	+ BAUSCH	<u>5MG;12.5MG</u>	<u>N019221 003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221 001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	! ATHENEX INC	<u>1.25MG/ML</u>	<u>A075634 001</u>	Aug 22, 2000
<u>AP</u>	DR REDDYS	<u>1.25MG/ML</u>	<u>A075578 001</u>	Aug 22, 2000
<u>AP</u>	HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687 001</u>	Dec 23, 2008
<u>AP</u>	! HOSPIRA	<u>1.25MG/ML</u>	<u>A075458 001</u>	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET; ORAL

IDHIFA

+	CELGENE CORP	EQ 50MG BASE	N209606 001	Aug 01, 2017
+	!	EQ 100MG BASE	N209606 002	Aug 01, 2017

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+	ARRAY BIOPHARMA INC	75MG	N210496 002	Jun 27, 2018
---	---------------------	------	-------------	--------------

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+	ROCHE	90MG/VIAL	N021481 001	Mar 13, 2003
---	-------	-----------	-------------	--------------

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	AMPHASTAR PHARMS INC	<u>300MG/3ML (100MG/ML)</u>	<u>A208600 001</u>	Mar 14, 2019
<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660 001</u>	Nov 28, 2011
<u>LOVENOX</u>				
<u>AB</u>	+ SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164 009</u>	Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684 001</u>	Sep 19, 2011
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684 002</u>	Sep 19, 2011
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684 003</u>	Sep 19, 2011
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684 004</u>	Sep 19, 2011
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076684 005</u>	Sep 19, 2011
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684 006</u>	Sep 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076684</u>	<u>007</u>	Sep 19, 2011
<u>AP</u>	APOTEX INC	<u>30MG/0.3ML (100MG/ML)</u>	<u>A078990</u>	<u>001</u>	Sep 28, 2018
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A078990</u>	<u>002</u>	Sep 28, 2018
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A078990</u>	<u>003</u>	Sep 28, 2018
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A078990</u>	<u>004</u>	Sep 28, 2018
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A078990</u>	<u>005</u>	Sep 28, 2018
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A078990</u>	<u>006</u>	Sep 28, 2018
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A078990</u>	<u>007</u>	Sep 28, 2018
<u>AP</u>	NANJING KING-FRIEND	<u>30MG/0.3ML (100MG/ML)</u>	<u>A206834</u>	<u>001</u>	Nov 29, 2019
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A206834</u>	<u>002</u>	Nov 29, 2019
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A206834</u>	<u>003</u>	Nov 29, 2019
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A206834</u>	<u>004</u>	Nov 29, 2019
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A206834</u>	<u>005</u>	Nov 29, 2019
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A206834</u>	<u>006</u>	Nov 29, 2019
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A206834</u>	<u>007</u>	Nov 29, 2019
<u>AP</u>	SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857</u>	<u>002</u>	Jul 23, 2010
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857</u>	<u>003</u>	Jul 23, 2010
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857</u>	<u>004</u>	Jul 23, 2010
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857</u>	<u>005</u>	Jul 23, 2010
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A077857</u>	<u>001</u>	Jul 23, 2010
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857</u>	<u>006</u>	Jul 23, 2010
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A077857</u>	<u>007</u>	Jul 23, 2010
<u>AP</u>	TEVA	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076726</u>	<u>001</u>	Jun 23, 2014
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076726</u>	<u>002</u>	Jun 23, 2014
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076726</u>	<u>003</u>	Jun 23, 2014
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076726</u>	<u>004</u>	Jun 23, 2014
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076726</u>	<u>005</u>	Jun 23, 2014
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076726</u>	<u>006</u>	Jun 23, 2014
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076726</u>	<u>007</u>	Jun 23, 2014
		<u>LOVENOX (PRESERVATIVE FREE)</u>			
<u>AP</u>	+	SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164</u>	<u>001</u> Mar 29, 1993
<u>AP</u>	+		<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164</u>	<u>002</u> Jan 30, 1998
<u>AP</u>	+		<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164</u>	<u>003</u> Mar 27, 1998
<u>AP</u>	+		<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164</u>	<u>004</u> Mar 27, 1998
<u>AP</u>	+		<u>100MG/ML (100MG/ML)</u>	<u>N020164</u>	<u>005</u> Mar 27, 1998
<u>AP</u>	+		<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164</u>	<u>007</u> Jun 02, 2000
<u>AP</u>	+		<u>150MG/ML (150MG/ML)</u>	<u>N020164</u>	<u>008</u> Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+	ORION PHARMA	<u>200MG</u>	<u>N020796</u>	<u>001</u> Oct 19, 1999
		<u>ENTACAPONE</u>			
<u>AB</u>		AJANTA PHARMA LTD	<u>200MG</u>	<u>A205792</u>	<u>001</u> Aug 31, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>200MG</u>	<u>A203437</u>	<u>001</u> Jun 19, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>200MG</u>	<u>A207210</u>	<u>001</u> Jun 05, 2017
<u>AB</u>		SUN PHARM	<u>200MG</u>	<u>A090690</u>	<u>001</u> Jul 16, 2012
<u>AB</u>		SUNSHINE LAKE	<u>200MG</u>	<u>A206669</u>	<u>001</u> Oct 03, 2018
<u>AB</u>		WOCKHARDT LTD	<u>200MG</u>	<u>A078941</u>	<u>001</u> Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUE

	+	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001 Mar 29, 2005
--	---	----------------------	-----------	---------	------------------

TABLET; ORAL

BARACLUE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>N021797</u>	<u>001</u> Mar 29, 2005
<u>AB</u>	+		<u>1MG</u>	<u>N021797</u>	<u>002</u> Mar 29, 2005
		<u>ENTECAVIR</u>			
<u>AB</u>		ACCORD HLTHCARE	<u>0.5MG</u>	<u>A205824</u>	<u>001</u> Aug 25, 2017
<u>AB</u>			<u>1MG</u>	<u>A205824</u>	<u>002</u> Aug 25, 2017
<u>AB</u>		AMNEAL PHARMS	<u>0.5MG</u>	<u>A206652</u>	<u>001</u> Nov 12, 2015
<u>AB</u>			<u>1MG</u>	<u>A206652</u>	<u>002</u> Nov 12, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A206217</u>	<u>001</u> Aug 26, 2015
<u>AB</u>			<u>1MG</u>	<u>A206217</u>	<u>002</u> Aug 26, 2015
<u>AB</u>		BRECKENRIDGE	<u>0.5MG</u>	<u>A208721</u>	<u>001</u> Mar 15, 2018
<u>AB</u>			<u>1MG</u>	<u>A208721</u>	<u>002</u> Mar 15, 2018

PRESCRIPTION DRUG PRODUCT LIST

ENTECAVIR

TABLET; ORAL

ENTECAVIR

<u>AB</u>	BRIGHTGENE	<u>0.5MG</u>	<u>A212126 001</u>	Sep 25, 2019
<u>AB</u>		<u>1MG</u>	<u>A212126 002</u>	Sep 25, 2019
<u>AB</u>	CASI PHARMS INC	<u>0.5MG</u>	<u>A206672 001</u>	May 11, 2017
<u>AB</u>		<u>1MG</u>	<u>A206672 002</u>	May 11, 2017
<u>AB</u>	CIPLA	<u>0.5MG</u>	<u>A206872 001</u>	Dec 06, 2016
<u>AB</u>		<u>1MG</u>	<u>A206872 002</u>	Dec 06, 2016
<u>AB</u>	HETERO LABS LTD V	<u>0.5MG</u>	<u>A205740 001</u>	Aug 21, 2015
<u>AB</u>		<u>1MG</u>	<u>A205740 002</u>	Aug 21, 2015
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A206226 001</u>	Mar 26, 2019
<u>AB</u>		<u>1MG</u>	<u>A206226 002</u>	Mar 26, 2019
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A208782 001</u>	Oct 10, 2017
<u>AB</u>		<u>1MG</u>	<u>A208782 002</u>	Oct 10, 2017
<u>AB</u>	TEVA PHARMS USA	<u>0.5MG</u>	<u>A202122 001</u>	Aug 26, 2014
<u>AB</u>		<u>1MG</u>	<u>A202122 002</u>	Aug 26, 2014
<u>AB</u>	YAOPHARMA CO LTD	<u>0.5MG</u>	<u>A212201 001</u>	Nov 04, 2019
<u>AB</u>		<u>1MG</u>	<u>A212201 002</u>	Nov 04, 2019
<u>AB</u>	ZYDUS PHARMS	<u>0.5MG</u>	<u>A206745 001</u>	Jun 23, 2017
<u>AB</u>		<u>1MG</u>	<u>A206745 002</u>	Jun 23, 2017

ENTRECTINIB

CAPSULE; ORAL

ROZLYTREK

	+ GENENTECH INC	100MG	N212725 001	Aug 15, 2019
	+!	200MG	N212725 002	Aug 15, 2019

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

	+! ASTELLAS	40MG	N203415 001	Aug 31, 2012
--	-------------	------	-------------	--------------

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOAZ

<u>AP</u>	+! AVADEL LEGACY	<u>50MG/ML (50MG/ML)</u>	<u>N208289 001</u>	Apr 29, 2016
	<u>CORPHEDRA</u>			
<u>AP</u>	PAR STERILE PRODUCTS	<u>50MG/ML (50MG/ML)</u>	<u>N208943 001</u>	Jan 27, 2017
	<u>EPHEDRINE SULFATE</u>			
<u>AP</u>	AKORN INC	<u>50MG/ML (50MG/ML)</u>	<u>N208609 001</u>	Mar 01, 2017
<u>AP</u>	AMNEAL	<u>50MG/ML (50MG/ML)</u>	<u>A212932 001</u>	Oct 23, 2019
<u>AP</u>	SANDOZ INC	<u>50MG/ML (50MG/ML)</u>	<u>A209784 001</u>	Aug 23, 2017

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

<u>AT</u>	+! ALLERGAN	<u>0.05%</u>	<u>N021565 001</u>	Oct 16, 2003
	<u>EPINASTINE HYDROCHLORIDE</u>			
<u>AT</u>	AKORN	<u>0.05%</u>	<u>A204055 001</u>	May 05, 2017
<u>AT</u>	APOTEX	<u>0.05%</u>	<u>A090919 001</u>	Oct 31, 2011
<u>AT</u>	BRECKENRIDGE	<u>0.05%</u>	<u>A090870 001</u>	Mar 14, 2011
<u>AT</u>	SOMERSET THERAPS LLC	<u>0.05%</u>	<u>A090951 001</u>	Oct 31, 2011

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

<u>AB</u>	TEVA PHARMS USA	<u>0.15MG/DELIVERY</u>	<u>A090589 002</u>	Aug 16, 2018
<u>AB</u>		<u>0.3MG/DELIVERY</u>	<u>A090589 001</u>	Aug 16, 2018
	<u>EPIPEN</u>			
<u>AB</u>	+! MYLAN SPECIALITY LP	<u>0.3MG/DELIVERY</u>	<u>N019430 001</u>	Dec 22, 1987
	<u>EPIPEN JR.</u>			
<u>AB</u>	+! MYLAN SPECIALITY LP	<u>0.15MG/DELIVERY</u>	<u>N019430 002</u>	Dec 22, 1987
	ADRENACLICK			
BX	+! IMPAX	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009
BX	+!	EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS			
	ADRENALIN			
	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200 001	Dec 07, 2012
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640 001	Dec 18, 2013

PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX	+	KALEO INC	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012
	+		EQ 0.1MG/DELIVERY	N201739 003	Nov 17, 2017

SYMJEPI

	+	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534 002	Sep 27, 2018
	+		0.3MG/0.3ML (0.3MG/0.3ML)	N207534 001	Jun 15, 2017

SOLUTION; INTRAVENOUS

EPINEPHRINE (COPACKAGED)

	+	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359 001	Nov 05, 2019
--	---	-------------	---------------------	-------------	--------------

SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029 001	Jul 29, 2014
--	---	--------------------	---------------------------------	-------------	--------------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

!	DEPROCO	EQ 0.02MG BASE/ML; 2%	A088389 001	Jan 22, 1985
---	---------	-----------------------	-------------	--------------

LIGNOSPAN STANDARD

!	DEPROCO	EQ 0.01MG BASE/ML; 2%	A088390 001	Jan 22, 1985
---	---------	-----------------------	-------------	--------------

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

<u>AP</u>	<u>+</u> !	<u>DENTSPLY PHARM</u>	<u>0.005MG/ML; 4%</u>	<u>N021383 001</u>	
-----------	------------	-----------------------	-----------------------	--------------------	--

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

<u>AP</u>		<u>SEPTODONT INC</u>	<u>0.005MG/ML; 4%</u>	<u>A078959 001</u>	Aug 30, 2011
-----------	--	----------------------	-----------------------	--------------------	--------------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>		<u>HOSPIRA</u>	<u>0.005MG/ML; 0.5%</u>	<u>A089635 001</u>	Jun 21, 1988
<u>AP</u>			<u>0.005MG/ML; 1.5%</u>	<u>A088571 001</u>	Sep 13, 1985
<u>AP</u>			<u>0.005MG/ML; 1.5%</u>	<u>A089645 001</u>	Jun 21, 1988
<u>AP</u>			<u>0.005MG/ML; 2%</u>	<u>A089651 001</u>	Jun 21, 1988
<u>AP</u>			<u>0.01MG/ML; 1%</u>	<u>A089644 001</u>	Jun 21, 1988
<u>AP</u>	!		<u>0.01MG/ML; 2%</u>	<u>A089646 001</u>	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

<u>AP</u>	<u>+</u> !	<u>FRESENIUS KABI USA</u>	<u>0.005MG/ML; 0.5%</u>	<u>N006488 012</u>	
<u>AP</u>	<u>+</u> !		<u>0.005MG/ML; 1.5%</u>	<u>N006488 017</u>	
<u>AP</u>	<u>+</u> !		<u>0.005MG/ML; 2%</u>	<u>N006488 019</u>	Nov 13, 1986
<u>AP</u>	<u>+</u> !		<u>0.01MG/ML; 1%</u>	<u>N006488 004</u>	
<u>AP</u>	<u>+</u> !		<u>0.02MG/ML; 2%</u>	<u>N006488 005</u>	
	<u>+</u> !		<u>0.005MG/ML; 1%</u>	<u>N006488 018</u>	Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

<u>AP</u>	<u>+</u> !	<u>PFIZER INC</u>	<u>200MG/100ML (2MG/ML)</u>	<u>N050778 001</u>	Sep 15, 1999
<u>AP</u>	<u>+</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050778 002</u>	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		<u>ACTAVIS TOTOWA</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A065445 002</u>	Sep 18, 2008
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065445 003</u>	Sep 18, 2008
<u>AP</u>		<u>AKORN INC</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A090163 001</u>	Jun 24, 2009
<u>AP</u>		<u>CIPLA LTD</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A065361 001</u>	Oct 22, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065361 002</u>	Oct 22, 2007
<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A065408 002</u>	Oct 15, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065408 004</u>	Oct 15, 2007
<u>AP</u>		<u>HISUN PHARM</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A090075 001</u>	Mar 25, 2010
		<u>HANGZHOU</u>			
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A090075 002</u>	Mar 25, 2010
<u>AP</u>		<u>IMPAX LABS INC</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A065331 001</u>	Aug 09, 2007
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065331 002</u>	Aug 09, 2007
<u>AP</u>		<u>WEST-WARD PHARMS</u>	<u>50MG/25ML (2MG/ML)</u>	<u>A065289 001</u>	Jun 27, 2007
		<u>INT</u>			
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A065289 002</u>	Jun 27, 2007
		<u>FRESENIUS KABI USA</u>	<u>10MG/5ML (2MG/ML)</u>	<u>A065408 001</u>	Oct 15, 2007
			<u>150MG/75ML (2MG/ML)</u>	<u>A065408 003</u>	Oct 15, 2007

PRESCRIPTION DRUG PRODUCT LIST

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A206922 001</u>	Jul 13, 2017
<u>AB</u>		<u>50MG</u>	<u>A206922 002</u>	Jul 13, 2017
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482 001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482 002</u>	Jul 30, 2008
<u>AB</u>	BRECKENRIDGE	<u>25MG</u>	<u>A208283 001</u>	Sep 14, 2018
<u>AB</u>		<u>50MG</u>	<u>A208283 002</u>	Sep 14, 2018
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A203896 001</u>	Feb 02, 2017
<u>AB</u>		<u>50MG</u>	<u>A203896 002</u>	Feb 02, 2017
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510 001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510 002</u>	Aug 01, 2008
<u>INSPRA</u>				
<u>AB</u>	+ GD SEARLE LLC	<u>25MG</u>	<u>N021437 001</u>	Sep 27, 2002
<u>AB</u>	+!	<u>50MG</u>	<u>N021437 002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396 001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396 002</u>	Apr 23, 2008
<u>FLOLAN</u>				
<u>AP</u>	+! GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444 001</u>	Sep 20, 1995
<u>AP</u>	+!	<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444 002</u>	Sep 20, 1995
<u>VELETRI</u>				
	+ ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260 002</u>	Jun 28, 2012
	+!	<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260 001</u>	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012 001</u>	Nov 16, 2011
<u>AB</u>	!	<u>EQ 600MG BASE</u>	<u>A202012 002</u>	Nov 16, 2011

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

<u>AP</u>	ACCORD HLTHCARE	<u>2MG/ML</u>	<u>A205557 001</u>	Nov 06, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A205557 002</u>	Nov 06, 2017
<u>AP</u>	AKORN	<u>2MG/ML</u>	<u>A204589 001</u>	Apr 18, 2017
<u>AP</u>		<u>75MG/100ML</u>	<u>A204589 002</u>	Apr 18, 2017
<u>AP</u>	AMNEAL PHARMS	<u>2MG/ML</u>	<u>A205581 001</u>	Dec 08, 2016
<u>AP</u>		<u>75MG/100ML</u>	<u>A205581 002</u>	Dec 08, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206127 001</u>	Dec 08, 2015
<u>AP</u>		<u>75MG/100ML</u>	<u>A206127 002</u>	Dec 08, 2015
<u>AP</u>	BAXTER HLTHCARE CORP	<u>2MG/ML</u>	<u>A208554 001</u>	Nov 23, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A208554 002</u>	Nov 23, 2018
<u>AP</u>	HAINAN POLY PHARM	<u>2MG/ML</u>	<u>A209864 001</u>	Jan 25, 2019
<u>AP</u>		<u>75MG/100ML</u>	<u>A209864 002</u>	Jan 25, 2019
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A203258 001</u>	Jul 20, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A203258 002</u>	Jul 20, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>2MG/ML</u>	<u>A204693 001</u>	Mar 07, 2018
<u>AP</u>		<u>75MG/100ML</u>	<u>A204693 002</u>	Mar 07, 2018
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A090854 001</u>	Jun 12, 2015
<u>INTEGRILIN</u>				
<u>AP</u>	+! SCHERING	<u>2MG/ML</u>	<u>N020718 001</u>	May 18, 1998
<u>AP</u>	+!	<u>75MG/100ML</u>	<u>N020718 002</u>	May 18, 1998

ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS

XERAVA

	+! TETRAPHASE PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>N211109 001</u>	Aug 27, 2018
--	----------------------	--------------------------	--------------------	--------------

ERDAFITINIB

TABLET; ORAL

BALVERSA

	+ JANSSEN BIOTECH	<u>3MG</u>	<u>N212018 001</u>	Apr 12, 2019
	+	<u>4MG</u>	<u>N212018 002</u>	Apr 12, 2019
	+!	<u>5MG</u>	<u>N212018 003</u>	Apr 12, 2019

PRESCRIPTION DRUG PRODUCT LIST

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001	
-----------	----------	--------------------------	------------------	----------------	------------	--

ERGOCALCIFEROL

AA		ORIT LABS LLC	50,000 IU	A040833	001	May 20, 2009
AA		PURACAP PHARM LLC	50,000 IU	A204276	001	Dec 07, 2018
AA		SIGMAPHARM LABS LLC	50,000 IU	A091004	001	Jul 14, 2010
AA		STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010
AA		SUN PHARM INDS INC	50,000 IU	A040865	001	Dec 29, 2009

VITAMIN D

AA		BIONPHARMA INC	50,000 IU	A080704	001	
-----------	--	-----------------------	------------------	----------------	------------	--

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991
----------	-----------------------------	------------	----------------	------------	---------------------

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

!	TERSERA THERAPS LLC	2MG	A087693	001	Feb 24, 1983
----------	----------------------------	------------	----------------	------------	---------------------

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010
----------	------------------	---------------------------	----------------	------------	---------------------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019
AB		EQ 100MG BASE	A208396	002	Nov 05, 2019
AB		EQ 150MG BASE	A208396	003	Nov 05, 2019
AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014
AB	NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019
AB		EQ 100MG BASE	A208488	002	Nov 05, 2019
AB		EQ 150MG BASE	A208488	003	Nov 05, 2019
AB	SHILPA MEDICARE LTD	EQ 25MG BASE	A211960	001	Nov 05, 2019
AB		EQ 100MG BASE	A211960	002	Nov 05, 2019
AB		EQ 150MG BASE	A211960	003	Nov 05, 2019
AB	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019
AB		EQ 100MG BASE	A210300	002	Nov 05, 2019
AB		EQ 150MG BASE	A210300	003	Nov 05, 2019
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015

TARCEVA

AB	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018
AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019

INVANZ

AP	+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001
-----------	----------	--------------------------	-------------------------	----------------	------------	---------------------

ERTUGLIFLOZIN

TABLET; ORAL

STEGLATRO

+	MERCK SHARP DOHME	5MG	N209803	001	Dec 19, 2017
+		15MG	N209803	002	Dec 19, 2017

PRESCRIPTION DRUG PRODUCT LIST

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SEGLUROMET

+	MERCK SHARP DOHME	2.5MG;500MG	N209806	001	Dec 19, 2017
+		2.5MG;1GM	N209806	002	Dec 19, 2017
+		7.5MG;500MG	N209806	003	Dec 19, 2017
+	!	7.5MG;1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017
+	!	15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB	+ !	MAYNE PHARMA	250MG	N050536	001	
AB		ARBOR PHARMS LLC	250MG	A062746	001	Dec 22, 1986

GEL; TOPICAL

ERYGEL

AT	+ !	MYLAN	2%	N050617	001	Oct 21, 1987
AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997
AT		PERRIGO CO	2%	A063211	001	Jan 29, 1993
AT		TELIGENT PHARMA INC	2%	A208154	001	Jul 19, 2017

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT		AKORN	0.5%	A064030	001	Jul 18, 1996
AT		BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994
AT	!	PERRIGO CO TENNESSEE	0.5%	A062447	001	Sep 26, 1983

SOLUTION; TOPICAL

ERYTHROMYCIN

AT	!	PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991
AT		TELIGENT PHARMA INC	2%	A208100	001	Nov 20, 2017
AT		WOCKHARDT BIO AG	2%	A062825	001	Oct 23, 1987

SWAB; TOPICAL

ERYTHROMYCIN

AT		AKORN	2%	A090215	001	May 12, 2010
AT	!	PERRIGO CO	2%	A064126	001	Jul 03, 1996

TABLET; ORAL

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018
AB			500MG	A209720	002	Mar 09, 2018
AB		ARBOR PHARMS LLC	250MG	A061621	001	
AB	!		500MG	A061621	002	

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

AB		ARBOR PHARMS LLC	250MG	A062298	001	
AB			333MG	A062298	003	Mar 29, 1982
AB	!		500MG	A062298	002	

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019
AB			333MG	A210954	002	Jul 02, 2019
AB			500MG	A210954	003	Jul 02, 2019

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001	
AB	+	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987
AB	+ !		EQ 400MG BASE/5ML	N050207	002	

ERYTHROMYCIN ETHYLSUCCINATE

AB		AMNEAL PHARMS	EQ 200MG BASE/5ML	A211204	001	Nov 01, 2019
AB			EQ 400MG BASE/5ML	A211204	002	Nov 01, 2019
AB		ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001	
AB			EQ 200MG BASE/5ML	A062055	003	Nov 02, 2018
AB			EQ 400MG BASE/5ML	A062055	002	Nov 02, 2018
AB		PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019
AB			EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019

PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

E.E.S. 400

BX ! ARBOR PHARMS LLC EQ 400MG BASE A061905 002 Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX ! ARBOR PHARMS LLC EQ 400MG BASE A061904 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP HOSPIRA EQ 500MG BASE/VIAL A062638 001 Oct 31, 1986

AP +! EQ 500MG BASE/VIAL N050609 001 Sep 24, 1986

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

! ARBOR PHARMS LLC EQ 250MG BASE A060359 001

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA ALLIED EQ 5MG BASE/5ML A203967 001 May 26, 2015

AA AMNEAL PHARMS EQ 5MG BASE/5ML A202227 001 Mar 14, 2012

AA AUROBINDO PHARMA EQ 5MG BASE/5ML A079062 001 Apr 02, 2012

LTD

AA HETERO LABS LTD III EQ 5MG BASE/5ML A202221 001 Jun 12, 2012

AA LANNETT CO INC EQ 5MG BASE/5ML A090477 001 Jun 12, 2013

AA MACLEODS PHARMS LTD EQ 5MG BASE/5ML A202754 001 Mar 31, 2016

AA TARO EQ 5MG BASE/5ML A079121 001 May 03, 2012

LEXAPRO

AA +! ALLERGAN EQ 5MG BASE/5ML N021365 001 Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATE

AB ACCORD HLTHCARE EQ 5MG BASE A202389 001 Sep 11, 2012

AB EQ 10MG BASE A202389 002 Sep 11, 2012

AB EQ 20MG BASE A202389 003 Sep 11, 2012

AB AMNEAL PHARMS EQ 5MG BASE A205619 001 May 17, 2017

AB EQ 10MG BASE A205619 002 May 17, 2017

AB EQ 20MG BASE A205619 003 May 17, 2017

AB AUROBINDO PHARMA EQ 5MG BASE A090432 001 Sep 11, 2012

LTD

AB EQ 10MG BASE A090432 002 Sep 11, 2012

AB EQ 20MG BASE A090432 003 Sep 11, 2012

AB CADILA EQ 5MG BASE A077734 001 Sep 11, 2012

AB EQ 10MG BASE A077734 002 Sep 11, 2012

AB EQ 20MG BASE A077734 003 Sep 11, 2012

AB GRAVITI PHARMS EQ 5MG BASE A078777 001 Sep 11, 2012

AB EQ 10MG BASE A078777 002 Sep 11, 2012

AB EQ 20MG BASE A078777 003 Sep 11, 2012

AB HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012

AB EQ 10MG BASE A078766 002 Sep 11, 2012

AB EQ 20MG BASE A078766 003 Sep 11, 2012

AB INVAGEN PHARMS EQ 5MG BASE A078604 001 Sep 11, 2012

AB EQ 10MG BASE A078604 002 Sep 11, 2012

AB EQ 20MG BASE A078604 003 Sep 11, 2012

AB JUBILANT GENERICS EQ 5MG BASE A202280 001 Sep 12, 2012

AB EQ 10MG BASE A202280 002 Sep 12, 2012

AB EQ 20MG BASE A202280 003 Sep 12, 2012

AB LUPIN LTD EQ 5MG BASE A078169 001 Sep 11, 2012

AB EQ 10MG BASE A078169 002 Sep 11, 2012

AB EQ 20MG BASE A078169 003 Sep 11, 2012

AB MACLEODS PHARMS LTD EQ 5MG BASE A202210 001 Sep 11, 2012

AB EQ 10MG BASE A202210 002 Sep 11, 2012

AB EQ 20MG BASE A202210 003 Sep 11, 2012

AB PHARM ASSOC EQ 5MG BASE A077512 001 Sep 12, 2012

AB EQ 10MG BASE A077512 002 Sep 12, 2012

AB EQ 20MG BASE A077512 003 Sep 12, 2012

AB PRINSTON INC EQ 5MG BASE A078032 001 Aug 28, 2015

AB EQ 10MG BASE A078032 002 Aug 28, 2015

AB EQ 20MG BASE A078032 003 Aug 28, 2015

AB TEVA PHARMS USA EQ 5MG BASE A076765 001 Mar 14, 2012

AB EQ 10MG BASE A076765 002 Mar 14, 2012

AB EQ 20MG BASE A076765 003 Mar 14, 2012

AB TORRENT PHARMS LTD EQ 5MG BASE A090939 001 Sep 11, 2012

PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939 003</u>	Sep 11, 2012

LEXAPRO

<u>AB</u>	+	ALLERGAN	<u>EQ 5MG BASE</u>	<u>N021323 001</u>	Aug 14, 2002
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N021323 002</u>	Aug 14, 2002
<u>AB</u>	+	!	<u>EQ 20MG BASE</u>	<u>N021323 003</u>	Aug 14, 2002

ESKETAMINE HYDROCHLORIDE

SPRAY; NASAL

SPRAVATO

+	!	JANSSEN PHARMS	EQ 28MG BASE	N211243 001	Mar 05, 2019
---	---	----------------	--------------	-------------	--------------

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIOM

+		SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
+			400MG	N022416 002	Nov 08, 2013
+			600MG	N022416 003	Nov 08, 2013
+	!		800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	!	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386 006</u>	Feb 25, 2003
-----------	---	---	-----------------	----------------	--------------------	--------------

ESMOLOL HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A205520 001</u>	Jul 23, 2015
-----------	--	----------------------	----------------	--------------------	--------------

<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005
-----------	--	--------------------	----------------	--------------------	--------------

<u>AP</u>		GLAND PHARMA LTD	<u>10MG/ML</u>	<u>A208538 001</u>	Aug 14, 2019
-----------	--	------------------	----------------	--------------------	--------------

<u>AP</u>		MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005
-----------	--	---------------------	----------------	--------------------	--------------

<u>AP</u>		MYLAN LABS LTD	<u>10MG/ML</u>	<u>A206608 001</u>	Jun 08, 2018
-----------	--	----------------	----------------	--------------------	--------------

<u>AP</u>			<u>20MG/ML</u>	<u>A206608 002</u>	Jun 08, 2018
-----------	--	--	----------------	--------------------	--------------

<u>AP</u>		SAGENT PHARMS INC	<u>10MG/ML</u>	<u>A207107 001</u>	Jun 08, 2018
-----------	--	-------------------	----------------	--------------------	--------------

<u>AP</u>			<u>20MG/ML</u>	<u>A207107 002</u>	Jun 08, 2018
-----------	--	--	----------------	--------------------	--------------

<u>AP</u>		WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004
-----------	--	----------------------	----------------	--------------------	--------------

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003
---	---	-----------------	-----------	-------------	--------------

BREVIBLOC IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001
---	---	-----------------	-----------	-------------	--------------

SOLUTION; INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+	!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703 002	Apr 07, 2016
---	---	-----------------	---------------------	-------------	--------------

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703 001	Apr 07, 2016
---	---	-----------------	-----------------------	-------------	--------------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A208333 001</u>	Oct 20, 2017
-----------	--	----------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A208333 002</u>	Oct 20, 2017
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A205606 001</u>	Apr 21, 2016
-----------	--	----------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205606 002</u>	Apr 21, 2016
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A078279 001</u>	Sep 25, 2015
-----------	--	--------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078279 002</u>	Sep 25, 2015
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		GLENMARK PHARMS	<u>EQ 20MG BASE</u>	<u>A209495 001</u>	May 10, 2019
-----------	--	-----------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A209495 002</u>	May 10, 2019
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A202784 001</u>	Sep 21, 2015
-----------	--	---------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202784 002</u>	Sep 21, 2015
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078003 001</u>	Jan 26, 2015
-----------	--	----------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078003 002</u>	Jan 26, 2015
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		LANNETT CO INC	<u>EQ 20MG BASE</u>	<u>A205563 001</u>	Sep 01, 2017
-----------	--	----------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205563 002</u>	Sep 01, 2017
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		MYLAN	<u>EQ 20MG BASE</u>	<u>A078936 001</u>	Aug 02, 2015
-----------	--	-------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078936 002</u>	Aug 03, 2015
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		SUN PHARM	<u>EQ 20MG BASE</u>	<u>A209735 001</u>	Apr 30, 2018
-----------	--	-----------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A209735 002</u>	Apr 30, 2018
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		TORRENT	<u>EQ 20MG BASE</u>	<u>A203636 001</u>	Oct 19, 2015
-----------	--	---------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A203636 002</u>	Oct 19, 2015
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		ZYDUS PHARMS	<u>EQ 20MG BASE</u>	<u>A206296 001</u>	May 22, 2019
-----------	--	--------------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM**AB** EQ 40MG BASE **A206296 002** May 22, 2019NEXIUM**AB** + ASTRAZENECA PHARMS EQ 20MG BASE **N021153 001** Feb 20, 2001**AB** +! EQ 40MG BASE **N021153 002** Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM+ ASTRAZENECA PHARMS EQ 2.5MG BASE/PACKET N021957 003 Dec 15, 2011+ EQ 5MG BASE/PACKET N021957 004 Dec 15, 2011+ EQ 10MG BASE/PACKET N022101 001 Feb 27, 2008+ EQ 20MG BASE/PACKET N021957 001 Oct 20, 2006+! EQ 40MG BASE/PACKET N021957 002 Oct 20, 2006ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

VIMOVO+ HORIZON EQ 20MG BASE;375MG N022511 002 Apr 30, 2010+! EQ 20MG BASE;500MG N022511 001 Apr 30, 2010ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM**AP** ACCORD HLTHCARE EQ 40MG BASE/VIAL **A205379 001** Sep 25, 2015**AP** ! AUROBINDO PHARMA EQ 40MG BASE/VIAL **A204657 002** Aug 10, 2016

LTD

AP DEVA HOLDING AS EQ 40MG BASE/VIAL **A207181 001** Mar 06, 2017**AP** MYLAN LABS LTD EQ 40MG BASE/VIAL **A202686 002** May 17, 2017**AP** SUN PHARMA GLOBAL EQ 40MG BASE/VIAL **A200882 002** Mar 18, 2013NEXIUM IV**AP** +! ASTRAZENECA PHARMS EQ 40MG BASE/VIAL **N021689 002** Mar 31, 2005ESTAZOLAM

TABLET;ORAL

ESTAZOLAM**AB** MAYNE PHARMA 1MG **A074921 001** Jul 10, 1997**AB** ! 2MG **A074921 002** Jul 10, 1997**AB** PAR PHARM 1MG **A074826 001** Jul 03, 1997**AB** 2MG **A074826 002** Jul 03, 1997**AB** WATSON LABS 1MG **A074818 001** Aug 19, 1997**AB** 2MG **A074818 002** Aug 19, 1997ESTRADIOL

CREAM;VAGINAL

ESTRACE**AB** ! ALLERGAN 0.01% **A086069 001** Jan 31, 1984ESTRADIOL**AB** ALVOGEN PINE BROOK 0.01% **A209767 001** Mar 05, 2018**AB** MYLAN 0.01% **A208788 001** Dec 29, 2017**AB** PERRIGO UK FINCO 0.01% **A210194 001** Jan 22, 2018**AB** TEVA PHARMS USA 0.01% **A210488 001** Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA**AB** + BAYER HLTHCARE 0.06MG/24HR **N020375 006** May 27, 2003ESTRADIOL**AB** MYLAN TECHNOLOGIES 0.06MG/24HR **A075182 005** Jul 20, 2006**AB1** AMNEAL PHARMS LLC 0.025MG/24HR **A211293 001** Feb 04, 2019**AB1** 0.0375MG/24HR **A211293 002** Feb 04, 2019**AB1** 0.05MG/24HR **A211293 003** Feb 04, 2019**AB1** 0.075MG/24HR **A211293 004** Feb 04, 2019**AB1** 0.1MG/24HR **A211293 005** Feb 04, 2019**AB1** MYLAN TECHNOLOGIES 0.025MG/24HR **A201675 001** Dec 19, 2014**AB1** 0.0375MG/24HR **A201675 002** Dec 19, 2014**AB1** 0.05MG/24HR **A201675 003** Dec 19, 2014**AB1** 0.075MG/24HR **A201675 004** Dec 19, 2014**AB1** 0.1MG/24HR **A201675 005** Dec 19, 2014VIVELLE-DOT**AB1** + NOVARTIS 0.025MG/24HR **N020538 009** May 03, 2002**AB1** + 0.0375MG/24HR **N020538 005** Jan 08, 1999**AB1** + 0.05MG/24HR **N020538 006** Jan 08, 1999**AB1** + 0.075MG/24HR **N020538 007** Jan 08, 1999**AB1** +! 0.1MG/24HR **N020538 008** Jan 08, 1999

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

<u>AB2</u>	+	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375 004</u>	Mar 05, 1999
<u>AB2</u>	+		<u>0.0375MG/24HR</u>	<u>N020375 005</u>	May 27, 2003
<u>AB2</u>	+		<u>0.05MG/24HR</u>	<u>N020375 001</u>	Dec 22, 1994
<u>AB2</u>	+		<u>0.075MG/24HR</u>	<u>N020375 003</u>	Mar 23, 1998
<u>AB2</u>	+	!	<u>0.1MG/24HR</u>	<u>N020375 002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182 003</u>	Jan 26, 2005
<u>AB2</u>			<u>0.0375MG/24HR</u>	<u>A075182 004</u>	Jul 20, 2006
<u>AB2</u>			<u>0.05MG/24HR</u>	<u>A075182 006</u>	Feb 24, 2000
<u>AB2</u>			<u>0.075MG/24HR</u>	<u>A075182 002</u>	Jan 26, 2005
<u>AB2</u>			<u>0.1MG/24HR</u>	<u>A075182 001</u>	Feb 24, 2000
<u>AB3</u>			<u>0.025MG/24HR</u>	<u>A206685 001</u>	Aug 15, 2018
<u>AB3</u>			<u>0.0375MG/24HR</u>	<u>A206685 002</u>	Aug 15, 2018
<u>AB3</u>			<u>0.05MG/24HR</u>	<u>A206685 003</u>	Aug 15, 2018
<u>AB3</u>			<u>0.075MG/24HR</u>	<u>A206685 004</u>	Aug 15, 2018
<u>AB3</u>			<u>0.1MG/24HR</u>	<u>A206685 005</u>	Aug 15, 2018

MINIVELLE

<u>AB3</u>	+	NOVEN	<u>0.025MG/24HR</u>	<u>N203752 005</u>	Sep 23, 2014
<u>AB3</u>	+		<u>0.0375MG/24HR</u>	<u>N203752 001</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.05MG/24HR</u>	<u>N203752 003</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.075MG/24HR</u>	<u>N203752 002</u>	Oct 29, 2012
<u>AB3</u>	+	!	<u>0.1MG/24HR</u>	<u>N203752 004</u>	Oct 29, 2012

ALORA

BX		ALLERGAN	0.025MG/24HR	N020655 004	Apr 05, 2002
BX			0.05MG/24HR	N020655 001	Dec 20, 1996
BX			0.075MG/24HR	N020655 002	Dec 20, 1996
BX			0.1MG/24HR	N020655 003	Dec 20, 1996

MENOSTAR

+	!	BAYER HLTHCARE	0.014MG/24HR	N021674 001	Jun 08, 2004
---	---	----------------	--------------	-------------	--------------

GEL;TRANSDERMAL

DIVIGEL

+	!	VERTICAL PHARMS LLC	0.1%	N022038 001	Jun 04, 2007
---	---	---------------------	------	-------------	--------------

GEL, METERED;TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006
---	---	---------------------	---------------------------	-------------	--------------

ESTROGEL

+	!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166 002	Feb 09, 2004
---	---	-------------------	---------------------------	-------------	--------------

INSERT;VAGINAL

IMVEXXY

+		THERAPEUTICSMD INC	0.004MG	N208564 001	May 29, 2018
---	--	--------------------	---------	-------------	--------------

+	!		0.01MG	N208564 002	May 29, 2018
---	---	--	--------	-------------	--------------

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+	!	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472 001	Apr 26, 1996
---	---	-------------------------	---------------	-------------	--------------

SPRAY;TRANSDERMAL

EVAMIST

+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014 001	Jul 27, 2007
---	---	---------------------	--------------	-------------	--------------

TABLET;ORAL

ESTRADIOL

<u>AB</u>		BARR LABS INC	<u>0.5MG</u>	<u>A040197 001</u>	Oct 22, 1997
<u>AB</u>			<u>1MG</u>	<u>A040197 002</u>	Oct 22, 1997
<u>AB</u>	!		<u>2MG</u>	<u>A040197 003</u>	Oct 22, 1997
<u>AB</u>		EPIC PHARMA INC	<u>0.5MG</u>	<u>A040275 001</u>	Dec 29, 1998
<u>AB</u>			<u>1MG</u>	<u>A040275 002</u>	Dec 29, 1998
<u>AB</u>			<u>2MG</u>	<u>A040275 003</u>	Dec 29, 1998
<u>AB</u>		MAYNE PHARMA	<u>0.5MG</u>	<u>A040114 003</u>	Mar 14, 1996
<u>AB</u>			<u>1MG</u>	<u>A040114 001</u>	Mar 14, 1996
<u>AB</u>			<u>2MG</u>	<u>A040114 002</u>	Mar 14, 1996
<u>AB</u>		MYLAN	<u>0.5MG</u>	<u>A040326 001</u>	Apr 21, 1999
<u>AB</u>			<u>1MG</u>	<u>A040326 002</u>	Apr 21, 1999
<u>AB</u>			<u>2MG</u>	<u>A040326 003</u>	Apr 21, 1999

TABLET;VAGINAL

ESTRADIOL

<u>AB</u>		AMNEAL PHARMS	<u>10MCG</u>	<u>A205256 001</u>	May 29, 2015
<u>AB</u>		GLENMARK PHARMS LTD	<u>10MCG</u>	<u>A210264 001</u>	Sep 14, 2018
<u>AB</u>		TEVA PHARMS USA	<u>10MCG</u>	<u>A206388 001</u>	Jul 21, 2017

VAGIFEM

<u>AB</u>	+	!	NOVO NORDISK INC	<u>10MCG</u>	<u>N020908 002</u>	Nov 25, 2009
-----------	---	---	------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

+ MILLICENT

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003

+!

EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

! PHARMACIA AND
UPJOHN

5MG/ML

A085470 003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGENAO +! PAR STERILE
PRODUCTS20MG/MLN009402 004AO +!40MG/MLN009402 003ESTRADIOL VALERATEAO AM REGENT20MG/MLA090920 001 Jan 19, 2010AO40MG/MLA090920 002 Jan 19, 2010

DELESTROGEN

+! PAR STERILE
PRODUCTS

10MG/ML

N009402 002

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

+! BAYER HLTHCARE

0.045MG/24HR;0.015MG/24HR

N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

+ NOVEN PHARMS INC

0.05MG/24HR;0.14MG/24HR

N020870 001 Aug 07, 1998

+!

0.05MG/24HR;0.25MG/24HR

N020870 002 Aug 07, 1998

TABLET;ORAL

ACTIVELLAAB + AMNEAL PHARMS LLC0.5MG;0.1MGN020907 002 Dec 28, 2006AB +!1MG;0.5MGN020907 001 Nov 18, 1998AMABELZAB LUPIN LTD0.5MG;0.1MGA203339 001 Jun 20, 2016AB1MG;0.5MGA203339 002 Jun 20, 2016ESTRADIOL AND NORETHINDRONE ACETATEAB BARR1MG;0.5MGA079193 001 May 11, 2010AB BRECKENRIDGE PHARM0.5MG;0.1MGA078324 002 Jun 09, 2011AB1MG;0.5MGA078324 001 Apr 17, 2008AB MYLAN LABS LTD0.5MG;0.1MGA207261 001 Feb 10, 2017AB1MG;0.5MGA207261 002 Feb 10, 2017AB NOVAST LABS0.5MG;0.1MGA210612 001 Apr 03, 2019AB1MG;0.5MGA210612 002 Apr 03, 2019AB TEVA PHARMS USA0.5MG;0.1MGA200747 001 Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

! BARR

1MG,1MG;N/A,0.09MG

A076812 001 Apr 29, 2005

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

+! THERAPEUTICSMD INC

1MG;100MG

N210132 001 Oct 28, 2018

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

+! PHARMACIA AND
UPJOHN

EQ 140MG PHOSPHATE

N018045 001

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

+! WYETH PHARMS

0.625MG/GM

N020216 001

INJECTABLE; INJECTION

PREMARIN

+! WYETH PHARMS

25MG/VIAL

N010402 001

PRESCRIPTION DRUG PRODUCT LIST

ESTROGENS, CONJUGATED

TABLET;ORAL

PREMARIN

+	WYETH PHARMS	0.3MG	N004782	003	
+		0.45MG	N004782	006	Jul 16, 2003
+	!	0.625MG	N004782	004	
+	!	0.9MG	N004782	005	Jan 26, 1984
+	!	1.25MG	N004782	001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

+	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995
+	!	0.3MG;1.5MG	N020527	005	Jun 04, 2003
+	!	0.45MG;1.5MG	N020527	004	Mar 12, 2003
+	!	0.625MG;2.5MG	N020527	001	Nov 17, 1995
+	!	0.625MG;5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001	
		0.625MG	A084948	001	
		1.25MG	A084950	001	
!		2.5MG	A084949	001	

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

	MYLAN	0.75MG	A040359	001	Aug 26, 1999
		1.5MG	A040359	002	Aug 26, 1999

OGEN 5

	PHARMACIA AND UPJOHN	6MG	A083220	004	
--	-------------------------	-----	---------	-----	--

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016
AB		2MG	A208451	002	Sep 15, 2016
AB		3MG	A208451	003	Sep 15, 2016
AB	DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014
AB		2MG	A091024	002	Apr 15, 2014
AB		3MG	A091024	003	Apr 15, 2014
AB	GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014
AB		2MG	A091166	002	Apr 15, 2014
AB		3MG	A091166	003	Apr 15, 2014
AB	HIKMA	1MG	A091153	001	Apr 15, 2014
AB		2MG	A091153	002	Apr 15, 2014
AB		3MG	A091153	003	Apr 15, 2014
AB	LUPIN LTD	1MG	A091124	001	Sep 13, 2011
AB		2MG	A091124	002	Sep 13, 2011
AB		3MG	A091124	003	Sep 13, 2011
AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015
AB		2MG	A202929	002	Jan 30, 2015
AB		3MG	A202929	003	Jan 30, 2015
AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013
AB		2MG	A091151	002	Mar 26, 2013
AB		3MG	A091151	003	Mar 26, 2013
AB	ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014
AB		2MG	A091113	002	Jun 10, 2014
AB		3MG	A091113	003	Jun 10, 2014
AB	SUN PHARM	1MG	A091103	001	Apr 03, 2013
AB		2MG	A091103	002	Apr 03, 2013
AB		3MG	A091103	003	Apr 03, 2013
AB	TEVA	1MG	A091169	001	May 23, 2011
AB		2MG	A091169	002	May 23, 2011
AB		3MG	A091169	003	May 23, 2011

LUNESTA

AB	+	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004
AB	+		2MG	N021476	002	Dec 15, 2004
AB	+		3MG	N021476	003	Dec 15, 2004

PRESCRIPTION DRUG PRODUCT LIST

ETELALCETIDE

SOLUTION; INTRAVENOUS

PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325 001	Feb 07, 2017
+	!		5MG/ML (5MG/ML)	N208325 002	Feb 07, 2017
+	!		10MG/2ML (5MG/ML)	N208325 003	Feb 07, 2017

ETEPLIRSEN

SOLUTION; INTRAVENOUS

EXONDYS 51

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488 001	Sep 19, 2016
+	!		500MG/10ML (50MG/ML)	N206488 002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIIN

<u>AP</u>	+	!	BAUSCH	<u>EQ 50MG BASE/VIAL</u>	<u>N016093 001</u>
-----------	---	---	--------	--------------------------	--------------------

ETHACRYNATE SODIUM

<u>AP</u>			MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A204634 001</u>	Aug 23, 2016
<u>AP</u>			PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A205473 001</u>	Jul 29, 2015
<u>AP</u>			ZYDUS PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A207758 001</u>	Nov 17, 2017

ETHACRYNIC ACID

TABLET; ORAL

EDECRIIN

<u>AB</u>	+	!	BAUSCH	<u>25MG</u>	<u>N016092 001</u>
-----------	---	---	--------	-------------	--------------------

ETHACRYNIC ACID

<u>AB</u>			AGNITIO	<u>25MG</u>	<u>A211809 001</u>	Jul 12, 2019
<u>AB</u>			ALVOGEN	<u>25MG</u>	<u>A205709 001</u>	Jul 24, 2018
<u>AB</u>			AMNEAL PHARMS CO	<u>25MG</u>	<u>A208805 001</u>	May 08, 2018
<u>AB</u>			EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205609 001</u>	Jun 30, 2016
<u>AB</u>			HIKMA	<u>25MG</u>	<u>A207262 001</u>	Feb 23, 2017
<u>AB</u>			LUPIN LTD	<u>25MG</u>	<u>A211719 001</u>	Sep 06, 2019
<u>AB</u>			PAR PHARM INC	<u>25MG</u>	<u>A208501 001</u>	Jul 21, 2017
<u>AB</u>			SCIEGEN PHARMS INC	<u>25MG</u>	<u>A211232 001</u>	Aug 27, 2019

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>			AKORN	<u>100MG</u>	<u>A075095 001</u>	Nov 30, 1999
<u>AB</u>				<u>400MG</u>	<u>A075095 002</u>	Nov 30, 1999
<u>AB</u>			BARR	<u>400MG</u>	<u>A076057 001</u>	Nov 26, 2001
<u>AB</u>			LUPIN	<u>100MG</u>	<u>A078939 001</u>	Jun 17, 2009
<u>AB</u>				<u>400MG</u>	<u>A078939 002</u>	Jun 17, 2009

MYAMBUTOL

<u>AB</u>	+		STI PHARMA LLC	<u>100MG</u>	<u>N016320 001</u>
<u>AB</u>	+	!		<u>400MG</u>	<u>N016320 003</u>

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+	!	QOL MEDCL	50MG/ML	N019357 001	Dec 22, 1988
---	---	-----------	---------	-------------	--------------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

<u>AB</u>			MYLAN LABS LTD	<u>0.035MG;1MG</u>	<u>A204703 001</u>	Jul 28, 2016
<u>AB</u>				<u>0.05MG;1MG</u>	<u>A204704 001</u>	Feb 09, 2016

KELNOR

<u>AB</u>			BARR	<u>0.035MG;1MG</u>	<u>A076785 001</u>	May 23, 2005
-----------	--	--	------	--------------------	--------------------	--------------

LO-MALMOREDE

<u>AB</u>			NOVAST LABS	<u>0.035MG;1MG</u>	<u>A209548 001</u>	Feb 11, 2019
-----------	--	--	-------------	--------------------	--------------------	--------------

MALMOREDE

<u>AB</u>			NOVAST LABS	<u>0.05MG;1MG</u>	<u>A209547 001</u>	Jul 25, 2018
-----------	--	--	-------------	-------------------	--------------------	--------------

ZOVIA 1/35E-28

<u>AB</u>			MAYNE PHARMA	<u>0.035MG;1MG</u>	<u>A072721 001</u>	Dec 30, 1991
-----------	--	--	--------------	--------------------	--------------------	--------------

ZOVIA 1/50E-28

<u>AB</u>	!		WATSON LABS	<u>0.05MG;1MG</u>	<u>A072723 001</u>	Dec 30, 1991
-----------	---	--	-------------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; ETNOGESTREL

RING;VAGINAL

ELURYNG

AB	AMNEAL PHARMS LLC	0.015MG/24HR;0.12MG/24HR	A210830 001	Dec 11, 2019
-----------	-------------------	---------------------------------	--------------------	--------------

NUVARING

AB	+! ORGANON SUB MERCK	0.015MG/24HR;0.12MG/24HR	N021187 001	Oct 03, 2001
-----------	----------------------	---------------------------------	--------------------	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163 001	Feb 23, 2015
-----------	-------------------	---------------------------------	--------------------	--------------

DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467 001	Apr 10, 2013
-----------	-----------	---------------------------------	--------------------	--------------

FAYOSIM

AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943 001	Mar 29, 2016
-----------	-----------	--	--------------------	--------------

ICLEVIA

AB	AUROBINDO PHARMA LTD	0.03MG;0.15MG	A206850 001	Jun 29, 2018
-----------	----------------------	----------------------	--------------------	--------------

INTROVALE

AB	XIROMED	0.03MG;0.15MG	A079064 001	Sep 27, 2010
-----------	---------	----------------------	--------------------	--------------

JAIMIESS

AB	XIROMED	0.03MG,0.01MG;0.15MG,N/A	A203770 001	Dec 27, 2017
-----------	---------	---------------------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	0.03MG;0.15MG	A203871 001	Nov 13, 2015
-----------	---------------	----------------------	--------------------	--------------

AB		0.03MG,0.01MG;0.15MG,N/A	A203872 001	Dec 22, 2015
-----------	--	---------------------------------	--------------------	--------------

AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791 001	Apr 09, 2015
-----------	-------------------	----------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164 001	Jun 12, 2015
-----------	---------------------	----------------------	--------------------	--------------

AB	LUPIN LTD	0.03MG;0.15MG	A091440 001	Oct 23, 2012
-----------	-----------	----------------------	--------------------	--------------

AB	MYLAN LABS LTD	0.03MG;0.15MG	A200490 001	Apr 21, 2015
-----------	----------------	----------------------	--------------------	--------------

AB	! WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011
-----------	---------------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	0.02MG,0.1MG;0.01MG,N/A	A091674 001	Oct 26, 2011
-----------	-----------	--------------------------------	--------------------	--------------

AB	MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407 001	Oct 25, 2011
-----------	--------------	--------------------------------	--------------------	--------------

AB		0.03MG,0.01MG;0.15MG,N/A	A078834 001	May 31, 2011
-----------	--	---------------------------------	--------------------	--------------

AB	MYLAN LABS LTD	0.02MG,0.15MG;	A206053 001	Oct 02, 2017
-----------	----------------	-----------------------	--------------------	--------------

		0.025MG,0.15MG;0.03MG,0.15MG;		
--	--	--------------------------------------	--	--

AB		0.02MG,0.1MG;0.01MG,N/A	A200493 001	Jun 17, 2015
-----------	--	--------------------------------	--------------------	--------------

AB		0.03MG,0.01MG;0.15MG,N/A	A200492 001	May 27, 2015
-----------	--	---------------------------------	--------------------	--------------

AB	XIROMED	0.02MG,0.1MG;0.01MG,N/A	A205131 001	Dec 14, 2017
-----------	---------	--------------------------------	--------------------	--------------

LO SIMPESE

AB	AUROBINDO PHARMA LTD	0.02MG,0.1MG;0.01MG,N/A	A206852 001	Apr 28, 2017
-----------	----------------------	--------------------------------	--------------------	--------------

LOSEASONIQUE

AB	TEVA BRANDED PHARM	0.02MG,0.1MG;0.01MG,N/A	N022262 001	Oct 24, 2008
-----------	--------------------	--------------------------------	--------------------	--------------

QUARTETTE

AB	+! TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061 001	Mar 28, 2013
-----------	-----------------------	--	--------------------	--------------

QUASENSE

AB	WATSON LABS	0.03MG;0.15MG	A077101 001	Sep 06, 2006
-----------	-------------	----------------------	--------------------	--------------

SEASONALE

AB	+! TEVA BRANDED PHARM	0.03MG;0.15MG	N021544 001	Sep 05, 2003
-----------	-----------------------	----------------------	--------------------	--------------

SEASONIQUE

AB	+! TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006
-----------	-----------------------	---------------------------------	--------------------	--------------

SETLAKIN

AB	NOVAST LABS	0.03MG;0.15MG	A090716 001	Sep 15, 2014
-----------	-------------	----------------------	--------------------	--------------

SIMPESE

AB	AUROBINDO PHARMA LTD	0.03MG,0.01MG;0.15MG,N/A	A206851 001	Apr 07, 2017
-----------	----------------------	---------------------------------	--------------------	--------------

SYLEVIA

AB	SUN PHARM	0.03MG;0.15MG	A202988 001	Feb 06, 2019
-----------	-----------	----------------------	--------------------	--------------

BALCOLTRA

	AVION PHARMS	0.02MG;0.1MG	N208612 001	Jan 09, 2018
--	--------------	--------------	-------------	--------------

TABLET;ORAL-28

ALTAVERA

AB	XIROMED	0.03MG;0.15MG	A079102 001	Aug 03, 2010
-----------	---------	----------------------	--------------------	--------------

AYUNA

AB	AUROBINDO PHARMA LTD	0.03MG;0.15MG	A206866 001	Sep 23, 2016
-----------	----------------------	----------------------	--------------------	--------------

ELIFEMME

AB	XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507 001	Dec 04, 2015
-----------	---------	--	--------------------	--------------

ENPRESSE-28

AB	DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809 002	Jul 16, 2001
-----------	---------------------	--	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

<u>KURVELO</u>					
AB	LUPIN LTD	0.03MG;0.15MG	A091408	001	Oct 17, 2012
<u>LEVONEST</u>					
AB	NOVAST LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A090719	001	Dec 29, 2010
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
AB	AMNEAL PHARMS	0.03MG;0.15MG	A201095	001	Dec 08, 2014
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015
AB	MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018
AB		0.03MG;0.15MG	A091663	001	Dec 21, 2012
<u>LEVORA 0.15/30-28</u>					
AB	MAYNE PHARMA	0.03MG;0.15MG	A073594	001	Dec 13, 1993
<u>MARLISSA</u>					
AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012
<u>MYZILRA</u>					
AB	VINTAGE PHARMS LLC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011
<u>PORTIA-28</u>					
AB	BARR	0.03MG;0.15MG	A075866	002	May 23, 2002
<u>TRIVORA-28</u>					
AB	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	002	Dec 18, 1997
<u>AFIRMELLE</u>					
AB1	AUROBINDO PHARMA LTD	0.02MG;0.1MG	A206886	001	Nov 14, 2016
<u>AVIANE-28</u>					
AB1	DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	001	Apr 30, 2001
<u>CERINTA</u>					
AB1	SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019
<u>FALMINA</u>					
AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
AB1	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014
AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013
AB1	MAYNE PHARMA	0.02MG;0.1MG	A076625	001	Nov 18, 2004
AB1	MYLAN LABS LTD	0.02MG;0.1MG	A200245	001	Oct 09, 2013
<u>ORSYTHIA</u>					
AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011
<u>VIENVA</u>					
AB1	XIROMED	0.02MG;0.1MG	A201088	001	May 21, 2015
<u>LESSINA-28</u>					
AB2	BARR	0.02MG;0.1MG	A075803	002	Mar 20, 2002
<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>					
AB2	MAYNE PHARMA	0.02MG;0.1MG	A077681	001	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL
XULANE

! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

AB	ALLERGAN	0.035MG;1MG	N017565	001	
<u>NORTREL 1/35-21</u>					
AB	BARR	0.035MG;1MG	A072693	001	Feb 28, 1992
	NORTREL 7/7/7				
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012
<u>ALYACEN 7/7/7</u>					
AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012
<u>ARANELLE</u>					
AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	A076783	001	Sep 29, 2004
<u>BALZIVA-28</u>					
AB	BARR	0.035MG;0.4MG	A076238	001	Apr 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	<u>BREVICON 28-DAY</u>			
AB	ALLERGAN	<u>0.035MG;0.5MG</u>	<u>N017743 001</u>	
	<u>BRIELLYN</u>			
AB	GLENMARK GENERICS	<u>0.035MG;0.4MG</u>	<u>A090538 001</u>	Mar 22, 2011
	<u>CYCLAFEM 0.5/35</u>			
AB	VINTAGE PHARMS	<u>0.035MG;0.5MG</u>	<u>A203413 001</u>	Dec 16, 2015
	<u>CYCLAFEM 1/35</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG;1MG</u>	<u>A076337 001</u>	Nov 12, 2010
	<u>CYCLAFEM 7/7/7</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A076338 001</u>	Nov 16, 2010
	<u>CYONANZ</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG;0.5MG</u>	<u>A207055 001</u>	Oct 21, 2016
	<u>DASETTA 1/35</u>			
AB	NOVAST LABS LTD	<u>0.035MG;1MG</u>	<u>A090948 001</u>	Dec 22, 2011
	<u>DASETTA 7/7/7</u>			
AB	NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A090946 001</u>	Dec 22, 2011
	<u>GILDAGIA</u>			
AB	VINTAGE PHARMS	<u>0.035MG;0.4MG</u>	<u>A078376 001</u>	Nov 06, 2012
	<u>NORETHINDRONE AND ETHINYL ESTRADIOL</u>			
AB	ACCORD HLTHCARE	<u>0.035MG;1MG</u>	<u>A206864 001</u>	Apr 28, 2017
AB	MAYNE PHARMA	<u>0.035MG;0.5MG</u>	<u>A070686 001</u>	Jan 29, 1987
AB	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323 001</u>	Feb 04, 2010
AB	WATSON LABS TEVA	<u>0.035MG;1MG</u>	<u>A070687 001</u>	Jan 29, 1987
	<u>NORINYL 1+35 28-DAY</u>			
AB	ALLERGAN	<u>0.035MG;1MG</u>	<u>N017565 002</u>	
	<u>NORTREL 0.5/35-28</u>			
AB	BARR	<u>0.035MG;0.5MG</u>	<u>A072695 001</u>	Feb 28, 1992
	<u>NORTREL 1/35-28</u>			
AB	! BARR	<u>0.035MG;1MG</u>	<u>A072696 001</u>	Feb 28, 1992
	<u>NORTREL 7/7/7</u>			
AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478 002</u>	Aug 30, 2002
	<u>NYLIA 1/35</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG;1MG</u>	<u>A207056 001</u>	Oct 21, 2016
	<u>NYLIA 7/7/7</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A207054 001</u>	Oct 21, 2016
	<u>ORTHO-NOVUM 7/7/7-28</u>			
AB	+! JANSSEN PHARMS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>N018985 002</u>	Apr 04, 1984
	<u>PHILITH</u>			
AB	NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947 001</u>	Dec 22, 2011
	<u>PIRMELLA 1/35</u>			
AB	LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512 001</u>	Apr 24, 2013
	<u>PIRMELLA 7/7/7</u>			
AB	LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510 001</u>	Apr 24, 2013
	<u>TRI-NORINYL 28-DAY</u>			
AB	+! MAYNE PHARMA	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977 002</u>	Apr 13, 1984
	<u>VYFEMLA</u>			
AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886 001</u>	Sep 26, 2013
	<u>WERA</u>			
AB	! NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204 001</u>	Mar 27, 2012
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
	WATSON LABS TEVA	<u>0.035MG,0.035MG;0.5MG,1MG</u>	<u>A071044 001</u>	Apr 01, 1988
	TABLET, CHEWABLE; ORAL			
	<u>KAITLIB FE</u>			
AB	LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448 001</u>	Dec 17, 2015
	<u>NEXESTA FE</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG;0.4MG</u>	<u>A207535 001</u>	Feb 02, 2017
	<u>NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>			
AB	ACCORD HLTHCARE	<u>0.035MG;0.4MG</u>	<u>A207066 001</u>	Mar 29, 2017
AB	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892 001</u>	Sep 26, 2011
AB	+! APIL	<u>0.025MG;0.8MG</u>	<u>N022573 001</u>	Dec 22, 2010
AB	BARR	<u>0.035MG;0.4MG</u>	<u>A078965 001</u>	Aug 05, 2010
AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A091332 001</u>	Mar 23, 2016
AB	MYLAN LABS LTD	<u>0.025MG;0.8MG</u>	<u>A203371 001</u>	Apr 23, 2014

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	!	0.035MG;0.4MG	A202086 001	Apr 01, 2015
-----------	----------	----------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

TAYTULLA

+! APIL

0.02MG;1MG

N204426 001 Apr 19, 2013

TABLET; ORAL

AUROVELA 24 FE

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207504 001	Jun 15, 2017
-----------	----------------------	-------------------	--------------------	--------------

BLISOVI 24 FE

AB	LUPIN LTD	0.02MG;1MG	A091398 001	Oct 28, 2015
-----------	-----------	-------------------	--------------------	--------------

FEMHRT

AB	APIL	0.0025MG;0.5MG	N021065 001	Jan 14, 2005
-----------	------	-----------------------	--------------------	--------------

FYAVOLV

AB	LUPIN LTD	0.005MG;1MG	A204213 002	Dec 10, 2015
-----------	-----------	--------------------	--------------------	--------------

AB		0.0025MG;0.5MG	A204213 001	Dec 10, 2015
-----------	--	-----------------------	--------------------	--------------

GILDESS 24 FE

AB	VINTAGE PHARMS	0.02MG;1MG	A090293 001	Dec 01, 2014
-----------	----------------	-------------------	--------------------	--------------

LARIN 24 FE

AB	NOVAST LABS	0.02MG;1MG	A202994 001	Feb 18, 2015
-----------	-------------	-------------------	--------------------	--------------

LERIBANE

AB	NOVAST LABS	0.0025MG;0.5MG	A203435 002	Jun 03, 2016
-----------	-------------	-----------------------	--------------------	--------------

AB		0.005MG;1MG	A203435 001	Jun 03, 2016
-----------	--	--------------------	--------------------	--------------

LOESTRIN 24 FE

AB	+ APIL	0.02MG;1MG	N021871 001	Feb 17, 2006
-----------	--------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	!	0.005MG;1MG	A076221 001	Nov 06, 2009
-----------	---	--------------------	--------------------	--------------

AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038 001	Apr 02, 2015
-----------	-------------------	-----------------------	--------------------	--------------

AB		0.005MG;1MG	A203038 002	Apr 02, 2015
-----------	--	--------------------	--------------------	--------------

AB	MYLAN LABS LTD	0.0025MG;0.5MG	A207260 001	Feb 02, 2017
-----------	----------------	-----------------------	--------------------	--------------

AB		0.005MG;1MG	A207259 001	Dec 27, 2016
-----------	--	--------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	!	0.02MG;1MG	A078267 001	Sep 01, 2009
-----------	---	-------------------	--------------------	--------------

AB	BARR LABS INC	0.02MG;1MG	A090938 001	Dec 01, 2014
-----------	---------------	-------------------	--------------------	--------------

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A204847 001	Nov 17, 2017
-----------	---------------------	-------------------	--------------------	--------------

AB	MYLAN LABS LTD	0.02MG;1MG	A202742 001	Oct 30, 2014
-----------	----------------	-------------------	--------------------	--------------

LO LOESTRIN FE

+! APIL

0.01MG,0.01MG;1MG,N/A

N022501 001 Oct 21, 2010

TABLET; ORAL-21

AUROVELA 1.5/30

AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207581 001	Jun 26, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA 1/20

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207506 001	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

GILDESS 1.5/30

AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075 002	Jul 24, 2012
-----------	--------------------	---------------------	--------------------	--------------

GILDESS 1/20

AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077 002	Jul 24, 2012
-----------	--------------------	-------------------	--------------------	--------------

HAILEY 1.5/30

AB	GLENMARK PHARMS	0.03MG;1.5MG	A209297 001	Jun 05, 2018
-----------	-----------------	---------------------	--------------------	--------------

JUNEL 1.5/30

AB	BARR	0.03MG;1.5MG	A076381 001	May 30, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL 1/20

AB	BARR	0.02MG;1MG	A076380 001	May 30, 2003
-----------	------	-------------------	--------------------	--------------

LARIN 1.5/30

AB	NOVAST LABS	0.03MG;1.5MG	A202996 001	Mar 20, 2014
-----------	-------------	---------------------	--------------------	--------------

LARIN 1/20

AB	NOVAST LABS	0.02MG;1MG	A202995 001	Dec 04, 2013
-----------	-------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

AB	+ APIL	0.03MG;1.5MG	N017875 001	
-----------	--------	---------------------	--------------------	--

LOESTRIN 21 1/20

AB	+ APIL	0.02MG;1MG	N017876 001	
-----------	--------	-------------------	--------------------	--

LOESTRIN FE 1.5/30

AB	+! APIL	0.03MG;1.5MG	N017355 001	
-----------	---------	---------------------	--------------------	--

MICROGESTIN 1.5/30

AB	MAYNE PHARMA	0.03MG;1.5MG	A075548 002	Jul 30, 2003
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

AB	MAYNE PHARMA	0.02MG;1MG	A075647 002	Jul 30, 2003
-----------	--------------	-------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<u>AB</u>	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206969 001</u>	Jan 20, 2016
<u>AB</u>	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202771 001</u>	Nov 06, 2013
<u>AB</u>		<u>0.03MG;1.5MG</u>	<u>A202770 001</u>	Feb 19, 2015

TRI-LEGEST 21

BARR

0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

A076405 001 Oct 26, 2007

TABLET; ORAL-28

AUROVELA FE 1.5/30

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.03MG;1.5MG</u>	<u>A207580 001</u>	Jun 15, 2017
-----------	----------------------	---------------------	--------------------	--------------

AUROVELA FE 1/20

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.02MG;1MG</u>	<u>A207505 001</u>	Jun 16, 2017
-----------	----------------------	-------------------	--------------------	--------------

BLISOVI FE 1.5/30

<u>AB</u>	LUPIN LTD	<u>0.03MG;1.5MG</u>	<u>A201585 001</u>	Nov 18, 2015
-----------	-----------	---------------------	--------------------	--------------

BLISOVI FE 1/20

<u>AB</u>	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A201584 001</u>	Nov 18, 2015
-----------	-----------	-------------------	--------------------	--------------

ESTROSTEP FE

<u>AB</u>	+! APIL	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>N020130 002</u>	Oct 09, 1996
-----------	---------	--	--------------------	--------------

GILDESS FE 1.5/30

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075 001</u>	Apr 28, 2005
-----------	--------------------	---------------------	--------------------	--------------

GILDESS FE 1/20

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 001</u>	May 20, 2005
-----------	--------------------	-------------------	--------------------	--------------

HAILEY FE 1.5/30

<u>AB</u>	GLENMARK PHARMS	<u>0.03MG;1.5MG</u>	<u>A209031 001</u>	Jun 05, 2018
-----------	-----------------	---------------------	--------------------	--------------

HAILEY FE 1/20

<u>AB</u>	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206597 001</u>	Nov 21, 2017
-----------	---------------------	-------------------	--------------------	--------------

JUNEL FE 1.5/30

<u>AB</u>	BARR	<u>0.03MG;1.5MG</u>	<u>A076064 001</u>	Sep 18, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL FE 1/20

<u>AB</u>	BARR	<u>0.02MG;1MG</u>	<u>A076081 001</u>	Sep 18, 2003
-----------	------	-------------------	--------------------	--------------

LARIN FE 1.5/30

<u>AB</u>	NOVAST LABS	<u>0.03MG;1.5MG</u>	<u>A091453 001</u>	Aug 23, 2013
-----------	-------------	---------------------	--------------------	--------------

LARIN FE 1/20

<u>AB</u>	NOVAST LABS	<u>0.02MG;1MG</u>	<u>A091454 001</u>	Aug 26, 2013
-----------	-------------	-------------------	--------------------	--------------

LOESTRIN FE 1/20

<u>AB</u>	+ APIL	<u>0.02MG;1MG</u>	<u>N017354 001</u>	
-----------	--------	-------------------	--------------------	--

MICROGESTIN FE 1.5/30

<u>AB</u>	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 001</u>	Feb 05, 2001
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN FE 1/20

<u>AB</u>	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 001</u>	Feb 05, 2001
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<u>AB</u>	MAYNE PHARMA	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629 001</u>	Mar 18, 2010
-----------	--------------	--	--------------------	--------------

<u>AB</u>	MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202772 001</u>	Nov 14, 2013
-----------	----------------	-------------------	--------------------	--------------

<u>AB</u>		<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A205069 001</u>	Jun 22, 2018
-----------	--	--	--------------------	--------------

<u>AB</u>		<u>0.03MG;1.5MG</u>	<u>A202741 001</u>	Feb 20, 2015
-----------	--	---------------------	--------------------	--------------

TRI-LEGEST FE

BARR

0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

A076105 001 Oct 26, 2007

TABLET, CHEWABLE; ORAL

MIBELAS 24 FE

<u>AB</u>	LUPIN ATLANTIS	<u>0.02MG;1MG</u>	<u>A206287 001</u>	May 24, 2016
-----------	----------------	-------------------	--------------------	--------------

MINASTRIN 24 FE

<u>AB</u>	+! APIL	<u>0.02MG;1MG</u>	<u>N203667 001</u>	May 08, 2013
-----------	---------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

<u>AB</u>	AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A207514 001</u>	Sep 11, 2017
-----------	---------------	-------------------	--------------------	--------------

<u>AB</u>	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A210369 001</u>	Dec 26, 2017
-----------	---------------------	-------------------	--------------------	--------------

<u>AB</u>	XIROMED	<u>0.02MG;1MG</u>	<u>A209609 001</u>	Jul 16, 2018
-----------	---------	-------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

<u>AB</u>	XIROMED	<u>0.035MG;0.25MG</u>	<u>A090794 001</u>	Jan 30, 2013
-----------	---------	-----------------------	--------------------	--------------

MILI

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG;0.25MG</u>	<u>A205449 001</u>	Jul 07, 2016
-----------	----------------------	-----------------------	--------------------	--------------

MONO-LINYAH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG;0.25MG</u>	<u>A090523 001</u>	May 23, 2012
-----------	-----------------	-----------------------	--------------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

<u>AB</u>	AMNEAL PHARMS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A203870 001</u>	Nov 12, 2015
-----------	---------------	--	--------------------	--------------

<u>AB</u>		<u>0.035MG;0.25MG</u>	<u>A203865 001</u>	Oct 27, 2015
-----------	--	-----------------------	--------------------	--------------

<u>AB</u>		<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,</u>	<u>A203873 001</u>	May 12, 2016
-----------	--	--	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A200494 001	Jun 17, 2011
AB		<u>0.035MG; 0.25MG</u>	A200538 001	Apr 05, 2012
AB	GLENMARK PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	A204057 001	Feb 23, 2016
AB	LUPIN LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A205588 001	Apr 26, 2016
AB		<u>0.035MG; 0.25MG</u>	A205630 001	Oct 27, 2016
AB	LUPIN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	A200541 001	Jun 25, 2012
AB	MYLAN LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A201897 001	Jan 27, 2016
AB		<u>0.035MG; 0.25MG</u>	A201896 001	Jan 27, 2016
AB	NAARI PTE LTD	<u>0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG</u>	A200383 001	Apr 07, 2015
AB		<u>0.035MG; 0.25MG</u>	A200384 001	Apr 07, 2015
	<u>ORTHO TRI-CYCLEN</u>			
AB	+! JANSSEN PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	N019697 001	Jul 03, 1992
	<u>ORTHO TRI-CYCLEN LO</u>			
AB	+! JANSSEN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	N021241 001	Aug 22, 2002
	<u>PREVIFEM</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG; 0.25MG</u>	A076334 001	Jan 09, 2004
	<u>SPRINTEC</u>			
AB	! BARR	<u>0.035MG; 0.25MG</u>	A075804 001	Sep 25, 2002
	<u>TRI LO SPRINTEC</u>			
AB	BARR LABS INC	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	A076784 001	Jun 29, 2009
	<u>TRI-ESTARYLLA</u>			
AB	XIROMED	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A090793 001	Jan 30, 2013
	<u>TRI-LINYAH</u>			
AB	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A090524 001	May 30, 2012
	<u>TRI-LO-ESTARYLLA</u>			
AB	XIROMED	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	A091232 001	Jun 29, 2015
	<u>TRI-LO-MILI</u>			
AB	AUROBINDO PHARMA LTD	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	A205762 001	Nov 04, 2016
	<u>TRI-MILI</u>			
AB	AUROBINDO PHARMA LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A205441 001	Jul 06, 2016
	<u>TRI-PREVIFEM</u>			
AB	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A076335 001	Mar 26, 2004
	<u>TRI-SPRINTEC</u>			
AB	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	A075808 001	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	A075840 001	Nov 30, 2001
	TABLET; ORAL-28			
	<u>CRYSELLE</u>			
AB	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	A075840 002	Nov 30, 2001
	<u>ELINEST</u>			
AB	NOVAST LABS LTD	<u>0.03MG; 0.3MG</u>	A091105 001	Mar 28, 2012
	<u>LOW-OGESTREL-28</u>			
AB	MAYNE PHARMA	<u>0.03MG; 0.3MG</u>	A075288 002	Jul 28, 1999
	OGESTREL 0.5/50-28			
	! WATSON LABS	0.05MG; 0.5MG	A075406 002	Dec 15, 1999

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL

ANNOVERA

	+! THERAPEUTICSMD INC	0.013MG/24HR; 0.15MG/24HR	N209627 001	Aug 10, 2018
--	-----------------------	---------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	
---	---	---------	---	---------	-----	--

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+	!	WYETH PHARMS	250MG	N013026	002	
---	---	--------------	-------	---------	-----	--

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

<u>AB</u>		AKORN	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
<u>AB</u>		BIONPHARMA INC	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		HERITAGE PHARMS INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012
<u>AB</u>		STRIDES PHARMA	<u>250MG</u>	<u>A211928</u>	<u>001</u>	Feb 19, 2019

ZARONTIN

<u>AB</u>	+	!	PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>
-----------	---	---	-------------	--------------	----------------	------------

SYRUP; ORAL

ETHOSUXIMIDE

<u>AA</u>		MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
<u>AA</u>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000

ZARONTIN

<u>AA</u>	!	PARKE-DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	
-----------	---	-------------	------------------	----------------	------------	--

ETHOTOIN

TABLET; ORAL

PEGANONE

+	!	RECORDATI RARE	250MG	N010841	001	
---	---	----------------	-------	---------	-----	--

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>		ANI PHARMS INC	<u>200MG</u>	<u>A075126</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>			<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>		APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>			<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>		TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	!		<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

<u>AB</u>		AMNEAL PHARMS CO	<u>400MG</u>	<u>A208834</u>	<u>001</u>	Jun 07, 2018
<u>AB</u>			<u>500MG</u>	<u>A208834</u>	<u>002</u>	Jun 07, 2018
<u>AB</u>		APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>			<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>		EDENBRIDGE PHARMS	<u>400MG</u>	<u>A209888</u>	<u>001</u>	Nov 30, 2018
<u>AB</u>			<u>500MG</u>	<u>A209888</u>	<u>002</u>	Nov 30, 2018
<u>AB</u>		SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>			<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>		TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	!		<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>		TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>			<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>		TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>			<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>			<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>		TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>			<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	!		<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>		ZYDUS PHARMS	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>			<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>			<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	!	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	---	---	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206126</u>	<u>001</u>	Feb 24, 2017
<u>AP</u>		EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014

PRESCRIPTION DRUG PRODUCT LIST

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209058</u>	<u>001</u>	Apr 18, 2017
<u>AP</u>	HIKMA	<u>2MG/ML</u>	<u>A202354</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A201044</u>	<u>001</u>	Feb 07, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>	ZYDUS PHARMS	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+! ORGANON USA INC 68MG/IMPLANT N021529 002 May 31, 2011

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

! MYLAN 50MG A075635 001 Sep 19, 2001

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>	! FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	MYLAN LABS LTD	<u>20MG/ML</u>	<u>A203507</u>	<u>001</u>	Nov 20, 2017
<u>AP</u>		<u>20MG/ML</u>	<u>A204927</u>	<u>001</u>	Oct 31, 2017
<u>AP</u>	TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996
<u>AP</u>	WEST-WARD PHARMS INT	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+! CHEPLAPHARM EQ 100MG BASE/VIAL N020457 001 May 17, 1996

ETRAVIRINE

TABLET; ORAL

INTELENCE

+	JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
+		100MG	N022187	001	Jan 18, 2008
+	!	200MG	N022187	002	Dec 22, 2010

EVEROLIMUS

TABLET; ORAL

AFINITOR

<u>AB</u>	+	NOVARTIS	<u>2.5MG</u>	<u>N022334</u>	<u>003</u>	Jul 09, 2010
<u>AB</u>	+	!	<u>5MG</u>	<u>N022334</u>	<u>001</u>	Mar 30, 2009
<u>AB</u>	+		<u>7.5MG</u>	<u>N022334</u>	<u>004</u>	Mar 30, 2012
<u>AB</u>	+		<u>10MG</u>	<u>N022334</u>	<u>002</u>	Mar 30, 2009

EVEROLIMUS

<u>AB</u>		HIKMA	<u>0.25MG</u>	<u>A206133</u>	<u>001</u>	Apr 12, 2018
<u>AB</u>			<u>0.5MG</u>	<u>A206133</u>	<u>002</u>	Apr 12, 2018
<u>AB</u>			<u>0.75MG</u>	<u>A206133</u>	<u>003</u>	Apr 12, 2018
<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A207934</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A207934</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A207934</u>	<u>003</u>	Dec 09, 2019
<u>AB</u>		TEVA PHARMS USA	<u>2.5MG</u>	<u>A210050</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A210050</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A210050</u>	<u>003</u>	Dec 09, 2019
<u>AB</u>			<u>10MG</u>	<u>A210050</u>	<u>004</u>	Dec 09, 2019

ZORTRESS

<u>AB</u>	+	NOVARTIS	<u>0.25MG</u>	<u>N021560</u>	<u>001</u>	Apr 20, 2010
<u>AB</u>	+		<u>0.5MG</u>	<u>N021560</u>	<u>002</u>	Apr 20, 2010
<u>AB</u>	+	!	<u>0.75MG</u>	<u>N021560</u>	<u>003</u>	Apr 20, 2010
	+		1MG	N021560	004	Aug 10, 2018

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
+		3MG	N203985	002	Aug 29, 2012
+	!	5MG	N203985	003	Aug 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	+ !	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999
-----------	------------	-------------------------	-------------	----------------	------------	--------------

EXEMESTANE

AB		ALVOGEN	25MG	A200898	001	Jul 28, 2014
AB		BRECKENRIDGE	25MG	A211031	001	Feb 21, 2019
AB		CIPLA	25MG	A210323	001	Apr 27, 2018
AB		HIKMA	25MG	A077431	001	Apr 01, 2011
AB		MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019
AB		MYLAN	25MG	A203315	001	Mar 10, 2017
AB		UPSHER SMITH LABS	25MG	A209208	001	Jul 26, 2017
AB		ZYDUS PHARMS	25MG	A202602	001	Oct 03, 2018

EXENATIDE

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

+ !	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017
------------	----------------	-------------------------	---------	-----	--------------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+ !	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012
------------	----------------	----------	---------	-----	--------------

BYDUREON PEN

+ !	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014
------------	----------------	-----	---------	-----	--------------

INJECTABLE;SUBCUTANEOUS

BYETTA

+ !	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
------------	----------------	--------------------------	---------	-----	--------------

+ !		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005
------------	--	--------------------------	---------	-----	--------------

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	10MG	A211550	001	Oct 26, 2018
AB		ALKEM LABS LTD	10MG	A209234	001	Dec 21, 2017
AB		AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017
AB		APOTEX	10MG	A208332	001	Jun 12, 2017
AB		AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017
AB		GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015
AB		MYLAN	10MG	A201790	001	Apr 26, 2019
AB		OHM LABS INC	10MG	A207311	001	Jun 12, 2017
AB		SANDOZ INC	10MG	A203931	001	Jun 12, 2017
AB		TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017
AB		WATSON LABS INC	10MG	A200831	001	Jun 12, 2017
AB		ZYDUS PHARMS	10MG	A204331	001	Jun 12, 2017

ZETIA

AB	+ !	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002
-----------	------------	---------------	-------------	----------------	------------	--------------

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	10MG;10MG	A209222	001	Dec 22, 2017
AB			10MG;20MG	A209222	002	Dec 22, 2017
AB			10MG;40MG	A209222	003	Dec 22, 2017
AB			10MG;80MG	A209222	004	Dec 22, 2017
AB		AMNEAL PHARMS CO	10MG;10MG	A208831	001	Nov 21, 2017
AB			10MG;20MG	A208831	002	Nov 21, 2017
AB			10MG;40MG	A208831	003	Nov 21, 2017
AB			10MG;80MG	A208831	004	Nov 21, 2017
AB		ANI PHARMS INC	10MG;10MG	A201890	001	Apr 26, 2017
AB			10MG;20MG	A201890	002	Apr 26, 2017
AB			10MG;40MG	A201890	003	Apr 26, 2017
AB			10MG;80MG	A201890	004	Apr 26, 2017
AB		DR REDDYS LABS SA	10MG;10MG	A200909	001	Apr 26, 2017
AB			10MG;20MG	A200909	002	Apr 26, 2017
AB			10MG;40MG	A200909	003	Apr 26, 2017
AB			10MG;80MG	A200909	004	Apr 26, 2017
AB		GLENMARK PHARMS LTD	10MG;10MG	A208699	001	Jun 27, 2019
AB			10MG;20MG	A208699	002	Jun 27, 2019
AB			10MG;40MG	A208699	003	Jun 27, 2019
AB			10MG;80MG	A208699	004	Jun 27, 2019
AB		WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017
AB			10MG;20MG	A202968	002	Apr 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

<u>AB</u>		<u>10MG; 40MG</u>	<u>A202968 003</u>	Apr 26, 2017
<u>AB</u>		<u>10MG; 80MG</u>	<u>A202968 004</u>	Apr 26, 2017
<u>VYTORIN</u>				
<u>AB</u>	+	MSD INTL	<u>10MG; 10MG</u>	<u>N021687 001</u> Jul 23, 2004
<u>AB</u>	+		<u>10MG; 20MG</u>	<u>N021687 002</u> Jul 23, 2004
<u>AB</u>	+		<u>10MG; 40MG</u>	<u>N021687 003</u> Jul 23, 2004
<u>AB</u>	+	!	<u>10MG; 80MG</u>	<u>N021687 004</u> Jul 23, 2004

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>		APOTEX	<u>125MG</u>	<u>A091480 001</u> Jul 22, 2011
<u>AB</u>			<u>250MG</u>	<u>A091480 002</u> Jul 22, 2011
<u>AB</u>			<u>500MG</u>	<u>A091480 003</u> Jul 22, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>125MG</u>	<u>A091114 001</u> Mar 21, 2011
<u>AB</u>			<u>250MG</u>	<u>A091114 002</u> Mar 21, 2011
<u>AB</u>			<u>500MG</u>	<u>A091114 003</u> Mar 21, 2011
<u>AB</u>		CIPLA	<u>125MG</u>	<u>A078278 001</u> Mar 21, 2011
<u>AB</u>			<u>250MG</u>	<u>A078278 002</u> Mar 21, 2011
<u>AB</u>			<u>500MG</u>	<u>A078278 003</u> Mar 21, 2011
<u>AB</u>		HETERO LABS LTD V	<u>125MG</u>	<u>A202438 001</u> Sep 10, 2014
<u>AB</u>			<u>250MG</u>	<u>A202438 002</u> Sep 10, 2014
<u>AB</u>			<u>500MG</u>	<u>A202438 003</u> Sep 10, 2014
<u>AB</u>		HIKMA	<u>125MG</u>	<u>A090128 001</u> Mar 21, 2011
<u>AB</u>			<u>250MG</u>	<u>A090128 002</u> Mar 21, 2011
<u>AB</u>			<u>500MG</u>	<u>A090128 003</u> Mar 21, 2011
<u>AB</u>		MACLEODS PHARMS LTD	<u>125MG</u>	<u>A201022 001</u> Jan 12, 2012
<u>AB</u>			<u>250MG</u>	<u>A201022 002</u> Jan 12, 2012
<u>AB</u>			<u>500MG</u>	<u>A201022 003</u> Jan 12, 2012
<u>AB</u>		MYLAN	<u>125MG</u>	<u>A201333 001</u> Mar 24, 2011
<u>AB</u>			<u>250MG</u>	<u>A201333 002</u> Mar 24, 2011
<u>AB</u>			<u>500MG</u>	<u>A201333 003</u> Mar 24, 2011
<u>AB</u>		TEVA PHARMS	<u>125MG</u>	<u>A077487 001</u> Aug 24, 2007
<u>AB</u>			<u>250MG</u>	<u>A077487 002</u> Aug 24, 2007
<u>AB</u>		!	<u>500MG</u>	<u>A077487 003</u> Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>		HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995 001</u> May 30, 2014
<u>AB</u>	!	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440 001</u> Jun 29, 2010
<u>AB</u>		NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020 001</u> May 27, 2010
<u>AB</u>		NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695 001</u> Dec 17, 2012

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>		ATHENEX INC	<u>10MG/ML</u>	<u>A075651 001</u> Apr 16, 2001
<u>AP</u>			<u>10MG/ML</u>	<u>A075684 001</u> Apr 16, 2001
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709 001</u> Apr 16, 2001
<u>AP</u>		MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078641 001</u> Jun 25, 2008
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A075488 001</u> Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>		ATHENEX INC	<u>10MG/ML</u>	<u>A075622 001</u> Apr 16, 2001
<u>AP</u>			<u>10MG/ML</u>	<u>A075825 001</u> Apr 17, 2001
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813 001</u> Apr 16, 2001
<u>AP</u>		MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078642 001</u> Jun 25, 2008
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A075486 001</u> Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	0.4MG/ML	A075591 001	May 10, 2001
---	-----------------	----------	-------------	--------------

TABLET; ORAL

FAMOTIDINE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916 001</u> May 22, 2009
<u>AB</u>			<u>40MG</u>	<u>A078916 002</u> May 22, 2009
<u>AB</u>		APOTEX	<u>20MG</u>	<u>A075611 001</u> Jul 23, 2001
<u>AB</u>			<u>40MG</u>	<u>A075611 002</u> Jul 23, 2001
<u>AB</u>		AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206530 001</u> Dec 22, 2015
<u>AB</u>			<u>40MG</u>	<u>A206530 002</u> Dec 22, 2015
<u>AB</u>		CARLSBAD	<u>20MG</u>	<u>A075805 001</u> Apr 16, 2001

PRESCRIPTION DRUG PRODUCT LIST

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	CELLTRION	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>	PERRIGO R AND D	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001

PEPCID

<u>AB</u>	+ VALEANT PHARMS NORTH	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+!	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

<u>AB</u>	+! HORIZON	26.6MG; 800MG	N022519	001	Apr 23, 2011
-----------	------------	---------------	---------	-----	--------------

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

<u>AB</u>	ALEMBIC PHARMS LTD	<u>40MG</u>	<u>A205421</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205421</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	HIKMA	<u>40MG</u>	<u>A205414</u>	<u>001</u>	Oct 15, 2019
<u>AB</u>		<u>80MG</u>	<u>A205414</u>	<u>002</u>	Oct 15, 2019
<u>AB</u>	INDOCO REMEDIES	<u>40MG</u>	<u>A210292</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210292</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MSN	<u>40MG</u>	<u>A210461</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210461</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A205385</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205385</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	SUN PHARM	<u>40MG</u>	<u>A205467</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205467</u>	<u>002</u>	Jul 01, 2019

ULORIC

<u>AB</u>	+ TAKEDA PHARMS USA	<u>40MG</u>	<u>N021856</u>	<u>001</u>	Feb 13, 2009
<u>AB</u>	+!	<u>80MG</u>	<u>N021856</u>	<u>002</u>	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

<u>AB</u>	+! IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019
-----------	-----------	---------------	---------	-----	--------------

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
<u>AB</u>	TARO	<u>600MG/5ML</u>	<u>A206314</u>	<u>001</u>	Jun 16, 2017
<u>AB</u>	VISTAPHARM	<u>600MG/5ML</u>	<u>A211333</u>	<u>001</u>	May 31, 2019

FELBATOL

<u>AB</u>	+! MYLAN SPECIALITY LP	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993
-----------	------------------------	------------------	----------------	------------	--------------

TABLET; ORAL

FELBAMATE

<u>AB</u>	ALVOGEN	<u>400MG</u>	<u>A204595</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>		<u>600MG</u>	<u>A204595</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>	ANI PHARMS INC	<u>400MG</u>	<u>A202284</u>	<u>001</u>	Nov 04, 2015
<u>AB</u>		<u>600MG</u>	<u>A202284</u>	<u>002</u>	Nov 04, 2015
<u>AB</u>	CADILA	<u>400MG</u>	<u>A208970</u>	<u>001</u>	May 30, 2017
<u>AB</u>		<u>600MG</u>	<u>A208970</u>	<u>002</u>	May 30, 2017
<u>AB</u>	TARO	<u>400MG</u>	<u>A207093</u>	<u>001</u>	Apr 20, 2017
<u>AB</u>		<u>600MG</u>	<u>A207093</u>	<u>002</u>	Apr 20, 2017

FELBATOL

<u>AB</u>	+ MYLAN SPECIALITY LP	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+!	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

PRESCRIPTION DRUG PRODUCT LIST

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417 001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417 002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417 003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365 001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365 002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365 003</u>	Dec 17, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG</u>	<u>A201964 001</u>	Nov 08, 2013
<u>AB</u>		<u>5MG</u>	<u>A201964 002</u>	Nov 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A201964 003</u>	Nov 08, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A203983 001</u>	Aug 19, 2016
<u>AB</u>		<u>5MG</u>	<u>A203983 002</u>	Aug 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A203983 003</u>	Aug 19, 2016
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203032 001</u>	May 21, 2015
<u>AB</u>		<u>5MG</u>	<u>A203032 002</u>	May 21, 2015
<u>AB</u>		<u>10MG</u>	<u>A203032 003</u>	May 21, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091200 001</u>	Dec 13, 2013
<u>AB</u>		<u>5MG</u>	<u>A091200 002</u>	Dec 13, 2013
<u>AB</u>		<u>10MG</u>	<u>A091200 003</u>	Dec 13, 2013
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A075896 001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896 002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896 003</u>	Nov 02, 2004
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170 001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170 002</u>	Nov 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A202170 003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815 001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815 002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815 003</u>	Oct 28, 2011
<u>AB</u>	YILING PHARM LTD	<u>2.5MG</u>	<u>A210847 001</u>	Oct 26, 2018
<u>AB</u>		<u>5MG</u>	<u>A210847 002</u>	Oct 26, 2018
<u>AB</u>		<u>10MG</u>	<u>A210847 003</u>	Oct 26, 2018
<u>AB</u>	YUNG SHIN PHARM	<u>2.5MG</u>	<u>A204800 001</u>	Apr 29, 2019
<u>AB</u>		<u>5MG</u>	<u>A204800 002</u>	Apr 29, 2019
<u>AB</u>		<u>10MG</u>	<u>A204800 003</u>	Apr 29, 2019

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

<u>AB</u>	+ LUPIN ATLANTIS	<u>43MG</u>	<u>N021695 001</u>	Nov 30, 2004
<u>AB</u>	+!	<u>130MG</u>	<u>N021695 003</u>	Nov 30, 2004

FENOFIBRATE

<u>AB</u>	SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748 001</u>	Oct 31, 2014
<u>AB</u>		<u>130MG</u>	<u>A201748 002</u>	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

<u>AB</u>	AJANTA PHARMA LTD	<u>67MG</u>	<u>A210705 001</u>	Sep 10, 2018
<u>AB</u>		<u>134MG</u>	<u>A210705 002</u>	Sep 10, 2018
<u>AB</u>		<u>200MG</u>	<u>A210705 003</u>	Sep 10, 2018
<u>AB</u>	AMERIGEN PHARMS LTD	<u>67MG</u>	<u>A209504 001</u>	Apr 30, 2018
<u>AB</u>		<u>134MG</u>	<u>A209504 002</u>	Apr 30, 2018
<u>AB</u>		<u>200MG</u>	<u>A209504 003</u>	Apr 30, 2018
<u>AB</u>	APOTEX	<u>43MG</u>	<u>A202252 001</u>	Jul 26, 2013
<u>AB</u>		<u>130MG</u>	<u>A202252 002</u>	Jul 26, 2013
<u>AB</u>	AUSTARPHARMA	<u>67MG</u>	<u>A207805 001</u>	Nov 16, 2017
<u>AB</u>		<u>134MG</u>	<u>A207805 002</u>	Nov 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A207805 003</u>	Nov 16, 2017
<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859 001</u>	Mar 01, 2012
<u>AB</u>		<u>130MG</u>	<u>A090859 002</u>	Mar 01, 2012
<u>AB</u>	GLENMARK PHARMS LTD	<u>67MG</u>	<u>A205566 001</u>	Apr 07, 2017
<u>AB</u>		<u>134MG</u>	<u>A205566 002</u>	Apr 07, 2017
<u>AB</u>		<u>200MG</u>	<u>A205566 003</u>	Apr 07, 2017
<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868 001</u>	Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868 002</u>	Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868 003</u>	Oct 27, 2003
<u>AB</u>	INVAGEN PHARMS	<u>67MG</u>	<u>A207378 001</u>	Mar 28, 2017
<u>AB</u>		<u>134MG</u>	<u>A207378 002</u>	Mar 28, 2017
<u>AB</u>		<u>200MG</u>	<u>A207378 003</u>	Mar 28, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>43MG</u>	<u>A202579 001</u>	Jan 10, 2013
<u>AB</u>		<u>67MG</u>	<u>A202676 001</u>	Oct 23, 2012
<u>AB</u>		<u>130MG</u>	<u>A202579 002</u>	Jan 10, 2013

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

<u>AB</u>		<u>134MG</u>	<u>A202676 002</u>	Oct 23, 2012
<u>AB</u>		<u>200MG</u>	<u>A202676 003</u>	Oct 23, 2012
<u>AB</u>	RHODES PHARMS	<u>67MG</u>	<u>A075753 001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753 002</u>	Apr 09, 2002
<u>AB</u>		<u>200MG</u>	<u>A075753 003</u>	Apr 09, 2002
<u>AB</u>	TORRENT	<u>67MG</u>	<u>A210782 001</u>	Jun 26, 2018
<u>AB</u>		<u>134MG</u>	<u>A210782 002</u>	Jun 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A210782 003</u>	Jun 26, 2018
	ANTARA (MICRONIZED)			
	+ LUPIN ATLANTIS	30MG	N021695 004	Oct 18, 2013
	+ LIPOFEN	90MG	N021695 005	Oct 18, 2013
	+ CIPHER PHARMS INC	50MG	N021612 001	Jan 11, 2006
	+!	150MG	N021612 003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	AJANTA PHARMA LTD	<u>54MG</u>	<u>A210138 001</u>	Jul 23, 2018
<u>AB</u>		<u>160MG</u>	<u>A210138 002</u>	Jul 23, 2018
<u>AB</u>	ALEMBIC PHARMS LTD	<u>48MG</u>	<u>A210476 001</u>	Aug 09, 2019
<u>AB</u>		<u>145MG</u>	<u>A210476 002</u>	Aug 09, 2019
<u>AB</u>	AMNEAL PHARMS LLC	<u>48MG</u>	<u>A209951 001</u>	Feb 09, 2018
<u>AB</u>		<u>54MG</u>	<u>A209950 001</u>	Mar 19, 2018
<u>AB</u>		<u>145MG</u>	<u>A209951 002</u>	Feb 09, 2018
<u>AB</u>		<u>160MG</u>	<u>A209950 002</u>	Mar 19, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>48MG</u>	<u>A205118 001</u>	May 05, 2016
<u>AB</u>		<u>145MG</u>	<u>A205118 002</u>	May 05, 2016
<u>AB</u>	AUSTARPHARMA	<u>54MG</u>	<u>A207803 001</u>	Dec 19, 2017
<u>AB</u>		<u>160MG</u>	<u>A207803 002</u>	Dec 19, 2017
<u>AB</u>	CIPLA	<u>48MG</u>	<u>A208709 001</u>	Dec 15, 2016
<u>AB</u>		<u>145MG</u>	<u>A208709 002</u>	Dec 15, 2016
<u>AB</u>	HETERO LABS LTD III	<u>48MG</u>	<u>A204598 001</u>	Jul 12, 2016
<u>AB</u>		<u>145MG</u>	<u>A204598 002</u>	Jul 12, 2016
<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509 001</u>	Mar 26, 2008
<u>AB</u>	!	<u>160MG</u>	<u>A076509 002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856 001</u>	Dec 23, 2011
<u>AB</u>		<u>54MG</u>	<u>A204019 001</u>	Aug 17, 2015
<u>AB</u>		<u>145MG</u>	<u>A090856 002</u>	Dec 23, 2011
<u>AB</u>		<u>160MG</u>	<u>A204019 002</u>	Aug 17, 2015
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A204475 001</u>	Jun 23, 2016
<u>AB</u>		<u>54MG</u>	<u>A076520 001</u>	Oct 25, 2007
<u>AB</u>		<u>120MG</u>	<u>A204475 002</u>	Jun 23, 2016
<u>AB</u>		<u>160MG</u>	<u>A076520 003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856 001</u>	Dec 07, 2012
<u>AB</u>		<u>145MG</u>	<u>A202856 002</u>	Dec 07, 2012
<u>AB</u>	NUVO PHARM	<u>54MG</u>	<u>A210670 001</u>	Sep 06, 2019
<u>AB</u>		<u>160MG</u>	<u>A210670 002</u>	Sep 06, 2019
<u>AB</u>	ORIT LABS LLC	<u>54MG</u>	<u>A209660 001</u>	Feb 11, 2019
<u>AB</u>		<u>160MG</u>	<u>A209660 002</u>	Feb 11, 2019
<u>AB</u>	PRINSTON INC	<u>48MG</u>	<u>A211080 001</u>	Aug 28, 2018
<u>AB</u>		<u>145MG</u>	<u>A211080 002</u>	Aug 28, 2018
<u>AB</u>	RHODES PHARMS	<u>54MG</u>	<u>A076433 001</u>	May 13, 2005
<u>AB</u>		<u>160MG</u>	<u>A076433 002</u>	May 13, 2005
<u>AB</u>	SUN PHARM	<u>48MG</u>	<u>A200884 001</u>	Sep 07, 2017
<u>AB</u>		<u>145MG</u>	<u>A200884 002</u>	Sep 07, 2017
<u>AB</u>	SUN PHARM INDS LTD	<u>54MG</u>	<u>A076635 001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635 003</u>	Oct 31, 2005
<u>AB</u>	VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715 001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715 002</u>	Apr 05, 2012
	<u>FENOGLIDE</u>			
<u>AB</u>	+ SALIX	<u>40MG</u>	<u>N022118 001</u>	Aug 10, 2007
<u>AB</u>	+!	<u>120MG</u>	<u>N022118 002</u>	Aug 10, 2007
	<u>TRICOR</u>			
<u>AB</u>	+ ABBVIE	<u>48MG</u>	<u>N021656 001</u>	Nov 05, 2004
<u>AB</u>	+!	<u>145MG</u>	<u>N021656 002</u>	Nov 05, 2004
	<u>TRIGLIDE</u>			
BX	+ SKYEPHARMA AG	160MG	N021350 002	May 07, 2005

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

SUN PHARM INDS LTD

107MG

A076635 002 Oct 31, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

+ ATHENA

35MG

N022418 001 Aug 14, 2009

+!

105MG

N022418 002 Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAMAP +! HOSPIRAEQ 10MG BASE/MLN019922 001 Sep 23, 1997FENOLDOPAM MESYLATEAP SANDOZ INCEQ 10MG BASE/MLA077155 001 Feb 15, 2005AP WEST-WARD PHARMS
INTEQ 10MG BASE/MLA076582 001 Oct 12, 2004FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+ XSPIRE PHARMA

EQ 200MG BASE

N017604 003

+!

EQ 400MG BASE

N017604 004 Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

! XSPIRE PHARMA

EQ 600MG BASE

A072267 001 Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100AB + JANSSEN PHARMS100MCG/HRN019813 001 Aug 07, 1990DURAGESIC-12AB + JANSSEN PHARMS12.5MCG/HRN019813 005 Feb 04, 2005DURAGESIC-25AB +! JANSSEN PHARMS25MCG/HRN019813 004 Aug 07, 1990DURAGESIC-37AB + JANSSEN PHARMS37.5MCG/HRN019813 006 Jan 24, 2018DURAGESIC-50AB + JANSSEN PHARMS50MCG/HRN019813 003 Aug 07, 1990DURAGESIC-75AB + JANSSEN PHARMS75MCG/HRN019813 002 Aug 07, 1990FENTANYL-100AB 3M DRUG DELIVERY100MCG/HRA202097 005 Nov 04, 2016AB AVEVA100MCG/HRA077449 004 Oct 20, 2008AB LAVIPHARM LABS100MCG/HRA077051 004 Aug 04, 2006AB MYLAN TECHNOLOGIES100MCG/HRA076258 004 Jan 28, 2005AB SPECGX LLC100MCG/HRA077154 004 Feb 09, 2011FENTANYL-12AB 3M DRUG DELIVERY12.5MCG/HRA202097 001 Nov 04, 2016AB AVEVA12.5MCG/HRA077449 005 Sep 11, 2015AB MYLAN TECHNOLOGIES12.5MCG/HRA076258 005 Jan 23, 2007AB SPECGX LLC12.5MCG/HRA077154 005 Jun 11, 2015FENTANYL-25AB 3M DRUG DELIVERY25MCG/HRA202097 002 Nov 04, 2016AB AVEVA25MCG/HRA077449 001 Oct 20, 2008AB LAVIPHARM LABS25MCG/HRA077051 001 Aug 04, 2006AB MYLAN TECHNOLOGIES25MCG/HRA076258 001 Jan 28, 2005AB SPECGX LLC25MCG/HRA077154 001 Feb 09, 2011FENTANYL-37AB AVEVA37.5MCG/HRA077449 006 Dec 06, 2017AB MYLAN TECHNOLOGIES37.5MCG/HRA076258 006 Dec 29, 2014FENTANYL-50AB 3M DRUG DELIVERY50MCG/HRA202097 003 Nov 04, 2016AB AVEVA50MCG/HRA077449 002 Oct 20, 2008AB LAVIPHARM LABS50MCG/HRA077051 002 Aug 04, 2006AB MYLAN TECHNOLOGIES50MCG/HRA076258 002 Jan 28, 2005AB SPECGX LLC50MCG/HRA077154 002 Feb 09, 2011FENTANYL-62AB AVEVA62.5MCG/HRA077449 007 Dec 06, 2017FENTANYL-75AB 3M DRUG DELIVERY75MCG/HRA202097 004 Nov 04, 2016AB AVEVA75MCG/HRA077449 003 Oct 20, 2008AB LAVIPHARM LABS75MCG/HRA077051 003 Aug 04, 2006

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-75

AB	MYLAN TECHNOLOGIES	75MCG/HR	A076258 003	Jan 28, 2005
AB	SPECGX LLC	75MCG/HR	A077154 003	Feb 09, 2011

FENTANYL-87

AB	AVEVA	87.5MCG/HR	A077449 008	Dec 06, 2017
	FENTANYL-62			
	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258 007	Dec 29, 2014
	FENTANYL-87			
	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258 008	Dec 29, 2014

SPRAY;SUBLINGUAL

SUBSYS

+	BTCP PHARMA	0.1MG	N202788 001	Jan 04, 2012
+		0.2MG	N202788 002	Jan 04, 2012
+	!	0.4MG	N202788 003	Jan 04, 2012
+		0.6MG	N202788 004	Jan 04, 2012
+		0.8MG	N202788 005	Jan 04, 2012
+		1.2MG	N202788 006	Aug 30, 2012
+		1.6MG	N202788 007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

AP	HOSPIRA	EQ 0.05MG BASE/ML	N019115 001	Jan 12, 1985
-----------	---------	--------------------------	--------------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762 001	May 03, 2019	
AP	HOSPIRA	EQ 0.05MG BASE/ML	A072786 001	Sep 24, 1991	
AP	+	WEST-WARD PHARMS	EQ 0.05MG BASE/ML	N019101 001	Jul 11, 1984

SUBLIMAZE PRESERVATIVE FREE

AP	+	AKORN	EQ 0.05MG BASE/ML	N016619 001
-----------	---	-------	--------------------------	--------------------

SPRAY, METERED;NASAL

LAZANDA

+	BTCP PHARMA	EQ 0.1MG BASE	N022569 001	Jun 30, 2011
+	!	EQ 0.4MG BASE	N022569 002	Jun 30, 2011

TABLET;BUCCAL, SUBLINGUAL

FENTORA

+	CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006
+		EQ 0.2MG BASE	N021947 002	Sep 25, 2006
+	!	EQ 0.4MG BASE	N021947 003	Sep 25, 2006
+		EQ 0.6MG BASE	N021947 004	Sep 25, 2006
+		EQ 0.8MG BASE	N021947 005	Sep 25, 2006

TROCHE/LOZENGE;TRANSMUCOSAL

ACTIQ

AB	+	CEPHALON	EQ 0.2MG BASE	N020747 001	Nov 04, 1998
AB	+	!	EQ 0.4MG BASE	N020747 002	Nov 04, 1998
AB	+		EQ 0.6MG BASE	N020747 003	Nov 04, 1998
AB	+		EQ 0.8MG BASE	N020747 004	Nov 04, 1998
AB	+		EQ 1.2MG BASE	N020747 005	Nov 04, 1998
AB	+		EQ 1.6MG BASE	N020747 006	Nov 04, 1998

FENTANYL CITRATE

AB	SPECGX LLC	EQ 0.2MG BASE	A078907 001	Oct 30, 2009
AB		EQ 0.4MG BASE	A078907 002	Oct 30, 2009
AB		EQ 0.6MG BASE	A078907 003	Oct 30, 2009
AB		EQ 0.8MG BASE	A078907 004	Oct 30, 2009
AB		EQ 1.2MG BASE	A078907 005	Oct 30, 2009
AB		EQ 1.6MG BASE	A078907 006	Oct 30, 2009

FERRIC CARBOXYMALTOSE

INJECTABLE;INTRAVENOUS

INJECTAFER

+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565 001	Jul 25, 2013
---	-----------	--------------------------------	-------------	--------------

FERRIC CITRATE

TABLET;ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874 001	Sep 05, 2014
---	-----------------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FERRIC HEXACYANOFERRATE(II)

CAPSULE;ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+! HEYL CHEMISCH 500MG N021626 001 Oct 02, 2003

FERRIC MALTOL

CAPSULE;ORAL

ACCRUFER

+! SHIELD TX 30MG IRON N212320 001 Jul 25, 2019

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+! ROCKWELL MEDICAL 272MG IRON/PACKET N208551 001 Apr 25, 2016
INC

SOLUTION;INTRAVENOUS

TRIFERIC

+! ROCKWELL MEDICAL 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015
INCFERUMOXYTOL

SOLUTION;INTRAVENOUS

FERAHEME

+! AMAG PHARMS INC EQ 510MG IRON/17ML (EQ 30MG IRON/ML) N022180 001 Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE**AB** AUROBINDO PHARMA **4MG** **A205007 001** Feb 17, 2017
LTD**AB** **8MG** **A205007 002** Feb 17, 2017**AB** DR REDDYS LABS LTD **4MG** **A204975 001** Aug 13, 2019**AB** **8MG** **A204975 002** Aug 13, 2019**AB** ZYDUS PHARMS **4MG** **A204946 001** Oct 03, 2017**AB** **8MG** **A204946 002** Oct 03, 2017TOVIAZ**AB** + PFIZER **4MG** **N022030 001** Oct 31, 2008**AB** +! **8MG** **N022030 002** Oct 31, 2008FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE**AB** BARR **30MG** **A076191 001** Aug 31, 2005**AB** **60MG** **A076191 002** Aug 31, 2005**AB** **180MG** **A076191 003** Aug 31, 2005**AB** DR REDDYS LABS LTD **30MG** **A076502 001** Apr 11, 2006**AB** **60MG** **A076502 002** Apr 11, 2006**AB** **180MG** **A076502 003** Apr 11, 2006**AB** MYLAN **60MG** **A077081 003** Apr 11, 2008**AB** **180MG** **A077081 001** Apr 16, 2007**AB** TEVA **30MG** **A076447 001** Sep 01, 2005**AB** **60MG** **A076447 002** Sep 01, 2005**AB** **180MG** **A076447 003** Sep 01, 2005FIDAXOMICIN

TABLET;ORAL

DIFICID

+! CUBIST PHARMS LLC 200MG N201699 001 May 27, 2011

FINASTERIDE

TABLET;ORAL

FINASTERIDE**AB** ACCORD HLTHCARE **1MG** **A091643 001** Nov 05, 2013**AB** **5MG** **A090121 001** Feb 23, 2010**AB** ACTAVIS TOTOWA **1MG** **A078371 001** Nov 05, 2013**AB** ACTAVIS TOTOWA TEVA **5MG** **A077914 001** Mar 28, 2007**AB** ALKEM LABS LTD **1MG** **A207750 001** Jan 06, 2017**AB** **5MG** **A204304 001** Jan 05, 2017**AB** AUROBINDO PHARMA **5MG** **A078341 001** Oct 30, 2007**AB** AUROBINDO PHARMA **1MG** **A203687 001** Nov 05, 2013
LTD**AB** CIPLA **1MG** **A077335 001** Nov 20, 2014**AB** DR REDDYS LABS INC **1MG** **A076436 001** Jul 28, 2006**AB** DR REDDYS LABS LTD **5MG** **A076437 001** Feb 28, 2007**AB** HETERO LABS LTD III **1MG** **A090060 001** Jul 01, 2013**AB** **5MG** **A090061 001** Jun 07, 2010**AB** SUN PHARM **1MG** **A090508 001** Jul 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

FINASTERIDE

TABLET; ORAL

FINASTERIDE

<u>AB</u>		<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>	TEVA	<u>1MG</u>	<u>A076905</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	+!	MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
-----------	----	-------	------------	----------------	------------	--------------

PROSCAR

<u>AB</u>	+!	MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992
-----------	----	-------	------------	----------------	------------	--------------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

<u>AB</u>		BIOCON LTD	<u>EQ 0.5MG BASE</u>	<u>A207979</u>	<u>001</u>	Dec 04, 2019
<u>AB</u>		HEC PHARM CO LTD	<u>EQ 0.5MG BASE</u>	<u>A207939</u>	<u>001</u>	Dec 04, 2019
<u>AB</u>		SUN PHARM	<u>EQ 0.5MG BASE</u>	<u>A208014</u>	<u>001</u>	Dec 04, 2019

GILENYA

<u>AB</u>	+!	NOVARTIS	<u>EQ 0.5MG BASE</u>	<u>N022527</u>	<u>001</u>	Sep 21, 2010
	+		EQ 0.25MG BASE	N022527	002	May 11, 2018

FISH OIL TRIGLYCERIDES

EMULSION; INTRAVENOUS

OMEGA VEN

	+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018
	+!		10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

	+!	FRESENIUS KABI USA	3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)	N207648	001	Jul 13, 2016
	+!		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)	N207648	002	Jul 13, 2016
	+!		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML)	N207648	003	Jul 13, 2016
	+!		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (1000ML)	N207648	004	Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>		EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	!	PADDOCK LLC	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

<u>AB</u>		AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>			<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>			<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>		ANI PHARMS INC	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>			<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>			<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>		AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A202821</u>	<u>001</u>	Nov 03, 2017
<u>AB</u>			<u>100MG</u>	<u>A202821</u>	<u>002</u>	Nov 03, 2017
<u>AB</u>			<u>150MG</u>	<u>A202821</u>	<u>003</u>	Nov 03, 2017
<u>AB</u>		HIKMA	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>			<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>	!		<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003
<u>AB</u>		SUN PHARM INDS LTD	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>			<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>			<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003

TAMBOCOR

<u>AB</u>	+	CNTY LINE PHARMS	<u>50MG</u>	<u>N018830</u>	<u>004</u>	Aug 23, 1988
<u>AB</u>	+		<u>100MG</u>	<u>N018830</u>	<u>001</u>	Oct 31, 1985
<u>AB</u>	+		<u>150MG</u>	<u>N018830</u>	<u>003</u>	Jun 03, 1988

PRESCRIPTION DRUG PRODUCT LIST

FLIBANSERIN

TABLET; ORAL

ADDYI

+! SPROUT PHARMS 100MG N022526 001 Aug 18, 2015

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+! LIFE MOLECULAR 30ML (1.4-135mCi/ML) N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+! AVID RADIOPHARMS 10-30ML (13.5-51mCi/ML) N202008 002 Apr 06, 2012

INC

+! 10-50ML (13.5-51mCi/ML) N202008 003 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE**AP** FRESENIUS KABI USA 500MG/VIAL **A075837 001** Feb 22, 2001**AP** ! WEST-WARD PHARMS 500MG/VIAL **A075387 001** Apr 16, 2000
INTFLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+! BLUE EARTH 9-221mCi/ML N208054 001 May 27, 2016

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN**AB** + PFIZER 50MG/5ML **N020090 001** Dec 23, 1993**AB** +! 200MG/5ML **N020090 002** Dec 23, 1993FLUCONAZOLE**AB** AUROBINDO PHARMA 50MG/5ML **A079150 001** Sep 18, 2009
LTD**AB** 200MG/5ML **A079150 002** Sep 18, 2009**AB** HIKMA 50MG/5ML **A076246 001** Jul 29, 2004**AB** 200MG/5ML **A076246 002** Jul 29, 2004

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER**AP** HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A078764 001** Jan 30, 2012**AP** 400MG/200ML (2MG/ML) **A078764 002** Jan 30, 2012**AP** ! HOSPIRA 200MG/100ML (2MG/ML) **A076304 001** Jul 29, 2004**AP** ! 400MG/200ML (2MG/ML) **A076304 002** Jul 29, 2004**AP** WOODWARD 200MG/100ML (2MG/ML) **A077988 001** May 26, 2010**AP** 400MG/200ML (2MG/ML) **A077988 002** May 26, 2010FLUCONAZOLE IN SODIUM CHLORIDE 0.9%**AP** BAXTER HLTHCARE 200MG/100ML (2MG/ML) **A077947 001** May 26, 2010
CORP**AP** 400MG/200ML (2MG/ML) **A077947 002** May 26, 2010**AP** FRESENIUS KABI USA 200MG/100ML (2MG/ML) **A076145 001** Jul 29, 2004**AP** 400MG/200ML (2MG/ML) **A076145 002** Jul 29, 2004**AP** HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A076736 001** Aug 23, 2005**AP** WEST-WARD PHARMS 200MG/100ML (2MG/ML) **A076087 001** Jul 29, 2004**AP** INT 400MG/200ML (2MG/ML) **A076087 003** Jul 29, 2004FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**AP** BAXTER HLTHCARE 200MG/100ML (2MG/ML) **A076766 001** Jul 29, 2004**AP** 400MG/200ML (2MG/ML) **A076766 002** Jul 29, 2004**AP** HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A078698 001** Jan 30, 2012**AP** 400MG/200ML (2MG/ML) **A078698 002** Jan 30, 2012**AP** HOSPIRA 200MG/100ML (2MG/ML) **A076303 001** Jul 29, 2004**AP** 400MG/200ML (2MG/ML) **A076303 002** Jul 29, 2004**AP** ! INFORLIFE 200MG/100ML (2MG/ML) **A079104 001** Jul 30, 2009**AP** ! 400MG/200ML (2MG/ML) **A079104 002** Jul 30, 2009**AP** WEST-WARD PHARMS 200MG/100ML (2MG/ML) **A078107 001** Jul 30, 2008**AP** INT 400MG/200ML (2MG/ML) **A078107 002** Jul 30, 2008**AP** WOODWARD 200MG/100ML (2MG/ML) **A077909 001** May 26, 2010**AP** 400MG/200ML (2MG/ML) **A077909 002** May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

WEST-WARD PHARMS 100MG/50ML (2MG/ML) A076087 002 Sep 26, 2008

INT

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

WOODWARD

100MG/50ML (2MG/ML)

A077909 003 Apr 20, 2015

TABLET; ORAL

DIFLUCAN

<u>AB</u>	+	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>	+		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>	+		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	!	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>		AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>			<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>			<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>		CHARTWELL	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		DR REDDYS LABS INC	<u>50MG</u>	<u>A076658</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076658</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076658</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076658</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>			<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>			<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>			<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>		HARRIS PHARM	<u>50MG</u>	<u>A078423</u>	<u>001</u>	Mar 07, 2011
<u>AB</u>			<u>100MG</u>	<u>A078423</u>	<u>002</u>	Mar 07, 2011
<u>AB</u>			<u>150MG</u>	<u>A078423</u>	<u>003</u>	Mar 07, 2011
<u>AB</u>			<u>200MG</u>	<u>A078423</u>	<u>004</u>	Mar 07, 2011
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>			<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>			<u>150MG</u>	<u>A076957</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>			<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
<u>AB</u>		ZYDUS PHARMS	<u>50MG</u>	<u>A208963</u>	<u>001</u>	Feb 16, 2017
<u>AB</u>			<u>100MG</u>	<u>A208963</u>	<u>002</u>	Feb 16, 2017
<u>AB</u>			<u>150MG</u>	<u>A208963</u>	<u>003</u>	Feb 16, 2017
<u>AB</u>			<u>200MG</u>	<u>A208963</u>	<u>004</u>	Feb 16, 2017

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	+	BAUSCH	<u>250MG</u>	<u>N017001</u>	<u>001</u>	
<u>AB</u>	+	!	<u>500MG</u>	<u>N017001</u>	<u>002</u>	

FLUCYTOSINE

<u>AB</u>		HIKMA	<u>250MG</u>	<u>A206550</u>	<u>001</u>	Oct 17, 2017
<u>AB</u>			<u>500MG</u>	<u>A206550</u>	<u>002</u>	Oct 17, 2017
<u>AB</u>		NOVEL LABS INC	<u>250MG</u>	<u>A204652</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>			<u>500MG</u>	<u>A204652</u>	<u>002</u>	Jul 07, 2017
<u>AB</u>		RECIPHARM	<u>250MG</u>	<u>A207536</u>	<u>001</u>	Jun 18, 2018
<u>AB</u>			<u>500MG</u>	<u>A207536</u>	<u>002</u>	Jun 18, 2018
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS LLC	<u>50MG/2ML (25MG/ML)</u>	<u>A203738</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	AREVA PHARMS	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	CUSTOPHARM INC	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>	! FRESENIUS KABI USA	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	! HOSPIRA	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A200648</u>	<u>001</u>	Oct 16, 2012
<u>AP</u>	SAGENT PHARMS INC	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004
<u>AP</u>	+! SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	3D IMAGING DRUG	<u>20-300mCi/ML</u>	<u>A203778</u>	<u>001</u>	Oct 30, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>20-300mCi/ML</u>	<u>A203710</u>	<u>001</u>	May 01, 2015
<u>AP</u>		<u>20-300mCi/ML</u>	<u>A203837</u>	<u>001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>20-300mCi/ML</u>	<u>A203603</u>	<u>001</u>	Nov 13, 2015
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	CPDC	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	DECATUR	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	+! FEINSTEIN	<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	JUBILANT DRAXIMAGE	<u>20-300mCi/ML</u>	<u>A203920</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	KETTERING MEDCTR	<u>4-40mCi/ML</u>	<u>A204759</u>	<u>001</u>	Oct 27, 2015
<u>AP</u>	KREITCHMAN PET CTR	<u>10-100mCi/ML</u>	<u>A203942</u>	<u>001</u>	Apr 11, 2016
<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	MEM SLOAN-KETTERING	<u>20-300mCi/ML</u>	<u>A208679</u>	<u>001</u>	Dec 08, 2016
<u>AP</u>	METHODIST HOSP RES	<u>20-300mCi/ML</u>	<u>A203904</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	MIPS CRF	<u>20-300mCi/ML</u>	<u>A204472</u>	<u>001</u>	Sep 11, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	! PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	! QUEEN HAMAMATSU PET	<u>10-100mCi/ML</u>	<u>A203771</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	SOFIE	<u>20-300mCi/ML</u>	<u>A203591</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	! TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	! UCLA BIOMEDICAL	<u>4-40mCi/ML</u>	<u>A203811</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV MICHIGAN	<u>20-300mCi/ML</u>	<u>A204531</u>	<u>001</u>	Jul 17, 2015
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>20-300mCi/ML</u>	<u>A204498</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	! IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>	!	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	MYLAN LABS LTD	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	SANDOZ INC	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071 001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071 002</u>	May 03, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256 002</u>	Oct 12, 2004
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787 002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256 001</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787 001</u>	Oct 12, 2004

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	! BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805 001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704 001</u>	Aug 03, 2006

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	ACP NIMBLE	<u>0.01%</u>	<u>A089526 001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A210747 001</u>	Nov 05, 2018
<u>AT</u>	FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088170 001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169 001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104 001</u>	Apr 27, 1982

SYNALAR

<u>AT</u>	+! MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787 004</u>	
<u>AT</u>	+!	<u>0.025%</u>	<u>N012787 002</u>	
<u>AT</u>	+!	<u>0.025%</u>	<u>N012787 005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

	+! ALIMERA SCIENCES INC	0.19MG	N201923 001	Sep 26, 2014
--	----------------------------	--------	-------------	--------------

RETISERT

	+! BAUSCH AND LOMB	0.59MG	N021737 001	Apr 08, 2005
--	--------------------	--------	-------------	--------------

YUTIQ

	+! EYEPOINT PHARMS	0.18MG	N210331 001	Oct 12, 2018
--	--------------------	--------	-------------	--------------

OIL; TOPICAL

DERMA-SMOOTH/FS

<u>AT</u>	+! HILL DERMAC	<u>0.01%</u>	<u>N019452 001</u>	Feb 03, 1988
<u>AT</u>	+!	<u>0.01%</u>	<u>N019452 002</u>	Nov 09, 2005

FLUCINOLONE ACETONIDE

<u>AT</u>	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210556 001</u>	Oct 25, 2018
-----------	---------------------	--------------	--------------------	--------------

FLUOCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.01%</u>	<u>A091514 001</u>	Jun 25, 2015
<u>AT</u>	IDENTI PHARMS INC	<u>0.01%</u>	<u>A201759 001</u>	Oct 17, 2011
<u>AT</u>		<u>0.01%</u>	<u>A201764 001</u>	Oct 17, 2011
<u>AT</u>	LYNE	<u>0.01%</u>	<u>A090982 001</u>	Apr 25, 2016
<u>AT</u>		<u>0.01%</u>	<u>A203377 001</u>	Apr 25, 2016
<u>AT</u>	PERRIGO ISRAEL	<u>0.01%</u>	<u>A202847 001</u>	Aug 09, 2013
<u>AT</u>		<u>0.01%</u>	<u>A202848 001</u>	Aug 09, 2013
<u>AT</u>	TARO	<u>0.01%</u>	<u>A202368 001</u>	May 19, 2016
<u>AT</u>		<u>0.01%</u>	<u>A209336 001</u>	May 19, 2016

FLUOCINONIDE ACETONIDE

<u>AT</u>	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210539 001</u>	Oct 26, 2018
-----------	---------------------	--------------	--------------------	--------------

OIL/DROPS; OTIC

DERMOTIC

<u>AT</u>	+! HILL DERMAC	<u>0.01%</u>	<u>N019452 003</u>	Nov 09, 2005
-----------	----------------	--------------	--------------------	--------------

FLAC

<u>AT</u>	ANDA REPOSITORY	<u>0.01%</u>	<u>A210736 001</u>	Apr 11, 2018
-----------	-----------------	--------------	--------------------	--------------

FLUOCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.01%</u>	<u>A202705 001</u>	Sep 09, 2016
<u>AT</u>	IDENTI PHARMS INC	<u>0.01%</u>	<u>A091306 001</u>	Oct 17, 2011
<u>AT</u>	LYNE	<u>0.01%</u>	<u>A203378 001</u>	Apr 25, 2016
<u>AT</u>	PERRIGO ISRAEL	<u>0.01%</u>	<u>A202849 001</u>	Jul 17, 2017

FLUOCINONIDE ACETONIDE

<u>AT</u>	GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A211815 001</u>	Dec 14, 2018
-----------	---------------------	--------------	--------------------	--------------

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	ACP NIMBLE	<u>0.025%</u>	<u>A089524 001</u>	Jul 26, 1988
<u>AT</u>	FOUGERA PHARMS INC	<u>0.025%</u>	<u>A088168 001</u>	Dec 16, 1982
<u>AT</u>	TARO	<u>0.025%</u>	<u>A040041 001</u>	Sep 15, 1994

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

SYNALAR

AT	+ !	MEDIMETRIKS PHARMS	0.025%	<u>N013960</u>	<u>001</u>	
		SHAMPOO; TOPICAL				
		CAPEX				
	+ !	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT		ENCUBE ETHICALS	0.01%	<u>A209913</u>	<u>001</u>	Feb 13, 2019
AT		FOUGERA PHARMS INC	0.01%	<u>A088167</u>	<u>001</u>	Dec 16, 1982
AT		GLASSHOUSE PHARMS	0.01%	<u>A209596</u>	<u>001</u>	Dec 26, 2017
AT		LUPIN	0.01%	<u>A206422</u>	<u>001</u>	Sep 02, 2015
AT		TARO	0.01%	<u>A089124</u>	<u>001</u>	Sep 11, 1985

SYNALAR

AT	+ !	MEDIMETRIKS PHARMS	0.01%	<u>N015296</u>	<u>001</u>	
-----------	------------	--------------------	--------------	-----------------------	-------------------	--

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ !	GALDERMA LABS LP	0.01%; 4%; 0.05%	N021112	001	Jan 18, 2002
------------	------------------	------------------	---------	-----	--------------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

!	MEDIMETRIKS PHARMS	0.025%; EQ 3.5MG BASE/GM	A060700	001	
----------	--------------------	--------------------------	---------	-----	--

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB		AMNEAL PHARMS LLC	0.1%	<u>A211111</u>	<u>001</u>	Jun 04, 2018
AB		FOUGERA PHARMS INC	0.1%	<u>A200735</u>	<u>001</u>	Jul 14, 2014
AB		GLENMARK GENERICS	0.1%	<u>A091282</u>	<u>001</u>	Jul 14, 2014
AB		PERRIGO ISRAEL	0.1%	<u>A090256</u>	<u>001</u>	Jan 14, 2014
AB		TARO	0.1%	<u>A200734</u>	<u>001</u>	Jul 14, 2014
AB		TEGENT PHARMA INC	0.1%	<u>A211758</u>	<u>001</u>	Apr 03, 2019

VANOS

AB	+ !	MEDICIS	0.1%	<u>N021758</u>	<u>001</u>	Feb 11, 2005
-----------	------------	---------	-------------	-----------------------	-------------------	--------------

FLUOCINONIDE

AB1		ACP NIMBLE	0.05%	<u>A073085</u>	<u>001</u>	Feb 14, 1992
AB1		FOUGERA PHARMS INC	0.05%	<u>A073030</u>	<u>001</u>	Oct 17, 1994
AB1		TARO	0.05%	<u>A071500</u>	<u>001</u>	Jun 10, 1987
AB1	+ !		0.05%	<u>N019117</u>	<u>001</u>	Jun 26, 1984
AB1		TEGENT PHARMA INC	0.05%	<u>A211410</u>	<u>001</u>	Oct 16, 2018
AB1		TEVA	0.05%	<u>A072488</u>	<u>001</u>	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		ACP NIMBLE	0.05%	<u>A074204</u>	<u>001</u>	Jun 13, 1995
AB2		FOUGERA PHARMS	0.05%	<u>A076586</u>	<u>001</u>	Jun 23, 2004
AB2	!	TARO PHARM INDS LTD	0.05%	<u>A072494</u>	<u>001</u>	Jan 19, 1989
AB2		TEVA	0.05%	<u>A072490</u>	<u>001</u>	Feb 07, 1989

LIDEX-E

AB2	+	CNTY LINE PHARMS	0.05%	<u>N016908</u>	<u>003</u>	
------------	----------	------------------	--------------	-----------------------	-------------------	--

GEL; TOPICAL

FLUOCINONIDE

AB		ACP NIMBLE	0.05%	<u>A072537</u>	<u>001</u>	Feb 07, 1989
AB	+	CNTY LINE PHARMS	0.05%	<u>N017373</u>	<u>001</u>	
AB		FOUGERA PHARMS INC	0.05%	<u>A072933</u>	<u>001</u>	Dec 30, 1994
AB	!	TARO	0.05%	<u>A074935</u>	<u>001</u>	Jul 29, 1997
AB		TEGENT PHARMA INC	0.05%	<u>A209030</u>	<u>001</u>	Jun 19, 2018

OINTMENT; TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS	0.05%	<u>A074905</u>	<u>001</u>	Aug 26, 1997
AB		NOVEL LABS INC	0.05%	<u>A207538</u>	<u>001</u>	Jul 31, 2017
AB	!	TARO	0.05%	<u>A075008</u>	<u>001</u>	Jun 30, 1999
AB		TEGENT PHARMA INC	0.05%	<u>A207680</u>	<u>001</u>	Sep 28, 2018
AB		TEVA	0.05%	<u>A073481</u>	<u>001</u>	Dec 27, 1991
AB		XIROMED	0.05%	<u>A212976</u>	<u>001</u>	Nov 26, 2019

LIDEX

AB	+	CNTY LINE PHARMS	0.05%	<u>N016909</u>	<u>002</u>	
-----------	----------	------------------	--------------	-----------------------	-------------------	--

SOLUTION; TOPICAL

FLUOCINONIDE

AT		ACP NIMBLE	0.05%	<u>A071535</u>	<u>001</u>	Dec 02, 1988
AT		ENCUBE ETHICALS	0.05%	<u>A209699</u>	<u>001</u>	Nov 29, 2018
AT		FOUGERA PHARMS INC	0.05%	<u>A072934</u>	<u>001</u>	Feb 27, 1995

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	GLASSHOUSE PHARMS	<u>0.05%</u>	<u>A209118</u>	<u>001</u>	Apr 23, 2018
<u>AT</u>	MACLEODS PHARMS LTD	<u>0.05%</u>	<u>A209283</u>	<u>001</u>	Apr 23, 2018
<u>AT</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A206003</u>	<u>001</u>	Jul 21, 2017
<u>AT</u>	! TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
<u>AT</u>	TELIGENT PHARMA INC	<u>0.05%</u>	<u>A207554</u>	<u>001</u>	Mar 18, 2019
<u>AT</u>	TEVA	<u>0.05%</u>	<u>A072511</u>	<u>001</u>	Feb 07, 1989
<u>AT</u>	ZYDUS PHARMS	<u>0.05%</u>	<u>A208948</u>	<u>001</u>	Jul 17, 2018

LIDEX

<u>AT</u>	+ CNTY LINE PHARMS	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984
-----------	--------------------	--------------	----------------	------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	+ AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008
-----------	---------	---	----------------	------------	--------------

FLUORESCITE

<u>AP</u>	+! ALCON LABS INC	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
	AK-FLUOR 25%				
	+! AKORN	<u>EQ 500MG BASE/2ML (EQ 250MG BASE/ML)</u>	<u>N022186</u>	<u>002</u>	Aug 08, 2008

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+!	FEINSTEIN	<u>0.42-8.33mCi/ML</u>	<u>N200655</u>	<u>001</u>	Oct 10, 2019
----	-----------	------------------------	----------------	------------	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

+!	ALLERGAN	<u>0.1%</u>	<u>N017760</u>	<u>001</u>	Sep 04, 1985
----	----------	-------------	----------------	------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

+!	ALLERGAN	<u>0.1%</u>	<u>N016851</u>	<u>002</u>	Jul 28, 1982
----	----------	-------------	----------------	------------	--------------

FML FORTE

+!	ALLERGAN	<u>0.25%</u>	<u>N019216</u>	<u>001</u>	Apr 23, 1986
----	----------	--------------	----------------	------------	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

+!	EYEVANCE	<u>0.1%</u>	<u>N019079</u>	<u>001</u>	Feb 11, 1986
----	----------	-------------	----------------	------------	--------------

FLUOROURACIL

CREAM; TOPICAL

CARAC

<u>AB</u>	+! VALEANT PHARMS NORTH	<u>0.5%</u>	<u>N020985</u>	<u>001</u>	Oct 27, 2000
-----------	----------------------------	-------------	----------------	------------	--------------

EFUDEX

<u>AB</u>	+! BAUSCH	<u>5%</u>	<u>N016831</u>	<u>003</u>	
-----------	-----------	-----------	----------------	------------	--

FLUOROURACIL

<u>AB</u>	MAYNE PHARMA	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
<u>AB</u>	MYLAN	<u>0.5%</u>	<u>A203122</u>	<u>001</u>	Apr 20, 2015
<u>AB</u>	TARO	<u>5%</u>	<u>A090368</u>	<u>001</u>	Mar 05, 2010

FLUOROPLEX

+!	ALMIRALL	<u>1%</u>	<u>N016988</u>	<u>001</u>	
----	----------	-----------	----------------	------------	--

TOLAK

+!	HILL DERMACEUTICALS	<u>4%</u>	<u>N022259</u>	<u>001</u>	Sep 18, 2015
----	---------------------	-----------	----------------	------------	--------------

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	! ACCORD HLTHCARE	<u>500MG/10ML (50MG/ML)</u>	<u>A040743</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>	!	<u>1GM/20ML (50MG/ML)</u>	<u>A040743</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>	!	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>	!	<u>5GM/100ML (50MG/ML)</u>	<u>A040798</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>	! FRESENIUS KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>	!	<u>1GM/20ML (50MG/ML)</u>	<u>A040279</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	!	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>	!	<u>5GM/100ML (50MG/ML)</u>	<u>A040278</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A210123</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A210123</u>	<u>002</u>	Oct 27, 2017
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A210124</u>	<u>001</u>	Dec 26, 2017
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A210124</u>	<u>002</u>	Dec 26, 2017
<u>AP</u>	INGENUS PHARMS LLC	<u>500MG/10ML (50MG/ML)</u>	<u>A209219</u>	<u>001</u>	Dec 12, 2019
<u>AP</u>		<u>500MG/10ML (50MG/ML)</u>	<u>A209271</u>	<u>001</u>	Dec 11, 2019
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A209219</u>	<u>002</u>	Dec 12, 2019
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A209271</u>	<u>002</u>	Dec 11, 2019

PRESCRIPTION DRUG PRODUCT LIST

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	MYLAN LABS LTD	<u>2.5GM/50ML (50MG/ML)</u>	<u>A202669 001</u>	Jul 17, 2012
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A202669 002</u>	Jul 17, 2012
<u>AP</u>	SAGENT PHARMS INC	<u>500MG/10ML (50MG/ML)</u>	<u>A203608 001</u>	May 11, 2017
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A203608 002</u>	May 11, 2017
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A203609 001</u>	Feb 17, 2016
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A203609 002</u>	Feb 17, 2016
<u>AP</u>	! TEVA PHARMS USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040333 001</u>	Jan 27, 2000
<u>AP</u>	!	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334 001</u>	Feb 25, 2000
<u>AP</u>	!	<u>5GM/100ML (50MG/ML)</u>	<u>A040334 002</u>	Feb 25, 2000

SOLUTION; TOPICAL

EFUDEX

<u>AT</u>	+! BAUSCH	<u>2%</u>	<u>N016831 001</u>	
<u>AT</u>	+!	<u>5%</u>	<u>N016831 002</u>	

FLUOROURACIL

<u>AT</u>	TARO	<u>2%</u>	<u>A076526 001</u>	Nov 05, 2003
<u>AT</u>		<u>5%</u>	<u>A076526 002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223 003</u>	Mar 19, 2009
<u>AB</u>	APNAR PHARMA LP	<u>EQ 40MG BASE</u>	<u>A075049 003</u>	Jan 29, 2002
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619 003</u>	Jan 31, 2008
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A206993 003</u>	May 23, 2019
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245 003</u>	Sep 28, 2004
<u>AB</u>	MARKSANS PHARMA	<u>EQ 40MG BASE</u>	<u>A075465 003</u>	Aug 02, 2001
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 40MG BASE</u>	<u>A204597 003</u>	Mar 16, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A076990 001</u>	Dec 13, 2004
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452 003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+! ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936 003</u>	Jun 15, 1999
-----------	---------------------	---------------------	--------------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223 001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223 002</u>	Mar 19, 2009
<u>AB1</u>	APNAR PHARMA LP	<u>EQ 10MG BASE</u>	<u>A075049 001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049 002</u>	Jan 29, 2002
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619 001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619 002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803 002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803 001</u>	Aug 02, 2001
<u>AB1</u>	CADILA PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A206993 001</u>	May 23, 2019
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A206993 002</u>	May 23, 2019
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245 002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245 001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464 001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464 002</u>	Jan 30, 2002
<u>AB1</u>	MARKSANS PHARMA	<u>EQ 10MG BASE</u>	<u>A075465 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465 002</u>	Jan 29, 2002
<u>AB1</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A204597 001</u>	Mar 16, 2015
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A204597 002</u>	Mar 16, 2015
<u>AB1</u>	SPECGX LLC	<u>EQ 10MG BASE</u>	<u>A075658 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001 002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	+ ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 006</u>	Dec 23, 1992
<u>AB1</u>	+	<u>EQ 20MG BASE</u>	<u>N018936 001</u>	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

!	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572 001</u>	Mar 22, 2010
---	--------------------	---------------------	--------------------	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	LANNETT CO INC	<u>EQ 20MG BASE/5ML</u>	<u>A077849 001</u>	Feb 09, 2007
<u>AA</u>	! PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015 001</u>	Jan 30, 2002
<u>AA</u>	SPECGX LLC	<u>EQ 20MG BASE/5ML</u>	<u>A075920 001</u>	Jan 29, 2002
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506 001</u>	Aug 02, 2001

PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	WOCKHARDT BIO AG	<u>EQ 20MG BASE/5ML</u>	<u>A075514 001</u>	Aug 29, 2002
TABLET;ORAL				
<u>FLUOXETINE HYDROCHLORIDE</u>				
AB	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A208698 001</u>	Apr 05, 2017
AB		<u>EQ 20MG BASE</u>	<u>A208698 002</u>	Apr 05, 2017
AB	+! ALVOGEN	<u>EQ 60MG BASE</u>	<u>N202133 001</u>	Oct 06, 2011
AB	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A076006 001</u>	Jan 30, 2002
AB		<u>EQ 20MG BASE</u>	<u>A076006 002</u>	Apr 23, 2018
AB		<u>EQ 60MG BASE</u>	<u>A211721 001</u>	Jan 25, 2019
AB	G AND W LABS INC	<u>EQ 60MG BASE</u>	<u>A212191 001</u>	Jul 05, 2019
AB	INVENTIA HLTHCARE	<u>EQ 60MG BASE</u>	<u>A209695 001</u>	Nov 20, 2017
AB	LUPIN LTD	<u>EQ 10MG BASE</u>	<u>A211653 001</u>	Apr 15, 2019
AB		<u>EQ 20MG BASE</u>	<u>A211653 002</u>	Apr 15, 2019
AB		<u>EQ 60MG BASE</u>	<u>A211632 001</u>	Feb 08, 2019
AB	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755 001</u>	Aug 02, 2001
AB	!	<u>EQ 20MG BASE</u>	<u>A075755 002</u>	Aug 02, 2001
AB	PAR FORM	<u>EQ 10MG BASE</u>	<u>A203836 001</u>	Aug 19, 2016
AB		<u>EQ 20MG BASE</u>	<u>A203836 002</u>	Aug 19, 2016
AB	PAR PHARM INC	<u>EQ 60MG BASE</u>	<u>A209419 001</u>	Nov 16, 2017
AB	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A210935 001</u>	Mar 20, 2019
AB		<u>EQ 20MG BASE</u>	<u>A210935 002</u>	Mar 20, 2019
AB		<u>EQ 60MG BASE</u>	<u>A211282 001</u>	Jan 10, 2019
AB	TARO	<u>EQ 60MG BASE</u>	<u>A211477 001</u>	Nov 21, 2018
AB	TEVA	<u>EQ 10MG BASE</u>	<u>A075872 001</u>	Jan 29, 2002
AB		<u>EQ 20MG BASE</u>	<u>A075872 002</u>	Jan 04, 2019
AB	TEVA PHARMS USA	<u>EQ 60MG BASE</u>	<u>A211051 001</u>	Dec 03, 2018
AB	UPSHER SMITH LABS	<u>EQ 10MG BASE</u>	<u>A211696 001</u>	Jan 30, 2019
AB		<u>EQ 20MG BASE</u>	<u>A211696 002</u>	Jan 30, 2019
AB1	TORRENT	<u>EQ 10MG BASE</u>	<u>A206937 001</u>	Oct 21, 2016
AB1		<u>EQ 20MG BASE</u>	<u>A206937 002</u>	Oct 21, 2016
<u>SARAFEM</u>				
AB1	+ APIL	<u>EQ 10MG BASE</u>	<u>N021860 001</u>	May 19, 2006
AB1	+	<u>EQ 15MG BASE</u>	<u>N021860 002</u>	May 19, 2006
AB1	+!	<u>EQ 20MG BASE</u>	<u>N021860 003</u>	May 19, 2006
<u>SELFEMRA</u>				
AB1	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151 001</u>	Feb 03, 2014
AB1		<u>EQ 15MG BASE</u>	<u>A200151 002</u>	Feb 03, 2014
AB1		<u>EQ 20MG BASE</u>	<u>A200151 003</u>	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742 001</u>	Nov 02, 2012
AB		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742 002</u>	Nov 02, 2012
AB		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742 003</u>	Nov 02, 2012
AB		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742 004</u>	Nov 02, 2012
AB		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742 005</u>	Nov 02, 2012
AB	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901 005</u>	Nov 16, 2012
AB		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901 001</u>	Nov 16, 2012
AB		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901 003</u>	Nov 16, 2012
AB		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901 002</u>	Nov 16, 2012
AB		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901 004</u>	Nov 16, 2012
AB	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074 001</u>	Mar 25, 2013
AB		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528 001</u>	Jun 19, 2012
AB		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528 002</u>	Jun 19, 2012
AB		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528 003</u>	Jun 19, 2012
AB		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528 004</u>	Jun 19, 2012
<u>SYMBYAX</u>				
AB	+ LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520 001</u>	Apr 09, 2007
AB	+	<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520 002</u>	Dec 24, 2003
AB	+	<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520 004</u>	Dec 24, 2003
AB	+!	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520 003</u>	Dec 24, 2003
AB	+	<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520 005</u>	Dec 24, 2003

PRESCRIPTION DRUG PRODUCT LIST

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

! UPSHER SMITH LABS

10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATEAO AUROBINDO PHARMA LTD25MG/MLA207739 001 Oct 17, 2017AO ! FRESENIUS KABI USA25MG/MLA071413 001 Jul 14, 1987AO MYLAN LABS LTD25MG/MLA075918 001 Aug 17, 2001AO PAR STERILE PRODUCTS25MG/MLA203732 001 Jul 03, 2014AO WEST-WARD PHARMS INT25MG/MLA074531 001 Aug 30, 1996FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

! PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

! FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDEAB LANNETT CO INC1MGA089743 002 Aug 25, 1988AB2.5MGA089743 003 Aug 25, 1988AB5MGA089743 004 Aug 25, 1988AB !10MGA089743 001 Aug 25, 1988AB MYLAN1MGA089804 002 Aug 12, 1988AB2.5MGA089804 003 Aug 12, 1988AB5MGA089804 004 Aug 12, 1988AB10MGA089804 001 Aug 12, 1988AB SANDOZ1MGA089586 002 Oct 16, 1987AB2.5MGA089586 003 Oct 16, 1987AB5MGA089586 004 Oct 16, 1987AB10MGA089586 001 Oct 16, 1987FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SPAT +! ALMIRALL0.05%N012806 002FLURANDRENOLIDEAT CINTEX SVCS0.05%A205342 001 Apr 13, 2016

CORDRAN SP

+! ALMIRALL

0.025%

N012806 003

LOTION; TOPICAL

CORDRANAT +! ALMIRALL0.05%N013790 001FLURANDRENOLIDEAT CINTEX SVCS0.05%A205343 001 Dec 22, 2016AT PERRIGO UK FINCO0.05%A207133 001 Aug 30, 2016

OINTMENT; TOPICAL

CORDRANAT +! ALMIRALL0.05%N012806 001FLURANDRENOLIDEAT TELIGENT PHARMA INC0.05%A207851 001 Dec 30, 2016

TAPE; TOPICAL

CORDRAN

+! ALMIRALL

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

!

30MG

A070345 001 Nov 27, 1985

PRESCRIPTION DRUG PRODUCT LIST

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

AB	!	MYLAN	100MG	A074358 002	Jun 20, 1994
AB		TEVA	100MG	A074431 001	May 31, 1995
		MYLAN	50MG	A074358 001	Jun 20, 1994

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

AT		BAUSCH AND LOMB	0.03%	A074447 001	Jan 04, 1995
AT	+	ALLERGAN	0.03%	N019404 001	Dec 31, 1986

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	!	CIPLA	125MG	A075780 001	Sep 19, 2001
AB		PAR PHARM	125MG	A075298 001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137 002	Oct 25, 2013
---	---	---------------	----------------------------	-------------	--------------

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+	!	GLAXOSMITHKLINE	0.05MG/INH	N205625 003	May 17, 2018
+	!		0.1MG/INH	N205625 001	Aug 20, 2014
+	!		0.2MG/INH	N205625 002	Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

TRELEGY ELLIPTA

+	!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482 001	Sep 18, 2017
---	---	-----------------	--	-------------	--------------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+	!	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275 001	May 10, 2013
+	!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275 002	Apr 30, 2015

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+	!	GLAXO GRP LTD	0.044MG/INH	N021433 003	May 14, 2004
+	!		0.11MG/INH	N021433 002	May 14, 2004
+	!		0.22MG/INH	N021433 001	May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB		ACP NIMBLE	0.05%	A077055 001	Jun 30, 2006
AB		ANDA REPOSITORY	0.05%	A076633 001	May 14, 2004
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004
AB	!	PERRIGO ISRAEL	0.05%	A076793 001	May 14, 2004

LOTION; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N021152 001	Mar 31, 2005
-----------	---	----------------	--------------	--------------------	--------------

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011
AB		PERRIGO ISRAEL	0.05%	A091553 001	Jul 30, 2013

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		ACP NIMBLE	0.005%	A077168 001	Mar 03, 2006
AB	!	PERRIGO NEW YORK	0.005%	A076668 001	May 14, 2004

POWDER; INHALATION

FLOVENT DISKUS 100

+	!	GLAXO GRP LTD	0.1MG/INH	N020833 002	Sep 29, 2000
---	---	---------------	-----------	-------------	--------------

FLOVENT DISKUS 250

+	!	GLAXO GRP LTD	0.25MG/INH	N020833 003	Sep 29, 2000
---	---	---------------	------------	-------------	--------------

FLOVENT DISKUS 50

+	!	GLAXO GRP LTD	0.05MG/INH	N020833 001	Sep 29, 2000
---	---	---------------	------------	-------------	--------------

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

AB		APOTEX INC	0.05MG/SPRAY	A077538 001	Sep 12, 2007
-----------	--	------------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AB	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
AB	! HIKMA	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006
AB	WOCKHARDT BIO AG	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012
	XHANCE				
	+! OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED;INHALATION

ADVAIR HFA

	+! GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+!	0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+!	0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER;INHALATION

ADVAIR DISKUS 100/50

AB	+! GLAXO GRP LTD	<u>0.1MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>001</u>	Aug 24, 2000
-----------	------------------	-------------------------------------	----------------	------------	--------------

ADVAIR DISKUS 250/50

AB	+! GLAXO GRP LTD	<u>0.25MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>002</u>	Aug 24, 2000
-----------	------------------	--------------------------------------	----------------	------------	--------------

ADVAIR DISKUS 500/50

AB	+! GLAXO GRP LTD	<u>0.5MG/INH;EQ 0.05MG BASE/INH</u>	<u>N021077</u>	<u>003</u>	Aug 24, 2000
-----------	------------------	-------------------------------------	----------------	------------	--------------

WIXELA INHUB

AB	MYLAN	<u>0.1MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>001</u>	Jan 30, 2019
AB		<u>0.25MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>002</u>	Jan 30, 2019
AB		<u>0.5MG/INH;EQ 0.05MG BASE/INH</u>	<u>A208891</u>	<u>003</u>	Jan 30, 2019

AIRDUO DIGIHALER

	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019
	+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019
	+	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019

AIRDUO RESPICLICK

	+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+!	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
AB	!	<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
AB	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
AB		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB	TEVA PHARMS USA	<u>EQ 80MG BASE</u>	<u>A079011</u>	<u>001</u>	Jan 27, 2016
-----------	-----------------	---------------------	----------------	------------	--------------

LESCOL XL

AB	+! NOVARTIS	<u>EQ 80MG BASE</u>	<u>N021192</u>	<u>001</u>	Oct 06, 2000
-----------	-------------	---------------------	----------------	------------	--------------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
AB	!	<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
AB	ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
AB		<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
AB	TORRENT	<u>100MG</u>	<u>A203240</u>	<u>001</u>	Oct 31, 2014
AB		<u>150MG</u>	<u>A203240</u>	<u>002</u>	Oct 31, 2014

TABLET;ORAL

FLUVOXAMINE MALEATE

AB	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
AB		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
AB		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
AB	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
AB		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
AB		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002
AB	UPSHER SMITH LABS	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
AB		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
AB	!	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000

LUVOX

AB	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
AB		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
AB		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

<u>AP</u>	EXELA PHARMA SCS LLC	<u>5MG/ML</u>	<u>A202522</u>	<u>001</u>	Nov 06, 2019
<u>AP</u>	! FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A089202</u>	<u>001</u>	Feb 18, 1986

TABLET; ORAL

FOLIC ACID

<u>AA</u>	! AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>	ATHEM	<u>1MG</u>	<u>A211064</u>	<u>001</u>	Mar 08, 2019
<u>AA</u>	CADILA PHARMS LTD	<u>1MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>	CHARTWELL MOLECULAR	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>	HIKMA PHARMS	<u>1MG</u>	<u>A080600</u>	<u>001</u>	
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>	NUVO PHARMS INC	<u>1MG</u>	<u>A204418</u>	<u>001</u>	Jul 28, 2015
<u>AA</u>	QINGDAO BAHEAL PHARM	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	! WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+!	ORGANON USA INC	300 IU/0.36ML	N021211	001	Mar 23, 2004
+!		600 IU/0.72ML	N021211	002	Mar 23, 2004
+!		900 IU/1.08ML	N021211	004	Feb 11, 2005

GONAL-F

+!	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
+		1,050 IU/VIAL	N020378	004	Feb 28, 2001

GONAL-F RFF

+!	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004
----	------------	------------	---------	-----	--------------

GONAL-F RFF REDI-JECT

+!	EMD SERONO	150 IU/0.25ML	N021684	004	Nov 25, 2019
+!		300 IU/0.5ML	N021684	001	May 25, 2004
+!		450 IU/0.75ML	N021684	002	May 25, 2004
+!		900 IU/1.5ML	N021684	003	May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

<u>AP</u>	AM REGENT	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
<u>AP</u>	NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

<u>AP</u>	+! MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
<u>AP</u>	+!	<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
<u>AP</u>	+!	<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
<u>AP</u>	+!	<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004

FONDAPARINUX SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>2.5MG/0.5ML</u>	<u>A206918</u>	<u>001</u>	Dec 26, 2017
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A206918</u>	<u>002</u>	Dec 26, 2017
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A206918</u>	<u>003</u>	Dec 26, 2017
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A206918</u>	<u>004</u>	Dec 26, 2017
<u>AP</u>	DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A091316</u>	<u>004</u>	Jul 11, 2011
<u>AP</u>	JIANGSU HENGRUI MED	<u>2.5MG/0.5ML</u>	<u>A206812</u>	<u>001</u>	May 15, 2018
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A206812</u>	<u>002</u>	May 15, 2018
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A206812</u>	<u>003</u>	May 15, 2018
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A206812</u>	<u>004</u>	May 15, 2018
<u>AP</u>	SCINOPHARM TAIWAN	<u>2.5MG/0.5ML</u>	<u>A208615</u>	<u>001</u>	Nov 14, 2018
<u>AP</u>		<u>5MG/0.4ML</u>	<u>A208615</u>	<u>002</u>	Nov 14, 2018
<u>AP</u>		<u>7.5MG/0.6ML</u>	<u>A208615</u>	<u>003</u>	Nov 14, 2018
<u>AP</u>		<u>10MG/0.8ML</u>	<u>A208615</u>	<u>004</u>	Nov 14, 2018

PRESCRIPTION DRUG PRODUCT LIST

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFORMIST

+! MYLAN SPECLT 0.02MG/2ML N022007 001 May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+! ASTRAZENECA PHARMS 0.0048MG/INH;0.0090MG/INH N208294 001 Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+ MERCK SHARP DOHME 0.005MG/INH;0.05MG/INH N022518 003 Aug 12, 2019

+! 0.005MG/INH;0.1MG/INH N022518 001 Jun 22, 2010

+! 0.005MG/INH;0.2MG/INH N022518 002 Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+! VIIV HLTHCARE EQ 50MG BASE/ML N022116 001 Jun 14, 2007

TABLET; ORAL

FOSAMPRENAVIR CALCIUM**AB** MYLAN **EQ 700MG BASE** **A204060 001** Apr 15, 2016**AB** SUN PHARM **EQ 700MG BASE** **A204024 001** Nov 20, 2019LEXIVA**AB** +! VIIV HLTHCARE **EQ 700MG BASE** **N021548 001** Oct 20, 2003FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND**AP** +! MERCK AND CO INC **EQ 150MG BASE/VIAL** **N022023 002** Nov 12, 2010FOSAPREPITANT DIMEGLUMINE**AP** APOTEX **EQ 150MG BASE/VIAL** **A205020 001** Sep 05, 2019**AP** BAXTER HLTHCARE **EQ 150MG BASE/VIAL** **A211860 001** Sep 05, 2019

CORP

AP BE PHARMS **EQ 150MG BASE/VIAL** **A212309 001** Sep 05, 2019**AP** FRESENIUS KABI USA **EQ 150MG BASE/VIAL** **A206197 001** Jun 09, 2016**AP** LUPIN LTD **EQ 150MG BASE/VIAL** **A210689 001** Sep 05, 2019**AP** MSN **EQ 150MG BASE/VIAL** **A209965 001** Sep 05, 2019**AP** MYLAN LABS LTD **EQ 150MG BASE/VIAL** **A204015 002** Sep 05, 2019**AP** SUNGEN PHARMA **EQ 150MG BASE/VIAL** **A211624 001** Sep 05, 2019

MYLAN LABS LTD EQ 115MG BASE/VIAL A204015 001 Sep 05, 2019

TEVA PHARMS USA EQ 150MG BASE/VIAL N210064 001 Sep 05, 2019

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR

+! CLINIGEN HLTHCARE 2.4GM/100ML N020068 001 Sep 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

MONUROL

+! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM**AB** APOTEX INC **10MG** **A076906 001** May 17, 2005**AB** **20MG** **A076906 002** May 17, 2005**AB** **40MG** **A076906 003** May 17, 2005**AB** AUROBINDO PHARMA **10MG** **A091163 001** Mar 30, 2011

LTD

AB **20MG** **A091163 002** Mar 30, 2011**AB** **40MG** **A091163 003** Mar 30, 2011**AB** INVAGEN PHARMS **10MG** **A077222 001** Apr 20, 2005**AB** **20MG** **A077222 002** Apr 20, 2005**AB** **40MG** **A077222 003** Apr 20, 2005**AB** PRINSTON INC **10MG** **A205670 001** Aug 29, 2016**AB** **20MG** **A205670 002** Aug 29, 2016**AB** **40MG** **A205670 003** Aug 29, 2016**AB** TEVA **10MG** **A076139 001** Nov 25, 2003**AB** **20MG** **A076139 002** Nov 25, 2003**AB** ! **40MG** **A076139 003** Nov 25, 2003**AB** UPSHER SMITH LABS **10MG** **A076483 001** Apr 23, 2004**AB** **20MG** **A076483 002** Apr 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		40MG	A076483 003	Apr 23, 2004
-----------	--	-------------	--------------------	--------------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA	10MG;12.5MG	A079245 001	Jul 09, 2009
AB		20MG;12.5MG	A079245 002	Jul 09, 2009
AB	EMCURE PHARMS LTD	10MG;12.5MG	A079025 001	Sep 17, 2010
AB	!	20MG;12.5MG	A079025 002	Sep 17, 2010
AB	INVAGEN PHARMS	10MG;12.5MG	A090228 001	Jul 09, 2009
AB		20MG;12.5MG	A090228 002	Jul 09, 2009
AB	SANDOZ	10MG;12.5MG	A076961 001	Sep 28, 2005
AB		20MG;12.5MG	A076961 002	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

+	!	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493 001	Apr 19, 2018
---	---	------------------	------------------------------	-------------	--------------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP	+	!	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450 001	Aug 05, 1996
-----------	---	---	-------------	--------------------------------	--------------------	--------------

FOSPHENYTOIN SODIUM

AP			AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476 001	Mar 18, 2008
AP			FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007
AP			HIKMA FARMACEUTICA	EQ 50MG PHENYTOIN NA/ML	A078765 001	Dec 02, 2009
AP			MYLAN LABS LTD	EQ 50MG PHENYTOIN NA/ML	A078736 001	Jun 08, 2010
AP			SUN PHARM	EQ 50MG PHENYTOIN NA/ML	A078417 001	Mar 18, 2008
AP			WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481 001	Aug 06, 2007
AP				EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007
AP			WOCKHARDT	EQ 50MG PHENYTOIN NA/ML	A078137 001	Aug 06, 2007

FOSTAMATINIB DISODIUM

TABLET; ORAL

TAVALISSE

+		RIGEL PHARMS INC	EQ 100MG BASE	N209299 001	Apr 17, 2018
+	!		EQ 150MG BASE	N209299 002	Apr 17, 2018

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

AB	+	!	ENDO PHARMS	EQ 2.5MG BASE	N021006 001	Nov 08, 2001
-----------	---	---	-------------	----------------------	--------------------	--------------

FROVATRIPTAN SUCCINATE

AB			AMNEAL PHARMS CO	EQ 2.5MG BASE	A211292 001	Nov 06, 2018
AB			GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730 001	Mar 11, 2016
AB			MYLAN	EQ 2.5MG BASE	A202931 001	Aug 28, 2014

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

AO	+	!	ASTRAZENECA	50MG/ML	N021344 001	Apr 25, 2002
-----------	---	---	-------------	----------------	--------------------	--------------

FULVESTRANT

AO			AMNEAL	50MG/ML	A210044 001	Mar 04, 2019
AO			GLENMARK PHARMS INC	50MG/ML	A207754 001	Aug 22, 2019
AO			HBT LABS INC	50MG/ML	A209714 001	Nov 21, 2019
AO			MYLAN INSTITUTIONAL	50MG/ML	A208811 001	Jul 23, 2019
AO			SAGENT PHARMS INC	50MG/ML	A205871 001	Aug 22, 2019
AO			SANDOZ INC	50MG/ML	A205935 001	May 14, 2019

SOLUTION; INTRAMUSCULAR

FULVESTRANT

			FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326 001	May 20, 2019
			TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063 001	Aug 19, 2019

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP			AMNEAL PHARMS CO	10MG/ML	A207552 001	Jul 20, 2016
AP			AUROBINDO PHARMA LTD	10MG/ML	A212174 001	May 03, 2019
AP	!		BAXTER HLTHCARE CORP	10MG/ML	A202747 001	Jan 27, 2014

PRESCRIPTION DRUG PRODUCT LIST

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428</u>	<u>001</u>	Aug 26, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	!	HIKMA	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>		WOCKHARDT BIO AG	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
		HIKMA	<u>40MG/5ML</u>	<u>A070433</u>	<u>001</u>	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>		AVET	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>			<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>		HIKMA	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>			<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>			<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>		IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>			<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>			<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>		LEADING PHARMA LLC	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>			<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>			<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>		MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>			<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>			<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>		PRINSTON INC	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>			<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>			<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>		SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>			<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>			<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984

LASIX

<u>AB</u>	+	US PHARM HOLDINGS	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>	+		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	!	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>		ACI HEALTHCARE LTD	<u>100MG</u>	<u>A206943</u>	<u>001</u>	May 14, 2018
<u>AB</u>			<u>300MG</u>	<u>A206943</u>	<u>002</u>	May 14, 2018
<u>AB</u>			<u>400MG</u>	<u>A206943</u>	<u>003</u>	May 14, 2018
<u>AB</u>		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>			<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>			<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>		ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>			<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>			<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>		AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>			<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>			<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>			<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>			<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>		EPIC PHARMA LLC	<u>100MG</u>	<u>A207099</u>	<u>001</u>	Mar 24, 2017
<u>AB</u>			<u>300MG</u>	<u>A207099</u>	<u>002</u>	Mar 24, 2017
<u>AB</u>			<u>400MG</u>	<u>A207099</u>	<u>003</u>	Mar 24, 2017
<u>AB</u>		GRANULES INDIA LTD	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>			<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>			<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>			<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>			<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>		JIANGSU HENGRUI MED	<u>100MG</u>	<u>A091008</u>	<u>001</u>	Oct 26, 2017
<u>AB</u>			<u>300MG</u>	<u>A091008</u>	<u>002</u>	Oct 26, 2017
<u>AB</u>			<u>400MG</u>	<u>A091008</u>	<u>003</u>	Oct 26, 2017
<u>AB</u>		MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>			<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A204989</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>		<u>300MG</u>	<u>A204989</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>		<u>400MG</u>	<u>A204989</u>	<u>003</u>	Feb 18, 2016
<u>AB</u>	STRIDES PHARMA	<u>100MG</u>	<u>A211314</u>	<u>001</u>	Oct 16, 2018
<u>AB</u>		<u>300MG</u>	<u>A211314</u>	<u>002</u>	Oct 16, 2018
<u>AB</u>		<u>400MG</u>	<u>A211314</u>	<u>003</u>	Oct 16, 2018
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004

NEURONTIN

<u>AB</u>	+	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>	+		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	!	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403</u>	<u>001</u>	May 01, 2012
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024</u>	<u>001</u>	Mar 23, 2012
<u>AA</u>	HI TECH PHARMA	<u>250MG/5ML</u>	<u>A078974</u>	<u>001</u>	Feb 18, 2011
<u>AA</u>	TARO	<u>250MG/5ML</u>	<u>A076672</u>	<u>001</u>	Jul 03, 2013
<u>AA</u>	TRIS PHARMA INC	<u>250MG/5ML</u>	<u>A091286</u>	<u>001</u>	Mar 14, 2016
<u>AA</u>	VISTAPHARM	<u>250MG/5ML</u>	<u>A211330</u>	<u>001</u>	Dec 03, 2019

NEURONTIN

<u>AA</u>	+	PARKE DAVIS	<u>250MG/5ML</u>	<u>N021129</u>	<u>001</u>	Mar 02, 2000
-----------	---	-------------	------------------	----------------	------------	--------------

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACI HEALTHCARE LTD	<u>600MG</u>	<u>A203244</u>	<u>002</u>	Jul 12, 2013
<u>AB</u>		<u>800MG</u>	<u>A203244</u>	<u>001</u>	Jul 12, 2013
<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A206402</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>800MG</u>	<u>A206402</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>	CSPC OUYI	<u>600MG</u>	<u>A207057</u>	<u>001</u>	Oct 26, 2017
<u>AB</u>		<u>800MG</u>	<u>A207057</u>	<u>002</u>	Oct 26, 2017
<u>AB</u>	GLENMARK PHARMS LTD	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764</u>	<u>001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764</u>	<u>002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	RUBICON	<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	SCIEGEN PHARMS INC	<u>600MG</u>	<u>A205101</u>	<u>001</u>	Feb 04, 2016
<u>AB</u>		<u>800MG</u>	<u>A205101</u>	<u>002</u>	Feb 04, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	TEVA PHARMS USA	<u>600MG</u>	<u>A205807</u>	<u>001</u>	Mar 10, 2017
<u>AB</u>		<u>800MG</u>	<u>A205807</u>	<u>002</u>	Mar 10, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926</u>	<u>001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926</u>	<u>002</u>	Feb 11, 2011

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

TABLET; ORAL

NEURONTIN

AB	+	PFIZER PHARMS	600MG	N020882 001	Oct 09, 1998
AB	+	!	800MG	N020882 002	Oct 09, 1998
GRALISE					
BX	+	ASSERTIO	300MG	N022544 001	Jan 28, 2011
BX	+	!	600MG	N022544 002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

+	ARBOR PHARMS LLC	300MG	N022399 002	Dec 13, 2011
+	!	600MG	N022399 001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357 001	Nov 23, 2004
+	!	5.29GM/10ML (529MG/ML)	N021357 002	Nov 23, 2004
+	!	7.935GM/15ML (529MG/ML)	N021357 003	Nov 23, 2004
+	!	10.58GM/20ML (529MG/ML)	N021357 004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358 001	Nov 23, 2004
+	!	52.9GM/100ML (529MG/ML)	N021358 002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277 006	Dec 18, 2013
+	!	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011
+	!	6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011
+	!	9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011
+	!	18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011
+	!	39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123 001	Jan 08, 1993
+	!	28.7GM/100ML (287MG/ML)	N022066 002	Sep 05, 2007

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

CLARISCAN

AP	GE HEALTHCARE	7.538GM/20ML (376.9MG/ML)	A210016 003	Nov 01, 2019
AP	!	3.769GM/10ML (376.9MG/ML)	A210016 001	Nov 01, 2019
AP	!	5.6535GM/15ML (376.9MG/ML)	A210016 002	Nov 01, 2019

DOTAREM

AP	+	GUERBET	3.769GM/10ML (376.9MG/ML)	N204781 002	Mar 20, 2013
AP	+	!	5.6535GM/15ML (376.9MG/ML)	N204781 003	Mar 20, 2013
AP	+	!	7.538GM/20ML (376.9MG/ML)	N204781 004	Mar 20, 2013
	+	!	37.69GM/100ML (376.9MG/ML)	N204781 001	Mar 20, 2013
	+	!	1.8845GM/5ML (376.9MG/ML)	N204781 005	Mar 31, 2017

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+	BRACCO	279.3MG/ML	N020131 001	Nov 16, 1992
+	!	279.3MG/ML	N021489 001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090 001	Jul 03, 2008
+	!	2.72145GM/15ML (181.43MG/ML)	N022090 002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895 001	Aug 05, 2016
AB	!	EQ 16MG BASE	A204895 002	Aug 05, 2016
AB	!	EQ 24MG BASE	A204895 003	Aug 05, 2016
AB	BARR	EQ 8MG BASE	A078189 001	Sep 15, 2008
AB	!	EQ 16MG BASE	A078189 002	Sep 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189 003</u>	Sep 15, 2008
<u>AB</u>	SUN PHARM	<u>EQ 8MG BASE</u>	<u>A090178 001</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090178 002</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090178 003</u>	Feb 02, 2011
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028 001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028 002</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A079028 003</u>	Dec 15, 2008

RAZADYNE ER

<u>AB</u>	+!	JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615 001</u>	Apr 01, 2005
<u>AB</u>	+		<u>EQ 16MG BASE</u>	<u>N021615 002</u>	Apr 01, 2005
<u>AB</u>	+		<u>EQ 24MG BASE</u>	<u>N021615 003</u>	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

! HIKMA

4MG/ML

A078185 001 Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>		APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781 001</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077781 002</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077781 003</u>	Sep 27, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957 001</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
<u>AB</u>		BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
<u>AB</u>		HIKMA	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
<u>AB</u>		SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
<u>AB</u>		YABAO PHARM	<u>EQ 4MG BASE</u>	<u>A077604 001</u>	Feb 06, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077604 002</u>	Feb 06, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077604 003</u>	Feb 06, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011
		<u>RAZADYNE</u>			
<u>AB</u>	+!	JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
<u>AB</u>	+		<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058 001
BS	LANTHEUS MEDCL	2mCi/ML	N017478 001

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

+! AAA USA INC

2.1-5.5mCi/ML

N208547 001 Jun 01, 2016

GALLIUM DOTATOC GA-68

SOLUTION;INTRAVENOUS

GALLIUM DOTATOC GA 68

+! UIHC PET IMAGING

0.5-4mCi/ML

N210828 001 Aug 21, 2019

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

+! BAUSCH AND LOMB

0.15%

N022211 001 Sep 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

GANCICLOVIR

SOLUTION; INTRAVENOUS

GANZYK-RTU

+! EXELA PHARMA SCS 500MG/250ML (2MG/ML)
LLC

N209347 001 Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENEAP +! CHEPLAPHARMEQ 500MG BASE/VIALN019661 001 Jun 23, 1989GANCICLOVIR SODIUMAP FRESENIUS KABI USAEQ 500MG BASE/VIALA090658 001 Jun 21, 2010AP HAINAN POLY PHARMEQ 500MG BASE/VIALA204204 001 Nov 08, 2018AP MYLAN LABS LTDEQ 500MG BASE/VIALA204560 001 Nov 17, 2017AP PAR STERILEEQ 500MG BASE/VIALA204950 001 Dec 06, 2016

PRODUCTS

AP PHARMASCIENCE INCEQ 500MG BASE/VIALA207645 001 Dec 08, 2017GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATEAP +! ORGANON USA INC250MCG/0.5MLN021057 001 Jul 29, 1999AP SUN PHARM250MCG/0.5MLA204246 001 Nov 30, 2018GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACINAT HI-TECH PHARMA CO0.5%A203189 001 Sep 03, 2014AT LUPIN LTD0.5%A202653 001 Aug 28, 2013AT MYLAN0.5%A206446 001 Jun 08, 2018AT SANDOZ INC0.5%A204227 001 Jul 11, 2016ZYMAXIDAT +! ALLERGAN0.5%N022548 001 May 18, 2010

ZYMAR

+! ALLERGAN

0.3%

N021493 001 Mar 28, 2003

GEFITINIB

TABLET; ORAL

IRESSA

+! ASTRAZENECA PHARMS 250MG

N206995 001 Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDEAP ACCORD HLTHCAREEQ 200MG BASE/VIALA091594 001 Jul 25, 2011APEQ 1GM BASE/VIALA091594 002 Jul 25, 2011APEQ 2GM BASE/VIALA091594 003 Jul 25, 2011AP APOTEX200MG/5.26ML (38MG/ML)A206776 001 May 23, 2017AP1GM/26.3ML (38MG/ML)A206776 002 May 23, 2017AP2GM/52.6ML (38MG/ML)A206776 003 May 23, 2017AP CIPLAEQ 200MG BASE/VIALA078759 001 Jul 25, 2011APEQ 1GM BASE/VIALA078759 002 Jul 25, 2011AP DR REDDYS LABS LTDEQ 200MG BASE/VIALA091365 001 Jul 25, 2011APEQ 1GM BASE/VIALA091365 002 Jul 25, 2011APEQ 2GM BASE/VIALA202997 001 May 07, 2013AP EMCURE PHARMS LTDEQ 200MG BASE/VIALA202063 001 Sep 11, 2012APEQ 1GM BASE/VIALA202063 002 Sep 11, 2012AP FRESENIUS KABI USAEQ 200MG BASE/VIALA090799 001 Jul 25, 2011APEQ 1GM BASE/VIALA090799 002 Jul 25, 2011APEQ 2GM BASE/VIALA090242 003 May 16, 2011APEQ 2GM BASE/VIALA090799 003 May 16, 2011AP GLAND PHARMA LTDEQ 200MG BASE/VIALA204520 001 Jan 05, 2016APEQ 1GM BASE/VIALA204520 002 Jan 05, 2016AP HOSPIRAEQ 200MG BASE/VIALA078339 001 Jul 25, 2011APEQ 1GM BASE/VIALA078339 002 Jul 25, 2011AP +! HOSPIRA INC200MG/5.26ML (38MG/ML)N200795 001 Aug 04, 2011AP +!1GM/26.3ML (38MG/ML)N200795 002 Aug 04, 2011AP !EQ 2GM BASE/VIALA079183 001 Nov 15, 2010AP +!2GM/52.6ML (38MG/ML)N200795 003 Aug 04, 2011AP JIANGSU HANSONHEQ 200MG BASE/VIALA202485 001 May 07, 2013

PHARM

APEQ 1GM BASE/VIALA202485 002 May 07, 2013AP MYLAN LABS LTDEQ 200MG BASE/VIALA200145 001 Jul 25, 2011AP200MG/5.26ML (38MG/ML)A205242 001 Dec 06, 2017APEQ 1GM BASE/VIALA200145 002 Jul 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>		<u>1GM/26.3ML (38MG/ML)</u>	<u>A205242 002</u>	Dec 06, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145 003</u>	Jul 25, 2011
<u>AP</u>		<u>2GM/52.6ML (38MG/ML)</u>	<u>A205242 003</u>	Dec 06, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>200MG/5.26ML (38MG/ML)</u>	<u>A209077 001</u>	Jul 20, 2018
<u>AP</u>		<u>1GM/26.3ML (38MG/ML)</u>	<u>A209077 002</u>	Jul 20, 2018
<u>AP</u>		<u>2GM/52.6ML (38MG/ML)</u>	<u>A209077 003</u>	Jul 20, 2018
<u>AP</u>	SHILPA MEDICARE LTD	<u>200MG/5.26ML (38MG/ML)</u>	<u>A210991 001</u>	Oct 04, 2019
<u>AP</u>		<u>1GM/26.3ML (38MG/ML)</u>	<u>A210991 002</u>	Oct 04, 2019
<u>AP</u>		<u>2GM/52.6ML (38MG/ML)</u>	<u>A210991 003</u>	Oct 04, 2019
<u>AP</u>	SUN PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A078433 001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078433 002</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A077983 002</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A077983 001</u>	Jan 25, 2011

GEMZAR

<u>AP</u>	<u>+</u> !	LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509 001</u>	May 15, 1996
<u>AP</u>	<u>+</u> !		<u>EQ 1GM BASE/VIAL</u>	<u>N020509 002</u>	May 15, 1996

SOLUTION; INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

<u>+</u> !	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604 002	Aug 03, 2017
<u>+</u> !		1.5GM/15ML (100MG/ML)	N209604 003	Aug 03, 2017
<u>+</u> !		2GM/20ML (100MG/ML)	N209604 004	Aug 03, 2017
<u>+</u> !		200MG/2ML (100MG/ML)	N209604 001	Aug 03, 2017

INFUGEM

<u>+</u> !	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313 001	Jul 16, 2018
<u>+</u> !		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313 002	Jul 16, 2018
<u>+</u> !		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313 003	Jul 16, 2018
<u>+</u> !		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313 004	Jul 16, 2018
<u>+</u> !		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313 005	Jul 16, 2018
<u>+</u> !		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313 006	Jul 16, 2018
<u>+</u> !		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313 007	Jul 16, 2018
<u>+</u> !		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313 008	Jul 16, 2018
<u>+</u> !		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313 009	Jul 16, 2018
<u>+</u> !		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313 010	Jul 16, 2018

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034 001</u>	Jul 20, 1998
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A202726 001</u>	Sep 16, 2015
<u>AB</u>	CADILA PHARMS LTD	<u>600MG</u>	<u>A203266 001</u>	Jun 17, 2016
<u>AB</u>	CARIBE HOLDINGS	<u>600MG</u>	<u>A078012 001</u>	Mar 26, 2007
<u>AB</u>	CHARTWELL MOLECULES	<u>600MG</u>	<u>A074270 001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599 001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207 001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836 001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072 001</u>	Sep 13, 2010
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256 001</u>	Oct 31, 1993
<u>AB</u>	ZYDUS PHARMS	<u>600MG</u>	<u>A204189 001</u>	Aug 28, 2018

LOPID

<u>AB</u>	<u>+</u> !	PFIZER PHARMS	<u>600MG</u>	<u>N018422 003</u>	Nov 20, 1986
-----------	------------	---------------	--------------	--------------------	--------------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

<u>AB</u>	<u>+</u> !	LG CHEM LTD	<u>EQ 320MG BASE</u>	<u>N021158 001</u>	Apr 04, 2003
-----------	------------	-------------	----------------------	--------------------	--------------

GEMIFLOXACIN MESYLATE

<u>AB</u>		ORCHID HLTHCARE	<u>EQ 320MG BASE</u>	<u>A090466 001</u>	Jun 15, 2015
-----------	--	-----------------	----------------------	--------------------	--------------

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>		ACP NIMBLE	<u>EQ 0.1% BASE</u>	<u>A064056 001</u>	Apr 29, 1994
<u>AT</u>	!	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307 001</u>	
<u>AT</u>		TELLIGENT PHARMA INC	<u>EQ 0.1% BASE</u>	<u>A209304 001</u>	Oct 18, 2019

INJECTABLE; INJECTION

GENTAMICIN SULFATE

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A062366 002</u>	Feb 06, 1986
<u>AP</u>	!		<u>EQ 40MG BASE/ML</u>	<u>A062366 001</u>	Aug 04, 1983
<u>AP</u>		HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420 001</u>	Aug 15, 1983
<u>AP</u>			<u>EQ 10MG BASE/ML</u>	<u>A062612 004</u>	Feb 20, 1986

PRESCRIPTION DRUG PRODUCT LIST

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP		EQ 40MG BASE/ML	A062420 002	Aug 15, 1983
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373 007	Sep 07, 1982
AP		EQ 1.6MG BASE/ML	A062373 008	Sep 07, 1982
AP		EQ 80MG BASE/100ML	A062373 002	Sep 07, 1982
AP		EQ 100MG BASE/100ML	A062373 005	Sep 07, 1982
AP	HOSPIRA	EQ 1.2MG BASE/ML	A062414 001	Aug 15, 1983
AP		EQ 1.6MG BASE/ML	A062414 003	Aug 15, 1983
AP		EQ 80MG BASE/100ML	A062414 008	Aug 15, 1983
AP		EQ 100MG BASE/100ML	A062414 010	Aug 15, 1983
	! BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373 009	Sep 07, 1982
	!	EQ 120MG BASE/100ML	A062373 006	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	! AKORN	EQ 0.3% BASE	A064093 001	Aug 31, 1995
AT	FERA PHARMS LLC	EQ 0.3% BASE	A065024 001	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	ACP NIMBLE	EQ 0.1% BASE	A064054 001	Apr 29, 1994
AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533 001	Oct 05, 1984
AT	! PERRIGO NEW YORK	EQ 0.1% BASE	A062351 001	Feb 18, 1982
AT	TARO	EQ 0.1% BASE	A062477 001	Dec 23, 1983
AT	TELEGENT PHARMA INC	EQ 0.1% BASE	A209233 001	Dec 31, 2018

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	! ALLERGAN	EQ 0.3% BASE	A062452 001	Oct 10, 1984
-----------	------------	---------------------	--------------------	--------------

GENTAK

AT	AKORN	EQ 0.3% BASE	A064163 001	Oct 12, 2001
-----------	-------	---------------------	--------------------	--------------

GENTAMICIN SULFATE

AT	AKORN	EQ 0.3% BASE	A062635 001	Jan 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	A064048 001	May 11, 1994
AT	PERRIGO CO	EQ 0.3% BASE	A065121 001	Jan 30, 2004
	TENNESSEE			
AT	SANDOZ INC	EQ 0.3% BASE	A062196 001	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

	+! ALLERGAN	EQ 0.3% BASE; 0.6%	N050612 001	Dec 01, 1989
--	-------------	--------------------	-------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

	+! ALLERGAN	EQ 0.3% BASE; 1%	N050586 001	Jun 10, 1988
--	-------------	------------------	-------------	--------------

GILTERITINIB FUMARATE

TABLET; ORAL

XOSPATA

	+! ASTELLAS	EQ 40MG BASE	N211349 001	Nov 28, 2018
--	-------------	--------------	-------------	--------------

GIVOSIRAN SODIUM

SOLUTION; SUBCUTANEOUS

GIVLAARI

	+! ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194 001	Nov 20, 2019
--	-----------------------	-------------------------------------	-------------	--------------

GLASDEGIB MALEATE

TABLET; ORAL

DAURISMO

	+ PFIZER INC	EQ 25MG BASE	N210656 001	Nov 21, 2018
--	--------------	--------------	-------------	--------------

	+!	EQ 100MG BASE	N210656 002	Nov 21, 2018
--	----	---------------	-------------	--------------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

AP	+! TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002
AP	+!	40MG/ML	N020622 003	Jan 28, 2014

GLATIRAMER ACETATE

AP	MYLAN	20MG/ML	A091646 001	Oct 03, 2017
AP		40MG/ML	A206936 001	Oct 03, 2017

GLATOPIA

AP	SANDOZ INC	20MG/ML	A090218 001	Apr 16, 2015
AP		40MG/ML	A206921 001	Feb 12, 2018

PRESCRIPTION DRUG PRODUCT LIST

GLECAPREVIR; PIBRENTASVIR

TABLET; ORAL

MAVYRET

+! ABBVIE INC

100MG; 40MG

N209394 001 Aug 03, 2017

GLIMEPIRIDE

TABLET; ORAL

AMARYL**AB** +! SANOFI AVENTIS US**1MG****N020496 001** Nov 30, 1995**AB** +**2MG****N020496 002** Nov 30, 1995**AB** +**4MG****N020496 003** Nov 30, 1995GLIMEPIRIDE**AB** ACCORD HLTHCARE**1MG****A078181 001** Aug 23, 2007**AB****2MG****A078181 002** Aug 23, 2007**AB****4MG****A078181 003** Aug 23, 2007**AB** AUROBINDO PHARMA LTD**1MG****A202759 001** Jun 29, 2012**AB****2MG****A202759 002** Jun 29, 2012**AB****4MG****A202759 003** Jun 29, 2012**AB** CARLSBAD**1MG****A077911 001** Sep 22, 2009**AB****2MG****A077911 002** Sep 22, 2009**AB****4MG****A077911 003** Sep 22, 2009**AB** DR REDDYS LABS LTD**1MG****A077091 001** Oct 06, 2005**AB****2MG****A077091 002** Oct 06, 2005**AB****4MG****A077091 003** Oct 06, 2005**AB** INDOCO REMEDIES**1MG****A202112 001** Apr 17, 2013**AB****2MG****A202112 002** Apr 17, 2013**AB****4MG****A202112 003** Apr 17, 2013**AB** INVAGEN PHARMS**1MG****A077295 001** Oct 06, 2005**AB****2MG****A077295 002** Oct 06, 2005**AB****4MG****A077295 003** Oct 06, 2005**AB** MICRO LABS**1MG****A091220 001** Jun 29, 2012**AB****2MG****A091220 002** Jun 29, 2012**AB****4MG****A091220 004** Jun 29, 2012**AB****8MG****A091220 006** Jun 29, 2012**AB** MYLAN**1MG****A077624 001** Nov 28, 2005**AB****2MG****A077624 002** Nov 28, 2005**AB****4MG****A077624 003** Nov 28, 2005**AB** PRINSTON INC**1MG****A077370 001** Dec 23, 2005**AB****2MG****A077370 002** Dec 23, 2005**AB****4MG****A077370 003** Dec 23, 2005**AB****8MG****A077370 004** Dec 23, 2005

MICRO LABS

3MG

A091220 003 Jun 29, 2012

6MG

A091220 005 Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT**AB** +! TAKEDA PHARMS USA**2MG; 30MG****N021925 001** Jul 28, 2006**AB** +**4MG; 30MG****N021925 002** Jul 28, 2006PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE**AB** SANDOZ**2MG; 30MG****A201049 001** Jan 04, 2013**AB****4MG; 30MG****A201049 002** Jan 04, 2013GLIPIZIDE

TABLET; ORAL

GLIPIZIDE**AB** ACCORD HLTHCARE**5MG****A074550 001** Sep 11, 1997**AB****10MG****A074550 002** Sep 11, 1997**AB** APOTEX**5MG****A075795 001** Jun 13, 2001**AB****10MG****A075795 002** Jun 13, 2001**AB** MYLAN**5MG****A074226 001** May 10, 1994**AB****10MG****A074226 002** May 10, 1994**AB** SANDOZ**5MG****A074305 001** Apr 07, 1995**AB****10MG****A074305 002** Apr 07, 1995**AB** SUN PHARM INDS INC**5MG****A077820 001** Jul 11, 2006**AB****10MG****A077820 002** Jul 11, 2006**AB** WATSON LABS TEVA**5MG****A074223 001** Feb 27, 1995**AB****10MG****A074223 002** Feb 27, 1995GLUCOTROL**AB** + PFIZER**5MG****N017783 001** May 08, 1984**AB** +!**10MG****N017783 002** May 08, 1984

PRESCRIPTION DRUG PRODUCT LIST

GLIPIZIDE

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB	AUROBINDO PHARMA LTD	2.5MG	A206928 001	May 12, 2017
AB		5MG	A206928 002	May 12, 2017
AB		10MG	A206928 003	May 12, 2017
AB	PAR PHARM	5MG	A076159 002	Sep 20, 2013
AB		10MG	A076159 001	Sep 20, 2013
AB	UNIQUE PHARM LABS	2.5MG	A204720 001	Dec 29, 2016
AB		5MG	A204720 002	Dec 29, 2016
AB		10MG	A204720 003	Dec 29, 2016
AB	WATSON LABS	2.5MG	A076467 003	Mar 27, 2006
AB		5MG	A076467 001	Sep 08, 2003
AB		10MG	A076467 002	Nov 07, 2003
AB	ZYDUS PHARMS	2.5MG	A203499 001	Jul 16, 2018
AB		5MG	A203499 002	Jul 16, 2018
AB		10MG	A203499 003	Jul 16, 2018
GLUCOTROL XL				
AB	+ PFIZER	2.5MG	N020329 003	Aug 10, 1999
AB	+	5MG	N020329 001	Apr 26, 1994
AB	+	10MG	N020329 002	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	2.5MG;250MG	A077507 001	Oct 27, 2005
AB		2.5MG;500MG	A077507 002	Oct 27, 2005
AB		5MG;500MG	A077507 003	Oct 27, 2005
AB	HERITAGE PHARMS INC	2.5MG;250MG	A078728 001	Jun 23, 2010
AB		2.5MG;500MG	A078728 002	Jun 23, 2010
AB		5MG;500MG	A078728 003	Jun 23, 2010
AB	TEVA PHARMS	2.5MG;250MG	A077270 001	Oct 28, 2005
AB		2.5MG;500MG	A077270 002	Oct 28, 2005
AB	!	5MG;500MG	A077270 003	Oct 28, 2005
AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011
AB		2.5MG;500MG	A078905 002	Jan 31, 2011
AB		5MG;500MG	A078905 003	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

+	LILLY	1MG/VIAL	N020928 001	Sep 11, 1998
POWDER;NASAL				
BAQSIMI				
+	ELI LILLY AND CO	3MG	N210134 001	Jul 24, 2019
SOLUTION;SUBCUTANEOUS				
GVOKE HYOPEN				
+	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 003	Sep 10, 2019
+		1MG/0.2ML (1MG/0.2ML)	N212097 004	Sep 10, 2019
GVOKE PFS				
+	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 001	Sep 10, 2019
+		1MG/0.2ML (1MG/0.2ML)	N212097 002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918 001	Jun 22, 1998
POWDER;INTRAMUSCULAR, INTRAVENOUS				
GLUCAGON				
+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB	DAVA PHARMS INC	1.5MG	A074591 001	Dec 22, 1997
AB		3MG	A074591 002	Dec 22, 1997
AB		4.5MG	A074591 003	Dec 22, 1997
AB		6MG	A074591 004	Dec 22, 1997
AB	HIKMA	1.5MG	A075890 001	Jul 31, 2003
AB		3MG	A075890 002	Jul 31, 2003
AB		6MG	A075890 003	Jul 31, 2003
AB	MYLAN	1.5MG	A074792 001	Jun 26, 1998
AB		3MG	A074792 002	Jun 26, 1998

PRESCRIPTION DRUG PRODUCT LIST

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

<u>AB</u>		<u>6MG</u>	<u>A074792</u>	<u>003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686</u>	<u>003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686</u>	<u>004</u>	Apr 20, 1999

GLYNASE

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051</u>	<u>001</u>	Mar 04, 1992
<u>AB</u>	+		<u>3MG</u>	<u>N020051</u>	<u>002</u>	Mar 04, 1992
<u>AB</u>	+	!	<u>6MG</u>	<u>N020051</u>	<u>004</u>	Sep 24, 1993

GLYBURIDE

<u>AB1</u>		AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537</u>	<u>001</u>	Oct 18, 2007
<u>AB1</u>			<u>2.5MG</u>	<u>A077537</u>	<u>002</u>	Oct 18, 2007
<u>AB1</u>			<u>5MG</u>	<u>A077537</u>	<u>003</u>	Oct 18, 2007
<u>AB1</u>		CADILA PHARMS LTD	<u>1.25MG</u>	<u>A203379</u>	<u>001</u>	Jan 04, 2019
<u>AB1</u>			<u>2.5MG</u>	<u>A203379</u>	<u>002</u>	Jan 04, 2019
<u>AB1</u>			<u>5MG</u>	<u>A203379</u>	<u>003</u>	Jan 04, 2019
<u>AB1</u>		EPIC PHARMA LLC	<u>1.25MG</u>	<u>A076257</u>	<u>001</u>	Jun 27, 2002
<u>AB1</u>			<u>2.5MG</u>	<u>A076257</u>	<u>002</u>	Jun 27, 2002
<u>AB1</u>			<u>5MG</u>	<u>A076257</u>	<u>003</u>	Jun 27, 2002
<u>AB1</u>		HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937</u>	<u>001</u>	Feb 28, 2011
<u>AB1</u>			<u>2.5MG</u>	<u>A090937</u>	<u>002</u>	Feb 28, 2011
<u>AB1</u>			<u>5MG</u>	<u>A090937</u>	<u>003</u>	Feb 28, 2011
<u>AB1</u>		PHARMADAX INC	<u>1.25MG</u>	<u>A203581</u>	<u>001</u>	Apr 14, 2016
<u>AB1</u>			<u>2.5MG</u>	<u>A203581</u>	<u>002</u>	Apr 14, 2016
<u>AB1</u>			<u>5MG</u>	<u>A203581</u>	<u>003</u>	Apr 14, 2016
<u>AB1</u>		TEVA	<u>1.25MG</u>	<u>A074388</u>	<u>001</u>	Aug 29, 1995
<u>AB1</u>			<u>2.5MG</u>	<u>A074388</u>	<u>002</u>	Aug 29, 1995
<u>AB1</u>		!	<u>5MG</u>	<u>A074388</u>	<u>003</u>	Aug 29, 1995
<u>AB1</u>		ZYDUS PHARMS	<u>1.25mg</u>	<u>A206749</u>	<u>001</u>	May 10, 2016
<u>AB1</u>			<u>2.5mg</u>	<u>A206749</u>	<u>002</u>	May 10, 2016
<u>AB1</u>			<u>5MG</u>	<u>A206749</u>	<u>003</u>	May 10, 2016

DIABETA

<u>AB2</u>	+	SANOFI AVENTIS US	<u>1.25MG</u>	<u>N017532</u>	<u>001</u>	May 01, 1984
<u>AB2</u>	+		<u>2.5MG</u>	<u>N017532</u>	<u>002</u>	May 01, 1984
<u>AB2</u>	+	!	<u>5MG</u>	<u>N017532</u>	<u>003</u>	May 01, 1984

GLYBURIDE

<u>AB2</u>		IMPAX LABS INC	<u>1.25MG</u>	<u>A206079</u>	<u>001</u>	Sep 30, 2015
<u>AB2</u>			<u>2.5MG</u>	<u>A206079</u>	<u>002</u>	Sep 30, 2015
<u>AB2</u>			<u>5MG</u>	<u>A206079</u>	<u>003</u>	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
<u>AB</u>		AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		!	<u>2.5MG;500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>			<u>5MG;500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
<u>AB</u>		IMPAX LABS INC	<u>1.25MG;250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
<u>AB</u>			<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004
<u>AB</u>		ZYDUS PHARMS	<u>1.25MG;250MG</u>	<u>A206748</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A206748</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>			<u>5MG;500MG</u>	<u>A206748</u>	<u>003</u>	Feb 29, 2016

GLYCEROL PHENYL BUTYRATE

LIQUID; ORAL

RAVICTI

+	!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013
---	---	----------------	----------	---------	-----	--------------

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>	+	!	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>
-----------	---	---	-----------------	--------------------	----------------	------------

GLYCINE 1.5% IN PLASTIC CONTAINER

<u>AT</u>			B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>
<u>AT</u>			ICU MEDICAL INC	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>	AM REGENT	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
<u>AP</u>	AMNEAL	<u>0.2MG/ML</u>	<u>A208973</u>	<u>001</u>	Jun 15, 2017
<u>AP</u>	APOTEX	<u>0.2MG/ML</u>	<u>A210246</u>	<u>001</u>	Oct 29, 2019
<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.2MG/ML</u>	<u>A210244</u>	<u>001</u>	Nov 28, 2018
<u>AP</u>	CAPLIN	<u>0.2MG/ML</u>	<u>A211705</u>	<u>001</u>	Mar 20, 2019
<u>AP</u>	FRESENIUS KABI USA	<u>0.2MG/ML</u>	<u>A209024</u>	<u>001</u>	Oct 31, 2018
<u>AP</u>		<u>0.2MG/ML</u>	<u>A209328</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>0.2MG/ML</u>	<u>A212612</u>	<u>001</u>	Sep 30, 2019
<u>AP</u>	! HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
<u>AP</u>	PIRAMAL CRITICAL	<u>0.2MG/ML</u>	<u>A210842</u>	<u>001</u>	Oct 25, 2018
<u>AP</u>	PRINSTON INC	<u>0.2MG/ML</u>	<u>A210927</u>	<u>001</u>	Oct 31, 2018
<u>AP</u>	SANDOZ INC	<u>0.2MG/ML</u>	<u>A211334</u>	<u>001</u>	May 14, 2019
<u>AP</u>	SOMERSET THERAPS LLC	<u>0.2MG/ML</u>	<u>A207639</u>	<u>001</u>	Jun 23, 2017

POWDER; INHALATION

SEEBRI

+! SUNOVION PHARMS INC 15.6MCG/INH N207923 001 Oct 29, 2015

SOLUTION; INHALATION

LONHALA MAGNAIR KIT

+! SUNOVION RESP 25MCG/ML N208437 001 Dec 05, 2017

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

EXELA PHARMA SCS 0.2MG/ML (0.2MG/ML) N210997 001 Jul 11, 2018

LLC

0.4MG/2ML (0.2MG/ML) N210997 002 Jul 11, 2018

SOLUTION; ORAL

CUVPOSA

+! MERZ PHARMS 1MG/5ML N022571 001 Jul 28, 2010

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		<u>2MG</u>	<u>A202675</u>	<u>002</u>	Oct 30, 2018
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>	HERITAGE PHARMS INC	<u>1MG</u>	<u>A207201</u>	<u>001</u>	Jan 03, 2017
<u>AA</u>		<u>2MG</u>	<u>A207201</u>	<u>002</u>	Jan 03, 2017
<u>AA</u>	KENTON	<u>1MG</u>	<u>A091182</u>	<u>001</u>	Feb 03, 2014
<u>AA</u>		<u>2MG</u>	<u>A091182</u>	<u>002</u>	Feb 03, 2014
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>		<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012
<u>AA</u>	NATCO PHARMA LTD	<u>1MG</u>	<u>A091413</u>	<u>001</u>	Jun 20, 2016
<u>AA</u>		<u>2MG</u>	<u>A091413</u>	<u>002</u>	Jun 20, 2016
<u>AA</u>	ORIT LABS LLC	<u>1MG</u>	<u>A203657</u>	<u>001</u>	Nov 30, 2018
<u>AA</u>		<u>2MG</u>	<u>A203657</u>	<u>002</u>	Nov 30, 2018
<u>AA</u>	OXFORD PHARMS	<u>1MG</u>	<u>A090020</u>	<u>001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020</u>	<u>002</u>	Oct 19, 2011
<u>AA</u>	! PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>	!	<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006
<u>AA</u>	RISING	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008
<u>AA</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009
	NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH; 27.5MCG/INH N207930 001 Oct 29, 2015

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

QBREXZA

+! DERMIRA INC EQ 2.4% BASE N210361 001 Jun 28, 2018

PRESCRIPTION DRUG PRODUCT LIST

GOLODIRSEN

SOLUTION; INTRAVENOUS

VYONDYS 53

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N211970 001 Dec 12, 2019

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

AP +! FERRING 10,000 UNITS/VIAL N017016 007

AP +! FRESENIUS KABI USA 10,000 UNITS/VIAL N017067 002

PREGNYL

AP +! ORGANON USA INC 10,000 UNITS/VIAL N017692 001

CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL N017016 006

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

+! TERSERA THERAPS LLC EQ 3.6MG BASE N019726 001 Dec 29, 1989

+! EQ 10.8MG BASE N020578 001 Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT AMRING PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A065187 001 Oct 28, 2005

AT ! BAUSCH AND LOMB 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A064047 001 Jan 31, 1996

NEOSPORIN

AT ! MONARCH PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A060582 001

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+! KYOWA KIRIN 3.1MG/24HR N022198 001 Sep 12, 2008

INJECTION, EXTENDED RELEASE; SUBCUTANEOUS

SUSTOL

+! HERON THERAPS INC 10MG/0.4ML (10MG/0.4ML) N022445 001 Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP AKORN INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A079119 001 Sep 10, 2009

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A079078 001 Sep 14, 2009

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A079078 002 Sep 14, 2009

AP AUROBINDO PHARMA LTD EQ 1MG BASE/ML (EQ 1MG BASE/ML) A204238 001 Jul 06, 2016

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A204238 002 Jul 06, 2016

AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078863 001 Jun 30, 2008

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008

AP CIPLA LTD EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078262 001 Dec 31, 2007

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078258 001 Jun 30, 2008

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078258 002 Jun 30, 2008

AP ! DR REDDYS EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078392 001 Dec 31, 2007

AP ! EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077297 001 Jun 30, 2008

AP FRESENIUS KABI USA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078522 001 Dec 31, 2007

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078090 001 Jun 30, 2008

AP HIKMA FARMACEUTICA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078629 001 Dec 23, 2009

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078629 002 Dec 23, 2009

AP MYLAN ASI EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A091136 001 Apr 09, 2010

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A091136 002 Apr 09, 2010

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A091137 002 Apr 09, 2010

AP MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A203454 001 Apr 04, 2017

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A203454 002 Apr 04, 2017

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A203453 001 Jan 31, 2017

AP SANDOZ INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078534 001 Apr 30, 2009

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078531 001 Apr 30, 2009

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078835 001 Jun 30, 2008

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078531 002 Apr 30, 2009

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078835 002 Jun 30, 2008

AP WEST-WARD PHARMS EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A077913 001 Jun 26, 2008

AP INT EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077186 001 Jun 30, 2008

AP EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077187 001 Jun 30, 2008

AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A077177 001 Dec 31, 2007

PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	BIONPHARMA INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
<u>AP</u>	! FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
<u>AB</u>	CHARTWELL MOLECULAR	<u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
<u>AB</u>	! HIKMA	<u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725 001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	! ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
<u>AB</u>	CHARTWELL RX	<u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
<u>AB</u>	CIPLA	<u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
<u>AB</u>	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

<u>AB</u>	! SANDOZ INC	<u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
	SANDOZ INC	250MG	A091592 001	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

<u>AB</u>	+ VALEANT PHARMS INC	<u>125MG</u>	<u>N050475 001</u>	
<u>AB</u>	+!	<u>250MG</u>	<u>N050475 002</u>	

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>	MOUNTAIN	<u>125MG</u>	<u>A204371 001</u>	Jan 09, 2014
<u>AB</u>		<u>250MG</u>	<u>A204371 002</u>	Jan 09, 2014
<u>AB</u>	SANDOZ INC	<u>125MG</u>	<u>A202805 001</u>	Dec 26, 2018
<u>AB</u>		<u>250MG</u>	<u>A202805 002</u>	Dec 26, 2018

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>	SIGMAPHARM LABS LLC	<u>125MG</u>	<u>A202545 001</u>	Oct 22, 2012
<u>AB</u>		<u>250MG</u>	<u>A202545 002</u>	Oct 22, 2012

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109 001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109 002</u>	Nov 25, 1998
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 1MG BASE</u>	<u>A074673 001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673 002</u>	Feb 28, 1997
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A074796 001</u>	Jan 27, 1997
<u>AB</u>	! WATSON LABS	<u>EQ 2MG BASE</u>	<u>A074796 002</u>	Jan 27, 1997
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A074145 001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145 002</u>	Oct 17, 1995

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A200881 001</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A200881 002</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A200881 003</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200881 004</u>	Oct 05, 2012
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A205430 001</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205430 002</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205430 003</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205430 004</u>	Jul 25, 2018
<u>AB</u>	SANDOZ INC	<u>EQ 1MG BASE</u>	<u>A202568 001</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202568 002</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A202568 003</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202568 004</u>	Jun 03, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1MG BASE</u>	<u>A205689 001</u>	Nov 16, 2017

PRESCRIPTION DRUG PRODUCT LIST

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB		<u>EQ 2MG BASE</u>	<u>A205689 002</u>	Nov 16, 2017
AB		<u>EQ 3MG BASE</u>	<u>A205689 003</u>	Nov 16, 2017
AB		<u>EQ 4MG BASE</u>	<u>A205689 004</u>	Nov 16, 2017
AB	TEVA PHARMS USA	<u>EQ 1MG BASE</u>	<u>A201382 001</u>	Jun 02, 2015
AB		<u>EQ 2MG BASE</u>	<u>A201382 002</u>	Jun 02, 2015
AB		<u>EQ 3MG BASE</u>	<u>A201382 003</u>	Jun 02, 2015
AB		<u>EQ 4MG BASE</u>	<u>A201382 004</u>	Jun 02, 2015
AB	TWI PHARMS	<u>EQ 1MG BASE</u>	<u>A201408 001</u>	Jun 02, 2015
AB		<u>EQ 2MG BASE</u>	<u>A201408 002</u>	Jun 02, 2015
AB		<u>EQ 3MG BASE</u>	<u>A201408 003</u>	Jun 02, 2015
AB		<u>EQ 4MG BASE</u>	<u>A201408 004</u>	Jun 02, 2015
<u>INTUNIV</u>				
AB	+ SHIRE	<u>EQ 1MG BASE</u>	<u>N022037 001</u>	Sep 02, 2009
AB	+	<u>EQ 2MG BASE</u>	<u>N022037 002</u>	Sep 02, 2009
AB	+	<u>EQ 3MG BASE</u>	<u>N022037 003</u>	Sep 02, 2009
AB	+	<u>EQ 4MG BASE</u>	<u>N022037 004</u>	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME

125MG

N001546 001

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB	MYLAN	<u>0.1%</u>	<u>A211027 001</u>	Aug 12, 2019
<u>HALOG</u>				
AB	+! SUN PHARM INDS INC	<u>0.1%</u>	<u>N017556 001</u>	
OINTMENT;TOPICAL				
HALOG				
	+! SUN PHARM INDS INC	0.1%	N017824 001	

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

LEXETTE

+! MAYNE PHARMA

0.05%

N210566 001 May 24, 2018

CREAM;TOPICAL

HALOBETASOL PROPIONATE

AB	! ACP NIMBLE	<u>0.05%</u>	<u>A078162 001</u>	Apr 24, 2007
AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A077001 001</u>	Dec 16, 2004
AB	PERRIGO ISRAEL	<u>0.05%</u>	<u>A077123 001</u>	Dec 16, 2004
AB	TARO	<u>0.05%</u>	<u>A077227 001</u>	Aug 04, 2005
LOTION;TOPICAL				
BRYHALI				
	+! BAUSCH	0.01%	N209355 001	Nov 06, 2018
ULTRAVATE				
	+! SUN PHARM INDUSTRIES	0.05%	N208183 001	Nov 06, 2015
OINTMENT;TOPICAL				
<u>HALOBETASOL PROPIONATE</u>				
AB	ACP NIMBLE	<u>0.05%</u>	<u>A077109 001</u>	Jun 14, 2005
AB	!	<u>0.05%</u>	<u>A077721 001</u>	Sep 07, 2006
AB	PERRIGO ISRAEL	<u>0.05%</u>	<u>A076872 001</u>	Dec 16, 2004
AB	TARO	<u>0.05%</u>	<u>A076994 001</u>	Dec 16, 2004
AB	TELIGENT PHARMA INC	<u>0.05%</u>	<u>A209978 001</u>	Mar 20, 2018
<u>ULTRAVATE</u>				
AB	+ SUN PHARM INDS INC	<u>0.05%</u>	<u>N019968 001</u>	Dec 17, 1990

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

+! BAUSCH

0.01%;0.045%

N209354 001 Apr 25, 2019

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	APPCO	<u>0.5MG</u>	<u>A211061 001</u>	Jan 08, 2020
AB		<u>1MG</u>	<u>A211061 002</u>	Jan 08, 2020
AB		<u>2MG</u>	<u>A211061 003</u>	Jan 08, 2020
AB		<u>5MG</u>	<u>A211061 004</u>	Jan 08, 2020
AB		<u>10MG</u>	<u>A211061 005</u>	Jan 08, 2020
AB		<u>20MG</u>	<u>A211061 006</u>	Jan 08, 2020

PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	INNOGENIX	<u>0.5MG</u>	<u>A071173 002</u>	Jan 02, 1987
<u>AB</u>		<u>1MG</u>	<u>A071173 003</u>	Jan 02, 1987
<u>AB</u>		<u>2MG</u>	<u>A071173 004</u>	Jan 02, 1987
<u>AB</u>		<u>5MG</u>	<u>A071173 005</u>	Jan 07, 1988
<u>AB</u>		<u>10MG</u>	<u>A071173 001</u>	Jan 07, 1988
<u>AB</u>		<u>20MG</u>	<u>A071173 006</u>	Jan 07, 1988
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278 006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278 004</u>	Jun 10, 1986
<u>AB</u>	!	<u>2MG</u>	<u>A070278 001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278 005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278 002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278 003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206 001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207 001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209 001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210 001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211 001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580 003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580 004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580 005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+!	JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701 001</u>	Jan 14, 1986
<u>AO</u>	+!		<u>EQ 100MG BASE/ML</u>	<u>N018701 002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893 001</u>	Dec 19, 1997
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A074893 002</u>	Dec 19, 1997
<u>AO</u>		GLAND PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A205241 001</u>	May 12, 2017
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A205241 002</u>	May 12, 2017
<u>AO</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/ML</u>	<u>A075440 001</u>	Feb 28, 2000
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075440 002</u>	Feb 28, 2000
<u>AO</u>		SOMERSET THERAPS LLC	<u>EQ 50MG BASE/ML</u>	<u>A209101 001</u>	Jul 03, 2018
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A209101 002</u>	Jul 03, 2018
<u>AO</u>		TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393 001</u>	May 11, 1999
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075393 002</u>	May 11, 1999
<u>AO</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074811 001</u>	Jan 30, 1998
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075305 001</u>	Sep 28, 1998
<u>AO</u>		ZYDUS PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A211180 001</u>	Oct 22, 2019
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A211180 002</u>	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>		LANNETT CO INC	<u>EQ 2MG BASE/ML</u>	<u>A073364 001</u>	Sep 28, 1993
<u>AA</u>	!	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037 001</u>	Feb 26, 1993

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+!	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923 001</u>	
-----------	----	----------------	-----------------------	--------------------	--

HALOPERIDOL

<u>AP</u>		AKORN	<u>EQ 5MG BASE/ML</u>	<u>A204849 001</u>	Sep 06, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689 001</u>	Mar 09, 2001
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774 001</u>	Aug 25, 2004
<u>AP</u>		MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347 001</u>	Sep 14, 2009
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637 001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742 001</u>	Sep 02, 2011
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035 001</u>	Aug 29, 2001
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>A075858 001</u>	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>		CASI PHARMS INC	<u>5,000 UNITS/ML</u>	<u>A091659 001</u>	Jun 08, 2011
<u>AP</u>	+!	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 001</u>	
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A206552 001</u>	Jun 10, 2016
<u>AP</u>	+!		<u>5,000 UNITS/ML</u>	<u>N017651 006</u>	
<u>AP</u>	+!		<u>10,000 UNITS/ML</u>	<u>N017029 003</u>	

PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	<u>+!</u>		<u>20,000 UNITS/ML</u>	<u>N017029 004</u>	
<u>AP</u>		GLAND PHARMA LTD	<u>5,000 UNITS/ML</u>	<u>A205323 001</u>	Feb 06, 2017
<u>AP</u>	<u>+!</u>	HIKMA	<u>1,000 UNITS/ML</u>	<u>N017037 001</u>	
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017037 002</u>	
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017037 003</u>	
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571 001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571 002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571 003</u>	Aug 31, 2009
<u>AP</u>		MYLAN LABS LTD	<u>1,000 UNITS/ML</u>	<u>A203851 001</u>	Nov 30, 2017
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A203851 002</u>	Nov 30, 2017
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203851 003</u>	Nov 30, 2017
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203852 001</u>	Nov 30, 2017
<u>AP</u>		NANJING KING-FRIEND	<u>1,000 UNITS/ML</u>	<u>A211005 001</u>	Dec 14, 2018
<u>AP</u>			<u>1,000 UNITS/ML</u>	<u>A211007 001</u>	May 28, 2019
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A211007 002</u>	May 28, 2019
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A211007 003</u>	May 28, 2019
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808 001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808 002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808 003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809 001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682 001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682 002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002 001</u>	Jun 08, 2011
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957 001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202733 001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202957 002</u>	Jun 12, 2014
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203198 001</u>	Jun 12, 2014
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203198 002</u>	Jun 12, 2014
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 001</u>	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>+!</u>	B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953 001</u>	Jul 20, 1992
<u>AP</u>	<u>+!</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 010</u>	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>		HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339 003</u>	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>		BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 002</u>	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>+!</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 011</u>	Jun 23, 1989
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>+!</u>	B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952 001</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805 001</u>	Jan 25, 1989
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>+!</u>	B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952 004</u>	Jul 20, 1992
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/100ML</u>	<u>N019952 005</u>	Jul 20, 1992
<u>AP</u>		HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339 004</u>	Mar 27, 1985
<u>AP</u>			<u>5,000 UNITS/100ML</u>	<u>N019805 002</u>	Jan 25, 1989
<u>AP</u>			<u>10,000 UNITS/100ML</u>	<u>N019339 002</u>	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>					
<u>AP</u>	<u>+!</u>	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 013</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017029 014</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017029 015</u>	Dec 05, 1985
<u>AP</u>	<u>+!</u>		<u>20,000 UNITS/ML</u>	<u>N017029 016</u>	Dec 05, 1985
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>					
<u>AP</u>	<u>+!</u>	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 010</u>	Apr 28, 1986
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810 001</u>	Jun 30, 2010
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202732 001</u>	Jun 12, 2014
HEPARIN SODIUM					
		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827 001	Nov 19, 2018
	<u>+!</u>	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 020	Mar 31, 2011
	<u>!</u>	HOSPIRA	5,000 UNITS/ML	A088100 001	Apr 28, 1983
	<u>+!</u>	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011
	<u>+!</u>		5,000 UNITS/ML	N201370 002	Jul 21, 2011
	<u>+!</u>		10,000 UNITS/ML	N201370 003	Jul 21, 2011
<u>HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
		HOSPIRA	5,000 UNITS/100ML	N019339 001	Mar 27, 1985
<u>HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
		HOSPIRA	5,000 UNITS/100ML	N018916 006	Jan 31, 1984

PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
		10,000 UNITS/100ML	N018916	008	Jan 31, 1984
	HEPARIN SODIUM PRESERVATIVE FREE				
+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010
!	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
+	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE; TOPICAL

PRE-OP

AT	+	DAVIS AND GECK	480MG	N017433	001
-----------	---	----------------	--------------	----------------	------------

PRE-OP II

AT	+	DAVIS AND GECK	480MG	N017433	002
-----------	---	----------------	--------------	----------------	------------

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010
---	---------------	------------	---------	-----	--------------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+	ENDO PHARM	50MG	N022058	001	May 03, 2007
---	------------	------	---------	-----	--------------

VANTAS

+	ENDO PHARM	50MG	N021732	001	Oct 12, 2004
---	------------	------	---------	-----	--------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA	+	GENUS	1.5MG/5ML; 5MG/5ML	N005213	002	Jul 26, 1988
-----------	---	-------	---------------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017
-----------	--	-----------	---------------------------	----------------	------------	--------------

AA		ACTAVIS MID ATLANTIC	1.5MG/5ML; 5MG/5ML	A088017	001	Jul 05, 1983
-----------	--	----------------------	---------------------------	----------------	------------	--------------

AA	!	HI TECH PHARMA	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008
-----------	---	----------------	---------------------------	----------------	------------	--------------

AA		NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017
-----------	--	----------------	---------------------------	----------------	------------	--------------

AA		PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017
-----------	--	-------------	---------------------------	----------------	------------	--------------

AA		WOCKHARDT BIO AG	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983
-----------	--	------------------	---------------------------	----------------	------------	--------------

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA		AVANTHI INC	1.5MG; 5MG	A207176	001	Aug 07, 2017
-----------	--	-------------	-------------------	----------------	------------	--------------

AA		NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011
-----------	--	----------------	-------------------	----------------	------------	--------------

TUSSIGON

AA	!	KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985
-----------	---	-------------	-------------------	----------------	------------	--------------

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+	AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004
---	-----------------	--------------	---------	-----	--------------

VITRASE

+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004
---	-----------------	----------------	---------	-----	--------------

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+	HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005
---	-----------------	--------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	!	AKORN	20MG/ML	A040730	001	Apr 21, 2009
-----------	---	-------	----------------	----------------	------------	--------------

AP		FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001
-----------	--	--------------------	----------------	----------------	------------	--------------

AP		MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016
-----------	--	---------------------	----------------	----------------	------------	--------------

AP		NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013
-----------	--	-------------	----------------	----------------	------------	--------------

AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015
-----------	--	------------------	----------------	----------------	------------	--------------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012
-----------	--	----------------	-------------	----------------	------------	--------------

AA			25MG	A200737	002	Dec 07, 2012
-----------	--	--	-------------	----------------	------------	--------------

AA			50MG	A200737	003	Dec 07, 2012
-----------	--	--	-------------	----------------	------------	--------------

AA			100MG	A200737	004	Dec 07, 2012
-----------	--	--	--------------	----------------	------------	--------------

AA		CADILA PHARMS LTD	25MG	A203845	001	Sep 18, 2014
-----------	--	-------------------	-------------	----------------	------------	--------------

AA			50MG	A203845	002	Sep 18, 2014
-----------	--	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>		<u>100MG</u>	<u>A203845</u>	<u>003</u>	Sep 18, 2014
<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	! PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	!	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	!	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	SCIEGEN PHARMS INC	<u>10MG</u>	<u>A205236</u>	<u>001</u>	May 26, 2017
<u>AA</u>		<u>25MG</u>	<u>A205236</u>	<u>002</u>	May 26, 2017
<u>AA</u>		<u>50MG</u>	<u>A205236</u>	<u>003</u>	May 26, 2017
<u>AA</u>		<u>100MG</u>	<u>A205236</u>	<u>004</u>	May 26, 2017
<u>AA</u>	STRIDES PHARMA	<u>10MG</u>	<u>A200770</u>	<u>004</u>	Jun 25, 2019
<u>AA</u>		<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013
<u>AA</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A209251</u>	<u>001</u>	Jul 09, 2018
<u>AA</u>		<u>25MG</u>	<u>A209251</u>	<u>002</u>	Jul 09, 2018
<u>AA</u>		<u>50MG</u>	<u>A209251</u>	<u>003</u>	Jul 09, 2018
<u>AA</u>		<u>100MG</u>	<u>A209251</u>	<u>004</u>	Jul 09, 2018

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

	PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
	!	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
---	------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>12.5MG</u>	<u>A203561</u>	<u>001</u>	Jan 14, 2019
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010

MICROZIDE

<u>AB</u>	! ALLERGAN	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	! ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780 001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780 002</u>	Jul 20, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182 002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182 001</u>	
<u>AB</u>	HIKMA INTL PHARMS	<u>50MG</u>	<u>A084878 001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807 001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807 002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807 003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177 001</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A083177 002</u>	
<u>AB</u>	LEADING PHARMA LLC	<u>12.5MG</u>	<u>A040702 003</u>	May 10, 2017
<u>AB</u>		<u>25MG</u>	<u>A040702 001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702 002</u>	Mar 16, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A040735 002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735 003</u>	Jan 23, 2007
<u>AB</u>	OXFORD PHARMS	<u>25MG</u>	<u>A087059 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068 001</u>	
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A040412 001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412 002</u>	Mar 29, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018 001</u>	Jul 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203018 002</u>	Jul 23, 2014
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907 001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907 002</u>	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+!	SANOFI AVENTIS US	<u>12.5MG; 150MG</u>	<u>N020758 002</u>	Sep 30, 1997
<u>AB</u>	+!		<u>12.5MG; 300MG</u>	<u>N020758 003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A091370 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091370 002</u>	Oct 15, 2012
<u>AB</u>		<u>25MG; 300MG</u>	<u>A091370 003</u>	Oct 12, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG; 150MG</u>	<u>A203630 001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203630 002</u>	Feb 22, 2013
<u>AB</u>		<u>25MG; 300MG</u>	<u>A203630 003</u>	Mar 31, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG; 150MG</u>	<u>A203500 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203500 002</u>	Sep 27, 2012
<u>AB</u>	HIKMA	<u>12.5MG; 150MG</u>	<u>A090351 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A090351 002</u>	Oct 15, 2012
<u>AB</u>		<u>25MG; 300MG</u>	<u>A090351 003</u>	Jun 08, 2017
<u>AB</u>	HISUN PHARM HANGZHOU	<u>12.5MG; 150MG</u>	<u>A207896 001</u>	Oct 14, 2016
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A207896 002</u>	Oct 14, 2016
<u>AB</u>	LUPIN LTD	<u>12.5MG; 150MG</u>	<u>A201524 001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201524 002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A202414 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A202414 002</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG; 150MG</u>	<u>A203072 001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203072 002</u>	May 09, 2014
<u>AB</u>	SANDOZ	<u>12.5MG; 150MG</u>	<u>A077446 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077446 002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG; 150MG</u>	<u>A077369 001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077369 002</u>	Mar 30, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>12.5MG; 150MG</u>	<u>A207018 001</u>	Sep 19, 2017
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A207018 002</u>	Sep 19, 2017

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO	<u>12.5MG; 10MG</u>	<u>A077606 001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A077606 002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG; 20MG</u>	<u>A077606 003</u>	Mar 14, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG; 10MG</u>	<u>A076265 001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076265 002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076265 003</u>	Jul 08, 2002
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG; 10MG</u>	<u>A204058 001</u>	May 23, 2017
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A204058 002</u>	May 23, 2017
<u>AB</u>		<u>25MG; 20MG</u>	<u>A204058 003</u>	May 23, 2017

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912 001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912 002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912 003</u>	Sep 27, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007 003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002
<u>ZESTORETIC</u>				
<u>AB</u>	+ ALVOGEN	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
<u>AB</u>	+!	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
<u>AB</u>	+!	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	+ MERCK SHARP DOHME	<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
<u>LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
<u>AB</u>	!	<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845 002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845 003</u>	Sep 18, 2012
<u>AB</u>	HIKMA	<u>12.5MG;50MG</u>	<u>A077732 002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732 001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732 003</u>	Oct 06, 2010
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682 001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682 002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682 003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245 002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289 001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289 002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289 003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652 003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>12.5MG;50MG</u>	<u>A204901 001</u>	Nov 06, 2017
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A204901 002</u>	Nov 06, 2017
<u>AB</u>		<u>25MG;100MG</u>	<u>A204901 003</u>	Nov 06, 2017
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948 003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948 002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157 001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528 003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528 002</u>	Oct 06, 2010
<u>AB</u>	UNICHEM LABS LTD	<u>12.5MG;50MG</u>	<u>A204832 001</u>	Jul 21, 2017
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A204832 002</u>	Jul 21, 2017
<u>AB</u>		<u>25MG;100MG</u>	<u>A204832 003</u>	Jul 21, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385 001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385 002</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986
!	25MG; 250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

+ CONCORDIA	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
+	12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+!	12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB +	US PHARMS HOLDINGS	25MG; 50MG	N018303	001	Dec 31, 1984
	I				

AB +!		25MG; 100MG	N018303	002	Dec 31, 1984
--------------	--	--------------------	----------------	------------	--------------

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	25MG; 50MG	A202870	001	Nov 06, 2013
AB		25MG; 100MG	A202870	002	Nov 06, 2013
AB		50MG; 100MG	A202870	003	Nov 06, 2013
AB	MYLAN	25MG; 50MG	A076792	001	Aug 20, 2004
AB		25MG; 100MG	A076792	002	Aug 20, 2004
AB		50MG; 100MG	A076792	003	Aug 20, 2004
AB	SUN PHARM INDS	25MG; 50MG	A090654	001	Jan 19, 2012
AB		25MG; 100MG	A090654	002	Jan 19, 2012
AB		50MG; 100MG	A090654	003	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS	12.5MG; 7.5MG	A090718	001	Mar 17, 2010
AB		12.5MG; 15MG	A090718	002	Mar 17, 2010
AB		25MG; 15MG	A090718	003	Mar 17, 2010
AB	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014
AB		12.5MG; 15MG	A202150	002	Mar 07, 2014
AB		25MG; 15MG	A202150	003	Mar 07, 2014
AB	TEVA	12.5MG; 7.5MG	A076980	001	Mar 07, 2007
AB		12.5MG; 15MG	A076980	003	Mar 07, 2007
AB	!	25MG; 15MG	A076980	002	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

AB +	DAIICHI SANKYO	12.5MG; 20MG	N021532	002	Jun 05, 2003
AB +		12.5MG; 40MG	N021532	003	Jun 05, 2003
AB +!		25MG; 40MG	N021532	005	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG; 20MG	A204233	001	Apr 24, 2017
AB		12.5MG; 40MG	A204233	002	Apr 24, 2017
AB		25MG; 40MG	A204233	003	Apr 24, 2017
AB	AUROBINDO PHARMA LTD	12.5MG; 20MG	A205391	001	Apr 24, 2017
AB		12.5MG; 40MG	A205391	002	Apr 24, 2017
AB		25MG; 40MG	A205391	003	Apr 24, 2017
AB	PRINSTON INC	12.5MG; 20MG	A207804	001	Apr 24, 2017
AB		12.5MG; 40MG	A207804	002	Apr 24, 2017
AB		25MG; 40MG	A207804	003	Apr 24, 2017
AB	TEVA PHARMS USA	12.5MG; 40MG	A200532	002	Apr 24, 2017
AB	TORRENT	12.5MG; 20MG	A206515	001	May 03, 2017
AB		12.5MG; 40MG	A206515	002	May 03, 2017
AB		25MG; 40MG	A206515	003	May 03, 2017
AB	UMEDICA LABS PVT LTD	12.5MG; 20MG	A208847	001	Sep 17, 2019
AB		12.5MG; 40MG	A208847	003	Sep 17, 2019
AB		25MG; 40MG	A208847	002	Sep 17, 2019

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	!	MYLAN	<u>25MG;80MG</u>	<u>A070947</u>	<u>001</u>	Apr 01, 1987
	!		25MG;40MG	A070947	002	Mar 04, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCURETIC

<u>AB</u>	+	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
<u>AB</u>	+		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
<u>AB</u>	+	!	<u>25MG;EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A091524</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A091524</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		INVAGEN PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A201356</u>	<u>001</u>	Apr 20, 2011
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A201356</u>	<u>002</u>	Apr 20, 2011
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A201356</u>	<u>003</u>	Apr 20, 2011

QUINARETIC

<u>AB</u>		LUPIN	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

<u>AB</u>	+	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
<u>AB</u>		SUN PHARM INDUSTRIES	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
<u>ALDACTAZIDE</u>						
	+	!	GD SEARLE LLC	50MG;50MG	N012616	005 Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162</u>	<u>001</u>	Nov 17, 2000
<u>AB</u>	+		<u>12.5MG;80MG</u>	<u>N021162</u>	<u>002</u>	Nov 17, 2000
<u>AB</u>	+	!	<u>25MG;80MG</u>	<u>N021162</u>	<u>003</u>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>12.5MG;40MG</u>	<u>A203010</u>	<u>001</u>	Feb 25, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A203010</u>	<u>002</u>	Feb 25, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A203010</u>	<u>003</u>	Feb 25, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG;40MG</u>	<u>A208727</u>	<u>001</u>	Dec 15, 2016
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A208727</u>	<u>002</u>	Dec 15, 2016
<u>AB</u>			<u>25MG;80MG</u>	<u>A208727</u>	<u>003</u>	Dec 15, 2016
<u>AB</u>		GLENMARK PHARMS LTD	<u>12.5MG;40MG</u>	<u>A202544</u>	<u>001</u>	Mar 04, 2019
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A202544</u>	<u>002</u>	Mar 04, 2019
<u>AB</u>			<u>25MG;80MG</u>	<u>A202544</u>	<u>003</u>	Mar 04, 2019
<u>AB</u>		LUPIN LTD	<u>12.5MG;40MG</u>	<u>A091351</u>	<u>001</u>	Aug 07, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A091351</u>	<u>002</u>	Aug 07, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A091351</u>	<u>003</u>	Aug 07, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>12.5MG;40MG</u>	<u>A204169</u>	<u>001</u>	Nov 02, 2015
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A204169</u>	<u>002</u>	Nov 02, 2015
<u>AB</u>			<u>25MG;80MG</u>	<u>A204169</u>	<u>003</u>	Nov 02, 2015
<u>AB</u>		MYLAN	<u>12.5MG;40MG</u>	<u>A091648</u>	<u>001</u>	Feb 25, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A091648</u>	<u>002</u>	Feb 25, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A091648</u>	<u>003</u>	Feb 25, 2014
<u>AB</u>		PRINSTON INC	<u>12.5MG;40MG</u>	<u>A209028</u>	<u>001</u>	Nov 06, 2017
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A209028</u>	<u>002</u>	Nov 06, 2017
<u>AB</u>			<u>25MG;80MG</u>	<u>A209028</u>	<u>003</u>	Nov 06, 2017
<u>AB</u>		TORRENT	<u>12.5MG;40MG</u>	<u>A201192</u>	<u>001</u>	Feb 25, 2014
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A201192</u>	<u>002</u>	Feb 25, 2014
<u>AB</u>			<u>25MG;80MG</u>	<u>A201192</u>	<u>003</u>	Feb 25, 2014
<u>AB</u>		ZYDUS PHARMS	<u>12.5MG;40MG</u>	<u>A204221</u>	<u>001</u>	Aug 15, 2017
<u>AB</u>			<u>12.5MG;80MG</u>	<u>A204221</u>	<u>002</u>	Aug 15, 2017
<u>AB</u>			<u>25MG;80MG</u>	<u>A204221</u>	<u>003</u>	Aug 15, 2017

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+!	GLAXOSMITHKLINE LLC	25MG; 37.5MG	N016042 003	Mar 03, 1994
-----------	-----------	---------------------	---------------------	--------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED PHARMS BARR	25MG; 37.5MG	A075052 001	Jun 18, 1999
AB		LANNETT CO INC	25MG; 37.5MG	A201407 001	Dec 09, 2011
AB		MYLAN	25MG; 37.5MG	A074701 001	Jun 07, 1996
AB		SANDOZ	25MG; 37.5MG	A074821 001	Jun 05, 1997
AB		ZYDUS PHARMS	25MG; 37.5MG	A208358 001	Feb 11, 2019

TABLET; ORAL

MAXZIDE

AB	+!	MYLAN PHARMS INC	50MG; 75MG	N019129 001	Oct 22, 1984
-----------	-----------	------------------	-------------------	--------------------	--------------

MAXZIDE-25

AB	+	MYLAN PHARMS INC	25MG; 37.5MG	N019129 003	May 13, 1988
-----------	----------	------------------	---------------------	--------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	25MG; 37.5MG	A071251 002	May 05, 1998
AB			50MG; 75MG	A071251 001	Apr 17, 1988
AB		PLIVA	25MG; 37.5MG	A074026 001	Apr 26, 1996
AB		SANDOZ	25MG; 37.5MG	A073281 001	Apr 30, 1992
AB			50MG; 75MG	A072011 001	Jun 17, 1988
AB		WATSON LABS	25MG; 37.5MG	A073449 001	Sep 23, 1993
AB			50MG; 75MG	A071851 001	Nov 30, 1988
AB		ZYDUS PHARMS	25MG; 37.5MG	A208360 001	Jun 29, 2018
AB			50MG; 75MG	A208360 002	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

AB	+	NOVARTIS	12.5MG; 80MG	N020818 001	Mar 06, 1998
AB	+		12.5MG; 160MG	N020818 002	Mar 06, 1998
AB	+		12.5MG; 320MG	N020818 004	Apr 28, 2006
AB	+		25MG; 160MG	N020818 003	Jan 17, 2002
AB	+!		25MG; 320MG	N020818 005	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMbic PHARMS LTD	12.5MG; 80MG	A201662 001	Mar 21, 2013
AB			12.5MG; 160MG	A201662 002	Mar 21, 2013
AB			12.5MG; 320MG	A201662 003	Mar 21, 2013
AB			25MG; 160MG	A201662 004	Mar 21, 2013
AB			25MG; 320MG	A201662 005	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	12.5MG; 80MG	A202519 001	Mar 21, 2013
AB			12.5MG; 160MG	A202519 002	Mar 21, 2013
AB			12.5MG; 320MG	A202519 003	Mar 21, 2013
AB			25MG; 160MG	A202519 004	Mar 21, 2013
AB			25MG; 320MG	A202519 005	Mar 21, 2013
AB		LUPIN LTD	12.5MG; 80MG	A078946 003	Mar 21, 2013
AB			12.5MG; 160MG	A078946 004	Mar 21, 2013
AB			12.5MG; 320MG	A078946 001	Mar 21, 2013
AB			25MG; 160MG	A078946 005	Mar 21, 2013
AB			25MG; 320MG	A078946 002	Mar 21, 2013
AB		MACLEODS PHARMS LTD	12.5MG; 80MG	A203145 001	Apr 19, 2013
AB			12.5MG; 160MG	A203145 002	Apr 19, 2013
AB			12.5MG; 320MG	A203145 003	Apr 19, 2013
AB			25MG; 160MG	A203145 004	Apr 19, 2013
AB			25MG; 320MG	A203145 005	Apr 19, 2013
AB		MYLAN PHARMS INC	12.5MG; 80MG	A078020 001	Sep 21, 2012
AB			12.5MG; 160MG	A078020 002	Sep 21, 2012
AB			12.5MG; 320MG	A078020 004	Sep 21, 2012
AB			25MG; 160MG	A078020 003	Sep 21, 2012
AB			25MG; 320MG	A078020 005	Sep 21, 2012
AB		PRINSTON INC	12.5MG; 80MG	A206083 001	Feb 08, 2016
AB			12.5MG; 160MG	A206083 002	Feb 08, 2016
AB			12.5MG; 320MG	A206083 003	Feb 08, 2016
AB			25MG; 160MG	A206083 004	Feb 08, 2016
AB			25MG; 320MG	A206083 005	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	!	PERSION	10MG	N202880 001	Oct 25, 2013
+			15MG	N202880 002	Oct 25, 2013
+			20MG	N202880 003	Oct 25, 2013
+			30MG	N202880 004	Oct 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	40MG	N202880	005	Oct 25, 2013
+	50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER

+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
+		30MG	N206627	002	Nov 20, 2014
+		40MG	N206627	003	Nov 20, 2014
+		60MG	N206627	004	Nov 20, 2014
+		80MG	N206627	005	Nov 20, 2014
+		100MG	N206627	006	Nov 20, 2014
+		120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	ACTAVIS LABS FL INC	7.5MG;200MG	A076604	001	Dec 31, 2003
AB	AMNEAL PHARMS NY	5MG;200MG	A076642	002	Mar 18, 2004
AB	!	7.5MG;200MG	A076642	001	Oct 12, 2004
AB	AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016
AB	VINTAGE PHARMS	5MG;200MG	A077727	001	Nov 06, 2006
AB		7.5MG;200MG	A077723	001	Nov 06, 2006
AB		10MG;200MG	A077723	002	Nov 06, 2006
REPREXAIN					
AB	AMNEAL PHARMS NY	10MG;200MG	A076642	004	Oct 19, 2007
		2.5MG;200MG	A076642	003	Oct 19, 2007

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT	CROWN LABS	2.5%	A080706	007	Jan 05, 2016
AT		1%	A080706	006	

ANUSOL HC

AT	SALIX PHARMS	2.5%	A088250	001	Jun 06, 1984
-----------	--------------	-------------	----------------	------------	--------------

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	1%	A087795	001	May 03, 1983
AT		2.5%	A089682	001	Mar 10, 1988
AT	!	1%	A080693	003	
AT	!	2.5%	A089414	001	Dec 16, 1986
AT	LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004
AT	PERRIGO NEW YORK	2.5%	A085025	001	
AT	RISING	2.5%	A040879	001	Aug 20, 2010
AT	TARO PHARM INDS LTD	2.5%	A088799	001	Nov 09, 1984
AT	TELISTENT PHARMA INC	2.5%	A203810	001	Jul 23, 2018

ENEMA;RECTAL

COLOCORT

AB	PADDOCK LLC	100MG/60ML	A075172	001	Dec 03, 1999
-----------	-------------	-------------------	----------------	------------	--------------

CORTENEMA

AB	+!	ANI PHARMS	100MG/60ML	N016199	001
-----------	----	------------	-------------------	----------------	------------

HYDROCORTISONE

AB	TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994
-----------	-------------	-------------------	----------------	------------	--------------

LOTION;TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000
AT		LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003
AT		TARO	2.5%	A040247	001	Jul 23, 1999
AT		TELISTENT PHARMA INC	2.5%	A203804	001	Jul 27, 2018

STIE-CORT

AT	PERRIGO CO	2.5%	A089074	001	Nov 26, 1985
-----------	------------	-------------	----------------	------------	--------------

ALA-SCALP

	MARNEL PHARMS	2%	A083231	001	
--	---------------	----	---------	-----	--

OINTMENT;TOPICAL

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982	
AT	!	FOUGERA PHARMS	1%	A080692	001	
AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993
AT	PERRIGO NEW YORK	2.5%	A085027	001		
AT	TARO	1%	A086257	001		

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

OINTMENT; TOPICAL

HYDROCORTISONE IN ABSORBASE**AT** CMP PHARMA INC **1%** **A088138 001** Sep 06, 1985

SOLUTION; TOPICAL

TEXACORT

! MISSION PHARMA 2.5%

A081271 001 Apr 17, 1992

TABLET; ORAL

CORTEF**AB** + PHARMACIA AND **5MG** **N008697 003**

UPJOHN

AB + **10MG** **N008697 001****AB** +! **20MG** **N008697 002**HYDROCORTISONE**AB** HIKMA INTL PHARMS **5MG** **A083365 002** Feb 23, 2015**AB** **10MG** **A083365 003** Feb 23, 2015**AB** **20MG** **A083365 001****AB** IMPAX LABS INC **5MG** **A040646 001** Mar 30, 2007**AB** **10MG** **A040646 002** Mar 30, 2007**AB** **20MG** **A040646 003** Mar 30, 2007**AB** PII **5MG** **A207029 001** Apr 27, 2017**AB** **10MG** **A207029 002** Apr 27, 2017**AB** **20MG** **A207029 003** Apr 27, 2017**AB** VINTAGE **5MG** **A040761 001** Jul 16, 2007**AB** **10MG** **A040761 002** Jul 16, 2007**AB** **20MG** **A040761 003** Jul 16, 2007HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+! MYLAN SPECIALITY LP 10%

N017351 001 Feb 10, 1982

CREAM; TOPICAL

MICORT-HC

SEBELA IRELAND LTD 2.5%

A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+! MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MYLAN SPECIALITY LP 1%;1% A086457 001

PROCTOFOAM HC

BX MYLAN SPECIALITY LP 1%;1% A086195 001

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%;1%

A083778 001

1%;1%

A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%;1%

A085980 001

2.5%;1%

A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO 1%;10%

A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS **0.1%** **A076654 001** Aug 03, 2005LOCOID**AB1** +! BAUSCH **0.1%** **N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** ACTAVIS MID **0.1%** **A205134 001** Dec 08, 2017

ATLANTIC

AB2 GLENMARK GENERICS **0.1%** **A202145 001** Sep 27, 2013LOCOID LIPOCREAM**AB2** +! PRECISION DERMAT **0.1%** **N020769 001** Sep 08, 1997

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE**AB** LUPIN LTD **0.1%** **A210209 001** Aug 17, 2018

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

AB	TELIGENT PHARMA INC	0.1%	A209556 001	Nov 21, 2017
-----------	---------------------	-------------	--------------------	--------------

LOCOID

AB	BAUSCH	0.1%	N022076 001	May 18, 2007
-----------	--------	-------------	--------------------	--------------

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

AB	TARO	0.1%	A076842 001	Dec 27, 2004
-----------	------	-------------	--------------------	--------------

LOCOID

AB	PRECISION DERMAT	0.1%	N018652 001	Oct 29, 1982
-----------	------------------	-------------	--------------------	--------------

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	0.1%	A076364 001	Jan 14, 2004
-----------	-----------------	-------------	--------------------	--------------

LOCOID

AT	BAUSCH	0.1%	N019116 001	Feb 25, 1987
-----------	--------	-------------	--------------------	--------------

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+	FOUGERA PHARMS	0.1%	N020453 001	Feb 28, 1997
---	----------------	------	-------------	--------------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

SOLU-CORTEF

+	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866 001	
---	----------------------	--------------------	-------------	--

+		EQ 250MG BASE/VIAL	N009866 002	
---	--	--------------------	-------------	--

+		EQ 500MG BASE/VIAL	N009866 003	
---	--	--------------------	-------------	--

+		EQ 1GM BASE/VIAL	N009866 004	
---	--	------------------	-------------	--

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	GLENMARK PHARMS LTD	0.2%	A211129 001	Oct 12, 2018
-----------	---------------------	-------------	--------------------	--------------

AB	LUPIN LTD	0.2%	A210307 001	Aug 15, 2019
-----------	-----------	-------------	--------------------	--------------

AB	PERRIGO ISRAEL	0.2%	A075666 001	May 24, 2000
-----------	----------------	-------------	--------------------	--------------

AB	TARO	0.2%	A075042 001	Aug 25, 1998
-----------	------	-------------	--------------------	--------------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB	GLENMARK PHARMS LTD	0.2%	A211750 001	Dec 14, 2018
-----------	---------------------	-------------	--------------------	--------------

AB	TARO	0.2%	A075043 001	Aug 25, 1998
-----------	------	-------------	--------------------	--------------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064053 001	Dec 29, 1995
-----------	-----------------	--	--------------------	--------------

AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423 001	Aug 25, 1983
-----------	------------	--	--------------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874 001	May 11, 1988
---	------------	-------------------------------------	-------------	--------------

SUSPENSION/DROPS; OTIC

CASPORYN HC

AT	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613 001	
-----------	-------------------	--	--------------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219 001	May 01, 2006
-----------	---------------	--	--------------------	--------------

AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488 001	Nov 06, 1985
-----------	------------	--	--------------------	--------------

OTICAIR

AT	BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064065 001	Aug 28, 1996
-----------	-----------------	--	--------------------	--------------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	FRESENIUS KABI USA	1MG/ML	N019034 003	Apr 30, 2009
-----------	--------------------	---------------	--------------------	--------------

AP		2MG/ML	N019034 004	Apr 30, 2009
-----------	--	---------------	--------------------	--------------

HYDROMORPHONE HYDROCHLORIDE

AP	AKORN	10MG/ML	A078228 001	Apr 14, 2010
-----------	-------	----------------	--------------------	--------------

AP		10MG/ML	A078261 001	Apr 14, 2010
-----------	--	----------------	--------------------	--------------

AP	BARR	10MG/ML	A076444 001	Apr 25, 2003
-----------	------	----------------	--------------------	--------------

AP	EUROHLTH INTL SARL	2MG/ML	A202159 001	Apr 27, 2018
-----------	--------------------	---------------	--------------------	--------------

AP	HOSPIRA INC	1MG/ML	N200403 001	Dec 01, 2011
-----------	-------------	---------------	--------------------	--------------

AP		2MG/ML	N200403 002	Dec 01, 2011
-----------	--	---------------	--------------------	--------------

AP		4MG/ML	N200403 003	Dec 01, 2011
-----------	--	---------------	--------------------	--------------

AP		10MG/ML	A078591 001	Jun 17, 2008
-----------	--	----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROMORPHONE HYDROCHLORIDE

SOLUTION;ORAL

DILAUDID

AA	+!	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992
-----------	-----------	---------------	----------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	5MG/5ML	A210176	001	Oct 27, 2017
-----------	--	-------------------	----------------	----------------	------------	--------------

AA		HIKMA	5MG/5ML	A074653	001	Jul 29, 1998
-----------	--	-------	----------------	----------------	------------	--------------

TABLET;ORAL

DILAUDID

AB	+	RHODES PHARMS	2MG	N019892	003	Nov 09, 2007
-----------	----------	---------------	------------	----------------	------------	--------------

AB	+		4MG	N019892	002	Nov 09, 2007
-----------	----------	--	------------	----------------	------------	--------------

AB	+!		8MG	N019892	001	Dec 07, 1992
-----------	-----------	--	------------	----------------	------------	--------------

HYDROMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018
-----------	--	-------------------	------------	----------------	------------	--------------

AB			4MG	A210506	002	Jan 17, 2018
-----------	--	--	------------	----------------	------------	--------------

AB			8MG	A210506	003	Jan 17, 2018
-----------	--	--	------------	----------------	------------	--------------

AB		AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016
-----------	--	---------------------	------------	----------------	------------	--------------

AB			4MG	A205814	002	May 13, 2016
-----------	--	--	------------	----------------	------------	--------------

AB			8MG	A205814	003	May 13, 2016
-----------	--	--	------------	----------------	------------	--------------

AB		ELITE LABS	8MG	A076723	001	Oct 18, 2005
-----------	--	------------	------------	----------------	------------	--------------

AB		HIKMA	4MG	A074597	003	May 29, 2009
-----------	--	-------	------------	----------------	------------	--------------

AB			8MG	A074597	001	Jul 29, 1998
-----------	--	--	------------	----------------	------------	--------------

AB		LANNETT CO INC	2MG	A077471	002	Dec 09, 2009
-----------	--	----------------	------------	----------------	------------	--------------

AB			4MG	A077471	003	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

AB			8MG	A077471	001	Dec 09, 2009
-----------	--	--	------------	----------------	------------	--------------

AB		SPECGX LLC	2MG	A076855	002	Sep 19, 2007
-----------	--	------------	------------	----------------	------------	--------------

AB			4MG	A076855	003	Sep 19, 2007
-----------	--	--	------------	----------------	------------	--------------

AB			8MG	A076855	001	Dec 23, 2004
-----------	--	--	------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		OSMOTICA	8MG	A205629	001	Jul 07, 2016
-----------	--	----------	------------	----------------	------------	--------------

AB			12MG	A205629	002	Jul 07, 2016
-----------	--	--	-------------	----------------	------------	--------------

AB			16MG	A205629	003	Jul 07, 2016
-----------	--	--	-------------	----------------	------------	--------------

AB	!		32MG	A205629	004	Jul 07, 2016
-----------	----------	--	-------------	----------------	------------	--------------

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015
-----------	--	-------------	------------	----------------	------------	--------------

AB			12MG	A204278	002	Apr 06, 2015
-----------	--	--	-------------	----------------	------------	--------------

AB			16MG	A204278	003	Apr 06, 2015
-----------	--	--	-------------	----------------	------------	--------------

AB			32MG	A204278	004	Sep 20, 2017
-----------	--	--	-------------	----------------	------------	--------------

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

+!	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
-----------	---------	--------------------	---------	-----	--------------

HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998	001	
----------	-------------	--------	---------	-----	--

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

PAREMYD

+!	AKORN	1%;0.25%	N019261	001	Jan 30, 1992
-----------	-------	----------	---------	-----	--------------

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ALKALOIDA ZRT	200MG	A201691	001	May 08, 2018
-----------	--	---------------	--------------	----------------	------------	--------------

AB		AMNEAL PHARMS CO	200MG	A210577	001	May 15, 2018
-----------	--	------------------	--------------	----------------	------------	--------------

AB		HIKMA PHARMS	200MG	A040760	001	Aug 15, 2007
-----------	--	--------------	--------------	----------------	------------	--------------

AB		IPCA LABS LTD	200MG	A040766	001	Jun 14, 2007
-----------	--	---------------	--------------	----------------	------------	--------------

AB		MYLAN	200MG	A040274	001	May 29, 1998
-----------	--	-------	--------------	----------------	------------	--------------

AB		SANDOZ	200MG	A040104	001	Nov 30, 1995
-----------	--	--------	--------------	----------------	------------	--------------

AB		TEVA PHARMS	200MG	A040081	001	Sep 30, 1994
-----------	--	-------------	--------------	----------------	------------	--------------

AB		TWI PHARMS	200MG	A210441	001	May 01, 2018
-----------	--	------------	--------------	----------------	------------	--------------

AB		WATSON LABS	200MG	A040133	001	Nov 30, 1995
-----------	--	-------------	--------------	----------------	------------	--------------

AB		ZYDUS PHARMS USA	200MG	A040657	001	Sep 21, 2007
-----------	--	------------------	--------------	----------------	------------	--------------

INC

PLAQUENIL

AB	+!	CONCORDIA	200MG	N009768	001	
-----------	-----------	-----------	--------------	----------------	------------	--

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP		AM REGENT	250MG/ML (250MG/ML)	A210723	001	Jun 21, 2018
-----------	--	-----------	----------------------------	----------------	------------	--------------

AP		ASPEN	250MG/ML (250MG/ML)	A211777	001	Aug 08, 2019
-----------	--	-------	----------------------------	----------------	------------	--------------

AP		EUGIA PHARMA	250MG/ML (250MG/ML)	A211071	001	Apr 16, 2019
-----------	--	--------------	----------------------------	----------------	------------	--------------

AP		SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019
-----------	--	---------------------	----------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

MAKENA PRESERVATIVE FREE

AP	+!	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945 002	Feb 19, 2016
-----------	-----------	-----------------	----------------------------	--------------------	--------------

HYDROXYPROGESTERON CAPROATE

AP1		AM REGENT	1250MG/5ML (250MG/ML)	A210724 001	Aug 09, 2019
------------	--	-----------	------------------------------	--------------------	--------------

HYDROXYPROGESTERONE CAPROATE

AP1		EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211070 001	Apr 16, 2019
------------	--	--------------	------------------------------	--------------------	--------------

AP1		SLAYBACK PHARMA LLC	1250MG/5ML (250MG/ML)	A210618 001	Dec 28, 2018
------------	--	---------------------	------------------------------	--------------------	--------------

AP1		SUN PHARM	1250MG/5ML (250MG/ML)	A208381 001	Apr 09, 2019
------------	--	-----------	------------------------------	--------------------	--------------

MAKENA

AP1	+!	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011
------------	-----------	-----------------	------------------------------	--------------------	--------------

HYDROXYPROGESTERONE CAPROATE

!		ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271 001	Aug 24, 2015
---	--	------------------	-----------------------	-------------	--------------

SOLUTION;SUBCUTANEOUS

MAKENA (AUTOINJECTOR)

+	!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945 004	Feb 14, 2018
---	---	-----------------	------------------------	-------------	--------------

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

+	!	VALEANT PHARMS INTL	5MG	N018771 001	
---	---	---------------------	-----	-------------	--

HYDROXYUREA

CAPSULE;ORAL

HYDREA

AB	+!	BRISTOL MYERS SQUIBB	500MG	N016295 001	
-----------	-----------	-------------------------	--------------	--------------------	--

HYDROXYUREA

AB		BARR	500MG	A075143 001	Oct 16, 1998
-----------	--	------	--------------	--------------------	--------------

AB		PAR PHARM	500MG	A075340 001	Feb 24, 1999
-----------	--	-----------	--------------	--------------------	--------------

DROXIA

+		BRISTOL MYERS SQUIBB	200MG	N016295 002	Feb 25, 1998
---	--	-------------------------	-------	-------------	--------------

+			300MG	N016295 003	Feb 25, 1998
---	--	--	-------	-------------	--------------

+			400MG	N016295 004	Feb 25, 1998
---	--	--	-------	-------------	--------------

TABLET;ORAL

SIKLOS

+		ADDMEDICA SAS	100MG	N208843 001	Dec 21, 2017
---	--	---------------	-------	-------------	--------------

+			1GM	N208843 002	Dec 21, 2017
---	--	--	-----	-------------	--------------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

!		LUITPOLD	25MG/ML	A087408 001	
---	--	----------	---------	-------------	--

!			50MG/ML	A087408 002	
---	--	--	---------	-------------	--

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA	!	HI TECH PHARMA	10MG/5ML	A040010 001	Oct 28, 1994
-----------	----------	----------------	-----------------	--------------------	--------------

AA		LANNETT CO INC	10MG/5ML	A201674 001	Aug 21, 2013
-----------	--	----------------	-----------------	--------------------	--------------

AA	!	VINTAGE PHARMS	10MG/5ML	A040391 001	Apr 10, 2002
-----------	----------	----------------	-----------------	--------------------	--------------

AA	!	WOCKHARDT BIO AG	10MG/5ML	A087294 001	Apr 12, 1982
-----------	----------	------------------	-----------------	--------------------	--------------

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	10MG	A040808 001	Sep 24, 2008
-----------	--	--------------	-------------	--------------------	--------------

AB			25MG	A040808 002	Sep 24, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040808 003	Sep 24, 2008
-----------	--	--	-------------	--------------------	--------------

AB		ECI PHARMS LLC	10MG	A040804 001	Jun 30, 2008
-----------	--	----------------	-------------	--------------------	--------------

AB			25MG	A040804 002	Jun 30, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040804 003	Jun 30, 2008
-----------	--	--	-------------	--------------------	--------------

AB		EPIC PHARMA LLC	10MG	A040604 002	Dec 28, 2004
-----------	--	-----------------	-------------	--------------------	--------------

AB			25MG	A040604 003	Dec 28, 2004
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040604 001	Dec 28, 2004
-----------	--	--	-------------	--------------------	--------------

AB		HERITAGE PHARMA	10MG	A204279 001	Aug 20, 2014
-----------	--	-----------------	-------------	--------------------	--------------

AB			25MG	A204279 002	Aug 20, 2014
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A204279 003	Aug 20, 2014
-----------	--	--	-------------	--------------------	--------------

AB		HETERO LABS LTD III	10MG	A040805 001	May 29, 2008
-----------	--	---------------------	-------------	--------------------	--------------

AB			25MG	A040805 002	May 29, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040805 003	May 29, 2008
-----------	--	--	-------------	--------------------	--------------

AB		INVAGEN PHARMS	10MG	A040812 001	Mar 12, 2008
-----------	--	----------------	-------------	--------------------	--------------

AB			25MG	A040812 002	Mar 12, 2008
-----------	--	--	-------------	--------------------	--------------

AB			50MG	A040812 003	Mar 12, 2008
-----------	--	--	-------------	--------------------	--------------

AB		KVK TECH	10MG	A040786 001	Mar 20, 2007
-----------	--	----------	-------------	--------------------	--------------

AB			25MG	A040786 002	Mar 20, 2007
-----------	--	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB		50MG	A040786 003	Mar 20, 2007
AB	NORTHSTAR HLTHCARE	10MG	A040840 002	Mar 31, 2008
AB		25MG	A040840 003	Mar 31, 2008
AB		50MG	A040840 001	Mar 31, 2008
AB	NUVO PHARM	10MG	A207120 001	Mar 29, 2017
AB		50MG	A207122 001	Mar 29, 2017
AB	NUVO PHARMS INC	25MG	A207121 001	Mar 29, 2017
AB	! PLIVA	10MG	A088617 001	Jan 10, 1986
AB	!	25MG	A088618 001	Jan 10, 1986
AB	!	50MG	A088619 001	Jan 10, 1986
AB	PRINSTON INC	10MG	A040579 001	May 27, 2005
AB		25MG	A040574 001	May 27, 2005
AB		50MG	A040580 001	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	BARR	EQ 25MG HYDROCHLORIDE	A088496 001	Jun 15, 1984
AB		EQ 50MG HYDROCHLORIDE	A088487 001	Jun 15, 1984
AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507 001	Jun 03, 2013
AB		EQ 50MG HYDROCHLORIDE	A201507 002	Jun 03, 2013
AB	IMPAX LABS INC	EQ 25MG HYDROCHLORIDE	A040156 001	Jul 15, 1996
AB		EQ 50MG HYDROCHLORIDE	A040156 002	Jul 15, 1996
AB	SANDOZ	EQ 25MG HYDROCHLORIDE	A087479 001	
AB	!	EQ 50MG HYDROCHLORIDE	A086183 001	
	BARR	EQ 100MG HYDROCHLORIDE	A088488 001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

AP	+! ROCHE	EQ 3MG BASE/3ML	N021858 001	Jan 06, 2006
	<u>IBANDRONATE SODIUM</u>			
AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058 001	Feb 05, 2016
AP	APOTEX	EQ 3MG BASE/3ML	A204222 001	Oct 16, 2015
AP	AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332 001	Aug 19, 2015
AP	MYLAN LABS LTD	EQ 3MG BASE/3ML	A202671 001	Sep 02, 2014
AP	SAGENT PHARMS INC	EQ 3MG BASE/3ML	A202235 001	Sep 02, 2014
AP	SUN PHARM	EQ 3MG BASE/3ML	A090853 001	Feb 14, 2014

TABLET; ORAL

BONIVA

AB	+! HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005
	<u>IBANDRONATE SODIUM</u>			
AB	APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012
AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502 001	Mar 11, 2016
AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012
AB	MACLEODS PHARMS LTD	EQ 150MG BASE	A206887 001	Oct 31, 2017
AB	ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012
AB	WATSON LABS TEVA	EQ 150MG BASE	A079003 001	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

+	PHARMACYCLICS INC	70MG	N205552 002	Dec 20, 2017
+	!	140MG	N205552 001	Nov 13, 2013

TABLET; ORAL

IMBRUVICA

+	PHARMACYCLICS INC	140MG	N210563 001	Feb 16, 2018
+		280MG	N210563 002	Feb 16, 2018
+		420MG	N210563 003	Feb 16, 2018
+	!	560MG	N210563 004	Feb 16, 2018

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

+	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348 002	Jun 11, 2009
+	!	800MG/200ML (4MG/ML)	N022348 003	Jan 25, 2019

SUSPENSION; ORAL

IBUPROFEN

AB	! ACTAVIS MID ATLANTIC	100MG/5ML	A074978 001	Mar 25, 1998
-----------	------------------------	------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	HI TECH	<u>100MG/5ML</u>	<u>A205647</u>	<u>001</u>	Nov 03, 2016
<u>AB</u>	L PERRIGO CO	<u>100MG/5ML</u>	<u>A076925</u>	<u>001</u>	Sep 23, 2004
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A209204</u>	<u>001</u>	Jun 23, 2017
	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018

TABLET; ORAL

IBU-TAB

<u>AB</u>	ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>		<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN

<u>AB</u>	AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>		<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071268</u>	<u>002</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A071268</u>	<u>003</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	!	<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>		<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>	GRANULES INDIA LTD	<u>400MG</u>	<u>A091625</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>		<u>600MG</u>	<u>A091625</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>800MG</u>	<u>A091625</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>	MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>		<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>	PERRIGO PHARMS CO	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>		<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>		<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>	SHANDONG XINHUA	<u>400MG</u>	<u>A202413</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>		<u>600MG</u>	<u>A202413</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>		<u>800MG</u>	<u>A202413</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>	STRIDES PHARMA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>		<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>	VINTAGE PHARMS	<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988

IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYISINE

<u>AP</u>	X-GEN PHARMS INC	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>A202402</u>	<u>001</u>	Mar 30, 2016
<u>AP</u>	+! RECORDATI RARE	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>N021903</u>	<u>001</u>	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

<u>AB</u>	ACTAVIS ELIZABETH	<u>400MG; 5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>	!	<u>400MG; 5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
<u>AP</u>	MYLAN INSTITUTIONAL	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

<u>AP</u>	+! SHIRE ORPHAN THERAP	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N022150</u>	<u>001</u>	Aug 25, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A210118</u>	<u>001</u>	Jul 15, 2019

PRESCRIPTION DRUG PRODUCT LIST

ICODEXTRINSOLUTION; INTRAPERITONEAL
EXTRANEAL

+! BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 500MG N202057 002 Feb 16, 2017

+! 1GM N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFSAP +! PHARMACIA AND UPJOHN 1MG/ML N050734 001 Feb 17, 1997IDARUBICIN HYDROCHLORIDEAP FRESENIUS KABI USA 1MG/ML A065440 001 Aug 04, 2009AP WEST-WARD PHARMS INT 1MG/ML A065275 001 Dec 14, 2006AP 1MG/ML A065288 001 May 15, 2007IDARUBICIN HYDROCHLORIDE PFSAP TEVA PHARMS USA 1MG/ML A065036 001 May 01, 2002IDELALISIB

TABLET; ORAL

ZYDELIG

+ GILEAD SCIENCES INC 100MG N205858 001 Jul 23, 2014

+! 150MG N205858 002 Jul 23, 2014

IFOSFAMIDE

INJECTABLE; INJECTION

IFEXAP + BAXTER HLTHCARE 1GM/VIAL N019763 001 Dec 30, 1988AP + 3GM/VIAL N019763 002 Dec 30, 1988IFOSFAMIDEAP ! FRESENIUS KABI USA 1GM/VIAL A076078 001 May 28, 2002AP ! 3GM/VIAL A076078 002 May 28, 2002AP ! TEVA PHARMS USA 1GM/20ML (50MG/ML) A076657 001 Apr 04, 2007AP ! 3GM/60ML (50MG/ML) A076657 002 Apr 04, 2007AP WEST-WARD PHARMS 1GM/20ML (50MG/ML) A076619 001 Jun 29, 2011AP INT 3GM/60ML (50MG/ML) A076619 002 Jun 29, 2011ILOPERIDONE

TABLET; ORAL

FANAPT

+! VANDA PHARMS INC 1MG N022192 001 May 06, 2009

+ 2MG N022192 002 May 06, 2009

+ 4MG N022192 003 May 06, 2009

+ 6MG N022192 004 May 06, 2009

+ 8MG N022192 005 May 06, 2009

+ 10MG N022192 006 May 06, 2009

+ 12MG N022192 007 May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+! ACTELION PHARMS LTD 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005

+! 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVECAB + NOVARTIS EQ 100MG BASE N021588 001 Apr 18, 2003AB +! EQ 400MG BASE N021588 002 Apr 18, 2003IMATINIB MESYLATEAB APOTEX EQ 100MG BASE A079179 001 Aug 05, 2016AB EQ 400MG BASE A079179 002 Aug 05, 2016AB BRECKENRIDGE EQ 100MG BASE A205990 001 Feb 08, 2019AB EQ 400MG BASE A205990 002 Feb 08, 2019AB DR REDDYS EQ 100MG BASE A206547 001 Aug 13, 2018AB EQ 400MG BASE A206547 002 Aug 13, 2018AB HIKMA EQ 100MG BASE A207586 001 Jul 13, 2018AB EQ 400MG BASE A207586 002 Jul 13, 2018AB MYLAN EQ 100MG BASE A204644 001 Jun 21, 2017

PRESCRIPTION DRUG PRODUCT LIST

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204644 002</u>	Jun 21, 2017
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 100MG BASE</u>	<u>A207818 001</u>	Mar 01, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207818 002</u>	Mar 01, 2019
<u>AB</u>	SHILPA MEDICARE LTD	<u>EQ 100MG BASE</u>	<u>A208302 001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208302 002</u>	Jan 17, 2019
<u>AB</u>	SUN PHARM	<u>EQ 100MG BASE</u>	<u>A078340 001</u>	Dec 03, 2015
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078340 002</u>	Dec 03, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A204285 001</u>	Aug 04, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204285 002</u>	Aug 04, 2016
<u>AB</u>	WOCKHARDT BIO AG	<u>EQ 100MG BASE</u>	<u>A208429 001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208429 002</u>	Jan 17, 2019

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

+	GENZYME	200 UNITS/VIAL	N020367 001	May 23, 1994
+	!	400 UNITS/VIAL	N020367 002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	LEADING PHARMA LLC	<u>10MG</u>	<u>A040903 001</u>	Oct 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A040903 002</u>	Oct 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A040903 003</u>	Oct 24, 2012
<u>AB</u>	PAR PHARM	<u>10MG</u>	<u>A088292 001</u>	Oct 21, 1983
<u>AB</u>		<u>25MG</u>	<u>A088262 001</u>	Oct 21, 1983
<u>AB</u>		<u>50MG</u>	<u>A088276 001</u>	Oct 21, 1983
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936 002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937 001</u>	
<u>AB</u>	SPECGX LLC	<u>10MG</u>	<u>A087846 002</u>	May 22, 1984
<u>AB</u>		<u>25MG</u>	<u>A087846 003</u>	May 22, 1984
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A081048 001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049 001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050 001</u>	Jun 05, 1990
<u>AB</u>	!	<u>50MG</u>	<u>A087846 001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	!	HIKMA	<u>EQ 75MG HYDROCHLORIDE</u>	<u>A091099 001</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 100MG HYDROCHLORIDE</u>	<u>A091099 002</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 125MG HYDROCHLORIDE</u>	<u>A091099 003</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 150MG HYDROCHLORIDE</u>	<u>A091099 004</u>	Apr 16, 2010
<u>AB</u>	LUPIN LTD		<u>EQ 75MG HYDROCHLORIDE</u>	<u>A090444 001</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 100MG HYDROCHLORIDE</u>	<u>A090444 002</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 125MG HYDROCHLORIDE</u>	<u>A090444 003</u>	Apr 16, 2010
<u>AB</u>			<u>EQ 150MG HYDROCHLORIDE</u>	<u>A090444 004</u>	Apr 16, 2010

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	!	BAUSCH	<u>5%</u>	<u>N020723 001</u>	Feb 27, 1997
-----------	---	---	--------	-----------	--------------------	--------------

IMIQUIMOD

<u>AB</u>			ANDA REPOSITORY	<u>5%</u>	<u>A091044 001</u>	Feb 28, 2011
<u>AB</u>			APOTEX INC	<u>5%</u>	<u>A091308 001</u>	Apr 06, 2012
<u>AB</u>			FOUGERA PHARMS	<u>5%</u>	<u>A078548 001</u>	Feb 25, 2010
<u>AB</u>			GLENMARK GENERICS	<u>5%</u>	<u>A201994 001</u>	Mar 06, 2012
<u>AB</u>			PERRIGO ISRAEL	<u>5%</u>	<u>A078837 001</u>	Sep 07, 2010
<u>AB</u>			TARO	<u>5%</u>	<u>A200173 001</u>	Apr 15, 2011

ZYCLARA

+	!	BAUSCH	2.5%	N022483 002	Jul 15, 2011
+	!		3.75%	N022483 001	Mar 25, 2010

PRESCRIPTION DRUG PRODUCT LIST

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

! WEST-WARD PHARMS EQ 5MG BASE/ML
INT

A075513 001 May 09, 2000

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE

N022383 001 Jul 01, 2011

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB	ACTAVIS ELIZABETH	1.25MG	A074722 001	Jun 17, 1996
AB		2.5MG	A074722 002	Jun 17, 1996
AB	AMERIGEN PHARMS LTD	1.25MG	A075201 001	Dec 04, 1998
AB		2.5MG	A075201 002	Dec 04, 1998
AB	ANI PHARMS INC	1.25MG	A074299 002	Apr 29, 1996
AB		2.5MG	A074299 001	Jul 27, 1995
AB	MYLAN	1.25MG	A074461 002	Mar 26, 1997
AB	!	2.5MG	A074461 001	Mar 27, 1996

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

+ MERCK SHARP DOHME EQ 200MG BASE

N020685 003 Mar 13, 1996

+! EQ 400MG BASE

N020685 001 Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+! CURIUM 5mCi/0.5ML

N019841 001 Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

AP	BWXT ITG	1mCi/ML	A202586 001	Jul 25, 2018
AP	+! GE HEALTHCARE	1mCi/ML	N019044 001	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+! GE HEALTHCARE 1mCi/ML

N017707 001 Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+! CURIUM 3mCi/ML

N020314 001 Jun 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AP	+! AKORN	25MG/VIAL	N011525 001	
-----------	----------	------------------	--------------------	--

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811 001	Nov 21, 2007
-----------	------------------	------------------	--------------------	--------------

POWDER; INTRAVENOUS, INTERSTITIAL

SPY AGENT GREEN KIT

+! NOVADAQ TECH 25MG/VIAL

N211580 001 Nov 21, 2018

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	CADILA	25MG	A090403 001	Nov 15, 2010
AB		50MG	A090403 002	Nov 15, 2010
AB	GLENMARK GENERICS	25MG	A091276 001	Dec 22, 2010
AB	!	50MG	A091276 002	Dec 22, 2010
AB	HERITAGE PHARMA	25MG	A070719 001	Feb 12, 1986
AB		50MG	A070756 001	Feb 12, 1986
AB	HERITAGE PHARMS INC	25MG	N018851 001	May 18, 1984
AB		50MG	N018851 002	May 18, 1984
AB	HETERO LABS LTD III	25MG	A091240 001	Apr 12, 2011
AB		50MG	A091240 002	Apr 12, 2011
AB	JUBILANT GENERICS	25MG	A205215 001	Aug 25, 2017
AB		50MG	A205215 002	Aug 25, 2017
AB	SANDOZ	25MG	A070673 001	Apr 29, 1987
AB		50MG	A070674 001	Apr 29, 1987

PRESCRIPTION DRUG PRODUCT LIST

INDOMETHACIN

CAPSULE; ORAL

TIVORBEX

+ GENUS

20MG

N204768 001 Feb 24, 2014

+!

40MG

N204768 002 Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	AMNEAL PHARMS	75MG	A091549 001	Dec 01, 2010
AB	AUROBINDO PHARMA LTD	75MG	A204243 001	Dec 27, 2016
AB	AVANTHI INC	75MG	A079175 001	Mar 06, 2009
AB	CHARTWELL RX	75MG	A200529 001	Nov 30, 2010
AB	GLENMARK PHARMS LTD	75MG	A203501 001	Jun 22, 2017
AB	HETERO LABS LTD III	75MG	A201807 001	Sep 28, 2012
AB	JUBILANT GENERICS	75MG	A202706 001	Oct 05, 2015
AB	MYLAN	75MG	A202139 001	Mar 20, 2014
AB	NOVAST LABS	75MG	A204853 001	May 08, 2017
AB	! SANDOZ	75MG	A074464 001	May 28, 1998
AB	ZYDUS PHARMS	75MG	A202711 001	Sep 25, 2017

INJECTABLE; INJECTION

INDOMETHACIN

+! FRESENIUS KABI USA

EQ 1MG BASE/VIAL

N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

! ACP NIMBLE

50MG

A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+! EGALET

25MG/5ML

N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+! RECORDATI RARE	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985
-----------	-------------------	-------------------------	--------------------	--------------

INDOMETHACIN SODIUM

AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A204118 001	Apr 19, 2016
AP	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561 001	Jul 19, 2017
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/VIAL	A078713 001	Jul 16, 2008

INGENOL MEBUTATE

GEL; TOPICAL

INGENOL MEBUTATE

AB	PERRIGO UK FINCO	0.015%	A209018 001	Jan 07, 2019
AB		0.05%	A209019 001	Jan 09, 2019
	PICATO			
AB	+! LEO LABS	0.015%	N202833 001	Jan 23, 2012
AB	+!	0.05%	N202833 002	Jan 23, 2012

INOTERSEN SODIUM

SOLUTION; SUBCUTANEOUS

TEGSEDI

+! AKCEA THERAPS

EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)

N211172 001 Oct 05, 2018

INSULIN ASPART

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

FIASP

+! NOVO

1000 UNITS/10ML (100 UNITS/ML)

N208751 001 Sep 29, 2017

SOLUTION; SUBCUTANEOUS

FIASP FLEXTOUCH

+! NOVO

300 UNITS/3ML (100 UNITS/ML)

N208751 002 Sep 29, 2017

FIASP PENFILL

+! NOVO

300 UNITS/3ML (100 UNITS/ML)

N208751 003 Sep 24, 2018

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+! NOVO NORDISK INC

700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)

N021172 001 Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

+! NOVO NORDISK INC

210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 004 May 03, 2002

PRESCRIPTION DRUG PRODUCT LISTINSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986 001	Jun 07, 2000
	NOVOLOG FLEXPEN			
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 003	Jan 19, 2001
	NOVOLOG PENFILL			
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 002	Jun 07, 2000

INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

TRESIBA

+	NOVO	300 UNITS/3ML (100 UNITS/ML)	N203314 001	Sep 25, 2015
+!		600 UNITS/3ML (200 UNITS/ML)	N203314 002	Sep 25, 2015
		1000 UNITS/10ML (100 UNITS/ML)	N203314 003	Nov 21, 2018

INSULIN DEGLUDEC; LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

XULTOPHY 100/3.6

+!	NOVO	300 UNITS/3ML; 10.8MG/3ML (100 UNITS/ML; 3.6MG/ML)	N208583 001	Nov 21, 2016
----	------	--	-------------	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536 001	Jun 16, 2005
	LEVEMIR FLEXTOUCH			
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 005	Oct 31, 2013

INSULIN GLARGINE

SOLUTION; SUBCUTANEOUS

BASAGLAR

	ELI LILLY AND CO	300 UNITS/3ML (100 UNITS/ML)	N205692 001	Dec 16, 2015
--	------------------	------------------------------	-------------	--------------

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+!	SANOFI AVENTIS US	100 UNITS/ML	N021081 001	Apr 20, 2000
	LANTUS SOLOSTAR			
+!	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081 002	Apr 27, 2007

SOLUTION; SUBCUTANEOUS

TOUJEO MAX SOLOSTAR

+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538 002	Mar 26, 2018
----	--------------------	------------------------------	-------------	--------------

TOUJEO SOLOSTAR

+!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538 001	Feb 25, 2015
----	--------------------	--------------------------------	-------------	--------------

INSULIN GLARGINE; LIXISENATIDE

SOLUTION; SUBCUTANEOUS

SOLIQUA 100/33

+!	SANOFI-AVENTIS US	300 UNITS/3ML; 99MCG/3ML (100 UNITS/ML; 33MCG/ML)	N208673 001	Nov 21, 2016
----	-------------------	---	-------------	--------------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

APIDRA

+!	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629 001	Apr 16, 2004
----	-------------------	--------------------------------	-------------	--------------

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

+	SANOFI AVENTIS US	300 UNITS/3ML	N021629 003	Feb 24, 2009
---	-------------------	---------------	-------------	--------------

INSULIN HUMAN

SOLUTION; INTRAVENOUS

MYXREDLIN

+!	BAXTER HLTHCARE CORP	100 UNITS/100ML (1 UNIT/ML)	N208157 001	Jun 20, 2019
----	----------------------	-----------------------------	-------------	--------------

SOLUTION; SUBCUTANEOUS

HUMULIN R

+!	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780 004	Mar 31, 1994
----	-------	---------------------------------	-------------	--------------

HUMULIN R KWIKPEN

+!	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780 002	Dec 29, 2015
----	-------	-------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

INSULIN LISPRO

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

ADMELOG

+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196 003	Oct 19, 2018
+		1000 UNITS/10ML (100 UNITS/ML)	N209196 001	Dec 11, 2017
ADMELOG SOLOSTAR				
+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196 002	Dec 11, 2017

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG MIX 50/50

+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018 001	Dec 22, 1999
HUMALOG MIX 50/50 KWIKPEN				
+	LILLY	50 UNITS/ML;50 UNITS/ML	N021018 002	Sep 06, 2007
HUMALOG MIX 75/25				
+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017 001	Dec 22, 1999
HUMALOG MIX 75/25 KWIKPEN				
+	LILLY	75 UNITS/ML;25 UNITS/ML	N021017 002	Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG

+	LILLY	100 UNITS/ML	N020563 001	Jun 14, 1996
HUMALOG KWIKPEN				
+	LILLY	100 UNITS/ML	N020563 003	Sep 06, 2007
+		200UNITS/ML	N020563 004	Nov 15, 2019
HUMALOG TEMPO PEN				
+	LILLY	100UNITS/ML	N020563 005	Nov 15, 2019
SOLUTION;SUBCUTANEOUS				
HUMALOG KWIKPEN				
+	ELI LILLY AND CO	200 UNITS/ML	N205747 001	May 26, 2015

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

+	MANNKIND	4 UNITS/INH	N022472 001	Jun 27, 2014
+		8 UNITS/INH	N022472 002	Jun 27, 2014
+		12 UNITS/INH	N022472 003	Apr 17, 2015

IOBENGUANE I-131

SOLUTION;INTRAVENOUS

AZEDRA

+	PROGENICS PHARMS INC	15mCi/ML	N209607 001	Jul 30, 2018
---	-------------------------	----------	-------------	--------------

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS

ADREVIEW

+	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290 001	Sep 19, 2008
---	---------------	---------------------	-------------	--------------

IODIXANOL

INJECTABLE;INJECTION

VISIPAQUE 270

+	GE HEALTHCARE	55%	N020351 001	Mar 22, 1996
VISIPAQUE 320				
+	GE HEALTHCARE	65.2%	N020351 002	Mar 22, 1996
		65.2%	N020808 002	Aug 29, 1997

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454 001	Jan 14, 2011
---	-----------------	----------------------	-------------	--------------

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383 001	Mar 26, 2015
--	-------------------------	-----------	-------------	--------------

INJECTABLE;INJECTION

OMNIPAQUE 140

+	GE HEALTHCARE	30.2%	N018956 005	Nov 30, 1988
---	---------------	-------	-------------	--------------

SOLUTION;INJECTION, ORAL

OMNIPAQUE 350

+	GE HEALTHCARE	75.5%	N018956 004	Dec 26, 1985
		75.5%	N020608 003	Oct 24, 1995

PRESCRIPTION DRUG PRODUCT LIST

IOHEXOL

SOLUTION;INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+! GE HEALTHCARE 38.8% N018956 001 Dec 26, 1985

OMNIPAQUE 240

+! GE HEALTHCARE 51.8% N018956 002 Dec 26, 1985

OMNIPAQUE 300

+! GE HEALTHCARE 64.7% N018956 003 Dec 26, 1985

64.7% N020608 002 Oct 24, 1995

SOLUTION;ORAL

OMNIPAQUE 12

+! GE HEALTHCARE 2.6% N018956 009 Apr 17, 2018

OMNIPAQUE 9

+! GE HEALTHCARE 1.9% N018956 008 Apr 17, 2018

IOPAMIDOL

INJECTABLE;INJECTION

ISOVUE-300**AP** +! BRACCO **61%** **N018735 002** Dec 31, 1985ISOVUE-370**AP** +! BRACCO **76%** **N018735 003** Dec 31, 1985SCANLUX-300**AP** SANOCHEMIA CORP USA **61%** **A090394 001** Jun 18, 2010SCANLUX-370**AP** SANOCHEMIA CORP USA **76%** **A090394 002** Jun 18, 2010

ISOVUE-200

+! BRACCO 41% N018735 006 Jul 07, 1987

ISOVUE-250

+! BRACCO 51% N018735 007 Jul 06, 1992

+! 51% N020327 002 Oct 12, 1994

ISOVUE-300

+! BRACCO 61% N020327 003 Oct 12, 1994

ISOVUE-370

+! BRACCO 76% N020327 004 Oct 12, 1994

ISOVUE-M 200

+! BRACCO 41% N018735 001 Dec 31, 1985

ISOVUE-M 300

+! BRACCO 61% N018735 004 Dec 31, 1985

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)

+! BAYER HLTHCARE 62.3% N021425 001 Sep 20, 2002

+! 76.9% N021425 002 Sep 20, 2002

ULTRAVIST 300

+! BAYER HLTHCARE 62.3% N020220 002 May 10, 1995

ULTRAVIST 370

+! BAYER HLTHCARE 76.9% N020220 001 May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

+! LIEBEL-FLARSHEIM 60% N013295 001

SOLUTION;INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM 17.2% N017057 002

IOTHALAMATE SODIUM I-125

INJECTABLE;INJECTION

GLOFIL-125

ISOTEX 250-300uCi/ML N017279 001

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 240

+! LIEBEL-FLARSHEIM 51% N019710 002 Dec 30, 1988

OPTIRAY 300

+! LIEBEL-FLARSHEIM 64% N019710 004 Jan 22, 1992

+! 64% N020923 004 May 13, 1999

OPTIRAY 320

+! LIEBEL-FLARSHEIM 68% N019710 001 Dec 30, 1988

+! 68% N020923 002 May 29, 1998

OPTIRAY 350

+! LIEBEL-FLARSHEIM 74% N019710 005 Jan 22, 1992

+! 74% N020923 003 May 28, 1998

PRESCRIPTION DRUG PRODUCT LIST

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+! BOEHRINGER 0.021MG/INH

N021527 001 Nov 27, 2004

INGELHEIM

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

<u>AN</u>	AUROBINDO PHARMA LTD	<u>0.02%</u>	<u>A206543</u>	<u>001</u>	Oct 27, 2016
<u>AN</u>	LANDELA PHARM	<u>0.02%</u>	<u>A077072</u>	<u>001</u>	Jul 19, 2005
<u>AN</u>	NEPHRON	<u>0.02%</u>	<u>A075562</u>	<u>001</u>	Sep 27, 2001
<u>AN</u>	! RITEDOSE CORP	<u>0.02%</u>	<u>A075693</u>	<u>001</u>	Jan 26, 2001
<u>AN</u>	SUN PHARM	<u>0.02%</u>	<u>A207903</u>	<u>001</u>	Jan 03, 2017
<u>AN</u>	WATSON LABS	<u>0.02%</u>	<u>A076291</u>	<u>001</u>	May 09, 2005

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

<u>AB</u>	APOTEX INC	<u>0.042MG/SPRAY</u>	<u>A076155</u>	<u>001</u>	Apr 18, 2003
<u>AB</u>	BAUSCH AND LOMB	<u>0.021MG/SPRAY</u>	<u>A076025</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>		<u>0.042MG/SPRAY</u>	<u>A076103</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	! HIKMA	<u>0.021MG/SPRAY</u>	<u>A076664</u>	<u>001</u>	Nov 05, 2003
<u>AB</u>	!	<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	+ SANOFI AVENTIS US	<u>75MG</u>	<u>N020757</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+	<u>150MG</u>	<u>N020757</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+!	<u>300MG</u>	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A204740</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>		<u>150MG</u>	<u>A204740</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>		<u>300MG</u>	<u>A204740</u>	<u>003</u>	Apr 17, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	CHARTWELL MOLECULAR	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	HIKMA	<u>75MG</u>	<u>A090201</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	HISUN PHARM HANGZHOU	<u>75MG</u>	<u>A206194</u>	<u>001</u>	Jun 14, 2016
<u>AB</u>		<u>150MG</u>	<u>A206194</u>	<u>002</u>	Jun 14, 2016
<u>AB</u>		<u>300MG</u>	<u>A206194</u>	<u>003</u>	Jun 14, 2016
<u>AB</u>	JUBILANT GENERICS	<u>75MG</u>	<u>A203534</u>	<u>001</u>	Feb 23, 2015
<u>AB</u>		<u>150MG</u>	<u>A203534</u>	<u>002</u>	Feb 23, 2015
<u>AB</u>		<u>300MG</u>	<u>A203534</u>	<u>003</u>	Feb 23, 2015
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>	NEOPHARMA	<u>75MG</u>	<u>A203161</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774</u>	<u>001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A204774</u>	<u>002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A204774</u>	<u>003</u>	Dec 07, 2015
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159</u>	<u>001</u>	Mar 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

IRBESARTAN

TABLET; ORAL

IRBESARTAN

<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>75MG</u>	<u>A203020 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A203020 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A203020 003</u>	Dec 07, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+!	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	+!		<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996
<u>AP</u>	+!		<u>300MG/15ML (20MG/ML)</u>	<u>N020571 003</u>	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

<u>AP</u>		ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
<u>AP</u>		ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A078589 003</u>	Nov 18, 2015
<u>AP</u>		AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
<u>AP</u>		CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219 001</u>	Feb 20, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077219 002</u>	Feb 20, 2008
<u>AP</u>		EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
<u>AP</u>		FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
<u>AP</u>		GLAND PHARMA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A212993 001</u>	Nov 18, 2019
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A212993 002</u>	Nov 18, 2019
<u>AP</u>		HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010
<u>AP</u>		HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
<u>AP</u>		HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
<u>AP</u>	!	INGENUS PHARMS LLC	<u>40MG/2ML (20MG/ML)</u>	<u>A206935 001</u>	May 26, 2017
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A206935 002</u>	May 26, 2017
<u>AP</u>		INTAS PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A203054 001</u>	Aug 31, 2017
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A203054 002</u>	Aug 31, 2017
<u>AP</u>		JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
<u>AP</u>		NEOPHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078953 001</u>	Apr 15, 2010
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078953 002</u>	Apr 15, 2010
<u>AP</u>		PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122 001</u>	Oct 31, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078122 002</u>	Oct 31, 2008
<u>AP</u>		QILU	<u>40MG/2ML (20MG/ML)</u>	<u>A203380 001</u>	May 03, 2016
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A203380 002</u>	May 03, 2016
<u>AP</u>			<u>300MG/15ML (20MG/ML)</u>	<u>A203380 003</u>	May 03, 2016
<u>AP</u>		SHILPA MEDICARE LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A208718 001</u>	Dec 28, 2018
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A208718 002</u>	Dec 28, 2018
<u>AP</u>		TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 002</u>	Feb 27, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
<u>AP</u>			<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008
<u>AP</u>		WEST-WARD PHARMS INT	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
<u>AP</u>		ZENNOVA	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
<u>AP</u>			<u>100MG/5ML (20MG/ML)</u>	<u>A090393 003</u>	May 13, 2011

INJECTABLE, LIPOSOMAL; INTRAVENOUS

ONIVYDE

	+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793 001	Oct 22, 2015
--	----	-----------	--------------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP +! ALLERGAN EQ 50MG IRON/ML N017441 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

+ AM REGENT

EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)

N021135 002 Mar 20, 2005

+!

EQ 100MG BASE/5ML (EQ 20MG BASE/ML)

N021135 001 Nov 06, 2000

+

EQ 200MG BASE/10ML (EQ 20MG BASE/ML)

N021135 004 Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+! ASTELLAS

186MG

N207500 001 Mar 06, 2015

POWDER; INTRAVENOUS

CRESEMBA

+! ASTELLAS

372MG

N207501 001 Mar 06, 2015

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+! VALIDUS PHARMS INC

10MG

N011961 001

ISOFLURANE

LIQUID; INHALATION

FORANE**AN** +! BAXTER HLTHCARE **99.9%** **N017624 001**ISOFLURANE**AN** HALOCARBON PRODS **99.9%** **A075225 001** Oct 20, 1999**AN** PIRAMAL CRITICAL **99.9%** **A074416 001** Sep 30, 1994**AN** PIRAMAL ENT **99.9%** **A074502 001** Jun 27, 1995ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

! SANDOZ INC

100MG/ML

A040648 001 Jul 05, 2005

SYRUP; ORAL

ISONIAZID

! CMP PHARMA INC

50MG/5ML

A088235 001 Nov 10, 1983

TABLET; ORAL

ISONIAZID**AA** ANDA REPOSITORY **100MG** **A040090 001** Jun 26, 1997**AA** **300MG** **A040090 002** Jun 26, 1997**AA** ! BARR **100MG** **A080936 001****AA** ! **300MG** **A080937 002****AA** THEPHARMANETWORK **100MG** **A202610 001** Oct 29, 2014

LLC

AA **300MG** **A202610 002** Oct 29, 2014ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+! SANOFI AVENTIS US

50MG; 300MG; 120MG

N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

! SANOFI AVENTIS US

150MG; 300MG

A061884 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE**AP** AMNEAL **0.2MG/ML** **A210576 001** Oct 17, 2018**AP** AMPHASTAR PHARMS **0.2MG/ML** **A210106 001** Jun 18, 2018

INC

AP CIPLA **0.2MG/ML** **A210322 001** Jun 12, 2018**AP** **0.2MG/ML** **A211738 001** Jun 28, 2019**AP** NEXUS PHARMS **0.2MG/ML** **A206961 001** Aug 02, 2017ISUPREL**AP** +! BAUSCH **0.2MG/ML** **N010515 001**

PRESCRIPTION DRUG PRODUCT LIST

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL

DILATRATE-SR

+! AUXILIUM PHARMS LLC 40MG

N019790 001 Sep 02, 1988

TABLET;ORAL

ISORDILAB + BAUSCH5MGN012093 007 Jul 29, 1988AB +!40MGN012093 001 Jul 29, 1988ISOSORBIDE DINITRATEAB HIKMA INTL PHARMS5MGA086067 001 Oct 29, 1987AB 10MGA086066 001 Oct 29, 1987AB 20MGA088088 001 Nov 02, 1987AB 30MGA040591 001 Jan 10, 2007AB PAR PHARM5MGA086923 001 Mar 12, 1987AB 10MGA086925 001 Mar 12, 1987AB 20MGA087537 001 Oct 02, 1987AB !30MGA087946 001 Jan 12, 1988AB SANDOZ5MGA086221 001 Jan 07, 1988AB 10MGA086223 001 Jan 07, 1988AB 20MGA089367 001 Apr 07, 1988AB ZYDUS5MGA213057 001 Nov 20, 2019AB 10MGA213057 002 Nov 20, 2019AB 20MGA213057 003 Nov 20, 2019AB 30MGA213057 004 Nov 20, 2019AB 40MGA213057 005 Nov 20, 2019

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

! SUN PHARM INDS INC 40MG

A040009 001 Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATEAB ACTAVIS ELIZABETH10MGA075037 002 Oct 30, 1998AB 20MGA075037 001 Oct 30, 1998AB HIKMA PHARMS20MGA075361 001 Oct 05, 2000MONOKETAB + LANNETT CO INC10MGN020215 002 Jun 30, 1993AB +!20MGN020215 001 Jun 30, 1993

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATEAB DEXCEL LTD30MGA075522 002 Sep 20, 2016AB 60MGA075522 001 Apr 17, 2000AB 120MGA210822 001 Aug 29, 2018AB HIKMA INTL PHARMS30MGA076813 002 Mar 30, 2006AB 60MGA076813 001 Jan 07, 2005AB LANNETT CO INC30MGA075155 002 Jan 13, 2000AB 60MGA075155 001 Oct 30, 1998AB !120MGA075155 003 Aug 04, 2000AB NESHER PHARMS30MGA075395 001 Mar 16, 2000AB 60MGA075395 002 Mar 16, 2000AB 120MGA075395 003 Mar 16, 2000AB RICONPHARMA LLC30MGA210918 001 Nov 05, 2018AB 60MGA210918 002 Nov 05, 2018AB 120MGA210918 003 Nov 05, 2018AB TORRENT PHARMS30MGA200270 001 Jun 03, 2011AB 60MGA200495 001 Jun 03, 2011AB 120MGA200495 002 Jun 03, 2011AB VINTAGE PHARMS30MGA090598 001 Aug 11, 2010AB 60MGA090598 002 Aug 11, 2010AB 120MGA090598 003 Aug 11, 2010ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUEAP AUROBINDO PHARMA LTD1%A206831 001 Feb 02, 2016AP ! MYLAN INSTITUTIONAL1%A090874 001 Jul 20, 2010

PRESCRIPTION DRUG PRODUCT LIST

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945 001</u>	Nov 08, 2002
<u>AB</u>		<u>20MG</u>	<u>A075945 002</u>	Nov 08, 2002
<u>AB</u>		<u>40MG</u>	<u>A075945 003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356 001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135 002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135 003</u>	May 11, 2006
<u>AB</u>	!	<u>40MG</u>	<u>A076135 001</u>	Apr 11, 2003

ISOTRETINOIN

<u>AB</u>	AMNEAL PHARMS NY	<u>10MG</u>	<u>A207792 001</u>	Sep 29, 2017
<u>AB</u>		<u>20MG</u>	<u>A207792 002</u>	Sep 29, 2017
<u>AB</u>		<u>30MG</u>	<u>A207792 003</u>	Sep 29, 2017
<u>AB</u>		<u>40MG</u>	<u>A207792 004</u>	Sep 29, 2017

MYORISAN

<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485 001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485 002</u>	Jan 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A076485 004</u>	Aug 25, 2015
<u>AB</u>		<u>40MG</u>	<u>A076485 003</u>	Jan 19, 2012

ZENATANE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099 001</u>	Mar 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202099 002</u>	Mar 25, 2013
<u>AB</u>		<u>30MG</u>	<u>A202099 004</u>	Feb 23, 2015
<u>AB</u>		<u>40MG</u>	<u>A202099 003</u>	Mar 25, 2013

ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951 001	May 25, 2012
BX	+		20MG	N021951 002	May 25, 2012
BX	+		30MG	N021951 003	May 25, 2012
BX	+	!	40MG	N021951 004	May 25, 2012
	+		25MG	N021951 005	Aug 15, 2014
	+		35MG	N021951 006	Aug 15, 2014
		ABSORICA LD			
	+	SUN PHARM	8MG	N211913 001	Nov 05, 2019
	+		16MG	N211913 002	Nov 05, 2019
	+		20MG	N211913 003	Nov 05, 2019
	+		24MG	N211913 004	Nov 05, 2019
	+		28MG	N211913 005	Nov 05, 2019
	+	!	32MG	N211913 006	Nov 05, 2019

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ELITE LABS INC	<u>2.5MG</u>	<u>A077169 001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169 002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS TEVA	<u>2.5MG</u>	<u>A077317 001</u>	Jan 05, 2006
<u>AB</u>	!	<u>5MG</u>	<u>A077317 002</u>	Jan 05, 2006

ISTRADIFYLLINE

TABLET; ORAL

NOURIANZ

	+	KYOWA KIRIN	20MG	N022075 001	Aug 27, 2019
	+	!	40MG	N022075 002	Aug 27, 2019

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A205991 001</u>	May 26, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A206741 001</u>	Dec 13, 2016
<u>AB</u>	ALKEM LABS LTD	<u>100MG</u>	<u>A208591 001</u>	Jun 12, 2017
<u>AB</u>	AMNEAL PHARMS	<u>100MG</u>	<u>A205080 001</u>	Sep 26, 2016
<u>AB</u>	JUBILANT GENERICS	<u>100MG</u>	<u>A203445 001</u>	Feb 23, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A200463 001</u>	Jul 20, 2012
<u>AB</u>	PAR PHARM INC	<u>100MG</u>	<u>A205724 001</u>	Dec 13, 2016
<u>AB</u>	PII	<u>100MG</u>	<u>A206410 001</u>	Jul 02, 2019
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A076104 001</u>	May 28, 2004
<u>AB</u>	TORRENT	<u>100MG</u>	<u>A209460 001</u>	Aug 24, 2018
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A204672 001</u>	Sep 19, 2017

SPORANOX

<u>AB</u>	+	JANSSEN PHARMS	<u>100MG</u>	<u>N020083 001</u>	Sep 11, 1992
-----------	---	----------------	--------------	--------------------	--------------

TOLSURA

	+	MAYNE PHARMA INTL	65MG	N208901 001	Dec 11, 2018
--	---	-------------------	------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ITRACONAZOLE

SOLUTION;ORAL

ITRACONAZOLE

AA	AMNEAL PHARMS	10MG/ML	A205573 001	Oct 30, 2015
AA	APOTEX	10MG/ML	A208481 001	Aug 02, 2019

SPORANOX

AA	+ ! JANSSEN PHARMS	10MG/ML	N020657 001	Feb 21, 1997
	TABLET;ORAL			
	ONMEL			
	+ ! SEBELA IRELAND LTD	200MG	N022484 001	Apr 29, 2010

IVABRADINE

SOLUTION;ORAL

CORLANOR

+ !	AMGEN INC	5MG/5ML (1MG/ML)	N209964 001	Apr 22, 2019
------------	-----------	------------------	-------------	--------------

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

+	AMGEN INC	EQ 5MG BASE	N206143 001	Apr 15, 2015
+ !		EQ 7.5MG BASE	N206143 002	Apr 15, 2015

IVACAFTOR

GRANULE;ORAL

KALYDECO

+	VERTEX PHARMS INC	25MG/PACKET	N207925 003	Apr 29, 2019
+		50MG/PACKET	N207925 001	Mar 17, 2015
+ !		75MG/PACKET	N207925 002	Mar 17, 2015

TABLET;ORAL

KALYDECO

+	VERTEX PHARMS	75MG	N203188 002	May 20, 2019
+ !		150MG	N203188 001	Jan 31, 2012

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET;ORAL

SYMDEKO (COPACKAGED)

+	VERTEX PHARMS INC	75MG,N/A;75MG, 50MG	N210491 002	Jun 21, 2019
+ !		150MG,N/A;150MG, 100MG	N210491 001	Feb 12, 2018

IVACAFTOR; LUMACAFTOR

GRANULE;ORAL

ORKAMBI

+	VERTEX PHARMS INC	125MG/PACKET;100MG/PACKET	N211358 001	Aug 07, 2018
+ !		188MG/PACKET;150MG/PACKET	N211358 002	Aug 07, 2018

TABLET;ORAL

ORKAMBI

+	VERTEX PHARMS INC	125MG;100MG	N206038 002	Sep 28, 2016
+ !		125MG;200MG	N206038 001	Jul 02, 2015

IVERMECTIN

CREAM;TOPICAL

IVERMECTIN

AB	TEVA PHARMS USA	1%	A210019 001	Sep 13, 2019
-----------	-----------------	-----------	--------------------	--------------

SOOLANTRA

AB	+ ! GALDERMA LABS LP	1%	N206255 001	Dec 19, 2014
-----------	-----------------------------	-----------	--------------------	--------------

LOTION;TOPICAL

SKLICE

+ !	ARBOR PHARMS LLC	0.5%	N202736 001	Feb 07, 2012
------------	------------------	------	-------------	--------------

TABLET;ORAL

IVERMECTIN

AB	EDENBRIDGE PHARMS	3MG	A204154 001	Oct 24, 2014
-----------	-------------------	------------	--------------------	--------------

STROMEKTOL

AB	+ ! MERCK SHARP DOHME	3MG	N050742 002	Oct 08, 1998
-----------	------------------------------	------------	--------------------	--------------

IVOSIDENIB

TABLET;ORAL

TIBSOVO

+ !	AGIOS PHARMS INC	250MG	N211192 001	Jul 20, 2018
------------	------------------	-------	-------------	--------------

IXABEPILONE

INJECTABLE;INTRAVENOUS

IXEMPRA KIT

+ !	R-PHARM US LLC	15MG/VIAL	N022065 001	Oct 16, 2007
+ !		45MG/VIAL	N022065 002	Oct 16, 2007

PRESCRIPTION DRUG PRODUCT LIST

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

+	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462 001	Nov 20, 2015
+		EQ 3MG BASE	N208462 002	Nov 20, 2015
+		EQ 4MG BASE	N208462 003	Nov 20, 2015

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>EQ 10MG BASE/ML</u>	<u>N016812 001</u>	
<u>AP</u>	+		<u>EQ 50MG BASE/ML</u>	<u>N016812 002</u>	
<u>AP</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N016812 003</u>	

KETAMINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A074549 001</u>	Jun 27, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074549 002</u>	Jun 27, 1996
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 10MG BASE/ML</u>	<u>A076092 001</u>	Sep 30, 2008
<u>AP</u>			<u>EQ 50MG BASE/ML</u>	<u>A076092 002</u>	Dec 28, 2001
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A076092 003</u>	Oct 25, 2002
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074524 001</u>	Mar 22, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074524 002</u>	Mar 22, 1996

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

<u>AT</u>	+	MYLAN	<u>2%</u>	<u>N021738 001</u>	Jun 12, 2007
-----------	---	-------	-----------	--------------------	--------------

KETOCONAZOLE

<u>AT</u>		PERRIGO ISRAEL	<u>2%</u>	<u>A091550 001</u>	Aug 25, 2011
-----------	--	----------------	-----------	--------------------	--------------

CREAM; TOPICAL

KETOCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A076294 001</u>	Apr 28, 2004
<u>AB</u>	!	TEVA	<u>2%</u>	<u>A075581 001</u>	Apr 25, 2000

KETOZOLE

<u>AB</u>		TARO	<u>2%</u>	<u>A075638 001</u>	Dec 18, 2002
-----------	--	------	-----------	--------------------	--------------

GEL; TOPICAL

XOLEGEL

+	ALMIRALL	2%	N021946 001	Jul 28, 2006
---	----------	----	-------------	--------------

SHAMPOO; TOPICAL

KETOCONAZOLE

<u>AB</u>		PERRIGO ISRAEL	<u>2%</u>	<u>A076419 001</u>	Jan 07, 2004
<u>AB</u>		TOLMAR	<u>2%</u>	<u>A076942 001</u>	Apr 11, 2005

NIZORAL

<u>AB</u>	+	JANSSEN PHARMS	<u>2%</u>	<u>N019927 001</u>	Aug 31, 1990
-----------	---	----------------	-----------	--------------------	--------------

TABLET; ORAL

KETOCONAZOLE

<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075597 001</u>	Dec 23, 1999
<u>AB</u>		STRIDES PHARMA	<u>200MG</u>	<u>A210457 001</u>	Jun 18, 2018
<u>AB</u>	!	TARO	<u>200MG</u>	<u>A075319 001</u>	Jun 15, 1999

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>		HERITAGE PHARMS INC	<u>50MG</u>	<u>A074014 002</u>	Jan 29, 1993
<u>AB</u>			<u>75MG</u>	<u>A074014 003</u>	Jan 29, 1993
<u>AB</u>		TEVA	<u>50MG</u>	<u>A073516 001</u>	Dec 22, 1992
<u>AB</u>	!		<u>75MG</u>	<u>A073517 001</u>	Dec 22, 1992
		HERITAGE PHARMS INC	25MG	A074014 001	Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

!	MYLAN	200MG	A075679 001	Feb 20, 2002
---	-------	-------	-------------	--------------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>		AMPHASTAR PHARM	<u>15MG/ML</u>	<u>A076209 001</u>	Jul 21, 2004
<u>AP</u>			<u>30MG/ML</u>	<u>A076209 002</u>	Jul 21, 2004
<u>AP</u>		BAXTER HLTHCARE CORP	<u>15MG/ML</u>	<u>A209900 002</u>	Jul 25, 2018
<u>AP</u>			<u>30MG/ML</u>	<u>A209900 001</u>	Sep 15, 2017
<u>AP</u>		FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784 001</u>	Jan 11, 2002
<u>AP</u>			<u>15MG/ML</u>	<u>A203242 001</u>	Oct 07, 2015
<u>AP</u>			<u>30MG/ML</u>	<u>A075784 002</u>	Jan 11, 2002
<u>AP</u>			<u>30MG/ML</u>	<u>A203242 002</u>	Oct 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	GLAND PHARMA LTD	<u>15MG/ML</u>	<u>A204216 001</u>	Nov 01, 2016
<u>AP</u>		<u>30MG/ML</u>	<u>A204216 002</u>	Nov 01, 2016
<u>AP</u>	! HOSPIRA	<u>15MG/ML</u>	<u>A074802 001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993 001</u>	Jan 27, 1999
<u>AP</u>	!	<u>30MG/ML</u>	<u>A074802 002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993 002</u>	Jan 27, 1999
<u>AP</u>	SAGENT PHARMS INC	<u>15MG/ML</u>	<u>A091065 001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065 002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ INC	<u>30MG/ML</u>	<u>A076271 002</u>	Oct 06, 2004
<u>AP</u>	WEST-WARD PHARMS INT	<u>15MG/ML</u>	<u>A075772 001</u>	Jul 21, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A075772 002</u>	Jul 21, 2004
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942 001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942 002</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+! ALLERGAN	<u>0.5%</u>	<u>N019700 001</u>	Nov 09, 1992
-----------	-------------	-------------	--------------------	--------------

ACULAR LS

<u>AT</u>	+! ALLERGAN	<u>0.4%</u>	<u>N021528 001</u>	May 30, 2003
-----------	-------------	-------------	--------------------	--------------

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434 001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109 001</u>	Nov 05, 2009
<u>AT</u>	MICRO LABS LTD INDIA	<u>0.5%</u>	<u>A203410 001</u>	Apr 05, 2019
<u>AT</u>	SANDOZ INC	<u>0.5%</u>	<u>A076583 001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARM	<u>0.5%</u>	<u>A090017 001</u>	Nov 05, 2009

ACUVAIL

+! ALLERGAN

0.45%

N022427 001 Jul 22, 2009

SPRAY, METERED; NASAL

SPRIX

+! ZYLA

15.75MG/SPRAY

N022382 001 May 14, 2010

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	CYCLE PHARMS LTD	<u>10MG</u>	<u>A210616 001</u>	Aug 16, 2018
<u>AB</u>	! MYLAN	<u>10MG</u>	<u>A074761 001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284 001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754 001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

<u>AT</u>	LUPIN LTD	<u>EQ 0.3% BASE;EQ 1% BASE</u>	<u>A210183 001</u>	Jul 01, 2019
-----------	-----------	--------------------------------	--------------------	--------------

OMIDRIA

<u>AT</u>	+! OMEROS	<u>EQ 0.3% BASE;EQ 1% BASE</u>	<u>N205388 001</u>	May 30, 2014
-----------	-----------	--------------------------------	--------------------	--------------

L-GLUTAMINE

FOR SOLUTION; ORAL

ENDARI

+ EMMAUS MEDCL

5GM/PACKET

N208587 001 Jul 07, 2017

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431 001</u>	Nov 29, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699 001</u>	Apr 03, 2012
<u>AP</u>	! HOSPIRA	<u>5MG/ML</u>	<u>A075239 001</u>	Nov 29, 1999
<u>AP</u>	!	<u>5MG/ML</u>	<u>A075240 001</u>	Nov 29, 1999
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/ML</u>	<u>A075303 001</u>	May 28, 1999

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	ATHEM	<u>100MG</u>	<u>A207863 001</u>	Feb 04, 2019
<u>AB</u>		<u>200MG</u>	<u>A207863 002</u>	Feb 04, 2019
<u>AB</u>		<u>300MG</u>	<u>A207863 003</u>	Feb 04, 2019
<u>AB</u>	CADILA PHARMS LTD	<u>100MG</u>	<u>A211325 001</u>	May 13, 2019
<u>AB</u>		<u>200MG</u>	<u>A211325 002</u>	May 13, 2019
<u>AB</u>		<u>300MG</u>	<u>A211325 003</u>	May 13, 2019
<u>AB</u>	INNOGENIX	<u>100MG</u>	<u>A075215 001</u>	Jul 29, 1999
<u>AB</u>		<u>200MG</u>	<u>A075215 002</u>	Jul 29, 1999

PRESCRIPTION DRUG PRODUCT LIST

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>		<u>300MG</u>	<u>A075215 003</u>	Jul 29, 1999
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908 001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908 002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908 003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113 001</u>	Aug 04, 1998
<u>AB</u>	!	<u>200MG</u>	<u>A075113 002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113 003</u>	Aug 04, 1998
<u>AB</u>	TWI PHARMS	<u>100MG</u>	<u>A209603 001</u>	Jun 20, 2018
<u>AB</u>		<u>200MG</u>	<u>A209603 002</u>	Jun 20, 2018
<u>AB</u>		<u>300MG</u>	<u>A209603 003</u>	Jun 20, 2018
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133 003</u>	Aug 03, 1998
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A207743 001</u>	Sep 19, 2017
<u>AB</u>		<u>200MG</u>	<u>A207743 002</u>	Sep 19, 2017
<u>AB</u>		<u>300MG</u>	<u>A207743 003</u>	Sep 19, 2017
<u>TRANDATE</u>				
<u>AB</u>	+ CNTY LINE PHARMS	<u>100MG</u>	<u>N018716 001</u>	May 24, 1985
<u>AB</u>	+	<u>200MG</u>	<u>N018716 002</u>	Aug 01, 1984
<u>AB</u>	+	<u>300MG</u>	<u>N018716 003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+! UCB INC

200MG/20ML (10MG/ML)

N022254 001 Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+! UCB INC

10MG/ML

N022255 001 Apr 20, 2010

TABLET; ORAL

VIMPAT

+ UCB INC

50MG

N022253 001 Oct 28, 2008

+

100MG

N022253 002 Oct 28, 2008

+

150MG

N022253 003 Oct 28, 2008

+!

200MG

N022253 004 Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

! CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997

!

20GM/PACKET

A074712 002 Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054 001</u>	Jul 26, 1988
<u>LACTULOSE</u>				
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503 001</u>	Jan 25, 2012
<u>AA</u>	! HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076 001</u>	Jul 03, 1995
<u>AA</u>	HIKMA	<u>10GM/15ML</u>	<u>A073591 001</u>	May 29, 1992
<u>AA</u>	LANNETT CO INC	<u>10GM/15ML</u>	<u>A075993 001</u>	Jul 26, 2001
<u>AA</u>	LIFEPHARMA	<u>10GM/15ML</u>	<u>A209517 001</u>	Nov 23, 2018
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623 001</u>	Jul 30, 1996
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138 001</u>	Sep 30, 1992
<u>AA</u>	WOCKHARDT BIO AG	<u>10GM/15ML</u>	<u>A074602 001</u>	Nov 14, 1996
<u>AA</u>	XTTRIUM LABS INC	<u>10GM/15ML</u>	<u>A075911 001</u>	Feb 21, 2002
SOLUTION; ORAL, RECTAL				
<u>CHOLAC</u>				
<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331 001</u>	Jul 26, 1988
<u>ENULOSE</u>				
<u>AA</u>	! ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548 001</u>	Aug 15, 1988
<u>GENERLAC</u>				
<u>AA</u>	WOCKHARDT BIO AG	<u>10GM/15ML</u>	<u>A074603 001</u>	Oct 31, 1996
<u>LACTULOSE</u>				
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502 001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077 001</u>	Jul 03, 1995

PRESCRIPTION DRUG PRODUCT LIST

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA	+ !	VIIV HLTHCARE	10MG/ML	N020596	001	Nov 17, 1995
-----------	------------	---------------	----------------	----------------	------------	--------------

LAMIVUDINE

AA		AUROBINDO PHARMA LTD	10MG/ML	A077695	001	Nov 21, 2016
-----------	--	----------------------	----------------	----------------	------------	--------------

AA		LANNETT CO INC	10MG/ML	A203564	001	Oct 31, 2014
-----------	--	----------------	----------------	----------------	------------	--------------

EPIVIR-HBV

+ !		GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998
------------	--	-----------------	--------	---------	-----	--------------

TABLET;ORAL

EPIVIR

AB	+	VIIV HLTHCARE	150MG	N020564	001	Nov 17, 1995
-----------	----------	---------------	--------------	----------------	------------	--------------

AB	+ !		300MG	N020564	003	Jun 24, 2002
-----------	------------	--	--------------	----------------	------------	--------------

EPIVIR-HBV

AB	+ !	GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998
-----------	------------	-----------------	--------------	----------------	------------	--------------

LAMIVUDINE

AB		ANNORA	100MG	A211306	001	Mar 21, 2019
-----------	--	--------	--------------	----------------	------------	--------------

AB		APOTEX	100MG	A202941	001	Jan 02, 2014
-----------	--	--------	--------------	----------------	------------	--------------

AB			150MG	A091606	001	Dec 02, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			300MG	A091606	002	Dec 02, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		ARISE	150MG	A206974	001	Nov 21, 2016
-----------	--	-------	--------------	----------------	------------	--------------

AB			300MG	A206974	002	Nov 21, 2016
-----------	--	--	--------------	----------------	------------	--------------

AB		AUROBINDO PHARMA LTD	150MG	A077464	001	Nov 21, 2016
-----------	--	----------------------	--------------	----------------	------------	--------------

AB			150MG	A202032	001	Nov 17, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			300MG	A077464	002	Nov 21, 2016
-----------	--	--	--------------	----------------	------------	--------------

AB			300MG	A202032	002	Nov 17, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		CIPLA	150MG	A077221	001	Mar 03, 2017
-----------	--	-------	--------------	----------------	------------	--------------

AB			300MG	A077221	002	Mar 03, 2017
-----------	--	--	--------------	----------------	------------	--------------

AB		ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016
-----------	--	----------------	--------------	----------------	------------	--------------

AB		HETERO LABS LTD V	100MG	A203260	001	Jan 02, 2014
-----------	--	-------------------	--------------	----------------	------------	--------------

AB			150MG	A203277	001	Jan 06, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB			300MG	A203277	002	Jan 06, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB		LUPIN LTD	150MG	A205217	001	Dec 18, 2014
-----------	--	-----------	--------------	----------------	------------	--------------

AB			300MG	A205217	002	Dec 18, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB		MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019
-----------	--	---------------------	--------------	----------------	------------	--------------

AB			300MG	A090198	002	May 01, 2019
-----------	--	--	--------------	----------------	------------	--------------

AB		MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019
-----------	--	----------------	--------------	----------------	------------	--------------

AB			300MG	A078545	002	Mar 05, 2019
-----------	--	--	--------------	----------------	------------	--------------

AB		STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018
-----------	--	----------------	--------------	----------------	------------	--------------

AB			300MG	A090457	002	Apr 19, 2018
-----------	--	--	--------------	----------------	------------	--------------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

CIMDUO

+ !		MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018
------------	--	----------------	-------------	---------	-----	--------------

TEMIXYS

		CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018
--	--	-----------	-------------	---------	-----	--------------

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

AB	+ !	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997
-----------	------------	---------------	--------------------	----------------	------------	--------------

LAMIVUDINE AND ZIDOVUDINE

AB		ANDA REPOSITORY	150MG;300MG	A206375	001	Apr 10, 2018
-----------	--	-----------------	--------------------	----------------	------------	--------------

AB		AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017
-----------	--	----------------------	--------------------	----------------	------------	--------------

AB			150MG;300MG	A202418	001	May 15, 2012
-----------	--	--	--------------------	----------------	------------	--------------

AB		CIPLA	150MG;300MG	A077411	001	Sep 07, 2018
-----------	--	-------	--------------------	----------------	------------	--------------

AB		HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015
-----------	--	---------------------	--------------------	----------------	------------	--------------

AB		HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014
-----------	--	-------------------	--------------------	----------------	------------	--------------

AB		LUPIN LTD	150MG;300MG	A090246	001	May 15, 2012
-----------	--	-----------	--------------------	----------------	------------	--------------

AB		MACLEODS PHARMS LTD	150MG;300MG	A090679	001	Aug 29, 2018
-----------	--	---------------------	--------------------	----------------	------------	--------------

AB		STRIDES PHARMA	150MG;300MG	A079128	001	May 13, 2015
-----------	--	----------------	--------------------	----------------	------------	--------------

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB	+ !	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994
-----------	------------	---------------------	-------------	----------------	------------	--------------

AB	+		100MG	N020241	001	Dec 27, 1994
-----------	----------	--	--------------	----------------	------------	--------------

AB	+		150MG	N020241	002	Dec 27, 1994
-----------	----------	--	--------------	----------------	------------	--------------

AB	+		200MG	N020241	003	Dec 27, 1994
-----------	----------	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	RUBICON	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>	+		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+		<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168</u>	<u>001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168</u>	<u>002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK PHARMS LTD	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+		<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>	+		<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>	+		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>	+		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>			<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>			<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>			<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>			<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>			<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>		AMNEAL PHARMS	<u>25MG</u>	<u>A207497 001</u>	Nov 30, 2018
<u>AB</u>			<u>50MG</u>	<u>A207497 002</u>	Nov 30, 2018
<u>AB</u>			<u>100MG</u>	<u>A207497 003</u>	Nov 30, 2018
<u>AB</u>			<u>200MG</u>	<u>A207497 004</u>	Nov 30, 2018
<u>AB</u>			<u>250MG</u>	<u>A207497 005</u>	Nov 30, 2018
<u>AB</u>			<u>300MG</u>	<u>A207497 006</u>	Nov 30, 2018
<u>AB</u>		ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>			<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>			<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012
<u>AB</u>			<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>			<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>			<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013
<u>AB</u>			<u>50MG</u>	<u>A202383 002</u>	Jun 19, 2013
<u>AB</u>			<u>100MG</u>	<u>A202383 003</u>	Jun 19, 2013
<u>AB</u>			<u>200MG</u>	<u>A202383 004</u>	Jun 19, 2013
<u>AB</u>			<u>300MG</u>	<u>A202383 005</u>	Jun 19, 2013
<u>AB</u>		PAR PHARM	<u>25MG</u>	<u>A201791 001</u>	Jan 18, 2013
<u>AB</u>			<u>50MG</u>	<u>A201791 002</u>	Jan 18, 2013
<u>AB</u>			<u>100MG</u>	<u>A201791 003</u>	Jan 18, 2013
<u>AB</u>			<u>200MG</u>	<u>A201791 004</u>	Jan 18, 2013
<u>AB</u>			<u>250MG</u>	<u>A201791 005</u>	Jan 18, 2013
<u>AB</u>			<u>300MG</u>	<u>A201791 006</u>	Jan 18, 2013
<u>AB</u>		RUBICON	<u>100MG</u>	<u>A202887 003</u>	Jun 17, 2013
<u>AB</u>			<u>200MG</u>	<u>A202887 004</u>	Jun 17, 2013
<u>AB</u>		TORRENT	<u>25MG</u>	<u>A203370 001</u>	Dec 23, 2013
<u>AB</u>			<u>50MG</u>	<u>A203370 002</u>	Dec 23, 2013
<u>AB</u>			<u>100MG</u>	<u>A203370 003</u>	Dec 23, 2013
<u>AB</u>			<u>200MG</u>	<u>A203370 004</u>	Dec 23, 2013
<u>AB</u>		WOCKHARDT LTD	<u>25MG</u>	<u>A202498 001</u>	Jan 04, 2013
<u>AB</u>			<u>50MG</u>	<u>A202498 002</u>	Jan 04, 2013
<u>AB</u>			<u>100MG</u>	<u>A202498 003</u>	Jan 04, 2013
<u>AB</u>			<u>200MG</u>	<u>A202498 004</u>	Jan 04, 2013
<u>AB</u>			<u>300MG</u>	<u>A202498 005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251 001</u>	May 08, 2009
<u>AB</u>	+		<u>50MG</u>	<u>N022251 002</u>	May 08, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022251 003</u>	May 08, 2009
<u>AB</u>	+		<u>200MG</u>	<u>N022251 004</u>	May 08, 2009

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

<u>AB</u>	IMPAX LABS INC	<u>25MG</u>	<u>A200828 001</u>	Jul 15, 2013
<u>AB</u>		<u>50MG</u>	<u>A200828 002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828 003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828 004</u>	Jul 15, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A204158 001</u>	Oct 27, 2015
<u>AB</u>		<u>50MG</u>	<u>A204158 002</u>	Oct 27, 2015
<u>AB</u>		<u>100MG</u>	<u>A204158 003</u>	Oct 27, 2015
<u>AB</u>		<u>200MG</u>	<u>A204158 004</u>	Oct 27, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A206382 001</u>	Jun 17, 2016
<u>AB</u>		<u>50MG</u>	<u>A206382 002</u>	Jun 17, 2016
<u>AB</u>		<u>100MG</u>	<u>A206382 003</u>	Jun 17, 2016
<u>AB</u>		<u>200MG</u>	<u>A206382 004</u>	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074 001	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074 002	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074 003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	ALKEM LABS LTD	<u>15MG</u>	<u>A207394 001</u>	Jan 18, 2019
<u>AB</u>		<u>30MG</u>	<u>A207394 002</u>	Jan 18, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269 001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269 002</u>	Oct 15, 2010
<u>AB</u>	INVENTIA	<u>15MG</u>	<u>A205868 001</u>	Aug 30, 2017
<u>AB</u>		<u>30MG</u>	<u>A205868 002</u>	Aug 30, 2017
<u>AB</u>	LANNETT CO INC	<u>15MG</u>	<u>A207156 001</u>	Sep 28, 2017
<u>AB</u>		<u>30MG</u>	<u>A207156 002</u>	Sep 28, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763 001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763 002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921 001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921 002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331 001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331 002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARM	<u>15MG</u>	<u>A202637 001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509 001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255 001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255 002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176 001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176 002</u>	Sep 14, 2012
<u>AB</u>	XIROMED	<u>15MG</u>	<u>A203203 001</u>	Jul 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A203203 002</u>	Jul 25, 2016
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366 001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366 002</u>	Aug 19, 2013

PREVACID

<u>AB</u>	+	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406 001</u>	May 10, 1995
<u>AB</u>	+		<u>30MG</u>	<u>N020406 002</u>	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A202396 001</u>	Nov 28, 2018
<u>AB</u>		<u>30MG</u>	<u>A202396 002</u>	Nov 28, 2018
<u>AB</u>	TEVA PHARMS USA	<u>15MG</u>	<u>A208784 001</u>	Sep 21, 2017
<u>AB</u>		<u>30MG</u>	<u>A208784 002</u>	Sep 21, 2017
<u>AB</u>	ZYDUS PHARMS	<u>15MG</u>	<u>A200816 001</u>	Nov 27, 2018
<u>AB</u>		<u>30MG</u>	<u>A200816 002</u>	Nov 27, 2018

PREVACID

<u>AB</u>	+	TAKEDA PHARMS USA	<u>15MG</u>	<u>N021428 001</u>	Aug 30, 2002
<u>AB</u>	+		<u>30MG</u>	<u>N021428 002</u>	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

+	SHIRE DEV LLC	EQ 750MG BASE	N204734 001	Sep 24, 2014
+		EQ 1GM BASE	N204734 002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

<u>AB</u>	+	SHIRE LLC	<u>EQ 500MG BASE</u>	<u>N021468 002</u>	Oct 26, 2004
-----------	---	-----------	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

AB	+	EQ 750MG BASE	N021468 003	Nov 23, 2005
AB	+	EQ 1GM BASE	N021468 004	Nov 23, 2005

LANTHANUM CARBONATE

AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978 001	Aug 11, 2017
AB		EQ 750MG BASE	A090978 002	Aug 11, 2017
AB		EQ 1GM BASE	A090978 003	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

+	NOVARTIS	EQ 250MG BASE	N022059 001	Mar 13, 2007
---	----------	---------------	-------------	--------------

LAROTRECTINIB SULFATE

CAPSULE;ORAL

VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861 001	Nov 26, 2018
---	----------------	--------------	-------------	--------------

+		EQ 100MG BASE	N210861 002	Nov 26, 2018
---	--	---------------	-------------	--------------

SOLUTION;ORAL

VITRAKVI

+	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710 001	Nov 26, 2018
---	------------------	-----------------	-------------	--------------

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

+	SUN PHARMA GLOBAL	0.005%	N206185 001	Sep 12, 2018
---	-------------------	--------	-------------	--------------

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT	AKORN	0.005%	A090887 001	Jul 19, 2011
AT	AMRING PHARMS	0.005%	A200925 001	Mar 22, 2011
AT	AUROBINDO PHARMA LTD	0.005%	A206519 001	Sep 03, 2019
AT	BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011
AT	DR REDDYS LABS LTD	0.005%	A202077 001	Feb 11, 2013
AT	FDC LTD	0.005%	A202442 001	Apr 22, 2016
AT	SANDOZ INC	0.005%	A091449 001	Mar 22, 2011
AT	SOMERSET	0.005%	A201786 001	Mar 22, 2011

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996
-----------	---	----------------------	---------------	--------------------	--------------

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

ROCKLATAN

+	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259 001	Mar 12, 2019
---	------------------	----------------------	-------------	--------------

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC

VYZULTA

+	BAUSCH AND LOMB	0.024%	N207795 001	Nov 02, 2017
---	-----------------	--------	-------------	--------------

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477 001	Aug 28, 2019
---	---------------------	----------------------	-------------	--------------

+		45MG;200MG/PACKET	N212477 002	Aug 28, 2019
---	--	-------------------	-------------	--------------

TABLET;ORAL

HARVONI

+	GILEAD SCIENCES INC	45MG;200MG	N205834 002	Aug 28, 2019
---	---------------------	------------	-------------	--------------

+		90MG;400MG	N205834 001	Oct 10, 2014
---	--	------------	-------------	--------------

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

+	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673 001	Aug 19, 2019
---	---------	--------------------------------------	-------------	--------------

TABLET;ORAL

XENLETA

+	NABRIVA	EQ 600MG BASE	N211672 001	Aug 19, 2019
---	---------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEFLUNOMIDE

TABLET; ORAL

ARAVA

<u>AB</u>	+	SANOFI AVENTIS US	<u>10MG</u>	<u>N020905</u>	<u>001</u>	Sep 10, 1998
<u>AB</u>	+	!	<u>20MG</u>	<u>N020905</u>	<u>002</u>	Sep 10, 1998

LEFLUNOMIDE

<u>AB</u>		ABHAI LLC	<u>10MG</u>	<u>A212453</u>	<u>001</u>	Jun 03, 2019
<u>AB</u>			<u>20MG</u>	<u>A212453</u>	<u>002</u>	Jun 03, 2019
<u>AB</u>		ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A091369</u>	<u>001</u>	Nov 21, 2011
<u>AB</u>			<u>20MG</u>	<u>A091369</u>	<u>002</u>	Nov 21, 2011
<u>AB</u>		APOTEX INC	<u>10MG</u>	<u>A077090</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>			<u>20MG</u>	<u>A077090</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>		BARR	<u>10MG</u>	<u>A077083</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>			<u>20MG</u>	<u>A077083</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>		HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>			<u>20MG</u>	<u>A077086</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>		TEVA PHARMS	<u>10MG</u>	<u>A077084</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>			<u>20MG</u>	<u>A077084</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>		ZYDUS	<u>10MG</u>	<u>A212308</u>	<u>001</u>	Apr 24, 2019
<u>AB</u>			<u>20MG</u>	<u>A212308</u>	<u>002</u>	Apr 24, 2019

ARAVA
+! SANOFI AVENTIS US 100MG N020905 003 Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

+	CELGENE	2.5MG	N021880	005	Dec 21, 2011
+		5MG	N021880	001	Dec 27, 2005
+		10MG	N021880	002	Dec 27, 2005
+		15MG	N021880	003	Jun 29, 2006
+		20MG	N021880	006	Jun 05, 2013
+	!	25MG	N021880	004	Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
+	!	EQ 10MG BASE	N206947	002	Feb 13, 2015

LETERMOVIR

SOLUTION; INTRAVENOUS

PREVYMIS

+	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
+	!	480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017

TABLET; ORAL

PREVYMIS

+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
+	!	480MG	N209939	002	Nov 08, 2017

LETROZOLE

TABLET; ORAL

FEMARA

<u>AB</u>	+	NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726</u>	<u>001</u>	Jul 25, 1997
-----------	---	-----------------	--------------	----------------	------------	--------------

LETROZOLE

<u>AB</u>		ACCORD HLTHCARE	<u>2.5MG</u>	<u>A090934</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A091303</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		BEIJING YILING	<u>2.5MG</u>	<u>A205869</u>	<u>001</u>	Nov 14, 2018
<u>AB</u>		DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A091191</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		EUGIA PHARMA	<u>2.5MG</u>	<u>A211717</u>	<u>001</u>	Jan 11, 2019
<u>AB</u>		HIKMA	<u>2.5MG</u>	<u>A090838</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		HIKMA PHARMS	<u>2.5MG</u>	<u>A203796</u>	<u>001</u>	Jun 03, 2016
<u>AB</u>		INDICUS PHARMA	<u>2.5MG</u>	<u>A201804</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		JIANGSU HENGRUI MED	<u>2.5MG</u>	<u>A202716</u>	<u>001</u>	May 16, 2013
<u>AB</u>		NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		TEVA PHARMS	<u>2.5MG</u>	<u>A090289</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789</u>	<u>001</u>	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET; ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+	NOVARTIS	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017
---	----------	-----------------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A207226 001</u>	Jul 27, 2018
<u>AP</u>	TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277 001</u>	Sep 28, 1993
<u>AP</u>		<u>EQ 350MG BASE/VIAL</u>	<u>A040174 001</u>	Jun 12, 1997
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A089384 001</u>	Sep 14, 1987
<u>AP</u>	!	<u>EQ 100MG BASE/VIAL</u>	<u>A089717 001</u>	Mar 28, 1988
<u>LEUCOVORIN CALCIUM PRESERVATIVE FREE</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258 001</u>	Feb 26, 1999
<u>AP</u>	!	<u>EQ 500MG BASE/VIAL</u>	<u>A040286 001</u>	Feb 26, 1999
<u>AP</u>	MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A203800 001</u>	May 19, 2017
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A203800 002</u>	May 19, 2017
<u>AP</u>		<u>EQ 350MG BASE/VIAL</u>	<u>A203800 003</u>	May 19, 2017
<u>AP</u>	SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753 001</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	<u>A200753 002</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A200753 003</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 350MG BASE/VIAL</u>	<u>A200855 001</u>	Sep 06, 2012
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 500MG BASE/VIAL</u>	<u>A209110 001</u>	Oct 26, 2017
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 10MG BASE/ML</u>	<u>A040347 001</u>	Apr 25, 2000
<u>AP</u>	!	<u>EQ 200MG BASE/VIAL</u>	<u>A040056 001</u>	May 23, 1995
<u>AP</u>	!	<u>EQ 350MG BASE/VIAL</u>	<u>A040335 001</u>	Apr 20, 2000

LEUCOVORIN CALCIUM

FRESENIUS KABI USA

EQ 10MG BASE/ML

A207241 001

Mar 14, 2018

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>	BARR	<u>EQ 5MG BASE</u>	<u>A071198 001</u>	Sep 24, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071199 001</u>	Sep 24, 1987
<u>AB</u>	HIKMA	<u>EQ 5MG BASE</u>	<u>A072733 001</u>	Feb 22, 1993
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A072736 001</u>	Feb 22, 1993
		EQ 10MG BASE	A072734 001	Feb 22, 1993
		EQ 15MG BASE	A072735 001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	! SANDOZ	<u>1MG/0.2ML</u>	<u>A074728 001</u>	Aug 04, 1998
<u>AP</u>	SUN PHARM	<u>1MG/0.2ML</u>	<u>A078885 001</u>	Mar 09, 2009
<u>AP</u>	TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471 001</u>	Oct 25, 2000
LUPRON DEPOT				
	+! ABBVIE ENDOCRINE INC	3.75MG	N020011 002	Oct 26, 1995
	+!	7.5MG/VIAL	N019732 001	Jan 26, 1989
	+!	11.25MG/VIAL	N020708 001	Mar 07, 1997
	+	22.5MG/VIAL	N020517 001	Dec 22, 1995
	+!	30MG/VIAL	N020517 002	May 30, 1997
	+!	45MG/VIAL	N020517 003	Jun 17, 2011
LUPRON DEPOT-PED				
	+! ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263 002	Apr 16, 1993
	+!	11.25MG/VIAL	N020263 005	Jan 21, 1994
	+!	11.25MG/VIAL	N020263 007	Aug 15, 2011
	+!	15MG/VIAL	N020263 006	Jan 21, 1994
	+!	30MG/VIAL	N020263 008	Aug 15, 2011
INJECTABLE; SUBCUTANEOUS				
ELIGARD				
	+! TOLMAR THERAP	7.5MG/VIAL	N021343 001	Jan 23, 2002
	+!	22.5MG/VIAL	N021379 001	Jul 24, 2002
	+!	30MG/VIAL	N021488 001	Feb 13, 2003
	+!	45MG/VIAL	N021731 001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

	+ ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696 001	Dec 14, 2012
	+!	11.25MG/VIAL, N/A; N/A, 5MG	N203696 002	Dec 14, 2012

PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	AUROBINDO PHARMA LTD	<u>EQ 0.25% BASE</u>	<u>A207628 001</u>	Jan 31, 2017
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A207625 001</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207625 002</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207625 003</u>	Dec 30, 2016
<u>AN</u>	CIPLA	<u>EQ 0.021% BASE</u>	<u>A078171 002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171 003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171 001</u>	Dec 13, 2013
<u>AN</u>	IMPAX LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008
<u>AN</u>	MYLAN SPECIALITY LP	<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.0103% BASE</u>	<u>A203653 001</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A203653 002</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A203653 003</u>	Mar 22, 2016
<u>AN</u>	SUN PHARM	<u>EQ 0.0103% BASE</u>	<u>A207820 001</u>	Nov 05, 2018
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207820 002</u>	Nov 05, 2018
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207820 003</u>	Nov 05, 2018
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013
<u>XOPENEX</u>				
<u>AN</u>	+! OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+!	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+!	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999
<u>AN</u>	+!	<u>EQ 0.25% BASE</u>	<u>N020837 004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+! SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ CSPC OUYI

EQ 1.25MG BASE

N212895 001 Dec 19, 2019

+

EQ 2.5MG BASE

N212895 002 Dec 19, 2019

+!

EQ 5MG BASE

N212895 003 Dec 19, 2019

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

KEPPRA

<u>AP</u>	+! UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872 001</u>	Jul 31, 2006
<u>LEVETIRACETAM</u>				
<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A204312 001</u>	Feb 01, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813 001</u>	May 26, 2010
<u>AP</u>		<u>500MG/5ML (100MG/ML)</u>	<u>A090876 001</u>	Aug 13, 2015
<u>AP</u>	HAINAN POLY PHARM	<u>500MG/5ML (100MG/ML)</u>	<u>A209781 001</u>	Mar 20, 2018
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981 001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/5ML (100MG/ML)</u>	<u>A202869 001</u>	Apr 06, 2012
<u>AP</u>	JUBILANT GENERICS	<u>500MG/5ML (100MG/ML)</u>	<u>A206838 001</u>	Jun 02, 2016
<u>AP</u>	MICRO LABS	<u>500MG/5ML (100MG/ML)</u>	<u>A211954 001</u>	Aug 09, 2019
<u>AP</u>	MYLAN LABS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A203308 001</u>	Sep 16, 2016
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627 001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754 001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485 001</u>	Aug 05, 2011
<u>LEVETIRACETAM IN SODIUM CHLORIDE</u>				
<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/100ML (5MG/ML)</u>	<u>A207160 001</u>	Jan 04, 2017
<u>AP</u>		<u>1000MG/100ML (10MG/ML)</u>	<u>A207160 002</u>	Jan 04, 2017
<u>AP</u>		<u>1500MG/100ML (15MG/ML)</u>	<u>A207160 003</u>	Jan 04, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/100ML (5MG/ML)</u>	<u>A206880 001</u>	Oct 25, 2017
<u>AP</u>		<u>1000MG/100ML (10MG/ML)</u>	<u>A206880 002</u>	Oct 25, 2017
<u>AP</u>		<u>1500MG/100ML (15MG/ML)</u>	<u>A206880 003</u>	Oct 25, 2017
<u>AP</u>	+! HQ SPECIALITY PHARMA	<u>500MG/100ML (5MG/ML)</u>	<u>N202543 001</u>	Nov 09, 2011
<u>AP</u>	+!	<u>1000MG/100ML (10MG/ML)</u>	<u>N202543 002</u>	Nov 09, 2011
<u>AP</u>	+!	<u>1500MG/100ML (15MG/ML)</u>	<u>N202543 003</u>	Nov 09, 2011

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

SOLUTION;ORAL

KEPPRA

<u>AA</u>	<u>+</u> !	UCB INC	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u>	Jul 15, 2003
-----------	------------	---------	-----------------	----------------	------------	--------------

LEVETIRACETAM

<u>AA</u>		ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u>	Oct 27, 2009
<u>AA</u>		ANDA REPOSITORY	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		AUROBINDO PHARMA LTD	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>		BRECKENRIDGE	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>		HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052</u>	<u>001</u>	Feb 28, 2013
<u>AA</u>		HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601</u>	<u>001</u>	Feb 28, 2012
<u>AA</u>		LANNETT CO INC	<u>100MG/ML</u>	<u>A090079</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>			<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>		LUPIN LTD	<u>100MG/ML</u>	<u>A090893</u>	<u>001</u>	Oct 17, 2011
<u>AA</u>		ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067</u>	<u>001</u>	May 09, 2013
<u>AA</u>		PHARM ASSOC	<u>100MG/ML</u>	<u>A201157</u>	<u>001</u>	Jun 04, 2015
<u>AA</u>		TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>		TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>		WOCKHARDT BIO AG	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET;ORAL

KEPPRA

<u>AB</u>	<u>+</u>	UCB INC	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>	<u>+</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>	<u>+</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	<u>+</u> !		<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>		ACCORD HLTHCARE	<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>			<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>			<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>			<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>		ACI HEALTHCARE LTD	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		ACIC PHARMS	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>			<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>			<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>			<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>			<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>			<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>			<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>			<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>			<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>			<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>		CHARTWELL RX	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>			<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>			<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>			<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>			<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		HETERO LABS LTD III	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>			<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>			<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>			<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>			<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>			<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		LOTUS PHARM CO LTD	<u>250MG</u>	<u>A090906</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>			<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>			<u>750MG</u>	<u>A090906</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>			<u>1GM</u>	<u>A090906</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>		LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>500MG</u>	<u>A078154 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025 001</u>	Jan 15, 2009
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919 001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919 002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919 003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261 001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484 001</u>	Aug 05, 2010
<u>AB</u>	OXFORD PHARMS	<u>250MG</u>	<u>A077319 001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319 002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319 003</u>	Mar 20, 2009
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106 001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106 002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106 003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106 004</u>	Feb 10, 2009
<u>AB</u>	SECAN PHARMS	<u>500MG</u>	<u>A205102 004</u>	Dec 16, 2015
<u>AB</u>		<u>1GM</u>	<u>A205102 003</u>	Dec 16, 2015
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960 004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960 003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960 002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960 001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101 004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858 004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A091491 001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491 002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491 003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491 004</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042 004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918 001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918 002</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	+	UCB INC	<u>500MG</u>	<u>N022285 001</u>	Sep 12, 2008
<u>AB</u>	+	!	<u>750MG</u>	<u>N022285 002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557 001</u>	Sep 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A091557 002</u>	Sep 12, 2011
<u>AB</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093 001</u>	Sep 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A091093 002</u>	Sep 12, 2011
<u>AB</u>		ANCHEN PHARMS	<u>500MG</u>	<u>A091360 001</u>	Oct 04, 2011
<u>AB</u>			<u>750MG</u>	<u>A091360 002</u>	Oct 04, 2011
<u>AB</u>		ANDA REPOSITORY	<u>500MG</u>	<u>A204511 001</u>	Feb 23, 2016
<u>AB</u>			<u>750MG</u>	<u>A204511 002</u>	Feb 23, 2016
<u>AB</u>		APOTEX INC	<u>500MG</u>	<u>A091261 001</u>	Sep 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A091261 002</u>	Sep 12, 2011
<u>AB</u>		DEXCEL PHARMA	<u>500MG</u>	<u>A202167 001</u>	Sep 04, 2015
<u>AB</u>			<u>750MG</u>	<u>A202167 002</u>	Sep 04, 2015
<u>AB</u>		ECI PHARMS LLC	<u>500MG</u>	<u>A204754 001</u>	Aug 26, 2016
<u>AB</u>			<u>750MG</u>	<u>A204754 002</u>	Aug 26, 2016
<u>AB</u>		HISUN PHARM HANGZHOU	<u>500MG</u>	<u>A207175 001</u>	Sep 28, 2017
<u>AB</u>			<u>750MG</u>	<u>A207175 002</u>	Sep 28, 2017
<u>AB</u>		LOTUS PHARM CO LTD	<u>500MG</u>	<u>A202095 002</u>	Jun 06, 2016
<u>AB</u>			<u>750MG</u>	<u>A202095 001</u>	Jun 06, 2016
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A091399 001</u>	Sep 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A091399 002</u>	Sep 12, 2011
<u>AB</u>		PHARMADAX INC	<u>500MG</u>	<u>A201464 001</u>	May 25, 2012

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>500MG</u>	<u>A203468</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A203468</u>	<u>002</u>	May 21, 2015
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012

ELEPSIA XR

+ SPARC

1GM

N204417 001 Dec 20, 2018

+!

1.5GM

N204417 002 Dec 20, 2018

LEVETIRACETAM

APOTEX

1GM

A202958 001 Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

+ APRECIA PHARMS

250MG

N207958 001 Jul 31, 2015

+

500MG

N207958 002 Jul 31, 2015

+

750MG

N207958 003 Jul 31, 2015

+!

1GM

N207958 004 Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+! ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+!	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
-----------	-----------------	-------------	----------------	------------	--------------

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

<u>AP</u>	+! LEADIANT BIOSCI INC	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	------------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	WEST-WARD PHARMS INT	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001

SOLUTION;ORAL

CARNITOR

<u>AA</u>	+! LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	------------------------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	+ LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	-----------------------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004
<u>AA</u>	NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>001</u>	Aug 14, 2019

LEVOCARNITINE SF

<u>AA</u>	NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>002</u>	Aug 14, 2019
-----------	-----------------	-----------------	----------------	------------	--------------

TABLET;ORAL

CARNITOR

<u>AB</u>	+! LEADIANT BIOSCI INC	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	------------------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>	RISING	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	--------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>	APOTEX	<u>2.5MG/5ML</u>	<u>A202915</u>	<u>001</u>	Aug 21, 2014
<u>AA</u>	! L PERRIGO CO	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>	LANNETT CO INC	<u>2.5MG/5ML</u>	<u>A204599</u>	<u>001</u>	May 15, 2017
<u>AA</u>	TARO PHARM INDS LTD	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

LEVOCETIRIZINE HYDROCHLORIDE

<u>AA</u>	HETERO LABS LTD III	<u>2.5MG/5ML</u>	<u>A210914</u>	<u>001</u>	Apr 01, 2019
-----------	---------------------	------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL

AA	+	SANOFI AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008
-----------	----------	-------------------	------------------	----------------	------------	--------------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		APOTEX	5MG	A203027	001	Feb 13, 2015
AB		DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011
AB		GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011
AB		HETERO LABS LTD III	5MG	A091264	001	Jun 29, 2012
AB		MACLEODS PHARMS LTD	5MG	A205564	001	Jan 11, 2016
AB		MICRO LABS LTD	5MG	A202046	001	Sep 17, 2013
		INDIA				
AB		NEOPHARMA	5MG	A204323	001	Dec 20, 2016
AB		SCIEGEN PHARMS INC	5MG	A203646	001	Sep 09, 2014
AB		SUN PHARM	5MG	A090362	001	Jan 31, 2013
AB		SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015
AB		SYNTHON PHARMS	5MG	A090229	001	Nov 26, 2010
AB		TEVA PHARMS	5MG	A090199	001	Aug 22, 2011

XYZAL

AB	+	SANOFI AVENTIS US	5MG	N022064	001	May 25, 2007
-----------	----------	-------------------	------------	----------------	------------	--------------

LEVODOPA

POWDER; INHALATION

INBRIJA

+	!	ACORDA	42MG	N209184	001	Dec 21, 2018
----------	----------	--------	------	---------	-----	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011
AP			EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011
AP	!	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013
AP		BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016
AP			EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016
AP			EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016
AP		BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013
AP			EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013
AP			EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013
AP		FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013
AP			EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013
AP			EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013
AP		HIKMA FARMACEUTICA	EQ 250MG/50ML (EQ 5MG/ML)	A091375	001	Sep 16, 2011
AP			EQ 500MG/100ML (EQ 5MG/ML)	A091375	002	Sep 16, 2011
AP			EQ 750MG/150ML (EQ 5MG/ML)	A091375	003	Sep 16, 2011
AP		HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015
AP			EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015
AP			EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015
AP	!	INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011
AP	!		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011
AP	!		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011

SOLUTION;ORAL

LEVOFLOXACIN

AA	!	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011
AA		LANNETT CO INC	250MG/10ML	A205222	001	May 25, 2018

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT		AKORN	0.5%	A090268	001	Dec 20, 2010
AT		MYLAN LABS LTD	0.5%	A204899	001	Dec 08, 2017
AT	!	RISING	0.5%	A077700	001	Dec 20, 2010
AT		WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011
		MICRO LABS LTD	1.5%	A205600	001	Feb 27, 2019
		INDIA				

TABLET;ORAL

LEVOFLOXACIN

AB		APOTEX INC	250MG	A090787	001	Sep 29, 2011
AB			500MG	A090787	002	Sep 29, 2011
AB			750MG	A090787	003	Sep 29, 2011

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043 002</u>	Jun 20, 2011
<u>AB</u>	!	<u>750MG</u>	<u>A201043 003</u>	Jun 20, 2011
<u>AB</u>	CELLTRION	<u>250MG</u>	<u>A090367 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367 003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890 001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890 002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890 003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710 003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250 003</u>	Jun 20, 2011
<u>AB</u>	HEC PHARM	<u>250MG</u>	<u>A204968 001</u>	Feb 05, 2019
<u>AB</u>		<u>500MG</u>	<u>A204968 002</u>	Feb 05, 2019
<u>AB</u>		<u>750MG</u>	<u>A204968 003</u>	Feb 05, 2019
<u>AB</u>	HETERO LABS LTD V	<u>250MG</u>	<u>A202801 001</u>	Jan 08, 2015
<u>AB</u>		<u>500MG</u>	<u>A202801 002</u>	Jan 08, 2015
<u>AB</u>		<u>750MG</u>	<u>A202801 003</u>	Jan 08, 2015
<u>AB</u>	JUBILANT GENERICS	<u>250MG</u>	<u>A203613 001</u>	Jun 19, 2015
<u>AB</u>		<u>500MG</u>	<u>A203613 002</u>	Jun 19, 2015
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424 003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839 001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839 002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839 003</u>	Mar 22, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200 001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200 002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200 003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438 003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361 003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722 003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652 001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652 002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652 003</u>	Sep 07, 2012

LEVOLEUCOVORIN

POWDER; INTRAVENOUS

KHAPZORY

+! ACROTECH

175MG/VIAL

N211226 001 Oct 19, 2018

+!

300MG/VIAL

N211226 002 Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

<u>AP</u>	+! ACROTECH	<u>EQ 50MG BASE/VIAL</u>	<u>N020140 001</u>	Mar 07, 2008
<u>AP</u>	ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206516 001</u>	Feb 13, 2017
<u>AP</u>	AMNEAL	<u>EQ 50MG BASE/VIAL</u>	<u>A207547 001</u>	Feb 13, 2017
<u>AP</u>	MEITHEAL	<u>EQ 50MG BASE/VIAL</u>	<u>A211003 001</u>	Aug 22, 2019
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A206263 001</u>	Jun 16, 2016

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

<u>AP</u>	AMNEAL	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A207548 001</u>	Sep 08, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A210892 001</u>	Sep 14, 2018
<u>AP</u>		<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A210892 002</u>	Sep 14, 2018
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A210623 001</u>	May 03, 2018
<u>AP</u>		<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A210623 002</u>	May 03, 2018
<u>AP</u>	MEITHEAL	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A211002 001</u>	Aug 16, 2019

PRESCRIPTION DRUG PRODUCT LIST

LEVOLEUCOVORIN CALCIUM

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A211002 002</u>	Aug 16, 2019
AP	SANDOZ INC	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203563 001</u>	Mar 09, 2015
AP	!	<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A203563 002</u>	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

+	ALLERGAN	EQ 20MG BASE	N204168 001	Jul 25, 2013
+		EQ 40MG BASE	N204168 002	Jul 25, 2013
+		EQ 80MG BASE	N204168 003	Jul 25, 2013
+	!	EQ 120MG BASE	N204168 004	Jul 25, 2013

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

!	DEPROCO	0.05MG/ML; 2%	A088388 001	Oct 10, 1984
---	---------	---------------	-------------	--------------

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

+	!	BAYER HLTHCARE	19.5MG	N208224 001	Sep 16, 2016
---	---	----------------	--------	-------------	--------------

LILETTA

		MEDICINES360	52MG	N206229 001	Feb 26, 2015
--	--	--------------	------	-------------	--------------

MIRENA

+	!	BAYER HLTHCARE	52MG	N021225 001	Dec 06, 2000
---	---	----------------	------	-------------	--------------

SKYLA

+	!	BAYER HLTHCARE	13.5MG	N203159 001	Jan 09, 2013
---	---	----------------	--------	-------------	--------------

TABLET; ORAL

LEVONORGESTREL

AB	!	L FERRIGO CO	<u>0.75MG</u>	<u>A090740 001</u>	Dec 30, 2010
AB		MYLAN LABS LTD	<u>0.75MG</u>	<u>A202740 001</u>	Sep 02, 2016

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	!	SENTYNL THERAPS INC	<u>2MG</u>	<u>A074278 001</u>	Mar 31, 2000
AB		SPECGX LLC	<u>2MG</u>	<u>A212024 001</u>	Dec 13, 2019
AB		VIRTUS PHARMS	<u>2MG</u>	<u>A211484 001</u>	Dec 13, 2018
	!	SENTYNL THERAPS INC	3MG	A074278 003	Jun 18, 2018

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

+		INSTITUT BIOCHIMIQUE	0.013MG	N021924 013	Aug 01, 2007
+			0.025MG	N021924 002	Oct 13, 2006
+			0.05MG	N021924 003	Oct 13, 2006
+			0.075MG	N021924 004	Oct 13, 2006
+			0.088MG	N021924 010	Oct 02, 2009
+			0.1MG	N021924 005	Oct 13, 2006
+			0.112MG	N021924 008	Oct 02, 2009
+			0.125MG	N021924 006	Oct 13, 2006
+			0.137MG	N021924 009	Oct 02, 2009
+			0.15MG	N021924 007	Oct 13, 2006
+			0.175MG	N021924 011	Apr 25, 2017
+	!		0.200MG	N021924 012	Apr 25, 2017

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	+	!	FRESENIUS KABI USA	<u>100MCG/VIAL</u>	<u>N202231 001</u>	Jun 24, 2011
AP	+	!		<u>200MCG/VIAL</u>	<u>N202231 002</u>	Jun 24, 2011
AP	+	!		<u>500MCG/VIAL</u>	<u>N202231 003</u>	Jun 24, 2011
AP			MAIA PHARMS INC	<u>100MCG/VIAL</u>	<u>A208749 001</u>	Dec 21, 2018
AP				<u>200MCG/VIAL</u>	<u>A208749 002</u>	Dec 21, 2018
AP				<u>500MCG/VIAL</u>	<u>A208749 003</u>	Dec 21, 2018
AP			PIRAMAL CRITICAL	<u>100MCG/VIAL</u>	<u>A206163 001</u>	Jun 29, 2016
AP				<u>500MCG/VIAL</u>	<u>A206163 002</u>	Jun 29, 2016

SOLUTION; INTRAVENOUS

LEVOTHYROXINE SODIUM

+	!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632 001	Apr 11, 2019
+	!		200MCG/5ML (40MCG/ML)	N210632 002	Apr 11, 2019
+	!		500MCG/5ML (100MCG/ML)	N210632 003	Apr 11, 2019

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

SOLUTION;ORAL

TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016
+		25MCG/ML	N206977	002	Dec 15, 2016
+		50MCG/ML	N206977	003	Dec 15, 2016
+		75MCG/ML	N206977	004	Dec 15, 2016
+		88MCG/ML	N206977	005	Dec 15, 2016
+		100MCG/ML	N206977	006	Dec 15, 2016
+		112MCG/ML	N206977	007	Dec 15, 2016
+		125MCG/ML	N206977	008	Dec 15, 2016
+		137MCG/ML	N206977	009	Dec 15, 2016
+		150MCG/ML	N206977	010	Dec 15, 2016
+		175MCG/ML	N206977	011	Dec 15, 2016
+	!	200MCG/ML	N206977	012	Dec 15, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

-->	+	ABBVIE	--> <u>AB1, AB2</u>	<u>0.025MG</u>	N021402	001	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.05MG</u>	N021402	002	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.075MG</u>	N021402	003	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.088MG</u>	N021402	004	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.1MG</u>	N021402	005	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.112MG</u>	N021402	006	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.125MG</u>	N021402	007	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.137MG</u>	N021402	008	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.15MG</u>	N021402	009	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.175MG</u>	N021402	010	Jul 24, 2002
-->	+		--> <u>AB1, AB2</u>	<u>0.2MG</u>	N021402	012	Jul 24, 2002
-->	+	!	--> <u>AB1, AB2</u>	<u>0.3MG</u>	N021402	011	Jul 24, 2002

LEVO-T

-->		CEDIPROF INC	--> <u>AB1, AB2, AB3</u>	<u>0.025MG</u>	N021342	001	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.05MG</u>	N021342	002	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.075MG</u>	N021342	003	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.088MG</u>	N021342	004	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.1MG</u>	N021342	005	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.112MG</u>	N021342	006	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.125MG</u>	N021342	007	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.137MG</u>	N021342	012	Dec 08, 2003
-->			--> <u>AB1, AB2, AB3</u>	<u>0.15MG</u>	N021342	008	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.175MG</u>	N021342	009	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.2MG</u>	N021342	010	Mar 01, 2002
-->			--> <u>AB1, AB2, AB3</u>	<u>0.3MG</u>	N021342	011	Mar 01, 2002

LEVOTHYROXINE SODIUM

-->		LUPIN ATLANTIS	--> <u>AB1, AB2, AB3</u>	<u>0.025MG</u>	A209713	001	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.05MG</u>	A209713	002	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.075MG</u>	A209713	003	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.088MG</u>	A209713	004	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.1MG</u>	A209713	005	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.112MG</u>	A209713	006	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.125MG</u>	A209713	007	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.137MG</u>	A209713	008	Jan 18, 2019
-->			--> <u>AB1, AB2, AB3</u>	<u>0.15MG</u>	A209713	009	Jan 18, 2019

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	A209713	010	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	A209713	011	Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	A209713	012	Jan 18, 2019

UNITHROID

-->	+	STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210	001	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210	002	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210	003	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210	004	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210	005	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210	006	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210	007	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210	012	Feb 08, 2008
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210	008	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210	009	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210	010	Aug 21, 2000
-->	+		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210	011	Aug 21, 2000

LEVOTHYROXINE SODIUM

-->		MYLAN	-->	<u>0.025MG</u>	A076187	001	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.05MG</u>	A076187	002	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.075MG</u>	A076187	003	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.088MG</u>	A076187	004	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.1MG</u>	A076187	005	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.112MG</u>	A076187	006	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.125MG</u>	A076187	007	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.137MG</u>	A076187	012	Dec 13, 2006
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.15MG</u>	A076187	008	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.175MG</u>	A076187	009	Jun 05, 2002
-->			<u>AB1,AB2,AB3,AB4</u>	<u>0.2MG</u>	A076187	010	Jun 05, 2002
-->	!		<u>AB1,AB2,AB3,AB4</u>	<u>0.3MG</u>	A076187	011	Jun 05, 2002

LEVOXYL

-->	+	KING PHARMS	--> <u>AB1,AB3</u>	<u>0.025MG</u>	N021301	001	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.05MG</u>	N021301	002	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.075MG</u>	N021301	003	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.088MG</u>	N021301	004	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.1MG</u>	N021301	005	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.112MG</u>	N021301	006	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.125MG</u>	N021301	007	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.137MG</u>	N021301	008	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.15MG</u>	N021301	009	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.175MG</u>	N021301	010	May 25, 2001
-->	+		--> <u>AB1,AB3</u>	<u>0.2MG</u>	N021301	011	May 25, 2001

EUTHYROX

<u>AB2</u>		PROVELL	<u>0.025MG</u>	<u>N021292</u>	<u>001</u>	May 31, 2002
<u>AB2</u>			<u>0.05MG</u>	<u>N021292</u>	<u>002</u>	May 31, 2002
<u>AB2</u>			<u>0.075MG</u>	<u>N021292</u>	<u>003</u>	May 31, 2002
<u>AB2</u>			<u>0.088MG</u>	<u>N021292</u>	<u>004</u>	May 31, 2002
<u>AB2</u>			<u>0.1MG</u>	<u>N021292</u>	<u>005</u>	May 31, 2002

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

<u>AB2</u>		<u>0.112MG</u>	<u>N021292 006</u>	May 31, 2002
<u>AB2</u>		<u>0.125MG</u>	<u>N021292 007</u>	May 31, 2002
<u>AB2</u>		<u>0.137MG</u>	<u>N021292 008</u>	May 31, 2002
<u>AB2</u>		<u>0.15MG</u>	<u>N021292 009</u>	May 31, 2002
<u>AB2</u>		<u>0.175MG</u>	<u>N021292 010</u>	May 31, 2002
<u>AB2</u>		<u>0.2MG</u>	<u>N021292 011</u>	May 31, 2002

THYRO-TABS

-->	+	ALVOGEN	--> <u>AB2, AB4</u>	<u>0.025MG</u>	N021116 001	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.05MG</u>	N021116 002	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.075MG</u>	N021116 003	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.088MG</u>	N021116 010	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.1MG</u>	N021116 004	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.112MG</u>	N021116 011	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.125MG</u>	N021116 005	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.137MG</u>	N021116 012	Dec 07, 2004
-->	+		--> <u>AB2, AB4</u>	<u>0.15MG</u>	N021116 006	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.175MG</u>	N021116 007	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.2MG</u>	N021116 008	Oct 24, 2002
-->	+		--> <u>AB2, AB4</u>	<u>0.3MG</u>	N021116 009	Oct 24, 2002

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

<u>AT</u>		ACP NIMBLE	<u>5%</u>	<u>A211019 001</u>	Dec 12, 2018
<u>AT</u>		ALEOR	<u>5%</u>	<u>A211469 001</u>	Nov 23, 2018
		DERMACEUTICALS			
<u>AT</u>		ALKEM LABS LTD	<u>5%</u>	<u>A207810 001</u>	Mar 10, 2017
<u>AT</u>		AMNEAL PHARMS	<u>5%</u>	<u>A206297 001</u>	Aug 07, 2015
<u>AT</u>	!	FOUGERA PHARMS INC	<u>5%</u>	<u>A080198 001</u>	
<u>AT</u>		GLENMARK PHARMS LTD	<u>5%</u>	<u>A206498 001</u>	Sep 09, 2016
<u>AT</u>		NOVAST LABS	<u>5%</u>	<u>A208604 001</u>	Sep 20, 2017
<u>AT</u>		SEPTODONT INC	<u>5%</u>	<u>A040911 001</u>	May 23, 2011
<u>AT</u>		STRIDES PHARMA	<u>5%</u>	<u>A210958 001</u>	Dec 11, 2018
<u>AT</u>		SUNGEN PHARMA	<u>5.0%</u>	<u>A212486 001</u>	Oct 17, 2019
<u>AT</u>		TARO	<u>5%</u>	<u>A086724 001</u>	
<u>AT</u>		TELIGENT PHARMA INC	<u>5%</u>	<u>A205318 001</u>	Feb 01, 2016
<u>AT</u>		TEVA PHARMS USA	<u>5%</u>	<u>A210256 001</u>	Jan 16, 2018
<u>AT</u>		VITRUVIAS THERAP	<u>5%</u>	<u>A208822 001</u>	Sep 25, 2017

PATCH;TOPICAL

LIDOCAINE

<u>AB</u>		ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675 001</u>	Aug 23, 2012
<u>AB</u>		MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346 001</u>	Aug 07, 2015

LIDODERM

<u>AB</u>	+	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612 001</u>	Mar 19, 1999
		ZTLIDO			
	+	SCILEX PHARMS INC	1.8%	N207962 001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

	+	AKORN	3.5%	N022221 001	Oct 07, 2008
--	---	-------	------	-------------	--------------

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>1%</u>	<u>A207182 001</u>	Oct 30, 2017
<u>AP</u>			<u>2%</u>	<u>A207182 002</u>	Oct 30, 2017
<u>AP</u>		B BRAUN MEDICAL INC	<u>1%</u>	<u>A208474 001</u>	Aug 03, 2018
<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A080404 002</u>	
<u>AP</u>			<u>2%</u>	<u>A080404 003</u>	
<u>AP</u>		HOSPIRA	<u>0.5%</u>	<u>A088328 001</u>	May 17, 1984
<u>AP</u>	!		<u>1%</u>	<u>A083158 001</u>	
<u>AP</u>			<u>1%</u>	<u>A088329 001</u>	May 17, 1984
<u>AP</u>			<u>2%</u>	<u>A040078 001</u>	Jun 23, 1995
<u>AP</u>	!		<u>2%</u>	<u>A083158 002</u>	
<u>AP</u>			<u>2%</u>	<u>A088294 001</u>	May 17, 1984
<u>AP</u>		INTL MEDICATION	<u>1%</u>	<u>A083173 001</u>	
<u>AP</u>			<u>2%</u>	<u>A083173 002</u>	
<u>AP</u>		SPECTRA MDCL DEVICES	<u>1%</u>	<u>A208017 001</u>	Apr 18, 2018

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830 002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461 002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830 003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461 003</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830 004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461 004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586 001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325 001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299 001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327 001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040 001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082 001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040 002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082 002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>2%</u>	<u>N017584 001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584 002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408 001</u>	
<u>AP</u>		<u>1.5%</u>	<u>A080408 002</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302 001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302 002</u>	Sep 28, 1998

XYLOCAINE

<u>AP</u>	+! FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488 008</u>	
<u>AP</u>	+!	<u>1%</u>	<u>N006488 007</u>	
<u>AP</u>	+!	<u>1.5%</u>	<u>N006488 010</u>	
<u>AP</u>	+!	<u>2%</u>	<u>N006488 002</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

!	HOSPIRA	4%	A088295 001	May 17, 1984
---	---------	----	-------------	--------------

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

!	HOSPIRA	5%	A083914 001	
---	---------	----	-------------	--

JELLY; TOPICAL

GLYDO

<u>AT</u>	SAGENT PHARMS INC	<u>2%</u>	<u>A201094 001</u>	Apr 28, 2014
-----------	-------------------	-----------	--------------------	--------------

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>2%</u>	<u>A040433 001</u>	Feb 12, 2003
<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283 001</u>	

XYLOCAINE

<u>AT</u>	+! OAK PHARMS	<u>2%</u>	<u>N008816 001</u>	
-----------	---------------	-----------	--------------------	--

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040014 001</u>	Jul 10, 1995
<u>AT</u>	WOCKHARDT BIO AG	<u>2%</u>	<u>A087872 001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>	! LANNETT CO INC	<u>2%</u>	<u>A040708 001</u>	Feb 27, 2007
-----------	------------------	-----------	--------------------	--------------

LIDOCAINE VISCOUS

<u>AT</u>	HIKMA	<u>2%</u>	<u>A088802 001</u>	Apr 26, 1985
-----------	-------	-----------	--------------------	--------------

SOLUTION; TOPICAL

LARYNG-O-JET KIT

<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364 001</u>	
-----------	-----------------	-----------	--------------------	--

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	! HIKMA	<u>4%</u>	<u>A088803 001</u>	Apr 03, 1985
<u>AT</u>	LANNETT CO INC	<u>4%</u>	<u>A040710 001</u>	Feb 27, 2007
<u>AT</u>	TELIGENT PHARMA INC	<u>4%</u>	<u>A204494 001</u>	Mar 12, 2014

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS	0.5MG	N022114 001	Aug 16, 2007
---------------	-------	-------------	--------------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

<u>AB</u>	+! TEVA BRANDED PHARM	<u>2.5%;2.5%</u>	<u>N019941 001</u>	Dec 30, 1992
-----------	-----------------------	------------------	--------------------	--------------

LIDOCAINE AND PRILOCAINE

<u>AB</u>	FOUGERA PHARMS	<u>2.5%;2.5%</u>	<u>A076453 001</u>	Aug 18, 2003
<u>AB</u>	HI TECH PHARMA	<u>2.5%;2.5%</u>	<u>A076290 001</u>	Sep 25, 2003

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	TELIGENT PHARMA INC	2.5%;2.5%	A205887 001	Jun 29, 2018
AB	TOLMAR	2.5%;2.5%	A076320 001	Aug 27, 2003
	GEL; PERIODONTAL			
	ORAQIX			
	+! DENTSPLY PHARM	2.5%;2.5%	N021451 001	Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+! TARO PHARMS 7%;7% N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+! GALEN SPECIALTY 70MG;70MG N021623 001 Jun 23, 2005

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+! NOVARTIS 5% N208073 001 Jul 11, 2016

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+! ALLERGAN 72MCG N202811 003 Jan 25, 2017

+! 145MCG N202811 001 Aug 30, 2012

+ 290MCG N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+! BOEHRINGER 5MG N201280 001 May 02, 2011

INGELHEIM

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

+ BOEHRINGER 2.5MG;500MG N201281 001 Jan 30, 2012

INGELHEIM

+ 2.5MG;850MG N201281 002 Jan 30, 2012

+! 2.5MG;1GM N201281 003 Jan 30, 2012

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

+ BOEHRINGER 2.5MG;1GM N208026 001 May 27, 2016

INGELHEIM

+! 5MG;1GM N208026 002 May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP	+! PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317 001	
-----------	-------------------------	-------------------------	--------------------	--

LINCOMYCIN

AP	X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746 001	Jun 04, 2015
-----------	------------------	-------------------------	--------------------	--------------

LINDANE

LOTION; TOPICAL

LINDANE

! OLTA PHARMS 1% A087313 001

SHAMPOO; TOPICAL

LINDANE

AT	OLTA PHARMS	1%	A087266 001	
-----------	-------------	-----------	--------------------	--

AT	! WOCKHARDT BIO AG	1%	A088191 001	Sep 18, 1984
-----------	--------------------	-----------	--------------------	--------------

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

AB	HIKMA	100MG/5ML	A200068 001	Jun 03, 2015
-----------	-------	------------------	--------------------	--------------

ZYVOX

AB	+! PHARMACIA AND UPJOHN	100MG/5ML	N021132 001	Apr 18, 2000
-----------	-------------------------	------------------	--------------------	--------------

SOLUTION; INTRAVENOUS

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917 001	Aug 04, 2016
-----------	----------------------	-----------------------------	--------------------	--------------

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764 001	Mar 15, 2016
-----------	--------------------	-----------------------------	--------------------	--------------

AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442 001	Jul 07, 2015
-----------	-------------	-----------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

<u>AP</u>	HQ SPCLT PHARMA	<u>200MG/100ML (2MG/ML)</u>	<u>A207001 001</u>	Jul 07, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A207001 002</u>	Jul 07, 2017
<u>AP</u>	MYLAN LABS LTD	<u>200MG/100ML (2MG/ML)</u>	<u>A205154 001</u>	Dec 06, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A205154 002</u>	Dec 06, 2017
<u>AP</u>	NANG KUANG PHARM CO	<u>200MG/100ML (2MG/ML)</u>	<u>A207354 001</u>	Dec 20, 2016
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A207354 002</u>	Dec 20, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>200MG/100ML (2MG/ML)</u>	<u>A204696 001</u>	Mar 02, 2017
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A204696 002</u>	Mar 02, 2017
<u>AP</u>	SANDOZ INC	<u>200MG/100ML (2MG/ML)</u>	<u>A200904 001</u>	Jul 16, 2015
<u>AP</u>		<u>600MG/300ML (2MG/ML)</u>	<u>A200904 002</u>	Jul 16, 2015
<u>AP</u>	TEVA PHARMS	<u>600MG/300ML (2MG/ML)</u>	<u>A200222 001</u>	Jun 27, 2012

ZYVOX

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>200MG/100ML (2MG/ML)</u>	<u>N021131 001</u>	Apr 18, 2000
<u>AP</u>	+!	<u>600MG/300ML (2MG/ML)</u>	<u>N021131 003</u>	Apr 18, 2000
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+! HOSPIRA INC	600MG/300ML (2MG/ML)	N206473 001	Jun 18, 2015

TABLET; ORAL

LINEZOLID

<u>AB</u>	ALEMBIC PHARMS LTD	<u>600MG</u>	<u>A205233 001</u>	Dec 21, 2015
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A205517 001</u>	Dec 21, 2015
<u>AB</u>	AMNEAL PHARMS	<u>600MG</u>	<u>A204536 001</u>	Dec 21, 2015
<u>AB</u>	CELLTRION	<u>600MG</u>	<u>A210702 001</u>	Apr 25, 2019
<u>AB</u>	GATE PHARMS	<u>600MG</u>	<u>A091210 001</u>	Feb 05, 2016
<u>AB</u>	GLENMARK PHARMS	<u>600MG</u>	<u>A078987 001</u>	Dec 21, 2015
<u>AB</u>	HETERO LABS LTD V	<u>600MG</u>	<u>A204239 001</u>	Dec 21, 2015
<u>AB</u>	NOVEL LABS INC	<u>600MG</u>	<u>A207526 001</u>	Aug 22, 2016
<u>AB</u>	TEVA PHARMS USA	<u>600MG</u>	<u>A078061 001</u>	May 18, 2015
<u>AB</u>	ZYDUS PHARMS	<u>600MG</u>	<u>A206097 001</u>	Feb 22, 2017

ZYVOX

<u>AB</u>	+! PHARMACIA AND UPJOHN	<u>600MG</u>	<u>N021130 002</u>	Apr 18, 2000
-----------	-------------------------	--------------	--------------------	--------------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	X GEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923 001</u>	Aug 17, 2005
	<u>TRIOSTAT</u>			
<u>AP</u>	+! PAR STERILE PRODUCTS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105 001</u>	Dec 31, 1991

TABLET; ORAL

CYTOMEL

<u>AB</u>	+ KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379 001</u>	
<u>AB</u>	+	<u>EQ 0.025MG BASE</u>	<u>N010379 002</u>	
<u>AB</u>	+	<u>EQ 0.05MG BASE</u>	<u>N010379 003</u>	

LIOTHYRONINE SODIUM

<u>AB</u>	MAYNE PHARMA INC	<u>EQ 0.005MG BASE</u>	<u>A090097 001</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097 002</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097 003</u>	Mar 20, 2009
<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295 001</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295 002</u>	Nov 29, 2012
<u>AB</u>	!	<u>EQ 0.05MG BASE</u>	<u>A200295 003</u>	Nov 29, 2012

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

	+! NOVO	18MG/3ML (6MG/ML)	N206321 001	Dec 23, 2014
	VICTOZA			
	+! NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341 001	Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

	+ SHIRE DEVELOPMENT	10MG	N021977 007	Oct 30, 2014
	+	20MG	N021977 004	Dec 10, 2007
	+	30MG	N021977 001	Feb 23, 2007
	+	40MG	N021977 005	Dec 10, 2007
	+	50MG	N021977 002	Feb 23, 2007
	+	60MG	N021977 006	Dec 10, 2007
	+!	70MG	N021977 003	Feb 23, 2007

PRESCRIPTION DRUG PRODUCT LIST

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL

VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017
+		20MG	N208510	002	Jan 28, 2017
+		30MG	N208510	003	Jan 28, 2017
+		40MG	N208510	004	Jan 28, 2017
+		50MG	N208510	005	Jan 28, 2017
+	!	60MG	N208510	006	Jan 28, 2017

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016
---	-------------------	--------	---------	-----	--------------

TABLET;ORAL

LISINOPRIL

AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013
AB		5MG	A202554	002	Jul 30, 2013
AB		10MG	A202554	003	Jul 30, 2013
AB		20MG	A202554	004	Jul 30, 2013
AB		30MG	A202554	005	Jul 30, 2013
AB		40MG	A202554	006	Jul 30, 2013
AB	APOTEX INC	2.5MG	A076102	001	Sep 30, 2002
AB		5MG	A076102	002	Sep 30, 2002
AB		10MG	A076102	003	Sep 30, 2002
AB		20MG	A076102	004	Sep 30, 2002
AB		30MG	A076102	005	Sep 30, 2002
AB		40MG	A076102	006	Sep 30, 2002
AB	AUROBINDO	2.5MG	A077622	001	Feb 22, 2006
AB		5MG	A077622	002	Feb 22, 2006
AB		10MG	A077622	003	Feb 22, 2006
AB		20MG	A077622	004	Feb 22, 2006
AB		30MG	A077622	005	Feb 22, 2006
AB		40MG	A077622	006	Feb 22, 2006
AB	CASI PHARMS INC	2.5MG	A075994	001	Jul 01, 2002
AB		5MG	A075994	002	Jul 01, 2002
AB		10MG	A075994	003	Jul 01, 2002
AB		20MG	A075994	004	Jul 01, 2002
AB		30MG	A075994	005	Jul 01, 2002
AB		40MG	A075994	006	Jul 01, 2002
AB	INVAGEN PHARMS	2.5MG	A203508	001	Oct 29, 2013
AB		5MG	A203508	002	Oct 29, 2013
AB		10MG	A203508	003	Oct 29, 2013
AB		20MG	A203508	004	Oct 29, 2013
AB		30MG	A203508	005	Oct 29, 2013
AB		40MG	A203508	006	Oct 29, 2013
AB	LUPIN	2.5MG	A077321	001	Sep 09, 2005
AB		5MG	A077321	002	Sep 09, 2005
AB		10MG	A077321	003	Sep 09, 2005
AB		20MG	A077321	004	Sep 09, 2005
AB		30MG	A077321	005	Sep 09, 2005
AB		40MG	A077321	006	Sep 09, 2005
AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002
AB		2.5MG	A076180	001	Jul 01, 2002
AB		5MG	A075743	002	Jul 01, 2002
AB		5MG	A076180	002	Jul 01, 2002
AB		10MG	A075743	003	Jul 01, 2002
AB		10MG	A076180	003	Jul 01, 2002
AB		20MG	A075743	004	Jul 01, 2002
AB		20MG	A076164	001	Jul 01, 2002
AB		30MG	A075743	005	Jul 01, 2002
AB		30MG	A076164	002	Jul 01, 2002
AB		40MG	A075743	006	Jul 01, 2002
AB		40MG	A076164	003	Jul 01, 2002
AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002
AB		5MG	A075944	002	Jul 01, 2002
AB		10MG	A075944	003	Jul 01, 2002
AB		20MG	A075944	004	Jul 01, 2002
AB		30MG	A075944	006	Feb 11, 2003
AB		40MG	A075944	005	Jul 01, 2002
AB	WATSON LABS	2.5MG	A076059	001	Jul 01, 2002
AB		5MG	A076059	002	Jul 01, 2002
AB		10MG	A076059	003	Jul 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<u>AB</u>		<u>20MG</u>	<u>A076059 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059 006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402 001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402 002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402 003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402 004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402 005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402 006</u>	Apr 19, 2007

PRINIVIL

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558 001</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558 004</u>	Oct 25, 1988

ZESTRIL

<u>AB</u>	+	ALVOGEN	<u>2.5MG</u>	<u>N019777 005</u>	Apr 29, 1993
<u>AB</u>	+		<u>5MG</u>	<u>N019777 001</u>	May 19, 1988
<u>AB</u>	+		<u>10MG</u>	<u>N019777 002</u>	May 19, 1988
<u>AB</u>	+		<u>20MG</u>	<u>N019777 003</u>	May 19, 1988
<u>AB</u>	+		<u>30MG</u>	<u>N019777 006</u>	Jan 20, 1999
<u>AB</u>	+		<u>40MG</u>	<u>N019777 004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>		ALEMBIC LTD	<u>150MG</u>	<u>A079159 001</u>	Jan 12, 2009
<u>AB</u>			<u>300MG</u>	<u>A079159 002</u>	Jan 12, 2009
<u>AB</u>			<u>600MG</u>	<u>A079159 003</u>	Jan 12, 2009
<u>AB</u>		GLENMARK GENERICS	<u>150MG</u>	<u>A079139 001</u>	Feb 03, 2009
<u>AB</u>			<u>300MG</u>	<u>A079139 002</u>	Feb 03, 2009
<u>AB</u>			<u>600MG</u>	<u>A079139 003</u>	Feb 03, 2009
<u>AB</u>		HETERO LABS LTD III	<u>150MG</u>	<u>A090702 001</u>	Sep 25, 2009
<u>AB</u>			<u>300MG</u>	<u>A090702 002</u>	Sep 25, 2009
<u>AB</u>			<u>600MG</u>	<u>A090702 003</u>	Sep 25, 2009
<u>AB</u>	+	HIKMA	<u>150MG</u>	<u>N017812 002</u>	Jan 28, 1987
<u>AB</u>	+		<u>300MG</u>	<u>N017812 001</u>	
<u>AB</u>	+		<u>600MG</u>	<u>N017812 003</u>	Jan 28, 1987
<u>AB</u>		MYLAN	<u>150MG</u>	<u>A076243 002</u>	Feb 24, 2003
<u>AB</u>			<u>300MG</u>	<u>A076243 001</u>	Jun 27, 2002

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	HIKMA	<u>300MG</u>	<u>N018558 001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027 001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>300MG</u>	<u>A204445 001</u>	Jun 10, 2015
<u>AB</u>		GLENMARK GENERICS	<u>450MG</u>	<u>A091616 001</u>	Feb 14, 2011
<u>AB</u>		GLENMARK PHARMS INC	<u>300MG</u>	<u>A091544 001</u>	Dec 27, 2010
<u>AB</u>		HERITAGE PHARMA	<u>300MG</u>	<u>A205532 001</u>	Sep 29, 2016
<u>AB</u>		HIKMA	<u>300MG</u>	<u>A076832 001</u>	Oct 28, 2004
<u>AB</u>	!		<u>450MG</u>	<u>A076691 001</u>	Jan 05, 2004
<u>AB</u>		MYLAN PHARMS INC	<u>300MG</u>	<u>A202288 001</u>	Jun 29, 2012
<u>AB</u>			<u>450MG</u>	<u>A202219 001</u>	Aug 08, 2012
<u>AB</u>		UNIQUE PHARM LABS	<u>300MG</u>	<u>A204779 001</u>	Jul 27, 2015
<u>AB</u>			<u>450MG</u>	<u>A205663 001</u>	Jun 05, 2017

LITHOBID

<u>AB</u>	+	ANI PHARMS INC	<u>300MG</u>	<u>N018027 001</u>	
-----------	---	----------------	--------------	--------------------	--

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	HIKMA	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421 001</u>	
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755 001</u>	May 21, 1986

LIXISENATIDE

SOLUTION; SUBCUTANEOUS

ADLYXIN

	+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471 001	Jul 27, 2016
	+		0.3MG/3ML (0.1MG/ML)	N208471 002	Jul 27, 2016

PRESCRIPTION DRUG PRODUCT LIST

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

+! NOVARTIS

EQ 0.1% BASE

N020191 001 Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

+! US WORLDMEDS LLC

EQ 0.18MG BASE

N209229 001 May 16, 2018

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+ AGERION

EQ 5MG BASE

N203858 001 Dec 21, 2012

+

EQ 10MG BASE

N203858 002 Dec 21, 2012

+

EQ 20MG BASE

N203858 003 Dec 21, 2012

+

EQ 30MG BASE

N203858 004 Apr 23, 2015

+

EQ 40MG BASE

N203858 005 Apr 23, 2015

+!

EQ 60MG BASE

N203858 006 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+ CORDEN PHARMA

10MG

N017588 001

+

40MG

N017588 002

+!

100MG

N017588 003

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE**AB** ! MYLAN**2MG****A072741 001** Sep 18, 1991**AB** TEVA**2MG****A073192 001** Apr 30, 1992LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRA**AA** +! ABBVIE**80MG/ML; 20MG/ML****N021251 001** Sep 15, 2000LOPINAVIR AND RITONAVIR**AA** LANNETT CO INC**80MG/ML; 20MG/ML****A207407 001** Dec 27, 2016

TABLET;ORAL

KALETRA

+ ABBVIE

100MG; 25MG

N021906 002 Nov 09, 2007

+!

200MG; 50MG

N021906 001 Oct 28, 2005

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM**AA** AMNEAL PHARMS**2MG/ML****A091383 001** Dec 23, 2009**AA** HI-TECH PHARMA CO**2MG/ML****A200169 001** Jan 30, 2012**AA** LANNETT CO INC**2MG/ML****A079244 001** Apr 28, 2009**AA** LUPIN LTD**2MG/ML****A091407 001** Feb 19, 2013**AA** PHARM ASSOC**2MG/ML****A090260 001** Jun 15, 2010LORAZEPAM INTENSOL**AA** ! HIKMA**2MG/ML****A072755 001** Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN**AP** +! HIKMA**2MG/ML****N018140 001****AP** +!**4MG/ML****N018140 002**LORAZEPAM**AP** AKORN**2MG/ML****A075025 001** Jul 23, 1998**AP** HOSPIRA**2MG/ML****A074243 001** Apr 12, 1994**AP****2MG/ML****A074282 001** May 27, 1994**AP****4MG/ML****A074243 002** Apr 12, 1994**AP****4MG/ML****A074282 002** May 27, 1994**AP** INTL MEDICATION SYS**2MG/ML****A076150 001** Nov 15, 2004

TABLET;ORAL

ATIVAN**AB** + BAUSCH**0.5MG****N017794 001****AB** +**1MG****N017794 002****AB** +!**2MG****N017794 003**LORAZEPAM**AB** AMNEAL PHARMS**0.5MG****A078826 001** Jun 23, 2010**AB****1MG****A078826 002** Jun 23, 2010**AB****2MG****A078826 003** Jun 23, 2010**AB** AUROLIFE PHARMA LLC**0.5MG****A203572 001** Dec 22, 2017

PRESCRIPTION DRUG PRODUCT LIST

LORAZEPAM

TABLET;ORAL

LORAZEPAM

<u>AB</u>		<u>1MG</u>	<u>A203572</u>	<u>002</u>	Dec 22, 2017
<u>AB</u>		<u>2MG</u>	<u>A203572</u>	<u>003</u>	Dec 22, 2017
<u>AB</u>	LEADING PHARMA LLC	<u>0.5MG</u>	<u>A078203</u>	<u>001</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>A078203</u>	<u>002</u>	Jul 30, 2007
<u>AB</u>		<u>2MG</u>	<u>A078203</u>	<u>003</u>	Jul 30, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077657</u>	<u>001</u>	Mar 16, 2006
<u>AB</u>		<u>1MG</u>	<u>A077657</u>	<u>002</u>	Mar 16, 2006
<u>AB</u>		<u>2MG</u>	<u>A077657</u>	<u>003</u>	Mar 16, 2006
<u>AB</u>	OXFORD PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071141</u>	<u>002</u>	Apr 21, 1987
<u>AB</u>		<u>1MG</u>	<u>A071141</u>	<u>003</u>	Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LORCASERIN HYDROCHLORIDE

TABLET;ORAL

BELVIQ

+! EISAI INC 10MG N022529 001 Jun 27, 2012

TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR

+! EISAI INC 20MG N208524 001 Jul 15, 2016

LORLATINIB

TABLET;ORAL

LORBRENA

+ PFIZER INC 25MG N210868 001 Nov 02, 2018

+! 100MG N210868 002 Nov 02, 2018

LOSARTAN POTASSIUM

TABLET;ORAL

COZAARAB +! MERCK SHARP DOHME 100MG N020386 003 Oct 13, 1998LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	HETERO LABS LTD V	<u>25MG</u>	<u>A203835</u>	<u>001</u>	Aug 12, 2015
<u>AB</u>		<u>50MG</u>	<u>A203835</u>	<u>002</u>	Aug 12, 2015
<u>AB</u>		<u>100MG</u>	<u>A203835</u>	<u>003</u>	Aug 12, 2015
<u>AB</u>	HIKMA	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>	MICRO LABS	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>		<u>50MG</u>	<u>A077424 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424 003</u>	Oct 06, 2010
<u>AB</u>	STRIDES PHARMA	<u>25MG</u>	<u>A090382 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382 003</u>	Oct 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467 003</u>	Oct 06, 2010
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A203030 001</u>	Oct 14, 2015
<u>AB</u>		<u>50MG</u>	<u>A203030 002</u>	Oct 14, 2015
<u>AB</u>		<u>100MG</u>	<u>A203030 003</u>	Oct 14, 2015
<u>AB</u>	UPSHER SMITH LABS	<u>25MG</u>	<u>A090544 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544 003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129 003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243 003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+! BAUSCH AND LOMB INC 0.5%

N202872 001 Sep 28, 2012

LOTEMAX SM

+! BAUSCH AND LOMB INC 0.38%

N208219 001 Feb 22, 2019

OINTMENT; OPHTHALMIC

LOTEMAX

+! BAUSCH AND LOMB 0.5%

N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAXAB +! BAUSCH AND LOMB 0.5%N020583 001 Mar 09, 1998LOTEPREDNOL ETABONATEAB HI TECH 0.5%A207609 001 Apr 17, 2019

ALREX

+! BAUSCH AND LOMB 0.2%

N020803 001 Mar 09, 1998

INVELTYS

+! KALA PHARMS INC 1%

N210565 001 Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+! BAUSCH AND LOMB 0.5%;0.3%

N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828 001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828 003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748 001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748 002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748 003</u>	Feb 28, 2007
<u>AB</u>	BEXIMCO PHARMS USA	<u>10MG</u>	<u>A075300 001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300 003</u>	Dec 17, 2001
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991 001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991 002</u>	Jun 05, 2002
<u>AB</u>	!	<u>40MG</u>	<u>A075991 003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296 001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296 002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296 003</u>	Nov 01, 2007
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075636 001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636 003</u>	Dec 17, 2001
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551 003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551 002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551 001</u>	Dec 17, 2001

PRESCRIPTION DRUG PRODUCT LIST

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

+	COVIS PHARMA BV	20MG	N021316	002	Jun 26, 2002
+		40MG	N021316	003	Jun 26, 2002
+	!	60MG	N021316	004	Jun 26, 2002

LOXAPINE

POWDER; INHALATION

ADASUVE

+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012
---	---------------	------	---------	-----	--------------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	<u>EQ 5MG BASE</u>	<u>A076868</u>	<u>001</u>	Aug 04, 2005
AB		<u>EQ 10MG BASE</u>	<u>A076868</u>	<u>002</u>	Aug 04, 2005
AB		<u>EQ 25MG BASE</u>	<u>A076868</u>	<u>003</u>	Aug 04, 2005
AB		<u>EQ 50MG BASE</u>	<u>A076868</u>	<u>004</u>	Aug 04, 2005
AB	LANNETT CO INC	<u>EQ 5MG BASE</u>	<u>A090695</u>	<u>001</u>	Sep 26, 2011
AB		<u>EQ 10MG BASE</u>	<u>A090695</u>	<u>002</u>	Sep 26, 2011
AB		<u>EQ 25MG BASE</u>	<u>A090695</u>	<u>003</u>	Sep 26, 2011
AB		<u>EQ 50MG BASE</u>	<u>A090695</u>	<u>004</u>	Sep 26, 2011
AB	MYLAN	<u>EQ 5MG BASE</u>	<u>A076762</u>	<u>001</u>	Nov 01, 2004
AB		<u>EQ 10MG BASE</u>	<u>A076762</u>	<u>002</u>	Nov 01, 2004
AB		<u>EQ 25MG BASE</u>	<u>A076762</u>	<u>003</u>	Nov 01, 2004
AB		<u>EQ 50MG BASE</u>	<u>A076762</u>	<u>004</u>	Nov 01, 2004
AB	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204</u>	<u>001</u>	Jun 15, 1988
AB		<u>EQ 10MG BASE</u>	<u>A072205</u>	<u>001</u>	Jun 15, 1988
AB	!	<u>EQ 25MG BASE</u>	<u>A072206</u>	<u>001</u>	Jun 15, 1988
AB		<u>EQ 50MG BASE</u>	<u>A072062</u>	<u>001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

+	SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008
+	!	24MCG	N021908	001	Jan 31, 2006

LULICONAZOLE

CREAM; TOPICAL

LUZU

+	MEDICIS	1%	N204153	001	Nov 14, 2013
---	---------	----	---------	-----	--------------

LUMATEPERONE TOSYLATE

CAPSULE; ORAL

CAPLYTA

+	INTRA-CELLULAR	EQ 42MG BASE	N209500	001	Dec 20, 2019
---	----------------	--------------	---------	-----	--------------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

AB	+	SUNOVION PHARMS INC	<u>20MG</u>	<u>N200603</u>	<u>003</u>	Dec 07, 2011
AB	+	!	<u>40MG</u>	<u>N200603</u>	<u>001</u>	Oct 28, 2010
AB	+		<u>60MG</u>	<u>N200603</u>	<u>005</u>	Jul 12, 2013
AB	+		<u>80MG</u>	<u>N200603</u>	<u>002</u>	Oct 28, 2010
AB	+		<u>120MG</u>	<u>N200603</u>	<u>004</u>	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	<u>20MG</u>	<u>A208049</u>	<u>001</u>	Jan 03, 2019
AB			<u>40MG</u>	<u>A208049</u>	<u>002</u>	Jan 03, 2019
AB			<u>60MG</u>	<u>A208049</u>	<u>003</u>	Jan 03, 2019
AB			<u>80MG</u>	<u>A208049</u>	<u>004</u>	Jan 03, 2019
AB			<u>120MG</u>	<u>A208049</u>	<u>005</u>	Jan 03, 2019
AB		SUN PHARM	<u>20MG</u>	<u>A208066</u>	<u>001</u>	Jan 04, 2019
AB			<u>40MG</u>	<u>A208066</u>	<u>002</u>	Jan 04, 2019
AB			<u>60MG</u>	<u>A208066</u>	<u>003</u>	Jan 04, 2019
AB			<u>80MG</u>	<u>A208066</u>	<u>004</u>	Jan 04, 2019
AB			<u>120MG</u>	<u>A208066</u>	<u>005</u>	Jan 04, 2019

LUSUTROMBOPAG

TABLET; ORAL

MULPLETA

+	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018
---	--------------	-----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

LUTETIUM DOTATATE LU-177

SOLUTION;INTRAVENOUS

LUTATHERA

+! AAA USA INC 10mCi/ML N208700 001 Jan 26, 2018

MACimorelin ACETATE

FOR SOLUTION;ORAL

MACRILEN

+! NOVO EQ 60MG BASE/POUCH N205598 001 Dec 20, 2017

MACITENTAN

TABLET;ORAL

OPSUMIT

+! ACTELION PHARMS LTD 10MG N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

+! MYLAN INSTITUTIONAL EQ 85MG BASE/GM N016763 001

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE**AT** NOVAST LABS **5%** **A206716 001** Jul 31, 2017**AT** PAR FORM **5%** **A201511 001** Feb 12, 2013SULFAMYLON**AT** +! MYLAN INSTITUTIONAL **5%** **N019832 003** Jun 05, 1998MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+! B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML N019696 001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML N019711 001 Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML N017586 001

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML N017378 001

PLASMA-LYTE A IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML N017378 002 Nov 22, 1982

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML N019024 001 Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML N017637 002 Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

+! DIALYSIS SUPS 0.21GM/100ML;2.8GM/100ML;9.07GM/100ML N021910 001 Jul 26, 2006

NORMOCARB HF 35

+! DIALYSIS SUPS 0.21GM/100ML;3.97GM/100ML;8.3GM/100ML N021910 002 Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER**AP** FRESENIUS KABI USA **1GM/100ML** **A206486 001** Mar 07, 2016**AP** +! HOSPIRA **1GM/100ML** **N020488 001** Jul 11, 1995**AP** HQ SPCLT PHARMA **1GM/100ML** **A207349 001** Mar 02, 2016**AP** MYLAN LABS LTD **1GM/100ML** **A209932 001** Sep 10, 2018MAGNESIUM SULFATE IN PLASTIC CONTAINER**AP** FRESENIUS KABI USA **4GM/100ML (40MG/ML)** **A206485 001** Mar 15, 2016**AP** **4GM/50ML (80MG/ML)** **A206485 002** Mar 15, 2016**AP** **2GM/50ML (40MG/ML)** **A206485 003** Mar 15, 2016**AP** **20GM/500ML (40MG/ML)** **A206485 004** Mar 15, 2016**AP** **40GM/1000ML (40MG/ML)** **A206485 005** Mar 15, 2016**AP** + HOSPIRA **2GM/50ML (40MG/ML)** **N020309 003** Jan 26, 2007**AP** +! **4GM/100ML (40MG/ML)** **N020309 001** Jun 24, 1994

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

<u>AP</u>	+		<u>4GM/50ML (80MG/ML)</u>	<u>N020309 002</u>	Jun 24, 1994
<u>AP</u>	+		<u>20GM/500ML (40MG/ML)</u>	<u>N020309 004</u>	Jan 18, 1995
<u>AP</u>	+		<u>40GM/1000ML (40MG/ML)</u>	<u>N020309 005</u>	Jan 18, 1995
<u>AP</u>		HQ SPCLT PHARMA	<u>2GM/50ML (40MG/ML)</u>	<u>A207350 001</u>	Dec 06, 2017
<u>AP</u>			<u>4GM/100ML (40MG/ML)</u>	<u>A207350 002</u>	Dec 06, 2017
<u>AP</u>			<u>4GM/50ML (80MG/ML)</u>	<u>A207350 003</u>	Dec 06, 2017
<u>AP</u>			<u>20GM/500ML (40MG/ML)</u>	<u>A207350 004</u>	Dec 06, 2017
<u>AP</u>			<u>40GM/1000ML (40MG/ML)</u>	<u>A207350 005</u>	Dec 06, 2017
<u>AP</u>		MYLAN LABS LTD	<u>2GM/50ML (40MG/ML)</u>	<u>A209911 001</u>	Sep 14, 2018
<u>AP</u>			<u>4GM/100ML (40MG/ML)</u>	<u>A209911 002</u>	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	!	HOSPIRA	2GM/100ML	N020488 002	Jul 11, 1995
---	---	---------	-----------	-------------	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

<u>AP</u>		EXELA PHARMA SCS LLC	<u>5GM/10ML (500MG/ML)</u>	<u>A206039 001</u>	Dec 18, 2014
<u>AP</u>	+	FRESENIUS KABI USA	<u>5GM/10ML (500MG/ML)</u>	<u>N019316 001</u>	Sep 08, 1986
<u>AP</u>	+		<u>10GM/20ML (500MG/ML)</u>	<u>N019316 003</u>	Jan 29, 2016
<u>AP</u>	!	HOSPIRA	<u>5GM/10ML (500MG/ML)</u>	<u>A075151 001</u>	Apr 25, 2000
<u>AP</u>		HOSPIRA INC	<u>10GM/20ML (500MG/ML)</u>	<u>A202411 001</u>	May 14, 2015
	+	FRESENIUS KABI USA	25GM/50ML (500MG/ML)	N019316 004	Jan 29, 2016

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316 002	Sep 08, 1986
---	---	--------------------	--------------------	-------------	--------------

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<u>AT</u>		BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018508 001</u>	Feb 19, 1982
-----------	--	-----------------	--	--------------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	<u>N018336 001</u>	
-----------	--	-----------------	--	--------------------	--

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

<u>AA</u>		NOVEL LABS INC	<u>1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT</u>	<u>A202511 001</u>	Feb 23, 2017
-----------	--	----------------	--	--------------------	--------------

SUPREP BOWEL PREP KIT

<u>AA</u>	+	BRAINTREE LABS	<u>1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT</u>	<u>N022372 001</u>	Aug 05, 2010
-----------	---	----------------	--	--------------------	--------------

MALATHION

LOTION; TOPICAL

MALATHION

!		SUVEN LIFE	0.5%	A091559 001	May 23, 2012
---	--	------------	------	-------------	--------------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962 001	Jun 26, 1986
---	---	---------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>10GM/100ML</u>	<u>N020006 002</u>	Jul 26, 1993
-----------	--	---------	-------------------	--------------------	--------------

MANNITOL 15% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>15GM/100ML</u>	<u>N020006 003</u>	Jul 26, 1993
-----------	--	---------	-------------------	--------------------	--------------

MANNITOL 20% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>20GM/100ML</u>	<u>N020006 004</u>	Jul 26, 1993
-----------	--	---------	-------------------	--------------------	--------------

<u>AP</u>		ICU MEDICAL INC	<u>20GM/100ML</u>	<u>N019603 004</u>	Jan 08, 1990
-----------	--	-----------------	-------------------	--------------------	--------------

MANNITOL 25%

<u>AP</u>		FRESENIUS KABI USA	<u>12.5GM/50ML</u>	<u>A080677 001</u>	
<u>AP</u>		HOSPIRA	<u>12.5GM/50ML</u>	<u>N016269 006</u>	Aug 25, 1994
<u>AP</u>		INTL MEDICATION	<u>12.5GM/50ML</u>	<u>A083051 001</u>	

MANNITOL 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>5GM/100ML</u>	<u>N020006 001</u>	Jul 26, 1993
-----------	--	---------	------------------	--------------------	--------------

OSMITROL 10% IN WATER

<u>AP</u>		BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684 002</u>	
-----------	--	-----------------	-------------------	--------------------	--

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N013684 006</u>	
-----------	--	-----------------	-------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

MANNITOL

INJECTABLE; INJECTION

OSMITROL 15% IN WATER

AP	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>004</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>15GM/100ML</u>	<u>N013684</u>	<u>008</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 20% IN WATER

AP	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>003</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N013684</u>	<u>007</u>
-----------	-----------------	-------------------	-----------------------	-------------------

OSMITROL 5% IN WATER

AP	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>001</u>
-----------	-----------------	------------------	-----------------------	-------------------

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N013684</u>	<u>005</u>
-----------	-----------------	------------------	-----------------------	-------------------

POWDER; INHALATION

ARIDOL KIT

+	!	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010
---	---	---------------	----------------------------	---------	-----	--------------

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML	N016772	002	
--	--	---------	-----------	---------	-----	--

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	!	ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001	
---	---	-----------------	--------------------------	---------	-----	--

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

		MYLAN	25MG	A072285	002	Oct 03, 1988
--	--	-------	------	---------	-----	--------------

	!		50MG	A072285	001	Oct 03, 1988
--	---	--	------	---------	-----	--------------

			75MG	A072285	003	Oct 03, 1988
--	--	--	------	---------	-----	--------------

MARAVIROC

SOLUTION; ORAL

SELZENTRY

+	!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016
---	---	---------------	---------	---------	-----	--------------

TABLET; ORAL

SELZENTRY

+		VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016
---	--	---------------	------	---------	-----	--------------

+			75MG	N022128	004	Nov 04, 2016
---	--	--	------	---------	-----	--------------

+			150MG	N022128	001	Aug 06, 2007
---	--	--	-------	---------	-----	--------------

+	!		300MG	N022128	002	Aug 06, 2007
---	---	--	-------	---------	-----	--------------

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

	!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995
--	---	----------------	-------	---------	-----	--------------

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

	!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013
--	---	---------------	-------	---------	-----	--------------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	!	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005
---	---	-----------	--------------------	---------	-----	--------------

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+	!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013
---	---	---------	----------------	---------	-----	--------------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	<u>12.5MG</u>	<u>N010721</u>	<u>006</u>	
-----------	---	-------------------	---------------	-----------------------	-------------------	--

AA	+		<u>25MG</u>	<u>N010721</u>	<u>004</u>	
-----------	---	--	-------------	-----------------------	-------------------	--

AA	+		<u>50MG</u>	<u>N010721</u>	<u>001</u>	Jan 20, 1982
-----------	---	--	-------------	-----------------------	-------------------	--------------

MECLIZINE HYDROCHLORIDE

AA	!	AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451</u>	<u>001</u>	Feb 23, 2011
-----------	---	---------------	---------------	-----------------------	-------------------	--------------

AA	!		<u>25MG</u>	<u>A201451</u>	<u>002</u>	Feb 23, 2011
-----------	---	--	-------------	-----------------------	-------------------	--------------

AA		AUREX	<u>12.5MG</u>	<u>A087127</u>	<u>001</u>	
-----------	--	-------	---------------	-----------------------	-------------------	--

AA			<u>25MG</u>	<u>A087128</u>	<u>001</u>	
-----------	--	--	-------------	-----------------------	-------------------	--

AA		EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294</u>	<u>001</u>	Apr 13, 2012
-----------	--	-----------------	---------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

<u>AA</u>		<u>25MG</u>	<u>A200294</u>	<u>002</u>	Apr 13, 2012
<u>AA</u>	INDICUS PHARMA	<u>12.5MG</u>	<u>A205136</u>	<u>001</u>	Feb 22, 2019
<u>AA</u>		<u>25MG</u>	<u>A205136</u>	<u>002</u>	Feb 22, 2019
<u>AA</u>	INVATECH	<u>25MG</u>	<u>A084092</u>	<u>003</u>	May 22, 1989
<u>AA</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A040659</u>	<u>002</u>	Jun 04, 2010
<u>AA</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A202640</u>	<u>001</u>	Sep 17, 2012
<u>AA</u>		<u>25MG</u>	<u>A202640</u>	<u>002</u>	Sep 17, 2012
<u>AA</u>	SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u>	May 22, 1989
<u>AA</u>	INDICUS PHARMA	50MG	A205136	003	Feb 22, 2019

TABLET, CHEWABLE;ORAL

ANTIVERT

<u>AA</u>	+	CASPER PHARMA LLC	<u>25MG</u>	<u>N010721</u>	<u>005</u>
-----------	---	-------------------	-------------	----------------	------------

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

!

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+	!	PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992
-----------	---	---	----------------------	-----------------	----------------	------------	--------------

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		AMPHASTAR PHARMS INC	<u>150MG/ML</u>	<u>A077235</u>	<u>001</u>	Nov 28, 2017
<u>AB</u>			<u>150MG/ML</u>	<u>A077334</u>	<u>001</u>	Nov 28, 2017
<u>AB</u>		MYLAN LABS LTD	<u>150MG/ML</u>	<u>A210227</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>		SUN PHARM	<u>150MG/ML</u>	<u>A210760</u>	<u>001</u>	May 01, 2019
<u>AB</u>			<u>150MG/ML</u>	<u>A210761</u>	<u>001</u>	Apr 24, 2019
<u>AB</u>		TEVA PHARMS USA	<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004

DEPO-PROVERA

+

!

PHARMACIA AND UPJOHN

400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+

!

PHARMACIA AND UPJOHN

104MG/0.65ML

N021583 001 Dec 17, 2004

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>		BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>			<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>			<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996

PROVERA

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>
-----------	---	----------------------	--------------	----------------	------------

<u>AB</u>	+		<u>5MG</u>	<u>N011839</u>	<u>003</u>
-----------	---	--	------------	----------------	------------

<u>AB</u>	+	!		<u>N011839</u>	<u>004</u>
-----------	---	---	--	----------------	------------

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

<u>AB</u>		BELCHER PHARMS LLC	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014
<u>AB</u>		LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>		MICRO LABS	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010

PONSTEL

<u>AB</u>	+	!	SHIONOGI INC	<u>250MG</u>	<u>N015034</u>	<u>003</u>
-----------	---	---	--------------	--------------	----------------	------------

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	!	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>		HIKMA	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

<u>AB</u>	+	!	ENDO PHARMS INC	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	---	---	-----------------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>		BRECKENRIDGE	<u>125MG/ML</u>	<u>A204688</u>	<u>001</u>	Dec 01, 2017
<u>AB</u>		HI TECH	<u>40MG/ML</u>	<u>A203960</u>	<u>001</u>	Jun 09, 2017

PRESCRIPTION DRUG PRODUCT LIST

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

<u>AB</u>	!	HIKMA	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>		PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>		TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>		TWI PHARMS	<u>12.5MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>		WOCKHARDT BIO AG	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>		BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>			<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>		HIKMA	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>			<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995
<u>AB</u>		PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	!		<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988

MELOXICAM

CAPSULE; ORAL

VIVLODEX

+ ZYLA

+!

5MG

10MG

N207233 001 Oct 22, 2015

N207233 002 Oct 22, 2015

TABLET; ORAL

MELOXICAM

<u>AB</u>		APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>			<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>		AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>			<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>		BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		CIPLA	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>			<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>		GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>		STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>			<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>		TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>			<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>			<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		YUNG SHIN PHARM	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>			<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>		ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>			<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+!		<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

TABLET, ORALLY DISINTEGRATING; ORAL

QMIIZ ODT

+ TERSERA THERAPS LLC

+!

7.5MG

15MG

N211210 001 Oct 19, 2018

N211210 002 Oct 19, 2018

MELPHALAN

TABLET; ORAL

ALKERAN

<u>AB</u>	+	APOTEX	<u>2MG</u>	<u>N014691</u>	<u>002</u>	
-----------	---	--------	------------	----------------	------------	--

MELPHALAN

<u>AB</u>		ALVOGEN	<u>2MG</u>	<u>A207809</u>	<u>001</u>	Mar 22, 2017
-----------	--	---------	------------	----------------	------------	--------------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	APOTEX	<u>EQ 50MG BASE/VIAL</u>	<u>N020207</u>	<u>001</u>	Nov 18, 1992
-----------	---	--------	--------------------------	----------------	------------	--------------

MELPHALAN HYDROCHLORIDE

<u>AP</u>		ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206018</u>	<u>001</u>	Dec 19, 2016
<u>AP</u>		ALVOGEN INC	<u>EQ 50MG BASE/VIAL</u>	<u>A204817</u>	<u>001</u>	May 17, 2019
<u>AP</u>		DR REDDYS LABS LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A203655</u>	<u>001</u>	Dec 08, 2017

PRESCRIPTION DRUG PRODUCT LIST

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A203393 001</u>	Dec 22, 2017
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A209826 001</u>	May 28, 2019
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270 001</u>	Jun 09, 2009
<u>AP</u>	NORATECH	<u>EQ 50MG BASE/VIAL</u>	<u>A211463 001</u>	Sep 13, 2019
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A204773 001</u>	Aug 22, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 50MG BASE/VIAL</u>	<u>A201379 001</u>	Feb 28, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A090303 001</u>	Oct 28, 2010
POWDER; INTRAVENOUS				
EVOMELA				
	+! ACROTECH	EQ 50MG BASE/VIAL	N207155 001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>7MG</u>	<u>A205825 001</u>	Oct 12, 2016
<u>AB</u>		<u>14MG</u>	<u>A205825 002</u>	Oct 12, 2016
<u>AB</u>		<u>21MG</u>	<u>A205825 003</u>	Oct 12, 2016
<u>AB</u>		<u>28MG</u>	<u>A205825 004</u>	Oct 12, 2016
<u>AB</u>	ANCHEN PHARMS	<u>7MG</u>	<u>A205784 001</u>	Jun 09, 2017
<u>AB</u>		<u>14MG</u>	<u>A205784 002</u>	Jun 09, 2017
<u>AB</u>		<u>21MG</u>	<u>A205784 003</u>	Jun 09, 2017
<u>AB</u>		<u>28MG</u>	<u>A205784 004</u>	Jun 09, 2017
<u>AB</u>	APOTEX	<u>7MG</u>	<u>A206135 001</u>	Nov 22, 2016
<u>AB</u>		<u>14MG</u>	<u>A206135 002</u>	Nov 22, 2016
<u>AB</u>		<u>21MG</u>	<u>A206135 003</u>	Nov 22, 2016
<u>AB</u>		<u>28MG</u>	<u>A206135 004</u>	Nov 22, 2016
<u>AB</u>	LUPIN LTD	<u>7MG</u>	<u>A206028 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206028 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206028 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206028 004</u>	Sep 28, 2016
<u>AB</u>	MYLAN	<u>7MG</u>	<u>A206032 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206032 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206032 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206032 004</u>	Sep 28, 2016
<u>AB</u>	SUN PHARM	<u>7MG</u>	<u>A205905 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A205905 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A205905 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A205905 004</u>	Sep 28, 2016
<u>AB</u>	ZYDUS PHARMS	<u>7MG</u>	<u>A203293 001</u>	Aug 03, 2017
<u>AB</u>		<u>14MG</u>	<u>A203293 002</u>	Aug 03, 2017
<u>AB</u>		<u>21MG</u>	<u>A203293 003</u>	Aug 03, 2017
<u>AB</u>		<u>28MG</u>	<u>A203293 004</u>	Aug 03, 2017

NAMENDA XR

<u>AB</u>	+ FOREST LABS LLC	<u>7MG</u>	<u>N022525 001</u>	Jun 21, 2010
<u>AB</u>	+	<u>14MG</u>	<u>N022525 002</u>	Jun 21, 2010
<u>AB</u>	+	<u>21MG</u>	<u>N022525 003</u>	Jun 21, 2010
<u>AB</u>	+!	<u>28MG</u>	<u>N022525 004</u>	Jun 21, 2010

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>	APOTEX	<u>2MG/ML</u>	<u>A209955 001</u>	Feb 09, 2018
<u>AA</u>	! LANNETT CO INC	<u>2MG/ML</u>	<u>A204033 001</u>	Oct 13, 2015
<u>AA</u>	MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790 001</u>	Oct 13, 2015

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528 001</u>	Nov 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A206528 002</u>	Nov 30, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A200891 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200891 002</u>	Oct 13, 2015
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A090041 001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090041 002</u>	Apr 10, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A203175 002</u>	Oct 13, 2015
<u>AB</u>	CADILA	<u>5MG</u>	<u>A090961 001</u>	Jul 10, 2017
<u>AB</u>		<u>10MG</u>	<u>A090961 002</u>	Jul 10, 2017
<u>AB</u>	CELLTRION	<u>5MG</u>	<u>A090073 001</u>	Sep 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A090073 002</u>	Sep 04, 2015
<u>AB</u>	CSPC OUYI	<u>5MG</u>	<u>A209527 001</u>	May 07, 2018

PRESCRIPTION DRUG PRODUCT LIST

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A209527</u>	<u>002</u>	May 07, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048</u>	<u>001</u>	Apr 14, 2010
<u>AB</u>		<u>10MG</u>	<u>A090048</u>	<u>002</u>	Apr 14, 2010
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A091585</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A091585</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	LANNETT CO INC	<u>5MG</u>	<u>A207236</u>	<u>001</u>	Nov 10, 2016
<u>AB</u>		<u>10MG</u>	<u>A207236</u>	<u>002</u>	Nov 10, 2016
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A090051</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090051</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A202840</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	PURACAP PHARM LLC	<u>5MG</u>	<u>A206855</u>	<u>001</u>	Nov 17, 2015
<u>AB</u>		<u>10MG</u>	<u>A206855</u>	<u>002</u>	Nov 17, 2015
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202350</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202350</u>	<u>002</u>	May 23, 2017
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A090058</u>	<u>001</u>	May 05, 2010
<u>AB</u>		<u>10MG</u>	<u>A090058</u>	<u>002</u>	May 05, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090052</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090052</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>	TORRENT	<u>5MG</u>	<u>A200155</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200155</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A200022</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200022</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A090043</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>		<u>10MG</u>	<u>A090043</u>	<u>002</u>	Jul 31, 2015

NAMENDA

<u>AB</u>	+ ALLERGAN	<u>5MG</u>	<u>N021487</u>	<u>001</u>	Oct 16, 2003
<u>AB</u>	+!	<u>10MG</u>	<u>N021487</u>	<u>002</u>	Oct 16, 2003

MENOTROPINS (FSH; LH)

INJECTABLE; SUBCUTANEOUS

MENOPUR

+!	FERRING	75 IU/VIAL; 75 IU/VIAL	N021663	001	Oct 29, 2004
----	---------	------------------------	---------	-----	--------------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+!	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>
<u>AP</u>	+!		<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>
<u>AP</u>	+!		<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>
<u>AP</u>	+!		<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		WEST-WARD PHARMS INT	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>
<u>AP</u>			<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>
<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>
<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>
<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>
<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>
<u>AP</u>			<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>
<u>AP</u>			<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

!	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993
---	-------------------------	---------	---------	-----	--------------

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

!	HIKMA	50MG/5ML	A088744	001	Jan 30, 1985
---	-------	----------	---------	-----	--------------

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

<u>AA</u>		EPIC PHARMA	<u>50MG</u>	<u>A040331</u>	<u>001</u>	May 28, 1999
<u>AA</u>			<u>100MG</u>	<u>A040331</u>	<u>002</u>	May 28, 1999
<u>AA</u>	!	HIKMA	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>	!		<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>		VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>			<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998

PRESCRIPTION DRUG PRODUCT LIST

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	<u>+</u> !	HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	<u>+</u> !		<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	<u>+</u> !		<u>2%</u>	<u>N012250</u>	<u>002</u>	

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	<u>!</u>	DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984
-----------	----------	---------	-----------	----------------	------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>		ALEM BIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>			<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	<u>!</u>	WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	<u>!</u>		<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

<u>+</u> !	NOVA LABS LTD	20MG/ML		N205919	001	Apr 28, 2014
------------	---------------	---------	--	---------	-----	--------------

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>		DR REDDYS LABS SA	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	<u>!</u>	HIKMA	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005

PURINETHOL

<u>AB</u>	<u>+</u>	STASON PHARMS	<u>50MG</u>	<u>N009053</u>	<u>002</u>	
-----------	----------	---------------	-------------	----------------	------------	--

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>			<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>		ACS DOBFAR SPA	<u>500MG/VIAL</u>	<u>A204139</u>	<u>001</u>	Jun 09, 2016
<u>AP</u>			<u>1GM/VIAL</u>	<u>A204139</u>	<u>002</u>	Jun 09, 2016
<u>AP</u>		AMNEAL PHARMS	<u>500MG/VIAL</u>	<u>A205883</u>	<u>001</u>	Apr 12, 2016
<u>AP</u>			<u>1GM/VIAL</u>	<u>A205883</u>	<u>002</u>	Apr 12, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>500MG/VIAL</u>	<u>A205835</u>	<u>001</u>	Mar 27, 2017
<u>AP</u>			<u>1GM/VIAL</u>	<u>A205835</u>	<u>002</u>	Mar 27, 2017
<u>AP</u>		DAEWOOONG PHARM CO	<u>500MG/VIAL</u>	<u>A204854</u>	<u>001</u>	Dec 18, 2015
<u>AP</u>			<u>1GM/VIAL</u>	<u>A204854</u>	<u>002</u>	Dec 18, 2015
<u>AP</u>		GLAND PHARMA LTD	<u>500MG/VIAL</u>	<u>A206141</u>	<u>001</u>	Jun 08, 2016
<u>AP</u>			<u>1GM/VIAL</u>	<u>A206141</u>	<u>002</u>	Jun 08, 2016
<u>AP</u>		HQ SPCLT PHARMA	<u>500MG/VIAL</u>	<u>A210773</u>	<u>001</u>	Aug 16, 2019
<u>AP</u>			<u>1GM/VIAL</u>	<u>A210773</u>	<u>002</u>	Aug 16, 2019
<u>AP</u>		SAVIOR LIFETEC CORP	<u>500MG/VIAL</u>	<u>A206086</u>	<u>001</u>	Apr 19, 2016
<u>AP</u>			<u>1GM/VIAL</u>	<u>A206086</u>	<u>002</u>	Apr 19, 2016

MERREM

<u>AP</u>	<u>+</u> !	PFIZER	<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996
<u>AP</u>	<u>+</u> !		<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996

POWDER; INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	B BRAUN MEDICAL INC	500MG/VIAL		N202106	001	Apr 30, 2015
		1GM/VIAL		N202106	002	Apr 30, 2015

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

<u>+</u> !	REMPLEX PHARMS	1GM/VIAL; 1GM/VIAL		N209776	001	Aug 29, 2017
------------	----------------	--------------------	--	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

AB	+ !	APIL	400MG	N204412	001	Feb 01, 2013
-----------	------------	------	--------------	----------------	------------	--------------

MESALAMINE

AB		TEVA PHARMS USA	400MG	A207873	001	May 09, 2019
-----------	--	-----------------	--------------	----------------	------------	--------------

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

AB	+ !	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008
-----------	------------	---------------------	--------------	----------------	------------	--------------

MESALAMINE

AB		MYLAN	375MG	A207271	001	Nov 20, 2019
-----------	--	-------	--------------	----------------	------------	--------------

PENTASA

	+	SHIRE	250MG	N020049	001	May 10, 1993
	+ !		500MG	N020049	002	Jul 08, 2004

ENEMA;RECTAL

MESALAMINE

AB		PERRIGO ISRAEL	4GM/60ML	A076751	001	Sep 17, 2004
-----------	--	----------------	-----------------	----------------	------------	--------------

ROWASA

AB	+ !	MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987
-----------	------------	---------------------	-----------------	----------------	------------	--------------

SFROWASA

AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008
-----------	----------	---------------------	-----------------	----------------	------------	--------------

SUPPOSITORY;RECTAL

CANASA

AB	+ !	ALLERGAN	1GM	N021252	002	Nov 05, 2004
-----------	------------	----------	------------	----------------	------------	--------------

MESALAMINE

AB		AMNEAL PHARMS LLC	1GM	A210509	001	Jan 02, 2020
AB		AMRING PHARMS	1GM	A208362	001	Jun 21, 2019
AB		MYLAN	1GM	A204354	001	Nov 24, 2015
AB		PHARM SOURCING	1GM	A207448	001	Apr 19, 2019
AB		SANDOZ INC	1GM	A202065	001	Jun 12, 2019

TABLET, DELAYED RELEASE;ORAL

ASACOL HD

AB	+ !	APIL	800MG	N021830	001	May 29, 2008
-----------	------------	------	--------------	----------------	------------	--------------

LIALDA

AB	+ !	SHIRE	1.2GM	N022000	001	Jan 16, 2007
-----------	------------	-------	--------------	----------------	------------	--------------

MESALAMINE

AB		ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018
AB		MYLAN	1.2GM	A203574	001	Nov 20, 2018
AB		SUN PHARM	1.2GM	A211858	001	Jan 25, 2019
AB		ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017
AB			1.2GM	A091640	001	Jun 05, 2017

MESNA

INJECTABLE;INTRAVENOUS

MESNA

AP		FRESENIUS KABI USA	100MG/ML	A075811	001	Apr 26, 2001
AP		GLAND PHARMA LTD	100MG/ML	A206992	001	Dec 18, 2017
AP		SAGENT PHARMS INC	100MG/ML	A090913	001	Apr 13, 2010
AP		TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001
AP		WEST-WARD PHARMS	100MG/ML	A075739	001	Jan 09, 2004

INT

MESNEX

AP	+ !	BAXTER HLTHCARE	100MG/ML	N019884	001	Dec 30, 1988
-----------	------------	-----------------	-----------------	----------------	------------	--------------

TABLET;ORAL

MESNEX

	+ !	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002
--	------------	-----------------	-------	---------	-----	--------------

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

!	LANNETT CO INC	10MG/5ML	A073632	001	Jul 22, 1992
---	----------------	----------	---------	-----	--------------

METAXALONE

TABLET;ORAL

METAXALONE

AB		ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017
AB		AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013
AB		APPCO	800MG	A208774	001	Sep 24, 2018
AB		LANNETT CO INC	800MG	A204770	001	Nov 22, 2016
AB		SANDOZ	800MG	A040445	001	Mar 31, 2010
AB		SCIEGEN PHARMS INC	800MG	A207466	001	Aug 31, 2017

SKELAXIN

AB	+ !	KING PHARMS	800MG	N013217	003	Aug 30, 2002
-----------	------------	-------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METAXALONE

TABLET;ORAL

METAXALONE

MOUNTAIN 400MG A040486 001 Feb 27, 2015

METFORMIN HYDROCHLORIDE

FOR SUSPENSION, EXTENDED RELEASE;ORAL

RIOMET ER

+! SUN PHARM 500MG/5ML N212595 001 Aug 29, 2019

SOLUTION;ORAL

RIOMET

+! SUN PHARM INDS LTD 500MG/5ML N021591 001 Sep 11, 2003

TABLET;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	ALKEM	<u>500MG</u>	<u>A091184 001</u>	Nov 01, 2010
<u>AB</u>		<u>850MG</u>	<u>A091184 002</u>	Nov 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A091184 003</u>	Nov 01, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A077880 001</u>	Jun 05, 2006
<u>AB</u>		<u>850MG</u>	<u>A077880 002</u>	Jun 05, 2006
<u>AB</u>		<u>1GM</u>	<u>A077880 003</u>	Jun 05, 2006
<u>AB</u>	APOTEX	<u>500MG</u>	<u>A075984 001</u>	Apr 23, 2002
<u>AB</u>		<u>500MG</u>	<u>A090666 001</u>	Dec 07, 2011
<u>AB</u>		<u>850MG</u>	<u>A075984 002</u>	Apr 23, 2002
<u>AB</u>		<u>850MG</u>	<u>A090666 002</u>	Dec 07, 2011
<u>AB</u>		<u>1GM</u>	<u>A075984 003</u>	Apr 23, 2002
<u>AB</u>		<u>1GM</u>	<u>A090666 003</u>	Dec 07, 2011
<u>AB</u>	ATLAS PHARMS LLC	<u>500MG</u>	<u>A076033 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A076033 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A076033 003</u>	Jan 24, 2002
<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A077095 001</u>	Jan 14, 2005
<u>AB</u>		<u>850MG</u>	<u>A077095 002</u>	Jan 14, 2005
<u>AB</u>		<u>1GM</u>	<u>A077095 003</u>	Jan 14, 2005
<u>AB</u>	CHARTWELL LIFE SCI	<u>500MG</u>	<u>A075972 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075972 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075972 003</u>	Jan 24, 2002
<u>AB</u>	CSPC OUYI	<u>500MG</u>	<u>A205096 001</u>	Jul 11, 2016
<u>AB</u>		<u>850MG</u>	<u>A205096 002</u>	Jul 11, 2016
<u>AB</u>		<u>1GM</u>	<u>A205096 003</u>	Jul 11, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787 001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787 002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787 003</u>	Aug 23, 2006
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170 001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170 002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170 003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564 001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564 002</u>	Apr 22, 2010
<u>AB</u>	!	<u>1GM</u>	<u>A090564 003</u>	Apr 22, 2010
<u>AB</u>	HERITAGE PHARMA	<u>500MG</u>	<u>A075978 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978 002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978 003</u>	Nov 05, 2002
<u>AB</u>	INDICUS PHARMA	<u>500MG</u>	<u>A079148 001</u>	Nov 25, 2008
<u>AB</u>		<u>850MG</u>	<u>A079148 002</u>	Nov 25, 2008
<u>AB</u>		<u>1GM</u>	<u>A079148 003</u>	Nov 25, 2008
<u>AB</u>	LAURUS LABS LTD	<u>500MG</u>	<u>A209882 001</u>	Aug 27, 2018
<u>AB</u>		<u>850MG</u>	<u>A209882 002</u>	Aug 27, 2018
<u>AB</u>		<u>1GM</u>	<u>A209882 003</u>	Aug 27, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A205330 001</u>	Oct 31, 2017
<u>AB</u>		<u>850MG</u>	<u>A205330 002</u>	Oct 31, 2017
<u>AB</u>		<u>1GM</u>	<u>A205330 003</u>	Oct 31, 2017
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888 001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888 002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888 003</u>	Mar 12, 2012
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973 001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075976 001</u>	Jan 24, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973 002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075976 002</u>	Jan 24, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973 003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075976 003</u>	Jan 24, 2002
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965 002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965 003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769 001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769 002</u>	Sep 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ALKEM LABS LTD	<u>750MG</u>	<u>A206145</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	! AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	BEXIMCO PHARMS USA	<u>750MG</u>	<u>A207427</u>	<u>002</u>	Dec 13, 2016
<u>AB</u>	CADILA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	CSPC OUYI	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	GRANULES INDIA LTD	<u>750MG</u>	<u>A209313</u>	<u>002</u>	Mar 16, 2018
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>750MG</u>	<u>A202306</u>	<u>002</u>	Feb 23, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>750MG</u>	<u>A206955</u>	<u>002</u>	Dec 07, 2016
<u>AB</u>	MARKSANS PHARMA	<u>750MG</u>	<u>A090295</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	PRINSTON INC	<u>750MG</u>	<u>A208880</u>	<u>002</u>	Sep 10, 2018
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB1</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>	ALIGNSCIENCE PHARMA	<u>500MG</u>	<u>A209303</u>	<u>001</u>	Mar 19, 2018
<u>AB1</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A206145</u>	<u>001</u>	Oct 22, 2018
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A207427</u>	<u>001</u>	Dec 13, 2016
<u>AB1</u>	CADILA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005
<u>AB1</u>	CSPC OUYI	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	GRANULES INDIA LTD	<u>500MG</u>	<u>A209313</u>	<u>001</u>	Mar 16, 2018
<u>AB1</u>	INTELLIPHARMACEUTIC S	<u>500MG</u>	<u>A202306</u>	<u>001</u>	Feb 23, 2017
<u>AB1</u>	INVENTIA	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A206955</u>	<u>001</u>	Dec 07, 2016
<u>AB1</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090295</u>	<u>001</u>	Apr 29, 2016
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	PRINSTON INC	<u>500MG</u>	<u>A208880</u>	<u>001</u>	Sep 10, 2018
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB2</u>	LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	!	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB2</u>		<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB2</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A203832</u>	<u>001</u>	Dec 26, 2017
<u>AB2</u>		<u>1GM</u>	<u>A203832</u>	<u>002</u>	Dec 26, 2017
<u>AB2</u>	NOVAST LABS	<u>500MG</u>	<u>A209674</u>	<u>001</u>	Nov 02, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209674</u>	<u>002</u>	Nov 02, 2018
<u>AB2</u>	QINGDAO BAHEAL PHARM	<u>500MG</u>	<u>A209993</u>	<u>001</u>	Dec 27, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209993</u>	<u>002</u>	Dec 27, 2018

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GLUMETZA

<u>AB3</u>	+	SANTARUS INC	<u>500MG</u>	<u>N021748</u>	<u>001</u>	Jun 03, 2005
<u>AB3</u>	+	!	<u>1GM</u>	<u>N021748</u>	<u>002</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A203755</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>			<u>1GM</u>	<u>A203755</u>	<u>002</u>	Aug 01, 2016
<u>AB3</u>		GLENMARK PHARMS LTD	<u>500MG</u>	<u>A212969</u>	<u>001</u>	Nov 25, 2019
<u>AB3</u>			<u>1GM</u>	<u>A212969</u>	<u>002</u>	Nov 25, 2019
<u>AB3</u>		LUPIN LTD	<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013
<u>AB3</u>			<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>		SUN PHARM	<u>500MG</u>	<u>A202917</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>			<u>1GM</u>	<u>A202917</u>	<u>002</u>	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

<u>AB</u>	+	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+	!	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>001</u>	Nov 05, 2015
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>002</u>	Nov 05, 2015
<u>AB</u>		SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
<u>AB</u>		TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>850MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>002</u>	Feb 13, 2013

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

	+	ASTRAZENECA AB	<u>500MG;EQ 5MG BASE</u>	<u>N200678</u>	<u>001</u>	Nov 05, 2010
	+		<u>1GM;EQ 2.5MG BASE</u>	<u>N200678</u>	<u>003</u>	Nov 05, 2010
	+	!	<u>1GM;EQ 5MG BASE</u>	<u>N200678</u>	<u>002</u>	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

	+	MERCK SHARP DOHME	<u>500MG;EQ 50MG BASE</u>	<u>N022044</u>	<u>001</u>	Mar 30, 2007
	+	!	<u>1GM;EQ 50MG BASE</u>	<u>N022044</u>	<u>002</u>	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

	+	MERCK SHARP DOHME	<u>500MG;EQ 50MG BASE</u>	<u>N202270</u>	<u>001</u>	Feb 02, 2012
	+		<u>1GM;EQ 50MG BASE</u>	<u>N202270</u>	<u>002</u>	Feb 02, 2012
	+	!	<u>1GM;EQ 100MG BASE</u>	<u>N202270</u>	<u>003</u>	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

	+	METHAPHARM	<u>100MG/VIAL</u>	<u>N019193</u>	<u>001</u>	Oct 31, 1986
--	---	------------	-------------------	----------------	------------	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>		HIKMA	<u>10MG/ML</u>	<u>A040180</u>	<u>001</u>	Apr 30, 1998
<u>AA</u>		PHARM ASSOC	<u>10MG/ML</u>	<u>A207368</u>	<u>001</u>	Aug 22, 2019
<u>AA</u>		VISTAPHARM	<u>10MG/ML</u>	<u>A040088</u>	<u>001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>		HIKMA	<u>10MG/ML</u>	<u>A089897</u>	<u>001</u>	Sep 06, 1988
-----------	--	-------	----------------	----------------	------------	--------------

METHADOSE

<u>AA</u>	+	!	SPECGX LLC	<u>10MG/ML</u>	<u>N017116</u>	<u>002</u>
-----------	---	---	------------	----------------	----------------	------------

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>10MG/ML</u>	<u>A208306</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	+	!	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>N021624</u>	<u>001</u>

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	!	HIKMA	<u>5MG/5ML</u>	<u>A087393</u>	<u>001</u>	
<u>AA</u>	!		<u>10MG/5ML</u>	<u>A087997</u>	<u>001</u>	Aug 30, 1982
<u>AA</u>		PHARM ASSOC	<u>5MG/5ML</u>	<u>A207537</u>	<u>001</u>	Oct 02, 2019

PRESCRIPTION DRUG PRODUCT LIST

METHADONE HYDROCHLORIDE

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>		<u>10MG/5ML</u>	<u>A207537 002</u>	Oct 01, 2019
<u>AA</u>	VISTAPHARM	<u>5MG/5ML</u>	<u>A090707 001</u>	Jun 30, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A090707 002</u>	Jun 30, 2010

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+!	HIKMA	<u>5MG</u>	<u>N006134 002</u>
<u>AA</u>	+!		<u>10MG</u>	<u>N006134 010</u>

METHADONE HYDROCHLORIDE

<u>AA</u>		ASCENT PHARMS INC	<u>5MG</u>	<u>A211228 001</u>	Jan 03, 2019
<u>AA</u>			<u>10MG</u>	<u>A211228 002</u>	Jan 03, 2019
<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502 001</u>	Aug 31, 2015
<u>AA</u>			<u>10MG</u>	<u>A203502 002</u>	Aug 31, 2015
<u>AA</u>		ELITE LABS INC	<u>5MG</u>	<u>A210484 001</u>	Aug 02, 2018
<u>AA</u>			<u>10MG</u>	<u>A210484 002</u>	Aug 02, 2018
<u>AA</u>		EPIC PHARMA LLC	<u>5MG</u>	<u>A090065 001</u>	Aug 18, 2015
<u>AA</u>			<u>10MG</u>	<u>A090065 002</u>	Aug 18, 2015
<u>AA</u>		SPECGX LLC	<u>5MG</u>	<u>A040517 001</u>	Apr 27, 2004
<u>AA</u>			<u>10MG</u>	<u>A040517 002</u>	Apr 27, 2004
<u>AA</u>		SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A208305 001</u>	Mar 30, 2018
<u>AA</u>			<u>10MG</u>	<u>A208305 002</u>	Mar 30, 2018
<u>AA</u>		THEPHARMANETWORK LLC	<u>10MG</u>	<u>A090635 001</u>	Nov 25, 2009
<u>AA</u>		VISTAPHARM	<u>10MG</u>	<u>A040241 002</u>	May 29, 1998

METHADOSE

<u>AA</u>		SPECGX LLC	<u>5MG</u>	<u>A040050 001</u>	Apr 15, 1993
<u>AA</u>			<u>10MG</u>	<u>A040050 002</u>	Apr 15, 1993

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+!	HIKMA	<u>40MG</u>	<u>N017058 001</u>	
<u>AA</u>		SPECGX LLC	<u>40MG</u>	<u>A077142 001</u>	Jul 12, 2005
<u>AA</u>		VISTAPHARM	<u>40MG</u>	<u>A075082 001</u>	Mar 25, 1998

METHADOSE

<u>AA</u>		SPECGX LLC	<u>40MG</u>	<u>A074184 001</u>	Apr 29, 1993
-----------	--	------------	-------------	--------------------	--------------

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

<u>AA</u>	+!	RECORDATI RARE	<u>5MG</u>	<u>N005378 002</u>
-----------	----	----------------	------------	--------------------

METHAMPHETAMINE HYDROCHLORIDE

<u>AA</u>		HIKMA	<u>5MG</u>	<u>A203846 001</u>	Nov 17, 2015
<u>AA</u>		MAYNE PHARMA INC	<u>5MG</u>	<u>A091189 001</u>	Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

<u>AB</u>		ANI PHARMS INC	<u>25MG</u>	<u>A040001 001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040001 002</u>	Jun 30, 1993
<u>AB</u>		MIKART	<u>25MG</u>	<u>A040062 001</u>	Jan 27, 1994
<u>AB</u>	!		<u>50MG</u>	<u>A040062 002</u>	Jan 27, 1994
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A040036 001</u>	Jun 30, 1993
<u>AB</u>			<u>50MG</u>	<u>A040036 002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

<u>AB</u>	+!	US PHARM HOLDINGS	<u>1GM</u>	<u>N017681 001</u>
-----------	----	-------------------	------------	--------------------

METHENAMINE HIPPURATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>1GM</u>	<u>A205661 001</u>	Jul 05, 2016
<u>AB</u>		IMPAX LABS INC	<u>1GM</u>	<u>A076411 001</u>	Jun 20, 2003
<u>AB</u>		MICRO LABS	<u>1GM</u>	<u>A212172 001</u>	Aug 01, 2019

UREX

<u>AB</u>		CNTY LINE PHARMS	<u>1GM</u>	<u>N016151 001</u>
-----------	--	------------------	------------	--------------------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

<u>AB</u>		CASI PHARMS INC	<u>5MG</u>	<u>A040411 001</u>	Mar 27, 2001
<u>AB</u>			<u>10MG</u>	<u>A040411 002</u>	Mar 27, 2001
<u>AB</u>		ECI PHARMS LLC	<u>5MG</u>	<u>A040547 001</u>	Feb 18, 2005
<u>AB</u>			<u>10MG</u>	<u>A040547 002</u>	Feb 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A040734 001</u>	Dec 14, 2007
<u>AB</u>		<u>10MG</u>	<u>A040734 002</u>	Dec 14, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A040350 001</u>	Mar 29, 2000
<u>AB</u>	!	<u>10MG</u>	<u>A040350 002</u>	Mar 29, 2000
<u>AB</u>	RISING	<u>5MG</u>	<u>A202068 001</u>	Mar 07, 2012
<u>AB</u>		<u>10MG</u>	<u>A202068 002</u>	Mar 07, 2012

TAPAZOLE

<u>AB</u>	KING PHARMS LLC	<u>5MG</u>	<u>A040320 001</u>	Mar 31, 2000
<u>AB</u>		<u>10MG</u>	<u>A040320 002</u>	Mar 31, 2000

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

<u>AP</u>	AM REGENT	<u>1GM/10ML (100MG/ML)</u>	<u>A207496 001</u>	Jun 22, 2017
<u>AP</u>	AUROBINDO PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A206128 001</u>	May 27, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>1GM/10ML (100MG/ML)</u>	<u>A209331 001</u>	Apr 17, 2018
<u>AP</u>	GLAND PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A211504 001</u>	Oct 26, 2018
<u>AP</u>	MONTEREY PHARMS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A205354 001</u>	Oct 27, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404 001</u>	Dec 05, 2014
<u>AP</u>	NAVINTA LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A206071 001</u>	Nov 24, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>1GM/10ML (100MG/ML)</u>	<u>A205404 001</u>	Jul 18, 2017
<u>AP</u>	SLATE	<u>1GM/10ML (100MG/ML)</u>	<u>A208116 001</u>	Jan 19, 2017
<u>AP</u>	SOMERSET THERAPS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A207522 001</u>	Jul 31, 2017

ROBAXIN

<u>AP</u>	+!	HIKMA	<u>1GM/10ML (100MG/ML)</u>	<u>N011790 001</u>
-----------	----	-------	----------------------------	--------------------

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958 001</u>	Oct 21, 2011	
<u>AA</u>		<u>750MG</u>	<u>A200958 002</u>	Oct 21, 2011	
<u>AA</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A208507 001</u>	Jul 21, 2017	
<u>AA</u>		<u>750MG</u>	<u>A208507 002</u>	Jul 21, 2017	
<u>AA</u>	DBL PHARMS	<u>500MG</u>	<u>A203550 001</u>	Feb 08, 2017	
<u>AA</u>		<u>750MG</u>	<u>A203550 002</u>	Feb 08, 2017	
<u>AA</u>	!	GRANULES INDIA LTD	<u>500MG</u>	<u>A209312 001</u>	May 07, 2018
<u>AA</u>		<u>750MG</u>	<u>A209312 002</u>	May 07, 2018	
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200 001</u>	Nov 06, 2009	
<u>AA</u>		<u>750MG</u>	<u>A090200 002</u>	Nov 06, 2009	
<u>AA</u>	HIKMA INTL PHARMS	<u>500MG</u>	<u>A085159 001</u>		
<u>AA</u>		<u>750MG</u>	<u>A085123 001</u>		
<u>AA</u>	OXFORD PHARMS	<u>500MG</u>	<u>A040489 001</u>	Jan 29, 2003	
<u>AA</u>		<u>750MG</u>	<u>A040489 002</u>	Jan 29, 2003	
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989 001</u>		
<u>AA</u>		<u>750MG</u>	<u>A086988 001</u>		

ROBAXIN-750

<u>AA</u>	+!	AUXILIUM PHARMS LLC	<u>750MG</u>	<u>N011011 006</u>
-----------	----	---------------------	--------------	--------------------

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+!	PAR STERILE PRODUCTS	500MG/VIAL	N011559 001
+!		2.5GM/VIAL	N011559 002

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

+!	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824 001	Oct 11, 2013
+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824 006	Mar 24, 2016
+!		15MG/0.4ML (15MG/0.4ML)	N204824 002	Oct 11, 2013
+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824 007	Mar 24, 2016
+!		20MG/0.4ML (20MG/0.4ML)	N204824 003	Oct 11, 2013
+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824 008	Mar 24, 2016
+!		25MG/0.4ML (25MG/0.4ML)	N204824 004	Oct 11, 2013

RASUVO

+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776 001	Jul 10, 2014
+!		10MG/0.20ML (10MG/0.20ML)	N205776 002	Jul 10, 2014
+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776 003	Jul 10, 2014
+!		15MG/0.30ML (15MG/0.30ML)	N205776 004	Jul 10, 2014
+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776 005	Jul 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE

SOLUTION;SUBCUTANEOUS

RASUVO

+	!	20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
+	!	22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
+	!	25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
+	!	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

REDITREX

CUMBERLAND PHARMS

7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019
25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	!	FRESENIUS KABI USA	<u>EQ 25MG BASE/ML</u>	<u>A040265</u>	<u>001</u>	Feb 26, 1999
AP	!		<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999

METHOTREXATE SODIUM

AP	!	FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
AP	+	HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004
AP	!	WEST-WARD PHARMS INT	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	!	ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
AP	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
AP	!		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
AP	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
AP		MYLAN LABS LTD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>001</u>	Mar 29, 2012
AP			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>002</u>	Mar 29, 2012
AP			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>003</u>	Mar 29, 2012
AP			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
AP			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
AP		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>002</u>	Jan 11, 2010
AP			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>003</u>	Feb 27, 2012
AP			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>004</u>	Jan 11, 2010
AP			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
AP		SAGENT PHARMS INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>001</u>	Aug 09, 2018
AP			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>002</u>	Aug 09, 2018
AP			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>003</u>	Aug 09, 2018
AP		SANDOZ INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
AP			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
AP			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
AP	!	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
AP	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986

METHOTREXATE SODIUM

!	!	WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
---	---	-------------------------	-------------------------------------	---------	-----	--------------

METHOTREXATE SODIUM PRESERVATIVE FREE

!	!	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
---	---	-------------------------	------------------	---------	-----	--------------

SOLUTION;ORAL

XATMEP

+	!	SILVERGATE PHARMS	EQ 2MG BASE/ML	N208400	001	Apr 25, 2017
---	---	-------------------	----------------	---------	-----	--------------

TABLET;ORAL

METHOTREXATE SODIUM

AB		AMNEAL PHARMS	<u>EQ 2.5MG BASE</u>	<u>A210040</u>	<u>001</u>	Dec 22, 2017
AB		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
AB	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
AB		HIKMA	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
AB		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
AB		SUN PHARM	<u>EQ 2.5MG BASE</u>	<u>A201749</u>	<u>001</u>	May 21, 2015
AB		ZYDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207812</u>	<u>001</u>	Jan 13, 2017

TREXALL

		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001

PRESCRIPTION DRUG PRODUCT LIST

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

AB	ACTAVIS INC	10MG	A202603 001	Jun 09, 2015
AB	STRIDES PHARMA	10MG	A202687 001	Jun 05, 2014
<u>OXSORALEN-ULTRA</u>				
AB	+ ! BAUSCH	10MG	N019600 001	Oct 30, 1986
INJECTABLE; INJECTION				
UVADEX				
	+ ! MALLINCKRODT HOSP	0.02MG/ML	N020969 001	Feb 25, 1999

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012
!		5MG	A200602 002	Sep 24, 2012

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+ !	PARKE DAVIS	300MG	N010596 008	
------------	-------------	-------	-------------	--

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB	ACCORD HLTHCARE	250MG	A070084 001	Oct 15, 1985
AB		500MG	A070085 001	Oct 15, 1985
AB	HERITAGE PHARMA	250MG	A070098 001	Feb 20, 1986
AB		500MG	A070343 001	Feb 20, 1986
AB	MYLAN	250MG	A070076 002	Apr 18, 1985
AB	!	500MG	A070076 001	Apr 18, 1985
AB	WATSON LABS	500MG	A070625 001	Jun 06, 1986

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+ !	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630 001	Apr 08, 2016
------------	----------------	--------------------	-------------	--------------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+ ! EDISON THERAPS LLC	0.2MG/ML	N006035 004	
-----------	-------------------------------	-----------------	--------------------	--

METHYLERGONOVINE MALEATE

AP	BRECKENRIDGE	0.2MG/ML	A040889 001	Sep 13, 2010
AP	LUITPOLD	0.2MG/ML	A090193 001	Nov 24, 2008

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	AMNEAL PHARMS	0.2MG	A211483 001	Sep 10, 2018
AB	GRANULES PHARMS	0.2MG	A210424 001	May 15, 2018
AB	!	NOVEL LABS INC	A091577 001	May 02, 2011
AB	TEVA PHARMS USA	0.2MG	A211455 001	Mar 20, 2019

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

+ !	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964 002	Sep 27, 2010
+ !		12MG/0.6ML (12MG/0.6ML)	N021964 001	Apr 24, 2008
+ !		12MG/0.6ML (12MG/0.6ML)	N021964 003	Sep 27, 2010

TABLET; ORAL

RELISTOR

+ !	SALIX	150MG	N208271 001	Jul 19, 2016
------------	-------	-------	-------------	--------------

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514 001	Apr 06, 2006
+		15MG/9HR (1.6MG/HR)	N021514 002	Apr 06, 2006
+		20MG/9HR (2.2MG/HR)	N021514 003	Apr 06, 2006
+ !		30MG/9HR (3.3MG/HR)	N021514 004	Apr 06, 2006

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489 001	Jun 19, 2017
+		17.3MG	N205489 002	Jun 19, 2017
+		25.9MG	N205489 003	Jun 19, 2017

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB1</u>	BARR LABS INC	<u>10MG</u>	<u>A079031 004</u>	Oct 15, 2014
<u>AB1</u>		<u>20MG</u>	<u>A079031 001</u>	Jul 13, 2012
<u>AB1</u>		<u>30MG</u>	<u>A079031 002</u>	Jul 13, 2012
<u>AB1</u>		<u>40MG</u>	<u>A079031 003</u>	Jul 13, 2012
<u>AB1</u>	GRANULES PHARMS	<u>10MG</u>	<u>A211796 001</u>	May 23, 2019
<u>AB1</u>		<u>20MG</u>	<u>A211796 002</u>	May 23, 2019
<u>AB1</u>		<u>30MG</u>	<u>A211796 003</u>	May 23, 2019
<u>AB1</u>		<u>40MG</u>	<u>A211796 004</u>	May 23, 2019
<u>AB1</u>		<u>60MG</u>	<u>A211796 005</u>	May 23, 2019
<u>AB1</u>	MAYNE PHARMA	<u>10MG</u>	<u>A200886 001</u>	Feb 26, 2018
<u>AB1</u>		<u>20MG</u>	<u>A078458 001</u>	Dec 01, 2011
<u>AB1</u>		<u>30MG</u>	<u>A078458 002</u>	Dec 01, 2011
<u>AB1</u>		<u>40MG</u>	<u>A078458 003</u>	Dec 01, 2011
<u>AB1</u>	!	<u>60MG</u>	<u>A078458 004</u>	Jun 23, 2016

RITALIN LA

<u>AB1</u>	+ NOVARTIS	<u>10MG</u>	<u>N021284 004</u>	Apr 10, 2004
<u>AB1</u>	+	<u>20MG</u>	<u>N021284 001</u>	Jun 05, 2002
<u>AB1</u>	+	<u>30MG</u>	<u>N021284 002</u>	Jun 05, 2002
<u>AB1</u>	+	<u>40MG</u>	<u>N021284 003</u>	Jun 05, 2002

METADATE CD

<u>AB2</u>	+ LANNETT CO INC	<u>10MG</u>	<u>N021259 003</u>	May 27, 2003
<u>AB2</u>	+	<u>20MG</u>	<u>N021259 001</u>	Apr 03, 2001
<u>AB2</u>	+	<u>30MG</u>	<u>N021259 002</u>	Jun 19, 2003
<u>AB2</u>	+	<u>40MG</u>	<u>N021259 004</u>	Feb 19, 2006
<u>AB2</u>	+	<u>50MG</u>	<u>N021259 005</u>	Feb 19, 2006
<u>AB2</u>	+	<u>60MG</u>	<u>N021259 006</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>	IMPAX LABS INC	<u>10MG</u>	<u>A205105 001</u>	Jul 28, 2016
<u>AB2</u>		<u>20MG</u>	<u>A205105 002</u>	Jul 28, 2016
<u>AB2</u>		<u>30MG</u>	<u>A205105 003</u>	Jul 28, 2016
<u>AB2</u>		<u>40MG</u>	<u>A205105 004</u>	Jul 28, 2016
<u>AB2</u>		<u>50MG</u>	<u>A205105 005</u>	Jul 28, 2016
<u>AB2</u>		<u>60MG</u>	<u>A205105 006</u>	Jul 28, 2016
<u>AB2</u>	SPECGX LLC	<u>10MG</u>	<u>A203583 001</u>	Sep 29, 2015
<u>AB2</u>		<u>20MG</u>	<u>A203583 002</u>	Sep 29, 2015
<u>AB2</u>		<u>30MG</u>	<u>A203583 003</u>	Sep 29, 2015
<u>AB2</u>		<u>40MG</u>	<u>A203583 004</u>	Sep 29, 2015
<u>AB2</u>		<u>50MG</u>	<u>A203583 005</u>	Sep 29, 2015
<u>AB2</u>		<u>60MG</u>	<u>A203583 006</u>	Sep 29, 2015
<u>AB2</u>	TEVA PHARMS	<u>10MG</u>	<u>A077707 001</u>	Jul 19, 2012
<u>AB2</u>		<u>20MG</u>	<u>A077707 002</u>	Jul 19, 2012
<u>AB2</u>		<u>30MG</u>	<u>A077707 003</u>	Jul 19, 2012
<u>AB2</u>		<u>40MG</u>	<u>A078873 001</u>	Jul 19, 2012
<u>AB2</u>		<u>50MG</u>	<u>A078873 002</u>	Jul 19, 2012
<u>AB2</u>		<u>60MG</u>	<u>A078873 003</u>	Jul 19, 2012

APTENSIO XR

<u>AB3</u>	+ RHODES PHARMS	<u>10MG</u>	<u>N205831 001</u>	Apr 17, 2015
<u>AB3</u>	+	<u>15MG</u>	<u>N205831 002</u>	Apr 17, 2015
<u>AB3</u>	+	<u>20MG</u>	<u>N205831 003</u>	Apr 17, 2015
<u>AB3</u>	+	<u>30MG</u>	<u>N205831 004</u>	Apr 17, 2015
<u>AB3</u>	+	<u>40MG</u>	<u>N205831 005</u>	Apr 17, 2015
<u>AB3</u>	+	<u>50MG</u>	<u>N205831 006</u>	Apr 17, 2015
<u>AB3</u>	+	<u>60MG</u>	<u>N205831 007</u>	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A208861 001</u>	Dec 13, 2018
<u>AB3</u>		<u>15MG</u>	<u>A208861 002</u>	Dec 13, 2018
<u>AB3</u>		<u>20MG</u>	<u>A208861 003</u>	Dec 13, 2018
<u>AB3</u>		<u>30MG</u>	<u>A208861 004</u>	Dec 13, 2018
<u>AB3</u>		<u>40MG</u>	<u>A208861 005</u>	Dec 13, 2018
<u>AB3</u>		<u>50MG</u>	<u>A208861 006</u>	Dec 13, 2018
<u>AB3</u>		<u>60MG</u>	<u>A208861 007</u>	Dec 13, 2018

ADHANSIA XR

+	PURDUE PHARMA LP	25MG	N212038 001	Feb 27, 2019
+		35MG	N212038 002	Feb 27, 2019
+		45MG	N212038 003	Feb 27, 2019
+		55MG	N212038 004	Feb 27, 2019
+		70MG	N212038 005	Feb 27, 2019
+		85MG	N212038 006	Feb 27, 2019

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

JORNAY PM

+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
+		40MG	N209311	002	Aug 08, 2018
+		60MG	N209311	003	Aug 08, 2018
+		80MG	N209311	004	Aug 08, 2018
+		100MG	N209311	005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012
---	----------	--------	---------	-----	--------------

SOLUTION;ORAL

METHYLIN

AA	+	SPECGX LLC	<u>5MG/5ML</u>	<u>N021419</u>	<u>001</u>	Dec 19, 2002
AA	+		<u>10MG/5ML</u>	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

AA		ABHAI LLC	<u>5MG/5ML</u>	<u>A207485</u>	<u>001</u>	Nov 18, 2016
AA			<u>10MG/5ML</u>	<u>A207485</u>	<u>002</u>	Nov 18, 2016
AA		BRECKENRIDGE	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013
AA			<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013
AA		NOVEL LABS INC	<u>5MG/5ML</u>	<u>A204602</u>	<u>001</u>	Aug 14, 2015
AA			<u>10MG/5ML</u>	<u>A204602</u>	<u>002</u>	Aug 14, 2015
AA		NOVELGENIX THERAPS	<u>5MG/5ML</u>	<u>A210139</u>	<u>001</u>	Oct 03, 2018
AA			<u>10MG/5ML</u>	<u>A210139</u>	<u>002</u>	Oct 03, 2018
AA		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010
AA			<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	<u>5MG</u>	<u>A206932</u>	<u>001</u>	May 11, 2017
AB			<u>10MG</u>	<u>A206932</u>	<u>002</u>	May 11, 2017
AB			<u>20MG</u>	<u>A206932</u>	<u>003</u>	May 11, 2017
AB		ACTAVIS LABS FL INC	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997
AB			<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997
AB			<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997
AB		ALKEM LABS LTD	<u>5MG</u>	<u>A211779</u>	<u>001</u>	Oct 04, 2019
AB			<u>10MG</u>	<u>A211779</u>	<u>002</u>	Oct 04, 2019
AB			<u>20MG</u>	<u>A211779</u>	<u>003</u>	Oct 04, 2019
AB		ASCENT PHARMS INC	<u>5MG</u>	<u>A207416</u>	<u>001</u>	Sep 22, 2015
AB			<u>10MG</u>	<u>A207416</u>	<u>002</u>	Sep 22, 2015
AB			<u>20MG</u>	<u>A207416</u>	<u>003</u>	Sep 22, 2015
AB		BIONPHARMA INC	<u>5MG</u>	<u>A209753</u>	<u>001</u>	Mar 02, 2018
AB			<u>10MG</u>	<u>A209753</u>	<u>002</u>	Mar 02, 2018
AB			<u>20MG</u>	<u>A209753</u>	<u>003</u>	Mar 02, 2018
AB		BRECKENRIDGE	<u>5MG</u>	<u>A207587</u>	<u>001</u>	Mar 03, 2017
AB			<u>10MG</u>	<u>A207587</u>	<u>002</u>	Mar 03, 2017
AB			<u>20MG</u>	<u>A207587</u>	<u>003</u>	Mar 03, 2017
AB		MOUNTAIN	<u>5MG</u>	<u>A091159</u>	<u>001</u>	Mar 12, 2014
AB			<u>10MG</u>	<u>A091159</u>	<u>002</u>	Mar 12, 2014
AB			<u>20MG</u>	<u>A091159</u>	<u>003</u>	Mar 12, 2014
AB		NOVEL LABS INC	<u>5MG</u>	<u>A207884</u>	<u>001</u>	Nov 13, 2015
AB			<u>10MG</u>	<u>A207884</u>	<u>002</u>	Nov 13, 2015
AB			<u>20MG</u>	<u>A207884</u>	<u>003</u>	Nov 13, 2015
AB		OXFORD PHARMS	<u>5MG</u>	<u>A202892</u>	<u>001</u>	Sep 23, 2014
AB			<u>10MG</u>	<u>A202892</u>	<u>002</u>	Sep 23, 2014
AB			<u>20MG</u>	<u>A202892</u>	<u>003</u>	Sep 23, 2014
AB		SPECGX LLC	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
AB			<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
AB			<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
AB		SUN PHARM INDS INC	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012
AB			<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012
AB			<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012

RITALIN

AB	+	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	
AB	+		<u>10MG</u>	<u>N010187</u>	<u>006</u>	
AB	+		<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	<u>2.5MG</u>	<u>A210354</u>	<u>001</u>	Dec 29, 2017
AB			<u>5MG</u>	<u>A210354</u>	<u>002</u>	Dec 29, 2017
AB			<u>10MG</u>	<u>A210354</u>	<u>003</u>	Dec 29, 2017
AB		BRECKENRIDGE	<u>2.5MG</u>	<u>A204954</u>	<u>001</u>	Jan 26, 2017
AB			<u>5MG</u>	<u>A204954</u>	<u>002</u>	Jan 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A204954</u>	<u>003</u>	Jan 26, 2017
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204115</u>	<u>001</u>	Feb 25, 2015
<u>AB</u>		<u>5MG</u>	<u>A204115</u>	<u>002</u>	Feb 25, 2015
<u>AB</u>	!	<u>10MG</u>	<u>A204115</u>	<u>003</u>	Feb 25, 2015
<u>AB</u>	RISING	<u>2.5MG</u>	<u>A205756</u>	<u>001</u>	Nov 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A205756</u>	<u>002</u>	Nov 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A205756</u>	<u>003</u>	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

<u>AB</u>	+	JANSSEN PHARMS	<u>18MG</u>	<u>N021121</u>	<u>001</u>	Aug 01, 2000
<u>AB</u>	+		<u>27MG</u>	<u>N021121</u>	<u>004</u>	Apr 01, 2002
<u>AB</u>	+		<u>36MG</u>	<u>N021121</u>	<u>002</u>	Aug 01, 2000
<u>AB</u>	+	!	<u>54MG</u>	<u>N021121</u>	<u>003</u>	Dec 08, 2000

METHYLIN ER

<u>AB</u>		SPECGX LLC	<u>10MG</u>	<u>A075629</u>	<u>001</u>	May 09, 2000
<u>AB</u>			<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ABHAI LLC	<u>10MG</u>	<u>A207488</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>	!		<u>20MG</u>	<u>A207488</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>		ACTAVIS LABS FL	<u>18MG</u>	<u>A076772</u>	<u>001</u>	Mar 22, 2018
<u>AB</u>			<u>27MG</u>	<u>A076772</u>	<u>002</u>	Mar 22, 2018
<u>AB</u>			<u>36MG</u>	<u>A076772</u>	<u>003</u>	Mar 22, 2018
<u>AB</u>			<u>54MG</u>	<u>A076655</u>	<u>001</u>	Mar 21, 2018
<u>AB</u>		ALVOGEN PINE BROOK	<u>18MG</u>	<u>A210818</u>	<u>001</u>	Nov 30, 2018
<u>AB</u>			<u>27MG</u>	<u>A210818</u>	<u>002</u>	Nov 30, 2018
<u>AB</u>			<u>36MG</u>	<u>A210818</u>	<u>003</u>	Nov 30, 2018
<u>AB</u>			<u>54MG</u>	<u>A210818</u>	<u>004</u>	Nov 30, 2018
<u>AB</u>		AMNEAL PHARMS	<u>18MG</u>	<u>A207515</u>	<u>001</u>	Feb 01, 2018
<u>AB</u>			<u>27MG</u>	<u>A207515</u>	<u>002</u>	Feb 01, 2018
<u>AB</u>			<u>36MG</u>	<u>A207515</u>	<u>003</u>	Feb 01, 2018
<u>AB</u>			<u>54MG</u>	<u>A207515</u>	<u>004</u>	Feb 01, 2018
<u>AB</u>		ANDOR PHARMS	<u>18MG</u>	<u>A211918</u>	<u>001</u>	Apr 24, 2019
<u>AB</u>			<u>27MG</u>	<u>A211918</u>	<u>002</u>	Apr 24, 2019
<u>AB</u>			<u>36MG</u>	<u>A211918</u>	<u>003</u>	Apr 24, 2019
<u>AB</u>			<u>54MG</u>	<u>A211918</u>	<u>004</u>	Apr 24, 2019
<u>AB</u>		ANI PHARMS INC	<u>18MG</u>	<u>A208607</u>	<u>001</u>	Jul 14, 2017
<u>AB</u>			<u>27MG</u>	<u>A208607</u>	<u>002</u>	Jul 14, 2017
<u>AB</u>			<u>36MG</u>	<u>A208607</u>	<u>003</u>	Jul 14, 2017
<u>AB</u>			<u>54MG</u>	<u>A208607</u>	<u>004</u>	Jul 14, 2017
<u>AB</u>		ASCENT PHARMS INC	<u>18MG</u>	<u>A211009</u>	<u>001</u>	Sep 03, 2019
<u>AB</u>			<u>27MG</u>	<u>A211009</u>	<u>002</u>	Sep 03, 2019
<u>AB</u>			<u>36MG</u>	<u>A211009</u>	<u>003</u>	Sep 03, 2019
<u>AB</u>			<u>54MG</u>	<u>A211009</u>	<u>004</u>	Sep 03, 2019
<u>AB</u>		CNTY LINE PHARMS	<u>10MG</u>	<u>A204772</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>			<u>20MG</u>	<u>A204772</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>		GRANULES PHARMS	<u>10MG</u>	<u>A210992</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>			<u>20MG</u>	<u>A210992</u>	<u>002</u>	Nov 21, 2018
<u>AB</u>		MYLAN	<u>18MG</u>	<u>A206726</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>			<u>27MG</u>	<u>A206726</u>	<u>002</u>	Oct 21, 2016
<u>AB</u>			<u>36MG</u>	<u>A206726</u>	<u>003</u>	Oct 21, 2016
<u>AB</u>			<u>54MG</u>	<u>A206726</u>	<u>004</u>	Oct 21, 2016
<u>AB</u>		OSMOTICA	<u>18MG</u>	<u>A205327</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>			<u>27MG</u>	<u>A205327</u>	<u>002</u>	Jul 28, 2017
<u>AB</u>			<u>36MG</u>	<u>A205327</u>	<u>003</u>	Jul 28, 2017
<u>AB</u>			<u>54MG</u>	<u>A205327</u>	<u>004</u>	Jul 28, 2017
BX		LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013
BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

	+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
	+		30MG	N207960	002	Dec 04, 2015
	+	!	40MG	N207960	003	Dec 04, 2015

PRESCRIPTION DRUG PRODUCT LIST

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>2MG</u>	<u>N011153</u>	<u>002</u>	
<u>AB</u>	+		<u>4MG</u>	<u>N011153</u>	<u>001</u>	
<u>AB</u>	+		<u>8MG</u>	<u>N011153</u>	<u>004</u>	
<u>AB</u>	+		<u>16MG</u>	<u>N011153</u>	<u>003</u>	
<u>AB</u>	+		<u>32MG</u>	<u>N011153</u>	<u>006</u>	

METHYLPREDNISOLONE

<u>AB</u>		DURAMED PHARMS BARR	<u>4MG</u>	<u>A088497</u>	<u>001</u>	Feb 21, 1984
<u>AB</u>		JUBILANT CADISTA	<u>4MG</u>	<u>A040189</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>			<u>8MG</u>	<u>A040189</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>			<u>16MG</u>	<u>A040189</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>			<u>32MG</u>	<u>A040189</u>	<u>004</u>	Jul 20, 2007
<u>AB</u>		SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		SUNGEN PHARMA	<u>4MG</u>	<u>A212262</u>	<u>001</u>	Jun 27, 2019
<u>AB</u>		TIANJIN TIANYAO	<u>4MG</u>	<u>A204072</u>	<u>001</u>	May 14, 2018
<u>AB</u>		VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u>	Dec 22, 1998
<u>AB</u>		WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u>	Oct 16, 1997
<u>AB</u>		ZYDUS PHARMS	<u>4MG</u>	<u>A206751</u>	<u>001</u>	Apr 23, 2018
<u>AB</u>			<u>8MG</u>	<u>A206751</u>	<u>002</u>	Apr 23, 2018
<u>AB</u>			<u>16MG</u>	<u>A206751</u>	<u>003</u>	Apr 23, 2018
<u>AB</u>			<u>32MG</u>	<u>A206751</u>	<u>004</u>	Apr 23, 2018

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>20MG/ML</u>	<u>N011757</u>	<u>002</u>	
<u>AB</u>	+		<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>	
<u>AB</u>	+		<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>	

METHYLPREDNISOLONE ACETATE

<u>AB</u>		SAGENT PHARMS INC	<u>20MG/ML</u>	<u>A201835</u>	<u>001</u>	Jun 27, 2018
<u>AB</u>			<u>40MG/ML</u>	<u>A201835</u>	<u>002</u>	Jun 27, 2018
<u>AB</u>			<u>80MG/ML</u>	<u>A201835</u>	<u>003</u>	Jun 27, 2018
<u>AB</u>		SANDOZ INC	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		TEVA PHARMS USA	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>			<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>			<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>			<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>		AMNEAL	<u>EQ 40MG BASE/VIAL</u>	<u>A207549</u>	<u>001</u>	Nov 09, 2016
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A207549</u>	<u>002</u>	Nov 09, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A207667</u>	<u>001</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A207667</u>	<u>002</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A207667</u>	<u>003</u>	Dec 15, 2015
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A207667</u>	<u>004</u>	Dec 15, 2015
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>		HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A202691</u>	<u>001</u>	Feb 16, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A202691</u>	<u>002</u>	Feb 16, 2016
<u>AP</u>		SAGENT PHARMS INC	<u>EQ 40MG BASE/VIAL</u>	<u>A040888</u>	<u>001</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 125MG BASE/VIAL</u>	<u>A040888</u>	<u>002</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A040888</u>	<u>003</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A040888</u>	<u>004</u>	Jul 18, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A040888</u>	<u>005</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	+		<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N011856</u>	<u>007</u>	Feb 27, 1985

PRESCRIPTION DRUG PRODUCT LIST

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015
-----------	----------------	-------------	----------------	------------	--------------

TESTRED

AB	! VALEANT PHARM INTL	10MG	A083976	001	
-----------	----------------------	-------------	----------------	------------	--

TABLET; ORAL

ANDROID 25

BP	VALEANT PHARM INTL	25MG	A087147	001	
----	--------------------	------	---------	-----	--

METHYLTESTOSTERONE

BP	IMPAX LABS	10MG	A080767	002	
----	------------	------	---------	-----	--

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

AP	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204756	001	Dec 20, 2013
-----------	-------------------	-----------------------	----------------	------------	--------------

METOCLOPRAMIDE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013
-----------	--------------------	-----------------------	----------------	------------	--------------

AP	! HOSPIRA	EQ 5MG BASE/ML	A073118	001	Jan 17, 1991
-----------	-----------	-----------------------	----------------	------------	--------------

AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991
-----------	-----------------	-----------------------	----------------	------------	--------------

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	ANI PHARMS	EQ 5MG BASE/5ML	A071402	001	Jun 25, 1993
-----------	------------	------------------------	----------------	------------	--------------

AA	PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991
-----------	-------------	------------------------	----------------	------------	--------------

AA	VISTAPHARM	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001
-----------	------------	------------------------	----------------	------------	--------------

AA	! WOCHKHARDT BIO AG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997
-----------	---------------------	------------------------	----------------	------------	--------------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	IMPAX LABS INC	EQ 5MG BASE	A071250	002	Dec 28, 1995
-----------	----------------	--------------------	----------------	------------	--------------

AB		EQ 10MG BASE	A071250	001	Feb 03, 1988
-----------	--	---------------------	----------------	------------	--------------

AB	IPCA LABS LTD	EQ 5MG BASE	A078807	001	Jun 12, 2008
-----------	---------------	--------------------	----------------	------------	--------------

AB		EQ 10MG BASE	A078807	002	Jun 12, 2008
-----------	--	---------------------	----------------	------------	--------------

AB	PAR PHARM INC	EQ 10MG BASE	A070581	001	Oct 17, 1985
-----------	---------------	---------------------	----------------	------------	--------------

AB	TEVA	EQ 5MG BASE	A072801	001	Jun 15, 1993
-----------	------	--------------------	----------------	------------	--------------

AB		EQ 10MG BASE	A070184	001	Jul 29, 1985
-----------	--	---------------------	----------------	------------	--------------

AB	VINTAGE PHARMS	EQ 5MG BASE	A077878	001	Aug 28, 2006
-----------	----------------	--------------------	----------------	------------	--------------

AB		EQ 10MG BASE	A077878	002	Aug 28, 2006
-----------	--	---------------------	----------------	------------	--------------

REGLAN

AB	+ ANI PHARMS	EQ 5MG BASE	N017854	002	May 05, 1987
-----------	--------------	--------------------	----------------	------------	--------------

AB	+!	EQ 10MG BASE	N017854	001	
-----------	----	---------------------	----------------	------------	--

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

NOVEL LABS INC EQ 5MG BASE

A202191 001 Aug 15, 2014

! EQ 10MG BASE

A202191 002 Aug 15, 2014

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	MYLAN	2.5MG	A076698	001	Dec 23, 2003
-----------	-------	--------------	----------------	------------	--------------

AB		5MG	A076698	002	Oct 19, 2004
-----------	--	------------	----------------	------------	--------------

AB		10MG	A076698	003	Oct 19, 2004
-----------	--	-------------	----------------	------------	--------------

AB	SANDOZ	2.5MG	A076732	001	Dec 19, 2003
-----------	--------	--------------	----------------	------------	--------------

AB		5MG	A076466	001	Dec 19, 2003
-----------	--	------------	----------------	------------	--------------

AB		10MG	A076466	002	Dec 19, 2003
-----------	--	-------------	----------------	------------	--------------

ZAROXOLYN

AB	+ LANNETT CO INC	2.5MG	N017386	001	
-----------	------------------	--------------	----------------	------------	--

AB	+!	5MG	N017386	002	
-----------	----	------------	----------------	------------	--

AB	+!	10MG	N017386	003	
-----------	----	-------------	----------------	------------	--

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE; ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
---	------	------------------	---------	-----	--------------

+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
---	--	------------------	---------	-----	--------------

+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
---	--	-------------------	---------	-----	--------------

+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018
----	--	-------------------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016
-----------	-------------------	-------------------------	----------------	------------	--------------

AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016
-----------	--	-------------------------	----------------	------------	--------------

AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016
-----------	--	--------------------------	----------------	------------	--------------

AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016
-----------	--	--------------------------	----------------	------------	--------------

AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009
-----------	---------------------	-------------------------	----------------	------------	--------------

AB		EQ 50MG TARTRATE	A076862	001	Aug 03, 2009
-----------	--	-------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298 002</u>	Apr 15, 2010
<u>AB</u>	CIPLA	<u>EQ 50MG TARTRATE</u>	<u>A207465 001</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A207465 002</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A207465 003</u>	Oct 26, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617 001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617 002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033 001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033 002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033 003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033 004</u>	Dec 15, 2011
<u>AB</u>	NOVAST LABS	<u>EQ 25MG TARTRATE</u>	<u>A204106 001</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A204106 002</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A204106 003</u>	Feb 06, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A204106 004</u>	Feb 06, 2018
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889 001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889 002</u>	Aug 15, 2012
<u>AB</u>	TWI PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A207206 001</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A207206 002</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A207206 003</u>	Dec 19, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A207206 004</u>	Dec 19, 2018
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615 001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615 002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615 003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615 004</u>	Jul 22, 2010
<u>AB</u>	ZYDUS PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A203894 001</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A203894 002</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A203894 003</u>	Mar 23, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A203894 004</u>	Mar 23, 2018

TOPROL-XL

<u>AB</u>	+ TOPROL	<u>EQ 25MG TARTRATE</u>	<u>N019962 004</u>	Feb 05, 2001
<u>AB</u>	+!	<u>EQ 50MG TARTRATE</u>	<u>N019962 001</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 100MG TARTRATE</u>	<u>N019962 002</u>	Jan 10, 1992
<u>AB</u>	+!	<u>EQ 200MG TARTRATE</u>	<u>N019962 003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

<u>AP</u>	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>A078950 001</u>	Apr 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045 001</u>	Oct 25, 2010
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205 001</u>	Aug 27, 2014
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761 001</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074133 001</u>	Dec 21, 1993
<u>AP</u>		<u>1MG/ML</u>	<u>A075160 001</u>	Jul 06, 1998
<u>AP</u>	!	<u>1MG/ML</u>	<u>A078085 001</u>	Apr 29, 2008
<u>AP</u>	MYLAN ASI	<u>1MG/ML</u>	<u>A090317 001</u>	Apr 19, 2010
<u>AP</u>	SANDOZ INC	<u>1MG/ML</u>	<u>A077360 001</u>	Oct 02, 2007
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A076495 001</u>	Jul 07, 2003

TABLET; ORAL

LOPRESSOR

<u>AB</u>	+ US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963 001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N017963 002</u>	

METOPROLOL TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871 001</u>	May 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A202871 002</u>	May 28, 2013
<u>AB</u>		<u>100MG</u>	<u>A202871 003</u>	May 28, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739 001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739 002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739 003</u>	Sep 11, 2007
<u>AB</u>	HERITAGE PHARMA	<u>50MG</u>	<u>A074141 001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141 002</u>	Jan 31, 1995
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459 001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459 002</u>	Jun 17, 2008
<u>AB</u>		<u>100MG</u>	<u>A078459 003</u>	Jun 17, 2008
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704 001</u>	Jan 16, 2004
<u>AB</u>		<u>37.5MG</u>	<u>A076704 004</u>	Mar 18, 2015
<u>AB</u>		<u>50MG</u>	<u>A076704 002</u>	Jan 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>		<u>75MG</u>	<u>A076704 005</u>	Mar 18, 2015
<u>AB</u>	!	<u>100MG</u>	<u>A076704 003</u>	Jan 16, 2004
<u>AB</u>	RUBICON	<u>25MG</u>	<u>A200981 001</u>	Oct 28, 2014
<u>AB</u>		<u>37.5MG</u>	<u>A200981 004</u>	Aug 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A200981 002</u>	Oct 28, 2014
<u>AB</u>		<u>75MG</u>	<u>A200981 005</u>	Aug 21, 2019
<u>AB</u>		<u>100MG</u>	<u>A200981 003</u>	Oct 28, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670 001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644 001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644 002</u>	Dec 10, 1996

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334 001</u>	May 03, 1995
-----------	---	---------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>375MG</u>	<u>A079065 001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522 001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531 001</u>	Sep 20, 1995
-----------	---	------------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		ACP NIMBLE	<u>0.75%</u>	<u>A077549 001</u>	Dec 19, 2007
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408 001</u>	May 28, 2004

NORITATE

	+	VALEANT PHARMS NORTH	1%	N020743 001	Sep 26, 1997
--	---	-------------------------	----	-------------	--------------

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737 001</u>	Nov 22, 1988
<u>AB</u>	+		<u>1%</u>	<u>N021789 001</u>	Jun 30, 2005

METRONIDAZOLE

<u>AB</u>		ACP NIMBLE	<u>0.75%</u>	<u>A078178 001</u>	Jan 19, 2011
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018 001</u>	Jun 06, 2006
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819 001</u>	Jul 18, 2006
<u>AB</u>			<u>1%</u>	<u>A204651 001</u>	Mar 14, 2017
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547 001</u>	Jul 13, 2006
<u>AB</u>			<u>1%</u>	<u>A090903 001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	BAUSCH	<u>0.75%</u>	<u>N020208 001</u>	Aug 17, 1992
-----------	---	--------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		PERRIGO UK FINCO	<u>0.75%</u>	<u>A211786 001</u>	Jul 02, 2019
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264 001</u>	Oct 31, 2006

VANDAZOLE

BX		TEVA PHARMS	0.75%	N021806 001	May 20, 2005
----	--	-------------	-------	-------------	--------------

NUVESSA

	+	CHEMO RESEARCH SL	1.3%	N205223 001	Mar 24, 2014
--	---	-------------------	------	-------------	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657 001</u>	
-----------	---	-----------------	--------------------	--------------------	--

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900 001</u>	Sep 29, 1983
-----------	---	---------	--------------------	--------------------	--------------

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE CORP	<u>500MG/100ML</u>	<u>A078084 001</u>	Mar 31, 2008
<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890 002</u>	Nov 18, 1983
<u>AP</u>		INFORLIFE	<u>500MG/100ML</u>	<u>A206191 001</u>	Feb 25, 2019
<u>AP</u>		MYLAN LABS LTD	<u>500MG/100ML</u>	<u>A205531 001</u>	May 09, 2017

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901 001</u>	Nov 24, 1998
-----------	---	------------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077197 001</u>	May 24, 2006
-----------	--	----------------	--------------	--------------------	--------------

TABLET; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>250MG</u>	<u>N012623 001</u>	
<u>AB</u>	+		<u>500MG</u>	<u>N012623 003</u>	

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>250MG</u>	<u>A079067 001</u>	Mar 13, 2009
-----------	--	--------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

<u>AB</u>		<u>500MG</u>	<u>A079067</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A203974</u>	<u>001</u>	May 29, 2015
<u>AB</u>		<u>500MG</u>	<u>A203974</u>	<u>002</u>	May 29, 2015
<u>AB</u>	CADILA	<u>250MG</u>	<u>A206560</u>	<u>001</u>	Nov 16, 2016
<u>AB</u>		<u>500MG</u>	<u>A206560</u>	<u>002</u>	Nov 16, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>250MG</u>	<u>A209794</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		<u>500MG</u>	<u>A209794</u>	<u>002</u>	Dec 12, 2017
<u>AB</u>	FLAMINGO PHARMS	<u>250MG</u>	<u>A207309</u>	<u>001</u>	May 16, 2016
<u>AB</u>		<u>500MG</u>	<u>A207309</u>	<u>002</u>	May 16, 2016
<u>AB</u>	HERITAGE PHARMS INC	<u>250MG</u>	<u>A205245</u>	<u>001</u>	Sep 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A205245</u>	<u>002</u>	Sep 23, 2015
<u>AB</u>	INNOGENIX	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
<u>AB</u>		<u>500MG</u>	<u>A070772</u>	<u>002</u>	Jul 16, 1986
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A209096</u>	<u>001</u>	Sep 12, 2017
<u>AB</u>		<u>500MG</u>	<u>A209096</u>	<u>002</u>	Sep 12, 2017
<u>AB</u>	ORIT LABS LLC	<u>250MG</u>	<u>A208681</u>	<u>001</u>	Jun 20, 2017
<u>AB</u>		<u>500MG</u>	<u>A208681</u>	<u>002</u>	Jun 20, 2017
<u>AB</u>	PLIVA	<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A070040</u>	<u>001</u>	Jan 29, 1985
<u>AB</u>		<u>250MG</u>	<u>A208162</u>	<u>001</u>	May 25, 2016
<u>AB</u>		<u>500MG</u>	<u>A070039</u>	<u>001</u>	Jan 29, 1985
<u>AB</u>		<u>500MG</u>	<u>A208162</u>	<u>002</u>	May 25, 2016
<u>AB</u>	TEVA PHARMS USA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
<u>AB</u>	UNICHEM LABS LTD	<u>250MG</u>	<u>A203458</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>		<u>500MG</u>	<u>A203458</u>	<u>002</u>	Jan 22, 2014
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
<u>AB</u>	WATSON LABS INC	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985

METYPAPONE

CAPSULE; ORAL

METOPIRONE

+! HRA PHARMA 250MG N012911 002 Aug 09, 1996

METYROSINE

CAPSULE; ORAL

DEMSEER

+! BAUSCH 250MG N017871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

TEVA 150MG A074377 001 May 16, 1995

200MG A074377 002 May 16, 1995

! 250MG A074377 003 May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A207344</u>	<u>001</u>	May 17, 2019
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	<u>A207344</u>	<u>002</u>	May 17, 2019

MYCAMINE

<u>AP</u>	+! ASTELLAS	<u>EQ 50MG BASE/VIAL</u>	<u>N021506</u>	<u>002</u>	Mar 16, 2005
<u>AP</u>	+!	<u>EQ 100MG BASE/VIAL</u>	<u>N021506</u>	<u>003</u>	Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+! FORTOVIA 50MG N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

<u>AB</u>	ACTAVIS PHARMA	<u>200MG</u>	<u>A073508</u>	<u>001</u>	Nov 19, 1993
-----------	----------------	--------------	----------------	------------	--------------

MONISTAT 3

<u>AB</u>	+!	MEYTECH PRODUCTS	<u>200MG</u>	<u>N018888</u>	<u>001</u>	Aug 15, 1984
-----------	----	------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+! MYLAN 0.25%; 81.35%; 15% N021026 001 Feb 16, 2006

MIDAZOLAM

SPRAY; NASAL

NAYZILAM

+! UCB INC 5MG/SPRAY N211321 001 May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 1MG BASE/ML</u>	<u>A075494 001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494 002</u>	Jun 30, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075154 001</u>	Jun 20, 2000
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696 001</u>	Feb 29, 2012
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090850 001</u>	Jan 25, 2012
<u>AP</u>	! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856 001</u>	Jun 13, 2002
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075293 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075856 002</u>	Jun 13, 2002
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 1MG BASE/ML</u>	<u>A075243 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075247 002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075324 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075421 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075243 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247 001</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421 001</u>	Jun 20, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A203460 001</u>	Aug 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A203460 002</u>	Aug 22, 2014
<u>AP</u>	! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857 001</u>	Jul 22, 2002
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075857 002</u>	Jul 22, 2002
<u>AP</u>	MYLAN ASI	<u>EQ 1MG BASE/ML</u>	<u>A090315 001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315 002</u>	Nov 29, 2010

MIDAZOLAM HYDROCHLORIDE

FRESENIUS KABI USA

SOLUTION; INTRAMUSCULAR

SEIZALAM

+! MERIDIAN MEDCL 5MG BASE/ML (EQ 5MG BASE/ML) N209566 001 Sep 14, 2018

TECHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u>	! HIKMA	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A077746 001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746 002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746 003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449 001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449 002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449 003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577 001</u>	Sep 10, 2003
<u>AB</u>		<u>5MG</u>	<u>A076577 002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577 003</u>	Sep 10, 2003
<u>AB</u>	PAR PHARM INC	<u>2.5MG</u>	<u>A207169 001</u>	Oct 29, 2018
<u>AB</u>		<u>5MG</u>	<u>A207169 002</u>	Oct 29, 2018
<u>AB</u>		<u>10MG</u>	<u>A207169 003</u>	Oct 29, 2018
<u>AB</u>	RUBICON	<u>2.5MG</u>	<u>A212543 001</u>	Aug 19, 2019
<u>AB</u>		<u>5MG</u>	<u>A212543 002</u>	Aug 19, 2019
<u>AB</u>		<u>10MG</u>	<u>A212543 003</u>	Aug 19, 2019
<u>AB</u>	UNIQUE PHARM LABS	<u>2.5MG</u>	<u>A207613 001</u>	Nov 02, 2018
<u>AB</u>		<u>5MG</u>	<u>A207613 002</u>	Nov 02, 2018
<u>AB</u>		<u>10MG</u>	<u>A207613 003</u>	Nov 02, 2018

ORVATEN

<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076725 001</u>	Nov 03, 2004
-----------	-------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

ORVATEN

AB	!		5MG	A076725	002	Nov 03, 2004
AB			10MG	A076725	003	Nov 03, 2004

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+	!	NOVARTIS	25MG	N207997	001	Apr 28, 2017
---	---	----------	------	---------	-----	--------------

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

AB	+	!	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000
-----------	----------	----------	----------------	--------------	----------------	------------	--------------

MIFEPRISTONE

AB			GENBIOPRO	200MG	A091178	001	Apr 11, 2019
-----------	--	--	-----------	--------------	----------------	------------	--------------

KORLYM

+	!	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012
---	---	----------------	-------	---------	-----	--------------

MIGALASTAT HYDROCHLORIDE

CAPSULE; ORAL

GALAFOLD

+	!	AMICUS THERAPS US	EQ 123MG BASE	N208623	001	Aug 10, 2018
---	---	-------------------	---------------	---------	-----	--------------

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	!	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996
-----------	----------	----------	----------------------	-------------	----------------	------------	--------------

AB	+			50MG	N020682	002	Dec 18, 1996
-----------	----------	--	--	-------------	----------------	------------	--------------

AB	+			100MG	N020682	003	Dec 18, 1996
-----------	----------	--	--	--------------	----------------	------------	--------------

MIGLITOL

AB			ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015
-----------	--	--	----------------------	-------------	----------------	------------	--------------

AB				50MG	A203965	002	Feb 24, 2015
-----------	--	--	--	-------------	----------------	------------	--------------

AB				100MG	A203965	003	Feb 24, 2015
-----------	--	--	--	--------------	----------------	------------	--------------

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB			AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018
-----------	--	--	---------------------	--------------	----------------	------------	--------------

ZAVESCA

AB	+	!	ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003
-----------	----------	----------	---------------------	--------------	----------------	------------	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+		ALLERGAN	12.5MG	N022256	001	Jan 14, 2009
---	--	----------	--------	---------	-----	--------------

+			25MG	N022256	002	Jan 14, 2009
---	--	--	------	---------	-----	--------------

+	!		50MG	N022256	003	Jan 14, 2009
---	---	--	------	---------	-----	--------------

+			100MG	N022256	004	Jan 14, 2009
---	--	--	-------	---------	-----	--------------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP			FRESENIUS KABI USA	EQ 1MG BASE/ML	A075936	001	May 28, 2002
-----------	--	--	--------------------	-----------------------	----------------	------------	--------------

AP	!		HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010
-----------	----------	--	--------------------	-----------------------	----------------	------------	--------------

AP			HOSPIRA INC	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014
-----------	--	--	-------------	-----------------------	----------------	------------	--------------

AP			INTL MEDICATED	EQ 1MG BASE/ML	A076013	001	Aug 02, 2002
-----------	--	--	----------------	-----------------------	----------------	------------	--------------

AP			WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002
-----------	--	--	----------------------	-----------------------	----------------	------------	--------------

AP				EQ 1MG BASE/ML	A075660	001	May 28, 2002
-----------	--	--	--	-----------------------	----------------	------------	--------------

MILRINONE LACTATE IN DEXTROSE 5%

AP			WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005
-----------	--	--	----------	--	----------------	------------	--------------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!		BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834	001	May 28, 2002
-----------	----------	--	-----------------	--	----------------	------------	--------------

AP	!			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834	002	May 28, 2002
-----------	----------	--	--	--	----------------	------------	--------------

AP			HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002
-----------	--	--	---------	--	----------------	------------	--------------

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002
-----------	--	--	--	--	----------------	------------	--------------

AP			WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008
-----------	--	--	----------------------	--	----------------	------------	--------------

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008
-----------	--	--	--	--	----------------	------------	--------------

MILRINONE LACTATE IN PLASTIC CONTAINER

AP			HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038	001	Jan 21, 2010
-----------	--	--	--------------------	--	----------------	------------	--------------

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038	002	Jan 21, 2010
-----------	--	--	--	--	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

+! KNIGHT THERAPS

50MG

N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+! FOAMIX

EQ 4% BASE

N212379 001 Oct 18, 2019

CAPSULE;ORAL

DYNACINAB CNTY LINE PHARMSEQ 50MG BASEA063067 003 Aug 14, 1990ABEQ 75MG BASEA063067 002 Sep 15, 1999ABEQ 100MG BASEA063067 001 Jul 31, 1990MINOCINAB + BAUSCHEQ 50MG BASEN050649 001 May 31, 1990AB +EQ 100MG BASEN050649 002 May 31, 1990MINOCYCLINE HYDROCHLORIDEAB AUROBINDO PHARMAEQ 50MG BASEA065470 001 Mar 11, 2008ABEQ 75MG BASEA065470 002 Mar 11, 2008ABEQ 100MG BASEA065470 003 Mar 11, 2008AB IMPAX LABSEQ 50MG BASEA065005 001 Mar 23, 1999ABEQ 75MG BASEA065005 003 Apr 18, 2001ABEQ 100MG BASEA065005 002 Mar 23, 1999AB SUN PHARM INDS INCEQ 50MG BASEA090867 001 May 13, 2013ABEQ 75MG BASEA090867 002 May 13, 2013ABEQ 100MG BASEA090867 003 May 13, 2013AB TORRENTEQ 50MG BASEA065062 001 Nov 30, 2000ABEQ 75MG BASEA065062 002 Nov 30, 2000ABEQ 100MG BASEA065062 003 Nov 30, 2000AB WATSON LABSEQ 75MG BASEA063065 002 Jun 10, 1999ABEQ 100MG BASEA063065 001 Dec 30, 1991AB WATSON LABS TEVAEQ 50MG BASEA063181 001 Dec 30, 1991AB ZYDUSEQ 50MG BASEA063011 001 Mar 02, 1992ABEQ 75MG BASEA063009 002 Aug 12, 2003AB !EQ 100MG BASEA063009 001 Mar 02, 1992

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

SUN PHARM INDS INC

EQ 45MG BASE

N201922 001 Jul 11, 2012

EQ 90MG BASE

N201922 003 Jul 11, 2012

EQ 135MG BASE

N201922 005 Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

+! REMPEX PHARMS

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

+! ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDEAB DR REDDYS LABS LTDEQ 50MG BASEA065436 001 Dec 26, 2007ABEQ 75MG BASEA065436 002 Dec 26, 2007ABEQ 100MG BASEA065436 003 Dec 26, 2007AB PAR PHARMEQ 50MG BASEA065131 001 Apr 16, 2003ABEQ 75MG BASEA065131 002 Apr 16, 2003AB !EQ 100MG BASEA065131 003 Apr 16, 2003AB SUN PHARMEQ 50MG BASEA090217 001 Jan 29, 2016

INDUSTRIES

ABEQ 75MG BASEA090217 002 Jan 29, 2016ABEQ 100MG BASEA090217 003 Jan 29, 2016AB TORRENTEQ 50MG BASEA065156 001 Jan 06, 2004ABEQ 75MG BASEA065156 002 Jan 06, 2004ABEQ 100MG BASEA065156 003 Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDEAB ALKEM LABS LTDEQ 45MG BASEA204453 001 Sep 28, 2016ABEQ 55MG BASEA204453 008 Dec 19, 2019ABEQ 65MG BASEA204453 006 Mar 16, 2018ABEQ 80MG BASEA204453 002 Sep 28, 2016ABEQ 90MG BASEA204453 003 Sep 28, 2016ABEQ 105MG BASEA204453 004 Sep 28, 2016ABEQ 115MG BASEA204453 007 Mar 16, 2018ABEQ 135MG BASEA204453 005 Sep 28, 2016AB AUROBINDO PHARMAEQ 45MG BASEA202261 001 Nov 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

LTD

<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A202261 008</u>	Aug 21, 2019
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A202261 002</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202261 006</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261 003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A202261 007</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A202261 004</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261 005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 65MG BASE</u>	<u>A065485 004</u>	May 18, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A065485 007</u>	Apr 26, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A065485 008</u>	Apr 26, 2017
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485 005</u>	May 18, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A091424 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	MYLAN	<u>EQ 80MG BASE</u>	<u>A203443 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443 003</u>	Aug 22, 2014
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>	!	<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394 001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394 004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394 005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394 007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A091118 003</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A091118 007</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>AB</u>	ZYDUS PHARMS	<u>EQ 45MG BASE</u>	<u>A203553 001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203553 004</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A203553 005</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203553 006</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A203553 008</u>	Nov 16, 2017

SOLODYN

<u>AB</u>	+	MEDICIS	<u>EQ 55MG BASE</u>	<u>N050808 008</u>	Aug 27, 2010
<u>AB</u>	+		<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>	+		<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>	+		<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>	+	!	<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009

MINOLIRA

EPI HLTH

EQ 105MG BASE

N209269 001 May 08, 2017

EQ 135MG BASE

N209269 002 May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

<u>AB</u>		PAR PHARM	<u>2.5MG</u>	<u>A071826 001</u>	Nov 14, 1988
<u>AB</u>			<u>10MG</u>	<u>A071839 001</u>	Nov 14, 1988
<u>AB</u>		SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A072709 002</u>	Dec 14, 1995
<u>AB</u>			<u>10MG</u>	<u>A072709 001</u>	Dec 14, 1995
<u>AB</u>		WATSON LABS	<u>2.5MG</u>	<u>A071344 001</u>	Mar 03, 1987
<u>AB</u>	!		<u>10MG</u>	<u>A071345 001</u>	Mar 03, 1987

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

<u>AB</u>		SAWAI USA	<u>25MG</u>	<u>A209446 001</u>	Dec 27, 2019
<u>AB</u>	+	!	<u>25MG</u>	<u>N202611 001</u>	Jun 28, 2012
	+		<u>50MG</u>	<u>N202611 002</u>	Jun 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666 001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666 002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666 003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921 001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921 002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921 003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921 004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122 003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541 004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541 001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541 002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541 003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119 001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119 002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119 003</u>	Jun 19, 2003
<u>AB</u>	UPSHER SMITH LABS	<u>15MG</u>	<u>A076219 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219 003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N020415 001</u>	Jun 14, 1996
<u>AB</u>	+	<u>30MG</u>	<u>N020415 002</u>	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376 002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376 003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376 004</u>	Feb 28, 2006
<u>AB</u>	IMPAX LABS INC	<u>15MG</u>	<u>A076901 001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901 002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901 003</u>	Jun 28, 2005
<u>AB</u>	ZYDUS PHARMS	<u>15MG</u>	<u>A205798 001</u>	Jun 01, 2017
<u>AB</u>		<u>30MG</u>	<u>A205798 002</u>	Jun 01, 2017
<u>AB</u>		<u>45MG</u>	<u>A205798 003</u>	Jun 01, 2017

REMERON SOLTAB

<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N021208 001</u>	Jan 12, 2001
<u>AB</u>	+	<u>30MG</u>	<u>N021208 002</u>	Jan 12, 2001
<u>AB</u>	+	<u>45MG</u>	<u>N021208 003</u>	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEK

<u>AB</u>	+ GD SEARLE LLC	<u>0.1MG</u>	<u>N019268 003</u>	Sep 21, 1990
<u>AB</u>	+!	<u>0.2MG</u>	<u>N019268 001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667 001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667 002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

+! MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE;INJECTION

MITOMYCIN

<u>AP</u>	! ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144 001</u>	Apr 30, 1998
<u>AP</u>	!	<u>20MG/VIAL</u>	<u>A064144 002</u>	Apr 30, 1998
<u>AP</u>	!	<u>40MG/VIAL</u>	<u>A064144 003</u>	Aug 11, 2009
<u>AP</u>	MYLAN LABS LTD	<u>5MG/VIAL</u>	<u>A202670 001</u>	Oct 13, 2017
<u>AP</u>		<u>20MG/VIAL</u>	<u>A202670 002</u>	Oct 13, 2017
<u>AP</u>		<u>40MG/VIAL</u>	<u>A203386 001</u>	Oct 13, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A064180 001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117 002</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180 002</u>	Dec 23, 1999
<u>AP</u>		<u>40MG/VIAL</u>	<u>A064117 003</u>	Jun 02, 1999

PRESCRIPTION DRUG PRODUCT LIST

MITOTANE

TABLET; ORAL

LYSODREN

+! HRA PHARMA

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496 003</u>	Apr 11, 2006
<u>AP</u>	! HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871 001</u>	Apr 11, 2006
<u>AP</u>	!	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871 002</u>	Apr 11, 2006
<u>AP</u>	!	<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871 003</u>	Apr 11, 2006
<u>AP</u>	TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356 003</u>	Apr 11, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611 003</u>	Apr 11, 2006

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>	ALEMBIC PHARMS LTD	<u>100MG</u>	<u>A202700 001</u>	Oct 18, 2012
<u>AB</u>		<u>200MG</u>	<u>A202700 002</u>	Oct 18, 2012
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077667 001</u>	Feb 03, 2014
<u>AB</u>		<u>200MG</u>	<u>A077667 002</u>	Feb 03, 2014
<u>AB</u>	APPCO	<u>100MG</u>	<u>A207196 001</u>	Aug 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A207196 002</u>	Aug 16, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566 001</u>	Sep 27, 2012
<u>AB</u>		<u>200MG</u>	<u>A202566 002</u>	Sep 27, 2012
<u>AB</u>	CADILA	<u>100MG</u>	<u>A209966 001</u>	Sep 14, 2017
<u>AB</u>		<u>200MG</u>	<u>A209966 002</u>	Sep 14, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076594 001</u>	Jul 16, 2012
<u>AB</u>		<u>200MG</u>	<u>A076594 002</u>	Jul 16, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>100MG</u>	<u>A078963 001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A078963 002</u>	Sep 26, 2012
<u>AB</u>	WATSON LABS INC	<u>100MG</u>	<u>A076715 001</u>	Nov 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A076715 002</u>	Nov 01, 2012
	<u>PROVIGIL</u>			
<u>AB</u>	+ CEPHALON	<u>100MG</u>	<u>N020717 001</u>	Dec 24, 1998
<u>AB</u>	+!	<u>200MG</u>	<u>N020717 002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454 001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454 002</u>	Jun 02, 2008
<u>AB</u>	CHARTWELL RX	<u>7.5MG</u>	<u>A077536 001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536 002</u>	Nov 30, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416 001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416 002</u>	Mar 30, 2010
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204 001</u>	May 08, 2003
<u>AB</u>	!	<u>15MG</u>	<u>A076204 002</u>	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A090453 001 Mar 20, 2015

10MG

A090453 002 Mar 20, 2015

!

25MG

A090453 003 Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

+ MERCK SHARP DOHME

0.05MG/INH

N205641 003 Aug 12, 2019

+

0.10MG/INH

N205641 001 Apr 25, 2014

+!

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	ACP NIMBLE	<u>0.1%</u>	<u>A077447 001</u>	May 22, 2006
<u>AB</u>	ANDA REPOSITORY	<u>0.1%</u>	<u>A076591 001</u>	Apr 18, 2007

PRESCRIPTION DRUG PRODUCT LIST

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	! GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004

IMPLANT; IMPLANTATION

SINUVA

+ INTERSECT ENT INC

1.35MG

N209310 001 Dec 08, 2017

LOTION; TOPICAL

ELOCON

<u>AB</u>	! MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
-----------	---------------------	-------------	----------------	------------	--------------

MOMETASONE FUROATE

<u>AB</u>	ACP NIMBLE	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	ANDA REPOSITORY	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO ISRAEL	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006

OINTMENT; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	ACP NIMBLE	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	ANDA REPOSITORY	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003
<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	! GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TORRENT	<u>0.1%</u>	<u>A207899</u>	<u>001</u>	Jul 13, 2018

POWDER; INHALATION

ASMANEX TWISTHALER

+ MERCK SHARP DOHME

0.11MG/INH

N021067 002 Feb 01, 2008

+!

0.22MG/INH

N021067 001 Mar 30, 2005

SPRAY, METERED; NASAL

MOMETASONE FUROATE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 0.05MG BASE/SPRAY</u>	<u>A207989</u>	<u>001</u>	Apr 03, 2017
<u>AB</u>	APOTEX INC	<u>EQ 0.05MG BASE/SPRAY</u>	<u>A091161</u>	<u>001</u>	Mar 22, 2016

NASONEX

<u>AB</u>	! MERCK SHARP DOHME	<u>EQ 0.05MG BASE/SPRAY</u>	<u>N020762</u>	<u>001</u>	Oct 01, 1997
-----------	---------------------	-----------------------------	----------------	------------	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A203438</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT	<u>EQ 4MG BASE/PACKET</u>	<u>A210431</u>	<u>001</u>	Jul 31, 2018

SINGULAIR

<u>AB</u>	! MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002
-----------	---------	---------------------------	----------------	------------	--------------

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A203432</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>	AMNEAL PHARMS	<u>EQ 10MG BASE</u>	<u>A204604</u>	<u>001</u>	Sep 04, 2015
<u>AB</u>	ANBISON LAB	<u>EQ 10MG BASE</u>	<u>A205683</u>	<u>001</u>	Jan 12, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	CIPLA	<u>EQ 10MG BASE</u>	<u>A207463</u>	<u>001</u>	Oct 28, 2016
<u>AB</u>	CSPC OUYI	<u>EQ 10MG BASE</u>	<u>A209012</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843</u>	<u>001</u>	Sep 10, 2014
<u>AB</u>	HIKMA	<u>EQ 10MG BASE</u>	<u>A090655</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	L PERRIGO CO	<u>EQ 10MG BASE</u>	<u>A206112</u>	<u>001</u>	Apr 26, 2017
<u>AB</u>	LANNETT CO INC	<u>EQ 10MG BASE</u>	<u>A201522</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366</u>	<u>001</u>	Sep 11, 2014
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 10MG BASE</u>	<u>A204290</u>	<u>001</u>	Oct 08, 2015
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859</u>	<u>001</u>	Oct 30, 2014

SINGULAIR

<u>AB</u>	! MSD MERCK CO	<u>EQ 10MG BASE</u>	<u>N020829</u>	<u>002</u>	Feb 20, 1998
-----------	----------------	---------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A203328 001</u>	Jul 31, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203328 002</u>	Jul 31, 2015
<u>AB</u>	ANBISON LAB	<u>EQ 4MG BASE</u>	<u>A205695 001</u>	Nov 05, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205695 002</u>	Nov 05, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096 002</u>	Aug 03, 2012
<u>AB</u>	CIPLA	<u>EQ 4MG BASE</u>	<u>A207464 001</u>	Dec 06, 2018
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207464 002</u>	Dec 06, 2018
<u>AB</u>	CSPC OUYI	<u>EQ 4MG BASE</u>	<u>A209011 001</u>	Apr 18, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A209011 002</u>	Apr 18, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581 001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581 002</u>	Aug 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 4MG BASE</u>	<u>A204093 001</u>	May 22, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204093 002</u>	May 22, 2015
<u>AB</u>	HIKMA	<u>EQ 4MG BASE</u>	<u>A091128 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128 002</u>	Aug 03, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 4MG BASE</u>	<u>A203795 001</u>	Feb 27, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203795 002</u>	Feb 27, 2015
<u>AB</u>	LANNETT CO INC	<u>EQ 4MG BASE</u>	<u>A200405 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A203582 001</u>	Mar 12, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203582 002</u>	Mar 12, 2015
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 4MG BASE</u>	<u>A208621 001</u>	Jul 02, 2018
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A208621 002</u>	Jul 02, 2018
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037 001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037 002</u>	Oct 30, 2014
	<u>SINGULAIR</u>			
<u>AB</u>	+ MSD MERCK CO	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000
<u>AB</u>	+!	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

<u>AB</u>	+! ALLERGAN	<u>10MG</u>	<u>N020616 008</u>	Apr 20, 2007
<u>AB</u>	+	<u>20MG</u>	<u>N020616 001</u>	Jul 03, 1996
<u>AB</u>	+	<u>30MG</u>	<u>N020616 004</u>	Mar 09, 2001
<u>AB</u>	+	<u>40MG</u>	<u>N020616 009</u>	Jul 09, 2012
<u>AB</u>	+	<u>50MG</u>	<u>N020616 002</u>	Jul 03, 1996
<u>AB</u>	+	<u>60MG</u>	<u>N020616 005</u>	Mar 09, 2001
<u>AB</u>	+	<u>70MG</u>	<u>N020616 010</u>	Jul 09, 2012
<u>AB</u>	+	<u>80MG</u>	<u>N020616 006</u>	Oct 27, 2006
<u>AB</u>	+!	<u>100MG</u>	<u>N020616 003</u>	Jul 03, 1996

MORPHINE SULFATE

<u>AB</u>	IMPAX LABS INC	<u>20MG</u>	<u>A200411 001</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A200411 002</u>	Apr 12, 2016
<u>AB</u>		<u>40MG</u>	<u>A200411 007</u>	Jul 25, 2018
<u>AB</u>		<u>50MG</u>	<u>A200411 003</u>	Apr 12, 2016
<u>AB</u>		<u>60MG</u>	<u>A200411 004</u>	Apr 12, 2016
<u>AB</u>		<u>80MG</u>	<u>A200411 005</u>	Apr 12, 2016
<u>AB</u>		<u>100MG</u>	<u>A200411 006</u>	Apr 12, 2016
<u>AB</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812 001</u>	Nov 10, 2011
<u>AB</u>		<u>30MG</u>	<u>A200812 002</u>	Nov 10, 2011
<u>AB</u>		<u>50MG</u>	<u>A200812 003</u>	Nov 10, 2011
<u>AB</u>		<u>60MG</u>	<u>A200812 004</u>	Nov 10, 2011
<u>AB</u>		<u>80MG</u>	<u>A200812 005</u>	Nov 10, 2011
<u>AB</u>		<u>100MG</u>	<u>A200812 006</u>	Nov 10, 2011
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A202718 001</u>	Dec 29, 2014
<u>AB</u>		<u>30MG</u>	<u>A202718 002</u>	Dec 29, 2014
<u>AB</u>		<u>40MG</u>	<u>A202718 007</u>	Jun 03, 2015
<u>AB</u>		<u>50MG</u>	<u>A202718 003</u>	Dec 29, 2014
<u>AB</u>		<u>60MG</u>	<u>A202718 004</u>	Dec 29, 2014
<u>AB</u>		<u>70MG</u>	<u>A202718 008</u>	Jun 03, 2015

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>		<u>80MG</u>	<u>A202718 005</u>	Dec 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202718 006</u>	Dec 29, 2014
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A202104 001</u>	Jun 03, 2013
<u>AB</u>		<u>20MG</u>	<u>A202104 002</u>	Jun 03, 2013
<u>AB</u>		<u>30MG</u>	<u>A202104 003</u>	Jun 03, 2013
<u>AB</u>		<u>50MG</u>	<u>A202104 004</u>	Jun 03, 2013
<u>AB</u>		<u>60MG</u>	<u>A202104 005</u>	Jun 03, 2013
<u>AB</u>		<u>80MG</u>	<u>A202104 006</u>	Jun 03, 2013
<u>AB</u>		<u>100MG</u>	<u>A202104 007</u>	Jun 03, 2013

KADIAN

+	ALLERGAN	130MG	N020616 011	Jul 09, 2012
+		150MG	N020616 012	Jul 09, 2012
+	!	200MG	N020616 007	Feb 27, 2007

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040 001	Jan 16, 2013
		45MG	A079040 002	Jan 16, 2013
		60MG	A079040 003	Jan 16, 2013
		75MG	A079040 004	Jan 16, 2013
		90MG	A079040 005	Jan 16, 2013
!		120MG	A079040 006	Jan 16, 2013

INJECTABLE; INJECTION

DURAMORPH PF

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>N018565 001</u>	Sep 18, 1984
<u>AP</u>	+	!	<u>1MG/ML</u>	<u>N018565 002</u>	Sep 18, 1984

INFUMORPH

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>N018565 003</u>	Jul 19, 1991
<u>AP</u>	+	!	<u>25MG/ML</u>	<u>N018565 004</u>	Jul 19, 1991

MITIGO

<u>AP</u>		PIRAMAL CRITICAL	<u>10MG/ML</u>	<u>A204393 001</u>	Jul 16, 2018
<u>AP</u>			<u>25MG/ML</u>	<u>A204393 002</u>	Jul 16, 2018

MORPHINE SULFATE

<u>AP</u>		EUROHLTH INTL SARL	<u>4MG/ML</u>	<u>A205758 001</u>	May 21, 2015
<u>AP</u>			<u>8MG/ML</u>	<u>A205758 002</u>	May 21, 2015
<u>AP</u>			<u>10MG/ML</u>	<u>A205758 003</u>	May 21, 2015
<u>AP</u>		HOSPIRA	<u>0.5MG/ML</u>	<u>A071849 001</u>	May 11, 1988
<u>AP</u>			<u>0.5MG/ML</u>	<u>A073509 001</u>	Sep 30, 1992
<u>AP</u>			<u>1MG/ML</u>	<u>A071850 001</u>	May 11, 1988
<u>AP</u>			<u>1MG/ML</u>	<u>A073510 001</u>	Sep 30, 1992
<u>AP</u>	+	HOSPIRA INC	<u>4MG/ML</u>	<u>N202515 002</u>	Nov 14, 2011
<u>AP</u>	+	!	<u>8MG/ML</u>	<u>N202515 003</u>	Nov 14, 2011
<u>AP</u>	+	!	<u>10MG/ML</u>	<u>N202515 004</u>	Nov 14, 2011
<u>AP</u>	+	ICU MEDICAL INC	<u>1MG/ML</u>	<u>N019916 001</u>	Oct 30, 1992
	+	HOSPIRA INC	2MG/ML	N202515 001	Nov 14, 2011
	+	MERIDIAN MEDCL TECHN	15MG/ML	N019999 001	Jul 12, 1990

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

+	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223 001	Oct 30, 2013
+		4MG/ML (4MG/ML)	N204223 002	Oct 30, 2013
+		5MG/ML (5MG/ML)	N204223 003	Oct 30, 2013
+		8MG/ML (8MG/ML)	N204223 004	Oct 30, 2013
+		10MG/ML (10MG/ML)	N204223 005	Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>		ANI PHARMS INC	<u>10MG/5ML</u>	<u>A205509 001</u>	Apr 17, 2018
<u>AA</u>			<u>20MG/5ML</u>	<u>A205509 002</u>	Apr 17, 2018
<u>AA</u>			<u>100MG/5ML</u>	<u>A205509 003</u>	Apr 17, 2018
<u>AA</u>		HI TECH	<u>100MG/5ML</u>	<u>A208809 001</u>	Jul 06, 2017
<u>AA</u>	+	HIKMA	<u>10MG/5ML</u>	<u>N022195 001</u>	Mar 17, 2008
<u>AA</u>	+		<u>20MG/5ML</u>	<u>N022195 002</u>	Mar 17, 2008
<u>AA</u>	+	!	<u>100MG/5ML</u>	<u>N022195 003</u>	Jan 25, 2010
<u>AA</u>		NOSTRUM LABS INC	<u>10MG/5ML</u>	<u>A201011 001</u>	Feb 05, 2014
<u>AA</u>			<u>20MG/5ML</u>	<u>A201011 002</u>	Feb 05, 2014
<u>AA</u>			<u>100MG/5ML</u>	<u>A201011 003</u>	Oct 06, 2016
<u>AA</u>		PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574 001</u>	Aug 06, 2012
<u>AA</u>		PHARM ASSOC	<u>100MG/5ML</u>	<u>A206573 001</u>	Nov 14, 2016
<u>AA</u>		RHODES PHARMS	<u>10MG/5ML</u>	<u>A206308 001</u>	Jun 22, 2017
<u>AA</u>			<u>20MG/5ML</u>	<u>A206420 001</u>	Jul 12, 2016

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

<u>AA</u>		<u>100MG/5ML</u>	<u>A206308 002</u>	Jun 22, 2017
<u>AA</u>	SPECGX LLC	<u>100MG/5ML</u>	<u>A202348 001</u>	Jul 15, 2011
<u>AA</u>	TRIS PHARMA INC	<u>10MG/5ML</u>	<u>A203518 001</u>	May 12, 2015
<u>AA</u>		<u>20MG/5ML</u>	<u>A203519 001</u>	May 18, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A203518 002</u>	May 12, 2015

TABLET;ORAL

MORPHINE SULFATE

<u>AB</u>	+	HIKMA	<u>15MG</u>	<u>N022207 001</u>	Mar 17, 2008
<u>AB</u>	+	!	<u>30MG</u>	<u>N022207 002</u>	Mar 17, 2008
<u>AB</u>		UPSHER SMITH LABS	<u>15MG</u>	<u>A210610 001</u>	Jul 22, 2019
<u>AB</u>			<u>30MG</u>	<u>A210610 002</u>	Jul 22, 2019

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>15MG</u>	<u>A203849 001</u>	Apr 06, 2015
<u>AB</u>			<u>30MG</u>	<u>A203849 002</u>	Apr 06, 2015
<u>AB</u>			<u>60MG</u>	<u>A203849 003</u>	Apr 06, 2015
<u>AB</u>			<u>100MG</u>	<u>A203849 004</u>	Apr 06, 2015
<u>AB</u>			<u>200MG</u>	<u>A203849 005</u>	Apr 06, 2015
<u>AB</u>		DAVA PHARMS INC	<u>15MG</u>	<u>A075407 001</u>	Jan 28, 2000
<u>AB</u>		MAYNE PHARMA INC	<u>15MG</u>	<u>A205386 001</u>	Oct 28, 2016
<u>AB</u>			<u>30MG</u>	<u>A205386 002</u>	Oct 28, 2016
<u>AB</u>			<u>60MG</u>	<u>A205386 003</u>	Oct 28, 2016
<u>AB</u>			<u>100MG</u>	<u>A205386 004</u>	Oct 28, 2016
<u>AB</u>		NESHER PHARMS	<u>15MG</u>	<u>A076733 001</u>	May 19, 2004
<u>AB</u>			<u>30MG</u>	<u>A076720 002</u>	Dec 23, 2005
<u>AB</u>			<u>60MG</u>	<u>A076720 001</u>	May 19, 2004
<u>AB</u>			<u>100MG</u>	<u>A077855 001</u>	Sep 27, 2007
<u>AB</u>			<u>200MG</u>	<u>A077855 002</u>	Sep 27, 2007
<u>AB</u>		NOVEL LABS INC	<u>15MG</u>	<u>A203602 001</u>	Dec 16, 2015
<u>AB</u>			<u>30MG</u>	<u>A203602 002</u>	Dec 16, 2015
<u>AB</u>			<u>60MG</u>	<u>A203602 003</u>	Dec 16, 2015
<u>AB</u>			<u>100MG</u>	<u>A203602 004</u>	Dec 16, 2015
<u>AB</u>			<u>200MG</u>	<u>A203602 005</u>	Dec 16, 2015
<u>AB</u>		RHODES PHARMS	<u>15MG</u>	<u>A074862 001</u>	Jul 07, 1998
<u>AB</u>			<u>30MG</u>	<u>A074862 002</u>	Jul 07, 1998
<u>AB</u>			<u>60MG</u>	<u>A074862 003</u>	Jul 07, 1998
<u>AB</u>			<u>100MG</u>	<u>A074769 001</u>	Jul 02, 1998
<u>AB</u>			<u>200MG</u>	<u>A074769 002</u>	Jul 02, 1998
<u>AB</u>		SPECGX LLC	<u>15MG</u>	<u>A076412 001</u>	Jul 31, 2003
<u>AB</u>			<u>30MG</u>	<u>A076412 002</u>	Jul 31, 2003
<u>AB</u>			<u>60MG</u>	<u>A076412 003</u>	Jul 31, 2003
<u>AB</u>			<u>100MG</u>	<u>A076438 001</u>	Jul 03, 2003
<u>AB</u>			<u>200MG</u>	<u>A076438 002</u>	Jul 03, 2003
<u>AB</u>		SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761 001</u>	May 11, 2012
<u>AB</u>			<u>30MG</u>	<u>A078761 002</u>	May 11, 2012
<u>AB</u>			<u>60MG</u>	<u>A078761 003</u>	May 11, 2012
<u>AB</u>			<u>100MG</u>	<u>A078761 004</u>	May 11, 2012
<u>AB</u>			<u>200MG</u>	<u>A078761 005</u>	May 11, 2012
<u>AB</u>		VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295 001</u>	Oct 28, 1998
<u>AB</u>			<u>30MG</u>	<u>A075295 002</u>	Oct 28, 1998
<u>AB</u>			<u>60MG</u>	<u>A075295 003</u>	Oct 28, 1998
<u>AB</u>			<u>100MG</u>	<u>A075295 004</u>	Sep 15, 2000
<u>AB</u>			<u>200MG</u>	<u>A075295 005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	+	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516 003</u>	Sep 12, 1989
<u>AB</u>	+		<u>30MG</u>	<u>N019516 001</u>	May 29, 1987
<u>AB</u>	+		<u>60MG</u>	<u>N019516 002</u>	Apr 08, 1988
<u>AB</u>	+	!	<u>100MG</u>	<u>N019516 004</u>	Jan 16, 1990
<u>AB</u>	+		<u>200MG</u>	<u>N019516 005</u>	Nov 08, 1993

MORPHABOND ER

	+	DAIICHI SANKYO INC	15MG	N206544 001	Oct 02, 2015
	+		30MG	N206544 002	Oct 02, 2015
	+		60MG	N206544 003	Oct 02, 2015
	+	!	100MG	N206544 004	Oct 02, 2015

PRESCRIPTION DRUG PRODUCT LIST

MOXIDECTIN

TABLET; ORAL

MOXIDECTIN

+! MDGH

2MG

N210867 001 Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

+! FRESENIUS KABI USA

EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)

N205572 001 Apr 03, 2015

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

! MYLAN LABS LTD

400MG/250ML (1.6MG/ML)

A205833 001 May 05, 2017

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDEAT1 AKORNEQ 0.5% BASEA202916 001 Nov 09, 2017AT1 ALEMBIC PHARMS LTDEQ 0.5% BASEA209469 001 Feb 13, 2019AT1 APOTEXEQ 0.5% BASEA090080 001 Jun 30, 2017AT1 AUROBINDO PHARMA LTDEQ 0.5% BASEA206242 001 Oct 04, 2017AT1 LUPIN LTDEQ 0.5% BASEA202867 001 Sep 04, 2014AT1 WATSON LABS INCEQ 0.5% BASEA202525 001 Mar 06, 2015VIGAMOXAT1 +! NOVARTISEQ 0.5% BASEN021598 001 Apr 15, 2003MOXEZAAT2 +! NOVARTISEQ 0.5% BASEN022428 001 Nov 19, 2010MOXIFLOXACIN HYDROCHLORIDEAT2 LUPIN LTDEQ 0.5% BASEA204079 001 May 28, 2015

TABLET; ORAL

AVELOXAB +! BAYER HLTHCAREEQ 400MG BASEN021085 001 Dec 10, 1999MOXIFLOXACIN HYDROCHLORIDEAB AUROBINDO PHARMA LTDEQ 400MG BASEA202632 001 Mar 04, 2014AB CROSSMEDIKA SAEQ 400MG BASEA205348 001 Jan 14, 2016AB DR REDDYS LABS LTDEQ 400MG BASEA076938 001 Mar 04, 2014AB MSNEQ 400MG BASEA208682 001 Sep 22, 2017AB NOVEL LABS INCEQ 400MG BASEA207285 001 Feb 13, 2017AB TEVA PHARMS USAEQ 400MG BASEA077437 001 Feb 18, 2014AB TORRENTEQ 400MG BASEA200160 001 Apr 03, 2014MUPIROICIN

OINTMENT; TOPICAL

MUPIROICINAB FOUGERA PHARMS2%A065192 001 Nov 30, 2005AB GLENMARK PHARMS2%A090480 001 Jun 08, 2011AB ! PERRIGO ISRAEL2%A065123 001 Nov 07, 2003AB TARO2%A065170 001 Sep 23, 2005AB TEVA2%A065085 001 Nov 07, 2003

CENTANY

BX PERRIGO NEW YORK

2%

N050788 001 Dec 04, 2002

MUPIROICIN CALCIUM

CREAM; TOPICAL

MUPIROICIN

! GLENMARK PHARMS INC

EQ 2% BASE

A201587 001 Jan 24, 2013

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPTAB +! ROCHE PALO250MGN050722 001 May 03, 1995MYCOPHENOLATE MOFETILAB ACCORD HLTHCARE250MGA090253 001 May 04, 2009AB ALKEM LABS LTD250MGA200197 001 Jun 13, 2013AB CONCORD BIOTECH LTD250MGA210181 001 Jan 08, 2019AB HIKMA250MGA065410 001 Jul 29, 2008AB MYLAN250MGA065520 001 May 04, 2009AB SANDOZ250MGA065379 001 Oct 15, 2008AB STRIDES PHARMA250MGA090055 001 Jun 10, 2010AB TEVA PHARMS250MGA065491 001 May 06, 2009AB VINTAGE PHARMS LLC250MGA090111 001 Dec 22, 2009AB ZHEJIANG HISUN250MGA204077 001 Nov 13, 2017

PHARM

SUSPENSION; ORAL

CELLCEPTAB +! ROCHE PALO200MG/MLN050759 001 Oct 01, 1998

PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL

MYCOPHENOLATE MOFETIL

<u>AB</u>	ALKEM LABS LTD	<u>200MG/ML</u>	<u>A203005</u>	<u>001</u>	Nov 14, 2014
<u>AB</u>	VISTAPHARM	<u>200MG/ML</u>	<u>A210370</u>	<u>001</u>	Feb 12, 2019

TABLET; ORAL

CELLCEPT

<u>AB</u>	<u>+</u> ! ROCHE PALO	<u>500MG</u>	<u>N050723</u>	<u>001</u>	Jun 19, 1997
-----------	-----------------------	--------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A065416</u>	<u>001</u>	May 04, 2009
<u>AB</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A091249</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>	HIKMA	<u>500MG</u>	<u>A065413</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A065521</u>	<u>001</u>	May 04, 2009
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065451</u>	<u>001</u>	Oct 15, 2008
<u>AB</u>	STRIDES PHARMA	<u>500MG</u>	<u>A090456</u>	<u>001</u>	Jun 10, 2010
<u>AB</u>	ZHEJIANG HISUN PHARM	<u>500MG</u>	<u>A204076</u>	<u>001</u>	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

<u>AP</u>	<u>+</u> ! ROCHE PALO	<u>500MG/VIAL</u>	<u>N050758</u>	<u>001</u>	Aug 12, 1998
-----------	-----------------------	-------------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>500MG/VIAL</u>	<u>A204043</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>	MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A203859</u>	<u>001</u>	Mar 31, 2017
<u>AP</u>	PAR STERILE PRODUCTS	<u>500MG/VIAL</u>	<u>A203575</u>	<u>001</u>	Oct 28, 2016
<u>AP</u>	ZYDUS PHARMS	<u>500MG/VIAL</u>	<u>A204473</u>	<u>001</u>	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

<u>AB</u>	ACCORD HLTHCARE	<u>180MG</u>	<u>A202555</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>		<u>360MG</u>	<u>A202555</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>	APOTEX INC	<u>180MG</u>	<u>A091558</u>	<u>001</u>	Aug 21, 2012
<u>AB</u>		<u>360MG</u>	<u>A091558</u>	<u>002</u>	Aug 19, 2014
<u>AB</u>	CONCORD BIOTECH LTD	<u>180MG</u>	<u>A211173</u>	<u>001</u>	Dec 13, 2019
<u>AB</u>		<u>360MG</u>	<u>A211173</u>	<u>002</u>	Dec 13, 2019
<u>AB</u>	MYLAN	<u>180MG</u>	<u>A091248</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>		<u>360MG</u>	<u>A091248</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>	TEVA PHARMS USA	<u>180MG</u>	<u>A202720</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>		<u>360MG</u>	<u>A202720</u>	<u>002</u>	Oct 30, 2014

MYFORTIC

<u>AB</u>	<u>+</u> NOVARTIS	<u>180MG</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
<u>AB</u>	<u>+</u> !	<u>360MG</u>	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

<u>+</u> !	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985
------------	---------------------	-----	---------	-----	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>	CASI PHARMS INC	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>		<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>	CHARTWELL MOLECULES	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>	IMPAX LABS INC	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	<u>!</u>	<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001
<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A090516</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>750MG</u>	<u>A090516</u>	<u>002</u>	Jul 12, 2010
<u>AB</u>	NEXGEN PHARMA INC	<u>500MG</u>	<u>A203166</u>	<u>001</u>	Aug 30, 2019
<u>AB</u>		<u>750MG</u>	<u>A203166</u>	<u>002</u>	Aug 30, 2019
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A090427</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>750MG</u>	<u>A090427</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A078420</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>750MG</u>	<u>A078420</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>		<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011
	NEXGEN PHARMA INC	1GM	A203166	003	Aug 30, 2019

PRESCRIPTION DRUG PRODUCT LIST

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	+	US WORLDMEDS LLC	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>	+		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+	!	<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>		AMNEAL PHARMS CO	<u>20MG</u>	<u>A208832</u>	<u>001</u>	Jun 02, 2017
<u>AB</u>			<u>40MG</u>	<u>A208832</u>	<u>002</u>	Jun 02, 2017
<u>AB</u>			<u>80MG</u>	<u>A208832</u>	<u>003</u>	Jun 02, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A201893</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>			<u>80MG</u>	<u>A201893</u>	<u>002</u>	Sep 16, 2015
<u>AB</u>		BEXIMCO PHARMS USA	<u>20MG</u>	<u>A210955</u>	<u>001</u>	Jul 23, 2018
<u>AB</u>			<u>40MG</u>	<u>A210955</u>	<u>002</u>	Jul 23, 2018
<u>AB</u>			<u>80MG</u>	<u>A210955</u>	<u>003</u>	Jul 23, 2018
<u>AB</u>		HERITAGE PHARMA	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>			<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>			<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>		INVAGEN PHARMS	<u>20MG</u>	<u>A203455</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>			<u>40MG</u>	<u>A203455</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>			<u>80MG</u>	<u>A203455</u>	<u>003</u>	Dec 18, 2015
<u>AB</u>		LUPIN LTD	<u>20MG</u>	<u>A209309</u>	<u>001</u>	Oct 05, 2017
<u>AB</u>			<u>40MG</u>	<u>A209309</u>	<u>002</u>	Oct 05, 2017
<u>AB</u>			<u>80MG</u>	<u>A209309</u>	<u>003</u>	Oct 05, 2017
<u>AB</u>		MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>			<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>			<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>		NOVAST LABS	<u>20MG</u>	<u>A210786</u>	<u>001</u>	Jun 01, 2018
<u>AB</u>			<u>40MG</u>	<u>A210786</u>	<u>002</u>	Jun 01, 2018
<u>AB</u>			<u>80MG</u>	<u>A210786</u>	<u>003</u>	Jun 01, 2018
<u>AB</u>		SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>			<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>			<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>		VGYAAN	<u>20MG</u>	<u>A212856</u>	<u>001</u>	Sep 13, 2019
<u>AB</u>			<u>40MG</u>	<u>A212856</u>	<u>002</u>	Sep 13, 2019
<u>AB</u>			<u>80MG</u>	<u>A212856</u>	<u>003</u>	Sep 13, 2019
<u>AB</u>		ZYDUS PHARMS	<u>20MG</u>	<u>A207761</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>			<u>40MG</u>	<u>A207761</u>	<u>002</u>	Jul 28, 2017
<u>AB</u>			<u>80MG</u>	<u>A207761</u>	<u>003</u>	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

	+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990
--	---	---------------	---------------------	---------	-----	--------------

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>		ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>		FRESENIUS	<u>EQ 1GM BASE/VIAL</u>	<u>A206682</u>	<u>001</u>	Dec 10, 2019
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A206682</u>	<u>002</u>	Dec 10, 2019
<u>AP</u>		ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>		SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	!	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A062527</u>	<u>004</u>	Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

PRESCRIPTION DRUG PRODUCT LIST

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TARO PHARMS	<u>2%</u>	<u>A206901</u>	<u>001</u>	Jan 06, 2016
<u>AB</u>	TOLMAR	<u>2%</u>	<u>A206960</u>	<u>001</u>	Apr 10, 2017

NAFTIN

<u>AB</u>	+!	SEBELA IRELAND LTD	<u>2%</u>	<u>N019599</u>	<u>002</u>	Jan 13, 2012
		NAFTIFINE HYDROCHLORIDE				
	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016

GEL; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TOLMAR	<u>1%</u>	<u>A206165</u>	<u>001</u>	Mar 20, 2019
-----------	--------	-----------	----------------	------------	--------------

NAFTIN

<u>AB</u>	+!	SEBELA IRELAND LTD	<u>1%</u>	<u>N019356</u>	<u>001</u>	Jun 18, 1990
<u>AB</u>	+!		<u>2%</u>	<u>N204286</u>	<u>001</u>	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	!	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	!		<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	!		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>	!		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989
<u>AP</u>		MYLAN LABS LTD	<u>10MG/ML</u>	<u>A206506</u>	<u>001</u>	Feb 06, 2019
<u>AP</u>			<u>10MG/ML</u>	<u>A207595</u>	<u>001</u>	Jan 11, 2019
<u>AP</u>			<u>20MG/ML</u>	<u>A206506</u>	<u>002</u>	Feb 06, 2019
<u>AP</u>			<u>20MG/ML</u>	<u>A207595</u>	<u>002</u>	Jan 11, 2019

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017
----	------	---------------	---------	-----	--------------

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
+!		EQ 25MG BASE	N204760	002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

<u>AP</u>		WEST-WARD PHARMS INT	<u>0.4MG/ML</u>	<u>A070299</u>	<u>001</u>	Sep 24, 1986
-----------	--	-------------------------	-----------------	----------------	------------	--------------

NALOXONE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>0.4MG/ML</u>	<u>A208871</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>			<u>0.4MG/ML</u>	<u>A208872</u>	<u>001</u>	Mar 14, 2017
<u>AP</u>		AUROBINDO PHARMA LTD	<u>0.4MG/ML</u>	<u>A212455</u>	<u>001</u>	Oct 15, 2019
<u>AP</u>			<u>0.4MG/ML</u>	<u>A212456</u>	<u>001</u>	Nov 04, 2019
<u>AP</u>	!	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>	!		<u>0.4MG/ML</u>	<u>A070254</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	!		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>	!		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
<u>AP</u>		INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639</u>	<u>001</u>	Sep 24, 1986
<u>AP</u>		MYLAN INSTITUTIONAL	<u>0.4MG/ML</u>	<u>A204997</u>	<u>001</u>	Mar 06, 2014
<u>AP</u>			<u>0.4MG/ML</u>	<u>A205014</u>	<u>001</u>	Jun 29, 2016
<u>AP</u>		SOMERSET THERAPS LLC	<u>0.4MG/ML</u>	<u>A207633</u>	<u>001</u>	Aug 08, 2017
<u>AP</u>			<u>0.4MG/ML</u>	<u>A207634</u>	<u>001</u>	Jul 26, 2017
	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO (AUTOINJECTOR)

+!	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016
----	-----------	-----------------------	---------	-----	--------------

SPRAY, METERED; NASAL

NARCAN

+!	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015
----	-------	-----------	---------	-----	--------------

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

<u>AB</u>		LUPIN	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
<u>AB</u>	!	WATSON LABS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

PRESCRIPTION DRUG PRODUCT LIST

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+! ALKERMES 380MG/VIAL N021897 001 Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A091205 001</u>	Aug 17, 2011
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A207905 001</u>	Jul 21, 2017
<u>AB</u>	BARR	<u>50MG</u>	<u>A074918 001</u>	May 08, 1998
<u>AB</u>	ELITE LABS	<u>50MG</u>	<u>A075274 001</u>	May 26, 1999
<u>AB</u>	! SPECGX LLC	<u>50MG</u>	<u>A076264 002</u>	Mar 22, 2002
<u>AB</u>	SUN PHARM	<u>50MG</u>	<u>A090356 001</u>	Feb 24, 2012
	SPECGX LLC	25MG	A076264 001	Mar 22, 2002
		100MG	A076264 003	Mar 22, 2002

NAPROXEN

SUSPENSION; ORAL

NAPROSYNAB + ATNAHS PHARMA US 25MG/ML N018965 001 Mar 23, 1987NAPROXENAB ! HIKMA 25MG/ML A074190 001 Mar 30, 1994

TABLET; ORAL

NAPROSYNAB +! ATNAHS PHARMA US 500MG N017581 004 Apr 15, 1982NAPROXEN

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927 001</u>	Dec 18, 2001
<u>AB</u>		<u>375MG</u>	<u>A075927 002</u>	Dec 18, 2001
<u>AB</u>		<u>500MG</u>	<u>A075927 003</u>	Dec 18, 2001
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A200429 001</u>	Nov 08, 2011
<u>AB</u>		<u>375MG</u>	<u>A200429 002</u>	Nov 08, 2011
<u>AB</u>		<u>500MG</u>	<u>A200429 003</u>	Nov 08, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A078250 001</u>	Mar 28, 2007
<u>AB</u>		<u>375MG</u>	<u>A078250 002</u>	Mar 28, 2007
<u>AB</u>		<u>500MG</u>	<u>A078250 003</u>	Mar 28, 2007
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A091305 001</u>	Aug 24, 2011
<u>AB</u>		<u>375MG</u>	<u>A091305 002</u>	Aug 24, 2011
<u>AB</u>		<u>500MG</u>	<u>A091305 003</u>	Aug 24, 2011
<u>AB</u>	MARKSANS PHARMA	<u>250MG</u>	<u>A091416 001</u>	Feb 14, 2011
<u>AB</u>		<u>375MG</u>	<u>A091416 002</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A091416 003</u>	Feb 14, 2011
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074121 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074121 003</u>	Dec 21, 1993
<u>AB</u>	PERRIGO PHARMS CO	<u>250MG</u>	<u>A077339 001</u>	Apr 27, 2005
<u>AB</u>		<u>375MG</u>	<u>A077339 002</u>	Apr 27, 2005
<u>AB</u>		<u>500MG</u>	<u>A077339 003</u>	Apr 27, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074201 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074201 003</u>	Dec 21, 1993
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620 001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620 002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620 003</u>	Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYNAB +! ATNAHS PHARMA US 375MG N020067 002 Oct 14, 1994AB +! 500MG N020067 003 Oct 14, 1994NAPROXEN

<u>AB</u>	PLIVA	<u>375MG</u>	<u>A075337 001</u>	May 26, 1999
<u>AB</u>		<u>500MG</u>	<u>A075337 002</u>	May 26, 1999
<u>AB</u>	SUNRISE PHARM INC	<u>375MG</u>	<u>A091432 001</u>	Sep 19, 2011
<u>AB</u>		<u>500MG</u>	<u>A091432 002</u>	Sep 19, 2011
<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227 001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227 002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX DSAB +! ATNAHS PHARMA US EQ 500MG BASE N018164 003 Sep 30, 1987NAPROXEN SODIUMAB AMNEAL PHARMS NY EQ 250MG BASE A078432 001 Apr 25, 2007AB EQ 500MG BASE A078432 002 Apr 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629 001</u>	Oct 31, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629 002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486 001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486 002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 250MG BASE</u>	<u>A078314 001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314 002</u>	Apr 27, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 250MG BASE</u>	<u>A212199 001</u>	Oct 30, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A212199 002</u>	Oct 30, 2019
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198 001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198 002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

<u>AB</u>	+ ALVOGEN	<u>EQ 375MG BASE</u>	<u>N020353 001</u>	Jan 05, 1996
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N020353 002</u>	Jan 05, 1996
<u>AB</u>	+!	<u>EQ 750MG BASE</u>	<u>N020353 003</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416 002</u>	Apr 23, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075416 001</u>	Aug 27, 2002
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075416 003</u>	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 85MG BASE</u>	<u>A207457 001</u>	Feb 15, 2018
<u>AB</u>	MYLAN	<u>500MG;EQ 85MG BASE</u>	<u>A090872 001</u>	Sep 04, 2018
<u>AB</u>	SUN PHARM	<u>500MG;EQ 85MG BASE</u>	<u>A202803 001</u>	Jul 20, 2018

TREXIMET

<u>AB</u>	+! CURRAX	<u>500MG;EQ 85MG BASE</u>	<u>N021926 001</u>	Apr 15, 2008
-----------	-----------	---------------------------	--------------------	--------------

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763 002</u>	Feb 10, 1998
<u>AB</u>	+!	<u>EQ 2.5MG BASE</u>	<u>N020763 001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502 001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502 002</u>	Feb 28, 2011
<u>AB</u>	HIKMA	<u>EQ 1MG BASE</u>	<u>A090381 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381 002</u>	Jul 07, 2010
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441 001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441 002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326 001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326 002</u>	Jul 08, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552 001</u>	Feb 14, 2011

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+!	NOVARTIS	5%	N050514	001
----	----------	----	---------	-----

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

<u>AB</u>	ALVOGEN	<u>60MG</u>	<u>A205055 001</u>	Dec 11, 2015
<u>AB</u>		<u>120MG</u>	<u>A205055 002</u>	Dec 11, 2015
<u>AB</u>	CADILA PHARMS LTD	<u>60MG</u>	<u>A206432 001</u>	Apr 19, 2019
<u>AB</u>		<u>120MG</u>	<u>A206432 002</u>	Apr 19, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011
<u>AB</u>	WILSHIRE PHARMS INC	<u>60MG</u>	<u>A205544 001</u>	Jun 18, 2018
<u>AB</u>		<u>120MG</u>	<u>A205544 002</u>	Jun 18, 2018
<u>AB</u>	ZYDUS PHARMS	<u>60MG</u>	<u>A205248 001</u>	Jul 06, 2016
<u>AB</u>	!	<u>120MG</u>	<u>A205248 002</u>	Jul 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

<u>AB</u>	+	ALLERGAN	<u>EQ 2.5MG BASE</u>	<u>N021742 002</u>	Dec 17, 2007
<u>AB</u>	+		<u>EQ 5MG BASE</u>	<u>N021742 003</u>	Dec 17, 2007
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N021742 004</u>	Dec 17, 2007
<u>AB</u>	+	!	<u>EQ 20MG BASE</u>	<u>N021742 005</u>	Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

<u>AT</u>	+	!	ALLERGAN	<u>2%</u>	<u>N021009 001</u>	Dec 08, 1999
<u>AT</u>			<u>NEDOCROMIL SODIUM</u>			
<u>AT</u>			AKORN	<u>2%</u>	<u>A090638 001</u>	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

		TEVA	50MG	A076037 001	Sep 16, 2003
			100MG	A076037 002	Sep 16, 2003
			150MG	A076037 003	Sep 16, 2003
			200MG	A076037 004	Sep 16, 2003
		!	250MG	A076037 005	Sep 16, 2003

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

	+	!	NOVARTIS	250MG/50ML (5MG/ML)	N021877 001	Oct 28, 2005
--	---	---	----------	---------------------	-------------	--------------

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

	+	!	AGOURON PHARMS	EQ 250MG BASE	N020779 001	Mar 14, 1997
	+	!		EQ 625MG BASE	N021503 001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

<u>AA</u>			BRECKENRIDGE	<u>500MG</u>	<u>A065468 001</u>	Mar 29, 2010
<u>AA</u>	!		TEVA	<u>500MG</u>	<u>A060304 001</u>	
<u>AA</u>			X GEN PHARMS	<u>500MG</u>	<u>A065220 001</u>	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<u>AT</u>			X GEN PHARMS	<u>EQ 40MG BASE/ML; 200,000 UNITS/ML</u>	<u>A065106 001</u>	Jan 31, 2006
<u>AT</u>				<u>EQ 40MG BASE/ML; 200,000 UNITS/ML</u>	<u>A065108 001</u>	Jan 31, 2006
<u>AT</u>	!		<u>NEOSPORIN G.U. IRRIGANT</u>	<u>EQ 40MG BASE/ML; 200,000 UNITS/ML</u>	<u>A060707 001</u>	

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

<u>AP</u>	+	!	AVADEL LEGACY	<u>5MG/10ML (0.5MG/ML)</u>	<u>N204078 001</u>	May 31, 2013
<u>AP</u>	+	!		<u>10MG/10ML (1MG/ML)</u>	<u>N204078 002</u>	May 31, 2013

NEOSTIGMINE METHYLSULFATE

<u>AP</u>			AM REGENT	<u>5MG/10ML (0.5MG/ML)</u>	<u>A209182 001</u>	May 04, 2018
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A209182 002</u>	May 04, 2018
<u>AP</u>			AMNEAL	<u>5MG/10ML (0.5MG/ML)</u>	<u>A210051 001</u>	Jun 15, 2018
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A210051 002</u>	Jun 15, 2018
<u>AP</u>			AMPHASTAR PHARMS INC	<u>5MG/10ML (0.5MG/ML)</u>	<u>A209933 001</u>	Sep 25, 2017
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A209933 002</u>	Sep 25, 2017
<u>AP</u>			AMRING PHARMS	<u>5MG/10ML (0.5MG/ML)</u>	<u>A210989 001</u>	Aug 22, 2018
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A210989 002</u>	Aug 22, 2018
<u>AP</u>			BE PHARMS	<u>5MG/10ML (0.5MG/ML)</u>	<u>A212512 001</u>	May 13, 2019
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A212512 002</u>	May 13, 2019
<u>AP</u>			DR REDDYS	<u>5MG/10ML (0.5MG/ML)</u>	<u>A209135 001</u>	Jul 10, 2018
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A209135 002</u>	Jul 10, 2018
<u>AP</u>			EUROHLTH INTL SARL	<u>5MG/10ML (0.5MG/ML)</u>	<u>A207042 001</u>	Dec 28, 2015
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A207042 002</u>	Dec 28, 2015
<u>AP</u>			GLAND PHARMA LTD	<u>5MG/10ML (0.5MG/ML)</u>	<u>A212968 001</u>	Oct 16, 2019
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A212968 002</u>	Oct 16, 2019
<u>AP</u>			PAR STERILE PRODUCTS	<u>5MG/10ML (0.5MG/ML)</u>	<u>A208405 001</u>	Apr 26, 2017
<u>AP</u>				<u>10MG/10ML (1MG/ML)</u>	<u>A208405 002</u>	Apr 26, 2017

PRESCRIPTION DRUG PRODUCT LIST

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

FRESENIUS KABI USA

3MG/3ML (1MG/ML)

N203629 003 Sep 18, 2018

5MG/10ML (0.5MG/ML)

N203629 001 Jan 08, 2015

10MG/10ML (1MG/ML)

N203629 002 Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

+! NOVARTIS

0.3%

N203491 001 Oct 16, 2012

NEVANAC

+! NOVARTIS

0.1%

N021862 001 Aug 19, 2005

NERATINIB MALEATE

TABLET;ORAL

NERLYNX

+! PUMA BIOTECH

EQ 40MG BASE

N208051 001 Jul 17, 2017

NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

+! AERIE PHARMS INC

EQ 0.02% BASE

N208254 001 Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL

AKYNZEO

+! HELSINN HLTHCARE

300MG;EQ 0.5MG BASE

N205718 001 Oct 10, 2014

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE**AA** AUROBINDO**50MG/5ML****A077702 001** May 22, 2012**AA** CIPLA**50MG/5ML****A207684 001** Aug 03, 2017VIRAMUNE**AA** +! BOEHRINGER**50MG/5ML****N020933 001** Sep 11, 1998

INGELHEIM

TABLET;ORAL

NEVIRAPINE**AB** AUROBINDO**200MG****A077521 001** May 22, 2012**AB** CIPLA**200MG****A077956 001** May 22, 2012**AB** HETERO LABS LTD III**200MG****A078584 001** May 22, 2012**AB** MACLEODS PHARMS LTD**200MG****A090688 001** Jan 14, 2019**AB** MICRO LABS LTD**200MG****A203080 001** May 22, 2012**AB** MYLAN LABS**200MG****A078864 001** May 22, 2012**AB** MYLAN PHARMS INC**200MG****A202523 001** May 22, 2012**AB** PRINSTON INC**200MG****A078644 001** May 22, 2012**AB** STRIDES PHARMA**200MG****A078195 001** May 22, 2012VIRAMUNE**AB** +! BOEHRINGER**200MG****N020636 001** Jun 21, 1996

INGELHEIM

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE**AB** ALVOGEN**100MG****A204621 002** Nov 09, 2015**AB****400MG****A204621 001** Jul 10, 2015**AB** AUROBINDO PHARMA**100MG****A208616 001** Nov 23, 2016

LTD

AB**400MG****A207698 001** Feb 28, 2017**AB** MACLEODS PHARMS LTD**400MG****A206879 001** Oct 06, 2017**AB** MYLAN**400MG****A205651 001** Oct 27, 2014**AB** SANDOZ INC**400MG****A203411 001** Apr 03, 2014VIRAMUNE XR**AB** + BOEHRINGER**100MG****N201152 002** Nov 08, 2012

INGELHEIM

AB +!**400MG****N201152 001** Mar 25, 2011NIACIN

TABLET;ORAL

NIACIN**AA** WOCKHARDT**500MG****A081134 001** Apr 28, 1992NIACOR**AA** ! AVONDALE PHARMS**500MG****A040378 001** May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN**AB** AMNEAL PHARMS**500MG****A203578 001** Jul 24, 2015**AB****750MG****A204178 001** Dec 11, 2015

PRESCRIPTION DRUG PRODUCT LIST

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

<u>AB</u>		<u>1GM</u>	<u>A203578</u>	<u>002</u>	Jul 24, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A209236</u>	<u>001</u>	Feb 01, 2018
<u>AB</u>		<u>750MG</u>	<u>A209236</u>	<u>002</u>	Feb 01, 2018
<u>AB</u>		<u>1GM</u>	<u>A209236</u>	<u>003</u>	Feb 01, 2018
<u>AB</u>	BARR	<u>500MG</u>	<u>A076378</u>	<u>001</u>	Apr 26, 2005
<u>AB</u>		<u>750MG</u>	<u>A076378</u>	<u>002</u>	Apr 26, 2005
<u>AB</u>		<u>1GM</u>	<u>A076250</u>	<u>001</u>	Apr 14, 2005
<u>AB</u>	JUBILANT GENERICS	<u>500MG</u>	<u>A209156</u>	<u>001</u>	May 14, 2018
<u>AB</u>		<u>750MG</u>	<u>A209156</u>	<u>002</u>	May 14, 2018
<u>AB</u>		<u>1GM</u>	<u>A209156</u>	<u>003</u>	May 14, 2018
<u>AB</u>	LANNETT CO INC	<u>500MG</u>	<u>A203899</u>	<u>001</u>	Jun 16, 2017
<u>AB</u>		<u>1GM</u>	<u>A203899</u>	<u>002</u>	Jun 16, 2017
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A090860</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>		<u>750MG</u>	<u>A090892</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>		<u>1GM</u>	<u>A090446</u>	<u>001</u>	Mar 20, 2014
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A203742</u>	<u>003</u>	Feb 22, 2019
<u>AB</u>		<u>500MG</u>	<u>A203742</u>	<u>001</u>	Feb 22, 2019
<u>AB</u>		<u>750MG</u>	<u>A203742</u>	<u>002</u>	Feb 22, 2019
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A200484</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>750MG</u>	<u>A201273</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>1GM</u>	<u>A200484</u>	<u>002</u>	Apr 23, 2014

NIASPAN

<u>AB</u>	+ ABBVIE	<u>500MG</u>	<u>N020381</u>	<u>002</u>	Jul 28, 1997
<u>AB</u>	+!	<u>750MG</u>	<u>N020381</u>	<u>003</u>	Jul 28, 1997
<u>AB</u>	+!	<u>1GM</u>	<u>N020381</u>	<u>004</u>	Jul 28, 1997

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>	!	<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008
--	----------------------	----------------------	---------	-----	--------------

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
----	----------------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
----	----------------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+!	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
----	----------------	-----------------------	---------	-----	--------------

NICOTINE

INHALANT;ORAL

NICOTROL

+!	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997
----	----------------------	---------------	---------	-----	--------------

SPRAY, METERED;NASAL

NICOTROL

+!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996
----	------------	-------------	---------	-----	--------------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	HERITAGE PHARMA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993
<u>AB</u>	LEADING PHARMA LLC	<u>10MG</u>	<u>A073250</u>	<u>001</u>	Oct 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A074045</u>	<u>001</u>	Apr 30, 1992

PROCARDIA

<u>AB</u>	+! PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>	
-----------	-----------	-------------	----------------	------------	--

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	+ ALVOGEN	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+!	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993

PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	<u>+</u> !		<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993
------------	------------	--	-------------	----------------	------------	--------------

NIFEDIPINE

<u>AB1</u>		MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>			<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>			<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>		NOVAST LABS	<u>30MG</u>	<u>A202987</u>	<u>001</u>	Aug 25, 2016
<u>AB1</u>			<u>60MG</u>	<u>A202987</u>	<u>002</u>	Aug 25, 2016
<u>AB1</u>			<u>90MG</u>	<u>A202987</u>	<u>003</u>	Aug 25, 2016
<u>AB1</u>		PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>			<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>			<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>		VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>			<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>			<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB1</u>		ZYDUS PHARMS	<u>30MG</u>	<u>A210184</u>	<u>001</u>	Jun 29, 2018
<u>AB1</u>			<u>60MG</u>	<u>A210184</u>	<u>002</u>	Jun 29, 2018
<u>AB1</u>			<u>90MG</u>	<u>A210184</u>	<u>003</u>	Jun 29, 2018
<u>AB2</u>		NOVAST LABS	<u>30MG</u>	<u>A210614</u>	<u>001</u>	Mar 12, 2019
<u>AB2</u>			<u>60MG</u>	<u>A210614</u>	<u>002</u>	Mar 12, 2019
<u>AB2</u>			<u>90MG</u>	<u>A210614</u>	<u>003</u>	Mar 12, 2019
<u>AB2</u>		OSMOTICA PHARM US	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>			<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>			<u>90MG</u>	<u>A077127</u>	<u>003</u>	Oct 03, 2007
<u>AB2</u>		SPIL	<u>30MG</u>	<u>A210838</u>	<u>001</u>	Apr 16, 2019
<u>AB2</u>			<u>60MG</u>	<u>A210838</u>	<u>002</u>	Apr 16, 2019
<u>AB2</u>			<u>90MG</u>	<u>A210838</u>	<u>003</u>	Apr 16, 2019
<u>AB2</u>		TWI PHARMS	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>			<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014
<u>AB2</u>			<u>90MG</u>	<u>A203126</u>	<u>003</u>	Apr 03, 2014
<u>AB2</u>		VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>			<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000
<u>AB2</u>		ZYDUS PHARMS	<u>30MG</u>	<u>A210012</u>	<u>001</u>	Dec 19, 2017
<u>AB2</u>			<u>60MG</u>	<u>A210012</u>	<u>002</u>	Dec 19, 2017
<u>AB2</u>			<u>90MG</u>	<u>A210012</u>	<u>003</u>	Dec 19, 2017

PROCARDIA XL

<u>AB2</u>	<u>+</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>	<u>+</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u>	<u>+</u> !		<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

<u>+</u>	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018
<u>+</u>		EQ 150MG BASE	N022068	002	Jun 17, 2010
<u>+</u> !		EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

<u>AB</u>	<u>+</u> !	CONCORDIA	<u>150MG</u>	<u>N020169</u>	<u>002</u>	Apr 30, 1999
-----------	------------	-----------	--------------	----------------	------------	--------------

NILUTAMIDE

<u>AB</u>		ANI PHARMS INC	<u>150MG</u>	<u>A207631</u>	<u>001</u>	Jul 15, 2016
-----------	--	----------------	--------------	----------------	------------	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<u>AB</u>	<u>!</u>	BIONPHARMA INC	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u>		HERITAGE PHARMS INC	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>		SOFGEN PHARMS	<u>30MG</u>	<u>A201832</u>	<u>001</u>	Jul 24, 2015
<u>AB</u>		THEPHARMANETWORK LLC	<u>30MG</u>	<u>A090103</u>	<u>001</u>	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

<u>+</u> !	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013
------------	------------------	-----------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832 001	Oct 15, 2014
+	!	EQ 150MG BASE	N205832 002	Oct 15, 2014

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	TESARO INC	EQ 100MG BASE	N208447 001	Mar 27, 2017
---	------------	---------------	-------------	--------------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<u>AB</u>	MYLAN	<u>8.5MG</u>	<u>A091001 001</u>	Jan 26, 2011
<u>AB</u>		<u>17MG</u>	<u>A091001 002</u>	Jan 26, 2011
<u>AB</u>		<u>34MG</u>	<u>A091001 004</u>	Jan 26, 2011
	<u>SULAR</u>			
<u>AB</u>	+	COVIS PHARMA BV	<u>8.5MG</u>	<u>N020356 008</u> Jan 02, 2008
<u>AB</u>	+		<u>17MG</u>	<u>N020356 007</u> Jan 02, 2008
<u>AB</u>	+		<u>34MG</u>	<u>N020356 005</u> Jan 02, 2008

NISOLDIPINE

MYLAN

		20MG	A079051 001	Jul 25, 2008
		25.5MG	A091001 003	Jan 26, 2011
!		30MG	A079051 002	Jul 25, 2008
!		40MG	A079051 003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION;ORAL

ALINIA

+	ROMARK	100MG/5ML	N021498 001	Nov 22, 2002
---	--------	-----------	-------------	--------------

TABLET;ORAL

ALINIA

+	ROMARK	500MG	N021497 001	Jul 21, 2004
---	--------	-------	-------------	--------------

NITISINONE

CAPSULE;ORAL

NITISINONE

<u>AB</u>	NOVITIUM PHARMA	<u>2MG</u>	<u>A211041 001</u>	Aug 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A211041 002</u>	Aug 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A211041 003</u>	Aug 26, 2019
	<u>ORFADIN</u>			
<u>AB</u>	+	SWEDISH ORPHAN	<u>2MG</u>	<u>N021232 001</u> Jan 18, 2002
<u>AB</u>	+		<u>5MG</u>	<u>N021232 002</u> Jan 18, 2002
<u>AB</u>	+		<u>10MG</u>	<u>N021232 003</u> Jan 18, 2002
	+			<u>N021232 004</u> Jun 13, 2016

SUSPENSION;ORAL

ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356 001	Apr 22, 2016
---	----------------	--------	-------------	--------------

TABLET;ORAL

NITYR

+	CYCLE PHARMS LTD	2MG	N209449 001	Jul 26, 2017
+		5MG	N209449 002	Jul 26, 2017
+	!	10MG	N209449 003	Jul 26, 2017

NITRIC OXIDE

GAS;INHALATION

INOMAX

<u>AA</u>	+	MALLINCKRODT HOSP	<u>800PPM</u>	<u>N020845 003</u> Dec 23, 1999
-----------	---	-------------------	---------------	---------------------------------

NOXIVENT

<u>AA</u>		PRAXAIR DISTRIBUTION	<u>800PPM</u>	<u>A207141 002</u> Oct 02, 2018
		GENOSYL		
	+	VERO BIOTECH	800PPM	N202860 001 Dec 20, 2019
		NOXIVENT		
		PRAXAIR DISTRIBUTION	100PPM	A207141 001 Oct 02, 2018

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

<u>AB</u>	+	CASPER PHARMA LLC	<u>25MG/5ML</u>	<u>N009175 001</u>
-----------	---	-------------------	-----------------	--------------------

NITROFURANTOIN

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>25MG/5ML</u>	<u>A205180 001</u> May 03, 2016
-----------	--	-------------------------	-----------------	---------------------------------

PRESCRIPTION DRUG PRODUCT LIST

NITROFURANTOIN

SUSPENSION; ORAL

NITROFURANTOIN

AB	AMNEAL PHARMS	<u>25MG/5ML</u>	<u>A201679</u>	<u>001</u>	May 11, 2011
AB	NOSTRUM LABS INC	<u>25MG/5ML</u>	<u>A201355</u>	<u>001</u>	Aug 14, 2013
AB	NOVEL LABS INC	<u>25MG/5ML</u>	<u>A201693</u>	<u>001</u>	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	+	ALVOGEN	<u>25MG</u>	<u>N016620</u>	<u>003</u>
AB	+		<u>50MG</u>	<u>N016620</u>	<u>001</u>
AB	+		<u>100MG</u>	<u>N016620</u>	<u>002</u>

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	<u>25MG</u>	<u>A091095</u>	<u>001</u>	Jun 18, 2015
AB			<u>50MG</u>	<u>A091095</u>	<u>002</u>	Jun 18, 2015
AB			<u>100MG</u>	<u>A091095</u>	<u>003</u>	Jun 18, 2015
AB		IMPAX LABS INC	<u>50MG</u>	<u>A073671</u>	<u>001</u>	Jan 28, 1993
AB			<u>100MG</u>	<u>A073652</u>	<u>001</u>	Jan 28, 1993
AB		NOVEL LABS INC	<u>50MG</u>	<u>A203233</u>	<u>001</u>	Jul 09, 2018
AB			<u>100MG</u>	<u>A203233</u>	<u>002</u>	Jul 09, 2018
AB		SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A201722</u>	<u>001</u>	Feb 16, 2016
AB			<u>50MG</u>	<u>A201722</u>	<u>002</u>	Feb 16, 2016
AB			<u>100MG</u>	<u>A201722</u>	<u>003</u>	Feb 16, 2016
AB		ZYDUS PHARMS	<u>50MG</u>	<u>A205005</u>	<u>001</u>	Dec 12, 2017
AB			<u>100MG</u>	<u>A205005</u>	<u>002</u>	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN	<u>75MG; 25MG</u>	<u>N020064</u>	<u>001</u>	Dec 24, 1991
-----------	----------	---------	-------------------	----------------	------------	--------------

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	<u>75MG; 25MG</u>	<u>A207372</u>	<u>001</u>	May 15, 2017
AB		MYLAN	<u>75MG; 25MG</u>	<u>A076648</u>	<u>001</u>	Mar 22, 2004
AB		SANDOZ	<u>75MG; 25MG</u>	<u>A077066</u>	<u>001</u>	Apr 05, 2005
AB		SUNNY PHARMTECH INC	<u>75MG; 25MG</u>	<u>A208516</u>	<u>001</u>	May 24, 2018
AB		WATSON LABS INC	<u>75MG; 25MG</u>	<u>A202250</u>	<u>001</u>	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+	!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006
----------	---	------	-------------	---------	-----	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB2		HERCON PHARM	<u>0.1MG/HR</u>	<u>A089885</u>	<u>002</u>	Oct 30, 2017
AB2			<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998
AB2			<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998
AB2			<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998
AB2	!	MYLAN TECHNOLOGIES	<u>0.1MG/HR</u>	<u>A074559</u>	<u>004</u>	Feb 06, 1998
AB2	!		<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
AB2	!		<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
AB2	!		<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995
+	!		0.2MG/HR	N020145	002	Apr 04, 1995
+	!		0.3MG/HR	N020145	003	Apr 04, 1995
+	!		0.4MG/HR	N020145	004	Apr 04, 1995
+	!		0.6MG/HR	N020145	005	Apr 04, 1995
+	!		0.8MG/HR	N020145	006	Apr 04, 1995

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	+	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
AP	+		<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
AP	+		<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989

NITROGLYCERIN

!		LUITPOLD	5MG/ML	A072034	001	May 24, 1988
---	--	----------	--------	---------	-----	--------------

OINTMENT; INTRA-ANAL

RECTIV

+	!	ALLERGAN	0.4%	N021359	001	Jun 21, 2011
----------	---	----------	------	---------	-----	--------------

OINTMENT; TRANSDERMAL

NITROGLYCERIN

!		FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988
---	--	--------------------	----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

NITROGLYCERIN

POWDER;SUBLINGUAL

GONITRO

+! POHL BOSKAMP 0.4MG/PACKET

N208424 001 Jun 08, 2016

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN**AB** PERRIGO ISRAEL 0.4MG/SPRAY**A091496 001** Sep 20, 2013NITROLINGUAL PUMPSPRAY**AB** +! POHL BOSKAMP 0.4MG/SPRAY**N018705 002** Jan 10, 1997

TABLET;SUBLINGUAL

NITROGLYCERIN**AB** ACTAVIS LABS FL INC 0.3MG**A203693 001** Oct 16, 2017**AB** 0.4MG**A203693 002** Oct 16, 2017**AB** 0.6MG**A203693 003** Oct 16, 2017**AB** ALVOGEN 0.3MG**A211604 001** Apr 30, 2019**AB** 0.4MG**A211604 002** Apr 30, 2019**AB** 0.6MG**A211604 003** Apr 30, 2019**AB** DR REDDYS 0.3MG**A208191 001** Aug 26, 2016**AB** 0.4MG**A208191 002** Aug 26, 2016**AB** 0.6MG**A208191 003** Aug 26, 2016**AB** GLENMARK PHARMS SA 0.3MG**A206391 001** Sep 19, 2017**AB** 0.4MG**A206391 002** Sep 19, 2017**AB** 0.6MG**A206391 003** Sep 19, 2017**AB** SIGMAPHARM LABS LLC 0.3MG**A207745 001** May 07, 2018**AB** 0.4MG**A207745 002** May 07, 2018**AB** 0.6MG**A207745 003** May 07, 2018NITROSTAT**AB** + PFIZER PHARMS 0.3MG**N021134 001** May 01, 2000**AB** + 0.4MG**N021134 002** May 01, 2000**AB** +! 0.6MG**N021134 003** May 01, 2000NIZATIDINE

CAPSULE;ORAL

NIZATIDINE**AB** DR REDDYS LABS LTD 150MG**A077314 001** Sep 15, 2005**AB** 300MG**A077314 002** Sep 15, 2005**AB** GLENMARK GENERICS 150MG**A090618 001** Jul 15, 2011**AB** 300MG**A090618 002** Jul 15, 2011**AB** MYLAN PHARMS INC 150MG**A075806 001** Jul 05, 2002**AB** ! 300MG**A075806 002** Jul 05, 2002**AB** SANDOZ 150MG**A076178 001** Jul 05, 2002**AB** 300MG**A076178 002** Jul 05, 2002**AB** WATSON LABS 150MG**A075616 001** Jul 09, 2002**AB** 300MG**A075616 002** Jul 09, 2002

SOLUTION;ORAL

NIZATIDINE

! AMNEAL PHARMS 15MG/ML

A090576 001 Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHED**AP** +! HOSPIRA EQ 1MG BASE/ML**N007513 001**NOREPINEPHRINE BITARTRATE**AP** AMNEAL EQ 1MG BASE/ML**A210839 001** Dec 17, 2018**AP** BAXTER HLTHCARE EQ 1MG BASE/ML**A040859 001** Mar 27, 2012

CORP

AP HIKMA EQ 1MG BASE/ML**A203662 001** Nov 07, 2018**AP** MYLAN LABS LTD EQ 1MG BASE/ML**A211242 001** Oct 04, 2018**AP** SANDOZ INC EQ 1MG BASE/ML**A211359 001** Oct 18, 2018**AP** TEVA PHARMS USA EQ 1MG BASE/ML**A040455 001** Mar 03, 2003**AP** WEST-WARD PHARMS EQ 1MG BASE/ML**A040462 001** Oct 31, 2003

INT

NORETHINDRONE

TABLET;ORAL-28

CAMILA**AB1** MAYNE PHARMA 0.35MG**A076177 001** Oct 21, 2002HEATHER**AB1** GLENMARK GENERICS 0.35MG**A090454 001** Apr 23, 2010INCASSIA**AB1** AUROBINDO PHARMA 0.35MG**A207304 001** Sep 23, 2016

LTD

NOR-QD**AB1** +! APIL 0.35MG**N017060 001**

PRESCRIPTION DRUG PRODUCT LIST

NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE

<u>AB1</u>	ACCORD HLTHCARE	<u>0.35MG</u>	<u>A206807 001</u>	Dec 13, 2016
<u>AB1</u>	AMNEAL PHARMS	<u>0.35MG</u>	<u>A202260 001</u>	Aug 01, 2013
<u>AB1</u>	LUPIN LTD	<u>0.35MG</u>	<u>A091325 001</u>	Sep 19, 2011
<u>AB1</u>	MYLAN LABS LTD	<u>0.35MG</u>	<u>A201483 001</u>	Jun 24, 2013
<u>AB1</u>	NOVAST LABS	<u>0.35MG</u>	<u>A202014 001</u>	Sep 13, 2013

ERRIN

<u>AB2</u>	MAYNE PHARMA	<u>0.35MG</u>	<u>A076225 001</u>	Oct 21, 2002
------------	--------------	---------------	--------------------	--------------

JENCYCLA

<u>AB2</u>	LUPIN LTD	<u>0.35MG</u>	<u>A091323 001</u>	Mar 28, 2013
------------	-----------	---------------	--------------------	--------------

NORETHINDRONE

<u>AB2</u>	GLENMARK GENERICS	<u>0.35MG</u>	<u>A091209 001</u>	Jul 22, 2010
<u>AB2</u>	! MYLAN LABS LTD	<u>0.35MG</u>	<u>A200980 001</u>	Jun 12, 2013
<u>AB2</u>	NOVAST LABS	<u>0.35MG</u>	<u>A200961 001</u>	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A200275 001</u>	Jul 30, 2012
<u>AB</u>	! BARR	<u>5MG</u>	<u>A075951 001</u>	May 25, 2001
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A091090 001</u>	Jul 21, 2010
<u>AB</u>	MYLAN LABS LTD	<u>5MG</u>	<u>A205278 001</u>	Nov 10, 2016
<u>AB</u>	NOVAST LABS	<u>5MG</u>	<u>A206490 001</u>	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	MAYNE PHARMA	<u>EQ 10MG BASE</u>	<u>A073556 002</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A073556 003</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A073556 004</u>	Mar 30, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A073556 001</u>	Mar 30, 1992
<u>AB</u>	TARO	<u>EQ 10MG BASE</u>	<u>A075520 004</u>	May 08, 2000
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A075520 003</u>	May 08, 2000
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520 001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520 002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132 001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132 002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132 003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132 004</u>	Mar 27, 1995

PAMELOR

<u>AB</u>	+ SPECGX LLC	<u>EQ 10MG BASE</u>	<u>N018013 001</u>	
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>N018013 002</u>	
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N018013 004</u>	
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N018013 003</u>	

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>	! PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606 001</u>	Aug 28, 2000
<u>AA</u>	TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965 001</u>	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

+	! BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531 001	Dec 23, 2016
---	---------------	---------------------	-------------	--------------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

<u>AT</u>	ACP NIMBLE	<u>100,000 UNITS/GM</u>	<u>A061966 001</u>	
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949 001</u>	Jun 13, 1988
<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM</u>	<u>A207733 001</u>	Sep 26, 2017
<u>AT</u>	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129 001</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225 001</u>	
<u>AT</u>	! TARO	<u>100,000 UNITS/GM</u>	<u>A064022 001</u>	Jan 29, 1993
<u>AT</u>	TORRENT	<u>100,000 UNITS/GM</u>	<u>A212557 001</u>	Jul 24, 2019
<u>AT</u>	VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315 001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	ACP NIMBLE	<u>100,000 UNITS/GM</u>	<u>A209114 001</u>	Oct 06, 2017
<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840 001</u>	Nov 13, 1987
<u>AT</u>	CADILA	<u>100,000 UNITS/GM</u>	<u>A207767 001</u>	May 25, 2018
<u>AT</u>	! FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062124 002</u>	Sep 23, 1982

PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	LYNE	<u>100,000 UNITS/GM</u>	<u>A209082 001</u>	May 21, 2018
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472 001</u>	Feb 13, 1984
<u>AT</u>	TORRENT	<u>100,000 UNITS/GM</u>	<u>A211838 001</u>	Jan 28, 2019

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	EPIC PHARMA LLC	<u>100,000 UNITS/GM</u>	<u>A210532 001</u>	Apr 30, 2018
<u>AT</u>	LUPIN	<u>100,000 UNITS/GM</u>	<u>A065138 001</u>	Jul 23, 2004
<u>AT</u>	LYNE	<u>100,000 UNITS/GM</u>	<u>A208838 001</u>	May 30, 2017
<u>AT</u>	! MAYNE PHARMA INC	<u>100,000 UNITS/GM</u>	<u>A065203 001</u>	Jul 15, 2004
<u>AT</u>	NESHER PHARMS	<u>100,000 UNITS/GM</u>	<u>A208581 001</u>	Jun 08, 2017
<u>AT</u>	UPSHER SMITH LABS	<u>100,000 UNITS/GM</u>	<u>A065183 001</u>	May 03, 2005
<u>AT</u>	X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175 001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>	PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118 001</u>	Aug 16, 1996
-----------	-------------	-------------------------	--------------------	--------------

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/ML</u>	<u>A062517 001</u>	Jun 07, 1984
<u>AA</u>	HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042 001</u>	Feb 28, 1994
<u>AA</u>	LANNETT CO INC	<u>100,000 UNITS/ML</u>	<u>A065148 001</u>	Jun 28, 2005
<u>AA</u>	PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621 001</u>	Jan 07, 2016
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876 001</u>	Feb 29, 1988
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142 001</u>	Jun 25, 1998
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422 001</u>	Mar 07, 2011
<u>AA</u>	! WOCKHARDT BIO AG	<u>100,000 UNITS/ML</u>	<u>A062512 001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474 001</u>	Dec 22, 1983
<u>AA</u>	SUN PHARM INDUSTRIES	<u>500,000 UNITS</u>	<u>A062838 001</u>	Dec 22, 1988
<u>AA</u>	! TEVA	<u>500,000 UNITS</u>	<u>A062506 001</u>	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	ACP NIMBLE	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062367 001</u>	May 28, 1985
-----------	------------	-------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	AMNEAL PHARMS LLC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A209990 001</u>	Feb 15, 2018
<u>AT</u>	CROWN LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207730 001</u>	Dec 26, 2017
<u>AT</u>	DR REDDYS	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208326 001</u>	Oct 26, 2016
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599 001</u>	Oct 08, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208136 001</u>	Oct 24, 2016
<u>AT</u>	LUPIN LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208205 001</u>	May 31, 2018
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208479 001</u>	Aug 14, 2017
<u>AT</u>	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364 001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	ACP NIMBLE	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062733 001</u>	Mar 06, 1987
-----------	------------	-------------------------------	--------------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207217 001</u>	Aug 04, 2017
<u>AT</u>	DR REDDYS	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207741 001</u>	Jan 31, 2017
<u>AT</u>	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602 001</u>	Oct 09, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208300 001</u>	Jun 23, 2016
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207380 001</u>	Dec 20, 2016
<u>AT</u>	RISING	<u>100,000 UNITS/GM; 0.1%</u>	<u>A206785 001</u>	Dec 29, 2016
<u>AT</u>	STRIDES PHARMA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A210077 001</u>	Jan 29, 2018
<u>AT</u>	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305 001</u>	Mar 29, 1993
<u>AT</u>	TELIGENT PHARMA INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208287 001</u>	Dec 30, 2016
<u>AT</u>	VITRUVIAS THERAP	<u>100000 UNITS/GM; 0.1%</u>	<u>A207316 001</u>	Nov 18, 2019

OBETICHOIC ACID

TABLET; ORAL

OCALIVA

+	INTERCEPT PHARMS INC	5MG	N207999 001	May 27, 2016
+	!	10MG	N207999 002	May 27, 2016

PRESCRIPTION DRUG PRODUCT LIST

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450 002</u>	Feb 10, 2006
<u>AP</u>	HERITAGE PHARMS INC	<u>EQ 0.05MG BASE/ML</u>	<u>A204669 001</u>	Dec 27, 2018
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A204669 002</u>	Dec 27, 2018
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A204669 003</u>	Dec 27, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.2MG BASE/ML</u>	<u>A091041 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041 002</u>	Nov 12, 2013
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957 001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957 002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959 001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957 003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959 002</u>	Nov 21, 2005
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.2MG BASE/ML</u>	<u>A076330 001</u>	Apr 08, 2005
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A076330 002</u>	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457 002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457 003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198 001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198 002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198 003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.05MG BASE/ML</u>	<u>A090834 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834 002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834 003</u>	Nov 12, 2013
<u>AP</u>	! WEST-WARD PHARMS INT	<u>EQ 0.05MG BASE/ML</u>	<u>A076313 001</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.1MG BASE/ML</u>	<u>A076313 003</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.5MG BASE/ML</u>	<u>A076313 002</u>	Mar 28, 2005

SANDOSTATIN

<u>AP</u>	+! NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667 001</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.1MG BASE/ML</u>	<u>N019667 002</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.2MG BASE/ML</u>	<u>N019667 004</u>	Jun 12, 1991
<u>AP</u>	+!	<u>EQ 0.5MG BASE/ML</u>	<u>N019667 003</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 1MG BASE/ML</u>	<u>N019667 005</u>	Jun 12, 1991
	SANDOSTATIN LAR			
	+ NOVARTIS	EQ 10MG BASE/VIAL	N021008 001	Nov 25, 1998
	+	EQ 20MG BASE/VIAL	N021008 002	Nov 25, 1998
	+!	EQ 30MG BASE/VIAL	N021008 003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+! ALLERGAN	<u>0.3%</u>	<u>N019921 001</u>	Jul 30, 1993
-----------	-------------	-------------	--------------------	--------------

OFLOXACIN

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407 001</u>	Apr 15, 2008
<u>AT</u>	ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692 001</u>	Apr 29, 2013
<u>AT</u>	ALVOGEN	<u>0.3%</u>	<u>A076830 001</u>	Aug 31, 2004
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076513 001</u>	May 14, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622 001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559 001</u>	Feb 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615 001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

OFLOXACIN

<u>AT</u>	AMNEAL	<u>0.3%</u>	<u>A211525 001</u>	Aug 30, 2019
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527 001</u>	Sep 28, 2007
<u>AT</u>	! BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128 001</u>	Mar 17, 2008
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616 001</u>	Mar 17, 2008

TABLET; ORAL

OFLOXACIN

<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A091656 001</u>	Sep 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A091656 002</u>	Sep 18, 2014
<u>AB</u>		<u>400MG</u>	<u>A091656 003</u>	Sep 18, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098 001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098 002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098 003</u>	Feb 10, 2006
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182 001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182 002</u>	Sep 02, 2003
<u>AB</u>	!	<u>400MG</u>	<u>A076182 003</u>	Sep 02, 2003

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>	AM REGENT	<u>10MG/VIAL</u>	<u>A201741 001</u>	Mar 20, 2012
<u>AP</u>	SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588 001</u>	Oct 24, 2011

ZYPREXA

<u>AP</u>	+! LILLY	<u>10MG/VIAL</u>	<u>N021253 001</u>	Mar 29, 2004
-----------	----------	------------------	--------------------	--------------

TABLET; ORAL

OLANZAPINE

<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A202295 001</u>	Oct 20, 2015
<u>AB</u>		<u>5MG</u>	<u>A202295 002</u>	Oct 20, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A202295 003</u>	Oct 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A202295 004</u>	Oct 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A202295 005</u>	Oct 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A202295 006</u>	Oct 20, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A090798 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A090798 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A090798 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A090798 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A090798 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A090798 006</u>	Apr 23, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202050 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050 006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133 001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133 002</u>	Oct 24, 2011
<u>AB</u>	HIKMA PHARMS	<u>2.5MG</u>	<u>A204866 001</u>	Jun 16, 2017
<u>AB</u>		<u>5MG</u>	<u>A204866 002</u>	Jun 16, 2017
<u>AB</u>		<u>7.5MG</u>	<u>A204866 003</u>	Jun 16, 2017
<u>AB</u>		<u>10MG</u>	<u>A204866 004</u>	Jun 16, 2017
<u>AB</u>		<u>15MG</u>	<u>A204866 005</u>	Jun 16, 2017
<u>AB</u>		<u>20MG</u>	<u>A204866 006</u>	Jun 16, 2017
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203333 001</u>	Mar 15, 2016
<u>AB</u>		<u>5MG</u>	<u>A203333 002</u>	Mar 15, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A203333 003</u>	Mar 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A203333 004</u>	Mar 15, 2016
<u>AB</u>		<u>15MG</u>	<u>A203333 005</u>	Mar 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A203333 006</u>	Mar 15, 2016
<u>AB</u>	IVAX PHARMS INC	<u>20MG</u>	<u>A077301 001</u>	Apr 29, 2015
<u>AB</u>	JIANGSU HANSON PHARM	<u>2.5MG</u>	<u>A209399 001</u>	Sep 24, 2018
<u>AB</u>		<u>5MG</u>	<u>A209399 002</u>	Sep 24, 2018
<u>AB</u>		<u>10MG</u>	<u>A209399 003</u>	Sep 24, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862 001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862 002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862 003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862 004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862 005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862 006</u>	Aug 15, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287 006</u>	Apr 23, 2012
<u>AB</u>	QILU	<u>2.5MG</u>	<u>A204319 001</u>	Jan 27, 2016
<u>AB</u>		<u>5MG</u>	<u>A204319 002</u>	Jan 27, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A204319 003</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A204319 004</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A204319 005</u>	Jan 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A204319 006</u>	Jan 27, 2016
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038 004</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET;ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A090459</u>	<u>001</u>	Jul 16, 2018
<u>AB</u>		<u>5MG</u>	<u>A090459</u>	<u>002</u>	Jul 16, 2018
<u>AB</u>		<u>7.5MG</u>	<u>A090459</u>	<u>003</u>	Jul 16, 2018
<u>AB</u>		<u>10MG</u>	<u>A090459</u>	<u>004</u>	Jul 16, 2018
<u>AB</u>		<u>15MG</u>	<u>A090459</u>	<u>005</u>	Jul 16, 2018
<u>AB</u>		<u>20MG</u>	<u>A090459</u>	<u>006</u>	Jul 16, 2018

ZYPREXA

<u>AB</u>	+	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	!	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>	+		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>	+		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>	+		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>	+		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708</u>	<u>001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708</u>	<u>002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708</u>	<u>003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708</u>	<u>004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A203456</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>		<u>10MG</u>	<u>A203456</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>		<u>15MG</u>	<u>A203456</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>		<u>20MG</u>	<u>A203456</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044</u>	<u>001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044</u>	<u>002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044</u>	<u>003</u>	Feb 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A203044</u>	<u>004</u>	Feb 20, 2015
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A202937</u>	<u>001</u>	Mar 02, 2015
<u>AB</u>		<u>10MG</u>	<u>A202937</u>	<u>002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937</u>	<u>003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937</u>	<u>004</u>	Mar 02, 2015
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>10MG</u>	<u>A090881 002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881 003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881 004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415 001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415 002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415 003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415 004</u>	Oct 25, 2011

ZYPREXA ZYDIS

<u>AB</u>	+!	LILLY	<u>5MG</u>	<u>N021086 001</u>	Apr 06, 2000
<u>AB</u>	+		<u>10MG</u>	<u>N021086 002</u>	Apr 06, 2000
<u>AB</u>	+		<u>15MG</u>	<u>N021086 003</u>	Apr 06, 2000
<u>AB</u>	+		<u>20MG</u>	<u>N021086 004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173 001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173 002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173 003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162 001	Dec 19, 2014
----	--------------------	------	-------------	--------------

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558 001	Aug 17, 2017
+!		150MG	N208558 002	Aug 17, 2017

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508 001	Oct 03, 2013
----	----------------------	------------------------------------	-------------	--------------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

<u>AB</u>	+	DAIICHI SANKYO	<u>5MG</u>	<u>N021286 001</u>	Apr 25, 2002
<u>AB</u>	+		<u>20MG</u>	<u>N021286 003</u>	Apr 25, 2002
<u>AB</u>	+!		<u>40MG</u>	<u>N021286 004</u>	Apr 25, 2002

OLMESARTAN MEDOXOMIL

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A207662 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A207662 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A207662 003</u>	Apr 24, 2017
<u>AB</u>		ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A203012 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A203012 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A203012 003</u>	Apr 24, 2017
<u>AB</u>		ALKEM LABS LTD	<u>5MG</u>	<u>A206763 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A206763 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A206763 003</u>	Apr 24, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A204798 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A204798 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A204798 003</u>	Apr 24, 2017
<u>AB</u>		GLENMARK PHARMS LTD	<u>5MG</u>	<u>A203281 001</u>	May 25, 2017
<u>AB</u>			<u>20MG</u>	<u>A203281 002</u>	May 25, 2017
<u>AB</u>			<u>40MG</u>	<u>A203281 003</u>	May 25, 2017
<u>AB</u>		JUBILANT GENERICS	<u>5MG</u>	<u>A205482 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A205482 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A205482 003</u>	Apr 24, 2017
<u>AB</u>		LUPIN LTD	<u>5MG</u>	<u>A206631 001</u>	Apr 27, 2017
<u>AB</u>			<u>20MG</u>	<u>A206631 002</u>	Apr 27, 2017
<u>AB</u>			<u>40MG</u>	<u>A206631 003</u>	Apr 27, 2017
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A204814 001</u>	Apr 24, 2017
<u>AB</u>			<u>20MG</u>	<u>A204814 002</u>	Apr 24, 2017
<u>AB</u>			<u>40MG</u>	<u>A204814 003</u>	Apr 24, 2017
<u>AB</u>		MICRO LABS	<u>5MG</u>	<u>A206372 001</u>	Sep 17, 2019
<u>AB</u>			<u>20MG</u>	<u>A206372 002</u>	Sep 17, 2019
<u>AB</u>			<u>40MG</u>	<u>A206372 003</u>	Sep 17, 2019
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A078276 001</u>	Oct 26, 2016
<u>AB</u>			<u>20MG</u>	<u>A078276 002</u>	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

<u>AB</u>		<u>40MG</u>	<u>A078276</u>	<u>003</u>	Oct 26, 2016
<u>AB</u>	QILU	<u>5MG</u>	<u>A210552</u>	<u>001</u>	Jan 10, 2019
<u>AB</u>		<u>20MG</u>	<u>A210552</u>	<u>002</u>	Jan 10, 2019
<u>AB</u>		<u>40MG</u>	<u>A210552</u>	<u>003</u>	Jan 10, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A208130</u>	<u>001</u>	Jun 29, 2018
<u>AB</u>		<u>20MG</u>	<u>A208130</u>	<u>002</u>	Jun 29, 2018
<u>AB</u>		<u>40MG</u>	<u>A208130</u>	<u>003</u>	Jun 29, 2018
<u>AB</u>	SUNSHINE LAKE	<u>5MG</u>	<u>A211049</u>	<u>001</u>	Feb 22, 2019
<u>AB</u>		<u>20MG</u>	<u>A211049</u>	<u>002</u>	Feb 22, 2019
<u>AB</u>		<u>40MG</u>	<u>A211049</u>	<u>003</u>	Feb 22, 2019
<u>AB</u>	TORRENT	<u>5MG</u>	<u>A202375</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A202375</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A202375</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>	UMEDICA LABS PVT LTD	<u>5MG</u>	<u>A207135</u>	<u>001</u>	Jul 18, 2019
<u>AB</u>		<u>20MG</u>	<u>A207135</u>	<u>002</u>	Jul 18, 2019
<u>AB</u>		<u>40MG</u>	<u>A207135</u>	<u>003</u>	Jul 18, 2019
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A205192</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>		<u>20MG</u>	<u>A205192</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>		<u>40MG</u>	<u>A205192</u>	<u>003</u>	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+! BOEHRINGER

INGELHEIM

EQ 0.0025MG BASE/INH

N203108 001 Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+! BOEHRINGER

INGELHEIM

EQ 0.0025MG BASE/INH; EQ 0.0025MG
BASE/INH

N206756 001 May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 0.2% BASE</u>	<u>A204723</u>	<u>001</u>	Dec 05, 2017
<u>AT</u>	AKORN INC	<u>EQ 0.1% BASE</u>	<u>A204532</u>	<u>001</u>	Jan 10, 2017
<u>AT</u>	ALEMBIC PHARMS LTD	<u>EQ 0.1% BASE</u>	<u>A209919</u>	<u>001</u>	Dec 07, 2018
<u>AT</u>		<u>EQ 0.2% BASE</u>	<u>A209420</u>	<u>001</u>	Apr 29, 2019
<u>AT</u>	APOTEX	<u>EQ 0.1% BASE</u>	<u>A078350</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	APOTEX INC	<u>EQ 0.2% BASE</u>	<u>A090918</u>	<u>001</u>	Dec 05, 2017
<u>AT</u>	AUROBINDO PHARMA LTD	<u>EQ 0.1% BASE</u>	<u>A204812</u>	<u>001</u>	Dec 18, 2015
<u>AT</u>		<u>EQ 0.2% BASE</u>	<u>A209995</u>	<u>001</u>	Apr 04, 2019
<u>AT</u>	BARR LABS INC	<u>EQ 0.2% BASE</u>	<u>A090848</u>	<u>001</u>	Jul 13, 2015
<u>AT</u>	CIPLA	<u>EQ 0.1% BASE</u>	<u>A206046</u>	<u>001</u>	Jul 26, 2017
<u>AT</u>		<u>EQ 0.2% BASE</u>	<u>A206087</u>	<u>001</u>	Dec 05, 2017
<u>AT</u>	FDC LTD	<u>EQ 0.1% BASE</u>	<u>A209282</u>	<u>001</u>	Sep 26, 2019
<u>AT</u>	GLAND PHARMA LTD	<u>EQ 0.1% BASE</u>	<u>A209619</u>	<u>001</u>	Aug 02, 2019
<u>AT</u>	MYLAN	<u>EQ 0.1% BASE</u>	<u>A204392</u>	<u>001</u>	Mar 21, 2018
<u>AT</u>	SOMERSET THERAPS LLC	<u>EQ 0.1% BASE</u>	<u>A206306</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	USV	<u>EQ 0.1% BASE</u>	<u>A203152</u>	<u>001</u>	Dec 07, 2015
<u>AT</u>	WOCKHARDT LTD	<u>EQ 0.1% BASE</u>	<u>A200810</u>	<u>001</u>	Jun 28, 2017
	<u>PATADAY</u>				
<u>AT</u>	+! NOVARTIS	<u>EQ 0.2% BASE</u>	<u>N021545</u>	<u>001</u>	Dec 22, 2004
	<u>PATANOL</u>				
<u>AT</u>	+! NOVARTIS	<u>EQ 0.1% BASE</u>	<u>N020688</u>	<u>001</u>	Dec 18, 1996
	PAZEO				
	+! NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015
	SPRAY, METERED; NASAL				
	<u>OLOPATADINE HYDROCHLORIDE</u>				
<u>AB</u>	APOTEX INC	<u>0.665MG/SPRAY</u>	<u>A091572</u>	<u>001</u>	Oct 08, 2014
<u>AB</u>	PERRIGO ISRAEL	<u>0.665MG/SPRAY</u>	<u>A202853</u>	<u>001</u>	Jan 31, 2017
	<u>PATANASE</u>				
<u>AB</u>	+! NOVARTIS	<u>0.665MG/SPRAY</u>	<u>N021861</u>	<u>001</u>	Apr 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+! MYLAN SPECIALITY LP 250MG N019715 001 Jul 31, 1990

OMACETAXINE MEPEUSUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012

OMADACYCLINE TOSYLATE

POWDER; INTRAVENOUS

NUZYRA

+! PARATEK PHARMS INC EQ 100MG BASE/VIAL N209817 001 Oct 02, 2018

TABLET; ORAL

NUZYRA

+! PARATEK PHARMS INC EQ 150MG BASE N209816 001 Oct 02, 2018

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+!	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004
-----------	-----------	---------------------------	---	----------------	------------	--------------

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015
AB		APOTEX	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014
AB		ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019
AB		BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019
AB		STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017
AB		SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020
AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB		ACTAVIS LABS FL INC	10MG	A075347	001	May 30, 2008
AB			20MG	A075347	002	May 30, 2008
AB			40MG	A075347	003	May 30, 2008
AB		APOTEX	10MG	A076048	001	Oct 22, 2007
AB			20MG	A076048	002	Oct 22, 2007
AB			40MG	A076048	003	Jan 21, 2009
AB		AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015
AB			20MG	A203270	002	Aug 19, 2015
AB			40MG	A203270	003	Aug 19, 2015
AB		BRECKENRIDGE	10MG	A203481	001	Jul 03, 2017
AB			20MG	A203481	002	Jul 03, 2017
AB			40MG	A203481	003	Jul 03, 2017
AB		DR REDDYS LABS LTD	10MG	A075576	003	Oct 22, 2007
AB			10MG	A078490	002	Mar 16, 2009
AB			20MG	A075576	002	Oct 22, 2007
AB			20MG	A078490	003	Mar 16, 2009
AB			40MG	A075576	001	Jan 21, 2009
AB			40MG	A078490	001	Apr 17, 2009
AB		GLENMARK GENERICS	10MG	A091672	001	Oct 31, 2014
AB			20MG	A091672	002	Oct 31, 2014
AB			40MG	A091672	003	Oct 31, 2014
AB		HETERO LABS LTD III	10MG	A204012	001	Sep 26, 2019
AB			20MG	A204012	002	Sep 26, 2019
AB		IMPAX LABS	10MG	A075785	001	Oct 22, 2007
AB			20MG	A075785	002	Oct 22, 2007
AB			40MG	A075785	003	Jan 21, 2009
AB		LANNETT CO INC	10MG	A075410	001	Nov 01, 2002
AB			20MG	A075410	002	Nov 01, 2002
AB			40MG	A075410	003	Jan 23, 2009
AB		MYLAN	10MG	A205070	001	Jun 29, 2018
AB			20MG	A075876	002	May 29, 2003
AB			20MG	A205070	002	Jun 29, 2018
AB			40MG	A205070	003	Jun 29, 2018

PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757 001</u>	Jan 28, 2003
<u>AB</u>	!	<u>20MG</u>	<u>A075757 002</u>	Jan 28, 2003
<u>AB</u>	!	<u>40MG</u>	<u>A076515 001</u>	Jan 21, 2009
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A204661 001</u>	Jun 13, 2017
<u>AB</u>		<u>40MG</u>	<u>A204661 002</u>	Jun 13, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352 001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352 002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352 003</u>	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056 001	Mar 20, 2008
+	!	EQ 10MG BASE/PACKET	N022056 002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG;1.1GM</u>	<u>A204228 001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204228 002</u>	Jul 15, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>20MG;1.1GM</u>	<u>A204922 001</u>	Aug 19, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204922 002</u>	Aug 19, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG;1.1GM</u>	<u>A204068 001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204068 002</u>	Jul 15, 2016
<u>AB</u>	SCIEGEN PHARMS INC	<u>20MG;1.1GM</u>	<u>A207476 001</u>	Dec 06, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A207476 002</u>	Dec 06, 2016
<u>AB</u>	ZYDUS PHARMS	<u>20MG;1.1GM</u>	<u>A203290 001</u>	May 25, 2018
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A203290 002</u>	May 25, 2018

ZEGERID

<u>AB</u>	+	SALIX	<u>20MG;1.1GM</u>	<u>N021849 001</u>	Feb 27, 2006
<u>AB</u>	+	!	<u>40MG;1.1GM</u>	<u>N021849 002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A205545 001</u>	Jul 27, 2016
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A205545 002</u>	Jul 27, 2016
<u>AB</u>	PAR PHARM	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A079182 001</u>	Apr 19, 2013
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A079182 002</u>	Apr 19, 2013

ZEGERID

<u>AB</u>	+	SALIX	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>N021636 001</u>	Jun 15, 2004
<u>AB</u>	+	!	<u>40MG/PACKET;1.68GM/PACKET</u>	<u>N021636 002</u>	Dec 21, 2004

ONDANSETRON

FILM;ORAL

ZUPLENZ

+	MIDATECH PHARMA US	4MG	N022524 001	Jul 02, 2010
+	!	8MG	N022524 002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469 001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469 002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693 002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152 001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152 002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139 002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050 001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050 002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557 001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557 002</u>	Aug 02, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602 001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602 002</u>	Feb 24, 2011
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810 001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810 002</u>	Jun 25, 2007

ZOFRAN ODT

<u>AB</u>	+	NOVARTIS	<u>4MG</u>	<u>N020781 001</u>	Jan 27, 1999
<u>AB</u>	+	!	<u>8MG</u>	<u>N020781 002</u>	Jan 27, 1999

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846 001</u>	Jul 13, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599 001</u>	Dec 21, 2012
<u>AP</u>	! BAXTER HLTHCARE CORP	<u>EQ 2MG BASE/ML</u>	<u>A078288 001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424 001</u>	Apr 16, 2010
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974 001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224 001</u>	Sep 25, 2009
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090648 001</u>	Jun 15, 2012
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781 001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840 001</u>	Jan 19, 2007
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A204906 001</u>	Jul 31, 2017
<u>AP</u>	QILU	<u>EQ 2MG BASE/ML</u>	<u>A203711 001</u>	Sep 08, 2014
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077430 001</u>	Jun 27, 2007
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876 001</u>	Nov 22, 2006
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A076967 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077365 001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577 001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206845 001</u>	Mar 10, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600 001</u>	Dec 21, 2012
<u>AP</u>	! BAXTER HLTHCARE CORP	<u>EQ 2MG BASE/ML</u>	<u>A078287 001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945 001</u>	Jan 03, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A202253 001</u>	Jul 19, 2013
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548 001</u>	Dec 26, 2006
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077551 001</u>	Jun 27, 2007
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A077011 001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077541 001</u>	Dec 26, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716 001</u>	Dec 26, 2006

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483 001</u>	Jan 31, 2011
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776 001</u>	Nov 28, 2007
<u>AA</u>	HIKMA	<u>EQ 4MG BASE/5ML</u>	<u>A076960 001</u>	Dec 26, 2006
<u>AA</u>	LANNETT CO INC	<u>EQ 4MG BASE/5ML</u>	<u>A091342 001</u>	Jan 27, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 4MG BASE/5ML</u>	<u>A078127 001</u>	Jun 25, 2007
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009 001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+! NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N020605 001</u>	Jan 24, 1997
-----------	-------------	------------------------	--------------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306 002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539 001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539 002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539 003</u>	Jul 31, 2007
<u>AB</u>	CASI PHARMS INC	<u>EQ 4MG BASE</u>	<u>A077517 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517 003</u>	Jun 25, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183 003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183 002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183 001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535 003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761 001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761 002</u>	Jan 23, 2014
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930 002</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851 002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112 003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050 001</u>	Jun 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050 002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252 003</u>	Jun 25, 2007

ZOFRAN

<u>AB</u>	+	NOVARTIS	<u>EQ 4MG BASE</u>	<u>N020103 001</u>	Dec 31, 1992
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>N020103 002</u>	Dec 31, 1992
<u>AB</u>	+	!	<u>EQ 24MG BASE</u>	<u>N020103 003</u>	Aug 27, 1999

ONDANSETRON HYDROCHLORIDE

DR REDDYS LABS LTD

EQ 16MG BASE

A076183 004 Dec 26, 2006

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS

ORBACTIV

+! MELINTA THERAP

EQ 400MG BASE/VIAL

N206334 001 Aug 06, 2014

ORLISTAT

CAPSULE; ORAL

XENICAL

+! CHEPLAPHARM

120MG

N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

<u>AP</u>	!	AKORN	<u>30MG/ML</u>	<u>A040484 001</u>	May 24, 2006
<u>AP</u>		SAGENT PHARMS	<u>30MG/ML</u>	<u>A090585 001</u>	Aug 30, 2011
<u>AP</u>		WATSON LABS	<u>30MG/ML</u>	<u>A084779 001</u>	Mar 15, 1982
<u>AP</u>		WEST-WARD PHARMS	<u>30MG/ML</u>	<u>A040463 001</u>	Mar 04, 2003

INT

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

<u>AB</u>		ANDA REPOSITORY	<u>100MG</u>	<u>A040249 001</u>	Jan 29, 1999
<u>AB</u>		IMPAX PHARMS	<u>100MG</u>	<u>A040368 001</u>	Jun 23, 2000
<u>AB</u>		INVAGEN PHARMS	<u>100MG</u>	<u>A091158 001</u>	Jul 27, 2012
<u>AB</u>		LUPIN	<u>100MG</u>	<u>A040284 001</u>	Jun 19, 1998
<u>AB</u>	!	SANDOZ	<u>100MG</u>	<u>A040327 001</u>	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>		ALEMbic PHARMS LTD	<u>EQ 30MG BASE</u>	<u>A211823 001</u>	Jun 24, 2019
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A211823 002</u>	Jun 24, 2019
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A211823 003</u>	Jun 24, 2019
<u>AB</u>		AMNEAL PHARMS	<u>EQ 30MG BASE</u>	<u>A209093 001</u>	May 17, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A209093 002</u>	May 17, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209093 003</u>	May 17, 2017
<u>AB</u>		HETERO LABS LTD III	<u>EQ 30MG BASE</u>	<u>A209438 001</u>	Feb 23, 2018
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A209438 002</u>	Feb 23, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209438 003</u>	Feb 23, 2018
<u>AB</u>		LUPIN ATLANTIS	<u>EQ 30MG BASE</u>	<u>A208348 001</u>	Jan 09, 2018
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A208348 002</u>	Jan 09, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A208348 003</u>	Jan 09, 2018
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 30MG BASE</u>	<u>A207211 001</u>	Sep 14, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A207211 002</u>	Sep 14, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A207211 003</u>	Sep 14, 2017
<u>AB</u>		NATCO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A202595 001</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A202595 002</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A202595 003</u>	Aug 03, 2016
<u>AB</u>		NESHER PHARMS	<u>EQ 30MG BASE</u>	<u>A208578 001</u>	Feb 24, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A208578 002</u>	Feb 24, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A208578 003</u>	Feb 24, 2017
<u>AB</u>		STRIDES PHARMA	<u>EQ 30MG BASE</u>	<u>A209421 001</u>	Jun 08, 2018
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A209421 002</u>	Jun 08, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209421 003</u>	Jun 08, 2018

TAMIFLU

<u>AB</u>	+	ROCHE	<u>EQ 30MG BASE</u>	<u>N021087 003</u>	Jul 02, 2007
<u>AB</u>	+		<u>EQ 45MG BASE</u>	<u>N021087 002</u>	Jul 02, 2007
<u>AB</u>	+	!	<u>EQ 75MG BASE</u>	<u>N021087 001</u>	Oct 27, 1999

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>		ALVOGEN PINE BROOK	<u>EQ 6MG BASE/ML</u>	<u>A208823 001</u>	Oct 31, 2017
<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 6MG BASE/ML</u>	<u>A210186 001</u>	Feb 27, 2018

PRESCRIPTION DRUG PRODUCT LIST

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>	LUPIN ATLANTIS	<u>EQ 6MG BASE/ML</u>	<u>A208347 001</u>	Feb 20, 2018
<u>AB</u>	NESHER PHARMS	<u>EQ 6MG BASE/ML</u>	<u>A209113 001</u>	Sep 14, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 6MG BASE/ML</u>	<u>A211125 001</u>	Feb 27, 2019

TAMIFLU

<u>AB</u>	+! ROCHE	<u>EQ 6MG BASE/ML</u>	<u>N021246 002</u>	Mar 21, 2011
-----------	----------	-----------------------	--------------------	--------------

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

+	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065 001	Nov 13, 2015
+	!	EQ 80MG BASE	N208065 002	Nov 13, 2015

OSPEMIFENE

TABLET; ORAL

OSPHENA

+	!	DUCHESNAY	60MG	N203505 001	Feb 26, 2013
---	---	-----------	------	-------------	--------------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539 001</u>	Jan 18, 2013	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201539 002</u>	Jan 18, 2013	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201538 001</u>	Jan 18, 2013	
<u>AP</u>	PIRAMAL CRITICAL	<u>EQ 1GM BASE/VIAL</u>	<u>A206681 001</u>	Sep 11, 2017	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A206681 002</u>	Sep 11, 2017	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206760 001</u>	Oct 26, 2017	
<u>AP</u>	!	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246 001</u>	Mar 30, 2012
<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A091246 002</u>	Mar 30, 2012
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A091245 001</u>	Mar 30, 2012
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 1GM BASE/VIAL</u>	<u>A207147 001</u>	Jul 31, 2017	
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A207147 002</u>	Jul 31, 2017	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A207148 001</u>	Nov 24, 2017	
	BACTOCILL IN PLASTIC CONTAINER				
+	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640 001	Oct 26, 1989
+	!		EQ 40MG BASE/ML	N050640 002	Oct 26, 1989

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

<u>AP</u>	+! SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759 001</u>	Jan 31, 2005
<u>AP</u>	+!	<u>100MG/20ML (5MG/ML)</u>	<u>N021759 002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>50MG/10ML (5MG/ML)</u>	<u>A207474 001</u>	Mar 21, 2017	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207474 002</u>	Mar 21, 2017	
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A207474 003</u>	Mar 21, 2017	
<u>AP</u>	ACTAVIS LLC	<u>50MG/10ML (5MG/ML)</u>	<u>A204880 001</u>	Mar 05, 2018	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204880 002</u>	Mar 05, 2018	
<u>AP</u>	!	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803 001</u>	Aug 08, 2012
<u>AP</u>	!		<u>100MG/VIAL</u>	<u>A078803 002</u>	Aug 08, 2012
<u>AP</u>	CIPLA	<u>50MG/10ML (5MG/ML)</u>	<u>A208523 001</u>	Feb 10, 2017	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A208523 002</u>	Feb 10, 2017	
<u>AP</u>	EUGIA PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A205529 001</u>	Sep 06, 2017	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A205529 002</u>	Sep 06, 2017	
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/10ML (5MG/ML)</u>	<u>A078811 001</u>	Jun 10, 2010	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078811 002</u>	Jun 10, 2010	
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078819 001</u>	Jun 02, 2010	
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A090030 001</u>	Jan 31, 2017	
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078819 002</u>	Jun 02, 2010	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A090030 002</u>	Jan 31, 2017	
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A090030 003</u>	Jan 31, 2017	
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A207325 001</u>	Feb 10, 2017	
<u>AP</u>		<u>50MG/VIAL</u>	<u>A207385 001</u>	May 23, 2017	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207325 002</u>	Feb 10, 2017	
<u>AP</u>		<u>100MG/VIAL</u>	<u>A207385 002</u>	May 23, 2017	
<u>AP</u>		<u>200MG/40ML (5MG/ML)</u>	<u>A207325 003</u>	Oct 18, 2017	
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009	
<u>AP</u>	INGENUS PHARMS LLC	<u>50MG/10ML (5MG/ML)</u>	<u>A207562 001</u>	Oct 16, 2018	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207562 002</u>	Oct 16, 2018	
<u>AP</u>	JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014	
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014	

PRESCRIPTION DRUG PRODUCT LIST

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

<u>AP</u>	MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>	QILU	<u>50MG/10ML (5MG/ML)</u>	<u>A204368 001</u>	Jun 07, 2016
<u>AP</u>		<u>50MG/VIAL</u>	<u>A204616 001</u>	May 11, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204368 002</u>	Jun 07, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204616 002</u>	May 11, 2016
<u>AP</u>	!	<u>200MG/40ML (5MG/ML)</u>	<u>A204368 003</u>	Jun 07, 2016
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817 001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817 002</u>	Jan 24, 2011
<u>AP</u>	+!	<u>50MG/10ML (5MG/ML)</u>	<u>N022160 001</u>	Aug 07, 2009
<u>AP</u>	+!	<u>100MG/20ML (5MG/ML)</u>	<u>N022160 002</u>	Aug 07, 2009

OXANDROLONE

TABLET; ORAL

OXANDROLONE

<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827 001</u>	Jun 22, 2007
<u>AB</u>	!	<u>10MG</u>	<u>A077827 002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076761 001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033 001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+!	GD SEARLE	<u>600MG</u>	<u>N018841 004</u>	Oct 29, 1992
-----------	----	-----------	--------------	--------------------	--------------

OXAPROZIN

<u>AB</u>	AMNEAL PHARMS CO	<u>600MG</u>	<u>A208633 001</u>	May 04, 2017
<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987 001</u>	Sep 02, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855 001</u>	Jan 31, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846 001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845 001</u>	Jan 31, 2001
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849 001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072253 002</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072253 003</u>	Apr 14, 1988
<u>AB</u>	!	<u>30MG</u>	<u>A072253 001</u>	Apr 14, 1988
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813 001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756 001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814 001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961 001</u>	Sep 17, 2012
<u>AB</u>	HIKMA	<u>300MG/5ML</u>	<u>A201193 001</u>	Oct 03, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>300MG/5ML</u>	<u>A078734 001</u>	Jun 26, 2009

TRILEPTAL

<u>AB</u>	+!	NOVARTIS	<u>300MG/5ML</u>	<u>N021285 001</u>	May 25, 2001
-----------	----	----------	------------------	--------------------	--------------

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069 001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069 002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069 003</u>	Jan 11, 2008
<u>AB</u>	GLENMARK PHARMS LTD	<u>150MG</u>	<u>A077802 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802 003</u>	Oct 09, 2007
<u>AB</u>	HIKMA	<u>150MG</u>	<u>A077795 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795 003</u>	Oct 09, 2007
<u>AB</u>	RUBICON	<u>150MG</u>	<u>A077747 001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747 002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747 003</u>	Apr 09, 2008
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794 003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801 001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801 002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801 003</u>	Nov 15, 2007

PRESCRIPTION DRUG PRODUCT LIST

OXCARBAZEPINE

TABLET;ORAL

TRILEPTAL

AB	+	NOVARTIS	150MG	N021014 001	Jan 14, 2000
AB	+		300MG	N021014 002	Jan 14, 2000
AB	+	!	600MG	N021014 003	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

	+	SUPERNU PHARMS	150MG	N202810 001	Oct 19, 2012
	+		300MG	N202810 002	Oct 19, 2012
	+	!	600MG	N202810 003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO PHARMS	EQ 1% BASE	A205076 001	Mar 07, 2016
-----------	--	-------------	-------------------	--------------------	--------------

OXISTAT

AB	+	!	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988
-----------	---	---	----------------	-------------------	--------------------	--------------

LOTION;TOPICAL

OXISTAT

	+	!	FOUGERA PHARMS	EQ 1% BASE	N020209 001	Sep 30, 1992
--	---	---	----------------	------------	-------------	--------------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

	+	!	ALLERGAN	3.9MG/24HR	N021351 002	Feb 26, 2003
--	---	---	----------	------------	-------------	--------------

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

	+	!	ALLERGAN	10% (100MG/PACKET)	N022204 001	Jan 27, 2009
--	---	---	----------	--------------------	-------------	--------------

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	5MG/5ML	A074520 001	Mar 29, 1996
AA		PHARM ASSOC	5MG/5ML	A075137 001	Dec 18, 1998
AA	!	WOCKHARDT BIO AG	5MG/5ML	A074868 001	Feb 12, 1997

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	5MG	A209335 001	Dec 22, 2017
AB		ARISE	5MG	A209025 001	Dec 21, 2017
AB		ATHEM	5MG	A211062 001	Feb 06, 2019
AB		EMCURE PHARMS LTD	5MG	A211682 001	May 10, 2019
AB		NOVAST LABS	5MG	A210611 001	Oct 30, 2019
AB		NOVITIUM PHARMA	5MG	A209823 001	Oct 23, 2017
AB		TEVA PHARMS USA	5MG	A071655 001	Nov 14, 1988
AB		TULEX PHARMS INC	5MG	A210125 001	Sep 06, 2018
AB		UPSHER SMITH LABS	5MG	A074625 001	Jul 31, 1996
AB	!	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

AB	+	JANSSEN PHARMS	5MG	N020897 001	Dec 16, 1998
AB	+		10MG	N020897 002	Dec 16, 1998

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	5MG	A207138 001	Feb 29, 2016
AB			10MG	A207138 002	Feb 29, 2016
AB	!		15MG	A207138 003	Feb 29, 2016
AB		AJANTA PHARMA LTD	5MG	A211655 001	Feb 28, 2019
AB			10MG	A211655 002	Feb 28, 2019
AB			15MG	A211655 003	Feb 28, 2019
AB		AMNEAL PHARMS	5MG	A204010 001	Nov 23, 2015
AB			10MG	A204010 002	Nov 23, 2015
AB			15MG	A204010 003	Nov 23, 2015
AB		BIONPHARMA INC	5MG	A210717 001	Dec 17, 2019
AB			10MG	A210717 002	Dec 17, 2019
AB			15MG	A210717 003	Dec 17, 2019
AB		IMPAX PHARMS	5MG	A076745 002	May 09, 2007
AB			10MG	A076745 003	May 09, 2007
AB			15MG	A076745 001	Nov 09, 2006
AB		MYLAN PHARMS INC	10MG	A076644 001	Nov 09, 2006
AB			15MG	A076644 002	May 10, 2007
AB		OSMOTICA PHARM US	5MG	A078503 001	Feb 04, 2009
AB			10MG	A078503 002	Feb 04, 2009
AB			15MG	A078503 003	Feb 04, 2009
AB		UNIQUE PHARM LABS	5MG	A206121 001	May 27, 2016

PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A206121</u>	<u>002</u>	May 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206121</u>	<u>003</u>	May 27, 2016
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A202332</u>	<u>001</u>	Jun 26, 2017
<u>AB</u>		<u>10MG</u>	<u>A202332</u>	<u>002</u>	Jun 26, 2017
<u>AB</u>		<u>15MG</u>	<u>A202332</u>	<u>003</u>	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>5MG</u>	<u>A205177</u>	<u>001</u>	Mar 31, 2016
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>	+! GENUS LIFESCIENCES	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010
<u>AB</u>	LANNETT CO INC	<u>5MG</u>	<u>A203823</u>	<u>001</u>	Aug 01, 2014
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752</u>	<u>001</u>	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ABHAI LLC	<u>5MG/5ML</u>	<u>A208593</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208593</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	ALKEM LABS LTD	<u>5MG/5ML</u>	<u>A211748</u>	<u>001</u>	Feb 07, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A211749</u>	<u>001</u>	Feb 04, 2019
<u>AA</u>	ANI PHARMS INC	<u>5MG/5ML</u>	<u>A204979</u>	<u>001</u>	Jun 01, 2015
<u>AA</u>		<u>100MG/5ML</u>	<u>A203447</u>	<u>001</u>	Aug 30, 2017
<u>AA</u>	ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A209021</u>	<u>001</u>	Nov 09, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A209021</u>	<u>002</u>	Nov 09, 2017
<u>AA</u>	EYWA	<u>5MG/5ML</u>	<u>A207511</u>	<u>001</u>	Nov 23, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A209897</u>	<u>001</u>	Sep 06, 2017
<u>AA</u>	+ GENUS LIFESCIENCES	<u>5MG/5ML</u>	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+!	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	HI TECH	<u>5MG/5ML</u>	<u>A208817</u>	<u>001</u>	Aug 10, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208795</u>	<u>001</u>	Aug 07, 2017
<u>AA</u>	HIKMA	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	MAYNE PHARMA INC	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014
<u>AA</u>	NOVEL LABS INC	<u>100MG/5ML</u>	<u>A204603</u>	<u>001</u>	Apr 29, 2015
<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A206914</u>	<u>001</u>	Feb 01, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A206822</u>	<u>001</u>	Aug 15, 2017
<u>AA</u>	SPECGX LLC	<u>5MG/5ML</u>	<u>A210758</u>	<u>001</u>	Apr 30, 2018
<u>AA</u>		<u>100MG/5ML</u>	<u>A210758</u>	<u>002</u>	Apr 30, 2018
<u>AA</u>	+! VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012
<u>AA</u>	WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A206456</u>	<u>001</u>	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A076636</u>	<u>003</u>	Apr 07, 2015
<u>AB</u>		<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	ASCENT PHARMS INC	<u>15MG</u>	<u>A207418</u>	<u>001</u>	Aug 07, 2017
<u>AB</u>		<u>30MG</u>	<u>A207418</u>	<u>002</u>	Aug 07, 2017
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	!	<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A202662</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A202662</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A202662</u>	<u>005</u>	Apr 27, 2017
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A202662</u>	<u>004</u>	Sep 22, 2015
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>10MG</u>	<u>A091313</u>	<u>004</u>	Apr 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>20MG</u>	<u>A091313</u>	<u>005</u>	Apr 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204021</u>	<u>001</u>	Jun 12, 2017
<u>AB</u>		<u>10MG</u>	<u>A204021</u>	<u>002</u>	Jun 12, 2017
<u>AB</u>		<u>15MG</u>	<u>A204021</u>	<u>003</u>	Jun 12, 2017
<u>AB</u>		<u>20MG</u>	<u>A204021</u>	<u>004</u>	Jun 12, 2017
<u>AB</u>		<u>30MG</u>	<u>A204021</u>	<u>005</u>	Jun 12, 2017
<u>AB</u>	NUVO PHARM	<u>5MG</u>	<u>A207119</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A207119</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A207119</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A207119</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A207119</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009

ROXICODONE

<u>AB</u>	+	SPECGX LLC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	!	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>	+		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

OXAYDO

ZYLA	5MG	N202080	001	Jun 17, 2011
	7.5MG	N202080	002	Jun 17, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
+		15MG	N022272	002	Apr 05, 2010
+		20MG	N022272	003	Apr 05, 2010
+		30MG	N022272	004	Apr 05, 2010
+	!	40MG	N022272	005	Apr 05, 2010
+		60MG	N022272	006	Apr 05, 2010
+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL

RHOFADÉ

+	!	EPI HLTH	1%	N208552	001	Jan 18, 2017
---	---	----------	----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+! ST RENATUS

0.1MG/SPRAY;6MG/SPRAY

N208032 001 Jun 29, 2016

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+! MYLAN SPECIALITY LP

50MG

N016848 001

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A210175 001	Feb 02, 2018
AB		10MG	A210175 002	Feb 02, 2018
AB	AUROLIFE PHARMA LLC	5MG	A204459 001	Apr 26, 2016
AB		10MG	A204459 002	Apr 26, 2016
AB	AVANTHI INC	5MG	A203601 001	Jan 30, 2013
AB	!	10MG	A203601 002	Jan 30, 2013
AB	EPIC PHARMA LLC	5MG	A201187 001	Dec 15, 2014
AB		10MG	A201187 002	Dec 15, 2014
AB	HIKMA	5MG	A090964 001	Sep 27, 2010
AB		10MG	A090964 002	Sep 27, 2010
AB	SPECGX LLC	5MG	A202321 001	Apr 25, 2013
AB		10MG	A202321 002	Apr 25, 2013
AB	TEVA	5MG	A091443 002	Feb 15, 2011
AB		10MG	A091443 001	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046 003	Jul 11, 2013
AB		7.5MG	A079046 001	Dec 13, 2010
AB		10MG	A079046 004	Jul 11, 2013
AB		15MG	A079046 002	Dec 13, 2010
AB		20MG	A079046 005	Jul 11, 2013
AB		30MG	A079046 006	Jul 11, 2013
AB		40MG	A079046 007	Jul 11, 2013
AB	HIKMA	5MG	A200822 002	Jul 15, 2013
AB		7.5MG	A200822 003	Jul 15, 2013
AB		10MG	A200822 004	Jul 15, 2013
AB		15MG	A200822 005	Jul 15, 2013
AB		20MG	A200822 006	Jul 15, 2013
AB		30MG	A200822 007	Jul 15, 2013
AB		40MG	A200822 001	Jul 15, 2013
AB	IMPAX LABS	5MG	A079087 001	Jun 14, 2010
AB		7.5MG	A079087 002	Dec 21, 2010
AB		10MG	A079087 003	Jun 14, 2010
AB		15MG	A079087 004	Dec 21, 2010
AB		20MG	A079087 005	Jun 14, 2010
AB		30MG	A079087 006	Jul 22, 2010
AB	SPECGX LLC	5MG	A202946 001	Jun 27, 2014
AB		7.5MG	A202946 002	Jun 27, 2014
AB		10MG	A202946 003	Jun 27, 2014
AB		15MG	A202946 004	Jun 27, 2014
AB		20MG	A202946 005	Jun 27, 2014
AB		30MG	A202946 006	Jun 27, 2014
AB		40MG	A202946 007	Jun 27, 2014
AB	!			
	IMPAX LABS	40MG	A079087 007	Jun 14, 2010

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+!	FRESENIUS KABI USA	10USP UNITS/ML (10USP UNITS/ML)	N018248 001	
AP	+!		100USP UNITS/10ML (10USP UNITS/ML)	N018248 002	
AP		HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219 001	Feb 13, 2013
AP		SAGENT PHARMS INC	10USP UNITS/ML (10USP UNITS/ML)	A091676 001	Jul 13, 2018
AP			100USP UNITS/10ML (10USP UNITS/ML)	A091676 002	Jul 13, 2018
AP	+!	WEST-WARD PHARMS INT	10USP UNITS/ML (10USP UNITS/ML)	N018243 001	
AP	+!		100USP UNITS/10ML (10USP UNITS/ML)	N018243 002	Jan 10, 2007
		PITOCIN			
AP	+!	PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261 001	
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018261 002	Jul 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

+! FRESENIUS KABI USA 300USP UNITS/30ML (10USP UNITS/ML) N018248 003 Jul 27, 2007

PITOCIN

+ PAR STERILE PRODUCTS 500USP UNITS/50ML (10USP UNITS/ML) N018261 003 Sep 05, 2012

OZENOXACIN

CREAM; TOPICAL

XEPI

+! FERRER INTERNACIONAL 1% N208945 001 Dec 11, 2017

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+! ABRAXIS BIOSCIENCE 100MG/VIAL N021660 001 Jan 07, 2005

INJECTABLE; INJECTION

PACITAXELAP GLAND PHARMA LTD 6MG/ML A207326 001 Aug 23, 2016PACLITAXELAP ACTAVIS TOTOWA 6MG/ML A090130 001 Dec 09, 2009AP FRESENIUS KABI USA 6MG/ML A077574 001 Nov 27, 2006AP ! HOSPIRA 6MG/ML A076131 001 May 08, 2002AP MYLAN LABS LTD 6MG/ML A091540 001 Sep 29, 2011AP TEVA PHARMS 6MG/ML A075184 001 Jan 25, 2002AP WEST-WARD PHARMS INT 6MG/ML A075190 001 Jan 28, 2002PALBOCICLIB

CAPSULE; ORAL

IBRANCE

+ PFIZER INC 75MG N207103 001 Feb 03, 2015

+ 100MG N207103 002 Feb 03, 2015

+! 125MG N207103 003 Feb 03, 2015

TABLET; ORAL

IBRANCE

+ PFIZER INC 75MG N212436 001 Nov 01, 2019

+ 100MG N212436 002 Nov 01, 2019

+! 125MG N212436 003 Nov 01, 2019

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGAAB + JANSSEN PHARMS 1.5MG N021999 006 Aug 26, 2008AB + 3MG N021999 001 Dec 19, 2006AB +! 6MG N021999 002 Dec 19, 2006AB + 9MG N021999 003 Dec 19, 2006PALIPERIDONEAB ACTAVIS LABS FL INC 1.5MG A202645 001 Aug 03, 2015AB 3MG A202645 002 Aug 03, 2015AB 6MG A202645 003 Aug 03, 2015AB 9MG A202645 004 Aug 03, 2015AB AMNEAL PHARMS 1.5MG A204707 001 Sep 23, 2019AB 3MG A204707 002 Sep 23, 2019AB 6MG A204707 003 Sep 23, 2019AB 9MG A204707 004 Sep 23, 2019AB INVENTIA 1.5MG A204452 001 Jun 12, 2019AB 3MG A204452 002 Jun 12, 2019AB 6MG A204452 003 Jun 12, 2019AB 9MG A204452 004 Jun 12, 2019AB MYLAN 1.5MG A203802 001 Sep 24, 2015AB 3MG A203802 002 Sep 24, 2015AB 6MG A203802 003 Sep 24, 2015AB 9MG A203802 004 Sep 24, 2015AB SUN PHARM 1.5mg A205618 001 Apr 06, 2018AB 3MG A205618 002 Apr 06, 2018AB 6MG A205618 003 Apr 06, 2018AB 9MG A205618 004 Apr 06, 2018

PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

AP +! HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) N021372 002 Feb 29, 2008

AP +! EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) N021372 001 Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

AP AUROBINDO PHARMA LTD EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A204702 001 Nov 06, 2018

AP CIPLA EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A206396 001 Sep 19, 2018

AP DR REDDYS LABS LTD EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A201533 002 Apr 21, 2016

AP FRESENIUS KABI USA EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A206801 001 Sep 19, 2018

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A206802 001 Sep 19, 2018

AP HOSPIRA INC EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A207005 001 Sep 19, 2018

AP EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) A207005 002 Sep 19, 2018

AP MYLAN INSTITUTIONAL EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A206416 001 Sep 19, 2018

AP QILU EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) A205648 002 Sep 19, 2018

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A205648 001 Sep 19, 2018

AP SAGENT PHARMS INC EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A204289 001 Sep 19, 2018

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A205870 001 Sep 19, 2018

AP SANDOZ INC EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A202521 001 Oct 13, 2015

AP TEVA PHARMS USA EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) A090713 002 Mar 23, 2018

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A090713 001 Mar 23, 2018

AP VIRTUS PHARM EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) A209287 001 Sep 19, 2018

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+ FRESENIUS KABI USA EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) N208109 001 Nov 21, 2017

HIKMA EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML) N207963 001 Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP AREVA PHARMS 30MG/VIAL A077433 001 Nov 26, 2008

AP 90MG/VIAL A077433 003 Nov 26, 2008

AP DR REDDYS 30MG/10ML (3MG/ML) A078156 001 Aug 19, 2008

AP 60MG/10ML (6MG/ML) A078156 002 Aug 19, 2008

AP 90MG/10ML (9MG/ML) A078156 003 Aug 19, 2008

AP FRESENIUS KABI USA 30MG/VIAL A075773 001 May 06, 2002

AP 30MG/10ML (3MG/ML) A076207 001 May 17, 2002

AP 90MG/VIAL A075773 002 May 06, 2002

AP 90MG/10ML (9MG/ML) A076207 002 May 17, 2002

AP ! HOSPIRA 30MG/10ML (3MG/ML) A075841 001 Jun 27, 2002

AP ! 60MG/10ML (6MG/ML) A075841 002 Jun 27, 2002

AP ! 90MG/10ML (9MG/ML) A075841 003 Jun 27, 2002

AP MYLAN LABS LTD 30MG/10ML (3MG/ML) A078520 001 Oct 31, 2008

AP 90MG/10ML (9MG/ML) A078520 002 Oct 31, 2008

AP SAGENT PHARMS INC 30MG/10ML (3MG/ML) A078373 001 Dec 23, 2008

AP 90MG/10ML (9MG/ML) A078373 002 Dec 23, 2008

AP TEVA PHARMS USA 30MG/10ML (3MG/ML) A076153 001 Mar 27, 2002

AP 90MG/10ML (9MG/ML) A076153 002 Mar 27, 2002

AP WEST-WARD PHARMS INT 30MG/VIAL A075290 001 Apr 30, 2001

AP +! 30MG/10ML (3MG/ML) N021113 001 Mar 04, 2002

AP 90MG/VIAL A075290 003 Apr 30, 2001

AP +! 90MG/10ML (9MG/ML) N021113 002 Mar 04, 2002

AREVA PHARMS 60MG/VIAL A077433 002 Nov 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

CREON

+	ABBVIE	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009
+		15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725 004	Jul 12, 2011
+		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009
+		180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725 005	Mar 14, 2013
+	!	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009

PANCREAZE

+	VIVUS INC	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523 005	Mar 07, 2014
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523 001	Apr 12, 2010
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523 002	Apr 12, 2010
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523 004	Apr 12, 2010
+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523 003	Apr 12, 2010

PERTZYE

+	DIGESTIVE CARE INC	30,250USP UNITS;8,000USP UNITS;28,750USP UNITS	N022175 001	May 17, 2012
+	!	60,500USP UNITS;16,000USP UNITS;57,500USP UNITS	N022175 002	May 17, 2012
+		15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175 003	Oct 06, 2016
+		90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175 004	Jul 13, 2017

ZENPEP

+	ZENPEP	168,000USP UNITS;40,000USP UNITS;126,000USP UNITS	N022210 007	Mar 25, 2014
+		14,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011
+		24,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210 001	Aug 27, 2009
+		42,000USP UNITS;10,000USP UNITS;32,000USP UNITS	N022210 002	Aug 27, 2009
+		63,000USP UNITS;15,000USP UNITS;47,000USP UNITS	N022210 003	Aug 27, 2009
+		84,000USP UNITS;20,000USP UNITS;63,000USP UNITS	N022210 004	Aug 27, 2009
+	!	105,000USP UNITS;25,000USP UNITS;79,000USP UNITS	N022210 006	Jul 13, 2011

TABLET;ORAL

VIOKACE

+	VIOKACE	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012
+	!	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

AP	!	DR REDDYS	1MG/ML	A072759 001	Jul 31, 1990
AP		HOSPIRA	1MG/ML	A072320 001	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760 001	Jul 31, 1990

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

+	SECURA	EQ 10MG BASE	N205353 001	Feb 23, 2015
+		EQ 15MG BASE	N205353 002	Feb 23, 2015
+	!	EQ 20MG BASE	N205353 003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+	!	WYETH PHARMS	EQ 40MG BASE	N022020 001	Nov 14, 2007
---	---	--------------	--------------	-------------	--------------

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP		AKORN INC	EQ 40MG BASE/VIAL	A079197 001	Nov 08, 2012
AP		AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675 001	Mar 30, 2016
AP		SANDOZ INC	EQ 40MG BASE/VIAL	A090296 001	Jul 14, 2015

PRESCRIPTION DRUG PRODUCT LIST

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	SUN PHARM	<u>EQ 40MG BASE/VIAL</u>	<u>A077674 001</u>	Aug 19, 2019
-----------	-----------	---------------------------------	---------------------------	--------------

PROTONIX IV

AP	+! WYETH PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>N020988 001</u>	Mar 22, 2001
-----------	-----------------	---------------------------------	---------------------------	--------------

POWDER; IV (INFUSION)

PANTOPRAZOLE SODIUM

+! HIKMA

TABLET, DELAYED RELEASE; ORAL

	EQ 40MG BASE/VIAL	N209463 001	Jun 30, 2017
--	-------------------	-------------	--------------

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797 001</u>	Feb 07, 2011
-----------	----------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A090797 002</u>	Feb 07, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A205119 001</u>	Jan 26, 2016
-----------	---------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A205119 002</u>	Jan 26, 2016
-----------	--	----------------------------	---------------------------	--------------

AB	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038 001</u>	Sep 28, 2012
-----------	----------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A202038 002</u>	Sep 28, 2012
-----------	--	----------------------------	---------------------------	--------------

AB	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619 001</u>	Jan 19, 2011
-----------	--------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A077619 002</u>	Jan 19, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882 001</u>	Sep 10, 2014
-----------	-------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A202882 002</u>	Sep 10, 2014
-----------	--	----------------------------	---------------------------	--------------

AB	INGENUS PHARMS LLC	<u>EQ 40MG BASE</u>	<u>A211368 001</u>	Mar 01, 2019
-----------	--------------------	----------------------------	---------------------------	--------------

AB	JUBILANT GENERICS	<u>EQ 20MG BASE</u>	<u>A090901 001</u>	Aug 30, 2011
-----------	-------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A090901 002</u>	Aug 30, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	L PERRIGO CO	<u>EQ 20MG BASE</u>	<u>A203024 001</u>	May 07, 2014
-----------	--------------	----------------------------	---------------------------	--------------

AB	LANNETT CO INC	<u>EQ 20MG BASE</u>	<u>A078281 001</u>	Jan 20, 2011
-----------	----------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A078281 002</u>	Jan 20, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A200821 001</u>	Feb 16, 2012
-----------	---------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A200821 002</u>	Feb 16, 2012
-----------	--	----------------------------	---------------------------	--------------

AB	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970 001</u>	Jan 19, 2011
-----------	------------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A090970 002</u>	Jan 19, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	ORCHID HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202052 001</u>	Dec 02, 2014
-----------	-----------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A202052 002</u>	Dec 02, 2014
-----------	--	----------------------------	---------------------------	--------------

AB	RUBICON	<u>EQ 20MG BASE</u>	<u>A090807 001</u>	May 02, 2012
-----------	---------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A090807 002</u>	May 02, 2012
-----------	--	----------------------------	---------------------------	--------------

AB	TEVA	<u>EQ 20MG BASE</u>	<u>A077056 001</u>	Aug 02, 2007
-----------	------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A077056 002</u>	Aug 02, 2007
-----------	--	----------------------------	---------------------------	--------------

AB	TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074 001</u>	Jan 19, 2011
-----------	----------------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A090074 002</u>	Jan 19, 2011
-----------	--	----------------------------	---------------------------	--------------

AB	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A091231 001</u>	Jan 19, 2011
-----------	-----------	----------------------------	---------------------------	--------------

AB		<u>EQ 40MG BASE</u>	<u>A091231 002</u>	Jan 19, 2011
-----------	--	----------------------------	---------------------------	--------------

PROTONIX

AB	+ WYETH PHARMS	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
-----------	----------------	----------------------------	---------------------------	--------------

AB	+!	<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000
-----------	----	----------------------------	---------------------------	--------------

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	AMNEAL PHARMS	<u>1MCG</u>	<u>A204327 001</u>	Jan 13, 2016
-----------	---------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A204327 002</u>	Jan 13, 2016
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A204327 003</u>	Jan 13, 2016
-----------	--	--------------------	---------------------------	--------------

AB	AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672 001</u>	Jan 14, 2016
-----------	----------------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A207672 002</u>	Jan 14, 2016
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A207672 003</u>	Jan 14, 2016
-----------	--	--------------------	---------------------------	--------------

AB	BIONPHARMA INC	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
-----------	----------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
-----------	--	--------------------	---------------------------	--------------

AB	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
-----------	--------------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
-----------	--	--------------------	---------------------------	--------------

AB	MARKSANS PHARMA	<u>1MCG</u>	<u>A204948 001</u>	Oct 07, 2016
-----------	-----------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A204948 002</u>	Oct 07, 2016
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A204948 003</u>	Oct 07, 2016
-----------	--	--------------------	---------------------------	--------------

AB	RISING	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
-----------	--------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
-----------	--	--------------------	---------------------------	--------------

AB		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
-----------	--	--------------------	---------------------------	--------------

AB	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
-----------	-----------------	--------------------	---------------------------	--------------

AB		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
-----------	--	--------------------	---------------------------	--------------

AB	!	<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013
-----------	---	--------------------	---------------------------	--------------

ZEMPLAR

AB	+ ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
-----------	----------	--------------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

AB + **2MCG** **N021606 002** May 26, 2005
SOLUTION; INTRAVENOUS

PARICALCITOL

AP ACCORD HLTHCARE **0.002MG/ML (0.002MG/ML)** **N207174 001** Feb 04, 2016
AP **0.005MG/ML (0.005MG/ML)** **N207174 002** Feb 04, 2016
AP **0.01MG/2ML (0.005MG/ML)** **N207174 003** Feb 04, 2016
AP AKORN **0.005MG/ML (0.005MG/ML)** **A207692 001** Oct 16, 2017
AP AMNEAL PHARMS CO **0.002MG/ML (0.002MG/ML)** **A206699 001** Mar 09, 2017
AP **0.005MG/ML (0.005MG/ML)** **A206699 002** Mar 09, 2017
AP **0.01MG/2ML (0.005MG/ML)** **A206699 003** Mar 09, 2017
AP AUROBINDO PHARMA LTD **0.002MG/ML (0.002MG/ML)** **A205982 001** Oct 09, 2018
AP **0.005MG/ML (0.005MG/ML)** **A205982 002** Oct 09, 2018
AP **0.01MG/2ML (0.005MG/ML)** **A205982 003** Oct 09, 2018
AP DR REDDYS **0.002MG/ML (0.002MG/ML)** **A204910 001** Aug 17, 2016
AP **0.005MG/ML (0.005MG/ML)** **A204910 002** Aug 17, 2016
AP **0.01MG/2ML (0.005MG/ML)** **A204910 003** Aug 17, 2016
AP HIKMA PHARMS **0.002MG/ML (0.002MG/ML)** **N205917 001** Nov 18, 2014
AP **0.005MG/ML (0.005MG/ML)** **N205917 002** Nov 18, 2014
AP **0.01MG/2ML (0.005MG/ML)** **N205917 003** Nov 18, 2014
AP HOSPIRA INC **0.002MG/ML (0.002MG/ML)** **N201657 001** Oct 21, 2014
AP **0.005MG/ML (0.005MG/ML)** **N201657 002** Oct 21, 2014
AP **0.01MG/2ML (0.005MG/ML)** **N201657 003** Oct 21, 2014
AP MYLAN LABS LTD **0.002MG/ML (0.002MG/ML)** **A203897 001** Nov 02, 2017
AP **0.005MG/ML (0.005MG/ML)** **A203897 002** Nov 02, 2017
AP **0.01MG/2ML (0.005MG/ML)** **A203897 003** Nov 02, 2017
AP SANDOZ INC **0.002MG/ML (0.002MG/ML)** **A091108 001** Jul 27, 2011
AP **0.005MG/ML (0.005MG/ML)** **A091108 002** Jul 27, 2011
AP **0.01MG/2ML (0.005MG/ML)** **A091108 003** Jul 27, 2011

ZEMPLAR

AP +! ABBEVIE **0.002MG/ML (0.002MG/ML)** **N020819 002** Feb 01, 2000
AP +! **0.005MG/ML (0.005MG/ML)** **N020819 001** Apr 17, 1998
AP +! **0.01MG/2ML (0.005MG/ML)** **N020819 003** Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

AA HERITAGE PHARMS INC **EQ 250MG BASE** **A065173 001** Dec 14, 2007
AA ! SUN PHARM INDS INC **EQ 250MG BASE** **A064171 001** Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

+! APOTEX TECHNOLOGIES **EQ 10MG BASE/5ML** **N020710 001** Jun 25, 1997

TABLET; ORAL

PAROXETINE

AB PRINSTON INC **EQ 10MG BASE** **A203854 001** Oct 31, 2014
AB **EQ 20MG BASE** **A203854 002** Oct 31, 2014
AB **EQ 30MG BASE** **A203854 003** Oct 31, 2014
AB **EQ 40MG BASE** **A203854 004** Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB APOTEX **EQ 10MG BASE** **A075356 001** Jul 30, 2003
AB **EQ 20MG BASE** **A075356 002** Jul 30, 2003
AB **EQ 30MG BASE** **A075356 003** Jul 30, 2003
AB **EQ 40MG BASE** **A075356 004** Jul 30, 2003
AB AUROBINDO PHARMA **EQ 10MG BASE** **A078406 001** Jul 25, 2007
AB **EQ 20MG BASE** **A078406 002** Jul 25, 2007
AB **EQ 30MG BASE** **A078406 003** Jul 25, 2007
AB **EQ 40MG BASE** **A078406 004** Jul 25, 2007
AB JUBILANT GENERICS **EQ 10MG BASE** **A205528 001** Nov 27, 2015
AB **EQ 20MG BASE** **A205528 002** Nov 27, 2015
AB **EQ 30MG BASE** **A205528 003** Nov 27, 2015
AB **EQ 40MG BASE** **A205528 004** Nov 27, 2015
AB MYLAN **EQ 10MG BASE** **A078902 001** Mar 13, 2008
AB **EQ 20MG BASE** **A078902 002** Mar 13, 2008
AB **EQ 30MG BASE** **A078902 003** Mar 13, 2008
AB **EQ 40MG BASE** **A078902 004** Mar 13, 2008
AB OXFORD PHARMS **EQ 10MG BASE** **A076968 001** Jun 21, 2010
AB **EQ 20MG BASE** **A076968 002** Jun 21, 2010
AB **EQ 30MG BASE** **A076968 003** Jun 21, 2010
AB **EQ 40MG BASE** **A076968 004** Jun 21, 2010

PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	LANNETT CO INC	<u>EQ 12.5MG BASE</u>	<u>A204744 001</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204744 002</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204744 003</u>	Jun 10, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 12.5MG BASE</u>	<u>A204134 001</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204134 002</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204134 003</u>	Jan 20, 2017
<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011
<u>AB</u>	SCIECURE PHARMA INC	<u>EQ 12.5MG BASE</u>	<u>A209293 001</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A209293 002</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A209293 003</u>	Jun 12, 2018

PAXIL CR

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+	!	<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

<u>AB</u>	+	!	SEBELA IRELAND LTD	<u>EQ 7.5MG BASE</u>	<u>N204516 001</u>	Jun 28, 2013
-----------	---	---	--------------------	----------------------	--------------------	--------------

PAROXETINE MESYLATE

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 7.5MG BASE</u>	<u>A207139 001</u>	Jun 20, 2017
<u>AB</u>		PRINSTON INC	<u>EQ 7.5MG BASE</u>	<u>A207188 001</u>	Aug 18, 2017

TABLET; ORAL

PEXEVA

+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299 001	Jul 03, 2003
+		EQ 20MG BASE	N021299 002	Jul 03, 2003
+		EQ 30MG BASE	N021299 003	Jul 03, 2003
+	!	EQ 40MG BASE	N021299 004	Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

+	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677 001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677 002	Dec 14, 2012
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677 003	Dec 14, 2012

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR

SIGNIFOR LAR KIT

+	NOVARTIS	EQ 10MG BASE/VIAL	N203255 004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255 001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255 005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255 002	Dec 15, 2014
+	!	EQ 60MG BASE/VIAL	N203255 003	Dec 15, 2014

PATIOROMER SORBITEX CALCIUM

POWDER; ORAL

VELTASSA

+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739 001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739 002	Oct 21, 2015
+	!	EQ 25.2GM BASE/PACKET	N205739 003	Oct 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

PATISIRAN SODIUM

SOLUTION; INTRAVENOUS

ONPATRO

+! ALNYLAM PHARMS INC EQ 10MG BASE/5ML (EQ 2MG BASE/ML) N210922 001 Aug 10, 2018

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+! NOVARTIS EQ 200MG BASE N022465 001 Oct 19, 2009

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+! VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML N021756 001 Dec 17, 2004

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+! PHARMACIA AND 10MG/VIAL N021106 001 Mar 25, 2003

UPJOHN

+! 15MG/VIAL N021106 002 Mar 25, 2003

+! 20MG/VIAL N021106 003 Mar 25, 2003

+! 25MG/VIAL N021106 004 Jul 31, 2014

+! 30MG/VIAL N021106 005 Jul 31, 2014

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

ALIMTA

+! LILLY EQ 100MG BASE/VIAL N021462 002 Sep 07, 2007

+! EQ 500MG BASE/VIAL N021462 001 Feb 04, 2004

PENCICLOVIR

CREAM; TOPICAL

DENA VIR

+! MYLAN 1% N020629 001 Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE**AB** +! VALEANT PHARMS INTL **250MG** **N019853 001**PENICILLAMINE**AB** AMERIGEN PHARMS LTD **250MG** **A209921 001** May 07, 2019**AB** PAR PHARM INC **250MG** **A211231 001** Dec 23, 2019**AB** WATSON LABS INC **250MG** **A210976 001** Jun 24, 2019

TABLET; ORAL

DEPEN**AB** +! MYLAN SPECIALITY LP **250MG** **N019854 001**PENICILLAMINE**AB** PAR PHARM INC **250MG** **A211196 001** Dec 23, 2019PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC +! KING PHARMS LLC 600,000 UNITS/ML N050141 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+! KING PHARMS LLC 300,000 UNITS/ML; 300,000 UNITS/ML N050138 001

BICILLIN C-R 900/300

+! KING PHARMS LLC 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM**AP** ACS DOBFAR SPA **20,000,000 UNITS/VIAL** **A205043 002** Oct 26, 2018**AP** **5,000,000 UNITS/VIAL** **A205043 001** Oct 26, 2018**AP** HANFORD GC **5,000,000 UNITS/VIAL** **A065149 002** Jul 23, 2009**AP** **20,000,000 UNITS/VIAL** **A065149 003** Jul 23, 2009**AP** ISTITUTO BIO ITA **5,000,000 UNITS/VIAL** **A065448 001** Aug 18, 2009

SPA

AP **20,000,000 UNITS/VIAL** **A065448 002** Aug 18, 2009**AP** SANDOZ **5,000,000 UNITS/VIAL** **A065079 002** Aug 30, 2002**AP** **20,000,000 UNITS/VIAL** **A065079 003** Aug 30, 2002PFIZERPEN**AP** ! PFIZER **5,000,000 UNITS/VIAL** **A060657 002****AP** ! **20,000,000 UNITS/VIAL** **A060657 003**

PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

HANFORD GC 1,000,000 UNITS/VIAL

A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 20,000 UNITS/ML

N050638 001 Jun 25, 1990

+! 40,000 UNITS/ML

N050638 002 Jun 25, 1990

+! 60,000 UNITS/ML

N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

! KING PHARMS LLC 300,000 UNITS/ML

A060101 002

! 600,000 UNITS/ML

A060101 001

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

! SANDOZ 5,000,000 UNITS/VIAL

A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUMAA DAVA PHARMS INCEQ 125MG BASE/5MLA062981 001 Feb 10, 1989AAEQ 250MG BASE/5MLA062981 002 Feb 10, 1989PENICILLIN-VKAA TEVAEQ 125MG BASE/5MLA060456 001AA !EQ 250MG BASE/5MLA060456 002

TABLET; ORAL

PENICILLIN V POTASSIUMAB AUROBINDO PHARMAEQ 250MG BASEA065435 001 Apr 29, 2008ABEQ 500MG BASEA065435 002 Apr 29, 2008AB DAVA PHARMS INCEQ 250MG BASEA062936 001 Nov 25, 1988ABEQ 500MG BASEA062935 001 Nov 23, 1988AB HIKMA PHARMSEQ 250MG BASEA090549 001 Oct 11, 2013ABEQ 500MG BASEA090549 002 Oct 11, 2013AB SANDOZEQ 250MG BASEA064071 001 Nov 30, 1995AB !EQ 500MG BASEA064071 002 Nov 30, 1995PENICILLIN-VKAB TEVAEQ 250MG BASEA060711 002ABEQ 500MG BASEA060711 003PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENTAN +! FRESENIUS KABI USA300MG/VIALN019887 001 Jun 15, 1989PENTAMIDINE ISETHIONATEAN SETON PHARMS300MG/VIALA206667 001 Apr 24, 2019

INJECTABLE; INJECTION

PENTAMAP +! FRESENIUS KABI USA300MG/VIALN019264 001 Oct 16, 1984PENTAMIDINE ISETHIONATEAP SETON PHARMS300MG/VIALA206666 001 Sep 28, 2017PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+! HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML)

N021749 001 Aug 11, 2004

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+! HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML)

N021751 001 Aug 11, 2004

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUMAP ! OAK PHARMS50MG/MLA083246 001PENTOBARBITAL SODIUMAP ATHENEX50MG/MLA206677 001 Nov 27, 2017AP CUSTOPHARM INC50MG/MLA203619 001 Nov 13, 2017AP SAGENT PHARMS INC50MG/MLA206404 001 May 23, 2016

PRESCRIPTION DRUG PRODUCT LIST

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+! JANSSEN PHARMS 100MG N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT**AP** +! HOSPIRA INC 10MG/VIAL **N020122 001** Oct 11, 1991PENTOSTATIN**AP** WEST-WARD PHARMS 10MG/VIAL **A077841 001** Aug 07, 2007
INTPENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE**AB** ! APOTEX 400MG **A075191 001** Jun 09, 1999**AB** VALEANT PHARMS 400MG **A075028 001** Jul 20, 1998PENTOXIL**AB** UPSHER SMITH LABS 400MG **A074962 001** Mar 31, 1999PERAMIVIR

SOLUTION; INTRAVENOUS

RAPIVAB

+! BIOCRYST 200MG/20ML (10MG/ML) N206426 001 Dec 19, 2014

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+! EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016

TABLET; ORAL

FYCOMPA

+ EISAI INC 2MG N202834 001 Oct 22, 2012

+ 4MG N202834 002 Oct 22, 2012

+ 6MG N202834 003 Oct 22, 2012

+ 8MG N202834 004 Oct 22, 2012

+ 10MG N202834 005 Oct 22, 2012

+! 12MG N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+! LANTHEUS MEDCL 6.52MG/ML N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE**AB** AUROBINDO PHARMA 2MG **A079070 001** Nov 10, 2009**AB** 4MG **A079070 002** Nov 10, 2009**AB** ! 8MG **A079070 003** Nov 10, 2009**AB** HIKMA 2MG **A090072 001** Nov 10, 2009**AB** 4MG **A090072 002** Nov 10, 2009**AB** 8MG **A090072 003** Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITE**AB** +! MYLAN 5% **N019855 001** Aug 25, 1989PERMETHRIN**AB** ACTAVIS LABS 5% **A074806 001** Jan 23, 1998**AB** ENCUBE ETHICALS 5% **A211303 001** Apr 03, 2019**AB** PERRIGO ISRAEL 5% **A076369 001** Apr 21, 2003PERPHENAZINE

TABLET; ORAL

PERPHENAZINE**AB** MYLAN 2MG **A206691 001** Apr 14, 2017**AB** 4MG **A206691 002** Apr 14, 2017**AB** 8MG **A206691 003** Apr 14, 2017**AB** 16MG **A206691 004** Apr 14, 2017**AB** RISING 2MG **A205056 001** Mar 01, 2019**AB** 4MG **A205056 002** Mar 01, 2019**AB** 8MG **A205056 003** Mar 01, 2019**AB** 16MG **A205056 004** Mar 01, 2019**AB** SANDOZ 2MG **A089685 002** Dec 08, 1988**AB** 4MG **A089685 003** Dec 08, 1988**AB** 8MG **A089685 001** Dec 08, 1988

PRESCRIPTION DRUG PRODUCT LIST

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u>	!		<u>16MG</u>	<u>A089685</u>	<u>004</u>	Dec 08, 1988
<u>AB</u>		VINTAGE PHARMS	<u>2MG</u>	<u>A040226</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>			<u>4MG</u>	<u>A040226</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>			<u>8MG</u>	<u>A040226</u>	<u>003</u>	Dec 31, 1998
<u>AB</u>			<u>16MG</u>	<u>A040226</u>	<u>004</u>	Dec 31, 1998
<u>AB</u>		WATSON LABS INC	<u>2MG</u>	<u>A207582</u>	<u>001</u>	Oct 17, 2016
<u>AB</u>			<u>4MG</u>	<u>A207582</u>	<u>002</u>	Oct 17, 2016
<u>AB</u>			<u>8MG</u>	<u>A207582</u>	<u>003</u>	Oct 17, 2016
<u>AB</u>			<u>16MG</u>	<u>A207582</u>	<u>004</u>	Oct 17, 2016
<u>AB</u>		WILSHIRE PHARMS INC	<u>2MG</u>	<u>A205973</u>	<u>001</u>	Dec 17, 2015
<u>AB</u>			<u>4MG</u>	<u>A205973</u>	<u>002</u>	Dec 17, 2015
<u>AB</u>			<u>8MG</u>	<u>A205973</u>	<u>003</u>	Dec 17, 2015
<u>AB</u>			<u>16MG</u>	<u>A205973</u>	<u>004</u>	Dec 17, 2015

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL

TURALIO

+! DAIICHI SANKYO INC EQ 200MG BASE N211810 001 Aug 02, 2019

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+! VIRTUS PHARMS 105MG N018074 001

TABLET; ORAL

BONTRIL PDM

<u>AA</u>	!	VALEANT	<u>35MG</u>	<u>A085272</u>	<u>001</u>	
<u>PHENDIMETRAZINE TARTRATE</u>						
<u>AA</u>		ELITE LABS INC	<u>35MG</u>	<u>A040762</u>	<u>001</u>	Jan 28, 2008
<u>AA</u>			<u>35MG</u>	<u>A203600</u>	<u>001</u>	Dec 27, 2017
<u>AA</u>		KVK TECH	<u>35MG</u>	<u>A091042</u>	<u>001</u>	Aug 31, 2010
<u>AA</u>		MIKART	<u>35MG</u>	<u>A089452</u>	<u>001</u>	Oct 30, 1991
<u>AA</u>		VIRTUS PHARMS	<u>35MG</u>	<u>A085588</u>	<u>001</u>	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+	PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>	
<u>PHENELZINE SULFATE</u>						
<u>AB</u>		NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

<u>AB</u>		HIKMA	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>	!	PAR PHARM INC	<u>10MG</u>	<u>A204522</u>	<u>001</u>	Jan 24, 2017

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	!	TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983
<u>PHENTERMINE HYDROCHLORIDE</u>						
<u>AA</u>		AUROLIFE PHARMA LLC	<u>15MG</u>	<u>A204318</u>	<u>001</u>	Nov 09, 2016
<u>AA</u>			<u>30MG</u>	<u>A204318</u>	<u>002</u>	Nov 09, 2016
<u>AA</u>		BARR	<u>15MG</u>	<u>A090591</u>	<u>001</u>	Mar 18, 2010
<u>AA</u>			<u>30MG</u>	<u>A090591</u>	<u>002</u>	Mar 18, 2010
<u>AA</u>		ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012
<u>AA</u>			<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012
<u>AA</u>		ELITE LABS INC	<u>37.5MG</u>	<u>A040228</u>	<u>001</u>	Jun 19, 1997
<u>AA</u>		INVAGEN PHARMS	<u>15MG</u>	<u>A202858</u>	<u>001</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A202858</u>	<u>002</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A204414</u>	<u>001</u>	May 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A202846</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>			<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>			<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>			<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>		LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>			<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		LANNETT CO INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>		NUVO PHARM	<u>15MG</u>	<u>A205019</u>	<u>001</u>	Dec 05, 2014
<u>AA</u>			<u>30MG</u>	<u>A205019</u>	<u>002</u>	Dec 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A205017</u>	<u>001</u>	Sep 25, 2014

PRESCRIPTION DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	!	SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>		
<u>AA</u>	!		<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20,	1983
<u>AA</u>	!		<u>30MG</u>	<u>A087190</u>	<u>001</u>		
<u>AA</u>		SUN PHARM INDUSTRIES	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23,	2003

TABLET; ORAL

ADIPEX-P

<u>AA</u>	!	TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>		
-----------	---	------	---------------	----------------	------------	--	--

LOMAIRA

<u>AA</u>	!	AVANTHI INC	<u>8MG</u>	<u>A203495</u>	<u>001</u>	Sep 12,	2016
-----------	---	-------------	------------	----------------	------------	---------	------

PHENTERMINE HYDROCHLORIDE

<u>AA</u>		AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068</u>	<u>001</u>	Aug 06,	2014
<u>AA</u>		BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31,	2009
<u>AA</u>		ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31,	2011
<u>AA</u>		ELITE LABS INC	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30,	1997
<u>AA</u>		INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942</u>	<u>001</u>	Feb 05,	2014
<u>AA</u>		KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31,	2008
<u>AA</u>		KVK TECH INC	<u>8MG</u>	<u>A203436</u>	<u>001</u>	Mar 17,	2017
<u>AA</u>		LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15,	2005
<u>AA</u>		NUVO PHARM	<u>37.5MG</u>	<u>A205008</u>	<u>001</u>	Sep 25,	2014
<u>AA</u>		POLYGEN PHARMS	<u>37.5MG</u>	<u>A206342</u>	<u>001</u>	Nov 18,	2016
<u>AA</u>		PRINSTON INC	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04,	2002
<u>AA</u>		SUN PHARM INDUSTRIES	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23,	2003

TABLET, ORALLY DISINTEGRATING; ORAL

PHENTERMINE HYDROCHLORIDE

		ZYDUS PHARMS	15MG	A204663	001	Jun 28,	2017
			30MG	A204663	002	Jun 28,	2017
			37.5MG	A204663	003	Jun 28,	2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

+	VIVUS	EQ 3.75MG BASE; 23MG		N022580	001	Jul 17,	2012
+		EQ 7.5MG BASE; 46MG		N022580	002	Jul 17,	2012
+		EQ 11.25MG BASE; 69MG		N022580	003	Jul 17,	2012
+	!	EQ 15MG BASE; 92MG		N022580	004	Jul 17,	2012

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<u>AP</u>		PRECISION DOSE INC	<u>5MG/VIAL</u>	<u>A207686</u>	<u>001</u>	Jul 14,	2017	
<u>AP</u>	!	WEST-WARD PHARMS INT	<u>5MG/VIAL</u>	<u>A040235</u>	<u>001</u>	Mar 11,	1998	
		ORAVERSE						
	+	!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09,	2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

<u>AP1</u>		AMNEAL	<u>10MG/ML (10MG/ML)</u>	<u>A211079</u>	<u>001</u>	Jul 05,	2018
<u>AP1</u>			<u>50MG/5ML (10MG/ML)</u>	<u>A211078</u>	<u>001</u>	Jul 19,	2018
<u>AP1</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A211078</u>	<u>002</u>	Jul 19,	2018
<u>AP1</u>		FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A210666</u>	<u>001</u>	Jan 30,	2019
<u>AP1</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A210666</u>	<u>002</u>	Jan 30,	2019
<u>AP1</u>		MEITHEAL	<u>50MG/5ML (10MG/ML)</u>	<u>A210333</u>	<u>001</u>	Apr 27,	2018
<u>AP1</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A210333</u>	<u>002</u>	Apr 27,	2018
<u>AP1</u>		PAR STERILE PRODUCTS	<u>10MG/ML (10MG/ML)</u>	<u>A210025</u>	<u>001</u>	Dec 21,	2018
<u>AP1</u>			<u>50MG/5ML (10MG/ML)</u>	<u>A210025</u>	<u>002</u>	Dec 21,	2018
<u>AP1</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A210025</u>	<u>003</u>	Dec 21,	2018
<u>AP1</u>		SANDOZ INC	<u>10MG/ML (10MG/ML)</u>	<u>A208905</u>	<u>001</u>	Jan 31,	2019
<u>AP1</u>			<u>50MG/5ML (10MG/ML)</u>	<u>A208905</u>	<u>002</u>	Jan 31,	2019
<u>AP1</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A208905</u>	<u>003</u>	Jan 31,	2019

VAZCULEP

<u>AP1</u>	+	!	AVADEL LEGACY	<u>10MG/ML (10MG/ML)</u>	<u>N204300</u>	<u>001</u>	Jun 27,	2014
<u>AP1</u>	+	!		<u>50MG/5ML (10MG/ML)</u>	<u>N204300</u>	<u>002</u>	Jun 27,	2014
<u>AP1</u>	+	!		<u>100MG/10ML (10MG/ML)</u>	<u>N204300</u>	<u>003</u>	Jun 27,	2014

PHENYLEPHRINE HYDROCHLORIDE

<u>AP2</u>		FRESENIUS KABI USA	<u>10MG/ML (10MG/ML)</u>	<u>A210665</u>	<u>001</u>	Jan 29,	2019	
<u>AP2</u>		MEITHEAL	<u>10MG/ML (10MG/ML)</u>	<u>A210334</u>	<u>001</u>	Apr 27,	2018	
<u>AP2</u>	+	!	WEST WARD PHARM	<u>10MG/ML (10MG/ML)</u>	<u>N203826</u>	<u>001</u>	Dec 20,	2012

PRESCRIPTION DRUG PRODUCT LIST

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

CORP

AP2	+ !		50MG/5ML (10MG/ML)	N203826 002	Jun 19, 2019
AP2	+ !		100MG/10ML (10MG/ML)	N203826 003	Jun 19, 2019

BIORPHEN

+! ETON PHARMS 0.1MG/ML (0.1MG/ML)

N212909 001 Oct 21, 2019

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+ !	AKORN INC	2.5%	N207926 001	Jan 15, 2015
AT	+ !		10%	N207926 002	Jan 15, 2015
AT	+ !	PARAGON BIOTECK	2.5%	N203510 001	Mar 21, 2013
AT	+ !		10%	N203510 002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		HI TECH	5MG/5ML; 6.25MG/5ML	A040675 001	Dec 23, 2014
AA	!	VINTAGE	5MG/5ML; 6.25MG/5ML	A040654 001	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	5MG/5ML; 6.25MG/5ML	A040902 001	Aug 25, 2009
-----------	--	---------------	----------------------------	--------------------	--------------

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB	+ !	PARKE DAVIS	125MG/5ML	N008762 001	
-----------	------------	-------------	------------------	--------------------	--

PHENYTOIN

AB		TARO	125MG/5ML	A040521 001	Mar 08, 2004
AB		VISTAPHARM	125MG/5ML	A040342 001	Jan 31, 2001
AB			125MG/5ML	A040610 001	Aug 18, 2005
AB		WOCKHARDT BIO AG	125MG/5ML	A040420 001	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

AB	!	PFIZER	50MG	A084427 001	
-----------	----------	--------	-------------	--------------------	--

PHENYTOIN

AB		EPIC PHARMA LLC	50MG	A040884 001	Nov 28, 2014
AB		MYLAN PHARMS INC	50MG	A200691 001	Dec 26, 2012
AB		TARO	50MG	A200565 001	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

AB	!	PARKE-DAVIS	100MG EXTENDED	A084349 002	
-----------	----------	-------------	-----------------------	--------------------	--

EXTENDED PHENYTOIN SODIUM

AB		AMNEAL PHARMS NY	100MG EXTENDED	A040765 001	Nov 12, 2008
AB		LUPIN LTD	100MG EXTENDED	A211633 001	Sep 30, 2019
AB		MYLAN	100MG EXTENDED	A040298 001	Dec 28, 1998
AB		SUN PHARM INDS	200MG EXTENDED	A040731 001	Jun 30, 2008
AB			300MG EXTENDED	A040731 002	Jun 30, 2008
AB		TARO	100MG EXTENDED	A040684 001	Sep 05, 2006

PHENYTEK

AB		MYLAN	200MG EXTENDED	A040298 002	Dec 06, 2001
AB	!		300MG EXTENDED	A040298 003	Dec 06, 2001

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309 001	Jun 10, 2015
-----------	--	----------------------	-----------------------	--------------------	--------------

DILANTIN

+! PARKE-DAVIS 30MG EXTENDED

A084349 001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP		ACELLA	50MG/ML	A040573 001	Sep 13, 2006
AP	!	WEST-WARD PHARMS INT	50MG/ML	A084307 001	

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB		DR REDDYS LABS LTD	10MG/ML	A207719 001	May 22, 2019
-----------	--	--------------------	----------------	--------------------	--------------

VITAMIN K1

AB	!	HOSPIRA	10MG/ML	A087955 001	Jul 25, 1983
-----------	----------	---------	----------------	--------------------	--------------

PHYTONADIONE

BP	!	INTL MEDICATION	1MG/0.5ML	A083722 001	
-----------	----------	-----------------	------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

BP ! HOSPIRA 1MG/0.5ML A087954 001 Jul 25, 1983

TABLET; ORAL

MEPHYTON**AB** +! BAUSCH **5MG** **N010104 003**PHYTONADIONE**AB** AMNEAL PHARMS CO **5MG** **A209373 001** May 11, 2018**AB** ZYDUS **5MG** **A210189 001** Feb 20, 2019PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE**AT** + NOVARTIS **1%** **N200890 001** Jun 22, 2010**AT** + **2%** **N200890 002** Jun 22, 2010**AT** +! **4%** **N200890 003** Jun 22, 2010PILOCARPINE HYDROCHLORIDE**AT** AKORN INC **1%** **A204398 001** Sep 27, 2017**AT** **2%** **A204398 002** Sep 27, 2017**AT** **4%** **A204398 003** Sep 27, 2017**AT** SOMERSET THERAPS **1%** **A210384 001** Nov 25, 2019

LLC

AT **2%** **A210384 002** Nov 25, 2019**AT** **4%** **A210384 003** Nov 25, 2019

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE**AB** AUROBINDO PHARMA **5MG** **A212377 001** Aug 13, 2019

LTD

AB **7.5MG** **A212377 002** Aug 13, 2019**AB** IMPAX LABS **5MG** **A077248 001** Mar 31, 2006**AB** **7.5MG** **A077248 002** Mar 31, 2006**AB** INNOGENIX **5MG** **A076963 001** Dec 22, 2004**AB** **7.5MG** **A076963 002** Feb 27, 2007**AB** LANNETT CO INC **5MG** **A077220 001** Oct 14, 2005**AB** **7.5MG** **A077220 002** May 06, 2009**AB** PERRIGO PHARMA INTL **5MG** **A076746 001** Nov 16, 2004SALAGEN**AB** + CONCORDIA **5MG** **N020237 001** Mar 22, 1994**AB** +! **7.5MG** **N020237 002** Apr 18, 2003PIMAVANSERIN TARTRATE

CAPSULE; ORAL

NUPLAZID

+! ACADIA PHARMS INC EQ 34MG BASE N210793 001 Jun 28, 2018

TABLET; ORAL

NUPLAZID

+! ACADIA PHARMS INC EQ 10MG BASE N207318 002 Jun 28, 2018

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL**AB** +! BAUSCH **1%** **N021302 001** Dec 13, 2001PIMECROLIMUS**AB** ACTAVIS LABS UT INC **1%** **A209345 001** Dec 27, 2018**AB** GLENMARK PHARMS LTD **1%** **A211769 001** Aug 29, 2019PIMOZIDE

TABLET; ORAL

PIMOZIDE

PAR PHARM 1MG A204521 001 Sep 28, 2015

! 2MG A204521 002 Sep 28, 2015

PINDOLOL

TABLET; ORAL

PINDOLOL**AB** ANI PHARMS INC **5MG** **A073609 002** Mar 29, 1993**AB** **10MG** **A073609 001** Mar 29, 1993**AB** BAYSHORE PHARMS LLC **5MG** **A211712 001** Aug 01, 2019**AB** **10MG** **A211712 002** Aug 01, 2019**AB** MYLAN PHARMS INC **5MG** **A074019 001** Sep 03, 1992**AB** ! **10MG** **A074019 002** Sep 03, 1992**AB** NOSTRUM LABS INC **5MG** **A205415 001** Jan 13, 2016**AB** **10MG** **A205415 002** Jan 13, 2016**AB** SUN PHARM **5MG** **A074063 001** Jan 27, 1994

PRESCRIPTION DRUG PRODUCT LIST

PINDOLOL

TABLET; ORAL

PINDOLOL

INDUSTRIES

<u>AB</u>		<u>10MG</u>	<u>A074063</u>	<u>002</u>	Jan 27, 1994
-----------	--	-------------	----------------	------------	--------------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

<u>AB</u>	+	TAKEDA PHARMS USA	<u>EQ 15MG BASE</u>	<u>N021073</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N021073</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>	+	!	<u>EQ 45MG BASE</u>	<u>N021073</u>	<u>003</u>	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 15MG BASE</u>	<u>A200044</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A200044</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A200044</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 15MG BASE</u>	<u>A200268</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A200268</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A200268</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>		BRECKENRIDGE	<u>EQ 15MG BASE</u>	<u>A078472</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078472</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078472</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>		CELLTRION	<u>EQ 15MG BASE</u>	<u>A076798</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076798</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A076798</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>		LUPIN LTD	<u>EQ 15MG BASE</u>	<u>A204133</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204133</u>	<u>002</u>	Apr 07, 2014
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A204133</u>	<u>003</u>	Apr 07, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467</u>	<u>001</u>	Feb 06, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202467</u>	<u>002</u>	Feb 06, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A202467</u>	<u>003</u>	Feb 06, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A076801</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A076801</u>	<u>003</u>	Aug 17, 2012
<u>AB</u>		NEOPHARMA	<u>EQ 15MG BASE</u>	<u>A078383</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078383</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078383</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>		PRINSTON INC	<u>EQ 15MG BASE</u>	<u>A207806</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A207806</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A207806</u>	<u>003</u>	Apr 17, 2018
<u>AB</u>		PURACAP PHARM LLC	<u>EQ 15MG BASE</u>	<u>A206738</u>	<u>001</u>	Oct 06, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A206738</u>	<u>002</u>	Oct 06, 2017
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A206738</u>	<u>003</u>	Oct 06, 2017
<u>AB</u>		SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A078670</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A078670</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>		TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210</u>	<u>001</u>	Jan 10, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A077210</u>	<u>002</u>	Jan 10, 2014
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A077210</u>	<u>003</u>	Jan 10, 2014
<u>AB</u>		TORRENT PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A091298</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A091298</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A091298</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202456</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>			<u>EQ 45MG BASE</u>	<u>A202456</u>	<u>003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>		APOLLO	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A207847</u>	<u>001</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A207847</u>	<u>002</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207848</u>	<u>002</u>	Jan 13, 2017
<u>AP</u>			<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A207847</u>	<u>003</u>	Jan 13, 2017

PRESCRIPTION DRUG PRODUCT LIST

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>		<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A207848 001</u>	May 11, 2018
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498 001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498 002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498 003</u>	May 23, 2011
<u>AP</u>	FRESENIUS KABI	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A203719 001</u>	May 18, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A203719 002</u>	May 18, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A203719 003</u>	May 18, 2018
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A203720 001</u>	May 11, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A206204 001</u>	May 11, 2018
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523 001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523 002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523 003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498 001</u>	May 31, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458 001</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458 002</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458 003</u>	Aug 15, 2014
<u>AP</u>	QILU	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A204959 001</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A204959 002</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A204959 003</u>	Aug 10, 2018
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362 001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362 002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362 003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362 003</u>	Oct 21, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A203557 001</u>	Oct 29, 2014
<u>AP</u>	WOCKHARDT BIO AG	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A206996 001</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A206996 002</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A206996 003</u>	Mar 22, 2017
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207146 001</u>	Mar 17, 2017
<u>ZOSYN</u>				
<u>AP</u>	+!	WYETH PHARMS	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684 001</u> Oct 22, 1993
<u>AP</u>	+!		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684 002</u> Oct 22, 1993
<u>AP</u>	+!		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684 003</u> Oct 22, 1993
<u>AP</u>	+!		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684 004</u> Oct 22, 1993
ZOSYN IN PLASTIC CONTAINER				
	+!	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001 Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002 Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003 Feb 24, 1998

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+! GENENTECH INC

267MG

N022535 001 Oct 15, 2014

TABLET; ORAL

ESBRIET

+ GENENTECH INC

267MG

N208780 001 Jan 11, 2017

+!

801MG

N208780 003 Jan 11, 2017

PIROXICAM

CAPSULE; ORAL

FELDENEAB + PFIZER10MGN018147 002 Apr 06, 1982AB +!20MGN018147 003 Apr 06, 1982PIROXICAMAB CADILA10MGA205585 001 Jul 17, 2018AB20MGA205585 002 Jul 17, 2018AB FLAMINGO PHARMS10MGA207938 001 Sep 09, 2016AB20MGA207938 002 Sep 09, 2016AB HIKMA PHARMS10MGA209256 001 Aug 11, 2017AB20MGA209256 002 Aug 11, 2017AB MICRO LABS10MGA206152 001 Dec 29, 2017AB20MGA206152 002 Dec 29, 2017AB NOSTRUM LABS INC10MGA074116 001 Jun 15, 1993AB20MGA074118 001 Jun 15, 1993AB PII10MGA206136 001 Jun 20, 2017AB20MGA206136 002 Jun 20, 2017AB STRIDES PHARMA10MGA210347 001 Jan 26, 2018AB20MGA210347 002 Jan 26, 2018

PRESCRIPTION DRUG PRODUCT LIST

PIROXICAM

CAPSULE; ORAL

PIROXICAM

<u>AB</u>	TEVA	<u>10MG</u>	<u>A074131 001</u>	Dec 11, 1992
<u>AB</u>		<u>20MG</u>	<u>A074131 002</u>	Dec 11, 1992
<u>AB</u>	UNICHEM LABS LTD	<u>10MG</u>	<u>A208340 001</u>	Apr 13, 2017
<u>AB</u>		<u>20MG</u>	<u>A208340 002</u>	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

<u>AB</u>	+	KOWA CO	<u>EQ 1MG BASE</u>	<u>N022363 001</u>	Aug 03, 2009
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N022363 002</u>	Aug 03, 2009
<u>AB</u>	+	!	<u>EQ 4MG BASE</u>	<u>N022363 003</u>	Aug 03, 2009

PITAVASTATIN CALCIUM

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 1MG BASE</u>	<u>A206015 001</u>	Dec 20, 2016
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A206015 002</u>	Dec 20, 2016
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A206015 003</u>	Dec 20, 2016
<u>AB</u>		ORIENT PHARMA CO LTD	<u>EQ 1MG BASE</u>	<u>A205932 001</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A205932 002</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A205932 003</u>	Feb 03, 2017
<u>AB</u>		SAWAI USA	<u>EQ 1MG BASE</u>	<u>A205955 001</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A205955 002</u>	Feb 03, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A205955 003</u>	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

	+	MEDICURE	EQ 2MG BASE	N208379 002	Jul 14, 2017
	+	!	EQ 4MG BASE	N208379 003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE

TABLET; ORAL

WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150 001	Aug 14, 2019
	+	!	EQ 17.8MG BASE	N211150 002	Aug 14, 2019

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS

ZEMDRI

	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303 001	Jun 25, 2018
--	---	-----------	--------------------------------------	-------------	--------------

PLECANATIDE

TABLET; ORAL

TRULANCE

	+	SALIX	3MG	N208745 001	Jan 19, 2017
--	---	-------	-----	-------------	--------------

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

	+	GENZYME	24MG/1.2ML (20MG/ML)	N022311 001	Dec 15, 2008
--	---	---------	----------------------	-------------	--------------

PODOFILOX

GEL; TOPICAL

CONDYLOX

	+	ALLERGAN	0.5%	N020529 001	Mar 13, 1997
--	---	----------	------	-------------	--------------

SOLUTION; TOPICAL

CONDYLOX

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N019795 001</u>	Dec 13, 1990
-----------	---	----------	-------------	--------------------	--------------

PODOFILOX

<u>AT</u>		PADDOCK LLC	<u>0.5%</u>	<u>A075600 001</u>	Jan 29, 2002
-----------	--	-------------	-------------	--------------------	--------------

POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

	+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201 001	Mar 30, 2010
--	---	----------------------	-------------------	-------------	--------------

	+	!	20MG/2ML (10MG/ML)	N021201 002	Mar 30, 2010
--	---	---	--------------------	-------------	--------------

VARITHENA

	+	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098 002	Dec 21, 2017
--	---	-----------	-------------------------	-------------	--------------

	+	!	180MG/18ML (10MG/ML)	N205098 001	Nov 25, 2013
--	---	---	----------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKS

AA	PADDOCK LLC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A079232 001	Feb 25, 2010
-----------	-------------	---	--------------------	--------------

NULYTELY

AA	+! BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	N019797 001	Apr 22, 1991
-----------	--------------	---	--------------------	--------------

NULYTELY-FLAVORED

AA	+! BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	N019797 002	Nov 18, 1994
-----------	--------------	---	--------------------	--------------

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	BRECKENRIDGE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A202060 001	Mar 08, 2017
-----------	--------------	---	--------------------	--------------

AA	NOVEL LABS INC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A090019 001	May 27, 2009
-----------	----------------	---	--------------------	--------------

AA	STRIDES PHARMA	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A204559 001	Apr 13, 2015
-----------	----------------	---	--------------------	--------------

TRILYTE

AA	MYLAN	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A076491 001	Feb 05, 2004
-----------	-------	---	--------------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

AA	MYLAN SPECIALITY LP	<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	N018983 012	Oct 08, 1998
-----------	---------------------	---	--------------------	--------------

GOLYTELY

AA	+! BRAINTREE	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	N019011 001	Jul 13, 1984
-----------	--------------	---	--------------------	--------------

PEG 3350 AND ELECTROLYTES

AA	NOVEL LABS INC	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	A090231 001	Jun 01, 2009
-----------	----------------	---	--------------------	--------------

AA		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	A090186 001	Jun 01, 2009
-----------	--	---	--------------------	--------------

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA	STRIDES PHARMA	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	A204558 001	Dec 21, 2018
-----------	----------------	---	--------------------	--------------

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	A206589 001	Apr 04, 2016
-----------	----------------------	-----------------------------------	--------------------	--------------

AP	FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	A065372 001	Jan 10, 2008
-----------	--------------------	-----------------------------------	--------------------	--------------

AP	! GLAND PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	A207322 001	Apr 14, 2016
-----------	--------------------	-----------------------------------	--------------------	--------------

AP	MYLAN ASI	<u>EQ 500,000 UNITS BASE/VIAL</u>	A090110 001	Jun 29, 2011
-----------	-----------	-----------------------------------	--------------------	--------------

AP	X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	A063000 001	Sep 30, 1994
-----------	--------------	-----------------------------------	--------------------	--------------

AP	XELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	A202766 001	Jan 15, 2014
-----------	-------------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

AT	+! ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	N050567 001	Oct 20, 1988
-----------	-------------	---------------------------------------	--------------------	--------------

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A065006 001	Dec 17, 1998
-----------	-----------	---------------------------------------	--------------------	--------------

AT	BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A064120 001	Feb 14, 1997
-----------	-----------------	---------------------------------------	--------------------	--------------

AT	SANDOZ INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A064211 001	Apr 13, 1998
-----------	------------	---------------------------------------	--------------------	--------------

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

+	CELGENE	1MG	N204026 001	Feb 08, 2013
---	---------	-----	-------------	--------------

+		2MG	N204026 002	Feb 08, 2013
---	--	-----	-------------	--------------

+		3MG	N204026 003	Feb 08, 2013
---	--	-----	-------------	--------------

+	!	4MG	N204026 004	Feb 08, 2013
---	---	-----	-------------	--------------

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

+	ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012
---	-------	--------------	-------------	--------------

+		EQ 30MG BASE	N203469 003	Apr 23, 2015
---	--	--------------	-------------	--------------

+	!	EQ 45MG BASE	N203469 002	Dec 14, 2012
---	---	--------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PORACTANT ALFASUSPENSION; INTRATRACHEAL
CUROSURF

+! CHIESI USA INC 80MG/ML N020744 001 Nov 18, 1999

PORFIMER SODIUMINJECTABLE; INJECTION
PHOTOFRIN

PINNACLE BIOLGS 75MG/VIAL N020451 001 Dec 27, 1995

POSACONAZOLESOLUTION; INTRAVENOUS
NOXAFIL

+! MERCK SHARP DOHME 300MG/16.7ML (18MG/ML) N205596 001 Mar 13, 2014

SUSPENSION; ORAL

NOXAFIL

+! SCHERING 40MG/ML N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL**AB** +! MERCK SHARP DOHME **100MG** **N205053 001** Nov 25, 2013POSACONAZOLE**AB** SINOTHERAPEUTICS **100MG** **A212411 001** Aug 21, 2019
INCPOTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE**AP** EXELA PHARMA SCS **2MEQ/ML** **A206203 001** Dec 29, 2015
LLC**AP** +! HOSPIRA **2MEQ/ML** **N018896 001** Jul 20, 1984POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON**AB** UPSHER SMITH LABS **8MEQ** **A203106 001** Jul 10, 2015**AB** **10MEQ** **A203106 002** Jul 10, 2015MICRO-K**AB** + NESHER PHARMS **8MEQ** **N018238 001**MICRO-K 10**AB** + NESHER PHARMS **10MEQ** **N018238 002** May 14, 1984POTASSIUM CHLORIDE**AB** ACTAVIS LABS FL INC **8MEQ** **A077419 001** Jun 02, 2008**AB** ! **10MEQ** **A077419 002** Jun 02, 2008**AB** ADARE PHARMS INC **8MEQ** **A208864 001** Mar 17, 2017**AB** **10MEQ** **A208864 002** Mar 17, 2017**AB** AMNEAL PHARMS **10MEQ** **A202128 001** Feb 22, 2013**AB** ANCHEN PHARMS **8MEQ** **A202886 001** Dec 26, 2013**AB** **10MEQ** **A202886 002** Dec 26, 2013**AB** GLENMARK PHARMS LTD **10MEQ** **A202868 001** Jan 19, 2016**AB** LANNETT CO INC **8MEQ** **A204210 001** Mar 28, 2016**AB** **10MEQ** **A204210 002** Mar 28, 2016**AB** LUPIN LTD **8MEQ** **A203002 001** Dec 18, 2015**AB** **10MEQ** **A203002 002** Dec 18, 2015**AB** NOVEL LABS INC **8MEQ** **A204828 001** Aug 16, 2016**AB** **10MEQ** **A204828 002** Aug 16, 2016**AB** PADDOCK LLC **8MEQ** **A200185 001** May 18, 2011**AB** **10MEQ** **A200185 002** May 18, 2011**AB** PII **8MEQ** **A205549 001** Dec 08, 2015**AB** **10MEQ** **A205549 002** Dec 08, 2015**AB** PRINSTON INC **8MEQ** **A209026 001** Jun 11, 2019**AB** **10MEQ** **A209026 002** Jun 11, 2019**AB** TRIS PHARMA INC **8MEQ** **A201944 001** Mar 04, 2016**AB** **10MEQ** **A201944 002** Mar 04, 2016**AB** ZYDUS PHARMS **8MEQ** **A208445 001** Mar 11, 2019**AB** **10MEQ** **A208445 002** Mar 11, 2019

FOR SOLUTION; ORAL

KLOR-CON**AA** UPSHER SMITH LABS **20MEQ** **A209662 001** Oct 23, 2017POTASSIUM CHLORIDE**AA** AMNEAL PHARMS LLC **20MEQ** **A210902 001** May 23, 2019**AA** BELCHER PHARMS LLC **20MEQ** **A212183 001** May 06, 2019**AA** EPIC PHARMA LLC **20MEQ** **A210200 001** Nov 23, 2018**AA** NOVEL LABS INC **20MEQ** **A210241 001** Nov 21, 2018**AA** +! PHARMA RES SOFTWARE **20MEQ** **N208019 001** Aug 19, 2015

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

<u>AP</u>	B BRAUN	<u>2MEQ/ML</u>	<u>A085870</u>	<u>001</u>	
<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A080225</u>	<u>001</u>	
<u>AP</u>	! HOSPIRA	<u>2MEQ/ML</u>	<u>A080205</u>	<u>001</u>	
<u>POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER</u>					
<u>AP</u>	+! BAXTER HLTHCARE	<u>14.9MG/ML</u>	<u>N019904</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>	+!	<u>746MG/100ML</u>	<u>N019904</u>	<u>005</u>	Dec 17, 1990
<u>AP</u>	+ ICU MEDICAL INC	<u>14.9MG/ML</u>	<u>N020161</u>	<u>005</u>	Nov 30, 1992
<u>AP</u>	+	<u>745MG/100ML</u>	<u>N020161</u>	<u>001</u>	Nov 30, 1992
<u>POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>					
<u>AP</u>	+! BAXTER HLTHCARE	<u>29.8MG/ML</u>	<u>N019904</u>	<u>002</u>	Dec 26, 1989
<u>AP</u>	+!	<u>1.49GM/100ML</u>	<u>N019904</u>	<u>006</u>	Dec 17, 1990
<u>AP</u>	+! ICU MEDICAL INC	<u>29.8MG/ML</u>	<u>N020161</u>	<u>006</u>	Aug 11, 1998
<u>AP</u>	+	<u>1.49GM/100ML</u>	<u>N020161</u>	<u>002</u>	Nov 30, 1992
<u>POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>					
<u>AP</u>	+! BAXTER HLTHCARE	<u>2.98GM/100ML</u>	<u>N019904</u>	<u>004</u>	Dec 26, 1989
<u>AP</u>	+! ICU MEDICAL INC	<u>2.98GM/100ML</u>	<u>N020161</u>	<u>004</u>	Aug 11, 1998
<u>POTASSIUM CHLORIDE IN PLASTIC CONTAINER</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088901</u>	<u>001</u>	Jan 25, 1985
<u>AP</u>		<u>2MEQ/ML</u>	<u>A088908</u>	<u>001</u>	Jan 25, 1985
POTASSIUM CHLORIDE					
	! FRESENIUS KABI USA	3MEQ/ML	A080225	003	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
	+! BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION; ORAL

POTASSIUM CHLORIDE

<u>AA</u>	AMNEAL PHARMS LLC	<u>20MEQ/15ML</u>	<u>A210041</u>	<u>001</u>	Jul 19, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A210041</u>	<u>002</u>	Jul 19, 2018
<u>AA</u>	APOTEX	<u>20MEQ/15ML</u>	<u>A211067</u>	<u>001</u>	Aug 08, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A211067</u>	<u>002</u>	Aug 08, 2018
<u>AA</u>	+ GENUS LIFESCIENCES	<u>20MEQ/15ML</u>	<u>N206814</u>	<u>001</u>	Dec 22, 2014
<u>AA</u>	+!	<u>40MEQ/15ML</u>	<u>N206814</u>	<u>002</u>	Dec 22, 2014
<u>AA</u>	NOVEL LABS INC	<u>20MEQ/15ML</u>	<u>A209786</u>	<u>001</u>	Aug 29, 2018
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A209786</u>	<u>002</u>	Aug 29, 2018
<u>AA</u>	PHARM ASSOC	<u>20MEQ/15ML</u>	<u>A210766</u>	<u>001</u>	Mar 29, 2019
<u>AA</u>		<u>40MEQ/15ML</u>	<u>A210766</u>	<u>002</u>	Mar 29, 2019

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10

<u>AB1</u>	UPSHER SMITH LABS	<u>10MEQ</u>	<u>A074726</u>	<u>002</u>	Aug 09, 2000
<u>KLOR-CON M15</u>					
<u>AB1</u>	UPSHER SMITH LABS	<u>15MEQ</u>	<u>A074726</u>	<u>003</u>	Jun 06, 2003
<u>KLOR-CON M20</u>					
<u>AB1</u>	! UPSHER SMITH LABS	<u>20MEQ</u>	<u>A074726</u>	<u>001</u>	Nov 20, 1998

POTASSIUM CHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>10MEQ</u>	<u>A075604</u>	<u>001</u>	Apr 10, 2002
<u>AB1</u>		<u>20MEQ</u>	<u>A075604</u>	<u>002</u>	Apr 10, 2002
<u>AB1</u>	ADARE PHARMS INC	<u>10MEQ</u>	<u>A076368</u>	<u>002</u>	Jun 05, 2019
<u>AB1</u>		<u>20MEQ</u>	<u>A076368</u>	<u>001</u>	Aug 18, 2004
<u>AB1</u>	GLENMARK PHARMS LTD	<u>10MEQ</u>	<u>A203562</u>	<u>001</u>	Jul 26, 2016
<u>AB1</u>		<u>20MEQ</u>	<u>A203562</u>	<u>002</u>	Jul 26, 2016
<u>AB1</u>	NOVEL LABS INC	<u>10MEQ</u>	<u>A206347</u>	<u>001</u>	Jan 21, 2016
<u>AB1</u>		<u>20MEQ</u>	<u>A206347</u>	<u>002</u>	Jan 21, 2016
<u>AB1</u>	PRINSTON INC	<u>10MEQ</u>	<u>A209922</u>	<u>001</u>	Apr 30, 2019
<u>AB1</u>		<u>15MEQ</u>	<u>A209922</u>	<u>002</u>	Apr 30, 2019
<u>AB1</u>		<u>20MEQ</u>	<u>A209922</u>	<u>003</u>	Apr 30, 2019

KLOR-CON

<u>AB2</u>	+ UPSHER SMITH LABS	<u>8MEQ</u>	<u>N019123</u>	<u>001</u>	Apr 17, 1986
<u>AB2</u>	+!	<u>10MEQ</u>	<u>N019123</u>	<u>002</u>	Apr 17, 1986
<u>POTASSIUM CHLORIDE</u>					
<u>AB2</u>	AUROBINDO PHARMA LTD	<u>8MEQ</u>	<u>A210921</u>	<u>001</u>	Dec 19, 2018
<u>AB2</u>		<u>10MEQ</u>	<u>A210921</u>	<u>002</u>	Dec 19, 2018
<u>AB2</u>	MYLAN	<u>8MEQ</u>	<u>A204662</u>	<u>001</u>	Aug 21, 2014
<u>AB2</u>		<u>10MEQ</u>	<u>A204662</u>	<u>002</u>	Aug 21, 2014
<u>AB2</u>	NOVEL LABS INC	<u>8MEQ</u>	<u>A206759</u>	<u>001</u>	Aug 09, 2016
<u>AB2</u>		<u>10MEQ</u>	<u>A206759</u>	<u>002</u>	Aug 09, 2016
<u>AB2</u>	PADDOCK LLC	<u>8MEQ</u>	<u>A205993</u>	<u>001</u>	Nov 05, 2015
<u>AB2</u>		<u>10MEQ</u>	<u>A205993</u>	<u>002</u>	Nov 05, 2015
<u>AB2</u>	SIGMAPHARM LABS LLC	<u>8MEQ</u>	<u>A207528</u>	<u>001</u>	Aug 19, 2016
<u>AB2</u>		<u>10MEQ</u>	<u>A207528</u>	<u>002</u>	Aug 19, 2016
<u>AB2</u>	STRIDES PHARMA	<u>8MEQ</u>	<u>A210733</u>	<u>001</u>	Aug 31, 2018

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

<u>AB2</u>		<u>10MEQ</u>	<u>A210733</u>	<u>002</u>	Aug 31, 2018
<u>AB2</u>	YICHANG HUMANWELL	<u>8MEQ</u>	<u>A209314</u>	<u>001</u>	Jun 22, 2018
<u>AB2</u>		<u>10MEQ</u>	<u>A209314</u>	<u>002</u>	Jun 22, 2018

K-TAB

<u>AB3</u>	+	ABBVIE	<u>10MEQ</u>	<u>N018279</u>	<u>001</u>	
<u>AB3</u>	+	!	<u>20MEQ</u>	<u>N018279</u>	<u>003</u>	Nov 25, 2013

POTASSIUM CHLORIDE

<u>AB3</u>	VITRUVIAS THERAP	<u>10MEQ</u>	<u>A209688</u>	<u>001</u>	Jan 12, 2018
<u>AB3</u>		<u>20MEQ</u>	<u>A209688</u>	<u>002</u>	Jan 12, 2018
<u>AB3</u>	YICHANG HUMANWELL	<u>10MEQ</u>	<u>A212561</u>	<u>001</u>	Sep 30, 2019
<u>AB3</u>		<u>20MEQ</u>	<u>A212561</u>	<u>002</u>	Sep 30, 2019

K-TAB

BC	+	ABBVIE	8MEQ	N018279	002	Aug 01, 1988
----	---	--------	------	---------	-----	--------------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	ICU MEDICAL INC	<u>149MG/100ML;450MG/100ML</u>	<u>A078446</u>	<u>001</u>	Sep 10, 2008
-----------	-----------------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>150MG/100ML;450MG/100ML</u>	<u>N017648</u>	<u>005</u>	Nov 26, 2002
-----------	---	-----------------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>150MG/100ML;900MG/100ML</u>	<u>N019708</u>	<u>004</u>	Sep 29, 1989
-----------	--	---------	--------------------------------	----------------	------------	--------------

<u>AP</u>	+	BAXTER HLTHCARE	<u>150MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>001</u>	
-----------	---	-----------------	--------------------------------	----------------	------------	--

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>300MG/100ML;900MG/100ML</u>	<u>N017648</u>	<u>002</u>	
-----------	---	-----------------	--------------------------------	----------------	------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		ICU MEDICAL INC	<u>149MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>001</u>	Oct 17, 1988
-----------	--	-----------------	--------------------------------	----------------	------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		ICU MEDICAL INC	<u>298MG/100ML;900MG/100ML</u>	<u>N019686</u>	<u>002</u>	Oct 17, 1988
-----------	--	-----------------	--------------------------------	----------------	------------	--------------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

<u>AB</u>		ANI PHARMS INC	<u>10MEQ</u>	<u>A212779</u>	<u>001</u>	Jan 14, 2020
<u>AB</u>			<u>15MEQ</u>	<u>A212779</u>	<u>002</u>	Jan 14, 2020
<u>AB</u>		MOUNTAIN	<u>5MEQ</u>	<u>A077440</u>	<u>001</u>	Jun 09, 2006
<u>AB</u>			<u>10MEQ</u>	<u>A077440</u>	<u>002</u>	Jun 09, 2006
<u>AB</u>		STRIDES PHARMA	<u>5MEQ</u>	<u>A206813</u>	<u>001</u>	Sep 11, 2017
<u>AB</u>			<u>10MEQ</u>	<u>A206813</u>	<u>002</u>	Sep 11, 2017
<u>AB</u>			<u>15MEQ</u>	<u>A206813</u>	<u>003</u>	Sep 11, 2017
<u>AB</u>		TEVA PHARMS USA INC	<u>5MEQ</u>	<u>A209758</u>	<u>001</u>	Mar 05, 2018
<u>AB</u>			<u>10MEQ</u>	<u>A209758</u>	<u>002</u>	Mar 05, 2018
<u>AB</u>			<u>15MEQ</u>	<u>A209758</u>	<u>003</u>	Mar 05, 2018
<u>AB</u>		ZYDUS PHARMS	<u>5MEQ</u>	<u>A203546</u>	<u>001</u>	Aug 06, 2014
<u>AB</u>			<u>10MEQ</u>	<u>A203546</u>	<u>002</u>	Aug 06, 2014
<u>AB</u>			<u>15MEQ</u>	<u>A203546</u>	<u>003</u>	Aug 06, 2014

UROCIT-K

<u>AB</u>	+	MISSION PHARMA	<u>5MEQ</u>	<u>N019071</u>	<u>001</u>	Aug 30, 1985
<u>AB</u>	+		<u>10MEQ</u>	<u>N019071</u>	<u>002</u>	Aug 31, 1992
<u>AB</u>	+	!	<u>15MEQ</u>	<u>N019071</u>	<u>003</u>	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

+	!	CMP DEV LLC	4.5GM/15ML (300MG/ML); 2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019
+	!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019
+	!		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019
+	!		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

+	!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986
---	---	------------------	----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

+ ACROTECH

20MG/ML (20MG/ML)

N022468 001 Sep 24, 2009

+!

40MG/2ML (20MG/ML)

N022468 002 Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

+! MERIDIAN MEDCL
TECHN

300MG/ML

N018986 001 Apr 26, 1983

PROTOPAM CHLORIDE

+! BAXTER HLTHCARE
CORP

1GM/VIAL

N014134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEXAB + BOEHRINGER
INGELHEIM0.125MGN020667 001 Jul 01, 1997AB +!0.25MGN020667 002 Jul 01, 1997AB +0.5MGN020667 006 Feb 12, 1998AB +0.75MGN020667 007 Jul 30, 2007AB +1MGN020667 003 Jul 01, 1997AB +1.5MGN020667 005 Jul 01, 1997PRAMIPEXOLE DIHYDROCHLORIDEAB ALEMBIC PHARMS LTD0.125MGA078894 001 Oct 08, 2010AB0.25MGA078894 002 Oct 08, 2010AB0.5MGA078894 003 Oct 08, 2010AB1MGA078894 004 Oct 08, 2010AB1.5MGA078894 005 Oct 08, 2010AB APOTEX INC0.125MGA090151 001 Apr 30, 2012AB0.25MGA090151 002 Apr 30, 2012AB0.5MGA090151 003 Apr 30, 2012AB0.75MGA090151 006 Apr 30, 2012AB1MGA090151 004 Apr 30, 2012AB1.5MGA090151 005 Apr 30, 2012AB AUROBINDO PHARMA
LTD0.125MGA202633 001 Oct 26, 2012AB0.25MGA202633 002 Oct 26, 2012AB0.5MGA202633 003 Oct 26, 2012AB0.75MGA202633 004 Oct 26, 2012AB1MGA202633 005 Oct 26, 2012AB1.5MGA202633 006 Oct 26, 2012AB BRECKENRIDGE PHARM0.125MGA091450 001 Oct 08, 2010AB0.25MGA091450 002 Oct 08, 2010AB0.5MGA091450 003 Oct 08, 2010AB1MGA091450 004 Oct 08, 2010AB1.5MGA091450 005 Oct 08, 2010AB CSPEC OUYI0.25MGA211088 001 Oct 03, 2018AB0.5MGA211088 002 Oct 03, 2018AB0.75MGA211088 003 Oct 03, 2018AB1MGA211088 004 Oct 03, 2018AB1.5MGA211088 005 Oct 03, 2018AB GLENMARK GENERICS0.125MGA090781 001 Oct 08, 2010AB0.25MGA090781 002 Oct 08, 2010AB0.5MGA090781 003 Oct 08, 2010AB0.75MGA090781 006 Sep 11, 2015AB1MGA090781 004 Oct 08, 2010AB1.5MGA090781 005 Oct 08, 2010AB HERITAGE PHARMA0.125MGA077724 001 Feb 19, 2008AB0.25MGA077724 002 Feb 19, 2008AB0.5MGA077724 003 Feb 19, 2008AB1MGA077724 004 Feb 19, 2008AB1.5MGA077724 005 Feb 19, 2008AB MACLEODS PHARMS LTD0.125MGA202164 001 Sep 20, 2012AB0.25MGA202164 002 Sep 20, 2012AB0.5MGA202164 003 Sep 20, 2012AB1MGA202164 004 Sep 20, 2012AB1.5MGA202164 005 Sep 20, 2012AB MYLAN0.125MGA077854 001 Oct 08, 2010AB0.25MGA077854 002 Oct 08, 2010AB0.5MGA077854 003 Oct 08, 2010AB0.75MGA090764 001 Apr 09, 2010

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>1MG</u>	<u>A077854 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854 005</u>	Oct 08, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865 006</u>	Oct 08, 2010
<u>AB</u>	UNICHEM LABS LTD	<u>0.125MG</u>	<u>A207011 001</u>	Dec 19, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A207011 002</u>	Dec 19, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A207011 003</u>	Dec 19, 2018
<u>AB</u>		<u>0.75MG</u>	<u>A207011 004</u>	Dec 19, 2018
<u>AB</u>		<u>1MG</u>	<u>A207011 005</u>	Dec 19, 2018
<u>AB</u>		<u>1.5MG</u>	<u>A207011 006</u>	Dec 19, 2018
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920 003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920 005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+!	BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421 001</u>	Feb 19, 2010
<u>AB</u>	+		<u>0.75MG</u>	<u>N022421 002</u>	Feb 19, 2010
<u>AB</u>	+		<u>1.5MG</u>	<u>N022421 003</u>	Feb 19, 2010
<u>AB</u>	+		<u>2.25MG</u>	<u>N022421 006</u>	Jun 17, 2011
<u>AB</u>	+		<u>3MG</u>	<u>N022421 004</u>	Feb 19, 2010
<u>AB</u>	+		<u>3.75MG</u>	<u>N022421 007</u>	Jun 17, 2011
<u>AB</u>	+		<u>4.5MG</u>	<u>N022421 005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.375MG</u>	<u>A201963 001</u>	Apr 21, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A201963 002</u>	Apr 21, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A201963 003</u>	Apr 21, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A203615 001</u>	Oct 14, 2016
<u>AB</u>		<u>3MG</u>	<u>A201963 004</u>	Apr 21, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A203615 002</u>	Jan 03, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A201963 005</u>	Apr 21, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.375MG</u>	<u>A204518 001</u>	Jan 02, 2019
<u>AB</u>		<u>0.75MG</u>	<u>A204518 002</u>	Jan 02, 2019
<u>AB</u>		<u>1.5MG</u>	<u>A204518 003</u>	Jan 02, 2019
<u>AB</u>		<u>2.25MG</u>	<u>A204518 004</u>	Jan 02, 2019
<u>AB</u>		<u>3MG</u>	<u>A204518 005</u>	Jan 02, 2019
<u>AB</u>		<u>3.75MG</u>	<u>A204518 006</u>	Jan 02, 2019
<u>AB</u>		<u>4.5MG</u>	<u>A204518 007</u>	Jan 02, 2019
<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206 001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206 002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206 003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206 004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206 005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206 006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206 007</u>	Feb 06, 2014
<u>AB</u>	DR REDDYS	<u>0.375MG</u>	<u>A203354 001</u>	Aug 07, 2015
<u>AB</u>		<u>0.75MG</u>	<u>A203354 002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354 003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354 004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354 005</u>	Aug 07, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.375MG</u>	<u>A206156 001</u>	Jun 24, 2016

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>0.75MG</u>	<u>A206156 002</u>	Jun 24, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A206156 003</u>	Jun 24, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A206156 004</u>	Jun 24, 2016
<u>AB</u>		<u>3MG</u>	<u>A206156 005</u>	Jun 24, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A206156 007</u>	Jan 23, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A206156 006</u>	Jun 24, 2016
<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353 001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353 002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353 003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353 004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353 005</u>	Dec 04, 2014
<u>AB</u>	ZYDUS PHARMS	<u>0.375MG</u>	<u>A202891 001</u>	Dec 12, 2017
<u>AB</u>		<u>0.75MG</u>	<u>A202891 002</u>	Dec 12, 2017
<u>AB</u>		<u>1.5MG</u>	<u>A202891 003</u>	Dec 12, 2017
<u>AB</u>		<u>2.25MG</u>	<u>A202891 004</u>	Dec 12, 2017
<u>AB</u>		<u>3MG</u>	<u>A202891 005</u>	Dec 12, 2017
<u>AB</u>		<u>3.75MG</u>	<u>A202891 006</u>	Dec 12, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A202891 007</u>	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332 002	Sep 25, 2007
+	!	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332 003	Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+	AMAG PHARMS INC	6.5MG	N208470 001	Nov 16, 2016
---	-----------------	-------	-------------	--------------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

<u>AB</u>	+	ELI LILLY AND CO	<u>EQ 5MG BASE</u>	<u>N022307 001</u>	Jul 10, 2009
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N022307 002</u>	Jul 10, 2009

PRASUGREL

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A205987 001</u>	Feb 02, 2018
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205987 002</u>	Feb 02, 2018
<u>AB</u>	AMNEAL PHARMS	<u>EQ 5MG BASE</u>	<u>A205913 001</u>	Jun 19, 2018
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205913 002</u>	Jun 19, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A205888 001</u>	Oct 16, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205888 002</u>	Oct 16, 2017
<u>AB</u>	HEC PHARM	<u>EQ 5MG BASE</u>	<u>A206021 001</u>	Jan 16, 2019
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206021 002</u>	Jan 16, 2019
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A205927 001</u>	Jul 12, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205927 002</u>	Jul 12, 2017
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 5MG BASE</u>	<u>A205897 001</u>	Oct 16, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205897 002</u>	Oct 16, 2017
<u>AB</u>	USPHARMA WINDLAS	<u>EQ 5MG BASE</u>	<u>A205790 001</u>	Oct 16, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205790 002</u>	Oct 16, 2017

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N019898 003</u>	Oct 31, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019898 004</u>	Mar 22, 1993
<u>AB</u>	+	!	<u>80MG</u>	<u>N019898 008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A207068 001</u>	Nov 17, 2016
<u>AB</u>		<u>20MG</u>	<u>A207068 002</u>	Nov 17, 2016
<u>AB</u>		<u>40MG</u>	<u>A207068 003</u>	Nov 17, 2016
<u>AB</u>		<u>80MG</u>	<u>A207068 004</u>	Nov 17, 2016
<u>AB</u>	APNAR PHARMA LP	<u>10MG</u>	<u>A077491 002</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077491 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077491 004</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491 001</u>	Feb 11, 2008
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341 004</u>	Dec 28, 2007

PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A203367 001</u>	Feb 02, 2017
<u>AB</u>		<u>20MG</u>	<u>A203367 002</u>	Feb 02, 2017
<u>AB</u>		<u>40MG</u>	<u>A203367 003</u>	Feb 02, 2017
<u>AB</u>		<u>80MG</u>	<u>A203367 004</u>	Feb 02, 2017
<u>AB</u>	CHARTWELL RX	<u>10MG</u>	<u>A209869 001</u>	Apr 13, 2018
<u>AB</u>		<u>20MG</u>	<u>A209869 002</u>	Apr 13, 2018
<u>AB</u>		<u>40MG</u>	<u>A209869 003</u>	Apr 13, 2018
<u>AB</u>		<u>80MG</u>	<u>A209869 004</u>	Apr 13, 2018
<u>AB</u>	CIPLA	<u>10MG</u>	<u>A077904 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077904 004</u>	Mar 22, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714 004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987 001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987 002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987 003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987 004</u>	Dec 28, 2007
<u>AB</u>	HISUN PHARM HANGZHOU	<u>20MG</u>	<u>A206061 001</u>	Nov 23, 2018
<u>AB</u>		<u>40MG</u>	<u>A206061 002</u>	Nov 23, 2018
<u>AB</u>		<u>80MG</u>	<u>A206061 003</u>	Nov 23, 2018
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917 001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917 002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917 003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917 004</u>	Jan 08, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187 001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187 002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187 003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187 004</u>	May 27, 2010
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056 001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056 002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056 003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793 001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939 004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939 002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939 001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751 001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751 002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751 003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751 004</u>	Apr 30, 2008

PRAZIOQUANTEL

TABLET; ORAL

BILTRICIDE

<u>AB</u>	+! BAYER HLTHCARE	<u>600MG</u>	<u>N018714 001</u>	Dec 29, 1982
<u>AB</u>	<u>PRAZIOQUANTEL</u>			
<u>AB</u>	PAR PHARM INC	<u>600MG</u>	<u>A208820 001</u>	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	+ PFIZER	<u>EQ 1MG BASE</u>	<u>N017442 002</u>	
<u>AB</u>	+!	<u>EQ 2MG BASE</u>	<u>N017442 003</u>	
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N017442 001</u>	
<u>AB</u>	<u>PRAZOSIN HYDROCHLORIDE</u>			
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575 003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575 002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575 001</u>	May 16, 1989
<u>AB</u>	NOVITIUM PHARMA	<u>EQ 1MG BASE</u>	<u>A210971 001</u>	Oct 03, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A210971 002</u>	Oct 03, 2018
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A210971 003</u>	Oct 03, 2018
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071745 002</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A071745 003</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745 001</u>	Sep 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

AB	+ !	VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993
-----------	------------	-----------------	-------------	----------------	------------	--------------

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006
-----------	--	----------------	-------------	----------------	------------	--------------

OINTMENT;TOPICAL

DERMATOP

AB	+ !	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991
-----------	------------	-------------------------	-------------	----------------	------------	--------------

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007
-----------	--	----------------	-------------	----------------	------------	--------------

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	!	HI TECH PHARMA CO	15MG/5ML	A040401	001	Feb 27, 2003
-----------	----------	-------------------	-----------------	----------------	------------	--------------

AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007
-----------	--	----------------	-----------------	----------------	------------	--------------

AA		PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003
-----------	--	-------------	-----------------	----------------	------------	--------------

AA		VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999
-----------	--	------------	-----------------	----------------	------------	--------------

AA		WOCKHARDT BIO AG	15MG/5ML	A040313	001	Sep 10, 2003
-----------	--	------------------	-----------------	----------------	------------	--------------

PRELONE

AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986
-----------	--	------	-----------------	----------------	------------	--------------

TABLET;ORAL

PREDNISOLONE**!** WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB		NOVARTIS	1%	N017469	001	
-----------	--	----------	-----------	----------------	------------	--

PRED FORTE

AB	+ !	ALLERGAN	1%	N017011	001	
-----------	------------	----------	-----------	----------------	------------	--

PRED MILD

+! ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

BLEPHAMIDE S.O.P.

! ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION;OPHTHALMIC

BLEPHAMIDE

+! ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	+ !	SETON PHARM	EQ 5MG BASE/5ML	N019157	001	May 28, 1986
-----------	------------	-------------	------------------------	----------------	------------	--------------

PREDNISOLONE SODIUM PHOSPHATE

AA		CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004
-----------	--	--------------	------------------------	----------------	------------	--------------

AA		EDENBRIDGE PHARMS	EQ 10MG BASE/5ML	A203559	001	Dec 20, 2016
-----------	--	-------------------	-------------------------	----------------	------------	--------------

AA			EQ 20MG BASE/5ML	A203559	002	Dec 20, 2016
-----------	--	--	-------------------------	----------------	------------	--------------

AA		HI TECH PHARMA	EQ 5MG BASE/5ML	A075183	001	Mar 26, 2003
-----------	--	----------------	------------------------	----------------	------------	--------------

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
-----------	----------	-------------	-------------------------	----------------	------------	--------------

AA			EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005
-----------	--	--	-------------------------	----------------	------------	--------------

AA	!		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008
-----------	----------	--	-------------------------	----------------	------------	--------------

AA		VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009
-----------	--	---------	-------------------------	----------------	------------	--------------

AA		WOCKHARDT BIO AG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002
-----------	--	------------------	------------------------	----------------	------------	--------------

AA	!		EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004
-----------	----------	--	-------------------------	----------------	------------	--------------

! MISSION PHARMA

EQ 25MG BASE/5ML

A091396 001 Sep 13, 2010

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006
-----------	----------	-------------------------	---------------------	----------------	------------	--------------

AB	+		EQ 15MG BASE	N021959	002	Jun 01, 2006
-----------	----------	--	---------------------	----------------	------------	--------------

AB	+ !		EQ 30MG BASE	N021959	003	Jun 01, 2006
-----------	------------	--	---------------------	----------------	------------	--------------

PREDNISOLONE SODIUM PHOSPHATE

AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013
-----------	--	------------------	---------------------	----------------	------------	--------------

AB			EQ 15MG BASE	A202179	002	Apr 10, 2013
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 30MG BASE	A202179	003	Apr 10, 2013
-----------	--	--	---------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB EQ 0.23% PHOSPHATE;10% A074449 001 Dec 29, 1995

PREDNISONE

SOLUTION;ORAL

PREDNISONE

! HIKMA 5MG/5ML A088703 001 Nov 08, 1984

PREDNISONE INTENSOL

! HIKMA 5MG/ML A088810 001 Feb 20, 1985

TABLET;ORAL

PREDNISONEAB GENEYORK PHARMS1MGA211496 001 Dec 28, 2018AB 2.5MGA211495 001 Dec 07, 2018AB 5MGA211495 002 Dec 07, 2018AB 10MGA210525 001 Dec 04, 2018AB 20MGA210525 002 Dec 04, 2018AB 50MGA210525 003 Dec 04, 2018AB ! HIKMA 1MGA087800 001 Apr 22, 1982AB ! 2.5MGA087801 001 Apr 22, 1982AB ! 5MGA080352 001AB ! 10MGA084122 001AB ! 20MGA087342 001AB ! 50MGA084283 001AB HIKMA PHARMS 50MGA088465 001 Jun 01, 1984AB JUBILANT CADISTA 1MGA040611 001 Jun 06, 2005AB 5MGA040362 002 Aug 29, 2001AB 10MGA040362 001 Aug 29, 2001AB 20MGA040362 003 Jun 29, 2005AB MYLAN 5MGA080292 001AB 10MGA088832 001 Dec 04, 1985AB 20MGA083677 001AB NOVITIUM PHARMA 2.5MGA211575 001 Nov 15, 2019AB 5MGA211575 002 Nov 15, 2019AB 10MGA211575 003 Nov 15, 2019AB 20MGA211575 004 Nov 15, 2019AB 50MGA211575 005 Nov 15, 2019AB SUN PHARMINDUSTRIES 5MGA089247 002 Dec 04, 1985AB 10MGA089247 003 Dec 04, 1985AB 20MGA089247 001 Dec 04, 1985AB VINTAGE PHARMS 1MGA040584 001 Dec 21, 2004AB 2.5MGA040581 001 Dec 21, 2004AB 5MGA040256 001 Jul 12, 2002AB 10MGA040256 002 Jul 12, 2002AB 20MGA040392 001 Feb 12, 2003AB WATSON LABS 5MGA080356 001AB 10MGA085162 001AB 20MGA085161 001

TABLET, DELAYED RELEASE;ORAL

PREDNISONEAB ACTAVIS LABS FL INC 1MGA204867 001 Apr 25, 2017AB 2MGA204867 002 Apr 25, 2017AB 5MGA204867 003 Apr 25, 2017RAYOSAB + HORIZON PHARMA USA 1MGN202020 001 Jul 26, 2012AB + 2MGN202020 002 Jul 26, 2012AB +! 5MGN202020 003 Jul 26, 2012PREGABALIN

CAPSULE;ORAL

LYRICAAB + PF PRISM CV 25MGN021446 001 Dec 30, 2004AB + 50MGN021446 002 Dec 30, 2004AB + 75MGN021446 003 Dec 30, 2004AB + 100MGN021446 004 Dec 30, 2004AB + 150MGN021446 005 Dec 30, 2004AB + 200MGN021446 006 Dec 30, 2004AB + 225MGN021446 007 Dec 30, 2004AB +! 300MGN021446 008 Dec 30, 2004PREGABALINAB ALEMBIC PHARMS LTD 25MGA203459 001 Jul 19, 2019AB 50MGA203459 002 Jul 19, 2019

PRESCRIPTION DRUG PRODUCT LIST

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>75MG</u>	<u>A203459 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A203459 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A203459 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A203459 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A203459 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A203459 008</u>	Jul 19, 2019
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A211177 001</u>	Sep 30, 2019
<u>AB</u>		<u>50MG</u>	<u>A211177 002</u>	Sep 30, 2019
<u>AB</u>		<u>75MG</u>	<u>A207799 001</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A207799 002</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A207799 003</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A207799 004</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A207799 005</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A207799 006</u>	Jul 19, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A209743 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209743 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209743 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209743 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209743 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209743 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209743 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209743 008</u>	Jul 19, 2019
<u>AB</u>	CIPLA	<u>25MG</u>	<u>A212280 001</u>	Jan 10, 2020
<u>AB</u>		<u>50MG</u>	<u>A212280 002</u>	Jan 10, 2020
<u>AB</u>		<u>75MG</u>	<u>A212280 003</u>	Jan 10, 2020
<u>AB</u>		<u>100MG</u>	<u>A212280 004</u>	Jan 10, 2020
<u>AB</u>		<u>150MG</u>	<u>A212280 005</u>	Jan 10, 2020
<u>AB</u>		<u>200MG</u>	<u>A212280 006</u>	Jan 10, 2020
<u>AB</u>		<u>225MG</u>	<u>A212280 007</u>	Jan 10, 2020
<u>AB</u>		<u>300MG</u>	<u>A212280 008</u>	Jan 10, 2020
<u>AB</u>	CSPC OUYI	<u>50MG</u>	<u>A210585 001</u>	Dec 26, 2019
<u>AB</u>		<u>75MG</u>	<u>A210585 002</u>	Dec 26, 2019
<u>AB</u>		<u>100MG</u>	<u>A210585 003</u>	Dec 26, 2019
<u>AB</u>		<u>150MG</u>	<u>A210585 004</u>	Dec 26, 2019
<u>AB</u>		<u>200MG</u>	<u>A210585 005</u>	Dec 26, 2019
<u>AB</u>		<u>300MG</u>	<u>A210585 006</u>	Dec 26, 2019
<u>AB</u>	DR REDDYS	<u>25MG</u>	<u>A209664 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209664 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209664 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209664 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209664 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209664 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209664 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209664 008</u>	Jul 19, 2019
<u>AB</u>	HETERO LABS LTD III	<u>25MG</u>	<u>A206912 001</u>	Oct 08, 2019
<u>AB</u>		<u>50MG</u>	<u>A206912 002</u>	Oct 08, 2019
<u>AB</u>		<u>75MG</u>	<u>A206912 003</u>	Oct 08, 2019
<u>AB</u>		<u>100MG</u>	<u>A206912 004</u>	Oct 08, 2019
<u>AB</u>		<u>150MG</u>	<u>A206912 005</u>	Oct 08, 2019
<u>AB</u>		<u>200MG</u>	<u>A206912 006</u>	Oct 08, 2019
<u>AB</u>		<u>225MG</u>	<u>A206912 007</u>	Oct 08, 2019
<u>AB</u>		<u>300MG</u>	<u>A206912 008</u>	Oct 08, 2019
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A211384 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A211384 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A211384 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A211384 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A211384 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A211384 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A211384 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A211384 008</u>	Jul 19, 2019
<u>AB</u>	MSN	<u>25MG</u>	<u>A209357 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209357 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209357 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209357 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209357 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209357 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209357 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209357 008</u>	Jul 19, 2019
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091228 001</u>	Sep 20, 2019

PRESCRIPTION DRUG PRODUCT LIST

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>50MG</u>	<u>A091228 002</u>	Sep 20, 2019
<u>AB</u>		<u>75MG</u>	<u>A091228 003</u>	Sep 20, 2019
<u>AB</u>		<u>100MG</u>	<u>A091228 004</u>	Sep 20, 2019
<u>AB</u>		<u>150MG</u>	<u>A091228 005</u>	Sep 20, 2019
<u>AB</u>		<u>200MG</u>	<u>A091228 006</u>	Sep 20, 2019
<u>AB</u>		<u>225MG</u>	<u>A091228 007</u>	Sep 20, 2019
<u>AB</u>		<u>300MG</u>	<u>A091228 008</u>	Sep 20, 2019
<u>AB</u>	RISING	<u>25MG</u>	<u>A210432 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A210432 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A210432 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A210432 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A210432 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A210432 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A210432 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A210432 008</u>	Jul 19, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A208677 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A208677 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A208677 003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A208677 004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A208677 005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A208677 006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A208677 007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A208677 008</u>	Jul 19, 2019
<u>AB</u>	SHUANGCHENG	<u>75MG</u>	<u>A210891 001</u>	Sep 30, 2019
<u>AB</u>		<u>300MG</u>	<u>A210891 002</u>	Sep 30, 2019
<u>AB</u>	SUN PHARM	<u>25MG</u>	<u>A091157 001</u>	Nov 29, 2019
<u>AB</u>		<u>50MG</u>	<u>A091157 002</u>	Nov 29, 2019
<u>AB</u>		<u>75MG</u>	<u>A091157 003</u>	Nov 29, 2019
<u>AB</u>		<u>100MG</u>	<u>A091157 004</u>	Nov 29, 2019
<u>AB</u>		<u>150MG</u>	<u>A091157 005</u>	Nov 29, 2019
<u>AB</u>		<u>200MG</u>	<u>A091157 006</u>	Nov 29, 2019
<u>AB</u>		<u>225MG</u>	<u>A091157 007</u>	Nov 29, 2019
<u>AB</u>		<u>300MG</u>	<u>A091157 008</u>	Nov 29, 2019
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A091219 001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A091219 002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A091224 001</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A091224 002</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A091224 003</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A091224 004</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A091224 005</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A091224 006</u>	Jul 19, 2019

SOLUTION; ORAL

LYRICA

<u>AA</u>	+!	PF PRISM CV	<u>20MG/ML</u>	<u>N022488 001</u>	Jan 04, 2010
-----------	----	-------------	----------------	--------------------	--------------

PREGABALIN

<u>AA</u>		ALKEM LABS LTD	<u>20MG/ML</u>	<u>A207623 001</u>	Jul 19, 2019
-----------	--	----------------	----------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

LYRICA CR

	+	PF PRISM CV	82.5MG	N209501 001	Oct 11, 2017
	+		165MG	N209501 002	Oct 11, 2017
	+	!	330MG	N209501 003	Oct 11, 2017

PRETOMANID

TABLET; ORAL

PRETOMANID

	+	!	MYLAN IRELAND LTD	200MG	N212862 001	Aug 14, 2019
--	---	---	-------------------	-------	-------------	--------------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

	!		SEPTODONT INC	4%	A079235 001	Sep 29, 2010
--	---	--	---------------	----	-------------	--------------

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

<u>AB</u>	+	!	SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316 001</u>	
-----------	---	---	-------------------	---------------------	--------------------	--

PRIMAQUINE PHOSPHATE

<u>AB</u>			ALVOGEN INC	<u>EQ 15MG BASE</u>	<u>A203924 001</u>	Feb 03, 2014
<u>AB</u>			BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476 001</u>	Feb 25, 2014
<u>AB</u>			NOVAST LABS	<u>EQ 15MG BASE</u>	<u>A206043 001</u>	Jun 23, 2016

PRESCRIPTION DRUG PRODUCT LIST

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+	VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>	
<u>AB</u>	+		<u>250MG</u>	<u>N009170</u>	<u>002</u>	

PRIMIDONE

<u>AB</u>		AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>			<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>		ANDA REPOSITORY	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>			<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>		HIKMA INTL PHARMS	<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>			<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>		OXFORD PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>			<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>		LANNETT	<u>500MG</u>	<u>A080966</u>	<u>001</u>	
-----------	--	---------	--------------	----------------	------------	--

PROBENECID

<u>AB</u>		MYLAN	<u>500MG</u>	<u>A084211</u>	<u>002</u>	
	!	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u>	!	HOSPIRA	<u>100MG/ML</u>	<u>A089069</u>	<u>001</u>	Feb 12, 1986
<u>AP</u>		INTL MEDICATION	<u>100MG/ML</u>	<u>A088636</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		NEXUS PHARMS	<u>100MG/ML</u>	<u>A206332</u>	<u>001</u>	Oct 13, 2017
<u>AP</u>			<u>500MG/ML</u>	<u>A206332</u>	<u>002</u>	Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

	+	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	
--	---	---------------------	--------------	---------	-----	--

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>		PADDOCK LLC	<u>25MG</u>	<u>A040246</u>	<u>001</u>	Jun 28, 2000
-----------	--	-------------	-------------	----------------	------------	--------------

PROCHLORPERAZINE

<u>AB</u>	!	ACP NIMBLE	<u>25MG</u>	<u>A040058</u>	<u>001</u>	Nov 24, 1993
-----------	---	------------	-------------	----------------	------------	--------------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>		ATHENEX INC	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004
<u>AP</u>	!	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204147</u>	<u>001</u>	Oct 15, 2013
<u>AP</u>		MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A210710</u>	<u>001</u>	Oct 25, 2018
<u>AP</u>		NEXUS PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A204860</u>	<u>001</u>	Feb 15, 2019
<u>AP</u>		WEST-WARD PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989
		INT				

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>		MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
<u>AB</u>	!		<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
		<u>PROCOMP</u>				
<u>AB</u>		JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>		AMNEAL PHARMS NY	<u>100MG</u>	<u>A207724</u>	<u>001</u>	Sep 07, 2017
<u>AB</u>			<u>200MG</u>	<u>A207724</u>	<u>002</u>	Sep 07, 2017
<u>AB</u>		BIONPHARMA INC	<u>100MG</u>	<u>A200900</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>			<u>200MG</u>	<u>A200900</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>		DR REDDYS	<u>100MG</u>	<u>A208801</u>	<u>001</u>	Feb 28, 2017
<u>AB</u>			<u>200MG</u>	<u>A208801</u>	<u>002</u>	Feb 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>	EUGIA PHARMA	<u>100MG</u>	<u>A211285</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A211285</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>	SOFGEN PHARMS	<u>100MG</u>	<u>A200456</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>200MG</u>	<u>A200456</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	XIROMED	<u>100MG</u>	<u>A205229</u>	<u>001</u>	Oct 20, 2017
<u>AB</u>		<u>200MG</u>	<u>A205229</u>	<u>002</u>	Oct 20, 2017

PROMETRIUM

<u>AB</u>	+ VIRTUS PHARMS	<u>100MG</u>	<u>N019781</u>	<u>001</u>	May 14, 1998
<u>AB</u>	+!	<u>200MG</u>	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

+!	ALLERGAN	4%	N020701	001	Jul 31, 1997
+!		8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	+! ACTAVIS LABS UT INC	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	
<u>AO</u>	EUGIA PHARMA	<u>50MG/ML</u>	<u>A210965</u>	<u>001</u>	Dec 06, 2018
<u>AO</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010

INSERT; VAGINAL

ENDOMETRIN

+!	FERRING	100MG	N022057	001	Jun 21, 2007
----	---------	-------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	! WEST-WARD PHARMS	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
	INT				
<u>AP</u>	!	<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	ACP NIMBLE	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	!	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO ISRAEL	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>	WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

!	ACP NIMBLE	50MG	A087165	001	Aug 14, 1987
---	------------	------	---------	-----	--------------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	NOSTRUM LABS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	! WOCKHARDT BIO AG	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982
-----------	--------------------	-------------------	----------------	------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>	KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>		<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A040712</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>		<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>		<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>	QUAGEN	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>		<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>		<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>	STRIDES PHARMA	<u>12.5MG</u>	<u>A209177</u>	<u>001</u>	Jun 30, 2017

PRESCRIPTION DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		<u>25MG</u>	<u>A209177 002</u>	Jun 30, 2017
<u>AB</u>		<u>50MG</u>	<u>A209177 003</u>	Jun 30, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863 001</u>	Dec 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040863 002</u>	Dec 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A040863 003</u>	Dec 30, 2008
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A083426 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A083711 001</u>	
<u>AB</u>	ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596 001</u>	Nov 18, 2005
<u>AB</u>		<u>25MG</u>	<u>A040596 002</u>	Nov 18, 2005
<u>AB</u>		<u>50MG</u>	<u>A040596 003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	GLENMARK PHARMS LTD	<u>225MG</u>	<u>A205268 001</u>	Sep 08, 2017
<u>AB</u>		<u>325MG</u>	<u>A205268 002</u>	Sep 08, 2017
<u>AB</u>		<u>425MG</u>	<u>A205268 003</u>	Sep 08, 2017
<u>AB</u>	MYLAN	<u>225MG</u>	<u>A203803 001</u>	Apr 29, 2016
<u>AB</u>		<u>325MG</u>	<u>A203803 002</u>	Apr 29, 2016
<u>AB</u>		<u>425MG</u>	<u>A203803 003</u>	Apr 29, 2016
<u>AB</u>	PAR PHARM	<u>225MG</u>	<u>A078540 001</u>	Oct 18, 2010
<u>AB</u>		<u>325MG</u>	<u>A078540 002</u>	Oct 18, 2010
<u>AB</u>		<u>425MG</u>	<u>A078540 003</u>	Oct 18, 2010
<u>AB</u>	SINOTHERAPEUTICS INC	<u>225MG</u>	<u>A210339 001</u>	Jan 04, 2019
<u>AB</u>		<u>325MG</u>	<u>A210339 002</u>	Jan 04, 2019
<u>AB</u>		<u>425MG</u>	<u>A210339 003</u>	Jan 04, 2019
<u>AB</u>	WATSON LABS INC	<u>225MG</u>	<u>A202688 001</u>	Aug 24, 2015
<u>AB</u>		<u>325MG</u>	<u>A202688 002</u>	Aug 24, 2015
<u>AB</u>		<u>425MG</u>	<u>A202688 003</u>	Aug 24, 2015
<u>AB</u>	WILSHIRE PHARMS INC	<u>225MG</u>	<u>A205956 001</u>	Jul 02, 2018
<u>AB</u>		<u>325MG</u>	<u>A205956 002</u>	Jul 02, 2018
<u>AB</u>		<u>425MG</u>	<u>A205956 003</u>	Jul 02, 2018
	<u>RYTHMOL SR</u>			
<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416 001</u>	Sep 04, 2003
<u>AB</u>	+	<u>325MG</u>	<u>N021416 002</u>	Sep 04, 2003
<u>AB</u>	+	<u>425MG</u>	<u>N021416 003</u>	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A076550 001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550 002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550 003</u>	Apr 23, 2004
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202445 001</u>	May 11, 2016
<u>AB</u>		<u>225MG</u>	<u>A202445 002</u>	May 11, 2016
<u>AB</u>		<u>300MG</u>	<u>A202445 003</u>	May 11, 2016
<u>AB</u>	SUN PHARM INDUSTRIES	<u>150MG</u>	<u>A075998 001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998 002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998 003</u>	Nov 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938 001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938 002</u>	Oct 17, 2002
<u>AB</u>	!	<u>300MG</u>	<u>A075938 003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203 001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203 002</u>	Oct 24, 2000

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

! HIKMA 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

<u>AT</u>	ALCON LABS INC	<u>0.5%</u>	<u>A080027 001</u>	
	<u>PROPARACAINE HYDROCHLORIDE</u>			
<u>AT</u>	! AKORN INC	<u>0.5%</u>	<u>A040277 001</u>	Mar 16, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074 001</u>	Sep 29, 1995

PRESCRIPTION DRUG PRODUCT LIST

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

<u>AB</u>	+!	FRESENIUS KABI USA	10MG/ML	<u>N019627</u>	<u>002</u>	Jun 11, 1996
-----------	-----------	--------------------	----------------	-----------------------	-------------------	--------------

PROPOFOL

<u>AB</u>		DR REDDYS	10MG/ML	<u>A205067</u>	<u>001</u>	Nov 15, 2018
<u>AB</u>		HOSPIRA	10MG/ML	<u>A077908</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		SAGENT PHARMS INC	10MG/ML	<u>A075102</u>	<u>001</u>	Jan 04, 1999
<u>AB</u>		WATSON LABS INC	10MG/ML	<u>A205307</u>	<u>001</u>	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<u>AB</u>	+	ANI PHARMS INC	60MG	<u>N018553</u>	<u>004</u>	Mar 18, 1987
<u>AB</u>	+		80MG	<u>N018553</u>	<u>002</u>	Apr 19, 1983
<u>AB</u>	+		120MG	<u>N018553</u>	<u>003</u>	Apr 19, 1983
<u>AB</u>	+!		160MG	<u>N018553</u>	<u>001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	60MG	<u>A078494</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>			80MG	<u>A078494</u>	<u>002</u>	Aug 10, 2007
<u>AB</u>			120MG	<u>A078494</u>	<u>003</u>	Aug 10, 2007
<u>AB</u>			160MG	<u>A078494</u>	<u>004</u>	Aug 10, 2007
<u>AB</u>		ADARE PHARMS INC	60MG	<u>A078703</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>			80MG	<u>A078703</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>			120MG	<u>A078703</u>	<u>003</u>	Jul 15, 2011
<u>AB</u>			160MG	<u>A078703</u>	<u>004</u>	Jul 15, 2011
<u>AB</u>		AMTA	60MG	<u>A212026</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>			80MG	<u>A212026</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>			120MG	<u>A212026</u>	<u>003</u>	Jan 06, 2020
<u>AB</u>			160MG	<u>A212026</u>	<u>004</u>	Jan 06, 2020
<u>AB</u>		NORTEC DEV ASSOC	60MG	<u>A078065</u>	<u>001</u>	Jan 26, 2007
<u>AB</u>			80MG	<u>A078065</u>	<u>002</u>	Jan 26, 2007
<u>AB</u>			120MG	<u>A078065</u>	<u>003</u>	Jan 26, 2007
<u>AB</u>			160MG	<u>A078065</u>	<u>004</u>	Jan 26, 2007
<u>AB</u>		ZYDUS PHARMS USA INC	60MG	<u>A090321</u>	<u>001</u>	Mar 25, 2011
<u>AB</u>			80MG	<u>A090321</u>	<u>002</u>	Mar 25, 2011
<u>AB</u>			120MG	<u>A090321</u>	<u>003</u>	Mar 25, 2011
<u>AB</u>			160MG	<u>A090321</u>	<u>004</u>	Mar 25, 2011

INNOPRAN XL

EX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003
BX	+!		120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>		ATHENEX INC	1MG/ML	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<u>AP</u>		FRESENIUS KABI USA	1MG/ML	<u>A075826</u>	<u>001</u>	Aug 31, 2001
	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008

SOLUTION; ORAL

HEMANGEOL

	+!	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014
	!	HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!		40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		IMPAX LABS INC	10MG	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>			20MG	<u>A071972</u>	<u>002</u>	Apr 06, 1988
<u>AB</u>			40MG	<u>A071972</u>	<u>003</u>	Apr 06, 1988
<u>AB</u>			60MG	<u>A071976</u>	<u>002</u>	May 13, 1986
<u>AB</u>	!		80MG	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		INNOGENIX	10MG	<u>A070322</u>	<u>002</u>	Oct 22, 1985
<u>AB</u>			20MG	<u>A070322</u>	<u>003</u>	Oct 22, 1985
<u>AB</u>			40MG	<u>A070322</u>	<u>004</u>	Oct 22, 1985
<u>AB</u>			60MG	<u>A070322</u>	<u>005</u>	Sep 24, 1986
<u>AB</u>			80MG	<u>A070322</u>	<u>001</u>	Aug 04, 1986
<u>AB</u>		IPCA LABS LTD	10MG	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>			20MG	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>			40MG	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>			60MG	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>			80MG	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>		MYLAN	10MG	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>			20MG	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>			40MG	<u>A070213</u>	<u>001</u>	Nov 19, 1985

PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>60MG</u>	<u>A070213</u>	<u>005</u>	Apr 08, 2011
<u>AB</u>		<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070221</u>	<u>002</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070221</u>	<u>003</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070219</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070221</u>	<u>004</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070221</u>	<u>005</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>60MG</u>	<u>A070178</u>	<u>002</u>	Apr 23, 2018
<u>AB</u>		<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+! DAVA PHARMS INC	50MG	N006188	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987
---	--------------------	---------	---------	-----	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A078913</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913</u>	<u>002</u>	Sep 16, 2008
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462</u>	<u>001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462</u>	<u>002</u>	May 03, 2010
	<u>VIVACTIL</u>				
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A073644</u>	<u>001</u>	Aug 24, 1995
<u>AB</u>	!	<u>10MG</u>	<u>A073645</u>	<u>001</u>	Aug 24, 1995

PRUCALOPRIDE SUCCINATE

TABLET; ORAL

MOTEGRITY

+	SHIRE DEV LLC	EQ 1MG BASE	N210166	001	Dec 14, 2018
+	!	EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	AKORN	<u>500MG</u>	<u>A081319</u>	<u>001</u>	Jun 30, 1992
<u>AB</u>	! DAVA PHARMS INC	<u>500MG</u>	<u>A080157</u>	<u>001</u>	

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+! BAUSCH	<u>5MG/ML</u>	<u>N009830</u>	<u>001</u>	
	<u>REGONOL</u>				
<u>AP</u>	SANDOZ INC	<u>5MG/ML</u>	<u>N017398</u>	<u>001</u>	

SYRUP; ORAL

MESTINON

<u>AA</u>	+! BAUSCH	<u>60MG/5ML</u>	<u>N015193</u>	<u>001</u>	
-----------	-----------	-----------------	----------------	------------	--

PYRIDOSTIGMINE BROMIDE

<u>AA</u>	AMNEAL PHARMS LLC	<u>60MG/5ML</u>	<u>A212702</u>	<u>001</u>	Jan 10, 2020
<u>AA</u>	INVATECH	<u>60MG/5ML</u>	<u>A208797</u>	<u>001</u>	Jan 09, 2020
<u>AA</u>	NOVITIUM PHARMA	<u>60MG/5ML</u>	<u>A211694</u>	<u>001</u>	Mar 08, 2019

TABLET; ORAL

MESTINON

<u>AB</u>	+! BAUSCH	<u>60MG</u>	<u>N009829</u>	<u>002</u>	
-----------	-----------	-------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

AB	ELYSIUM	60MG	<u>A211181</u>	<u>001</u>	Jul 20, 2018
AB	IMPAX LABS	60MG	<u>A040502</u>	<u>001</u>	Apr 24, 2003
AB	ZYDUS PHARMS	60MG	<u>A205650</u>	<u>001</u>	Jun 22, 2015
	ELYSIUM	30MG	A211181	002	May 14, 2019

TABLET, EXTENDED RELEASE; ORAL

MESTINON

AB	+ !	BAUSCH	180MG	<u>N011665</u>	<u>001</u>
-----------	------------	--------	--------------	-----------------------	-------------------

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN	180MG	<u>A204737</u>	<u>001</u>	Jun 26, 2015
AB	IMPAX LABS INC	180MG	<u>A203184</u>	<u>001</u>	Sep 15, 2015
AB	RISING	180MG	<u>A205464</u>	<u>001</u>	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

!	FRESENIUS KABI USA	100MG/ML	A080618	001
---	--------------------	----------	---------	-----

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+ !	VYERA PHARMS LLC	25MG	N008578	001
------------	------------------	------	---------	-----

QUAZEPAM

TABLET; ORAL

DORAL

+ !	GALT PHARMS	15MG	N018708	001	Dec 27, 1985
------------	-------------	------	---------	-----	--------------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	<u>A202152</u>	<u>001</u>	Mar 27, 2012
AB		EQ 50MG BASE	<u>A202152</u>	<u>002</u>	Mar 27, 2012
AB		EQ 100MG BASE	<u>A202152</u>	<u>003</u>	Mar 27, 2012
AB		EQ 200MG BASE	<u>A202152</u>	<u>004</u>	Mar 27, 2012
AB		EQ 300MG BASE	<u>A202152</u>	<u>005</u>	Mar 27, 2012
AB		EQ 400MG BASE	<u>A202152</u>	<u>006</u>	Mar 27, 2012
AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	<u>A203390</u>	<u>001</u>	Oct 28, 2014
AB		EQ 50MG BASE	<u>A203390</u>	<u>002</u>	Oct 28, 2014
AB		EQ 100MG BASE	<u>A203390</u>	<u>003</u>	Oct 28, 2014
AB		EQ 200MG BASE	<u>A203390</u>	<u>004</u>	Oct 28, 2014
AB		EQ 300MG BASE	<u>A203390</u>	<u>005</u>	Oct 28, 2014
AB		EQ 400MG BASE	<u>A203390</u>	<u>006</u>	Oct 28, 2014
AB	ALKEM LABS LTD	EQ 25MG BASE	<u>A201504</u>	<u>001</u>	Feb 12, 2013
AB		EQ 50MG BASE	<u>A201504</u>	<u>002</u>	Feb 12, 2013
AB		EQ 100MG BASE	<u>A201504</u>	<u>003</u>	Feb 12, 2013
AB		EQ 150MG BASE	<u>A201504</u>	<u>004</u>	Feb 12, 2013
AB		EQ 200MG BASE	<u>A201504</u>	<u>005</u>	Feb 12, 2013
AB		EQ 300MG BASE	<u>A201504</u>	<u>006</u>	Feb 12, 2013
AB		EQ 400MG BASE	<u>A201504</u>	<u>007</u>	Feb 12, 2013
AB	APOTEX INC	EQ 25MG BASE	<u>A090960</u>	<u>001</u>	Mar 27, 2012
AB		EQ 50MG BASE	<u>A090960</u>	<u>002</u>	Mar 27, 2012
AB		EQ 100MG BASE	<u>A090960</u>	<u>003</u>	Mar 27, 2012
AB		EQ 200MG BASE	<u>A090960</u>	<u>004</u>	Mar 27, 2012
AB		EQ 300MG BASE	<u>A090960</u>	<u>005</u>	Mar 27, 2012
AB		EQ 400MG BASE	<u>A090960</u>	<u>006</u>	Mar 27, 2012
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	<u>A091388</u>	<u>001</u>	Mar 27, 2012
AB		EQ 50MG BASE	<u>A091388</u>	<u>002</u>	Mar 27, 2012
AB		EQ 100MG BASE	<u>A091388</u>	<u>003</u>	Mar 27, 2012
AB		EQ 150MG BASE	<u>A091388</u>	<u>004</u>	Mar 27, 2012
AB		EQ 200MG BASE	<u>A091388</u>	<u>005</u>	Mar 27, 2012
AB		EQ 300MG BASE	<u>A091388</u>	<u>006</u>	Mar 27, 2012
AB		EQ 400MG BASE	<u>A091388</u>	<u>007</u>	Mar 27, 2012
AB	DR REDDYS LABS LTD	EQ 25MG BASE	<u>A077380</u>	<u>001</u>	Mar 27, 2012
AB		EQ 50MG BASE	<u>A077380</u>	<u>002</u>	Mar 27, 2012
AB		EQ 100MG BASE	<u>A077380</u>	<u>003</u>	Mar 27, 2012
AB		EQ 150MG BASE	<u>A077380</u>	<u>004</u>	Mar 27, 2012
AB		EQ 200MG BASE	<u>A077380</u>	<u>005</u>	Mar 27, 2012
AB		EQ 300MG BASE	<u>A077380</u>	<u>006</u>	Mar 27, 2012
AB		EQ 400MG BASE	<u>A077380</u>	<u>007</u>	Mar 27, 2012
AB	HIKMA	EQ 25MG BASE	<u>A090120</u>	<u>001</u>	Mar 27, 2012
AB		EQ 50MG BASE	<u>A090749</u>	<u>001</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012	
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013	
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012	
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203359 001</u>	May 17, 2016	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203359 002</u>	May 17, 2016	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203359 003</u>	May 17, 2016	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203359 004</u>	May 17, 2016	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203359 005</u>	May 17, 2016	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203359 006</u>	May 17, 2016	
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012	
<u>AB</u>	SUN PHARM	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012	
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012	
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012	
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A202674 001</u>	Mar 08, 2016	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202674 002</u>	Mar 08, 2016	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202674 003</u>	Mar 08, 2016	
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202674 004</u>	Mar 08, 2016	
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202674 005</u>	Mar 08, 2016	
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202674 006</u>	Mar 08, 2016	
<u>SEROQUEL</u>					
<u>AB</u>	+!	<u>ASTRAZENECA PHARMS</u>	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+!		<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>	+		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 50MG BASE</u>	<u>A206252 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090681 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090681 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090681 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090681 004</u>	Nov 01, 2016
<u>AB</u>	ALIGNSCIENCE PHARMA	<u>EQ 150MG BASE</u>	<u>A209497 001</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209497 002</u>	Sep 28, 2018
<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A090757 001</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090757 002</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090757 003</u>	Dec 01, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090757 004</u>	Dec 01, 2017

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE</u>	<u>A207655 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A207655 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A207655 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A207655 004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A207655 005</u>	Nov 29, 2017
<u>AB</u>	INTELLIPHARMACEUTICS	<u>EQ 50MG BASE</u>	<u>A202939 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A202939 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202939 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202939 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202939 005</u>	May 09, 2017
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204203 001</u>	May 17, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A204203 002</u>	May 17, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204203 003</u>	May 17, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204203 004</u>	May 17, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204203 005</u>	May 17, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A204253 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A204253 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204253 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204253 004</u>	Nov 29, 2017
<u>AB</u>	NOVAST LABS	<u>EQ 50MG BASE</u>	<u>A208947 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208947 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A208947 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A208947 004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208947 005</u>	Nov 29, 2017
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A090482 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090482 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090482 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090482 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090482 005</u>	May 09, 2017
<u>AB</u>	PHARMADAX INC	<u>EQ 50MG BASE</u>	<u>A206260 001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A206260 002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A206260 003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206260 004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A206260 005</u>	May 09, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 50MG BASE</u>	<u>A209635 005</u>	Nov 16, 2018
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209635 001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209635 002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209635 003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A209635 004</u>	Nov 29, 2017

SEROQUEL XR

<u>AB</u>	+	ASTRAZENECA	<u>EQ 50MG BASE</u>	<u>N022047 001</u>	May 17, 2007
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N022047 005</u>	Aug 11, 2008
<u>AB</u>	+	!	<u>EQ 200MG BASE</u>	<u>N022047 002</u>	May 17, 2007
<u>AB</u>	+		<u>EQ 300MG BASE</u>	<u>N022047 003</u>	May 17, 2007
<u>AB</u>	+		<u>EQ 400MG BASE</u>	<u>N022047 004</u>	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

<u>AB</u>	+	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885 001</u>	Nov 19, 1991
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N019885 002</u>	Nov 19, 1991
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N019885 003</u>	Nov 19, 1991
<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N019885 004</u>	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725 003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725 004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457 004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004

PRESCRIPTION DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004
<u>AB</u>	PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A205823 001</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205823 002</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205823 003</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205823 004</u>	Sep 15, 2016

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

!	SUN PHARM INDUSTRIES	324MG	A089338 001	Feb 11, 1987
---	----------------------	-------	-------------	--------------

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A088072 002</u>	
<u>AB</u>		<u>300MG</u>	<u>A088072 001</u>	Sep 26, 1983
<u>AB</u>	!	<u>200MG</u>	<u>A083288 001</u>	
<u>AB</u>	!	<u>300MG</u>	<u>A085583 001</u>	

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

<u>AB</u>	+!	SUN PHARM INDUSTRIES	<u>324MG</u>	<u>N021799 001</u>	Aug 12, 2005
-----------	----	----------------------	--------------	--------------------	--------------

QUININE SULFATE

<u>AB</u>		AMNEAL PHARMS	<u>324MG</u>	<u>A203729 001</u>	Jul 15, 2015
<u>AB</u>		LUPIN LTD	<u>324MG</u>	<u>A203112 001</u>	Apr 24, 2015
<u>AB</u>		NOVAST LABS	<u>324MG</u>	<u>A204372 001</u>	Jul 22, 2015
<u>AB</u>		TEVA PHARMS	<u>324MG</u>	<u>A091661 001</u>	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+	AYTU	5MG	N204736 001	Mar 26, 2013
+	!	10MG	N204736 002	Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

<u>AB</u>	+!	EISAI INC	<u>20MG</u>	<u>N020973 002</u>	Aug 19, 1999
-----------	----	-----------	-------------	--------------------	--------------

RABEPRAZOLE SODIUM

<u>AB</u>		ALKEM LABS LTD	<u>20MG</u>	<u>A208644 001</u>	Apr 24, 2018
<u>AB</u>		AMNEAL PHARMS	<u>20MG</u>	<u>A204179 001</u>	Jul 31, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A205761 001</u>	Feb 17, 2017
<u>AB</u>		DR REDDYS	<u>20MG</u>	<u>A076824 001</u>	Nov 08, 2013
<u>AB</u>		LANNETT CO INC	<u>20MG</u>	<u>A090678 001</u>	Nov 08, 2013
<u>AB</u>		LUPIN LTD	<u>20MG</u>	<u>A078964 001</u>	Nov 08, 2013
<u>AB</u>		RUBICON	<u>20MG</u>	<u>A204237 001</u>	Nov 18, 2015
<u>AB</u>		TEVA PHARMS USA	<u>20MG</u>	<u>A076822 001</u>	Nov 08, 2013
<u>AB</u>		TORRENT	<u>20MG</u>	<u>A202376 001</u>	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

+	!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971 001	May 15, 2013
---	---	----------------	-----------------------	-------------	--------------

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

<u>AB</u>	+!	LILLY	<u>60MG</u>	<u>N020815 001</u>	Dec 09, 1997
-----------	----	-------	-------------	--------------------	--------------

RALOXIFENE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS	<u>60MG</u>	<u>A208206 001</u>	Apr 08, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>60MG</u>	<u>A204310 001</u>	Aug 28, 2015
<u>AB</u>		GLENMARK PHARMS LTD	<u>60MG</u>	<u>A204491 001</u>	Mar 22, 2016
<u>AB</u>		INVAGEN PHARMS	<u>60MG</u>	<u>A090842 001</u>	Sep 24, 2014
<u>AB</u>		SCIEGEN PHARMS INC	<u>60MG</u>	<u>A206384 001</u>	Oct 12, 2016
<u>AB</u>		TEVA PHARMS USA	<u>60MG</u>	<u>A078193 001</u>	Mar 04, 2014
<u>AB</u>		WATSON LABS INC	<u>60MG</u>	<u>A200825 001</u>	Jan 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+! MERCK SHARP DOHME EQ 100MG BASE/PACKET N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+! MERCK SHARP DOHME EQ 400MG BASE N022145 001 Oct 12, 2007

ISENTRESS HD

+! MERCK SHARP DOHME EQ 600MG BASE N022145 002 May 26, 2017

TABLET, CHEWABLE; ORAL

ISENTRESS

+ MERCK SHARP DOHME EQ 25MG BASE N203045 001 Dec 21, 2011

+! EQ 100MG BASE N203045 002 Dec 21, 2011

RAMELTEON

TABLET; ORAL

RAMELTEONAB ACTAVIS LABS FL INC 8MG A091610 001 Aug 19, 2015AB DR REDDYS LABS SA 8MG A091693 001 Jul 26, 2013AB ZYDUS PHARMS 8MG A211567 001 Jul 22, 2019ROZEREMAB +! TAKEDA PHARMS USA 8MG N021782 001 Jul 22, 2005RAMIPRIL

CAPSULE; ORAL

ALTACEAB + KING PHARMS LLC 1.25MG N019901 001 Jan 28, 1991AB + 2.5MG N019901 002 Jan 28, 1991AB + 5MG N019901 003 Jan 28, 1991AB +! 10MG N019901 004 Jan 28, 1991RAMIPRILAB ACCORD HLTHCARE 1.25MG A202392 001 Apr 15, 2014AB 2.5MG A202392 002 Apr 15, 2014AB 5MG A202392 003 Apr 15, 2014AB 10MG A202392 004 Apr 15, 2014AB APOTEX 1.25MG A079116 001 Jun 20, 2008AB 2.5MG A079116 002 Jun 20, 2008AB 5MG A079116 003 Jun 20, 2008AB 10MG A079116 004 Jun 20, 2008AB AUROBINDO PHARMA LTD 1.25MG A091604 001 Jun 08, 2011AB 2.5MG A091604 002 Jun 08, 2011AB 5MG A091604 003 Jun 08, 2011AB 10MG A091604 004 Jun 08, 2011AB CHARTWELL MOLECULAR 1.25MG A078745 001 Jun 18, 2008AB 2.5MG A078745 002 Jun 18, 2008AB 5MG A078745 003 Jun 18, 2008AB 10MG A078745 004 Jun 18, 2008AB DR REDDYS LABS LTD 1.25MG A078191 001 Jun 18, 2008AB 2.5MG A078191 002 Jun 18, 2008AB 5MG A078191 003 Jun 18, 2008AB 10MG A078191 004 Jun 18, 2008AB HIKMA 1.25MG A077900 001 Jun 18, 2008AB 2.5MG A077900 002 Jun 18, 2008AB 5MG A077900 003 Jun 18, 2008AB 10MG A077900 004 Jun 18, 2008AB LUPIN 1.25MG A077626 001 Jun 09, 2008AB 2.5MG A077626 002 Jun 09, 2008AB 5MG A077626 003 Jun 09, 2008AB 10MG A077626 004 Jun 09, 2008AB TEVA PHARMS 1.25MG A077470 001 Jun 18, 2008AB 2.5MG A077470 002 Jun 18, 2008AB 5MG A077470 003 Jun 18, 2008AB 10MG A077470 004 Jun 18, 2008AB WATSON LABS 1.25MG A076549 001 Oct 24, 2005AB 2.5MG A076549 002 Oct 24, 2005AB 10MG A076549 004 Oct 24, 2005AB ZYDUS PHARMS USA 1.25MG A078832 001 Sep 02, 2008AB 2.5MG A078832 002 Sep 02, 2008AB 5MG A078832 003 Sep 02, 2008AB 10MG A078832 004 Sep 02, 2008

PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A209859 001</u>	Sep 27, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209859 002</u>	Sep 27, 2018
<u>AB</u>	APPCO	<u>EQ 150MG BASE</u>	<u>A211893 001</u>	Apr 05, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A211893 002</u>	Apr 05, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A211058 001</u>	Jul 16, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A211058 002</u>	Jul 16, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742 001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742 002</u>	Nov 29, 2000
<u>AB</u>	NOVITIUM PHARMA	<u>EQ 150MG BASE</u>	<u>A210681 001</u>	Nov 23, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A210681 002</u>	Nov 23, 2018
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655 001</u>	Oct 22, 1997
<u>AB</u>	!	<u>EQ 300MG BASE</u>	<u>A074655 002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	MYLAN LABS LTD	<u>EQ 25MG BASE/ML</u>	<u>A079076 001</u>	Jun 09, 2016
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 25MG BASE/ML</u>	<u>A074777 001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458 001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>EQ 25MG BASE/ML</u>	<u>A091534 001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+! TELIGENT	<u>EQ 25MG BASE/ML</u>	<u>N019090 001</u>	Oct 19, 1984
-----------	-------------	------------------------	--------------------	--------------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312 001</u>	Sep 02, 2008
<u>AA</u>	ANDA REPOSITORY	<u>EQ 15MG BASE/ML</u>	<u>A090054 001</u>	Nov 15, 2010
<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 15MG BASE/ML</u>	<u>A090623 001</u>	Jul 28, 2010
<u>AA</u>	BRECKENRIDGE	<u>EQ 15MG BASE/ML</u>	<u>A078684 001</u>	Aug 27, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078 001</u>	Mar 22, 2011
<u>AA</u>	LANNETT CO INC	<u>EQ 15MG BASE/ML</u>	<u>A078890 001</u>	Jul 01, 2010
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A091288 001</u>	Dec 09, 2010
<u>AA</u>	NOSTRUM LABS INC	<u>EQ 15MG BASE/ML</u>	<u>A091091 001</u>	Sep 20, 2011
<u>AA</u>	!	<u>EQ 15MG BASE/ML</u>	<u>A077405 001</u>	Sep 21, 2007
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476 001</u>	Jun 13, 2011

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	ACIC PHARMS	<u>EQ 150MG BASE</u>	<u>A203694 001</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203694 002</u>	Nov 30, 2017
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824 001</u>	Oct 13, 2006
<u>AB</u>	!	<u>EQ 300MG BASE</u>	<u>A077824 002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>	HERITAGE PHARMA	<u>EQ 150MG BASE</u>	<u>A075165 001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165 002</u>	Sep 30, 1998
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	STRIDES PHARMA	<u>EQ 150MG BASE</u>	<u>A205512 001</u>	Aug 22, 2016
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A210010 001</u>	Aug 01, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A205512 002</u>	Aug 22, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A210010 002</u>	Aug 01, 2018
<u>AB</u>	VKT PHARMA PVT LTD	<u>EQ 150MG BASE</u>	<u>A211289 001</u>	Jan 31, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A211289 002</u>	Jan 31, 2019
<u>AB</u>	WOCKHARDT LTD	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+ GILEAD	<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
<u>AB</u>	+!	<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007

RANOLAZINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A208862 001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A208862 002</u>	May 28, 2019

PRESCRIPTION DRUG PRODUCT LIST

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

<u>AB</u>	AJANTA PHARMA LTD	<u>500MG</u>	<u>A210054 001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A210054 002</u>	May 28, 2019
<u>AB</u>	AMERIGEN PHARMS LTD	<u>500MG</u>	<u>A210482 001</u>	Oct 29, 2019
<u>AB</u>		<u>1GM</u>	<u>A210482 002</u>	Oct 29, 2019
<u>AB</u>	CADILA	<u>500MG</u>	<u>A210188 001</u>	Aug 19, 2019
<u>AB</u>		<u>1GM</u>	<u>A210188 002</u>	Aug 19, 2019
<u>AB</u>	CIPLA	<u>500MG</u>	<u>A211291 001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A211291 002</u>	May 28, 2019
<u>AB</u>	GLENMARK PHARMS LTD	<u>500MG</u>	<u>A211082 001</u>	Jul 05, 2019
<u>AB</u>		<u>1GM</u>	<u>A211082 002</u>	Jul 05, 2019
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A211829 001</u>	Jun 04, 2019
<u>AB</u>		<u>1GM</u>	<u>A211829 002</u>	Jun 04, 2019
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A211707 001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A211707 002</u>	May 28, 2019

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

<u>AB</u>	+ TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+!	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006

RASAGILINE MESYLATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A201889 001</u>	Oct 30, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201889 002</u>	Oct 30, 2017
<u>AB</u>	INDOCO REMEDIES	<u>EQ 0.5MG BASE</u>	<u>A206153 001</u>	Oct 04, 2019
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206153 002</u>	Oct 04, 2019
<u>AB</u>	MICRO LABS	<u>EQ 0.5MG BASE</u>	<u>A207004 001</u>	Mar 29, 2019
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A207004 002</u>	Mar 29, 2019
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A201971 001</u>	May 15, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201971 002</u>	May 15, 2017
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A201970 001</u>	Mar 15, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201970 002</u>	Mar 15, 2016
<u>AB</u>	SANDOZ INC	<u>EQ 0.5MG BASE</u>	<u>A201892 001</u>	Jul 27, 2018
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201892 002</u>	Jul 27, 2018
<u>AB</u>	WATSON LABS INC	<u>EQ 0.5MG BASE</u>	<u>A201823 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201823 002</u>	Jul 01, 2013

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

+!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	<u>N022161 001</u>	Apr 10, 2008
----	----------	-----------------------	--------------------	--------------

REGORAFENIB

TABLET;ORAL

STIVARGA

+!	BAYER HLTHCARE	40MG	<u>N203085 001</u>	Sep 27, 2012
----	----------------	------	--------------------	--------------

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/VIAL</u>	<u>A206223 001</u>	Jan 16, 2018
<u>AP</u>		<u>EQ 2MG BASE/VIAL</u>	<u>A206223 002</u>	Jan 16, 2018
<u>AP</u>		<u>EQ 5MG BASE/VIAL</u>	<u>A206223 003</u>	Jan 16, 2018

ULTIVA

<u>AP</u>	+ MYLAN INSTITUTIONAL	<u>EQ 1MG BASE/VIAL</u>	<u>N020630 001</u>	Jul 12, 1996
<u>AP</u>	+!	<u>EQ 2MG BASE/VIAL</u>	<u>N020630 002</u>	Jul 12, 1996
<u>AP</u>		<u>EQ 5MG BASE/VIAL</u>	<u>N020630 003</u>	Jul 12, 1996

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u>	Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014
<u>AB</u>	!	<u>2MG</u>	<u>A203820 003</u>	Jan 22, 2014
<u>AB</u>	BOSCOGEN	<u>0.5MG</u>	<u>A091517 001</u>	Apr 24, 2015
<u>AB</u>		<u>1MG</u>	<u>A091517 002</u>	Apr 24, 2015
<u>AB</u>		<u>2MG</u>	<u>A091517 003</u>	Apr 24, 2015

PRESCRIPTION DRUG PRODUCT LIST

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	CASI PHARMS INC	0.5MG	A078555 001	Nov 22, 2013
AB		1MG	A078555 002	Jan 22, 2014
AB		2MG	A078555 003	Jan 22, 2014
AB	PADDOCK LLC	0.5MG	A201189 001	Jul 17, 2013
AB		1MG	A201189 002	Jan 22, 2014
AB		2MG	A201189 003	Jan 22, 2014
AB	SUN PHARM INDS INC	1MG	A077571 002	Jul 11, 2013
AB		2MG	A077571 003	Jul 11, 2013

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+! ALMIRALL 1% N022055 001 Apr 12, 2007

REVEFENACIN

SOLUTION; INHALATION

YUPELRI

+! MYLAN IRELAND LTD 175MCG/3ML N210598 001 Nov 09, 2018

RIBAVIRIN

CAPSULE; ORAL

REBETOL**AB** +! MERCK SHARP DOHME **200MG** **N020903 002** Jul 25, 2001RIBASPHERE**AB** KADMON PHARMS LLC **200MG** **A076203 001** Apr 06, 2004RIBAVIRIN**AB** AUROBINDO PHARMA **200MG** **A079117 001** Sep 17, 2009**AB** TEVA **200MG** **A076277 001** Oct 04, 2004**AB** ZYDUS PHARMS USA **200MG** **A077224 001** Oct 28, 2005

FOR SOLUTION; INHALATION

RIBAVIRIN**AN** NAVINTA LLC **6GM/VIAL** **A207366 001** Oct 06, 2016VIRAZOLE**AN** +! VALEANT PHARM INTL **6GM/VIAL** **N018859 001** Dec 31, 1985

TABLET; ORAL

RIBAVIRIN**AB** AUROBINDO PHARMA **200MG** **A079111 001** Sep 17, 2009**AB** BEXIMCO PHARMS USA **200MG** **A202546 001** Aug 12, 2014**AB** **400MG** **A202546 002** Aug 12, 2014**AB** **500MG** **A202546 003** Aug 12, 2014**AB** **600MG** **A202546 004** Aug 12, 2014**AB** KADMON PHARMS LLC **200MG** **A077456 001** Dec 05, 2005**AB** **400MG** **A077456 002** Dec 05, 2005**AB** ! **600MG** **A077456 003** Dec 05, 2005**AB** SANDOZ **200MG** **A077743 001** Oct 03, 2006**AB** ZYDUS PHARMS USA **200MG** **A077094 001** Dec 05, 2005**AB** **400MG** **A077094 002** Mar 16, 2007**AB** **500MG** **A077094 004** Apr 18, 2008**AB** **600MG** **A077094 003** Mar 16, 2007RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

+! NOVARTIS EQ 200MG BASE N209092 001 Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+! AVEDRO INC 0.146% N203324 001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+! AVEDRO INC 0.146% N203324 002 Apr 15, 2016

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN**AB** +! PHARMACIA AND UPJOHN **150MG** **N050689 001** Dec 23, 1992RIFABUTIN**AB** LUPIN LTD **150MG** **A090033 001** Feb 24, 2014

PRESCRIPTION DRUG PRODUCT LIST

RIFAMPIN

CAPSULE; ORAL

RIFADIN

AB		SANOFI AVENTIS US	150MG	A062303	001	
AB	+		300MG	N050420	001	
<u>RIFAMPIN</u>						
AB		AKORN	150MG	A065028	001	Mar 14, 2001
AB			300MG	A065028	002	Mar 14, 2001
AB		LANNETT CO INC	150MG	A065390	001	Mar 28, 2008
AB			300MG	A065390	002	Mar 28, 2008
AB		LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013
AB			300MG	A090034	002	Aug 21, 2013
AB		SANDOZ	150MG	A064150	002	Jan 02, 1998
AB			300MG	A064150	001	May 28, 1997

RIMACTANE

AB		OXFORD PHARMS	300MG	N050429	001	
INJECTABLE; INJECTION						

RIFADIN

AP	+	SANOFI AVENTIS US	600MG/VIAL	N050627	001	May 25, 1989
-----------	----------	-------------------	-------------------	----------------	------------	--------------

RIFAMPIN

AP		AKORN	600MG/VIAL	A065502	001	Sep 21, 2010
AP		EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014
AP		FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014
AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016
AP		MYLAN LABS LTD	600MG/VIAL	A065421	001	May 22, 2008
AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016
AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE; ORAL

AEMCOLO

+		REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018
----------	--	---------	---------------	---------	-----	--------------

RIFAPENTINE

TABLET; ORAL

PRIFTIN

+		SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
----------	--	-------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+		SALIX PHARMS	200MG	N021361	001	May 25, 2004
+			550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+		JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011
----------	--	---------------	--------------	---------	-----	--------------

RILUZOLE

FILM; ORAL

EXSERVAN

+		AQUESTIVE THERAP	50MG	N212640	001	Nov 22, 2019
----------	--	------------------	------	---------	-----	--------------

SUSPENSION; ORAL

TIGLUTIK KIT

+		ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018
----------	--	-----------------	-----------	---------	-----	--------------

TABLET; ORAL

RILUTEK

AB	+	COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995
-----------	----------	-----------------	-------------	----------------	------------	--------------

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016
AB		APOTEX CORP	50MG	A091300	001	Jun 18, 2013
AB		GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013
AB		IMPAX LABS	50MG	A076173	001	Jan 29, 2003
AB		MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013
AB		STANDARD CHEM PHARM	50MG	A206045	001	Dec 09, 2019
AB		SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

AB	+	SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993
-----------	----------	--------------------	--------------	----------------	------------	--------------

RIMANTADINE HYDROCHLORIDE

AB		IMPAX LABS	100MG	A076132	001	Aug 30, 2002
-----------	--	------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

RIOCIGUAT

TABLET;ORAL

ADEMPAS

+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
+		1MG	N204819	002	Oct 08, 2013
+		1.5MG	N204819	003	Oct 08, 2013
+		2MG	N204819	004	Oct 08, 2013
+		2.5MG	N204819	005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

AB	+	APIL	5MG	N020835	002	Apr 14, 2000
AB	+		30MG	N020835	001	Mar 27, 1998
AB	+		35MG	N020835	003	May 25, 2002
AB	+		150MG	N020835	005	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	35MG	A090877	001	Nov 30, 2015
AB			75MG	A090877	002	Jun 10, 2014
AB			150MG	A090877	003	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	5MG	A200296	001	Nov 30, 2015
AB			30MG	A200296	002	Nov 30, 2015
AB			35MG	A200296	003	Nov 30, 2015
AB			150MG	A206768	001	Oct 21, 2016
AB		MACLEODS PHARMS LTD	5MG	A203533	001	Dec 09, 2015
AB			30MG	A203533	002	Dec 09, 2015
AB			35MG	A203533	003	Nov 29, 2016
AB		ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019
AB			35MG	A205280	002	May 13, 2019
AB		SUN PHARM	5MG	A090886	001	Nov 30, 2015
AB			30MG	A090886	002	Nov 30, 2015
AB			35MG	A090886	003	Nov 30, 2015
AB			75MG	A090886	004	Jun 10, 2014
AB			150MG	A090886	005	Jun 10, 2014
AB		TEVA PHARMS USA	5MG	A077132	001	Oct 05, 2007
AB			30MG	A077132	002	Oct 05, 2007
AB			35MG	A077132	003	Oct 05, 2007
AB			150MG	A079215	001	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010
-----------	---	------	-------------	----------------	------------	--------------

RISEDRONATE SODIUM

AB		SUN PHARM	35MG	A203925	001	Jul 09, 2019
AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

+	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
+		120MG	N210655	002	Jul 27, 2018

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
+		25MG/VIAL	N021346	001	Oct 29, 2003
+		37.5MG/VIAL	N021346	002	Oct 29, 2003
+		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION;ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996
-----------	---	----------------	---------------	----------------	------------	--------------

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011
AA		AUROBINDO PHARMA LTD	1MG/ML	A078452	001	Sep 04, 2009
AA		HIKMA	1MG/ML	A076904	001	Jul 29, 2009
AA		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010
AA		PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009
AA		TARO	1MG/ML	A090347	001	Feb 07, 2011
AA		TRIS PHARMA INC	1MG/ML	A079059	001	Dec 12, 2012

TABLET;ORAL

RISPERDAL

AB	+	JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999
AB	+		0.5MG	N020272	007	Jan 27, 1999
AB	+		1MG	N020272	001	Dec 29, 1993

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERDAL

AB	+	2MG	N020272	002	Dec 29, 1993
AB	+	3MG	N020272	003	Dec 29, 1993
AB	+	4MG	N020272	004	Dec 29, 1993

RISPERIDONE

AB	AJANTA PHARMA LTD	0.25MG	A201003	001	Aug 24, 2011
AB		0.5MG	A201003	002	Aug 24, 2011
AB		1MG	A201003	003	Aug 24, 2011
AB		2MG	A201003	004	Aug 24, 2011
AB		3MG	A201003	005	Aug 24, 2011
AB		4MG	A201003	006	Aug 24, 2011
AB	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008
AB		0.5MG	A077953	002	Sep 15, 2008
AB		1MG	A077953	003	Sep 15, 2008
AB		2MG	A077953	004	Sep 15, 2008
AB		3MG	A077953	005	Sep 15, 2008
AB		4MG	A077953	006	Sep 15, 2008
AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008
AB		0.5MG	A078871	002	Oct 09, 2008
AB		1MG	A078871	003	Oct 09, 2008
AB		2MG	A078871	004	Oct 09, 2008
AB		3MG	A078871	005	Oct 09, 2008
AB		4MG	A078871	006	Oct 09, 2008
AB	CHARTWELL MOLECULAR	0.25MG	A077543	001	May 18, 2011
AB		0.5MG	A077543	002	May 18, 2011
AB		1MG	A077543	003	May 18, 2011
AB		2MG	A077543	004	May 18, 2011
AB		3MG	A077543	005	May 18, 2011
AB		4MG	A077543	006	May 18, 2011
AB	DR REDDYS LABS LTD	0.25MG	A076879	001	Oct 24, 2008
AB		0.5MG	A076879	002	Oct 24, 2008
AB		1MG	A076879	003	Oct 24, 2008
AB		2MG	A076879	004	Oct 24, 2008
AB		3MG	A076879	005	Oct 24, 2008
AB		4MG	A076879	006	Oct 24, 2008
AB	MYLAN	0.25MG	A076288	001	Sep 15, 2008
AB		0.5MG	A076288	002	Sep 15, 2008
AB		1MG	A076288	003	Sep 15, 2008
AB		2MG	A076288	004	Sep 15, 2008
AB		3MG	A076288	005	Sep 15, 2008
AB		4MG	A076288	006	Sep 15, 2008
AB	OXFORD PHARMS	0.25MG	A078071	001	Jun 17, 2009
AB		0.5MG	A078071	002	Jun 17, 2009
AB		1MG	A078071	003	Jun 17, 2009
AB		2MG	A078071	004	Jun 17, 2009
AB		3MG	A078071	005	Jun 17, 2009
AB		4MG	A078071	006	Jun 17, 2009
AB	PRINSTON INC	0.25MG	A077493	001	Nov 29, 2011
AB		0.5MG	A077493	002	Nov 29, 2011
AB		1MG	A077493	003	Nov 29, 2011
AB		2MG	A077493	004	Nov 29, 2011
AB		3MG	A077493	005	Nov 29, 2011
AB		4MG	A077493	006	Nov 29, 2011
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008
AB		0.5MG	A078707	002	Dec 29, 2008
AB		1MG	A078707	003	Dec 29, 2008
AB		2MG	A078707	004	Dec 29, 2008
AB		3MG	A078707	005	Dec 29, 2008
AB		4MG	A078707	006	Dec 29, 2008
AB	RISING	0.25MG	A078269	001	Oct 08, 2008
AB		0.5MG	A078269	002	Oct 08, 2008
AB		1MG	A078269	003	Oct 08, 2008
AB		2MG	A078269	004	Oct 08, 2008
AB		3MG	A078269	005	Oct 08, 2008
AB		4MG	A078269	006	Oct 08, 2008
AB	SANDOZ	0.25MG	A078528	001	Oct 16, 2009
AB		0.5MG	A078528	002	Oct 16, 2009
AB		1MG	A078528	003	Oct 16, 2009
AB		2MG	A078528	004	Oct 16, 2009
AB		3MG	A078528	005	Oct 16, 2009

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	+	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	!	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>	+		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>	+		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>		ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>			<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>			<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>			<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>			<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>			<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>			<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>			<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>			<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>		HERITAGE PHARMA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>			<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>			<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>		JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>			<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>			<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>			<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>			<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>		PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>			<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>			<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>			<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>			<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>		SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>			<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>			<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>			<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>			<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>		SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>			<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>			<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>			<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>			<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>			<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>			<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>			<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>			<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>			<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>			<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
		PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

RITONAVIR

POWDER; ORAL

NORVIR

+! ABBVIE INC

100MG/PACKET

N209512 001 Jun 07, 2017

SOLUTION; ORAL

NORVIR

+! ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET; ORAL

NORVIRAB +! ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB AMNEAL PHARMS LLC100MGA208890 001 Sep 17, 2018AB AUROBINDO PHARMA LTD100MGA206614 001 Sep 17, 2018AB HETERO LABS LTD III100MGA204587 001 Sep 17, 2018AB HIKMA100MGA202573 001 Jan 15, 2015RIVAROXABAN

TABLET; ORAL

XARELTO

+ JANSSEN PHARMS

2.5MG

N022406 004 Oct 11, 2018

+

10MG

N022406 001 Jul 01, 2011

+

15MG

N022406 002 Nov 04, 2011

+!

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELONAB + NOVARTIS4.6MG/24HRN022083 001 Jul 06, 2007AB +!9.5MG/24HRN022083 002 Jul 06, 2007AB +13.3MG/24HRN022083 005 Aug 31, 2012RIVASTIGMINEAB ALVOGEN4.6MG/24HRA204403 001 Sep 03, 2015AB9.5MG/24HRA204403 002 Sep 03, 2015AB13.3MG/24HRA204403 003 Aug 31, 2015AB AMNEAL PHARMS4.6MG/24HRA207308 001 Jan 08, 2019AB9.5MG/24HRA207308 002 Jan 08, 2019AB13.3MG/24HRA207308 003 Jan 08, 2019AB BRECKENRIDGE4.6MG/24HRA209063 001 Nov 26, 2019AB9.5MG/24HRA209063 002 Nov 26, 2019AB13.3MG/24HRA209063 003 Nov 26, 2019AB MYLAN TECHNOLOGIES4.6MG/24HRA205622 001 Jun 20, 2018AB9.5MG/24HRA205622 002 Jun 20, 2018AB13.3MG/24HRA205622 003 Jun 20, 2018AB ZYDUS NOVELTECH INC4.6MG/24HRA206318 001 Mar 04, 2019AB9.5MG/24HRA206318 002 Mar 04, 2019AB13.3MG/24HRA206318 003 Mar 04, 2019RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATEAB ALEMBIC PHARMS LTDEQ 1.5MG BASEA091689 001 Jun 12, 2012ABEQ 3MG BASEA091689 002 Jun 12, 2012ABEQ 4.5MG BASEA091689 003 Jun 12, 2012ABEQ 6MG BASEA091689 004 Jun 12, 2012AB APOTEX INCEQ 1.5MG BASEA091072 001 May 16, 2013ABEQ 3MG BASEA091072 002 May 16, 2013ABEQ 4.5MG BASEA091072 003 May 16, 2013ABEQ 6MG BASEA091072 004 May 16, 2013AB AUROBINDO PHARMA LTDEQ 1.5MG BASEA204572 001 Mar 25, 2016ABEQ 3MG BASEA204572 002 Mar 25, 2016ABEQ 4.5MG BASEA204572 003 Mar 25, 2016ABEQ 6MG BASEA204572 004 Mar 25, 2016AB CADILA PHARMS LTDEQ 1.5MG BASEA203844 001 Feb 13, 2017ABEQ 3MG BASEA203844 002 Feb 13, 2017ABEQ 4.5MG BASEA203844 003 Feb 13, 2017ABEQ 6MG BASEA203844 004 Feb 13, 2017AB CHARTWELL RXEQ 1.5MG BASEA207797 001 Sep 28, 2017ABEQ 3MG BASEA207797 002 Sep 28, 2017ABEQ 4.5MG BASEA207797 003 Sep 28, 2017ABEQ 6MG BASEA207797 004 Sep 28, 2017AB ! DR REDDYS LABS INCEQ 1.5MG BASEA077130 001 Oct 31, 2007ABEQ 3MG BASEA077130 002 Oct 31, 2007

PRESCRIPTION DRUG PRODUCT LIST

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130 003</u>	Oct 31, 2007
<u>AB</u>	!	<u>EQ 6MG BASE</u>	<u>A077130 004</u>	Oct 31, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148 001</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203148 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203148 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203148 004</u>	Aug 22, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1.5MG BASE</u>	<u>A090879 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090879 002</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A090879 003</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090879 004</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1.5MG BASE</u>	<u>A077131 001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131 002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131 003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131 004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129 003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129 004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

<u>AB</u>	+	MERCK	<u>EQ 10MG BASE</u>	<u>N020864 002</u>	Jun 29, 1998
-----------	---	-------	---------------------	--------------------	--------------

RIZATRIPTAN BENZOATE

<u>AB</u>		ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A203269 001</u>	Feb 18, 2016
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203269 002</u>	Feb 18, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202490 002</u>	Dec 31, 2012
<u>AB</u>		CELLTRION	<u>EQ 5MG BASE</u>	<u>A077526 001</u>	Mar 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077526 002</u>	Mar 26, 2013
<u>AB</u>		ECI PHARMS LLC	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>		EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090 001</u>	Nov 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204090 002</u>	Nov 26, 2013
<u>AB</u>		GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201967 002</u>	Dec 31, 2012
<u>AB</u>		INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339 001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204339 002</u>	Jul 01, 2013
<u>AB</u>		JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252 001</u>	Dec 31, 2014
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203252 002</u>	Dec 31, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147 001</u>	Feb 11, 2014
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203147 002</u>	Feb 11, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201993 002</u>	Dec 31, 2012
<u>AB</u>		NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A200482 002</u>	Dec 31, 2012
<u>AB</u>		SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>		TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012
<u>AB</u>		UNICHEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A207836 001</u>	Mar 07, 2017
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A207836 002</u>	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

<u>AB</u>	+	MERCK	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998
-----------	---	-------	---------------------	--------------------	--------------

RIZATRIPTAN BENZOATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>		GLENMARK PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>		JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203334 001</u>	Oct 16, 2015
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203334 002</u>	Oct 16, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173 001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A078173 002</u>	Dec 31, 2012
<u>AB</u>		NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722 001	Jan 11, 2017
AB		EQ 10MG BASE	A204722 002	Jan 11, 2017
AB	SANDOZ	EQ 5MG BASE	A078739 001	Jul 01, 2013
AB		EQ 10MG BASE	A078739 002	Jul 01, 2013
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835 001	Mar 07, 2017
AB		EQ 10MG BASE	A207835 002	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206 001	Apr 12, 2017
AP		100MG/10ML (10MG/ML)	A206206 002	Apr 12, 2017
AP	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A078651 001	Dec 29, 2008
AP		100MG/10ML (10MG/ML)	A078651 002	Dec 29, 2008
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A205656 001	Apr 04, 2018
AP		100MG/10ML (10MG/ML)	A205656 002	Apr 04, 2018
AP	HOSPIRA	50MG/5ML (10MG/ML)	A078519 001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A078519 002	Nov 26, 2008
AP	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A079199 001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A079199 002	Nov 26, 2008
AP	SAGENT PHARMS INC	50MG/5ML (10MG/ML)	A091458 001	Jul 28, 2010
AP		100MG/10ML (10MG/ML)	A091458 002	Jul 28, 2010
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195 001	Dec 05, 2008
AP	!	100MG/10ML (10MG/ML)	A079195 002	Dec 05, 2008
AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437 001	Aug 13, 2019
AP		100MG/10ML (10MG/ML)	A210437 002	Aug 13, 2019
AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012
AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012
AP	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679 001	Feb 28, 2017
AP		100MG/10ML (10MG/ML)	A204679 002	Feb 28, 2017

ROFLUMILAST

TABLET; ORAL

DALIRESP

AB	+! ASTRAZENECA PHARMS	500MCG	N022522 001	Feb 28, 2011
-----------	-----------------------	---------------	--------------------	--------------

ROFLUMILAST

AB	BRECKENRIDGE	500MCG	A208236 001	Oct 03, 2018
AB	HETERO LABS LTD III	500MCG	A208213 001	Nov 23, 2018
AB	MICRO LABS	500MCG	A208180 001	Mar 22, 2019
AB	TORRENT	500MCG	A208272 001	Aug 06, 2018

DALIRESP

	+ ASTRAZENECA PHARMS	250MCG	N022522 002	Jan 23, 2018
--	----------------------	---------------	--------------------	--------------

ROLAPITANT HYDROCHLORIDE

TABLET; ORAL

VARUBI

	+! TERSERA THERAPS LLC	EQ 90MG BASE	N206500 001	Sep 01, 2015
--	------------------------	---------------------	--------------------	--------------

ROMIDEPSIN

POWDER; INTRAVENOUS

ISTODAX

	+! CELGENE	10MG/VIAL	N022393 001	Nov 05, 2009
--	------------	------------------	--------------------	--------------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

AB	+! GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658 001	Sep 19, 1997
AB	+	EQ 0.5MG BASE	N020658 002	Sep 19, 1997
AB	+	EQ 1MG BASE	N020658 003	Sep 19, 1997
AB	+	EQ 2MG BASE	N020658 004	Sep 19, 1997
AB	+	EQ 3MG BASE	N020658 006	Jan 27, 1999
AB	+	EQ 4MG BASE	N020658 007	Jan 27, 1999
AB	+	EQ 5MG BASE	N020658 005	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022 001	Feb 28, 2017
AB		EQ 0.5MG BASE	A204022 002	Feb 28, 2017
AB		EQ 1MG BASE	A204022 003	Feb 28, 2017
AB		EQ 2MG BASE	A204022 004	Feb 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204022</u>	<u>005</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A204022</u>	<u>006</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204022</u>	<u>007</u>	Feb 28, 2017
<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010
<u>AB</u>	CADILA	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009
<u>AB</u>	CELLTRION	<u>EQ 0.25MG BASE</u>	<u>A079050</u>	<u>001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050</u>	<u>002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050</u>	<u>003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050</u>	<u>004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050</u>	<u>005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135</u>	<u>002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135</u>	<u>003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135</u>	<u>004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135</u>	<u>005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135</u>	<u>006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135</u>	<u>007</u>	Feb 25, 2010
<u>AB</u>	HIKMA	<u>EQ 0.25MG BASE</u>	<u>A077852</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852</u>	<u>007</u>	May 19, 2008
<u>AB</u>	MLV	<u>EQ 0.25MG BASE</u>	<u>A079165</u>	<u>001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165</u>	<u>002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165</u>	<u>003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165</u>	<u>004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165</u>	<u>005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165</u>	<u>006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165</u>	<u>007</u>	Feb 07, 2012
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229</u>	<u>003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229</u>	<u>004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229</u>	<u>005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229</u>	<u>006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229</u>	<u>007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110</u>	<u>007</u>	Jul 11, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008</u>	<u>001</u>	Jun 13, 2008
-----------	---	---------------------	--------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

<u>AB</u>	+		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>N022008 004</u>	Jun 13, 2008
<u>AB</u>	+		<u>EQ 12MG BASE</u>	<u>N022008 005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869 001</u>	May 17, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A090869 002</u>	May 17, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A090869 003</u>	May 17, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090869 004</u>	May 17, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090869 005</u>	May 17, 2012
<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A202786 001</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A202786 002</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A202786 003</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A202786 004</u>	Apr 22, 2013
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A202786 005</u>	Apr 22, 2013
<u>AB</u>		CELLTRION	<u>EQ 2MG BASE</u>	<u>A091395 001</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A091395 002</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091395 003</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A091395 004</u>	Aug 27, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A091395 005</u>	Aug 27, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201576 002</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201576 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201576 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201576 005</u>	Jun 06, 2012
<u>AB</u>		SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A201047 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201047 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201047 005</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A201047 006</u>	Jun 06, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431 001</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A200431 002</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A200431 003</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A200431 004</u>	Jun 06, 2012
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A200431 005</u>	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/10ML (2MG/ML)</u>	<u>N020533 001</u>	May 01, 1998
<u>AP</u>	+		<u>40MG/20ML (2MG/ML)</u>	<u>N020533 002</u>	Sep 24, 1996
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N020533 003</u>	May 01, 1998
<u>AP</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N020533 005</u>	Sep 24, 1996
<u>AP</u>	+		<u>150MG/20ML (7.5MG/ML)</u>	<u>N020533 004</u>	Sep 24, 1996
<u>AP</u>	+		<u>150MG/30ML (5MG/ML)</u>	<u>N020533 008</u>	Sep 24, 1996
<u>AP</u>	+		<u>200MG/100ML (2MG/ML)</u>	<u>N020533 006</u>	Sep 24, 1996
<u>AP</u>	+		<u>200MG/20ML (10MG/ML)</u>	<u>N020533 011</u>	Sep 24, 1996
<u>AP</u>	+		<u>400MG/200ML (2MG/ML)</u>	<u>N020533 007</u>	Sep 24, 1996
<u>AP</u>	+		<u>500MG/100ML (5MG/ML)</u>	<u>N020533 009</u>	Jan 04, 2011
<u>AP</u>	+		<u>1GM/200ML (5MG/ML)</u>	<u>N020533 010</u>	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>200MG/100ML (2MG/ML)</u>	<u>A204636 001</u>	Mar 16, 2018
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A204636 002</u>	Mar 16, 2018
<u>AP</u>		AKORN INC	<u>150MG/30ML (5MG/ML)</u>	<u>A203955 001</u>	Apr 11, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>40MG/20ML (2MG/ML)</u>	<u>A205612 001</u>	Jul 13, 2016
<u>AP</u>			<u>100MG/20ML (5MG/ML)</u>	<u>A205612 003</u>	Jul 13, 2016
<u>AP</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A205612 006</u>	Jul 13, 2016
<u>AP</u>			<u>150MG/30ML (5MG/ML)</u>	<u>A205612 004</u>	Jul 13, 2016
<u>AP</u>			<u>150MG/20ML (7.5MG/ML)</u>	<u>A205612 005</u>	Jul 13, 2016
<u>AP</u>			<u>200MG/100ML (2MG/ML)</u>	<u>A205612 002</u>	Jul 13, 2016
<u>AP</u>			<u>200MG/20ML (10MG/ML)</u>	<u>A205612 007</u>	Jul 13, 2016
<u>AP</u>		HOSPIRA	<u>20MG/10ML (2MG/ML)</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>			<u>40MG/20ML (2MG/ML)</u>	<u>A090194 005</u>	Sep 23, 2014
<u>AP</u>			<u>100MG/10ML (10MG/ML)</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>			<u>150MG/30ML (5MG/ML)</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>			<u>150MG/20ML (7.5MG/ML)</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>			<u>200MG/20ML (10MG/ML)</u>	<u>A090194 006</u>	Sep 23, 2014
<u>AP</u>		INFORLIFE	<u>200MG/100ML (2MG/ML)</u>	<u>A206166 001</u>	Jun 11, 2018
<u>AP</u>			<u>400MG/200ML (2MG/ML)</u>	<u>A206166 002</u>	Jun 11, 2018
<u>AP</u>			<u>500MG/100ML (5MG/ML)</u>	<u>A206166 003</u>	Jun 11, 2018

PRESCRIPTION DRUG PRODUCT LIST

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>1GM/200ML (5MG/ML)</u>	<u>A206166 004</u>	Jun 11, 2018
<u>AP</u>	MYLAN ASI	<u>40MG/20ML (2MG/ML)</u>	<u>A090318 001</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090318 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090318 004</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>150MG/30ML (5MG/ML)</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SOMERSET THERAPS LLC	<u>20MG/10ML (2MG/ML)</u>	<u>A207636 001</u>	Jun 15, 2018
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A207636 002</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207636 003</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A207636 006</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A207636 004</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A207636 005</u>	Jun 15, 2018
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A207636 007</u>	Jun 15, 2018

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ SB PHARMCO
+

EQ 2MG BASE
EQ 4MG BASE

N021071 002 May 25, 1999
N021071 003 May 25, 1999

ROSUVASTATIN CALCIUM

CAPSULE; ORAL

EZALLOR

+ SUN PHARMA GLOBAL
+
+
+!

EQ 5MG BASE
EQ 10MG BASE
EQ 20MG BASE
EQ 40MG BASE

N208647 001 Dec 18, 2018
N208647 002 Dec 18, 2018
N208647 003 Dec 18, 2018
N208647 004 Dec 18, 2018

TABLET; ORAL

CRESTOR

<u>AB</u>	+	<u>5MG</u>	<u>N021366 002</u>	Aug 12, 2003
<u>AB</u>	+	<u>10MG</u>	<u>N021366 003</u>	Aug 12, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021366 004</u>	Aug 12, 2003
<u>AB</u>	+	<u>40MG</u>	<u>N021366 005</u>	Aug 12, 2003

ROSUVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A206434 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A206434 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A206434 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A206434 004</u>	Oct 31, 2016
<u>AB</u>	ALKEM LABS LTD	<u>5MG</u>	<u>A206465 001</u>	Mar 21, 2017
<u>AB</u>		<u>10MG</u>	<u>A206465 002</u>	Mar 21, 2017
<u>AB</u>		<u>20MG</u>	<u>A206465 003</u>	Mar 21, 2017
<u>AB</u>		<u>40MG</u>	<u>A206465 004</u>	Mar 21, 2017
<u>AB</u>	ALLIED	<u>5MG</u>	<u>A079168 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079168 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079168 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079168 004</u>	Jul 19, 2016
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A079145 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079145 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079145 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079145 004</u>	Jul 19, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A079170 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079170 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079170 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079170 004</u>	Jul 19, 2016
<u>AB</u>	BIOCON LTD	<u>5MG</u>	<u>A207752 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207752 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207752 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207752 004</u>	Oct 31, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>5MG</u>	<u>A207453 001</u>	Nov 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A207453 002</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A207453 003</u>	Nov 23, 2016
<u>AB</u>		<u>40MG</u>	<u>A207453 004</u>	Nov 23, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>5MG</u>	<u>A207408 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207408 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207408 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207408 004</u>	Oct 31, 2016
<u>AB</u>	GLENMARK PHARMS	<u>5MG</u>	<u>A079172 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079172 002</u>	Jul 19, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

<u>AB</u>		<u>20MG</u>	<u>A079172</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079172</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A207616</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207616</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207616</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207616</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A207062</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207062</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207062</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207062</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A205587</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		<u>10MG</u>	<u>A205587</u>	<u>002</u>	Jul 31, 2017
<u>AB</u>		<u>20MG</u>	<u>A205587</u>	<u>003</u>	Jul 31, 2017
<u>AB</u>		<u>40MG</u>	<u>A205587</u>	<u>004</u>	Jul 31, 2017
<u>AB</u>	MSN	<u>5MG</u>	<u>A208898</u>	<u>001</u>	Nov 22, 2017
<u>AB</u>		<u>10MG</u>	<u>A208898</u>	<u>002</u>	Nov 22, 2017
<u>AB</u>		<u>20MG</u>	<u>A208898</u>	<u>003</u>	Nov 22, 2017
<u>AB</u>		<u>40MG</u>	<u>A208898</u>	<u>004</u>	Nov 22, 2017
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A079171</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079171</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079171</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079171</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	SHANDONG	<u>5MG</u>	<u>A207375</u>	<u>001</u>	May 07, 2019
<u>AB</u>		<u>10MG</u>	<u>A207375</u>	<u>002</u>	May 07, 2019
<u>AB</u>		<u>20MG</u>	<u>A207375</u>	<u>003</u>	May 07, 2019
<u>AB</u>		<u>40MG</u>	<u>A207375</u>	<u>004</u>	May 07, 2019
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A079169</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079169</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079169</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079169</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	TORRENT	<u>5MG</u>	<u>A201619</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A201619</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A201619</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A201619</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A079167</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A079167</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A079167</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A079167</u>	<u>004</u>	Apr 29, 2016
<u>AB</u>	ZHEJIANG YONGTAI	<u>5MG</u>	<u>A212059</u>	<u>001</u>	Nov 04, 2019
<u>AB</u>		<u>10MG</u>	<u>A212059</u>	<u>002</u>	Nov 04, 2019
<u>AB</u>		<u>20MG</u>	<u>A212059</u>	<u>003</u>	Nov 04, 2019
<u>AB</u>		<u>40MG</u>	<u>A212059</u>	<u>004</u>	Nov 04, 2019

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+	!	2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

SOLUTION; INTRAVENOUS

RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 250MG BASE	N209115	003	May 01, 2017
+	!	EQ 300MG BASE	N209115	002	Dec 19, 2016

PRESCRIPTION DRUG PRODUCT LIST

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

AB	+ !	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011
-----------	------------	-----------	----------------	--------------------	--------------

RUFINAMIDE

AB		BIONPHARMA INC	40MG/ML	A211388 001	Apr 23, 2019
-----------	--	----------------	----------------	--------------------	--------------

AB		HIKMA	40MG/ML	A207363 001	Apr 23, 2019
-----------	--	-------	----------------	--------------------	--------------

TABLET; ORAL

BANZEL

AB	+	EISAI INC	200MG	N021911 002	Nov 14, 2008
-----------	----------	-----------	--------------	--------------------	--------------

AB	+ !		400MG	N021911 003	Nov 14, 2008
-----------	------------	--	--------------	--------------------	--------------

RUFINAMIDE

AB		GLENMARK PHARMS LTD	200MG	A205075 001	May 16, 2016
-----------	--	---------------------	--------------	--------------------	--------------

AB			400MG	A205075 002	May 16, 2016
-----------	--	--	--------------	--------------------	--------------

AB		HIKMA	200MG	A204988 001	May 16, 2016
-----------	--	-------	--------------	--------------------	--------------

AB			400MG	A204988 002	May 16, 2016
-----------	--	--	--------------	--------------------	--------------

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

+		INCYTE CORP	EQ 5MG BASE	N202192 001	Nov 16, 2011
----------	--	-------------	-------------	-------------	--------------

+			EQ 10MG BASE	N202192 002	Nov 16, 2011
----------	--	--	--------------	-------------	--------------

+			EQ 15MG BASE	N202192 003	Nov 16, 2011
----------	--	--	--------------	-------------	--------------

+			EQ 20MG BASE	N202192 004	Nov 16, 2011
----------	--	--	--------------	-------------	--------------

+ !			EQ 25MG BASE	N202192 005	Nov 16, 2011
------------	--	--	--------------	-------------	--------------

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ !		QOL MEDCL	8,500 IU/ML	N020772 001	Apr 09, 1998
------------	--	-----------	-------------	-------------	--------------

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

+		NOVARTIS PHARMS	24MG;26MG	N207620 001	Jul 07, 2015
----------	--	-----------------	-----------	-------------	--------------

+		CORP	49MG;51MG	N207620 002	Jul 07, 2015
----------	--	------	-----------	-------------	--------------

+ !			97MG;103MG	N207620 003	Jul 07, 2015
------------	--	--	------------	-------------	--------------

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+		US WORLDMEDS LLC	50MG	N207145 001	Mar 21, 2017
----------	--	------------------	------	-------------	--------------

+ !			100MG	N207145 002	Mar 21, 2017
------------	--	--	-------	-------------	--------------

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ !		GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692 001	Sep 19, 1997
------------	--	-----------------	--------------------	-------------	--------------

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ !		LANTHEUS MEDICAL	50mCi/ML	N020570 001	Mar 28, 1997
------------	--	------------------	----------	-------------	--------------

SAPROTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

AB	+ !	BIOMARIN PHARM	100MG/PACKET	N205065 001	Dec 19, 2013
-----------	------------	----------------	---------------------	--------------------	--------------

SAPROTERIN DIHYDROCHLORIDE

AB		PAR PHARM INC	100MG/PACKET	A207207 001	Aug 20, 2019
-----------	--	---------------	---------------------	--------------------	--------------

KUVAN

+		BIOMARIN PHARM	500MG/PACKET	N205065 002	Oct 27, 2015
----------	--	----------------	--------------	-------------	--------------

TABLET; ORAL

KUVAN

+ !		BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007
------------	--	----------------	-------	-------------	--------------

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+ !		HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004
------------	--	-------------------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SARECYCLINE HYDROCHLORIDE

TABLET; ORAL

SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521 001	Oct 01, 2018
+		EQ 100MG BASE	N209521 002	Oct 01, 2018
+	!	EQ 150MG BASE	N209521 003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+	!	EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE

AB	MYLAN TECHNOLOGIES	1MG/72HR	A203753 001	Jun 19, 2019
AB	PERRIGO PHARMS CO	1MG/72HR	A078830 001	Jan 30, 2015
TRANSDERM SCOP				
AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874 001

SECNIDAZOLE

GRANULE; ORAL

SOLOSEC

+	LUPIN	2GM/PACKET	N209363 001	Sep 15, 2017
---	-------	------------	-------------	--------------

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

!	VALEANT PHARMS NORTH	50MG	A086101 001	Oct 03, 1983
!		100MG	A086101 002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+	CHIRHOCLIN	16MCG/VIAL	N021256 001	Apr 09, 2004
+		40MCG/VIAL	N021256 002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+	SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
+		9MG/24HR	N021336 002	Feb 27, 2006
+		12MG/24HR	N021336 003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX	5MG	A075321 001	Dec 04, 1998
AB		DAVA PHARMS INC	5MG	A075352 001	Nov 30, 1998
AB		RISING	5MG	A206803 001	Apr 02, 2019

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX INC	5MG	A074871 001	Jun 06, 1997
AB		BOSCOGEN	5MG	A074912 001	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+	BAUSCH	1.25MG	N021479 001	Jun 14, 2006
---	--------	--------	-------------	--------------

SELENIOUS ACID

SOLUTION; INTRAVENOUS

SELENIOUS ACID

+	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379 001	Apr 30, 2019
---	-----------	--	-------------	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT	!	PERRIGO NEW YORK	2.5%	A089996 001	Jan 10, 1991
AT		WOCKHARDT BIO AG	2.5%	A088228 001	Sep 01, 1983

SELEXIPAG

TABLET; ORAL

UPTRAVI

+	ACTELION PHARMS LTD	0.2MG	N207947 001	Dec 21, 2015
+		0.4MG	N207947 002	Dec 21, 2015
+		0.6MG	N207947 003	Dec 21, 2015
+		0.8MG	N207947 004	Dec 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

SELEXIPAG

TABLET; ORAL

UPTRA VI

+	1MG	N207947 005	Dec 21, 2015
+	1.2MG	N207947 006	Dec 21, 2015
+	1.4MG	N207947 007	Dec 21, 2015
+	1.6MG	N207947 008	Dec 21, 2015

SELINEXOR

TABLET; ORAL

XPOVIO

+	KARYOPHARM THERAPS	20MG	N212306 001	Jul 03, 2019
---	--------------------	------	-------------	--------------

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

OZEMPIC

+	NOVO	2MG/1.5ML (1.34MG/ML)	N209637 001	Dec 05, 2017
---	------	-----------------------	-------------	--------------

TABLET; ORAL

RYBELSUS

+	NOVO	3MG	N213051 001	Sep 20, 2019
+		7MG	N213051 002	Sep 20, 2019
+		14MG	N213051 003	Sep 20, 2019

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	BAUSCH	2%	N021385 001	Dec 10, 2003
---	--------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

AA	AUROBINDO PHARMA	EQ 20MG BASE/ML	A078861 001	Oct 31, 2008
-----------	------------------	------------------------	--------------------	--------------

ZOLOFT

AA	+	PFIZER	EQ 20MG BASE/ML	N020990 001	Dec 07, 1999
-----------	---	--------	------------------------	--------------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202825 001	Nov 07, 2014
AB		EQ 50MG BASE	A202825 002	Nov 07, 2014
AB		EQ 100MG BASE	A202825 003	Nov 07, 2014
AB	APOTEX INC	EQ 25MG BASE	A076882 001	Feb 06, 2007
AB		EQ 50MG BASE	A076882 002	Feb 06, 2007
AB		EQ 100MG BASE	A076882 003	Feb 06, 2007
AB	AUROBINDO PHARMA	EQ 25MG BASE	A077206 001	Feb 06, 2007
AB		EQ 50MG BASE	A077206 002	Feb 06, 2007
AB		EQ 100MG BASE	A077206 003	Feb 06, 2007
AB	AUSTARPHARMA LLC	EQ 25MG BASE	A078677 001	Mar 04, 2009
AB		EQ 50MG BASE	A078677 002	Mar 04, 2009
AB		EQ 100MG BASE	A078677 003	Mar 04, 2009
AB	INVAGEN PHARMS	EQ 25MG BASE	A077397 001	Feb 06, 2007
AB		EQ 50MG BASE	A077397 002	Feb 06, 2007
AB		EQ 100MG BASE	A077397 003	Feb 06, 2007
AB	LUPIN	EQ 25MG BASE	A077670 001	Feb 06, 2007
AB		EQ 50MG BASE	A077670 002	Feb 06, 2007
AB		EQ 100MG BASE	A077670 003	Feb 06, 2007
AB	OXFORD PHARMS	EQ 25MG BASE	A078175 001	Jul 21, 2010
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977 001	Feb 06, 2007
AB		EQ 50MG BASE	A077977 002	Feb 06, 2007
AB		EQ 100MG BASE	A077977 003	Feb 06, 2007
AB	TORRENT PHARMS	EQ 25MG BASE	A077765 001	Feb 06, 2007
AB		EQ 50MG BASE	A077765 002	Feb 06, 2007
AB		EQ 100MG BASE	A077765 003	Feb 06, 2007
AB	WOCKHARDT	EQ 25MG BASE	A078403 001	Jan 08, 2008
AB		EQ 50MG BASE	A078403 002	Jan 08, 2008
AB		EQ 100MG BASE	A078403 003	Jan 08, 2008

ZOLOFT

AB	+	PFIZER	EQ 25MG BASE	N019839 005	Mar 06, 1996
AB	+		EQ 50MG BASE	N019839 001	Dec 30, 1991
AB	+		EQ 100MG BASE	N019839 002	Dec 30, 1991

SERTRALINE HYDROCHLORIDE

SUN PHARM INDS LTD

EQ 150MG BASE	A077977 004	Feb 06, 2007
EQ 200MG BASE	A077977 005	Feb 06, 2007

PRESCRIPTION DRUG PRODUCT LIST

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

<u>AB</u>	<u>+</u>	GENZYME	<u>800MG/PACKET</u>	<u>N022318</u>	<u>001</u>	Aug 12, 2009
<u>AB</u>	<u>+</u>	!	<u>2.4GM/PACKET</u>	<u>N022318</u>	<u>002</u>	Feb 18, 2009

SEVELAMER CARBONATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>800MG/PACKET</u>	<u>A207624</u>	<u>001</u>	Jun 13, 2017
<u>AB</u>			<u>2.4GM/PACKET</u>	<u>A207624</u>	<u>002</u>	Jun 13, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>800MG/PACKET</u>	<u>A210464</u>	<u>001</u>	Oct 25, 2018
<u>AB</u>			<u>2.4GM/PACKET</u>	<u>A210464</u>	<u>002</u>	Oct 25, 2018

TABLET;ORAL

RENVELA

<u>AB</u>	<u>+</u>	SANOFI	<u>800MG</u>	<u>N022127</u>	<u>001</u>	Oct 19, 2007
-----------	----------	--------	--------------	----------------	------------	--------------

SEVELAMER CARBONATE

<u>AB</u>		AMNEAL PHARMS CO	<u>800MG</u>	<u>A207288</u>	<u>001</u>	Nov 28, 2017
<u>AB</u>		AUROBINDO PHARMA LTD	<u>800MG</u>	<u>A207179</u>	<u>001</u>	Jul 17, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>800MG</u>	<u>A206094</u>	<u>001</u>	Sep 29, 2017
<u>AB</u>		IMPAX LABS INC	<u>800MG</u>	<u>A090975</u>	<u>001</u>	Oct 23, 2017
<u>AB</u>		INVAGEN PHARMS	<u>800MG</u>	<u>A203860</u>	<u>001</u>	Oct 26, 2017
<u>AB</u>		TWI PHARMS	<u>800MG</u>	<u>A200959</u>	<u>001</u>	Mar 20, 2018
<u>AB</u>		WILSHIRE PHARMS INC	<u>800MG</u>	<u>A204451</u>	<u>001</u>	Nov 29, 2018

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

<u>AB</u>	<u>+</u>	GENZYME	<u>400MG</u>	<u>N021179</u>	<u>001</u>	Jul 12, 2000
<u>AB</u>	<u>+</u>	!	<u>800MG</u>	<u>N021179</u>	<u>002</u>	Jul 12, 2000

SEVELAMER HYDROCHLORIDE

<u>AB</u>		GLENMARK PHARMS LTD	<u>400MG</u>	<u>A204724</u>	<u>001</u>	Feb 08, 2019
<u>AB</u>			<u>800MG</u>	<u>A204724</u>	<u>002</u>	Feb 08, 2019

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

<u>AN</u>		BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>		HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
<u>AN</u>		SHANGHAI HENGRUI	<u>100%</u>	<u>A203793</u>	<u>001</u>	Nov 03, 2015

SOJOURN

<u>AN</u>		PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007
-----------	--	------------------	-------------	----------------	------------	--------------

ULTANE

<u>AN</u>	<u>+</u>	ABEVIE	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995
-----------	----------	--------	-------------	----------------	------------	--------------

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

<u>AB</u>	<u>+</u>	PFIZER	<u>EQ 10MG BASE/ML</u>	<u>N203109</u>	<u>001</u>	Aug 30, 2012
-----------	----------	--------	------------------------	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 10MG BASE/ML</u>	<u>A212883</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		ALKEM LABS LTD	<u>EQ 10MG BASE/ML</u>	<u>A212440</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		AMNEAL PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A211092</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		NOVITIUM PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A212260</u>	<u>001</u>	May 31, 2019

SOLUTION;INTRAVENOUS

REVATIO

<u>AP</u>	<u>+</u>	PFIZER	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>N022473</u>	<u>001</u>	Nov 18, 2009
-----------	----------	--------	---	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>A203988</u>	<u>001</u>	Apr 01, 2015
-----------	--	----------------------	---	----------------	------------	--------------

TABLET;ORAL

REVATIO

<u>AB</u>	<u>+</u>	PFIZER	<u>EQ 20MG BASE</u>	<u>N021845</u>	<u>001</u>	Jun 03, 2005
-----------	----------	--------	---------------------	----------------	------------	--------------

SILDENAFIL CITRATE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A210394</u>	<u>001</u>	May 04, 2018
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A206401</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A206401</u>	<u>002</u>	Oct 12, 2018
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A206401</u>	<u>003</u>	Oct 12, 2018
<u>AB</u>		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A202025</u>	<u>001</u>	Feb 28, 2013
<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 25MG BASE</u>	<u>A202023</u>	<u>001</u>	Jun 27, 2018
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A202023</u>	<u>002</u>	Jun 27, 2018
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A202023</u>	<u>003</u>	Jun 27, 2018
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A203963</u>	<u>001</u>	Nov 18, 2015
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A203962</u>	<u>001</u>	Jun 11, 2018
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A203962</u>	<u>002</u>	Jun 11, 2018

PRESCRIPTION DRUG PRODUCT LIST

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203962 003</u>	Jun 11, 2018
<u>AB</u>	HEBEI CHANGSHAN	<u>EQ 20MG BASE</u>	<u>A202598 001</u>	Nov 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A203623 001</u>	Nov 26, 2014
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A202659 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202659 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202659 003</u>	Jun 11, 2018
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A212051 001</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A212051 002</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A212051 003</u>	Mar 22, 2019
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203814 001</u>	Dec 17, 2013
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A201171 001</u>	Mar 25, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201171 002</u>	Mar 25, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201171 003</u>	Mar 25, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150 001</u>	Nov 09, 2012
<u>AB</u>	RUBICON	<u>EQ 20MG BASE</u>	<u>A204883 001</u>	Jun 20, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204882 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A204882 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204882 003</u>	Jun 11, 2018
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A077342 001</u>	Mar 09, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077342 002</u>	Mar 09, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077342 003</u>	Mar 09, 2016
<u>AB</u>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380 001</u>	Jan 07, 2013
<u>AB</u>	TORRENT	<u>EQ 25MG BASE</u>	<u>A091448 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091448 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091448 003</u>	Jun 11, 2018
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479 001</u>	Nov 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503 001</u>	Nov 06, 2012
<u>VIAGRA</u>				
<u>AB</u>	+ PFIZER INC	<u>EQ 25MG BASE</u>	<u>N020895 001</u>	Mar 27, 1998
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N020895 002</u>	Mar 27, 1998
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N020895 003</u>	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO

<u>AB</u>	+	ALLERGAN	<u>4MG</u>	<u>N022206 001</u>	Oct 08, 2008
<u>AB</u>	+		<u>8MG</u>	<u>N022206 002</u>	Oct 08, 2008

SILODOSIN

<u>AB</u>		AJANTA PHARMA LTD	<u>4MG</u>	<u>A211060 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A211060 002</u>	Dec 03, 2018
<u>AB</u>		ALEMBIC PHARMS LTD	<u>4MG</u>	<u>A211731 001</u>	Nov 22, 2019
<u>AB</u>			<u>8MG</u>	<u>A211731 002</u>	Nov 22, 2019
<u>AB</u>		AMNEAL PHARMS CO	<u>4MG</u>	<u>A209745 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A209745 002</u>	Dec 03, 2018
<u>AB</u>		AUROBINDO PHARMA LTD	<u>4MG</u>	<u>A210626 001</u>	Dec 10, 2018
<u>AB</u>			<u>8MG</u>	<u>A210626 002</u>	Dec 10, 2018
<u>AB</u>		LUPIN LTD	<u>4MG</u>	<u>A206541 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A206541 002</u>	Dec 03, 2018
<u>AB</u>		MACLEODS PHARMS LTD	<u>4MG</u>	<u>A211166 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A211166 002</u>	Dec 03, 2018
<u>AB</u>		MSN	<u>4MG</u>	<u>A210687 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A210687 002</u>	Dec 03, 2018
<u>AB</u>		SANDOZ INC	<u>4MG</u>	<u>A204726 001</u>	Mar 31, 2017
<u>AB</u>			<u>8MG</u>	<u>A204726 002</u>	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

<u>AB</u>	+	KING PHARMS LLC	<u>1%</u>	<u>N017381 001</u>	
<u>SSD</u>					
<u>AB</u>		DR REDDYS LA	<u>1%</u>	<u>N018578 001</u>	Feb 25, 1982
<u>THERMAZENE</u>					
<u>AB</u>		THEPHARMANETWORK LLC	<u>1%</u>	<u>N018810 001</u>	Dec 23, 1985

PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

SUSPENSION; ORAL

FLOLIPID

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
+	!	40MG/5ML	N206679	002	Apr 21, 2016

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A078155</u>	<u>005</u>	Apr 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>		<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	BIOCON LIMITED	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>5MG</u>	<u>A077752</u>	<u>005</u>	Jan 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
<u>AB</u>		<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
<u>AB</u>		<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
<u>AB</u>		<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	WATSON LABS TEVA	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	+	MSD MERCK CO	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>	+		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>	+		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	!	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+	BRACCO	0.005MG/VIAL	N017697	001	
---	--------	--------------	---------	-----	--

PRESCRIPTION DRUG PRODUCT LIST

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+! FOUGERA PHARMS INC 15% N021902 001 Oct 31, 2006

SIPONIMOD FUMARIC ACID

TABLET; ORAL

MAYZENT

+ NOVARTIS EQ 0.25MG BASE N209884 001 Mar 26, 2019

+! EQ 2MG BASE N209884 002 Mar 26, 2019

SIROLIMUS

SOLUTION; ORAL

RAPAMUNEAA +! PF PRISM CV 1MG/ML N021083 001 Sep 15, 1999SIROLIMUSAA AMNEAL PHARMS LLC 1MG/ML A211212 001 Oct 18, 2019AA APOTEX 1MG/ML A211406 001 Oct 22, 2019AA NOVITIUM PHARMA 1MG/ML A211040 001 Jan 28, 2019

TABLET; ORAL

RAPAMUNEAB + PF PRISM CV 0.5MG N021110 004 Jan 25, 2010AB + 1MG N021110 001 Aug 25, 2000AB +! 2MG N021110 002 Aug 22, 2002SIROLIMUSAB DR REDDYS LABS LTD 1MG A201578 001 Oct 27, 2014AB 2MG A201578 002 Oct 27, 2014AB ZYDUS PHARMS 0.5MG A201676 003 Jan 08, 2014SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

+ MERCK SHARP DOHME EQ 25MG BASE N021995 001 Oct 16, 2006

+ EQ 50MG BASE N021995 002 Oct 16, 2006

+! EQ 100MG BASE N021995 003 Oct 16, 2006

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

FRESENIUS KABI USA 4MEQ/ML A206687 001 Oct 30, 2017

+! HOSPIRA 2MEQ/ML N018893 001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

AMMONULAP +! MEDICIS 10%;10% (5GM/50ML;5GM/50ML) N020645 001 Feb 17, 2005SODIUM PHENYLACETATE AND SODIUM BENZOATEAP AILEX PHARMS LLC 10%;10% (5GM/50ML;5GM/50ML) A207096 001 Feb 24, 2016AP MAIA PHARMS INC 10%;10% (5GM/50ML;5GM/50ML) A208521 001 May 08, 2017AP NAVINTA LLC 10%;10% (5GM/50ML;5GM/50ML) A205880 001 Aug 04, 2016SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATEAP EXELA PHARMA SCS 0.5MEQ/ML A211091 001 Jun 20, 2019AP 0.9MEQ/ML A211091 002 Jun 20, 2019AP 1MEQ/ML A211091 003 Jun 20, 2019AP ! HOSPIRA 0.9MEQ/ML A077394 001 Nov 09, 2005AP ! 1MEQ/ML A077394 002 Nov 09, 2005AP HOSPIRA INC 0.5MEQ/ML A202981 001 Mar 04, 2016AP 0.9MEQ/ML A202494 001 Mar 06, 2017AP 1MEQ/ML A202432 001 Sep 26, 2017AP 1MEQ/ML A202494 002 Mar 06, 2017AP INTL MEDICATION SYS 1MEQ/ML A203449 001 Sep 19, 2017

HOSPIRA INC 1MEQ/ML A202495 001 Mar 06, 2017

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP FRESENIUS KABI USA 9MG/ML A088911 001 Feb 07, 1985AP +! HOSPIRA 9MG/ML N018800 001 Oct 29, 1982SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINERAP + B BRAUN 450MG/100ML N019635 001 Mar 09, 1988AP BAXTER HLTHCARE 450MG/100ML N018016 001AP FRESENIUS KABI USA 450MG/100ML A208122 001 Jul 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>450MG/100ML</u>	<u>N019759</u>	<u>001</u>	Jun 08, 1988
<u>AP</u>	+! ICU MEDICAL INC	<u>450MG/100ML</u>	<u>N018090</u>	<u>001</u>	

SODIUM CHLORIDE 0.9%

<u>AP</u>	SPECTRA MDCL DEVICES	<u>9MG/ML</u>	<u>A206171</u>	<u>001</u>	Jul 21, 2017
<u>AP</u>	WEST-WARD PHARMS INT	<u>9MG/ML</u>	<u>A201850</u>	<u>001</u>	Jan 20, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+! B BRAUN	<u>900MG/100ML</u>	<u>N017464</u>	<u>001</u>	
<u>AP</u>	+! BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N019635</u>	<u>002</u>	Mar 09, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N016677</u>	<u>004</u>	Oct 30, 1985
<u>AP</u>	+ BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N020178</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+! BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N016677</u>	<u>001</u>	
<u>AP</u>	+! BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N020178</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	! FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088912</u>	<u>001</u>	Jan 10, 1985
<u>AP</u>	FRESENIUS KABI USA	<u>900MG/100ML</u>	<u>A207310</u>	<u>001</u>	Sep 19, 2017
<u>AP</u>	FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177</u>	<u>001</u>	Apr 12, 2007
<u>AP</u>	HAEMONETICS	<u>900MG/100ML</u>	<u>A076316</u>	<u>001</u>	Oct 27, 2004
<u>AP</u>	+! HOSPIRA	<u>9MG/ML</u>	<u>N018803</u>	<u>001</u>	Oct 29, 1982
<u>AP</u>	+ HOSPIRA	<u>9MG/ML</u>	<u>N019465</u>	<u>002</u>	Jul 15, 1985
<u>AP</u>	+! HOSPIRA	<u>900MG/100ML</u>	<u>N019465</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+! HOSPIRA	<u>900MG/100ML</u>	<u>N019480</u>	<u>001</u>	Sep 17, 1985
<u>AP</u>	+! ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N016366</u>	<u>001</u>	
<u>AP</u>	JUBILANT CADISTA	<u>9MG/ML</u>	<u>A203352</u>	<u>001</u>	May 18, 2016
<u>AP</u>	LABORATORIOS GRIFOLS	<u>900MG/100ML</u>	<u>A207956</u>	<u>001</u>	May 25, 2017
<u>AP</u>	! TARO	<u>9MG/ML</u>	<u>A077407</u>	<u>001</u>	Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>3GM/100ML</u>	<u>N019635</u>	<u>003</u>	Mar 09, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>3GM/100ML</u>	<u>N019022</u>	<u>001</u>	Nov 01, 1983
<u>AP</u>	FRESENIUS KABI USA	<u>3GM/100ML</u>	<u>A209476</u>	<u>001</u>	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N019635</u>	<u>004</u>	Mar 09, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N019022</u>	<u>002</u>	Nov 01, 1983
SODIUM CHLORIDE 0.9%					
	+ B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016
	+ MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
	WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+ LIEBEL-FLARSHEIM	1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006
SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>	+! B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	
<u>AT</u>	ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	
<u>AT</u>	ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985
-----------------	-------------	---------	-----	--------------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

<u>AB</u>	+! SANOFI AVENTIS US	<u>62.5MG/5ML</u>	<u>N020955</u>	<u>001</u>	Feb 18, 1999
-----------	----------------------	-------------------	----------------	------------	--------------

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

<u>AB</u>	WEST-WARD PHARMS INT	<u>62.5MG/5ML</u>	<u>A078215</u>	<u>001</u>	Mar 31, 2011
-----------	-------------------------	-------------------	----------------	------------	--------------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

<u>AP</u>	3D IMAGING DRUG	<u>10-200mCi/ML</u>	<u>A203777</u>	<u>001</u>	Oct 19, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>10-200mCi/ML</u>	<u>A204351</u>	<u>001</u>	Jan 09, 2015
<u>AP</u>	CARDINAL HEALTH 414	<u>10-200mCi/ML</u>	<u>A203780</u>	<u>001</u>	Jul 30, 2015
<u>AP</u>	DECATUR	<u>10-200mCi/ML</u>	<u>A204464</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>10-200mCi/ML</u>	<u>A204541</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	HOT SHOTS NM LLC	<u>10-200mCi/ML</u>	<u>A204530</u>	<u>001</u>	Jul 29, 2015

PRESCRIPTION DRUG PRODUCT LIST

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

<u>AP</u>	JUBILANT DRAXIMAGE	<u>10-200mCi/ML</u>	<u>A203968 001</u>	Oct 23, 2015
<u>AP</u>	KREITCHMAN PET CTR	<u>10-200mCi/ML</u>	<u>A203936 001</u>	May 19, 2016
<u>AP</u>	MIDWEST MEDCL	<u>10-200mCi/ML</u>	<u>A204440 001</u>	Nov 17, 2015
<u>AP</u>	MIPS CRF	<u>10-200mCi/ML</u>	<u>A204517 001</u>	Jul 21, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>10-200mCi/ML</u>	<u>A204513 001</u>	Nov 28, 2014
<u>AP</u>	PETNET	<u>10-200mCi/ML</u>	<u>A203890 001</u>	Sep 28, 2015
<u>AP</u>	PRECISION NUCLEAR	<u>10-200mCi/ML</u>	<u>A204542 001</u>	Feb 27, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>10-200mCi/ML</u>	<u>A204315 001</u>	Sep 22, 2014
<u>AP</u>	SOFIE	<u>10-200mCi/ML</u>	<u>A203592 001</u>	Aug 18, 2015
<u>AP</u>	!	<u>10-200mCi/ML</u>	<u>A203544 001</u>	Dec 26, 2012
<u>AP</u>	SPECTRON MRC LLC	<u>10-200mCi/ML</u>	<u>A203912 001</u>	Apr 22, 2015
<u>AP</u>	UCSF RODIOPHARM	<u>10-200mCi/ML</u>	<u>A204437 001</u>	Mar 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>10-200mCi/ML</u>	<u>A204497 001</u>	Apr 20, 2015
!	MCPRF	10-91.5mCi/ML	A203605 001	Jun 28, 2013
	THE FEINSTEIN INST	20-600mCi/ML	A204328 001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

<u>AA</u>	+!	CARDINAL HEALTH 418	<u>100uCi</u>	<u>N018671 001</u>	May 27, 1982
<u>AA</u>	+!		<u>200uCi</u>	<u>N018671 002</u>	May 27, 1982
<u>AA</u>		MALLINKRODT NUCLEAR	<u>100uCi</u>	<u>A071909 001</u>	Feb 28, 1989
<u>AA</u>			<u>200uCi</u>	<u>A071910 001</u>	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ JUBILANT DRAXIMAGE 0.009-0.1mCi N021305 006 May 19, 2005

SOLUTION; ORAL

HICON

+! JUBILANT DRAXIMAGE 250-1000mCi N021305 007 Dec 05, 2011

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

+! HOSPIRA 5MEQ/ML N018947 001 Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+! HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+! HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML) N201444 001 Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESSAP ! HOSPIRA 25MG/ML A071961 001 Aug 01, 1988SODIUM NITROPRUSSIDEAP AKORN 25MG/ML A208635 001 May 04, 2017AP AMNEAL 25MG/ML A209493 001 Nov 07, 2017AP AMPHASTAR PHARMS 25MG/ML A209832 001 Dec 18, 2017

INC

AP CAPLIN 25MG/ML A211016 001 Nov 29, 2019AP CIPLA 25MG/ML A210855 001 Jul 16, 2018AP DR REDDYS LABS LTD 25MG/ML A210114 001 Apr 10, 2019AP MEDICURE 25MG/ML A209584 001 Aug 10, 2018AP MICRO LABS 25MG/ML A209352 001 Dec 08, 2017AP MYLAN LABS LTD 25MG/ML A210763 001 Apr 17, 2018AP NEXUS PHARMS 25MG/ML A207499 001 May 25, 2017AP SAGENT PHARMS INC 25MG/ML A207426 001 Dec 08, 2016AP SOMERSET THERAPS 25MG/ML A210882 001 Aug 17, 2018

LLC

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+! EXELA PHARMA SCS 20MG/100ML (0.2MG/ML) N209387 003 Jul 13, 2018

+! LLC 50MG/100ML (0.5MG/ML) N209387 001 Mar 08, 2017

PRESCRIPTION DRUG PRODUCT LIST

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA	+	HIKMA	500MG/ML	A202090 001	Jan 17, 2017
		XYREM			
AA	+	JAZZ PHARMS	500MG/ML	N021196 001	Jul 17, 2002

SODIUM PHENYL BUTYRATE

POWDER;ORAL

BUPHENYL

AB	+	HORIZON THERAP	3GM/TEASPOONFUL	N020573 001	Apr 30, 1996
-----------	----------	----------------	------------------------	--------------------	--------------

SODIUM PHENYL BUTYRATE

AB		PAR PHARM	3GM/TEASPOONFUL	A203918 001	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819 001	Mar 22, 2013

TABLET;ORAL

BUPHENYL

AB	+	HORIZON THERAP	500MG	N020572 001	May 13, 1996
-----------	----------	----------------	--------------	--------------------	--------------

SODIUM PHENYL BUTYRATE

AB		ALVOGEN	500MG	A090910 001	Nov 18, 2011
AB		PAR PHARM	500MG	A204395 001	Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

OSMOPREP

+	SALIX PHARMS	0.398GM;1.102GM	N021892 001	Mar 16, 2006
----------	--------------	-----------------	--------------------	--------------

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+	HOSPIRA	142MG/ML;276MG/ML	N018892 001	May 10, 1983
----------	---------	-------------------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	!	KVK TECH	454GM/BOT	A040905 001	Mar 30, 2009
-----------	----------	----------	------------------	--------------------	--------------

KIONEX

AA		PADDOCK LLC	454GM/BOT	A040029 001	Feb 06, 1998
-----------	--	-------------	------------------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	454GM/BOT	A205727 001	Feb 23, 2016
AA		CMP PHARMA INC	454GM/BOT	A089910 001	Jan 19, 1989
AA		ECI PHARMS LLC	453.6GM/BOT	A090313 001	Dec 21, 2011
AA		EPIC PHARMA LLC	453.6GM/BOT	A202333 001	Mar 19, 2014
AA		NOVELGENIX THERAPS	454GM/BOT	A206815 001	Feb 18, 2016
AA		NUVO PHARMS INC	454GM/BOT	A204071 001	Nov 28, 2014

KALEXATE

	KVK TECH	15GM/BOT	A040905 002	Apr 03, 2015
--	----------	----------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

	NUVO PHARMS INC	15GM/BOT	A204071 002	Nov 28, 2014
--	-----------------	----------	--------------------	--------------

SUSPENSION;ORAL, RECTAL

KIONEX

AA		PADDOCK LLC	15GM/60ML	A040028 001	Sep 17, 2007
-----------	--	-------------	------------------	--------------------	--------------

SODIUM POLYSTYRENE SULFONATE

AA		HIKMA	15GM/60ML	A089049 001	Nov 17, 1986
AA		PADDOCK LLC	15GM/60ML	A090590 001	May 13, 2011

SPS

AA	!	CMP PHARMA INC	15GM/60ML	A087859 001	Dec 08, 1982
-----------	----------	----------------	------------------	--------------------	--------------

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		CUSTOPHARM INC	60MG/2ML (30MG/ML)	A209937 001	Dec 09, 2019
-----------	--	----------------	---------------------------	--------------------	--------------

SOTRADECOL

AP	!	MYLAN INSTITUTIONAL	60MG/2ML (30MG/ML)	A040541 002	Nov 12, 2004
	!		20MG/2ML (10MG/ML)	A040541 001	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923 001	Feb 14, 2012
----------	-------------	------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

+	ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018
+	!	10GM/PACKET	N207078	002	May 18, 2018

SOFOBUVIR

PELLETS;ORAL

SOVALDI

+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019
+	!	200MG/PACKET	N212480	002	Aug 28, 2019

TABLET;ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019
+	!	400MG	N204671	001	Dec 06, 2013

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016
---	---------------------	-------------	---------	-----	--------------

SOFOBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

+	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017
---	---------------------	-------------------	---------	-----	--------------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019
AB		10MG	A205483	002	May 20, 2019
AB	ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019
AB		10MG	A205575	002	May 20, 2019
AB	ALKEM LABS LTD	5MG	A210224	001	May 20, 2019
AB		10MG	A210224	002	May 20, 2019
AB	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019
AB		10MG	A209719	002	May 20, 2019
AB	BRECKENRIDGE	5MG	A209818	001	May 20, 2019
AB		10MG	A209818	002	May 20, 2019
AB	CELLTRION	5MG	A210582	001	May 20, 2019
AB		10MG	A210582	002	May 20, 2019
AB	CIPLA	5MG	A209839	001	May 20, 2019
AB		10MG	A209839	002	May 20, 2019
AB	CSPC OUYI	5MG	A211423	001	Dec 11, 2019
AB		10MG	A211423	002	Dec 11, 2019
AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019
AB		10MG	A209239	002	May 20, 2019
AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019
AB		10MG	A210281	002	May 20, 2019
AB	MSN	5MG	A210688	001	May 20, 2019
AB		10MG	A210688	002	May 20, 2019
AB	QILU	5MG	A209333	001	May 20, 2019
AB		10MG	A209333	002	May 20, 2019
AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019
AB		10MG	A211657	002	May 20, 2019
AB	STRIDES PHARMA	5MG	A212214	001	Sep 26, 2019
AB		10MG	A212214	002	Sep 26, 2019
AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014
AB		10MG	A091464	002	Apr 02, 2014
AB	UNICHEM LABS LTD	5MG	A211701	001	Aug 27, 2019
AB		10MG	A211701	002	Aug 27, 2019
AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019
AB		10MG	A202551	002	May 20, 2019
<u>VESICARE</u>					
AB	+	ASTELLAS	5MG	N021518	001 Nov 19, 2004
AB	+	!	10MG	N021518	002 Nov 19, 2004

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019
+		150MG	N211230	002	Jun 17, 2019

PRESCRIPTION DRUG PRODUCT LIST

SOMATROPIN

INJECTABLE; INJECTION						
GENOTROPIN						
BX	+	PHARMACIA	5.8MG/VIAL	N020280	006	Aug 24, 1995
NORDITROPIN FLEXPRO						
BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
BX			10MG/1.5ML	N021148	009	Mar 01, 2010
OMNITROPE						
BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
BX			5MG/1.5ML	N021426	003	Jan 16, 2008
BX			5.8MG/VIAL	N021426	001	May 30, 2006
BX			10MG/1.5ML	N021426	004	Aug 25, 2008
SAIZEN						
BX	+	EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
SEROSTIM						
BX		EMD SERONO	5MG/VIAL	N020604	002	Aug 23, 1996
BX			6MG/VIAL	N020604	001	Aug 23, 1996
ZOMACTON						
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
GENOTROPIN						
	+	PHARMACIA	13.8MG/VIAL	N020280	007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE						
	+	PHARMACIA	0.2MG/VIAL	N020280	001	Jan 27, 1998
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998
	+		1MG/VIAL	N020280	008	Jan 27, 1998
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998
	+		2MG/VIAL	N020280	013	Jan 27, 1998
NORDITROPIN FLEXPRO						
		NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
			30MG/3ML	N021148	011	Jan 23, 2015
NUTROPIN AQ NUSPIN						
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
SAIZEN						
	+	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
SEROSTIM						
		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
ZOMACTON						
	+	FERRING	10MG/VIAL	N019774	003	Mar 07, 2012

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION						
HUMATROPE						
BX	+	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
BX	+		6MG/VIAL	N019640	005	Feb 04, 1999
	+		12MG/VIAL	N019640	006	Feb 04, 1999
	+		24MG/VIAL	N019640	007	Feb 04, 1999
ZORBTIVE						
	+	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SONIDEGIB PHOSPHATE

CAPSULE; ORAL						
ODOMZO						
	+	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015

SORAFENIB TOSYLATE

TABLET; ORAL						
NEXAVAR						
	+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION; IRRIGATION						
SORBITOL 3% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	3GM/100ML	N017863	001	
SORBITOL 3.3% IN PLASTIC CONTAINER						
		B BRAUN	3.3GM/100ML	N016741	001	

PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+	!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009
---	---	-------------------------	----------------------	---------	-----	--------------

SOLUTION; ORAL

SOTYLIZE

+	!	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014
---	---	------------------	-----------------	---------	-----	--------------

TABLET; ORAL

BETAPACE

AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992
AB	+		120MG	N019865	005	Apr 20, 1994
AB	+	!	160MG	N019865	002	Oct 30, 1992
AB	+		240MG	N019865	003	Oct 30, 1992

BETAPACE AF

AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000
AB	+		120MG	N021151	002	Feb 22, 2000
AB	+	!	160MG	N021151	003	Feb 22, 2000

SORINE

AB		UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001
AB			120MG	A075500	004	Apr 27, 2001
AB			160MG	A075500	002	Apr 27, 2001
AB			240MG	A075500	003	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB		APOTEX	80MG	A076140	001	Sep 26, 2002
AB			80MG	A076214	001	Aug 27, 2003
AB			120MG	A076140	002	Sep 26, 2002
AB			120MG	A076214	002	Aug 27, 2003
AB			160MG	A076140	003	Sep 26, 2002
AB			160MG	A076214	003	Aug 27, 2003
AB			240MG	A076140	004	Sep 26, 2002
AB		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016
AB			80MG	A207429	001	Nov 02, 2018
AB			120MG	A207428	002	Oct 21, 2016
AB			120MG	A207429	002	Nov 02, 2018
AB			160MG	A207428	003	Oct 21, 2016
AB			160MG	A207429	003	Nov 02, 2018
AB		EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005
AB			120MG	A077070	002	Nov 04, 2005
AB			160MG	A077070	003	Nov 04, 2005
AB		MYLAN	80MG	A077616	001	Feb 07, 2007
AB			120MG	A077616	002	Feb 07, 2007
AB			160MG	A077616	003	Feb 07, 2007
AB		OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003
AB			120MG	A075563	002	Nov 07, 2003
AB			160MG	A075563	003	Nov 07, 2003
AB			240MG	A075563	004	Nov 07, 2003
AB		TEVA	80MG	A075429	001	May 01, 2000
AB			120MG	A075429	002	May 01, 2000
AB			160MG	A075429	003	May 01, 2000
AB			240MG	A075429	004	May 01, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

AP	+	!	FRESENIUS	10%	N017643	001
-----------	---	---	-----------	------------	----------------	------------

INTRALIPID 20%

AP	+	!	FRESENIUS	20%	N018449	001
-----------	---	---	-----------	------------	----------------	------------

AP	+	!		20%	N020248	001	Aug 07, 1996
-----------	---	---	--	------------	----------------	------------	--------------

NUTRILIPID 10%

AP	+	!	B BRAUN	10%	N019531	001	May 28, 1993
-----------	---	---	---------	------------	----------------	------------	--------------

NUTRILIPID 20%

AP	+	!	B BRAUN	20%	N019531	002	May 28, 1993
-----------	---	---	---------	------------	----------------	------------	--------------

INTRALIPID 30%

+	!	FRESENIUS	30%	N019942	001	Dec 30, 1993
---	---	-----------	-----	---------	-----	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	!	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011
---	---	-------------	------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

SPIRONOLACTONE

SUSPENSION; ORAL

CAROSPIR

+! CMP DEV LLC

25MG/5ML

N209478 001 Aug 04, 2017

TABLET; ORAL

ALDACTONEAB + GD SEARLE LLC25MGN012151 009 Dec 30, 1983AB +50MGN012151 008 Dec 30, 1982AB +!100MGN012151 010 Dec 30, 1983SPIRONOLACTONEAB ACCORD HLTHCARE25MGA203512 001 Sep 19, 2016AB50MGA203512 002 Sep 19, 2016AB100MGA203512 003 Sep 19, 2016AB AMNEAL PHARMS25MGA091426 001 Jul 02, 2010AB50MGA091426 002 Jul 02, 2010AB100MGA091426 003 Jul 02, 2010AB JUBILANT GENERICS25MGA203253 001 Apr 23, 2014AB50MGA203253 002 Apr 23, 2014AB100MGA203253 003 Apr 23, 2014AB MYLAN25MGA040424 001 Aug 20, 2001AB50MGA040424 002 Aug 20, 2001AB100MGA040424 003 Aug 20, 2001AB OXFORD PHARMS25MGA040750 001 Aug 29, 2006AB50MGA040750 002 Aug 29, 2006AB100MGA040750 003 Aug 29, 2006AB SUN PHARM25MGA089424 001 Jul 23, 1986

INDUSTRIES

AB50MGA089424 002 Aug 11, 1999AB100MGA089424 003 Aug 11, 1999AB ZYDUS PHARMS25MGA205936 001 Jul 18, 2018AB50MGA205936 002 Jul 18, 2018AB100MGA205936 003 Jul 18, 2018STAVUDINE

CAPSULE; ORAL

STAVUDINEAB AUROBINDO PHARMA15MGA077672 003 Dec 29, 2008AB20MGA077672 004 Dec 29, 2008AB30MGA077672 001 Dec 29, 2008AB40MGA077672 002 Dec 29, 2008ZERITAB + BRISTOL MYERS15MGN020412 002 Jun 24, 1994

SQUIBB

AB +20MGN020412 003 Jun 24, 1994AB +30MGN020412 004 Jun 24, 1994AB +!40MGN020412 005 Jun 24, 1994STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINERAP +! HOSPIRA100%N018802 001 Oct 27, 1982STERILE WATER FOR INJECTIONAP FRESENIUS KABI USA100%A209689 001 Nov 24, 2017AP +! HOSPIRA100% (10ML)N018801 002 Oct 27, 1982AP MEDEFIL INC100% (10ML)A211188 005 Dec 02, 2019AP WEST-WARD PHARMS100% (10ML)A206369 001 Sep 02, 2015

INT

STERILE WATER FOR INJECTION IN PLASTIC CONTAINERAP +! B BRAUN100%N019633 001 Feb 29, 1988AP +! BAXTER HLTHCARE100%N018632 001 Jun 30, 1982AP +!100%N018632 002 Apr 19, 1988AP FRESENIUS KABI USA100%A088400 001 Jan 16, 1984AP +! ICU MEDICAL INC100%N018233 001AP +!100%N019869 001 Dec 26, 1989AP TARO100%A077393 001 Aug 11, 2006STERILE WATER FOR INJECTION

+! HOSPIRA

100% (20ML)

N018801 003 Oct 27, 1982

+!

100% (50ML)

N018801 004 Oct 27, 1982

+!

100% (100ML)

N018801 005 Oct 27, 1982

MEDEFIL INC

100% (1ML)

A211188 001 Dec 02, 2019

!

100% (2.5ML)

A211188 002 Dec 02, 2019

!

100% (3ML)

A211188 003 Dec 02, 2019

!

100% (5ML)

A211188 004 Dec 02, 2019

PRESCRIPTION DRUG PRODUCT LIST

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER**AT** + BAXTER HLTHCARE **100%** **N017428 001**STERILE WATER IN PLASTIC CONTAINER**AT** + B BRAUN **100%** **N016734 001****AT** BAXTER HLTHCARE **100%** **N017866 001****AT** ICU MEDICAL INC **100%** **N017513 001****AT** **100%** **N018313 001**STIRIPENTOL

CAPSULE; ORAL

DIACOMIT

+ BIOCDEX SA 250MG N206709 001 Aug 20, 2018

+! 500MG N206709 002 Aug 20, 2018

FOR SUSPENSION; ORAL

DIACOMIT

+ BIOCDEX SA 250MG/PACKET N207223 001 Aug 20, 2018

+! 500MG/PACKET N207223 002 Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

! X GEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+! TEVA PHARMS USA 1GM/VIAL N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON**AP** +! Q BIOMED **1mCi/ML** **N020134 001** Jun 18, 1993STRONTIUM CHLORIDE SR-89**AP** Q BIOMED **1mCi/ML** **A075941 001** Jan 06, 2003SUCCIMER

CAPSULE; ORAL

CHEMET

+! RECORDATI RARE 100MG N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE**AP** +! SANDOZ INC **20MG/ML** **N008453 002**QUELICIN**AP** +! HOSPIRA **20MG/ML** **N008845 006**SUCCINYLCHOLINE CHLORIDE**AP** AMNEAL **20MG/ML** **A211432 001** Nov 16, 2018**AP** AMRING PHARMS **20MG/ML** **A210231 001** Jun 04, 2018**AP** BRECKENRIDGE **20MG/ML** **A212638 001** Oct 09, 2019**AP** DR REDDYS **20MG/ML** **A210698 001** Aug 02, 2019**AP** SOMERSET THERAPS **20MG/ML** **A211589 001** Jan 15, 2020**AP** ! ZYDUS PHARMS **20MG/ML** **A209467 001** May 04, 2018**AP** ! ZYDUS PHARMS **20MG/ML** **A209467 001** May 04, 2018SUCRALFATE

SUSPENSION; ORAL

CARAFATE**AB** +! ALLERGAN **1GM/10ML** **N019183 001** Dec 16, 1993SUCRALFATE**AB** AMNEAL PHARMS LLC **1GM/10ML** **A209356 001** Dec 02, 2019

TABLET; ORAL

CARAFATE**AB** +! ALLERGAN **1GM** **N018333 001**SUCRALFATE**AB** TEVA **1GM** **A070848 001** Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+! VIFOR FRESENIUS 500MG N205109 001 Nov 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE

AP	+!	AKORN	EQ 0.05MG BASE/ML	N019050 001	May 04, 1984
-----------	-----------	--------------	--------------------------	--------------------	--------------

SUFENTANIL CITRATE

AP		HOSPIRA	EQ 0.05MG BASE/ML	A074534 001	Dec 11, 1996
-----------	--	----------------	--------------------------	--------------------	--------------

AP		WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A074413 001	Dec 15, 1995
-----------	--	---------------------------------	--------------------------	--------------------	--------------

TABLET; SUBLINGUAL

DSUVIA

+!	ACELRX PHARMS	EQ 0.03MG BASE	N209128 001	Nov 02, 2018
-----------	----------------------	-----------------------	--------------------	--------------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225 002	Dec 15, 2015
----------	--------------------------	---	--------------------	--------------

+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225 001	Dec 15, 2015
-----------	--	---	--------------------	--------------

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+!	JOURNEY	1%	N018737 001	Feb 28, 1989
-----------	----------------	-----------	--------------------	--------------

SOLUTION; TOPICAL

EXELDERM

+!	JOURNEY	1%	N018738 001	Aug 30, 1985
-----------	----------------	-----------	--------------------	--------------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

AB	+!	VALEANT PHARMS NORTH	10%	N019931 001	Dec 23, 1996
-----------	-----------	---------------------------------	------------	--------------------	--------------

SULFACETAMIDE SODIUM

AB		FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006
-----------	--	-----------------------	------------	--------------------	--------------

AB		PERRIGO CO TENNESSEE	10%	A078649 001	Mar 23, 2009
-----------	--	---------------------------------	------------	--------------------	--------------

AB		TARO	10%	A078668 001	May 20, 2009
-----------	--	-------------	------------	--------------------	--------------

OINTMENT; OPHTHALMIC

SULFACETAMIDE SODIUM

!	PERRIGO CO TENNESSEE	10%	A080029 001	
----------	---------------------------------	------------	--------------------	--

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

AT	!	ALLERGAN	10%	A080028 001	
-----------	----------	-----------------	------------	--------------------	--

SULFACETAMIDE SODIUM

AT		AKORN	10%	A040215 001	May 25, 1999
-----------	--	--------------	------------	--------------------	--------------

AT		BAUSCH AND LOMB	10%	A040066 001	Dec 28, 1994
-----------	--	------------------------	------------	--------------------	--------------

AT		SANDOZ INC	10%	A089560 001	Oct 18, 1988
-----------	--	-------------------	------------	--------------------	--------------

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

!	SANDOZ	500MG	A040091 001	Jul 29, 1994
----------	---------------	--------------	--------------------	--------------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	!	MYLAN LABS LTD	80MG/ML; 16MG/ML	A206607 001	Aug 30, 2017
-----------	----------	-----------------------	-------------------------	--------------------	--------------

AP		SOMERSET	80MG/ML; 16MG/ML	A212231 001	Jun 26, 2019
-----------	--	-----------------	-------------------------	--------------------	--------------

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		ANI PHARMS INC	200MG/5ML; 40MG/5ML	A077612 001	Nov 13, 2006
-----------	--	-----------------------	----------------------------	--------------------	--------------

AB		AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348 001	Jun 08, 2010
-----------	--	-------------------------	----------------------------	--------------------	--------------

AB	!	HI TECH PHARMA	200MG/5ML; 40MG/5ML	A074650 001	Dec 29, 1997
-----------	----------	-----------------------	----------------------------	--------------------	--------------

AB		LANNETT CO INC	200MG/5ML; 40MG/5ML	A077785 001	Jan 24, 2007
-----------	--	-----------------------	----------------------------	--------------------	--------------

SULFATRIM PEDIATRIC

AB		PHARM ASSOC	200MG/5ML; 40MG/5ML	N018615 001	Jan 07, 1983
-----------	--	--------------------	----------------------------	--------------------	--------------

TABLET; ORAL

BACTRIM

AB	+	SUN PHARM INDUSTRIES	400MG; 80MG	N017377 001	
-----------	----------	---------------------------------	--------------------	--------------------	--

BACTRIM DS

AB	+!	SUN PHARM INDUSTRIES	800MG; 160MG	N017377 002	
-----------	-----------	---------------------------------	---------------------	--------------------	--

SEPTRA

AB		MONARCH PHARMS	400MG; 80MG	N017376 001	
-----------	--	-----------------------	--------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SEPTRA DS

AB	MONARCH PHARMS	800MG;160MG	N017376 002	
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	AMNEAL PHARMS NY	400MG;80MG	A076899 001	Jan 27, 2005
AB		800MG;160MG	A076899 002	Jan 27, 2005
AB	AUROBINDO PHARMA	400MG;80MG	A090624 001	Feb 16, 2010
AB		800MG;160MG	A090624 002	Feb 16, 2010
AB	CHARTWELL MOLECULES	400MG;80MG	A078060 002	Jan 25, 2007
AB		800MG;160MG	A078060 001	Jan 25, 2007
AB	GLENMARK GENERICS	400MG;80MG	A090828 002	Dec 22, 2010
AB		800MG;160MG	A090828 001	Dec 22, 2010
AB	SUN PHARM INDUSTRIES	400MG;80MG	A071017 002	Aug 25, 1986
AB		800MG;160MG	A071017 001	Aug 25, 1986
AB	VISTA PHARMS	400MG;80MG	A076817 001	Oct 07, 2005
AB		800MG;160MG	A076817 002	Oct 07, 2005

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MYLAN SPECIALITY LP	15%	N006530 003	Jan 27, 1987
---	---------------------	-----	-------------	--------------

SULFASALAZINE

TABLET; ORAL

AZULFIDINE

AB	+	PHARMACIA AND UPJOHN	500MG	N007073 001	
SULFASALAZINE					
AB		VINTAGE PHARMS	500MG	A040349 001	Jan 11, 2002
AB		WATSON LABS	500MG	A085828 001	

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

AB	+	PHARMACIA AND UPJOHN	500MG	N007073 002	Apr 06, 1983
SULFASALAZINE					
AB		VINTAGE PHARMS	500MG	A075339 001	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+	BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014
---	--------	-------------	-------------	--------------

SULINDAC

TABLET; ORAL

SULINDAC

AB		EPIC PHARMA	150MG	A072710 001	Mar 25, 1991
AB			200MG	A072711 001	Mar 25, 1991
AB		MYLAN	150MG	A073039 002	Jun 22, 1993
AB			200MG	A073039 001	Jun 22, 1993
AB		SUN PHARM INDUSTRIES	150MG	A072050 001	Apr 17, 1991
AB			200MG	A072051 001	Apr 17, 1991
AB		WATSON LABS	150MG	A071891 001	Apr 03, 1990
AB	!		200MG	A071795 001	Apr 03, 1990

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626 001	Aug 26, 1997
AB	+		20MG/SPRAY	N020626 003	Aug 26, 1997
SUMATRIPTAN					
AB		LANNETT CO INC	5MG/SPRAY	A204841 001	Feb 19, 2016
AB			20MG/SPRAY	A204841 002	Feb 19, 2016
TOSYMRA					
+	UPHER SMITH LABS	10MG/SPRAY	N210884 001	Jan 25, 2019	

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080 002	Feb 01, 2006
AB	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996
SUMATRIPTAN SUCCINATE					
AB		ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078319 001	Dec 10, 2015
AB			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078319 002	Dec 10, 2015

PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

<u>AB</u>	DR REDDYS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495 001</u>	Jan 29, 2014
<u>AB</u>	SUN PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358 001</u>	Jun 21, 2011

IMITREX

<u>AP</u>	+! GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 001</u>	Dec 28, 1992
-----------	--------------------	--	--------------------	--------------

SUMATRIPTAN SUCCINATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758 001</u>	Apr 23, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242 001</u>	Mar 02, 2009
<u>AP</u>	HIKMA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183 001</u>	Sep 16, 2013
<u>AP</u>	MYLAN ASI	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314 001</u>	Jun 10, 2010
<u>AP</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641 001</u>	Jul 28, 2010
<u>AP</u>	PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332 001</u>	Oct 09, 2009
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123 001</u>	Feb 06, 2009
<u>AP</u>	WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593 001</u>	Feb 06, 2009

POWDER; NASAL

ONZETRA XSAIL

+! CURRAX

EQ 11MG BASE

N206099 001 Jan 27, 2016

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+ UPSHER SMITH LABS

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N208223 001 Jan 28, 2016

TABLET; ORAL

IMITREX

<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132 002</u>	Jun 01, 1995
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N020132 003</u>	Jun 01, 1995
<u>AB</u>	+!	<u>EQ 100MG BASE</u>	<u>N020132 001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263 001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200263 002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200263 003</u>	Jun 19, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

+ CPPI CV

EQ 12.5MG BASE

N021938 001 Jan 26, 2006

+

EQ 25MG BASE

N021938 002 Jan 26, 2006

+

EQ 37.5MG BASE

N021938 004 Mar 31, 2009

+!

EQ 50MG BASE

N021938 003 Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

+ MERCK SHARP DOHME

5MG

N204569 001 Aug 13, 2014

+

10MG

N204569 002 Aug 13, 2014

+

15MG

N204569 003 Aug 13, 2014

+!

20MG

N204569 004 Aug 13, 2014

PRESCRIPTION DRUG PRODUCT LIST

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	+	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>	+		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	!	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>		BELCHER PHARMS LLC	<u>EQ 0.5MG BASE</u>	<u>A206651 001</u>	Nov 30, 2017
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A206651 002</u>	Nov 30, 2017
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A206651 003</u>	Nov 30, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>		MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>		PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>		SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>		STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096 001	Jul 19, 2013
+		EQ 1MG BASE	N204096 002	Jul 19, 2013
+	!	EQ 5MG BASE	N204096 003	Jul 19, 2013

FOR SUSPENSION; ORAL

PROGRAF

+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115 001	May 24, 2018
+	!	EQ 1MG BASE/PACKET	N210115 002	May 24, 2018

INJECTABLE; INJECTION

PROGRAF

<u>AP</u>	+	!	ASTELLAS	<u>EQ 5MG BASE/ML</u>	<u>N050709 001</u>	Apr 08, 1994
-----------	---	---	----------	-----------------------	--------------------	--------------

TACROLIMUS

<u>AP</u>			HOSPIRA INC	<u>EQ 5MG BASE/ML</u>	<u>A203900 001</u>	Aug 25, 2017
-----------	--	--	-------------	-----------------------	--------------------	--------------

OINTMENT; TOPICAL

PROTOPIC

<u>AB</u>	+	!	LEO PHARMA AS	<u>0.03%</u>	<u>N050777 001</u>	Dec 08, 2000
<u>AB</u>	+	!		<u>0.1%</u>	<u>N050777 002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>			ACCORD HLTHCARE	<u>0.03%</u>	<u>A211688 001</u>	Jan 31, 2019
<u>AB</u>				<u>0.1%</u>	<u>A211688 002</u>	Jan 31, 2019
<u>AB</u>			FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744 001</u>	Sep 09, 2014
<u>AB</u>				<u>0.1%</u>	<u>A200744 002</u>	Sep 09, 2014
<u>AB</u>			GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A210393 001</u>	Apr 16, 2018

TABLET, EXTENDED RELEASE; ORAL

ENVARUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406 001	Jul 10, 2015
+		EQ 1MG BASE	N206406 002	Jul 10, 2015
+	!	EQ 4MG BASE	N206406 003	Jul 10, 2015

TADALAFIL

TABLET; ORAL

CIALIS

<u>AB</u>	+	LILLY	<u>2.5MG</u>	<u>N021368 004</u>	Jan 07, 2008
<u>AB</u>	+		<u>5MG</u>	<u>N021368 001</u>	Nov 21, 2003
<u>AB</u>	+		<u>10MG</u>	<u>N021368 002</u>	Nov 21, 2003

TADALAFIL

<u>AB</u>			ACCORD HLTHCARE	<u>2.5MG</u>	<u>A209167 001</u>	Mar 26, 2019
<u>AB</u>				<u>5MG</u>	<u>A209167 002</u>	Mar 26, 2019
<u>AB</u>			AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A209654 001</u>	Mar 26, 2019
<u>AB</u>				<u>5MG</u>	<u>A209654 002</u>	Mar 26, 2019
<u>AB</u>				<u>10MG</u>	<u>A209654 003</u>	Mar 26, 2019
<u>AB</u>			ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204809 001</u>	Mar 26, 2019
<u>AB</u>				<u>5MG</u>	<u>A204809 002</u>	Mar 26, 2019
<u>AB</u>				<u>10MG</u>	<u>A204809 003</u>	Mar 26, 2019

PRESCRIPTION DRUG PRODUCT LIST

TADALAFIL

TABLET; ORAL

TADALAFIL

<u>AB</u>	AMNEAL PHARMS CO	<u>2.5MG</u>	<u>A209744 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209744 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209744 003</u>	Mar 26, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A206285 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A206285 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A206285 003</u>	Mar 26, 2019
<u>AB</u>	CIPLA	<u>2.5MG</u>	<u>A209539 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209539 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209539 003</u>	Mar 26, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A210069 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210069 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210069 003</u>	Mar 26, 2019
<u>AB</u>	HETERO LABS LTD III	<u>2.5MG</u>	<u>A209908 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209908 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209908 003</u>	Mar 26, 2019
<u>AB</u>	LUPIN LTD	<u>2.5MG</u>	<u>A210567 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210567 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210567 003</u>	Mar 26, 2019
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A207244 001</u>	Oct 07, 2019
<u>AB</u>		<u>5MG</u>	<u>A207244 002</u>	Oct 07, 2019
<u>AB</u>		<u>10MG</u>	<u>A207244 003</u>	Oct 07, 2019
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A206956 001</u>	Apr 29, 2019
<u>AB</u>		<u>5MG</u>	<u>A206957 001</u>	Apr 29, 2019
<u>AB</u>		<u>10MG</u>	<u>A206956 002</u>	Apr 29, 2019
<u>AB</u>	QILU	<u>2.5MG</u>	<u>A210420 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A210420 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A210420 003</u>	Mar 26, 2019
<u>AB</u>	SUN PHARM	<u>2.5MG</u>	<u>A208934 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A208934 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A208934 003</u>	Mar 26, 2019
<u>AB</u>	SUNSHINE LAKE	<u>2.5MG</u>	<u>A211335 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A211335 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A211335 003</u>	Mar 26, 2019
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090141 001</u>	May 22, 2018
<u>AB</u>		<u>5MG</u>	<u>A090141 002</u>	May 22, 2018
<u>AB</u>		<u>10MG</u>	<u>A090141 003</u>	May 22, 2018
<u>AB</u>	TORRENT	<u>2.5MG</u>	<u>A211839 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A211839 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A211839 003</u>	Mar 26, 2019
<u>AB</u>	UNICHEM LABS LTD	<u>2.5MG</u>	<u>A209250 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A209250 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A209250 003</u>	Mar 26, 2019
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A206693 001</u>	Mar 26, 2019
<u>AB</u>		<u>5MG</u>	<u>A206693 002</u>	Mar 26, 2019
<u>AB</u>		<u>10MG</u>	<u>A206693 003</u>	Mar 26, 2019

CTALIS

<u>AB1</u>	+! LILLY	<u>20MG</u>	<u>N021368 003</u>	Nov 21, 2003
------------	----------	-------------	--------------------	--------------

TADALAFIL

<u>AB1</u>	ACCORD HLTHCARE	<u>20MG</u>	<u>A209167 004</u>	Mar 26, 2019
<u>AB1</u>	AJANTA PHARMA LTD	<u>20MG</u>	<u>A209654 004</u>	Mar 26, 2019
<u>AB1</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A204809 004</u>	Mar 26, 2019
<u>AB1</u>	AMNEAL PHARMS CO	<u>20MG</u>	<u>A209744 004</u>	Mar 26, 2019
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206285 004</u>	Mar 26, 2019
<u>AB1</u>	CIPLA	<u>20MG</u>	<u>A209539 004</u>	Mar 26, 2019
<u>AB1</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A210069 004</u>	Mar 26, 2019
<u>AB1</u>	HETERO LABS LTD III	<u>20MG</u>	<u>A209908 004</u>	Mar 26, 2019
<u>AB1</u>	LUPIN LTD	<u>20MG</u>	<u>A210567 004</u>	Mar 26, 2019
<u>AB1</u>	MACLEODS PHARMS LTD	<u>20MG</u>	<u>A207244 004</u>	Oct 07, 2019
<u>AB1</u>	MYLAN	<u>20MG</u>	<u>A206956 003</u>	Apr 29, 2019
<u>AB1</u>	QILU	<u>20MG</u>	<u>A210420 004</u>	Mar 26, 2019
<u>AB1</u>	SUN PHARM	<u>20MG</u>	<u>A208934 004</u>	Mar 26, 2019
<u>AB1</u>	SUNSHINE LAKE	<u>20MG</u>	<u>A211335 004</u>	Mar 26, 2019
<u>AB1</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A090141 004</u>	May 22, 2018
<u>AB1</u>	TORRENT	<u>20MG</u>	<u>A211839 004</u>	Mar 26, 2019
<u>AB1</u>	UNICHEM LABS LTD	<u>20MG</u>	<u>A209250 004</u>	Mar 26, 2019
<u>AB1</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A206693 004</u>	Mar 26, 2019

PRESCRIPTION DRUG PRODUCT LIST

TADALAFIL

TABLET;ORAL

ADCIRCA**AB2** +! ELI LILLY CO **20MG** **N022332 001** May 22, 2009ALYO**AB2** TEVA PHARMS USA **20MG** **A209942 001** Feb 05, 2019TADALAFIL**AB2** AJANTA PHARMA LTD **20MG** **A210392 001** Feb 05, 2019**AB2** AUROBINDO PHARMA LTD **20MG** **A206286 001** Feb 05, 2019**AB2** CIPLA **20MG** **A210255 001** Feb 05, 2019**AB2** DR REDDYS LABS LTD **20MG** **A210145 001** Feb 05, 2019**AB2** HETERO LABS LTD III **20MG** **A209907 001** Feb 05, 2019**AB2** LUPIN LTD **20MG** **A210572 001** Feb 05, 2019**AB2** MACLEODS PHARMS LTD **20MG** **A207290 001** Oct 16, 2019**AB2** MYLAN **20MG** **A200630 001** Aug 03, 2018**AB2** TORRENT **20MG** **A212062 001** Mar 26, 2019TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

+! FOLDRX PHARMS 61MG N212161 001 May 03, 2019

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

+! FOLDRX PHARMS 20MG N211996 001 May 03, 2019

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

+! 60 DEGREES PHARMS EQ 100MG BASE N210607 001 Aug 08, 2018

KRINTAFEL

+! GLAXOSMITHKLINE EQ 150MG BASE N210795 001 Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST**AT** MICRO LABS **0.0015%** **A209051 001** Aug 19, 2019ZIOPATAN**AT** +! OAK PHARMS INC **0.0015%** **N202514 001** Feb 10, 2012TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

+ PFIZER INC EQ 0.25MG BASE N211651 001 Oct 16, 2018

+! EQ 1MG BASE N211651 002 Oct 16, 2018

TALC

AEROSOL;INTRAPLEURAL

SCLEROSOL

+! LYMOL MEDCL 4GM/SPRAY N020587 001 Dec 24, 1997

POWDER;INTRAPLEURAL

STERITALC

+ NOVATECH SA 2GM/VIAL N205555 001 May 01, 2017

+ 3GM/VIAL N205555 002 May 01, 2017

+! 4GM/VIAL N205555 003 May 01, 2017

TALC

+! LYMOL MEDCL 5GM/BOT N021388 001 Dec 15, 2003

TALIGLUCERASE ALFA

POWDER;INTRAVENOUS

ELELYSO

+! PFIZER 200 UNITS/VIAL N022458 001 May 01, 2012

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

FORTOVIA EQ 20MG BASE/10ML N021807 001 Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE**AB** ACTAVIS LABS FL INC **EQ 10MG BASE** **A070929 001** Feb 20, 2003**AB** **EQ 20MG BASE** **A070929 002** Feb 20, 2003**AB** APOTEX **EQ 10MG BASE** **A090878 001** Sep 23, 2011**AB** **EQ 20MG BASE** **A090878 002** Sep 23, 2011**AB** MAYNE PHARMA **EQ 10MG BASE** **A075797 001** Feb 20, 2003**AB** ! **EQ 20MG BASE** **A075797 002** Feb 20, 2003

PRESCRIPTION DRUG PRODUCT LIST

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074732 002</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A074732 001</u>	Feb 20, 2003
<u>AB</u>	ZYDUS PHARMS	<u>EQ 10MG BASE</u>	<u>A206694 001</u>	Oct 27, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206694 002</u>	Oct 27, 2017

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

<u>AB</u>	+!	SANOFI AVENTIS US	<u>0.4MG</u>	<u>N020579 001</u>	Apr 15, 1997
-----------	----	-------------------	--------------	--------------------	--------------

TAMSULOSIN HYDROCHLORIDE

<u>AB</u>		ALKEM LABS LTD	<u>0.4MG</u>	<u>A207405 001</u>	Aug 11, 2017
<u>AB</u>		ANBISON LAB	<u>0.4MG</u>	<u>A211885 001</u>	Oct 17, 2019
<u>AB</u>		ANCHEN PHARMS	<u>0.4MG</u>	<u>A202010 001</u>	Jan 04, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.4MG</u>	<u>A202433 001</u>	Apr 30, 2013
<u>AB</u>		IMPAX LABS	<u>0.4MG</u>	<u>A090377 001</u>	Mar 02, 2010
<u>AB</u>		MACLEODS PHARMS LTD	<u>0.4MG</u>	<u>A204645 001</u>	Jan 20, 2017
<u>AB</u>		SANDOZ	<u>0.4MG</u>	<u>A078015 001</u>	Apr 27, 2010
<u>AB</u>		SUN PHARM INDS LTD	<u>0.4MG</u>	<u>A090931 001</u>	Jul 15, 2010
<u>AB</u>		SYNTHON PHARMS	<u>0.4MG</u>	<u>A078801 001</u>	Apr 27, 2010
<u>AB</u>		TEVA PHARMS	<u>0.4MG</u>	<u>A077630 001</u>	Apr 27, 2010
<u>AB</u>		WOCKHARDT	<u>0.4MG</u>	<u>A078938 001</u>	Apr 27, 2010
<u>AB</u>		ZYDUS PHARMS USA INC	<u>0.4MG</u>	<u>A078225 001</u>	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

NUCYNTA

	+	DEPO NF	EQ 50MG BASE	N022304 001	Nov 20, 2008
	+		EQ 75MG BASE	N022304 002	Nov 20, 2008
	+		EQ 100MG BASE	N022304 003	Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

	+	DEPO NF	EQ 50MG BASE	N200533 001	Aug 25, 2011
	+		EQ 100MG BASE	N200533 002	Aug 25, 2011
	+		EQ 150MG BASE	N200533 003	Aug 25, 2011
	+		EQ 200MG BASE	N200533 004	Aug 25, 2011
	+		EQ 250MG BASE	N200533 005	Aug 25, 2011

TASIMELTEON

CAPSULE; ORAL

HETLIOZ

	+	VANDA PHARMS INC	20MG	N205677 001	Jan 31, 2014
--	---	------------------	------	-------------	--------------

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

	+	ANACOR PHARMS INC	5%	N204427 001	Jul 07, 2014
--	---	-------------------	----	-------------	--------------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

	+	MAYNE PHARMA	0.1%	N202428 001	May 11, 2012
--	---	--------------	------	-------------	--------------

CREAM; TOPICAL

AVAGE

<u>AB</u>	+	ALLERGAN	<u>0.1%</u>	<u>N021184 003</u>	Sep 30, 2002
-----------	---	----------	-------------	--------------------	--------------

TAZAROTENE

<u>AB</u>		ACP NIMBLE	<u>0.1%</u>	<u>A208662 001</u>	Dec 22, 2017
<u>AB</u>		TARO PHARMS	<u>0.1%</u>	<u>A208258 001</u>	Apr 03, 2017

TAZORAC

<u>AB</u>	+	ALLERGAN	<u>0.1%</u>	<u>N021184 002</u>	Sep 29, 2000
	+		0.05%	N021184 001	Sep 29, 2000

GEL; TOPICAL

TAZORAC

	+	ALLERGAN	0.05%	N020600 001	Jun 13, 1997
	+		0.1%	N020600 002	Jun 13, 1997

LOTION; TOPICAL

ARAZLO

	+	BAUSCH	0.045%	N211882 001	Dec 18, 2019
--	---	--------	--------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS +! DRAXIMAGE N/A N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

+! LANTHEUS MEDCL N/A

N020256 001 Nov 23, 1994

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+! GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

POWDER; INTRAVENOUS

DRAX EXAMETAZIME

JUBILANT DRAXIMAGE N/A

N208870 001 Aug 17, 2017

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC**AP +! BRACCO N/A****N018963 001** Jan 21, 1987**TECHNETIUM TC-99M MEBROFENIN****AP PHARMALUCENCE N/A****A078242 001** Jan 29, 2008TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+! JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP

PHARMALUCENCE N/A

N018124 001

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3**AP +! CURIUM N/A****N019882 001** Jun 15, 1990**TECHNETIUM TC99M MERTIATIDE KIT****AP PHARMALUCENCE N/A****A208994 001** Jul 12, 2019TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+! CURIUM N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

DRAXIMAGE DTPA

+! JUBILANT DRAXIMAGE N/A

N018511 001 Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO**AP PHARMALUCENCE N/A****N019039 001** Jun 30, 1987**TECHNESCAN PYP KIT****AP CURIUM N/A****N017538 001**TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

+! CURIUM N/A

N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE**AP +! LANTHEUS MEDCL N/A****N019785 001** Dec 21, 1990**TECHNETIUM TC 99M SESTAMIBI****AP CARDINAL HEALTH 414 N/A****A078809 001** Apr 28, 2009**AP JUBILANT DRAXIMAGE N/A****A078806 001** Apr 29, 2009**AP MALLINKRODT NUCLEAR N/A****A078098 001** Sep 22, 2008**AP PHARMALUCENCE 10-30mCi****A079157 001** Jul 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

TECHNELITE

+! LANTHEUS MEDCL 1-20 CI/GENERATOR N017771 002 Feb 12, 2014

ULTRA-TECHNEKOW FM

+! CURIUM 1-19 CI/GENERATOR N017243 003 Feb 18, 2014

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC

RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR N202158 001 Feb 08, 2018

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

AN-SULFUR COLLOID

+! PHARMALUCENCE N/A N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEV 30ML

+! GE HEALTHCARE N/A N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

+! CARDINAL HEALTH 414 N/A N202207 001 Mar 13, 2013

TECOVIRIMAT

CAPSULE;ORAL

TPOXX

+! SIGA TECHNOLOGIES 200MG N208627 001 Jul 13, 2018

TEDIZOLID PHOSPHATE

POWDER;INTRAVENOUS

SIVEXTRO

+! CUBIST PHARMS LLC 200MG/VIAL N205436 001 Jun 20, 2014

TABLET;ORAL

SIVEXTRO

+! CUBIST PHARMS LLC 200MG N205435 001 Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER;SUBCUTANEOUS

GATTEX KIT

+! NPS PHARMS INC 5MG/VIAL N203441 001 Dec 21, 2012

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+! ALFASIGMA EQ 6MG BASE N021200 002 Jul 24, 2002

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+! CUMBERLAND PHARMS EQ 750MG BASE/VIAL N022110 002 Sep 11, 2009

TELMISARTAN

TABLET;ORAL

MICARDIS**AB + BOEHRINGER 20MG N020850 003 Apr 04, 2000**
INGELHEIM**AB + 40MG N020850 001 Nov 10, 1998****AB +! 80MG N020850 002 Nov 10, 1998****TELMISARTAN****AB ALEMbic PHARMS LTD 20MG A202130 001 Jul 07, 2014****AB 40MG A202130 002 Jul 07, 2014****AB 80MG A202130 003 Jul 07, 2014****AB AMNEAL PHARMS 20MG A204415 001 Sep 08, 2015****AB 40MG A204415 002 Sep 08, 2015****AB 80MG A204415 003 Sep 08, 2015****AB AUROBINDO PHARMA 20MG A206511 001 Sep 03, 2015**
LTD**AB 40MG A206511 002 Sep 03, 2015****AB 80MG A206511 003 Sep 03, 2015****AB CADILA PHARMS LTD 20MG A208605 001 Jul 25, 2017****AB 40MG A208605 002 Jul 25, 2017****AB 80MG A208605 003 Jul 25, 2017****AB GLENMARK PHARMS LTD 20MG A090032 001 Jul 07, 2014****AB 40MG A090032 002 Jul 07, 2014****AB 80MG A090032 003 Jul 07, 2014**

PRESCRIPTION DRUG PRODUCT LIST

TELMISARTAN

TABLET; ORAL

TELMISARTAN

<u>AB</u>	HETERO LABS LTD V	<u>20MG</u>	<u>A205901 001</u>	Apr 22, 2016
<u>AB</u>		<u>40MG</u>	<u>A205901 002</u>	Apr 22, 2016
<u>AB</u>		<u>80MG</u>	<u>A205901 003</u>	Apr 22, 2016
<u>AB</u>	INVENTIA	<u>20MG</u>	<u>A205150 001</u>	Oct 30, 2015
<u>AB</u>		<u>40MG</u>	<u>A205150 002</u>	Oct 30, 2015
<u>AB</u>		<u>80MG</u>	<u>A205150 003</u>	Oct 30, 2015
<u>AB</u>	JUBILANT GENERICS	<u>20MG</u>	<u>A204164 001</u>	Aug 22, 2016
<u>AB</u>		<u>40MG</u>	<u>A204164 002</u>	Aug 22, 2016
<u>AB</u>		<u>80MG</u>	<u>A204164 003</u>	Aug 22, 2016
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A202397 001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A202397 002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A202397 003</u>	Jul 07, 2014
<u>AB</u>	PRINSTON INC	<u>20MG</u>	<u>A207882 001</u>	May 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A207882 002</u>	May 03, 2017
<u>AB</u>		<u>80MG</u>	<u>A207882 003</u>	May 03, 2017
<u>AB</u>	SANDOZ INC	<u>20MG</u>	<u>A203867 001</u>	Nov 03, 2014
<u>AB</u>		<u>40MG</u>	<u>A203867 002</u>	Nov 03, 2014
<u>AB</u>		<u>80MG</u>	<u>A203867 003</u>	Nov 03, 2014
<u>AB</u>	TORRENT	<u>20MG</u>	<u>A203171 001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A203171 002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A203171 003</u>	Jul 07, 2014
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A203325 001</u>	Aug 26, 2014
<u>AB</u>		<u>40MG</u>	<u>A203325 002</u>	Aug 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A203325 003</u>	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET; ORAL

XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE N208794 001 Feb 28, 2017

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	+ SPECGX LLC	<u>7.5MG</u>	<u>N018163 003</u>	Oct 25, 1991
<u>AB</u>	+	<u>15MG</u>	<u>N018163 001</u>	
<u>AB</u>	+	<u>22.5MG</u>	<u>N018163 004</u>	Nov 02, 2004
<u>AB</u>	+!	<u>30MG</u>	<u>N018163 002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071620 002</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620 001</u>	Aug 07, 1987
<u>AB</u>	ALEMBIC PHARMS LTD	<u>7.5MG</u>	<u>A211542 001</u>	Nov 23, 2018
<u>AB</u>		<u>15MG</u>	<u>A211542 002</u>	Nov 23, 2018
<u>AB</u>		<u>22.5MG</u>	<u>A211542 003</u>	Nov 23, 2018
<u>AB</u>		<u>30MG</u>	<u>A211542 004</u>	Nov 23, 2018
<u>AB</u>	AMNEAL PHARMS	<u>7.5MG</u>	<u>A203482 001</u>	May 23, 2016
<u>AB</u>		<u>15MG</u>	<u>A203482 002</u>	May 23, 2016
<u>AB</u>		<u>22.5MG</u>	<u>A203482 003</u>	May 23, 2016
<u>AB</u>		<u>30MG</u>	<u>A203482 004</u>	May 23, 2016
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A070920 002</u>	May 21, 2010
<u>AB</u>		<u>15MG</u>	<u>A070920 004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920 003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920 001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>7.5MG</u>	<u>A071457 002</u>	Jun 22, 2012
<u>AB</u>		<u>15MG</u>	<u>A071456 001</u>	Apr 21, 1987
<u>AB</u>		<u>22.5MG</u>	<u>A071457 003</u>	Jun 22, 2012
<u>AB</u>		<u>30MG</u>	<u>A071457 001</u>	Apr 21, 1987
<u>AB</u>	PRINSTON INC	<u>7.5MG</u>	<u>A201781 001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781 002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781 003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781 004</u>	Jun 04, 2015
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427 001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428 001</u>	Jan 12, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>7.5MG</u>	<u>A078581 001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175 002</u>	Sep 14, 2009

PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029</u>	<u>001</u>	Aug 11, 1999
<u>AB</u>	+		<u>20MG</u>	<u>N021029</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>	+		<u>100MG</u>	<u>N021029</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	+		<u>140MG</u>	<u>N021029</u>	<u>005</u>	Oct 19, 2006
<u>AB</u>	+		<u>180MG</u>	<u>N021029</u>	<u>006</u>	Oct 19, 2006
<u>AB</u>	+		<u>250MG</u>	<u>N021029</u>	<u>004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A201528</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>			<u>20MG</u>	<u>A201528</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>			<u>100MG</u>	<u>A201528</u>	<u>003</u>	Feb 27, 2017
<u>AB</u>			<u>140MG</u>	<u>A201528</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>			<u>180MG</u>	<u>A201528</u>	<u>005</u>	Feb 27, 2017
<u>AB</u>			<u>250MG</u>	<u>A201528</u>	<u>006</u>	Feb 27, 2017
<u>AB</u>		AMERIGEN PHARMS LTD	<u>5MG</u>	<u>A203490</u>	<u>001</u>	Jul 13, 2016
<u>AB</u>			<u>20MG</u>	<u>A203490</u>	<u>002</u>	Jul 13, 2016
<u>AB</u>			<u>100MG</u>	<u>A203490</u>	<u>003</u>	Jul 13, 2016
<u>AB</u>			<u>140MG</u>	<u>A203490</u>	<u>004</u>	Jul 13, 2016
<u>AB</u>			<u>180MG</u>	<u>A203490</u>	<u>005</u>	Jul 13, 2016
<u>AB</u>			<u>250MG</u>	<u>A203490</u>	<u>006</u>	Jul 13, 2016
<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A203691</u>	<u>001</u>	May 08, 2015
<u>AB</u>			<u>20MG</u>	<u>A203691</u>	<u>002</u>	May 08, 2015
<u>AB</u>			<u>100MG</u>	<u>A203691</u>	<u>003</u>	May 08, 2015
<u>AB</u>			<u>140MG</u>	<u>A203691</u>	<u>004</u>	May 08, 2015
<u>AB</u>			<u>180MG</u>	<u>A203691</u>	<u>005</u>	May 08, 2015
<u>AB</u>			<u>250MG</u>	<u>A203691</u>	<u>006</u>	May 08, 2015
<u>AB</u>		BARR	<u>5MG</u>	<u>A078879</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>			<u>20MG</u>	<u>A078879</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>			<u>100MG</u>	<u>A078879</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>			<u>140MG</u>	<u>A078879</u>	<u>005</u>	Mar 01, 2010
<u>AB</u>			<u>180MG</u>	<u>A078879</u>	<u>006</u>	Mar 01, 2010
<u>AB</u>			<u>250MG</u>	<u>A078879</u>	<u>004</u>	Mar 01, 2010
<u>AB</u>		CHEMI SPA	<u>5MG</u>	<u>A204639</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>			<u>20MG</u>	<u>A204639</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>			<u>100MG</u>	<u>A204639</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>			<u>140MG</u>	<u>A204639</u>	<u>004</u>	Nov 23, 2016
<u>AB</u>			<u>180MG</u>	<u>A204639</u>	<u>005</u>	Nov 23, 2016
<u>AB</u>			<u>250MG</u>	<u>A204639</u>	<u>006</u>	Nov 23, 2016
<u>AB</u>		DEVA HOLDING AS	<u>5MG</u>	<u>A207658</u>	<u>001</u>	Apr 26, 2017
<u>AB</u>			<u>20MG</u>	<u>A207658</u>	<u>002</u>	Apr 26, 2017
<u>AB</u>			<u>100MG</u>	<u>A207658</u>	<u>003</u>	Apr 26, 2017
<u>AB</u>			<u>140MG</u>	<u>A207658</u>	<u>004</u>	Apr 26, 2017
<u>AB</u>			<u>180MG</u>	<u>A207658</u>	<u>005</u>	Apr 26, 2017
<u>AB</u>			<u>250MG</u>	<u>A207658</u>	<u>006</u>	Apr 26, 2017
<u>AB</u>		IDT AUSTRALIA LTD	<u>5MG</u>	<u>A206413</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>			<u>20MG</u>	<u>A206413</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>			<u>100MG</u>	<u>A206413</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>			<u>140MG</u>	<u>A206413</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>			<u>180MG</u>	<u>A206413</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>			<u>250MG</u>	<u>A206413</u>	<u>006</u>	Apr 12, 2016
<u>AB</u>		RISING	<u>5MG</u>	<u>A206309</u>	<u>001</u>	Apr 27, 2016
<u>AB</u>			<u>20MG</u>	<u>A206309</u>	<u>002</u>	Apr 27, 2016
<u>AB</u>			<u>100MG</u>	<u>A206309</u>	<u>003</u>	Apr 27, 2016
<u>AB</u>			<u>140MG</u>	<u>A206309</u>	<u>004</u>	Apr 27, 2016
<u>AB</u>			<u>180MG</u>	<u>A206309</u>	<u>005</u>	Apr 27, 2016
<u>AB</u>			<u>250MG</u>	<u>A206309</u>	<u>006</u>	Apr 27, 2016
<u>AB</u>		SUN PHARM	<u>5MG</u>	<u>A201742</u>	<u>001</u>	Feb 12, 2014
<u>AB</u>			<u>20MG</u>	<u>A201742</u>	<u>002</u>	Feb 12, 2014
<u>AB</u>			<u>100MG</u>	<u>A201742</u>	<u>003</u>	Feb 12, 2014
<u>AB</u>			<u>140MG</u>	<u>A201742</u>	<u>004</u>	Feb 12, 2014
<u>AB</u>			<u>180MG</u>	<u>A201742</u>	<u>005</u>	Feb 12, 2014
<u>AB</u>			<u>250MG</u>	<u>A201742</u>	<u>006</u>	Feb 12, 2014
<u>AB</u>		WATSON LABS TEVA	<u>5MG</u>	<u>A203959</u>	<u>001</u>	Apr 18, 2017
<u>AB</u>			<u>20MG</u>	<u>A203959</u>	<u>002</u>	Apr 18, 2017
<u>AB</u>			<u>100MG</u>	<u>A203959</u>	<u>003</u>	Apr 18, 2017
<u>AB</u>			<u>140MG</u>	<u>A203959</u>	<u>004</u>	Apr 18, 2017
<u>AB</u>			<u>250MG</u>	<u>A203959</u>	<u>005</u>	Apr 18, 2017
<u>AB</u>		ZYDUS PHARMS	<u>5MG</u>	<u>A206750</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>			<u>20MG</u>	<u>A206750</u>	<u>002</u>	Jul 31, 2017
<u>AB</u>			<u>100MG</u>	<u>A206750</u>	<u>003</u>	Jul 31, 2017

PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

<u>AB</u>		<u>140MG</u>	<u>A206750 004</u>	Jul 31, 2017
<u>AB</u>		<u>180MG</u>	<u>A206750 005</u>	Jul 31, 2017
<u>AB</u>		<u>250MG</u>	<u>A206750 006</u>	Jul 31, 2017

POWDER; INTRAVENOUS

TEMODAR

+	!	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009
---	---	-------------------	------------	-------------	--------------

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUS

<u>AP</u>		ACCORD HLTHCARE	<u>25MG/ML (25MG/ML)</u>	<u>A203153 001</u>	Jul 30, 2018
<u>AP</u>		GLAND PHARMA LTD	<u>25MG/ML (25MG/ML)</u>	<u>A207383 001</u>	Aug 16, 2019

TORISEL

<u>AP</u>	+	!	PF PRISM CV	<u>25MG/ML (25MG/ML)</u>	<u>N022088 001</u>	May 30, 2007
-----------	---	---	-------------	--------------------------	--------------------	--------------

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

+	!	ARDELYX INC	EQ 50MG BASE	N211801 001	Sep 12, 2019
---	---	-------------	--------------	-------------	--------------

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

VEMLIDY

+	!	GILEAD SCIENCES INC	EQ 25MG BASE	N208464 001	Nov 10, 2016
---	---	---------------------	--------------	-------------	--------------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012
---	---	---------------------	---------------	-------------	--------------

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A090647 001</u>	Jan 26, 2018
<u>AB</u>			<u>200MG</u>	<u>A090647 002</u>	Jan 26, 2018
<u>AB</u>			<u>250MG</u>	<u>A090647 003</u>	Jan 26, 2018
<u>AB</u>			<u>300MG</u>	<u>A090647 004</u>	Jan 26, 2018
<u>AB</u>		CASI PHARMS INC	<u>300MG</u>	<u>A209550 001</u>	Feb 26, 2018
<u>AB</u>		CIPLA	<u>300MG</u>	<u>A078800 001</u>	Jan 26, 2018
<u>AB</u>		HETERO LABS LTD III	<u>300MG</u>	<u>A090636 001</u>	Jan 26, 2018
<u>AB</u>		MACLEODS PHARMS LTD	<u>300MG</u>	<u>A203232 001</u>	Jan 26, 2018
<u>AB</u>		MYLAN	<u>150MG</u>	<u>A206569 001</u>	Nov 27, 2018
<u>AB</u>			<u>200MG</u>	<u>A206569 002</u>	Nov 27, 2018
<u>AB</u>			<u>250MG</u>	<u>A206569 003</u>	Nov 27, 2018
<u>AB</u>			<u>300MG</u>	<u>A206569 004</u>	Nov 27, 2018
<u>AB</u>		QILU	<u>200MG</u>	<u>A209498 001</u>	Mar 02, 2018
<u>AB</u>			<u>250MG</u>	<u>A209498 002</u>	Mar 02, 2018
<u>AB</u>			<u>300MG</u>	<u>A209498 003</u>	Mar 02, 2018
<u>AB</u>		STRIDES PHARMA	<u>300MG</u>	<u>A090742 001</u>	Jan 26, 2018
<u>AB</u>		TEVA PHARMS USA	<u>150MG</u>	<u>A091612 002</u>	Jan 26, 2018
<u>AB</u>			<u>200MG</u>	<u>A091612 003</u>	Jan 26, 2018
<u>AB</u>			<u>250MG</u>	<u>A091612 004</u>	Jan 26, 2018
<u>AB</u>			<u>300MG</u>	<u>A091612 001</u>	Mar 18, 2015
		<u>VIREAD</u>			
<u>AB</u>	+	GILEAD SCIENCES INC	<u>150MG</u>	<u>N021356 002</u>	Jan 18, 2012
<u>AB</u>	+		<u>200MG</u>	<u>N021356 003</u>	Jan 18, 2012
<u>AB</u>	+		<u>250MG</u>	<u>N021356 004</u>	Jan 18, 2012
<u>AB</u>	+	!	<u>300MG</u>	<u>N021356 001</u>	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>		APNAR PHARMA LP	<u>EQ 1MG BASE</u>	<u>A074823 001</u>	Mar 30, 1998
<u>AB</u>	!		<u>EQ 2MG BASE</u>	<u>A074823 002</u>	Mar 30, 1998
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A074823 003</u>	Mar 30, 1998
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A074823 004</u>	Mar 30, 1998
<u>AB</u>		HERITAGE PHARMA	<u>EQ 1MG BASE</u>	<u>A075614 002</u>	Jan 30, 2001
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075614 001</u>	Jan 30, 2001
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A075614 003</u>	Jan 30, 2001
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A075614 004</u>	Jan 30, 2001
<u>AB</u>		HIKMA	<u>EQ 1MG BASE</u>	<u>A075498 001</u>	Apr 12, 2001
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075498 002</u>	Apr 12, 2001
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A075498 003</u>	Apr 12, 2001

PRESCRIPTION DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498 004</u>	Apr 12, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317 001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317 002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317 003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317 004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140 002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140 003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140 001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140 004</u>	Feb 11, 2000

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

LAMISIL

<u>AB</u>	+!	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539 001</u>	May 10, 1996
-----------	----	----------	----------------------	--------------------	--------------

TERBINAFINE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297 001</u>	Jul 02, 2007
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714 001</u>	Jun 04, 2010
<u>AB</u>		CIPLA	<u>EQ 250MG BASE</u>	<u>A077137 001</u>	Jul 02, 2007
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390 001</u>	Jul 02, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157 001</u>	Jul 02, 2007
<u>AB</u>		HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919 001</u>	Jul 02, 2007
<u>AB</u>		HERITAGE PHARMA	<u>EQ 250MG BASE</u>	<u>A076377 001</u>	Jul 02, 2007
<u>AB</u>		INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533 001</u>	Jul 02, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163 001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>		AKORN	<u>1MG/ML</u>	<u>A078151 001</u>	Jan 07, 2008
<u>AP</u>	!	ATHENEX INC	<u>1MG/ML</u>	<u>A076770 001</u>	Apr 23, 2004
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887 001</u>	May 26, 2004
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630 001</u>	May 20, 2009
<u>AP</u>		UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122 001</u>	Nov 08, 2013

TABLET; ORAL

BRETHINE

<u>AB</u>	+	ANI PHARMS INC	<u>2.5MG</u>	<u>N017849 001</u>	
<u>AB</u>	+		<u>5MG</u>	<u>N017849 002</u>	
<u>AB</u>		IMPAX LABS	<u>2.5MG</u>	<u>A075877 001</u>	Jun 26, 2001
<u>AB</u>			<u>5MG</u>	<u>A075877 002</u>	Jun 26, 2001
<u>AB</u>		LANNETT CO INC	<u>2.5MG</u>	<u>A077152 001</u>	Mar 25, 2005
<u>AB</u>	!		<u>5MG</u>	<u>A077152 002</u>	Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.4%</u>	<u>A076712 001</u>	Feb 18, 2005
<u>AB</u>	!	TARO	<u>0.4%</u>	<u>A076043 001</u>	Jan 19, 2005
<u>BX</u>	+!	FOUGERA PHARMS INC	0.8%	N021735 001	Oct 01, 2004
<u>BX</u>	!	TARO	0.8%	A075953 001	Apr 06, 2004

SUPPOSITORY; VAGINAL

TERCONAZOLE

<u>AB</u>	!	PERRIGO ISRAEL	<u>80MG</u>	<u>A077149 001</u>	Mar 17, 2006
<u>AB</u>		TARO	<u>80MG</u>	<u>A077553 001</u>	Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

<u>AB</u>	+	SANOFI AVENTIS US	<u>7MG</u>	<u>N202992 001</u>	Sep 12, 2012
<u>AB</u>	+!		<u>14MG</u>	<u>N202992 002</u>	Sep 12, 2012

TERIFLUNOMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>7MG</u>	<u>A209690 001</u>	Jan 07, 2019
<u>AB</u>			<u>14MG</u>	<u>A209690 002</u>	Jan 07, 2019
<u>AB</u>		ALEMBIC PHARMS LTD	<u>7MG</u>	<u>A209572 001</u>	Apr 19, 2019
<u>AB</u>			<u>14MG</u>	<u>A209572 002</u>	Apr 19, 2019
<u>AB</u>		GLENMARK PHARMS	<u>7MG</u>	<u>A209663 001</u>	Nov 15, 2018
<u>AB</u>			<u>14MG</u>	<u>A209663 002</u>	Nov 15, 2018
<u>AB</u>		SANDOZ INC	<u>7MG</u>	<u>A209710 001</u>	Jan 03, 2019
<u>AB</u>			<u>14MG</u>	<u>A209710 002</u>	Jan 03, 2019

PRESCRIPTION DRUG PRODUCT LIST

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008

SOLUTION; SUBCUTANEOUS

BONSITY

ALVOGEN 0.62MG/2.48ML (0.25MG/ML) N211939 001 Oct 04, 2019

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+! THERATECHNOLOGIES EQ 1MG BASE/VIAL N022505 001 Nov 10, 2010

+! EQ 2MG BASE/VIAL N022505 002 Nov 29, 2011

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+! ALLERGAN 2MG/24HR N020489 003 Oct 20, 2011

+! 4MG/24HR N020489 004 Oct 20, 2011

GEL; TRANSDERMAL

ANDROGELAB1 + ABBVIE 25MG/2.5GM PACKET N021015 001 Feb 28, 2000AB1 +! 50MG/5GM PACKET N021015 002 Feb 28, 2000TESTOSTERONEAB1 ACTAVIS LABS UT INC 25MG/2.5GM PACKET A076737 001 Jan 27, 2006AB1 50MG/5GM PACKET A076737 002 Jan 27, 2006AB1 PAR PHARM 50MG/5GM PACKET A076744 002 May 23, 2007ANDROGELAB2 + ABBVIE 1.62% (20.25MG/1.25GM PACKET) N022309 002 Sep 07, 2012AB2 +! 1.62% (40.5MG/2.5GM PACKET) N022309 003 Sep 07, 2012TESTIMAB2 +! AUXILIUM PHARMS LLC 50MG/5GM PACKET N021454 001 Oct 31, 2002TESTOSTERONEAB2 ACTAVIS LABS UT INC 50MG/5GM PACKET A091073 001 Sep 18, 2017AB2 PERRIGO UK FINCO 1.62% (20.25MG/1.25GM PACKET) A205781 001 Jul 12, 2017AB2 1.62% (40.5MG/2.5GM PACKET) A205781 002 Jul 12, 2017VOGELXOAB2 UPSHER SMITH LABS 50MG/5GM PACKET N204399 002 Jun 04, 2014

GEL, METERED; NASAL

NATESTO

ACERUS 5.5MG/0.122GM ACTUATION N205488 001 May 28, 2014

GEL, METERED; TRANSDERMAL

ANDROGELAB +! ABBVIE 1.62% (20.25MG/1.25GM ACTUATION) N022309 001 Apr 29, 2011AB +! 12.5MG/1.25GM ACTUATION N021015 003 Sep 26, 2003FORTESTAAB +! ENDO PHARMS 10MG/0.5GM ACTUATION N021463 001 Dec 29, 2010TESTOSTERONEAB ACTAVIS LABS UT INC 1.62% (20.25MG/1.25GM ACTUATION) A204570 001 Apr 10, 2019AB 10MG/0.5GM ACTUATION A204571 001 Aug 05, 2015AB 12.5MG/1.25GM ACTUATION A076737 003 Mar 09, 2015AB AMNEAL PHARMS LLC 1.62% (20.25MG/1.25GM ACTUATION) A207373 001 Apr 10, 2019AB DR REDDYS 1.62% (20.25MG/1.25GM ACTUATION) A208620 001 Apr 10, 2019AB LUPIN ATLANTIS 1.62% (20.25MG/1.25GM ACTUATION) A208560 001 Apr 10, 2019AB PERRIGO ISRAEL 1.62% (20.25MG/1.25GM ACTUATION) A204268 001 Aug 04, 2015AB TWI PHARMS 1.62% (20.25MG/1.25GM ACTUATION) A209390 001 Sep 23, 2019

VOGELXO

BX UPSHER SMITH LABS 12.5MG/1.25GM ACTUATION N204399 003 Jun 04, 2014

PELLET; IMPLANTATION

TESTOPEL

! AUXILIUM PHARMS INC 75MG A080911 001

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONEAT ACTAVIS LABS UT INC 30MG/1.5ML ACTUATION A205328 001 Aug 07, 2017AT CIPLA 30MG/1.5ML ACTUATION A209533 001 Jan 29, 2018AT LUPIN LTD 30MG/1.5ML ACTUATION A208061 001 Oct 23, 2017AT ! PERRIGO ISRAEL 30MG/1.5ML ACTUATION A204255 001 Feb 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

<u>AO</u>	!	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635</u>	<u>002</u>	
<u>AO</u>	!		<u>200MG/ML</u>	<u>A085635</u>	<u>003</u>	
<u>TESTOSTERONE CYPIONATE</u>						
<u>AO</u>		AM REGENT	<u>200MG/ML</u>	<u>A207742</u>	<u>001</u>	Jun 16, 2017
<u>AO</u>		CIPLA	<u>100MG/ML</u>	<u>A210362</u>	<u>001</u>	Jun 19, 2018
<u>AO</u>			<u>200MG/ML</u>	<u>A210362</u>	<u>002</u>	Jun 19, 2018
<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091244</u>	<u>001</u>	May 01, 2012
<u>AO</u>		PADDOCK LLC	<u>200MG/ML</u>	<u>A040530</u>	<u>001</u>	Jan 31, 2005
<u>AO</u>		SANDOZ INC	<u>100MG/ML</u>	<u>A040615</u>	<u>001</u>	Aug 10, 2006
<u>AO</u>			<u>200MG/ML</u>	<u>A040615</u>	<u>002</u>	Aug 10, 2006
<u>AO</u>		SUN PHARM INDS LTD	<u>100MG/ML</u>	<u>A201720</u>	<u>001</u>	Jun 03, 2013
<u>AO</u>			<u>200MG/ML</u>	<u>A201720</u>	<u>002</u>	Jun 03, 2013
<u>AO</u>		WATSON PHARMS INC	<u>200MG/ML</u>	<u>A086030</u>	<u>001</u>	
<u>AO</u>		WEST-WARD PHARMS INT	<u>100MG/ML</u>	<u>A090387</u>	<u>001</u>	Jul 15, 2010
<u>AO</u>			<u>200MG/ML</u>	<u>A090387</u>	<u>002</u>	Jul 15, 2010
<u>AO</u>		WILSHIRE PHARMS INC	<u>200MG/ML</u>	<u>A206368</u>	<u>001</u>	Apr 24, 2019

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

<u>AO</u>		HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>		NEXUS PHARMS	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>	!	WATSON PHARMS INC	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	
SOLUTION; SUBCUTANEOUS						
XYOSTED (AUTOINJECTOR)						
	+	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

JATENZO

+	CLARUS	158MG	N206089	001	Mar 27, 2019
+		198MG	N206089	002	Mar 27, 2019
+		237MG	N206089	003	Mar 27, 2019

INJECTABLE; INTRAMUSCULAR

AVEED

+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014
---	-----------------	----------------------	---------	-----	--------------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>		ACTAVIS LABS FL INC	<u>25MG</u>	<u>A206686</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>		BIONPHARMA INC	<u>12.5MG</u>	<u>A208826</u>	<u>001</u>	Dec 18, 2017
<u>AB</u>			<u>25MG</u>	<u>A208826</u>	<u>002</u>	Dec 18, 2017
<u>AB</u>		DR REDDYS	<u>12.5MG</u>	<u>A209284</u>	<u>001</u>	Jan 08, 2018
<u>AB</u>			<u>25MG</u>	<u>A209284</u>	<u>002</u>	Jan 08, 2018
<u>AB</u>		HETERO LABS LTD V	<u>12.5MG</u>	<u>A204574</u>	<u>001</u>	Feb 03, 2016
<u>AB</u>			<u>25MG</u>	<u>A204574</u>	<u>002</u>	Feb 03, 2016
<u>AB</u>		HIKMA	<u>12.5MG</u>	<u>A209739</u>	<u>001</u>	Apr 08, 2019
<u>AB</u>			<u>25MG</u>	<u>A209739</u>	<u>002</u>	Apr 08, 2019
<u>AB</u>		LUPIN LTD	<u>12.5MG</u>	<u>A210544</u>	<u>001</u>	Apr 20, 2018
<u>AB</u>			<u>25MG</u>	<u>A210544</u>	<u>002</u>	Apr 20, 2018
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A207682</u>	<u>001</u>	Jan 31, 2017
<u>AB</u>			<u>25MG</u>	<u>A207682</u>	<u>002</u>	Jan 31, 2017
<u>AB</u>		SUN PHARM	<u>12.5MG</u>	<u>A206129</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>			<u>25MG</u>	<u>A206129</u>	<u>002</u>	Aug 17, 2015
<u>XENAZINE</u>						
<u>AB</u>	+	VALEANT PHARMS NORTH	<u>12.5MG</u>	<u>N021894</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>	+		<u>25MG</u>	<u>N021894</u>	<u>002</u>	Aug 15, 2008

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	ALCON LABS	0.5%	N208135	001	Feb 29, 2016
	BAUSCH	0.5%	N210821	001	Mar 12, 2019

PRESCRIPTION DRUG PRODUCT LIST

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

<u>AB</u>	+	AVET	<u>250MG</u>	<u>N050278</u>	<u>003</u>	
<u>AB</u>	+	!	<u>500MG</u>	<u>N050278</u>	<u>001</u>	

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS NY	<u>250MG</u>	<u>A210674</u>	<u>001</u>	Sep 18, 2018
<u>AB</u>			<u>500MG</u>	<u>A210674</u>	<u>002</u>	Sep 18, 2018
<u>AB</u>		BRECKENRIDGE	<u>250MG</u>	<u>A210662</u>	<u>001</u>	Nov 07, 2018
<u>AB</u>			<u>500MG</u>	<u>A210662</u>	<u>002</u>	Nov 07, 2018
<u>AB</u>		CHARTWELL TETRA	<u>250MG</u>	<u>A062752</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>			<u>500MG</u>	<u>A062752</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A061837</u>	<u>002</u>	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION;NASAL

TYZINE

!	FOUGERA PHARMS	0.05%	A086576	002	
		0.1%	A086576	001	

SPRAY;NASAL

TYZINE

!	FOUGERA PHARMS	0.1%	A086576	003	
---	----------------	------	---------	-----	--

THALIDOMIDE

CAPSULE;ORAL

THALOMID

+	CELGENE	50MG	N020785	001	Jul 16, 1998
+		100MG	N020785	002	Jan 17, 2003
+		150MG	N020785	004	Jan 10, 2007
+	!	200MG	N020785	003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

<u>AP</u>	+	!	CURIUM	<u>1mCi/ML</u>	<u>N018150</u>	<u>001</u>	
<u>AP</u>	+	!	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110</u>	<u>002</u>	Feb 27, 1996
<u>AP</u>	+	!	LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806</u>	<u>001</u>	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEO-24

		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983
!		AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992
		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983
			300MG	A087944	001	Aug 22, 1983

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992
---	---	---------	------------	---------	-----	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	80MG/100ML	N019826	002	Aug 14, 1992
---	---	---------	------------	---------	-----	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992
---	---	---------	-------------	---------	-----	--------------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992
---	---	---------	-------------	---------	-----	--------------

SOLUTION;ORAL

THEOPHYLLINE

<u>AA</u>	!	LANNETT CO INC	<u>80MG/15ML</u>	<u>A091156</u>	<u>001</u>	Apr 13, 2011
<u>AA</u>		TRIS PHARMA INC	<u>80MG/15ML</u>	<u>A091586</u>	<u>001</u>	Jun 15, 2012

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

<u>AA</u>	!	NOSTRUM LABS INC	<u>80MG/15ML</u>	<u>A085186</u>	<u>001</u>	
-----------	---	------------------	------------------	----------------	------------	--

THEOPHYLLINE

<u>AA</u>		PHARM ASSOC	<u>80MG/15ML</u>	<u>A206344</u>	<u>001</u>	Dec 16, 2016
-----------	--	-------------	------------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

<u>AB</u>		NOSTRUM PHARMS LLC	<u>100MG</u>	<u>A087400</u>	<u>003</u>	Feb 21, 1985
<u>AB</u>			<u>200MG</u>	<u>A087400</u>	<u>004</u>	Feb 21, 1985

THEOPHYLLINE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>300MG</u>	<u>A090430</u>	<u>001</u>	Oct 27, 2010
<u>AB</u>		GLENMARK GENERICS	<u>400MG</u>	<u>A090355</u>	<u>001</u>	Jul 13, 2010
<u>AB</u>			<u>600MG</u>	<u>A090355</u>	<u>002</u>	Jul 13, 2010
<u>AB</u>	!	HERITAGE PHARMA	<u>100MG</u>	<u>A089807</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	!		<u>200MG</u>	<u>A089808</u>	<u>001</u>	Apr 30, 1990

PRESCRIPTION DRUG PRODUCT LIST

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

<u>AB</u>		<u>300MG</u>	<u>A089763</u>	<u>001</u>	Apr 30, 1990
<u>AB</u>	NOSTRUM LABS INC	<u>400MG</u>	<u>A040560</u>	<u>003</u>	Apr 21, 2006
<u>AB</u>	!	<u>600MG</u>	<u>A040560</u>	<u>002</u>	Apr 21, 2006
<u>AB</u>	RHODES PHARMS	<u>400MG</u>	<u>A040086</u>	<u>002</u>	Sep 01, 1982
<u>AB</u>		<u>600MG</u>	<u>A040086</u>	<u>001</u>	Apr 15, 1996
	!	ALEMBIC PHARMS LTD	A090430	002	Oct 27, 2010

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<u>AP</u>	!	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556</u>	<u>001</u>
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623</u>	<u>001</u>
<u>AP</u>		SAGENT PHARMS INC	<u>100MG/ML</u>	<u>A206106</u>	<u>001</u>

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	!	ASPEN GLOBAL INC	40MG	N012429	001
---	---	------------------	------	---------	-----

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

		MYLAN	10MG	A088004	002	Mar 15, 1983
			25MG	A088004	003	Mar 15, 1983
			50MG	A088004	004	Mar 15, 1983
	!		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

<u>AP</u>		DR REDDYS	<u>15MG/VIAL</u>	<u>A210337</u>	<u>001</u>	May 04, 2018
<u>AP</u>		JIANGSU HENGRUI MED	<u>15MG/VIAL</u>	<u>A209150</u>	<u>001</u>	May 04, 2018
<u>AP</u>		STI PHARMA LLC	<u>15MG/VIAL</u>	<u>A208242</u>	<u>001</u>	Jan 10, 2020
<u>AP</u>	!	WEST-WARD PHARMS	<u>15MG/VIAL</u>	<u>A075547</u>	<u>001</u>	Apr 02, 2001
		INT				
		POWDER; INTRAVENOUS				
		TEPADINA				
	+	!	ADIENNE SA	N208264	001	Jan 26, 2017
	+	!		N208264	002	Jan 26, 2017

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

<u>AB</u>		MYLAN	<u>1MG</u>	<u>A071093</u>	<u>002</u>	Jun 23, 1987
<u>AB</u>			<u>2MG</u>	<u>A071093</u>	<u>003</u>	Jun 23, 1987
<u>AB</u>			<u>5MG</u>	<u>A071093</u>	<u>004</u>	Jun 23, 1987
<u>AB</u>			<u>10MG</u>	<u>A071093</u>	<u>001</u>	Jun 23, 1987
<u>AB</u>		NOVITIUM PHARMA	<u>1MG</u>	<u>A211642</u>	<u>001</u>	Apr 05, 2019
<u>AB</u>			<u>2MG</u>	<u>A211642</u>	<u>002</u>	Apr 05, 2019
<u>AB</u>	!		<u>5MG</u>	<u>A211642</u>	<u>003</u>	Apr 05, 2019
<u>AB</u>			<u>10MG</u>	<u>A211642</u>	<u>004</u>	Apr 05, 2019

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+	!	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998
---	---	---------	------------	---------	-----	--------------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

<u>AB</u>	+	CEPHALON	<u>2MG</u>	<u>N020646</u>	<u>005</u>	Apr 16, 1999
<u>AB</u>	+	!	<u>4MG</u>	<u>N020646</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+		<u>12MG</u>	<u>N020646</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+		<u>16MG</u>	<u>N020646</u>	<u>003</u>	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS CO	<u>2MG</u>	<u>A208181</u>	<u>001</u>	Dec 08, 2017
<u>AB</u>			<u>4MG</u>	<u>A208181</u>	<u>002</u>	Dec 08, 2017
<u>AB</u>			<u>12MG</u>	<u>A208181</u>	<u>003</u>	Dec 08, 2017
<u>AB</u>			<u>16MG</u>	<u>A208181</u>	<u>004</u>	Dec 08, 2017
<u>AB</u>		SUN PHARM INDS	<u>2MG</u>	<u>A077555</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>			<u>4MG</u>	<u>A077555</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		WILSHIRE PHARMS INC	<u>2MG</u>	<u>A206857</u>	<u>001</u>	Oct 13, 2017
<u>AB</u>			<u>4MG</u>	<u>A206857</u>	<u>002</u>	Oct 13, 2017

PRESCRIPTION DRUG PRODUCT LIST

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

TIAGABINE HYDROCHLORIDE

<u>AB</u>		<u>12MG</u>	<u>A206857</u>	<u>003</u>	Oct 13, 2017
<u>AB</u>		<u>16MG</u>	<u>A206857</u>	<u>004</u>	Oct 13, 2017

TICAGRELOR

TABLET; ORAL

BRILINTA

<u>AB</u>	<u>+</u> !	ASTRAZENECA PHARMS	<u>90MG</u>	<u>N022433</u>	<u>001</u>	Jul 20, 2011
-----------	------------	--------------------	-------------	----------------	------------	--------------

TICAGRELOR

<u>AB</u>		HISUN PHARM HANGZHOU	<u>90MG</u>	<u>A208575</u>	<u>001</u>	Jan 23, 2019
-----------	--	-------------------------	-------------	----------------	------------	--------------

BRILINTA

<u>+</u>		ASTRAZENECA PHARMS	<u>60MG</u>	<u>N022433</u>	<u>002</u>	Sep 03, 2015
----------	--	--------------------	-------------	----------------	------------	--------------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>	<u>!</u>	TEVA	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999
-----------	----------	------	--------------	----------------	------------	--------------

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

<u>AP</u>		AMNEAL PHARMS LLC	<u>50MG/VIAL</u>	<u>N211158</u>	<u>001</u>	Aug 02, 2018
-----------	--	-------------------	------------------	----------------	------------	--------------

<u>AP</u>		APOTEX	<u>50MG/VIAL</u>	<u>A204439</u>	<u>001</u>	Dec 21, 2018
-----------	--	--------	------------------	----------------	------------	--------------

<u>AP</u>		AUROBINDO PHARMA LTD	<u>50MG/VIAL</u>	<u>A206335</u>	<u>001</u>	Jun 11, 2019
-----------	--	-------------------------	------------------	----------------	------------	--------------

<u>AP</u>		FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N205645</u>	<u>001</u>	Dec 01, 2016
-----------	--	--------------------	------------------	----------------	------------	--------------

<u>AP</u>		SANDOZ INC	<u>50MG/VIAL</u>	<u>A091620</u>	<u>001</u>	May 27, 2015
-----------	--	------------	------------------	----------------	------------	--------------

<u>AP</u>		XELLIA PHARMS APS	<u>50MG/VIAL</u>	<u>A205722</u>	<u>001</u>	Oct 18, 2019
-----------	--	-------------------	------------------	----------------	------------	--------------

TYGACIL

<u>AP</u>	<u>+</u> !	PF PRISM CV	<u>50MG/VIAL</u>	<u>N021821</u>	<u>001</u>	Jun 15, 2005
-----------	------------	-------------	------------------	----------------	------------	--------------

TIGECYCLINE

		ACCORD HLTHCARE INC	<u>50MG/VIAL</u>	<u>N208744</u>	<u>001</u>	Jan 18, 2018
--	--	---------------------	------------------	----------------	------------	--------------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

<u>AT</u>	<u>+</u> !	OAK PHARMS INC	<u>EQ 0.25% BASE</u>	<u>N020439</u>	<u>001</u>	Mar 31, 1995
-----------	------------	----------------	----------------------	----------------	------------	--------------

<u>AT</u>	<u>+</u> !		<u>EQ 0.5% BASE</u>	<u>N020439</u>	<u>002</u>	Mar 31, 1995
-----------	------------	--	---------------------	----------------	------------	--------------

TIMOLOL

<u>AT</u>		AKORN	<u>EQ 0.25% BASE</u>	<u>A205309</u>	<u>001</u>	Sep 30, 2016
-----------	--	-------	----------------------	----------------	------------	--------------

<u>AT</u>			<u>EQ 0.5% BASE</u>	<u>A205309</u>	<u>002</u>	Sep 30, 2016
-----------	--	--	---------------------	----------------	------------	--------------

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AB</u>	<u>+</u> !	SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
-----------	------------	------------	----------------------	----------------	------------	--------------

<u>AB</u>	<u>+</u> !		<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998
-----------	------------	--	---------------------	----------------	------------	--------------

TIMOPTIC-XE

<u>AB</u>	<u>+</u> !	VALEANT PHARMS LLC	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
-----------	------------	--------------------	----------------------	----------------	------------	--------------

<u>AB</u>	<u>+</u> !		<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993
-----------	------------	--	---------------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>		BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
-----------	--	-----------------	----------------------	----------------	------------	--------------

<u>AT</u>		FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
-----------	--	---------	----------------------	----------------	------------	--------------

<u>AT</u>		PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997
-----------	--	----------------	----------------------	----------------	------------	--------------

<u>AT</u>	<u>!</u>	SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>A074261</u>	<u>001</u>	Apr 28, 1995
-----------	----------	------------	----------------------	----------------	------------	--------------

<u>AT</u>		WOCKHARDT	<u>EQ 0.25% BASE</u>	<u>A078771</u>	<u>001</u>	Sep 28, 2009
-----------	--	-----------	----------------------	----------------	------------	--------------

TIMOPTIC

<u>AT</u>	<u>+</u>	VALEANT PHARMS INTL	<u>EQ 0.25% BASE</u>	<u>N018086</u>	<u>001</u>	
-----------	----------	---------------------	----------------------	----------------	------------	--

TIMOLOL MALEATE

<u>AT1</u>		AKORN	<u>EQ 0.5% BASE</u>	<u>A074466</u>	<u>001</u>	Mar 25, 1997
------------	--	-------	---------------------	----------------	------------	--------------

<u>AT1</u>			<u>EQ 0.5% BASE</u>	<u>A074516</u>	<u>001</u>	Mar 25, 1997
------------	--	--	---------------------	----------------	------------	--------------

<u>AT1</u>		BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A074776</u>	<u>001</u>	Mar 25, 1997
------------	--	-----------------	---------------------	----------------	------------	--------------

<u>AT1</u>		FDC LTD	<u>EQ 0.5% BASE</u>	<u>A077259</u>	<u>002</u>	Apr 30, 2008
------------	--	---------	---------------------	----------------	------------	--------------

<u>AT1</u>		HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A075163</u>	<u>001</u>	Sep 10, 2002
------------	--	----------------	---------------------	----------------	------------	--------------

<u>AT1</u>		PACIFIC PHARMA	<u>EQ 0.5% BASE</u>	<u>A074747</u>	<u>001</u>	Mar 25, 1997
------------	--	----------------	---------------------	----------------	------------	--------------

<u>AT1</u>	<u>!</u>	SANDOZ INC	<u>EQ 0.5% BASE</u>	<u>A074262</u>	<u>001</u>	Apr 28, 1995
------------	----------	------------	---------------------	----------------	------------	--------------

<u>AT1</u>		WOCKHARDT	<u>EQ 0.5% BASE</u>	<u>A078771</u>	<u>002</u>	Sep 28, 2009
------------	--	-----------	---------------------	----------------	------------	--------------

TIMOPTIC

<u>AT1</u>	<u>+</u>	VALEANT PHARMS INTL	<u>EQ 0.5% BASE</u>	<u>N018086</u>	<u>002</u>	
------------	----------	---------------------	---------------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

ISTALOL**AT2** +! BAUSCH AND LOMB **EQ 0.5% BASE** **N021516 001** Jun 04, 2004TIMOLOL MALEATE**AT2** APOTEX **EQ 0.5% BASE** **A204936 001** Apr 17, 2015

TIMOPTIC IN OCUDOSE

+! VALEANT PHARMS INTL EQ 0.25% BASE N019463 001 Nov 05, 1986

+! EQ 0.5% BASE N019463 002 Nov 05, 1986

TABLET;ORAL

TIMOLOL MALEATE**AB** ELYSIUM **5MG** **A207556 001** May 02, 2019**AB** **10MG** **A207556 002** May 02, 2019**AB** **20MG** **A207556 003** May 02, 2019**AB** MYLAN **5MG** **A072668 002** Jun 08, 1990**AB** **10MG** **A072668 003** Jun 08, 1990**AB** ! **20MG** **A072668 001** Jun 08, 1990TINIDAZOLE

TABLET;ORAL

TINDAMAX**AB** + MISSION PHARMA **250MG** **N021618 001** May 17, 2004**AB** +! **500MG** **N021618 002** May 17, 2004TINIDAZOLE**AB** EDENBRIDGE PHARMS **250MG** **A203808 001** Aug 04, 2015**AB** **500MG** **A203808 002** Aug 04, 2015**AB** HIKMA **250MG** **A201172 001** Apr 30, 2012**AB** **500MG** **A201172 002** Apr 30, 2012**AB** NOVEL LABS INC **250MG** **A202044 001** Apr 30, 2012**AB** **500MG** **A202044 002** Apr 30, 2012**AB** UNIQUE PHARM LABS **250MG** **A202489 001** Oct 09, 2013**AB** **500MG** **A202489 002** Oct 09, 2013TIOPRONIN

TABLET;ORAL

THIOLA

+! MISSION PHARMA 100MG N019569 001 Aug 11, 1988

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

+ MISSION PHARMACAL 100MG N211843 001 Jun 28, 2019

CO

+! 300MG N211843 002 Jun 28, 2019

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+! BOEHRINGER EQ 0.018MG BASE/INH N021395 001 Jan 30, 2004

INGELHEIM

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+ BOEHRINGER EQ 0.00125MG BASE/INH N021936 002 Sep 15, 2015

INGELHEIM

+! EQ 0.0025MG BASE/INH N021936 001 Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

+ TAIHO ONCOLOGY EQ 6.14MG BASE;15MG N207981 001 Sep 22, 2015

+! EQ 8.19MG BASE;20MG N207981 002 Sep 22, 2015

TIPRANAVIR

CAPSULE;ORAL

APTIVUS

+! BOEHRINGER 250MG N021814 001 Jun 22, 2005

INGELHEIM

SOLUTION;ORAL

APTIVUS

+! BOEHRINGER 100MG/ML N022292 001 Jun 23, 2008

INGELHEIM

PRESCRIPTION DRUG PRODUCT LIST

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

+ MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+!

EQ 12.5MG BASE/250ML (EQ 0.05MG
BASE/ML)

N020913 003 Apr 20, 2000

SOLUTION; INJECTION

AGGRASTAT

+! MEDICURE

EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)

N020912 002 Aug 31, 2016

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A213223 001</u>	Jan 13, 2020
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A213223 002</u>	Jan 13, 2020
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A213223 003</u>	Jan 13, 2020
<u>AB</u>	ALKEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A212196 001</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A212196 002</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A212196 003</u>	Mar 27, 2019
<u>AB</u>	APOTEX INC	<u>EQ 2MG BASE</u>	<u>A078868 001</u>	Feb 03, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078868 002</u>	Feb 03, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A078868 003</u>	Feb 03, 2012
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A210021 001</u>	Mar 26, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A210021 002</u>	Mar 26, 2019
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A210021 003</u>	Mar 26, 2019
<u>AB</u>	JUBILANT GENERICS	<u>EQ 2MG BASE</u>	<u>A209605 001</u>	Aug 04, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A209605 002</u>	Aug 04, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A209605 003</u>	Aug 04, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A091502 001</u>	Nov 09, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091502 002</u>	Nov 09, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091502 003</u>	Nov 09, 2012
<u>AB</u>	NOVAST LABS	<u>EQ 2MG BASE</u>	<u>A210267 001</u>	Mar 12, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A210267 002</u>	Mar 12, 2019
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A210267 003</u>	Mar 12, 2019
<u>AB</u>	PAR PHARM INC	<u>EQ 2MG BASE</u>	<u>A207199 001</u>	Mar 14, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A207199 002</u>	Mar 14, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A207199 003</u>	Mar 14, 2017
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208622 001</u>	Mar 03, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208622 002</u>	Mar 03, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A208622 003</u>	Mar 03, 2017

ZANAFLEX

<u>AB</u>	+ COVIS PHARMA BV	<u>EQ 2MG BASE</u>	<u>N021447 001</u>	Aug 29, 2002
<u>AB</u>	+	<u>EQ 4MG BASE</u>	<u>N021447 002</u>	Aug 29, 2002
<u>AB</u>	+!	<u>EQ 6MG BASE</u>	<u>N021447 003</u>	Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A211798 001</u>	Jan 25, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A211798 002</u>	Jan 25, 2019
<u>AB</u>	APOTEX	<u>EQ 2MG BASE</u>	<u>A076533 001</u>	Jan 16, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076533 002</u>	Jan 16, 2004
<u>AB</u>	CASI PHARMS INC	<u>EQ 2MG BASE</u>	<u>A076280 001</u>	Nov 26, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076280 002</u>	Jun 27, 2002
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286 001</u>	Jul 03, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076286 002</u>	Jul 03, 2002
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2MG BASE</u>	<u>A076347 001</u>	Oct 11, 2002
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076347 002</u>	Oct 11, 2002
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A076354 001</u>	Mar 28, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076354 002</u>	Mar 28, 2003
<u>AB</u>	OXFORD PHARMS	<u>EQ 2MG BASE</u>	<u>A076281 001</u>	Oct 20, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076281 002</u>	Oct 20, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2MG BASE</u>	<u>A076416 001</u>	Sep 29, 2003
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076416 002</u>	Sep 29, 2003
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283 002</u>	Nov 28, 2012
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208187 001</u>	Mar 09, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208187 002</u>	Mar 09, 2018

ZANAFLEX

<u>AB</u>	+! COVIS PHARMA BV	<u>EQ 4MG BASE</u>	<u>N020397 001</u>	Nov 27, 1996
-----------	--------------------	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBEX

+! NOVARTIS 0.3% N050555 001

POWDER; INHALATION

TOBI PODHALER

+! MYLAN SPECIALITY LP 28MG N201688 001 Mar 22, 2013

SOLUTION; INHALATION

KITABIS PAK**AN** PULMOFLOW INC 300MG/5ML **N205433 001** Dec 02, 2014TOBI**AN** +! MYLAN SPECIALITY LP 300MG/5ML **N050753 001** Dec 22, 1997TOBRAMYCIN**AN** AKORN INC 300MG/5ML **A201422 001** May 28, 2014**AN** AMNEAL PHARMS 300MG/5ML **A205501 001** Jul 13, 2015**AN** DR REDDYS LABS SA 300MG/5ML **A207080 001** Jul 09, 2018**AN** LUPIN 300MG/5ML **A208964 001** Mar 22, 2017**AN** MYLAN 300MG/5ML **A209554 001** Oct 13, 2017**AN** SUN PHARM 300MG/5ML **A207136 001** Dec 26, 2019**AN** TEVA PHARMS USA 300MG/5ML **A091589 001** Oct 10, 2013

BETHKIS

+! CHIESI USA INC 300MG/4ML N201820 001 Oct 12, 2012

SOLUTION/DROPS;OPHTHALMIC

AKTOB**AT** AKORN 0.3% **A064096 001** Jan 31, 1996TOBRAMYCIN**AT** ALEMBIC PHARMS LTD 0.3% **A211847 001** Apr 19, 2019**AT** BAUSCH AND LOMB 0.3% **A064052 001** Nov 29, 1993**AT** FERA PHARMS 0.3% **A065026 001** Sep 11, 2001**AT** SOMERSET THERAPS 0.3% **A207444 001** Jun 28, 2017

LLC

TOBEX**AT** +! NOVARTIS 0.3% **N050541 001****AT** SANDOZ INC 0.3% **A062535 001** Dec 13, 1984TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE**AP** AKORN EQ 40MG BASE/ML **A205179 001** Sep 16, 2014**AP** BAXTER HLTHCARE EQ 40MG BASE/ML **A206965 001** Jul 01, 2016

CORP

AP FRESENIUS KABI USA EQ 10MG BASE/ML **A065122 001** Nov 29, 2002**AP** ! EQ 40MG BASE/ML **A065122 002** Nov 29, 2002**AP** EQ 1.2GM BASE/VIAL **N050789 001** Jul 13, 2004**AP** ! HOSPIRA EQ 10MG BASE/ML **A063112 001** Apr 30, 1991**AP** EQ 40MG BASE/ML **A063111 001** Apr 30, 1991**AP** MYLAN LABS LTD EQ 40MG BASE/ML **A065407 001** Mar 11, 2008**AP** TEVA PHARMS USA EQ 40MG BASE/ML **A063100 001** Jan 30, 1992**AP** WEST-WARD PHARMS EQ 40MG BASE/ML **A063117 001** Apr 26, 1991

INT

AP ! X GEN PHARMS EQ 1.2GM BASE/VIAL **A065013 001** Aug 17, 2001**AP** XELLIA PHARMS APS EQ 1.2GM BASE/VIAL **A205685 001** Sep 16, 2014

TOBRAMYCIN SULFATE (PHARMACY BULK)

! FRESENIUS KABI USA EQ 40MG BASE/ML A065120 001 Nov 29, 2002

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

! HOSPIRA EQ 1.2MG BASE/ML A063081 003 Jul 31, 1990

! EQ 1.6MG BASE/ML A063081 006 Jun 02, 1993

! EQ 80MG BASE/100ML A063081 001 Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+ PF PRISM CV EQ 5MG BASE N203214 001 Nov 06, 2012

+! EQ 10MG BASE N203214 002 May 30, 2018

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+! PFIZER INC EQ 11MG BASE N208246 001 Feb 23, 2016

+ EQ 22MG BASE N208246 002 Dec 12, 2019

PRESCRIPTION DRUG PRODUCT LIST

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC	250MG	A070259 001	Jan 02, 1986
!	500MG	A070259 003	Mar 17, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

MYLAN PHARMS INC	500MG	A086445 001	
------------------	-------	-------------	--

TOLCAPONE

TABLET; ORAL

TASMAR

<u>AB</u> +!	BAUSCH	<u>100MG</u>	<u>N020697 001</u>	Jan 29, 1998
--------------	--------	--------------	--------------------	--------------

TOLCAPONE

<u>AB</u>	MAYNE PHARMA	<u>100MG</u>	<u>A210095 001</u>	Aug 01, 2019
-----------	--------------	--------------	--------------------	--------------

<u>AB</u>	NOVAST LABS	<u>100MG</u>	<u>A208937 001</u>	Aug 07, 2018
-----------	-------------	--------------	--------------------	--------------

<u>AB</u>	PAR PHARM INC	<u>100MG</u>	<u>A204584 001</u>	Mar 26, 2015
-----------	---------------	--------------	--------------------	--------------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

<u>AB</u>	MYLAN	<u>EQ 400MG BASE</u>	<u>A073393 001</u>	May 27, 1993
-----------	-------	----------------------	--------------------	--------------

<u>AB</u> !	TEVA	<u>EQ 400MG BASE</u>	<u>A073290 001</u>	Nov 27, 1991
-------------	------	----------------------	--------------------	--------------

TABLET; ORAL

TOLMETIN SODIUM

!	MYLAN	EQ 600MG BASE	A074473 001	Aug 30, 1994
---	-------	---------------	-------------	--------------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

<u>AB</u> +	PHARMACIA AND UPJOHN	<u>2MG</u>	<u>N021228 001</u>	Dec 22, 2000
-------------	----------------------	------------	--------------------	--------------

<u>AB</u> +!		<u>4MG</u>	<u>N021228 002</u>	Dec 22, 2000
--------------	--	------------	--------------------	--------------

TOLTERODINE TARTRATE

<u>AB</u>	HETERO LABS LTD III	<u>2MG</u>	<u>A206419 001</u>	Dec 12, 2017
-----------	---------------------	------------	--------------------	--------------

<u>AB</u>		<u>4MG</u>	<u>A206419 002</u>	Dec 12, 2017
-----------	--	------------	--------------------	--------------

<u>AB</u>	INVENTIA HLTHCARE	<u>2MG</u>	<u>A204562 001</u>	Aug 19, 2019
-----------	-------------------	------------	--------------------	--------------

<u>AB</u>		<u>4MG</u>	<u>A204562 002</u>	Aug 19, 2019
-----------	--	------------	--------------------	--------------

<u>AB</u>	MYLAN	<u>2MG</u>	<u>A201486 001</u>	Oct 31, 2013
-----------	-------	------------	--------------------	--------------

<u>AB</u>		<u>4MG</u>	<u>A201486 002</u>	Oct 31, 2013
-----------	--	------------	--------------------	--------------

<u>AB</u>	TEVA PHARMS USA	<u>2MG</u>	<u>A079141 001</u>	Nov 22, 2016
-----------	-----------------	------------	--------------------	--------------

<u>AB</u>		<u>4MG</u>	<u>A079141 002</u>	Nov 22, 2016
-----------	--	------------	--------------------	--------------

<u>AB</u>	TORRENT	<u>2MG</u>	<u>A203016 001</u>	Aug 11, 2015
-----------	---------	------------	--------------------	--------------

<u>AB</u>		<u>4MG</u>	<u>A203016 002</u>	Aug 11, 2015
-----------	--	------------	--------------------	--------------

TABLET; ORAL

DETROL

<u>AB</u> +	PHARMACIA AND UPJOHN	<u>1MG</u>	<u>N020771 001</u>	Mar 25, 1998
-------------	----------------------	------------	--------------------	--------------

<u>AB</u> +!		<u>2MG</u>	<u>N020771 002</u>	Mar 25, 1998
--------------	--	------------	--------------------	--------------

TOLTERODINE TARTRATE

<u>AB</u>	INVATECH	<u>1MG</u>	<u>A210775 001</u>	Dec 30, 2019
-----------	----------	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A210775 002</u>	Dec 30, 2019
-----------	--	------------	--------------------	--------------

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1MG</u>	<u>A077006 001</u>	Feb 23, 2015
-----------	----------------------	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A077006 002</u>	Feb 23, 2015
-----------	--	------------	--------------------	--------------

<u>AB</u>	MACLEODS PHARMS LTD	<u>1MG</u>	<u>A203409 001</u>	Aug 31, 2015
-----------	---------------------	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A203409 002</u>	Aug 31, 2015
-----------	--	------------	--------------------	--------------

<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A202641 001</u>	Nov 27, 2012
-----------	------------------	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A202641 002</u>	Nov 27, 2012
-----------	--	------------	--------------------	--------------

TOLVAPTAN

TABLET; ORAL

JYNARQUE

+	OTSUKA PHARM CO LTD	15MG	N204441 001	Apr 23, 2018
---	---------------------	------	-------------	--------------

+		30MG	N204441 002	Apr 23, 2018
---	--	------	-------------	--------------

+	!	45MG	N204441 003	Apr 23, 2018
---	---	------	-------------	--------------

+		60MG	N204441 004	Apr 23, 2018
---	--	------	-------------	--------------

+		90MG	N204441 005	Apr 23, 2018
---	--	------	-------------	--------------

SAMSCA

+	OTSUKA AMERICA PHARM	15MG	N022275 001	May 19, 2009
---	----------------------	------	-------------	--------------

+	!	30MG	N022275 002	May 19, 2009
---	---	------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998
<u>AB</u>	+	!	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>		TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>			<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>		WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009
<u>AB</u>			<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>			<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

<u>AB</u>		ZYDUS PHARMS	<u>25MG</u>	<u>A207382</u>	<u>001</u>	Nov 24, 2017
<u>AB</u>			<u>50MG</u>	<u>A207382</u>	<u>002</u>	Nov 24, 2017
<u>AB</u>			<u>100MG</u>	<u>A207382</u>	<u>003</u>	Nov 24, 2017

TROKENDI XR

<u>AB</u>	+	SUPERNUS PHARMS	<u>25MG</u>	<u>N201635</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>	+		<u>50MG</u>	<u>N201635</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>	+		<u>100MG</u>	<u>N201635</u>	<u>003</u>	Aug 16, 2013

QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014
BC	+		50MG	N205122	002	Mar 11, 2014
BC	+		100MG	N205122	003	Mar 11, 2014
BC	+	!	200MG	N205122	005	Mar 11, 2014

TROKENDI XR

BC	+	!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013
----	---	---	-----------------	-------	---------	-----	--------------

QUDEXY XR

	+	UPSHER SMITH LABS	150MG	N205122	004	Mar 11, 2014
--	---	-------------------	-------	---------	-----	--------------

TABLET; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996
<u>AB</u>	+		<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996
<u>AB</u>	+	!	<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996
<u>AB</u>	+		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>		ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		SUN PHARM	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153 004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162 004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH LABS	<u>25MG</u>	<u>A078499 001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499 002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499 003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499 004</u>	Jan 07, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235 004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

+ NOVARTIS

+!

EQ 0.25MG BASE

EQ 1MG BASE

N020981 001 Oct 11, 2007

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTIN

<u>AP</u>	+! NOVARTIS	<u>EQ 4MG BASE/VIAL</u>	<u>N020671 001</u>	May 28, 1996
-----------	-------------	-------------------------	--------------------	--------------

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351 001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620 001</u>	Dec 02, 2010
<u>AP</u>	CIPLA	<u>EQ 4MG BASE/VIAL</u>	<u>A091199 001</u>	Dec 01, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191 001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089 001</u>	Nov 29, 2010
<u>AP</u>	MEITHEAL	<u>EQ 4MG BASE/VIAL</u>	<u>A201166 001</u>	Aug 08, 2012
<u>AP</u>	NOVAST LABS	<u>EQ 4MG BASE/VIAL</u>	<u>A206962 001</u>	Nov 30, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284 001</u>	Jan 26, 2011

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204406 002</u>	Jul 06, 2017
<u>AP</u>	+! HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582 001</u>	Feb 02, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A206074 001</u>	Nov 24, 2017
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453 001</u>	Dec 20, 2012
	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406 001	Jul 06, 2017

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

<u>AB</u>	+! KYOWA KIRIN	<u>EQ 60MG BASE</u>	<u>N020497 001</u>	May 29, 1997
-----------	----------------	---------------------	--------------------	--------------

TOREMIFENE CITRATE

<u>AB</u>	RISING	<u>EQ 60MG BASE</u>	<u>A208813 001</u>	Dec 04, 2018
-----------	--------	---------------------	--------------------	--------------

TORSEMIDE

TABLET; ORAL

DEMADEX

<u>AB</u>	+ MYLAN SPECIALITY LP	<u>5MG</u>	<u>N020136 001</u>	Aug 23, 1993
<u>AB</u>	+	<u>10MG</u>	<u>N020136 002</u>	Aug 23, 1993
<u>AB</u>	+!	<u>20MG</u>	<u>N020136 003</u>	Aug 23, 1993
<u>AB</u>	+	<u>100MG</u>	<u>N020136 004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894 001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894 002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894 003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894 004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249 001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249 002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249 003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249 004</u>	Oct 17, 2007
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234 001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234 002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234 003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234 004</u>	Jan 27, 2009
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A076943 001</u>	Mar 01, 2005

PRESCRIPTION DRUG PRODUCT LIST

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011

TRABECTEDIN

POWDER; INTRAVENOUS

YONDELIS

+! JANSSEN PRODS 1MG/VIAL N207953 001 Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
+		150MG	N022370	004	Aug 01, 2011
+		200MG	N022370	002	May 07, 2010
+		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACI HEALTHCARE LTD	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A205702</u>	<u>001</u>	Sep 25, 2015
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	RUBICON	<u>50MG</u>	<u>A208708</u>	<u>001</u>	Jun 28, 2019
<u>AB</u>		<u>100MG</u>	<u>A208708</u>	<u>002</u>	Jun 28, 2019
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	UNICHEM LABS LTD	<u>50MG</u>	<u>A211825</u>	<u>001</u>	Aug 09, 2019
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+!	JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	----	----------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	!	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>			<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>			<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	MYLAN		<u>100MG</u>	<u>A205257</u>	<u>001</u>	Dec 22, 2015
<u>AB1</u>			<u>200MG</u>	<u>A205257</u>	<u>002</u>	Dec 22, 2015
<u>AB1</u>			<u>300MG</u>	<u>A205257</u>	<u>003</u>	Dec 22, 2015
<u>AB1</u>	SUN PHARM		<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>			<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>			<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011
<u>AB2</u>	ACTAVIS ELIZABETH		<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>			<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>			<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS		<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>			<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>			<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	!	SUN PHARM	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>			<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB2		300MG	A091607 003	Dec 30, 2011
------------	--	--------------	--------------------	--------------

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+	NOVARTIS	EQ 0.5MG	N204114 001	May 29, 2013
---	----------	----------	-------------	--------------

+	!	EQ 2MG	N204114 003	May 29, 2013
---	---	--------	-------------	--------------

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB	AUROBINDO PHARMA	1MG	A078438 001	Jun 12, 2007
AB		2MG	A078438 002	Jun 12, 2007
AB		4MG	A078438 003	Jun 12, 2007
AB	EPIC PHARMA	1MG	A078508 003	Jun 18, 2008
AB		2MG	A078508 001	Jun 18, 2008
AB		4MG	A078508 002	Jun 18, 2008
AB	LUPIN	1MG	A077522 001	Jun 12, 2007
AB		2MG	A077522 002	Jun 12, 2007
AB	!	4MG	A077522 003	Jun 12, 2007
AB	TEVA PHARMS	1MG	A077489 001	Dec 12, 2006
AB		2MG	A077489 002	Dec 12, 2006
AB		4MG	A077489 003	Dec 12, 2006

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

AB	+	ABEVIE	2MG;180MG	N020591 001	Oct 22, 1996
AB	+		2MG;240MG	N020591 004	Oct 22, 1996
AB	+	!	4MG;240MG	N020591 002	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

AB	GLENMARK GENERICS	2MG;180MG	A079135 001	May 26, 2010
AB		2MG;240MG	A079135 002	May 26, 2010
AB		4MG;240MG	A079135 003	May 05, 2010
		1MG;240MG	A079135 004	Aug 30, 2010

TRANEXAMIC ACID

INJECTABLE;INJECTION

CYKLOKAPRON

AP	+	!	PHARMACIA AND UPJOHN	100MG/ML	N019281 001	Dec 30, 1986
-----------	---	---	----------------------	-----------------	--------------------	--------------

TRANEXAMIC ACID

AP	ACIC PHARMS	100MG/ML	A202436 001	Feb 11, 2014
AP	AKORN	100MG/ML	A202373 001	Nov 17, 2011
AP		100MG/ML	A206594 001	Sep 28, 2017
AP		100MG/ML	A206634 001	Jun 09, 2016
AP	AMNEAL PHARMS CO	100MG/ML	A208840 001	Feb 28, 2017
AP	APOLLO	100MG/ML	A212676 001	Jul 17, 2019
AP	APOTEX	100MG/ML	A209860 001	Jan 14, 2020
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035 001	Jan 14, 2016
AP	CAPLIN	100MG/ML	A212360 001	Jul 17, 2019
AP	EMCURE PHARMS LTD	100MG/ML	A203521 001	Aug 12, 2014
AP	FRESENIUS KABI USA	100MG/ML	A091596 001	Mar 02, 2012
AP	GLAND PHARMA LTD	100MG/ML	A207239 001	Feb 13, 2017
AP	LUITPOLD	100MG/ML	A201885 001	Aug 10, 2011
AP	MICRO LABS	100MG/ML	A206713 001	Jun 27, 2017
AP	MYLAN INSTITUTIONAL	100MG/ML	A091657 001	Nov 03, 2011
AP	X-GEN PHARMS INC	100MG/ML	A201580 001	Jun 14, 2013
AP	ZYDUS PHARMS	100MG/ML	A205228 001	Jul 17, 2017

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

+	!	EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020 001	Apr 15, 2019
---	---	----------------------	---------------------	-------------	--------------

TABLET;ORAL

LYSTEDA

AB	+	!	FERRING PHARMS INC	650MG	N022430 001	Nov 13, 2009
-----------	---	---	--------------------	--------------	--------------------	--------------

TRANEXAMIC ACID

AB	ACTAVIS LABS FL INC	650MG	A202093 001	Dec 27, 2012
AB	APOTEX INC	650MG	A202286 001	Jan 27, 2014
AB	MYLAN	650MG	A205133 001	Sep 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

TRANLYCYPROMINE SULFATE

TABLET;ORAL

PARNATE

<u>AB</u>	<u>+!</u>	CONCORDIA	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985
-----------	-----------	-----------	---------------------	----------------	------------	--------------

TRANLYCYPROMINE SULFATE

<u>AB</u>		CNTY LINE PHARMS	<u>EQ 10MG BASE</u>	<u>A206856</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

<u>AT</u>	<u>+!</u>	NOVARTIS	<u>0.004%</u>	<u>N021994</u>	<u>001</u>	Sep 21, 2006
-----------	-----------	----------	---------------	----------------	------------	--------------

TRAVOPROST

<u>AT</u>		APOTEX	<u>0.004%</u>	<u>A203431</u>	<u>001</u>	Jul 10, 2015
<u>AT</u>		MYLAN	<u>0.004%</u>	<u>A205050</u>	<u>001</u>	Jul 07, 2017
<u>AT1</u>		ALEMBIC PHARMS LTD	<u>0.004%</u>	<u>A210458</u>	<u>001</u>	Dec 20, 2019
<u>AT1</u>	<u>!</u>	PAR PHARM	<u>0.004%</u>	<u>A091340</u>	<u>001</u>	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>50MG</u>	<u>A206923</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>			<u>100MG</u>	<u>A206923</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>			<u>150MG</u>	<u>A206923</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>			<u>300MG</u>	<u>A206923</u>	<u>004</u>	Sep 08, 2017
<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>			<u>100MG</u>	<u>A071514</u>	<u>001</u>	Apr 18, 1988
<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>	<u>!</u>	APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>			<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>			<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999
<u>AB</u>		OXFORD PHARMS	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>			<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>		PLIVA	<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988
<u>AB</u>		SUN PHARM INDUSTRIES	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993
<u>AB</u>			<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993
<u>AB</u>			<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995
<u>AB</u>		TEVA PHARMS USA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>			<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>		TORRENT	<u>50MG</u>	<u>A202180</u>	<u>001</u>	Nov 27, 2013
<u>AB</u>			<u>100MG</u>	<u>A202180</u>	<u>002</u>	Nov 27, 2013
<u>AB</u>			<u>150MG</u>	<u>A202180</u>	<u>003</u>	Nov 27, 2013
<u>AB</u>			<u>300MG</u>	<u>A202180</u>	<u>004</u>	Nov 27, 2013
<u>AB</u>		ZYDUS PHARMS	<u>50MG</u>	<u>A205253</u>	<u>001</u>	Oct 10, 2017
<u>AB</u>			<u>100MG</u>	<u>A205253</u>	<u>002</u>	Oct 10, 2017
<u>AB</u>			<u>150MG</u>	<u>A205253</u>	<u>003</u>	Oct 10, 2017
<u>AB</u>			<u>300MG</u>	<u>A205253</u>	<u>004</u>	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

<u>AP</u>	<u>+!</u>	UNITED THERAP	<u>1MG/ML</u>	<u>N021272</u>	<u>001</u>	May 21, 2002
<u>AP</u>	<u>+!</u>		<u>2.5MG/ML</u>	<u>N021272</u>	<u>002</u>	May 21, 2002
<u>AP</u>	<u>+!</u>		<u>5MG/ML</u>	<u>N021272</u>	<u>003</u>	May 21, 2002
<u>AP</u>	<u>+!</u>		<u>10MG/ML</u>	<u>N021272</u>	<u>004</u>	May 21, 2002

TREPROSTINIL

<u>AP</u>		PAR STERILE PRODUCTS	<u>1MG/ML</u>	<u>A209382</u>	<u>001</u>	Sep 24, 2019
<u>AP</u>			<u>2.5MG/ML</u>	<u>A209382</u>	<u>002</u>	Sep 24, 2019
<u>AP</u>			<u>5MG/ML</u>	<u>A209382</u>	<u>003</u>	Sep 24, 2019
<u>AP</u>			<u>10MG/ML</u>	<u>A209382</u>	<u>004</u>	Sep 24, 2019
<u>AP</u>		SANDOZ INC	<u>1MG/ML</u>	<u>A203649</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>			<u>2.5MG/ML</u>	<u>A203649</u>	<u>002</u>	Nov 30, 2017
<u>AP</u>			<u>5MG/ML</u>	<u>A203649</u>	<u>003</u>	Nov 30, 2017
<u>AP</u>			<u>10MG/ML</u>	<u>A203649</u>	<u>004</u>	Nov 30, 2017
<u>AP</u>		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A206648</u>	<u>001</u>	Sep 26, 2019
<u>AP</u>			<u>2.5MG/ML</u>	<u>A206648</u>	<u>002</u>	Sep 26, 2019
<u>AP</u>			<u>5MG/ML</u>	<u>A206648</u>	<u>003</u>	Sep 26, 2019
<u>AP</u>			<u>10MG/ML</u>	<u>A206648</u>	<u>004</u>	Sep 26, 2019

SOLUTION;INHALATION

TYVASO

<u>+!</u>	UNITED THERAP	0.6MG/ML	<u>N022387</u>	<u>001</u>	Jul 30, 2009
-----------	---------------	----------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TREPROSTINIL

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

UNITED THERAP	20MG/20ML (1MG/ML)	N208276 001	Jul 30, 2018
	50MG/20ML (2.5MG/ML)	N208276 002	Jul 30, 2018
	100MG/20ML (5MG/ML)	N208276 003	Jul 30, 2018
	200MG/20ML (10MG/ML)	N208276 004	Jul 30, 2018

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+ UNITED THERAP	EQ 0.125MG BASE	N203496 001	Dec 20, 2013
+	EQ 0.25MG BASE	N203496 002	Dec 20, 2013
+!	EQ 1MG BASE	N203496 003	Dec 20, 2013
+	EQ 2.5MG BASE	N203496 004	Dec 20, 2013
+	EQ 5MG BASE	N203496 005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB	ANCHEN PHARMS	10MG	A201687 001	Oct 24, 2012
AB	! BARR LABS INC	10MG	A077684 001	Jun 22, 2007
AB	GLENMARK PHARMS LTD	10MG	A208279 001	Dec 23, 2016

CREAM;TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997
-----------	------------------	---------------	--------------------	--------------

RETIN-A

AB	+! VALEANT BERMUDA	0.025%	N019049 001	Sep 16, 1988
AB	+! VALEANT PHARMS NORTH	0.1%	N017340 001	

TRETINOIN

AB	PERRIGO PHARMA INTL	0.025%	A075264 001	Dec 24, 1998
AB		0.1%	A075213 001	Dec 24, 1998
AB	TARO PHARMS	0.1%	A211645 001	Jan 22, 2019

RETIN-A

AB1	+! VALEANT BERMUDA	0.05%	N017522 001	
------------	--------------------	--------------	--------------------	--

TRETINOIN

AB1	PERRIGO PHARMA INTL	0.05%	A075265 001	Dec 24, 1998
AB1	TARO PHARMS	0.05%	A211644 001	Jan 25, 2019

RENOVA

AB2	+! VALEANT PHARMS NORTH	0.05%	N019963 001	Dec 29, 1995
------------	----------------------------	--------------	--------------------	--------------

TRETINOIN

AB2	ZO SKIN HEALTH	0.05%	A076498 001	Sep 15, 2005
	RENOVA			
	+! VALEANT PHARMS NORTH	0.02%	N021108 001	Aug 31, 2000

GEL;TOPICAL

ATRALIN

AB	+! DOW PHARM	0.05%	N022070 001	Jul 26, 2007
-----------	--------------	--------------	--------------------	--------------

RETIN-A

AB	+! VALEANT INTL	0.01%	N017955 001	
AB	+!	0.025%	N017579 002	

RETIN-A MICRO

AB	+! VALEANT INTL	0.04%	N020475 002	May 10, 2002
AB	+!	0.1%	N020475 001	Feb 07, 1997

TRETINOIN

AB	MYLAN	0.04%	A202567 001	Jul 17, 2013
AB		0.05%	A207955 001	Aug 13, 2015
AB		0.1%	A202026 001	Jul 17, 2013
AB	PERRIGO PHARMA INTL	0.01%	A075589 001	Jun 11, 2002
AB		0.025%	A075529 001	Feb 22, 2000

AVITA

BT	MYLAN	0.025%	N020400 001	Jan 29, 1998
----	-------	--------	-------------	--------------

RETIN-A-MICRO

	+! VALEANT INTL	0.06%	N020475 004	Oct 23, 2017
	+!	0.08%	N020475 003	Jan 28, 2014

LOTION;TOPICAL

ALTRENO

	+! DOW PHARM	0.05%	N209353 001	Aug 23, 2018
--	--------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ACP NIMBLE	<u>0.025%</u>	<u>A089797 001</u>	May 31, 1991
<u>AT</u>		<u>0.1%</u>	<u>A089798 001</u>	May 31, 1991
<u>AT</u>	ALKEM LABS LTD	<u>0.025%</u>	<u>A207651 001</u>	Dec 26, 2017
<u>AT</u>		<u>0.1%</u>	<u>A207651 002</u>	Dec 26, 2017
<u>AT</u>		<u>0.5%</u>	<u>A207651 003</u>	Dec 26, 2017
<u>AT</u>	! FOUGERA PHARMS	<u>0.025%</u>	<u>A085692 001</u>	
<u>AT</u>	!	<u>0.1%</u>	<u>A085692 003</u>	
<u>AT</u>	!	<u>0.5%</u>	<u>A085692 002</u>	
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A207117 001</u>	Aug 05, 2016
<u>AT</u>	LUPIN ATLANTIS	<u>0.025%</u>	<u>A208763 001</u>	Feb 01, 2017
<u>AT</u>		<u>0.1%</u>	<u>A208763 002</u>	Feb 01, 2017
<u>AT</u>		<u>0.5%</u>	<u>A208763 003</u>	Feb 01, 2017
<u>AT</u>	MACLEODS PHARMS LTD	<u>0.025%</u>	<u>A209535 001</u>	May 18, 2018
<u>AT</u>		<u>0.1%</u>	<u>A209535 002</u>	May 18, 2018
<u>AT</u>		<u>0.5%</u>	<u>A209535 003</u>	May 18, 2018
<u>AT</u>	MLV	<u>0.025%</u>	<u>A040671 001</u>	Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671 002</u>	Jun 09, 2006
<u>AT</u>	+ MYLAN	<u>0.025%</u>	<u>N011601 003</u>	
<u>AT</u>	+	<u>0.1%</u>	<u>N011601 006</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>0.025%</u>	<u>A086413 002</u>	
<u>AT</u>		<u>0.1%</u>	<u>A086413 003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086413 001</u>	
<u>AT</u>	STRIDES PHARMA	<u>0.025%</u>	<u>A210346 001</u>	Feb 11, 2019
<u>AT</u>		<u>0.1%</u>	<u>A210346 002</u>	Feb 11, 2019
<u>AT</u>		<u>0.5%</u>	<u>A210346 003</u>	Feb 11, 2019
<u>AT</u>	TARO PHARM INDS LTD	<u>0.1%</u>	<u>A040039 001</u>	Nov 26, 1997
<u>AT</u>	TELIGENT PHARMA INC	<u>0.1%</u>	<u>A208848 001</u>	Sep 18, 2017

TRIDERM

<u>AT</u>	CROWN LABS	<u>0.025%</u>	<u>A088042 002</u>	Mar 25, 2015
<u>AT</u>		<u>0.1%</u>	<u>A088042 001</u>	Mar 19, 1984
<u>AT</u>		<u>0.5%</u>	<u>A088042 003</u>	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+! FLEXION THERAPS INC 32MG/VIAL

N208845 001 Oct 06, 2017

INJECTABLE; INJECTION

KENALOG-40

<u>AB</u>	+! APOTHECON	<u>40MG/ML</u>	<u>N014901 001</u>	
-----------	--------------	----------------	--------------------	--

TRIAMCINOLONE ACETONIDE

<u>AB</u>	AMNEAL	<u>40MG/ML</u>	<u>A207550 001</u>	Dec 11, 2017
<u>AB</u>	TEVA PHARMS USA	<u>40MG/ML</u>	<u>A209852 001</u>	Oct 05, 2018
	KENALOG-10			
	+ APOTHECON	10MG/ML	N012041 001	
	KENALOG-80			
	+! APOTHECON	80MG/ML	N014901 002	Apr 12, 2019

INJECTABLE; INTRAVITREAL

TRIESENCE

+! NOVARTIS 40MG/ML (40MG/ML)

N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ACP NIMBLE	<u>0.1%</u>	<u>A089129 001</u>	Aug 14, 1986
<u>AT</u>	AKORN	<u>0.025%</u>	<u>A202374 001</u>	May 08, 2013
<u>AT</u>		<u>0.1%</u>	<u>A202374 002</u>	May 08, 2013
<u>AT</u>	ALLIED	<u>0.1%</u>	<u>A040672 002</u>	Dec 13, 2006
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A040467 001</u>	Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467 002</u>	Apr 21, 2003
<u>AT</u>	TELIGENT PHARMA INC	<u>0.025%</u>	<u>A204608 001</u>	Jul 07, 2016
<u>AT</u>		<u>0.1%</u>	<u>A204606 001</u>	Jul 07, 2016
<u>AT</u>	! WOCKHARDT BIO AG	<u>0.025%</u>	<u>A088450 001</u>	Apr 01, 1985
<u>AT</u>	!	<u>0.1%</u>	<u>A088451 001</u>	Apr 03, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETATE

<u>AT</u>	MACLEODS PHARMS LTD	<u>0.025%</u>	<u>A209828 001</u>	Nov 23, 2018
<u>AT</u>		<u>0.1%</u>	<u>A209828 002</u>	Nov 23, 2018
<u>AT</u>		<u>0.5%</u>	<u>A209828 003</u>	Nov 23, 2018

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ACP NIMBLE	<u>0.025%</u>	<u>A089795 001</u>	Dec 23, 1988
<u>AT</u>		<u>0.1%</u>	<u>A089796 001</u>	Dec 23, 1988
<u>AT</u>		<u>0.5%</u>	<u>A208925 001</u>	Oct 06, 2017
<u>AT</u>	ENCUBE	<u>0.05%</u>	<u>A212384 001</u>	Nov 29, 2019

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	<u>0.025%</u>	<u>A085691</u>	<u>001</u>	
AT		<u>0.1%</u>	<u>A085691</u>	<u>003</u>	
AT		<u>0.5%</u>	<u>A085691</u>	<u>002</u>	
AT	GLENMARK PHARMS	<u>0.1%</u>	<u>A208320</u>	<u>001</u>	Aug 22, 2017
AT	GLENMARK PHARMS LTD	<u>0.5%</u>	<u>A206379</u>	<u>001</u>	Jul 22, 2016
AT	NOVEL LABS INC	<u>0.1%</u>	<u>A207365</u>	<u>001</u>	Oct 12, 2018
AT	! PERRIGO NEW YORK	<u>0.025%</u>	<u>A087385</u>	<u>002</u>	
AT	!	<u>0.1%</u>	<u>A087385</u>	<u>003</u>	
AT	!	<u>0.5%</u>	<u>A087385</u>	<u>001</u>	
AT	TARO PHARM INDS LTD	<u>0.1%</u>	<u>A040037</u>	<u>001</u>	Sep 30, 1994
AT	TELLIGENT PHARMA INC	<u>0.1%</u>	<u>A205373</u>	<u>001</u>	May 13, 2016
AT		<u>0.5%</u>	<u>A208590</u>	<u>001</u>	Mar 03, 2017

TRIAMCINOLONE ACETONIDE IN ABSORBABLE

AT	! CMP PHARMA INC	<u>0.05%</u>	<u>A089595</u>	<u>001</u>	Mar 23, 1995
-----------	------------------	--------------	----------------	------------	--------------

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	ACP NIMBLE	<u>0.1%</u>	<u>A205592</u>	<u>001</u>	Jan 12, 2017
AT	AKORN	<u>0.1%</u>	<u>A206312</u>	<u>001</u>	Aug 11, 2016
AT	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u>	Jul 01, 2010
AT	! TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

AT	+! SUN PHARM INDS INC	<u>0.147MG/GM</u>	<u>N012104</u>	<u>001</u>	
-----------	-----------------------	-------------------	----------------	------------	--

TRIAMCINOLONE ACETONIDE

AT	AKORN	<u>0.147MG/GM</u>	<u>A207094</u>	<u>001</u>	Dec 07, 2016
AT	PERRIGO UK FINCO	<u>0.147MG/GM</u>	<u>A205782</u>	<u>001</u>	Apr 13, 2015
AT	RISING	<u>0.147MG/GM</u>	<u>A206786</u>	<u>001</u>	Sep 08, 2017

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

	+! SANDOZ INC	5MG/ML	N016466	001	
	+!	20MG/ML	N016466	002	

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

AB	+ CONCORDIA	<u>50MG</u>	<u>N013174</u>	<u>001</u>	
AB	+!	<u>100MG</u>	<u>N013174</u>	<u>002</u>	

TRIAMTERENE

AB	AGNITIO	<u>50MG</u>	<u>A211581</u>	<u>001</u>	Aug 19, 2019
AB		<u>100MG</u>	<u>A211581</u>	<u>002</u>	Aug 19, 2019

TRIAZOLAM

TABLET; ORAL

HALCION

AB	+ PHARMACIA AND UPJOHN	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
AB	+!	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982

TRIAZOLAM

AB	HIKMA	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
AB		<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994
AB	MYLAN PHARMS INC	<u>0.125MG</u>	<u>A074031</u>	<u>001</u>	Mar 25, 1994
AB		<u>0.25MG</u>	<u>A074031</u>	<u>002</u>	Mar 25, 1994

TRICLABENDAZOLE

TABLET; ORAL

EGATEN

	+! NOVARTIS	250MG	N208711	001	Feb 13, 2019
--	-------------	-------	---------	-----	--------------

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

CLOVIQUE

AB	KADMON PHARMS LLC	<u>250MG</u>	<u>A209731</u>	<u>001</u>	Oct 21, 2019
-----------	-------------------	--------------	----------------	------------	--------------

SYPRINE

AB	+! BAUSCH	<u>250MG</u>	<u>N019194</u>	<u>001</u>	Nov 08, 1985
-----------	-----------	--------------	----------------	------------	--------------

TRIENTINE HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	<u>250MG</u>	<u>A210619</u>	<u>001</u>	Feb 08, 2019
AB	DR REDDYS LABS LTD	<u>250MG</u>	<u>A211076</u>	<u>001</u>	Jul 03, 2019
AB	KADMON PHARMS LLC	<u>250MG</u>	<u>A209415</u>	<u>001</u>	Sep 16, 2019
AB	MSN	<u>250MG</u>	<u>A211134</u>	<u>001</u>	May 22, 2019
AB	NAVINTA LLC	<u>250MG</u>	<u>A211251</u>	<u>001</u>	Jan 16, 2019

PRESCRIPTION DRUG PRODUCT LIST

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB	PAR PHARM INC	250MG	A210096 001	Sep 25, 2019
AB	WATSON LABS TEVA	250MG	A207567 001	Feb 07, 2018
AB	ZYDUS PHARMS	250MG	A211554 001	Apr 26, 2019

TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+	GALDERMA R AND D	0.005%	N211527 001	Oct 04, 2019
---	------------------	--------	-------------	--------------

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB	MYLAN	EQ 1MG BASE	A040209 001	Jul 07, 1997
AB		EQ 2MG BASE	A040209 002	Jul 07, 1997
AB		EQ 5MG BASE	A040209 003	Jul 07, 1997
AB	!	EQ 10MG BASE	A040209 004	Jul 07, 1997
AB	SANDOZ	EQ 1MG BASE	A085785 001	
AB		EQ 2MG BASE	A085786 001	
AB		EQ 5MG BASE	A085789 001	
AB		EQ 10MG BASE	A085788 001	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT	HI TECH	1%	A205438 001	Jul 28, 2017
AT	SANDOZ INC	1%	A074311 001	Oct 06, 1995
VIROPTIC				
AT	+	MONARCH PHARMS	1%	N018299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA	MIKART	2MG/5ML	A040251 001	Sep 27, 1999
AA	!	PHARM ASSOC	2MG/5ML	A040177 001

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA	NATCO PHARMA LTD	2MG	A091630 001	Nov 17, 2010
AA		5MG	A091630 002	Nov 17, 2010
AA	NOVITIUM PHARMA	2MG	A040254 001	Dec 24, 1998
AA		5MG	A040254 002	Dec 24, 1998
AA	!	WATSON LABS	2MG	A084363 001
AA	!		5MG	A084364 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB	+	KING PHARMS LLC	300MG	N017531 006	Dec 13, 2001
-----------	---	-----------------	--------------	--------------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	LUPIN	300MG	A076546 001	Aug 20, 2003
AB	SUN PHARM INDUSTRIES	300MG	A076570 001	Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

+	PAR STERILE PRODUCTS	100MG/ML	N017530 001	
---	----------------------	----------	-------------	--

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	+	MAYNE PHARMA	100MG	N018679 001	Jul 30, 1982
AB		NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011
AB		WATSON LABS	100MG	A070049 001	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	ALLEGIS	EQ 50MG BASE/5ML	N074973 001	Jan 24, 2000
---	---------	------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

<u>AB</u>		CROSSMEDIKA SA	<u>EQ 25MG BASE</u>	<u>A208127 001</u>	Apr 15, 2016
<u>AB</u>	!		<u>EQ 50MG BASE</u>	<u>A208127 002</u>	Apr 15, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A208127 003</u>	Apr 15, 2016
<u>AB</u>		ELITE LABS INC	<u>EQ 25MG BASE</u>	<u>A077361 001</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077361 002</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077361 003</u>	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

TRIPOTODUR KIT

+! ARBOR PHARMS LLC EQ 22.5MG BASE/VIAL N208956 001 Jun 29, 2017

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+! ALLERGAN EQ 3.75MG BASE/VIAL N020715 001 Jun 15, 2000

+! EQ 11.25MG BASE/VIAL N021288 001 Jun 29, 2001

+! EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

<u>AT</u>	!	NOVARTIS	<u>1%</u>	<u>A084306 001</u>	
<u>AT</u>	!	SANDOZ INC	<u>0.5%</u>	<u>A084305 001</u>	

TROPICACYL

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A040314 001</u>	Sep 29, 2000
<u>AT</u>			<u>1%</u>	<u>A040315 001</u>	Sep 29, 2000

TROPICAMIDE

<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040067 001</u>	Jul 27, 1994
<u>AT</u>			<u>1%</u>	<u>A040064 001</u>	Jul 27, 1994
<u>AT</u>		SOMERSET THERAPS LLC	<u>1%</u>	<u>A207524 001</u>	Dec 12, 2019

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

<u>AB</u>	!	ACTAVIS LABS FL INC	<u>60MG</u>	<u>A091289 001</u>	Oct 12, 2012
<u>AB</u>		PADDOCK LLC	<u>60MG</u>	<u>A201291 001</u>	May 24, 2013

TABLET; ORAL

TROSPIUM CHLORIDE

<u>AB</u>		APOTEX	<u>20MG</u>	<u>A091513 001</u>	Dec 06, 2011
<u>AB</u>	!	GLENMARK GENERICS	<u>20MG</u>	<u>A091575 001</u>	Aug 13, 2010
<u>AB</u>		HERITAGE PHARMS INC	<u>20MG</u>	<u>A204945 001</u>	Aug 30, 2016
<u>AB</u>		INVAGEN PHARMS	<u>20MG</u>	<u>A091688 001</u>	Aug 23, 2016
<u>AB</u>		PADDOCK LLC	<u>20MG</u>	<u>A091573 001</u>	Nov 17, 2010

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+! DORC 0.15% N022278 001 Feb 20, 2009

VISIONBLUE

+! DORC 0.06% N021670 001 Dec 16, 2004

UBROGEPANT

TABLET; ORAL

UBRELVY

+ ALLERGAN 50MG N211765 001 Dec 23, 2019

+! 100MG N211765 002 Dec 23, 2019

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

<u>AB</u>	!	LAB HRA PHARMA	<u>30MG</u>	<u>N022474 001</u>	Aug 13, 2010
-----------	---	----------------	-------------	--------------------	--------------

LOGILIA

<u>AB</u>		TEVA PHARMS USA	<u>30MG</u>	<u>A207952 001</u>	Feb 13, 2017
-----------	--	-----------------	-------------	--------------------	--------------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND EQ 62.5MCG BASE/INH N205382 001 Apr 30, 2014

PRESCRIPTION DRUG PRODUCT LIST

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013
---	-----------------	---	---------	-----	--------------

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL

RINVOQ

+	ABBVIE INC	15MG	N211675	001	Aug 16, 2019
---	------------	------	---------	-----	--------------

UREA, C-14

CAPSULE; ORAL

PYTEST

+	AVENT	1uCi	N020617	001	May 09, 1997
---	-------	------	---------	-----	--------------

PYTEST KIT

+	AVENT	1uCi	N020617	002	May 09, 1997
---	-------	------	---------	-----	--------------

URIDINE TRIACETATE

GRANULE; ORAL

VISTOGARD

+	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015
---	-----------------	-------------	---------	-----	--------------

XURIDEN

+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015
---	-----------------	------------	---------	-----	--------------

URSODIOL

CAPSULE; ORAL

ACTIGALL

AB	+	ALLERGAN	300MG	<u>N019594</u>	<u>002</u>	Dec 31, 1987
-----------	---	----------	--------------	-----------------------	-------------------	--------------

URSODIOL

AB		ABHAI LLC	300MG	<u>A210707</u>	<u>001</u>	May 17, 2018
-----------	--	-----------	--------------	-----------------------	-------------------	--------------

AB		AMNEAL PHARMS CO	300MG	<u>A211301</u>	<u>001</u>	Oct 16, 2018
-----------	--	------------------	--------------	-----------------------	-------------------	--------------

AB		EPIC PHARMA	300MG	<u>A075517</u>	<u>001</u>	Mar 14, 2000
-----------	--	-------------	--------------	-----------------------	-------------------	--------------

AB		EYWA PHARMA	300MG	<u>A212452</u>	<u>001</u>	Oct 30, 2019
-----------	--	-------------	--------------	-----------------------	-------------------	--------------

AB		LANNETT CO INC	300MG	<u>A079082</u>	<u>001</u>	Dec 15, 2008
-----------	--	----------------	--------------	-----------------------	-------------------	--------------

AB		MYLAN	300MG	<u>A090530</u>	<u>001</u>	Feb 17, 2010
-----------	--	-------	--------------	-----------------------	-------------------	--------------

AB		TEVA PHARMS	300MG	<u>A075592</u>	<u>001</u>	May 25, 2000
-----------	--	-------------	--------------	-----------------------	-------------------	--------------

TABLET; ORAL

URSO 250

AB	+	ALLERGAN	250MG	<u>N020675</u>	<u>001</u>	Dec 10, 1997
-----------	---	----------	--------------	-----------------------	-------------------	--------------

URSO FORTE

AB	+	ALLERGAN	500MG	<u>N020675</u>	<u>002</u>	Jul 21, 2004
-----------	---	----------	--------------	-----------------------	-------------------	--------------

URSODIOL

AB		GLENMARK GENERICS	250MG	<u>A090801</u>	<u>001</u>	Jul 12, 2011
-----------	--	-------------------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A090801</u>	<u>002</u>	Jul 12, 2011
-----------	--	--	--------------	-----------------------	-------------------	--------------

AB		IMPAX LABS INC	250MG	<u>A200826</u>	<u>001</u>	Dec 23, 2011
-----------	--	----------------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A200826</u>	<u>002</u>	Dec 23, 2011
-----------	--	--	--------------	-----------------------	-------------------	--------------

AB		PAR PHARM	250MG	<u>A202540</u>	<u>001</u>	Feb 14, 2013
-----------	--	-----------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A202540</u>	<u>002</u>	Feb 14, 2013
-----------	--	--	--------------	-----------------------	-------------------	--------------

AB		ZYDUS	250MG	<u>A211145</u>	<u>001</u>	Oct 30, 2018
-----------	--	-------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A211145</u>	<u>002</u>	Oct 30, 2018
-----------	--	--	--------------	-----------------------	-------------------	--------------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX	EQ 500MG BASE	<u>A090500</u>	<u>001</u>	Apr 04, 2014
-----------	--	--------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A090500</u>	<u>002</u>	Apr 04, 2014
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		AUROBINDO PHARMA	EQ 500MG BASE	<u>A090682</u>	<u>001</u>	May 24, 2010
-----------	--	------------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A090682</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		CIPLA	EQ 500MG BASE	<u>A077135</u>	<u>001</u>	May 24, 2010
-----------	--	-------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A077135</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		HETERO LABS LTD V	EQ 500MG BASE	<u>A203047</u>	<u>001</u>	Apr 08, 2015
-----------	--	-------------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A203047</u>	<u>002</u>	Apr 08, 2015
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		HIKMA	EQ 500MG BASE	<u>A078656</u>	<u>001</u>	May 24, 2010
-----------	--	-------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A078656</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		JUBILANT GENERICS	EQ 500MG BASE	<u>A201506</u>	<u>001</u>	Apr 03, 2012
-----------	--	-------------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A201506</u>	<u>002</u>	Apr 03, 2012
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		MYLAN PHARMS INC	EQ 500MG BASE	<u>A078518</u>	<u>001</u>	May 24, 2010
-----------	--	------------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A078518</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		SANDOZ	EQ 500MG BASE	<u>A077478</u>	<u>001</u>	May 24, 2010
-----------	--	--------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A077478</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		SUN PHARM INDS LTD	EQ 500MG BASE	<u>A076588</u>	<u>001</u>	Jan 31, 2007
-----------	--	--------------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A076588</u>	<u>002</u>	Jan 31, 2007
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		TEVA PHARMS	EQ 500MG BASE	<u>A077655</u>	<u>001</u>	May 24, 2010
-----------	--	-------------	----------------------	-----------------------	-------------------	--------------

AB			EQ 1GM BASE	<u>A077655</u>	<u>002</u>	May 24, 2010
-----------	--	--	--------------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>	TIME-CAP LABS INC	<u>EQ 500MG BASE</u>	<u>A079012 001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A079012 002</u>	May 24, 2010
<u>AB</u>	WOCKHARDT	<u>EQ 500MG BASE</u>	<u>A090216 001</u>	May 24, 2010
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090216 002</u>	May 24, 2010
<u>AB</u>	ZYDUS PHARMS	<u>EQ 500MG BASE</u>	<u>A079137 001</u>	Dec 29, 2017
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A079137 002</u>	Dec 29, 2017

VALTREX

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487 001</u>	Jun 23, 1995
<u>AB</u>	+	!	<u>EQ 1GM BASE</u>	<u>N020487 002</u>	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

	+	NEUROCRINE	EQ 40MG BASE	N209241 001	Apr 11, 2017
	+	!	EQ 80MG BASE	N209241 002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>50MG/ML</u>	<u>N022257 001</u>	Aug 28, 2009
-----------	---	-------------------	----------------	--------------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>50MG/ML</u>	<u>A205220 001</u>	Jul 18, 2016
<u>AB</u>		AJANTA PHARMA LTD	<u>50MG/ML</u>	<u>A212890 001</u>	Jan 13, 2020

TABLET; ORAL

VALCYTE

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304 001</u>	Mar 29, 2001
-----------	---	-------------------	----------------------	--------------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A212234 001</u>	Dec 26, 2019
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A204750 001</u>	Mar 31, 2016
<u>AB</u>		CIPLA	<u>EQ 450MG BASE</u>	<u>A209672 001</u>	Nov 09, 2018
<u>AB</u>		DR REDDYS	<u>EQ 450MG BASE</u>	<u>A206876 001</u>	Dec 12, 2017
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511 001</u>	Nov 04, 2014
<u>AB</u>		ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790 001</u>	Nov 04, 2014
<u>AB</u>		HETERO LABS LTD V	<u>EQ 450MG BASE</u>	<u>A205166 001</u>	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

<u>AP</u>		ATHENEX INC	<u>EQ 100MG BASE/ML</u>	<u>A076295 001</u>	Nov 14, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539 001</u>	Jun 26, 2003
<u>AP</u>	!	HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523 001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

<u>AB</u>	!	BIONPHARMA INC	<u>250MG</u>	<u>A073484 001</u>	Jun 29, 1993
<u>AB</u>		CATALENT	<u>250MG</u>	<u>A073229 001</u>	Oct 29, 1991
<u>AB</u>		NOVELGENIX THERAPS	<u>250MG</u>	<u>A207611 001</u>	Aug 05, 2019
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037 001</u>	Feb 22, 2013

SYRUP; ORAL

VALPROIC ACID

<u>AA</u>		ECI PHARMS LLC	<u>250MG/5ML</u>	<u>A090517 001</u>	May 28, 2010
<u>AA</u>		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060 001</u>	Jan 13, 1995
<u>AA</u>		LANNETT CO INC	<u>250MG/5ML</u>	<u>A077960 001</u>	Oct 13, 2006
<u>AA</u>	!	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379 001</u>	Dec 15, 2000
<u>AA</u>		VISTAPHARM	<u>250MG/5ML</u>	<u>A075782 001</u>	Dec 22, 2000
<u>AA</u>		WOCKHARDT BIO AG	<u>250MG/5ML</u>	<u>A070868 001</u>	Jul 01, 1986

VALRUBICIN

SOLUTION; INTRAVESICAL

VALRUBICIN

<u>AO</u>		CUSTOPHARM INC	<u>40MG/ML</u>	<u>A206430 001</u>	Apr 19, 2019	
<u>AO</u>	+	!	ENDO PHARM	<u>40MG/ML</u>	<u>N020892 001</u>	Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVAN

<u>AB</u>	+	NOVARTIS	<u>40MG</u>	<u>N021283 004</u>	Aug 14, 2002
<u>AB</u>	+		<u>80MG</u>	<u>N021283 001</u>	Jul 18, 2001
<u>AB</u>	+		<u>160MG</u>	<u>N021283 002</u>	Jul 18, 2001
<u>AB</u>	+	!	<u>320MG</u>	<u>N021283 003</u>	Jul 18, 2001

PRESCRIPTION DRUG PRODUCT LIST

VALSARTAN

TABLET; ORAL

VALSARTAN

<u>AB</u>	ALEMbic PHARMS LTD	<u>40MG</u>	<u>A091367 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A091367 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A091367 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A091367 004</u>	Jan 05, 2015
<u>AB</u>	ALKEM LABS LTD	<u>40MG</u>	<u>A205536 001</u>	Mar 12, 2019
<u>AB</u>		<u>80MG</u>	<u>A205536 002</u>	Mar 12, 2019
<u>AB</u>		<u>160MG</u>	<u>A205536 003</u>	Mar 12, 2019
<u>AB</u>		<u>320MG</u>	<u>A205536 004</u>	Mar 12, 2019
<u>AB</u>	AMNEAL PHARMS	<u>40MG</u>	<u>A204011 001</u>	Jan 11, 2016
<u>AB</u>		<u>80MG</u>	<u>A204011 002</u>	Jan 11, 2016
<u>AB</u>		<u>160MG</u>	<u>A204011 003</u>	Jan 11, 2016
<u>AB</u>		<u>320MG</u>	<u>A204011 004</u>	Jan 11, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A202223 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A202223 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A202223 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A202223 004</u>	Jan 05, 2015
<u>AB</u>	HETERO LABS LTD V	<u>40MG</u>	<u>A203311 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203311 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203311 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203311 004</u>	Jan 05, 2015
<u>AB</u>	IVAX PHARMS	<u>40MG</u>	<u>A077530 001</u>	Jan 04, 2016
<u>AB</u>		<u>80MG</u>	<u>A077530 002</u>	Jan 04, 2016
<u>AB</u>		<u>160MG</u>	<u>A077530 003</u>	Jan 04, 2016
<u>AB</u>		<u>320MG</u>	<u>A077530 004</u>	Jan 04, 2016
<u>AB</u>	JUBILANT GENERICS	<u>40MG</u>	<u>A203536 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203536 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203536 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203536 004</u>	Jan 05, 2015
<u>AB</u>	LUPIN LTD	<u>40MG</u>	<u>A201677 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A201677 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A201677 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A201677 004</u>	Jan 05, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>40MG</u>	<u>A202696 001</u>	Sep 16, 2016
<u>AB</u>		<u>80MG</u>	<u>A202696 002</u>	Sep 16, 2016
<u>AB</u>		<u>160MG</u>	<u>A202696 003</u>	Sep 16, 2016
<u>AB</u>		<u>320MG</u>	<u>A202696 004</u>	Sep 16, 2016
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A090866 001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090866 002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090866 003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090866 004</u>	Jan 05, 2015
<u>AB</u>	OHM LABS INC	<u>40MG</u>	<u>A077492 001</u>	Jun 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A077492 002</u>	Jun 26, 2014
<u>AB</u>		<u>160MG</u>	<u>A077492 003</u>	Jun 26, 2014
<u>AB</u>		<u>320MG</u>	<u>A077492 004</u>	Jun 26, 2014
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A204821 001</u>	Jun 09, 2015
<u>AB</u>		<u>80MG</u>	<u>A204821 002</u>	Jun 09, 2015
<u>AB</u>		<u>160MG</u>	<u>A204821 003</u>	Jun 09, 2015
<u>AB</u>		<u>320MG</u>	<u>A204821 004</u>	Jun 09, 2015
<u>AB</u>	SQUARE PHARMS LTD	<u>40MG</u>	<u>A205347 001</u>	Apr 09, 2018
<u>AB</u>		<u>80MG</u>	<u>A205347 002</u>	Apr 09, 2018
<u>AB</u>		<u>160MG</u>	<u>A205347 003</u>	Apr 09, 2018
<u>AB</u>		<u>320MG</u>	<u>A205347 004</u>	Apr 09, 2018
<u>AB</u>	UNICHEM LABS LTD	<u>40MG</u>	<u>A209261 001</u>	May 04, 2018
<u>AB</u>		<u>80MG</u>	<u>A209261 002</u>	May 04, 2018
<u>AB</u>		<u>160MG</u>	<u>A209261 003</u>	May 04, 2018
<u>AB</u>		<u>320MG</u>	<u>A209261 004</u>	May 04, 2018

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOcin HYDROCHLORIDE

<u>AB</u>	+ ANI PHARMS INC	<u>EQ 125MG BASE</u>	<u>N050606 001</u>	Apr 15, 1986
<u>AB</u>	+!	<u>EQ 250MG BASE</u>	<u>N050606 002</u>	Apr 15, 1986
<u>VANCOMYCIN HYDROCHLORIDE</u>				
<u>AB</u>	AKORN	<u>EQ 125MG BASE</u>	<u>A065478 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065478 002</u>	Apr 09, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439 001</u>	Jan 28, 2015
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A090439 002</u>	Jan 28, 2015
<u>AB</u>	ORIENT PHARMA CO LTD	<u>EQ 125MG BASE</u>	<u>A210729 001</u>	Apr 29, 2019

PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A210729 002</u>	Apr 29, 2019
<u>AB</u>	STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065490 002</u>	Apr 09, 2012
<u>AB</u>	WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065510 002</u>	Apr 09, 2012

FOR SOLUTION; ORAL

FIRVANQ KIT

+	!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910 001	Jan 26, 2018
+	!		EQ 50MG BASE/ML	N208910 002	Jan 26, 2018

VANCOCIN HYDROCHLORIDE

		ANI PHARMS INC	EQ 250MG BASE/5ML	A061667 002	Jul 13, 1983
--	--	----------------	-------------------	-------------	--------------

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205780 001</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205780 002</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A205779 001</u>	Mar 29, 2016
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A205779 002</u>	Mar 29, 2016
<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663 001</u>	Mar 17, 1987
<u>AP</u>			<u>EQ 750MG BASE/VIAL</u>	<u>A062663 005</u>	Aug 17, 2016
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062663 002</u>	Jul 31, 1987
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A062663 003</u>	Jun 03, 1988
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A062663 004</u>	Nov 28, 1997
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205694 001</u>	Jan 21, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205694 002</u>	Jan 21, 2016
<u>AP</u>		HIKMA	<u>EQ 5GM BASE/VIAL</u>	<u>A204360 001</u>	Oct 15, 2018
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A204360 002</u>	Oct 15, 2018
<u>AP</u>		HIKMA PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A206616 001</u>	Oct 03, 2018
<u>AP</u>	!	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911 001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A062931 001</u>	Oct 29, 1992
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062912 002</u>	Jan 07, 2009
<u>AP</u>	!		<u>EQ 750MG BASE/VIAL</u>	<u>A062933 002</u>	May 27, 2009
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062912 001</u>	Aug 04, 1988
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062933 001</u>	Oct 29, 1992
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A063076 001</u>	Dec 21, 1990
<u>AP</u>		HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455 001</u>	Apr 29, 2009
<u>AP</u>		MUSTAFA NEVZAT ILAC	<u>EQ 500MG BASE/VIAL</u>	<u>A065401 001</u>	Jun 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065401 002</u>	Jun 30, 2008
<u>AP</u>		MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397 001</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065397 002</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A065432 001</u>	Dec 30, 2008
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A091554 001</u>	Sep 19, 2011
<u>AP</u>		SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837 001</u>	Aug 10, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A200837 002</u>	Sep 02, 2014
<u>AP</u>		SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250 001</u>	Apr 27, 2010
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A090250 002</u>	Apr 27, 2010
<u>AP</u>		SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048 001</u>	Aug 10, 2012
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A201048 002</u>	Aug 10, 2012
<u>AP</u>		XELLIA PHARMS APS	<u>EQ 5GM BASE/VIAL</u>	<u>A204125 001</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A204125 002</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A204107 001</u>	Dec 28, 2015
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A204107 002</u>	Dec 28, 2015

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671 001	Apr 29, 1993
+	!		EQ 750MG BASE/150ML	N050671 002	Dec 20, 2010
+	!		EQ 1GM BASE/200ML	N050671 003	Mar 01, 1999

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	!	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481 001	Jul 10, 2018
+	!		EQ 750MG BASE/VIAL	N209481 002	Jul 10, 2018
+	!		EQ 1.25GM BASE/VIAL	N209481 003	Jul 10, 2018
+	!		EQ 1.5GM BASE/VIAL	N209481 004	Jul 10, 2018

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A091532 001	Jan 06, 2016
--	--	--------------	---------------	-------------	--------------

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962 001	Feb 15, 2019
+	!		EQ 1GM BASE/200ML	N211962 002	Feb 15, 2019
+	!		EQ 1.5GM BASE/300ML	N211962 003	Feb 15, 2019
+	!		EQ 2GM BASE/400ML	N211962 004	Feb 15, 2019

PRESCRIPTION DRUG PRODUCT LIST

VANDETANIB

TABLET;ORAL

CAPRELSA

+ GENZYME CORP

100MG

N022405 001 Apr 06, 2011

+!

300MG

N022405 002 Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRAAB + BAYER HLTHCARE5MGN021400 001 Aug 19, 2003AB +10MGN021400 002 Aug 19, 2003AB +!20MGN021400 004 Aug 19, 2003VARDENAFIL HYDROCHLORIDEAB CROSSMEDIKA SA2.5MGA209057 001 Oct 31, 2018AB5MGA209057 002 Oct 31, 2018AB10MGA209057 003 Oct 31, 2018AB20MGA209057 004 Oct 31, 2018AB MACLEODS PHARMS LTD2.5MGA204632 001 Oct 22, 2019AB5MGA204632 002 Oct 22, 2019AB10MGA204632 003 Oct 22, 2019AB20MGA204632 004 Oct 22, 2019AB TEVA PHARMS2.5MGA091347 001 May 03, 2012AB5MGA091347 002 May 03, 2012AB10MGA091347 003 May 03, 2012AB20MGA091347 004 May 03, 2012AB ZYDUS PHARMS2.5MGA208960 001 Oct 31, 2018AB5MGA208960 002 Oct 31, 2018AB10MGA208960 003 Oct 31, 2018AB20MGA208960 004 Oct 31, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYNAB +! BAYER HLTHCARE10MGN200179 001 Jun 17, 2010VARDENAFIL HYDROCHLORIDEAB ALEMBIC PHARMS LTD10MGA208324 001 Nov 16, 2018VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+ PF PRISM CV

EQ 0.5MG BASE

N021928 001 May 10, 2006

+!

EQ 1MG BASE

N021928 002 May 10, 2006

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+! PAR STERILE
PRODUCTS

20UNITS/ML (20UNITS/ML)

N204485 001 Apr 17, 2014

+!

200UNITS/10ML (20UNITS/ML)

N204485 002 Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDEAP AUROBINDO PHARMA
LTD10MG/VIALA206670 001 Dec 20, 2018AP20MG/VIALA206670 002 Dec 20, 2018AP GLAND PHARMA LTD10MG/VIALA205390 001 May 26, 2016AP20MG/VIALA205390 002 May 26, 2016AP HIKMA10MG/VIALA203725 001 Jul 30, 2019AP20MG/VIALA203725 002 Jul 30, 2019AP HOSPIRA10MG/VIALA075164 001 Oct 21, 1999AP20MG/VIALA075164 002 Oct 21, 1999AP MYLAN LABS LTD10MG/VIALA090243 001 May 11, 2010AP20MG/VIALA090243 002 May 11, 2010AP SAGENT PHARMS INC10MG/VIALA078274 001 Dec 29, 2008AP20MG/VIALA078274 002 Dec 29, 2008AP ! SUN PHARM10MG/VIALA079001 001 Jun 17, 2009AP !20MG/VIALA079001 002 Jun 17, 2009AP TEVA PHARMS USA10MG/VIALA074688 001 Aug 25, 1999AP20MG/VIALA074688 002 Aug 25, 1999AP WEST-WARD PHARMS
INT10MG/VIALA075549 001 Jun 13, 2000AP20MG/VIALA075549 002 Jun 13, 2000

PRESCRIPTION DRUG PRODUCT LIST

VELAGLUCERASE ALFA

INJECTABLE; INTRAVENOUS

VPRIV

SHIRE HUMAN GENETIC 400 UNITS/VIAL

N022575 001 Feb 26, 2010

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+! HOFFMANN LA ROCHE 240MG

N202429 001 Aug 17, 2011

VENETOCLAX

TABLET; ORAL

VENCLEXTA

+ ABBVIE INC 10MG

N208573 001 Apr 11, 2016

+ 50MG

N208573 002 Apr 11, 2016

+! 100MG

N208573 003 Apr 11, 2016

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XRAB + WYETH PHARMS EQ 37.5MG BASEN020699 001 Oct 20, 1997AB + EQ 75MG BASEN020699 002 Oct 20, 1997AB +! EQ 150MG BASEN020699 004 Oct 20, 1997VENLAFAXINE HYDROCHLORIDEAB ANNORA PHARMA EQ 37.5MG BASEA212277 001 Jul 08, 2019AB EQ 75MG BASEA212277 002 Jul 08, 2019AB EQ 150MG BASEA212277 003 Jul 08, 2019AB AUROBINDO PHARMA EQ 37.5MG BASEA200834 001 Apr 14, 2011

LTD

AB EQ 75MG BASEA200834 002 Apr 14, 2011AB EQ 150MG BASEA200834 003 Apr 14, 2011AB DR REDDYS LABS LTD EQ 37.5MG BASEA078421 001 May 06, 2011AB EQ 75MG BASEA078421 002 May 06, 2011AB EQ 150MG BASEA078421 003 May 06, 2011AB INTELLIPHARMACEUTIC EQ 37.5MG BASEA201272 001 Nov 23, 2018

S

AB EQ 75MG BASEA201272 002 Nov 23, 2018AB EQ 150MG BASEA201272 003 Nov 23, 2018AB MACLEODS PHARMS LTD EQ 37.5MG BASEA204889 001 Oct 05, 2017AB EQ 75MG BASEA204889 002 Oct 05, 2017AB EQ 150MG BASEA204889 003 Oct 05, 2017AB ORCHID HLTHCARE EQ 37.5MG BASEA091123 001 Jul 11, 2011AB EQ 75MG BASEA091123 002 Jul 11, 2011AB EQ 150MG BASEA091123 003 Jul 11, 2011AB TEVA EQ 37.5MG BASEA076565 001 Jun 28, 2010AB EQ 75MG BASEA076565 002 Jun 28, 2010AB EQ 150MG BASEA076565 003 Jun 28, 2010AB TORRENT PHARMS LLC EQ 37.5MG BASEA090899 001 Jun 01, 2011AB EQ 75MG BASEA090899 002 Jun 01, 2011AB EQ 150MG BASEA090899 003 Jun 01, 2011AB VALEANT PHARMS EQ 37.5MG BASEA090071 001 Apr 15, 2011

NORTH

AB EQ 75MG BASEA090071 002 Apr 15, 2011AB EQ 150MG BASEA090071 003 Apr 15, 2011AB WOCKHARDT EQ 37.5MG BASEA078865 001 Apr 14, 2011AB EQ 75MG BASEA078865 002 Apr 14, 2011AB EQ 150MG BASEA078865 003 Apr 14, 2011AB ZYDUS PHARMS USA EQ 37.5MG BASEA090174 001 Apr 14, 2011

INC

AB EQ 75MG BASEA090174 002 Apr 14, 2011AB EQ 150MG BASEA090174 003 Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDEAB ALEMBIC PHARMS LTD EQ 25MG BASEA078932 001 Dec 14, 2010AB EQ 37.5MG BASEA078932 002 Dec 14, 2010AB EQ 50MG BASEA078932 003 Dec 14, 2010AB EQ 75MG BASEA078932 004 Dec 14, 2010AB EQ 100MG BASEA078932 005 Dec 14, 2010AB AMNEAL PHARMS EQ 25MG BASEA079098 001 May 11, 2010AB EQ 37.5MG BASEA079098 002 May 11, 2010AB EQ 50MG BASEA079098 003 May 11, 2010AB EQ 75MG BASEA079098 004 May 11, 2010AB EQ 100MG BASEA079098 005 May 11, 2010AB AUROBINDO PHARMA EQ 25MG BASEA090555 001 Apr 07, 2010AB EQ 37.5MG BASEA090555 002 Apr 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A206250 001</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A206250 002</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A206250 003</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A206250 004</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A206250 005</u>	Nov 21, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>	!	<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036 003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036 004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036 005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	CADILA PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A211323 001</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A211323 002</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A211323 003</u>	Aug 29, 2019
<u>AB</u>	DEXCEL PHARMA	<u>EQ 150MG BASE</u>	<u>A209193 001</u>	Oct 31, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A209193 002</u>	Oct 31, 2019
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 150MG BASE</u>	<u>A205468 002</u>	Mar 24, 2017
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A205468 003</u>	Mar 24, 2017
<u>AB</u>	+ OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+!	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 225MG BASE</u>	<u>N022104 004</u>	May 20, 2008
<u>AB</u>	SUN PHARM	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A091272 004</u>	Jan 08, 2019

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>VERELAN</u>				
<u>AB</u>	+ RECRO GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>	+	<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992

PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	+		240MG	<u>N019614</u>	<u>002</u>	May 29, 1990
	+!		360MG	N019614	004	May 10, 1996
		VERELAN PM				
	+	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998
	+		200MG	N020943	002	Nov 25, 1998
	+!		300MG	N020943	003	Nov 25, 1998

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL	<u>5MG/2ML (2.5MG/ML)</u>	<u>A210994</u>	<u>001</u>	Jul 13, 2018
AP			<u>10MG/4ML (2.5MG/ML)</u>	<u>A210994</u>	<u>002</u>	Jul 13, 2018
AP		EXELA PHARMA SCS LLC	<u>5MG/2ML (2.5MG/ML)</u>	<u>N018925</u>	<u>001</u>	Mar 30, 1984
AP			<u>10MG/4ML (2.5MG/ML)</u>	<u>N018925</u>	<u>002</u>	Apr 05, 2018
AP	!	HOSPIRA	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
AP	!		<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998
AP	!		<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
AP	!		<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737</u>	<u>002</u>	May 06, 1987
AP		MICRO LABS	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211370</u>	<u>001</u>	Dec 28, 2018
AP			<u>10MG/4ML (2.5MG/ML)</u>	<u>A211370</u>	<u>002</u>	Dec 28, 2018
AP		SOMERSET	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211035</u>	<u>001</u>	Jun 18, 2018
AP			<u>10MG/4ML (2.5MG/ML)</u>	<u>A211035</u>	<u>002</u>	Jun 18, 2018
AP		SOMERSET THERAPS LLC	<u>5MG/2ML (2.5MG/ML)</u>	<u>A211015</u>	<u>001</u>	Jun 18, 2018
AP			<u>10MG/4ML (2.5MG/ML)</u>	<u>A211015</u>	<u>002</u>	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS INC	<u>40MG</u>	<u>A071881</u>	<u>002</u>	Oct 14, 2015
AB			<u>80MG</u>	<u>A071881</u>	<u>003</u>	Apr 05, 1988
AB	!		<u>120MG</u>	<u>A071881</u>	<u>001</u>	Apr 05, 1988
AB		MYLAN	<u>80MG</u>	<u>A071483</u>	<u>002</u>	Feb 15, 1989
AB			<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989
AB		WATSON LABS	<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
AB			<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
AB			<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

AB	+	PFIZER	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
AB	+		<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	<u>180MG</u>	<u>A206173</u>	<u>001</u>	May 05, 2017
AB			<u>240MG</u>	<u>A206173</u>	<u>002</u>	May 05, 2017
AB		GLENMARK GENERICS	<u>120MG</u>	<u>A090700</u>	<u>001</u>	Aug 03, 2011
AB	!		<u>180MG</u>	<u>A090700</u>	<u>002</u>	Aug 03, 2011
AB			<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
AB		IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
AB			<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
AB			<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
AB		MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997
AB			<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997
AB			<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996
AB		PAR PHARM	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
AB			<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
AB		SUN PHARM INDS INC	<u>120MG</u>	<u>A090529</u>	<u>001</u>	Dec 30, 2011
AB			<u>180MG</u>	<u>A090529</u>	<u>002</u>	Dec 30, 2011
AB			<u>240MG</u>	<u>A090529</u>	<u>003</u>	Dec 30, 2011

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000
--	---	--------------------	-----------	---------	-----	--------------

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+	LUNDBECK PHARMS LLC	<u>500MG/PACKET</u>	<u>N022006</u>	<u>001</u>	Aug 21, 2009
-----------	---	---------------------	----------------------------	-----------------------	-------------------	--------------

VIGABATRIN

AA		AMNEAL PHARMS	<u>500MG/PACKET</u>	<u>A210155</u>	<u>001</u>	Mar 13, 2018
AA		DR REDDYS LABS LTD	<u>500MG/PACKET</u>	<u>A211481</u>	<u>001</u>	Nov 20, 2018
AA		INVAGEN PHARMS	<u>500MG/PACKET</u>	<u>A211592</u>	<u>001</u>	Dec 03, 2019
AA		PAR PHARM INC	<u>500MG/PACKET</u>	<u>A208218</u>	<u>001</u>	Apr 27, 2017

PRESCRIPTION DRUG PRODUCT LIST

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN**AA** TEVA PHARMS USA **500MG/PACKET** **A209824 001** Apr 23, 2018VIGADRONE**AA** AUCTA **500MG/PACKET** **A210196 001** Jun 21, 2018

TABLET;ORAL

SABRIL**AB** +! LUNDBECK PHARMS LLC **500MG** **N020427 001** Aug 21, 2009VIGABATRIN**AB** TEVA PHARMS USA **500MG** **A209822 001** Jan 14, 2019VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD**AB** +! ALLERGAN **10MG** **N022567 001** Jan 21, 2011**AB** + **20MG** **N022567 002** Jan 21, 2011**AB** + **40MG** **N022567 003** Jan 21, 2011VILAZODONE HYDROCHLORIDE**AB** ALEMBIC PHARMS LTD **10MG** **A208202 001** Jan 10, 2020**AB** **20MG** **A208202 002** Jan 10, 2020**AB** **40MG** **A208202 003** Jan 10, 2020**AB** TEVA PHARMS USA **10MG** **A208212 001** Sep 30, 2019**AB** **20MG** **A208212 002** Sep 30, 2019**AB** **40MG** **A208212 003** Sep 30, 2019VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

! FRESENIUS KABI USA 1MG/ML A089515 001 Apr 29, 1987

! WEST-WARD PHARMS 10MG/VIAL A089395 001 Apr 09, 1987

INT

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

! HOSPIRA 1MG/ML A071484 001 Apr 19, 1988

INJECTABLE, LIPOSOMAL;INTRAVENOUS

MARQIBO KIT

+! ACROTECH 5MG/5ML (1MG/ML) N202497 001 Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE**AP** ACTAVIS TOTOWA **EQ 10MG BASE/ML** **A078011 001** Jul 22, 2009**AP** DR REDDYS **EQ 10MG BASE/ML** **A202017 001** Sep 12, 2013**AP** FRESENIUS KABI USA **EQ 10MG BASE/ML** **A076849 001** Apr 18, 2005**AP** JIANGSU HANSON PHARM **EQ 10MG BASE/ML** **A091106 001** Sep 26, 2012**AP** TEVA PHARMS USA **EQ 10MG BASE/ML** **A076028 001** Feb 03, 2003**AP** WEST-WARD PHARMS **EQ 10MG BASE/ML** **A075992 001** Jun 10, 2003

INT

AP **EQ 10MG BASE/ML** **A076461 001** Dec 11, 2003VISMODEGIB

CAPSULE;ORAL

ERIVEDGE

+! GENENTECH 150MG N203388 001 Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

+! CASPER PHARMA LLC EQ 50,000 UNITS BASE/ML N006823 001

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

+! TOPROL EQ 2.08MG BASE N204886 001 May 08, 2014

VORICONAZOLE

FOR SUSPENSION;ORAL

VFEND**AB** +! PF PRISM CV **200MG/5ML** **N021630 001** Dec 19, 2003VORICONAZOLE**AB** AMNEAL PHARMS **200MG/5ML** **A205034 001** Apr 13, 2016**AB** NOVEL LABS INC **200MG/5ML** **A206799 001** May 31, 2016

PRESCRIPTION DRUG PRODUCT LIST

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VFEND

AP	+!	PF PRISM CV	200MG/VIAL	N021267 001	May 24, 2002
-----------	-----------	-------------	-------------------	--------------------	--------------

VORICONAZOLE

AP		ALVOGEN	200MG/VIAL	A206398 001	Mar 23, 2016
AP		HAINAN POLY PHARM	200MG/VIAL	A211661 001	Nov 30, 2018
AP		SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012
AP		ZYDUS PHARMS	200MG/VIAL	A208983 001	Jul 16, 2018

POWDER; INTRAVENOUS

VORICONAZOLE

AP		XELLIA PHARMS APS	200MG/VIAL	N208562 001	Mar 09, 2017
-----------	--	-------------------	-------------------	--------------------	--------------

TABLET; ORAL

VFEND

AB	+	PF PRISM CV	50MG	N021266 001	May 24, 2002
AB	+!		200MG	N021266 002	May 24, 2002

VORICONAZOLE

AB		AJANTA PHARMA LTD	50MG	A206181 001	May 24, 2016
AB			200MG	A206181 002	May 24, 2016
AB		AKORN	50MG	A207049 001	Sep 07, 2016
AB			200MG	A207049 002	Sep 07, 2016
AB		APPCO	50MG	A206762 001	May 24, 2016
AB			200MG	A206762 002	May 24, 2016
AB		AUROBINDO PHARMA LTD	50MG	A206837 001	Jan 22, 2016
AB			200MG	A206837 002	Jan 22, 2016
AB		CADILA	50MG	A206747 001	May 24, 2016
AB			200MG	A206747 002	May 24, 2016
AB		GLENMARK PHARMS LTD	50MG	A203503 001	Sep 02, 2015
AB			200MG	A203503 002	Sep 02, 2015
AB		MYLAN PHARMS INC	50MG	A090547 001	Apr 22, 2010
AB			200MG	A090547 002	Apr 22, 2010
AB		NOVEL LABS INC	50MG	A207371 001	May 24, 2016
AB			200MG	A207371 002	May 24, 2016
AB		PRINSTON INC	50MG	A206654 001	Aug 08, 2016
AB			200MG	A206654 002	Aug 08, 2016
AB		SANDOZ INC	50MG	A200265 001	Dec 12, 2011
AB			200MG	A200265 002	Dec 12, 2011

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+!	MERCK	100MG	N021991 001	Oct 06, 2006
-----------	-------	-------	--------------------	--------------

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447 001	Sep 30, 2013
+		EQ 10MG BASE	N204447 002	Sep 30, 2013
+!		EQ 20MG BASE	N204447 004	Sep 30, 2013

VOXELOTOR

TABLET; ORAL

OXBRYTA

+!	GLOBAL BLOOD THERAPIS	500MG	N213137 001	Nov 25, 2019
-----------	-----------------------	-------	--------------------	--------------

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

AB	+	BRISTOL MYERS SQUIBB	1MG	N009218 022	Mar 01, 1990
AB	+		2MG	N009218 013	
AB	+		2.5MG	N009218 018	
AB	+		3MG	N009218 025	Nov 18, 1996
AB	+		4MG	N009218 023	Aug 24, 1993
AB	+		5MG	N009218 007	
AB	+		6MG	N009218 026	Nov 18, 1996
AB	+		7.5MG	N009218 016	
AB	+!		10MG	N009218 005	

JANTOVEN

AB		UPSHER SMITH LABS	1MG	A040416 001	Oct 02, 2003
AB			2MG	A040416 002	Oct 02, 2003
AB			2.5MG	A040416 003	Oct 02, 2003
AB			3MG	A040416 004	Oct 02, 2003

PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

JANTOVEN

<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>1MG</u>	<u>A202202</u>	<u>001</u>	Mar 04, 2013
<u>AB</u>		<u>2MG</u>	<u>A202202</u>	<u>002</u>	Mar 04, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A202202</u>	<u>003</u>	Mar 04, 2013
<u>AB</u>		<u>3MG</u>	<u>A202202</u>	<u>004</u>	Mar 04, 2013
<u>AB</u>		<u>4MG</u>	<u>A202202</u>	<u>005</u>	Mar 04, 2013
<u>AB</u>		<u>5MG</u>	<u>A202202</u>	<u>006</u>	Mar 04, 2013
<u>AB</u>		<u>6MG</u>	<u>A202202</u>	<u>007</u>	Mar 04, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A202202</u>	<u>008</u>	Mar 04, 2013
<u>AB</u>		<u>10MG</u>	<u>A202202</u>	<u>009</u>	Mar 04, 2013
<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145</u>	<u>003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145</u>	<u>008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935</u>	<u>001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935</u>	<u>002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935</u>	<u>003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935</u>	<u>004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935</u>	<u>005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935</u>	<u>006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935</u>	<u>007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935</u>	<u>008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935</u>	<u>009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104</u>	<u>001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104</u>	<u>002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104</u>	<u>003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104</u>	<u>004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104</u>	<u>005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104</u>	<u>006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104</u>	<u>007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104</u>	<u>008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104</u>	<u>009</u>	Jun 27, 2013
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

PRESCRIPTION DRUG PRODUCT LIST

XENON XE-133

GAS; INHALATION

XENON XE 133

CURIUM

10mCi/VIAL

N018327 001 Mar 09, 1982

20mCi/VIAL

N018327 002 Mar 09, 1982

LANTHEUS MEDCL

10mCi/VIAL

N017284 001

20mCi/VIAL

N017284 002

ZAFIRLUKAST

TABLET; ORAL

ACCOLATEAB + PAR PHARM INC10MGN020547 003 Sep 17, 1999AB +!20MGN020547 001 Sep 26, 1996ZAFIRLUKASTAB DR REDDYS LABS LTD10MGA090372 001 Nov 18, 2010AB20MGA090372 002 Nov 18, 2010ZALEPLON

CAPSULE; ORAL

SONATAAB + PFIZER5MGN020859 001 Aug 13, 1999AB +!10MGN020859 002 Aug 13, 1999ZALEPLONAB AUROBINDO PHARMA5MGA078829 001 Jun 06, 2008AB10MGA078829 002 Jun 06, 2008AB CIPLA LTD5MGA077505 001 Jun 20, 2008AB10MGA077505 002 Jun 20, 2008AB HIKMA5MGA077237 001 Jun 06, 2008AB10MGA077237 002 Jun 06, 2008AB HIKMA PHARMS5MGA078147 001 Nov 25, 2008AB10MGA078147 002 Nov 25, 2008AB ORCHID HLTHCARE5MGA090374 001 Sep 17, 2009AB10MGA090374 002 Sep 17, 2009AB TEVA PHARMS5MGA077239 001 Jun 06, 2008AB10MGA077239 002 Jun 06, 2008AB UNICHEM5MGA078989 001 Jun 06, 2008AB10MGA078989 002 Jun 06, 2008ZANAMIVIR

POWDER; INHALATION

RELENZA

+! GLAXOSMITHKLINE

5MG

N021036 001 Jul 26, 1999

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+! BEIGENE

80MG

N213217 001 Nov 14, 2019

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+! TERSERA THERAPS LLC

100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004

+!

500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004

+!

500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIRAB +! VIIV HLTHCARE100MGN019655 001 Mar 19, 1987ZIDOVUDINEAB AUROBINDO PHARMA100MGA078128 001 Mar 27, 2006

LTD

AB CIPLA LTD100MGA078349 001 May 23, 2007

INJECTABLE; INJECTION

RETROVIRAP +! VIIV HLTHCARE10MG/MLN019951 001 Feb 02, 1990

SYRUP; ORAL

RETROVIRAA +! VIIV HLTHCARE50MG/5MLN019910 001 Sep 28, 1989ZIDOVUDINEAA AUROBINDO50MG/5MLA077268 001 Sep 19, 2005AA CIPLA LTD50MG/5MLA077981 001 Jun 26, 2008

TABLET; ORAL

ZIDOVUDINEAB AUROBINDO300MGA077267 001 Sep 19, 2005AB CIPLA300MGA090561 001 Oct 27, 2010

PRESCRIPTION DRUG PRODUCT LIST

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

<u>AB</u>	!	HETERO LABS LTD III	<u>300MG</u>	<u>A090092</u>	<u>001</u>	Apr 25, 2008
<u>AB</u>		HIKMA	<u>300MG</u>	<u>A076844</u>	<u>001</u>	Sep 19, 2005
<u>AB</u>		MYLAN PHARMS INC	<u>300MG</u>	<u>A078922</u>	<u>001</u>	Feb 14, 2008

ZILEUTON

TABLET;ORAL

ZYFLO

+	!	CHIESI USA INC	600MG	N020471	003	Dec 09, 1996
---	---	----------------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

<u>AB</u>		LUPIN LTD	<u>600MG</u>	<u>A211972</u>	<u>001</u>	Nov 05, 2019	
<u>AB</u>		PAR PHARM INC	<u>600MG</u>	<u>A212670</u>	<u>001</u>	Dec 16, 2019	
<u>AB</u>		RISING	<u>600MG</u>	<u>A204929</u>	<u>001</u>	Mar 17, 2017	
<u>AB</u>	+	!	CHIESI USA INC	<u>600MG</u>	<u>N022052</u>	<u>001</u>	May 30, 2007

ZINC ACETATE

CAPSULE;ORAL

GALZIN

+		TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
+	!		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986
---	---	---------	----------------	---------	-----	--------------

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

+	!	AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019
+	!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

<u>AB</u>	+	!	PFIZER	<u>EQ 20MG BASE</u>	<u>N020825</u>	<u>001</u>	Feb 05, 2001
<u>AB</u>	+			<u>EQ 40MG BASE</u>	<u>N020825</u>	<u>002</u>	Feb 05, 2001
<u>AB</u>	+			<u>EQ 60MG BASE</u>	<u>N020825</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>	+			<u>EQ 80MG BASE</u>	<u>N020825</u>	<u>004</u>	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 20MG BASE</u>	<u>A077561</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077561</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A077561</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A077561</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A204117</u>	<u>001</u>	Dec 27, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A204117</u>	<u>002</u>	Dec 27, 2016
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204117</u>	<u>003</u>	Dec 27, 2016
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A204117</u>	<u>004</u>	Dec 27, 2016
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 20MG BASE</u>	<u>A077565</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077565</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A077565</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A077565</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>		LUPIN PHARMS	<u>EQ 20MG BASE</u>	<u>A077560</u>	<u>001</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077560</u>	<u>002</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A077560</u>	<u>003</u>	Mar 02, 2012
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A077560</u>	<u>004</u>	Mar 02, 2012
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204375</u>	<u>001</u>	Feb 17, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A204375</u>	<u>002</u>	Feb 17, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204375</u>	<u>003</u>	Feb 17, 2017
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A204375</u>	<u>004</u>	Feb 17, 2017
<u>AB</u>		SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077562</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A077562</u>	<u>003</u>	Jun 01, 2012
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A077562</u>	<u>004</u>	Jun 01, 2012
<u>AB</u>		WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090348</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090348</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A090348</u>	<u>004</u>	Sep 05, 2012

PRESCRIPTION DRUG PRODUCT LIST

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

<u>AP</u>	<u>+!</u> PFIZER	<u>EQ 20MG BASE/ML</u>	<u>N020919 001</u>	Jun 21, 2002
-----------	------------------	------------------------	--------------------	--------------

ZIPRASIDONE MESYLATE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 20MG BASE/ML</u>	<u>A211908 001</u>	Dec 26, 2019
-----------	------------------	------------------------	--------------------	--------------

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

RECLAST

<u>AP</u>	<u>+!</u> NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817 001</u>	Apr 16, 2007
-----------	--------------------	--------------------------	--------------------	--------------

ZOLEDRONIC

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/100ML</u>	<u>A205749 001</u>	Jun 29, 2018
-----------	------------------	--------------------------	--------------------	--------------

ZOLEDRONIC ACID

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/5ML</u>	<u>A205279 001</u>	Nov 28, 2016
-----------	-----------------	------------------------	--------------------	--------------

<u>AP</u>	AKORN	<u>EQ 5MG BASE/100ML</u>	<u>A200918 001</u>	Aug 21, 2014
-----------	-------	--------------------------	--------------------	--------------

<u>AP</u>	AKORN INC	<u>EQ 4MG BASE/5ML</u>	<u>A202548 001</u>	May 22, 2014
-----------	-----------	------------------------	--------------------	--------------

<u>AP</u>	APOTEX	<u>EQ 5MG BASE/100ML</u>	<u>A204367 001</u>	Dec 24, 2015
-----------	--------	--------------------------	--------------------	--------------

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A207751 001</u>	Sep 26, 2016
-----------	----------------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209125 001</u>	Dec 08, 2017
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	BPI LABS LLC	<u>EQ 4MG BASE/5ML</u>	<u>A207341 001</u>	Dec 29, 2017
-----------	--------------	------------------------	--------------------	--------------

<u>AP</u>	BRECKENRIDGE	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
-----------	--------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
-----------	--	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	CIPLA	<u>EQ 4MG BASE/100ML</u>	<u>A210174 001</u>	Oct 27, 2017
-----------	-------	--------------------------	--------------------	--------------

<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186 001</u>	Mar 04, 2013
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363 001</u>	Mar 29, 2013
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783 001</u>	Mar 12, 2013
-----------	-------------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801 001</u>	Mar 29, 2013
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/5ML</u>	<u>A091516 001</u>	Apr 23, 2015
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930 001</u>	Aug 05, 2013
-----------	------------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A204217 001</u>	Aug 18, 2016
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209578 001</u>	Aug 08, 2019
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182 001</u>	Jun 03, 2013
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>	HOSPIRA INC	<u>EQ 4MG BASE/5ML</u>	<u>A090621 001</u>	Mar 19, 2015
-----------	-------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	INFORLIFE	<u>EQ 4MG BASE/100ML</u>	<u>N203231 001</u>	Aug 02, 2013
-----------	-----------	--------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828 001</u>	Sep 23, 2013
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013
-----------	----------------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A203841 001</u>	Feb 14, 2017
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A205254 001</u>	Oct 27, 2017
-----------	--	--------------------------	--------------------	--------------

<u>AP</u>	SAGENT PHARMS INC	<u>EQ 4MG BASE/5ML</u>	<u>A091493 001</u>	Nov 24, 2014
-----------	-------------------	------------------------	--------------------	--------------

<u>AP</u>	USV	<u>EQ 4MG BASE/5ML</u>	<u>A202923 001</u>	Sep 04, 2014
-----------	-----	------------------------	--------------------	--------------

ZOMETA

<u>AP</u>	<u>+!</u> NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223 002</u>	Mar 07, 2003
-----------	--------------------	------------------------	--------------------	--------------

<u>AP</u>	<u>+!</u>	<u>EQ 4MG BASE/100ML</u>	<u>N021223 003</u>	Jun 17, 2011
-----------	-----------	--------------------------	--------------------	--------------

SOLUTION; INTRAVENOUS

ZOLEDRONIC ACID

	HOSPIRA INC	<u>EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)</u>	<u>N204016 001</u>	Dec 28, 2015
--	-------------	--	--------------------	--------------

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

<u>+</u>	ASTRAZENECA	<u>2.5MG/SPRAY</u>	<u>N021450 003</u>	Sep 16, 2013
----------	-------------	--------------------	--------------------	--------------

<u>+!</u>		<u>5MG/SPRAY</u>	<u>N021450 004</u>	Sep 30, 2003
-----------	--	------------------	--------------------	--------------

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A204041 001</u>	May 20, 2016
-----------	-------------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A204041 002</u>	May 20, 2016
-----------	--	------------	--------------------	--------------

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204232 001</u>	Sep 30, 2015
-----------	--------------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A204232 002</u>	Sep 30, 2015
-----------	--	------------	--------------------	--------------

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A207021 001</u>	May 11, 2016
-----------	----------------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A207021 002</u>	May 11, 2016
-----------	--	------------	--------------------	--------------

<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779 001</u>	May 14, 2013
-----------	-------------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A201779 002</u>	May 14, 2013
-----------	--	------------	--------------------	--------------

<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284 001</u>	Apr 09, 2014
-----------	----------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A204284 002</u>	Apr 09, 2014
-----------	--	------------	--------------------	--------------

<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279 001</u>	Nov 20, 2014
-----------	-------------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A202279 002</u>	Nov 20, 2014
-----------	--	------------	--------------------	--------------

<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203726 001</u>	Oct 21, 2019
-----------	-----------------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A203726 002</u>	Oct 21, 2019
-----------	--	------------	--------------------	--------------

<u>AB</u>	PLD ACQUISITIONS	<u>2.5MG</u>	<u>A207867 001</u>	Feb 27, 2017
-----------	------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

LLC

<u>AB</u>		<u>5MG</u>	<u>A207867</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>	TWI PHARMS	<u>2.5MG</u>	<u>A206973</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>		<u>5MG</u>	<u>A206973</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A203019</u>	<u>001</u>	Jul 11, 2018
<u>AB</u>		<u>5MG</u>	<u>A203019</u>	<u>002</u>	Jul 11, 2018

ZOMIG

<u>AB</u>	+	IPR	<u>2.5MG</u>	<u>N020768</u>	<u>001</u>	Nov 25, 1997
<u>AB</u>	+	!	<u>5MG</u>	<u>N020768</u>	<u>002</u>	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A205074</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		<u>5MG</u>	<u>A205074</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560</u>	<u>002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A202855</u>	<u>001</u>	Sep 20, 2019
<u>AB</u>		<u>5MG</u>	<u>A202855</u>	<u>002</u>	Sep 20, 2019
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890</u>	<u>001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890</u>	<u>002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	+	ASTRAZENECA	<u>2.5MG</u>	<u>N021231</u>	<u>001</u>	Feb 13, 2001
<u>AB</u>	+	!	<u>5MG</u>	<u>N021231</u>	<u>002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008
---	------	-----------	---------	-----	--------------

TABLET;ORAL

AMBIEN

<u>AB</u>	+	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992
<u>AB</u>	+	!	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	ACME LABS	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>	YUNG SHIN PHARM	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

<u>AB</u>	+	MYLAN SPECIALITY LP	<u>5MG</u>	<u>N021997</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>	+	!	<u>10MG</u>	<u>N021997</u>	<u>002</u>	Mar 13, 2009

ZOLPIDEM TARTRATE

<u>AB</u>	DR REDDYS	<u>1.75MG</u>	<u>A204503</u>	<u>001</u>	Nov 18, 2016
<u>AB</u>		<u>3.5MG</u>	<u>A204503</u>	<u>002</u>	Nov 18, 2016
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A202657</u>	<u>001</u>	Aug 08, 2016
<u>AB</u>		<u>10MG</u>	<u>A202657</u>	<u>002</u>	Aug 08, 2016
<u>AB</u>	NOVEL LABS INC	<u>1.75MG</u>	<u>A204299</u>	<u>001</u>	Jun 03, 2015
<u>AB</u>	!	<u>3.5MG</u>	<u>A204299</u>	<u>002</u>	Jun 03, 2015
<u>AB</u>	PAR FORM	<u>5MG</u>	<u>A201509</u>	<u>001</u>	Aug 01, 2016
<u>AB</u>		<u>10MG</u>	<u>A201509</u>	<u>002</u>	Aug 01, 2016
<u>AB</u>	PAR PHARM INC	<u>1.75MG</u>	<u>A204229</u>	<u>001</u>	Sep 11, 2017
<u>AB</u>		<u>3.5MG</u>	<u>A204229</u>	<u>002</u>	Sep 11, 2017

PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

<u>AB</u>	+	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	!	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179</u>	<u>002</u>	Oct 13, 2010
<u>AB</u>			<u>12.5MG</u>	<u>A078179</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A090153</u>	<u>002</u>	Mar 25, 2013
<u>AB</u>		ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		APOTEX INC	<u>6.25MG</u>	<u>A200266</u>	<u>001</u>	Sep 10, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A200266</u>	<u>002</u>	Sep 10, 2013
<u>AB</u>		LUPIN LTD	<u>6.25MG</u>	<u>A078970</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A078970</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>		SUN PHARM	<u>6.25MG</u>	<u>A204170</u>	<u>001</u>	Jan 24, 2017
<u>AB</u>			<u>12.5MG</u>	<u>A204170</u>	<u>002</u>	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	+	SUNOVION PHARMS INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>	+	!	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>		APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>			<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>			<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>		BIONPHARMA INC	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>		CELLTRION	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>			<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>			<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>			<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>			<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>			<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>			<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>		SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>			<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>			<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>		ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE	120MG	N018060 001
	325MG	A072344 001 Mar 27, 1992
	650MG	A072237 001 Mar 27, 1992

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607 001 Apr 06, 1987
	650MG	A070608 001 Dec 01, 1986
+ TARO PHARM INDS LTD	120MG	N018337 003 Sep 12, 1983
+	325MG	N018337 002
+!	650MG	N018337 001

INFANTS' FEVERALL

+ TARO PHARM INDS LTD	80MG	N018337 004 Aug 26, 1992
-----------------------	------	--------------------------

NEOPAP

POLYMEDICA	120MG	N016401 001
------------	-------	-------------

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

AUROBINDO PHARMA LTD	650MG	A207229 001 Nov 09, 2016
GRANULES INDIA LTD	650MG	A211544 001 Apr 16, 2019
HERITAGE PHARMA	650MG	A207035 001 May 31, 2018
OHM LABS	650MG	A076200 001 Mar 19, 2002
PERRIGO	650MG	A075077 001 Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569 001 Dec 14, 2011

TYLENOL

+! J AND J CONSUMER INC	650MG	N019872 001 Jun 08, 1994
+!	650MG	N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG;250MG;65MG	A075794 001 Nov 26, 2001
---------	------------------	--------------------------

EXCEDRIN (MIGRAINE)

+! GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802 001 Jan 14, 1998
-------------------------	------------------	--------------------------

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314 002 Jul 09, 2019
-------------------	------	--------------------------

DIFFERIN

+! GALDERMA LABS LP	0.1%	N020380 002 Jul 08, 2016
---------------------	------	--------------------------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

AVAGARD

+! 3M	61%;1%	N021074 001 Jun 07, 2001
-------	--------	--------------------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

+ SANOFI AVENTIS US	80MG;20MG	N018685 001 Dec 09, 1983
---------------------	-----------	--------------------------

ASPIRIN

CAPSULE;ORAL

VAZALORE

+! PLX PHARMA	325MG	N203697 001 Jan 14, 2013
---------------	-------	--------------------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM;TOPICAL

ANTHELIOS SX

+! LOREAL USA	2%;2%;10%	N021502 001 Jul 21, 2006
---------------	-----------	--------------------------

CAPITAL SOLEIL 15

+! LOREAL USA	2%;3%;10%	N021501 001 Oct 02, 2006
---------------	-----------	--------------------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM;TOPICAL

ANTHELIOS 20

+! LOREAL USA	2%;2%;10%;2%	N021471 001 Oct 05, 2006
---------------	--------------	--------------------------

ANTHELIOS 40

+! LOREAL USA	2%;3%;10%;5%	N022009 001 Mar 31, 2008
---------------	--------------	--------------------------

+!	2%;3%;10%;5%	N022009 002 Oct 29, 2009
----	--------------	--------------------------

OTC DRUG PRODUCT LIST

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+! STAND HOMEOPATH 5% N020532 001 Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

LUMIFY

+! BAUSCH AND LOMB INC 0.025% N208144 001 Dec 22, 2017

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015

RHINOCORT ALLERGY

+! ASTRAZENECA PHARMS 0.032MG/SPRAY N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS 1% A205181 001 Nov 16, 2017

LOTRIMIN ULTRA

+! BAYER HEALTHCARE 1% N021307 001 Dec 07, 2001

LLC

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG A077355 001 Feb 06, 2008

800MG;10MG;165MG A204782 001 Aug 29, 2016

PEPCID COMPLETE

+! J AND J CONSUMER 800MG;10MG;165MG N020958 001 Oct 16, 2000

INC

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX 10MG A207235 001 Aug 12, 2016

AUROBINDO PHARMA 10MG A209107 001 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG N022429 001 Jul 23, 2009

+! 10MG N022429 004 Jul 23, 2009

STRIDES PHARMA 10MG A205291 001 Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA 10MG A209107 002 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG N022429 003 Jul 23, 2009

+! 10MG N022429 002 Jul 23, 2009

SOLUTION; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN 5MG/5ML A212266 001 May 16, 2019

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML A090765 002 Oct 07, 2009

ATHEM 5MG/5ML A091327 001 Oct 17, 2011

AUROBINDO PHARMA 5MG/5ML A090750 002 Feb 02, 2010

HETERO LABS LTD III 5MG/5ML A210622 001 Mar 13, 2019

LANNETT CO INC 5MG/5ML A091130 001 Apr 22, 2011

PERRIGO R AND D 5MG/5ML A204226 001 Sep 09, 2013

5MG/5ML A090254 002 Apr 09, 2008

TARO 5MG/5ML A090182 002 Apr 22, 2008

5MG/5ML A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML A090765 001 Oct 07, 2009

ATHEM 5MG/5ML A091327 002 Oct 17, 2011

AUROBINDO PHARMA 5MG/5ML A090750 001 Feb 02, 2010

LANNETT CO INC 5MG/5ML A091130 002 Apr 22, 2011

PERRIGO R AND D 5MG/5ML A090254 001 Apr 09, 2008

TARO 5MG/5ML A090182 001 Apr 22, 2008

5MG/5ML A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+! J AND J CONSUMER 5MG/5ML N022155 002 Nov 16, 2007

INC

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S ZYRTEC HIVES RELIEF

+! J AND J CONSUMER 5MG/5ML
INC

N022155 001 Nov 16, 2007

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG

A078780 001 Jan 21, 2010

10MG

A078780 004 Jan 21, 2010

APOTEX INC 5MG

A078317 001 Dec 27, 2007

10MG

A078317 002 Dec 27, 2007

AUROBINDO PHARMA 5MG

A090760 001 Aug 05, 2015

LTD

10MG

A090760 003 Aug 05, 2015

CIPLA LTD 5MG

A077318 001 Jul 25, 2013

10MG

A077318 002 Jul 25, 2013

CONTRACT PHARMACAL 5MG

A076047 001 Dec 27, 2007

10MG

A076047 002 Dec 27, 2007

DR REDDYS LABS LTD 5MG

A078343 004 Jan 15, 2008

10MG

A078343 003 Jan 15, 2008

GRANULES INDIA LTD 10MG

A209274 001 Dec 22, 2017

IPCA LABS LTD 5MG

A202277 002 Mar 11, 2014

10MG

A202277 004 Mar 11, 2014

MARKSANS PHARMA 5MG

A078933 001 Jun 15, 2010

10MG

A078933 002 Jun 15, 2010

MYLAN 5MG

A076677 001 Dec 27, 2007

10MG

A076677 002 Dec 27, 2007

ORCHID HLTHCARE 5MG

A078862 001 Feb 19, 2009

10MG

A078862 002 Feb 19, 2009

PERRIGO R AND D 5MG

A078336 001 Dec 27, 2007

10MG

A078336 002 Dec 27, 2007

PLD ACQUISITIONS 5MG

A077946 001 Dec 27, 2007

10MG

A077946 002 Dec 27, 2007

SUN PHARM INDS LTD 5MG

A077498 001 Dec 27, 2007

10MG

A077498 002 Dec 27, 2007

TARO 5MG

A078072 001 Jul 22, 2009

5MG

A078072 003 Jul 22, 2009

TORRENT PHARMS LLC 5MG

A079191 001 Apr 15, 2010

10MG

A079191 004 Apr 15, 2010

UNICHEM 5MG

A078680 003 Jun 26, 2009

10MG

A078680 004 Jun 26, 2009

UNIQUE PHARM LABS 5MG

A077829 001 Aug 26, 2009

10MG

A077829 004 Aug 26, 2009

WOCKHARDT 5MG

A078427 003 Dec 28, 2007

10MG

A078427 004 Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 5MG

A078343 001 Jan 15, 2008

10MG

A078343 002 Jan 15, 2008

IPCA LABS LTD 5MG

A202277 001 Mar 11, 2014

10MG

A202277 003 Mar 11, 2014

MARKSANS PHARMA 5MG

A078933 003 Jun 15, 2010

10MG

A078933 004 Jun 15, 2010

MYLAN 5MG

A076677 004 Dec 27, 2007

10MG

A076677 003 Dec 27, 2007

ORCHID HLTHCARE 5MG

A078862 003 Feb 19, 2009

10MG

A078862 004 Feb 19, 2009

PERRIGO R AND D 5MG

A078336 003 Dec 27, 2007

10MG

A078336 004 Dec 27, 2007

SUN PHARM INDS LTD 5MG

A077498 003 Dec 27, 2007

10MG

A077498 004 Dec 27, 2007

UNICHEM 5MG

A078680 001 Jun 26, 2009

10MG

A078680 002 Jun 26, 2009

UNIQUE PHARM LABS 5MG

A077829 003 Aug 26, 2009

! 10MG

A077829 002 Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY 5MG

A078780 003 Jan 21, 2010

10MG

A078780 002 Jan 21, 2010

AUROBINDO PHARMA 5MG

A090760 002 Aug 05, 2015

LTD

10MG

A090760 004 Aug 05, 2015

TARO 10MG

A078072 002 Jul 22, 2009

10MG

A078072 004 Jul 22, 2009

TORRENT PHARMS LLC 5MG

A079191 003 Apr 15, 2010

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE HIVES RELIEF
10MG

A079191 002 Apr 15, 2010

ZYRTEC ALLERGY

+! J AND J CONSUMER
INC 10MG

N019835 004 Nov 16, 2007

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG
10MG

A091116 001 Feb 19, 2015

A091116 002 Feb 19, 2015

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016

10MG

A206793 002 Mar 08, 2016

SANDOZ 5MG

A078692 001 Feb 14, 2008

! 10MG

A078692 002 Feb 14, 2008

SUN PHARM 5MG

A090142 001 Aug 30, 2011

10MG

A090142 002 Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS 5MG

A091116 003 Feb 19, 2015

10MG

A091116 004 Feb 19, 2015

SUN PHARM 5MG

A090142 003 Aug 30, 2011

10MG

A090142 004 Aug 30, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PERRIGO R AND D 10MG

A205490 001 Sep 02, 2015

ZYRTEC ALLERGY

+! J AND J CONSUMER
INC 10MG

N022578 001 Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA 5MG;120MG

A077170 001 Feb 25, 2008

PHARMS

PLD ACQUISITIONS 5MG;120MG

A077991 001 Mar 05, 2008

SUN PHARM INDS LTD 5MG;120MG

A090922 001 Sep 28, 2012

ZYRTEC-D 12 HOUR

+! J AND J CONSUMER
INC 5MG;120MG

N021150 002 Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+! XTTRIUM 4%

N019127 001 Dec 24, 1984

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+! SAGE PRODS 2%

N021669 001 Apr 25, 2005

READYPREP CHG

MEDLINE INDUSTRIES 2%

N207964 001 Nov 20, 2018

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO 4%

A071419 001 Dec 17, 1987

CHG SCRUB

ECOLAB 4%

N019258 002 Jul 22, 1986

CHLORHEXIDINE GLUCONATE

BAJAJ 0.75%

N020111 001 Sep 11, 1997

CIDA-STAT

ECOLAB 2%

N019258 001 Jul 22, 1986

EXIDINE

+! XTTRIUM 2%

N019422 001 Dec 17, 1985

4%

N019125 001 Dec 24, 1984

HIBICLENS

+! MOLNLYCKE HLTH 4%

N017768 001

HIBISTAT

+! MOLNLYCKE HLTH 0.5%

N018300 001

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN 4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

! BECTON DICKINSON 4%

A072525 001 Oct 24, 1989

OTC DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP

+! 3M HEALTH CARE 2%;70% N208288 001 Aug 08, 2018

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO 2%;70% (3ML) N020832 001 Jul 14, 2000

+! 2%;70% (10.5ML) N020832 004 Aug 20, 2003

+! 2%;70% (26ML) N020832 006 Nov 21, 2006

+! 2%;70% (1ML) N020832 008 Oct 23, 2008

CHLORAPREP ONE-STEP FREPP

+! BECTON DICKINSON CO 2%;70% (1.5ML) N020832 003 Apr 26, 2002

CHLORAPREP WITH TINT

+! BECTON DICKINSON CO 2%;70% (26ML) N020832 002 May 03, 2005

+! 2%;70% (10.5ML) N020832 005 Apr 03, 2006

+! 2%;70% (3ML) N020832 007 Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+! BECTON DICKINSON CO 2%;70% (0.67ML) N021555 001 Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+! BECTON DICKINSON CO 2%;70% (1.75ML) N021555 002 May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+! BECTON DICKINSON CO 2%;70% (5.25ML) N021555 003 Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+! PROF DSPLS 3.15%;70% (5.1ML) N021524 003 Jun 03, 2005

PREVANTICS SWAB

+! PROF DSPLS 3.15%;70% (1ML) N021524 001 Jun 03, 2005

PREVANTICS SWABSTICK

+! PROF DSPLS 3.15%;70% (1.6ML) N021524 002 Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC 12MG A040829 001 May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+! GLAXOSMITHKLINE 4MG;200MG;10MG N022113 001 Dec 21, 2011

ADVIL MULTI-SYMPTOM COLD & FLU

+! GLAXOSMITHKLINE 4MG;200MG;10MG N022113 002 Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+! GLAXOSMITHKLINE 1MG/5ML;100MG/5ML;15MG/5ML N021587 001 Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+! GLAXOSMITHKLINE 2MG;200MG;30MG N021441 001 Dec 19, 2002

CIMETIDINE

TABLET;ORAL

CIMETIDINE

APOTEX 100MG A074948 001 Jun 19, 1998

200MG A074948 002 Jul 26, 2002

IVAX SUB TEVA 200MG A075345 001 Jun 16, 1999

PHARMS

L PERRIGO CO 200MG A075285 001 Oct 29, 1998

TAGAMET HB

+! MEDTECH PRODUCTS 200MG N020238 002 Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

! L PERRIGO CO 1.34MG A074512 001 Nov 22, 1995

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

! P AND L 1% A074165 001 Jul 16, 1993

TARO 1% A072641 001 Dec 04, 1995

TRIVAGIZOLE 3

TARO 2% N021143 001 Apr 12, 2000

OTC DRUG PRODUCT LIST

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001
	PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018
	MUCINEX DM				
+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+	!	60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+	!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982
---	---	---------	--------------------------	---------	-----	--------------

DEXTROMETHORPHAN POLISTIREX

	AMNEAL PHARMS LLC	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+	!	GLAXOSMITHKLINE	38MG;200MG	N021394	001	Dec 21, 2005
---	---	-----------------	------------	---------	-----	--------------

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+	!	GLAXOSMITHKLINE	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005
---	---	-----------------	--	---------	-----	--------------

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+	!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014
---	---	----------------	------------	---------	-----	--------------

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018
	APOTEX	25MG;220MG	A211830	001	Aug 22, 2019
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019

DOCOSANOL

CREAM;TOPICAL

ABREVA

+	!	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000
---	---	-----------------	-----	---------	-----	--------------

DOCOSANOL

	P AND L	10%	A208754	001	Nov 19, 2018
--	---------	-----	---------	-----	--------------

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996

UNISOM

+	!	CHATTEM	25MG	N018066	001
---	---	---------	------	---------	-----

OTC DRUG PRODUCT LIST

EPINEPHRINE

AEROSOL, METERED; INHALATION

PRIMATENE MIST

+! ARMSTRONG PHARMS 0.125MG/INH N205920 001 Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE A209716 001 Jun 05, 2019

AUROBINDO PHARMA EQ 20MG BASE A209339 001 Oct 16, 2017

LTD

DR REDDYS LABS LTD EQ 20MG BASE A207673 001 May 15, 2018

MYLAN EQ 20MG BASE A212376 001 Oct 16, 2019

PERRIGO R AND D EQ 20MG BASE A207193 001 Aug 18, 2017

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014

TABLET, DELAYED RELEASE; ORAL

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE N207920 001 Nov 23, 2015

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AUROBINDO PHARMA 10MG A206531 001 Apr 26, 2016

LTD

20MG A206531 002 Apr 26, 2016

DR REDDYS LABS LTD 10MG A075758 001 Aug 17, 2001

20MG A077367 001 Sep 25, 2006

MYLAN 10MG A075674 001 Dec 21, 2001

P AND L 10MG A075512 001 Jul 26, 2001

PERRIGO 10MG A075400 001 Mar 18, 2005

PERRIGO R AND D 20MG A077351 001 Sep 25, 2006

SUN PHARM INDS LTD 10MG A090283 001 Nov 17, 2009

20MG A090283 002 Nov 17, 2009

TEVA 10MG A075312 001 May 31, 2001

WOCKHARDT 10MG A077146 001 Mar 07, 2005

20MG A090837 001 Aug 04, 2010

PEPCID AC

+ J AND J CONSUMER 10MG N020325 001 Apr 28, 1995

INC

10MG N020902 001 Aug 05, 1999

+! 20MG N020325 002 Sep 23, 2003

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG A075715 001 Aug 22, 2003

PEPCID AC

+! J AND J CONSUMER 20MG N020801 002 Dec 17, 2007

INC

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+! SANOFI AVENTIS US 30MG/5ML N201373 001 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L 30MG/5ML A203330 001 Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! P AND L 30MG/5ML A203330 002 Nov 18, 2014

TABLET; ORAL

ALLEGRA ALLERGY

+ SANOFI AVENTIS US 60MG N020872 007 Jan 24, 2011

+! 180MG N020872 010 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC 30MG A202039 001 Nov 19, 2014

DR REDDYS LABS LTD 30MG A076502 004 Apr 12, 2011

HETERO LABS LTD V 30MG A204097 001 Aug 19, 2016

SUN PHARM INDS 30MG A091567 002 Feb 06, 2012

TEVA 30MG A076447 004 Apr 13, 2011

WOCKHARDT LTD 30MG A079112 002 Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG A076502 005 Apr 12, 2011

SUN PHARM INDS 30MG A091567 001 Feb 06, 2012

TEVA 30MG A076447 005 Apr 13, 2011

WOCKHARDT LTD 30MG A079112 001 Feb 08, 2012

OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
	180MG	A202039	003	Nov 19, 2014
DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
	180MG	A076502	008	Apr 12, 2011
GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019
	180MG	A211075	002	Oct 18, 2019
HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
	180MG	A204097	003	Aug 19, 2016
MYLAN	60MG	A077081	006	Jul 21, 2011
	180MG	A077081	008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
	180MG	A204507	003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
	180MG	A204507	005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! SANOFI AVENTIS US 60MG;120MG N020786 002 Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+! SANOFI AVENTIS US 180MG;240MG N021704 002 Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 60MG;120MG A209116 001 Oct 30, 2017

DR REDDYS LABS LTD 60MG;120MG A076667 001 Nov 18, 2014

180MG;240MG A079043 002 Jun 22, 2011

SUN PHARM 60MG;120MG A090818 001 Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED; NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY N022051 002 Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS 0.05MG/SPRAY N205434 001 Jul 23, 2014

FLUTICASONE PROPIONATE

APOTEX 0.05MG/SPRAY A208150 001 Feb 29, 2016

HI TECH 0.05MG/SPRAY A208024 001 Apr 17, 2019

HIKMA 0.05MG/SPRAY A207957 001 May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

ACTAVIS LABS FL 1.2GM A091009 002 Sep 03, 2015

AMNEAL PHARMS 600MG A207342 001 Jul 11, 2018

1.2GM A207342 002 Jul 11, 2018

AUROBINDO PHARMA LTD 600MG A210453 001 Oct 21, 2019

1.2GM A210453 002 Oct 21, 2019

GUARDIAN DRUG 600MG A209215 001 Sep 06, 2017

1.2GM A209215 002 Sep 06, 2017

OTC DRUG PRODUCT LIST

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
MUCINEX				
+ RB HLTH	600MG	N021282	001	Jul 12, 2002
+!	1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
	1.2GM;120MG	A091071	002	May 27, 2015
DR REDDYS LABS LTD	600MG;60MG	A208369	001	Dec 29, 2017
	1.2GM;120MG	A208369	002	Dec 29, 2017
MUCINEX D				
+ RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!	1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+! GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS				
+! GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
MIDOL LIQUID GELS				
+! BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED				
GLAXOSMITHKLINE	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S IBUPROFEN				
PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN				
+! J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995

IBUPROFEN

APTAPHARMA INC	100MG/5ML	A210602	001	Nov 23, 2018
ARISE	100MG/5ML	A200457	001	Aug 18, 2011
AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
P AND L	100MG/5ML	A074916	001	Apr 30, 1999
TARO	100MG/5ML	A209207	001	Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+! J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
-------------------------	---------	---------	-----	--------------

IBUPROFEN

GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009

INFANT'S ADVIL

+! GLAXOSMITHKLINE	50MG/1.25ML	N020812	002	Jan 12, 2000
--------------------	-------------	---------	-----	--------------

TABLET;ORAL

ADVIL

GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984
-----------------	-------	---------	-----	--------------

IBU-TAB 200

ALRA	200MG	A071057	001	Aug 11, 1988
------	-------	---------	-----	--------------

IBUPROFEN

AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
	200MG	A072199	001	May 23, 1988
AUROBINDO PHARMA	200MG	A208865	001	Nov 08, 2017

OTC DRUG PRODUCT LIST

IBUPROFEN

TABLET;ORAL

IBUPROFEN

LTD

AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
CONTRACT PHARMACAL	200MG	A072299	001	Jul 01, 1988
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
LNK	200MG	A075010	001	Mar 01, 1999
	200MG	A075139	001	Mar 01, 1999
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
	200MG	A091239	001	Feb 01, 2011
MCNEIL	200MG	A073019	001	Mar 30, 1994
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
OHM	200MG	A071163	001	Jul 15, 1986
PAR PHARM	200MG	A070481	001	Sep 24, 1986
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
! PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
SHANDONG XINHUA	200MG	A206990	001	Aug 21, 2018
	200MG	A207095	001	May 05, 2017
STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
	200MG	A091355	001	Apr 04, 2011
	200MG	A206989	001	Jun 29, 2018
	200MG	A207052	001	May 30, 2017
ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE 100MG N020267 002 Dec 13, 1996

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO 100MG A075367 001 Apr 22, 1999

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER INC 100MG N020602 001 Jun 10, 1996

MOTRIN IB

+ J AND J CONSUMER INC 200MG N019012 003 Dec 17, 1990

TAB-PROFEN

PERRIGO 200MG A072095 001 Dec 08, 1987

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE 50MG N020944 001 Dec 18, 1998

IBUPROFEN

! PERRIGO 100MG A076359 002 Jan 16, 2004

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE 100MG N020944 002 Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+! GLAXOSMITHKLINE EQ 200MG BASE N201803 001 Jun 12, 2012

IBUPROFEN SODIUM

PERRIGO R AND D EQ 200MG BASE A206581 001 Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF

+! GLAXOSMITHKLINE 200MG;10MG N022565 001 May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D 200MG;10MG A203200 001 Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

ADVIL COLD AND SINUS

+! GLAXOSMITHKLINE EQ 200MG FREE ACID AND POTASSIUM SALT;30MG N021374 001 May 30, 2002

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM SALT;30MG A209235 001 Dec 01, 2017

OTC DRUG PRODUCT LIST

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD GLAXOSMITHKLINE	100MG/5ML;15MG/5ML	N021373 001	Apr 18, 2002
CHILDREN'S MOTRIN COLD +! J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128 001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE PERRIGO	100MG/5ML;15MG/5ML	A076478 001	Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS +! GLAXOSMITHKLINE	200MG;30MG	N019771 001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD	200MG;30MG	A077628 001	Aug 14, 2006
IBUPROHM COLD AND SINUS OHM LABS	200MG;30MG	A074567 001	Apr 17, 2001
SINE-AID IB J AND J CONSUMER INC	200MG;30MG	N019899 001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R PEN +! LILLY	100 UNITS/ML	N018780 005	Aug 06, 1998
NOVOLIN R +! NOVO NORDISK INC	100 UNITS/ML	N019938 001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R +! LILLY	100 UNITS/ML	N018780 001	Oct 28, 1982
-----------------------	--------------	-------------	--------------

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30 +! LILLY	30 UNITS/ML;70 UNITS/ML	N019717 001	Apr 25, 1989
HUMULIN 70/30 PEN +! LILLY	30 UNITS/ML;70 UNITS/ML	N019717 002	Aug 06, 1998
NOVOLIN 70/30 +! NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991 001	Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N +! LILLY	100 UNITS/ML	N018781 001	Oct 28, 1982
NOVOLIN N +! NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP +! 3M	EQ 0.7% IODINE;74% (6ML)	N021586 001	Sep 29, 2006
+!	EQ 0.7% IODINE;74% (26ML)	N021586 002	Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D +! KRAMER	1%	N020310 001	Oct 10, 1997
--------------------------	----	-------------	--------------

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALWAY +! BAUSCH AND LOMB	EQ 0.025% BASE	N021996 001	Dec 01, 2006
+	EQ 0.035% BASE	N021996 002	Feb 11, 2015
KETOTIFEN FUMARATE AKORN	EQ 0.025% BASE	A077958 001	Jul 26, 2007
APOTEX INC	EQ 0.025% BASE	A077354 001	May 09, 2006
ZADITOR ! ALCON PHARMS LTD	EQ 0.025% BASE	A077200 001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE DR REDDYS LABS LTD	15MG	A202194 001	May 18, 2012
LANNETT CO INC	15MG	A207157 001	Sep 29, 2017
MYLAN	15MG	A203187 001	Jun 01, 2016
NATCO PHARMA LTD	15MG	A203306 001	Jan 13, 2016

OTC DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012

PREVACID 24 HR

+! PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009
------------------------	------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016
---------------	------	---------	-----	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! SANOFI AVENTIS US	2.5MG/5ML	N209090	001	Jan 31, 2017
----------------------	-----------	---------	-----	--------------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018
--------------------	-----	---------	-----	--------------

MICRO LABS	5MG	A211551	001	Nov 20, 2018
------------	-----	---------	-----	--------------

XYZAL ALLERGY 24HR

+! SANOFI AVENTIS US	5MG	N209089	001	Jan 31, 2017
----------------------	-----	---------	-----	--------------

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
----------------------	-------	---------	-----	--------------

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
-----------	-------	---------	-----	--------------

HER STYLE

NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016
-------------	-------	---------	-----	--------------

LEVONORGESTREL

AMNEAL PHARMS	1.5MG	A204044	001	Jul 03, 2018
---------------	-------	---------	-----	--------------

GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
---------------------	-------	---------	-----	--------------

! L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010
----------------	--------	---------	-----	--------------

MYLAN LABS LTD	0.75MG	A202740	001	Sep 02, 2016
----------------	--------	---------	-----	--------------

	1.5MG	A202739	001	Oct 31, 2014
--	-------	---------	-----	--------------

NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015
---------------	-------	---------	-----	--------------

NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
----------------	-------	---------	-----	--------------

PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
-----------------	-------	---------	-----	--------------

OPCICON ONE-STEP

SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
-----------	-------	---------	-----	--------------

PLAN B ONE-STEP

+! FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009
-----------------	-------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

+ BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
------------------	-----	---------	-----	--------------

+!	2MG	N021855	002	Aug 04, 2005
----	-----	---------	-----	--------------

SOLUTION;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
-------------------------	---------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
----------------	---------	---------	-----	--------------

PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
---------	---------	---------	-----	--------------

WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997
------------------	---------	---------	-----	--------------

SUSPENSION;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
-----------------	-----------	---------	-----	--------------

TABLET;ORAL

IMODIUM A-D

+! J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
-------------------------	-----	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
----------------------	-----	---------	-----	--------------

L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
--------------	-----	---------	-----	--------------

LNK	2MG	A076497	001	Jun 10, 2003
-----	-----	---------	-----	--------------

OHM LABS	2MG	A074091	001	Dec 10, 1992
----------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPOM RELIEF

+	!	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
---	---	-------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

		PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
		SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

!		PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002
---	--	---------	-----------	---------	-----	--------------

LORATADINE

CAPSULE;ORAL

CLARITIN

+	!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
---	---	-------------------------	------	---------	-----	--------------

LORATADINE

		MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
		STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020

SUSPENSION;ORAL

LORATADINE

+	!	TARO	1MG/ML	N021734	001	Oct 04, 2005
---	---	------	--------	---------	-----	--------------

SYRUP;ORAL

CLARITIN

+	!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
---	---	-------------------------	--------	---------	-----	--------------

LORATADINE

		AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
		LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
		PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
		TARO	1MG/ML	A076805	001	Aug 20, 2004
			1MG/ML	A201865	001	Jul 31, 2015
		TEVA	1MG/ML	A075505	001	Nov 07, 2003
		WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004

TABLET;ORAL

CLARITIN

+	!	BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
---	---	-------------------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF

+	!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
---	---	-------------------------	------	---------	-----	--------------

LORATADINE

		APOTEX INC	10MG	A076471	001	Feb 14, 2006
		AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
		GRANULES INDIA LTD	10MG	A210722	001	Dec 23, 2019
		GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019
		MYLAN	10MG	A075790	001	Nov 07, 2008
			10MG	A076154	001	Aug 20, 2003
			10MG	A078447	001	Aug 12, 2011
		PERRIGO	10MG	A076301	001	Jun 25, 2004
		PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
		SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+	!	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
---	---	-------------------------	-----	---------	-----	--------------

CLARITIN

+		BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018
---	--	-------------------------	------	---------	-----	--------------

LORATADINE

		PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
		SUN PHARM	5MG	A210088	001	Apr 16, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

		GLAXOSMITHKLINE	10MG	N021375	001	Dec 19, 2002
--	--	-----------------	------	---------	-----	--------------

CLARITIN HIVES RELIEF REDITAB

+	!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
---	---	-------------------------	------	---------	-----	--------------

CLARITIN REDITABS

+	!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
---	---	-------------------------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+! 10MG N020704 002 Nov 27, 2002

LORATADINE

ACTAVIS LABS FL INC 10MG A075990 001 Nov 03, 2003

AUROBINDO PHARMA 10MG A208477 001 Apr 11, 2018

LTD

GLAXOSMITHKLINE 10MG A075822 001 Feb 10, 2003

PERRIGO PHARMA INTL 10MG A076011 001 Sep 29, 2003

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+! BAYER HEALTHCARE 5MG;120MG N019670 002 Nov 27, 2002

LLC

CLARITIN-D 24 HOUR

+! BAYER HEALTHCARE 10MG;240MG N020470 002 Nov 27, 2002

LLC

LORATADINE AND PSEUDOEPHEDRINE SULFATE

P AND L 10MG;240MG A075706 001 Feb 21, 2003

PERRIGO PHARMA INTL 5MG;120MG A076050 001 Jan 30, 2003

10MG;240MG A075989 001 Mar 04, 2004

SUN PHARM INDS LTD 10MG;240MG A076557 001 Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+! HISAMITSU PHARM CO 3%;10% N022029 001 Feb 20, 2008

+ 3%;10% N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%,4% A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,4% N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+! MEDTECH PRODUCTS 2%,4% N021261 001 Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3

TARO 4% A076773 001 Mar 02, 2005

MICONAZOLE 7

P AND L 2% A074164 001 Mar 29, 1996

MICONAZOLE NITRATE

ACP NIMBLE 2% A074366 001 Feb 22, 1996

PERRIGO 2% A074760 001 May 15, 1997

PERRIGO R AND D 4% A091366 001 Jan 15, 2010

TARO PHARMS 2% A074444 001 Jan 13, 1997

MONISTAT 3

+! MEDTECH PRODUCTS 4% N020827 001 Mar 30, 1998

MONISTAT 7

+! MEDTECH PRODUCTS 2% N017450 002 Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

P AND L 2%,200MG A074926 001 Apr 16, 1999

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM A079114 001 Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 2%,200MG A075329 001 Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM N021308 001 Jun 29, 2001

MONISTAT 3 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,200MG N020670 002 Apr 16, 1996

MONISTAT 7 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,100MG N020288 002 Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACP NIMBLE 100MG A074414 001 Apr 30, 1997

P AND L 100MG A073507 001 Nov 19, 1993

! PERRIGO 100MG A074395 001 Mar 20, 1997

OTC DRUG PRODUCT LIST

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MONISTAT 7

+! MEDTECH PRODUCTS 100MG N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+! JOHNSON AND JOHNSON 5% N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5% A091344 001 Apr 28, 2011

MINOXIDIL (FOR MEN)

P AND L 5% A208092 001 Feb 17, 2017

TARO 5% A209074 001 Dec 31, 2018

MINOXIDIL (FOR WOMEN)

P AND L 5% A208092 002 Jul 27, 2017

TARO 5% A209074 002 Apr 22, 2019

WOMEN'S ROGAINE

+! JOHNSON AND JOHNSON 5% N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

HI TECH PHARMA 2% A074731 001 Dec 24, 1996

L PERRIGO CO 2% A075357 001 Jul 30, 1999

P AND L 2% A074588 001 Apr 05, 1996

WOCKHARDT BIO AG 2% A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2% A074731 002 May 11, 2005

L PERRIGO CO 2% A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

AVACOR PRODS 5% A075619 001 Nov 17, 2000

P AND L 5% A075518 001 Nov 17, 2000

PERRIGO 5% A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5% A075737 001 Mar 15, 2002

WOCKHARDT BIO AG 5% A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+! JOHNSON AND JOHNSON 2% N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+! JOHNSON AND JOHNSON 2% N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+! JOHNSON AND JOHNSON 5% N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2% A078176 001 Nov 09, 2007

5% A076239 001 Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3% A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315% A078208 001 Sep 27, 2010

NAPHCON-A

+! ALCON 0.025%;0.3% N020226 001 Jun 08, 1994

OPCON-A

+! BAUSCH AND LOMB 0.02675%;0.315% N020065 001 Jun 08, 1994

VISINE

+! JOHNSON AND JOHNSON 0.025%;0.3% N020485 001 Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+! BIONPHARMA INC EQ 200MG BASE N021920 001 Feb 17, 2006

CATALENT EQ 200MG BASE A202807 001 Jan 04, 2019

PURACAP PHARM LLC EQ 200MG BASE A208363 001 Mar 15, 2018

TABLET;ORAL

ALEVE

+! BAYER 220MG N020204 002 Jan 11, 1994

NAPROXEN SODIUM

AMNEAL PHARMS NY 220MG A079096 001 Dec 16, 2008

AUROBINDO PHARMA LTD 220MG A205497 001 Mar 18, 2016

CONTRACT PHARMACAL 220MG A074635 001 Jan 13, 1997

DR REDDYS LABS INC 220MG A075168 001 Jul 28, 1998

GRANULES INDIA 220MG A091353 001 Sep 20, 2011

LNK INTL INC 220MG A204872 001 Jan 23, 2017

MARKSANS PHARMA 220MG A090545 001 Mar 16, 2011

OTC DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
PERRIGO	220MG	A074661	001	Jan 13, 1997
SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011
YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+! BAYER	220MG;120MG	N021076	001	Nov 29, 1999
----------	-------------	---------	-----	--------------

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+	14MG/24HR	N020076	005	Nov 12, 1999
+!	21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
+	14MG/24HR	N020165	005	Aug 02, 1996
+!	21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+	EQ 2MG BASE	N018612	004	Sep 25, 2000
+!	EQ 4MG BASE	N020066	002	Feb 09, 1996
+	EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+	EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
	EQ 2MG BASE	A076776	001	Sep 16, 2004
	EQ 2MG BASE	A076777	001	Sep 16, 2004
	EQ 4MG BASE	A076778	001	Sep 16, 2004
	EQ 4MG BASE	A076779	001	Sep 16, 2004
	EQ 4MG BASE	A076789	001	Sep 16, 2004
P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
	EQ 2MG BASE	A076569	001	Jul 29, 2004
	EQ 2MG BASE	A078699	001	Dec 29, 2008
	EQ 2MG BASE	A079044	001	Jul 08, 2009
	EQ 2MG BASE	A079216	001	Jul 08, 2009
	EQ 2MG BASE	A204794	001	May 10, 2016
	EQ 4MG BASE	A074707	001	Mar 19, 1999
	EQ 4MG BASE	A076568	002	Jul 29, 2004
	EQ 4MG BASE	A078697	001	Dec 29, 2008
	EQ 4MG BASE	A079038	001	Jul 08, 2009
	EQ 4MG BASE	A079219	001	Jul 08, 2009
	EQ 4MG BASE	A204833	001	Feb 26, 2016
PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
	EQ 2MG BASE	A078547	001	May 24, 2007
	EQ 2MG BASE	A078967	001	Apr 23, 2008
	EQ 2MG BASE	A091349	001	Jul 20, 2011
	EQ 2MG BASE	A206394	001	Dec 15, 2016
	EQ 4MG BASE	A078326	001	Oct 30, 2006
	EQ 4MG BASE	A078546	001	May 24, 2007
	EQ 4MG BASE	A078968	001	Apr 23, 2008
	EQ 4MG BASE	A091354	001	Jul 20, 2011
	EQ 4MG BASE	A206393	001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N021330	001	Oct 31, 2002
CONS				

OTC DRUG PRODUCT LIST

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+	EQ 2MG BASE	N022360 001	May 18, 2009
+!	EQ 4MG BASE	N021330 002	Oct 31, 2002
+!	EQ 4MG BASE	N022360 002	May 18, 2009

NICOTINE POLACRILEX

DR REDDYS LABS SA	EQ 2MG BASE	A212796 001	Jan 08, 2020
	EQ 4MG BASE	A212796 002	Jan 08, 2020
P AND L	EQ 2MG BASE	A208875 001	Oct 31, 2019
	EQ 2MG BASE	A209206 001	Jun 26, 2018
	EQ 2MG BASE	A209519 001	Jul 02, 2018
	EQ 2MG BASE	A209520 001	Oct 31, 2019
	EQ 2MG BASE	A210711 001	Oct 31, 2019
	EQ 2MG BASE	A210712 001	Sep 06, 2019
	EQ 2MG BASE	A212056 001	Jul 26, 2019
	EQ 4MG BASE	A208875 002	Oct 31, 2019
	EQ 4MG BASE	A209206 002	Jun 26, 2018
	EQ 4MG BASE	A209519 002	Jul 02, 2018
	EQ 4MG BASE	A209520 002	Oct 31, 2019
	EQ 4MG BASE	A210711 002	Oct 31, 2019
	EQ 4MG BASE	A210712 002	Sep 06, 2019
	EQ 4MG BASE	A212056 002	Jul 26, 2019
PERRIGO R AND D	EQ 2MG BASE	A077007 001	Jan 31, 2006
	EQ 2MG BASE	A090711 001	Jul 10, 2009
	EQ 2MG BASE	A090821 001	Jul 10, 2009
	EQ 2MG BASE	A203690 001	Oct 09, 2012
	EQ 4MG BASE	A077007 002	Jan 31, 2006
	EQ 4MG BASE	A090711 002	Jul 10, 2009
	EQ 4MG BASE	A090821 002	Jul 10, 2009
	EQ 4MG BASE	A203690 002	Oct 09, 2012
PLD ACQUISITIONS	EQ 2MG BASE	A207868 001	Feb 07, 2019
	EQ 4MG BASE	A207868 002	Feb 07, 2019

NIZATIDINE

TABLET;ORAL

AXID AR

+!	GLAXOSMITHKLINE	75MG	N020555 001	May 09, 1996
----	-----------------	------	-------------	--------------

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+!	MAYER LABS INC	1GM	N018683 001	Apr 01, 1983
----	----------------	-----	-------------	--------------

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL PHARMA	20MG	N022032 001	Dec 04, 2007
	DR REDDYS	20MG	A207740 001	Nov 05, 2018
	SUN PHARM	20MG	A207891 001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400 001	Jul 05, 2017
---	---------------	------	-------------	--------------

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878 001	Jun 05, 2009
	SPIL	EQ 20MG BASE	A210593 001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877 001	Jun 06, 2018
	PERRIGO R AND D	EQ 20MG BASE	A204152 001	Jul 30, 2015
	PRILOSEC OTC			
+!	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229 001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	ACTAVIS ELIZABETH	20MG;1.1GM	A204137 001	Jul 15, 2016
	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923 001	Nov 07, 2016
	PAR PHARM	20MG;1.1GM	A201946 001	Jul 15, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361 001	Jul 15, 2016
	ZYDUS PHARMS	20MG;1.1GM	A203345 001	Mar 16, 2018

OTC DRUG PRODUCT LIST

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+	!	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009
---	---	-------------------------	------------	---------	-----	--------------

FOR SUSPENSION;ORAL

ZEGERID OTC

+	!	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013
---	---	-------------------------	---------------------------	---------	-----	--------------

ORLISTAT

CAPSULE;ORAL

ALLI

+	!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007
---	---	-------------------------	------	---------	-----	--------------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+	!	ALLERGAN	3.9MG/24HR	N202211	001	Jan 25, 2013
---	---	----------	------------	---------	-----	--------------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

+	!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989
---	---	---------------------	--------	---------	-----	--------------

PERMETHRIN

LOTION;TOPICAL

NIX

+	!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
---	---	------------------	----	---------	-----	--------------

PERMETHRIN

ACTAVIS MID

1%

A075014 001 Mar 28, 2000

ATLANTIC

PERRIGO NEW YORK

1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

+	!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
---	---	-------------------------	---------------	---------	-----	--------------

POLYETHYLENE GLYCOL 3350

ANI PHARMS INC

17GM/SCOOPFUL

A202850 001 Dec 15, 2015

AUROBINDO PHARMA

17GM/SCOOPFUL

A209017 001 Apr 09, 2018

LTD

MYLAN

17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009

NEXGEN PHARMA

17GM/SCOOPFUL

A090812 001 Oct 07, 2009

NOVEL LABS INC

17GM/SCOOPFUL

A091077 001 Oct 06, 2009

NOVELGENIX THERAPS

17GM/SCOOPFUL

A202071 001 Dec 28, 2012

NUVO PHARMS INC

17GM/SCOOPFUL

A206105 001 Oct 28, 2016

PAR PHARM

17GM/SCOOPFUL

A079214 001 Jan 31, 2013

PERRIGO R AND D

17GM/PACKET

A090685 001 Oct 06, 2009

17GM/SCOOPFUL

A090685 002 Oct 06, 2009

STRIDES PHARMA

17GM/SCOOPFUL

A203928 001 Aug 24, 2016

17GM/PACKET

A203928 002 Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL

65MG/ML

A206211 001 Mar 24, 2016

CO

THYROSHIELD

!
 ARCO PHARMS LLC | 65MG/ML | A077218 | 001 | Jan 12, 2005 |

TABLET;ORAL

IOSAT

+
 ANBEX | 65MG | N018664 | 002 | May 12, 2011 |

+	!		130MG	N018664	001	Oct 14, 1982
---	---	--	-------	---------	-----	--------------

THYROSAFE

!		RECIP	65MG	A076350	001	Sep 10, 2002
---	--	-------	------	---------	-----	--------------

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+	!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
---	---	---------------------	----	---------	-----	--------------

SPONGE;TOPICAL

E-Z SCRUB 201

+	!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
---	---	------------------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

POVIDONE-IODINE

SPONGE; TOPICAL

E-Z SCRUB 241

+! BECTON DICKINSON 10% N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 120MG A209008 001 Jun 09, 2017

L PERRIGO CO 120MG A075153 001 Feb 26, 1999

SUN PHARM INDS LTD 120MG A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

! MCNEIL CONS 120MG A073585 001 Oct 31, 1991

SUDAFED 24 HOUR

+! J AND J CONSUMER INC 240MG N020021 002 Dec 15, 1992

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+! NIAGARA PHARMS 98.3% N022305 001 Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC EQ 75MG BASE A075167 001 May 04, 2000

EQ 150MG BASE A200172 001 May 31, 2012

AUROBINDO PHARMA LTD EQ 75MG BASE A207579 001 Nov 13, 2017

EQ 150MG BASE A207578 001 Nov 13, 2017

DR REDDYS LABS LTD EQ 75MG BASE A075294 001 Mar 28, 2000

EQ 150MG BASE A078192 001 Aug 31, 2007

GRANULES INDIA LTD EQ 150MG BASE A210243 001 Aug 20, 2018

EQ 150MG BASE A210243 002 Aug 20, 2018

PERRIGO EQ 75MG BASE A076195 001 Aug 30, 2002

PERRIGO R AND D EQ 150MG BASE A091429 001 May 11, 2011

EQ 150MG BASE A091429 002 May 11, 2011

STRIDES PHARMA EQ 75MG BASE A201745 001 Feb 29, 2012

EQ 75MG BASE A209160 001 Mar 05, 2018

EQ 150MG BASE A200536 001 Jun 28, 2011

EQ 150MG BASE A209161 001 Feb 22, 2018

UNIQUE PHARM LABS EQ 75MG BASE A210250 001 Aug 30, 2019

EQ 150MG BASE A210228 001 Aug 30, 2019

WOCKHARDT EQ 75MG BASE A076760 001 Feb 24, 2006

ZANTAC 150

+! SANOFI US EQ 150MG BASE N021698 001 Aug 31, 2004

+ EQ 150MG BASE N021698 002 Mar 13, 2007

ZANTAC 75

+ SANOFI US EQ 75MG BASE N020520 001 Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+! BLAIREX 0.9% N019912 001 Sep 03, 1992

TERBINAFINE

GEL; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1% N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+! GLAXOSMITHKLINE 1% N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO 1% A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1% N021124 001 Mar 17, 2000

SPRAY; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1% N021124 002 Mar 17, 2000

OTC DRUG PRODUCT LISTTIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

PERRIGO

6.5%

A075915 001 Nov 21, 2001

VAGISTAT-1

+! COMBE

6.5%

N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+! SANOFI AVENTIS US

0.055MG/SPRAY

N020468 002 Oct 11, 2013

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL

0.055MG/SPRAY

A078104 002 Nov 14, 2014

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS KABI AG

N125695

Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS
MANUFACTURING INC

A710497

Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL
SYSTEMS, INC

N011057

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

HAEMONETICS

MANUFACTURING INC

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:

DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:

DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:

AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

0.042GM/100ML;0.276GM/100ML;

N820915

Oct 19, 1984

MANUFACTURING INC

0.410GM/100ML;0.30GM/100ML;

1.10GM/100ML;0.588GM/100ML

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:

AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983
-------------	---	---------	--------------

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
LABORATORIES GRIFOIS, S.A.		A125697	Oct 25, 2019
TERUMO BCT		N125608	Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003
-----------------------------	--	---------	--------------

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION
(CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016
------------	--	---------	--------------

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984
---------	--	---------	--------------

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992
-------------	----------------------	---------	--------------

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992
-------------	------------------------	---------	--------------

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999
-------------	-----------	---------	--------------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML A740193 Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N890105 Apr 04, 1991

NONE

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML A740592 Nov 12, 1998
MEDICINES INCHYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL A110013 Jan 09, 2015

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML N070012 Dec 27, 2007
DEUTSCHLAND GMBHISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINERSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

HAEMONETICS CORP N090067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP N110059 Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTIONSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIBASIC
ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATESTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 Dec 09, 2009
1.53G/500ML; 0.465G/500ML

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ABACAIVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAIVIR SULFATE AND LAMIVUDINE

ZYDUS PHARMS EQ 600MG BASE; 300MG A208990 001 Nov 15, 2018

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

BARR LABS DIV TEVA 333MG A200143 001 Nov 18, 2013

CAMPRAL

+ FOREST LABS 333MG ** N021431 001 Jul 29, 2004

ACARBOSE

TABLET; ORAL

ACARBOSE

MYLAN 25MG A091053 001 Jan 06, 2011

50MG A091053 002 Jan 06, 2011

100MG A091053 003 Jan 06, 2011

PRECOSE

+ BAYER HLTHCARE 25MG N020482 004 May 29, 1997

+ 50MG N020482 001 Sep 06, 1995

+ 100MG N020482 002 Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

ANI PHARMS INC EQ 200MG BASE A074007 001 Oct 18, 1995

EQ 400MG BASE A074007 002 Oct 18, 1995

SECTRAL

+ PROMIUS PHARMA EQ 200MG BASE N018917 001 Dec 28, 1984

+ EQ 400MG BASE N018917 003 Dec 28, 1984

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

ACP NIMBLE 120MG A072218 001 Mar 27, 1992

325MG N018060 003 Dec 18, 1986

650MG N018060 002

ACETAMINOPHEN

ABLE 120MG A073106 001 Feb 27, 1995

325MG A073107 001 Feb 27, 1995

650MG A073108 001 Feb 27, 1995

ACINO PRODS 120MG A071010 001 May 12, 1987

650MG A071011 001 May 12, 1987

TYLENOL

J AND J CONSUMER INC 120MG N017756 002

650MG N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG A081095 001 Oct 26, 1990

150MG; 180MG; 30MG A081096 001 Oct 26, 1990

150MG; 180MG; 60MG A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG A085638 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT 650MG; 50MG A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT 650MG; 50MG A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG A087550 001 Oct 19, 1984

BUTAPAP

MIKART 650MG; 50MG A089988 001 Oct 26, 1992

PHRENILIN

VALEANT 325MG; 50MG ** A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND 650MG; 50MG A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG; 50MG; 40MG ** A088825 001 Dec 05, 1984

GRAHAM DM 325MG; 50MG; 40MG A088743 001 Jul 18, 1985

325MG; 50MG; 40MG A088765 001 Mar 27, 1985

325MG; 50MG; 40MG A089067 001 Apr 19, 1985

HIKMA PHARMS 500MG; 50MG; 40MG A040261 001 Oct 28, 1998

MALLINCKRODT 325MG; 50MG; 40MG A088758 001 Mar 27, 1985

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A040085 001 Mar 28, 1996

FEMCET

MALLINCKRODT 325MG; 50MG; 40MG A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG; 50MG; 40MG A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT 325MG; 50MG; 40MG A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE 325MG; 50MG; 40MG A040390 001 Jul 23, 2001

500MG; 50MG; 40MG A040394 001 Jul 23, 2001

GILBERT LABS 325MG; 50MG; 40MG A087629 001 Nov 13, 1984

HIKMA PHARMS 500MG; 50MG; 40MG A040336 001 Aug 18, 1999

MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003

MIRROR PHARMS LLC 500MG; 50MG; 40MG A040883 001 Dec 23, 2008

NOVAST LABS 325MG; 50MG; 40MG A040864 001 Dec 01, 2008

SUN PHARM INDUSTRIES 325MG; 50MG; 40MG A040601 001 Jul 29, 2005

VINTAGE PHARMS 500MG; 50MG; 40MG A040513 001 Aug 25, 2003

WATSON LABS 325MG; 50MG; 40MG A089536 001 Feb 16, 1988

500MG; 50MG; 40MG A040267 001 Jul 30, 1998

ESGIC

FOREST PHARMS 325MG; 50MG; 40MG A089660 001 Dec 23, 1988

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG; 50MG; 40MG; 30MG A076528 001 Aug 21, 2003

HIKMA INTL PHARMS 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
DHC PLUS				
PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
SYNALGOS-DC-A				
LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001
----------	---------------------------	---------	-----	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG;15MG	A088537	001	Jun 04, 1984
	300MG;30MG	A088324	001	Dec 29, 1983
	300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3				
ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4				
ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3				
SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3				
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4				
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACI HEALTHCARE LTD	120MG/5ML;12MG/5ML	A086366	001	
ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
LANNETT CO INC	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	

SUSPENSION;ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452	001	Aug 01, 2002
	300MG;60MG	A040459	001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;60MG	A081249	001	Jul 16, 1992
HALSEY	300MG;15MG	A083871	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG **	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;30MG	A085794	001	
	300MG;60MG	A087653	001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
	300MG;30MG	A089673	003	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
	325MG;15MG **	A085056	002	
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG;15MG	A085055	002	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS				
SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE				
CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081067	001	Nov 30, 1989
	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989
	500MG;5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016

TABLET; ORAL

ANEXSIA				
MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ALVOGEN PINE BROOK	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998
BARR	500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY	500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997

ROXILOX

ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995
--------	------------	---------	-----	--------------

TYLOX

JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984
----------------	------------	---------	-----	--------------

TYLOX-325

ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001	Nov 08, 1984
--------------------	------------	---------	-----	--------------

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART INC	300MG/5ML; 10MG/5ML	A202142	001	Nov 27, 2018
SPECGX LLC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

VINTAGE PHARMS	325MG/5ML; 5MG/5ML	A203573	001	Dec 18, 2014
----------------	--------------------	---------	-----	--------------

ROXICET

HIKMA	325MG/5ML; 5MG/5ML	A089351	001	Dec 03, 1986
-------	--------------------	---------	-----	--------------

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001	
----------------------	--------------	---------	-----	--

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001	
----------------------	------------	---------	-----	--

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999
	325MG; 7.5MG	A040800	001	Apr 03, 2012
	325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007
	650MG; 10MG	A040789	002	Nov 27, 2007
BARR	325MG; 5MG	A087406	001	
DURAMED PHARMS BARR	325MG; 5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004
	650MG; 10MG	A040550	002	Jun 30, 2004
MAYNE PHARMA INC	500MG; 7.5MG	A090177	005	Oct 20, 2008
	650MG; 10MG	A090177	006	Oct 20, 2008
MIKART	400MG; 2.5MG	A040679	001	May 16, 2006
	400MG; 5MG	A040687	001	Apr 27, 2006
	400MG; 7.5MG	A040698	001	Apr 27, 2006
	400MG; 10MG	A040692	001	Apr 27, 2006
	500MG; 10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000
	650MG; 10MG	A040371	002	Dec 29, 2000

PERCOCET

VINTAGE PHARMS LLC	325MG; 5MG	A085106	002	
	500MG; 7.5MG	A040341	001	Jul 26, 1999
	650MG; 10MG	A040341	002	Jul 26, 1999

ROXICET 5/500

ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989
--------	------------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+ MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014
--------------------	--------------	---------	-----	--------------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001	
--------------------	----------------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000
TALACEN				
SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG;32.5MG	N016844	001	
---------------	--------------	---------	-----	--

DOLENE AP-65

LEDERLE	650MG;65MG	A085100	001	
---------	------------	---------	-----	--

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996

WYGESIC

CARACO	650MG;65MG	A084999	001	
--------	------------	---------	-----	--

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
----------------	-------------	---------	-----	--------------

DARVOCET-N 100

XANODYNE PHARM	650MG;100MG	N017122	002	
----------------	-------------	---------	-----	--

DARVOCET-N 50

XANODYNE PHARM	325MG;50MG	N017122	001	
----------------	------------	---------	-----	--

PROPACET 100

TEVA	650MG;100MG	A070107	001	Jun 12, 1985
------	-------------	---------	-----	--------------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985
	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

CSPC OUYI	325MG;37.5MG	A076914	001	Jul 26, 2006
PAR PHARM	325MG;37.5MG	A076475	001	Apr 21, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018
MYLAN	500MG	A203917	001	Jun 18, 2019

DIAMOX

+ TEVA BRANDED PHARM	500MG	N012945	001	
----------------------	-------	---------	-----	--

TABLET;ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	

DIAMOX

+ TEVA BRANDED PHARM	125MG **	N008943	001	
+	250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014
HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017

DIAMOX

+ TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	
---------------	-----------------------	---------	-----	--

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	
----------------------	----	---------	-----	--

ACETIC ACID

KV PHARM	2%	A085493	001	
----------	----	---------	-----	--

ORLEX

WARNER CHILCOTT	2%	A086845	001	
-----------------	----	---------	-----	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994
-----------------	----------	---------	-----	--------------

BOROFAIR

PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985
------------	----------	---------	-----	--------------

DOMEBORO

BAYER PHARMS	2%;0.79%	A084476	001	
--------------	----------	---------	-----	--

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON

BAYER PHARMS	2%;0.05%	N017914	001	
--------------	----------	---------	-----	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

ACTAVIS MID ATLANTIC	2%;1%	A087143	001	Jan 13, 1982
----------------------	-------	---------	-----	--------------

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492	001	
----------	-------	---------	-----	--

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
-----------------	-------	---------	-----	--------------

WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996
-----------	-------	---------	-----	--------------

ORLEX HC

WARNER CHILCOTT	2%;1%	A086844	001	
-----------------	-------	---------	-----	--

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC

NEO-CORT-DOME

BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238	001	
--------------	---------------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

ANI PHARMS INC	250MG	A070869 001	Feb 09, 1987
	500MG	A070870 001	Feb 09, 1987
USL PHARMA	250MG	A070753 001	Nov 03, 1986
	500MG	A070754 001	Nov 03, 1986
WATSON LABS TEVA	250MG	A071893 001	Nov 25, 1987
	500MG	A071894 001	Nov 25, 1987
DYMELOR			
LILLY	250MG	N013378 002	
	500MG	N013378 001	

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING	20MG	N012254 002	
----------	------	-------------	--

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM	53%	N009008 001	
--------------------	-----	-------------	--

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

+ NOVARTIS	20MG/VIAL **	N016211 001	
------------	--------------	-------------	--

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624 001	Jun 19, 2015
---------------------	---------------------	-------------	--------------

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA	10%	A071364 001	May 01, 1989
	20%	A071365 001	May 01, 1989
ROXANE	10%	A072323 001	Apr 30, 1992
	10%	A072621 001	Sep 30, 1992
	20%	A072324 001	Apr 30, 1992
	20%	A072622 001	Sep 30, 1992

MUCOMYST

+ APOTHECON	10% **	N013601 002	
-------------	--------	-------------	--

+ MUCOSIL-10	20% **	N013601 001	
--------------	--------	-------------	--

DEY

DEY	10%	A070575 001	Oct 14, 1986
-----	-----	-------------	--------------

MUCOSIL-20

DEY	20%	A070576 001	Oct 14, 1986
-----	-----	-------------	--------------

TABLET, EFFERVESCENT; ORAL

CETYLEV

+ ARBOR PHARMS LLC	500MG	N207916 001	Jan 29, 2016
--------------------	-------	-------------	--------------

+ 2.5GM		N207916 002	Jan 29, 2016
---------	--	-------------	--------------

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON	10%; 0.05%	N017366 001	
--------------	------------	-------------	--

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS	0.1MG	N009436 001	
----------	-------	-------------	--

ACITRETIN

CAPSULE; ORAL

ACITRETIN

MYLAN	17.5MG	A203707 001	Sep 10, 2015
-------	--------	-------------	--------------

	22.5MG	A203707 002	Sep 10, 2015
--	--------	-------------	--------------

SORIATANE

+ STIEFEL LABS INC	17.5MG	N019821 003	Aug 06, 2009
--------------------	--------	-------------	--------------

+ 22.5MG		N019821 004	Aug 06, 2009
----------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACRISORCIN

CREAM;TOPICAL

AKRINOL

SCHERING 2MG/GM N012470 001

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997
IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
LEK PHARM	200MG	A074750	001	Apr 22, 1997
MYLAN	200MG	A074727	001	Apr 22, 1997
	200MG	A074977	001	Apr 13, 1998
RANBAXY	200MG	A074975	001	Sep 30, 1998
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
WATSON LABS	200MG	A075101	001	Apr 15, 1998

ZOVIRAX

+ MYLAN 200MG N018828 001 Jan 25, 1985

OINTMENT;OPHTHALMIC

AVACLYR

+ FERA PHARMS LLC 3% N202408 001 Mar 29, 2019

OINTMENT;TOPICAL

ACYCLOVIR

PERRIGO UK FINCO 5% A205659 001 Feb 20, 2019

TABLET;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	400MG	A075211	001	Sep 28, 1998
	800MG	A074976	002	Apr 13, 1998
	800MG	A075211	002	Sep 28, 1998
SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
	800MG	A074980	002	Sep 30, 1998
TEVA	200MG **	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR

ABBVIE EQ 50MG BASE/ML A075114 001 Jul 26, 1999

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

EUROHLTH INTL SARL EQ 500MG BASE/VIAL A074885 001 Dec 19, 1997

EQ 1GM BASE/VIAL A074885 002 Dec 19, 1997

ACYCLOVIR SODIUM

APOTHECON EQ 500MG BASE/VIAL A074897 001 Feb 27, 1998

EQ 1GM BASE/VIAL A074897 002 Feb 27, 1998

ATHENEX INC EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997

EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997

EUROHLTH INTL SARL EQ 500MG BASE/VIAL A074913 001 Oct 15, 1997

EQ 1GM BASE/VIAL A074913 002 Oct 15, 1997

FRESENIUS KABI USA EQ 500MG BASE/VIAL A075015 001 Apr 30, 1998

HIKMA PHARMS EQ 500MG BASE/VIAL A205771 001 Feb 29, 2016

EQ 1GM BASE/VIAL A205771 002 Feb 29, 2016

HOSPIRA EQ 25MG BASE/ML A074720 001 Apr 22, 1997

EQ 50MG BASE/ML A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL A074758 001 Apr 22, 1997

EQ 1GM BASE/VIAL A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL A074758 002 Apr 22, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927 001	Mar 29, 2017
	EQ 1GM BASE/VIAL	A203927 002	Mar 29, 2017
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001
	EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997
ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606 001	Jun 13, 2017
	EQ 1GM BASE/VIAL	A206606 002	Jun 13, 2017
ZOVIRAX			
+ GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603 003	Aug 30, 1983
+	EQ 500MG BASE/VIAL **	N018603 001	Oct 22, 1982
+	EQ 1GM BASE/VIAL **	N018603 002	Jun 29, 1989

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

+ GALDERMA LABS LP	0.1% **	N020338 001	May 31, 1996
--------------------	---------	-------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

TARO	0.3%; 2.5%	A209148 001	Oct 17, 2018
------	------------	-------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+ ASTELLAS	3MG/ML **	N019937 002	Oct 30, 1989
------------	-----------	-------------	--------------

ADENOSINE

LUITPOLD	3MG/ML	A090010 001	Apr 28, 2009
TEVA PHARMS USA	3MG/ML	A076564 001	Jun 16, 2004
	3MG/ML	A078676 001	Jul 31, 2008
WEST-WARD PHARMS INT	3MG/ML	A076501 001	Jun 16, 2004
WOCKHARDT	3MG/ML	A090220 001	Jul 20, 2009

SOLUTION; INTRAVENOUS

ADENOSCAN

+ ASTELLAS	60MG/20ML (3MG/ML) **	N020059 001	May 18, 1995
+	90MG/30ML (3MG/ML) **	N020059 002	May 18, 1995

ADENOSINE

EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313 001	Sep 15, 2014
	90MG/30ML (3MG/ML)	A202313 002	Sep 15, 2014

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER	EQ 200MG BASE/VIAL	N020760 001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760 002	Dec 18, 1997

ALBENDAZOLE

TABLET, CHEWABLE; ORAL

ALBENZA

AMEDRA PHARMS LLC	200MG	N207844 001	Jun 11, 2015
-------------------	-------	-------------	--------------

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX	100uCi/VIAL	N017835 001	
	250uCi/VIAL	N017835 002	
	500uCi/VIAL	N017835 003	

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS	2.5uCi/AMP	N017846 001	
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125			
MALLINCKRODT	6.67uCi/ML	N017844 003	
	10uCi/ML	N017844 001	
	100uCi/ML	N017844 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX	2mCi/VIAL	N017837	003
	5uCi/AMP	N017837	004
	20uCi/AMP	N017837	005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
-----------------	---------------	---------	-----	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
+ SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
+ **	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621	001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

	EQ 4MG BASE	A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120 001	Sep 29, 1992
	EQ 4MG BASE	A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817 001	Jan 09, 1990
	EQ 4MG BASE	A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629 001	Jan 31, 1991
	EQ 2MG BASE	A072764 001	Aug 28, 1991
	EQ 4MG BASE	A072630 001	Jan 31, 1991
	EQ 4MG BASE	A072765 001	Aug 28, 1991
YAOPHARMA CO LTD	EQ 2MG BASE	A072151 001	Dec 05, 1989
	EQ 4MG BASE	A072152 001	Dec 05, 1989
PROVENTIL			
+ SCHERING	EQ 2MG BASE **	N017853 001	May 07, 1982
+	EQ 4MG BASE **	N017853 002	May 07, 1982
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE	N019112 001	Jul 10, 1986
	EQ 4MG BASE	N019112 002	Jul 10, 1986
TABLET, EXTENDED RELEASE; ORAL			
PROVENTIL			
SCHERING	EQ 4MG BASE	N019383 001	Jul 13, 1987
VOLMAX			
MURO	EQ 4MG BASE	N019604 002	Dec 23, 1992
	EQ 8MG BASE	N019604 001	Dec 23, 1992
VOSPIRE ER			
DAVA PHARMS INC	EQ 8MG BASE	A076130 003	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291 001	Oct 24, 1996
SOLUTION; INHALATION			
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE			
APOTEX INC	EQ 0.083% BASE;0.017%	A077117 001	Dec 31, 2007
FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724 001	Dec 31, 2007
DUONEB			
+ MYLAN SPECIALITY LP	EQ 0.083% BASE;0.017% **	N020950 001	Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

+ FOUGERA PHARMS	0.05% **	N018707 001	Dec 14, 1982
------------------	----------	-------------	--------------

OINTMENT; TOPICAL

ACLOVATE

+ FOUGERA PHARMS	0.05% **	N018702 001	Dec 14, 1982
------------------	----------	-------------	--------------

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 10% AND DEXTROSE 5%

B BRAUN

10ML/100ML;5GM/100ML

N004589 006

ALCOHOL 5% AND DEXTROSE 5%

B BRAUN

5ML/100ML;5GM/100ML

N004589 004

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML;5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+ MERCK

EQ 70MG BASE/75ML **

N021575 001 Sep 17, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN

EQ 5MG BASE

A076584 001 Aug 04, 2008

EQ 10MG BASE

A076584 002 Aug 04, 2008

EQ 35MG BASE

A076584 003 Aug 04, 2008

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A076584 004 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

UPSHER SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

FOSAMAX

+ MERCK AND CO INC

EQ 5MG BASE **

N020560 003 Apr 25, 1997

+

EQ 10MG BASE **

N020560 001 Sep 29, 1995

+

EQ 35MG BASE **

N020560 004 Oct 20, 2000

+

EQ 40MG BASE **

N020560 002 Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

HERITAGE PHARMA

10MG

A079056 001 Jul 18, 2011

MYLAN

10MG

A079014 001 Jul 18, 2011

WOCKHARDT LTD

10MG

A090221 001 Aug 10, 2012

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET; ORAL

TEKTURNA

+ NODEN PHARMA

EQ 37.5MG BASE

N210709 001 Nov 14, 2017

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE

N022545 001 Aug 26, 2010

EQ 150MG BASE; EQ 10MG BASE

N022545 002 Aug 26, 2010

EQ 300MG BASE; EQ 5MG BASE

N022545 003 Aug 26, 2010

EQ 300MG BASE; EQ 10MG BASE

N022545 004 Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE; 12.5MG

N200045 001 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 12.5MG

N200045 002 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 25MG

N200045 003 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 12.5MG

N200045 004 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 25MG

N200045 005 Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

FOSUN PHARMA	100MG	A070268 001	Dec 31, 1985
MUTUAL PHARM	100MG	A070466 001	Dec 24, 1985
	300MG	A070467 001	Dec 24, 1985
PURACAP PHARM	100MG	A070150 001	Dec 10, 1985
	300MG	A070147 001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
	300MG	A070580 001	Apr 14, 1986
SANDOZ	300MG	A070269 001	Dec 31, 1985
SUN PHARM INDS INC	100MG	A078390 001	Aug 30, 2007
	300MG	A078390 002	Aug 30, 2007
SUPERPHARM	100MG	A070950 001	Nov 30, 1988
	300MG	A070951 001	Nov 30, 1988
WATSON LABS	100MG	N018241 001	Nov 16, 1984
	100MG	N018785 001	Sep 28, 1984
	300MG	N018241 002	Nov 16, 1984
	300MG	N018785 002	Sep 28, 1984

LOPURIN

ABBOTT

100MG	N018297 001
300MG	N018297 002

ALLOPURINOL; LESINURAD

TABLET;ORAL

DUZALLO

+ IRONWOOD PHARMS INC	200MG;200MG	N209203 001	Aug 18, 2017
+	300MG;200MG	N209203 002	Aug 18, 2017

ALMOTRIPTAN MALATE

TABLET;ORAL

AXERT

+ JANSSEN PHARMS	EQ 6.25MG BASE	N021001 001	May 07, 2001
+	EQ 12.5MG BASE	N021001 002	May 07, 2001

ALPRAZOLAM

SOLUTION;ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
--------	-----------	-------------	--------------

TABLET;ORAL

ALPRAZOLAM

ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
	0.5MG	A074085 002	Feb 16, 1994
	1MG	A074085 003	Feb 16, 1994
	2MG	A074085 004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
	0.5MG	A074294 002	Jul 29, 1994
	1MG	A074294 003	Jul 29, 1994
	2MG	A074294 004	Jul 29, 1994
MYLAN PHARMS INC	0.25MG	A074046 001	Oct 19, 1993
	0.5MG	A074046 002	Oct 19, 1993
	1MG	A074046 003	Oct 19, 1993
	2MG	A074046 004	May 07, 1997
ROXANE	0.25MG	A074199 001	Oct 19, 1993
	0.5MG	A074199 002	Oct 19, 1993
	1MG	A074199 003	Oct 19, 1993
WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
	0.25MG	A074479 001	Jan 21, 1997
	0.5MG	A074456 002	Aug 31, 1995
	0.5MG	A074479 002	Jan 21, 1997
	1MG	A074456 003	Aug 31, 1995
	1MG	A074479 003	Jan 21, 1997

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

ACTAVIS LABS FL INC	0.5MG	A077198 001	May 13, 2010
	1MG	A077198 002	May 13, 2010
	2MG	A077198 003	May 13, 2010
	3MG	A077198 004	May 13, 2010
ANI PHARMS INC	0.5MG	A077725 001	Jul 31, 2006
	0.5MG	A077979 001	Feb 28, 2007
	1MG	A077725 002	Jul 31, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ALPRAZOLAMTABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

	1MG	A077979 002	Feb 28, 2007	
	2MG	A077725 004	Jul 31, 2006	
	2MG	A077979 003	Feb 28, 2007	
	3MG	A077725 003	Jul 31, 2006	
	3MG	A077979 004	Feb 28, 2007	
HERITAGE PHARMS INC	0.5MG	A078489 001	Oct 17, 2008	
	1MG	A078489 002	Oct 17, 2008	
	2MG	A078489 003	Oct 17, 2008	
	3MG	A078489 004	Oct 17, 2008	
IMPAX LABS	0.5MG	A077968 004	May 24, 2007	
	1MG	A077968 003	May 24, 2007	
	2MG	A077968 002	May 24, 2007	
	3MG	A077968 001	May 24, 2007	
IMPAX LABS INC	0.5MG	A077996 001	Jan 31, 2007	
	1MG	A077996 002	Jan 31, 2007	
	2MG	A077996 003	Jan 31, 2007	
	3MG	A077996 004	Jan 31, 2007	
MYLAN	0.5MG	A077391 002	Jan 26, 2006	
	1MG	A077391 003	Jan 26, 2006	
	2MG	A077391 004	Jan 26, 2006	
	3MG	A077391 001	Jan 26, 2006	
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006	
	1MG	A077777 002	Jun 30, 2006	
	2MG	A077777 003	Jun 30, 2006	
	3MG	A077777 004	Jun 30, 2006	
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007	
	1MG	A078442 002	Oct 15, 2007	
	2MG	A078442 003	Oct 15, 2007	
	3MG	A078442 004	Oct 15, 2007	
TABLET, ORALLY DISINTEGRATING;ORAL				
NIRAVAM				
+	UCB INC	0.25MG **	N021726 001	Jan 19, 2005
+		0.5MG **	N021726 002	Jan 19, 2005
+		1MG **	N021726 003	Jan 19, 2005
+		2MG **	N021726 004	Jan 19, 2005

ALPROSTADILINJECTABLE;INJECTION
CAVERJECT

PFIZER	0.005MG/ML	N020755 001	Oct 31, 1997	
	0.01MG/ML	N020755 002	Oct 01, 1997	
	0.02MG/ML	N020755 003	Oct 01, 1997	
+	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379 003	Jun 27, 1996
EDEX				
AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649 001	Jun 12, 1997	

ALSEROXYLON

TABLET;ORAL

RAUTENSIN			
NOVARTIS	2MG	N009215 001	
RAUWILOID			
3M	2MG	N008867 001	

ALTRETAMINE

CAPSULE;ORAL

HEXALEN				
+	EISAI INC	50MG	N019926 001	Dec 26, 1990

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE				
PENNEX	80MG;20MG	A089449 001	Nov 27, 1987	
FOAMCOAT				
GUARDIAN DRUG	80MG;20MG	A071793 001	Sep 04, 1987	
FOAMICON				
NOVARTIS	80MG;20MG	A072687 001	Jun 28, 1989	
GAVISCON				
+	SANOFI AVENTIS US	160MG;40MG	N018685 002	Dec 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
LANNETT CO INC	100MG	A209221	001	Jun 15, 2017
WATSON LABS	100MG	A071382	001	Jan 21, 1987

SYMADINE

SOLVAY	100MG	A071000	001	Sep 04, 1986
--------	-------	---------	-----	--------------

SYMMETREL

+ ENDO PHARMS	100MG **	N016020	001	
---------------	----------	---------	-----	--

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
LANNETT CO INC	50MG/5ML	A076352	001	Sep 10, 2004
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006

SYMMETREL

+ ENDO PHARMS	50MG/5ML **	N016023	002	
---------------	-------------	---------	-----	--

TABLET; ORAL

SYMMETREL

+ ENDO PHARMS	100MG **	N018101	001	
---------------	----------	---------	-----	--

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US	10MG	N010155	002	
-------------------	------	---------	-----	--

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+ ASTELLAS	0.025%	N018116	001	
------------	--------	---------	-----	--

+	0.1%	N018116	002	
---	------	---------	-----	--

LOTION; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988
------------	------	---------	-----	--------------

OINTMENT; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1%	N018498	001	
------------	------	---------	-----	--

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999
----------	------------	---------	-----	--------------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
--------	------------------	---------	-----	--------------

	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
--	------------------	---------	-----	--------------

HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
---------	-----------------	---------	-----	--------------

	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
--	-----------------	---------	-----	--------------

	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
--	-------------------	---------	-----	--------------

	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
--	------------------	---------	-----	--------------

	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
--	------------------	---------	-----	--------------

	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
--	------------------	---------	-----	--------------

	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
--	------------------	---------	-----	--------------

IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
--------------	-----------------	---------	-----	--------------

	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
--	------------------	---------	-----	--------------

TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
-----------------	-----------------	---------	-----	--------------

	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993
--	------------------	---------	-----	--------------

WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992
----------------------	-----------------	---------	-----	--------------

	EQ 250MG BASE/ML	A063275	001	May 18, 1992
--	------------------	---------	-----	--------------

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
---------	---------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN

APOTHECON	EQ 50MG BASE/ML	A062311 001	
	EQ 50MG BASE/ML	A062562 001	Sep 20, 1984
+	EQ 50MG BASE/ML **	N050495 001	
	EQ 250MG BASE/ML	A062311 002	
	EQ 250MG BASE/ML	A062562 002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495 002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
APOTHECON	EQ 5MG BASE/ML	N050618 002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618 001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

TEVA	EQ 5MG ANHYDROUS; 50MG	A070795 001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS; 50MG	A073334 001	Jul 19, 1991
YAOPHARMA CO LTD	EQ 5MG ANHYDROUS; 50MG	A073357 001	Nov 27, 1991
HYDRO-RIDE			
PAR PHARM	EQ 5MG ANHYDROUS; 50MG	A070347 001	Dec 25, 1990
MODURETIC 5-50			
+	MERCK	EQ 5MG ANHYDROUS; 50MG **	N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901 001	Apr 06, 1984
AMINOSYN 10%			
ICU MEDICAL INC	10% (10GM/100ML)	N017673 003	
AMINOSYN 10% (PH6)			
ICU MEDICAL INC	10% (10GM/100ML)	N017673 008	Nov 18, 1985
AMINOSYN 3.5%			
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789 004	
AMINOSYN 3.5% IN PLASTIC CONTAINER			
ABBOTT	3.5% (3.5GM/100ML)	N018804 001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875 001	Aug 08, 1984
AMINOSYN 5%			
ICU MEDICAL INC	5% (5GM/100ML)	N017673 001	
AMINOSYN 7%			
ICU MEDICAL INC	7% (7GM/100ML)	N017673 002	
AMINOSYN 7% (PH6)			
ICU MEDICAL INC	7% (7GM/100ML)	N017673 006	Nov 18, 1985
AMINOSYN 8.5%			
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673 004	
AMINOSYN 8.5% (PH6)			
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673 007	Nov 18, 1985
AMINOSYN II 10%			
ICU MEDICAL INC	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 3.5%			
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438 001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER			
ABBOTT	3.5% (3.5GM/100ML)	N019491 001	Oct 10, 1986
AMINOSYN II 5%			
ICU MEDICAL INC	5% (5GM/100ML)	N019438 002	Apr 03, 1986
AMINOSYN II 7%			
ICU MEDICAL INC	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
ICU MEDICAL INC	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER			
ABBOTT	7% (7GM/100ML)	N019400 001	Jul 23, 1986
AMINOSYN-HF 8%			
ICU MEDICAL INC	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-RF 5.2%			
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429 001	
BRANCHAMIN 4%			
BAXTER HLTHCARE	4% (4GM/100ML)	N018678 001	Sep 28, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS

INJECTABLE; INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4% (4GM/100ML)	N018684 001	Sep 28, 1984
FREAMINE 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 001	
FREAMINE II 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 002	
HEPATASOL 8%			
BAXTER HLTHCARE	8% (8GM/100ML)	A020360 001	Apr 04, 1996
NEOPHAM 6.4%			
HOSPIRA	6.4% (6.4GM/100ML)	N018792 001	Jan 17, 1984
NOVAMINE 11.4%			
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957 003	Aug 09, 1982
NOVAMINE 15%			
HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER			
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107 001	Feb 05, 1993
NOVAMINE 8.5%			
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957 002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES			
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493 007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES			
BAXTER HLTHCARE	10% (10GM/100ML)	N017493 006	
TRAVASOL 5.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493 004	
TRAVASOL 8.5% W/O ELECTROLYTES			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493 005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 001	Sep 12, 1988
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 002	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 004	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100M L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714 003	Sep 12, 1988
HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683 004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%; 25GM/100ML	N019118 001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER			
ABBOTT	3.5%; 5GM/100ML	N019120 001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	4.25%; 25GM/100ML	N019119 001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER			
ABBOTT	3.5%; 25GM/100ML	N019505 002	Nov 07, 1986
	3.5%; 25GM/100ML	N019713 006	Sep 09, 1988
HOSPIRA	3.5%; 25GM/100ML	N019681 001	Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506 001	Nov 07, 1986
	3.5%;5GM/100ML	N019713 002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681 002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713 001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681 004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713 004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986
	5%;25GM/100ML	N019713 003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988
-----------------	-----------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988
-----------------	-----------------	-------------	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712 002	Sep 08, 1988
--------	--	-------------	--------------

HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682 003	Nov 01, 1988
-------------	--	-------------	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 002	Dec 16, 1986
--------	---	-------------	--------------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 004	Dec 16, 1986
--------	--	-------------	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 001	Dec 16, 1986
--------	---	-------------	--------------

	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712 001	Sep 08, 1988
--	---	-------------	--------------

HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988
-------------	---	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML; 120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 20MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995
BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995
BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 004	Oct 23, 1995
BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 005	Oct 23, 1995
BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147 001	Oct 23, 1995
BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 007	Oct 23, 1995
BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 008	Oct 23, 1995
BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 009	Oct 23, 1995
BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 010	Oct 23, 1995
BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147 006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789 003	
ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005	
-----------------	---	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML ;49MG/100ML	N019493 001	Oct 16, 1986
--------	--	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957 001	
-------------	--	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
-----------------	--	-------------	--------------

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML	N019437 006	Apr 03, 1986
-----------------	---	-------------	--------------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437 005	Apr 03, 1986
-----------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML ;425MG/100ML	N017673 009	Oct 25, 2002
-----------------	---	-------------	--------------

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML ;425MG/100ML	N019437 008	Oct 25, 2002
-----------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986
-----------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
-----------------	--	-------------	--------------

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493 003	
-----------------	--	-------------	--

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173 001	Oct 27, 1995
-----------------	--	-------------	--------------

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N017493 001	
-----------------	--	-------------	--

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173 002	Oct 27, 1995
-----------------	--	-------------	--------------

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N017493 002	
-----------------	--	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
-----------------	--	-------------	--

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673 005	
-----------------	--	-------------	--

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

+ CLOVER PHARMS	250MG/ML **	N015229 002	
-----------------	-------------	-------------	--

AMINOCAPROIC ACID

ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
---------------	----------	-------------	--------------

BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
-----------------	----------	-------------	--------------

HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
---------	----------	-------------	--------------

SYRUP; ORAL

AMINOCAPROIC ACID

AKORN	1.25GM/5ML	A074759 001	Sep 02, 1998
-------	------------	-------------	--------------

TABLET; ORAL

AMINOCAPROIC

AKORN	500MG	A075602 001	May 24, 2001
-------	-------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCCK

20%

N005619 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

25MG/ML

A087239 001

ELKINS SINN

25MG/ML

A087601 001 Jul 23, 1982

HOSPIRA

25MG/ML

A087209 001 Feb 01, 1982

INTL MEDICATION

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

25MG/ML

A086606 001

KING PHARMS

25MG/ML

A087240 001

LUITPOLD

25MG/ML

A087600 001

25MG/ML

A087431 001

LYPHOMED

25MG/ML

A087387 001 Jun 03, 1983

PHARMA SERVE NY

25MG/ML

A087392 001 Dec 15, 1983

25MG/ML

A088429 001 May 30, 1985

SMITH AND NEPHEW

25MG/ML

A088749 001 May 30, 1985

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

ACP NIMBLE

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

AMINOPHYLLINE

ANI PHARMS INC

100MG

A085261 004

200MG

A085261 002

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

BARR

100MG

A088297 001 Aug 19, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

	200MG	A088298 001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182 001	Mar 31, 1983
	200MG	A088183 001	Mar 31, 1983
HALSEY	100MG	A084674 001	
HIKMA INTL PHARMS	100MG	A084540 001	
	200MG	A085003 001	
IMPAX LABS	100MG	A084574 001	
	200MG	A084576 001	
KV PHARM	100MG	A085284 001	
	200MG	A085289 001	
LANNETT	100MG	A084588 001	
	200MG	A084588 002	
PAL PAK	100MG	A084533 001	
PANRAY	100MG	A084552 001	
	200MG	A084552 002	
PUREPAC PHARM	100MG	A084699 001	
	200MG	A085333 001	
ROXANE	100MG	A087500 001	Feb 09, 1982
	200MG	A087501 001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563 001	
VANGARD	100MG	A088314 001	Oct 03, 1983
	200MG	A088319 001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409 001	
	200MG	A085410 001	
WATSON LABS	100MG	A085567 001	
	200MG	A085564 001	

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS	100MG	A084577 001	
	200MG	A084575 001	
TABLICAPS	100MG	A084632 002	
VALE	100MG	A084531 001	
	200MG	A084530 001	

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC	225MG	A086760 001	
-----------------	-------	-------------	--

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947 001	
----------------	------------	-------------	--

SODIUM AMINOSALICYLATE

HEXCEL	100%	A080097 001	
--------	------	-------------	--

TABLET; ORAL

PARASAL SODIUM

PANRAY	500MG	N006811 006	
--------	-------	-------------	--

	1GM	N006811 011	
--	-----	-------------	--

SODIUM P.A.S.

LANNETT	500MG	A080138 002	
---------	-------	-------------	--

TEEBACIN

CONSOLIDATED MIDLAND	500MG	N007320 002	
----------------------	-------	-------------	--

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC	846MG; 112MG	A080059 002	
---------------------	--------------	-------------	--

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY	500MG	N006811 001	
--------	-------	-------------	--

	1GM	N006811 002	
--	-----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AKORN 50MG/ML

A076232 001 Jul 05, 2006

BEDFORD 50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS 50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE 50MG/ML

A076088 001 Oct 15, 2002

DR REDDYS 50MG/ML

A076163 001 Sep 05, 2003

HOSPIRA 50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS 50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS 50MG/ML

A076394 001 Apr 25, 2003

CORDARONE

+ WYETH PHARMS INC 50MG/ML **

N020377 001 Aug 03, 1995

NEXTERONE

+ BAXTER HLTHCARE 50MG/ML **

N022325 001 Dec 24, 2008

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

MYLAN 200MG

A075188 001 Feb 24, 1999

TEVA 200MG

A074895 001 Apr 16, 1999

CORDARONE

+ WYETH PHARMS 200MG **

N018972 001 Dec 24, 1985

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE 40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML

A085594 001

ELAVIL

ASTRAZENECA 10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB 10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT 10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP 25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

ANI PHARMS INC 10MG

A085031 002

25MG

A085031 001

50MG

A085031 003

75MG

A085031 004

10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY 10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

50MG

A087557 001 Mar 05, 1982

75MG

A085926 001 May 20, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	100MG	A085927 001	May 20, 1983
LEDERLE	10MG	A086744 001	
	10MG	A087366 001	Jan 04, 1982
	25MG	A086746 001	
	25MG	A087367 001	May 03, 1982
	50MG	A086743 001	
	50MG	A087181 001	Jan 04, 1982
	75MG	A086745 001	
	75MG	A087369 001	Jan 04, 1982
	100MG	A086747 001	
	100MG	A087368 001	May 03, 1982
	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUN PHARM INDS INC	10MG	A040816 002	Jun 27, 2008
	25MG	A040816 001	Jun 27, 2008
	50MG	A040816 003	Jun 27, 2008
	75MG	A040816 004	Jun 27, 2008
	100MG	A040816 005	Jun 27, 2008
	150MG	A040816 006	Jun 27, 2008
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	
ELAVIL				
+ ASTRAZENECA	10MG **	N012703	001	
+	25MG **	N012703	003	
+	50MG **	N012703	004	
+	75MG **	N012703	005	
+	100MG **	N012703	006	
+	150MG **	N012703	007	
ENDEP				
ROCHE	10MG	A083639	001	
	25MG	A083639	002	
	50MG	A083639	003	
	75MG	A083639	004	
	100MG	A083639	005	
	150MG	A085303	001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
LIMBITROL				
+ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949	001	
LIMBITROL DS				
+ HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10

SCHERING	10MG;2MG **	N014713	007	
ETRAFON 2-25				
SCHERING	25MG;2MG **	N014713	004	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON-A

SCHERING 10MG; 4MG ** N014713 002

ETRAFON-FORTE

SCHERING 25MG; 4MG ** N014713 006

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

FOSUN PHARMA 10MG; 2MG A071062 001 Nov 27, 1987

10MG; 4MG A071862 001 Dec 21, 1987

25MG; 2MG A071063 001 Nov 27, 1987

25MG; 4MG A071064 001 Nov 27, 1987

50MG; 4MG A071863 001 Dec 21, 1987

HERITAGE PHARMA 10MG; 2MG A073007 001 Oct 17, 1991

10MG; 4MG A073009 001 Oct 17, 1991

25MG; 2MG A073008 001 Oct 17, 1991

25MG; 4MG A073010 001 Oct 17, 1991

IVAX SUB TEVA PHARMS 10MG; 2MG A070935 001 Sep 11, 1986

10MG; 4MG A070937 001 Sep 11, 1986

25MG; 2MG A070936 001 Sep 11, 1986

25MG; 4MG A070938 001 Sep 11, 1986

50MG; 4MG A070939 001 Sep 12, 1986

PAR PHARM 10MG; 2MG A070565 001 Sep 11, 1986

10MG; 4MG A070620 001 Sep 11, 1986

25MG; 2MG A070621 001 Sep 11, 1986

25MG; 4MG A070595 001 Sep 11, 1986

50MG; 4MG A070574 001 Sep 11, 1986

SUN PHARM INDUSTRIES 10MG; 2MG A071077 001 Nov 12, 1986

10MG; 4MG A071078 001 Nov 12, 1986

25MG; 2MG A070297 001 Nov 12, 1986

25MG; 4MG A071079 001 Nov 12, 1986

WATSON LABS 10MG; 2MG A070373 001 Aug 25, 1986

10MG; 2MG A072539 001 Feb 15, 1989

10MG; 4MG A070375 001 Aug 25, 1986

10MG; 4MG A072540 001 Feb 15, 1989

25MG; 2MG A070374 001 Aug 25, 1986

25MG; 2MG A072541 001 Feb 15, 1989

25MG; 4MG A070376 001 Aug 25, 1986

25MG; 4MG A072134 001 Feb 15, 1989

50MG; 4MG A070377 001 Nov 04, 1986

50MG; 4MG A071558 001 Mar 02, 1987

50MG; 4MG A072135 001 Feb 15, 1989

TRIAVIL 2-10

NEW RIVER 10MG; 2MG ** N014715 004

TRIAVIL 2-25

NEW RIVER 25MG; 2MG ** N014715 002

TRIAVIL 4-10

NEW RIVER 10MG; 4MG ** N014715 003

TRIAVIL 4-25

NEW RIVER 25MG; 4MG ** N014715 005

TRIAVIL 4-50

NEW RIVER 50MG; 4MG ** N014715 006

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU 5% N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU 2MG N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AMNEAL PHARMS NY EQ 2.5MG BASE A078477 001 Jan 16, 2008

EQ 5MG BASE A078477 002 Jan 16, 2008

EQ 10MG BASE A078477 003 Jan 16, 2008

GEDEON RICHTER USA EQ 2.5MG BASE A077333 001 Jul 17, 2007

EQ 5MG BASE A077333 002 Jul 17, 2007

EQ 10MG BASE A077333 003 Jul 17, 2007

GENPHARM EQ 2.5MG BASE A077362 001 Jul 09, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	EQ 5MG BASE	A077362 002	Jul 09, 2007
	EQ 10MG BASE	A077362 003	Jul 09, 2007
MYLAN	EQ 2.5MG BASE	A078224 001	Feb 27, 2008
	EQ 5MG BASE	A078224 002	Feb 27, 2008
	EQ 10MG BASE	A078224 003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007
	EQ 5MG BASE	A078131 002	Sep 04, 2007
	EQ 10MG BASE	A078131 003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900 001	Jul 23, 2015
	EQ 5MG BASE	A204900 002	Jul 23, 2015
	EQ 10MG BASE	A204900 003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231 001	Nov 30, 2007
	EQ 5MG BASE	A078231 002	Nov 30, 2007
	EQ 10MG BASE	A078231 003	Nov 30, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081 001	Jan 31, 2008
	EQ 5MG BASE	A078081 002	Jan 31, 2008
	EQ 10MG BASE	A078081 003	Jan 31, 2008
SUNSHINE LAKE	EQ 2.5MG BASE	A206524 001	May 04, 2018
	EQ 5MG BASE	A206524 002	May 04, 2018
	EQ 10MG BASE	A206524 003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080 001	Jun 27, 2007
	EQ 5MG BASE	A077080 002	Jun 27, 2007
	EQ 10MG BASE	A077080 003	Jun 27, 2007
TEVA	EQ 2.5MG BASE	A076846 001	Jun 28, 2007
	EQ 5MG BASE	A076846 002	Jun 28, 2007
	EQ 10MG BASE	A076846 003	Jun 28, 2007
YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859 001	Sep 10, 2007
	EQ 5MG BASE	A076859 002	Sep 10, 2007
	EQ 10MG BASE	A076859 003	Sep 10, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026 001	Sep 27, 2007
	EQ 5MG BASE	N022026 002	Sep 27, 2007
	EQ 10MG BASE	N022026 003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762 001	Jan 11, 2019
	EQ 2.5MG BASE;EQ 20MG BASE	A207762 002	Jan 11, 2019
	EQ 2.5MG BASE;EQ 40MG BASE	A207762 003	Jan 11, 2019
	EQ 5MG BASE;EQ 10MG BASE	A207762 004	Jan 11, 2019
	EQ 5MG BASE;EQ 20MG BASE	A207762 005	Jan 11, 2019
	EQ 5MG BASE;EQ 40MG BASE	A207762 006	Jan 11, 2019
	EQ 5MG BASE;EQ 80MG BASE	A207762 007	Jan 11, 2019
	EQ 10MG BASE;EQ 10MG BASE	A207762 008	Jan 11, 2019
	EQ 10MG BASE;EQ 20MG BASE	A207762 009	Jan 11, 2019
	EQ 10MG BASE;EQ 40MG BASE	A207762 010	Jan 11, 2019
	EQ 10MG BASE;EQ 80MG BASE	A207762 011	Jan 11, 2019

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215 001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215 002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215 003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215 004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375 001	May 21, 2010
	EQ 5MG BASE;10MG	A077375 002	May 21, 2010
	EQ 5MG BASE;20MG	A077375 003	May 21, 2010
	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375 004	May 21, 2010
	EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179 001	May 18, 2007
	EQ 5MG BASE;10MG	A077179 002	May 18, 2007
	EQ 5MG BASE;20MG	A077179 003	May 18, 2007
	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

EQ 10MG BASE; 20MG

A077179 004 May 18, 2007

EQ 10MG BASE; 40MG

A077179 006 Jul 05, 2011

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

TEVA PHARMS USA EQ 5MG BASE; 12.5MG; 20MG

A202491 001 Nov 03, 2016

EQ 5MG BASE; 12.5MG; 40MG

A202491 002 Nov 03, 2016

EQ 5MG BASE; 25MG; 40MG

A202491 003 Nov 03, 2016

EQ 10MG BASE; 12.5MG; 40MG

A202491 004 Nov 03, 2016

EQ 10MG BASE; 25MG; 40MG

A202491 005 Nov 03, 2016

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

TEVA PHARMS 5MG; 12.5MG; 160MG

A200435 001 Sep 25, 2012

5MG; 25MG; 160MG

A200435 002 Sep 25, 2012

10MG; 12.5MG; 160MG

A200435 005 Sep 25, 2012

10MG; 25MG; 160MG

A200435 003 Sep 25, 2012

10MG; 25MG; 320MG

A200435 004 Sep 25, 2012

TORRENT 5MG; 12.5MG; 160MG

A201593 001 Jun 03, 2015

5MG; 25MG; 160MG

A201593 002 Jun 03, 2015

10MG; 12.5MG; 160MG

A201593 003 Jun 03, 2015

10MG; 25MG; 160MG

A201593 004 Jun 03, 2015

10MG; 25MG; 320MG

A201593 005 Jun 03, 2015

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC EQ 5MG BASE; 20MG

A209600 001 Aug 30, 2018

EQ 5MG BASE; 40MG

A209600 003 Aug 30, 2018

EQ 10MG BASE; 20MG

A209600 002 Aug 30, 2018

EQ 10MG BASE; 40MG

A209600 004 Aug 30, 2018

TEVA PHARMS USA EQ 5MG BASE; 20MG

A091154 001 Oct 26, 2016

EQ 5MG BASE; 40MG

A091154 002 Oct 26, 2016

EQ 10MG BASE; 20MG

A091154 003 Oct 26, 2016

EQ 10MG BASE; 40MG

A091154 004 Oct 26, 2016

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

TEVA PHARMS USA EQ 5MG BASE; 160MG

A091235 001 Mar 30, 2015

EQ 5MG BASE; 320MG

A091235 003 Mar 30, 2015

EQ 10MG BASE; 160MG

A091235 002 Mar 30, 2015

EQ 10MG BASE; 320MG

A091235 004 Mar 30, 2015

TORRENT EQ 5MG BASE; 160MG

A202377 001 Mar 30, 2015

EQ 5MG BASE; 320MG

A202377 002 Mar 30, 2015

EQ 10MG BASE; 160MG

A202377 003 Mar 30, 2015

EQ 10MG BASE; 320MG

A202377 004 Mar 30, 2015

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC 2.5MG

N021435 001 Oct 31, 2003

5MG

N021435 002 Oct 31, 2003

10MG

N021435 003 Oct 31, 2003

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM 3.75-260mCi/ML

A204539 001 Jun 23, 2015

UNIV TX MD ANDERSON 30mCi-300mCi/8ML (3.75-37.5mCi/ML)

A203933 001 Jun 27, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT 5MEQ/ML

A083130 001

GD SEARLE LLC 3MEQ/ML

A086205 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW 900MG/100ML

N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN 40MEQ/100ML

A085734 001

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

SUN PHARM INDS INC EQ 12% BASE **

N020508 001 Aug 29, 1996

LOTION; TOPICAL

LAC-HYDRIN

+ SUN PHARM INDS INC EQ 12% BASE **

N019155 001 Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS EQ 200MG BASE

N006441 001

AMOXAPINE

TABLET; ORAL

AMOXAPINE

UPSHER SMITH LABS 25MG

A072943 001 Jun 28, 1991

50MG

A072944 001 Jun 28, 1991

100MG

A072878 001 Jun 28, 1991

150MG

A072879 001 Jun 28, 1991

WATSON PHARMS TEVA 25MG

A072418 001 Aug 01, 1989

50MG

A072419 001 Aug 01, 1989

100MG

A072420 001 May 11, 1989

150MG

A072421 001 May 11, 1989

ASENDIN

LEDERLE 25MG

N018021 001

50MG

N018021 002

100MG

N018021 003

150MG

N018021 004

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL 250MG

A062528 001 Aug 07, 1985

500MG

A062528 002 Aug 07, 1985

MYLAN 250MG

A062067 001

500MG

A062067 002

SUN PHARM INDS LTD 250MG

A065016 001 Apr 08, 1999

500MG

A065016 002 Apr 08, 1999

TEVA 250MG

A062853 001 Dec 22, 1987

250MG

A063030 001 Feb 28, 1989

500MG

A062854 001 Dec 22, 1987

500MG

A063031 001 Feb 28, 1989

AMOXIL

+ GLAXOSMITHKLINE 250MG **

N050459 001

+ 500MG **

N050459 002

TRIMOX

APOTHECON 250MG

A061885 001

250MG

A062098 001

250MG

A062152 001

250MG

A063099 001 Mar 20, 1992

500MG

A061885 002

500MG

A062098 002

500MG

A062152 002

500MG

A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS 250MG

A062107 001

500MG

A062107 002

WYMOX

WYETH AYERST 250MG

A062120 001

500MG

A062120 002

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS 125MG/5ML

A062059 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

		250MG/5ML	A062059	002	
	MYLAN	125MG/5ML	A062090	001	
		250MG/5ML	A062090	002	
	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002
		400MG/5ML	A065113	002	Nov 29, 2002
	TEVA	125MG/5ML	A061931	001	
		125MG/5ML	A062946	001	Nov 01, 1988
		250MG/5ML	A063001	001	Jan 06, 1989
	AMOXIL				
	+ GLAXOSMITHKLINE	50MG/ML **	N050460	005	
		125MG/5ML **	N050460	001	
		250MG/5ML **	N050460	002	
	+ NEOPHARMA	200MG/5ML **	N050760	001	Apr 15, 1999
		400MG/5ML **	N050760	002	Apr 15, 1999
	LAROTID				
	+ GLAXOSMITHKLINE	50MG/ML **	N050460	006	
	POLYMOX				
	APOTHECON	125MG/5ML	A061851	001	
		125MG/5ML	A062323	001	
		250MG/5ML	A061851	002	
		250MG/5ML	A062323	002	
	TRIMOX				
	APOTHECON	50MG/ML	A061886	001	
		125MG/5ML	A061886	002	
		125MG/5ML	A062099	001	
		125MG/5ML	A062154	001	
		125MG/5ML	A062885	001	Mar 08, 1988
		250MG/5ML	A061886	003	
		250MG/5ML	A062099	002	
		250MG/5ML	A062154	002	
		250MG/5ML	A062885	002	Mar 08, 1988
	UTIMOX				
	PARKE DAVIS	125MG/5ML	A062127	001	
		250MG/5ML	A062127	002	
	WYMOX				
	WYETH AYERST	125MG/5ML	A062131	001	
		250MG/5ML	A062131	002	
	TABLET;ORAL				
	AMOXICILLIN				
	DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000
		875MG	A065059	002	Nov 24, 2000
	AMOXIL				
	+ NEOPHARMA	500MG **	N050754	002	Jul 10, 1998
		875MG **	N050754	001	Jul 10, 1998
	TABLET, CHEWABLE;ORAL				
	AMOXICILLIN				
	APOTHECON	125MG	A064131	001	May 06, 1996
		250MG	A064131	002	May 06, 1996
	DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996
		250MG	A064139	002	Jan 29, 1996
	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999
		200MG	A065060	001	Nov 29, 2000
		250MG	A065021	002	Dec 23, 1999
		400MG	A065060	002	Nov 29, 2000
	TEVA	125MG	A064031	001	Dec 19, 1996
		250MG	A064031	002	Dec 19, 1996
	AMOXIL				
	+ NEOPHARMA	125MG **	N050542	002	
		200MG	N050761	001	Apr 15, 1999
		250MG **	N050542	001	
		400MG	N050761	002	Apr 15, 1999
	TABLET, EXTENDED RELEASE;ORAL				
	MOXATAG				
	+ PRAGMA	775MG	N050813	001	Jan 23, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMOXICILLIN

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007
	400MG	A065324 002	Jan 17, 2007
DISPERMOX			
RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003
	400MG	A065080 001	Aug 11, 2003
	600MG	A065159 001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

ANI PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30M G	A200218 001	Aug 30, 2013
PREVPAC			
+ TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30M G	N050757 001	Dec 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132 001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132 002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207 002	Jan 30, 2007
AUGMENTIN '200'			
+ NEOPHARMA	200MG/5ML;EQ 28.5MG BASE/5ML	N050725 001	May 31, 1996
AUGMENTIN '400'			
+ NEOPHARMA	400MG/5ML;EQ 57MG BASE/5ML	N050725 002	May 31, 1996
AUGMENTIN ES-600			
+ NEOPHARMA	600MG/5ML;EQ 42.9MG BASE/5ML	N050755 001	Jun 22, 2001

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102 001	Sep 17, 2002
AUGMENTIN '250'			
+ NEOPHARMA	250MG;EQ 125MG BASE **	N050564 001	Aug 06, 1984
AUGMENTIN '500'			
+ NEOPHARMA	500MG;EQ 125MG BASE **	N050564 002	Aug 06, 1984

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SANDOZ	200MG;EQ 28.5MG BASE	A065065 001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065 002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161 001	Dec 03, 2003
	400MG;EQ 57MG BASE	A065161 002	Dec 03, 2003
AUGMENTIN '125'			
+ NEOPHARMA	125MG;EQ 31.25MG BASE **	N050597 001	Jul 22, 1985
AUGMENTIN '200'			
+ NEOPHARMA	200MG;EQ 28.5MG BASE	N050726 001	May 31, 1996
AUGMENTIN '250'			
+ NEOPHARMA	250MG;EQ 62.5MG BASE **	N050597 002	Jul 22, 1985
AUGMENTIN '400'			
+ NEOPHARMA	400MG;EQ 57MG BASE	N050726 002	May 31, 1996

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG **	A083564 001
	2.5MG;2.5MG;2.5MG;2.5MG **	A083564 002
	3.75MG;3.75MG;3.75MG;3.75MG **	A083564 003
	5MG;5MG;5MG;5MG **	A083564 004

TABLET;ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563 004
	2.5MG;2.5MG;2.5MG;2.5MG	A083563 003
	3.75MG;3.75MG;3.75MG;3.75MG	A083563 002
	5MG;5MG;5MG;5MG	A083563 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715 001	May 17, 2019
	2.5MG;2.5MG;2.5MG;2.5MG	A211715 002	May 17, 2019
	3.75MG;3.75MG;3.75MG;3.75MG	A211715 003	May 17, 2019
	5MG;5MG;5MG;5MG	A211715 004	May 17, 2019
	6.25MG;6.25MG;6.25MG;6.25MG	A211715 005	May 17, 2019
	7.5MG;7.5MG;7.5MG;7.5MG	A211715 006	May 17, 2019

TABLET; ORAL

ADDERALL 10

+ TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522 007	Feb 13, 1996
---------------	----------------------------	-------------	--------------

ADDERALL 12.5

+ TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522 012	Aug 31, 2000
---------------	------------------------------------	-------------	--------------

ADDERALL 15

+ TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522 013	Aug 31, 2000
---------------	--------------------------------	-------------	--------------

ADDERALL 20

+ TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522 008	Feb 13, 1996
---------------	--------------------	-------------	--------------

ADDERALL 30

+ TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522 010	May 12, 1997
---------------	----------------------------	-------------	--------------

ADDERALL 5

+ TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522 009	May 12, 1997
---------------	--------------------------------	-------------	--------------

ADDERALL 7.5

+ TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522 011	Aug 31, 2000
---------------	------------------------------------	-------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456 001	May 06, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040456 002	May 06, 2003
	5MG;5MG;5MG;5MG	A040456 003	May 06, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040456 004	May 06, 2003
TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093 007
---------	-------------------------------	-------------

BIPHETAMINE 20

UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093 003
---------	---------------------------	-------------

BIPHETAMINE 7.5

UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093 009
---------	-------------------------------	-------------

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT	5MG	A083901 001	Aug 31, 1984
	10MG	A083901 002	Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON	3%	N050314 001
-----------	----	-------------

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT	50MG/VIAL	A064141 001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728 001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062 001	Mar 31, 1995

FUNGIZONE

APOTHECON	50MG/VIAL	A060517 001
-----------	-----------	-------------

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996
	100MG/VIAL	N050729 002	Nov 22, 1996

LOTION; TOPICAL

FUNGIZONE

APOTHECON	3%	A060570 001
-----------	----	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPHOTERICIN BOINTMENT; TOPICAL
FUNGIZONE

APOTHECON 3% N050313 001

SUSPENSION; ORAL
FUNGIZONE

BRISTOL MYERS SQUIBB 100MG/ML N050341 003

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860 001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860 002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860 003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860 004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860 005	Feb 05, 1988
AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499 001	Aug 17, 2010
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936 005	
	EQ 250MG BASE/VIAL	A061936 001	
	EQ 500MG BASE/VIAL	A061936 002	
	EQ 1GM BASE/VIAL	A061936 003	
	EQ 2GM BASE/VIAL	A061936 004	
HANFORD GC	EQ 125MG BASE/VIAL	A062772 005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772 008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772 002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772 004	Apr 15, 1993
HOSPIRA INC	EQ 250MG BASE/VIAL	A202864 001	Sep 04, 2015
	EQ 500MG BASE/VIAL	A202864 002	Sep 04, 2015
	EQ 1GM BASE/VIAL	A202864 003	Sep 04, 2015
	EQ 2GM BASE/VIAL	A202864 004	Sep 04, 2015
	EQ 10GM BASE/VIAL	A202865 001	Sep 04, 2015
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634 003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797 001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565 001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988
WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
OMNIPEN-N			
WYETH AYERST	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986
PENBRITIN-S			
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072 001	
+	EQ 250MG BASE/VIAL **	N050072 002	
+	EQ 500MG BASE/VIAL **	N050072 003	
+	EQ 1GM BASE/VIAL **	N050072 004	
+	EQ 2GM BASE/VIAL **	N050072 005	
+	EQ 4GM BASE/VIAL **	N050072 006	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN SODIUM

INJECTABLE; INJECTION

POLYCILLIN-N

BRISTOL	EQ 125MG BASE/VIAL **	N050309 001	
	EQ 250MG BASE/VIAL **	N050309 002	
	EQ 500MG BASE/VIAL **	N050309 003	
	EQ 1GM BASE/VIAL **	N050309 004	
	EQ 2GM BASE/VIAL **	N050309 005	

TOTACILLIN-N

GLAXOSMITHKLINE

	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	
	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

HOSPIRA INC

	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375 001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653 001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375 002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653 002	Dec 21, 2011
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646 001	Dec 21, 2011
MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316 001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316 002	Jun 29, 2007

UNASYN

PFIZER

	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986
--	---------------------------------------	-------------	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

	EQ 250MG BASE	A062041 001	
	EQ 500MG BASE	A062041 002	

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

	EQ 250MG BASE	A061602 001	
	EQ 500MG BASE	A061602 002	

HERITAGE PHARMA

	EQ 250MG BASE	A061502 001	
	EQ 500MG BASE	A061502 002	

IVAX SUB TEVA PHARMS

	EQ 250MG BASE	A060765 001	
	EQ 500MG BASE	A060765 002	

LEDERLE

	EQ 250MG BASE	A062208 001	
	EQ 500MG BASE	A062208 002	

MYLAN

	EQ 250MG BASE	A061755 001	
	EQ 500MG BASE	A061755 002	

PUREPAC PHARM

	EQ 250MG BASE	A061853 001	
	EQ 500MG BASE	A061853 002	

VITARINE

	EQ 250MG BASE	A061387 001	
	EQ 500MG BASE	A061387 003	

OMNIPEN (AMPICILLIN)

WYETH AYERST

	250MG	A060624 001	
	500MG	A060624 002	

PENBRITIN

WYETH AYERST

	EQ 250MG BASE	A060908 001	
	EQ 500MG BASE	A060908 002	

PFIZERPEN-A

PFIZER

	EQ 250MG BASE	A062050 001	
	EQ 500MG BASE	A062050 002	

POLYCILLIN

BRISTOL

	EQ 250MG BASE	N050310 001	
	EQ 500MG BASE	N050310 002	

PRINCIPEN

APOTHECON

	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988

BRISTOL MYERS SQUIBB

	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	

PRINCIPEN '250'

APOTHECON

	EQ 250MG BASE	A062157 002	
--	---------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PRINCIPEN '250'

EQ 250MG BASE N050056 001

PRINCIPEN '500'

APOTHECON

EQ 500MG BASE A062157 001

EQ 500MG BASE N050056 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 250MG BASE A060060 001

EQ 250MG BASE A062212 001

EQ 500MG BASE A060060 002

EQ 500MG BASE A062212 002

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS

EQ 125MG BASE/5ML A062030 001

EQ 250MG BASE/5ML A062030 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 125MG BASE/5ML A061601 001

EQ 250MG BASE/5ML A061601 002

MYLAN

EQ 125MG BASE/5ML A061829 002

EQ 250MG BASE/5ML A061829 001

PUREPAC PHARM

EQ 125MG BASE/5ML A061980 001

EQ 250MG BASE/5ML A061980 002

TEVA

EQ 125MG BASE/5ML A061370 001

EQ 250MG BASE/5ML A061370 002

OMNIPEN (AMPICILLIN)

WYETH AYERST

100MG/ML A060625 001

125MG/5ML A060625 002

250MG/5ML A060625 003

500MG/5ML A060625 004

PENBRITIN

WYETH AYERST

EQ 100MG BASE/ML N050019 001

EQ 125MG BASE/5ML N050019 002

EQ 250MG BASE/5ML N050019 003

PFIZERPEN-A

PFIZER

EQ 125MG BASE/5ML A062049 001

EQ 250MG BASE/5ML A062049 002

POLYCILLIN

APOTHECON

EQ 125MG BASE/5ML A062297 001

EQ 250MG BASE/5ML A062297 002

BRISTOL

EQ 100MG BASE/ML N050308 004

EQ 125MG BASE/5ML N050308 001

EQ 250MG BASE/5ML N050308 002

EQ 500MG BASE/5ML N050308 003

PRINCIPEN

APOTHECON

EQ 100MG BASE/ML A061394 001

EQ 125MG BASE/5ML A061394 002

EQ 250MG BASE/5ML A061394 003

PRINCIPEN '125'

APOTHECON

EQ 125MG BASE/5ML A060127 002

EQ 125MG BASE/5ML A062151 001

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE/5ML A060127 001

EQ 250MG BASE/5ML A062151 002

TOTACILLIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML A060666 001

EQ 125MG BASE/5ML A062223 001

EQ 250MG BASE/5ML A060666 002

EQ 250MG BASE/5ML A062223 002

TABLET, CHEWABLE; ORAL

POLYCILLIN

BRISTOL

EQ 125MG BASE N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN W/ PROBENECID

APOTHECON

EQ 389MG BASE;111MG A062150 001

EQ 389MG BASE;111MG N050488 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON

EQ 3.5GM BASE/BOT;1GM/BOT

A061898 001

BRISTOL

EQ 3.5GM BASE/BOT;1GM/BOT

N050457 001

PROBAMPACIN

ACP NIMBLE

EQ 3.5GM BASE/BOT;1GM/BOT

A061741 001

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE

50MG

N021007 001 Apr 15, 1999

150MG

N021007 002 Apr 15, 1999

SOLUTION;ORAL

AGENERASE

+ GLAXOSMITHKLINE

15MG/ML **

N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

+ SHIRE LLC

EQ 1MG BASE **

N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

MYLAN

EQ 0.5MG BASE

A076811 001 Apr 18, 2005

EQ 1MG BASE

A076811 002 Apr 18, 2005

MYLAN PHARMS INC

EQ 0.5MG BASE

A077613 001 Jun 27, 2006

EQ 1MG BASE

A077613 002 Jun 27, 2006

ROXANE

EQ 0.5MG BASE

A076489 001 Apr 18, 2005

EQ 1MG BASE

A076489 002 Apr 18, 2005

UPSHER SMITH LABS

EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

LANNETT CO INC

1MG

A091331 001 Jan 05, 2011

SANDOZ

1MG

A079007 001 Jun 28, 2010

SUN PHARM INDS LTD

1MG

A091177 001 Jul 15, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

WATSON LABS TEVA

1MG

A078984 001 Jun 28, 2010

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

GIAPREZA

+ LA JOLLA PHARMA

EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)

N209360 002 Dec 21, 2017

ANILERIDINE HYDROCHLORIDE

TABLET;ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE;INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET;ORAL

MIRADON

SCHERING

50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET;ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%;0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APREPITANT

CAPSULE;ORAL

EMEND

+ MERCK

40MG

N021549 003 Jun 30, 2006

APROTININ

INJECTABLE;INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE;INJECTION

NORMIFLO

+ PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **

N020227 002 May 23, 1997

+ 10,000 UNITS/0.5ML **

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION;INTRAVENOUS

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIPIRAZOLE

INJECTABLE;INTRAMUSCULAR

ABILIFY

OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION;ORAL

ABILIFY

+ OTSUKA

1MG/ML **

N021713 001 Dec 10, 2004

TABLET;ORAL

ARIPIPIRAZOLE

MYLAN

2MG

A206240 001 Sep 19, 2018

5MG

A206240 002 Sep 19, 2018

10MG

A206240 003 Sep 19, 2018

15MG

A206240 004 Sep 19, 2018

20MG

A206240 005 Sep 19, 2018

30MG

A206240 006 Sep 19, 2018

TEVA PHARMS USA

2MG

A078607 001 Apr 28, 2015

5MG

A078607 002 Apr 28, 2015

10MG

A078608 001 Apr 28, 2015

15MG

A078708 001 Apr 28, 2015

20MG

A078708 002 Apr 28, 2015

30MG

A078708 003 Apr 28, 2015

ZYDUS PHARMS

2MG

A090472 001 Jan 07, 2019

5MG

A090472 002 Jan 07, 2019

10MG

A090472 003 Jan 07, 2019

15MG

A090472 004 Jan 07, 2019

20MG

A090472 005 Jan 07, 2019

30MG

A090472 006 Jan 07, 2019

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

+ OTSUKA

10MG **

N021729 002 Jun 07, 2006

+

15MG **

N021729 003 Jun 07, 2006

+

20MG **

N021729 004 Jun 07, 2006

+

30MG **

N021729 005 Jun 07, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

APOTEX INC

50MG

A201514 001 Mar 25, 2019

150MG

A201514 002 Mar 25, 2019

250MG

A201514 003 Mar 25, 2019

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

NUVIGIL

+ CEPHALON

100MG **

N021875 002 Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+ CEPHALON

1MG/ML **

N021248 001 Sep 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

HOSPIRA

4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG
BASE/ML)

A079138 001 Jun 18, 2010

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;
100
IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;

N006071 003 Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

N018440 002 Aug 08, 1985

M.V.I.-12 ADULT

HOSPIRA

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

N008809 004 Aug 08, 1985

+

20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;
0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0
.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML

N008809 006 Sep 09, 2004

MVC PLUS

WATSON LABS

10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2
0
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

HOSPIRA

20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;2
0
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15M
G/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4
MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001
MG/VIAL;400
IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VI
AL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/
VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ

N020176 001 Dec 29, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E
 INJECTABLE; INJECTION
 VITAPED

BASE/10ML,N/A; 7 IU/10ML,N/A

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER 500MG N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER 650MG N016030 001

MEASURIN

BAYER 650MG N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS 650MG; 50MG A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC 325MG; 50MG; 40MG A078149 001 Jun 13, 2007

WATSON LABS 325MG; 50MG; 40MG A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH 325MG; 50MG; 40MG A086710 002 Aug 23, 1983

FOSUN PHARMA 325MG; 50MG; 40MG A086398 002 Apr 06, 1984

HALSEY 325MG; 50MG; 40MG A089448 001 Dec 01, 1986

IVAX PHARMS 325MG; 50MG; 40MG A085441 002 Oct 31, 1984

PURACAP PHARM 325MG; 50MG; 40MG A087048 002 Dec 09, 1983

QUANTUM PHARMICS 325MG; 50MG; 40MG A088972 001 Jun 18, 1985

WATSON LABS 325MG; 50MG; 40MG A086237 002 Mar 23, 1984

FIORINAL

+ ALLERGAN 325MG; 50MG; 40MG ** N017534 003 Apr 16, 1986

LANORINAL

LANNETT 325MG; 50MG; 40MG A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC 325MG; 50MG; 40MG; 30MG A075351 001 Mar 05, 1999

WATSON LABS 325MG; 50MG; 40MG; 30MG A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ SUN PHARM INDUSTRIES 356.4MG; 30MG; 16MG N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ 385MG; 30MG; 25MG A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ 770MG; 60MG; 50MG A074817 002 Nov 27, 1996

NORGESIC

+ MEDICIS 385MG; 30MG; 25MG ** N013416 003 Oct 27, 1982

NORGESIC FORTE

+ MEDICIS 770MG; 60MG; 50MG ** N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ 385MG; 30MG; 25MG A074654 001 Dec 31, 1996

770MG; 60MG; 50MG A074654 002 Dec 31, 1996

STEVENS J 385MG; 30MG; 25MG A074988 001 Apr 30, 1999

770MG; 60MG; 50MG A074988 002 Apr 30, 1999

ORPHENGESIC

GALT PHARMS 385MG; 30MG; 25MG A075141 001 May 29, 1998

ORPHENGESIC FORTE

GALT PHARMS 770MG; 60MG; 50MG A075141 002 May 29, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA	389MG; 32.4MG; 65MG	A084553 002	Aug 17, 1983
DARVON COMPOUND			
XANODYNE PHARM	389MG; 32.4MG; 32MG	N010996 006	Mar 08, 1983
DARVON COMPOUND-65			
XANODYNE PHARM	389MG; 32.4MG; 65MG	N010996 007	Mar 08, 1983
PROPOXYPHENE COMPOUND 65			
IVAX SUB TEVA PHARMS	389MG; 32.4MG; 65MG	A083077 002	Dec 07, 1984
SANDOZ	389MG; 32.4MG; 65MG	A080044 002	Sep 16, 1983
TEVA	389MG; 32.4MG; 65MG	A089025 001	Mar 29, 1985
PROPOXYPHENE COMPOUND-65			
SANDOZ	389MG; 32.4MG; 65MG	A083101 002	Jun 24, 1985
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE			
WATSON LABS	389MG; 32.4MG; 65MG	A085732 002	Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

OXFORD PHARMS	325MG; 200MG	A040252 001	Dec 10, 1997
CARISOPRODOL COMPOUND			
WATSON LABS	325MG; 200MG	A088809 001	Oct 03, 1985
SOMA COMPOUND			
MEDA PHARMS	325MG; 200MG **	N012365 005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

OXFORD PHARMS	325MG; 200MG; 16MG	A040283 001	Dec 29, 1998
SOMA COMPOUND W/ CODEINE			
MEDA PHARMS	325MG; 200MG; 16MG **	N012366 002	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

ANI PHARMS INC	25MG; 200MG	A206964 001	Jan 18, 2017
----------------	-------------	-------------	--------------

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA	500MG; 5MG **	A089420 001	Jan 25, 1988
VICOPRIN			
ABBOTT	500MG; 5MG	A086333 001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

SUN PHARM INDUSTRIES	325MG; 200MG	N011702 003	Dec 29, 1983
MEPRO-ASPIRIN			
SANDOZ	325MG; 200MG	A089127 001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN			
PAR PHARM	325MG; 200MG	A089126 001	Aug 19, 1986
MICRAININ			
MEDPOINTE PHARM HLC	325MG; 200MG	A084978 001	
Q-GESIC			
QUANTUM PHARMICS	325MG; 200MG	A088740 001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG; 400MG	A087211 001	Dec 22, 1982
MCNEIL	325MG; 400MG	A089193 001	Feb 12, 1986
PAR PHARM	325MG; 400MG	A089657 001	Nov 04, 1988
ROBAXISAL			
ROBINS AH	325MG; 400MG	N012281 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY	325MG; 4.5MG; 0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN				
ANI PHARMS INC	325MG; 4.5MG; 0.38MG	A040255	001	Feb 27, 1998
SUN PHARM INDUSTRIES	325MG; 4.5MG; 0.38MG	A040260	001	Jul 17, 1998
	325MG; 4.5MG; 0.38MG	A087794	001	May 26, 1982
OXYCODONE AND ASPIRIN (HALF-STRENGTH)				
ROXANE	325MG; 2.25MG; 0.19MG	A087742	001	Jun 04, 1982
PERCODAN				
ENDO PHARMS	325MG; 4.5MG; 0.38MG **	N007337	006	
PERCODAN-DEMI				
ENDO PHARMS	325MG; 2.25MG; 0.19MG **	N007337	005	
ROXIPRIN				
ROXANE	325MG; 4.5MG; 0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

+ SANOFI AVENTIS US	325MG; EQ 12.5MG BASE **	N016891	001	
---------------------	--------------------------	---------	-----	--

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG, N/A; N/A, 80MG	N021387	006	Jun 24, 2003
----------------------	-----------------------	---------	-----	--------------

TABLET, TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003
	81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003
	81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003
	325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003
	325MG, N/A; N/A, 40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG; 65MG	N010996	005	
----------------	-------------	---------	-----	--

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016829	001	
---------------	--------------	---------	-----	--

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016863	001	
---------------	--------------	---------	-----	--

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

+ BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567	001	Jun 20, 2003
------------------------	------------------	---------	-----	--------------

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

+ ASTRAZENECA	0.5MG/ML **	N019058	001	Sep 13, 1989
---------------	-------------	---------	-----	--------------

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907	001	Jul 30, 2004
	50MG	A076907	002	Jul 30, 2004
	100MG	A076907	003	Jul 30, 2004
APOTHECON	50MG	A073317	001	Mar 20, 1992
	100MG	A073318	001	Mar 20, 1992
DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992
INVATECH	25MG	A074265	001	Feb 28, 1994
	50MG	A074265	002	Feb 28, 1994
	100MG	A074265	003	Feb 28, 1994
MYLAN	25MG	A074126	003	Aug 26, 1998
	50MG	A074126	001	Mar 23, 1994
	100MG	A074126	002	Mar 23, 1994
NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009
	50MG	A078254	002	Sep 25, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATENOLOL

TABLET; ORAL

ATENOLOL

	100MG	A078254	003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
	100MG	A074127	002	Feb 21, 1995
PLIVA	25MG	A074101	001	Jul 17, 1997
	50MG	A074101	002	Jul 17, 1997
	100MG	A074101	003	Jul 17, 1997
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007
	50MG	A078210	002	Jul 10, 2007
	100MG	A078210	003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997
	50MG	A073475	001	Mar 30, 1993
	100MG	A073476	001	Mar 30, 1993
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995
WATSON LABS	50MG	A073352	001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404	001	May 14, 1998
	100MG; 25MG	A074404	002	May 14, 1998
PLIVA	50MG; 25MG	A074107	001	Sep 24, 1997
	100MG; 25MG	A074107	002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG; 25MG	A073582	002	Apr 29, 1993
	100MG; 25MG	A073582	001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002
-------	-----	---------	-----	--------------

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019
	EQ 20MG BASE	A204991	002	Mar 06, 2019
	EQ 40MG BASE	A204991	003	Mar 06, 2019
	EQ 80MG BASE	A204991	004	Mar 06, 2019
TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

+	MERCK SHARP DOHME	EQ 10MG BASE; 10MG **	N200153	001	May 03, 2013
+		EQ 20MG BASE; 10MG **	N200153	002	May 03, 2013
+		EQ 40MG BASE; 10MG **	N200153	003	May 03, 2013
+		EQ 80MG BASE; 10MG **	N200153	004	May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

+	GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992
---	---------------------	----------	---------	-----	--------------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
	10MG/ML	A074740	001	Mar 28, 1997
MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE				
BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017
WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998

TRACRIUM

+ HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE				
+ HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPINE

ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
ATROPINE (AUTOINJECTOR)				
RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
---------	--------------------	---------	-----	--------------

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ HOSPIRA	0.5MG/5ML (0.1MG/ML) **	N021146	001	Jul 09, 2001
-----------	-------------------------	---------	-----	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

SEBELA IRELAND LTD	0.025MG; 0.5MG	N017744	001	
--------------------	----------------	---------	-----	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP	0.025MG; 2.5MG	A086440	001	
------------	----------------	---------	-----	--

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC	0.025MG/5ML; 2.5MG/5ML	A085735	001	
---------------------	------------------------	---------	-----	--

LOMANATE

ALPHARMA US PHARMS	0.025MG/5ML; 2.5MG/5ML	A085746	001	
--------------------	------------------------	---------	-----	--

LOMOTIL

GD SEARLE LLC	0.025MG/5ML; 2.5MG/5ML	N012699	001	
---------------	------------------------	---------	-----	--

TABLET; ORAL

COLONOID

MEDPOINTE PHARM HLC	0.025MG; 2.5MG	A085737	001	
---------------------	----------------	---------	-----	--

DI-ATRO

MD PHARM	0.025MG; 2.5MG	A085266	001	
----------	----------------	---------	-----	--

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE	0.025MG; 2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG; 2.5MG	A087934	001	Jul 19, 1983
FOSUN PHARMA	0.025MG; 2.5MG	A086173	001	
HEATHER	0.025MG; 2.5MG	A086798	001	
HIKMA PHARMS	0.025MG; 2.5MG	A087765	001	Mar 15, 1982
INWOOD LABS	0.025MG; 2.5MG	A085509	001	
KV PHARM	0.025MG; 2.5MG	A085659	001	
LEDERLE	0.025MG; 2.5MG	A086950	001	
PARKE DAVIS	0.025MG; 2.5MG	A087131	001	
PVT FORM	0.025MG; 2.5MG	A085766	001	
R AND S PHARMA	0.025MG; 2.5MG	A085035	001	
ROXANE	0.025MG; 2.5MG	A086057	001	
SUN PHARM INDUSTRIES	0.025MG; 2.5MG	A085506	001	
USL PHARMA	0.025MG; 2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG; 2.5MG	A087195	001	Feb 16, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

WATSON LABS	0.025MG;2.5MG	A085876	001	
LO-TROL				
VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOGEN				
SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LONOX				
FOSUN PHARMA	0.025MG;2.5MG	A085311	002	
LOW-QUEL				
HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002
---------	-----------------------	---------	-----	--------------

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992
---	----------------------	------------	---------	-----	--------------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019
-----------	------------	---------	-----	--------------

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING	1MG	N017601	001	
----------	-----	---------	-----	--

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982
----------	-----------	---------	-----	--------------

AZATHIOPRINE

TABLET; ORAL

IMURAN

+	SEBELA IRELAND LTD	25MG **	N016324	002
---	--------------------	---------	---------	-----

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

+	CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391	001
---	-------------------	-----------------------	---------	-----

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+	MYLAN SPECIALITY LP	0.05% **	N021127	001	May 22, 2000
---	---------------------	----------	---------	-----	--------------

SPRAY, METERED; NASAL

ASTEPRO

MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008
---------------------	-----------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

+ PFIZER

EQ 250MG BASE **

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

LUPIN LTD

EQ 100MG BASE/5ML

A065488 001 May 15, 2015

EQ 200MG BASE/5ML

A065488 002 May 15, 2015

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCIN

CSPC OUYI

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

TABLET; ORAL

AZITHROMYCIN

APOTEX CORP

EQ 250MG BASE

A065507 001 Jul 13, 2011

EQ 500MG BASE

A065509 001 Jul 13, 2011

EQ 600MG BASE

A065508 001 Jul 13, 2011

MYLAN

EQ 250MG BASE

A065365 001 May 30, 2007

EQ 500MG BASE

A065366 001 May 30, 2007

TEVA

EQ 250MG BASE

A065153 001 Nov 14, 2005

EQ 600MG BASE

A065150 001 Nov 14, 2005

ZITHROMAX

+ PFIZER

EQ 600MG BASE **

N050730 001 Jun 12, 1996

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB 500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB 10MG/ML

N050632 003 May 24, 1989

+

20MG/ML

N050632 002 May 24, 1989

+

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

WEST-WARD PHARMS INT 1GM/VIAL

A065286 001 Mar 23, 2011

2GM/VIAL

A065286 002 Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

MYLAN ASI	50,000 UNITS/VIAL	A090211 001	May 11, 2010
PFIZER	50,000 UNITS/VIAL	A060282 001	
PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733 001	

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	A060734 001	
----------------------	--------------	-------------	--

BACITRACIN

LILLY	500 UNITS/GM	A060687 001	
PHARMADERM	500 UNITS/GM	A062158 001	
PHARMAFAIR	500 UNITS/GM	A062453 001	Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE	500 UNITS/GM	A062799 001	May 14, 1987
NASKA	500 UNITS/GM	A062857 001	Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	
--------------	---------------------	-------------	--

BACITRACIN

APOTHEKERNES	5,000,000 UNITS/BOT	A061699 001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456 001	Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS	500,000 UNITS/BOT	A061737 001	
--------------	-------------------	-------------	--

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

+ CASPER PHARMA LLC	400 UNITS/GM; 1% EQ 3.5MG BASE/GM; 10,000 UNITS/GM **	N050416 002	
---------------------	---	-------------	--

ZINC BACITRACIN, NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM; 1% EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062389 001	Jul 02, 1982
------------	--	-------------	--------------

OINTMENT; TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM; 1% EQ 3.5MG BASE/GM; 5,000 UNITS/GM	A062381 001	Sep 06, 1985
------------	---	-------------	--------------

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

LANABIOTIC

COMBE	400 UNITS/GM; 40MG/GM; EQ 5MG BASE/GM; 5,000 UNITS/GM	A062499 001	Jun 03, 1985
-------	---	-------------	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062386 001	Sep 09, 1982
------------	---	-------------	--------------

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM	400 UNITS/GM; EQ 3.5MG BASE/GM; 5,000 UNITS/GM	A062167 001	
------------	--	-------------	--

NEO-POLYCIN

DOW PHARM	500 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A060647 001	
-----------	---	-------------	--

OINTMENT; TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA	400 UNITS/GM; EQ 3.5MG BASE/GM; 5,000 UNITS/GM	A062833 001	Nov 09, 1987
-------	--	-------------	--------------

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL

POLYSPORIN

GLAXOSMITHKLINE	10,000 UNITS/GM; 2,000,000 UNITS/GM	N050167 002	Mar 01, 1985
-----------------	-------------------------------------	-------------	--------------

OINTMENT; OPHTHALMIC

OCUMYCIN

PHARMAFAIR	500 UNITS/GM; 10,000 UNITS/GM	A062430 001	Apr 08, 1983
------------	-------------------------------	-------------	--------------

POLYSPORIN

MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM **	A061229 001	
----------------	----------------------------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A061048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM;5,000 UNITS/GM

N050598 001 Sep 22, 1986

BACLOFEN

TABLET; ORAL

BACLOFEN

MYLAN

10MG

A077181 001 Jul 29, 2005

SUN PHARM INDS INC

10MG

A077862 001 Aug 14, 2006

20MG

A077862 002 Aug 14, 2006

TEVA

10MG

A073043 001 Feb 27, 1992

20MG

A073044 001 Feb 27, 1992

USL PHARMA

10MG

A071260 001 May 06, 1988

20MG

A071261 001 May 06, 1988

WATSON LABS

10MG

A072824 001 Sep 18, 1991

10MG

A073092 001 Jan 28, 1994

10MG

A074698 001 Aug 20, 1996

20MG

A072825 001 Sep 18, 1991

20MG

A073093 001 Jan 28, 1994

20MG

A074698 002 Aug 20, 1996

LIORESAL

+ NOVARTIS

10MG **

N017851 001

+

20MG **

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

UCB INC

10MG

N021589 001 Oct 30, 2003

20MG

N021589 002 Oct 30, 2003

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

MYLAN

750MG

A077807 001 Dec 28, 2007

TABLET; ORAL

BALSALAZIDE DISODIUM

PAR PHARM INC

1.1GM

A206336 001 Sep 08, 2015

GIAZO

+ VALEANT PHARMS INTL

1.1GM

N022205 001 Feb 03, 2012

BIARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-CAT DRY

+ BRACCO

40% (9GM/POUCH)

N208036 003 Jan 03, 2017

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE

0.042MG/INH

N018153 001

QVAR 40

+ TEVA BRANDED PHARM

0.04MG/INH **

N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM

0.08MG/INH **

N020911 001 Sep 15, 2000

VANCERIL

SCHERING

0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING

0.084MG/INH

N020486 001 Dec 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;NASAL

BECONASE

GLAXOSMITHKLINE 0.042MG/INH

N018584 001

VANCENASE

SCHERING 0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

VANCENASE AQ

SCHERING EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

ANI PHARMS INC 5MG

A076333 001 Feb 11, 2004

10MG

A076333 002 Feb 11, 2004

20MG

A076333 003 Feb 11, 2004

40MG

A076333 004 Feb 11, 2004

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

HERITAGE PHARMA

5MG

A076267 001 Feb 11, 2004

10MG

A076267 002 Feb 11, 2004

20MG

A076267 003 Feb 11, 2004

40MG

A076267 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC 5MG;6.25MG

A076342 001 Feb 11, 2004

5MG;6.25MG

A076348 001 Feb 11, 2004

10MG;12.5MG

A076342 002 Feb 11, 2004

10MG;12.5MG

A076348 002 Feb 11, 2004

20MG;12.5MG

A076342 003 Feb 11, 2004

20MG;12.5MG

A076348 003 Feb 11, 2004

20MG;25MG

A076342 004 Feb 11, 2004

20MG;25MG

A076348 004 Feb 11, 2004

MYLAN PHARMS INC

5MG;6.25MG

A076612 001 Feb 11, 2004

10MG;12.5MG

A076612 002 Feb 11, 2004

20MG;12.5MG

A076612 003 Feb 11, 2004

20MG;25MG

A076612 004 Feb 11, 2004

SUN PHARM INDS LTD

5MG;6.25MG

A077483 001 Sep 08, 2005

10MG;12.5MG

A077483 002 Sep 08, 2005

20MG;12.5MG

A077483 003 Sep 08, 2005

20MG;25MG

A077483 004 Sep 08, 2005

LOTENSIN HCT

+ US PHARMS HOLDINGS I 5MG;6.25MG **

N020033 001 May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

TREANDA

+ CEPHALON 45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+ 180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE

TABLET;ORAL

NATURETIN-10

APOTHECON 10MG

N012164 003

NATURETIN-2.5

APOTHECON 2.5MG

N012164 001

NATURETIN-5

APOTHECON 5MG

N012164 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

MYLAN

5MG; 40MG

A078688 001 Feb 15, 2008

5MG; 80MG

A078688 002 Feb 15, 2008

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND

0.4%

A084149 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS

500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

SUN PHARM INDS INC

100MG

A040587 001 Mar 19, 2008

200MG

A040587 002 Mar 19, 2008

TESSALON

+ PFIZER

200MG **

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAFLIN

BAUSCH

5%; EQ 1% BASE

N050756 002 Apr 20, 2007

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

ANDA REPOSITORY

2.5%; EQ 1.2% BASE

A207194 001 Aug 19, 2019

TARO

3.75%; EQ 1.2% BASE

A208683 001 Jun 05, 2018

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+ BIOFRONTERA

5%; 3%

N050769 001 Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

EPIC PHARMA LLC

50MG

A040714 001 Oct 29, 2007

IMPAX LABS

50MG

A040845 001 Nov 18, 2008

TEDOR PHARM

25MG

A040747 002 Nov 20, 2015

50MG

A040747 001 Mar 30, 2007

DIDREX

+ PHARMACIA AND UPJOHN

25MG **

N012427 003

+

50MG **

N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

LUITPOLD

1MG/ML

A091152 001 Mar 29, 2010

TABLET; ORAL

BENZTROPINE MESYLATE

CHARTWELL RX

1MG

A081265 002 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

LANNETT CO INC

0.5MG **

A088877 001 Apr 11, 1985

1MG **

A088894 001 Apr 11, 1985

2MG **

A088895 001 Apr 11, 1985

OXFORD PHARMS

0.5MG

A040706 002 Feb 14, 2008

1MG

A040706 003 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

UPSHER SMITH LABS

0.5MG

A040103 001 Dec 12, 1996

1MG

A040103 002 Dec 12, 1996

2MG

A040103 003 Dec 12, 1996

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

+ MERCK

0.5MG **

N009193 004

+

1MG **

N009193 003

+

2MG **

N009193 002

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

APOTEX

1.5%

A206066 001 Mar 05, 2019

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE BENZOATE

CREAM;TOPICAL

UTICORT

PARKE DAVIS 0.025% N016998 002

GEL;TOPICAL

UTICORT

PARKE DAVIS 0.025% N017244 001

LOTION;TOPICAL

UTICORT

PARKE DAVIS 0.025% N017528 001

OINTMENT;TOPICAL

UTICORT

PARKE DAVIS 0.025% N018089 001

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE A072536 001 Jan 31, 1990

EQ 0.05% BASE A074579 001 Nov 26, 1997

PHARMADERM EQ 0.05% BASE N019136 001 Jun 26, 1984

TARO EQ 0.05% BASE A071143 001 Jun 17, 1987

TEVA EQ 0.05% BASE A071476 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE N017536 001

CREAM, AUGMENTED;TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE N019408 001 Jan 31, 1986

DISC;TOPICAL

DIPROSONE

SCHERING EQ 0.1% BASE N017829 001

GEL, AUGMENTED;TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE N019408 002 Nov 22, 1991

LOTION;TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ACP NIMBLE EQ 0.05% BASE A071882 001 Jun 06, 1988

ALPHARMA US PHARMS EQ 0.05% BASE A071085 001 Feb 03, 1987

PHARMADERM EQ 0.05% BASE A070274 001 Aug 12, 1985

TARO EQ 0.05% BASE A072276 001 Aug 24, 1988

EQ 0.05% BASE A074272 001 Sep 30, 1994

DIPROSONE

+ SCHERING

EQ 0.05% BASE ** N017781 001

LOTION, AUGMENTED;TOPICAL

DIPROLENE

+ MERCK SHARP DOHME

EQ 0.05% BASE N019716 001 Aug 01, 1988

OINTMENT;TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML A085738 001

CELESTONE

+ SCHERING

EQ 3MG BASE/ML ** N017561 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070485 001 May 29, 1987

TARO EQ 0.1% BASE A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE N016322 002

EQ 0.1% BASE N016322 001

LOTION; TOPICAL

BETA-VAL

ACP NIMBLE EQ 0.1% BASE A070072 001 Jun 27, 1985

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE N018863 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC EQ 0.5% BASE A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG ** N019507 001 Oct 27, 1989

20MG ** N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US 5MG;12.5MG N019807 001 Oct 30, 1992

10MG;12.5MG N019807 002 Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON EQ 0.25% BASE;1.75% N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY 50MG/ML N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

+ ODYSSEY PHARMS 5MG/ML ** N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE 5MG A040492 001 Jul 27, 2004

10MG A040483 001 Jul 27, 2004

25MG A040485 001 Jul 27, 2004

50MG A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH 5MG A040552 001 Oct 28, 2004

10MG A040553 001 Oct 28, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	25MG	A040554	001	Oct 28, 2004
	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IMPAX LABS	5MG	A040721	001	Nov 01, 2006
	10MG	A040721	002	Nov 01, 2006
	25MG	A040721	003	Nov 01, 2006
	50MG	A040721	004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
	10MG	A040897	002	Apr 22, 2009
	25MG	A040897	003	Apr 22, 2009
	50MG	A040897	004	Apr 22, 2009
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	
	10MG	A085842	001	
	25MG	A084441	001	
	25MG	A085229	001	
	25MG	A085839	001	
	50MG	A087397	001	
	50MG	A087444	001	
MYOTONACHOL				
GLENWOOD	5MG	A084188	001	
	10MG	A084188	003	
	25MG	A084188	004	
URECHOLINE				
+ ODYSSEY PHARMS	5MG **	N006536	003	
+	10MG **	N006536	002	
+	25MG **	N006536	004	
+	50MG **	N006536	005	

BETHANIDINE SULFATE

TABLET;ORAL

TENATHAN

ROBINS AH	10MG	N017675	001	
	25MG	N017675	002	

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010
KUDCO IRELAND	50MG	A077995	001	Jul 06, 2009
ROXANE	50MG	A078285	001	Mar 24, 2011
SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009
TEVA	50MG	A076932	001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018
LUMIGAN				
+ ALLERGAN	0.03% **	N021275	001	Mar 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

ABBVIE

2MG

N012003 001

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE

5MG/ML

N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+ BRAINTREE

5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM
; N/A, 5.6GM **

N021551 003 Jul 16, 2010

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

NOVEL LABS INC

5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM
; N/A, 5.6GM

A202217 001 Aug 20, 2014

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+ CASPER PHARMA LLC

262.4MG, N/A; N/A; N/A, 250MG, N/A; N/A, N/A, 5
00MG **

N050719 001 Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MYLAN

5MG

A075831 001 Dec 14, 2005

10MG

A075831 002 Dec 14, 2005

ZEBETA

+ TEVA WOMENS

5MG **

N019982 002 Jul 31, 1992

+

10MG **

N019982 001 Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG; 6.25MG

A075672 001 Sep 25, 2000

5MG; 6.25MG

A075672 002 Sep 25, 2000

10MG; 6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG; 6.25MG

A075642 002 Dec 27, 2000

5MG; 6.25MG

A075642 001 Dec 27, 2000

10MG; 6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG

A075632 001 Sep 27, 2000

5MG; 6.25MG

A075632 002 Sep 27, 2000

10MG; 6.25MG

A075632 003 Sep 27, 2000

MYLAN

2.5MG; 6.25MG

A075768 001 Sep 25, 2000

5MG; 6.25MG

A075768 002 Sep 25, 2000

10MG; 6.25MG

A075768 003 Sep 25, 2000

SANDOZ

2.5MG; 6.25MG

A075527 001 Sep 25, 2000

5MG; 6.25MG

A075527 003 Sep 25, 2000

10MG; 6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG; 6.25MG

A075686 001 Jan 19, 2001

5MG; 6.25MG

A075686 002 Jan 19, 2001

10MG; 6.25MG

A075686 003 Jan 19, 2001

WATSON LABS TEVA

2.5MG; 6.25MG

A075469 001 Sep 25, 2000

5MG; 6.25MG

A075469 002 Sep 25, 2000

10MG; 6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

+	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	**	N050443	001	
+		EQ 30 UNITS BASE/VIAL	**	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL		A065201	001	Dec 13, 2007
	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL		A064084	001	Jun 01, 1996
		EQ 30 UNITS BASE/VIAL		A064084	002	Jun 01, 1996

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

	MERCK SHARP DOHME	200MG		N202258	001	May 13, 2011
--	-------------------	-------	--	---------	-----	--------------

BORTEZOMIB

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+	HOSPIRA INC	1MG/VIAL		N209191	002	Dec 28, 2018
+		2.5MG/VIAL		N209191	001	Jul 12, 2018

BOSENTAN

TABLET; ORAL

BOSENTAN

	ALVOGEN PINE BROOK	62.5MG		A206002	001	Apr 26, 2019
		125MG		A206002	002	Apr 26, 2019

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

	ABRAXIS PHARM	50MG/ML		A070134	001	Apr 29, 1986
		100MG/ML		A071298	001	Feb 13, 1987
	ASTRAZENECA	50MG/ML		A071151	001	Aug 10, 1987
		50MG/ML		A071152	001	Aug 10, 1987
		50MG/ML		A071153	001	Aug 10, 1987
	EUROHLTH INTL SARL	50MG/ML		A070546	001	May 14, 1986
+	HOSPIRA	50MG/ML **		N019030	001	Apr 29, 1986
		50MG/ML		N019033	001	Apr 29, 1986
	INTL MEDICATION	50MG/ML		A070119	001	Apr 29, 1986
	LUITPOLD	50MG/ML		A070891	001	Jul 26, 1988
	WEST-WARD PHARMS INT	50MG/ML		A070545	001	May 14, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5%

	ABBOTT	200MG/100ML		N019005	002	Apr 29, 1986
		400MG/100ML		N019005	003	Apr 29, 1986
		800MG/100ML		N019005	001	Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	100MG/100ML		N019121	001	Apr 29, 1986
		200MG/100ML		N019121	002	Apr 29, 1986
		400MG/100ML		N019121	003	Apr 29, 1986
	BAXTER HLTHCARE	200MG/100ML		N019837	002	Apr 12, 1989
		400MG/100ML		N019837	001	Apr 12, 1989
	HOSPIRA INC	200MG/100ML		N019008	002	Apr 29, 1986
		400MG/100ML		N019008	003	Apr 29, 1986
		800MG/100ML		N019008	001	Apr 29, 1986

BRETYLOL

	HOSPIRA	50MG/ML		N017954	001	
--	---------	---------	--	---------	-----	--

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

+	ALLERGAN	0.2% **		N020613	001	Sep 06, 1996
		0.5%		N020490	001	Mar 13, 1997

BRIMONIDINE TARTRATE

	TEVA PARENTERAL	0.2%		A076372	001	Sep 10, 2004
--	-----------------	------	--	---------	-----	--------------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+	BAUSCH AND LOMB INC	EQ 0.09% ACID **		N021664	002	Oct 16, 2010
---	---------------------	------------------	--	---------	-----	--------------

BROMFENAC SODIUM

	AMRING PHARMS	EQ 0.09% ACID		A202030	001	Jan 09, 2013
	APOTEX	EQ 0.09% ACID		A202435	001	Jun 19, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

	EQ 0.09% ACID	A202620 001	Jun 23, 2014
COASTAL PHARMS	EQ 0.09% ACID	A201211 001	May 11, 2011
VISTAPHARM	EQ 0.09% ACID	A201941 001	Feb 10, 2015
XIBROM			
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664 001	Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100 001	Dec 10, 1998
-----------	-------------	-------------	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984 001	
-------------	------	-------------	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP;ORAL

AMBENYL

FOREST LABS	12.5MG/5ML;10MG/5ML	N009319 006	Jan 10, 1984
-------------	---------------------	-------------	--------------

BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343 001	Aug 15, 1984
--------------------	---------------------	-------------	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626 001	Oct 12, 1984
-----------	---------------------	-------------	--------------

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936 001	
KV PHARM	2MG/5ML	A085466 001	
PHARM ASSOC	2MG/5ML	A087517 001	
USL PHARMA	2MG/5ML	A087964 001	Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821 001	
-------------	---------	-------------	--

	100MG/ML	A083820 001	
--	----------	-------------	--

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418 002	
--------------	---------	-------------	--

TABLET;ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468 001	
IVAX SUB TEVA PHARMS	4MG	A084351 001	
NEWTRON PHARMS	4MG	A086987 001	
NEXGEN PHARMA INC	4MG	A086187 001	
PAR PHARM	4MG	A087009 001	
PIONEER PHARMS	4MG	A088604 001	Jul 13, 1984
UPSHER SMITH LABS	4MG	A083215 001	
VITARINE	4MG	A085850 001	
WATSON LABS	4MG	A083123 001	
	4MG	A085769 001	

DIMETANE

WYETH CONS	4MG	N010799 003	
------------	-----	-------------	--

TABLET, EXTENDED RELEASE;ORAL

DIMETANE

WYETH CONS	8MG	N010799 010	Jun 10, 1983
------------	-----	-------------	--------------

	12MG	N010799 011	Jun 10, 1983
--	------	-------------	--------------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722 001	Mar 07, 1985
--------------------	---------------------------	-------------	--------------

BROMFED-DM

WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681 001	Dec 22, 1988
-----------	---------------------------	-------------	--------------

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940 001	Jul 21, 2014
----------------	---------------------------	-------------	--------------

DIMETANE-DX

+ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279 001	Aug 24, 1984
-------------	------------------------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA 16MG;240MG N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET;ORAL

BUCLADIN-S

STUART PHARMS 50MG N010911 006

BUDESONIDE

AEROSOL, METERED;NASAL

RHINOCORT

ASTRAZENECA 0.032MG/INH N020233 001 Feb 14, 1994

POWDER, METERED;INHALATION

PULMICORT

ASTRAZENECA 0.16MG/INH N020441 002 Jun 24, 1997

0.32MG/INH N020441 003 Jun 24, 1997

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

ATHENEX INC 0.25MG/ML A074441 001 Jan 27, 1995

HOSPIRA 0.25MG/ML A074160 001 Oct 30, 1997

TEVA PARENTERAL 0.25MG/ML A074613 001 Nov 18, 1997

BUMEX

+ VALIDUS PHARMS 0.25MG/ML ** N018226 001 Feb 28, 1983

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA 0.75% A070587 001 Mar 03, 1987

MYLAN ASI 0.25% A091503 001 Oct 18, 2011

0.5% A091503 002 Oct 18, 2011

NOVOCOL HEALTHCARE 0.5% A211096 001 Feb 19, 2019

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA 0.075% N019978 001 Sep 03, 1992

0.114% N019978 002 Sep 03, 1992

0.23% N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED 0.25% A076012 001 Jan 09, 2002

0.5% A076012 002 Jan 09, 2002

0.75% A076012 003 Jan 09, 2002

MYLAN ASI 0.25% A091487 002 Oct 18, 2011

0.5% A091487 001 Oct 18, 2011

0.75% A091487 003 Oct 18, 2011

INJECTABLE;SPINAL

SENSORCAINE

FRESENIUS KABI USA 0.75% A071202 001 Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA 0.25%;0.005MG/ML A071166 001 Jun 16, 1988

0.5%;0.005MG/ML A071169 001 Jun 16, 1988

0.75%;0.005MG/ML A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+ HOSPIRA 0.5%;0.0091MG/ML N022046 001 Jul 13, 1983

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML);EQ 1% N021496 001 May 23, 2003

(100MG/10ML)

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

BARR	EQ 2MG BASE	A090360 001	May 07, 2010
	EQ 8MG BASE	A090360 002	May 07, 2010
MYLAN	EQ 2MG BASE	A201066 001	Mar 06, 2015
	EQ 8MG BASE	A201066 002	Mar 06, 2015

SUBUTEX

+ INDIVIOR INC	EQ 2MG BASE **	N020732 002	Oct 08, 2002
+	EQ 8MG BASE **	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;SUBLINGUAL

CASSIPA

+ TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042 001	Sep 07, 2018
-------------------	--------------------------	-------------	--------------

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149 001	Sep 08, 2014
	EQ 8MG BASE;EQ 2MG BASE	A091149 002	Sep 08, 2014

SUBOXONE

+ INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **	N020733 001	Oct 08, 2002
+	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

HERITAGE PHARMA	75MG	A075310 001	Nov 29, 1999
	100MG	A075310 002	Nov 29, 1999
INVATECH	75MG	A075613 002	Oct 10, 2000
	100MG	A075613 001	Oct 10, 2000

WELLBUTRIN

+ GLAXOSMITHKLINE	50MG **	N018644 001	Dec 30, 1985
+	75MG **	N018644 002	Dec 30, 1985
+	100MG **	N018644 003	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
IMPAX LABS	300MG	A077415 002	Dec 15, 2006
MYLAN	100MG	A090325 001	Apr 08, 2010
	150MG	A090325 002	Apr 08, 2010
	150MG	A090941 001	May 03, 2010
	150MG	A090942 001	Jul 14, 2010
	200MG	A090325 003	Apr 08, 2010
	300MG	A090942 002	Jul 14, 2010
SANDOZ	100MG	A076845 001	Jul 14, 2005
	150MG	A076834 001	Jul 14, 2005
	150MG	A076845 002	Jul 14, 2005
SUN PHARM	150MG	A200695 001	Dec 18, 2014
WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012
	150MG	A201331 002	Aug 30, 2012
	200MG	A201331 003	Aug 30, 2012
YICHANG HUMANWELL	100MG	A211347 001	Oct 16, 2018
	150MG	A211347 002	Oct 16, 2018
	200MG	A211347 003	Oct 16, 2018

WELLBUTRIN SR

GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996
-----------------	------	-------------	--------------

ZYBAN

GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997
+	150MG	N020711 003	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190 001	Dec 20, 2000
	7.5MG	N021190 002	Dec 20, 2000
	10MG	N021190 003	Dec 20, 2000
	15MG	N021190 004	Dec 20, 2000

TABLET;ORAL

BUSPAR

+ BRISTOL MYERS SQUIBB	5MG **	N018731 001	Sep 29, 1986
+	10MG **	N018731 002	Sep 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

+	15MG **	N018731 003	Apr 22, 1996
+	30MG **	N018731 004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

EGIS	5MG	A075119 001	Mar 14, 2002
	10MG	A075119 002	Mar 14, 2002
	15MG	A075119 003	Jan 23, 2003
FOSUN PHARMA	5MG	A075413 001	Mar 19, 2002
	10MG	A075413 002	Mar 19, 2002
	15MG	A075413 003	Mar 19, 2002
IVAX SUB TEVA PHARMS	5MG **	A075385 001	Mar 01, 2002
	10MG **	A075385 002	Mar 01, 2002
	15MG **	A075385 003	Mar 01, 2002
MYLAN	5MG	A075467 001	Feb 28, 2002
	10MG	A075467 003	Feb 28, 2002
	15MG	A075467 004	Feb 28, 2002
NESHER PHARMS	5MG	A075572 001	Feb 27, 2002
	10MG	A075572 002	Feb 27, 2002
	15MG	A075572 003	Feb 27, 2002
OXFORD PHARMS	5MG	A075388 001	May 09, 2002
	10MG	A075388 002	May 09, 2002
	15MG	A075388 003	May 09, 2002
RUBICON	5MG	A075521 001	Apr 05, 2002
	10MG	A075521 002	Apr 05, 2002
	15MG	A075521 003	Apr 05, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381 001	
	30MG	A085381 002	
	50MG	A085381 003	
	100MG	A085381 004	

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873 001	
--------------------	----------	-------------	--

BUTABARBITAL SODIUM

WOCKHARDT	30MG/5ML	A085383 001	
-----------	----------	-------------	--

BUTALAN

LANNETT	33.3MG/5ML	A085880 001	
---------	------------	-------------	--

BUTISOL SODIUM

MEDA PHARMS	30MG/5ML	A085380 001	
-------------	----------	-------------	--

SARISOL

HALSEY	30MG/5ML	A084723 001	
--------	----------	-------------	--

TABLET; ORAL

BUTABARBITAL

BUNDY	30MG	A085550 001	
-------	------	-------------	--

BUTABARBITAL SODIUM

SANDOZ	15MG	A084292 003	Feb 09, 1982
	15MG	A085938 001	
	30MG	A084272 002	
	30MG	A085934 001	
SOLVAY	16.2MG	A083606 001	
	32.4MG	A083898 001	
	48.6MG	A083897 001	
	97.2MG	A083896 001	
TEVA	15MG	A088632 001	May 18, 1985
	30MG	A088631 001	May 01, 1985
WATSON LABS	15MG	A085764 001	
	30MG	A085772 001	
WHITEWORTH TOWN PLSN	15MG	A083325 002	
	30MG	A083337 001	

BUTISOL SODIUM

MYLAN SPECIALITY LP	15MG	N000793 002	
	50MG	N000793 003	
	100MG	N000793 005	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

BUTABARBITAL SODIUM

TABLET; ORAL

SARISOL NO. 1				
HALSEY	15MG		A084719	001
SARISOL NO. 2				
HALSEY	30MG		A084719	002
SODIUM BUTABARBITAL				
HIKMA PHARMS	15MG		A085418	001
	30MG		A085432	001
IVAX SUB TEVA PHARMS	15MG		A083484	001
	30MG		A084040	001
LANNETT	15MG		A085849	001
	30MG		A085866	001
	100MG		A085881	001
MARSHALL PHARMA	16.2MG		A083524	001
	32.4MG		A083858	001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN	1%		N021408	001	Oct 17, 2002
-------	----	--	---------	-----	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

PERRIGO PHARMA INTL	2%		N019881	001	Feb 07, 1997
---------------------	----	--	---------	-----	--------------

FEMSTAT

ROCHE PALO	2%		N019215	001	Nov 25, 1985
------------	----	--	---------	-----	--------------

FEMSTAT 3

+ BAYER	2%		N020421	001	Dec 21, 1995
---------	----	--	---------	-----	--------------

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO	100MG		N019359	001	Nov 25, 1985
------------	-------	--	---------	-----	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

BAXTER HLTHCARE CORP	2MG/ML		A075697	001	Oct 23, 2001
----------------------	--------	--	---------	-----	--------------

HIKMA FARMACEUTICA	2MG/ML		A078247	001	Apr 29, 2009
--------------------	--------	--	---------	-----	--------------

HOSPIRA	1MG/ML		A075342	001	Nov 04, 1999
---------	--------	--	---------	-----	--------------

	1MG/ML		A075559	001	Mar 20, 2000
--	--------	--	---------	-----	--------------

	2MG/ML		A075342	002	Nov 04, 1999
--	--------	--	---------	-----	--------------

	2MG/ML		A075559	002	Mar 20, 2000
--	--------	--	---------	-----	--------------

BUTORPHANOL TARTRATE PRESERVATIVE FREE

BAXTER HLTHCARE CORP	1MG/ML		A075695	001	Oct 23, 2001
----------------------	--------	--	---------	-----	--------------

	2MG/ML		A075695	002	Oct 23, 2001
--	--------	--	---------	-----	--------------

HOSPIRA	1MG/ML		A074620	001	Jan 22, 1997
---------	--------	--	---------	-----	--------------

	1MG/ML		A075170	001	Sep 28, 1998
--	--------	--	---------	-----	--------------

	2MG/ML		A074620	002	Jan 22, 1997
--	--------	--	---------	-----	--------------

	2MG/ML		A075170	002	Sep 28, 1998
--	--------	--	---------	-----	--------------

STADOL

+ APOTHECON	2MG/ML	**	N017857	004	
-------------	--------	----	---------	-----	--

STADOL PRESERVATIVE FREE

+ APOTHECON	1MG/ML	**	N017857	001	
-------------	--------	----	---------	-----	--

+	2MG/ML	**	N017857	002	
---	--------	----	---------	-----	--

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	**	N019890	001	Dec 12, 1991
----------------------	-----------	----	---------	-----	--------------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

ACTAVIS LABS FL INC	0.5MG		A078035	001	Apr 21, 2008
---------------------	-------	--	---------	-----	--------------

APOTEX CORP	0.5MG		A201503	001	Mar 08, 2013
-------------	-------	--	---------	-----	--------------

IMPAX LABS INC	0.5MG		A077843	001	Jul 03, 2007
----------------	-------	--	---------	-----	--------------

DOSTINEX

+ PHARMACIA AND UPJOHN	0.5MG	**	N020664	001	Dec 23, 1996
------------------------	-------	----	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

LUITPOLD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090064 001 Nov 20, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

CAFERGOT

+ NOVARTIS

100MG;2MG **

N009000 002

TABLET;ORAL

CAFERGOT

NOVARTIS

100MG;1MG

N006620 001

WIGRAINE

ORGANON USA INC

100MG;1MG

A086562 001

CALCIFEDIOL

CAPSULE;ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT;TOPICAL

DOVONEX

+ LEO PHARMA AS

0.005% **

N020273 001 Dec 29, 1993

SOLUTION;TOPICAL

DOVONEX

+ LEO PHARM

0.005% **

N020611 001 Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE;INJECTION

CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCIMAR

+ SANOFI AVENTIS US

200 IU/ML **

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

+ MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

SPRAY, METERED;NASAL

MIACALCIN

+ MYLAN IRELAND LTD

200 IU/SPRAY

N020313 002 Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

UPSHER SMITH LABS

200 IU/SPRAY **

N021406 001 Aug 12, 2005

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

SUN PHARM

0.25MCG

A204556 001 Feb 21, 2019

0.5MCG

A204556 002 Feb 21, 2019

INJECTABLE;INJECTION

CALCIJEX

+ ABBVIE

0.001MG/ML **

N018874 001 Sep 25, 1986

+

0.002MG/ML **

N018874 002 Sep 25, 1986

CALCITRIOL

AKORN

0.002MG/ML

A078066 002 Jan 29, 2008

FRESENIUS KABI USA

0.001MG/ML

A075836 001 Dec 31, 2002

0.002MG/ML

A075836 002 Dec 31, 2002

FRESENIUS MEDCL

0.001MG/ML

A075766 001 Feb 20, 2003

FRESENIUS MEDCL

0.002MG/ML

A075766 002 Feb 20, 2003

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

LUITPOLD

0.001MG/ML

A075746 001 Sep 26, 2003

0.002MG/ML

A075746 002 Sep 26, 2003

ROCKWELL MEDCL

0.001MG/ML

A076206 001 Sep 17, 2003

SAGENT PHARMS

0.001MG/ML

A077102 001 Feb 08, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

TEVA PARENTERAL	0.001MG/ML	A075823 001	Mar 31, 2003
	0.002MG/ML	A075823 002	Mar 31, 2003

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL	333.5MG	N021160 001	Apr 02, 2001
	667MG	N021160 002	Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

HIKMA	667MG	A077693 001	Jan 30, 2008
-------	-------	-------------	--------------

ELIPHOS

CYPRESS PHARM	667MG	A078502 001	Nov 25, 2008
---------------	-------	-------------	--------------

PHOSLO

+ FRESENIUS MEDCL	667MG **	N019976 001	Dec 10, 1990
-------------------	----------	-------------	--------------

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT	EQ 500MG BASE, N/A; N/A, 35MG **	N021823 001	Aug 12, 2005
-------------------	----------------------------------	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

METHOTREXATE SODIUM

AKORN	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N020079 001	Feb 26, 1999
-------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 010	Oct 10, 2008
------------------------	---	-------------	--------------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 012	Oct 10, 2008
----------------------	--	-------------	--------------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 013	Oct 10, 2008
------------------------	--	-------------	--------------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 005	Oct 25, 2006
----------------------	---	-------------	--------------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 008	Oct 25, 2006
----------------------	--	-------------	--------------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 007	Oct 25, 2006
----------------------	--	-------------	--------------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 001	Oct 25, 2006
------------------------	---	-------------	--------------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 009	Oct 25, 2006
----------------------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATHIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193 001	Jul 24, 2008
------------------	--	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N019864	001	Jun 10, 1993
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867	001	Dec 20, 1993
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001	

**

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807	001	Aug 26, 1983
	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807	003	Aug 26, 1983
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807	002	Aug 26, 1983
	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807	004	Aug 26, 1983
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002	
DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003	
DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988
DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001	
DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982
DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982
DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982
-----------------	--	---------	-----	--------------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986
---------	--	---------	-----	--------------

	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	002	
--	---	---------	-----	--

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983
---------	--	---------	-----	--------------

	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	008	Jan 29, 1986
--	--	---------	-----	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986
---------	---	---------	-----	--------------

	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	004	
--	--	---------	-----	--

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001	
-----------------	---	---------	-----	--

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	003	
-----------------	---	---------	-----	--

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	002	
-----------------	--	---------	-----	--

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992
-------------------	---	---------	-----	--------------

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	007	Jul 09, 1984
-----------------	---	---------	-----	--------------

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	008	Jul 09, 1984
-----------------	---	---------	-----	--------------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985
-----------------	---	---------	-----	--------------

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	009	Jul 09, 1984
-----------------	--	---------	-----	--------------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985
-------------------	---	---------	-----	--------------

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994
-----------	---	---------	-----	--------------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994
-----------	---	---------	-----	--------------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994
-----------	---	---------	-----	--------------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994
-----------	--	---------	-----	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018258	001	
---------	---	---------	-----	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

HOSPIRA	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018254	001	
---------	--	---------	-----	--

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256	001	
---------	--	---------	-----	--

	33MG/100ML; 5GM/100ML; 30MG/100ML;	N020000	001	Apr 17, 1992
--	------------------------------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	860MG/100ML		
BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N016695 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634 002	Feb 24, 1988
---------	--	-------------	--------------

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510 001	
---------	---	-------------	--

MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499 001	
-------	---	-------------	--

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005	Oct 17, 1988
-------------------	--	-------------	--------------

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006	Oct 17, 1988
-------------------	--	-------------	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007	Oct 17, 1988
-------------------	--	-------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 008	Oct 17, 1988
-------------------	--	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003	Oct 17, 1988
-------------------	--	-------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 004	Oct 17, 1988
-------------------	--	-------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 001	Oct 17, 1988
-------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 48MG/100ML	N019395 001	Mar 26, 1986
-----------------	--	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 48MG/100ML	N019395 002	Mar 26, 1986
-----------------	--	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 48MG/100ML	N019395 003	Mar 26, 1986
-----------------	---	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N019399 001	Jun 16, 1986
--------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018899 001	Oct 31, 1983
---------	--	-------------	--------------

	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019718 001	Sep 29, 1989
--	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438 001	
-----------------	--	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018725 001	Nov 29, 1982
---------	--	-------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N018721 001	Nov 09, 1982
---------	-------------------------------------	-------------	--------------

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML; 30MG/100ML; 860MG/100ML	N018462 001	
--------	-------------------------------------	-------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019485 001	Oct 24, 1985
--------	--	-------------	--------------

B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018023 001	
---------	--	-------------	--

MILES	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018417 001	
-------	--	-------------	--

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933 001	Aug 29, 1989
-----------------	--	-------------	--------------

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
--------	---------------------	-------------	--

	EQ 90MG CALCIUM/5ML	A083159 001	
--	---------------------	-------------	--

ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
---------------	---------------------	-------------	--------------

LILLY	EQ 90MG CALCIUM/5ML	N006470 001	
-------	---------------------	-------------	--

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML	N016847 001	
---------------	--	-------------	--

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML; 140.1MG/ML; 461.8MG/ML	N017506 001	
---------------	-----------------------------------	-------------	--

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

APOTEX INC	4MG	A202079 001	Jan 10, 2014
------------	-----	-------------	--------------

	8MG	A202079 002	Jan 10, 2014
--	-----	-------------	--------------

	16MG	A202079 003	Jan 10, 2014
--	------	-------------	--------------

	32MG	A202079 004	Jan 10, 2014
--	------	-------------	--------------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

APOTEX INC	16MG; 12.5MG	A202884 001	Dec 04, 2012
------------	--------------	-------------	--------------

	32MG; 12.5MG	A202884 002	Dec 04, 2012
--	--------------	-------------	--------------

	32MG; 25MG	A202884 003	Jun 03, 2013
--	------------	-------------	--------------

CANDICIDIN

OINTMENT; VAGINAL

VANOVID

SANOFI AVENTIS US	0.6MG/GM	A061596 001	
-------------------	----------	-------------	--

TABLET; VAGINAL

VANOVID

SANOFI AVENTIS US	3MG	A061613 001	
-------------------	-----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRIL

TABLET; ORAL

CAPOTEN

+	PAR PHARM	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995

CAPTOPRIL

ACP NIMBLE

		12.5MG	A074433 001	Feb 13, 1996
		12.5MG	A074462 001	Feb 13, 1996
		12.5MG	A074483 001	Feb 13, 1996
		25MG	A074433 002	Feb 13, 1996
		25MG	A074462 002	Feb 13, 1996
		25MG	A074483 002	Feb 13, 1996
		50MG	A074433 003	Feb 13, 1996
		50MG	A074462 003	Feb 13, 1996
		50MG	A074483 003	Feb 13, 1996
		100MG	A074433 004	Feb 13, 1996
		100MG	A074462 004	Feb 13, 1996
		100MG	A074483 004	Feb 13, 1996
	APOTEX	12.5MG	A074737 001	Oct 28, 1998
		25MG	A074737 002	Oct 28, 1998
		50MG	A074737 003	Oct 28, 1998
		100MG	A074737 004	Oct 28, 1998
	APOTHECON	12.5MG	A074472 001	Mar 31, 1995
		25MG	A074472 002	Mar 31, 1995
		50MG	A074472 003	Mar 31, 1995
		100MG	A074472 004	Mar 31, 1995
	DAVA PHARMS INC	12.5MG	A074423 001	Feb 13, 1996
		25MG	A074423 002	Feb 13, 1996
		50MG	A074423 003	Feb 13, 1996
		100MG	A074423 004	Feb 13, 1996
	EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
		25MG	A074748 002	May 29, 1997
		50MG	A074748 001	May 29, 1997
		100MG	A074748 003	May 29, 1997
	G AND W LABS INC	12.5MG	A074590 004	Aug 30, 1996
		25MG	A074590 002	Aug 30, 1996
		50MG	A074590 001	Aug 30, 1996
		100MG	A074590 003	Aug 30, 1996
	OXFORD PHARMS	12.5MG	A074418 001	Feb 13, 1996
		25MG	A074418 002	Feb 13, 1996
		50MG	A074418 003	Feb 13, 1996
		100MG	A074418 004	Feb 13, 1996
	PAR PHARM	12.5MG	A074493 001	Feb 13, 1996
		25MG	A074493 002	Feb 13, 1996
		50MG	A074493 003	Feb 13, 1996
		100MG	A074493 004	Feb 13, 1996
	PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
		25MG	A074640 002	Mar 31, 1997
		50MG	A074640 003	Mar 31, 1997
		100MG	A074640 004	Mar 31, 1997
	SANDOZ	12.5MG	A074481 001	Feb 13, 1996
		25MG	A074481 002	Feb 13, 1996
		50MG	A074481 003	Feb 13, 1996
		100MG	A074481 004	Feb 13, 1996
	WATSON LABS	12.5MG	A074451 001	Feb 13, 1996
		12.5MG	A074576 001	Apr 23, 1996
		25MG	A074451 002	Feb 13, 1996
		25MG	A074576 002	Apr 23, 1996
		50MG	A074451 003	Feb 13, 1996
		50MG	A074576 003	Apr 23, 1996
		100MG	A074451 004	Feb 13, 1996
		100MG	A074576 004	Apr 23, 1996
	YAOPHARMA CO LTD	12.5MG	A074363 001	Nov 09, 1995
		12.5MG	A074519 001	Feb 13, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CAPTOPRILTABLET; ORAL
CAPTOPRIL

25MG	A074363	002	Nov 09, 1995
25MG	A074519	002	Feb 13, 1996
50MG	A074363	003	Nov 09, 1995
50MG	A074519	003	Feb 13, 1996
100MG	A074363	004	Nov 09, 1995
100MG	A074519	004	Feb 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

+ APOTHECON

25MG;15MG **

N018709 001 Oct 12, 1984

CAPOZIDE 25/25

+ APOTHECON

25MG;25MG **

N018709 002 Oct 12, 1984

CAPOZIDE 50/15

+ APOTHECON

50MG;15MG **

N018709 004 Oct 12, 1984

CAPOZIDE 50/25

+ APOTHECON

50MG;25MG **

N018709 003 Oct 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

ACP NIMBLE

25MG;15MG

A074827 001 Dec 29, 1997

25MG;25MG

A074827 002 Dec 29, 1997

50MG;15MG

A074827 004 Dec 29, 1997

50MG;25MG

A074827 003 Dec 29, 1997

IVAX SUB TEVA PHARMS

25MG;15MG

A075055 001 Jun 18, 1998

25MG;25MG

A075055 002 Jun 18, 1998

50MG;15MG

A075055 004 Jun 18, 1998

50MG;25MG

A075055 003 Jun 18, 1998

VINTAGE PHARMS LLC

25MG;15MG

A074788 001 Dec 29, 1997

25MG;25MG

A074788 002 Dec 29, 1997

50MG;15MG

A074788 004 Dec 29, 1997

50MG;25MG

A074788 003 Dec 29, 1997

WATSON LABS

50MG;25MG

A074832 001 Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR

0.01%

A070292 001 May 21, 1986

CARBASTAT

NOVARTIS

0.01%

A073677 001 Apr 28, 1995

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

NOSTRUM LABS INC

100MG

A076697 001 May 20, 2011

200MG

A076697 002 May 20, 2011

300MG

A076697 003 May 20, 2011

SOLUTION; INTRAVENOUS

CARNEXIV

+ LUNDBECK PHARMS LLC

200MG/20ML (10MG/ML)

N206030 001 Oct 07, 2016

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001 Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001 Nov 09, 1987

INWOOD LABS

200MG

A070231 001 Aug 14, 1986

PLIVA

200MG

A071479 001 Jul 24, 1987

USL PHARMA

200MG

A070300 001 May 15, 1986

WARNER CHILCOTT

200MG

A070429 001 Jan 02, 1987

TERIL

TARO

200MG

A076525 001 Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG	EQ 1GM BASE/VIAL	N050306 001
	EQ 2GM BASE/VIAL	N050306 004
	EQ 5GM BASE/VIAL	N050306 002
	EQ 10GM BASE/VIAL	N050306 006
	EQ 30GM BASE/VIAL	N050306 007

PYOPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001
	EQ 2GM BASE/VIAL	N050298 002
	EQ 5GM BASE/VIAL	N050298 003
	EQ 10GM BASE/VIAL	N050298 006
	EQ 20GM BASE/VIAL	N050298 007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER	EQ 382MG BASE	N050435 001
--------	---------------	-------------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

WOCKHARDT LTD	12.5MG; 200MG; 50MG	A090786 001	Nov 20, 2012
	18.75MG; 200MG; 75MG	A090833 001	Nov 20, 2012
	25MG; 200MG; 100MG	A090833 002	Nov 20, 2012
	31.25MG; 200MG; 125MG	A090833 003	Nov 20, 2012
	37.5MG; 200MG; 150MG	A090833 004	Nov 20, 2012
	50MG; 200MG; 200MG	A090833 005	Nov 20, 2012

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

ANI PHARMS INC	10MG; 100MG	A073587 002	Jun 29, 1995
	25MG; 100MG	A073587 001	Jun 29, 1995
	25MG; 250MG	A073587 003	Jun 29, 1995
SCS	10MG; 100MG	A074080 001	Mar 25, 1994
	25MG; 100MG	A074080 002	Mar 25, 1994
	25MG; 250MG	A074080 003	Mar 25, 1994
WATSON LABS	10MG; 100MG	A073381 001	Sep 28, 1993
	25MG; 100MG	A073382 001	Sep 28, 1993
	25MG; 250MG	A073383 001	Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM	50MG; 200MG	A076663 001	Jun 24, 2004
----------	-------------	-------------	--------------

SINEMET CR

+ MERCK SHARP DOHME 50MG; 200MG

N019856 001 May 30, 1991

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY	10MG; 100MG	A076643 001	Jun 10, 2005
	25MG; 100MG	A076643 002	Jun 10, 2005
	25MG; 250MG	A076643 003	Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS	10MG; 100MG	A090631 001	Jun 08, 2010
	25MG; 100MG	A090631 002	Jun 08, 2010
	25MG; 250MG	A090631 003	Jun 08, 2010

PARCOPA

UCB INC	10MG; 100MG **	A076699 001	Aug 27, 2004
	25MG; 100MG **	A076699 002	Aug 27, 2004
	25MG; 250MG **	A076699 003	Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

+ MCNEIL 4MG/5ML ** N008955 001

SOLUTION; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010
VINTAGE PHARMS	4MG/5ML	A040814 001	Feb 26, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM

4MG

A090417 001 Aug 23, 2010

VINTAGE PHARMS

4MG

A040639 002 May 30, 2008

CLISTIN

+ ORTHO MCNEIL PHARM

4MG **

N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL

A077383 001 Jan 27, 2006

150MG/VIAL

A077383 002 Jan 27, 2006

450MG/VIAL

A077383 003 Jan 27, 2006

FRESENIUS KABI USA

50MG/VIAL

A076235 001 Oct 14, 2004

150MG/VIAL

A076235 002 Oct 14, 2004

450MG/VIAL

A076235 003 Oct 14, 2004

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

MYLAN LABS LTD

50MG/VIAL

A091510 001 May 29, 2012

150MG/VIAL

A091510 002 May 29, 2012

450MG/VIAL

A091510 003 May 29, 2012

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

450MG/VIAL

A076602 003 Nov 16, 2004

SANDOZ

50MG/VIAL

A076959 001 Mar 18, 2005

150MG/VIAL

A076959 002 Mar 18, 2005

450MG/VIAL

A076959 003 Mar 18, 2005

WATSON LABS TEVA

50MG/VIAL

A076162 001 Oct 14, 2004

150MG/VIAL

A076162 002 Oct 14, 2004

450MG/VIAL

A076162 003 Oct 14, 2004

WEST-WARD PHARMS INT

50MG/VIAL

A076099 001 Oct 14, 2004

150MG/VIAL

A076099 002 Oct 14, 2004

450MG/VIAL

A076099 003 Oct 14, 2004

PARAPLATIN

+ CORDEN PHARMA

50MG/VIAL **

N019880 001 Mar 03, 1989

+

150MG/VIAL **

N019880 002 Mar 03, 1989

+

450MG/VIAL **

N019880 003 Mar 03, 1989

INJECTABLE; INTRAVENOUS

CARBOPLATIN

ACTAVIS TOTOWA

50MG/5ML (10MG/ML)

A078732 001 Feb 06, 2012

150MG/15ML (10MG/ML)

A078732 002 Feb 06, 2012

450MG/45ML (10MG/ML)

A078732 003 Feb 06, 2012

600MG/60ML (10MG/ML)

A078732 004 Feb 06, 2012

FRESENIUS KABI USA

50MG/5ML (10MG/ML)

A077432 001 Sep 29, 2006

150MG/15ML (10MG/ML)

A077432 002 Sep 29, 2006

450MG/45ML (10MG/ML)

A077432 003 Sep 29, 2006

50MG/5ML (10MG/ML)

A077247 001 Oct 21, 2004

50MG/5ML (10MG/ML)

A077266 001 Feb 15, 2006

150MG/15ML (10MG/ML)

A077247 002 Oct 21, 2004

150MG/15ML (10MG/ML)

A077266 002 Feb 15, 2006

MYLAN INSTITUTIONAL

50MG/5ML (10MG/ML)

A077998 001 Apr 24, 2007

150MG/15ML (10MG/ML)

A077998 002 Apr 24, 2007

450MG/45ML (10MG/ML)

A077998 003 Apr 24, 2007

MYLAN LABS LTD

50MG/5ML (10MG/ML)

A091063 001 Nov 09, 2011

150MG/15ML (10MG/ML)

A091063 002 Nov 09, 2011

450MG/45ML (10MG/ML)

A091063 003 Nov 09, 2011

600MG/60ML (10MG/ML)

A091063 004 Nov 09, 2011

1GM/100ML (10MG/ML)

A091478 001 Nov 23, 2011

PHARMACHEMIE BV

50MG/5ML (10MG/ML)

A077679 001 Feb 25, 2009

150MG/15ML (10MG/ML)

A077679 002 Feb 25, 2009

450MG/45ML (10MG/ML)

A077679 003 Feb 25, 2009

TEVA PARENTERAL

50MG/5ML (10MG/ML)

A077389 001 Mar 30, 2007

150MG/15ML (10MG/ML)

A077389 002 Mar 30, 2007

450MG/45ML (10MG/ML)

A077389 003 Mar 30, 2007

PARAPLATIN

+ CORDENPHARMA

50MG/5ML (10MG/ML) **

N020452 001 Jul 14, 2003

+

150MG/15ML (10MG/ML) **

N020452 002 Jul 14, 2003

+

450MG/45ML (10MG/ML) **

N020452 003 Jul 14, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARBOPLATIN

INJECTABLE; INTRAVENOUS

PARAPLATIN

+

60MG/60ML (10MG/ML) **

N020452 004 Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

+

MYLAN SPECIALITY LP

250MG

N011792 003

TABLET; ORAL

CARISOPRODOL

ABLE

350MG

A040421 001 Jun 21, 2001

EPIC PHARMA LLC

350MG

A040397 001 Sep 21, 2000

FOSUN PHARMA

350MG

A081025 001 Apr 13, 1989

OXFORD PHARMS

350MG

A040188 001 Mar 07, 1997

PIONEER PHARMS

350MG

A089390 001 Oct 13, 1988

SANDOZ

350MG

A089566 001 Aug 30, 1988

SUN PHARM INDS LTD

350MG

A040755 001 Feb 27, 2007

SUN PHARM INDUSTRIES

350MG

A089346 001 Oct 17, 1991

WATSON LABS

350MG

A040152 001 Dec 03, 1996

350MG

A085433 001

WATSON LABS TEVA

350MG

A086179 001

RELA

SCHERING

350MG

N012155 001

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST

50MG/ML

N014173 001

TABLET; ORAL

PROKETAZINE

WYETH AYERST

12.5MG

N012768 001

25MG

N012768 002

50MG

N012768 004

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE

100MG

N018550 002 Dec 31, 1987

150MG

N018550 003 Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC

1%

A076097 001 Feb 06, 2002

BAUSCH AND LOMB

1%

A075546 001 Jan 20, 2000

OCUPRESS

+

NOVARTIS

1% **

N019972 001 May 23, 1990

TABLET; ORAL

CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET; ORAL

CARVEDILOL

HIKMA

3.125MG

A077887 001 Sep 07, 2007

6.25MG

A077887 002 Sep 07, 2007

12.5MG

A077887 003 Sep 07, 2007

25MG

A077887 004 Sep 07, 2007

PLIVA HRVATSKA DOO

3.125MG

A078240 001 Oct 30, 2007

6.25MG

A078240 002 Oct 30, 2007

12.5MG

A078240 003 Oct 30, 2007

25MG

A078240 004 Oct 30, 2007

SUN PHARM INDS INC

3.125MG

A077346 004 Sep 05, 2007

6.25MG

A077346 001 Sep 05, 2007

12.5MG

A077346 002 Sep 05, 2007

25MG

A077346 003 Sep 05, 2007

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CARVEDILOLTABLET; ORAL
CARVEDILOL

25MG

A078786 004 Dec 22, 2009

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CASPOFUNGIN ACETATE

CIPLA

50MG/VIAL

A209489 001 Jul 12, 2018

70MG/VIAL

A209489 002 Jul 12, 2018

CEFACTOR

CAPSULE; ORAL

CECLOR

+ LILLY

EQ 250MG BASE **

N050521 001

+

EQ 500MG BASE **

N050521 002

CEFACTOR

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

HERITAGE PHARMA

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

FOR SUSPENSION; ORAL

CECLOR

+ LILLY

EQ 125MG BASE/5ML **

N050522 001

+

EQ 250MG BASE/5ML **

N050522 002

CEFACTOR

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

WATSON LABS INC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

EQ 375MG BASE/5ML

A064207 001 Feb 18, 1998

TABLET, CHEWABLE; ORAL

RANICLOR

RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003

EQ 187MG BASE

A065092 002 Dec 22, 2003

EQ 250MG BASE

A065092 003 Dec 22, 2003

EQ 375MG BASE

A065092 004 Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY

EQ 375MG BASE

N050673 001 Jun 28, 1996

EQ 500MG BASE

N050673 002 Jun 28, 1996

CEFACTOR

WORLD GEN

EQ 500MG BASE

A065057 001 Jan 05, 2001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

CSPC OUYI	EQ 500MG BASE	A205072 001	Jul 28, 2017
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
SANDOZ	EQ 500MG BASE	A062291 001	
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
+	EQ 500MG BASE **	N050512 001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
---------	---------------	-------------	--------------

FOR SUSPENSION; ORAL

CEFADROXIL

ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115 001	Mar 26, 2003
	EQ 250MG BASE/5ML	A065115 002	Mar 26, 2003
	EQ 500MG BASE/5ML	A065115 003	Mar 26, 2003

DURICEF

+	WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527 002
+		EQ 250MG BASE/5ML **	N050527 003
+		EQ 500MG BASE/5ML **	N050527 001

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
---------	-------------	-------------	--------------

DURICEF

+	WARNER CHILCOTT	EQ 1GM BASE **	N050528 001
---	-----------------	----------------	-------------

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504 001	
	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001
+		EQ 500MG BASE/VIAL	N050461 002
+		EQ 1GM BASE/VIAL **	N050461 003
+		EQ 5GM BASE/VIAL **	N050461 004
+		EQ 10GM BASE/VIAL **	N050461 005

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

ANCEF IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
-----------------	-----------------	-------------	--------------

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 500MG BASE/VIAL

N050779 001 Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062688 002 Nov 17, 1986

EQ 1GM BASE/VIAL

A062688 003 Nov 17, 1986

EQ 10GM BASE/VIAL

A062688 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062688 005 Aug 03, 1987

AUROBINDO PHARMA

EQ 500MG BASE/VIAL

A065395 001 Aug 08, 2008

EQ 1GM BASE/VIAL

A065395 002 Aug 08, 2008

BEDFORD

EQ 250MG BASE/VIAL

A062894 001 Jul 21, 1988

EQ 500MG BASE/VIAL

A062894 002 Jul 21, 1988

EQ 1GM BASE/VIAL

A062894 003 Jul 21, 1988

EQ 5GM BASE/VIAL

A062894 004 Jul 21, 1988

EQ 10GM BASE/VIAL

A062894 005 Jul 21, 1988

CEPHAZONE PHARMA

EQ 500MG BASE/VIAL

A065280 001 Mar 18, 2009

EQ 1GM BASE/VIAL

A065280 002 Mar 18, 2009

EQ 10GM BASE/VIAL

A065295 001 Mar 18, 2009

EQ 20GM BASE/VIAL

A065296 001 Mar 18, 2009

DR REDDYS

EQ 250MG BASE/VIAL

A062988 001 Dec 29, 1989

EQ 500MG BASE/VIAL

A062988 002 Dec 29, 1989

EQ 1GM BASE/VIAL

A062988 003 Dec 29, 1989

EQ 5GM BASE/VIAL

A062989 001 Dec 29, 1989

EQ 10GM BASE/VIAL

A062989 002 Dec 29, 1989

EQ 20GM BASE/VIAL

A062989 003 Dec 29, 1989

FACTA FARMA

EQ 500MG BASE/VIAL

A063214 001 Dec 27, 1991

EQ 1GM BASE/VIAL

A063207 001 Dec 27, 1991

EQ 10GM BASE/VIAL

A063209 001 Dec 27, 1991

EQ 20GM BASE/VIAL

A063209 002 Apr 30, 1999

FRESENIUS KABI USA

EQ 500MG BASE/VIAL **

A064169 001 Aug 14, 1998

EQ 1GM BASE/VIAL **

A064169 002 Aug 14, 1998

EQ 10GM BASE/VIAL

A064170 001 Mar 18, 1998

EQ 20GM BASE/VIAL

A064170 002 Mar 18, 1998

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A064033 001 Oct 31, 1993

HOSPIRA INC

EQ 500MG BASE/VIAL

A065226 001 Apr 21, 2005

EQ 1GM BASE/VIAL

A065226 002 Apr 21, 2005

EQ 1GM BASE/VIAL

A065244 001 Aug 12, 2005

EQ 1GM BASE/VIAL

A201654 001 Feb 03, 2016

EQ 10GM BASE/VIAL

A065247 001 Aug 12, 2005

STERI PHARMA

EQ 500MG BASE/VIAL

A063216 001 Dec 27, 1991

EQ 1GM BASE/VIAL

A063208 001 Dec 27, 1991

TEVA PHARMS

EQ 250MG BASE/VIAL

A063016 001 Mar 14, 1989

EQ 500MG BASE/VIAL

A063016 002 Mar 14, 1989

EQ 1GM BASE/VIAL

A063016 003 Mar 14, 1989

EQ 5GM BASE/VIAL

A063018 001 Mar 05, 1990

EQ 10GM BASE/VIAL

A063018 002 Mar 05, 1990

WEST-WARD PHARMS INT

EQ 250MG BASE/VIAL

A062807 001 Jan 12, 1988

EQ 500MG BASE/VIAL

A062807 002 Jan 12, 1988

EQ 1GM BASE/VIAL

A062807 003 Jan 12, 1988

EQ 5GM BASE/VIAL

A062807 004 Jan 12, 1988

EQ 10GM BASE/VIAL

A062807 005 Jan 12, 1988

EQ 20GM BASE/VIAL

A062807 006 Jan 12, 1988

KEFZOL

ACS DOBFAR

EQ 250MG BASE/VIAL

A061773 001

EQ 500MG BASE/VIAL

A061773 002

EQ 1GM BASE/VIAL

A061773 003

EQ 10GM BASE/VIAL

A061773 004

EQ 20GM BASE/VIAL

A061773 005 Sep 08, 1987

LILLY

EQ 500MG BASE/VIAL

A062557 001 Sep 10, 1985

EQ 1GM BASE/VIAL

A062557 002 Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

+ ABBVIE

300MG **

N050739 001 Dec 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

+ ABBVIE

125MG/5ML **

N050749 001 Dec 04, 1997

+

250MG/5ML **

N050749 002 Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFDITOREN PIVOXILTABLET; ORAL
SPECTRACEF

VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
	400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007
	EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007
	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012
	EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007
	EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

SANDOZ INC	100MG/5ML	A206144 001	Nov 17, 2017
	200MG/5ML	A206144 002	Nov 17, 2017

SUPRAX

+ LEDERLE

100MG/5ML **	N050622 001	Apr 28, 1989
--------------	-------------	--------------

TABLET; ORAL

SUPRAX

+ LEDERLE

200MG **	N050621 001	Apr 28, 1989
----------	-------------	--------------

+

400MG **	N050621 002	Apr 28, 1989
----------	-------------	--------------

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N050571 001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571 002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571 003	Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

+ PHARMACIA AND UPJOHN EQ 1GM BASE/VIAL **

N050637 001	Dec 11, 1989
-------------	--------------

+ EQ 2GM BASE/VIAL **

N050637 002	Dec 11, 1989
-------------	--------------

ZEFAZONE IN PLASTIC CONTAINER

+ PHARMACIA AND UPJOHN EQ 20MG BASE/ML **

N050683 001	Dec 29, 1992
-------------	--------------

+ EQ 40MG BASE/ML **

N050683 002	Dec 29, 1992
-------------	--------------

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579 001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295 001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579 002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579 003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579 004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333 001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551 001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333 002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551 002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551 003	Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER	EQ 20MG BASE/ML	N050613 002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613 001	Jul 23, 1986

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON	500MG/VIAL	A062579 001	Nov 26, 1984
	1GM/VIAL	A062579 002	Nov 26, 1984
	2GM/VIAL	A062579 003	Nov 26, 1984
	10GM/VIAL	A062579 004	Nov 26, 1984
	20GM/VIAL	A062579 005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554 001	May 24, 1984
	1GM/VIAL	N050554 002	May 24, 1984
	2GM/VIAL	N050554 003	May 24, 1984
	10GM/VIAL	N050554 004	May 24, 1984
	20GM/VIAL	N050554 005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200 001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200 002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200 003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201 001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201 002	Mar 24, 2000
WOCKHARDT	EQ 1GM BASE/VIAL	A065197 001	Aug 29, 2006
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER			
B BRAUN	EQ 2GM BASE	N050792 001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER			
B BRAUN	EQ 1GM BASE	N050792 002	Jul 29, 2004
CEFOTAXIME SODIUM			
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517 001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517 002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517 003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516 001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006
	EQ 1GM BASE/VIAL	A203132 001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006
	EQ 2GM BASE/VIAL	A203132 002	Feb 19, 2016
	EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006
LUPIN	EQ 500MG BASE/VIAL	A065124 001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124 002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124 003	Sep 24, 2003
WOCKHARDT	EQ 500MG BASE/VIAL	A065197 002	Jun 20, 2008
	EQ 2GM BASE/VIAL	A065197 003	Jun 20, 2008
CLAFORAN			
SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987
	EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987
+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL **	N050547 001	
+	EQ 1GM BASE/VIAL **	N050547 002	
+	EQ 2GM BASE/VIAL **	N050547 003	
+	EQ 10GM BASE/VIAL **	N050547 004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596 002	May 20, 1985
	EQ 40MG BASE/ML	N050596 004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596 001	May 20, 1985
	EQ 40MG BASE/ML	N050596 003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

TELIGENT	EQ 10GM BASE/VIAL	N050588 003	Apr 25, 1988
TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293 001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293 002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER			
TELIGENT	EQ 20MG BASE/ML	N050694 002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694 001	Jul 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375 001	Aug 09, 2007
WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030 001	Oct 26, 2011

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601 001	Dec 30, 1988
--------	------------------	-------------	--------------

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011
	EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011
	EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011
FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012 001	Jul 03, 2000
	EQ 2GM BASE/VIAL **	A065012 002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011 001	Jul 03, 2000
HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006
	EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006
	EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006

MEFOXIN

MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757 001	Jan 08, 1987
+	EQ 1GM BASE/VIAL **	N050517 001	
	EQ 2GM BASE/VIAL	A062757 002	Jan 08, 1987
+	EQ 2GM BASE/VIAL **	N050517 002	
	EQ 10GM BASE/VIAL **	N050517 003	

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	MERCK	EQ 20MG BASE/ML **	N050581 003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581 004	Sep 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MERCK	EQ 20MG BASE/ML **	N050581 002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581 001	Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633 002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633 003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633 005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO	EQ 50MG BASE/5ML	N050688 002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688 001	Aug 07, 1992

CEFPODOXIME PROXETIL

SANDOZ	EQ 50MG BASE/5ML	A090031 001	Jan 14, 2009
	EQ 100MG BASE/5ML	A090031 002	Jan 14, 2009
SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082 001	May 31, 2002
	EQ 100MG BASE/5ML	A065082 002	May 31, 2002

VANTIN

+	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675 001	Aug 07, 1992
+		EQ 100MG BASE/5ML **	N050675 002	Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO	EQ 100MG BASE	N050687 001	Aug 07, 1992
	EQ 200MG BASE	N050687 002	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD	EQ 100MG BASE	A065083 001	Aug 20, 2003
	EQ 200MG BASE	A065083 002	Aug 20, 2003

VANTIN

+	PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674 001	Aug 07, 1992
+		EQ 200MG BASE **	N050674 002	Aug 07, 1992

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006
	250MG/5ML	A065202 002	Jun 30, 2006

CEFZIL

+ CORDEN PHARMA	125MG/5ML **	N050665 001	Dec 23, 1991
+	250MG/5ML **	N050665 002	Dec 23, 1991

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006
	500MG	A065198 002	Dec 13, 2006

CEFZIL

+ CORDEN PHARMA	250MG **	N050664 001	Dec 23, 1991
+	500MG **	N050664 002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

ACS DOBFAR	500MG/VIAL	A062640 001	Nov 20, 1985
AUROBINDO PHARMA LTD	500MG/VIAL	A065481 001	May 28, 2010
	1GM/VIAL	A065481 002	May 28, 2010
	2GM/VIAL	A065481 003	May 28, 2010
	6GM/VIAL	A065482 001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646 001	Sep 27, 1990
	1GM/VIAL	N050646 002	Sep 27, 1990
	2GM/VIAL	N050646 003	Sep 27, 1990
	10GM/VIAL	N050646 004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322 001	Nov 07, 1995
	1GM/VIAL	A064006 001	Mar 31, 1992
	2GM/VIAL	A063322 002	Nov 07, 1995
	2GM/VIAL	A064006 002	Mar 31, 1992
	6GM/VIAL	A064008 001	Mar 31, 1992
	10GM/VIAL	A064008 002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655 001	Nov 20, 1985
	2GM/VIAL	A062655 002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739 001	Jul 10, 1986
	2GM/VIAL	A062739 002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221 003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

TELIGENT	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989
+	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989
+	EQ 40MG BASE/ML	N050634 003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

SI PHARMS	EQ 400MG BASE	N050685 002	Dec 20, 1995
-----------	---------------	-------------	--------------

FOR SUSPENSION; ORAL

CEDAX

+ SI PHARMS	EQ 90MG BASE/5ML **	N050686 001	Dec 20, 1995
+	EQ 180MG BASE/5ML **	N050686 002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560 001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294 002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560 002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294 003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560 003	Sep 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
BEDFORD	EQ 10GM BASE/VIAL	A065475	001	Aug 18, 2008
FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006
HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005
	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012
	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005
	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012
LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006
TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006
ROCEPHIN				
HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993
	EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993
	EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
+	EQ 10GM BASE/VIAL **	N050585	005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER				
+	HOFFMANN LA ROCHE EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+	EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+	EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS				
CEFTRIAZONE				
AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
	EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
	EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
	EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ROCEPHIN

+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585 001	Dec 21, 1984
+		EQ 500MG BASE/VIAL **	N050585 002	Dec 21, 1984
+		EQ 1GM BASE/VIAL **	N050585 003	Dec 21, 1984
+		EQ 2GM BASE/VIAL **	N050585 004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585 007	May 08, 1996
		EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585 006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672 001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672 002	Apr 29, 1997

CEFUROXIME AXETIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323 001	Feb 05, 2008
		EQ 250MG BASE/5ML	A065323 002	Feb 05, 2008

TABLET; ORAL

CEFTIN

+	GLAXOSMITHKLINE	EQ 125MG BASE **	N050605 001	Dec 28, 1987
+		EQ 250MG BASE **	N050605 002	Dec 28, 1987
+		EQ 500MG BASE **	N050605 003	Dec 28, 1987

CEFUROXIME AXETIL

	ANI PHARMS INC	EQ 250MG BASE	A065190 001	Oct 18, 2004
		EQ 500MG BASE	A065190 002	Oct 18, 2004
	FOSUN PHARMA	EQ 250MG BASE	A065126 001	Oct 28, 2003
		EQ 500MG BASE	A065126 002	Oct 28, 2003
	RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002
		EQ 250MG BASE	A065043 002	Feb 15, 2002
		EQ 500MG BASE	A065043 001	Feb 15, 2002
	SUN PHARM INDS LTD	EQ 125MG BASE	A065118 001	Apr 25, 2003
		EQ 250MG BASE	A065118 002	Apr 25, 2003
		EQ 500MG BASE	A065118 003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

	FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
		EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008
		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008
		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008
	TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
	WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
		EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
		EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009

KEFUROX

	ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
		EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
	LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

	LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
--	-------	--------------------	-------------	--------------

ZINACEF IN PLASTIC CONTAINER

	TELIGENT	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008
	TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
		EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
	WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEFUROXIME SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

KEFUROX

ACS DOBFAR EQ 750MG BASE/VIAL A062591 001 Jan 10, 1986

INJECTABLE;INTRAVENOUS

KEFUROX

LILLY EQ 750MG BASE/VIAL A062592 001 Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY EQ 750MG BASE/VIAL A062590 001 Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER;ORAL

CALCIBIND

MISSION PHARMA 2.5GM/PACKET N018757 002 Dec 28, 1982

300GM/BOT N018757 003 Oct 16, 1984

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

APOTHECON EQ 250MG BASE A062973 001 Nov 08, 1988

EQ 250MG BASE A063063 001 Sep 29, 1989

EQ 250MG BASE A063186 001 Dec 30, 1994

EQ 500MG BASE A062974 001 Nov 23, 1988

EQ 500MG BASE A063063 002 Sep 29, 1989

EQ 500MG BASE A063186 002 Dec 30, 1994

BARR EQ 250MG BASE A062773 001 Jun 26, 1987

EQ 500MG BASE A062775 001 Apr 22, 1987

FACTA FARMA EQ 250MG BASE A062118 001

EQ 500MG BASE A062118 002

IVAX SUB TEVA PHARMS EQ 250MG BASE A061969 001

EQ 500MG BASE A061969 002

PUREPAC PHARM EQ 250MG BASE A062809 001 Apr 22, 1987

EQ 500MG BASE A062809 002 Apr 22, 1987

STEVENS J EQ 250MG BASE A062870 001 Mar 17, 1988

EQ 500MG BASE A062869 001 Mar 17, 1988

SUN PHARM INDS (IN) EQ 250MG BASE A062791 001 Jun 11, 1987

EQ 500MG BASE A062791 002 Jun 11, 1987

SUN PHARM INDS LTD EQ 250MG BASE A065007 001 Sep 16, 1999

EQ 500MG BASE A065007 002 Sep 16, 1999

TEVA EQ 250MG BASE A062760 001 Apr 24, 1987

EQ 250MG BASE A062821 001 Feb 05, 1988

EQ 500MG BASE A062761 001 Apr 24, 1987

EQ 500MG BASE A062823 001 Feb 05, 1988

YOSHITOMI EQ 250MG BASE A062872 001 Jun 20, 1988

EQ 500MG BASE A062871 001 Jul 05, 1988

KEFLEX

+ PRAGMA EQ 333MG BASE **

N050405 004 May 12, 2006

FOR SUSPENSION;ORAL

CEPHALEXIN

APOTHECON EQ 125MG BASE/5ML A062986 001 Apr 18, 1991

EQ 250MG BASE/5ML A062987 001 Jul 25, 1989

BARR EQ 125MG BASE/5ML A062778 001 Aug 06, 1987

EQ 250MG BASE/5ML A062777 001 Aug 06, 1987

FACTA FARMA EQ 100MG BASE/ML ** A062117 001

EQ 125MG BASE/5ML ** A062117 002

EQ 250MG BASE/5ML ** A062117 003

HIKMA PHARMS EQ 125MG BASE/5ML A065444 001 Aug 28, 2009

EQ 250MG BASE/5ML A065444 002 Aug 28, 2009

SUN PHARM INDS LTD EQ 125MG BASE/5ML A065081 001 Jul 27, 2001

EQ 250MG BASE/5ML A065081 002 Jul 27, 2001

TEVA EQ 125MG BASE/5ML A062767 001 Jun 16, 1987

EQ 125MG BASE/5ML A062873 001 May 23, 1988

EQ 250MG BASE/5ML A062768 001 Jun 16, 1987

EQ 250MG BASE/5ML A062867 001 Apr 15, 1988

VITARINE EQ 125MG BASE/5ML A062779 001 Dec 22, 1987

EQ 250MG BASE/5ML A062781 001 Dec 22, 1987

KEFLEX

+ PRAGMA EQ 100MG BASE/ML ** N050406 003

+ EQ 125MG BASE/5ML ** N050406 001

+ EQ 250MG BASE/5ML ** N050406 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHALEXIN

TABLET; ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988

KEFLET

LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY	250MG	N050219 001	
-------	-------	-------------	--

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730 002	Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 002	Jan 31, 1984

KEFLIN

LILLY	EQ 1GM BASE/VIAL	N050482 001	
	EQ 2GM BASE/VIAL	N050482 002	
	EQ 4GM BASE/VIAL	N050482 003	
	EQ 20GM BASE/VIAL	N050482 007	

KEFLIN IN PLASTIC CONTAINER

LILLY	EQ 1GM BASE/VIAL	A062549 001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549 002	Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435 001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435 002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435 003	Nov 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 500MG BASE/VIAL	A062961 001	Sep 20, 1988
EQ 500MG BASE/VIAL	N050446 005	
EQ 1GM BASE/VIAL	A061769 001	
EQ 1GM BASE/VIAL	A062724 001	Dec 23, 1986
EQ 1GM BASE/VIAL	A062961 002	Sep 20, 1988
EQ 1GM BASE/VIAL	N050446 001	
EQ 2GM BASE/VIAL	A061769 002	
EQ 2GM BASE/VIAL	A062724 002	Dec 23, 1986
EQ 2GM BASE/VIAL	A062961 003	Sep 20, 1988
EQ 2GM BASE/VIAL	N050446 002	
EQ 4GM BASE/VIAL	A061769 003	
EQ 4GM BASE/VIAL	A062961 004	Sep 20, 1988
EQ 4GM BASE/VIAL	N050446 003	
EQ 20GM BASE/VIAL	N050446 004	

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL	A062723 001	Nov 17, 1986
EQ 1GM BASE/VIAL	A062723 002	Nov 17, 1986
EQ 2GM BASE/VIAL	A062723 003	Nov 17, 1986
EQ 4GM BASE/VIAL	A062723 004	Nov 17, 1986
EQ 20GM BASE/VIAL	A062723 005	Nov 17, 1986

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987
EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987
EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987
EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG	A061859 001	
500MG	A061859 002	

CEPHRADINE

BARR

250MG	A062850 001	Apr 22, 1988
500MG	A062851 001	Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG	A062762 001	Mar 06, 1987
500MG	A062762 002	Mar 06, 1987

TEVA

250MG	A062683 001	Jan 09, 1987
500MG	A062683 002	Jan 09, 1987

VITARINE

250MG	A062813 001	Feb 25, 1988
500MG	A062813 002	Feb 25, 1988

VELOSEF

APOTHECON

250MG	A061764 001	
500MG	A061764 002	

VELOSEF '250'

ERSANA

250MG	N050548 001	
-------	-------------	--

VELOSEF '500'

ERSANA

500MG	N050548 002	
-------	-------------	--

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML	A061866 001	
250MG/5ML	A061866 002	

CEPHRADINE

BARR

125MG/5ML	A062858 001	May 19, 1988
250MG/5ML	A062859 001	May 19, 1988

TEVA

125MG/5ML	A062693 001	Jan 09, 1987
250MG/5ML	A062693 002	Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML	A061763 001	
-----------	-------------	--

VELOSEF '250'

APOTHECON

250MG/5ML	A061763 002	
-----------	-------------	--

INJECTABLE; INJECTION

VELOSEF

APOTHECON

250MG/VIAL	A061976 001	
500MG/VIAL	A061976 002	
1GM/VIAL	A061976 004	
2GM/VIAL	A061976 003	
4GM/VIAL	A061976 005	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CEPHRADINE

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB 1GM

N050530 001

CERITINIB

CAPSULE; ORAL

ZYKADIA

+ NOVARTIS 150MG

N205755 001 Apr 29, 2014

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS 0.05MG
 0.1MG
 0.2MG
 0.3MG
 0.4MG
 0.8MG

N020740 001 Jun 26, 1997
 N020740 002 Jun 26, 1997
 N020740 003 Jun 26, 1997
 N020740 004 Jun 26, 1997
 N020740 005 May 24, 1999
 N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 5MG/5ML
 AUROBINDO PHARMA LTD 5MG/5ML
 LANNETT CO INC 5MG/5ML
 PHARM ASSOC 5MG/5ML
 RANBAXY LABS LTD 5MG/5ML
 TORRENT 5MG/5ML
 WOCKHARDT 5MG/5ML

A078617 001 Feb 02, 2010
 A090751 001 Dec 16, 2009
 A078496 001 Sep 25, 2009
 A078412 001 Jun 18, 2008
 A077472 001 Jun 18, 2008
 A078870 001 Apr 27, 2009
 A078757 001 Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 5MG/5ML
 CYPRESS PHARM 5MG/5ML
 PHARM ASSOC 5MG/5ML
 RANBAXY LABS LTD 5MG/5ML
 TORRENT 5MG/5ML

A090378 002 May 09, 2008
 A090300 001 Oct 10, 2008
 A090188 002 Apr 22, 2008
 A090183 002 Apr 24, 2008
 A090474 002 Mar 30, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC 5MG/5ML
 CYPRESS PHARM 5MG/5ML
 PHARM ASSOC 5MG/5ML
 RANBAXY LABS LTD 5MG/5ML
 TORRENT 5MG/5ML

A090378 001 May 09, 2008
 A090300 002 Oct 10, 2008
 A090188 001 Apr 22, 2008
 A090183 001 Apr 24, 2008
 A090474 001 Mar 30, 2009

ZYRTEC

J AND J CONSUMER INC 5MG/5ML **

N020346 001 Sep 27, 1996

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

HERITAGE PHARMA 5MG
 10MG
 SUN PHARM INDS INC 5MG
 10MG

A078615 003 Dec 28, 2007
 A078615 004 Dec 28, 2007
 A077499 001 Dec 27, 2007
 A077499 002 Dec 27, 2007

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS INC 5MG
 10MG

A077499 003 Dec 27, 2007
 A077499 004 Dec 27, 2007

ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG

N019835 003 Nov 16, 2007

ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG

N019835 005 Nov 16, 2007

+ 10MG

N019835 006 Nov 16, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG
 10MG

A077631 004 Jan 11, 2008
 A077631 003 Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG
 10MG

A077631 001 Jan 11, 2008
 A077631 002 Jan 11, 2008

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG **
+ 10MG **N021621 003 Nov 16, 2007
N021621 004 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG **
+ 10MG **N021621 005 Nov 16, 2007
N021621 006 Nov 16, 2007CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO R AND D 5MG;120MG

A210719 001 Nov 16, 2018

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

EMD SERONO INC EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

APOTEX INC 30MG

A091260 001 Aug 25, 2011

CHENODIOL

TABLET;ORAL

CHENIX

+ LEADIANT BIOSCI INC 250MG **

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL

ULO

3M 25MG/5ML

N012126 001

CHLORAMPHENICOL

CREAM;TOPICAL

CHLOROMYCETIN

PARKE DAVIS 1%

N050183 001

FOR SOLUTION;OPHTHALMIC

CHLOROMYCETIN

PARKEDALE 25MG/VIAL

N050143 001

INJECTABLE;INJECTION

CHLOROMYCETIN

PARKE DAVIS 250MG/ML

N050153 001

OINTMENT;OPHTHALMIC

CHLORAMPHENICOL

ALTANA 1%

A060133 001

CHLOROFAIR

PHARMAFAIR 1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1%

A061187 001

ECONOCHLOR

ALCON 1%

A061648 001

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL

AKORN 0.5%

A062042 001

ALCON 0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5%

N050091 001

ECONOCHLOR

ALCON 0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE 0.5%

A061220 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORAMPHENICOLSOLUTION/DROPS;OPHTHALMIC
OPTOMYCIN

OPTOPICS 0.5% A062171 001 Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN

PARKEDALE 0.5% N050205 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL A062278 001

CHLOROMYCETIN

+ PARKEDALE EQ 1GM BASE/VIAL N050155 001

MYCHEL-S

ANGUS EQ 1GM BASE/VIAL A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

+ PARKE DAVIS 10MG/GM;666 UNITS/GM;1 UNITS/GM N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE 12.5MG/VIAL;25MG/VIAL N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

OPHTHOCORT

PARKEDALE 10MG/GM;5MG/GM;10,000 UNITS/GM N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CHLOROMYXIN

PARKE DAVIS 1%;10,000 UNITS/GM N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT;OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN 1%;0.5% A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE;ORAL

LIBRELEASE

VALEANT PHARM INTL 30MG N017813 001 Sep 12, 1983

TABLET;ORAL

LIBRITABS

VALEANT PHARM INTL 5MG A085482 001

10MG A085481 001

25MG A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

A-POXIDE

ABBOTT 5MG A085447 001

5MG A085517 001

10MG A085447 002

10MG A085518 001

25MG A085447 003

25MG A085513 001

CHLORDIAZACHEL

RACHELLE 5MG A085086 001

10MG A084639 001

25MG A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT 5MG A087525 001 Jan 07, 1982

10MG A087524 001 Jan 07, 1982

25MG A087512 001 Jan 07, 1982

FERRANTE 5MG A085118 001

10MG A085119 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	25MG		A085120	001	
HALSEY	5MG		A085340	001	
	10MG		A085339	001	
	25MG		A084685	001	
IMPAX LABS	5MG		A086213	001	
	10MG		A085113	001	
	25MG		A086212	001	
IVAX SUB TEVA PHARMS	5MG		A083741	001	
	10MG		A083742	001	
	25MG		A083570	001	
LEDERLE	5MG		A086892	001	
	5MG		A087234	001	
	10MG		A086876	001	
	10MG		A087037	001	
	25MG		A086893	001	
	25MG		A087231	001	
MAST MM	10MG		A086217	001	
MYLAN	5MG		A084886	001	
	10MG		A084601	001	
	25MG		A084887	001	
PARKE DAVIS	5MG		A085163	001	
	10MG		A084598	001	
	25MG		A085164	001	
PIONEER PHARMS	10MG		A089533	001	Jul 15, 1988
	25MG		A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG		A085155	001	
	10MG		A084939	002	
	25MG		A085144	001	
ROXANE	5MG		A084706	001	
	10MG		A084700	001	
	25MG		A084705	001	
SUPERPHARM	5MG		A088987	001	Apr 25, 1985
	10MG		A088986	001	Apr 25, 1985
	25MG		A088988	001	Apr 25, 1985
TEVA	5MG		A088705	001	Jan 18, 1985
	10MG		A088706	001	Jan 18, 1985
	25MG		A086494	001	
	25MG		A088707	001	Jan 18, 1985
UPSHER SMITH LABS	5MG		A084678	001	
	5MG		A084919	001	
	10MG		A084041	001	
	10MG		A084920	001	
	25MG		A084679	002	
	25MG		A084823	001	
USL PHARMA	5MG		A084644	001	
	10MG		A084623	001	
	25MG		A084645	001	
VANGARD	5MG		A088129	001	Mar 28, 1983
	10MG		A088010	001	Mar 28, 1983
	25MG		A088130	001	Mar 28, 1983
WATSON LABS	5MG		A086383	001	
	10MG		A086294	001	
	25MG		A086382	001	
WEST WARD	5MG		A085014	001	
	10MG		A085000	001	
	25MG		A085294	001	
LIBRIUM					
+ VALEANT PHARM INTL	5MG **		N012249	002	
+	10MG **		N012249	001	
+	25MG **		N012249	003	
LYGEN					
ALRA	5MG		A085107	001	
	10MG		A085009	001	
	25MG		A085108	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION

LIBRIUM

BAUSCH 100MG/AMP N012301 001

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE 10MG; 0.4MG N014740 006

MENRIUM 5-2

ROCHE 5MG; 0.2MG N014740 002

MENRIUM 5-4

ROCHE 5MG; 0.4MG N014740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

BAJAJ 0.12% A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTTRIUM 2.5% N019421 001 Dec 17, 1985

MICRODERM

J AND J 4% A072255 001 Apr 15, 1991

PREVACARE R

J AND J 0.5% A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL 4% A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL 4% N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON 4% A073416 001 Mar 14, 2000

HIBICLENS

+ MOLNLYCKE HLTH 4% ** N018423 001

MICRODERM

J AND J 4% A072295 001 Feb 28, 1991

PHARMASEAL SCRUB CARE

CAREFUSION 2200 4% N019793 001 Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO 0.6-1.4mCi/ML N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US 100MG N011467 003

200MG N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA 2% N009435 003

3% N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US EQ 40MG BASE/ML N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

+ SANOFI AVENTIS US EQ 300MG BASE N006002 001

CHLOROQUINE PHOSPHATE

IMPAX LABS EQ 150MG BASE A080880 001

EQ 300MG BASE A040516 001 Aug 29, 2003

MD PHARM EQ 150MG BASE A087228 001

PUREPAC PHARM EQ 150MG BASE A080886 001

TEVA EQ 150MG BASE A087504 001 Jan 13, 1982

WATSON LABS EQ 150MG BASE A087979 001 Dec 21, 1982

EQ 300MG BASE A088030 001 Dec 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US EQ 300MG BASE; EQ 45MG BASE N014860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569	001	
HIKMA INTL PHARMS	250MG	A086028	001	Jul 14, 1982
	500MG	A087736	001	Jul 14, 1982
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
+ OAK PHARMS AKORN	250MG **	N011145	004	
+	500MG **	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK 150MG; 250MG N016016 001

ALDOCLOR-250

MERCK 250MG; 250MG N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM 150MG; 250MG A070783 001 Nov 06, 1987

250MG; 250MG A070654 001 Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS 250MG; 0.125MG A088557 001 Dec 22, 1983

500MG; 0.125MG A088365 001 Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 250MG; 0.125MG A084853 001

500MG; 0.125MG A088151 001 Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN 250MG; 0.125MG A087744 001 May 06, 1982

500MG; 0.125MG A087745 001 May 06, 1982

DIUPRES-250

MERCK 250MG; 0.125MG N011635 003 Aug 26, 1987

DIUPRES-500

MERCK 500MG; 0.125MG N011635 006 Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS 12MG A084652 001

TACE

SANOFI AVENTIS US 12MG N008102 004

25MG N011444 001

72MG N016235 001

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB 2% N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PAMLAB LLC 400MG N014217 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE 8MG

N017369 001

12MG

N017369 002

INJECTABLE;INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH 10MG/ML

N008826 001

100MG/ML

N008794 001

CHLORPHENIRAMINE MALEATE

BEL MAR 10MG/ML

A080821 001

ELKINS SINN 10MG/ML

A080797 001

WATSON LABS 10MG/ML

A083593 001

10MG/ML

A086096 001

100MG/ML

A086095 001

PYRIDAMAL 100

BEL MAR 100MG/ML

A083733 001

SYRUP;ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML

N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML

A087520 001 Feb 10, 1982

TABLET;ORAL

ANTAGONATE

BAYER PHARMS 4MG

A083381 001

CHLOR-TRIMETON

SCHERING 4MG

N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG

A083078 001

AUROLIFE PHARMA LLC 4MG

A080961 001

BELL PHARMA 4MG

A083062 001

ELKINS SINN 4MG

A080938 001

IMPAX LABS 4MG

A080809 001

IVAX SUB TEVA PHARMS 4MG

A080779 001

KV PHARM 4MG

A087164 001

LEDERLE 4MG

A086941 001

NEWTRON PHARMS 4MG

A086519 001

PANRAY 4MG

A083243 001

PHARMAVITE 4MG

A085104 001

PHARMERAL 4MG

A083753 001

PIONEER PHARMS 4MG

A088556 001 Jul 13, 1984

PUREPAC PHARM 4MG

A086306 001

PVT FORM 4MG

A080786 001

ROXANE 4MG

A080626 001

SUN PHARM INDUSTRIES 4MG

A080700 001

VITARINE 4MG

A085837 001

WATSON LABS 4MG

A080696 001

4MG

A080791 001

4MG

A085139 001

4MG

A083787 001

KLOROMIN

HALSEY 4MG

A083629 001

PHENETRON

LANNETT 4MG

A080846 001

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC 8MG **

N007638 001

+ 12MG **

N007638 002

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG

N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

ACELLA 4MG/5ML;5MG/5ML

A206891 001 Jun 09, 2017

TRIS PHARMA INC 4MG/5ML;5MG/5ML

A206438 001 Jan 27, 2015

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

VITUZ

+	PERSION	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013
---	---------	-----------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657 001	Aug 03, 2015
------------------	--------------------------	-------------	--------------

TORRENT	4MG/5ML;5MG/5ML;60MG/5ML	A206660 001	May 15, 2017
---------	--------------------------	-------------	--------------

TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838 001	Nov 26, 2014
-----------------	--------------------------	-------------	--------------

ZUTRIPRO

+	PERSION	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011
---	---------	--------------------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

COLD CAPSULE IV

GRAHAM DM	12MG;75MG	N018793 001	Apr 25, 1985
-----------	-----------	-------------	--------------

COLD CAPSULE V

GRAHAM DM	8MG;75MG	N018794 001	Apr 23, 1985
-----------	----------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

TRIAMINIC-12

NOVARTIS	12MG;75MG	N018115 001	
----------	-----------	-------------	--

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA	12MG;120MG	N018935 001	Apr 15, 1985
----------------	------------	-------------	--------------

ISOCLOR

FISONS	8MG;120MG	N018747 001	Mar 06, 1986
--------	-----------	-------------	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG;120MG	N019428 001	Aug 02, 1988
-------------	-----------	-------------	--------------

GRAHAM DM	8MG;120MG	N018844 001	Mar 20, 1985
-----------	-----------	-------------	--------------

	12MG;120MG	N018843 001	Mar 18, 1985
--	------------	-------------	--------------

KV PHARM	12MG;120MG	A071455 001	Mar 01, 1989
----------	------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	8MG;120MG	N018397 001
---	----------------------	-----------	-------------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

CODEPREX

LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369 001	Jun 21, 2004
----------------	-------------------------------------	-------------	--------------

PENNTUSS

FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928 001	Aug 14, 1985
--------	-------------------------------------	-------------	--------------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUSSIONEX PENNKINETIC

+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111 001	Dec 31, 1987
---	---------	--	-------------	--------------

CHLORPHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PRE-SATE

PARKE DAVIS	EQ 65MG BASE	N014696 001	
-------------	--------------	-------------	--

CHLORPROMAZINE

SUPPOSITORY;RECTAL

THORAZINE

+	GLAXOSMITHKLINE	25MG **	N009149 024
---	-----------------	---------	-------------

+		100MG **	N009149 033
---	--	----------	-------------

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120 016	
-----------------	------	-------------	--

	75MG	N011120 017	
--	------	-------------	--

	150MG	N011120 018	
--	-------	-------------	--

	200MG	N011120 019	
--	-------	-------------	--

	300MG	N011120 020	
--	-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	
CHLORPROMAZINE HYDROCHLORIDE	INTENSOL			
HIKMA	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

FOSUN PHARMA	30MG/ML	A080983	004	
	100MG/ML	A080983	005	

THORAZINE

+	GLAXOSMITHKLINE	30MG/ML **	N009149	032
+		100MG/ML **	N009149	043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
DR REDDYS	25MG/ML	A080365	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

+	GLAXOSMITHKLINE	25MG/ML **	N009149	011
---	-----------------	------------	---------	-----

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001	
--------------------	----------	---------	-----	--

SONAZINE

FOSUN PHARMA	10MG/5ML	A083040	001	
--------------	----------	---------	-----	--

THORAZINE

+	GLAXOSMITHKLINE	10MG/5ML **	N009149	022
---	-----------------	-------------	---------	-----

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
CYCLE PHARMS LTD	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
SANDOZ	10MG **	A080439	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	25MG **	A080439 002	
	50MG **	A080439 003	
	100MG **	A080439 004	
	200MG **	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A088921 001	Apr 12, 1985
	100MG	A089446 001	Nov 17, 1986
	250MG	A087353 001	
	250MG	A088813 001	Oct 19, 1984
	250MG	A088826 001	Sep 26, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A088922 001	Apr 12, 1985
	250MG	A089447 001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
MYLAN	100MG	A088549 002	Jun 01, 1984
	250MG	A088549 001	Jun 01, 1984
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852 001	Sep 26, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORPROPAMIDE

TABLET; ORAL

DIABINESE

+ PFIZER

100MG

N011641 003

+

250MG

N011641 006

GLUCAMIDE

ANI PHARMS INC

250MG

A088641 001 Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE

100MG/5ML

N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE

12.5MG/ML

N012487 001

TABLET; ORAL

TARACTAN

ROCHE

10MG

N012486 005

25MG

N012486 004

50MG

N012486 003

100MG

N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE

1%

N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT

25MG

A087364 001

50MG

A087384 001

ACP NIMBLE

50MG

A088651 001 May 30, 1985

ANI PHARMS INC

25MG

A087296 001

25MG

A087706 001

25MG

A088164 001 Jan 09, 1984

50MG

A087689 001

ASCOT

25MG

A087698 001 Oct 20, 1982

50MG

A087699 001 Oct 20, 1982

BARR LABS INC

25MG

A088902 001 Sep 19, 1985

50MG

A088903 001 Sep 19, 1985

DAVA PHARMS INC

25MG

A087451 001

50MG

A087450 001

IVAX PHARMS

25MG

A087555 001

50MG

A087176 001

50MG

A087947 001 Feb 27, 1984

KV PHARM

25MG

A087311 001

50MG

A087312 001

MUTUAL PHARM

25MG

A087292 001

25MG

A089738 001 Sep 19, 1988

50MG

A087293 001

50MG

A089739 001 Sep 19, 1988

PIONEER PHARMS

50MG

A089591 001 Jul 21, 1988

PUREPAC PHARM

25MG

A088139 001 Jul 16, 1986

50MG

A088140 001 Aug 11, 1983

SANDOZ

25MG

A087380 001

50MG

A087118 001

50MG

A087381 001

SUPERPHARM

25MG

A087473 001 Feb 09, 1983

50MG

A087247 001 Feb 09, 1983

USL PHARMA

25MG

A089051 001 Jun 01, 1987

50MG

A089052 001 Jun 01, 1987

VANGARD

25MG

A088012 001 Jul 14, 1982

50MG

A088073 001 Mar 25, 1983

WARNER CHILCOTT

25MG

A087515 001 Jan 24, 1983

50MG

A087516 001 Feb 09, 1983

WATSON LABS

25MG

A087050 001

25MG

A087100 001

50MG

A087029 001

50MG

A087082 001

50MG

A087521 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHLORTHALIDONE

TABLET; ORAL

HYGROTON

+	SANOFI AVENTIS US	25MG **	N012283	004	
+		50MG **	N012283	003	

THALITONE

+	CASPER PHARMA LLC	15MG **	N019574	001	Dec 20, 1988
		25MG	N019574	002	Feb 12, 1992
	MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG; 0.1MG	A071179	001	Dec 16, 1987
	15MG; 0.2MG	A071178	001	Dec 16, 1987
	15MG; 0.3MG	A071142	001	Dec 16, 1987

CLORPRES

MYLAN	15MG; 0.1MG	A071325	003	Feb 09, 1987
	15MG; 0.2MG	A071325	002	Feb 09, 1987
	15MG; 0.3MG	A071325	001	Feb 09, 1987

COMBIPRES

+	BOEHRINGER INGELHEIM	15MG; 0.1MG **	N017503	001	
+		15MG; 0.2MG **	N017503	002	
+		15MG; 0.3MG **	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG; 100MG	N019451	001	Dec 31, 1987
	25MG; 200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG; 0.125MG	N015103	002	
-------------------	---------------	---------	-----	--

REGROTON

SANOFI AVENTIS US	50MG; 0.25MG	N015103	001	
-------------------	--------------	---------	-----	--

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
BARR	500MG	A089895	001	May 04, 1988
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
SUN PHARM INDUSTRIES	500MG	A089970	001	Sep 27, 1990
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A040137	001	Aug 09, 1996
	500MG	A081019	001	Jul 29, 1991
	500MG	A081040	001	Aug 22, 1989

PARAFLEX

+	ORTHO MCNEIL PHARM	250MG **	N011300	003	
---	--------------------	----------	---------	-----	--

PARAFON FORTE DSC

+	JANSSEN R AND D	500MG **	N011529	002	Jun 15, 1987
---	-----------------	----------	---------	-----	--------------

STRIFON FORTE DSC

FERNDAL LABS	500MG	A081008	001	Dec 23, 1988
--------------	-------	---------	-----	--------------

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771 001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771 002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347 002	May 28, 1998

CHOLESTYRAMINE LIGHT

TEVA	EQ 4GM RESIN/PACKET	A074348 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348 002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555 001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555 002	Sep 30, 1998

LOCHOLEST

SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561 002	Aug 15, 1996

LOCHOLEST LIGHT

INVATECH	EQ 4GM RESIN/PACKET	A074562 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562 002	Aug 15, 1996

QUESTRAN

+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640 001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640 003	

QUESTRAN LIGHT

+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669 001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669 003	Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403 002	Dec 27, 1999
	EQ 1GM RESIN	A073403 001	Apr 28, 1994

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013
	EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013
TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469 001	Jul 05, 2019
	EQ 135MG FENOFIBRIC ACID	A210469 002	Jul 05, 2019

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO	0.25MG/VIAL	N021149 001	Sep 20, 2000
------------	-------------	-------------	--------------

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271 001	May 05, 1987
---------------	------------------------	-------------	--------------

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

CURIUM	5mCi/ML	N017084 001	
--------	---------	-------------	--

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663 002	Aug 21, 1984
+	10,000 UNITS/VIAL **	N018663 001	Nov 10, 1982

DISCASE

ABBOTT	12,500 UNITS/VIAL	N018625 001	Jan 18, 1984
--------	-------------------	-------------	--------------

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND	750 UNITS/VIAL	N011837 001	
------------------	----------------	-------------	--

CATARASE

CIBA	300 UNITS/VIAL	N016938 001	
NOVARTIS	150 UNITS/VIAL	N018121 001	

ZOLYSE

ALCON	750 UNITS/VIAL	N011903 001	
-------	----------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007
TEVA PHARMS	8%	A078079	001	Sep 18, 2007

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

+ GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638	001	Jun 26, 1996
-----------------------	--------------------	---------	-----	--------------

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987
	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990
	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

HOSPIRA INC

	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011
	EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011
	EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011

PRIMAXIN

+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N050587	001	Nov 26, 1985
---------	--------------------------------	---------	-----	--------------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005
	100MG	A077022	001	Nov 23, 2004
IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MYLAN	50MG	A077323	002	Apr 20, 2006
	100MG	A077323	001	Apr 20, 2006
MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004
	100MG	A077019	002	Nov 23, 2004
PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
	100MG	A077898	002	Oct 29, 2007

PLETAL

+ OTSUKA	50MG **	N020863	001	Jan 15, 1999
----------	---------	---------	-----	--------------

+	100MG **	N020863	002	Jan 15, 1999
---	----------	---------	-----	--------------

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
-----------------	------------	---------	-----	--------------

TABLET; ORAL

CIMETIDINE

CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
	300MG	A074329	003	May 17, 1994
	400MG	A074329	004	May 17, 1994
	800MG	A074329	001	May 17, 1994
CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIMETIDINE

TABLET; ORAL

CIMETIDINE

PERRIGO	100MG	A074972 001	Jun 19, 1998
PLIVA	200MG	A074568 001	Feb 27, 1997
	300MG	A074568 002	Feb 27, 1997
	400MG	A074568 003	Feb 27, 1997
SANDOZ INC	100MG	A075122 001	Jun 19, 1998
	200MG	A074250 001	Jun 29, 1995
	200MG	A075122 002	Jun 19, 1998
	300MG	A074250 002	Jun 29, 1995
	400MG	A074250 003	Jun 29, 1995
	800MG	A074250 004	Jun 29, 1995
TEVA	200MG	A074365 001	Feb 28, 1995
	300MG	A074365 002	Feb 28, 1995
	400MG	A074365 003	Feb 28, 1995
	800MG	A074365 004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506 001	Jan 24, 1996
	300MG	A074506 002	Jan 24, 1996
	400MG	A074506 003	Jan 24, 1996
	800MG	A074506 004	Jan 24, 1996
WATSON LABS INC	200MG	A074349 001	Aug 30, 1996
	300MG	A074349 002	Aug 30, 1996
	400MG	A074349 003	Aug 30, 1996
	800MG	A074316 001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425 001	Jul 29, 1999
YAOPHARMA CO LTD	200MG	A074100 001	Jan 31, 1995
	300MG	A074100 002	Jan 31, 1995
	400MG	A074100 003	Jan 31, 1995
	800MG	A074100 004	Jan 31, 1995

TAGAMET

GLAXOSMITHKLINE	200MG **	N017920 002	
	300MG **	N017920 003	
	400MG **	N017920 004	Dec 14, 1983
	800MG **	N017920 005	Apr 30, 1986

TAGAMET HB

+ MEDTECH PRODUCTS	100MG **	N020238 001	Jun 19, 1995
--------------------	----------	-------------	--------------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939 002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434 001	Oct 31, 1985

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074610 001	Sep 26, 1996
	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
LANNETT CO INC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994
PHARM ASSOC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

TAGAMET

GLAXOSMITHKLINE EQ 300MG BASE/5ML ** N017924 001

CINOXACIN

CAPSULE; ORAL

CINOBAC

LILLY 250MG N018067 001
500MG N018067 002

CINOXACIN

TEVA 250MG A073005 001 Feb 28, 1992
500MG A073006 001 Feb 28, 1992CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPROFLOXACIN

LUPIN LTD 250MG/5ML A200563 001 Mar 05, 2014
500MG/5ML A200563 002 Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

+ BAYER HLTHCARE 400MG/40ML (10MG/ML) ** N019847 001 Dec 26, 1990
+ 200MG/20ML (10MG/ML) ** N019847 002 Dec 26, 1990
1200MG/120ML (10MG/ML) ** N019847 003 Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 200MG/100ML ** N019857 001 Dec 26, 1990
+ 400MG/200ML ** N019857 002 Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS 200MG/100ML N019858 001 Dec 26, 1990

CIPROFLOXACIN

BEDFORD LABS 200MG/20ML (10MG/ML) A076992 001 Aug 28, 2006
400MG/40ML (10MG/ML) A076992 002 Aug 28, 2006
1200MG/120ML (10MG/ML) A076993 001 Aug 28, 2006
DR REDDYS 200MG/20ML (10MG/ML) A077782 001 Aug 28, 2006
400MG/40ML (10MG/ML) A077782 002 Aug 28, 2006
FRESENIUS KABI USA 200MG/20ML (10MG/ML) A076484 001 Aug 28, 2006
400MG/40ML (10MG/ML) A076484 002 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA 200MG/100ML A076757 001 Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 200MG/100ML A077888 001 Mar 18, 2008
400MG/200ML A077888 002 Mar 18, 2008
BEDFORD 200MG/100ML A078114 001 Mar 18, 2008
400MG/200ML A078114 002 Mar 18, 2008
TEVA PHARMS 200MG/100ML A077138 001 Mar 18, 2008
400MG/200ML A077138 002 Mar 18, 2008CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AMRING PHARMS EQ 0.3% BASE A078598 001 Jan 16, 2008
RUBICON EQ 0.3% BASE A075928 001 Jun 09, 2004

TABLET; ORAL

CIPRO

+ BAYER HLTHCARE EQ 100MG BASE ** N019537 001 Apr 08, 1996
+ EQ 750MG BASE ** N019537 004 Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

ANI PHARMS INC EQ 100MG BASE A075939 001 Mar 03, 2005
EQ 250MG BASE A075939 002 Jun 09, 2004
EQ 500MG BASE A075939 003 Jun 09, 2004
EQ 750MG BASE A075939 004 Jun 09, 2004
BARR EQ 250MG BASE A074124 001 Jun 09, 2004
EQ 500MG BASE A074124 002 Jun 09, 2004
EQ 750MG BASE A074124 003 Jun 09, 2004
FOSUN PHARMA EQ 250MG BASE A076593 002 Jun 09, 2004
EQ 500MG BASE A076593 003 Jun 09, 2004
EQ 750MG BASE A076593 004 Jun 09, 2004
MYLAN EQ 100MG BASE A075817 001 Jun 25, 2007
EQ 250MG BASE A075685 002 Jun 09, 2004
EQ 250MG BASE A075817 002 Jun 09, 2004
EQ 500MG BASE A075685 003 Jun 09, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

	EQ 750MG BASE	A075685 001	Jun 09, 2004
	EQ 750MG BASE	A075817 004	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138 001	Jun 09, 2004
	EQ 500MG BASE	A076138 002	Jun 09, 2004
	EQ 750MG BASE	A076138 003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005
	EQ 250MG BASE	A076426 002	Jun 15, 2005
	EQ 500MG BASE	A076426 003	Jun 15, 2005
	EQ 750MG BASE	A076426 004	Jun 15, 2005
SUN PHARM INDS LTD	EQ 250MG BASE	A075747 001	Jun 09, 2004
	EQ 500MG BASE	A075747 002	Jun 09, 2004
	EQ 750MG BASE	A075747 003	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136 001	Jun 09, 2004
	EQ 500MG BASE	A076136 002	Jun 09, 2004
	EQ 750MG BASE	A076136 003	Jun 09, 2004

TABLET, EXTENDED RELEASE;ORAL

PROQUIN XR

DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005
-------------	---------------	-------------	--------------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPRO XR

BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473 001	Dec 13, 2002
	425.2MG;EQ 574.9MG BASE **	N021473 002	Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417 001	Nov 30, 2010
	425.2MG;EQ 574.9MG BASE	A077809 001	Nov 30, 2010
DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007
FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712 001	Dec 11, 2007
MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183 001	Mar 22, 2007
	425.2MG;EQ 574.9MG BASE	A078183 002	Mar 22, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL

PROPULSID

JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
----------------	----------------	-------------	--------------

TABLET;ORAL

PROPULSID

JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
	EQ 20MG BASE	N020210 002	Dec 23, 1993

TABLET, ORALLY DISINTEGRATING;ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997
----------------	--------------	-------------	--------------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873 001	Jun 16, 2017
HOSPIRA INC	EQ 2MG BASE/ML	A203238 001	Mar 30, 2018

CISATRACURIUM BESYLATE PRESERVATIVE FREE

ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872 001	Jun 16, 2017
	EQ 10MG BASE/ML	A205872 002	Jun 16, 2017

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

BEDFORD	10MG/VIAL	A074713 001	Nov 14, 2000
	50MG/VIAL	A074713 002	Nov 14, 2000
MYLAN LABS LTD	1MG/ML	A091062 001	Apr 18, 2012
TEVA PHARMS USA	1MG/ML	A074814 001	May 16, 2000

PLATINOL

+ HQ SPCLT PHARMA	10MG/VIAL	N018057 001	
+	50MG/VIAL	N018057 002	

PLATINOL-AQ

+ HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984
-------------------	----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION; ORAL

CELEXA

+ FOREST LABS

EQ 10MG BASE/5ML **

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

PHARM ASSOC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET; ORAL

CELEXA

ALLERGAN

EQ 60MG BASE

N020822 004 Jul 17, 1998

CITALOPRAM HYDROBROMIDE

EPIC PHARMA LLC

EQ 10MG BASE

A077036 001 Oct 28, 2004

EQ 20MG BASE

A077036 002 Oct 28, 2004

EQ 40MG BASE

A077036 003 Oct 28, 2004

FOSUN PHARMA

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

HERITAGE PHARMA

EQ 10MG BASE

A077033 001 Oct 28, 2004

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 10MG BASE

A077232 001 Oct 31, 2005

EQ 20MG BASE

A077033 002 Oct 28, 2004

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 20MG BASE

A077232 002 Oct 31, 2005

EQ 40MG BASE

A077033 003 Oct 28, 2004

EQ 40MG BASE

A077034 003 Jun 30, 2005

EQ 40MG BASE

A077213 003 Mar 31, 2006

EQ 40MG BASE

A077232 003 Oct 31, 2005

MYLAN

EQ 10MG BASE

A077039 001 Feb 03, 2005

EQ 20MG BASE

A077039 002 Feb 03, 2005

EQ 40MG BASE

A077039 003 Feb 03, 2005

MYLAN PHARMS INC

EQ 10MG BASE

A077037 001 Nov 05, 2004

EQ 20MG BASE

A077037 002 Nov 05, 2004

EQ 40MG BASE

A077037 003 Nov 05, 2004

NATCO PHARMA LTD

EQ 20MG BASE

A077141 002 Apr 10, 2008

EQ 40MG BASE

A077141 001 Apr 10, 2008

ROXANE

EQ 10MG BASE

A077041 001 Nov 23, 2004

EQ 20MG BASE

A077041 002 Nov 23, 2004

EQ 40MG BASE

A077041 003 Nov 23, 2004

SUN PHARM INDS INC

EQ 10MG BASE

A077032 001 Nov 12, 2004

EQ 20MG BASE

A077032 002 Nov 12, 2004

EQ 40MG BASE

A077032 003 Nov 12, 2004

SUN PHARM INDUSTRIES

EQ 10MG BASE

A077052 001 Jul 03, 2006

EQ 20MG BASE

A077052 002 Jul 03, 2006

EQ 40MG BASE

A077052 003 Jul 03, 2006

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018904 001 May 27, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+ FERRING PHARMS INC 12GM/PACKET;3.5GM/PACKET;10MG/PACKET N202535 001 Jul 16, 2012

CLADRIBINE

INJECTABLE;INJECTION

LEUSTATIN

+ JANSSEN PHARMS 1MG/ML ** N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

+ ABBVIE 125MG/5ML N050698 001 Dec 23, 1993

187MG/5ML N050698 003 Sep 30, 1998

+ 250MG/5ML N050698 002 Dec 23, 1993

CLARITHROMYCIN

SUN PHARM INDS LTD 125MG/5ML A065382 001 Aug 30, 2007

250MG/5ML A065382 002 Aug 30, 2007

TABLET;ORAL

BIAXIN

+ ABBVIE 250MG ** N050662 001 Oct 31, 1991

+ 500MG ** N050662 002 Oct 31, 1991

CLARITHROMYCIN

AJANTA PHARMA LTD 250MG A206714 001 Apr 25, 2019

500MG A206714 002 Apr 25, 2019

IVAX SUB TEVA PHARMS 250MG A065137 001 May 31, 2005

500MG A065137 002 May 31, 2005

MYLAN 250MG A065195 001 Mar 11, 2005

500MG A065195 002 Mar 11, 2005

SUN PHARM INDS LTD 250MG A065174 001 Sep 24, 2004

500MG A065174 002 Sep 24, 2004

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

+ ABBVIE 500MG ** N050775 001 Mar 03, 2000

CLARITHROMYCIN

ANI PHARMS INC 500MG A065250 001 Aug 25, 2005

LUPIN LTD 500MG A202532 001 Sep 15, 2015

RANBAXY 1GM A065210 001 Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL A062691 001 Dec 19, 1986

EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL N050590 001 Apr 01, 1985

EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL N050590 002 Apr 01, 1985

EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL N050590 003 Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE EQ 100MG BASE/100ML;EQ 3GM BASE/100ML N050658 001 Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML A074075 001 Oct 31, 1993

APOTEX INC EQ 0.5MG BASE/5ML A075703 001 Nov 27, 2000

LANNETT CO INC EQ 0.5MG BASE/5ML A074884 001 Dec 17, 1997

TEVA PHARMS EQ 0.5MG BASE/5ML A073095 001 Apr 21, 1992

WOCKHARDT BIO AG EQ 0.5MG BASE/5ML A074863 001 Mar 13, 1998

TAVIST

+ NOVARTIS EQ 0.5MG BASE/5ML ** N018675 001 Jun 28, 1985

TABLET;ORAL

CLEMASTINE FUMARATE

ANI PHARMS INC 1.34MG A073282 001 Jan 31, 1992

1.34MG A073282 002 Dec 03, 1992

PLD ACQUISITIONS LLC 1.34MG A073458 001 Oct 31, 1993

SANDOZ 2.68MG A073459 001 Oct 31, 1993

TAVIST

+ NOVARTIS 2.68MG N017661 001

TAVIST-1

+ GLAXOSMITHKLINE CONS 1.34MG N020925 001 Aug 21, 1992

NOVARTIS 1.34MG N017661 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLEMASTINE FUMARATETABLET; ORAL
TAVIST-1

1.34MG

N017661 003 Aug 21, 1992

CLEVIDIPINEEMULSION; INTRAVENOUS
CLEVIPREX

+ CHIESI USA INC

125MG/250ML (0.5MG/ML)

N022156 003 Nov 08, 2013

CLIDINIUM BROMIDECAPSULE; ORAL
QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

MYLAN PHARMS INC

EQ 75MG BASE

A091225 001 May 31, 2011

EQ 150MG BASE

A091225 002 May 31, 2011

EQ 300MG BASE

A091225 003 May 31, 2011

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE/5ML **

A061827 001

CLINDAMYCIN PALMITATE HYDROCHLORIDE

MYLAN

EQ 75MG BASE/5ML

A203063 001 May 25, 2016

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN

EQ 150MG BASE/ML

A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

LOCH

EQ 150MG BASE/ML

A062905 001 May 09, 1988

MARSAM PHARMS LLC

EQ 150MG BASE/ML

A062913 001 Oct 20, 1988

SOLOPAK

EQ 150MG BASE/ML

A062819 001 Mar 15, 1988

EQ 150MG BASE/ML

A062852 001 Mar 17, 1988

TEVA PARENTERAL

EQ 150MG BASE/ML

A063041 001 Dec 29, 1989

EQ 150MG BASE/ML

A063282 001 May 29, 1992

WATSON LABS

EQ 150MG BASE/ML

A062900 001 Jun 08, 1988

EQ 150MG BASE/ML

A063079 001 Mar 05, 1990

WEST-WARD PHARMS INT

EQ 150MG BASE/ML

A062806 001 Oct 15, 1987

EQ 150MG BASE/ML

A062953 001 Apr 21, 1988

EQ 150MG BASE/ML

A063068 001 Aug 28, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM

EQ 12MG BASE/ML

N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT LABS

EQ 6MG BASE/ML

A065027 001 Jun 29, 2001

EQ 12MG BASE/ML

A065027 002 Jun 29, 2001

EQ 18MG BASE/ML

A065027 003 Jun 29, 2001

BAXTER HLTHCARE

EQ 6MG BASE/ML

N050648 001 Dec 29, 1989

EQ 12MG BASE/ML

N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML

N050648 003 Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN

EQ 1% BASE

A062363 001 Feb 08, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC	EQ 1% BASE	A062944 001	Jan 11, 1989
NOVAST LABS	EQ 1% BASE	A064108 001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930 001	Jun 28, 1989
WOCKHARDT BIO AG	EQ 1% BASE	A063304 001	Jul 15, 1997

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235 001	
--------------	--------------------------	-------------	--

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

TARO	2.5MG/ML	A210978 001	Apr 15, 2019
------	----------	-------------	--------------

TABLET; ORAL

CLOBAZAM

ACCORD HLTHCARE	10MG	A212398 001	May 23, 2019
	20MG	A212398 002	May 23, 2019
TARO	10MG	A209440 001	Oct 22, 2018
	20MG	A209440 002	Oct 22, 2018

ONFI

LUNDBECK PHARMS LLC	5MG **	N202067 001	Oct 21, 2011
---------------------	--------	-------------	--------------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

TEVA PHARMS USA	0.05%	A074087 001	Feb 16, 1994
-----------------	-------	-------------	--------------

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019322 001	Dec 27, 1985
------------------	----------	-------------	--------------

TEMOVATE E

+ FOUGERA PHARMS	0.05% **	N020340 001	Jun 17, 1994
------------------	----------	-------------	--------------

GEL; TOPICAL

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N020337 001	Apr 29, 1994
------------------	----------	-------------	--------------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

HI TECH	0.05%	A211348 001	Oct 26, 2018
---------	-------	-------------	--------------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128 001	Aug 03, 1994
----------------------	-------	-------------	--------------

AMNEAL PHARMS LLC	0.05%	A210551 001	Aug 21, 2018
-------------------	-------	-------------	--------------

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019323 001	Dec 27, 1985
------------------	----------	-------------	--------------

SOLUTION; TOPICAL

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019966 001	Feb 22, 1990
------------------	----------	-------------	--------------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

APOTEX	0.05%	A210446 001	Apr 17, 2018
--------	-------	-------------	--------------

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

HOSPIRA INC	20MG/20ML (1MG/ML)	A210283 001	Dec 27, 2018
-------------	--------------------	-------------	--------------

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS	50MG	N019500 002	Dec 15, 1986
------------	------	-------------	--------------

	100MG	N019500 001	Dec 15, 1986
--	-------	-------------	--------------

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST	500MG	N016099 002	
--------------	-------	-------------	--

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396 001	Mar 20, 1992
-------------------	-------	-------------	--------------

SANDOZ	500MG	A072191 001	May 02, 1988
--------	-------	-------------	--------------

TEVA	500MG	A072600 001	Jul 25, 1991
------	-------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

+ SANOFI AVENTIS US	50MG	N016131	002	
MILOPHENE				
MILEX	50MG	A072196	001	Dec 20, 1988
SEROPHENE				
EMD SERONO	50MG	N018361	001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019
	50MG	A211767	002	Apr 08, 2019
	75MG	A211767	003	Apr 08, 2019
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996
	75MG	A074751	003	Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997
	1MG	A074940	002	Oct 30, 1997
	2MG	A074940	003	Oct 30, 1997
RUBICON	0.5MG	A075468	001	Oct 06, 2000
	1MG	A075468	002	Oct 06, 2000
	2MG	A075468	003	Oct 06, 2000
SANDOZ	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001
	1MG	A075423	002	Apr 27, 2001
	2MG	A075423	003	Apr 27, 2001
TEVA	0.5MG	A074920	001	Aug 04, 1998
	1MG	A074920	002	Aug 04, 1998
	2MG	A074920	003	Aug 04, 1998
KLONOPIN				
ROCHE	0.125MG	N017533	005	Apr 09, 1997
	0.25MG	N017533	006	Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

+ ROCHE	0.125MG **	N020813	001	Dec 23, 1997
+	0.25MG **	N020813	002	Dec 23, 1997
+	0.5MG **	N020813	003	Dec 23, 1997
+	1MG **	N020813	004	Dec 23, 1997
+	2MG **	N020813	005	Dec 23, 1997

CLONIDINE

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009
-----------------	-------------------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

LUITPOLD

1MG/10ML (0.1MG/ML)

A091104 001 Oct 08, 2009

5MG/10ML (0.5MG/ML)

A091104 002 Oct 08, 2009

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

AUROLIFE PHARMA LLC

0.1MG

A070886 002 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A070886 003 Aug 31, 1988

CHARTWELL MOLECULES

0.1MG

A071785 002 Apr 05, 1988

0.2MG

A071785 003 Apr 05, 1988

0.3MG

A071785 001 Apr 05, 1988

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

SUN PHARM INDS INC

0.1MG

A090329 001 Jul 03, 2014

0.2MG

A090329 002 Jul 03, 2014

0.3MG

A090329 003 Jul 03, 2014

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

WARNER CHILCOTT

0.1MG

A072138 001 Jun 13, 1988

0.2MG

A072139 001 Jun 13, 1988

0.3MG

A072140 001 Jun 13, 1988

WATSON LABS

0.1MG

A070395 001 Mar 23, 1987

0.1MG

A070965 001 Jul 08, 1986

0.2MG

A070396 001 Mar 23, 1987

0.2MG

A070964 001 Jul 08, 1986

0.3MG

A070397 001 Mar 23, 1987

0.3MG

A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

0.2MG

A202792 002 May 15, 2015

0.2MG

A203320 002 May 15, 2015

ANCHEN PHARMS

0.1MG

A202983 001 Apr 02, 2014

0.2MG

A202983 002 Apr 02, 2014

0.2MG

A202984 002 Sep 30, 2013

UPSHER SMITH LABS

0.1MG

A211433 001 Oct 12, 2018

JENLOGA

+ CONCORDIA PHARMS INC

0.1MG **

N022331 001 Sep 30, 2009

+

0.2MG **

N022331 002 May 25, 2010

KAPVAY

+ CONCORDIA PHARMS INC

0.2MG **

N022331 004 Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA

EQ 75MG BASE

A090307 001 May 28, 2013

ANI PHARMS INC

EQ 300MG BASE

A090625 001 May 17, 2012

EQ 300MG BASE

A091216 001 May 17, 2012

CADILA

EQ 75MG BASE

A201686 001 Oct 10, 2012

MYLAN PHARMS INC

EQ 75MG BASE

A077665 001 May 17, 2012

EQ 300MG BASE

A077665 002 May 17, 2012

SUN PHARM INDUSTRIES

EQ 75MG BASE

A078133 001 Jun 10, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017
	7.5MG	A072112	003	Aug 11, 2017
	15MG	A072112	001	Aug 26, 1988
DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
RECORDATI RARE	3.75MG **	N017105	001	
	7.5MG **	N017105	002	
	15MG **	N017105	003	

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990
	7.5MG	A072514	003	May 11, 1990
	15MG	A072514	001	May 11, 1990
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
	7.5MG	A076911	002	Sep 29, 2004
	15MG	A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

TRANXENE

RECORDATI RARE 3.75MG ** N017105 006

+ 15MG ** N017105 008

TRANXENE SD

RECORDATI RARE 11.25MG ** N017105 005

22.5MG ** N017105 004

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

SCHERING PLOUGH 1% ** N017619 001

MYCELEX

BAYER HEALTHCARE LLC 1% N018183 001

CREAM; VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 1% ** N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 2% N020574 001 Nov 24, 1998

MYCELEX-7

BAYER HEALTHCARE LLC 1% N018230 002 Dec 26, 1991

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%, 200MG N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%, 100MG N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE LLC 1%, 100MG N020389 002 Jun 23, 1994

LOTION; TOPICAL

LOTRIMIN

SCHERING 1% N018813 001 Feb 17, 1984

SOLUTION; TOPICAL

LOTRIMIN

+ SCHERING PLOUGH 1% ** N017613 001

MYCELEX

+ BAYER HLTHCARE 1% ** N018181 001

TABLET; VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG N020525 001 Jul 29, 1996

GYNIX

TEVA PHARMS 100MG A073249 001 Feb 13, 1998

MYCELEX-7

BAYER HEALTHCARE LLC 100MG N018182 002 Dec 26, 1991

MYCELEX-G

BAYER PHARMS 500MG N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

+ BAYER HLTHCARE 10MG ** N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON EQ 250MG BASE A061452 001

EQ 500MG BASE A061452 002

TEVA EQ 250MG BASE A062240 001

EQ 500MG BASE A062240 002

CLOXAPEN

GLAXOSMITHKLINE EQ 250MG BASE A061806 001

EQ 250MG BASE A062233 001

EQ 500MG BASE A061806 002

EQ 500MG BASE A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA EQ 125MG BASE/5ML A062268 001

EQ 125MG BASE/5ML A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON EQ 125MG BASE/5ML A061453 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CLOXACILLIN SODIUMFOR SOLUTION;ORAL
TEGOPEN

EQ 125MG BASE/5ML N050192 001

CLOZAPINETABLET;ORAL
CLOZAPINE

MYLAN	12.5MG	A075417 003	Apr 15, 2010
PAR PHARM	25MG	A075162 001	Apr 26, 2005
	100MG	A075162 002	Apr 26, 2005
SANDOZ	25MG	A074546 001	Aug 30, 1996
	100MG	A074546 002	Aug 30, 1996
ZYDUS PHARMS	25MG	A209480 001	Dec 06, 2017
	50MG	A209480 002	Dec 06, 2017
	100MG	A209480 003	Dec 06, 2017
	200MG	A209480 004	Dec 06, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

+ JAZZ	12.5MG	N021590 004	May 30, 2007
+	25MG	N021590 001	Feb 10, 2004
	50MG	N021590 003	Jun 03, 2005
+	100MG	N021590 002	Feb 10, 2004
+	150MG	N021590 005	Jul 09, 2010
+	200MG	N021590 006	Jul 09, 2010

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-57 KIT

BRACCO N/A;N/A;N/A;N/A N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-60 KIT

BRACCO N/A;N/A;N/A;N/A N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

+ ANI PHARMS 10MG/5ML;5MG/5ML;6.25MG/5ML ** N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY 10MG/5ML;5MG/5ML;6.25MG/5ML A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI 10MG/5ML;5MG/5ML;6.25MG/5ML A088816 001 Nov 22, 1985

WOCKHARDT 10MG/5ML;5MG/5ML;6.25MG/5ML A088896 001 Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

+ ANI PHARMS 10MG/5ML;6.25MG/5ML ** N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY 10MG/5ML;6.25MG/5ML A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC 10MG/5ML;6.25MG/5ML A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI 10MG/5ML;6.25MG/5ML A088814 001 Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE 10MG/5ML;30MG/5ML;1.25MG/5ML N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI 10MG/5ML;30MG/5ML;1.25MG/5ML A089018 001 Jul 23, 1986

TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT 10MG/5ML;30MG/5ML;1.25MG/5ML A088833 001 Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

HIKMA 30MG/5ML N202245 001 Jun 30, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

COLCHICINE

CAPSULE; ORAL

COLCHICINE

PAR PHARM INC

0.6MG

A208678 001 Nov 29, 2018

TABLET; ORAL

COLCHICINE

AMNEAL PHARMS

0.6MG

A204711 001 Sep 28, 2016

ZYDUS PHARMS

0.6MG

A211519 001 Feb 19, 2019

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID

+ MERCK

0.5MG; 500MG **

N012383 001

PROBEN-C

WATSON LABS

0.5MG; 500MG

A085552 001

PROBENECID AND COLCHICINE

ANI PHARMS INC

0.5MG; 500MG

A083734 001

BEECHAM

0.5MG; 500MG

A084321 001

IMPAX LABS

0.5MG; 500MG

A083720 002

SANDOZ

0.5MG; 500MG

A086130 001

PROBENECID W/ COLCHICINE

LEDERLE

0.5MG; 500MG

A086954 001

WATSON LABS

0.5MG; 500MG

A083221 001

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

DAIICHI SANKYO

375MG

N021141 001 May 26, 2000

FOR SUSPENSION; ORAL

WELCHOL

+ DAIICHI SANKYO

1.875GM/PACKET

N022362 001 Oct 02, 2009

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S

PARKE DAVIS

EQ 25MG BASE/5ML

N050355 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL

CUMBERLAND PHARMS

20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7

GD SEARLE LLC

89MG

N017408 001

TATUM-T

GD SEARLE LLC

120MG

N018205 001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE

25 UNITS/VIAL

N008317 002

40 UNITS/VIAL

N008317 004

ACTHAR

SANOFI AVENTIS US

25 UNITS/VIAL

N007504 002

40 UNITS/VIAL

N007504 003

CORTICOTROPIN

ORGANICS LAGRANGE

40 UNITS/ML

N010831 001

80 UNITS/ML

N010831 002

WATSON LABS

40 UNITS/VIAL

A088772 001 Nov 21, 1984

H.P. ACTHAR GEL

MALLINCKRODT ARD

40 UNITS/ML

N008372 006

PURIFIED CORTROPHIN GEL

ANI PHARMS INC

40 UNITS/ML

N008975 001

80 UNITS/ML

N008975 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ANI PHARMS INC 40 UNITS/ML N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN 25MG/ML N008126 002

WATSON LABS 25MG/ML A083147 003

25MG/ML A085677 001

50MG/ML A083147 004

50MG/ML A085677 002

CORTONE

MERCK 25MG/ML N007110 002

50MG/ML N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR 25MG A083471 001

ELKINS SINN 25MG A080836 001

EVERYLIFE 25MG A084246 001

HEATHER 25MG A085736 001

IMPAX LABS 25MG N009458 001

INWOOD LABS 25MG A080731 001

IVAX SUB TEVA PHARMS 25MG A080630 001

25MG A083536 001

LANNETT 25MG A080694 001

PANRAY 5MG N008284 002

25MG N008284 001

PHARMACIA AND UPJOHN 5MG N008126 003

10MG N008126 004

25MG N008126 001

PUREPAC PHARM 25MG A080493 001

VITARINE 25MG A080333 001

WATSON LABS 25MG A085884 001

WHITEWORTH TOWN PLSN 25MG A080341 001

CORTONE

+ MERCK 25MG ** N007750 003

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ INC 0.25MG/ML (0.25MG/ML) N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PHARMS LLC 0.8MG/INH N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

+ SANOFI AVENTIS US 20MG ** N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC 100MG N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 10MG/ML A075067 001 Jul 19, 1999

BAUSCH AND LOMB 10MG/ML A075585 001 Dec 21, 2000

FERA PHARMS LLC 10MG/ML A075437 001 Apr 21, 2000

HIKMA 10MG/ML A075333 001 Apr 30, 2002

MYLAN SPECIALITY LP 10MG/ML A074209 001 Apr 26, 1994

ROXANE 10MG/ML A075175 001 Sep 30, 1999

WATSON LABS 10MG/ML A076469 001 Jun 17, 2005

INTAL

+ KING PHARMS LLC 10MG/ML ** N018596 001 May 28, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CROMOLYN SODIUM

SOLUTION/DROPS;OPHTHALMIC

CROLOM					
BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995	
CROMOLYN SODIUM					
APOTEX INC	4%	A075615	001	Jan 26, 2001	
CROMOPTIC					
KING PHARMS	4%	A075088	001	Apr 27, 1999	
OPTICROM					
+ ALLERGAN	4% **	N018155	001	Oct 03, 1984	
SPRAY, METERED;NASAL					
CROMOLYN SODIUM					
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001	
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007	
NASALCROM					
+ BLACKSMITH BRANDS	5.2MG/SPRAY **	N020463	001	Jan 03, 1997	

CROTAMITON

CREAM;TOPICAL

EURAX					
+ SUN PHARM INDS INC	10%	N006927	001		

CRYPTENAMINE ACETATES

INJECTABLE;INJECTION

UNITENSEN					
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001		

CRYPTENAMINE TANNATES

TABLET;ORAL

UNITENSEN					
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001		

CUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE					
ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987	

CYANOCOBALAMIN

GEL, METERED;NASAL

NASCOBAL					
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996	

INJECTABLE;INJECTION

BERUBIGEN					
PHARMACIA AND UPJOHN	1MG/ML	N006798	001		
BETALIN 12					
LILLY	0.1MG/ML	A080855	001		
	1MG/ML	A080855	002		
COBAVITE					
WATSON LABS	0.1MG/ML	A083013	001		
	1MG/ML	A083064	001		
CYANOCOBALAMIN					
ABRAXIS PHARM	0.03MG/ML	A080510	003		
	0.1MG/ML	A080510	001		
	1MG/ML	A080510	002		
AKORN	1MG/ML	A087969	001	Nov 10, 1983	
DELL LABS	0.03MG/ML	A080689	001		
	0.1MG/ML	A080689	002		
	1MG/ML	A080689	003		
DR REDDYS	0.1MG/ML	A080573	002		
	1MG/ML	A080573	001		
FRESENIUS KABI USA	0.1MG/ML	A080557	002		
LUITPOLD	0.03MG/ML	A080668	001		
LYPHOMED	1MG/ML	A083075	001		
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003	
SANOFI AVENTIS US	1MG/ML	A080564	001		
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984	
WARNER CHILCOTT	1MG/ML	N007085	002		
WATSON LABS	0.1MG/ML	A083120	001		
	1MG/ML	A083120	002		
WYETH AYERST	0.1MG/ML	A080554	001		
	1MG/ML	A080554	002		

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYANOCOBALAMIN

INJECTABLE; INJECTION

DODEX				
ACCORD HLTHCARE	1MG/ML		A083022	001
REDISOL				
MERCK	1MG/ML		N006668	010
RUBIVITE				
BEL MAR	0.03MG/ML		N010791	004
	0.05MG/ML		N010791	001
	0.1MG/ML		N010791	002
	0.12MG/ML		N010791	005
	1MG/ML		N010791	003
RUBRAMIN PC				
BRISTOL MYERS SQUIBB	0.1MG/ML		N006799	002
+	1MG/ML **		N006799	004
+	1MG/ML **		N006799	010
RUVITE				
SAVAGE LABS	1MG/ML		A080570	002
VI-TWEL				
BAYER HLTHCARE	1MG/ML		N007012	002
SPRAY, METERED; NASAL				
CALOMIST				
PAR PHARM	25MCG/SPRAY		N022102	001
				Jul 27, 2007
TABLET; ORAL				
CYANOCOBALAMIN				
WEST WARD	1MG		A084264	001

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57				
BRACCO	0.5-1uCi		N016089	002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60				
BRACCO	0.5-1uCi		N016090	002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT				
GE HEALTHCARE	N/A; N/A; N/A		N017406	001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT				
MALLINCKRODT	0.1MG; 0.5uCi; 60MG		N016635	001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR				
ARMOUR PHARM	0.5MG/ML; 2.3MG/ML; 1MG/ML		N011208	001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W				
WYETH AYERST	125MG/5ML		N050508	001
	250MG/5ML		N050508	002
	500MG/5ML		N050508	003

TABLET; ORAL

CYCLACILLIN				
TEVA	250MG		A062895	001
	500MG		A062895	002
				Aug 04, 1988
CYCLAPEN-W				
WYETH AYERST	250MG		N050509	001
	500MG		N050509	002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE				
GLAXOSMITHKLINE	50MG/ML		N009495	001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ	10MG	A073683	001	Feb 26, 1993
UPSHER SMITH LABS	5MG	A072854	002	Feb 03, 2006
	10MG	A072854	001	Nov 19, 1991
WATSON LABS	10MG	A073143	001	Nov 27, 1991
	10MG	A074436	001	Nov 30, 1994

FLEXERIL

+	JANSSEN RES AND DEV	5MG **	N017821	001
+		10MG **	N017821	002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN	1%	A085555	001	
-------	----	---------	-----	--

AKPENTOLATE

AKORN	2%	A040165	001	Jan 13, 1997
-------	----	---------	-----	--------------

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	

PENTOLAIR

PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986

CYTOXAN

+	BAXTER HLTHCARE	100MG/VIAL **	N012142	001
+		200MG/VIAL **	N012142	002

CYTOXAN (LYOPHILIZED)

+	BAXTER HLTHCARE	500MG/VIAL	N012142	003
+		500MG/VIAL **	N012142	008
+		1GM/VIAL	N012142	004
+		1GM/VIAL **	N012142	010
+		2GM/VIAL	N012142	005
+		2GM/VIAL **	N012142	009

LYOPHILIZED CYTOXAN

+	BAXTER HLTHCARE	100MG/VIAL **	N012142	006
+		200MG/VIAL **	N012142	007

NEOSAR

BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A087442	005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	200MG/VIAL	A040015	002	Apr 29, 1993
	500MG/VIAL	A040015	003	Apr 29, 1993
	1GM/VIAL	A040015	004	Apr 29, 1993
	2GM/VIAL	A040015	005	Apr 29, 1993

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE	25MG	A040032	001	Aug 17, 1999
	50MG	A040032	002	Aug 17, 1999

CYTOXAN

+	BAXTER HLTHCARE	25MG **	N012141	002
+		50MG **	N012141	001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYCLOSPORINE

CAPSULE; ORAL

GENGRAF

ABBVIE

50MG

A065003 002 May 12, 2000

NEORAL

+ NOVARTIS

50MG **

N050715 003 Jul 14, 1995

SOLUTION; ORAL

CYCLOSPORINE

PHARM ASSOC

100MG/ML

A065167 001 Jan 05, 2005

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY

2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN

2MG

N018173 001

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY

1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

2MG/5ML **

A086833 001

HALSEY

2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE

2MG/5ML

A087001 001 Nov 04, 1982

NASKA

2MG/5ML

A089021 001 Dec 21, 1987

PERIACTIN

+ MERCK

2MG/5ML **

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

CHARTWELL RX

4MG

A088212 001 May 26, 1983

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

FOSUN PHARMA

4MG

A086808 001

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

SUPERPHARM

4MG

A087405 001

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

+ MERCK

4MG **

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

+ HOSPIRA

7.25% **

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

MYLAN LABS LTD

20MG/ML

A200916 001 Dec 13, 2011

+ TEVA PARENTERAL

100MG/VIAL **

N016793 001

+

500MG/VIAL **

N016793 002

+

1GM/VIAL **

N016793 003 Dec 21, 1987

+

2GM/VIAL **

N016793 004 Dec 21, 1987

CYTOSAR-U

TEVA PHARMS USA

100MG/VIAL

A075206 001 Dec 30, 1998

500MG/VIAL

A075206 002 Dec 30, 1998

1GM/VIAL

A075206 004 Dec 30, 1998

2GM/VIAL

A075206 003 Dec 30, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+ PACIRA PHARMS INC 10MG/ML N021041 001 Apr 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM 100MG/VIAL A070962 001 Aug 28, 1986

200MG/VIAL A070990 001 Aug 28, 1986

DTIC-DOME

+ BAYER HLTHCARE 100MG/VIAL ** N017575 001

+ 200MG/VIAL ** N017575 002

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+ BRISTOL-MYERS SQUIBB EQ 30MG BASE N206843 001 Jul 24, 2015

+ EQ 60MG BASE N206843 002 Jul 24, 2015

+ EQ 90MG BASE N206843 003 Apr 13, 2016

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AM REGENT 0.5MG/VIAL A202562 001 Aug 23, 2013

WEST-WARD PHARMS INT 0.5MG/VIAL A090304 001 Mar 16, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

KING PHARMS 420MG/VIAL; 180MG/VIAL N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER INC 7,500 IU/0.75ML N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC 10,000IU/0.4ML (25,000IU/ML) N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML) N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC 750 UNITS/0.6ML N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP 200MG A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US 50MG ** N017557 003

100MG ** N017557 004

200MG ** N017557 002

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

MYLAN INSTITUTIONAL 20MG/VIAL A205239 001 Feb 18, 2016

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

BARADAINA LLC 0.5% A204902 001 May 30, 2019

+ FERA PHARMS 0.5% ** N019849 001 Dec 31, 1990

DAPSONE

GEL; TOPICAL

DAPSONE

TARO PHARMS 7.5% A210191 001 Jun 26, 2019

TABLET; ORAL

DAPSONE

TARO 25MG A209430 001 Mar 01, 2019

100MG A209430 002 Mar 01, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

CUBIST PHARMS LLC 250MG/VIAL N021572 001 Sep 12, 2003

DARUNAVIRTABLET; ORAL
PREZISTA

+ JANSSEN PRODS 300MG ** N021976 001 Jun 23, 2006

+ 400MG ** N021976 003 Oct 21, 2008

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016

DASATINIBTABLET; ORAL
DASATINIB

APOTEX INC 20MG A202103 001 Jun 10, 2016

50MG A202103 002 Jun 10, 2016

70MG A202103 003 Jun 10, 2016

100MG A202103 004 Jun 10, 2016

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

SANOFI AVENTIS US EQ 20MG BASE/VIAL A061876 001

WYETH AYERST EQ 20MG BASE/VIAL ** N050484 001

DAUNORUBICIN HYDROCHLORIDE

HISUN PHARM HANGZHOU EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019

TEVA PARENTERAL EQ 20MG BASE/VIAL A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL A064212 002 May 03, 1999

DECAMETHONIUM BROMIDEINJECTABLE; INJECTION
SYNCURINE

GLAXOSMITHKLINE 1MG/ML N006931 002

DEFERIPRONETABLET; ORAL
DEFERIPRONE

TARO PHARM INDS LTD 500MG A208800 001 Feb 08, 2019

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

DR REDDYS 500MG/VIAL A076806 001 Mar 31, 2006

2GM/VIAL A076806 002 Mar 31, 2006

DELAVIRDINE MESYLATETABLET; ORAL
RESCRIPTOR

+ VIIV HLTHCARE 100MG N020705 001 Apr 04, 1997

DEMECARIUM BROMIDESOLUTION/DROPS; OPHTHALMIC
HUMORSOL

MERCK 0.125% N011860 002

0.25% N011860 001

DEMECLOCYCLINE HYDROCHLORIDECAPSULE; ORAL
DECLOMYCIN

LEDERLE 150MG N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE 75MG/5ML N050257 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

COREPHARMA	75MG	N050261	001
	150MG	N050261	002
	300MG	N050261	003

DEMECLOCYCLINE HYDROCHLORIDE

IMPAX LABS	150MG	A065094	001	Mar 22, 2004
	300MG	A065094	002	Mar 22, 2004

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE	0.1MG	N010796	001
	0.25MG	N010796	002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE	0.125MG; 25MG	N012148	001
--------	---------------	---------	-----

ORETICYL 50

ABBVIE	0.125MG; 50MG	N012148	003
--------	---------------	---------	-----

ORETICYL FORTE

ABBVIE	0.25MG; 25MG	N012148	002
--------	--------------	---------	-----

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT	0.25MG; 5MG	N012775	001
--------	-------------	---------	-----

ENDURONYL FORTE

ABBOTT	0.5MG; 5MG	N012775	002
--------	------------	---------	-----

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG; 5MG	A088486	001	Aug 10, 1984
	0.5MG; 5MG	A088452	001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US	25MG	N013621	001
	50MG	N013621	002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987
	50MG	A071803	003	Dec 08, 1987
	75MG	A071803	004	Dec 08, 1987
	100MG	A071803	001	May 29, 1997
	150MG	A071803	005	May 29, 1997
USL PHARMA	25MG	A071864	001	Sep 09, 1987
	50MG	A071865	001	Sep 09, 1987
	75MG	A071866	001	Sep 09, 1987
	100MG	A071867	001	Sep 09, 1987

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+ VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003
------------------------	-----------	---------	-----	--------------

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS	0.2MG/ML	N009282	002
----------	----------	---------	-----

DESLORATADINE

TABLET; ORAL

DESLORATADINE

MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012
------------------	-----	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC 0.015MG/ML N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD 0.004MG/ML A074575 001 Feb 18, 2000

HOSPIRA 0.004MG/ML A075220 001 Aug 28, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD 0.004MG/ML A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING 0.01% N019776 001 Dec 26, 1990

DESMOPRESSIN ACETATE

SUN PHARM INDS 0.01% A077212 001 Apr 12, 2012

SPRAY, METERED; NASAL

DDAVP

+ FERRING PHARMS INC 0.01MG/SPRAY ** N017922 002 Feb 06, 1989

NOCTIVA

+ ALYVANT 0.00083MG/SPRAY N201656 001 Mar 03, 2017

+ 0.00166MG/SPRAY N201656 002 Mar 03, 2017

STIMATE

FERRING PHARMS INC 0.15MG/SPRAY N020355 001 Mar 07, 1994

TABLET; ORAL

DESMOPRESSIN ACETATE

FERRING 0.1MG N021795 001 May 08, 2008

0.2MG N021795 002 May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC 0.15MG;0.03MG N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR 0.15MG;0.03MG A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS 0.15MG;0.03MG N020301 001 Dec 14, 1992

TABLET; ORAL-28

DESOGEN

ORGANON USA INC 0.15MG;0.03MG N020071 002 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

ACCORD HLTHCARE 0.15MG;0.03MG A207067 001 Sep 13, 2018

MIRCETTE

+ TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG ** N020713 001 Apr 22, 1998

ORTHO-CEPT

JANSSEN PHARMS 0.15MG;0.03MG N020301 002 Dec 14, 1992

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

CADILA 0.25% A205620 001 Sep 28, 2018

TOPICORT

+ TARO PHARM INDS LTD 0.25% ** N017856 001

TOPICORT LP

+ TARO PHARM INDS LTD 0.05% ** N018309 001

GEL; TOPICAL

TOPICORT

+ TARO PHARM INDS LTD 0.05% ** N018586 001 Mar 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA 0.25% A073440 001 Apr 01, 1998

TOPICORT

+ TARO PHARM INDS LTD 0.25% ** N018763 001 Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC 5MG/ML N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS 125MG N005151 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

KHEDEZLA

OSMOTICA PHARM CORP

50MG

N204683 001 Jul 10, 2013

100MG

N204683 002 Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+ SUN PHARMA GLOBAL

EQ 50MG BASE

N205583 001 Jan 28, 2014

+

EQ 100MG BASE

N205583 002 Jan 28, 2014

TEVA PHARMS USA

EQ 50MG BASE

N205208 001 Oct 11, 2013

EQ 100MG BASE

N205208 002 Oct 11, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

MYLAN

EQ 100MG BASE

A204095 002 Jun 29, 2015

YICHANG HUMANWELL

EQ 50MG BASE

A210014 001 Oct 01, 2018

EQ 100MG BASE

A210014 002 Oct 01, 2018

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% **

A083296 002

DECASPRAY

+ MERCK

0.04% **

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

HEXADROL

ASPEN GLOBAL INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

+ MERCK

0.25MG **

N011664 004

+

0.5MG **

N011664 001

+

0.75MG **

N011664 002

+

1.5MG **

N011664 003

+

4MG **

N011664 005

+

6MG **

N011664 006 Jul 30, 1982

DEXAMETHASONE

ANI PHARMS INC

0.75MG

A080399 001

HERITAGE PHARMA

1.5MG

A085456 001

IMPAX LABS

0.75MG

A085376 001

PAR PHARM

0.25MG

A088149 001 Apr 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SUN PHARM INDUSTRIES

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

WATSON LABS	0.25MG	A085455	001
	0.5MG	A085458	001
	0.75MG	A080968	001
	0.75MG	A084457	001
	0.75MG	A085818	001
	1.5MG	A085840	001
WHITEWORTH TOWN PLSN	0.75MG	A084327	001
DEXONE 0.5			
SOLVAY	0.5MG	A084991	001
DEXONE 0.75			
SOLVAY	0.75MG	A084993	001
DEXONE 1.5			
SOLVAY	1.5MG	A084990	001
DEXONE 4			
SOLVAY	4MG	A084992	001
HEXADROL			
ASPEN GLOBAL INC	0.5MG	N012675	004
	0.75MG	N012675	007
	1.5MG	N012675	009
	4MG	N012675	010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

+ MERCK	EQ 8MG BASE/ML **	N016675	001
DEXAMETHASONE ACETATE			
WATSON LABS	EQ 8MG BASE/ML	A084315	001
WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001 May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242	001
---------	------------------------	---------	-----

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413	001
---------	------------------------	---------	-----

CREAM; TOPICAL

DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011983	002
-------	-------------------	---------	-----

INJECTABLE; INJECTION

DECADRON

+ MERCK	EQ 4MG PHOSPHATE/ML **	N012071	002
+	EQ 24MG PHOSPHATE/ML **	N012071	004

DEXACEN-4

CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342	001
-------------	---------------------	---------	-----

DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001 Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469	001 Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493	001
AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001 Jun 07, 2019
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001
DR REDDYS	EQ 4MG PHOSPHATE/ML	A089169	001 Apr 09, 1986
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001 Feb 17, 1984
LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001 Jul 21, 1982
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065	001
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001 Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126	001 Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001
	EQ 4MG PHOSPHATE/ML	A084355	001
	EQ 10MG PHOSPHATE/ML	A087668	001 Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606	001
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001

HEXADROL

+ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694	002
+	EQ 10MG PHOSPHATE/ML **	N014694	003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HEXADROL

EQ 20MG PHOSPHATE/ML

N014694 004

OINTMENT; OPHTHALMIC

DECADRON

MERCCK

EQ 0.05% PHOSPHATE

N011977 001

DEXAIR

PHARMAFAIR

EQ 0.05% PHOSPHATE

A088071 001 Dec 28, 1982

MAXIDEX

ALCON

EQ 0.05% PHOSPHATE

A083342 001

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR

EQ 0.1% PHOSPHATE

A088433 001 Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND

EQ 0.1% PHOSPHATE

A084170 001

EQ 0.1% PHOSPHATE

A084173 001

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

+ MERCCK

EQ 0.1% PHOSPHATE

N011984 001

DEXAMETHASONE SODIUM PHOSPHATE

SANDOZ INC

EQ 0.1% PHOSPHATE

A088771 001 Jan 16, 1985

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 0.1% PHOSPHATE

A084855 001

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

MERCCK

EQ 4MG PHOSPHATE/ML; 10MG/ML

N013334 002

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEODECADRON

MERCCK

EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM

N050324 001

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

MERCCK

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

N050322 001

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A064055 001 Oct 30, 1995

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A062714 001 Jul 21, 1986

PHARMAFAIR

EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML

A062539 001 Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062566 001 Feb 22, 1985

DEXASPORIN

PHARMAFAIR

0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

A062411 001 May 16, 1983

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

NOVARTIS

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062544 001 Oct 29, 1984

DEXASPORIN

PHARMAFAIR

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062428 001 May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD

0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML

A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP; ORAL

DISOMER

SCHERING

2MG/5ML

N011814 002

TABLET; ORAL

DISOMER

SCHERING

2MG

N011814 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET; ORAL			
DISOPHROL			
SCHERING	2MG; 60MG	N012394	002
TABLET, EXTENDED RELEASE; ORAL			
BROMPHERIL			
COPLY PHARM	6MG; 120MG	A089116	001 Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE			
AVANTHI INC	6MG; 120MG	A078648	001 Feb 27, 2013
DISOBROM			
SANDOZ	6MG; 120MG	A070770	001 Sep 30, 1991
DISOPHROL			
SCHERING PLOUGH	6MG; 120MG	N013483	004 Sep 13, 1982
DRIXORAL			
+ SCHERING PLOUGH	6MG; 120MG **	N013483	003 Sep 13, 1982
RESPORAL			
PIONEER PHARMS	6MG; 120MG	A089139	001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL			
POLARAMINE			
SCHERING	2MG/5ML	A086837	001 Jul 19, 1982
TABLET; ORAL			
DEXCHLORPHENIRAMINE MALEATE			
ANI PHARMS INC	2MG	A088682	001 Jan 17, 1986
POLARAMINE			
SCHERING	2MG	A086835	001

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL			
DEXILANT SOLUTAB			
+ TAKEDA PHARMS USA	30MG	N208056	001 Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION			
DEXMEDETOMIDINE HYDROCHLORIDE			
AM REGENT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001 May 12, 2017
CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001 Jan 18, 2019

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL			
DEXMETHYLPHENIDATE HYDROCHLORIDE			
LANNETT CO INC	2.5MG	A209468	001 Sep 25, 2017
	5MG	A209468	002 Sep 25, 2017
	10MG	A209468	003 Sep 25, 2017
TEVA PHARMS	2.5MG	A077107	003 Jan 29, 2007
	5MG	A077107	001 Jan 29, 2007
	10MG	A077107	002 Jan 29, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL			
DEXAMPEX			
TEVA	15MG	A085355	001
CAPSULE, EXTENDED RELEASE; ORAL			
DEXTROAMPHETAMINE SULFATE			
ABLE	5MG	A076814	001 Aug 25, 2004
	10MG	A076814	002 Aug 25, 2004
	15MG	A076814	003 Aug 25, 2004
MYLAN	5MG	A206735	001 Jan 27, 2016
	10MG	A206735	002 Jan 27, 2016
	15MG	A206735	003 Jan 27, 2016
ELIXIR; ORAL			
DEXEDRINE			
GLAXOSMITHKLINE	5MG/5ML **	A083902	001
TABLET; ORAL			
DEXAMPEX			
TEVA	5MG	A083735	001
	10MG	A083735	002
DEXEDRINE			
GLAXOSMITHKLINE	5MG	A084935	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

ANI PHARMS INC	5MG	A085370	001	
EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014
	10MG	A090652	002	Mar 07, 2014
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
NESHER PHARMS	5MG	A040365	001	Oct 31, 2002
	10MG	A040367	001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125	001	
SANDOZ	10MG	A085371	001	
VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999
VITARINE	5MG	A084986	001	
	10MG	A085892	001	
DEXTROSTAT				
SHIRE	5MG **	A084051	001	
	10MG **	A084051	002	
FERNDEX				
FERNDALE LABS	5MG	A084001	001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913	001	Mar 02, 1987
PROMETH W/ DEXTROMETHORPHAN				
G AND W LABS INC	15MG/5ML; 6.25MG/5ML **	A088762	001	Oct 31, 1984
PROMETHAZINE DM				
VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011
+ ANI PHARMS	15MG/5ML; 6.25MG/5ML **	N011265	002	Apr 02, 1984
TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001	
MILES	10GM/100ML	N018504	001	
DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML	N018358	001	
	2.5GM/100ML	N019626	001	Feb 02, 1988
DEXTROSE 20% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	20GM/100ML **	N017521	004	
DEXTROSE 30% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	30GM/100ML	N017521	003	
DEXTROSE 38.5% IN PLASTIC CONTAINER				
ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
DEXTROSE 40% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	40GM/100ML	N017521	002	
DEXTROSE 5% IN PLASTIC CONTAINER				
DHL	5GM/100ML	N019971	001	Sep 28, 1995
+ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984
DEXTROSE 50% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	50GM/100ML **	N017521	001	
ICU MEDICAL INC	50GM/100ML	N019894	001	Dec 26, 1989
DEXTROSE 60%				
B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER				
B BRAUN	60GM/100ML	N017995	001	
+ BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982
	60GM/100ML	N020047	002	Jul 02, 1991
HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER				
B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
DEXTROSE 70% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	70GM/100ML	N017521	006	Mar 26, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385 001	
-----------------	---	-------------	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019025 001	Dec 27, 1984
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515 001	May 08, 1986
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844 001	Jun 10, 1993
---------	---	-------------	--------------

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N018273 001	
---------	---	-------------	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843 001	Aug 09, 1993
---------	--	-------------	--------------

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274 001	
---------	--	-------------	--

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451 001	
-------------------	--	-------------	--

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 37MG/100ML	N019699 001	Sep 29, 1989
---------	-----------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML	N018744 001	Nov 09, 1982
---------	-----------------------	-------------	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N019699 003	Sep 29, 1989
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML	N018744 002	Nov 09, 1982
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744 003	Nov 09, 1982
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML	N018744 004	Nov 09, 1982
---------	------------------------	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371 003	
-----------------	------------------------	-------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371 002	
-----------------	------------------------	-------------	--

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG/100ML; 207MG/100ML	N019514 001	May 08, 1986
---------	---	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML N019870 001 Jun 10, 1993

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML N018270 001

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML N018840 001 Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%
 B BRAUN 5GM/100ML;75MG/100ML;200MG/100ML N018268 009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;150MG/100ML;200MG/100ML N018268 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N018268 005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;300MG/100ML;200MG/100ML N018268 006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;75MG/100ML;330MG/100ML N018268 011 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;150MG/100ML;330MG/100ML N018268 012 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N018268 013 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;300MG/100ML;330MG/100ML N018268 014 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%
 B BRAUN 5GM/100ML;75MG/100ML;450MG/100ML N018268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;150MG/100ML;450MG/100ML N018268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N018268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 B BRAUN 5GM/100ML;300MG/100ML;450MG/100ML N018268 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5GM/100ML;224MG/100ML;450MG/100ML N018008 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5GM/100ML;300MG/100ML;450MG/100ML N018008 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5GM/100ML;75MG/100ML;450MG/100ML N018008 002

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 002 Jul 05, 1983
 + 5GM/100ML;149MG/100ML;225MG/100ML N018365 006 Mar 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;300MG/100ML N018876 001 Jan 17, 1986
 5GM/100ML;149MG/100ML;300MG/100ML N018876 006 Mar 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N019691 002 Mar 24, 1988
 + 5GM/100ML;149MG/100ML;900MG/100ML N019691 004 Mar 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 ICU MEDICAL INC 5GM/100ML;224MG/100ML;225MG/100ML N018365 008 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 ICU MEDICAL INC 5GM/100ML;224MG/100ML;300MG/100ML N018876 007 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N018362 006 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N019691 006 Mar 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;298MG/100ML;225MG/100ML N018365 009 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 ICU MEDICAL INC 5GM/100ML;298MG/100ML;300MG/100ML N018876 008 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 + ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML N018362 007 Mar 28, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML	N019691 008	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008	Mar 28, 1988
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001	Mar 24, 1988
+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691 003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;200MG/100ML	N018386 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;450MG/100ML	N018229 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;900MG/100ML	N018047 001	
BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;450MG/100ML	N018030 001	
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	2.5GM/100ML;900MG/100ML	N018376 001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	3.3GM/100ML;300MG/100ML	N018055 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML	N018030 005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;200MG/100ML	N018030 004	
MILES	5GM/100ML;200MG/100ML	N018399 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;225MG/100ML	N019482 001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;300MG/100ML	N019486 001	Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;330MG/100ML	N018030 003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;450MG/100ML	N019484 001	Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030 002	
MILES	5GM/100ML;450MG/100ML	N018400 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML;900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026 001	
MILES	5GM/100ML;900MG/100ML	N018500 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBVIE	1MG	N012302 005
	2MG	N012302 002
	4MG	N012302 004
	6MG	N012302 006

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982
----------------	-----	-------------	--------------

CARDIOGRAFIN

BRACCO	85%	N011620 002	
--------	-----	-------------	--

DIATRIZOATE MEGLUMINE

BRACCO	76%	N010040 017	
--------	-----	-------------	--

HYPAQUE

GE HEALTHCARE	30%	N016403 002	
---------------	-----	-------------	--

	60%	N016403 001	
--	-----	-------------	--

RENO-60

BRACCO	60%	N010040 016	
--------	-----	-------------	--

RENO-DIP

BRACCO	30%	N010040 012	
--------	-----	-------------	--

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982
----------------	-----	-------------	--------------

SOLUTION; URETERAL

RENO-30

BRACCO	30%	N010040 021	
--------	-----	-------------	--

UROVIST CYSTO

BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982
----------------	-----	-------------	--------------

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982
----------------	-----	-------------	--------------

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE	30%	N016403 003	
---------------	-----	-------------	--

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE	52%;8%	A087724 001	Sep 23, 1982
----------------	--------	-------------	--------------

ANGIOVIST 370

BAYER HLTHCARE	66%;10%	A087723 001	Sep 23, 1982
----------------	---------	-------------	--------------

DIATRIZOATE-60

INTL MEDICATION	52%;8%	A088166 001	Jun 17, 1983
-----------------	--------	-------------	--------------

HYPAQUE-76

GE HEALTHCARE	66%;10%	A086505 001	
---------------	---------	-------------	--

HYPAQUE-M, 75%

GE HEALTHCARE	50%;25%	N010220 003	
---------------	---------	-------------	--

HYPAQUE-M, 90%

GE HEALTHCARE	60%;30%	N010220 002	
---------------	---------	-------------	--

MD-60

MALLINCKRODT	52%;8%	A087074 001	
--------------	--------	-------------	--

MD-76

MALLINCKRODT	66%;10%	A087073 001	
--------------	---------	-------------	--

MD-76R

+ LIEBEL-FLARSHEIM	66%;10%	N019292 001	Sep 29, 1989
--------------------	---------	-------------	--------------

RENOCAL-76

BRACCO	66%;10%	A089347 001	Jun 01, 1988
--------	---------	-------------	--------------

RENOGRAFIN-60

BRACCO	52%;8%	N010040 006	
--------	--------	-------------	--

RENOGRAFIN-76

+ BRACCO	66%;10%	N010040 001	
----------	---------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOVIST

BRACCO 34.3%;35% N010040 020

RENOVIST II

BRACCO 28.5%;29.1% N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10% A087728 001 Sep 23, 1982

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

+ BRACCO 52.7%;26.8% N011324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100% N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25% N009561 003

50% N009561 001

MD-50

MALLINCKRODT 50% A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50% A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40% N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20% N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE 15MG N018179 001

GEL; RECTAL

DIASTAT

+ BAUSCH 5MG/ML (5MG/ML) ** N020648 002 Jul 29, 1997

+ 10MG/2ML (5MG/ML) ** N020648 003 Jul 29, 1997

+ 15MG/3ML (5MG/ML) ** N020648 004 Jul 29, 1997

+ 20MG/4ML (5MG/ML) ** N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM 5MG/ML A070662 001 Jun 25, 1986

HOSPIRA 5MG/ML A071584 001 Oct 13, 1987

MARSAM PHARMS LLC 5MG/ML A072371 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML A076815 001 Apr 15, 2004

US ARMY 5MG/ML ** N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML A071613 001 Oct 22, 1987

5MG/ML A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML A070296 001 Feb 12, 1986

5MG/ML A070911 001 Aug 28, 1986

5MG/ML A070912 001 Aug 28, 1986

5MG/ML A070930 001 Dec 01, 1986

WATSON LABS INC 5MG/ML A072370 001 Jan 29, 1993

5MG/ML A072397 001 Jan 29, 1993

WEST-WARD PHARMS INT 5MG/ML A070311 001 Dec 16, 1985

5MG/ML A070312 001 Dec 16, 1985

5MG/ML A070313 001 Dec 16, 1985

5MG/ML A071308 001 Jul 17, 1987

5MG/ML A071309 001 Jul 17, 1987

5MG/ML A071310 001 Jul 17, 1987

DIZAC

PHARMACIA AND UPJOHN 5MG/ML ** N019287 001 Jun 18, 1993

VALIUM

+ ROCHE 5MG/ML ** N016087 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIAZEPAM

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986
	5MG	A070706 001	Mar 19, 1986
	10MG	A070707 001	Mar 19, 1986
DAVA PHARMS INC	2MG	A070228 002	Sep 26, 1985
	5MG	A070228 003	Sep 26, 1985
	10MG	A070228 001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986
	5MG	A070895 001	Aug 27, 1986
	10MG	A070896 001	Aug 27, 1986
FERNDALE LABS	2MG	A070903 001	Apr 01, 1987
	5MG	A070904 001	Apr 01, 1987
	10MG	A070905 001	Apr 01, 1987
HALSEY	2MG	A070987 001	Aug 15, 1986
	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
NUVO PHARM	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
UPSHER SMITH LABS	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
VIRTUS PHARMS	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985
Q-PAM			
QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001	
	100MG	N017425 002	

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987
HYPERSTAT			
SCHERING	15MG/ML	N016996 001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203 001	
----------	----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

+ STRONGBRIDGE US 50MG ** N011366 001

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

LICART

+ IBSA INST BIO 1.3% N206976 001 Dec 19, 2018

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

+ NOVARTIS 25MG ** N020142 001 Nov 24, 1993

50MG ** N020142 002 Nov 24, 1993

DICLOFENAC POTASSIUM

SANDOZ 50MG A075582 001 Feb 23, 2001

SUN PHARM INDUSTRIES 50MG A075470 001 Feb 21, 2002

WATSON LABS TEVA 50MG A075152 001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION; INTRAVENOUS

DICLOFENAC SODIUM

MYLAN LABS LTD 37.5MG/ML (37.5MG/ML) A208786 001 Jun 18, 2019

DYLOJECT

+ JAVELIN PHARMS INC 37.5MG/ML (37.5MG/ML) N022396 001 Dec 23, 2014

SOLUTION; TOPICAL

DICLOFENAC SODIUM

RICONPHARMA LLC 1.5% A206715 001 Aug 07, 2017

PENNSAID

+ NUVO PHARMS INC 1.5% ** N020947 001 Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC 0.1% A077600 001 Nov 13, 2008

FALCON PHARMS 0.1% N020809 001 May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

ALLIED 50MG A074986 001 Feb 26, 1999

75MG A074986 002 Feb 26, 1999

CASI PHARMS INC 25MG A074376 001 Sep 28, 1995

50MG A074376 002 Sep 28, 1995

75MG A074394 001 Nov 30, 1995

PLIVA 50MG A074432 002 Jul 29, 1999

75MG A074432 003 Jul 29, 1999

ROXANE 25MG A074391 001 Jun 29, 1995

50MG A074391 002 Jun 29, 1995

75MG A074391 003 Jun 29, 1995

TEVA 50MG A074723 001 Mar 30, 1999

75MG A074390 001 Aug 15, 1996

TEVA PHARMS 25MG A074459 001 Jun 25, 1997

50MG A074459 002 Jun 25, 1997

75MG A074459 003 Jun 25, 1997

VOLTAREN

+ NOVARTIS 25MG ** N019201 001 Jul 28, 1988

+ 50MG ** N019201 002 Jul 28, 1988

+ 75MG ** N019201 003 Jul 28, 1988

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

ACTAVIS ELIZABETH 100MG A075910 001 Jan 07, 2002

MYLAN 100MG A076152 001 Dec 13, 2001

VOLTAREN-XR

+ NOVARTIS 100MG ** N020254 001 Mar 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

EXELA HOLDINGS 50MG; 0.2MG A200540 001 Mar 14, 2014

75MG; 0.2MG A200540 002 Mar 14, 2014

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002
	EQ 250MG BASE	A062238	001
	EQ 500MG BASE	A060254	003
	EQ 500MG BASE	A062238	002

PATHOCIL

WYETH AYERST	EQ 250MG BASE	N050011	002
	EQ 500MG BASE	N050011	003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON	EQ 62.5MG BASE/5ML	A061455	001
-----------	--------------------	---------	-----

DYNAPEN

APOTHECON	EQ 62.5MG BASE/5ML	N050337	002
-----------	--------------------	---------	-----

PATHOCIL

WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001
--------------	--------------------	---------	-----

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY	25MG	N005509	003
	50MG	N005509	001

TABLET; ORAL

DICUMAROL

ABBVIE	25MG	N005545	003
	50MG	N005545	004
	100MG	N005545	005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

+ ALLERGAN	10MG	N007409	003 Oct 15, 1984
------------	------	---------	------------------

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS	10MG	A089361	001 Jan 10, 1989
SUN PHARM INDUSTRIES	10MG	A084505	001 Oct 21, 1986
WATSON LABS	10MG	A083179	001 Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

DR REDDYS	10MG/ML	A080614	001 Feb 11, 1986
-----------	---------	---------	------------------

SYRUP; ORAL

BENTYL

+ APTALIS PHARMA US	10MG/5ML **	N007961	002 Oct 15, 1984
---------------------	-------------	---------	------------------

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A084479	001
--------------------	----------	---------	-----

TABLET; ORAL

BENTYL

+ ALLERGAN	20MG	N007409	001 Oct 15, 1984
------------	------	---------	------------------

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS	20MG	A088585	001 Aug 20, 1986
SUN PHARM INDUSTRIES	20MG	A084600	001 Jul 29, 1985
WATSON LABS	20MG	A084361	001 Feb 06, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

BARR	200MG	A077167	001 Dec 03, 2004
	250MG	A077167	002 Dec 03, 2004
	400MG	A077167	003 Dec 03, 2004
MYLAN PHARMS INC	125MG	A090788	001 Apr 08, 2010
	200MG	A090788	002 Apr 08, 2010
	250MG	A090788	003 Apr 08, 2010
	400MG	A090788	004 Apr 08, 2010

FOR SOLUTION; ORAL

DIDANOSINE

AUROBINDO PHARMA	10MG/ML	A078112	001 Mar 08, 2007
------------------	---------	---------	------------------

VIDEX

BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003 Oct 09, 1991
	167MG/PACKET	N020155	004 Oct 09, 1991
	250MG/PACKET	N020155	005 Oct 09, 1991
	375MG/PACKET	N020155	006 Oct 09, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIRIDANOSINE

TABLET, CHEWABLE;ORAL

VIDEX

+	BRISTOL MYERS SQUIBB	25MG **	N020154 002	Oct 09, 1991
+		50MG **	N020154 003	Oct 09, 1991
+		100MG **	N020154 004	Oct 09, 1991
+		150MG **	N020154 005	Oct 09, 1991
+		200MG **	N020154 006	Oct 28, 1999

TABLET, FOR SUSPENSION;ORAL

DIRIDANOSINE

AUROBINDO	100MG	A077275 001	Aug 14, 2012
	150MG	A077275 002	Aug 14, 2012
	200MG	A077275 003	Aug 14, 2012

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM	0.01%	N006110 005	
--------------------	-------	-------------	--

DV

SANOFI AVENTIS US	0.01%	A083518 001	
-------------------	-------	-------------	--

ESTRAGUARD

SOLVAY	0.01%	A084436 001	
--------	-------	-------------	--

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US	0.7MG	A083517 001	
-------------------	-------	-------------	--

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE	50MG	N006459 001	
---------	------	-------------	--

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

CHARTWELL RX	25MG	A088267 001	Aug 25, 1983
	25MG	A088268 001	Aug 25, 1983
EPIC PHARMA LLC	25MG	A040828 001	Nov 05, 2008
SANDOZ	25MG	A085916 001	
TEVA	25MG	A088642 001	Sep 20, 1984
UCB INC	25MG	A085544 001	
WATSON LABS	25MG	A085741 001	

TENUATE

SANOFI AVENTIS US	25MG	N017668 001	
-------------------	------	-------------	--

+

TEVA BRANDED PHARM	25MG	N011722 002	
--------------------	------	-------------	--

TEPANIL

3M	25MG	N011673 001	
----	------	-------------	--

TABLET, EXTENDED RELEASE;ORAL

TENUATE

SANOFI AVENTIS US	75MG	N017669 001	
-------------------	------	-------------	--

TENUATE DOSPAN

+

TEVA BRANDED PHARM	75MG	N012546 001	
--------------------	------	-------------	--

TEPANIL TEN-TAB

3M	75MG	N017956 001	
----	------	-------------	--

DIETHYLSTILBESTROL

INJECTABLE;INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003	
	0.5MG/ML	N004056 004	
	1MG/ML	N004056 005	
	5MG/ML	N004056 006	

SUPPOSITORY;VAGINAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004040 001	
-------	-------	-------------	--

	0.5MG	N004040 002	
--	-------	-------------	--

STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056 001	
----------------------	-------	-------------	--

	0.5MG	N004056 002	
--	-------	-------------	--

TABLET;ORAL

DIETHYLSTILBESTROL

LILLY	0.1MG	N004041 002	
-------	-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIETHYLSTILBESTROL

TABLET; ORAL

DIETHYLSTILBESTROL

0.5MG	N004041 003
1MG	N004041 004
5MG	N004041 005

STILBESTROL

TABLICAPS

0.5MG	A083004 001
1MG	A083002 001
5MG	A083006 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG	N004056 007
0.25MG	N004056 017
0.5MG	N004056 008
1MG	N004056 009
5MG	N004056 010

TABLET, DELAYED RELEASE; ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG	N004039 002
0.25MG	N004039 005
0.5MG	N004039 003
1MG	N004039 004
5MG	N004039 006

STILBESTROL

TABLICAPS

0.5MG	A083003 001
1MG	A083005 001
5MG	A083007 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG	N004056 011
0.5MG	N004056 012
1MG	N004056 013
5MG	N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS

250MG/5ML	N010010 001
-----------	-------------

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS

50MG	N010010 002
------	-------------

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS

0.05%	A075187 001	Mar 30, 1998
-------	-------------	--------------

FLORONE

PHARMACIA AND UPJOHN

0.05% **	N017741 001
----------	-------------

FLORONE E

PHARMACIA AND UPJOHN

0.05%	N019259 001	Aug 28, 1985
-------	-------------	--------------

PSORCON

+ TARO PHARMS NORTH

0.05% **	N020205 001	Nov 20, 1992
----------	-------------	--------------

OINTMENT; TOPICAL

PSORCON

+ PHARMACIA AND UPJOHN

0.05%	N019260 001	Aug 28, 1985
-------	-------------	--------------

PSORCON E

PHARMACIA AND UPJOHN

0.05%	N017994 001
-------	-------------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

ANI PHARMS INC

500MG	A074604 001	Jun 10, 1996
-------	-------------	--------------

PUREPAC PHARM

250MG	A074285 001	May 07, 1996
-------	-------------	--------------

500MG	A074285 002	May 07, 1996
-------	-------------	--------------

SOCORRO

250MG	A073562 001	Nov 27, 1992
-------	-------------	--------------

500MG	A073563 001	Nov 27, 1992
-------	-------------	--------------

TEVA

250MG	A073679 001	Jul 31, 1992
-------	-------------	--------------

WATSON LABS

250MG	A074400 001	Jul 17, 1997
-------	-------------	--------------

500MG	A074400 002	Jul 17, 1997
-------	-------------	--------------

DOLOBID

+ MERCK

250MG **	N018445 001	Apr 19, 1982
----------	-------------	--------------

+

500MG **	N018445 002	Apr 19, 1982
----------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

LANOXIN

+ CONCORDIA

0.1875MG

N020405 003 Sep 30, 1997

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML
0.5MG/0.7ML; 5,000
UNITS/0.7ML; 7.46MG/0.7ML

N018885 001 Nov 30, 1984

N018885 002 Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

+ BIOVAIL

60MG **

N019471 001 Jan 23, 1989

+

90MG **

N019471 002 Jan 23, 1989

+

120MG **

N019471 003 Jan 23, 1989

+

180MG **

N019471 004 Jan 23, 1989

DILACOR XR

+ ALLERGAN

120MG **

N020092 001 May 29, 1992

+

180MG **

N020092 002 May 29, 1992

+

240MG **

N020092 003 May 29, 1992

DILT-CD

APOTEX

120MG

A076151 001 May 20, 2004

180MG

A076151 002 May 20, 2004

240MG

A076151 003 May 20, 2004

300MG

A076151 004 May 20, 2004

DILTIAZEM HYDROCHLORIDE

ACTAVIS LABS FL INC

120MG

A074852 001 Oct 10, 1997

180MG

A074852 002 Oct 10, 1997

240MG

A074852 003 Oct 10, 1997

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

MYLAN

120MG

A075124 002 Mar 18, 1998

180MG

A075124 003 Mar 18, 1998

240MG

A075124 001 Mar 18, 1998

NESHER PHARMS

120MG

A076563 002 Sep 12, 2006

180MG

A076563 003 Sep 12, 2006

240MG

A076563 004 Sep 12, 2006

300MG

A076563 005 Sep 12, 2006

360MG

A076563 006 Sep 12, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

	420MG	A076563 001	Sep 12, 2006
PAR PHARM	360MG	A209766 001	May 30, 2018
TEVA	60MG	A074079 001	Nov 30, 1993
	90MG	A074079 002	Nov 30, 1993
	120MG	A074079 003	Nov 30, 1993

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL **	N020792 001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **	N020027 001	Oct 24, 1991
+	25MG/VIAL **	N020027 003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

DR REDDYS	5MG/ML	A074894 001	Aug 26, 1997
HOSPIRA	5MG/ML	A075004 001	Feb 16, 2000
	5MG/ML	A075106 001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML	A075375 001	Sep 30, 1999

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051 001	Mar 31, 1993
	60MG	A074051 002	Mar 31, 1993
	90MG	A074051 003	Mar 31, 1993
	120MG	A074051 004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093 001	Nov 05, 1992
	60MG	A074093 002	Nov 05, 1992
	90MG	A074093 003	Nov 05, 1992
	120MG	A074093 004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168 001	Mar 03, 1995
	60MG	A074168 002	Mar 03, 1995
	90MG	A074168 003	Mar 03, 1995
	120MG	A074168 004	Mar 03, 1995
TEVA	30MG	A074084 001	Feb 25, 1994
	60MG	A074084 002	Feb 25, 1994
TEVA PHARMS	30MG	A074067 001	Nov 05, 1992
	60MG	A074067 002	Nov 05, 1992
	90MG	A074067 003	Nov 05, 1992
	120MG	A074067 004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE;ORAL

TIAMATE

MERCK	EQ 120MG HYDROCHLORIDE	N020506 001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE	N020506 002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE;ORAL

TECZEM

BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507 001	Oct 04, 1996
---------	----------------------------	-------------	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001
WATSON LABS	50MG/ML	A083531 001
WATSON LABS TEVA	50MG/ML	A080615 001
WYETH AYERST	50MG/ML	A084316 001

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001
------	------------	-------------

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001
NEXGEN PHARMA INC	50MG	A085985 001
WATSON LABS	50MG	A085166 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

MYLAN INSTITUTIONAL 50%

A076185 001 Nov 29, 2002

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

VESSELON SPV LLC 0.92MG/VIAL;0.092MG/VIAL

N021191 001 May 31, 2002

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN EQ 5MG BASE/ML

N017434 001

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING 100MG

N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS 25MG

N005845 007

50MG

N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA 25MG

A080519 004

50MG

A080519 003

ANABOLIC 50MG

A083275 001

ELKINS SINN 25MG

A085701 001

50MG

A085701 002

FOSUN PHARMA 25MG

A080832 001

25MG

A080845 002

50MG

A080832 002

50MG

A080845 001

HALSEY 50MG

A087914 001

Jun 04, 1984

HEATHER 25MG

A084524 001

50MG

A083953 001

HERITAGE PHARMA 50MG

A080727 001

50MG

A080738 001

HIKMA INTL PHARMS 50MG

A083567 001

IMPAX LABS 25MG

A080807 001

50MG

A080807 002

IVAX SUB TEVA PHARMS 25MG

A080762 001

50MG

A080762 002

LANNETT 25MG

A080868 001

50MG

A080868 002

LEDERLE 25MG

A086874 001

50MG

A086875 001

LNK 25MG

A087977 001

Jan 27, 1983

50MG

A087978 001

Jan 27, 1983

MK LABS 25MG

A083087 001

50MG

A083087 002

MUTUAL PHARM 25MG

A084506 001

NEWTRON PHARMS 25MG

A086543 001

50MG

A086544 001

NEXGEN PHARMA INC 25MG

A083634 001

PERRIGO 25MG

A083061 001

50MG

A083061 002

PIONEER PHARMS 25MG

A089101 001

Dec 20, 1985

50MG

A088880 001

Dec 20, 1985

PUREPAC PHARM 25MG

A085156 001

50MG

A085150 001

PVT FORM 25MG

A083027 001

50MG

A083027 002

ROXANE 50MG

A080635 001

SUN PHARM INDUSTRIES 25MG

A089488 001

Jan 02, 1987

50MG

A089489 001

Jan 02, 1987

SUPERPHARM 25MG

A089040 001

May 15, 1985

50MG

A089041 001

May 15, 1985

TEVA 25MG

A085874 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
--------	------------	---------	-----	--------------

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004	
-------------	------------	---------	-----	--

DIBENIL

CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
-------	------------	---------	-----	--------------

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001	
------------	------------	---------	-----	--

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	
PUREPAC PHARM	12.5MG/5ML	A083237	001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001	
ROXANE	12.5MG/5ML	A080643	001	

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002	
--------------------	------------	---------	-----	--

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001	
+	50MG/ML **	N006146	002	

BENADRYL PRESERVATIVE FREE

+	MCNEIL CONS	50MG/ML **	N009486	001
---	-------------	------------	---------	-----

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822	001	
DR REDDYS	10MG/ML	A080873	001	
	50MG/ML	A080873	002	
EUROHLTH INTL SARL	50MG/ML	A083183	001	
LYPHOMED	10MG/ML	A087066	001	
WATSON LABS	10MG/ML	A083533	001	
WYETH AYERST	50MG/ML	A080577	001	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002	
DR REDDYS	50MG/ML	A080873	003	
INTL MEDICATION	50MG/ML	A084094	001	

SYRUP; ORAL

ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001	Apr 10, 1987
---------	------------	---------	-----	--------------

BELDIN

HALSEY	12.5MG/5ML	A089179	001	Jun 05, 1986
--------	------------	---------	-----	--------------

BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004	
-------------	------------	---------	-----	--

DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001	Oct 01, 1985
--------------	------------	---------	-----	--------------

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497	001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611	001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML	A072416	001	Sep 28, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML

A070205 001 Jan 28, 1986

SILPHEN

LANNETT CO INC 12.5MG/5ML

A072646 001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT 12.5MG/5ML

A070524 001 Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

P AND L 25MG; 220MG

A207597 001 Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS 12.5MG/5ML; 30MG/5ML

N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE EQ 25MG BASE

N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE 5MG

N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AKORN 0.1%

A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1%

A074188 001 May 19, 1995

FALCON PHARMS 0.1%

A073636 001 Jun 30, 1994

PROPINE

ALLERGAN 0.1%

N018239 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

DR REDDYS 5MG/ML

A074952 001 Nov 26, 1997

HOSPIRA 5MG/ML

A074601 001 Dec 19, 1997

MYLAN LABS LTD 5MG/ML

A075769 001 Nov 27, 2002

IV PERSANTINE

+ BOEHRINGER INGELHEIM 5MG/ML **

N019817 001 Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

ANI PHARMS INC 25MG

A086944 002 Apr 16, 1991

50MG

A086944 001 Feb 25, 1992

75MG

A086944 003 Feb 25, 1992

GLENMARK GENERICS 25MG

A088999 001 Feb 05, 1991

50MG

A089000 001 Feb 05, 1991

75MG

A089001 001 Feb 05, 1991

LANNETT CO INC 25MG

A040898 001 Apr 23, 2008

50MG

A040898 002 Apr 23, 2008

75MG

A040898 003 Apr 23, 2008

OXFORD PHARMS 25MG

A040542 001 Apr 21, 2006

50MG

A040542 002 Apr 21, 2006

75MG

A040542 003 Apr 21, 2006

PUREPAC PHARM 25MG

A089425 001 Jul 12, 1990

50MG

A089426 001 Jul 12, 1990

75MG

A089427 001 Jul 12, 1990

WATSON LABS 50MG

A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS 250MG

N050678 001 Jun 19, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987
---------------	---------------	---------	-----	--------------

DISULFIRAM

TABLET; ORAL

ANTABUSE

+ TEVA WOMENS	250MG **	N007883	003	
+	500MG **	N007883	002	

DISULFIRAM

MYLAN	250MG	A203916	001	Mar 04, 2015
	500MG	A203916	002	Mar 04, 2015
PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990

DIVALPROEX SODIUM

MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008
TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

ACP NIMBLE	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009
ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009
	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
DR REDDYS	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
TEGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTREX

+ LILLY

EQ 12.5MG BASE/ML

N017820 002

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+ SUN PHARMA GLOBAL

20MG/VIAL

N022534 001 May 03, 2011

+

80MG/VIAL

N022534 002 May 03, 2011

DOCETAXEL

+ ACCORD HLTHCARE

20MG/0.5ML (40MG/ML)

N201195 001 Jun 08, 2011

+

80MG/2ML (40MG/ML)

N201195 002 Jun 08, 2011

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012

CIPLA

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018

+ HOSPIRA INC

120MG/6ML (20MG/ML)

N022234 006 Jun 23, 2016

PFIZER LABS

20MG/2ML (10MG/ML)

N202356 001 Mar 13, 2014

80MG/8ML (10MG/ML)

N202356 002 Mar 13, 2014

130MG/13ML (10MG/ML)

N202356 003 Mar 13, 2014

200MG/20ML (10MG/ML)

N202356 004 Mar 13, 2014

SHILPA MEDICARE LTD

20MG/ML (20MG/ML)

A210327 001 May 16, 2019

80MG/4ML (20MG/ML)

A210327 002 May 16, 2019

160MG/8ML (20MG/ML)

A210327 003 May 16, 2019

TEVA PHARMS USA

20MG/ML (20MG/ML)

A203877 001 Sep 16, 2015

80MG/4ML (20MG/ML)

A203877 002 Sep 16, 2015

TAXOTERE

+ SANOFI AVENTIS US

40MG/ML **

N020449 001 May 14, 1996

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ US PHARM HOLDINGS

12.5MG/0.625ML (20MG/ML)

N020624 002 Sep 11, 1997

+

100MG/5ML (20MG/ML)

N020624 001 Sep 11, 1997

500MG/25ML (20MG/ML)

N020624 003 Dec 11, 2001

TABLET; ORAL

ANZEMET

+ US PHARM HOLDINGS

50MG

N020623 001 Sep 11, 1997

+

100MG

N020623 002 Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC

5MG/5ML

N021719 001 Oct 18, 2004

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE

5MG

A201335 001 Aug 29, 2011

10MG

A201335 002 Aug 29, 2011

APOTEX

5MG

A078841 001 Jun 02, 2011

10MG

A078841 002 Jun 02, 2011

HIKMA PHARMS

5MG

A090247 001 May 31, 2011

10MG

A090247 002 May 31, 2011

OSMOTICA PHARM US

23MG

A203114 001 Jan 26, 2016

PAR PHARM

23MG

A202542 001 Jul 24, 2013

SUN PHARM

23MG

A204293 001 Jun 05, 2015

SUN PHARM INDS LTD

5MG

A076786 001 Nov 26, 2010

10MG

A076786 002 Nov 26, 2010

WOCKHARDT

5MG

A091267 001 May 31, 2011

10MG

A091267 002 May 31, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

+ EISAI INC

5MG

N021720 001 Oct 18, 2004

+

10MG

N021720 002 Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

HERITAGE PHARMA

5MG

A078388 002 Nov 26, 2010

10MG

A078388 001 Nov 26, 2010

SUN PHARM INDUSTRIES

5MG

A077975 002 Dec 11, 2009

10MG

A077975 001 Dec 11, 2009

ZYDUS PHARMS USA INC

5MG

A090175 001 May 10, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DONEPEZIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

10MG

A090175 002 May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AMNEAL PHARMS

10MG;14MG

A208328 001 Jan 27, 2017

10MG;28MG

A208328 002 Jan 27, 2017

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT

40MG/ML

A070656 001 Jan 24, 1989

80MG/ML

A070657 001 Jan 24, 1989

ABRAXIS PHARM

40MG/ML

A070012 001 Jun 12, 1985

40MG/ML

A070058 001 Mar 20, 1985

80MG/ML

A070013 001 Jun 12, 1985

80MG/ML

A070059 001 Mar 20, 1985

160MG/ML

A070364 001 Dec 04, 1985

AM REGENT

40MG/ML

A070799 001 Feb 11, 1987

80MG/ML

A070820 001 Feb 11, 1987

160MG/ML

A070826 001 Feb 11, 1987

BAXTER HLTHCARE

40MG/ML

N018398 001

80MG/ML

N018398 002 Mar 22, 1982

HOSPIRA

40MG/ML

A074403 001 May 23, 1996

IGI LABS INC

40MG/ML

A070087 001 Oct 23, 1985

80MG/ML

A070089 001 Oct 23, 1985

80MG/ML

A070090 001 Oct 23, 1985

80MG/ML

A070091 001 Oct 23, 1985

160MG/ML

A070092 001 Oct 23, 1985

160MG/ML

A070093 001 Oct 23, 1985

160MG/ML

A070094 001 Oct 23, 1985

INTL MEDICATION

40MG/ML

N018014 001

LYPHOMED

40MG/ML

N018549 001 Mar 11, 1983

SMITH AND NEPHEW

40MG/ML

A070011 001 Aug 29, 1985

40MG/ML

A070046 001 Aug 29, 1985

80MG/ML

A070047 001 Aug 29, 1985

TELIGENT

40MG/ML

N018656 001 Jun 28, 1983

TEVA PARENTERAL

40MG/ML

A072999 001 Oct 23, 1991

80MG/ML

A073000 001 Oct 23, 1991

WARNER CHILCOTT

40MG/ML

A070558 001 Sep 20, 1985

40MG/ML

N018138 001

80MG/ML

A070559 001 Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

1.6MG/ML

N020542 001 Aug 30, 1995

INTROPIN

HOSPIRA

40MG/ML

N017395 001

80MG/ML

N017395 002

160MG/ML

N017395 003

DORIPENEM

INJECTABLE;INTRAVENOUS

DORIBAX

+ SHIONOGI INC

250MG/VIAL

N022106 002 Oct 05, 2010

+

500MG/VIAL

N022106 001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

LUITPOLD

EQ 2% BASE

A079186 001 Nov 18, 2009

RUBICON

EQ 2% BASE

A078395 001 Oct 28, 2008

TEVA PHARMS

EQ 2% BASE

A078756 001 Dec 04, 2008

WATSON LABS INC

EQ 2% BASE

A202053 001 Sep 11, 2014

ZAMBON SPA

EQ 2% BASE

A091034 001 Dec 04, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295 001	Jun 13, 2019
LANNETT CO INC	EQ 2% BASE;EQ 0.5% BASE	A201998 001	Dec 17, 2014
RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201 001	Oct 28, 2008
WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054 001	Sep 03, 2014
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180 001	Dec 04, 2013

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946 001	Mar 07, 1991
--------	----------------	-------------	--------------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529 001	Jan 30, 1992
-------------	---------	-------------	--------------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574 001	Oct 18, 2000
	EQ 2MG BASE	A075574 002	Oct 18, 2000
	EQ 4MG BASE	A075574 003	Oct 18, 2000
	EQ 8MG BASE	A075574 004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466 001	Oct 18, 2000
	EQ 2MG BASE	A075466 002	Oct 18, 2000
	EQ 4MG BASE	A075466 003	Oct 18, 2000
	EQ 8MG BASE	A075466 004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453 001	Oct 18, 2000
	EQ 2MG BASE	A075453 002	Oct 18, 2000
	EQ 4MG BASE	A075453 003	Oct 18, 2000
	EQ 8MG BASE	A075453 004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000
	EQ 2MG BASE	A075609 002	Oct 18, 2000
	EQ 4MG BASE	A075609 003	Oct 18, 2000
	EQ 8MG BASE	A075609 004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353 001	Jan 12, 2001
	EQ 2MG BASE	A075353 002	Jan 12, 2001
	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000
YAOPHARMA CO LTD	EQ 1MG BASE	A075646 001	Oct 18, 2000
	EQ 2MG BASE	A075646 002	Oct 18, 2000
	EQ 4MG BASE	A075646 003	Oct 18, 2000
	EQ 8MG BASE	A075646 004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987 001	Mar 29, 1991
SINEQUAN			
+ PFIZER	EQ 10MG BASE **	N016798 003	
+	EQ 25MG BASE **	N016798 001	
+	EQ 50MG BASE **	N016798 002	
+	EQ 75MG BASE **	N016798 006	
+	EQ 100MG BASE **	N016798 005	
+	EQ 150MG BASE **	N016798 007	

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC

EQ 10MG BASE/ML A075924 001 Jan 15, 2004

SINEQUAN

+ PFIZER

EQ 10MG BASE/ML ** N017516 001

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

MYLAN

EQ 3MG BASE A202337 001 Jan 20, 2016

EQ 6MG BASE A202337 002 Jan 20, 2016

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

+ HOSPIRA INC

10MCG/5ML (2MCG/ML) N208614 002 Jul 24, 2018

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML A063165 001 Jan 30, 1991

200MG/100ML A063165 002 Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

ALVOGEN INC

2MG/ML A065515 001 Nov 08, 2012

HISUN PHARM HANGZHOU

20MG/VIAL A206062 001 May 13, 2019

HLTHCARE

2MG/ML A200146 001 Jul 18, 2012

MYLAN LABS LTD

2MG/ML A200901 001 Feb 14, 2012

10MG/VIAL A200170 001 Oct 28, 2011

PHARMACIA AND UPJOHN

10MG/VIAL N050467 001

20MG/VIAL N050467 003 May 20, 1985

50MG/VIAL N050467 002

150MG/VIAL N050467 004 Jul 22, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

RUBEX

BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	A065055	004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000

MONODOX

+ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992
+	EQ 75MG BASE	N050641	003	Oct 18, 2006
+	EQ 100MG BASE	N050641	001	Dec 29, 1989

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE	EQ 25MG BASE/5ML	A061720	001	
----------	------------------	---------	-----	--

TABLET; ORAL

DOXYCYCLINE

MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006
	EQ 75MG BASE	A065377	002	Nov 07, 2006
	EQ 100MG BASE	A065377	003	Nov 07, 2006
	EQ 150MG BASE	A065427	001	Jun 07, 2007
PAR PHARM	EQ 50MG BASE	A065070	001	Dec 15, 2000
	EQ 75MG BASE	A065070	003	Dec 30, 2002
	EQ 100MG BASE	A065070	002	Dec 15, 2000
	EQ 150MG BASE	A065070	004	Jul 14, 2005
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016
------------	--------------	---------	-----	--------------

DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984

DOXYCYCLINE HYCLATE

AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018
	EQ 100MG BASE	A211012	002	Sep 24, 2018
HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
	EQ 100MG BASE	A062119	001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
	EQ 100MG BASE	A062463	002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005
INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982
	EQ 100MG BASE	A062337	002	Mar 29, 1982
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

WATSON LABS

EQ 50MG BASE

A061717 001

EQ 50MG BASE

A062142 001

EQ 100MG BASE

A061717 002

EQ 100MG BASE

A062142 002

PERIOSTAT

+ COLLAGENEX

EQ 20MG BASE **

N050744 001 Sep 30, 1998

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE **

N050007 001

CAPSULE, COATED PELLETS;ORAL

DOXYCYCLINE HYCLATE

PLIVA

EQ 100MG BASE

A063187 001 Jun 30, 1992

CAPSULE, DELAYED RELEASE;ORAL

DORYX

+ MAYNE PHARMA INTL

EQ 75MG BASE

N050582 002 Aug 13, 2001

+ EQ 100MG BASE

N050582 001 Jul 22, 1985

WARNER CHILCOTT

EQ 100MG BASE

A062653 001 Oct 30, 1985

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005

EQ 100MG BASE

A065281 002 Dec 21, 2005

INJECTABLE;INJECTION

DOXYCHEL HYCLATE

RACHELLE

EQ 100MG BASE/VIAL

A061953 001

DOXYCYCLINE

WEST-WARD PHARMS INT

EQ 100MG BASE/VIAL

A062450 001 Oct 27, 1983

EQ 200MG BASE/VIAL

A062450 002 Oct 27, 1983

EQ 200MG BASE/VIAL

A062569 002 Mar 09, 1988

DOXYCYCLINE HYCLATE

WEST-WARD PHARMS INT

EQ 100MG BASE/VIAL

A062992 001 Feb 16, 1989

EQ 200MG BASE/VIAL

A062992 002 Feb 16, 1989

VIBRAMYCIN

+ PFIZER

EQ 100MG BASE/VIAL **

N050442 002

+ EQ 200MG BASE/VIAL **

N050442 001

TABLET;ORAL

DOXY-LEMMON

TEVA

EQ 100MG BASE

A062581 001 Mar 15, 1985

DOXYCYCLINE HYCLATE

HEATHER

EQ 100MG BASE

A062462 001 May 11, 1983

INTERPHARM

EQ 100MG BASE

A062764 001 Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE

A062391 001 Sep 30, 1982

SUPERPHARM

EQ 100MG BASE

A062494 001 Feb 20, 1985

VINTAGE PHARMS

EQ 100MG BASE

A062538 001 Apr 07, 1986

WARNER CHILCOTT

EQ 100MG BASE

A062593 001 Aug 28, 1985

WATSON LABS

EQ 50MG BASE

A062392 001 Mar 31, 1983

EQ 100MG BASE

A062392 002 Mar 31, 1983

LYMEPAK

+ CHARTWELL PHARMA

EQ 100MG BASE

N209844 001 Jun 15, 2018

PERIOSTAT

+ GALDERMA LABS LP

EQ 20MG BASE **

N050783 001 Feb 02, 2001

VIBRA-TABS

+ PFIZER

EQ 100MG BASE **

N050533 001

TABLET, DELAYED RELEASE;ORAL

DORYX

+ MAYNE PHARMA

EQ 80MG BASE

N050795 004 Apr 11, 2013

DORYX MPC

+ MAYNE PHARMA

EQ 60MG BASE **

N050795 007 May 20, 2016

DOXYCYCLINE HYCLATE

IMPAX LABS INC

EQ 75MG BASE

A090505 001 Dec 28, 2010

EQ 100MG BASE

A090505 002 Dec 28, 2010

MYLAN

EQ 75MG BASE

A090431 001 Dec 28, 2010

EQ 80MG BASE

A090431 004 Apr 29, 2016

EQ 100MG BASE

A090431 002 Dec 28, 2010

EQ 200MG BASE

A090431 005 May 19, 2016

MYLAN PHARMS INC

EQ 150MG BASE

A091052 001 Feb 08, 2012

ZYDUS PHARMS

EQ 75MG BASE

A206772 001 Dec 21, 2018

EQ 100MG BASE

A206772 002 Dec 21, 2018

EQ 150MG BASE

A206772 003 Dec 21, 2018

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER 25MG N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US 12.5MG N006412 015

25MG N006412 014

DOXY-SLEEP-AID

PAR PHARM 25MG A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM 25MG A088900 002 Feb 12, 1988

QUANTUM PHARMICS 25MG A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US 10MG;10MG ** N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY 50MG/ML N012936 001

DRONABINOL

CAPSULE; ORAL

DRONABINOL

INSYS THERAP 2.5MG A078501 001 Aug 19, 2011

5MG A078501 002 Aug 19, 2011

10MG A078501 003 Aug 19, 2011

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM 2.5MG/ML A070992 001 Nov 17, 1986

2.5MG/ML A070993 001 Nov 17, 1986

ASTRAZENECA 2.5MG/ML A072018 001 Oct 20, 1988

HOSPIRA 2.5MG/ML A071645 001 Apr 07, 1988

2.5MG/ML A072272 001 Aug 31, 1995

IGI LABS INC 2.5MG/ML A072019 001 Oct 19, 1988

2.5MG/ML A072020 001 Oct 19, 1988

2.5MG/ML A072021 001 Oct 19, 1988

LUITPOLD 2.5MG/ML A072335 001 Oct 24, 1988

SMITH AND NEPHEW 2.5MG/ML A071750 001 Sep 06, 1988

SOLOPAK 2.5MG/ML A071754 001 Sep 06, 1988

2.5MG/ML A071755 001 Sep 06, 1988

WATSON LABS 2.5MG/ML A073520 001 Nov 27, 1991

2.5MG/ML A073521 001 Nov 27, 1991

2.5MG/ML A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA 2.5MG/ML;EQ 0.05MG BASE/ML A072026 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072027 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML A072028 001 Apr 13, 1989

HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML A071982 001 May 04, 1988

INNOVAR

AKORN MFG 2.5MG/ML;EQ 0.05MG BASE/ML N016049 001

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

TEVA PHARMS USA EQ 20MG BASE A090783 001 Dec 11, 2013

EQ 30MG BASE A090783 002 Dec 11, 2013

EQ 60MG BASE A090783 003 Dec 11, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

DUTASTERIDE

CAPSULE; ORAL

DUTASTERIDE

BRECKENRIDGE	0.5MG	A204705 001	Nov 20, 2015
MYLAN	0.5MG	A203241 001	Jun 14, 2016
PII	0.5MG	A208227 001	Jun 22, 2018
RISING	0.5MG	A202530 001	Nov 20, 2015

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

+ ASTRAZENECA	0.5% **	N009925 002	
+	1% **	N009925 001	

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY	5MG **	N017388 001	
	10MG **	N017388 002	

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA	160MG/15ML	N007794 003	
------	------------	-------------	--

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA	250MG/ML	N009088 001	
------	----------	-------------	--

TABLET; ORAL

DILOR

SAVAGE LABS	200MG	A084514 001	
-------------	-------	-------------	--

DILOR-400

SAVAGE LABS	400MG	A084751 001	
-------------	-------	-------------	--

LUFYLLIN

MYLAN SPECIALITY LP	200MG	A084566 001	
---------------------	-------	-------------	--

	400MG	A084566 002	
--	-------	-------------	--

NEOTHYLLINE

TEVA	200MG	N007794 001	
------	-------	-------------	--

	400MG	N007794 002	
--	-------	-------------	--

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS	0.03%	N011963 002	
--------------	-------	-------------	--

	0.06%	N011963 004	
--	-------	-------------	--

	0.25%	N011963 003	
--	-------	-------------	--

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

CASI PHARMS INC	1%	A076075 001	Nov 26, 2002
-----------------	----	-------------	--------------

EDETATE CALCIUM DISODIUM

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS	500MG	N008922 002	
---------	-------	-------------	--

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA	10MG/ML	A040131 001	Feb 24, 1998
---------	---------	-------------	--------------

WATSON LABS	10MG/ML	A040044 001	Mar 20, 1996
-------------	---------	-------------	--------------

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS	10MG/ML	A040043 001	Mar 20, 1996
-------------	---------	-------------	--------------

ENLON

MYLAN INSTITUTIONAL	10MG/ML	A088873 001	Aug 06, 1985
---------------------	---------	-------------	--------------

REVERSOL

ORGANON USA INC	10MG/ML	A089624 001	May 13, 1988
-----------------	---------	-------------	--------------

TENSILON

+ TELIGENT	10MG/ML **	N007959 001	
------------	------------	-------------	--

TENSILON PRESERVATIVE FREE

+ TELIGENT	10MG/ML **	N007959 002	
------------	------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EFAVIRENZCAPSULE;ORAL
SUSTIVA

+ BRISTOL MYERS SQUIBB 100MG **

N020972 002 Sep 17, 1998

TABLET;ORAL
SUSTIVA

+ BRISTOL MYERS SQUIBB 300MG **

N021360 001 Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

TEVA PHARMS USA 600MG;200MG;300MG

A091215 001 Nov 09, 2018

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AUROBINDO PHARMA LTD 600MG;300MG;300MG

N022343 001 Aug 15, 2018

MACLEODS PHARMS LTD 400MG;300MG;300MG

N210649 001 Mar 15, 2019

EFLORNITHINE HYDROCHLORIDE

INJECTABLE;INJECTION

ORNIDYL

SANOFI AVENTIS US 200MG/ML

N019879 002 Nov 28, 1990

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+ NOVARTIS EQ 100MG ACID

N022291 005 Nov 16, 2012

ELVITEGRAVIR

TABLET;ORAL

VITEKTA

+ GILEAD SCIENCES INC 85MG

N203093 001 Sep 24, 2014

+ 150MG

N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS;OPHTHALMIC

EMADINE

+ NOVARTIS 0.05%

N020706 001 Dec 29, 1997

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AMNEAL PHARMS CO 100MG;150MG

A209721 001 Aug 22, 2018

133MG;200MG

A209721 002 Aug 22, 2018

167MG;250MG

A209721 003 Aug 22, 2018

200MG;300MG

A209721 004 Aug 22, 2018

LAURUS LABS LTD 200MG;300MG

A212114 001 Jul 26, 2019

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+ SILVERGATE PHARMS 1MG/ML

N204308 001 Aug 13, 2013

TABLET;ORAL

ENALAPRIL MALEATE

APOTHECON 2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

BEXIMCO PHARMS USA 2.5MG

A075621 001 Aug 22, 2000

5MG

A075621 002 Aug 22, 2000

10MG

A075621 003 Aug 22, 2000

20MG

A075621 004 Aug 22, 2000

IVAX SUB TEVA PHARMS 2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO 2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

MYLAN 2.5MG

A075472 001 Aug 22, 2000

2.5MG

A075480 001 Aug 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

	5MG	A075472 002	Aug 22, 2000
	5MG	A075480 002	Aug 22, 2000
	10MG	A075472 003	Aug 22, 2000
	10MG	A075480 003	Aug 22, 2000
	20MG	A075472 004	Aug 22, 2000
	20MG	A075480 004	Aug 22, 2000
SANDOZ	2.5MG	A075048 001	Aug 22, 2000
	5MG	A075048 002	Aug 22, 2000
	10MG	A075048 003	Aug 22, 2000
	20MG	A075048 004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556 001	Aug 22, 2000
	5MG	A075556 002	Aug 22, 2000
	10MG	A075556 003	Aug 22, 2000
	20MG	A075556 004	Aug 22, 2000
WATSON LABS	2.5MG	A075501 001	Aug 22, 2000
	5MG	A075501 002	Aug 22, 2000
	10MG	A075501 003	Aug 22, 2000
	20MG	A075501 004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668 002	Oct 28, 1998
	5MG; 5MG	N020668 001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736 001	Mar 25, 2003
	10MG; 25MG	A075736 002	Mar 25, 2003
UPSHER SMITH LABS	5MG; 12.5MG	A076116 001	Sep 19, 2001
	10MG; 25MG	A076116 002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000
VASOTEC			
+ BIOVAIL LABS INTL	1.25MG/ML **	N019309 001	Feb 09, 1988

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+ ARRAY BIOPHARMA INC	50MG	N210496 001	Jun 27, 2018
-----------------------	------	-------------	--------------

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803 001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396 001	Jul 29, 1994
ETHRANE			
BAXTER HLTHCARE	99.9%	N017087 001	

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US	200MG	N019616 004	Dec 31, 1991
	400MG	N019616 005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

+ SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164 006	Jun 02, 2000
---------------------	--------------------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ENTACAPONETABLET; ORAL
ENTACAPONE

MYLAN PHARMS INC 200MG A202394 001 May 13, 2013

ENTECAVIRTABLET; ORAL
ENTECAVIRPAR PHARM INC 0.5MG A206294 001 Nov 23, 2016
1MG A206294 002 Nov 23, 2016EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDECASI PHARMS INC 0.05% A203384 001 Dec 07, 2016
SUN PHARM INDS 0.05% A091626 001 Oct 31, 2011EPINEPHRINEAEROSOL, METERED; INHALATION
BRONKAID MIST

STERLING 0.25MG/INH N016803 001

EPINEPHRINE

ARMSTRONG PHARMS 0.2MG/INH A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS 0.2MG/INH N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

FOREST LABS 1.5MG/AMP N007942 003 Feb 05, 1999
5MG/ML N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPECIALITY LP 0.15MG/DELIVERY N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECIALITY LP 0.3MG/DELIVERY N019430 003 Aug 03, 1995

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.15

IMPAX EQ 0.15MG/DELIVERY N020800 002 May 28, 2004

TWINJECT 0.3

IMPAX EQ 0.3MG/DELIVERY N020800 001 May 30, 2003

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

AM REGENT EQ 1MG BASE/ML (EQ 1MG BASE/ML) A207568 001 Jul 06, 2018

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS 0.3MG/INH N016126 002

MEDIHALER-EPI

3M 0.3MG/INH N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 1% ** N017751 006

+ 0.005MG/ML; 1.5% ** N017751 007

+ DENTSPLY PHARM 0.005MG/ML; 1.5% ** N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA 0.005MG/ML; 4% N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.005MG/ML; 0.5% ** N017751 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE				
CARLISLE	0.01MG/ML;2%	A084720	001	
	0.02MG/ML;2%	A084732	001	
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983
	0.02MG/ML;2%	A080504	005	Oct 19, 1983
EASTMAN KODAK	0.01MG/ML;2%	A040057	002	Feb 26, 1993
	0.02MG/ML;2%	A040057	001	Feb 26, 1993
HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988
	0.01MG/ML;2%	A078772	001	May 12, 2008
	0.02MG/ML;2%	A078772	002	May 12, 2008
WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
ABBOTT	0.01MG/ML;1%	A083154	001	
BEL MAR	0.01MG/ML;1%	A080820	001	
	0.01MG/ML;2%	A080757	001	
DELL LABS	0.01MG/ML;1%	A083389	001	
	0.01MG/ML;2%	A083390	001	
INTL MEDICATION	0.01MG/ML;1%	A086402	001	
WATSON LABS	0.01MG/ML;1%	A080377	003	
	0.01MG/ML;1%	A085463	001	
	0.01MG/ML;2%	A080377	004	
LIDOCATON				
PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983
OCTOCAINE				
SEPTODONT	0.01MG/ML;2%	A084048	001	
	0.02MG/ML;2%	A084048	002	
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2% **	N021381	001	
	0.02MG/ML;2% **	N021381	002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	
PATCH; IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
SOLUTION; IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
SOLUTION; IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE				
ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
FRESENIUS KABI USA	200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007
	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007
HOSPIRA	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007
	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
	150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007
	200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012
	200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012
ZENNOVA	50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011

POWDER; INTRAVENOUS

EPIRUBICIN HYDROCHLORIDE

HOSPIRA	50MG/VIAL	N050807 001	Sep 15, 2006
	200MG/VIAL	N050807 002	Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPIRA

GD SEARLE LLC	100MG	N021437 003	Sep 27, 2002
---------------	-------	-------------	--------------

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE	EQ 300MG BASE	N020738 004	Dec 22, 1997
+	EQ 400MG BASE	N020738 005	Dec 22, 1997
+	EQ 600MG BASE	N020738 006	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE	600MG; 12.5MG	N021268 001	Nov 01, 2001
	600MG; 25MG	N021268 002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

TEVA PHARMS USA	75MG/100ML	A091555 001	Jun 05, 2015
USV	2MG/ML	A204361 001	Mar 14, 2019
	2MG/ML	A204362 001	Mar 11, 2019
	75MG/100ML	A204361 002	Mar 14, 2019

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY	50,000 IU	A080884 001	
-------	-----------	-------------	--

VITAMIN D

CHASE CHEM	50,000 IU	A080747 001	
EVERYLIFE	50,000 IU	A080956 001	
IMPAX LABS	50,000 IU	A080951 001	
LANNETT	50,000 IU	A080825 001	
VITARINE	50,000 IU	A084053 001	
WEST WARD	50,000 IU	A083102 001	

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS	1MG	N018706 001	Jan 18, 1983
----------	-----	-------------	--------------

SOLUTION; ORAL

HYDERGINE

NOVARTIS	1MG/ML	N018418 001	
----------	--------	-------------	--

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM	1MG	A088891 001	Nov 01, 1985
WATSON LABS	1MG	A086433 001	May 27, 1982
	1MG	A087244 001	Aug 16, 1982

GERIMAL

WATSON LABS	1MG	A088207 001	Mar 22, 1984
-------------	-----	-------------	--------------

HYDERGINE

NOVARTIS	0.5MG	N017993 003	
----------	-------	-------------	--

+	1MG	N017993 001	
---	-----	-------------	--

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ	0.5MG	A085153 001	
	1MG	A087417 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERGOLOID MESYLATES

TABLET;SUBLINGUAL

CIRCANOL

3M	0.5MG	A084868	001
	1MG	A085809	001

DEAPRIL-ST

BRISTOL MYERS SQUIBB	1MG	A085020	002
----------------------	-----	---------	-----

ERGOLOID MESYLATES

KV PHARM	0.5MG	A085899	001
	0.5MG	A086265	001
	1MG	A085900	001
	1MG	A086264	001

LEDERLE	0.5MG	A086984	001
	1MG	A086985	001

SUN PHARM INDUSTRIES	0.5MG	A087407	001
	1MG	A087552	001

SUPERPHARM	0.5MG	A089233	001 Sep 23, 1986
	1MG	A089234	001 Sep 23, 1986

VANGARD	0.5MG	A088013	001 Sep 20, 1982
	1MG	A088014	001 Sep 20, 1982

WATSON LABS	0.5MG	A084930	001
	0.5MG	A087233	001
	1MG	A085177	001
	1MG	A087183	001

GERIMAL

WATSON LABS	0.5MG	A086189	001
	1MG	A086188	001

HYDERGINE

NOVARTIS	0.5MG	N009087	002
	1MG	N009087	001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS	0.5MG	A087186	001
	1MG	A087185	001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE

3M	0.36MG/INH	N012102	001
----	------------	---------	-----

TABLET;SUBLINGUAL

ERGOSTAT

WATSON LABS INC	2MG	A088337	001 Jun 08, 1984
-----------------	-----	---------	------------------

WIGRETTES

ORGANON USA INC	2MG	A086750	001 Jul 29, 1982
-----------------	-----	---------	------------------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

PARKE DAVIS	250MG	A062546	001 Jul 25, 1985
	250MG	A062618	001 Sep 25, 1985
	250MG	A062338	001

ERYC 125

PARKE DAVIS	125MG	A062648	001 Oct 24, 1985
-------------	-------	---------	------------------

ERYC SPRINKLES

HOSPIRA	125MG	N050593	001 Jul 22, 1985
---------	-------	---------	------------------

ERYTHROMYCIN

BARR	250MG	A063098	001 May 04, 1989
------	-------	---------	------------------

GEL;TOPICAL

E-GLADES

MYLAN	2%	A065009	001 Mar 18, 2002
-------	----	---------	------------------

EMGEL

ALTANA	2%	A063107	001 Aug 23, 1991
--------	----	---------	------------------

LOTION;TOPICAL

E-SOLVE 2

SYOSSET	2%	A062467	001 Jul 03, 1985
---------	----	---------	------------------

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM	5MG/GM	A062446	001 Sep 26, 1983
PHARMAFAIR	5MG/GM	A062481	001 Apr 05, 1984

ILOTYCIN

DISTA	0.5%	N050368	001
-------	------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN

OINTMENT; TOPICAL			
AKNE-MYCIN			
+ BAUSCH	2%	N050584 001	Jan 10, 1985
POWDER; FOR RX COMPOUNDING			
ERYTHROMYCIN			
PADDOCK LLC	100%	N050610 001	Nov 07, 1986
SOLUTION; TOPICAL			
A/T/S			
TARO	2%	A062405 001	Nov 18, 1982
C-SOLVE-2			
FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985
ERYDERM			
ARBOR PHARMS INC	2%	A062290 001	
ERYMAX			
MERZ PHARMS	2%	A062508 002	Jul 11, 1985
ERYTHRA-DERM			
MLV	2%	A062687 001	Feb 05, 1988
ERYTHRO-STATIN			
HI TECH PHARMA	2%	A064101 001	Oct 22, 1996
ERYTHROMYCIN			
ALPHARMA US PHARMS	1.5%	A062328 001	Apr 19, 1982
	2%	A062326 001	Apr 19, 1982
	2%	A062327 001	Apr 19, 1982
	2%	A062342 001	Feb 25, 1982
	2%	A062957 001	Jul 21, 1988
BAUSCH AND LOMB	2%	A064039 001	Jan 27, 1994
FOUGERA PHARMS	2%	A064187 001	Sep 30, 1997
LILLY	2%	N050532 001	
PHARMAFAIR	1.5%	A062485 001	Jul 11, 1984
	2%	A062616 001	Jul 25, 1985
RENAISSANCE PHARMA	2%	A064127 001	Feb 14, 1997
SANSAC			
DOW PHARM	2%	A062522 001	Jan 24, 1985
STATICIN			
+ WESTWOOD SQUIBB	1.5% **	N050526 001	
T-STAT			
WESTWOOD SQUIBB	2% **	A062436 001	Mar 09, 1983
SWAB; TOPICAL			
C-SOLVE-2			
IVAX SUB TEVA PHARMS	2%	A062751 001	Jul 30, 1993
ERYCETTE			
+ JOHNSON AND JOHNSON	2% **	N050594 001	Feb 15, 1985
ERYTHROMYCIN			
FOUGERA PHARMS	2%	A065320 001	Jul 25, 2006
MYLAN	2%	A064128 001	Jul 03, 1996
T-STAT			
WESTWOOD SQUIBB	2%	A062748 001	Jul 23, 1987
TABLET, COATED PARTICLES; ORAL			
PCE			
+ ARBOR PHARMS LLC	333MG	N050611 001	Sep 09, 1986
+	500MG	N050611 002	Aug 22, 1990
TABLET, DELAYED RELEASE; ORAL			
E-BASE			
BARR	333MG	A063028 001	May 15, 1990
	333MG	A063086 001	May 15, 1990
	500MG	A062999 001	Nov 25, 1988
E-MYCIN			
ARBOR PHARMS INC	250MG	A060272 001	
	333MG	A060272 002	
ILOTYCIN			
DISTA	250MG	A061910 001	
R-P MYCIN			
SOLVAY	250MG	A061659 001	
ROBIMYCIN			
ROBINS AH	250MG	A061633 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162 001	
	EQ 250MG BASE	A062162 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237 001	
WATSON LABS	EQ 250MG BASE	A062087 001	

ILOSONE

LILLY	EQ 125MG BASE	A061897 001	
	EQ 250MG BASE	A061897 002	

FOR SUSPENSION; ORAL

ILOSONE

DISTA	EQ 125MG BASE/5ML	A061893 001	
-------	-------------------	-------------	--

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ACP NIMBLE	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982

ILOSONE

LILLY	EQ 125MG BASE/5ML	A061894 001	
	EQ 125MG BASE/5ML	N050010 001	
	EQ 250MG BASE/5ML	A061894 002	
	EQ 250MG BASE/5ML	N050010 002	

SUSPENSION/DROPS; ORAL

ILOSONE

LILLY	EQ 100MG BASE/ML	A061894 003	
-------	------------------	-------------	--

TABLET; ORAL

ILOSONE

LILLY	EQ 500MG BASE	A061896 001	
-------	---------------	-------------	--

TABLET, CHEWABLE; ORAL

ILOSONE

DISTA	EQ 125MG BASE	A061895 001	
	EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML; EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989
-------	--------------------------------------	-------------	--------------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
-----------	-------------------	-------------	--

SUSPENSION; ORAL

E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
	EQ 400MG BASE/5ML	A062198 002	

E.E.S. 200

ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001	
------------------	----------------------	-------------	--

E.E.S. 400

ARBOR PHARMS LLC	EQ 400MG BASE/5ML **	A061639 002	
------------------	----------------------	-------------	--

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
	EQ 400MG BASE/5ML	A062200 002	
DISTA	EQ 200MG BASE/5ML	A062177 001	
	EQ 400MG BASE/5ML	A062177 002	
NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
	EQ 400MG BASE/5ML	A062231 002	
PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
	EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985

PEDIAMYCIN

ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
------------------	-------------------	-------------	--

PEDIAMYCIN 400

ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
------------------	-------------------	-------------	--

WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
	EQ 400MG BASE/5ML	A062123 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION/DROPS;ORAL

PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

TABLET;ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

TABLET, CHEWABLE;ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE N050297 002

ERYPED

ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

BARR EQ 200MG BASE/5ML;EQ 600MG BASE/5ML A062759 001 May 20, 1988

ERYZOLE

ALRA EQ 200MG BASE/5ML;EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML;EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

EQ 1GM BASE/VIAL N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL N050182 002

EQ 1GM BASE/VIAL A062638 002 Oct 31, 1986

EQ 1GM BASE/VIAL N050182 003

+ EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL A062993 001 May 09, 1989

EQ 1GM BASE/VIAL A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL A063253 001 Jul 30, 1993

EQ 1GM BASE/VIAL A063253 002 Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET;ORAL

BRISTAMYCIN

BRISTOL EQ 250MG BASE A061304 001

EQ 250MG BASE A061887 001

ERYPAR

PARKE DAVIS EQ 250MG BASE A062032 001

EQ 500MG BASE A062032 002

WARNER CHILCOTT EQ 250MG BASE A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC EQ 125MG BASE A060359 002

EQ 500MG BASE A060359 003

ERYTHROMYCIN STEARATE

ANI PHARMS INC EQ 250MG BASE A061461 001

EQ 250MG BASE A061591 001

EQ 500MG BASE A061461 002

EQ 500MG BASE A063179 001 May 15, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROMYCIN STEARATE

LEDERLE	EQ 250MG BASE	A062089 001	
	EQ 500MG BASE	A062089 002	
MYLAN	EQ 250MG BASE	A061505 001	
	EQ 500MG BASE	A061505 002	
PUREPAC PHARM	EQ 250MG BASE	A061743 001	
WATSON LABS	EQ 250MG BASE	A062121 002	
	EQ 500MG BASE	A062121 001	
ETHRIL 250			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001	
ETHRIL 500			
BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002	
PFIZER-E			
PFIZER	EQ 250MG BASE	A061791 001	
	EQ 500MG BASE	A061791 002	
WYAMYCIN S			
WYETH AYERST	EQ 250MG BASE	A061675 001	
	EQ 500MG BASE	A061675 002	

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007
	EQ 10MG BASE	A077660 002	Jul 31, 2007
	EQ 20MG BASE	A077660 003	Jul 31, 2007

TABLET; ORAL

ESCITALOPRAM OXALATE

MYLAN	EQ 5MG BASE	A077550 001	May 14, 2015
	EQ 10MG BASE	A077550 002	May 14, 2015
	EQ 20MG BASE	A077550 003	May 14, 2015

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988
	20MG/ML	N019386 007	May 28, 2003

ESMOLOL HYDROCHLORIDE

AM REGENT	10MG/ML	A201126 001	Feb 20, 2015
-----------	---------	-------------	--------------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY	EQ 20MG BASE	A209647 001	Apr 10, 2019
	EQ 40MG BASE	A209647 002	Apr 10, 2019
HEC PHARM	EQ 20MG BASE	A207265 002	May 18, 2018
	EQ 40MG BASE	A207265 001	May 18, 2018

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

P AND L	EQ 20MG BASE	A209202 001	Mar 05, 2019
---------	--------------	-------------	--------------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657 001	Aug 10, 2016
MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686 001	May 17, 2017
SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882 001	Mar 18, 2013
NEXIUM IV			
+ ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL **	N021689 001	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

+ R2 PHARMA LLC	24.65MG	N202342 001	Aug 06, 2013
+	49.3MG	N202342 002	Aug 06, 2013

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTAZOLAM

TABLET; ORAL

PROSOM

+ ABBOTT

1MG **

N019080 001 Dec 26, 1990

+

2MG **

N019080 002 Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE 0.025MG/24HR
 0.0375MG/24HR
 0.05MG/24HR
 0.075MG/24HR
 0.1MG/24HR

N020847 001 Aug 04, 1998
 N020847 002 Aug 04, 1998
 N020847 003 Aug 04, 1998
 N020847 004 Aug 04, 1998
 N020847 005 Aug 04, 1998

ESTRADERM

+ NOVARTIS

0.05MG/24HR

N019081 002 Sep 10, 1986

+

0.1MG/24HR

N019081 003 Sep 10, 1986

ESTRADIOL

ORTHO MCNEIL PHARM 0.05MG/24HR
 0.075MG/24HR
 0.1MG/24HR

N021048 001 Sep 20, 1999
 N021048 002 Sep 20, 1999
 N021048 003 Sep 20, 1999

FEMPATCH

PARKE DAVIS 0.025MG/24HR

N020417 001 Dec 03, 1996

VIVELLE

NOVARTIS 0.025MG/24HR
 0.0375MG/24HR
 0.05MG/24HR
 0.075MG/24HR
 0.1MG/24HR

N020323 005 Aug 16, 2000
 N020323 001 Oct 28, 1994
 N020323 002 Oct 28, 1994
 N020323 003 Oct 28, 1994
 N020323 004 Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND THERAPS US 0.06%

N021166 001 Feb 09, 2004

TABLET; ORAL

ESTRACE

BRISTOL MYERS SQUIBB 0.5MG
 1MG
 2MG

A081295 001 Jun 30, 1993
 A084499 001
 A084500 001

ESTRADIOL

LANNETT HOLDINGS INC 0.5MG
 1MG
 2MG
 USL PHARMA 0.5MG
 1MG
 2MG

A040138 001 Jan 30, 1998
 A040138 002 Jan 30, 1998
 A040138 003 Jan 30, 1998
 A040297 001 Apr 17, 2002
 A040297 002 Apr 17, 2002
 A040297 003 Apr 17, 2002

GYNODIOL

DURAMED PHARMS BARR 0.5MG
 1MG
 1.5MG
 2MG

A040212 001 Dec 29, 1997
 A040212 002 Dec 29, 1997
 A040212 003 Dec 29, 1997
 A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC 0.5MG
 1MG
 2MG

A040312 001 Nov 19, 1999
 A040312 002 Nov 19, 1999
 A040312 003 Nov 19, 1999

TABLET; VAGINAL

VAGIFEM

+ NOVO NORDISK INC 25MCG **

N020908 001 Mar 26, 1999

ESTRADIOL ACETATE

TABLET; ORAL

FEMTRACE

+ APIL 0.45MG

N021633 001 Aug 20, 2004

+

0.9MG

N021633 002 Aug 20, 2004

+

1.8MG

N021633 003 Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN 1MG/ML
 3MG/ML

A085470 001

A085470 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTRADIOL CYPIONATEINJECTABLE; INJECTION
ESTRADIOL CYPIONATE
DR REDDYS

5MG/ML

A085620 001

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATEINJECTABLE; INTRAMUSCULAR
LUNELLE

PHARMACIA AND UPJOHN 5MG/0.5ML; 25MG/0.5ML

N020874 001 Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
DEPO-TESTADIOL

PHARMACIA AND UPJOHN 2MG/ML; 50MG/ML

N017968 001

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
WATSON LABS

2MG/ML; 50MG/ML

A085603 001 Mar 13, 1986

ESTRADIOL HEMIHYDRATEEMULSION; TOPICAL
ESTRASORB

+ EXELTIS USA INC

0.25%

N021371 001 Oct 09, 2003

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

DR REDDYS 20MG/ML

A083547 001

40MG/ML

A083714 001

FOSUN PHARMA 10MG/ML

A040628 001 Oct 04, 2007

20MG/ML

A040628 002 Oct 04, 2007

40MG/ML

A040628 003 Oct 04, 2007

WATSON LABS 10MG/ML

A083546 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
DITATE-DS

SAVAGE LABS 8MG/ML; 180MG/ML

A086423 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS 4MG/ML; 90MG/ML

A085865 001

8MG/ML; 180MG/ML

A085860 001

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

ACCORD HLTHCARE 1MG; 0.5MG

A210233 001 Feb 28, 2018

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ TEVA WOMENS

1MG, 1MG; N/A, 0.09MG **

N021040 001 Oct 22, 1999

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS 2.5MG

N004782 002

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS 0.625MG/GM

N021788 001 Nov 28, 2008

TABLET; ORAL

CENESTIN

+ ASPEN

0.3MG **

N020992 001 Jun 21, 2002

+

0.45MG **

N020992 005 Feb 05, 2004

+

0.625MG **

N020992 002 Mar 24, 1999

+

0.9MG **

N020992 003 Mar 24, 1999

+

1.25MG **

N020992 004 Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVA

ASPEN 0.3MG

N021443 001 Dec 20, 2004

0.45MG

N021443 002 Dec 20, 2004

0.625MG **

N021443 003 May 10, 2004

0.9MG

N021443 005 Apr 27, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

1.25MG **

N021443 004 May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC 0.625MG, 0.625MG; N/A, 5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC 0.625MG, 0.625MG; 2.5MG, 2.5MG

N020303 001 Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC 0.45MG; 200MG

N011045 002

MILPREM-400

MEDPOINTE PHARM HLC 0.45MG; 400MG

N011045 001

PMB 200

WYETH AYERST 0.45MG; 200MG

N010971 005

PMB 400

WYETH AYERST 0.45MG; 400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB 0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM 0.625MG

A083414 001

1.25MG

A083765 001

2.5MG

A085907 001

SANDOZ 1.25MG

A085302 001

ESTRATAB

SOLVAY 0.3MG

A086715 001

0.625MG

A083209 001

1.25MG

A083856 001

2.5MG

A083857 001

EVEX

ROCHE PALO 0.625MG

A084215 001

1.25MG

A083376 002

FEMOGEN

PVT FORM 0.625MG

A085076 001

1.25MG

A085008 001

2.5MG

A085007 001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST 2MG/ML

A083488 001

ESTRONE

DR REDDYS 5MG/ML

A085239 001

WATSON LABS 2MG/ML

A083397 001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS 2MG/ML

A085237 001 Nov 23, 1982

THEELIN

PARKEDALE 1MG/ML

N003977 001

2MG/ML

N003977 002

5MG/ML

N003977 003

ESTROPIPATE

CREAM; VAGINAL

OGEN

PHARMACIA AND UPJOHN 1.5MG/GM

A084710 001

TABLET; ORAL

ESTROPIPATE

BARR 0.75MG

A040135 001 Nov 27, 1996

1.5MG

A040135 002 Nov 27, 1996

3MG

A040135 003 Nov 27, 1996

DURAMED PHARMS BARR 0.75MG

A040296 001 Nov 01, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

	1.5MG	A040296 002	Nov 01, 1999
	3MG	A040296 003	Nov 01, 1999
MYLAN	3MG	A040359 003	Aug 26, 1999
WATSON LABS	0.75MG	A081213 001	Sep 23, 1993
	1.5MG	A081214 001	Sep 23, 1993
	6MG	A081216 001	Sep 23, 1993
WATSON LABS TEVA	3MG	A081215 001	Sep 23, 1993
OGEN .625			
PHARMACIA AND UPJOHN	0.75MG	A083220 001	
OGEN 1.25			
PHARMACIA AND UPJOHN	1.5MG	A083220 002	
OGEN 2.5			
PHARMACIA AND UPJOHN	3MG	A083220 003	
ORTHO-EST			
SUN PHARM INDS INC	0.75MG	A089567 001	Feb 27, 1991
	1.5MG	A089582 001	Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

BRECKENRIDGE	1MG	A203087 001	May 08, 2019
	2MG	A203087 002	May 08, 2019
	3MG	A203087 003	May 08, 2019
WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011
	2MG	A091165 002	Jul 14, 2011
	3MG	A091165 003	Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

BAUSCH	50MG	N016092 002	
--------	------	-------------	--

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

STI PHARMA LLC	200MG	N016320 002	
	500MG	N016320 004	

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463 001	
	200MG	A084463 002	
	500MG	A084463 003	
	750MG	A084463 004	

PLACIDYL

ABBVIE	100MG	N010021 004	
	200MG	N010021 007	
	500MG	N010021 002	
	750MG	N010021 010	

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA	500MG	N009750 001	
-------	-------	-------------	--

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING	0.02MG	N005292 001	
	0.05MG	N005292 002	
	0.5MG	N005292 003	

FEMINONE

PHARMACIA AND UPJOHN	0.05MG	N016649 001	
----------------------	--------	-------------	--

LYNORAL

ORGANON USA INC	0.01MG	N005490 003	
	0.05MG	N005490 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC 0.035MG;1MG **

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC 0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON PHARMS TEVA 0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS 0.05MG;1MG

A072722 001 Dec 30, 1991

TABLET;ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC 0.035MG;1MG **

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC 0.05MG;1MG **

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE

GD SEARLE LLC 0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS 0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS 0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LYBREL

+ WYETH PHARMS INC 0.02MG;0.09MG **

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM 0.05MG;0.25MG

N020946 001 Sep 01, 1998

TABLET;ORAL-21

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG **

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR 0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR 0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG **

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS 0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM 0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR 0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

+ WYETH PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **

N019192 001 Nov 01, 1984

TRIVORA-21

MAYNE PHARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A074538 001 Dec 18, 1997

TABLET;ORAL-28

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG **

N020683 002 Mar 27, 1997

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG **

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG

A075862 002 Apr 29, 2003

MYLAN LABS LTD 0.02MG;0.1MG

A202247 001 Dec 08, 2014

NORDETTE-28

+ TEVA BRANDED PHARM 0.03MG;0.15MG **

N018782 001 Jul 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

TRIPHASIL-28

+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov	01, 1984
---	------------------	--	---------	-----	-----	----------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov	20, 2001
---	----------------	-----------------------------	---------	-----	-----	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BALZIVA-21

BARR	0.035MG;0.4MG	A076198	001	Apr	22, 2004
------	---------------	---------	-----	-----	----------

BREVICON 21-DAY

ALLERGAN	0.035MG;0.5MG	N017566	001		
----------	---------------	---------	-----	--	--

GENCEPT 10/11-21

BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb	28, 1992
------	---------------------------	---------	-----	-----	----------

MODICON 21

ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001		
--------------------	------------------	---------	-----	--	--

N.E.E. 1/35 21

LPI	0.035MG;1MG	A071541	001	Dec	14, 1987
-----	-------------	---------	-----	-----	----------

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb	09, 1989
--------------------	-------------	---------	-----	-----	----------

NORETHIN 1/35E-21

WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr	12, 1988
--------------------	-------------	---------	-----	-----	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS	0.035MG;0.4MG	A078379	001	Feb	23, 2010
-------------	---------------	---------	-----	-----	----------

	0.035MG;0.5MG	A070684	001	Jan	29, 1987
--	---------------	---------	-----	-----	----------

WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan	29, 1987
--------------------	-------------	---------	-----	-----	----------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr	01, 1988
-------------	---------------------------	---------	-----	-----	----------

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep	24, 1991
------------------	---------------------------	---------	-----	-----	----------

NORTREL 0.5/35-21

BARR	0.035MG;0.5MG	A072692	001	Feb	28, 1992
------	---------------	---------	-----	-----	----------

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM	0.035MG;1MG **	N017489	002		
--------------------	----------------	---------	-----	--	--

ORTHO-NOVUM 10/11-21

+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **	N018354	001	Jan	11, 1982
---	----------------------	------------------------------	---------	-----	-----	----------

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	001	Apr	04, 1984
--------------------	------------------------------	---------	-----	-----	----------

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985	001	Apr	04, 1984
----------------	--	---------	-----	-----	----------

OVCON-35

+	WARNER CHILCOTT	0.035MG;0.4MG **	N018127	001		
---	-----------------	------------------	---------	-----	--	--

OVCON-50

WARNER CHILCOTT	0.05MG;1MG	N018128	001		
-----------------	------------	---------	-----	--	--

TRI-NORINYL 21-DAY

MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr	13, 1984
--------------	---	---------	-----	-----	----------

TABLET;ORAL-28

GENCEPT 10/11-28

BARR	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb	28, 1992
------	---------------------------	---------	-----	-----	----------

MODICON 28

+	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001		
---	----------------	---------------	---------	-----	--	--

N.E.E. 1/35 28

LPI	0.035MG;1MG	A071542	001	Dec	14, 1987
-----	-------------	---------	-----	-----	----------

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb	09, 1989
--------------------	-------------	---------	-----	-----	----------

NORETHIN 1/35E-28

WATSON LABS	0.035MG;1MG	A071481	001	Apr	12, 1988
-------------	-------------	---------	-----	-----	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

MYLAN LABS LTD	0.035MG;0.4MG	A200897	001	May	11, 2015
----------------	---------------	---------	-----	-----	----------

	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec	28, 2015
--	--	---------	-----	-----	----------

	0.035MG;0.5MG	A200488	001	Oct	21, 2015
--	---------------	---------	-----	-----	----------

	0.035MG;1MG	A200489	001	Oct	21, 2015
--	-------------	---------	-----	-----	----------

	0.05MG;1MG	A203006	001	Aug	05, 2013
--	------------	---------	-----	-----	----------

WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,	A076393	001	Feb	04, 2010
-------------	---------------------------------------	---------	-----	-----	----------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL
1MG

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG

A071042 001 Sep 24, 1991

ORTHO-NOVUM 1/35-28

+ JANSSEN PHARMS 0.035MG;1MG

N017919 002

ORTHO-NOVUM 10/11-28

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG

N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG **

N019004 002 Apr 04, 1984

OVCON-35

+ WARNER CHILCOTT LLC 0.035MG;0.4MG **

N017716 001

OVCON-50

WARNER CHILCOTT LLC 0.05MG;1MG **

N017576 001

TABLET, CHEWABLE;ORAL

FEMCON FE

+ APIL 0.035MG;0.4MG

N021490 001 Nov 14, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

+ APIL 0.005MG;1MG **

N021065 002 Oct 15, 1999

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

MYLAN LABS LTD 0.01MG,0.01MG;1MG,N/A

A205049 001 May 31, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

APOTEX 0.02MG;1MG

A208639 001 Mar 21, 2018

TABLET;ORAL-21

ESTROSTEP 21

+ APIL 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **

N020130 001 Oct 09, 1996

NORLESTRIN 21 1/50

PARKE DAVIS 0.05MG;1MG

N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS 0.05MG;2.5MG

N016852 001

TABLET;ORAL-28

NORLESTRIN 28 1/50

PARKE DAVIS 0.05MG;1MG

N016723 001

TABLET, CHEWABLE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

MYLAN LABS LTD 0.02MG;1MG

A206120 001 Sep 12, 2017

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

+ APIL 0.01MG,0.01MG,N/A;1MG,N/A,N/A

N204654 001 Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21

ORTHO CYCLEN-21

JANSSEN PHARMS 0.035MG;0.25MG

N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,
0.25MG

N019697 002 Jul 03, 1992

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,
0.25MG

A202132 001 Sep 09, 2015

WATSON LABS 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,
0.25MG

A090479 001 Mar 09, 2011

0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,
0.25MG

A076626 001 Aug 17, 2006

0.035MG;0.25MG

A076627 001 Aug 17, 2006

ORTHO CYCLEN-28

+ JANSSEN PHARMS 0.035MG;0.25MG

N019653 002 Dec 29, 1989

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

CADENCE HEALTH 0.03MG;0.3MG

N017612 001

LOW-OGESTREL-21

MAYNE PHARMA 0.03MG;0.3MG

A075288 001 Jul 28, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21				
OGESTREL 0.5/50-21				
WATSON LABS	0.05MG; 0.5MG		A075406 001	Dec 15, 1999
OVRAL				
WYETH PHARMS	0.05MG; 0.5MG		N016672 001	
TABLET; ORAL-28				
LO/OVRAL-28				
WYETH PHARMS	0.03MG; 0.3MG **		N017802 001	
NORGESTREL AND ETHINYL ESTRADIOL				
MYLAN LABS LTD	0.03MG; 0.3MG		A201828 001	Jun 21, 2016
	0.05MG; 0.5MG		A202875 001	May 08, 2017
OVRAL-28				
WYETH PHARMS	0.05MG; 0.5MG		N016806 001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL				
PARSIDOL				
PARKE DAVIS	10MG		N009078 003	
	50MG		N009078 006	
	100MG		N009078 008	

ETHOSUXIMIDE

SYRUP; ORAL				
ETHOSUXIMIDE				
TEVA PHARMS	250MG/5ML		A081306 001	Jul 30, 1993

ETHOTOIN

TABLET; ORAL				
PEGANONE				
RECORDATI RARE	500MG		N010841 003	

ETHOXZOLAMIDE

TABLET; ORAL				
CARDRASE				
PHARMACIA AND UPJOHN	62.5MG		N011047 002	
	125MG		N011047 001	
ETHAMIDE				
ALLERGAN	125MG		N016144 001	

ETHYLESTRENOL

ELIXIR; ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG/5ML		N014006 002	
TABLET; ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG		N014005 002	

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20				
OVULEN				
GD SEARLE LLC	1MG; 0.1MG		N016029 002	
TABLET; ORAL-21				
OVULEN-21				
GD SEARLE LLC	1MG; 0.1MG		N016029 003	
TABLET; ORAL-28				
OVULEN-28				
GD SEARLE LLC	1MG; 0.1MG		N016705 001	

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
DURANEST				
+ ASTRAZENECA	0.5% **		N017751 003	
+	1% **		N017751 005	

ETIDRONATE DISODIUM

INJECTABLE; INJECTION				
DIDRONEL				
MGI PHARMA INC	50MG/ML		N019545 001	Apr 20, 1987
TABLET; ORAL				
DIDRONEL				
+ APIL	200MG **		N017831 001	
+	400MG **		N017831 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETIDRONATE DISODIUM

TABLET;ORAL

ETIDRONATE DISODIUM

MYLAN

200MG

A075800 001 Jan 24, 2003

400MG

A075800 002 Jan 24, 2003

ETODOLAC

CAPSULE;ORAL

ETODOLAC

ANI PHARMS INC

200MG

A074840 001 Aug 29, 1997

200MG

A074844 001 Dec 23, 1997

200MG

A074899 001 Jul 08, 1997

300MG

A074840 002 Aug 29, 1997

300MG

A074844 002 Dec 23, 1997

300MG

A074899 002 Jul 08, 1997

CHARTWELL MOLECULES

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

ECI PHARMS LLC

300MG

A074929 001 Jan 30, 1998

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074942 001 Sep 30, 1997

300MG

A074942 002 Sep 30, 1997

LODINE

+ WYETH PHARMS INC

200MG **

N018922 002 Jan 31, 1991

+

300MG

N018922 003 Jan 31, 1991

TABLET;ORAL

ETODOLAC

CHARTWELL MOLECULES

400MG

A074841 001 Jun 27, 1997

ECI PHARMS LLC

400MG

A074927 001 Oct 30, 1997

INVATECH

400MG

A074839 001 Jul 11, 1997

400MG

A074846 001 Feb 28, 1997

IVAX SUB TEVA PHARMS

400MG

A074883 001 Feb 28, 1997

500MG

A074883 002 Nov 20, 1998

MYLAN

400MG

A075012 001 Sep 30, 1998

400MG

A075104 001 Feb 06, 1998

500MG

A075012 002 Sep 30, 1998

500MG

A075104 002 Nov 20, 1998

OXFORD PHARMS

400MG

A074819 001 Feb 28, 1997

500MG

A074819 002 Apr 28, 1998

RANBAXY LABS LTD

400MG

A075226 001 Nov 24, 1998

500MG

A075226 002 Nov 24, 1998

TEVA

400MG

A074847 001 Apr 23, 1999

500MG

A074847 002 Apr 23, 1999

WATSON LABS

400MG

A074892 001 Apr 16, 1997

400MG

A075069 001 Apr 16, 1998

500MG

A074892 002 Oct 29, 1998

LODINE

+ WYETH PHARMS INC

400MG **

N018922 004 Jul 29, 1993

+

500MG **

N018922 005 Jun 28, 1996

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

ACTAVIS ELIZABETH

400MG

A075696 001 Jul 31, 2000

ANI PHARMS INC

400MG

A075943 001 Jul 26, 2002

500MG

A075943 002 Jul 26, 2002

600MG

A075943 003 Jul 26, 2002

WATSON LABS FLORIDA

400MG

A075829 001 Nov 30, 2001

500MG

A075829 002 Nov 30, 2001

LODINE XL

WYETH PHARMS INC

400MG **

N020584 001 Oct 25, 1996

500MG **

N020584 003 Jan 20, 1998

+

600MG **

N020584 002 Oct 25, 1996

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

LUITPOLD 2MG/ML
PAR STERILE PRODUCTS 2MG/MLA078867 001 Dec 22, 2009
A091297 001 Jun 20, 2012ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

ORGANON USA INC 68MG/IMPLANT

N021529 001 Jul 17, 2006

ETOPOSIDE

CAPSULE; ORAL

VEPESID

+ DAVA PHARMS INC 50MG
+ 100MGN019557 001 Dec 30, 1986
N019557 002 Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA 20MG/ML
20MG/ML
PHARMACHEMIE BV 20MG/ML
PIERRE FABRE 20MG/ML
TEVA PARENTERAL 20MG/ML
TEVA PHARMS USA 20MG/ML
WATSON LABS 20MG/ML
WATSON LABS INC 20MG/MLA074320 001 Aug 30, 1995
A074351 001 Aug 30, 1995
A074227 001 Feb 22, 1996
A074813 001 Jul 09, 1997
A074510 001 Jun 29, 1995
A074284 001 Feb 10, 1994
A074228 001 Oct 15, 1996
A074968 001 Jan 09, 1998

TOPOSAR

TEVA PARENTERAL 20MG/ML

A074166 001 Feb 27, 1995

VEPESID

+ CORDEN PHARMA 20MG/ML **

N018768 001 Nov 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL
EQ 1GM BASE/VIALN020906 001 Feb 27, 1998
N020906 002 Feb 27, 1998ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE 10MG
25MGN019369 001 Sep 30, 1986
N019369 002 Sep 30, 1986EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS 0.5% **

N008041 001

EVEROLIMUS

TABLET, FOR SUSPENSION; ORAL

EVEROLIMUS

MYLAN 2MG
3MG
5MGA210130 001 Apr 19, 2019
A210130 002 Apr 19, 2019
A210130 003 Apr 19, 2019EXEMESTANE

TABLET; ORAL

EXEMESTANE

AMNEAL PHARMS 25MG

A206421 001 Dec 28, 2018

EZOGABINE

TABLET; ORAL

POTIGA

+ GLAXOSMITHKLINE 50MG
+ 200MG
+ 300MG
+ 400MGN022345 001 Jun 10, 2011
N022345 002 Jun 10, 2011
N022345 003 Jun 10, 2011
N022345 004 Jun 10, 2011

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FAMCICLOVIR

TABLET; ORAL

FAMVIR

+	NOVARTIS	125MG **	N020363 003	Dec 11, 1995
+		250MG **	N020363 001	Apr 26, 1996
+		500MG **	N020363 002	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID

+	SALIX PHARMS	40MG/5ML	N019527 001	Feb 02, 1987
---	--------------	----------	-------------	--------------

INJECTABLE; INJECTION

FAMOTIDINE

	APOTEX INC	10MG/ML	A075942 001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707 001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075705 001	Apr 16, 2001
		10MG/ML	A075870 001	Nov 23, 2001
		10MG/ML	A075905 001	Nov 23, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075799 001	Apr 30, 2002

FAMOTIDINE PRESERVATIVE FREE

	APOTEX INC	10MG/ML	A076324 001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708 001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075669 001	Apr 16, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075789 001	Apr 30, 2002

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

	APOTEX INC	10MG/ML	A076322 001	Nov 27, 2002
--	------------	---------	-------------	--------------

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	ABBVIE	0.4MG/ML	A075729 001	Dec 17, 2001
--	--------	----------	-------------	--------------

PEPCID

+	MERCK	10MG/ML **	N019510 001	Nov 04, 1986
---	-------	------------	-------------	--------------

PEPCID PRESERVATIVE FREE

+	MERCK	10MG/ML **	N019510 004	Nov 04, 1986
---	-------	------------	-------------	--------------

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+	MERCK SHARP DOHME	0.4MG/ML **	N020249 001	Feb 18, 1994
---	-------------------	-------------	-------------	--------------

TABLET; ORAL

FAMOTIDINE

	ACTAVIS ELIZABETH	20MG	A075650 001	Sep 14, 2001
		40MG	A075650 002	Sep 14, 2001
	APOTEX	10MG	A075610 001	Mar 12, 2002
	MYLAN	40MG	A075704 002	Apr 16, 2001
	MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001
		40MG	A075457 002	Apr 18, 2001
	PLD ACQUISITIONS	20MG	A075302 001	Apr 16, 2001
		40MG	A075302 002	Apr 16, 2001
	SANDOZ	10MG	A076101 001	Oct 21, 2002
		20MG	A075607 001	May 10, 2001
		20MG	A075793 001	Apr 16, 2001
		40MG	A075607 002	May 10, 2001
		40MG	A075793 002	Apr 16, 2001
	SUN PHARM INDUSTRIES	20MG	A075639 002	Dec 12, 2001
		40MG	A075639 001	Dec 12, 2001
	WATSON LABS	10MG	A075404 001	Nov 28, 2001
		20MG	A075062 002	Apr 16, 2001
		40MG	A075062 001	Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

+	J AND J CONSUMER INC	10MG **	N020801 001	Sep 24, 1998
---	----------------------	---------	-------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	UCB INC	20MG	N021712 001	Sep 24, 2004
		40MG	N021712 002	Sep 24, 2004

PEPCID RPD

	MERCK	20MG	N020752 001	May 28, 1998
		40MG	N020752 002	May 28, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

MYLAN	2.5MG	A078855 001	Apr 17, 2008
	5MG	A078855 002	Apr 17, 2008
	10MG	A078855 003	Apr 17, 2008
WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012
	5MG	A091484 002	Aug 15, 2012
	10MG	A091484 003	Aug 15, 2012
PLENDIL			
+ ASTRAZENECA	2.5MG **	N019834 004	Sep 22, 1994
+	5MG **	N019834 001	Jul 25, 1991
+	10MG **	N019834 002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695 002	Nov 30, 2004
----------------	------	-------------	--------------

FENOFIBRATE (MICRONIZED)

NOVAST LABS	67MG	A207564 001	Apr 19, 2019
	134MG	A207564 002	Apr 19, 2019
	200MG	A207564 003	Apr 19, 2019

LIPIDIL

ABBVIE	100MG	N019304 001	Dec 31, 1993
--------	-------	-------------	--------------

LIPOFEN

CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006
-------------------	-------	-------------	--------------

TRICOR (MICRONIZED)

+ ABBVIE	67MG **	N019304 002	Feb 09, 1998
+	134MG **	N019304 003	Jun 30, 1999
+	200MG **	N019304 004	Jun 30, 1999

TABLET;ORAL

FENOFIBRATE

GRAVITI PHARMS	54MG	A210606 001	Aug 17, 2018
	160MG	A210606 002	Aug 17, 2018
MYLAN	107MG	A076520 002	Dec 29, 2005

TRICOR

+ ABBVIE INC	54MG **	N021203 001	Sep 04, 2001
+	160MG **	N021203 003	Sep 04, 2001

TRIGLIDE

SKYE PHARMA AG	50MG	N021350 001	May 07, 2005
----------------	------	-------------	--------------

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
	EQ 300MG BASE	A072308 001	Aug 22, 1988
AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394 001	Oct 17, 1988
	EQ 300MG BASE	A072395 001	Oct 17, 1988
HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
	EQ 300MG BASE	A072356 001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
	EQ 300MG BASE	A072438 001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
	EQ 300MG BASE	A071738 001	Aug 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
	EQ 300MG BASE	A072472 001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
	EQ 200MG BASE	A072981 001	Aug 19, 1991
	EQ 300MG BASE	A072293 001	Aug 17, 1988
	EQ 300MG BASE	A072982 001	Aug 19, 1991
NALFON			
XSPIRE PHARMA	EQ 300MG BASE	N017604 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
ANI PHARMS INC	EQ 600MG BASE	A072274 001	May 02, 1988
AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396 001	Oct 17, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429 001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902 001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165 001	Aug 17, 1988
	EQ 600MG BASE	A072602 001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407 001	Aug 17, 1988

NALFON

DISTA	EQ 600MG BASE	N017710 001	
-------	---------------	-------------	--

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

ACTAVIS LABS UT INC	100MCG/HR	A076709 004	Aug 20, 2007
MAYNE PHARMA	100MCG/HR	A077062 004	Aug 20, 2007
NOVEN	100MCG/HR	A077775 004	Oct 16, 2009

FENTANYL-25

ACTAVIS LABS UT INC	25MCG/HR	A076709 001	Aug 20, 2007
MAYNE PHARMA	25MCG/HR	A077062 001	Aug 20, 2007
NOVEN	25MCG/HR	A077775 001	Oct 16, 2009

FENTANYL-50

ACTAVIS LABS UT INC	50MCG/HR	A076709 002	Aug 20, 2007
MAYNE PHARMA	50MCG/HR	A077062 002	Aug 20, 2007
NOVEN	50MCG/HR	A077775 002	Oct 16, 2009

FENTANYL-75

ACTAVIS LABS UT INC	75MCG/HR	A076709 003	Aug 20, 2007
MAYNE PHARMA	75MCG/HR	A077062 003	Aug 20, 2007
NOVEN	75MCG/HR	A077775 003	Oct 16, 2009

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

BDSI	EQ 0.2MG BASE	N022266 001	Jul 16, 2009
	EQ 0.4MG BASE	N022266 002	Jul 16, 2009
	EQ 0.6MG BASE	N022266 003	Jul 16, 2009
	EQ 0.8MG BASE	N022266 004	Jul 16, 2009
	EQ 1.2MG BASE	N022266 005	Jul 16, 2009

INJECTABLE;INJECTION

FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636 001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637 001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488 001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE			
DR REDDYS	EQ 0.05MG BASE/ML	A074917 001	Feb 03, 1998

SPRAY, METEDED;NASAL

LAZANDA

+ BTCP PHARMA	EQ 0.3MG BASE	N022569 003	Dec 21, 2015
---------------	---------------	-------------	--------------

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS	EQ 0.1MG BASE	A079075 001	Jan 07, 2011
	EQ 0.2MG BASE	A079075 002	Jan 07, 2011
	EQ 0.4MG BASE	A079075 003	Jan 07, 2011
	EQ 0.6MG BASE	A079075 004	Jan 07, 2011
	EQ 0.8MG BASE	A079075 005	Jan 07, 2011

FENTORA

+ CEPHALON	EQ 0.3MG BASE **	N021947 006	Mar 02, 2007
------------	------------------	-------------	--------------

TABLET;SUBLINGUAL

ABSTRAL

+ SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011
+	EQ 0.2MG BASE	N022510 002	Jan 07, 2011
+	EQ 0.3MG BASE	N022510 003	Jan 07, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

+	EQ 0.4MG BASE	N022510 004	Jan 07, 2011
+	EQ 0.6MG BASE	N022510 005	Jan 07, 2011
+	EQ 0.8MG BASE	N022510 006	Jan 07, 2011

FENTANYL CITRATE

ACTAVIS LABS FL INC

EQ 0.1MG BASE	A207338 001	Nov 17, 2017
EQ 0.2MG BASE	A207338 002	Nov 17, 2017
EQ 0.3MG BASE	A207338 003	Nov 17, 2017
EQ 0.4MG BASE	A207338 004	Nov 17, 2017
EQ 0.6MG BASE	A207338 005	Nov 17, 2017
EQ 0.8MG BASE	A207338 006	Nov 17, 2017

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE	N020195 007	Oct 30, 1995
EQ 0.2MG BASE	N020195 001	Oct 04, 1993
EQ 0.3MG BASE	N020195 002	Oct 04, 1993
EQ 0.4MG BASE	N020195 003	Oct 04, 1993

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

PAR PHARM

EQ 0.2MG BASE	A077312 001	Oct 30, 2009
EQ 0.4MG BASE	A077312 002	Oct 30, 2009
EQ 0.6MG BASE	A077312 003	Oct 30, 2009
EQ 0.8MG BASE	A077312 004	Oct 30, 2009
EQ 1.2MG BASE	A077312 005	Oct 30, 2009
EQ 1.6MG BASE	A077312 006	Oct 30, 2009

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338 001	May 22, 2006
---	------------------	--------------------------	-------------	--------------

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET	N020292 001	Oct 14, 1997
--------------	-------------	--------------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION; INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317 002	Sep 04, 2015
---	----------------------	----------------------------------	-------------	--------------

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML	N016729 001	
----------	-------------	--

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG; 0.33MG	N006012 003	
---------------	-------------	--

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML	N020416 001	Aug 30, 1996
-------------------	-------------	--------------

FERUMOXSIIL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML	N020410 001	Dec 06, 1996
--------------------	-------------	--------------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

ALKEM LABS LTD

4MG

A204827 001	Dec 10, 2015
-------------	--------------

8MG

A204827 002	Dec 10, 2015
-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US 60MG **

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR 60MG

A076169 001 Jul 13, 2005

SUSPENSION; ORAL

ALLEGRA

+ SANOFI AVENTIS US 30MG/5ML

N021963 001 Oct 16, 2006

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG/5ML

N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

TARO 30MG/5ML

A208123 001 Nov 09, 2017

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

TARO 30MG/5ML

A208123 002 Nov 09, 2017

FEXOFENADINE HYDROCHLORIDE

P AND L 30MG/5ML

A201311 001 Jul 25, 2012

TABLET; ORAL

ALLEGRA HIVES

+ SANOFI AVENTIS US 60MG

N020872 008 Jan 24, 2011

+ 180MG

N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

MYLAN 30MG

A077081 004 Jul 21, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

MYLAN 30MG

A077081 005 Jul 21, 2011

FEXOFENADINE HYDROCHLORIDE

MYLAN 30MG

A077081 002 Apr 11, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG

N021909 002 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N021909 003 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

BARR 60MG; 120MG

A076236 001 Apr 14, 2005

IMPAX PHARMS 60MG; 120MG

A076298 001 Nov 12, 2010

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE 154uCi/VIAL

N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT 140uCi/ML

N017787 001

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

+ MERLION PHARMS GMBH 0.3%

N206307 001 Dec 17, 2014

FINASTERIDE

TABLET; ORAL

FINASTERIDE

GEDEON RICHTER USA 5MG

A077251 001 Dec 22, 2006

IVAX SUB TEVA PHARMS 5MG

A076340 001 Jun 19, 2006

MYLAN 1MG

A078161 001 Nov 05, 2013

5MG

A077578 001 Dec 18, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

IMPAX PHARMS

100MG

A076234 001 Aug 28, 2003

URISPAS

ORTHO MCNEIL JANSSEN 100MG

N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

ANI PHARMS INC

50MG

A076030 001 Oct 28, 2002

100MG

A076030 002 Oct 28, 2002

150MG

A076030 003 Oct 28, 2002

APOTEX INC

50MG

A079164 001 Jul 09, 2009

100MG

A079164 002 Jul 09, 2009

150MG

A079164 003 Jul 09, 2009

TAMBOCOR

CNTY LINE PHARMS 200MG

N018830 002 Oct 31, 1985

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML)

N202008 001 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

LUITPOLD

500MG/VIAL

A203008 001 Nov 22, 2017

FUDR

+

HOSPIRA

500MG/VIAL **

N016929 001

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

IVAX SUB TEVA PHARMS 50MG/5ML

A077523 001 Sep 12, 2007

200MG/5ML

A077523 002 Sep 12, 2007

SUN PHARM INDS LTD

50MG/5ML

A076332 001 Jul 29, 2004

200MG/5ML

A076332 002 Jul 29, 2004

TARO PHARM INDS

50MG/5ML

A076918 001 Dec 18, 2006

200MG/5ML

A076918 002 Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+

PFIZER

200MG/100ML (2MG/ML)

N019950 003 Sep 29, 1992

+

PFIZER

400MG/200ML (2MG/ML)

N019950 005 Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+

PFIZER

200MG/100ML (2MG/ML)

N019950 001 Jan 29, 1990

+

PFIZER

400MG/200ML (2MG/ML)

N019950 006 Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+

PFIZER

200MG/100ML (2MG/ML)

N019950 002 Jan 29, 1990

+

PFIZER

400MG/200ML (2MG/ML)

N019950 004 Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

MYLAN LABS LTD

200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

DR REDDYS

200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004

400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

DR REDDYS

200MG/100ML (2MG/ML)

A076837 001 Jan 13, 2005

400MG/200ML (2MG/ML)

A076837 002 Jan 13, 2005

HOSPIRA

200MG/100ML (2MG/ML)

A076617 001 Jul 29, 2004

400MG/200ML (2MG/ML)

A076617 002 Jul 29, 2004

MYLAN LABS LTD

200MG/100ML (2MG/ML)

A076889 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076889 002 Mar 25, 2005

TABLET; ORAL

FLUCONAZOLE

ANI PHARMS INC

50MG

A076086 001 Jul 29, 2004

100MG

A076086 002 Jul 29, 2004

150MG

A076086 003 Jul 29, 2004

200MG

A076086 004 Jul 29, 2004

GEDEON RICHTER USA

50MG

A076432 001 Jul 29, 2004

100MG

A076432 002 Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

	150MG	A076432 003	Jul 29, 2004
	200MG	A076432 004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042 001	Jul 29, 2004
	100MG	A076042 002	Jul 29, 2004
	150MG	A076042 003	Jul 29, 2004
	200MG	A076042 004	Jul 29, 2004
PLIVA	50MG	A076424 001	Jul 29, 2004
	100MG	A076424 002	Jul 29, 2004
	150MG	A076424 003	Jul 29, 2004
	200MG	A076424 004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004
	100MG	A076386 002	Jul 29, 2004
	150MG	A076386 003	Jul 29, 2004
	200MG	A076386 004	Jul 29, 2004
ROXANE	50MG	A076213 001	Jul 29, 2004
	100MG	A076213 002	Jul 29, 2004
	150MG	A076213 003	Jul 29, 2004
	200MG	A076213 004	Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

+ GENZYME CORP 50MG/VIAL ** N020038 001 Apr 18, 1991

FLUDARABINE PHOSPHATE

MYLAN LABS LTD 50MG/2ML (25MG/ML) A200647 001 Dec 21, 2011

TABLET; ORAL

OFORTA

SANOFI AVENTIS US 10MG N022273 001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

+ DOWNSTATE CLINCL 4-40mCi/ML ** N020306 001 Aug 19, 1994

+ 4-90mCi/ML ** N020306 002 Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+ FEINSTEIN 20-200mCi/ML N021870 001 Aug 19, 2005

MIDWEST MEDCL 20-200mCi/ML A203736 001 Nov 19, 2015

WEILL MEDCL COLL 10-100mCi/ML ** N021768 001 Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

+ CASPER PHARMA LLC 0.1MG ** N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

BAXTER HLTHCARE CORP 0.5MG/5ML (0.1MG/ML) A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML) A076755 001 Oct 12, 2004

DR REDDYS 0.5MG/5ML (0.1MG/ML) A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML) A076589 001 Oct 12, 2004

MYLAN LABS LTD 1MG/10ML (0.1MG/ML) A078595 002 May 13, 2008

ROMAZICON

+ HOFFMANN LA ROCHE 1MG/10ML (0.1MG/ML) ** N020073 001 Dec 20, 1991

+ 0.5MG/5ML (0.1MG/ML) ** N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS 0.03% N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO 0.25MG/INH N018340 001 Aug 17, 1984

AEROSPAN HFA

+ MYLAN SPECIALITY LP 0.078MG/INH N021247 001 Jan 27, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

APOTEX

0.029MG/SPRAY

A077436 001 Aug 09, 2007

NASALIDE

IVAX RES

0.025MG/SPRAY **

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ACP NIMBLE

0.025%

A089525 001 Jul 26, 1988

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

INVATECH

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

TARO

0.025%

A088506 001 Aug 02, 1984

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL;TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.025%

A088172 001 Mar 09, 1983

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

ACP NIMBLE

0.01%

A207441 001 Sep 28, 2016

ACTAVIS LABS UT INC

0.01%

A208386 001 Oct 21, 2016

ALPHARMA US PHARMS

0.01%

A087159 001 Jun 16, 1982

BAUSCH AND LOMB

0.01%

A040059 001 Dec 20, 1993

INVATECH

0.01%

A088048 001 Dec 16, 1982

MORTON GROVE

0.01%

A088312 001 Jan 27, 1984

PHARMAFAIR

0.01%

A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT

0.01%

A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS

0.01%

A088171 001 Mar 09, 1983

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AMNEAL PHARMS LLC

0.05%

A210554 001 Aug 21, 2018

PERRIGO NEW YORK

0.05%

A071790 001 Jul 13, 1988

LIDEX

+ CNTY LINE PHARMS

0.05%

N016908 002

SOLUTION;TOPICAL

FLUOCINONIDE

TARO

0.05%

A072857 001 Aug 02, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

TEVA PHARMS

0.05%

A072522 001 Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

+ NOVARTIS

25% **

N017869 001

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN

0.025%

N011748 001

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS

0.1%

A070185 001 Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

EYEVANCE

0.1%; 0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN

0.1%; 10%

N019525 001 Sep 29, 1989

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN

50MG/ML

A081222 001 Jun 28, 1991

+

TEVA PARENTERAL

50MG/ML

N017959 001

TEVA PARENTERAL

50MG/ML

A040023 001 Oct 18, 1991

TEVA PARENTERAL

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC

50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM

50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

A089519 001 Mar 12, 1987

BEDFORD

50MG/ML

A089508 001 Jan 26, 1988

EBEWE PHARMA

500MG/10ML (50MG/ML)

A040772 001 Aug 11, 2008

FRESENIUS KABI USA

50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

A040379 001 Nov 15, 2000

MARCHAR

50MG/ML

A087791 001 Jan 18, 1983

MYLAN LABS LTD

500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012

1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012

SANDOZ

2.5GM/50ML (50MG/ML)

A091299 001 May 02, 2011

5GM/100ML (50MG/ML)

A091299 002 May 02, 2011

SMITH AND NEPHEW

50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

SPECTRUM PHARMS

50MG/ML

A087792 001 Oct 13, 1982

+

500MG/10ML (50MG/ML) **

N012209 001

+

2.5GM/50ML (50MG/ML)

N012209 002 Jul 29, 2016

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC

1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

SUN PHARM INDUSTRIES

EQ 10MG BASE

A075787 001 Jan 29, 2002

EQ 20MG BASE

A075787 002 Jan 29, 2002

WATSON LABS

EQ 10MG BASE

A075662 001 Jan 29, 2002

EQ 20MG BASE

A075662 002 Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ANI PHARMS INC

EQ 10MG BASE

A076287 001 May 20, 2008

EQ 20MG BASE

A076287 002 May 20, 2008

BARR

EQ 40MG BASE

A076251 001 May 18, 2005

BEXIMCO PHARMS USA

EQ 10MG BASE

A075807 001 Jan 29, 2002

EQ 20MG BASE

A075807 002 Jan 29, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002
	EQ 20MG BASE	A076022 002	Jan 30, 2002
CELLTRION	EQ 10MG BASE	A078143 001	Jan 16, 2008
	EQ 20MG BASE	A078143 002	Jan 16, 2008
	EQ 40MG BASE	A078143 003	Jan 16, 2008
CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002
	EQ 20MG BASE	A076165 002	Feb 01, 2002
HERITAGE PHARMS INC	EQ 10MG BASE	A201336 001	Oct 01, 2012
	EQ 20MG BASE	A201336 002	Oct 01, 2012
	EQ 40MG BASE	A201336 003	Oct 01, 2012
MYLAN	EQ 10MG BASE	A075207 001	Jan 30, 2002
	EQ 10MG BASE	A078045 001	Nov 17, 2008
	EQ 20MG BASE	A075207 002	Jan 30, 2002
	EQ 20MG BASE	A078045 002	Nov 17, 2008
	EQ 40MG BASE	A075207 003	May 25, 2007
MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002
	EQ 20MG BASE	A075577 002	Jan 29, 2002
PAR PHARM	EQ 10MG BASE	A076922 001	Dec 16, 2004
	EQ 20MG BASE	A076922 002	Dec 16, 2004
	EQ 40MG BASE	A076922 003	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A077469 001	Nov 17, 2008
	EQ 20MG BASE	A077469 002	Nov 17, 2008
PROZAC			
ELI LILLY AND CO	EQ 60MG BASE	N018936 004	Jun 15, 1999
SARAFEM			
+ ELI LILLY AND CO	EQ 10MG BASE **	N018936 007	Jul 06, 2000
+ ELI LILLY AND CO	EQ 20MG BASE **	N018936 008	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010
PROZAC WEEKLY			
+ LILLY	EQ 90MG BASE	N021235 001	Feb 26, 2001

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209 001	Mar 20, 2009
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
LANNETT CO INC	EQ 20MG BASE/5ML	A076458 001	May 14, 2004
NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
PROZAC			
+ LILLY	EQ 20MG BASE/5ML **	N020101 001	Apr 24, 1991

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
FOSUN PHARMA	EQ 10MG BASE	A076024 001	Jan 29, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
	EQ 40MG BASE	A075865 003	Aug 30, 2004
PROZAC			
+ LILLY	EQ 10MG BASE **	N020974 001	Mar 09, 1999
+ LILLY	EQ 20MG BASE **	N020974 002	Mar 09, 1999

FLUOXYMESTERONE

TABLET;ORAL

ANDROID-F

VALEANT PHARM INTL	10MG	A087196 001	
FLUOXYMESTERONE			
VALEANT PHARM INTL	10MG	A088221 001	May 05, 1983
WATSON LABS	2MG	A088260 001	Dec 06, 1983
	5MG	A088265 001	Dec 06, 1983
	10MG	A088309 001	Dec 06, 1983
HALOTESTIN			
PHARMACIA AND UPJOHN	2MG	N010611 002	
	5MG	N010611 006	
	10MG	N010611 010	
ORA-TESTRYL			
BRISTOL MYERS SQUIBB	2MG	N011359 001	
	5MG	N011359 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA 25MG/ML

A074966 001 Apr 16, 1998

TEVA PARENTERAL 25MG/ML

A074795 001 Sep 10, 1996

PROLIXIN DECANOATE

+ BRISTOL MYERS SQUIBB 25MG/ML **

N016727 001

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON 25MG/ML **

N016110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC 5MG/ML

A073058 001 Aug 30, 1991

PERMITIL

SCHERING 5MG/ML **

N016008 001

PROLIXIN

APOTHECON 5MG/ML

A070533 001 Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC 2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

+ APOTHECON 2.5MG/5ML **

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON 2.5MG/ML **

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS 1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING 0.25MG

N012034 001

2.5MG

N012034 004

5MG

N012034 005

10MG

N012034 006

PROLIXIN

+ APOTHECON 1MG **

N011751 004

+ 2.5MG **

N011751 001

+ 5MG **

N011751 003

+ 10MG **

N011751 002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING 1MG

N012419 004

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN 1.5MG

N012259 002

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

+ ALMIRALL 0.025% **

N012806 004

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050345 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL	15MG **	N016721 001	
+	30MG **	N016721 002	
<u>FLURAZEPAM HYDROCHLORIDE</u>			
AUROLIFE PHARMA LLC	15MG	A071717 002	Jul 31, 1991
	30MG	A071717 001	Jul 31, 1991
HALSEY	15MG	A071808 001	Jan 07, 1988
	30MG	A071809 001	Jan 07, 1988
HERITAGE PHARMA	15MG	A071205 001	Nov 25, 1986
	15MG	A072368 001	Mar 30, 1989
	30MG	A071068 001	Nov 25, 1986
	30MG	A072369 001	Mar 30, 1989
HIKMA INTL PHARMS	15MG	A071107 001	Dec 08, 1986
HIKMA PHARMS	30MG	A071108 001	Dec 08, 1986
PAR PHARM	15MG	A070444 001	Mar 20, 1986
	30MG	A070445 001	Mar 20, 1986
PUREPAC PHARM	15MG	A071927 001	Sep 09, 1987
	30MG	A071551 001	Sep 09, 1987
SUN PHARM INDUSTRIES	15MG	A070454 001	Aug 04, 1986
	30MG	A070455 001	Aug 04, 1986
SUPERPHARM	15MG	A071659 001	Aug 04, 1988
	30MG	A071660 001	Aug 04, 1988
USL PHARMA	15MG	A070562 001	Jul 09, 1987
	30MG	A070563 001	Jul 09, 1987
WARNER CHILCOTT	15MG	A071767 001	Dec 04, 1987
	30MG	A071768 001	Dec 04, 1987

FLURBIPROFEN

TABLET; ORAL

ANSAID

PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
	100MG	N018766 003	Oct 31, 1988
<u>FLURBIPROFEN</u>			
AUROLIFE PHARMA LLC	50MG	A074448 001	Jul 28, 1995
	100MG	A074448 002	Jul 28, 1995
IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
	100MG	A074411 002	May 31, 1995
PLIVA	50MG	A074647 001	Apr 01, 1997
	100MG	A074647 002	Apr 01, 1997
SUN PHARM INDS INC	50MG	A075058 001	Apr 27, 2001
	100MG	A075058 002	Apr 27, 2001
TEVA	50MG	A074405 002	May 24, 1995
	100MG	A074405 001	May 24, 1995
THERAGEN	100MG	A074560 002	May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

+	SCHERING	125MG	N018554 001	Jan 27, 1989
<u>FLUTAMIDE</u>				
	ACTAVIS LABS FL INC	125MG	A075820 001	Sep 18, 2001
	MYLAN	125MG	A076224 001	May 09, 2003
	YAOPHARMA CO LTD	125MG	A075818 001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
---	---------------	---------------------------	-------------	--------------

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

	GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
		0.11MG/INH	N020548 002	Mar 27, 1996
		0.22MG/INH	N020548 003	Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

+	FOUGERA PHARMS	0.05% **	N019958 001	Dec 18, 1990
---	----------------	----------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUTICASONE PROPIONATE

CREAM;TOPICAL

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

OINTMENT;TOPICAL

CUTIVATE

+ FOUGERA PHARMS

0.005%

N019957 001 Dec 14, 1990

FLUTICASONE PROPIONATE

FOUGERA PHARMS

0.005%

A076300 001 May 14, 2004

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

POWDER;INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM

0.055MG/INH

N208798 001 Jan 27, 2017

+

0.113MG/INH

N208798 002 Jan 27, 2017

+

0.232MG/INH

N208798 003 Jan 27, 2017

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

SPRAY, METERED;NASAL

FLONASE

+ GLAXOSMITHKLINE

0.05MG/SPRAY **

N020121 001 Oct 19, 1994

FLUVASTATIN SODIUM

CAPSULE;ORAL

LESCOL

+ NOVARTIS

EQ 20MG BASE **

N020261 001 Dec 31, 1993

+

EQ 40MG BASE **

N020261 002 Dec 31, 1993

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

MYLAN

EQ 80MG BASE

A202458 001 Sep 11, 2015

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

LUVOX CR

+ JAZZ PHARMS

100MG **

N022033 001 Feb 28, 2008

+

150MG **

N022033 002 Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

ANI PHARMS INC

25MG

A075897 001 Jan 25, 2001

25MG

A075898 001 Mar 12, 2001

50MG

A075897 002 Jan 25, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075897 003 Jan 25, 2001

100MG

A075898 003 Mar 12, 2001

ECI PHARMS LLC

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

HERITAGE PHARMA

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

MYLAN

25MG

A075889 001 Nov 29, 2000

50MG

A075889 002 Nov 29, 2000

50MG

A075950 001 Oct 15, 2001

100MG

A075889 003 Nov 29, 2000

100MG

A075950 002 Oct 15, 2001

SUN PHARM INDUSTRIES

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

UPSHER SMITH LABS

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

LUVOX

+ SOLVAY

25MG **

N020243 001 Dec 05, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

+	50MG **	N020243 002	Dec 05, 1994
+	100MG **	N020243 003	Dec 05, 1994
+	150MG **	N020243 004	Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

+ WYETH PHARMS INC

5MG/ML

N005897 008

TABLET; ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

CONTRACT PHARMACAL

1MG

A085061 001

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

IMPAX LABS

1MG

A080686 001

IVAX SUB TEVA PHARMS

1MG

A083000 001

JUBILANT CADISTA

1MG

A040514 001 Jun 14, 2005

LANNETT

1MG

A080816 001

LILLY

1MG

N006135 003

MK LABS

1MG

A083526 001

NEXGEN PHARMA INC

1MG

A084915 001

PHARMERAL

1MG

A084158 001

PIONEER PHARMS

1MG

A088949 001 Sep 13, 1985

PUREPAC PHARM

1MG

A080784 001

SANDOZ

1MG

A084472 001

SUN PHARM INDUSTRIES

1MG

A040582 001 Jul 18, 2005

TABLICAPS

1MG

A083133 002

UDL

1MG

A088199 001 Mar 29, 1983

USL PHARMA

1MG

A087828 001 May 13, 1982

VALEANT PHARM INTL

1MG

A080903 001

VANGARD

1MG

A088730 001 Mar 23, 1984

VINTAGE PHARMS

1MG

A086296 001

WATSON LABS

1MG

A083141 001

1MG

A085141 002

WHITEWORTH TOWN PLSN

1MG

A080691 002

FOLICET

MISSION PHARMA

1MG

A087438 001

FOLVITE

+ WYETH PHARMS INC

1MG

N005897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC

75 IU/VIAL

N020582 001 Sep 29, 1997

150 IU/VIAL

N020582 002 Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

150 IU/0.18ML

N021211 003 Feb 11, 2004

150 IU/0.5ML

N021273 002 Aug 26, 2005

GONAL-F

EMD SERONO

37.5 IU/VIAL

N020378 003 May 25, 2000

37.5 IU/VIAL

N021765 001 Mar 25, 2004

75 IU/VIAL

N020378 001 Sep 29, 1997

150 IU/VIAL

N020378 002 Sep 29, 1997

150 IU/VIAL

N021765 003 Mar 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

+ PAR PHARM INC

1.5GM/1.5ML (1GM/ML)

N020696 001 Dec 04, 1997

FOMEPIZOLE

MYLAN INSTITUTIONAL

1.5GM/1.5ML (1GM/ML)

A079033 001 Apr 07, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS

6.6MG/ML

N020961 001 Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ NOVARTIS

0.012MG/INH

N020831 001 Feb 16, 2001

FORADIL CERTIHALER

NOVARTIS

0.0085MG/INH

N021592 001 Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+ MERCK AND CO INC

EQ 115MG BASE/VIAL **

N022023 001 Jan 25, 2008

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

HOSPIRA

2.4GM/100ML

A077174 001 May 31, 2005

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

ACTAVIS LABS FL INC

10MG

A076620 001 Oct 15, 2004

20MG

A076620 002 Oct 15, 2004

40MG

A076620 003 Oct 15, 2004

RANBAXY LABS LTD

10MG

A076580 001 Apr 23, 2004

20MG

A076580 002 Apr 23, 2004

40MG

A076580 003 Apr 23, 2004

UPSHER SMITH LABS

10MG

A076188 001 Oct 08, 2004

20MG

A076188 002 Oct 08, 2004

40MG

A076188 003 Oct 08, 2004

WATSON LABS

10MG

A076987 001 Dec 23, 2004

10MG

A077531 001 Aug 31, 2006

20MG

A076987 002 Dec 23, 2004

20MG

A077531 002 Aug 31, 2006

40MG

A076987 003 Dec 23, 2004

40MG

A077531 003 Aug 31, 2006

MONOPRIL

+ BRISTOL MYERS SQUIBB

10MG **

N019915 002 May 16, 1991

+ 20MG **

N019915 003 May 16, 1991

+ 40MG **

N019915 004 Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC

10MG; 12.5MG

A076608 001 Dec 03, 2004

10MG; 12.5MG

A077144 001 Aug 16, 2005

20MG; 12.5MG

A076608 002 Dec 03, 2004

20MG; 12.5MG

A077144 002 Aug 16, 2005

MYLAN

10MG; 12.5MG

A077705 001 Aug 14, 2006

20MG; 12.5MG

A077705 002 Aug 14, 2006

SUN PHARM INDS LTD

10MG; 12.5MG

A076739 001 Dec 17, 2004

20MG; 12.5MG

A076739 002 Dec 17, 2004

TEVA

10MG; 12.5MG

A076945 001 Jul 05, 2006

20MG; 12.5MG

A076945 002 Jul 05, 2006

MONOPRIL-HCT

+ BRISTOL MYERS SQUIBB

10MG; 12.5MG **

N020286 002 Nov 30, 1994

+ 20MG; 12.5MG **

N020286 001 Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML

A078126 001 Aug 06, 2007

DR REDDYS

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007

HOSPIRA

EQ 50MG PHENYTOIN NA/ML

A078158 001 Aug 06, 2007

LUITPOLD

EQ 50MG PHENYTOIN NA/ML

A078277 001 Aug 06, 2007

EQ 50MG PHENYTOIN NA/ML

A090099 001 May 13, 2010

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC

1050MG/30ML (35MG/ML)

N022244 001 Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001 Jul 30, 1982

10MG/ML

N019036 001 Aug 13, 1984

ACCORD HLTHCARE

10MG/ML

A070017 001 Dec 15, 1986

ASTRAZENECA

10MG/ML

A070014 001 Sep 09, 1985

HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987

10MG/ML

A072080 001 Aug 13, 1991

10MG/ML

A074337 001 Oct 31, 1994

IGI LABS INC

10MG/ML

A070095 001 Sep 09, 1985

10MG/ML

A070096 001 Sep 09, 1985

INTL MEDICATION

10MG/ML

N018025 001

+ LUITPOLD

10MG/ML **

N018579 001 Nov 30, 1983

MARSAM PHARMS LLC

10MG/ML

A074017 001 Jun 30, 1994

SMITH AND NEPHEW

10MG/ML

A070023 001 Feb 05, 1986

10MG/ML

A070078 001 Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001 Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001 Sep 22, 1986

10MG/ML

A070604 001 Jan 02, 1987

WEST-WARD PHARMS INT

10MG/ML

A071439 001 Sep 14, 1990

10MG/ML

N018267 001

WYETH AYERST

10MG/ML

N018670 001 Jul 20, 1982

LASIX

+ SANOFI AVENTIS US

10MG/ML **

N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

ANI PHARMS INC

20MG

A071379 001 Jan 02, 1987

40MG

A070413 001 Feb 26, 1986

80MG

A071594 001 Feb 09, 1988

DAVA PHARMS INC

20MG

N018415 001 Jul 27, 1982

40MG

N018415 002 Jul 27, 1982

80MG

N018415 003 Nov 26, 1984

INTL MEDICATION

20MG

N018753 001 Feb 28, 1984

40MG

N018753 002 Feb 28, 1984

KALAPHARM

20MG

N018868 001 Jun 28, 1983

40MG

N018868 002 Jun 28, 1983

SANDOZ

40MG

N018750 002 Jul 30, 1984

SUN PHARM INDS INC

20MG

A091258 001 Apr 01, 2014

40MG

A091258 002 Apr 01, 2014

40MG

N018790 001 Nov 29, 1983

80MG

A091258 003 Apr 01, 2014

SUN PHARM INDUSTRIES

20MG

A070043 001 Sep 26, 1985

80MG

A070100 001 Jan 26, 1988

SUPERPHARM

20MG

N018370 002 Jun 26, 1984

40MG

N018370 001 Feb 10, 1983

WARNER CHILCOTT

20MG

N018419 001 Jan 31, 1983

40MG

N018419 002 Jan 31, 1983

80MG

N018419 003 Nov 13, 1984

WATSON LABS

20MG

A070412 001 Feb 26, 1986

20MG

N018369 001 May 14, 1982

40MG

A070450 001 Nov 22, 1985

40MG

N018369 002 May 14, 1982

WATSON LABS TEVA

20MG

A070449 001 Nov 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

FUROSEMIDETABLET; ORAL
FUROSEMIDE

80MG A070528 001 Jan 07, 1986

GABAPENTINCAPSULE; ORAL
GABAPENTIN

CSPC OUYI	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
HIKMA	100MG	A078150 001	Sep 25, 2007
	300MG	A078150 002	Sep 25, 2007
	400MG	A078150 003	Sep 25, 2007
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
	300MG	A076606 002	Oct 07, 2005
	400MG	A076606 003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
INVATECH	600MG	A076877 001	Jul 06, 2006
	800MG	A076877 002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG	A076017 004	Apr 29, 2005
	800MG	A076017 005	Apr 29, 2005
LUPIN LTD	600MG	A209306 001	Aug 24, 2018
	800MG	A209306 002	Aug 24, 2018
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	800MG	A076120 002	Jan 27, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDEINJECTABLE; INJECTION
OMNISCAN

GE HEALTHCARE 14.35GM/50ML (287MG/ML) N022066 001 Sep 05, 2007

GADOFOSESET TRISODIUMSOLUTION; INTRAVENOUS
ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINEINJECTABLE; INJECTION
MAGNEVIST

+ BAYER HLTHCARE	469.01MG/ML	N019596 001	Jun 02, 1988
+ BAYER HLTHCARE	469.01MG/ML	N021037 001	Mar 10, 2000

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937 001	Dec 08, 1999
+ LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020937 002	Dec 08, 1999
+ LIEBEL-FLARSHEIM	4963.5MG/15ML (330.9MG/ML)	N020937 003	Dec 08, 1999
+ LIEBEL-FLARSHEIM	6618MG/20ML (330.9MG/ML)	N020937 004	Dec 08, 1999
+ LIEBEL-FLARSHEIM	16.545GM/50ML (330.9MG/ML)	N020975 001	Dec 08, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009
		EQ 16MG BASE	A078484	002	May 27, 2009
		EQ 24MG BASE	A078484	003	May 27, 2009
	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011
		EQ 16MG BASE	A090900	002	Jan 24, 2011
		EQ 24MG BASE	A090900	003	Jan 24, 2011

SOLUTION; ORAL

RAZADYNE

	JANSSEN PHARMS	4MG/ML **	N021224	001	Jun 22, 2001
--	----------------	-----------	---------	-----	--------------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009
		EQ 4MG BASE	A077587	001	Jul 09, 2009
		EQ 8MG BASE	A077585	002	Sep 15, 2009
		EQ 8MG BASE	A077587	002	Jul 09, 2009
		EQ 12MG BASE	A077585	003	Sep 15, 2009
		EQ 12MG BASE	A077587	003	Jul 09, 2009
	MYLAN	EQ 4MG BASE	A077590	001	May 29, 2009
		EQ 4MG BASE	A077603	001	Aug 28, 2008
		EQ 8MG BASE	A077590	002	May 29, 2009
		EQ 8MG BASE	A077603	002	Aug 28, 2008
		EQ 12MG BASE	A077590	003	May 29, 2009
		EQ 12MG BASE	A077603	003	Aug 28, 2008

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

	DAVIS AND GECK	20MG/ML	N007842	001	
		100MG/ML	N007842	002	

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

	GE HEALTHCARE	1mCi/ML	N017700	001	
	NEOSCAN				
	GE HEALTHCARE	2mCi/ML	N017655	001	

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

	CHEPLAPHARM	25MG/ML **	N019961	002	Jan 17, 1991
--	-------------	------------	---------	-----	--------------

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

+	ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+		500MG **	N020460	002	Dec 12, 1997

GANCICLOVIR

	RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
		500MG	A076457	002	Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996
--	-----------------	-------	---------	-----	--------------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

	CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019
	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013
	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET;ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

ACTAVIS INC

200MG/5.26ML (38MG/ML)

A204549 001 Apr 11, 2016

1GM/26.3ML (38MG/ML)

A204549 002 Apr 11, 2016

2GM/52.6ML (38MG/ML)

A204549 003 Apr 11, 2016

ACTAVIS TOTOWA

EQ 200MG BASE/VIAL

A079160 001 Jul 25, 2011

EQ 1GM BASE/VIAL

A079160 002 Jul 25, 2011

EQ 2GM BASE/VIAL

A079160 003 Jul 28, 2016

HAMELN RDS GMBH

EQ 200MG BASE/VIAL

A090663 001 Sep 10, 2012

EQ 1GM BASE/VIAL

A090663 002 Sep 10, 2012

INGENUS PHARMS LLC

200MG/5.26ML (38MG/ML)

A210383 001 Feb 14, 2019

1GM/26.3ML (38MG/ML)

A210383 002 Feb 14, 2019

2GM/52.6ML (38MG/ML)

A210383 003 Feb 14, 2019

LUITPOLD

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013

SAGENT PHARMS

EQ 200MG BASE/VIAL

A091597 001 May 07, 2013

EQ 1GM BASE/VIAL

A091597 002 May 07, 2013

SHILPA MEDICARE LTD

EQ 200MG BASE/VIAL

A207575 001 Feb 22, 2019

EQ 1GM BASE/VIAL

A207575 002 Feb 22, 2019

GEMFIBROZIL

CAPSULE;ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET;ORAL

GEMFIBROZIL

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SUN PHARM INDS INC

600MG

A079239 001 Dec 29, 2008

WATSON LABS

600MG

A074156 001 Oct 24, 1994

600MG

A074442 001 Apr 28, 1995

YAOPHARMA CO LTD

600MG

A074615 001 Sep 29, 1995

GEMTUZUMAB OZOGAMICIN

INJECTABLE;INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM;TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE **

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

FOUGERA PHARMS INC

EQ 0.1% BASE

A062531 001 Jul 05, 1984

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

TARO

EQ 0.1% BASE

A062427 001 May 26, 1983

INJECTABLE;INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GARAMYCIN

SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	

GENTAFAIR

PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
------------	-----------------	---------	-----	--------------

GENTAMICIN

INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983

FRESENIUS KABI USA

	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982

KALAPHARM

	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
--	-----------------	---------	-----	--------------

PHARM SPEC

	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
--	-----------------	---------	-----	--------------

SOLOPAK

	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
--	-----------------	---------	-----	--------------

	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
--	-----------------	---------	-----	--------------

TEVA PARENTERAL

	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
--	-----------------	---------	-----	--------------

	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
--	-----------------	---------	-----	--------------

WATSON LABS

	EQ 10MG BASE/ML	A062318	002	
--	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A062318	001	
--	-----------------	---------	-----	--

WEST-WARD PHARMS INT

	EQ 10MG BASE/ML	A062251	002	
--	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A062251	001	
--	-----------------	---------	-----	--

WYETH AYERST

	EQ 10MG BASE/ML	A062264	001	
--	-----------------	---------	-----	--

	EQ 40MG BASE/ML	A062264	002	
--	-----------------	---------	-----	--

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987

BAXTER HLTHCARE

	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
--	------------------	---------	-----	--------------

	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
--	------------------	---------	-----	--------------

	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
--	--------------------	---------	-----	--------------

	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
--	--------------------	---------	-----	--------------

HOSPIRA

	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
--	------------------	---------	-----	--------------

	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
--	------------------	---------	-----	--------------

	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
--	------------------	---------	-----	--------------

	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
--	------------------	---------	-----	--------------

	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
--	------------------	---------	-----	--------------

	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
--	------------------	---------	-----	--------------

	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
--	----------------	---------	-----	--------------

	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
--	----------------	---------	-----	--------------

	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
--	--------------------	---------	-----	--------------

	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
--	--------------------	---------	-----	--------------

	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
--	--------------------	---------	-----	--------------

	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
--	--------------------	---------	-----	--------------

	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
--	--------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN EQ 10MG BASE/ML	A062248	001	
EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

+ SCHERING EQ 2MG BASE/ML **	N050505	001	
------------------------------	---------	-----	--

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING EQ 0.3% BASE	N050425	001	
-----------------------	---------	-----	--

GENTACIDIN

NOVARTIS EQ 0.3% BASE	A062501	001	Jul 26, 1984
-----------------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR EQ 3MG BASE/GM	A062443	001	May 26, 1983
---------------------------	---------	-----	--------------

OINTMENT; TOPICAL

GARAMYCIN

SCHERING EQ 0.1% BASE **	A060463	001	
--------------------------	---------	-----	--

GENTAFAIR

PHARMAFAIR EQ 0.1% BASE	A062444	001	May 26, 1983
-------------------------	---------	-----	--------------

GENTAMICIN SULFATE

ALPHARMA US PHARMS EQ 0.1% BASE	A062496	001	Mar 14, 1984
---------------------------------	---------	-----	--------------

PHARMADERM EQ 0.1% BASE	A062534	001	Oct 10, 1984
-------------------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

+ SCHERING EQ 0.3% BASE **	N050039	002	
----------------------------	---------	-----	--

GENTACIDIN

NOVARTIS EQ 0.3% BASE	A062480	001	Mar 30, 1984
-----------------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR EQ 0.3% BASE	A062440	001	May 03, 1983
-------------------------	---------	-----	--------------

GENTAMICIN SULFATE

ALCON PHARMS LTD EQ 0.3% BASE	A062523	001	Nov 25, 1985
-------------------------------	---------	-----	--------------

PACO EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
---------------------	---------	-----	--------------

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS 0.4%	A083513	001	
------------------	---------	-----	--

TAMPON; VAGINAL

GENAPAX

KEY PHARMS 5MG	A085017	001	
----------------	---------	-----	--

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA 20MG/VIAL	N020622	001	Dec 20, 1996
---------------------------	---------	-----	--------------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

ACTAVIS LABS FL INC 1MG	A076995	001	Apr 27, 2010
2MG	A076995	002	Apr 27, 2010
4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC 1MG	A077274	001	Oct 06, 2005
2MG	A077274	002	Oct 06, 2005
4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS 1MG	A078952	001	Aug 01, 2013
2MG	A078952	002	Aug 01, 2013
4MG	A078952	003	Aug 01, 2013
MYLAN 1MG	A077486	001	Feb 10, 2006
2MG	A077486	002	Feb 10, 2006
4MG	A077486	003	Feb 10, 2006
RANBAXY 3MG	A077366	001	Oct 06, 2005
6MG	A077366	002	Oct 06, 2005
RANBAXY LABS LTD 1MG	A076875	001	Oct 06, 2005
2MG	A076875	002	Oct 06, 2005
4MG	A076875	003	Oct 06, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	8MG	A076875 004	Oct 06, 2005
TEVA	1MG	A076802 001	Oct 06, 2005
	2MG	A076802 002	Oct 06, 2005
	4MG	A076802 003	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

+	SB PHARMCO	1MG;4MG **	N021700 001	Nov 23, 2005
+		2MG;4MG **	N021700 002	Nov 23, 2005
+		2MG;8MG **	N021700 004	Mar 30, 2007
+		4MG;4MG **	N021700 003	Nov 23, 2005
+		4MG;8MG **	N021700 005	Mar 30, 2007

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

TEVA PHARMS USA	1MG;4MG	A078709 001	Apr 01, 2016
	2MG;4MG	A078709 002	Apr 01, 2016
	2MG;8MG	A078709 004	Apr 01, 2016
	4MG;4MG	A078709 003	Apr 01, 2016
	4MG;8MG	A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

ANI PHARMS INC	5MG	A074387 001	Mar 04, 1996
	5MG	A074497 001	Aug 31, 1995
	10MG	A074387 002	Mar 04, 1996
	10MG	A074497 002	Aug 31, 1995
BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
BEXIMCO PHARMS USA	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
MYLAN	5MG	A074438 001	Jun 20, 1995
	10MG	A074438 002	Jun 20, 1995
OXFORD PHARMS	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994

GLUCOTROL

PFIZER	2.5MG	N017783 003	May 11, 1993
--------	-------	-------------	--------------

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

MYLAN	2.5MG	A202298 001	May 19, 2015
	5MG	A202298 002	May 19, 2015
	10MG	A202298 003	May 19, 2015

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

MYLAN	2.5MG;250MG	A078083 001	Apr 12, 2007
	2.5MG;500MG	A078083 002	Apr 12, 2007
	5MG;500MG	A078083 003	Apr 12, 2007
SUN PHARM INDS INC	2.5MG;250MG	A077620 001	Jan 11, 2008
	2.5MG;500MG	A077620 002	Jan 11, 2008
	5MG;500MG	A077620 003	Jan 11, 2008

METAGLIP

+	BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460 001	Oct 21, 2002
+		2.5MG;500MG **	N021460 002	Oct 21, 2002
+		5MG;500MG **	N021460 003	Oct 21, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	EQ 1MG BASE/VIAL **	N012122	001	
+		EQ 10MG BASE/VIAL **	N012122	002	

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

	SANOFI AVENTIS US	500MG	N009519	008	
--	-------------------	-------	---------	-----	--

TABLET; ORAL

DORIDEN

	SANOFI AVENTIS US	250MG	N009519	002	
		500MG	N009519	005	

GLUTETHIMIDE

	HALSEY	250MG	A089458	001	Oct 10, 1986
		500MG	A089459	001	Oct 10, 1986
	LANNETT	250MG	A083475	001	
		500MG	A085571	001	
	UCB INC	500MG	A085171	001	
	UPSHER SMITH LABS	500MG	A083234	002	
	VITARINE	500MG	A087297	001	
	WATSON LABS	500MG	A084362	001	
		500MG	A085763	001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

	ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
		3MG	A075947	002	Nov 14, 2002
		6MG	A075947	003	Nov 14, 2002
	ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019
		2.5MG	A206483	002	Feb 22, 2019
		5MG	A206483	003	Feb 22, 2019

GLYBURIDE (MICRONIZED)

	SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
		3MG	N020055	002	Apr 17, 1992
		6MG	N020055	003	Mar 08, 2000
	YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998
		3MG	A075174	002	Jun 22, 1998

GLYNASE

+	PHARMACIA AND UPJOHN	4.5MG **	N020051	003	Sep 24, 1993
---	----------------------	----------	---------	-----	--------------

MICRONASE

+	PHARMACIA AND UPJOHN	1.25MG **	N017498	001	May 01, 1984
		2.5MG	N017498	002	May 01, 1984
+		5MG **	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

+	BRISTOL MYERS SQUIBB	1.25MG; 250MG **	N021178	001	Jul 31, 2000
+		2.5MG; 500MG **	N021178	002	Jul 31, 2000
+		5MG; 500MG **	N021178	003	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	HERITAGE PHARMS INC	1.25MG; 250MG	A079009	001	Jun 03, 2009
		2.5MG; 500MG	A079009	002	Jun 03, 2009
		5MG; 500MG	A079009	003	Jun 03, 2009
	IMPAX LABS INC	1.25MG; 250MG	A076731	001	Nov 19, 2004
		2.5MG; 500MG	A076731	002	Nov 19, 2004
		5MG; 500MG	A076731	003	Nov 19, 2004
	TEVA	1.25MG; 250MG	A076821	001	Jan 27, 2005
		2.5MG; 500MG	A076821	002	Jan 27, 2005
		5MG; 500MG	A076821	003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
	HOSPIRA	1.5GM/100ML	N017633	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983

ROBINUL

+ HIKMA	0.2MG/ML **	N017558	001	
ROBINS AH	0.2MG/ML	N014764	001	

TABLET; ORAL

GLYCOPYRROLATE

HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
RENATA	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

ROBINUL

+ CASPER PHARMA LLC	1MG **	N012827	001	
---------------------	--------	---------	-----	--

ROBINUL FORTE

+ CASPER PHARMA LLC	2MG **	N012827	002	
---------------------	--------	---------	-----	--

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
----------------------	-------------------	---------	-----	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427	001	
-----------	--	---------	-----	--

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818	001	Oct 11, 1988
--------	--	---------	-----	--------------

WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788	001	Jun 11, 1987
-------------	--	---------	-----	--------------

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383	001	Aug 31, 1982
------------	--	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274 001	Sep 22, 2010
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963 001	Jan 03, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007
-----------	---------------------------------	-------------	--------------

KYTRIL

+ ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239 003	Sep 17, 2004
+	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239 004	Mar 11, 1994
+	EQ 3MG BASE/ML **	N020239 001	Dec 29, 1993
+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239 002	Mar 11, 1994

SOLUTION; ORAL

GRANISOL

PEDIATRAX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
-----------	------------------	-------------	--------------

KYTRIL

+ ROCHE	EQ 2MG BASE/10ML **	N021238 001	Jun 27, 2001
---------	---------------------	-------------	--------------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260 001	Dec 31, 2007
TEVA PHARMS	EQ 1MG BASE	A078080 001	Dec 31, 2007

KYTRIL

+ ROCHE	EQ 1MG BASE **	N020305 001	Mar 16, 1995
+	EQ 2MG BASE **	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

WYETH AYERST	125MG	N050051 002	
	250MG	N050051 001	

SUSPENSION; ORAL

GRIFULVIN V

+ JOHNSON AND JOHNSON	125MG/5ML **	N050448 001	
-----------------------	--------------	-------------	--

TABLET; ORAL

FULVICIN-U/F

CHARTWELL RX	250MG	A060569 002	
	500MG	A060569 001	

GRIFULVIN V

J AND J	125MG	A060618 001	
	250MG	A060618 002	
	500MG	A060618 003	
VALEANT LUXEMBOURG	125MG	A062279 001	
	250MG **	A062279 002	

GRISACTIN

WYETH AYERST	500MG	A060212 001	
--------------	-------	-------------	--

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

VALEANT LUXEMBOURG	125MG/5ML **	A062483 001	Jan 26, 1984
--------------------	--------------	-------------	--------------

TABLET; ORAL

GRIFULVIN V

VALEANT LUXEMBOURG	500MG	A062279 003	
--------------------	-------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

CHARTWELL RX

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

CHARTWELL RX

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

CHARTWELL RX

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

OHM LABS INC

600MG

A209254 001 Jul 16, 2018

1.2GM

A209254 002 Jul 16, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

BKK PHARMS

200MG/5ML; 2.5MG/5ML

N022424 001 May 14, 2015

OBREDON

+ SOVEREIGN PHARMS

200MG/5ML; 2.5MG/5ML

N205474 001 Nov 14, 2014

TABLET; ORAL

XTRELUS

+ ECI PHARMS LLC

400MG; 5MG

N208085 001 Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+ BKK PHARMS

200MG/5ML; 2.5MG/5ML; 30MG/5ML

N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

ANI PHARMS INC

EQ 4MG BASE

A074149 001 Apr 07, 1995

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074149 002 Apr 07, 1995

EQ 8MG BASE

A074267 002 Jun 01, 1994

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

YAOPHARMA CO LTD

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET; ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

EQ 25MG SULFATE

N012329 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS

10MG; 25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

+

PROMIUS PHARMA

EQ 1MG BASE

N019032 001 Oct 27, 1986

+

EQ 2MG BASE

N019032 002 Nov 07, 1988

EQ 3MG BASE

N019032 003 Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC

EQ 1MG BASE

A202238 001 Oct 20, 2015

EQ 2MG BASE

A202238 002 Oct 20, 2015

EQ 3MG BASE

A202238 003 Oct 20, 2015

EQ 4MG BASE

A202238 004 Oct 20, 2015

MYLAN

EQ 1MG BASE

A202578 001 Jun 02, 2015

EQ 2MG BASE

A202578 002 Jun 02, 2015

EQ 3MG BASE

A202578 003 Jun 02, 2015

EQ 4MG BASE

A202578 004 Jun 02, 2015

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

SUN PHARM INDS INC

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

SUN PHARM INDS INC

0.1%

N017823 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE

+

SUN PHARM INDS INC

0.05%

N019967 001 Dec 27, 1990

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

+

ORTHO MCNEIL

0.5MG **

N015921 001

+

1MG **

N015921 002

+

2MG **

N015921 003

+

5MG **

N015921 004

+

10MG **

N015921 005

+

20MG **

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

CYCLE PHARMS LTD

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

2MG

A071130 001 Feb 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	5MG	A071131	001	Feb 17, 1987
	10MG	A071132	001	May 12, 1987
	20MG	A071133	001	May 12, 1987
DURAMED PHARMS BARR	0.5MG	A071216	001	Dec 04, 1986
	1MG	A071217	001	Dec 04, 1986
	2MG	A071218	001	Dec 04, 1986
	5MG	A071219	001	Dec 04, 1986
	10MG	A071220	001	Jul 07, 1987
	20MG	A071221	001	Jul 07, 1987
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SANDOZ	2MG	A071208	001	Nov 17, 1986
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922 001	
--------------	-------------------	-------------	--

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318 001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710 001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726 001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015 001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML	A071617 001	Dec 01, 1988

HALOPERIDOL INTENSOL

HIKMA	EQ 2MG BASE/ML	A072045 001	Apr 12, 1988
-------	----------------	-------------	--------------

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004
FOSUN PHARMA	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004
FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356 001	Jul 01, 2019
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995
----------------------	----------------	-------------	--------------

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942 001	
-----------------	----	-------------	--

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943 001	
-----------------	----	-------------	--

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST	99.99%	N011338 001	
--------------	--------	-------------	--

HALOTHANE

BH	99.99%	A084977 001	
HALOCARBON	99.99%	A080810 001	
HOSPIRA	99.99%	A083254 001	

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	
-------------------	-----------------	-------------	--

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264 010	
INTL MEDICATION	10 UNITS/ML	A086357 001	
	500 UNITS/ML	A086357 002	
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
	100 UNITS/ML	A089064 001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346 006	
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
	10 UNITS/ML	A087958 001	Apr 20, 1983
	10 UNITS/ML	A088458 001	Jul 26, 1984
	10 UNITS/ML	A088580 001	Oct 25, 1984
	100 UNITS/ML	A087906 001	Apr 20, 1983
	100 UNITS/ML	A087959 001	Apr 20, 1983
	100 UNITS/ML	A088460 001	Jul 26, 1984
	100 UNITS/ML	A088581 001	Oct 25, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983
	10 UNITS/ML	A088457 001	Oct 25, 1984
	100 UNITS/ML	A087905 001	Apr 20, 1983
	100 UNITS/ML	A088459 001	Jul 26, 1984
HEPARIN SODIUM			
ABRAXIS PHARM	1,000 UNITS/ML	N017033 001	
	1,000 UNITS/ML	N017979 001	
	5,000 UNITS/ML	N017979 003	
	10,000 UNITS/ML	N017979 002	
AKORN	1,000 UNITS/ML	N017486 001	
	5,000 UNITS/ML	N017486 002	
	10,000 UNITS/ML	N017486 003	
	20,000 UNITS/ML	N017486 004	
	40,000 UNITS/ML	N017486 005	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130 001	
	5,000 UNITS/ML	N017130 002	
	10,000 UNITS/ML	N017130 003	
	20,000 UNITS/ML	N017130 004	
DELL LABS	1,000 UNITS/ML	N017540 001	
	5,000 UNITS/ML	N017540 002	
	10,000 UNITS/ML	N017540 003	
	20,000 UNITS/ML	N017540 004	
	40,000 UNITS/ML	N017540 005	
DR REDDYS	1,000 UNITS/ML	A040007 001	Jun 07, 1996
	1,000 UNITS/ML	N017064 002	
	2,500 UNITS/ML	N017064 015	
	3,000 UNITS/ML	N017064 016	
	4,000 UNITS/ML	N017064 017	
	5,000 UNITS/ML	N017064 003	
	6,000 UNITS/ML	N017064 018	
	7,500 UNITS/ML	N017064 019	
	10,000 UNITS/ML	N017064 004	
	20,000 UNITS/ML	N017064 005	
	40,000 UNITS/ML	N017064 006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651 005	
	5,000 UNITS/ML	N017029 002	
	10,000 UNITS/ML	N017651 003	
	20,000 UNITS/ML	N017651 008	
HIKMA	5,000 UNITS/0.5ML	N017037 013	Apr 07, 1986
HOSPIRA	2,500 UNITS/ML	A088099 001	Apr 28, 1983
	10,000 UNITS/ML	A040095 001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521 001	
	10,000 UNITS/ML	N005521 002	
	20,000 UNITS/ML	N005521 004	
LUITPOLD	1,000 UNITS/ML	A087452 001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552 008	
	5,000 UNITS/ML	N000552 009	
	10,000 UNITS/ML	N000552 010	
PARKE DAVIS	1,000 UNITS/ML	N017346 001	
	5,000 UNITS/ML	N017346 002	
	7,500 UNITS/ML	N017346 003	
	10,000 UNITS/ML	N017346 004	
	20,000 UNITS/ML	N017346 005	
PHARM SPEC	1,000 UNITS/ML	N017780 001	
	5,000 UNITS/ML	N017780 002	
	10,000 UNITS/ML	N017780 003	
	20,000 UNITS/ML	N017780 004	
	40,000 UNITS/ML	N017780 005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570 001	
	5,000 UNITS/ML	N004570 002	
	10,000 UNITS/ML	N004570 003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239 001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043 001	
	5,000 UNITS/ML	A087077 001	
	5,000 UNITS/0.5ML	A087395 001	
	10,000 UNITS/ML	A087107 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
+	WEST-WARD PHARMS INT	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	
+		7,500 UNITS/ML **	N017007	003	
+		10,000 UNITS/ML **	N017007	004	
+		15,000 UNITS/ML **	N017007	005	
+		20,000 UNITS/ML **	N017007	006	
HEPARIN SODIUM	1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
	MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM	1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM	10,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM	10,000 UNITS	IN DEXTROSE 5%			
	HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM	10,000 UNITS	IN SODIUM CHLORIDE 0.45%			
	HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
		10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM	10,000 UNITS	IN SODIUM CHLORIDE 0.9%			
	HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
		10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM	12,500 UNITS	IN DEXTROSE 5%			
	HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM	12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM	12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
	HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
		5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM	2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
	MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM	2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM	20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM	25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
		10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM	25,000 UNITS	IN DEXTROSE 5%			
	HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
		10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM	25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM	25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
		10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM	25,000 UNITS	IN SODIUM CHLORIDE 0.9%			
	HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM	25,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
		5,000 UNITS/100ML	N019802	003	Jul 20, 1992
	HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM	5,000 UNITS	AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM	5,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
	MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM	5,000 UNITS	IN SODIUM CHLORIDE 0.45%			
	HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
		100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM	5,000 UNITS	IN SODIUM CHLORIDE 0.9%			
	HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM	5,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	

LIPO-HEPIN

3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	

LIQUAEMIN LOCK FLUSH

ORGANON USA INC	100 UNITS/ML	N000552	007	
-----------------	--------------	---------	-----	--

LIQUAEMIN SODIUM

ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986

PANHEPRIN

HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	

SODIUM HEPARIN

ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL	EQ 112.5MG AMPICIL/ML	A061398	001	
	EQ 112.5MG AMPICIL/5ML	N050060	001	
	EQ 112.5MG AMPICIL/ML	N050060	003	
	EQ 225MG AMPICIL/5ML	A061398	002	

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL	EQ 225MG AMPICIL	A061396	001	
	EQ 450MG AMPICIL	A061396	002	

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS	0.23%	N017424	001	
-------------	-------	---------	-----	--

TURGEX

XTRTRIUM	3%	N018375	001	
----------	----	---------	-----	--

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS	3%	N017411	001	
-----------------	----	---------	-----	--

PHISOHEX

SANOFI AVENTIS US	3%	N006882	001	
	3%	N008402	001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HEXACHLOROPHENE

EMULSION; TOPICAL

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK

5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA

10MG

A086308 001

HOMAPIN-5

MISSION PHARMA

5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA

3MG

A086310 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

BRECKENRIDGE	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019
IVAX SUB TEVA PHARMS	1.5MG/5ML; 5MG/5ML	A040285	001	Jul 19, 1999
TORRENT	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017

HYDRODANE

HALSEY	1.5MG/5ML; 5MG/5ML	A088066	001	Jun 28, 1985
--------	--------------------	---------	-----	--------------

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000
-------------------	------------	---------	-----	--------------

HYCODAN

+ GENUS	1.5MG; 5MG **	N005213	001	Jul 26, 1988
---------	---------------	---------	-----	--------------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005
-----------	--------------	---------	-----	--------------

VITRASE

BAUSCH AND LOMB	6,200 UNITS/VIAL	N021640	001	May 05, 2004
-----------------	------------------	---------	-----	--------------

WYDASE

BAXTER HLTHCARE	150 UNITS/ML **	N006343	002	
	150 UNITS/VIAL **	N006343	006	
	1,500 UNITS/VIAL **	N006343	005	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

+ NOVARTIS	20MG/ML **	N008303	003	
------------	------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997
SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET; ORAL

APRESOLINE

+ NOVARTIS	10MG **	N008303	004	
	25MG **	N008303	001	
	50MG **	N008303	002	
	100MG **	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	
------	------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013
	25MG	A091679	002	Mar 04, 2013
	50MG	A091679	003	Mar 04, 2013
	100MG	A091679	004	Mar 04, 2013
ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986
	25MG	A089258	001	May 05, 1986
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
MYLAN	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001	
	50MG; 50MG	A084810	001	
	100MG; 50MG	A084811	001	

HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001	Oct 21, 1985
-----------	-------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001	Feb 08, 1982
	50MG; 50MG	A087213	001	Feb 08, 1982
	100MG; 50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001	Feb 09, 1987
	50MG; 50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001	Mar 04, 1982
	50MG; 50MG	A085446	001	Mar 04, 1982
	100MG; 50MG	A085440	001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG; 50MG	A088358	001	Apr 10, 1984
-------------	-------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG; 25MG	A088356	001	Apr 10, 1984
-------------	------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG; 50MG	A088357	001	Apr 10, 1984
-------------	------------	---------	-----	--------------

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002	
----------	------------	---------	-----	--

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001	
-------------	------------	---------	-----	--

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001	
-------------	------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
MYLAN	25MG;15MG;0.1MG	A087085	001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	25MG;15MG;0.1MG	A085771	001	
HYDRAP-ES				
SANDOZ	25MG;15MG;0.1MG	A084876	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
WATSON LABS	25MG;15MG;0.1MG	A083770	001	
HYDROSERPINE PLUS (R-H-H)				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;15MG;0.1MG	A088376	001	Oct 28, 1983
SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001	
	25MG;15MG;0.1MG	A087556	001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
LEDERLE	25MG;15MG;0.1MG	A087709	001	May 13, 1982
SER-A-GEN				
SOLVAY	25MG;15MG;0.1MG	A087210	001	
SER-AP-ES				
NOVARTIS	25MG;15MG;0.1MG	N012193	005	
UNIPRES				
SOLVAY	25MG;15MG;0.1MG	A085893	001	
	25MG;15MG;0.1MG	A086298	001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP				
SANDOZ	25MG;0.1MG	A084617	001	
SERPASIL-APRESOLINE				
NOVARTIS	25MG;0.1MG	N009296	004	
	50MG;0.2MG	N009296	002	

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

APOTEX	12.5MG	A078389	001	May 16, 2008
HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
LANNETT CO INC	12.5MG	A091662	001	Jan 27, 2012

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
ROXANE	50MG/5ML	A088587	001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL				
ROXANE	100MG/ML	A088588	001	Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS	25MG	N011793	005	
	50MG	N011793	008	
	100MG	N011793	009	

HYDRO-D

HALSEY	25MG	A086504	001	
	50MG	A083891	002	

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
APOTEX	25MG	A040774	001	Oct 03, 2007
	50MG	A040774	002	Oct 03, 2007
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	50MG	A083965	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
	25MG	A040810	001	Mar 27, 2007
	50MG	A040810	002	Mar 27, 2007
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	
HYDRODIURIL				
+ MERCK	25MG **	N011835	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRODIURIL

+		50MG **	N011835	006
+		100MG **	N011835	007

ORETIC

	ABBVIE	25MG	N011971	001
		50MG	N011971	002

ZIDE

	SOLVAY	50MG	A083925	001
--	--------	------	---------	-----

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

+	SANOFI AVENTIS US	12.5MG; 75MG **	N020758	001	Sep 30, 1997
+		25MG; 300MG **	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	APOTEX INC	12.5MG; 150MG	A201505	001	Oct 15, 2012
		12.5MG; 300MG	A201505	002	Oct 15, 2012
	ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016
		12.5MG; 300MG	A203036	002	Jan 15, 2016
		25MG; 300MG	A203036	003	Jan 15, 2016
	MYLAN PHARMS INC	12.5MG; 150MG	A077969	001	Sep 27, 2012
		12.5MG; 300MG	A077969	002	Sep 27, 2012
		25MG; 300MG	A077969	003	Jul 20, 2016
	TEVA	25MG; 300MG	A077369	003	Mar 30, 2012
	WATSON LABS INC	12.5MG; 150MG	A091539	001	Oct 22, 2012
		12.5MG; 300MG	A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

	SCHERING	25MG; 100MG	N019046	001	Apr 06, 1987
		25MG; 200MG	N019046	002	Apr 06, 1987
		25MG; 300MG	N019046	003	Apr 06, 1987
		25MG; 400MG	N019046	004	Apr 06, 1987

TRANDATE HCT

	GLAXOSMITHKLINE	25MG; 100MG	N019174	001	Apr 10, 1987
		25MG; 200MG	N019174	002	Apr 10, 1987
		25MG; 300MG	N019174	003	Apr 10, 1987
		25MG; 400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

	APOTEX	12.5MG; 10MG	A076674	001	Oct 05, 2004
		12.5MG; 20MG	A076674	002	Oct 05, 2004
		25MG; 20MG	A076674	003	Oct 05, 2004
	HERITAGE PHARMA	12.5MG; 10MG	A075776	001	Jul 01, 2002
		12.5MG; 20MG	A075776	002	Jul 01, 2002
		25MG; 20MG	A075776	003	Jul 01, 2002
	MYLAN	12.5MG; 10MG	A076113	001	Jul 01, 2002
		12.5MG; 20MG	A076113	002	Jul 01, 2002
		25MG; 20MG	A076113	003	Jul 01, 2002
	SANDOZ	12.5MG; 10MG	A075926	001	Jul 01, 2002
		12.5MG; 20MG	A075926	002	Jul 01, 2002
		25MG; 20MG	A075926	003	Jul 01, 2002
	TEVA	12.5MG; 10MG	A075869	001	Jul 01, 2002
		12.5MG; 20MG	A075869	002	Jul 01, 2002
		25MG; 20MG	A075869	003	Jul 01, 2002

PRINZIDE

+	MERCK	12.5MG; 10MG **	N019778	003	Nov 18, 1993
+		12.5MG; 20MG **	N019778	001	Feb 16, 1989
+		25MG; 20MG **	N019778	002	Feb 16, 1989

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

+	MERCK SHARP DOHME	12.5MG; 50MG	N020387 001	Apr 28, 1995
+		25MG; 100MG	N020387 002	Nov 10, 1998
	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE			
	APOTEX	12.5MG; 50MG	A090150 001	Oct 06, 2010
		12.5MG; 100MG	A090150 002	Aug 11, 2010
		25MG; 100MG	A090150 003	Oct 06, 2010
	WATSON LABS	12.5MG; 50MG	A200180 001	Jan 12, 2011
		12.5MG; 100MG	A200180 002	Jan 12, 2011
		25MG; 100MG	A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

	MERCK	15MG; 250MG	N013402 001	
	ALDORIL 25			
	MERCK	25MG; 250MG	N013402 002	
	ALDORIL D30			
	MERCK	30MG; 500MG	N013402 003	
	ALDORIL D50			
	MERCK	50MG; 500MG	N013402 004	
	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
	DAVA PHARMS INC	15MG; 250MG	A072507 001	Jun 02, 1989
		25MG; 250MG	A072508 001	Jun 02, 1989
		30MG; 500MG	A072509 001	Jun 02, 1989
		50MG; 500MG	A072510 001	Jun 02, 1989
	IVAX SUB TEVA PHARMS	15MG; 250MG	A071458 001	Mar 08, 1988
		25MG; 250MG	A071459 001	Mar 08, 1988
		30MG; 500MG	A071460 001	Mar 08, 1988
		50MG; 500MG	A071461 001	Mar 08, 1988
	PAR PHARM	15MG; 250MG	A070616 001	Feb 02, 1987
		25MG; 250MG	A070612 001	Feb 02, 1987
		30MG; 500MG	A070613 001	Feb 02, 1987
		50MG; 500MG	A070614 001	Feb 02, 1987
	PARKE DAVIS	15MG; 250MG	A071897 001	Nov 23, 1987
		25MG; 250MG	A071898 001	Nov 23, 1987
		30MG; 500MG	A071899 001	Nov 23, 1987
		50MG; 500MG	A071900 001	Nov 23, 1987
	PUREPAC PHARM	15MG; 250MG	A070853 001	Oct 08, 1986
		25MG; 250MG	A070688 001	Apr 24, 1986
		30MG; 500MG	A070854 001	Oct 08, 1986
		50MG; 500MG	A070689 001	Apr 24, 1986
	SANDOZ	15MG; 250MG	A070829 001	Mar 09, 1987
		25MG; 250MG	A070830 001	Mar 09, 1987
	TEVA	15MG; 250MG	A071819 001	Apr 08, 1988
		25MG; 250MG	A071820 001	Apr 08, 1988
		30MG; 500MG	A071821 001	Apr 08, 1988
		50MG; 500MG	A071822 001	Apr 08, 1988
	WATSON LABS	15MG; 250MG	A070365 001	Mar 19, 1986
		15MG; 250MG	A070958 001	Feb 06, 1989
		15MG; 250MG	A071920 001	Aug 29, 1988
		25MG; 250MG	A070366 001	Apr 16, 1986
		25MG; 250MG	A070959 001	Jan 19, 1989
		25MG; 250MG	A071921 001	Aug 29, 1988
		30MG; 500MG	A070367 001	Mar 19, 1986
		30MG; 500MG	A071069 001	Jan 19, 1989
		30MG; 500MG	A071922 001	Aug 29, 1988
		50MG; 500MG	A070368 001	Apr 16, 1986
		50MG; 500MG	A070960 001	Feb 06, 1989
		50MG; 500MG	A071923 001	Aug 29, 1988
	YAOPHARMA CO LTD	15MG; 250MG	A070182 001	Jan 15, 1986
		25MG; 250MG	A070183 001	Jan 15, 1986
		30MG; 500MG	A070543 001	Jan 15, 1986
		50MG; 500MG	A070544 001	Jan 15, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

+ US PHARMS HOLDINGS I 50MG;100MG **

N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX 12.5MG; 7.5MG

A090096 001 Sep 25, 2008

12.5MG; 15MG

A090096 002 Sep 25, 2008

25MG; 15MG

A090096 003 Sep 25, 2008

UNIRETIC

UCB INC 12.5MG; 7.5MG **

N020729 001 Jun 27, 1997

12.5MG; 15MG **

N020729 003 Feb 14, 2002

25MG; 15MG **

N020729 002 Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

ACCORD HLTHCARE 12.5MG; 20MG

A209281 001 Feb 07, 2019

12.5MG; 40MG

A209281 002 Feb 07, 2019

25MG; 40MG

A209281 003 Feb 07, 2019

MYLAN 12.5MG; 20MG

A078827 001 Oct 26, 2016

12.5MG; 40MG

A078827 002 Oct 26, 2016

25MG; 40MG

A078827 003 Oct 26, 2016

TEVA PHARMS USA 12.5MG; 20MG

A200532 001 Apr 24, 2017

25MG; 40MG

A200532 003 Apr 24, 2017

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS 25MG; 5MG

N018872 001 Jul 22, 1987

25MG; 10MG

N018872 002 Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST 50MG; 120MG

N019059 002 Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST 50MG; 160MG

N019059 003 Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST 50MG; 80MG

N019059 001 Jul 03, 1985

TABLET; ORAL

INDERIDE-40/25

+ WYETH PHARMS INC 25MG; 40MG **

N018031 001

INDERIDE-80/25

+ WYETH PHARMS INC 25MG; 80MG **

N018031 002

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR 25MG; 40MG

A071126 001 Mar 02, 1987

25MG; 80MG

A071127 001 Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH 25MG; 40MG

A070851 001 May 15, 1986

25MG; 80MG

A070852 001 May 15, 1986

ANI PHARMS INC 25MG; 40MG

A070704 001 Oct 01, 1986

25MG; 40MG

A072042 001 Mar 14, 1988

25MG; 80MG

A070705 001 Oct 01, 1986

25MG; 80MG

A072043 001 Mar 14, 1988

IVAX SUB TEVA PHARMS 25MG; 40MG

A071552 001 Dec 01, 1988

25MG; 80MG

A071553 001 Dec 01, 1988

WARNER CHILCOTT 25MG; 40MG

A071771 001 Jan 26, 1988

25MG; 80MG

A071772 001 Jan 26, 1988

WATSON LABS 25MG; 40MG

A070301 001 Apr 18, 1986

25MG; 40MG

A071498 001 Dec 18, 1991

25MG; 80MG

A070305 001 Apr 18, 1986

25MG; 80MG

A071501 001 Dec 18, 1991

YAOPHARMA CO LTD 25MG; 40MG

A071060 001 Aug 26, 1987

25MG; 80MG

A071061 001 Aug 26, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN	12.5MG;EQ 10MG BASE	A077093 001	Mar 28, 2005
	12.5MG;EQ 20MG BASE	A077093 002	Mar 28, 2005
	25MG;EQ 20MG BASE	A077093 003	Mar 28, 2005
SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211 001	Mar 04, 2009
	12.5MG;EQ 20MG BASE	A078211 002	Mar 04, 2009
	25MG;EQ 20MG BASE	A078211 003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338 001	
HYDRO-RESERP			
ABC HOLDING	50MG;0.125MG	A084714 002	Jun 29, 1982
HYDRO-SERP "25"			
SANDOZ	25MG;0.125MG	A084827 001	
HYDRO-SERP "50"			
SANDOZ	50MG;0.125MG	A085213 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE			
IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572 001	
	25MG;0.125MG	A083571 001	
	50MG;0.1MG	A083568 001	
	50MG;0.125MG	A083573 001	
PHARMERAL	25MG;0.125MG	A085421 001	
	50MG;0.125MG	A085420 001	
ROXANE	50MG;0.125MG	A084603 001	
WATSON LABS	25MG;0.125MG	A084466 001	
	25MG;0.125MG	A085317 001	
	25MG;0.125MG	A086330 002	
	50MG;0.125MG	A083666 001	
	50MG;0.125MG	A084467 001	
	50MG;0.125MG	A086331 001	
HYDROPRES 25			
MERCK	25MG;0.125MG	N011958 002	
HYDROPRES 50			
MERCK	50MG;0.125MG	N011958 003	
RESERPINE AND HYDROCHLOROTHIAZIDE			
BARR	25MG;0.125MG	A084580 001	
	50MG;0.125MG	A084579 001	
SANDOZ	50MG;0.125MG	A088200 001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50			
WEST WARD	50MG;0.125MG	A088189 001	May 10, 1984
SERPASIL-ESIDRIX #1			
NOVARTIS	25MG;0.1MG	N011878 003	
SERPASIL-ESIDRIX #2			
NOVARTIS	50MG;0.1MG	N011878 005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025 001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267 001	
PUREPAC PHARM	25MG;25MG	A087999 001	Nov 06, 1985
SUPERPHARM	25MG;25MG	A089137 001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398 001	
YAOPHARMA CO LTD	25MG;25MG	A086881 001	
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE			
IVAX PHARMS	25MG;25MG	A087004 002	May 24, 1982
LEDERLE	25MG;25MG	A087511 001	
PARKE DAVIS	25MG;25MG	A087948 001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054 001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553 001	
USL PHARMA	25MG;25MG	A087651 001	
VANGARD	25MG;25MG	A087655 001	
WATSON LABS	25MG;25MG	A085974 001	
	25MG;25MG	A086026 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK

25MG;10MG

N018061 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC 25MG;50MG

N016042 002

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC 25MG;37.5MG

A074970 001 Jan 06, 1998

25MG;50MG

A074259 001 Mar 30, 1995

CASI PHARMS INC 25MG;50MG

A073191 001 Jul 31, 1991

NOVARTIS 25MG;37.5MG

A074857 001 Sep 09, 1997

VITARINE 25MG;50MG

A071737 001 Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP 50MG;75MG

A072022 001 Apr 17, 1988

ANI PHARMS INC 50MG;75MG

A073467 001 Jan 31, 1996

QUANTUM PHARMICS 50MG;75MG

A071980 001 Apr 17, 1988

WATSON LABS 50MG;75MG

A071969 001 Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC 12.5MG;80MG

A203026 001 Mar 21, 2013

12.5MG;160MG

A203026 002 Mar 21, 2013

12.5MG;320MG

A203026 003 Mar 21, 2013

25MG;160MG

A203026 004 Mar 21, 2013

25MG;320MG

A203026 005 Mar 21, 2013

WATSON LABS TEVA 12.5MG;80MG

A091519 001 Mar 21, 2013

12.5MG;160MG

A091519 002 Mar 21, 2013

12.5MG;320MG

A091519 003 Mar 21, 2013

25MG;160MG

A091519 004 Mar 21, 2013

25MG;320MG

A091519 005 Mar 21, 2013

ZYDUS PHARMS 12.5MG;80MG

A203000 001 Mar 15, 2019

12.5MG;160MG

A203000 002 Mar 15, 2019

12.5MG;320MG

A203000 003 Mar 15, 2019

25MG;160MG

A203000 004 Mar 15, 2019

25MG;320MG

A203000 005 Mar 15, 2019

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+ TEVA BRANDED PHARM 15MG

N207975 001 Jan 17, 2017

+ 30MG

N207975 002 Jan 17, 2017

+ 45MG

N207975 003 Jan 17, 2017

+ 60MG

N207975 004 Jan 17, 2017

+ 90MG

N207975 005 Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

ANI PHARMS INC 5MG;200MG

A077454 001 Jun 23, 2010

SUN PHARM INDS INC 2.5MG;200MG

A091633 001 May 28, 2013

5MG;200MG

A091633 002 May 28, 2013

7.5MG;200MG

A091633 003 May 28, 2013

10MG;200MG

A091633 004 May 28, 2013

TEVA 7.5MG;200MG

A076023 001 Apr 11, 2003

VICOPROFEN

+ ABBVIE 7.5MG;200MG

N020716 001 Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS 5MG/5ML;25MG/5ML

A075103 001 Sep 29, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC	5MG/5ML; 60MG/5ML	A205658	001	Nov 17, 2015
PADDOCK LLC	5MG/5ML; 60MG/5ML	A204658	001	Apr 29, 2014
TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019
TRIS PHARMA INC	5MG/5ML; 60MG/5ML	A203839	001	Oct 28, 2014
REZIRA				
+ PERSION	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL

MAGNACORT

PFIZER	0.5%	N010554	001	
--------	------	---------	-----	--

HYDROCORTISONE

AEROSOL;TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	
------------------	------	---------	-----	--

CREAM;TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

DERMACORT

MONARCH PHARMS	1%	A083011	002	
----------------	----	---------	-----	--

ELDECORT

VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	

FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

H-CORT

PHARM ASSOC	0.5%	A086823	001	
-------------	------	---------	-----	--

HC #1

BAYER PHARMS	0.5%	A080438	001	
--------------	------	---------	-----	--

HC #4

BAYER PHARMS	1%	A080438	002	
--------------	----	---------	-----	--

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	

HI-COR

C AND M PHARMA	2.5%	A080483	001	
----------------	------	---------	-----	--

HYDROCORTISONE

ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	
	1%	A080848	003	
AMBIX	1%	A086080	001	
	2.5%	A086271	001	
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
TARO PHARM INDS LTD	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

USL PHARMA	1%	A088027 001	Sep 27, 1983
	2.5%	A088029 001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496 002	

HYTONE

VALEANT INTL	1% **	A080472 003	
	2.5% **	A080472 004	

NOGENIC HC

IVAX PHARMS	1%	A087427 001	Apr 04, 1988
-------------	----	-------------	--------------

NUTRACORT

BAUSCH	0.5%	A080442 002	
	1%	A080442 003	

PENECORT

ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
------------------	----	-------------	--------------

PROTOCORT

MONARCH PHARMS	1%	A083011 001	
----------------	----	-------------	--

SYNACORT

MEDICIS	0.5%	A087459 001	
	1%	A087458 001	
	2.5%	A087457 001	

GEL;TOPICAL

NUTRACORT

HEALTHPOINT	1%	A084698 001	
-------------	----	-------------	--

PENECORT

ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
------------------	----	-------------	--------------

INJECTABLE; INJECTION

CORTEF

PHARMACIA AND UPJOHN	50MG/ML	N009864 001	
----------------------	---------	-------------	--

LOTION;TOPICAL

ACTICORT

BAKER NORTON	1%	A086535 001	
--------------	----	-------------	--

ALA-CORT

CROWN LABS	1%	A083201 001	
------------	----	-------------	--

BALNEOL-HC

SOLVAY	1%	A088041 001	Dec 03, 1982
--------	----	-------------	--------------

BETA-HC

BETA DERMAC	1%	A089495 001	Jan 25, 1988
-------------	----	-------------	--------------

CETACORT

BAUSCH	0.5%	A080426 002	
	1%	A080426 001	

CORT-DOME

BAYER PHARMS	0.5%	N009895 003	
	1%	N009895 001	

DERMACORT

SOLVAY	0.5%	A084573 002	
	1%	A086462 001	

EPICORT

BLULINE	0.5%	A083219 002	
---------	------	-------------	--

GLYCORT

HERAN	1%	A087489 001	Oct 03, 1983
-------	----	-------------	--------------

H-CORT

PHARM ASSOC	0.5%	A086824 001	
-------------	------	-------------	--

HYDROCORTISONE

ALPHARMA US PHARMS	0.5%	A087317 001	Jun 07, 1982
	1%	A087315 001	Jun 07, 1982

MERICON	0.5%	A085282 001	
	1%	A085282 002	Feb 26, 1987

NASKA	1%	A089705 001	Apr 25, 1988
-------	----	-------------	--------------

PERRIGO NEW YORK	0.5%	A085662 001	
	1%	A085663 001	

TARO	1%	A089024 001	Feb 12, 1986
------	----	-------------	--------------

HYTONE

VALEANT INTL	1% **	A080473 003	
	2.5% **	A080473 004	Nov 30, 1982

NUTRACORT

DOW PHARM	0.5%	A080443 002	
	1%	A080443 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE

LOTION;TOPICAL				
NUTRACORT	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PERRIGO CO	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
	2.5%	A040310	001	Dec 29, 2000
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
DERMIK LABS	1% **	A080474	003	
	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONETABLET; ORAL
HYDROCORTONE

20MG

N008506 011

TABLET; VAGINAL
CORTRIL

PFIPHARMECS

10MG

N009796 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE

1%

A081274 001 Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI

1%

A080419 001 Jan 25, 1982

FERNDAL LABS

2.5%

A040259 001 Jul 29, 1999

PARKE DAVIS

1%

A089914 001 Jan 03, 1989

PUREPAC PHARM

0.5%

A086050 001

1%

A086052 001

MICORT-HC

SEBELA IRELAND LTD

2%

A040398 001 Mar 29, 2002

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN

50MG/ML

N009378 002

CORTRIL

PFIZER

25MG/ML

N009164 001

HYDROCORTISONE ACETATE

AKORN

25MG/ML

N009637 001

50MG/ML

N009637 002

BEL MAR

25MG/ML

A083739 001

50MG/ML

A083739 002

WATSON LABS

25MG/ML

A083128 001

25MG/ML

A083759 001

50MG/ML

A083759 002

50MG/ML

A085214 001

HYDROCORTONE

MERCK

25MG/ML

N008228 001

50MG/ML

N008228 004

LOTION; TOPICAL

DRICORT

INGRAM PHARM

0.5%

A086207 001

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS

0.5%

A080828 001

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK

1.5%

N009018 003

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN

1%

N008917 002

+

2.5% **

N008917 001

PASTE; TOPICAL

ORABASE HCA

COLGATE

0.5%

A083205 001

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS

100%

A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM

A061049 001

2.5%;EQ 3.5MG BASE/GM

A061049 002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM

A060610 001

1.5%;EQ 3.5MG BASE/GM

A060610 002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM

A060751 001

1%;EQ 3.5MG BASE/GM

A060751 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

2.5%;EQ 3.5MG BASE/GM

A060751 003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN

1.5%;EQ 3.5MG BASE/ML

A060188 001

NEO-CORTEF

PHARMACIA AND UPJOHN

0.5%;EQ 3.5MG BASE/ML

A060612 002

1.5%;EQ 3.5MG BASE/ML

A060612 001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

PFIZER

1.5%;EQ 5MG BASE/ML

A061016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

GENUS

1%;1%

A089440 001 May 17, 1988

LOTION; TOPICAL

PRAMOSONE

FERNDAL LABS

0.5%;1%

A083213 002

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS

1%;10%

A080505 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001 Jan 07, 1983

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001 Jul 03, 1984

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001 Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN

EQ 10MG BASE/5ML

N009900 001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCCK

EQ 50MG BASE/ML

N012052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL

A085928 001

EQ 100MG BASE/VIAL

A089577 001 Apr 11, 1989

EQ 250MG BASE/VIAL

A089578 001 Apr 11, 1989

EQ 500MG BASE/VIAL

A089579 001 Apr 11, 1989

EQ 1GM BASE/VIAL

A089580 001 Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL

A040666 001 Apr 06, 2006

EQ 100MG BASE/VIAL

A085929 001

EQ 250MG BASE/VIAL

A085930 001

EQ 500MG BASE/VIAL

A085931 001

EQ 1GM BASE/VIAL

A085932 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001 Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001 Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A088670 001 Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL

A086619 001

EQ 250MG BASE/VIAL

A087567 001

EQ 500MG BASE/VIAL

A087568 001

EQ 1GM BASE/VIAL

A087569 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
	EQ 100MG BASE/VIAL	A084738 001	
	EQ 250MG BASE/VIAL	A084737 001	
	EQ 500MG BASE/VIAL	A084747 001	
	EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

ACP NIMBLE	0.2%	A074489 001	Aug 12, 1998
------------	------	-------------	--------------

WESTCORT

+ SUN PHARM INDS INC	0.2% **	N017950 001	
----------------------	---------	-------------	--

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
----------------	------	-------------	--------------

WESTCORT

+ SUN PHARM INDS INC	0.2% **	N018726 001	Aug 08, 1983
----------------------	---------	-------------	--------------

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **	N050479 001	
------------------	--	-------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216 001	Oct 31, 2005
---------------	-------------------------------------	-------------	--------------

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982
------------	-------------------------------------	-------------	--------------

OTOCORT

WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	
-------------	-------------------------------------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
----------------	-------------------------------------	-------------	--

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985
------------	-------------------------------------	-------------	--------------

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
------------	-------------------------------------	-------------	--------------

OTICAIR

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982
------------	-------------------------------------	-------------	--------------

OTOBIONE

SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
----------	-------------------------------------	-------------	--

OTOCORT

ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985
---------------------	-------------------------------------	-------------	--------------

PEDIOTIC

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987
----------------	-------------------------------------	-------------	--------------

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBIOIC

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
----------	--------------------------------	-------------	--

PYOCIDIN

FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	
-------------	--------------------------------	-------------	--

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

ACHROMYCIN

LEDERLE	1.5%;1%	N050272 001	
---------	---------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

BIOGLAN 1%;10% A086008 001

CALMURID HC

PHARMACIA AND UPJOHN 1%;10% A083947 001

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST 50MG A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM 50MG A088850 001 May 31, 1985

WATSON LABS 50MG A088031 001 Apr 06, 1983

50MG A088528 001 Aug 15, 1984

SALURON

+ SHIRE LLC 50MG N011949 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA 50MG;0.125MG A088195 001 Oct 26, 1983

WATSON LABS 25MG;0.125MG A088127 001 Mar 22, 1983

50MG;0.125MG A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS 50MG;0.125MG A088932 001 Jan 11, 1985

PAR PHARM 50MG;0.125MG A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE 50MG;0.125MG N012359 003

SALUTENSIN-DEMI

SHIRE 25MG;0.125MG N012359 004

HYDROGEN PEROXIDE

SOLUTION; TOPICAL

ESKATA

+ ACLARIS 40% N209305 001 Dec 14, 2017

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP 12MG N021044 001 Sep 24, 2004

16MG N021044 002 Sep 24, 2004

24MG N021044 003 Sep 24, 2004

32MG N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

DILAUDID

+ FRESENIUS KABI USA 4MG/ML N019034 005 Apr 30, 2009

DILAUDID-HP

+ FRESENIUS KABI USA 10MG/ML N019034 001 Jan 11, 1984

250MG/VIAL N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

HOSPIRA 10MG/ML A074598 001 Jun 19, 1997

WATSON LABS 10MG/ML A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS 2MG A077311 001 Nov 09, 2005

4MG A077311 002 Nov 09, 2005

8MG A077311 003 Nov 09, 2005

TABLET, EXTENDED RELEASE; ORAL

EXALGO

+ SPECGX LLC 8MG N021217 001 Mar 01, 2010

+ 12MG N021217 002 Mar 01, 2010

+ 16MG N021217 003 Mar 01, 2010

+ 32MG N021217 004 Aug 24, 2012

HYDROMORPHONE HYDROCHLORIDE

ACTAVIS LABS FL INC 8MG A202144 001 May 12, 2014

12MG A202144 002 May 12, 2014

16MG A202144 003 May 12, 2014

32MG A202144 004 Jun 30, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCCK

1MG/ML

A080778 001

CYANOKIT

SERB SA

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

INVATECH

200MG

A040150 001 Jan 27, 1996

LAURUS LABS LTD

200MG

A210959 001 Jan 15, 2019

LUPIN LTD

200MG

A210543 001 Jul 06, 2018

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

ALLERGAN

125MG/ML

N017439 001

250MG/ML

N017439 002

SOLUTION; INTRAMUSCULAR

DELALUTIN

+ BRISTOL MYERS SQUIBB 125MG/ML (125MG/ML) **

N010347 004

+ 125MG/ML (125MG/ML) **

N016911 001

+ 250MG/ML (250MG/ML) **

N010347 002

+ 250MG/ML (250MG/ML) **

N016911 002

HYDROXYPROGESTERONE CAPROATE

EUGIA PHARMA

1250MG/5ML (250MG/ML)

A211142 001 May 09, 2019

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

DR REDDYS

50MG/ML

A085779 001

FRESENIUS KABI USA

25MG/ML

A087329 001

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A087329 002

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAK				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
+ PFIZER	25MG/ML **	N011111	001	
+	50MG/ML **	N011111	002	
SYRUP; ORAL				
ATARAX				
ROERIG	10MG/5ML **	N010485	001	
HYDROXYZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
ANIMA	10MG/5ML	A086880	001	
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
TORRENT	10MG/5ML	A210634	001	Feb 26, 2019
TABLET; ORAL				
ATARAX				
+ PFIZER	10MG **	N010392	001	
+	25MG **	N010392	004	
+	50MG **	N010392	006	
+	100MG **	N010392	005	
HYDROXYZINE HYDROCHLORIDE				
ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982
	25MG	A087871	003	Dec 20, 1982
	50MG	A087871	001	Dec 20, 1982
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
MYLAN	10MG	A091176	001	Jun 07, 2010
	25MG	A091176	002	Jun 07, 2010
	50MG	A091176	003	Jun 07, 2010
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982
VISTARIL				
+	PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002
+		EQ 50MG HYDROCHLORIDE	N011459	004
		EQ 100MG HYDROCHLORIDE **	N011459	006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

HYDROXYZINE PAMOATE

SUSPENSION;ORAL

VISTARIL

PFIZER

EQ 25MG HYDROCHLORIDE/5ML

N011795 001

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

EMCURE PHARMS LTD

EQ 3MG BASE/3ML

A203987 001 Sep 02, 2014

TABLET;ORAL

BONIVA

+ HOFFMANN LA ROCHE

EQ 2.5MG BASE **

N021455 001 May 16, 2003

IBANDRONATE SODIUM

MYLAN PHARMS INC

EQ 150MG BASE

A078995 001 Mar 19, 2012

SUN PHARM INDUSTRIES

EQ 150MG BASE

A078996 001 Aug 15, 2012

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

CONTRACT PHARMACAL

200MG

A074782 001 Jul 06, 1998

STRIDES PHARMA

EQ 200MG FREE ACID AND POTASSIUM SALT

A204469 001 Mar 28, 2018

MIDOL

BAYER

200MG **

A070626 001 Sep 02, 1987

200MG **

A071002 001 Sep 02, 1987

SOLUTION;INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS

400MG/4ML (100MG/ML)

N022348 001 Jun 11, 2009

SUSPENSION;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE

100MG/5ML

N019833 002 Sep 19, 1989

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH

100MG/5ML

N021604 001 Jan 07, 2004

IBU

ABBOTT

100MG/5ML

N019784 001 Dec 18, 1989

IBUPROFEN

GUARDIAN DRUG

100MG/5ML

A210149 001 Aug 17, 2018

MOTRIN

+ MCNEIL CONSUMER

100MG/5ML **

N019842 001 Sep 19, 1989

SUSPENSION/DROPS;ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001 May 25, 1995

PEDIATRIC ADVIL

+ GLAXOSMITHKLINE

100MG/2.5ML

N020812 001 Jan 30, 1998

TABLET;ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001 Dec 08, 1987

IBU

BASF

400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA

800MG

A071965 001 Aug 11, 1988

IBUPRIN

PLIVA

200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001 Jun 14, 1985

ANI PHARMS INC

800MG

A071264 001 Jul 25, 1986

200MG

A071144 001 Jan 20, 1987

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

AUROLIFE PHARMA LLC

300MG

A070736 002 Jun 12, 1986

400MG

A070736 003 Jun 12, 1986

600MG

A070736 001 Jun 12, 1986

800MG

A071938 001 Jan 14, 1988

CONTRACT PHARMACAL

200MG

A071265 001 Oct 15, 1986

200MG

A071265 002 Sep 10, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	200MG	A071735 001	Sep 10, 1987
	200MG	A073691 001	Feb 25, 1994
	200MG	A074931 001	Jul 20, 1998
HALSEY	200MG	A071027 001	Sep 29, 1987
	300MG	A071028 001	Mar 23, 1987
	400MG	A071029 001	Mar 23, 1987
	600MG	A071030 001	Mar 23, 1987
	800MG	A072137 001	Feb 05, 1988
HEC PHARM	400MG	A204062 001	Sep 10, 2018
	600MG	A204062 002	Sep 10, 2018
	800MG	A204062 003	Sep 10, 2018
IVAX SUB TEVA PHARMS	200MG	A071154 001	Oct 27, 1987
	200MG	A072040 001	Apr 29, 1988
	400MG	A071145 001	Sep 23, 1986
	600MG	A071146 001	Sep 23, 1986
	800MG	A071769 001	May 08, 1987
J AND J CONSUMER INC	400MG	A070081 001	Jun 16, 1986
LEDERLE	400MG	A070629 001	Sep 19, 1986
	600MG	A070630 001	Sep 19, 1986
LEINER	300MG	A071266 001	Oct 15, 1986
LNK	100MG	A076741 001	Jun 17, 2004
MCNEIL	600MG	A070476 001	Jun 16, 1986
MYLAN	200MG	A071870 001	May 05, 1988
	400MG	A070045 001	Sep 24, 1985
	600MG	A070057 001	Sep 24, 1985
	800MG	A071999 001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007
	600MG	A078132 002	Sep 10, 2007
	800MG	A078132 003	Sep 10, 2007
OHM LABS	400MG	A070818 001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733 001	Sep 19, 1986
PAR PHARM	200MG	A071575 001	May 08, 1987
	300MG	A070328 001	Aug 06, 1985
	400MG	A070329 001	Aug 06, 1985
	600MG	A070330 001	Aug 06, 1985
	800MG	A070986 001	Jul 25, 1986
PERRIGO	200MG	A072098 001	Dec 08, 1987
PLIVA	400MG	A071666 001	Jun 18, 1987
	600MG	A071667 001	Jun 18, 1987
	800MG	A071668 001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122 001	Oct 03, 1986
	200MG	A071664 001	Feb 03, 1987
	300MG	A071123 001	Sep 19, 1986
	400MG	A071124 001	Sep 19, 1986
	600MG	A071125 001	Sep 19, 1986
	800MG	A071964 001	Feb 01, 1988
SANDOZ	200MG	A071807 001	Feb 25, 1988
	200MG	A074525 001	Dec 15, 1995
	200MG	A074533 001	Dec 15, 1995
	400MG	A072064 001	Jan 14, 1988
	600MG	A072065 001	Jan 14, 1988
	800MG	A072169 001	Dec 11, 1987
SUN PHARM INDUSTRIES	200MG	A070493 001	Dec 24, 1985
	200MG	A070908 001	Sep 26, 1986
	200MG	A071462 001	Oct 02, 1986
	400MG	A070079 001	Jul 24, 1985
	600MG	A070080 001	Jul 24, 1985
	800MG	A071448 001	Feb 18, 1987
SUPERPHARM	600MG	A070709 001	Apr 25, 1986
TEVA	200MG	A073141 001	May 29, 1992
	400MG	A073343 001	Jun 30, 1992
	600MG	A073344 001	Jun 30, 1992
	800MG	A073345 001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249 001	Jan 10, 1989
	300MG	A071230 001	Oct 22, 1986
	400MG	A071231 001	Oct 22, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	600MG		A071232	001	Oct 22, 1986
	800MG		A072004	001	Nov 18, 1987
WATSON LABS	200MG		A070435	001	Mar 05, 1986
	200MG		A071765	001	Sep 04, 1987
	200MG		A071905	001	Mar 08, 1988
	300MG		A071338	001	Dec 01, 1986
	400MG		A070038	001	Sep 06, 1985
	400MG		A070436	001	Aug 21, 1985
	600MG		A070041	001	Sep 06, 1985
	600MG		A070437	001	Aug 21, 1985
	800MG		A071547	001	Jul 02, 1987
	800MG		A071911	001	Oct 13, 1987
IBUPROHM					
OHM LABS	200MG		A071214	001	Dec 01, 1986
	400MG		A070469	001	Aug 29, 1985
MEDIPREN					
MCNEIL	200MG		A070475	001	Feb 06, 1986
	200MG		A071215	001	Jun 26, 1986
MIDOL					
BAYER	200MG		A070591	001	Sep 02, 1987
	200MG		A071001	001	Sep 02, 1987
MOTRIN					
+ MCNEIL CONSUMER	300MG **		N017463	003	
+	400MG **		N017463	002	
+	600MG **		N017463	004	
+	800MG **		N017463	005	May 22, 1985
MCNEIL PED	100MG		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN					
J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000
NUPRIN					
BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
	200MG		A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984
	200MG		N019012	002	Jul 29, 1987
RUFEN					
BASF	600MG		N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL					
CHILDREN'S MOTRIN					
+ J AND J CONSUMER INC	50MG		N020601	001	Nov 15, 1996
IBUPROFEN					
PERRIGO	50MG		A076359	001	Jan 16, 2004
JUNIOR STRENGTH MOTRIN					
+ J AND J CONSUMER INC	100MG		N020601	003	Nov 15, 1996
MOTRIN					
MCNEIL PED	50MG		N020135	001	Nov 16, 1994
	100MG		N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS	400MG; 5MG **		N021378	001	Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN					
WATSON LABS	400MG; 5MG		A078394	001	Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL	200MG; 30MG		A075588	001	Apr 08, 2002
--------------------	-------------	--	---------	-----	--------------

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

IBUTILIDE FUMARATE

LUITPOLD	0.1MG/ML		A090240	001	Jan 11, 2010
MYLAN INSTITUTIONAL	0.1MG/ML		A090924	001	Jan 11, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

MYLAN LABS LTD	1MG/ML	A200144	001	Oct 11, 2012
SANDOZ	1MG/ML	A091293	001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE	0.5%	N015868	001	
-----------------	------	---------	-----	--

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+ ALCON	0.1%	N014169	001	
---------	------	---------	-----	--

HERPLEX

ALLERGAN	0.1%	N013935	002	
----------	------	---------	-----	--

STOXIL

GLAXOSMITHKLINE	0.1%	N013934	001	
-----------------	------	---------	-----	--

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
	3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012
	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE	1GM/VIAL; 100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL; 100MG/ML	N019763	004	Oct 10, 1992

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002
	3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

ILOPERIDONE

INVENTIA	1MG	A207231	001	Nov 28, 2016
	2MG	A207231	002	Nov 28, 2016
	4MG	A207231	003	Nov 28, 2016
	6MG	A207231	004	Nov 28, 2016
	8MG	A207231	005	Nov 28, 2016
	10MG	A207231	006	Nov 28, 2016
	12MG	A207231	007	Nov 28, 2016
TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019
	2MG	A207098	002	Jul 22, 2019
	4MG	A207098	003	Jul 22, 2019
	6MG	A207098	004	Jul 22, 2019
	8MG	A207098	005	Jul 22, 2019
	10MG	A207098	006	Jul 22, 2019
	12MG	A207098	007	Jul 22, 2019

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
---------------------	----------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

+ NOVARTIS

EQ 50MG BASE **

N021335 001 May 10, 2001

+

EQ 100MG BASE **

N021335 002 May 10, 2001

TABLET; ORAL

IMATINIB MESYLATE

AMNEAL PHARMS

EQ 100MG BASE

A207495 001 Feb 08, 2019

EQ 400MG BASE

A207495 002 Feb 08, 2019

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

LUPIN LTD

10MG

A090441 002 Mar 11, 2010

25MG

A090441 003 Mar 11, 2010

50MG

A090441 001 Mar 11, 2010

OXFORD PHARMS

10MG

A040751 003 Feb 28, 2008

25MG

A040751 002 Feb 28, 2008

50MG

A040751 001 Feb 28, 2008

PAR PHARM

10MG

A089422 001 Jul 14, 1987

25MG

A089497 001 Jul 14, 1987

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

MYLAN PHARMS INC

EQ 75MG HYDROCHLORIDE

A202338 001 Jun 28, 2013

EQ 100MG HYDROCHLORIDE

A202338 002 Jun 28, 2013

EQ 125MG HYDROCHLORIDE

A202338 003 Jun 28, 2013

EQ 150MG HYDROCHLORIDE

A202338 004 Jun 28, 2013

TOFRANIL-PM

+ SPECGX LLC

EQ 75MG HYDROCHLORIDE **

N017090 001

+

EQ 100MG HYDROCHLORIDE **

N017090 004

+

EQ 125MG HYDROCHLORIDE **

N017090 003

+

EQ 150MG HYDROCHLORIDE **

N017090 002

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

ACP NIMBLE

5%

A200481 001 Apr 18, 2011

STRIDES PHARMA

5%

A202002 001 Jun 24, 2014

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001 May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001 Jul 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

ANI PHARMS INC

1.25MG

A074498 002 Feb 12, 1998

2.5MG

A074498 001 Oct 31, 1996

MYLAN PHARMS INC

1.25MG

A075105 001 Jul 23, 1998

2.5MG

A075105 002 Jul 23, 1998

TEVA

1.25MG

A074665 001 Apr 04, 1997

2.5MG

A074665 002 Apr 04, 1997

WATSON LABS

1.25MG

A074585 001 Sep 26, 1996

2.5MG

A074585 002 Sep 26, 1996

YAOPHARMA CO LTD

1.25MG

A074594 001 May 23, 1996

2.5MG

A074594 002 May 23, 1996

LOZOL

+ SANOFI AVENTIS US

1.25MG **

N018538 002 Apr 29, 1993

+

2.5MG **

N018538 001 Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY

EQ 50MG BASE

N019693 001 Dec 29, 1989

EQ 75MG BASE

N019693 002 Dec 29, 1989

EQ 100MG BASE

N019693 003 Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME

EQ 100MG BASE

N020685 006 Apr 19, 2000

EQ 333MG BASE

N020685 005 Dec 17, 1998

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+ GE HEALTHCARE

2mCi/0.2ML

N019862 001 Dec 29, 1992

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN

10MG/VIAL **

N011525 003

40MG/VIAL **

N011525 004

50MG/VIAL **

N011525 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985

INDOCIN

+	EGALET	25MG **	N016059	001
+		50MG **	N016059	002

INDOMETHACIN

ABLE	25MG	A076666	001	Dec 17, 2003
	50MG	A076666	002	Dec 17, 2003
ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985
	50MG	A070354	001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
	50MG	A070327	001	Oct 18, 1985
HALSEY	25MG	A070782	001	Jun 03, 1987
	50MG	A070635	001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
	50MG	N018730	002	May 04, 1984
MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
	50MG	A070068	001	Oct 03, 1986
MYLAN	25MG	N018858	001	Apr 20, 1984
	50MG	A070624	001	Sep 04, 1985
	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
	50MG	A091401	002	Mar 28, 2013
SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
	50MG	A070900	001	Feb 09, 1987
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

+	EGALET	75MG **	N018185	001	Feb 23, 1982
---	--------	---------	---------	-----	--------------

INDOMETHACIN

ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989
WATSON LABS INC	75MG	A202572	001	Dec 09, 2013

SUPPOSITORY; RECTAL

INDOCIN

+	EGALET	50MG **	N017814	001	Aug 13, 1984
---	--------	---------	---------	-----	--------------

SUSPENSION; ORAL

INDOMETHACIN

HIKMA	25MG/5ML	A071412	001	Mar 18, 1987
-------	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC 50 UNITS/ML;50 UNITS/ML

N021810 001 Aug 26, 2008

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC 210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 002 Nov 01, 2001

NOVO NORDISK INC 210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 003 Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 005 Oct 31, 2013

NOVOLOG INNOLET

NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 004 Apr 23, 2004

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

RYZODEG 70/30

+ NOVO 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)

N203313 001 Sep 25, 2015

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN

NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 002 Jun 16, 2005

LEVEMIR INNOLET

NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 003 Jun 16, 2005

LEVEMIR PENFILL

NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 004 Jun 16, 2005

INSULIN GLULISINE RECOMBINANT

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML)

N021629 002 Dec 20, 2005

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG MIX 50/50 PEN

LILLY 50 UNITS/ML;50 UNITS/ML

N021018 003 Dec 22, 1999

HUMALOG MIX 75/25 PEN

LILLY 75 UNITS/ML;25 UNITS/ML

N021017 003 Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG PEN

LILLY 100 UNITS/ML

N020563 002 Aug 06, 1998

INSULIN PORK

INJECTABLE;INJECTION

ILETIN I

LILLY 500 UNITS/ML

N017931 001

INSULIN

NOVO NORDISK INC 40 UNITS/ML

N017926 001

REGULAR INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017926 003

INSULIN PURIFIED BEEF

INJECTABLE;INJECTION

REGULAR ILETIN II

LILLY 100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE;INJECTION

ILETIN II

LILLY 500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY 100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC 100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC 100 UNITS/ML

N018193 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY 100 UNITS/ML N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC 100 UNITS/ML N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER 1MG/INH N021868 001 Jan 27, 2006

3MG/INH N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY 50 UNITS/ML; 50 UNITS/ML N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC 100 UNITS/ML N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC 100 UNITS/ML N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS 30 UNITS/ML; 70 UNITS/ML N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC 40 UNITS/ML N017929 001

100 UNITS/ML N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY 40 UNITS/ML N017936 001

100 UNITS/ML N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY 100 UNITS/ML N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC 100 UNITS/ML N018194 001

NPH ILETIN II (PORK)

LILLY 100 UNITS/ML N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC 100 UNITS/ML N018623 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC 100 UNITS/ML N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML N019065 001 Jan 23, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE;INJECTION

PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017932	001
	100 UNITS/ML	N017932	002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE;INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N018476	001
-------	--------------	---------	-----

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928	001
	100 UNITS/ML	N017928	003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE;INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N018346	001
-------	--------------	---------	-----

INSULIN ZINC SUSP BEEF

INJECTABLE;INJECTION

LENTE INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017998	001
	100 UNITS/ML	N017998	003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE;INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017997	003
------------------	--------------	---------	-----

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE;INJECTION

ULTRALENTE

NOVO NORDISK INC	100 UNITS/ML	N018385	001
------------------	--------------	---------	-----

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN U

LILLY	40 UNITS/ML	N019571	001	Jun 10, 1987
	100 UNITS/ML	N019571	002	Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE;INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017996	003
------------------	--------------	---------	-----

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE;INJECTION

SEMILENTE

NOVO NORDISK INC	100 UNITS/ML	N018382	001
------------------	--------------	---------	-----

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE;INJECTION

LENTE ILETIN II

LILLY	100 UNITS/ML	N018477	001
-------	--------------	---------	-----

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE;INJECTION

LENTARD

NOVO NORDISK INC	100 UNITS/ML	N018384	001
------------------	--------------	---------	-----

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE;INJECTION

LENTE

NOVO NORDISK INC	100 UNITS/ML	N018383	001
------------------	--------------	---------	-----

LENTE ILETIN II (PORK)

LILLY	100 UNITS/ML	N018347	001
-------	--------------	---------	-----

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE;INJECTION

HUMULIN L

LILLY	100 UNITS/ML	N019377	002	Sep 30, 1985
-------	--------------	---------	-----	--------------

NOVOLIN L

NOVO NORDISK INC	100 UNITS/ML	N019965	001	Jun 25, 1991
------------------	--------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC 100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX 100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT 750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO 65%

N017902 001

RENOVUE-DIP

BRACCO 24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO 10.3%

N009321 007

+

52%

N009321 003

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO 20%

N009321 001

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE 55%

N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE 1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPPURAN I 131

MALLINCKRODT 0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO 1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE 0.2mCi/ML

N017313 001

IO DOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO 9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP 1mCi/ML

N019432 001 Dec 24, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IOPHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210					
GE HEALTHCARE	45.3%		N018956	006	Jun 30, 1989
SOLUTION; INJECTION, ORAL, RECTAL					
OMNIPAQUE 240					
GE HEALTHCARE	51.8%		N020608	001	Oct 24, 1995
SOLUTION; URETHRAL					
OMNIPAQUE 70					
GE HEALTHCARE	15.1%		N018956	007	Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL					
BAXTER HLTHCARE	41%		A074629	001	Nov 06, 1996
	51%		A074629	004	Mar 31, 1998
	61%		A074629	002	Nov 06, 1996
	76%		A074629	003	Nov 06, 1996
HOSPIRA	61%		A074734	001	Dec 10, 1996
	76%		A074734	002	Dec 10, 1996
IOPAMIDOL-200					
COOK IMAGING	41%		A074881	001	Jul 28, 2000
HOSPIRA	41%		A074898	001	Dec 30, 1997
IOPAMIDOL-200 IN PLASTIC CONTAINER					
HOSPIRA	41%		A074636	001	Dec 30, 1997
IOPAMIDOL-250					
COOK IMAGING	51%		A074881	002	Jul 28, 2000
FRESENIUS KABI USA	51%		A074679	001	Apr 02, 1997
HOSPIRA	51%		A074898	002	Dec 30, 1997
	51%		A075005	001	Feb 24, 1998
IOPAMIDOL-250 IN PLASTIC CONTAINER					
HOSPIRA	51%		A074636	002	Dec 30, 1997
IOPAMIDOL-300					
ABBVIE	61%		A074638	001	Apr 30, 1997
COOK IMAGING	61%		A074881	003	Jul 28, 2000
FRESENIUS KABI USA	61%		A074679	002	Apr 02, 1997
HOSPIRA	61%		A074898	003	Dec 30, 1997
	61%		A075005	002	Feb 24, 1998
IOPAMIDOL-300 IN PLASTIC CONTAINER					
HOSPIRA	61%		A074636	003	Dec 30, 1997
	61%		A074637	001	Apr 03, 1997
IOPAMIDOL-370					
COOK IMAGING	76%		A074881	004	Jul 28, 2000
FRESENIUS KABI USA	76%		A074679	003	Apr 02, 1997
HOSPIRA	76%		A074898	004	Dec 30, 1997
	76%		A075005	003	Feb 24, 1998
IOPAMIDOL-370 IN PLASTIC CONTAINER					
HOSPIRA	76%		A074636	004	Dec 30, 1997
ISOVUE-128					
BRACCO	26%		N018735	005	Oct 21, 1986
ISOVUE-200					
BRACCO	41%		N020327	001	Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE					
GE HEALTHCARE	500MG		N008032	001	

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE					
ALCON	100%		N005319	001	

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)					
+ BAYER HLTHCARE	49.9%		N021425	003	Mar 12, 2004
ULTRAVIST 150					
+ BAYER HLTHCARE	31.2%		N020220	004	May 10, 1995
ULTRAVIST 240					
+ BAYER HLTHCARE	49.9%		N020220	003	May 10, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IOPROMIDE

INJECTABLE; INJECTION			
ULTRAVIST 300 IN PLASTIC CONTAINER			
+ BAYER HLTHCARE	62.3%	N020220 005	Nov 18, 2008

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION			
CONRAY 30			
+ LIEBEL-FLARSHEIM	30%	N016983 001	
CONRAY 43			
+ LIEBEL-FLARSHEIM	43%	N013295 002	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION			
VASCORAY			
MALLINCKRODT	52%;26%	N016783 001	

IOTHALAMATE SODIUM

INJECTABLE; INJECTION			
ANGIO-CONRAY			
MALLINCKRODT	80%	N013319 001	
CONRAY 325			
MALLINCKRODT	54.3%	N017685 001	
CONRAY 400			
MALLINCKRODT	66.8%	N014295 001	

IOTROLAN

INJECTABLE; INTRATHECAL			
OSMOVIST 190			
BAYER HLTHCARE	40.6%	N019580 001	Dec 07, 1989
OSMOVIST 240			
BAYER HLTHCARE	51.3%	N019580 002	Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION			
OPTIRAY 160			
LIEBEL-FLARSHEIM	34%	N019710 003	Dec 30, 1988
OPTIRAY 240			
LIEBEL-FLARSHEIM	51%	N020923 001	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION			
HEXABRIX			
GUERBET	39.3%;19.6%	N018905 002	Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION			
OXILAN-300			
GUERBET	62%	N020316 001	Dec 21, 1995
OXILAN-350			
GUERBET	73%	N020316 002	Dec 21, 1995

IPODATE CALCIUM

GRANULE; ORAL			
ORAGRAFIN CALCIUM			
BRACCO	3GM/PACKET	N012968 001	

IPODATE SODIUM

CAPSULE; ORAL			
BILIVIST			
BAYER HLTHCARE	500MG	A087768 001	Aug 11, 1982
ORAGRAFIN SODIUM			
BRACCO	500MG	N012967 001	

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION			
ATROVENT			
BOEHRINGER INGELHEIM	0.018MG/INH	N019085 001	Dec 29, 1986
SOLUTION; INHALATION			
ATROVENT			
+ BOEHRINGER INGELHEIM	0.02% **	N020228 001	Sep 29, 1993
IPRATROPIUM BROMIDE			
ACTAVIS MID ATLANTIC	0.02%	A075111 001	Apr 22, 1999
APOTEX INC	0.02%	A075441 001	Mar 28, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001
MYLAN SPECIALITY LP	0.02%	A074755	001	Jan 10, 1997
PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001
ROXANE	0.02%	A075867	001	Jul 22, 2002
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000

SPRAY, METERED; NASAL

ATROVENT

+ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995
+	0.042MG/SPRAY	N020394	001	Oct 20, 1995

IPRATROPIUM BROMIDE

APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003
MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003
	0.042MG/SPRAY	A075553	001	Mar 31, 2003

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
APOTEX INC	75MG	A200832	001	Oct 15, 2012
	150MG	A200832	002	Oct 15, 2012
	300MG	A200832	003	Oct 15, 2012
MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008
SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009
SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008
	100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
IRON DEXTRAN				
SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
PROFERDEX				
NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

AM REGENT	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON	1%	A086711	001	
BRONKOSOL				
SANOFI AVENTIS US	0.25%	N012339	009	
	1%	N012339	008	

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

	0.125%	A089615	001	Jun 13, 1991
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656	001	
-------	--------	---------	-----	--

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML **	N008662	001	
--------	-------------	---------	-----	--

RIMIFON

ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	

SYRUP; ORAL

ISONIAZID

ANDA REPOSITORY	50MG/5ML	A081118	001	Jul 21, 1997
-----------------	----------	---------	-----	--------------

LANIAZID

LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
---------	----------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISONIAZID

SYRUP;ORAL

RIMIFON

ROCHE	50MG/5ML	N008420	001
-------	----------	---------	-----

TABLET;ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330	002
-----------	-------	---------	-----

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003
	300MG	A080134	004

INH

NOVARTIS	300MG	A080935	001
----------	-------	---------	-----

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
---------------------	-------	---------	-----	--------------

	300MG	A088119	001	Mar 17, 1983
--	-------	---------	-----	--------------

HALSEY	50MG	A083632	001
--------	------	---------	-----

HIKMA INTL PHARMS	100MG	A080212	001
-------------------	-------	---------	-----

	300MG	A087425	001
--	-------	---------	-----

IMPAX LABS	100MG	A080153	001
------------	-------	---------	-----

IVAX SUB TEVA PHARMS	100MG	A080270	001
----------------------	-------	---------	-----

	300MG	A083610	001
--	-------	---------	-----

LILLY	100MG	N008499	002
-------	-------	---------	-----

	300MG	N008499	003
--	-------	---------	-----

MK LABS	100MG	A080941	001
---------	-------	---------	-----

NEXGEN PHARMA INC	100MG	A084050	001
-------------------	-------	---------	-----

PANRAY	50MG	N008428	001
--------	------	---------	-----

	100MG	N008428	002
--	-------	---------	-----

	300MG	N008428	003
--	-------	---------	-----

PERRIGO	100MG	A083060	001
---------	-------	---------	-----

PHARMAVITE	100MG	A085091	001
------------	-------	---------	-----

PHOENIX LABS NY	50MG	A080368	001
-----------------	------	---------	-----

	100MG	A080368	002
--	-------	---------	-----

PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
---------------	------	---------	-----	--------------

	100MG	A080132	004	Jul 14, 1982
--	-------	---------	-----	--------------

+ SANDOZ	100MG	N008678	002
----------	-------	---------	-----

+ SUN PHARM INDUSTRIES	100MG	N008678	003
------------------------	-------	---------	-----

	300MG	A080136	001
--	-------	---------	-----

	300MG	A083633	001
--	-------	---------	-----

WATSON LABS	50MG	A080522	001
-------------	------	---------	-----

	100MG	A080401	001
--	-------	---------	-----

	100MG	A080523	001
--	-------	---------	-----

	100MG	A085790	001
--	-------	---------	-----

	300MG	A080521	001
--	-------	---------	-----

	300MG	A083178	001
--	-------	---------	-----

	300MG	A085784	001
--	-------	---------	-----

WHITEWORTH TOWN PLSN	100MG	A080120	002
----------------------	-------	---------	-----

LANIAZID

LANNETT	50MG	A080140	001
---------	------	---------	-----

	100MG	A080140	002
--	-------	---------	-----

	300MG	A089776	001	Jun 13, 1988
--	-------	---------	-----	--------------

NYDRAZID

BRISTOL MYERS SQUIBB	100MG	N008392	003
----------------------	-------	---------	-----

STANOZIDE

EVERYLIFE	100MG	A080126	001
-----------	-------	---------	-----

	300MG	A080126	002
--	-------	---------	-----

ISONIAZID; RIFAMPIN

CAPSULE;ORAL

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005
-------------------	-------------	---------	-----	--------------

ISOPROPAMIDE IODIDE

TABLET;ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001
-----------------	-------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

ZURAGARD

+ ZUREX PHARMA 70% (10.5ML) N210872 001 Apr 26, 2019

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M 0.12MG/INH N010375 004

ALPHARMA US PHARMS 0.12MG/INH A085904 001

ISUPREL

SANOFI AVENTIS US 0.103MG/INH N011178 001

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT 0.25% N016814 001

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM 0.2MG/ML A083431 001

BAXTER HLTHCARE 0.2MG/ML A083486 001

HOSPIRA 0.02MG/ML A083283 001

0.2MG/ML A083346 001

INTL MEDICATION 0.2MG/ML A083724 001

SOLUTION; INHALATION

AEROLONE

LILLY 0.25% N007245 001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM 0.031% A087935 001 Nov 18, 1982

0.062% A087936 001 Nov 18, 1982

DEY 0.5% A086764 001 Jan 04, 1982

PARKE DAVIS 0.25% A085994 001

0.5% A085540 001

ISUPREL

SANOFI AVENTIS US 0.5% N006327 002

1% N006327 003

VAPO-ISO

FISONS

0.5% N016813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US 10MG N006328 001

15MG N006328 002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M 0.16MG/INH; 0.24MG/INH N013296 001

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M 0.08MG/INH N010375 003

POWDER; INHALATION

NORISODRINE

ABBVIE 10% N006905 003

25% N006905 002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON 100GM/220ML N017063 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST 40MG N012882 002 Jul 29, 1988

TABLET; ORAL

ISORDIL

+ BAUSCH 10MG ** N012093 002 Jul 29, 1988

+ 20MG ** N012093 006 Jul 29, 1988

+ 30MG ** N012093 005 Jul 29, 1988

ISOSORBIDE DINITRATE

ANI PHARMS INC 10MG A086032 001 Jan 07, 1988

SUN PHARM INDUSTRIES 5MG A086166 002 Sep 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

10MG	A086169	001	Sep 19, 1986
20MG	A086167	001	Sep 19, 1986
30MG	A087564	001	Sep 18, 1986
SUPERPHARM	A089190	001	Feb 17, 1987
5MG	A089191	001	Feb 17, 1987
10MG	A089192	001	Feb 17, 1987
20MG	A089192	001	Feb 17, 1987
5MG	A086034	001	Jan 06, 1988
WATSON LABS			
SORBITRATE			
ASTRAZENECA	N016192	001	Apr 01, 1996
5MG	N016192	002	Apr 01, 1996
10MG	A086405	002	Aug 21, 1990
20MG	A088124	001	Aug 21, 1990
30MG	A088124	001	Aug 21, 1990
40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

+ BIOVAIL	2.5MG	**	N012940	004	Jul 29, 1988
+	5MG	**	N012940	003	Jul 29, 1988
+	10MG	**	N012940	005	Jul 29, 1988

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS	2.5MG		A086054	001	Oct 29, 1987
	5MG		A086055	001	Nov 02, 1987
SANDOZ	2.5MG		A086225	001	Feb 19, 1988
	5MG		A086222	001	Feb 19, 1988
SUN PHARM INDUSTRIES	2.5MG		A084204	001	Sep 18, 1986
	5MG		A086168	001	Sep 18, 1986
	10MG		A087545	001	Sep 18, 1986
WATSON LABS	2.5MG	**	A086033	001	Feb 26, 1988
WATSON LABS TEVA	5MG	**	A086031	001	Sep 29, 1987

SORBITRATE

ASTRAZENECA	2.5MG		N016191	002	Apr 01, 1996
	5MG		N016191	001	Apr 01, 1996

TABLET, CHEWABLE; ORAL

SORBITRATE

ASTRAZENECA	5MG		N016776	002	Apr 01, 1996
	10MG		N016776	003	Apr 01, 1996

TABLET, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG		N012882	001	Jul 29, 1988
--------------	------	--	---------	-----	--------------

ISOSORBIDE DINITRATE

IMPAX LABS INC	40MG		A040723	001	Mar 17, 2008
----------------	------	--	---------	-----	--------------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

PROMIUS PHARMA	20MG		N019091	001	Dec 30, 1991
----------------	------	--	---------	-----	--------------

ISOSORBIDE MONONITRATE

ANI PHARMS INC	20MG		A075147	001	Nov 27, 1998
----------------	------	--	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

IMDUR

+ SCHERING PLOUGH	30MG	**	N020225	001	Aug 12, 1993
+	60MG	**	N020225	002	Aug 12, 1993
+	120MG	**	N020225	003	Mar 30, 1995

ISOSORBIDE MONONITRATE

ACCORD HLTHCARE	30MG		A209684	001	Oct 24, 2017
	60MG		A209684	002	Oct 24, 2017
	120MG		A209684	003	Oct 24, 2017
ACTAVIS ELIZABETH	30MG		A075306	001	Dec 31, 1998
	60MG		A075306	002	Dec 31, 1998
ALKERMES GAINESVILLE	60MG		A075041	001	Sep 22, 1998
IVAX SUB TEVA PHARMS	30MG		A075448	002	Aug 07, 2001
	60MG		A075448	001	Jun 19, 2000
	120MG		A075448	003	Aug 07, 2001
SKYEPHARMA AG	60MG		A075166	001	Oct 07, 1999

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

BELOTECA INC	1%	A210714	001	Jan 16, 2019
SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019

LYMPHAZURIN

+ COVIDIEN	1% **	N018310	001	
------------	-------	---------	-----	--

ISOTRETINOIN

CAPSULE; ORAL

ACCUANE

+ HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
	20MG **	N018662	004	Mar 28, 1983
	40MG **	N018662	003	May 07, 1982

SOTRET

SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
	20MG	A076041	002	Dec 24, 2002
	30MG	A076503	001	Jun 20, 2003
	40MG	A076041	003	Dec 24, 2002

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

+ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
	5MG	N019546	002	Dec 20, 1990

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

+ GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
	10MG **	N020336	002	Jun 01, 1994

ISRADIPINE

MYLAN	5MG	A201067	001	Nov 27, 2015
	10MG	A201067	002	Nov 27, 2015

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

JANSSEN PHARMS	10MG/ML	N020966	001	Mar 30, 1999
----------------	---------	---------	-----	--------------

IVERMECTIN

TABLET; ORAL

STROMECTOL

MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996
-------------------	-----	---------	-----	--------------

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	

KANAMYCIN SULFATE

ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

EQ 1GM BASE/3ML

A062170 003

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

+ JANSSEN PHARMA

2% **

N019084 001 Dec 31, 1985

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

HAVIX

200MG

A075912 001 Jan 10, 2002

HERITAGE PHARMA

200MG

A074971 001 Jun 15, 1999

200MG

A075362 001 Jun 15, 1999

SUN PHARM INDUSTRIES

200MG

A075314 001 Jun 15, 1999

TEVA

200MG

A075273 001 Jun 15, 1999

NIZORAL

+ JANSSEN PHARMS

200MG **

N018533 001

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AUROLIFE PHARMA LLC

50MG

A074024 001 Dec 29, 1995

75MG

A074024 002 Dec 29, 1995

MYLAN

50MG

A074035 002 Dec 31, 1996

75MG

A074035 003 Dec 31, 1996

TEVA

25MG

A073515 001 Dec 22, 1992

ORUDIS

+ WYETH AYERST

25MG **

N018754 001 Jul 31, 1987

+

50MG **

N018754 002 Jan 09, 1986

+

75MG **

N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ACTAVIS LABS FL INC

100MG

A075270 002 Mar 24, 1999

150MG

A075270 003 Mar 24, 1999

200MG

A075270 001 Mar 24, 1999

ALKERMES GAINESVILLE

200MG

A074879 001 Dec 10, 1997

MYLAN

100MG

A075679 003 Feb 20, 2002

150MG

A075679 002 Feb 20, 2002

ORUVAIL

+ WYETH PHARMS INC

100MG **

N019816 003 Feb 08, 1995

+

150MG **

N019816 002 Feb 08, 1995

+

200MG **

N019816 001 Sep 24, 1993

FILM; ORAL

NEXCEDE

NOVARTIS

12.5MG

N022470 001 Nov 25, 2009

TABLET; ORAL

ACTRON

BAYER

12.5MG

N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO

12.5MG

A075364 001 Feb 07, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

KETOPROFEN

TABLET; ORAL

ORUDIS KT

+ WYETH CONS 12.5MG ** N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

APOTEX INC 30MG/ML A075626 001 Jul 24, 2001

30MG/ML A077201 001 Oct 14, 2005

APOTHECON 15MG/ML A075348 001 Nov 28, 2000

30MG/ML A075348 002 Nov 28, 2000

BAXTER HLTHCARE CORP 15MG/ML A075631 002 Jun 29, 2001

30MG/ML A075631 001 Jun 29, 2001

BEDFORD 15MG/ML A075230 002 Oct 25, 1999

30MG/ML A075230 001 Oct 25, 1999

GLAND PHARMA LTD 15MG/ML A076722 001 Jul 27, 2004

30MG/ML A076722 002 Jul 27, 2004

HOSPIRA 15MG/ML A074801 001 Jun 05, 1997

30MG/ML A074801 002 Jun 05, 1997

LUITPOLD 15MG/ML A078145 001 Jan 14, 2008

30MG/ML A078145 002 Jan 14, 2008

MYLAN LABS LTD 15MG/ML A078299 001 Jul 16, 2007

15MG/ML A201155 001 Aug 04, 2014

30MG/ML A078299 002 Jul 16, 2007

30MG/ML A201155 002 Aug 04, 2014

SANDOZ INC 15MG/ML A076271 001 Oct 06, 2004

SUN PHARM 15MG/ML A078737 001 Oct 06, 2008

30MG/ML A078737 002 Oct 06, 2008

WEST-WARD PHARMS INT 15MG/ML ** A075222 001 Apr 26, 1999

15MG/ML A075299 001 Nov 03, 1999

30MG/ML ** A075222 002 Apr 26, 1999

30MG/ML ** A075228 001 Apr 26, 1999

30MG/ML A075299 002 Nov 03, 1999

WOCKHARDT 30MG/ML A077943 001 Mar 27, 2007

TORADOL

+ ROCHE PALO 15MG/ML ** N019698 001 Nov 30, 1989

+ 30MG/ML ** N019698 002 Nov 30, 1989

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

ALLERGAN 0.5% N020811 001 Nov 03, 1997

KETOROLAC TROMETHAMINE

AKORN 0.45% A203376 001 Feb 10, 2014

AUROBINDO PHARMA LTD 0.4% A205191 001 Nov 15, 2018

SANDOZ INC 0.4% A078721 001 Nov 05, 2009

TABLET; ORAL

KETOROLAC TROMETHAMINE

CYCLE PHARMS LTD 10MG A074790 001 Jun 26, 1997

WATSON LABS 10MG A074955 001 Sep 19, 1997

TORADOL

+ ROCHE PALO 10MG ** N019645 001 Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE ** N021066 002 Oct 19, 2006

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE N/A N018088 001

L-GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL 5GM/PACKET N021667 001 Jun 10, 2004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AKORN INC	5MG/ML	A075524	001	Nov 29, 1999
APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002
HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010

NORMODYNE

SCHERING	5MG/ML	N018686	001	Aug 01, 1984
----------	--------	---------	-----	--------------

TRANDATE

+ SEBELA IRELAND LTD	5MG/ML **	N019425	001	Dec 31, 1985
----------------------	-----------	---------	-----	--------------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223	001	Nov 20, 1998
	200MG	A075223	002	Nov 20, 1998
	300MG	A075223	003	Nov 20, 1998
HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998
	200MG	A074787	002	Aug 03, 1998
	300MG	A074787	003	Aug 03, 1998
TEVA	100MG	A074989	001	Sep 30, 1998
	200MG	A074989	002	Sep 30, 1998
	300MG	A074989	003	Sep 30, 1998

NORMODYNE

+ SCHERING	100MG **	N018687	001	Aug 31, 1987
+	200MG **	N018687	002	Aug 01, 1984
+	300MG **	N018687	003	Aug 01, 1984
+	400MG **	N018687	004	Aug 01, 1984

TRANDATE

+ CNTY LINE PHARMS	400MG **	N018716	004	Aug 01, 1984
--------------------	----------	---------	-----	--------------

LACTULOSE

SOLUTION; ORAL

CHRONULAC

+ SANOFI AVENTIS US	10GM/15ML **	N017884	001	
---------------------	--------------	---------	-----	--

CONSTULOSE

ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
----------------------	-----------	---------	-----	--------------

DUPHALAC

SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
--------	-----------	---------	-----	--------------

EVALOSE

TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
-------------	-----------	---------	-----	--------------

LACTULOSE

ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007
MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
PACO	10GM/15ML	A073160	001	Aug 25, 1992
TORRENT	10GM/15ML	A207786	001	Jun 11, 2018

LAXILOSE

NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993
--------------	-----------	---------	-----	--------------

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
--------------	-----------	---------	-----	--------------

CEPHULAC

+ SANOFI AVENTIS US	10GM/15ML **	N017657	001	
---------------------	--------------	---------	-----	--

GENERLAC

MORTON GROVE	10GM/15ML	A071842	001	Sep 27, 1988
--------------	-----------	---------	-----	--------------

HEPTALAC

TEVA PHARMS	10GM/15ML	A073504	001	May 28, 1993
-------------	-----------	---------	-----	--------------

LACTULOSE

ANI PHARMS	10GM/15ML	A090426	001	Nov 21, 2008
BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003
PACO	10GM/15ML	A072029	001	Aug 25, 1992
ROXANE	10GM/15ML	A073590	001	May 29, 1992
SOLVAY	10GM/15ML	N017906	001	
TORRENT	10GM/15ML	A203762	001	Mar 27, 2015

PORTALAC

SOLVAY	10GM/15ML	A072374	001	Mar 22, 1989
--------	-----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

MYLAN	100MG	A204002	001	Dec 31, 2014
	150MG	A204528	001	Mar 04, 2016
	300MG	A204528	002	Mar 04, 2016

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

+ MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018
--------------	-------------------	---------	-----	--------------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015
-------------------	---------------------	---------	-----	--------------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018
----------------------	-------------	---------	-----	--------------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

MYLAN	150MG;300MG	A079079	001	Aug 12, 2019
	150MG;300MG	A204005	001	Aug 28, 2014
PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017
TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+ GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+	250MG **	N020241	004	Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
CELLTRION	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC 100MG N020764 003 Aug 24, 1998

LAMOTRIGINE

MYLAN 5MG A076630 001 Jan 22, 2009

25MG A076630 002 Jan 22, 2009

SANDOZ 5MG A078409 002 Jan 22, 2009

25MG A078409 003 Jan 22, 2009

TEVA 5MG A076420 001 Jun 21, 2006

25MG A076420 002 Jun 21, 2006

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

RUBICON 25MG A202887 001 Jun 17, 2013

50MG A202887 002 Jun 17, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AJANTA PHARMA LTD 15MG A203957 001 Oct 14, 2016

30MG A203957 002 Oct 14, 2016

BRECKENRIDGE 15MG A203964 001 Oct 17, 2018

30MG A203964 002 Oct 17, 2018

KRKA TOVARNA ZDRAVIL 15MG A091212 001 Sep 16, 2013

30MG A091212 002 Sep 16, 2013

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA 15MG/PACKET N021281 001 May 03, 2001

30MG/PACKET N021281 002 May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

+ TAKEDA PHARMS NA 30MG/VIAL ** N021566 001 May 27, 2004

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

ANI PHARMS INC 15MG A078730 001 Oct 15, 2010

30MG A078730 002 Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

+ TAKEDA PHARMS NA 15MG,N/A;N/A,250MG ** N021507 002 Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA 15MG,N/A;N/A,375MG N021507 003 Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA 15MG,N/A;N/A,500MG N021507 004 Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

SHIRE LLC EQ 250MG BASE N021468 001 Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS 0.5%;1.8% N011914 001

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC 0.005% A077697 001 Mar 22, 2011

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

FOSUN PHARMA 10MG A077087 001 Sep 13, 2005

20MG A077087 002 Sep 13, 2005

SANDOZ 10MG A077085 001 Sep 13, 2005

20MG A077085 002 Sep 13, 2005

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

BAYER HLTHCARE

50MG/VIAL

N020807 001 Mar 06, 1998

LESINURAD

TABLET; ORAL

ZURAMPIC

+ IRONWOOD PHARMS INC

200MG

N207988 001 Dec 22, 2015

LETROZOLE

TABLET; ORAL

LETROZOLE

ACTAVIS TOTOWA

2.5MG

A090292 001 Jul 13, 2011

FRESENIUS KABI USA

2.5MG

A090491 001 Jun 03, 2011

IMPAX LABS

2.5MG

A091638 001 Jun 03, 2011

LANNETT CO INC

2.5MG

A091098 001 Jun 03, 2011

2.5MG

A202048 001 Oct 29, 2014

MYLAN

2.5MG

A078190 001 Dec 24, 2008

SUN PHARM INDS LTD

2.5MG

A091466 001 Jun 03, 2011

SYNTHON PHARMS

2.5MG

A090196 001 Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

HOSPIRA

EQ 60MG BASE/VIAL

N008107 003 Jan 30, 1987

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABIC

EQ 3MG BASE/ML

A089352 001 Jun 01, 1988

EQ 50MG BASE/VIAL

A089353 001 Jun 01, 1988

ABRAXIS PHARM

EQ 50MG BASE/VIAL

A088939 001 Dec 01, 1986

ELKINS SINN

EQ 50MG BASE/VIAL

A070480 001 Jan 02, 1987

EQ 100MG BASE/VIAL

A081224 001 Jun 03, 1994

+ HOSPIRA

EQ 3MG BASE/ML **

N008107 001

+

EQ 50MG BASE/VIAL **

N008107 002

+

EQ 100MG BASE/VIAL **

N008107 004 May 23, 1988

+

EQ 350MG BASE/VIAL **

N008107 005 Apr 05, 1989

INGENUS PHARMS LLC

EQ 10MG BASE/ML

A210917 001 Nov 23, 2018

PHARMACHEMIE

EQ 350MG BASE/VIAL

A040262 001 Dec 15, 1999

PHARMACHEMIE USA

EQ 50MG BASE/VIAL

A089628 001 Apr 17, 1997

EQ 100MG BASE/VIAL

A089915 001 Apr 17, 1997

TEVA PARENTERAL

EQ 50MG BASE/VIAL

A081278 001 Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AM REGENT

EQ 50MG BASE/VIAL

A040338 001 Jan 31, 2001

HOSPIRA

EQ 10MG BASE/ML **

A040147 001 Jun 25, 1997

TEVA PARENTERAL

EQ 10MG BASE/ML

A040332 001 Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE

EQ 5MG BASE/ML

A087439 001 Oct 19, 1982

EQ 25MG BASE/VIAL

A089833 001 Jan 23, 1989

EQ 50MG BASE/VIAL

A089465 001 Jan 23, 1989

EQ 100MG BASE/VIAL

A089834 001 Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

ANI PHARMS INC

EQ 15MG BASE

A075327 001 Mar 24, 1999

EPIC PHARMA LLC

EQ 5MG BASE

A074544 001 Aug 28, 1997

EQ 25MG BASE

A074544 002 Aug 28, 1997

PAR PHARM

EQ 5MG BASE

A071600 001 Oct 14, 1987

EQ 25MG BASE

A071598 001 Oct 14, 1987

PHARMACHEMIE

EQ 5MG BASE

A073099 001 Mar 28, 1997

EQ 25MG BASE

A073101 001 Mar 28, 1997

XANODYNE PHARM

EQ 5MG BASE

N018459 001 Jan 30, 1986

EQ 10MG BASE

A071962 001 Nov 19, 1987

EQ 15MG BASE

A071104 001 Mar 04, 1987

WELLCOVORIN

+ GLAXOSMITHKLINE

EQ 5MG BASE **

N018342 001 Jul 08, 1983

+

EQ 25MG BASE **

N018342 002 Jul 08, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEUPROLIDE ACETATE

FOR SUSPENSION; INTRAMUSCULAR

LUTRATE DEPOT KIT

+ GP-PHARM SA 22.5MG/VIAL N205054 001 Aug 28, 2018

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN EQ 65MG BASE N021088 001 Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME 1MG/0.2ML A075721 001 Nov 29, 2001

LUPRON

+ ABBVIE ENDOCRINE INC 1MG/0.2ML ** N019010 001 Apr 09, 1985

LUPRON DEPOT

+ ABBVIE ENDOCRINE INC 3.75MG/VIAL ** N020011 001 Oct 22, 1990

LUPRON DEPOT-PED

+ ABBVIE ENDOCRINE INC 3.75MG/VIAL, 7.5MG/VIAL ** N020263 003 Apr 16, 1993

+ 7.5MG/VIAL, 7.5MG/VIAL ** N020263 004 Apr 16, 1993

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

MYLAN SPECIALITY LP EQ 0.0103% BASE A077800 001 Mar 15, 2013

EQ 0.021% BASE A077800 002 Mar 15, 2013

EQ 0.042% BASE A077800 003 Mar 15, 2013

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE 1MG/ML N010423 001

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA EQ 50MG BASE N020035 001 Jun 18, 1990

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018

AM REGENT 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012

SOLUTION; ORAL

LEVETIRACETAM

ACI HEALTHCARE LTD 100MG/ML A078582 001 Jan 15, 2009

APOTEX INC 100MG/ML A090187 001 Aug 05, 2011

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC 250MG A077408 001 Mar 02, 2009

500MG A077408 002 Mar 02, 2009

750MG A077408 003 Mar 02, 2009

FOSUN PHARMA 250MG A077324 001 Jan 15, 2009

500MG A077324 002 Jan 15, 2009

750MG A077324 003 Jan 15, 2009

1GM A077324 004 Jan 15, 2009

MYLAN 250MG A078731 001 Feb 10, 2009

500MG A078731 002 Feb 10, 2009

750MG A078731 003 Feb 10, 2009

1GM A078731 004 Feb 10, 2009

WATSON LABS INC 250MG A078797 002 Jan 15, 2009

500MG A078797 003 Jan 15, 2009

750MG A078797 004 Jan 15, 2009

1GM A078797 001 Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

MYLAN PHARMS INC 500MG A200475 001 Dec 19, 2011

750MG A200475 002 Dec 19, 2011

1GM A200475 003 Dec 07, 2015

SANDOZ 500MG A091668 001 Nov 01, 2012

750MG A091668 002 Nov 01, 2012

SUN PHARM INDUSTRIES 500MG A091285 001 Sep 12, 2011

750MG A091285 002 Sep 12, 2011

VIRTUS PHARMS 500MG A091291 001 Sep 12, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVETIRACETAMTABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

750MG A091291 002 Sep 12, 2011

LEVOBETAXOLOL HYDROCHLORIDESUSPENSION/DROPS;OPHTHALMIC
BETAXON

ALCON PHARMS LTD EQ 0.5% BASE N021114 001 Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

ALCON LABS INC 0.25% A074851 001 Oct 28, 1996

APOTEX INC 0.25% A075473 001 Aug 03, 2000

0.5% A075475 001 Aug 03, 2000

BAUSCH AND LOMB 0.25% A074307 001 Mar 04, 1994

SANDOZ INC 0.5% A074850 001 Oct 28, 1996

LEVOPUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP EQ 2.5MG BASE/ML N020997 001 Aug 05, 1999

EQ 5MG BASE/ML N020997 002 Aug 05, 1999

EQ 7.5MG BASE/ML N020997 003 Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDESUSPENSION/DROPS;OPHTHALMIC
LIVOSTIN

NOVARTIS EQ 0.05% BASE N020219 001 Nov 10, 1993

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

TEVA PHARMS USA 200MG/ML A075881 001 Mar 29, 2001

SOLUTION;ORAL

CARNITOR

LEADIANT BIOSCI INC 1GM/10ML N018948 002 Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

FOSUN PHARMA 5MG A090486 001 Mar 26, 2013

PERRIGO R AND D 5MG A211983 001 Mar 28, 2019

LEVODOPA

CAPSULE;ORAL

BENDOPA

VALEANT PHARM INTL 100MG N016948 003

250MG N016948 001

500MG N016948 002

DOPAR

SHIRE 100MG N016913 003

250MG N016913 001

500MG N016913 002

LARODOPA

ROCHE 100MG N016912 002

250MG N016912 001

500MG N016912 006

TABLET;ORAL

DOPAR

SHIRE 250MG N016913 004

500MG N016913 005

LARODOPA

ROCHE 100MG N016912 005

250MG N016912 003

500MG N016912 004

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996

LEVOFLOXACIN

EMCURE PHARMS LTD		EQ 500MG/20ML (EQ 25MG/ML)	A202590 001	Jan 24, 2013
		EQ 750MG/30ML (EQ 25MG/ML)	A202590 002	Jan 24, 2013
HOSPIRA INC		EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
		EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015
MYLAN ASI		EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011
		EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011
ZYDUS PHARMS		EQ 500MG/20ML (EQ 25MG/ML)	A205968 001	Jun 01, 2017
		EQ 750MG/30ML (EQ 25MG/ML)	A205968 002	Jun 01, 2017

SOLUTION; ORAL

LEVAQUIN

+	JANSSEN PHARMS	250MG/10ML	N021721 001	Oct 21, 2004
---	----------------	------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

IQIIX

+	SANTEN	1.5% **	N021571 001	Mar 01, 2004
---	--------	---------	-------------	--------------

LEVOFLOXACIN

APOTEX INC		0.5%	A078282 001	Dec 20, 2010
------------	--	------	-------------	--------------

QUIXIN

+	SANTEN	0.5% **	N021199 001	Aug 18, 2000
---	--------	---------	-------------	--------------

TABLET; ORAL

LEVAQUIN

+	JANSSEN PHARMS	250MG	N020634 001	Dec 20, 1996
+		500MG	N020634 002	Dec 20, 1996
+		750MG	N020634 003	Sep 08, 2000

LEVOFLOXACIN

MYLAN		250MG	A076276 001	Jun 20, 2011
		500MG	A076276 002	Jun 20, 2011
		750MG	A077097 001	Jun 20, 2011
WATSON LABS INC		250MG	A201484 001	Nov 22, 2013
		500MG	A201484 002	Nov 22, 2013
		750MG	A201484 003	Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

+	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723 001	Sep 29, 2016
---	-------------	--------------------	-------------	--------------

SOLUTION; INTRAVENOUS

FUSILEV

+	ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **	N020140 002	Apr 29, 2011
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140 003	Apr 29, 2011

LEVOLEUCOVORIN CALCIUM

MYLAN TEORANTA		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576 001	Oct 20, 2015
		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576 002	Oct 20, 2015

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX		20MG/ML	N015865 001	
---------	--	---------	-------------	--

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

+	ROXANE	10MG/ML **	N020315 001	Jul 09, 1993
---	--------	------------	-------------	--------------

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

LEVOMILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS CO		EQ 20MG BASE	A210790 001	Feb 04, 2019
		EQ 40MG BASE	A210790 002	Feb 04, 2019
		EQ 80MG BASE	A210790 003	Feb 04, 2019
		EQ 120MG BASE	A210790 004	Feb 04, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN SOLVAY	0.05MG/ML;2%	A085010	001	
CARBOCAINE W/ NEO-COBEFRIN EASTMAN KODAK	0.05MG/ML;2%	N012125	002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN SEPTODONT INC	0.05MG/ML;2%	A084697	001	
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN DENTSPLY PHARM	0.05MG/ML;2%	A089517	001	Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592	007	
---	-------------------	---------	-----	--

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE + POPULATION COUNCIL	75MG/IMPLANT **	N020544	001	Nov 01, 1996
LEVONORGESTREL WYETH PHARMS INC	75MG/IMPLANT	N020627	001	Aug 15, 1996
NORPLANT POPULATION COUNCIL	36MG/IMPLANT	N019897	001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER WYETH PHARMS INC	36MG/IMPLANT	N020088	001	Dec 10, 1990

TABLET; ORAL

LEVONORGESTREL ACCORD HLTHCARE	1.5MG	A207660	001	May 02, 2019
ALVOGEN	1.5MG	A202246	001	Jun 05, 2015
APOTEX	1.5MG	A205329	001	Sep 18, 2018
FDN CONSUMER	0.75MG **	A078665	001	Aug 28, 2009
	1.5MG	A200670	001	Jul 12, 2012
LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016
LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013
WATSON LABS	0.75MG	A078666	001	Jun 24, 2009
PLAN B + FDN CONSUMER	0.75MG **	N021045	001	Jul 28, 1999
+	0.75MG **	N021045	002	Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD LILLY	EQ 50MG BASE	N012928	006	
	EQ 100MG BASE	N012928	004	

SUSPENSION; ORAL

NOVRAD LILLY	EQ 50MG BASE/5ML	N012928	002	
-----------------	------------------	---------	-----	--

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN VALEANT PHARM INTL	2MG/ML	N008719	001	Dec 19, 1991
-------------------------------------	--------	---------	-----	--------------

TABLET; ORAL

LEVO-DROMORAN + VALEANT PHARM INTL	2MG **	N008720	001	Dec 19, 1991
LEVORPHANOL TARTRATE SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015
--	-------------	---------	-----	--------------

TABLET; ORAL

EUTHYROX PROVELL	0.3MG	N021292	012	May 31, 2002
LEVOLET GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003
	0.05MG	N021137	002	Jun 06, 2003
	0.075MG	N021137	003	Jun 06, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

0.088MG	N021137 004	Jun 06, 2003
0.1MG	N021137 005	Jun 06, 2003
0.112MG	N021137 006	Jun 06, 2003
0.125MG	N021137 007	Jun 06, 2003
0.137MG	N021137 008	Jun 06, 2003
0.15MG	N021137 009	Jun 06, 2003
0.175MG	N021137 010	Jun 06, 2003
0.2MG	N021137 011	Jun 06, 2003
0.3MG	N021137 012	Jun 06, 2003

LEVOTHYROXINE SODIUM

AMNEAL PHARMS LLC

0.025MG	A210831 001	Feb 19, 2019
0.05MG	A210831 002	Feb 19, 2019
0.075MG	A210831 003	Feb 19, 2019
0.088MG	A210831 004	Feb 19, 2019
0.1MG	A210831 005	Feb 19, 2019
0.112MG	A210831 006	Feb 19, 2019
0.125MG	A210831 007	Feb 19, 2019
0.137MG	A210831 008	Feb 19, 2019
0.15MG	A210831 009	Feb 19, 2019
0.175MG	A210831 010	Feb 19, 2019
0.2MG	A210831 011	Feb 19, 2019
0.3MG	A210831 012	Feb 19, 2019

MERCK KGAA

0.025MG	A076752 001	Jun 16, 2005
0.05MG	A076752 002	Jun 16, 2005
0.075MG	A076752 003	Jun 16, 2005
0.088MG	A076752 004	Jun 16, 2005
0.1MG	A076752 005	Jun 16, 2005
0.112MG	A076752 006	Jun 16, 2005
0.125MG	A076752 007	Jun 16, 2005
0.15MG	A076752 008	Jun 16, 2005
0.175MG	A076752 009	Jun 16, 2005
0.2MG	A076752 010	Jun 16, 2005
0.3MG	A076752 011	Jun 16, 2005

LEVOXYL

+ KING PHARMS

0.3MG **

N021301 012 May 25, 2001

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

5%

A084947 001

LIDOCAINE

BELMORA LLC

5%

A080210 001

XYLOCAINE

+ ASTRAZENECA

5% **

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%

N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG

N013077 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE 2% A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT 10% A087980 001 Feb 02, 1983

20% A089362 001 May 25, 1988

ABRAXIS PHARM 1% A080420 001

1% A086761 001

1.5% A080420 005

2% A080420 002

2% A080420 004

2% A086761 002

2% N017508 001

4% N017508 002

20% N017508 004

AKORN 1% A085037 001

2% A085037 002

BEL MAR 1% A080710 001

2% A080760 001

BELMORA LLC 2% A080504 001

DELL LABS 1% A083387 001

2% A083388 001

ELKINS SINN 0.5% A085131 001

4% A084626 001

GD SEARLE LLC 1% A083135 001

2% A083135 002

HOSPIRA 1% A040013 001 Jun 23, 1995

1.5% A088330 001 May 17, 1984

2% A088331 001 May 17, 1984

20% A083158 003

INTL MEDICATION 1% N017701 002

2% N017701 001

1GM/VIAL N018543 001

2GM/VIAL N018543 002

LUITPOLD 1% A080850 001

1% A091564 001 Aug 14, 2015

2% A083198 001

LYPHOMED 1% A080390 001

2% A080390 002

MILES 1% A080414 001

2% A080414 002

MYLAN LABS LTD 0.5% A091056 001 Dec 08, 2010

0.5% A091058 001 Sep 30, 2010

1% A091056 002 Dec 08, 2010

1% A091058 002 Sep 30, 2010

2% A202242 001 Apr 11, 2014

WATSON LABS 1% A080377 001

1% A083627 001

2% A080377 002

2% A083627 002

WEST-WARD PHARMS INT 1% A080407 001

2% A080407 002

WYETH AYERST 1% A083083 001

2% A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 100MG/100ML N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 200MG/100ML N018967 001 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA 200MG/100ML A083158 005

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 200MG/100ML N018954 001 Jul 09, 1985

HOSPIRA 200MG/100ML N018388 001

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 400MG/100ML N018967 002 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%

HOSPIRA 400MG/100ML A083158 006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	400MG/100ML	N018388	002
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967	003 Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	800MG/100ML	N018388	003 Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326	001 Jul 31, 1984
	10%	A088367	001 Jul 31, 1984
	20%	A088368	001 Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
INTL MEDICATION	4%	N017702	002
	20%	N017702	001
MYLAN LABS LTD	2%	A090665	001 Sep 27, 2010
WEST-WARD PHARMS INT	1%	A084625	001
	2%	A084625	002
LIDOCATON			
PHARMATON	2%	A084727	001 Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549	001
XYLOCAINE			
ASTRAZENECA	1%	N010418	005
	1.5%	N010418	009
	2%	N010418	007
XYLOCAINE 4% PRESERVATIVE FREE			
+ FRESENIUS KABI USA	4%	N010417	001
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380	001
XYLOCAINE PRESERVATIVE FREE			
+ FRESENIUS KABI USA	1%	N016801	005 Jan 19, 1988
	2%	N016801	001
	4%	N016801	002
	10%	N016801	003
	20%	N016801	004
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297	001
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496	002 Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BIONPHARMA INC	2%	A080429	001
LIDOCAINE HYDROCHLORIDE			
ACP NIMBLE	2%	A081318	001 Apr 29, 1993
WATSON LABS INC	2%	A040837	001 Mar 23, 2011
SOLUTION; ORAL			
LIDOCAINE HYDROCHLORIDE VISCOUS			
ACTAVIS MID ATLANTIC	2%	A086578	001
INTL MEDICATION	2%	A086389	001 Feb 02, 1982
XYLOCAINE VISCOUS			
+ FRESENIUS KABI USA	2% **	N009470	001
SOLUTION; TOPICAL			
LARYNGOTRACHEAL ANESTHESIA KIT			
KENDALL IL	4%	A087931	001 Jun 10, 1983
LIDOCAINE HYDROCHLORIDE			
PACO	4%	A089688	001 Jun 30, 1989
WOCKHARDT BIO AG	4%	A087881	001 Nov 18, 1982
LTA II KIT			
HOSPIRA	4%	A080409	001
	4%	A088542	001 Jul 31, 1984
PEDIATRIC LTA KIT			
ABBOTT	2%	A088572	001 Jul 31, 1984
HOSPIRA	2%	A085995	001
XYLOCAINE 4% PRESERVATIVE FREE			
+ FRESENIUS KABI USA	4%	N010417	002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

2%; 50MG/ML
2%; 125MG/MLA060567 001
A060567 002LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA

2.5%; 2.5%

N020962 001 Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN

EQ 250MG BASE
EQ 500MG BASEN050316 001
N050316 002

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS

EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%
1%A084218 001
N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%
1%A084218 002
N006309 003

LINDANE

WOCKHARDT

1%

A088190 001 Aug 16, 1984

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%
1%A084219 001
N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

SOLUTION; INTRAVENOUS

ZYVOX

+

PHARMACIA AND UPJOHN

400MG/200ML (2MG/ML) **

N021131 002 Apr 18, 2000

TABLET; ORAL

LINEZOLID

MYLAN

600MG

A078845 001 Dec 21, 2015

ZYVOX

+

PHARMACIA AND UPJOHN

400MG **

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

MYLAN

EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASEA090326 001 Jul 14, 2009
A090326 002 Jul 14, 2009
A090326 003 Jul 14, 2009

SUN PHARM

EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASEA091382 001 Apr 20, 2016
A091382 002 Apr 20, 2016
A091382 003 Apr 20, 2016

TEVA PHARMS USA

EQ 0.005MG BASE
EQ 0.025MG BASEA211510 001 Oct 26, 2018
A211510 002 Oct 26, 2018

WATSON LABS

EQ 0.05MG BASE
EQ 0.025MG BASEA211510 003 Oct 26, 2018
A085755 001 Jan 25, 1982
A085753 001 Feb 03, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LIOTRIX (T4;T3)

TABLET;ORAL

EUTHROID-0.5

PARKE DAVIS 0.03MG;0.0075MG N016680 001

EUTHROID-1

PARKE DAVIS 0.06MG;0.015MG N016680 002

EUTHROID-2

PARKE DAVIS 0.12MG;0.03MG N016680 003

EUTHROID-3

PARKE DAVIS 0.18MG;0.045MG N016680 004

THYROLAR-0.25

+ ALLERGAN 0.0125MG;0.0031MG N016807 001

THYROLAR-0.5

+ ALLERGAN 0.025MG;0.0063MG N016807 005

THYROLAR-1

+ ALLERGAN 0.05MG;0.0125MG N016807 004

THYROLAR-2

+ ALLERGAN 0.1MG;0.025MG N016807 002

THYROLAR-3

+ ALLERGAN 0.15MG;0.0375MG N016807 003

THYROLAR-5

ALLERGAN 0.25MG;0.0625MG N016807 006

LISINOPRIL

TABLET;ORAL

LISINOPRIL

HERITAGE PHARMA 2.5MG A075752 001 Jul 01, 2002

5MG A075752 002 Jul 01, 2002

10MG A075752 003 Jul 01, 2002

20MG A075752 004 Jul 01, 2002

30MG A075752 005 Jul 01, 2002

40MG A075752 006 Jul 01, 2002

HIKMA INTL PHARMS 2.5MG A076063 001 Jul 01, 2002

5MG A076063 002 Jul 01, 2002

10MG A076063 003 Jul 01, 2002

20MG A076063 004 Jul 01, 2002

30MG A076063 006 Jun 27, 2003

40MG A076063 005 Jul 01, 2002

INVATECH 2.5MG A075903 001 Jul 01, 2002

2.5MG A075999 001 Jul 01, 2002

5MG A075903 002 Jul 01, 2002

5MG A075999 002 Jul 01, 2002

10MG A075903 003 Jul 01, 2002

10MG A075999 003 Jul 01, 2002

20MG A075903 004 Jul 01, 2002

20MG A075999 004 Jul 01, 2002

30MG A075903 005 Jul 01, 2002

30MG A075999 005 Jul 01, 2002

40MG A075903 006 Jul 01, 2002

40MG A075999 006 Jul 01, 2002

MYLAN 2.5MG A076071 001 Jul 01, 2002

5MG A076071 002 Jul 01, 2002

10MG A076071 003 Jul 01, 2002

20MG A076071 004 Jul 01, 2002

30MG A076071 005 Jul 01, 2002

40MG A076071 006 Jul 01, 2002

TEVA 2.5MG A075783 001 Jul 01, 2002

5MG A075783 002 Jul 01, 2002

10MG A075783 003 Jul 01, 2002

20MG A075783 004 Jul 01, 2002

30MG A075783 005 Jul 01, 2002

40MG A075783 006 Jul 01, 2002

PRINIVIL

MERCK 2.5MG N019558 006 Jan 28, 1994

10MG N019558 002 Dec 29, 1987

20MG N019558 003 Dec 29, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LITHIUM CARBONATE

CAPSULE;ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

MYLAN

600MG

A078763 001 Apr 15, 2008

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET;ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG

A078715 001 Dec 28, 2010

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE;ORAL

ESKALITH CR

JDS PHARMS

450MG **

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

HERITAGE PHARMA

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

HIKMA INTL PHARMS

450MG

A076490 001 Jun 17, 2003

LITHIUM CITRATE

SYRUP;ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+ CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

J AND J CONSUMER INC

2MG **

N017690 001

+

2MG **

N017694 001

LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

TEVA

2MG

A073122 001 Aug 30, 1991

YAOPHARMA CO LTD

2MG

A072993 001 Aug 28, 1992

SOLUTION;ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALLIED

1MG/5ML

A073079 001 Apr 30, 1992

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

CONTRACT PHARMACAL

2MG

A073254 001 Jul 30, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LOPERAMIDE HYDROCHLORIDE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO

2MG

A074194 001 Oct 30, 1992

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996

LOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

ABBVIE

133.3MG;33.3MG

N021226 001 Sep 15, 2000

LORACARBEF

CAPSULE;ORAL

LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

FOR SUSPENSION;ORAL

LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

LORATADINE

CAPSULE;ORAL

LORATADINE

BIONPHARMA INC

10MG

A202538 001 Dec 21, 2018

SYRUP;ORAL

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 1MG/ML **

N020641 003 Nov 19, 2003

LORATADINE

PHARM ASSOC

1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD

1MG/ML

A076529 001 Aug 20, 2004

TABLET;ORAL

LORATADINE

PERRIGO

10MG

N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

HERITAGE PHARMA

5MG;120MG

A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN

2MG/ML

A074974 001 Jul 23, 1998

BEDFORD

2MG/ML

A077076 001 Jul 13, 2005

4MG/ML

A077076 002 Jul 13, 2005

DAVA PHARMS INC

2MG/ML

A074793 001 Mar 16, 2000

4MG/ML

A074793 002 Mar 16, 2000

DR REDDYS

1MG/0.5ML

A074551 003 Sep 12, 1996

2MG/ML

A074535 001 Sep 12, 1996

2MG/ML

A074551 001 Sep 12, 1996

4MG/ML

A074535 002 Sep 12, 1996

4MG/ML

A074551 002 Sep 12, 1996

HOSPIRA

2MG/ML

A074280 001 May 27, 1994

2MG/ML

A074300 001 Apr 12, 1994

4MG/ML

A074280 002 May 27, 1994

4MG/ML

A074300 003 Mar 19, 1997

MYLAN ASI

2MG/ML

A200217 001 Apr 04, 2017

2MG/ML

A200542 001 Apr 28, 2017

4MG/ML

A200217 002 Apr 04, 2017

4MG/ML

A200542 002 Apr 28, 2017

WATSON LABS

2MG/ML

A074276 001 Apr 15, 1994

4MG/ML

A074276 002 Apr 15, 1994

WEST-WARD PHARMS INT

2MG/ML

A074496 001 Sep 28, 1998

4MG/ML

A074496 002 Sep 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM PRESERVATIVE FREE

BEDFORD LABS

2MG/ML

A077074 001 Jul 13, 2005

4MG/ML

A077074 002 Jul 13, 2005

SOLUTION; ORAL

LORAZEPAM

ROXANE

0.5MG/5ML

A074648 001 Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS

0.5MG

A070200 001 Aug 09, 1985

1MG

A070201 001 Aug 09, 1985

2MG

A070202 001 Aug 09, 1985

LORAZEPAM

AM THERAP

0.5MG

A070727 001 Mar 07, 1986

1MG

A070728 001 Mar 07, 1986

2MG

A070729 001 Mar 07, 1986

ANDA REPOSITORY

0.5MG

A072555 002 Mar 29, 1991

1MG

A072555 003 Mar 29, 1991

2MG

A072555 001 Mar 29, 1991

ANI PHARMS INC

0.5MG

A077396 001 Dec 13, 2006

1MG

A077396 002 Dec 13, 2006

2MG

A077396 003 Dec 13, 2006

HALSEY

0.5MG

A071434 001 Sep 01, 1987

1MG

A071435 001 Sep 01, 1987

2MG

A071436 001 Sep 01, 1987

MUTUAL PHARM

0.5MG

A070472 001 Dec 10, 1985

1MG

A070473 001 Dec 10, 1985

2MG

A070474 001 Dec 10, 1985

MYLAN

0.5MG

A071591 002 Oct 13, 1987

1MG

A071591 003 Oct 13, 1987

2MG

A071591 001 Oct 13, 1987

PAR PHARM

0.5MG

A070675 001 Dec 01, 1986

1MG

A070676 001 Dec 01, 1986

2MG

A070677 001 Dec 01, 1986

SANDOZ

0.5MG

A071193 001 Apr 15, 1988

1MG

A071194 001 Apr 15, 1988

2MG

A071195 001 Apr 15, 1988

SUN PHARM INDS LTD

0.5MG

A076045 001 Aug 29, 2001

1MG

A076045 002 Aug 29, 2001

2MG

A076045 003 Aug 29, 2001

SUPERPHARM

0.5MG

A071245 001 Feb 09, 1987

1MG

A071246 001 Feb 09, 1987

2MG

A071247 001 Feb 09, 1987

USL PHARMA

1MG

A070539 001 Dec 22, 1986

2MG

A070540 001 Dec 22, 1986

WARNER CHILCOTT

1MG

A071038 001 Jan 12, 1988

2MG

A071039 001 Jan 12, 1988

WATSON LABS

0.5MG

A071086 001 Mar 23, 1987

0.5MG

A071117 001 Jul 24, 1986

1MG

A071087 001 Mar 23, 1987

1MG

A071118 001 Jul 24, 1986

2MG

A071088 001 Mar 23, 1987

2MG

A071110 001 Jul 24, 1986

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

+ MERCK SHARP DOHME

25MG

N020386 001 Apr 14, 1995

+

50MG

N020386 002 Apr 14, 1995

LOSARTAN POTASSIUM

APOTEX CORP

25MG

A090790 001 Oct 06, 2010

50MG

A090790 002 Oct 06, 2010

100MG

A090790 003 Oct 06, 2010

HISUN PHARM HANGZHOU

25MG

A204795 001 Apr 04, 2019

50MG

A204795 002 Apr 04, 2019

100MG

A204795 003 Apr 04, 2019

TEVA

25MG

A076958 001 Apr 06, 2010

50MG

A076958 002 Apr 06, 2010

100MG

A076958 003 Apr 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998
---------	------	---------	-----	--------------

LOVASTATIN

TABLET;ORAL

LOVASTATIN

MYLAN	10MG	A075451	001	Dec 17, 2001
	10MG	A075935	001	Dec 17, 2001
	20MG	A075451	002	Dec 17, 2001
	20MG	A075935	002	Dec 17, 2001
	40MG	A075451	003	Dec 17, 2001
	40MG	A075935	003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG	A077520	001	Apr 14, 2006
	20MG	A077520	002	Apr 14, 2006
	40MG	A077520	003	Apr 14, 2006

MEVACOR

+ MERCK	10MG **	N019643	002	Mar 28, 1991
+	20MG **	N019643	003	Aug 31, 1987
+	40MG **	N019643	004	Dec 14, 1988

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002
-----------------	------	---------	-----	--------------

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001	
--------------------	-----------------	---------	-----	--

INJECTABLE;INJECTION

LOXITANE IM

ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001	
---------------------	-----------------	---------	-----	--

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXITANE

+ TEVA BRANDED PHARM	EQ 5MG BASE **	N017525	001	
+	EQ 10MG BASE **	N017525	002	
+	EQ 25MG BASE **	N017525	003	
+	EQ 50MG BASE **	N017525	004	

TABLET;ORAL

LOXITANE

+ TEVA BRANDED PHARM	EQ 10MG BASE **	N017525	006	
+	EQ 25MG BASE **	N017525	007	
+	EQ 50MG BASE **	N017525	008	

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012
-----------------	-------	---------	-----	--------------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019
	40MG	A208002	002	Jan 03, 2019
	60MG	A208002	003	Jan 03, 2019
	80MG	A208002	004	Jan 03, 2019
	120MG	A208002	005	Jan 03, 2019
EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019
	40MG	A208058	002	Sep 04, 2019
	60MG	A208058	003	Sep 04, 2019
	80MG	A208058	004	Sep 04, 2019
INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019
	40MG	A208028	002	Jan 03, 2019
	60MG	A208028	003	Jan 03, 2019
	80MG	A208028	004	Jan 03, 2019
	120MG	A208028	005	Jan 03, 2019
LUPIN LTD	20MG	A208031	001	Jan 03, 2019
	40MG	A208031	002	Jan 03, 2019
	60MG	A208031	003	Jan 03, 2019
	80MG	A208031	004	Jan 03, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

	120MG	A208031 005	Jan 03, 2019
TEVA PHARMS USA	20MG	A208060 001	May 17, 2019
	40MG	A208060 002	May 17, 2019
	60MG	A208060 003	May 17, 2019
	80MG	A208060 004	May 17, 2019
	120MG	A208060 005	May 17, 2019
TORRENT	20MG	A208055 001	Jan 03, 2019
	40MG	A208055 002	Jan 03, 2019
	80MG	A208055 003	Jan 03, 2019
	120MG	A208055 004	Jan 03, 2019
ZYDUS PHARMS	20MG	A208052 001	Mar 19, 2019
	40MG	A208052 002	Mar 19, 2019
	60MG	A208052 003	Mar 19, 2019
	80MG	A208052 004	Mar 19, 2019
	120MG	A208052 005	Mar 19, 2019

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004
------------	------------	-------------	--------------

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS	0.185MG/ML	N016755 001	
----------	------------	-------------	--

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047 001	Jun 15, 1984
-----------------	--------------------------------------	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	N019006 001	Apr 04, 1984
---------	---	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018252 001	
---------	---	-------------	--

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N018406 001	
-------------	---	-------------	--

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N018406 002	Jul 08, 1982
-------------	---	-------------	--------------

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N019326 001	Jan 25, 1985
-----------------	---	-------------	--------------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001	Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001	Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002	Mar 24, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **	N203595 001	Jan 18, 2013
---	----------------	--	-------------	--------------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER;ORAL

COLPREP KIT

+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553 001	Dec 27, 2016
---	--------------	---------------------------------	-------------	--------------

MALATHION

LOTION;TOPICAL

MALATHION

	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
--	------------------	------	-------------	--------------

OVIDE

+	TARO PHARM INDS LTD	0.5%	N018613 001	Aug 02, 1982
---	---------------------	------	-------------	--------------

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

	IC TARGETS	37.9MG/ML	N020652 001	Nov 26, 1997
--	------------	-----------	-------------	--------------

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION;ORAL

LUMENHANCE

	BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
--	--------	-----------	-------------	--------------

MANGANESE SULFATE

INJECTABLE;INJECTION

MANGANESE SULFATE

	ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987
--	---------------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10%

	B BRAUN	10GM/100ML	N016080 002	
--	---------	------------	-------------	--

	HOSPIRA	10GM/100ML	N016269 002	
--	---------	------------	-------------	--

	MILES	10GM/100ML	N016472 002	
--	-------	------------	-------------	--

MANNITOL 10% IN PLASTIC CONTAINER

	ICU MEDICAL INC	10GM/100ML	N019603 002	Jan 08, 1987
--	-----------------	------------	-------------	--------------

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

	B BRAUN	10GM/100ML	N016080 006	
--	---------	------------	-------------	--

MANNITOL 15%

	B BRAUN	15GM/100ML	N016080 003	
--	---------	------------	-------------	--

	HOSPIRA	15GM/100ML	N016269 003	
--	---------	------------	-------------	--

	MILES	15GM/100ML	N016472 005	
--	-------	------------	-------------	--

MANNITOL 15% IN PLASTIC CONTAINER

	ICU MEDICAL INC	15GM/100ML	N019603 003	Jan 08, 1990
--	-----------------	------------	-------------	--------------

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

	B BRAUN	15GM/100ML	N016080 005	
--	---------	------------	-------------	--

MANNITOL 20%

	B BRAUN	20GM/100ML	N014738 001	
--	---------	------------	-------------	--

		20GM/100ML	N016080 004	
--	--	------------	-------------	--

	HOSPIRA	20GM/100ML	N016269 004	
--	---------	------------	-------------	--

	MILES	20GM/100ML	N016472 004	
--	-------	------------	-------------	--

MANNITOL 25%

	ABRAXIS PHARM	12.5GM/50ML	A086754 001	
--	---------------	-------------	-------------	--

	HOSPIRA	12.5GM/50ML	N016269 005	
--	---------	-------------	-------------	--

	IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
--	--------------	-------------	-------------	--------------

		12.5GM/50ML	A089240 001	May 06, 1987
--	--	-------------	-------------	--------------

	LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
--	----------	-------------	-------------	--------------

	MERCK	12.5GM/50ML	N005620 001	
--	-------	-------------	-------------	--

	WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983
--	-------------	-------------	-------------	--------------

MANNITOL 5%

	B BRAUN	5GM/100ML	N016080 001	
--	---------	-----------	-------------	--

	HOSPIRA	5GM/100ML	N016269 001	
--	---------	-----------	-------------	--

MANNITOL 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML	N019603 001	Jan 08, 1987
--	-----------------	-----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MANNITOL

INJECTABLE; INJECTION

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN

5GM/100ML

N016080 007

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN

5GM/100ML

N016704 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA

540MG/100ML; 2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS

25MG

N017543 001

50MG

N017543 002

75MG

N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

25MG

A072129 001 Jan 14, 1988

50MG

A072130 001 Jan 14, 1988

75MG

A072131 001 Jan 14, 1988

HERITAGE PHARMA

25MG

A072162 001 Jun 01, 1988

WATSON LABS

25MG

A071943 001 Dec 30, 1987

50MG

A071944 001 Dec 30, 1987

75MG

A071945 001 Dec 30, 1987

75MG

A072164 001 Jun 01, 1988

WATSON LABS TEVA

50MG

A072163 001 Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR

10%

N019940 001 Sep 04, 1992

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST

1MG

N017980 002

2MG

N017980 001

SANOREX

+ HEXIM

1MG **

N017247 001

+

2MG **

N017247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

+ JANSSEN PHARMS

100MG **

N017481 001

+

500MG

N208398 001 Oct 19, 2016

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC

600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

+ TARGACEPT

2.5MG **

N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED

36MG/0.6ML

N021884 001 Dec 12, 2005

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE

10MG/VIAL

N006695 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253	001	
	25MG	A085252	001	
AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011
ANABOLIC	25MG	A085891	001	
ANI PHARMS INC	12.5MG	A084657	002	
	12.5MG	A085269	001	
	12.5MG	A088732	001	Dec 11, 1985
	25MG	A084657	001	
	25MG	A085740	001	
BUNDY	12.5MG	A084382	001	
	25MG	A084872	001	
IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
MYLAN PHARMS INC	50MG	A202640	003	Sep 17, 2012
PAR PHARM	50MG	A089674	001	Mar 31, 1988
PLIVA	25MG	A088734	001	Dec 11, 1985
RISING	12.5MG	A040179	001	Jan 30, 1997
	25MG	A040179	002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518	001	
---------------------	----	---------	-----	--

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
ANI PHARMS INC	EQ 50MG BASE	A071468	001	Apr 15, 1987
	EQ 100MG BASE	A071469	001	Apr 15, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987

MECLOMEN

PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+ PHARMACIA AND UPJOHN 100MG/ML **

N012541 002

MEDROXYPROGESTERONE ACETATE

CIPLA 150MG/ML

A210335 001 Jan 25, 2019

SANDOZ INC 150MG/ML

A078711 001 May 20, 2009

TEVA PHARMS USA 150MG/ML

A076552 001 Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS 10MG

A083242 001

CURRETAB

SOLVAY 10MG

A085686 001

CYCRIN

ESI 2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR 2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

UPSHER SMITH LABS 10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN 1%

N016624 003

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

BRECKENRIDGE 250MG

A090359 001 Feb 05, 2013

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

+ ROCHE 250MG **

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA INTL PHARMS 250MG

A077699 001 Apr 21, 2010

SANDOZ 250MG

A076175 001 Feb 20, 2002

US ARMY WALTER REED 250MG **

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 40MG/ML **

N020264 001 Sep 10, 1993

MEGESTROL ACETATE

PHARM ASSOC 40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 20MG **

N016979 001

+ 40MG **

N016979 002

MEGESTROL ACETATE

TEVA 40MG

A074745 001 Feb 27, 1998

USL PHARMA 20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ AVONDALE PHARMS 7.5MG/5ML **

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAM

ANDA REPOSITORY 7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

CR DOUBLE CRANE 7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

HERITAGE PHARMA 7.5MG

A077936 001 Jul 19, 2006

15MG

A077936 002 Jul 19, 2006

IMPAX LABS INC 7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

MYLAN 7.5MG

A077923 001 Jul 19, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MELOXICAMTABLET; ORAL
MELOXICAM

	7.5MG	A077934 001	Jul 20, 2006
	15MG	A077923 002	Jul 19, 2006
	15MG	A077934 002	Jul 20, 2006
ROXANE	7.5MG	A077925 001	Jul 19, 2006
	15MG	A077925 002	Jul 19, 2006
SUN PHARM INDS INC	7.5MG	A077937 001	Jul 19, 2006
	15MG	A077937 002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933 001	Jul 19, 2006
	15MG	A077933 002	Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299 001	Oct 27, 2009
US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032 001	May 03, 2019

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

TORRENT	2MG/ML	A205446 001	Dec 07, 2015
---------	--------	-------------	--------------

NAMENDA

+ ALLERGAN

2MG/ML	N021627 001	Apr 18, 2005
--------	-------------	--------------

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

APOTEX INC	5MG	A090244 001	Jul 11, 2018
	10MG	A090244 002	Jul 11, 2018
MYLAN	5MG	A079225 001	Jan 30, 2015
	10MG	A079225 002	Jan 30, 2015
ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
	10MG	A090044 002	Mar 12, 2012

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY	10MG/ML	N005725 001
-------	---------	-------------

SYNKAYVITE

ROCHE	5MG/ML	N003718 004
-------	--------	-------------

	10MG/ML	N003718 006
--	---------	-------------

	37.5MG/ML	N003718 008
--	-----------	-------------

TABLET; ORAL

SYNKAYVITE

ROCHE	5MG	N003718 010
-------	-----	-------------

MENADIONE

TABLET; ORAL

MENADIONE

LILLY	5MG	N002139 003
-------	-----	-------------

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC	75 IU/VIAL; 75 IU/VIAL	N020328 001	Sep 01, 1994
-----------------	------------------------	-------------	--------------

	150 IU/VIAL; 150 IU/VIAL	N020328 002	Sep 01, 1994
--	--------------------------	-------------	--------------

MENOTROPINS

FERRING	75 IU/VIAL; 75 IU/VIAL	A073598 001	Jan 30, 1997
---------	------------------------	-------------	--------------

	150 IU/VIAL; 150 IU/VIAL	A073599 001	Jan 30, 1997
--	--------------------------	-------------	--------------

PERGONAL

SERONO	75 IU/AMP; 75 IU/AMP	N017646 001
--------	----------------------	-------------

	150 IU/AMP; 150 IU/AMP	N017646 002	May 20, 1985
--	------------------------	-------------	--------------

REPRONEX

FERRING	150 IU/VIAL; 150 IU/VIAL	N021047 002	Aug 27, 1999
---------	--------------------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

FERRING	75 IU/VIAL; 75 IU/VIAL	N021047 001	Aug 27, 1999
---------	------------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US 25MG/5ML N010679 004

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US 25MG N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

US PHARM HOLDINGS 25MG/ML N005010 007
 50MG/ML N005010 002
 75MG/ML N005010 009
 100MG/ML N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML A080388 001
 50MG/ML A080385 001
 50MG/ML A080387 001
 75MG/ML A080389 001
 100MG/ML A080386 001

BAXTER HLTHCARE

25MG/ML A088279 001 Jun 15, 1984
 50MG/ML A088280 001 Jun 15, 1984
 75MG/ML A088281 001 Jun 15, 1984
 100MG/ML A088282 001 Jun 15, 1984

IGI LABS INC

25MG/ML A089781 001 Mar 31, 1989
 50MG/ML A089782 001 Mar 31, 1989
 50MG/ML A089783 001 Mar 31, 1989
 50MG/ML A089784 001 Mar 31, 1989
 75MG/ML A089785 001 Mar 31, 1989
 100MG/ML A089786 001 Mar 31, 1989
 100MG/ML A089787 001 Mar 31, 1989
 100MG/ML A089788 001 Mar 31, 1989

INTL MEDICATION

10MG/ML A086332 001

PARKE DAVIS

50MG/ML A080364 002
 75MG/ML A080364 003
 100MG/ML A080364 001

WATSON LABS

50MG/ML A073444 001 Mar 17, 1992
 100MG/ML A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML A040305 001 Mar 10, 1999

ICU MEDICAL INC

10MG/ML A088432 001 Aug 16, 1984

INTL MEDICATION

10MG/ML A081309 001 Aug 30, 1993

SPECGX LLC

10MG/ML A040163 001 May 12, 1997

WATSON LABS

10MG/ML A073443 001 Mar 17, 1992

SYRUP; ORAL

DEMEROL

US PHARM HOLDINGS 50MG/5ML ** N005010 005

TABLET; ORAL

DEMEROL

+ US PHARM HOLDINGS 50MG N005010 001

+ 100MG N005010 004

MEPERIDINE HYDROCHLORIDE

ANDA REPOSITORY

50MG A040893 001 Jun 24, 2009

75MG A040893 002 Jun 24, 2009

100MG A040893 003 Jun 24, 2009

150MG A040893 004 Jun 24, 2009

BARR

50MG A088639 001 Jul 02, 1984

100MG A088640 001 Sep 19, 1984

DURAMED PHARMS BARR

50MG A040318 001 Oct 05, 1999

100MG A040318 002 Oct 05, 1999

SPECGX LLC

50MG A040352 001 Jun 13, 2000

100MG A040352 002 Jun 13, 2000

SUN PHARM INDS INC

50MG A040446 001 Aug 08, 2002

100MG A040446 002 Aug 08, 2002

SUN PHARM INDUSTRIES

50MG A080448 001

100MG A080448 002

WATSON LABS

50MG A040186 001 Jun 30, 1997

100MG A040186 002 Jun 30, 1997

WYETH AYERST

50MG A080454 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

HIKMA

25MG/ML; 25MG/ML

N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP

EQ 15MG BASE/ML

N008248 002

EQ 30MG BASE/ML

N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

+ NOVARTIS

100MG **

N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY

3%

A084777 002 Apr 18, 1982

CARBOCAINE

+ EASTMAN KODAK

3% **

N012125 003

ISOCAINE HYDROCHLORIDE

SEPTODONT INC

3%

A080925 001

MEPIVACAINE HYDROCHLORIDE

BELMORA LLC

3%

A083559 001

HOSPIRA INC

3%

A040806 001 Apr 28, 2008

INTL MEDICATION SYS

1%

A087509 001 Oct 05, 1982

WATSON LABS

1%

A088769 001 Nov 20, 1984

2%

A088770 001 Nov 20, 1984

POLOCAINE

DENTSPLY PHARM

3%

A088653 001 Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING

4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST

400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC

200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS

400MG

A084030 001

BAMATE

ALRA

200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST

200MG

N010028 005

400MG

N010028 004

MEPRIAM

TEVA

400MG

N016069 001

MEPROBAMATE

AUROLIFE PHARMA LLC

400MG

A080655 001

BARR

600MG

A084230 001

ELKINS SINN

200MG

N015426 002

400MG

N015426 001

HEATHER

400MG

N016928 003

600MG

A084329 001

IMPAX LABS

200MG

N014322 002

400MG

N014322 001

IVAX SUB TEVA PHARMS

200MG

N015438 001

400MG

N015438 002

600MG

A084181 001

IVC INDS

400MG

A084153 001

LANNETT

200MG

N014882 002

400MG

N014882 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

LEDERLE	400MG	A086299	001	
LEE KM	400MG	A089538	001	Nov 25, 1987
MALLARD	400MG	N015072	002	
MK LABS	200MG	N014368	004	
	400MG	N014368	002	
MYLAN	400MG	A083618	001	
NEXGEN PHARMA INC	200MG	A084220	001	
	400MG	A084589	001	
PARKE DAVIS	200MG	A084744	001	
	400MG	A084744	002	
PERRIGO	200MG	A084546	001	
	400MG	A084547	001	
PHARMAVITE	400MG	A084438	001	
PUREPAC PHARM	200MG	A084804	001	
	400MG	A084804	002	
PVT FORM	400MG	N014601	001	
ROXANE	600MG	A084332	001	
SANDOZ	200MG	N014547	002	
	400MG	N014547	001	
SCHERER LABS	400MG	A083343	001	
SOLVAY	200MG	A084435	001	
STANLABS PHARM	200MG	N014474	002	
	400MG	N014474	004	
SUN PHARM INDUSTRIES	200MG	A080699	001	
	400MG	A080699	002	
TABLICAPS	400MG	A083494	001	
TARO	200MG	A200998	001	May 23, 2011
	400MG	A200998	002	May 23, 2011
USL PHARMA	200MG	A087825	001	Mar 18, 1982
	400MG	A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139	006	
	400MG	N015139	005	
VANGARD	400MG	A088011	001	Jul 14, 1982
WATSON LABS	200MG	A085720	001	
	400MG	A085721	001	
	600MG	A084274	001	
	600MG	A085719	001	
WEST WARD	200MG	N015417	003	
	400MG	N015417	002	
WHITEWORTH TOWN PLSN	200MG	A083830	001	
	400MG	A083442	001	
MILTOWN				
+ MEDPOINTE PHARM HLC	200MG **	N009698	004	
+	400MG **	N009698	002	
	600MG	A083919	001	
NEURAMATE				
HALSEY	200MG	N014359	002	
	400MG	N014359	001	
TRANMEP				
SOLVAY	400MG	A084369	001	
	400MG	N016249	001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999
----------	----------	---------	-----	--------------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010
	1GM/VIAL	A090940	002	Jun 22, 2010
SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011
	1GM/VIAL	A091201	002	Mar 29, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS

100MG/ML; 50MG/ML

A084875 001

MESALAMINE

ENEMA; RECTAL

MESALAMINE

G AND W LABS INC

4GM/60ML

A076841 001 Sep 30, 2004

SUPPOSITORY; RECTAL

CANASA

ALLERGAN

500MG

N021252 001 Jan 05, 2001

ROWASA

+ MEDA PHARMS

500MG **

N019919 001 Dec 18, 1990

TABLET, DELAYED RELEASE; ORAL

ASACOL

APIL

400MG

N019651 001 Jan 31, 1992

MESNA

INJECTABLE; INTRAVENOUS

MESNA

MYLAN INSTITUTIONAL

100MG/ML

A076488 001 Mar 08, 2012

MYLAN LABS LTD

100MG/ML

A203364 001 Jul 18, 2014

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016997 001

INJECTABLE; INJECTION

SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS

EQ 10MG BASE

N016774 001

EQ 25MG BASE

N016774 002

EQ 50MG BASE

N016774 003

EQ 100MG BASE

N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

ACTAVIS LABS UT INC

0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

HERITAGE PHARMA

0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

ACTAVIS LABS UT INC

0.05MG; 1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC

0.08MG; 1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM

0.05MG; 1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM

0.08MG; 1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM

0.06MG; 10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM

0.1MG; 2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

HERITAGE PHARMA

0.05MG; 1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070759 001 Jul 01, 1988

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC

0.05MG; 1MG

N016659 001

NORINYL 1+80 28-DAY

GD SEARLE LLC

0.08MG; 1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN

0.05MG; 1MG

N016709 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG;1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC 0.075MG;5MG
0.15MG;9.85MG

N010976 008

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG;5MG

N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG;2.5MG

N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC 0.1MG;2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM 0.4%
0.6%
5%

N018761 002 Oct 10, 1986

N018761 001 Jun 30, 1983

N017659 001

METAPROTERENOL SULFATE

APOTEX INC 0.4%
0.6%

A075402 001 Feb 28, 2001

A075403 001 Feb 28, 2001

ASTRAZENECA 0.4%
0.6%

A071275 001 Jul 27, 1988

A071018 001 Jul 27, 1988

DEY 0.33%
0.5%

A071806 001 Aug 05, 1988

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

MYLAN SPECIALITY LP 0.4%
0.6%

A071786 001 Aug 05, 1988

A070804 001 Aug 17, 1987

NEPHRON 0.4%
0.6%

A071855 001 Jul 14, 1988

A071726 001 Jul 14, 1988

WOCKHARDT 0.4%
0.6%

A075586 001 May 30, 2002

A075586 002 May 30, 2002

5%

A072190 001 Jun 07, 1988

PROMETA

MURO 5%

A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG/5ML

N017571 001

METAPROTERENOL SULFATE

ACP NIMBLE 10MG/5ML

A072761 001 Feb 27, 1992

APOTEX INC 10MG/5ML

A075235 001 Jan 27, 2000

G AND W LABS INC 10MG/5ML

A073034 001 Aug 30, 1991

MORTON GROVE 10MG/5ML

A071656 001 Oct 13, 1987

WOCKHARDT 10MG/5ML

A074702 001 Mar 24, 1997

PROMETA

MURO 10MG/5ML

A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM 10MG
20MG

N015874 002

N015874 001

METAPROTERENOL SULFATE

AM THERAP 10MG
20MG

A072054 001 Jun 23, 1988

A072055 001 Jun 23, 1988

HERITAGE PHARMA 10MG
20MG

A072519 001 Mar 30, 1990

A072520 001 Mar 30, 1990

PAR PHARM 10MG
20MG

A072024 001 Jun 28, 1988

A072025 001 Jun 28, 1988

USL PHARMA 10MG
20MG

A071013 001 Jan 25, 1988

A071014 001 Jan 25, 1988

WATSON LABS 10MG

A073013 001 Jan 31, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METAPROTERENOL SULFATE

TABLET; ORAL

METAPROTERENOL SULFATE

20MG

A072795 001 Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

+ MERCK

EQ 10MG BASE/ML **

N009509 002 Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML

A080431 001

ELKINS SINN

EQ 10MG BASE/ML

A083363 001

FRESENIUS KABI USA

EQ 10MG BASE/ML

A080722 001

GD SEARLE LLC

EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

METAXALONE

+ PRIMUS PHARMS

640MG **

N022503 001 Jun 01, 2015

SKELAXIN

+ KING PHARMS

400MG **

N013217 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

+ EMD SERONO INC

500MG

N020357 001 Mar 03, 1995

+

625MG **

N020357 003 Nov 05, 1998

+

750MG **

N020357 004 Nov 05, 1998

+

850MG

N020357 002 Mar 03, 1995

+

1GM

N020357 005 Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR

500MG

A075971 001 Jan 25, 2002

850MG

A075971 002 Jan 25, 2002

1GM

A075971 003 Jan 25, 2002

IPCA LABS LTD

500MG

A078422 001 Aug 06, 2007

850MG

A078422 002 Aug 06, 2007

1GM

A078422 003 Aug 06, 2007

IVAX SUB TEVA PHARMS

500MG

A075975 001 Jan 24, 2002

625MG

A075975 004 Jan 24, 2002

750MG

A075975 005 Jan 24, 2002

850MG

A075975 002 Jan 24, 2002

1GM

A075975 003 Jan 24, 2002

MYLAN PHARMS INC

500MG

A075969 001 Jan 29, 2002

850MG

A075969 002 Jan 29, 2002

1GM

A075969 003 Jan 29, 2002

PROVIDENT PHARM

500MG

A077853 001 Jul 28, 2006

850MG

A077853 002 Jul 28, 2006

1GM

A077853 003 Jul 28, 2006

SANDOZ

500MG

A075985 001 Jan 25, 2002

850MG

A075985 002 Jan 25, 2002

1GM

A075985 003 Jan 25, 2002

SUN PHARM INDUSTRIES

500MG

A076038 001 Feb 21, 2002

850MG

A076038 002 Feb 21, 2002

1GM

A076038 003 Feb 21, 2002

SUNSHINE LAKE

500MG

A208999 001 Oct 12, 2018

850MG

A208999 002 Oct 12, 2018

1GM

A208999 003 Oct 12, 2018

TEVA

500MG

A076328 001 Dec 16, 2002

850MG

A076328 002 Dec 16, 2002

1GM

A076328 003 Dec 16, 2002

WATSON LABS

500MG

A075979 001 Jan 24, 2002

850MG

A075979 002 Jan 24, 2002

1GM

A075979 003 Jan 24, 2002

WATSON LABS FLORIDA

500MG

A075961 001 Jan 25, 2002

850MG

A075961 002 Jan 25, 2002

1GM

A075961 003 Jan 25, 2002

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

+ ANDRX LABS LLC

500MG **

N021574 001 Apr 27, 2004

+

1GM **

N021574 002 Apr 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

+	EMD SERONO INC	500MG	N021202	001	Oct 13, 2000
+		750MG	N021202	004	Apr 11, 2003

METFORMIN HYDROCHLORIDE

	ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
		750MG	A076878	001	Apr 13, 2005
	BARR	500MG	A076496	001	Nov 25, 2005
	IMPAX LABS	500MG	A076249	001	Jul 30, 2004
		750MG	A076985	001	Sep 13, 2005
	IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
	MYLAN	500MG	A076650	001	Sep 13, 2005
		750MG	A077113	001	Sep 08, 2005
	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
		750MG	A077211	001	Jun 29, 2005
	SANDOZ	500MG	A076223	001	Dec 14, 2004
	SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
	TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004
	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018
		750MG	A211052	002	Sep 24, 2018

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
		500MG;2MG	A200624	002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE **	N021410	005	Aug 25, 2003

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
		500MG;EQ 1MG BASE	A077337	005	May 19, 2017
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014
		1GM;EQ 4MG BASE	A077337	004	May 07, 2014
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016
---	------------	-------------	---------	-----	--------------

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

	MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
		EQ 280MG BASE	A060641	002	

SYRUP;ORAL

RONDONMYCIN

	MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	
--	---------------------	------------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT INC

50GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

HIKMA

10MG/30ML

N006134 004

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE

5MG

A088108 001 Mar 08, 1983

10MG

A088109 001 Mar 08, 1983

40MG

A074081 001 Apr 28, 1995

VISTAPHARM

5MG

A040241 001 May 29, 1998

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ

2.5MG

N017108 001

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ

5MG

N017108 002

10MG

N017108 003

40MG

N017108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPEX

TEVA

10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE

5MG

A040529 001 Feb 25, 2004

REXAR

5MG

A084931 001

10MG

A084931 002

TEVA

5MG

A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

RECORDATI RARE

5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE

50MG

N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE

100MG

N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL

25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

INVATECH

25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

MICRO LABS

25MG

A207438 001 Oct 05, 2018

50MG

A207438 002 Oct 05, 2018

NEPTAZANE

+ LEDERLE

25MG **

N011721 002 Nov 25, 1991

+

50MG **

N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB

3.6MG

N011950 009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHCILLIN

APOTHECON EQ 900MG BASE/VIAL A061449 001

EQ 900MG BASE/VIAL N050117 001

EQ 3.6GM BASE/VIAL A061449 002

EQ 3.6GM BASE/VIAL N050117 002

EQ 5.4GM BASE/VIAL A061449 003

EQ 5.4GM BASE/VIAL N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

ECI PHARMS LLC 15MG A040619 003 Jul 12, 2005

20MG A040547 004 Feb 18, 2005

MYLAN 20MG A040350 003 Jun 07, 2001

SUN PHARM INDS INC 5MG A040870 001 Sep 25, 2007

10MG A040870 002 Sep 25, 2007

TAPAZOLE

+ KING PHARMS 5MG ** N007517 002

+ 10MG ** N007517 004

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS 1MG N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

DR REDDYS 100MG/ML A086459 001

MARSAM PHARMS LLC 100MG/ML A089849 001 Dec 27, 1991

TABLET; ORAL

DELAXIN

FERNDALE LABS 500MG A085454 001

FORBAXIN

FOREST LABS 750MG A085136 001

METHOCARBAMOL

ABLE 500MG A040413 001 Mar 17, 2003

750MG A040413 002 Mar 17, 2003

AM THERAP 500MG A089417 001 Feb 11, 1987

750MG A089418 001 Feb 11, 1987

ANI PHARMS INC 500MG A084277 001

750MG A084276 002

ASCOT 500MG A087660 001 Oct 27, 1982

750MG A087661 001 Oct 27, 1982

CLONMEL HLTHCARE 500MG A085961 001

750MG A085963 001

FOSUN PHARMA 500MG A084616 001

750MG A084615 001

HEATHER 500MG A084675 001

750MG A084924 001

IMPAX LABS 500MG A084927 001

750MG A084928 001

INWOOD LABS 500MG A085137 001

IVAX SUB TEVA PHARMS 500MG A084648 001

750MG A084649 001

KV PHARM 500MG A085660 001

750MG A085658 001

LANNETT CO INC 500MG A084756 002 Mar 31, 2003

750MG A084756 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

MYLAN	500MG	A084259	001	
	750MG	A084323	001	
NYLOS	750MG	A085033	001	
PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
	750MG	A089082	001	Dec 13, 1985
PURACAP PHARM	500MG	A084231	002	
	750MG	A084471	001	
PUREPAC PHARM	500MG	A085718	001	
	750MG	A085718	002	
ROXANE	500MG	A088646	001	Feb 29, 1984
	750MG	A088647	001	Feb 29, 1984
SANDOZ	500MG	A087283	001	
	750MG	A087282	001	
SOLVAY	500MG	A084448	001	
	750MG	A084449	001	
SUN PHARM INDUSTRIES	500MG	A084488	001	
	750MG	A084486	001	
SUPERPHARM	500MG	A087589	001	Jan 22, 1982
	750MG	A087590	001	Jan 22, 1982
TABLICAPS	500MG	A084846	001	
UPSHER SMITH	500MG	A087453	001	
	750MG	A087454	001	
WATSON LABS	500MG	A083605	001	
	500MG	A085180	001	
	750MG	A083605	002	
	750MG	A085192	001	
ROBAXIN				
+ AUXILIUM PHARMS LLC	500MG	N011011	004	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
	5GM/VIAL	N011559	003	

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

+ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
OTREXUP PFS				
+ ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+	25MG/ML (25MG/ML)	N204824	014	May 31, 2017
RASUVO				
+ MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
	EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
	EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
	EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX				
PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS				
PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF				
HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719 014	Apr 13, 2005
+	EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719 013	Apr 13, 2005
	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719 011	Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML	A089323 001	Jun 13, 1986
EQ 20MG BASE/VIAL	A088935 001	Oct 11, 1985
EQ 25MG BASE/ML	A089263 001	Jun 13, 1986
EQ 25MG BASE/ML	A089322 001	Jun 13, 1986
EQ 50MG BASE/VIAL	A088936 001	Oct 11, 1985
EQ 100MG BASE/VIAL	A088937 001	Oct 11, 1985

FRESENIUS KABI USA

HOSPIRA

EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263 002	Feb 26, 1999
EQ 2.5MG BASE/ML	N011719 004	
EQ 20MG BASE/VIAL	N011719 001	
EQ 25MG BASE/ML	N011719 005	
EQ 50MG BASE/VIAL	N011719 003	
EQ 100MG BASE/VIAL	N011719 006	

NORBROOK

PHARMACHEMIE USA

EQ 25MG BASE/ML	A088648 001	May 09, 1986
EQ 25MG BASE/ML	A089158 001	Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL	N011719 009	Apr 07, 1988
------------------	-------------	--------------

MEXATE

BRISTOL

EQ 20MG BASE/VIAL	A086358 001	
EQ 50MG BASE/VIAL	A086358 002	
EQ 100MG BASE/VIAL	A086358 003	
EQ 250MG BASE/VIAL	A086358 004	

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML	A088760 001	Feb 14, 1985
-----------------	-------------	--------------

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML	A089887 001	Apr 14, 1989
-----------------	-------------	--------------

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ 2.5MG BASE	A040233 001	Jun 17, 1999
---------------	-------------	--------------

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE

10MG/ML	N006772 002	
20MG/ML	N006772 001	

METHOXSALEN

CAPSULE; ORAL

8-MOP

+ VALEANT PHARM INTL

10MG	N009048 001	
------	-------------	--

METHOXSALEN

ANI PHARMS INC

10MG	A087781 001	Jun 08, 1982
------	-------------	--------------

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL

1%	N009048 002	
----	-------------	--

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

BRECKENRIDGE PHARM

2.5MG	A040642 001	Dec 06, 2011
5MG	A040642 002	Dec 06, 2011
PVT FORM	A080970 001	
2.5MG	A040624 001	Dec 28, 2006
5MG	A040624 002	Dec 28, 2006

PVT FORM

VINTAGE PHARMS

PAMINE

FOUGERA PHARMS

2.5MG **	N008848 001	
----------	-------------	--

PAMINE FORTE

FOUGERA PHARMS

5MG **	N008848 002	Mar 25, 2003
--------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+ PARKE DAVIS 150MG N010596 007

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC 5MG N017364 001

ENDURON

+ ABBVIE 2.5MG ** N012524 001

+ 5MG ** N012524 004

METHYCLOTHIAZIDE

IVAX PHARMS 2.5MG A087913 001 Jun 03, 1982

5MG A087786 001 May 18, 1982

MYLAN 2.5MG A087671 001 Aug 17, 1982

MYLAN PHARMS INC 5MG A087672 001 Aug 17, 1982

PAR PHARM 2.5MG A089135 001 Feb 12, 1986

5MG A089136 001 Feb 12, 1986

USL PHARMA 5MG A088745 001 Mar 21, 1985

WATSON LABS 2.5MG A085487 001 Mar 11, 1982

2.5MG A088750 001 Sep 06, 1984

5MG A085476 001 Mar 11, 1982

5MG A088724 001 Sep 06, 1984

YAOPHARMA CO LTD 2.5MG A089835 001 Aug 18, 1988

5MG A089837 001 Aug 18, 1988

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT 5MG; 25MG N016047 001

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC 2.5MG; 0.1MG N012708 005

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP EQ 16.8% BASE N021415 001 Jul 27, 2004

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK 250MG/5ML N018389 001

TABLET; ORAL

ALDOMET

+ MERCK 125MG ** N013400 003

+ 250MG ** N013400 001

+ 500MG ** N013400 002

METHYLDOPA

ACCORD HLTHCARE 125MG A070070 003 Oct 15, 1985

DURAMED PHARMS BARR 250MG A071006 001 Dec 16, 1986

500MG A071009 001 Dec 16, 1986

HALSEY 125MG A071751 001 Mar 28, 1988

250MG A071752 001 Mar 28, 1988

500MG A071753 001 Mar 28, 1988

PAR PHARM 125MG A070535 001 Jan 02, 1987

250MG A070536 001 Jan 02, 1987

500MG A070537 001 Jan 02, 1987

PARKE DAVIS 125MG A070331 001 Apr 15, 1986

250MG A070332 001 Apr 15, 1986

500MG A070333 001 Apr 15, 1986

PLIVA 125MG A072126 001 Jul 07, 1988

250MG A072127 001 Jul 07, 1988

500MG A072128 001 Jul 07, 1988

PUREPAC PHARM 125MG A070749 001 Feb 07, 1986

250MG A070750 001 Feb 07, 1986

500MG A070452 001 Feb 07, 1986

ROXANE 125MG A070192 001 Apr 25, 1986

250MG A070193 001 Apr 25, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLDOPATABLET; ORAL
METHYLDOPA

	500MG	A070194	001	Apr 25, 1986
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

+ MERCK	50MG/ML **	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

+ EDISON THERAPS LLC	0.2MG **	N006035	003	
----------------------	----------	---------	-----	--

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

RITALIN LA

+ NOVARTIS	60MG **	N021284	005	Oct 27, 2014
------------	---------	---------	-----	--------------

FOR SUSPENSION, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018
---------------------	--------	---------	-----	--------------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002
AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018
	10MG	A209276	002	Oct 25, 2018
	20MG	A209276	003	Oct 25, 2018
CEDIPROF INC	5MG	A208737	001	Feb 01, 2019
	10MG	A208737	002	Feb 01, 2019
	20MG	A208737	003	Feb 01, 2019
CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016
	10MG	A206840	002	Sep 15, 2016
	20MG	A206840	003	Sep 15, 2016
LANNETT CO INC	5MG	A086429	001	
	10MG	A085799	001	
	20MG	A086428	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

METHYLIN

+	SPECGX LLC	2.5MG **	N021475 001	Apr 15, 2003
+		5MG **	N021475 002	Apr 15, 2003
+		10MG **	N021475 003	Apr 15, 2003

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

LANNETT CO INC	10MG	A040306 001	Oct 20, 1999
	20MG	A089601 001	Jun 01, 1988

METHYLPHENIDATE HYDROCHLORIDE

ABLE	20MG	A076032 001	May 09, 2001
HERITAGE PHARMA	20MG	A075450 001	Dec 21, 2001
PAR PHARM	36MG	A204659 001	Jul 15, 2019
	54MG	A204659 002	Jul 15, 2019
WATSON LABS	20MG	A040410 001	Feb 09, 2001

RITALIN-SR

+	NOVARTIS	20MG **	N018029 001	Mar 30, 1982
---	----------	---------	-------------	--------------

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153 005	
----------------------	------	-------------	--

METHYLPREDNISOLONE

HEATHER	4MG	A085650 001	
INVATECH	4MG	A087341 001	
LUPIN LTD	2MG	A209097 001	Feb 22, 2019
	4MG	A209097 002	Feb 22, 2019
	8MG	A209097 003	Feb 22, 2019
	16MG	A209097 004	Feb 22, 2019
	32MG	A209097 005	Feb 22, 2019
NOVAST LABS	4MG	A210985 001	Jan 09, 2019
PAR PHARM	16MG	A089207 001	Apr 25, 1988
	24MG	A089208 001	Apr 25, 1988
	32MG	A089209 001	Apr 25, 1988
WATSON LABS	4MG	A086161 001	Feb 09, 1982
	16MG	A086159 001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA;RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102 001	
----------------------	----------	-------------	--

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666 001	
	80MG/ML	A087135 001	

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903 001	Oct 20, 1982
	80MG/ML	A086903 002	Oct 20, 1982
AMNEAL	40MG/ML	A210043 001	May 20, 2019
	80MG/ML	A210043 002	May 20, 2019
WATSON LABS	20MG/ML	A085597 001	
	20MG/ML	A087248 001	
	40MG/ML	A085374 001	
	40MG/ML	A085600 001	
	80MG/ML	A085595 001	
	80MG/ML	A086507 001	

OINTMENT;TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421 001	
	1%	N012421 002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611 002	
	1%;EQ 3.5MG BASE/GM	A060611 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005
	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	
HOSPIRA INC	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008
	EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008

METHYLPREDNISOLONE

ELKINS SINN

EQ 125MG BASE/VIAL	A086906	002		
EQ 500MG BASE/VIAL	A086906	003		
EQ 1GM BASE/VIAL	A086906	004		
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986

BEDFORD LABS

EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007

ELKINS SINN

EQ 40MG BASE/VIAL	A086906	001	
-------------------	---------	-----	--

INTL MEDICATION

EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983

TEVA PARENTERAL

EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992

WATSON LABS

EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001
----------------------	-----------------------	---------	-----

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967	001
---------	------	---------	-----

VIRILON

CHARTWELL	10MG	A087750	001	Nov 24, 1982
-----------	------	---------	-----	--------------

TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL	5MG	A087222	001
--------------------	-----	---------	-----

ORETON

SCHERING	10MG	A080281	001
----------	------	---------	-----

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METHYLTESTOSTERONE

TABLET;BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS	5MG	N003240 004
	10MG	N003240 001
	10MG	N003240 005
	25MG	N003240 003

METHYLTESTOSTERONE

IMPAX LABS	10MG	A084287 001
LILLY	10MG	A080256 001
	25MG	A080256 002
PUREPAC PHARM	10MG	A080308 001
	10MG	A080475 001
	10MG	A080475 002
	25MG	A080475 003
PVT FORM	5MG	A083836 001
TABLICAPS	10MG	A085125 001
USL PHARMA	10MG	A080271 001

TABLET;ORAL

ANDROID 10

VALEANT PHARMS NORTH	10MG	A086450 001
----------------------	------	-------------

METHYLTESTOSTERONE

IMPAX LABS	25MG	A084310 001
INWOOD LABS	10MG	A080839 001
	25MG	A080973 001
KV PHARM	10MG	A084312 001
LANNETT	10MG	A087092 001
	25MG	A087111 001
PARKE DAVIS	10MG	A084244 001
	25MG	A084241 001
PUREPAC PHARM	10MG	A080309 001
	25MG	A080310 001
PVT FORM	5MG	A080214 001
	10MG	A080214 002
	25MG	A080214 003
TABLICAPS	10MG	A080313 001
	25MG	A085270 001
WATSON LABS	10MG	A080933 001
	25MG	A080931 001
WEST WARD	10MG	A084331 001
	25MG	A084331 002
	25MG	A084642 001

Nov 05, 1982
Jan 27, 1983

ORETON METHYL

SCHERING	10MG	N003158 001
	25MG	N003158 002

METHYPRYLON

CAPSULE;ORAL

NOLUDAR

ROCHE	300MG	N009660 008
-------	-------	-------------

ELIXIR;ORAL

NOLUDAR

ROCHE	50MG/5ML	N009660 007
-------	----------	-------------

TABLET;ORAL

NOLUDAR

ROCHE	50MG	N009660 002
	200MG	N009660 004

METHYSERGIDE MALEATE

TABLET;ORAL

SANSERT

NOVARTIS	2MG	N012516 001
----------	-----	-------------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

SANDOZ INC	0.3%	A075720 001	Aug 06, 2001
------------	------	-------------	--------------

OPTIPRANOLOL

+ BAUSCH AND LOMB	0.3%	N019907 001	Dec 29, 1989
-------------------	------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
--------	-----------------	---------	-----	--------------

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247	001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

REGLAN

WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001	
	EQ 10MG BASE/ML	N017862	004	May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
LANNETT CO INC	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993

REGLAN

+ ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
-------------	--------------------	---------	-----	--------------

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
------------------	--------------	---------	-----	--------------

MAXOLON

KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
-------------	--------------	---------	-----	--------------

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
	EQ 10MG BASE	A078374	002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 10MG BASE	A070850	001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
	EQ 10MG BASE	A071536	001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987
YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A072215	001	Jan 30, 1990
	EQ 10MG BASE	A074478	002	Oct 05, 1995

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

+ SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
+	EQ 10MG BASE **	N022246	002	Sep 04, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

REGLAN ODT

MEDA PHARMS

EQ 5MG BASE
EQ 10MG BASEN021793 001 Jun 10, 2005
N021793 002 Jun 10, 2005METOCURINE IODIDE

INJECTABLE;INJECTION

METUBINE IODIDE

LILLY

2MG/ML

N006632 003

METOLAZONE

TABLET;ORAL

DIULO

GD SEARLE LLC

2.5MG
5MG
10MGN018535 001
N018535 002
N018535 003

METOLAZONE

ANI PHARMS INC

2.5MG
5MG
10MGA076600 001 Jan 06, 2004
A076833 001 Mar 01, 2004
A075543 003 Dec 24, 2003

ROXANE

10MG

A076482 002 Apr 29, 2004

WATSON LABS

10MG

A076891 001 Jul 21, 2004

MYKROX

LANNETT CO INC

0.5MG

N019532 001 Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE;ORAL

LOPRESSOR

NOVARTIS

EQ 100MG TARTRATE
EQ 200MG TARTRATE
EQ 300MG TARTRATE
EQ 400MG TARTRATEN019786 001 Dec 27, 1989
N019786 002 Dec 27, 1989
N019786 003 Dec 27, 1989
N019786 004 Dec 27, 1989METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

NESHER PHARMS

EQ 25MG TARTRATE
EQ 50MG TARTRATE
EQ 100MG TARTRATE
EQ 200MG TARTRATE
EQ 25MG TARTRATE
EQ 50MG TARTRATE
EQ 100MG TARTRATE
EQ 200MG TARTRATEA077779 001 Mar 20, 2008
A077176 001 May 14, 2008
A076640 002 May 18, 2007
A076640 001 May 18, 2007
A076969 001 Jul 31, 2006
A076969 002 May 18, 2007
A076969 003 Mar 20, 2008
A076969 004 Mar 20, 2008

SANDOZ

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR

+

NOVARTIS

1MG/ML

N018704 001 Mar 30, 1984

METOPROLOL TARTRATE

LUITPOLD

1MG/ML

A090386 001 Sep 30, 2009

WATSON LABS

1MG/ML

A091307 001 Dec 29, 2010

TABLET;ORAL

METOPROLOL TARTRATE

APOTHECON

50MG
100MGA074258 001 Jan 27, 1994
A074258 002 Jan 27, 1994

MYLAN

50MG

A073666 001 Dec 21, 1993

PUREPAC PHARM

100MG

A073666 002 Dec 21, 1993

PUREPAC PHARM

50MG

A074380 001 Jul 29, 1994

RENATA

100MG

A074380 002 Jul 29, 1994

RENATA

50MG

A074453 001 Apr 27, 1995

SUN PHARM INDUSTRIES

100MG

A074453 002 Apr 27, 1995

SUN PHARM INDUSTRIES

25MG

A073654 002 Jul 15, 2009

SUN PHARM INDUSTRIES

50MG

A073654 003 Dec 21, 1993

SUN PHARM INDUSTRIES

100MG

A073654 001 Dec 21, 1993

TEVA

50MG

A074143 001 Sep 30, 1994

TEVA

100MG

A074143 002 Sep 30, 1994

TEVA PHARMS

50MG

A074333 001 Jan 27, 1994

TEVA PHARMS

100MG

A074333 002 Jan 27, 1994

WATSON LABS

50MG

A074217 001 May 27, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

	100MG	A074217 002	May 27, 1994
YAOPHARMA CO LTD	50MG	A073288 001	Mar 25, 1994
	100MG	A073289 001	Mar 25, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982 003	Sep 12, 1983
	3.75GM/VIAL	N017982 001	
	6.75GM/VIAL	N017982 002	
	13.5GM/VIAL	N017982 004	Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505 001	Nov 13, 2003
------	-------	-------------	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353 002	
--------	-------------	-------------	--

METRO I.V.

B BRAUN	500MG/100ML	N018674 001	Aug 31, 1982
---------	-------------	-------------	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889 001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071 001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004 001	May 08, 1985
WATSON LABS	500MG/100ML	A070042 001	Dec 20, 1984
	500MG/100ML	A070170 001	Apr 01, 1986
WEST-WARD PHARMS INT	500MG/100ML	N018907 001	Mar 30, 1984

TABLET; ORAL

METROMIDOL

LABS AF	250MG	A074523 001	Oct 24, 1996
	500MG	A074523 002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519 001	Jun 27, 2003
	500MG	A076519 002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845 001	Aug 18, 1983
	500MG	N018930 001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620 001	Mar 04, 1982
	250MG	N018740 001	Oct 22, 1982
	500MG	N018620 002	Jun 02, 1983
	500MG	N018740 002	Oct 22, 1982
HALSEY	250MG	A070021 001	Apr 02, 1985
	500MG	A070593 001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517 001	
	500MG	N018517 002	May 05, 1982
LNK	250MG	N019029 001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818 001	Feb 16, 1983
	500MG	N018818 002	Feb 16, 1983
SUPERPHARM	250MG	A070008 001	Dec 11, 1984
	500MG	A070009 001	Dec 11, 1984
WATSON LABS	250MG	N018599 001	Sep 17, 1982
	250MG	N018764 001	Sep 17, 1982
	500MG	N018599 002	Feb 13, 1984
	500MG	N018764 002	Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM	250MG	N018871 001	Mar 02, 1983
	500MG	N018871 002	Mar 02, 1983

SATRIC

SAVAGE LABS	250MG	A070029 001	Mar 19, 1985
	500MG	A070731 001	Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+ GD SEARLE LLC	750MG	N020868 001	Nov 26, 1997
-----------------	-------	-------------	--------------

METRONIDAZOLE

ABLE	750MG	A076462 001	Jun 25, 2003
ALEMBIC PHARMS LTD	750MG	A090222 001	May 05, 2010

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL **

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYPAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

ANI PHARMS INC

150MG

A074450 001 May 16, 1996

200MG

A074450 002 May 16, 1996

250MG

A074450 003 May 16, 1996

WATSON LABS

150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

MEXITIL

+ BOEHRINGER INGELHEIM

150MG

N018873 002 Dec 30, 1985

+

200MG

N018873 003 Dec 30, 1985

+

250MG

N018873 004 Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS

EQ 1GM BASE/VIAL

A062333 001

EQ 1GM BASE/VIAL

A062372 005 Jan 13, 1983

EQ 1GM BASE/VIAL

N050549 001

EQ 2GM BASE/VIAL

A062333 002

EQ 2GM BASE/VIAL

A062372 001 May 13, 1982

EQ 2GM BASE/VIAL

N050549 002

EQ 3GM BASE/VIAL

A062333 003

EQ 3GM BASE/VIAL

A062372 002 May 13, 1982

EQ 3GM BASE/VIAL

A062697 001 Jan 22, 1987

EQ 3GM BASE/VIAL

N050549 003

EQ 4GM BASE/VIAL

A062333 004

EQ 4GM BASE/VIAL

A062372 003 May 13, 1982

EQ 4GM BASE/VIAL

A062697 002 Jan 22, 1987

EQ 4GM BASE/VIAL

N050549 004

EQ 20GM BASE/VIAL

A062372 004 Mar 02, 1988

EQ 20GM BASE/VIAL

N050549 005 Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA

10MG/ML

N018040 001

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017494 001

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA

2%

A074136 001 Jan 04, 1995

TEVA PHARMS

2%

A074030 001 Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC

2%, 100MG

A074586 001 Jul 17, 1997

MICONAZOLE 7 COMBINATION PACK

ACP NIMBLE

2%, 100MG

A076585 001 Mar 26, 2004

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017739 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MICONAZOLE NITRATE

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS 100MG N018592 001 Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AKORN INC EQ 5MG BASE/ML A075481 001 Jun 30, 2000

APOTHECON EQ 1MG BASE/ML A075620 001 Nov 01, 2000

EQ 5MG BASE/ML A075620 002 Nov 01, 2000

EQ 5MG BASE/ML A075641 001 Oct 19, 2000

BAXTER HLTHCARE CORP EQ 1MG BASE/ML A075637 001 Oct 31, 2000

EQ 5MG BASE/ML A075637 002 Oct 31, 2000

BEDFORD EQ 5MG BASE/ML A075249 001 Jun 23, 2000

BEN VENUE EQ 5MG BASE/ML A075455 001 Jun 20, 2000

HOSPIRA EQ 1MG BASE/ML A075396 001 Jun 20, 2000

EQ 5MG BASE/ML A075396 002 Jun 20, 2000

EQ 5MG BASE/ML A075484 001 Jun 20, 2000

HOSPIRA INC EQ 1MG BASE/ML A075409 002 Jun 20, 2000

EQ 5MG BASE/ML A075409 001 Jun 20, 2000

IGI LABS INC EQ 5MG BASE/ML A075263 001 Jun 26, 2000

INTL MEDICATED EQ 1MG BASE/ML A076144 001 Jan 26, 2005

EQ 5MG BASE/ML A076144 002 Jan 26, 2005

INTL MEDICATION EQ 1MG BASE/ML A076020 001 Jul 16, 2004

EQ 5MG BASE/ML A076020 002 Jul 16, 2004

WOCKHARDT EQ 1MG BASE/ML A078141 001 May 30, 2008

EQ 1MG BASE/ML A078511 001 Nov 10, 2008

EQ 5MG BASE/ML A078141 002 May 30, 2008

EQ 5MG BASE/ML A078511 002 Nov 10, 2008

MIDOZALAM HYDROCHLORIDE

MYLAN ASI

EQ 1MG BASE/ML A090316 001 May 04, 2011

EQ 5MG BASE/ML A090316 002 May 04, 2011

VERSED

+ HLR EQ 1MG BASE/ML **

N018654 002 May 26, 1987

+ EQ 5MG BASE/ML **

N018654 001 Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

PHARM ASSOC

EQ 2MG BASE/ML A077115 001 Sep 09, 2005

SUN PHARM INDS LTD

EQ 2MG BASE/ML A076058 001 Mar 15, 2002

VERSED

+ ROCHE EQ 2MG BASE/ML **

N020942 001 Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

CASI PHARMS INC

2.5MG A076514 001 Sep 11, 2003

5MG A076514 002 Sep 11, 2003

10MG A076514 003 Jul 02, 2004

PROAMATINE

+ SHIRE LLC 2.5MG **

N019815 001 Sep 06, 1996

+ 5MG **

N019815 002 Sep 06, 1996

+ 10MG **

N019815 003 Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS

12.5MG A205081 001 Apr 22, 2016

25MG A205081 002 Apr 22, 2016

50MG A205081 003 Apr 22, 2016

100MG A205081 004 Apr 22, 2016

USPHARMA WINDLAS

12.5MG A205071 001 Jan 27, 2016

25MG A205071 002 Jan 27, 2016

50MG A205071 003 Jan 27, 2016

100MG A205071 004 Jan 27, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
	EQ 1MG BASE/ML	A075884	001	May 28, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075852	001	May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005

PRIMACOR

+ SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987
---------------------	-------------------	---------	-----	--------------

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+	EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994
	**			
+	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994
	**			

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

+ BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
TRIAx PHARMS	EQ 50MG BASE	N050315	002	
	EQ 100MG BASE	N050315	001	

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

SUN PHARM INDS INC	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
	EQ 112.5MG BASE	N201922	004	Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
---------	--------------------	---------	-----	--

SUSPENSION; ORAL

MINOCIN

BAUSCH	EQ 50MG BASE/5ML	N050445	001	
--------	------------------	---------	-----	--

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

+ TRIAX PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+	EQ 100MG BASE **	N050451	002	Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009
	EQ 90MG BASE	A065485	002	Mar 17, 2009
	EQ 135MG BASE	A065485	003	Mar 17, 2009
IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
	EQ 90MG BASE	A090024	002	Feb 03, 2009
	EQ 135MG BASE	A090024	003	Feb 03, 2009
MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019
MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019
	EQ 115MG BASE	A201467	002	Jul 30, 2019
MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
	EQ 90MG BASE	A090911	002	Jul 20, 2010
	EQ 135MG BASE	A090911	003	Jul 20, 2010

SOLODYN

+ MEDICIS	EQ 45MG BASE **	N050808	001	May 08, 2006
+	EQ 90MG BASE **	N050808	002	May 08, 2006
+	EQ 135MG BASE **	N050808	003	May 08, 2006

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924	001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPLY PHARM	2%	A074500	001	May 23, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR WOMEN)

APOTEX INC	2%	A074924	002	Apr 29, 1998
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001
------------	----	---------	-----	--------------

TABLET; ORAL

LONITEN

+ PHARMACIA AND UPJOHN	2.5MG **	N018154	001	
+	10MG **	N018154	003	

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+ KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013
----------------------	---------------------	---------	-----	--------------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003
	30MG	A076176	002	Jun 19, 2003
	45MG	A076176	003	Jun 19, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003
WATSON LABS	15MG	A076312	001	Jun 19, 2003
	30MG	A076312	002	Jun 19, 2003
	45MG	A076312	003	Jun 19, 2003

REMERON

+ ORGANON USA INC	45MG **	N020415	003	Mar 17, 1997
-------------------	---------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011
ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
	30MG	A076307	002	Dec 17, 2003
	45MG	A076307	003	Feb 28, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

ANI PHARMS INC	0.1MG	A076095 001	Jul 10, 2002
	0.2MG	A076095 002	Jul 10, 2002
ZYDUS PHARMS	0.1MG	A210201 001	Jul 02, 2019
	0.2MG	A210201 002	Jul 02, 2019

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106 001	Nov 29, 1995
WEST-WARD PHARMS INT	5MG/VIAL	A064117 001	Apr 19, 1995
MITOZYTREX			
+ SUPERGEN	5MG/VIAL **	N050763 001	Nov 14, 2002
MUTAMYCIN			
+ BRISTOL	5MG/VIAL **	N050450 001	
+ BRISTOL MYERS	20MG/VIAL **	N050450 002	
	5MG/VIAL	A062336 001	
	20MG/VIAL	A062336 002	
	40MG/VIAL	A062336 003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008
MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980 001	Apr 13, 2009
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980 002	Apr 13, 2009
MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012
NOVANTRONE			
+ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987
+ EMD SERONO	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297 002	Dec 23, 1987
+ EMD SERONO	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297 003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992

MIVACURIUM CHLORIDE

MYLAN LABS LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009
----------------	----------------	-------------	--------------

SOLUTION; INTRAVENOUS

MIVACRON

+ ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098 001	Jan 22, 1992
+ ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098 004	Jan 22, 1992
+ ABBVIE	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098 005	Jan 22, 1992

MODAFINIL

TABLET; ORAL

MODAFINIL

HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012
	200MG	A090543 002	Sep 26, 2012

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIVASC

UCB INC	7.5MG **	N020312 001	Apr 19, 1995
	15MG **	N020312 002	Apr 19, 1995

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

+ ENDO PHARMS	5MG **	N017111 001	
+ ENDO PHARMS	10MG **	N017111 002	
+ ENDO PHARMS	25MG **	N017111 003	

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS	20MG/ML	N017938 001	
-------------	---------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOBAN

+	ENDO PHARMS	5MG **	N017111 004
+		10MG **	N017111 005
+		25MG **	N017111 006
+		50MG **	N017111 007
+		100MG **	N017111 008

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987
+		0.1%	N019625 002	Apr 19, 2013

OINTMENT; TOPICAL

ELOCON

+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987
---	-------------------	------	-------------	--------------

MOMETASONE FUROATE

	TARO	0.1%	A076624 001	Dec 03, 2004
--	------	------	-------------	--------------

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

	VALEANT PHARM INTL	20%	N008173 003
--	--------------------	-----	-------------

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

	ETHITEK	100%	N019368 001	Oct 29, 1985
--	---------	------	-------------	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

	MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776 001	Dec 18, 2012
--	------------------	--------------------	-------------	--------------

TABLET; ORAL

MONTELUKAST SODIUM

	APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012
--	-------------	--------------	-------------	--------------

	MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012
--	------------------	--------------	-------------	--------------

	VINTAGE PHARMS LLC	EQ 10MG BASE	A091576 001	Aug 03, 2012
--	--------------------	--------------	-------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

	APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012
--	------------	-------------	-------------	--------------

		EQ 5MG BASE	A201508 002	Aug 03, 2012
--	--	-------------	-------------	--------------

	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012
--	------------------	-------------	-------------	--------------

		EQ 5MG BASE	A079142 002	Aug 03, 2012
--	--	-------------	-------------	--------------

	VINTAGE PHARMS LLC	EQ 4MG BASE	A091588 001	Aug 03, 2012
--	--------------------	-------------	-------------	--------------

		EQ 5MG BASE	A091588 002	Aug 03, 2012
--	--	-------------	-------------	--------------

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

	SHIRE	200MG	N019753 001	Jun 19, 1990
--	-------	-------	-------------	--------------

		250MG	N019753 002	Jun 19, 1990
--	--	-------	-------------	--------------

		300MG	N019753 003	Jun 19, 1990
--	--	-------	-------------	--------------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

	KING PHARMS LLC	30MG	N021260 001	Mar 20, 2002
--	-----------------	------	-------------	--------------

		45MG	N021260 005	Dec 18, 2008
--	--	------	-------------	--------------

		60MG	N021260 002	Mar 20, 2002
--	--	------	-------------	--------------

		75MG	N021260 006	Dec 18, 2008
--	--	------	-------------	--------------

		90MG	N021260 003	Mar 20, 2002
--	--	------	-------------	--------------

		120MG	N021260 004	Mar 20, 2002
--	--	-------	-------------	--------------

INJECTABLE; INJECTION

ASTRAMORPH PF

	FRESENIUS KABI USA	0.5MG/ML	A071050 001	Oct 07, 1986
--	--------------------	----------	-------------	--------------

		0.5MG/ML	A071051 001	Oct 07, 1986
--	--	----------	-------------	--------------

		1MG/ML	A071052 001	Oct 07, 1986
--	--	--------	-------------	--------------

		1MG/ML	A071053 001	Oct 07, 1986
--	--	--------	-------------	--------------

MORPHINE SULFATE

+	HOSPIRA INC	15MG/ML	N202515 005	Nov 14, 2011
---	-------------	---------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

ICU MEDICAL INC	0.5MG/ML	N019917 001	Oct 30, 1992
+	5MG/ML	N019916 002	Oct 27, 2006
SPECGX LLC	1MG/ML	N020631 001	Jul 03, 1996
	2MG/ML	N020631 002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373 001	Sep 30, 1991
	0.5MG/ML	A073375 001	Sep 30, 1991
	1MG/ML	A073374 001	Sep 30, 1991
	1MG/ML	A073376 001	Sep 30, 1991

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671 003	May 18, 2004

SOLUTION; ORAL

MORPHINE SULFATE

LANNETT CO INC	10MG/5ML	A202309 001	Nov 25, 2015
	20MG/5ML	A202310 001	Oct 30, 2015
	100MG/5ML	N201517 001	Jun 23, 2011
VISTAPHARM	10MG/5ML	A201947 001	Jan 05, 2012
	20MG/5ML	A201947 002	Jan 05, 2012

TABLET, EXTENDED RELEASE; ORAL

ARYMO ER

+	ZYLA	15MG	N208603 001	Jan 09, 2017
+		30MG	N208603 002	Jan 09, 2017
+		60MG	N208603 003	Jan 09, 2017

MORPHINE SULFATE

EPIC PHARMA LLC	15MG	A091357 001	Jun 23, 2016
	30MG	A091357 002	Jun 23, 2016
	60MG	A091357 003	Jun 23, 2016
	100MG	A091357 004	Jun 23, 2016
	200MG	A091357 005	Jun 23, 2016
MYLAN PHARMS INC	15MG	A200824 001	Oct 18, 2011
	30MG	A200824 002	Oct 18, 2011
	60MG	A200824 003	Oct 18, 2011
	100MG	A200824 004	Oct 18, 2011
	200MG	A200824 005	Oct 18, 2011
SUN PHARM INDUSTRIES	15MG	A205634 001	Aug 25, 2016
	30MG	A205634 002	Aug 25, 2016
	60MG	A205634 003	Aug 25, 2016
	100MG	A205634 004	Aug 25, 2016
	200MG	A205634 005	Aug 25, 2016
WATSON LABS	100MG	A075656 001	Jan 30, 2001
ORAMORPH SR			
XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994
	30MG	N019977 001	Aug 15, 1991
	60MG	N019977 002	Aug 15, 1991
	100MG	N019977 003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

+	ALPHARMA PHARMS	20MG; 0.8MG	N022321 001	Aug 13, 2009
+		30MG; 1.2MG	N022321 002	Aug 13, 2009
+		50MG; 2MG	N022321 003	Aug 13, 2009
+		60MG; 2.4MG	N022321 004	Aug 13, 2009
+		80MG; 3.2MG	N022321 005	Aug 13, 2009
+		100MG; 4MG	N022321 006	Aug 13, 2009

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY	EQ 250MG BASE/VIAL	N050550 001
	EQ 500MG BASE/VIAL	N050550 002
	EQ 1GM BASE/VIAL	N050550 003
	EQ 2GM BASE/VIAL	N050550 004
	EQ 10GM BASE/VIAL	N050550 008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 400MG/250ML (1.6MG/ML) ** N021277 001 Nov 30, 2001

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

MYLAN EQ 400MG BASE A204635 001 Aug 31, 2015

SUNSHINE LAKE EQ 400MG BASE A206295 001 Sep 28, 2018

MUPIROICIN

OINTMENT;TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE 2% ** N050591 001 Dec 31, 1987

MUPIROICIN CALCIUM

CREAM;TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE ** N050746 001 Dec 11, 1997

OINTMENT;NASAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE N050703 001 Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

APOTEX CORP 250MG A090419 001 Apr 22, 2009

DR REDDYS LABS LTD 250MG A091315 001 Oct 27, 2011

JUBILANT CADISTA 250MG A090762 001 Dec 15, 2014

ZYDUS PHARMS USA INC 250MG A065433 001 May 04, 2009

TABLET;ORAL

MYCOPHENOLATE MOFETIL

APOTEX 500MG A090499 001 Apr 22, 2009

DR REDDYS LABS LTD 500MG A090464 001 Sep 13, 2010

JUBILANT CADISTA 500MG A090661 001 Dec 15, 2014

OXFORD PHARMS 500MG A090606 001 Jul 16, 2010

TEVA PHARMS 500MG A065457 001 May 04, 2009

ZYDUS PHARMS USA INC 500MG A065477 001 May 04, 2009

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM 750MG A075179 001 Jun 06, 2000

OXFORD PHARMS 500MG A079093 001 Feb 27, 2009

750MG A079093 002 Feb 27, 2009

SANDOZ 500MG A075590 001 Feb 25, 2002

750MG A075590 002 Feb 25, 2002

RELAFEN

+ SMITHKLINE BEECHAM 500MG ** N019583 001 Dec 24, 1991

+ 750MG ** N019583 002 Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

US WORLDMEDS LLC 120MG N018063 003

160MG N018063 004

NADOLOL

HERITAGE PHARMA 120MG A074255 002 Jan 24, 1996

160MG A074255 003 Jan 24, 1996

TEVA PHARMS 80MG A074368 001 Aug 31, 1994

120MG A074368 002 Aug 31, 1994

160MG A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE N050111 001

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE/5ML N050199 001

INJECTABLE;INJECTION

NAFCILLIN SODIUM

APOTHECON EQ 500MG BASE/VIAL A061984 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

	EQ 1GM BASE/VIAL	A061984 002	
	EQ 2GM BASE/VIAL	A061984 003	
	EQ 4GM BASE/VIAL	A061984 005	
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002 001	Apr 07, 2014
	EQ 2GM BASE/VIAL	A200002 002	Apr 07, 2014
SANDOZ	EQ 500MG BASE/VIAL	A062527 001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844 001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844 002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844 003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844 004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844 005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008 001	Sep 29, 1988
NALLPEN			
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999 001	
	EQ 1GM BASE/VIAL	A061999 002	
	EQ 1GM BASE/VIAL	A062755 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999 003	
	EQ 2GM BASE/VIAL	A062755 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999 004	
UNIPEN			
WYETH AYERST	EQ 500MG BASE/VIAL **	A062717 001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320 001	
	EQ 1GM BASE/VIAL **	A062717 002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717 004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320 003	
+	EQ 4GM BASE/VIAL **	N050320 004	
+	EQ 10GM BASE/VIAL **	N050320 005	
+	EQ 20GM BASE/VIAL **	N050320 006	
UNIPEN IN PLASTIC CONTAINER			
+	WYETH AYERST EQ 1GM BASE/VIAL **	N050320 002	
TABLET; ORAL			
UNIPEN			
WYETH AYERST	EQ 500MG BASE	N050462 001	

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	SEBELA IRELAND LTD	1%	N019599 001	Feb 29, 1988
GEL; TOPICAL				
NAFTIFINE HYDROCHLORIDE				
TARO	2%	A208201 001	Apr 10, 2019	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751 001	Jul 02, 1986	
	20MG/ML	A070752 001	Sep 24, 1986	
NALBUPHINE HYDROCHLORIDE				
ABBOTT	20MG/ML	A070917 001	Feb 03, 1989	
ABBVIE	1.5MG/ML	N020200 001	Mar 12, 1993	
DR REDDYS	10MG/ML	A074471 001	Mar 19, 1998	
	20MG/ML	A074471 002	Mar 19, 1998	
IGI LABS INC	10MG/ML	A072070 001	Apr 10, 1989	
	10MG/ML	A072071 001	Apr 10, 1989	
	10MG/ML	A072072 001	Apr 10, 1989	
	20MG/ML	A072073 001	Apr 10, 1989	
	20MG/ML	A072074 001	Apr 10, 1989	
	20MG/ML	A072075 001	Apr 10, 1989	
NUBAIN				
+	PAR PHARM INC	10MG/ML **	N018024 001	
+		20MG/ML **	N018024 002	May 27, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US 250MG/5ML N017430 001

TABLET; ORAL

NALIDIXIC ACID

SUN PHARM INDUSTRIES 250MG A070270 001 Jun 29, 1988

500MG A070271 001 Jun 29, 1988

1GM A070272 001 Jun 29, 1988

WATSON LABS 250MG A071936 001 Jun 29, 1988

500MG A072061 001 Jun 29, 1988

1GM A071919 001 Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US 250MG N014214 002

500MG N014214 004

1GM N014214 005

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+ EUROHLTH INTL SARL EQ 0.1MG BASE/ML ** N020459 001 Apr 17, 1995

+ EQ 1MG BASE/ML ** N020459 002 Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

WEST-WARD PHARMS INT 0.4MG/ML A070298 001 Sep 24, 1986

0.4MG/ML A070496 001 Sep 24, 1986

WYETH AYERST 0.02MG/ML A070188 001 Sep 24, 1986

0.02MG/ML A070189 001 Sep 24, 1986

0.4MG/ML A070190 001 Sep 24, 1986

0.4MG/ML A070191 001 Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM 0.02MG/ML A070648 001 Nov 17, 1986

0.02MG/ML A070661 001 Nov 17, 1986

0.4MG/ML A070649 001 Nov 17, 1986

1MG/ML A071604 001 Dec 16, 1988

ASTRAZENECA 0.02MG/ML A072081 001 Apr 11, 1989

EUROHLTH INTL SARL 0.02MG/ML A071272 001 May 24, 1988

1MG/ML A071273 001 May 24, 1988

1MG/ML A071274 001 May 24, 1988

1MG/ML A071287 001 May 24, 1988

HOSPIRA 0.02MG/ML A070171 001 Sep 24, 1986

0.02MG/ML A070252 001 Jan 16, 1987

0.02MG/ML A070253 001 Jan 16, 1987

0.4MG/ML A070255 001 Jan 07, 1987

IGI LABS INC 0.02MG/ML A072082 001 Apr 11, 1989

0.02MG/ML A072083 001 Apr 11, 1989

0.02MG/ML A072084 001 Apr 11, 1989

0.02MG/ML A072085 001 Apr 11, 1989

0.4MG/ML A072086 001 Apr 11, 1989

0.4MG/ML A072087 001 Apr 11, 1989

0.4MG/ML A072088 001 Apr 11, 1989

0.4MG/ML A072089 001 Apr 11, 1989

0.4MG/ML A072090 001 Apr 11, 1989

1MG/ML A072091 001 Apr 11, 1989

1MG/ML A072092 001 Apr 11, 1989

1MG/ML A072093 001 Apr 11, 1989

INTL MEDICATION 0.4MG/ML A070417 001 Sep 24, 1986

1MG/ML A072115 001 Apr 27, 1988

MARSAM PHARMS LLC 0.4MG/ML A071811 001 Jul 19, 1988

SMITH AND NEPHEW 0.02MG/ML A071671 001 Nov 17, 1987

0.4MG/ML A071681 001 Nov 17, 1987

0.4MG/ML A071682 001 Nov 17, 1987

SOLOPAK 0.02MG/ML A071672 001 Nov 17, 1987

0.4MG/ML A071683 001 Nov 17, 1987

VIRTUS PHARMS 0.4MG/ML A207846 001 Dec 17, 2018

WATSON LABS 0.4MG/ML A071339 001 Nov 18, 1987

NARCAN

+ ADAPT 0.02MG/ML ** N016636 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NARCAN

+		0.4MG/ML **	N016636	001	
+		1MG/ML **	N016636	003	Jun 14, 1982
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
---	-----------	---------------------------	---------	-----	--------------

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019
--	-----------------	-----------	---------	-----	--------------

NARCAN

+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017
---	-------	-----------	---------	-----	--------------

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

+	PURDUE PHARMA LP	5MG; 10MG	N205777	001	Jul 23, 2014
+		10MG; 20MG	N205777	002	Jul 23, 2014
+		20MG; 40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

	SANOFI AVENTIS US	EQ 0.5MG BASE; EQ 50MG BASE **	N018733	001	Dec 16, 1982
--	-------------------	--------------------------------	---------	-----	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000
--	--------------	------	---------	-----	--------------

REVIA

	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984
--	-------------	------	---------	-----	--------------

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROXYCA ER

	PFIZER INC	1.2MG; 10MG	N207621	001	Aug 19, 2016
		2.4MG; 20MG	N207621	002	Aug 19, 2016
		3.6MG; 30MG	N207621	003	Aug 19, 2016
		4.8MG; 40MG	N207621	004	Aug 19, 2016
		7.2MG; 60MG	N207621	005	Aug 19, 2016
		9.6MG; 80MG	N207621	006	Aug 19, 2016

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

	ASPEN GLOBAL INC	50MG/ML	N013132	001	Jun 12, 1986
		100MG/ML	N013132	002	Jun 12, 1986
+		200MG/ML **	N013132	003	Jun 12, 1986

NANDROLONE DECANOATE

	ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
		200MG/ML	A088317	001	Oct 14, 1983
	AKORN	100MG/ML	A087519	001	Sep 28, 1983
	LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010
	WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
		50MG/ML	A087598	001	Oct 06, 1983
		50MG/ML	A088554	001	Feb 10, 1986
		100MG/ML	A086598	001	Jan 13, 1984
		100MG/ML	A087599	001	Oct 06, 1983
		200MG/ML	A088128	001	Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

	ORGANON USA INC	25MG/ML	N011891	001	
		50MG/ML	N011891	002	

NANDROLONE PHENPROPIONATE

	WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
		50MG/ML	A087488	001	Jun 17, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON

ALLERGAN	0.1% **	A080248	001	
NAFAZAIR				
BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
AKORN INC	0.1%	A083590	001	
NAPHCN FORTE				
ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983

NAPROXEN

TABLET;ORAL

NAPROSYN

+ ATNAHS PHARMA US	250MG	N017581	002	
+	375MG	N017581	003	

NAPROXEN

CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993
	375MG	A074140	002	Dec 21, 1993
	500MG	A074140	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995
WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001
	500MG	A075390 002	Apr 19, 2001

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

+ ATNAHS PHARMA US

EQ 250MG BASE **

N018164 001

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
CONTRACT PHARMACAL	220MG	A074789 001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE	A074106 001	Aug 31, 1993
	EQ 500MG BASE	A074106 002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480 002	Feb 18, 1998
	EQ 500MG BASE	A074480 001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230 001	Mar 14, 1995
	EQ 500MG BASE	A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367 001	Aug 31, 1994
	EQ 500MG BASE	A074367 002	Aug 31, 1994
PLD ACQUISITIONS LLC	220MG	A074646 001	Jan 13, 1997
PLIVA	EQ 250MG BASE	A074242 001	Jun 20, 1996
	EQ 500MG BASE	A074242 002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319 001	Mar 20, 1995
	EQ 500MG BASE	A074319 002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257 001	Dec 21, 1993
	EQ 500MG BASE	A074257 002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

+ CURRAX

60MG;EQ 10MG BASE

N021926 002 May 14, 2015

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

ANI PHARMS INC	EQ 1MG BASE	A078751 001	Jul 07, 2010
	EQ 2.5MG BASE	A078751 002	Jul 07, 2010
APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011
	EQ 2.5MG BASE	A091373 002	Apr 22, 2011
CASI PHARMS INC	EQ 1MG BASE	A090288 001	Jul 07, 2010
	EQ 2.5MG BASE	A090288 002	Jul 07, 2010
MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012
	EQ 2.5MG BASE	A202431 002	May 31, 2012

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009
STARLIX			
+ NOVARTIS	60MG	N021204 001	Dec 22, 2000
+	120MG	N021204 002	Dec 22, 2000

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741 001	Jun 24, 2015
	EQ 5MG BASE	A203741 002	Jun 24, 2015
	EQ 10MG BASE	A203741 003	Jun 24, 2015
	EQ 20MG BASE	A203741 004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659 001	Apr 16, 2015
	EQ 5MG BASE	A203659 002	Apr 16, 2015
	EQ 10MG BASE	A203659 003	Apr 16, 2015
	EQ 20MG BASE	A203659 004	Apr 16, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821 001	May 25, 2017
	EQ 5MG BASE	A203821 002	May 25, 2017
	EQ 10MG BASE	A203821 003	May 25, 2017
	EQ 20MG BASE	A203821 004	May 25, 2017
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828 001	Jul 29, 2015
	EQ 5MG BASE	A203828 002	Jul 29, 2015
	EQ 10MG BASE	A203828 003	Jul 29, 2015
	EQ 20MG BASE	A203828 004	Jul 29, 2015
TORRENT	EQ 2.5MG BASE	A203966 001	Mar 02, 2018
	EQ 5MG BASE	A203966 002	Mar 02, 2018
	EQ 10MG BASE	A203966 003	Mar 02, 2018
	EQ 20MG BASE	A203966 004	Mar 02, 2018
WATSON LABS INC	EQ 2.5MG BASE	A203683 001	Nov 27, 2015
	EQ 5MG BASE	A203683 002	Nov 27, 2015
	EQ 10MG BASE	A203683 003	Nov 27, 2015
	EQ 20MG BASE	A203683 004	Nov 27, 2015

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+ ALLERGAN	EQ 5MG BASE;80MG	N206302 001	Jun 03, 2016
------------	------------------	-------------	--------------

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS LLC	1.75MG/INH	N019660 001	Dec 30, 1992
-----------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

ANI PHARMS INC	50MG	A076072 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
	100MG	A076309 002	Sep 16, 2003
	150MG	A076309 003	Sep 16, 2003
	200MG	A076309 004	Sep 16, 2003
	250MG	A076309 005	Sep 16, 2003
FOSUN PHARMA	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
+	BRISTOL MYERS SQUIBB 50MG **	N020152 001	Dec 22, 1994
+	100MG **	N020152 002	Dec 22, 1994
+	150MG **	N020152 003	Dec 22, 1994
+	200MG **	N020152 004	Dec 22, 1994
+	250MG **	N020152 005	Dec 22, 1994
+	300MG **	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
----------------	-----------------------	-------------	--------------

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
----------------------	--------------------	-------------	--

NEO-FRADIN

X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002
--------------	--------------------	-------------	--------------

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
----------------------	---------------	-------------	--

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475 001	
--------	---------------	-------------	--

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365 001	
----------------------	-------	-------------	--

LANNETT	500MG	A060607 001	
---------	-------	-------------	--

LANNETT CO INC	500MG	A204435 001	Jun 10, 2016
----------------	-------	-------------	--------------

LILLY	500MG	A060385 001	
-------	-------	-------------	--

ROXANE	500MG	A062173 001	
--------	-------	-------------	--

SANDOZ	500MG	A061586 001	
--------	-------	-------------	--

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050176 002	Jan 14, 1985
-----------------	-----------------------------------	-------------	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050344 002	
-------	-----------------------------------	-------------	--

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664 001	Apr 08, 1986
-------------	-----------------------------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML; 16,250 UNITS/ML	A062339 001	Nov 30, 1984
-------	-----------------------------------	-------------	--------------

	EQ 3.5MG BASE/ML; 16,250 UNITS/ML	N050456 001	
--	-----------------------------------	-------------	--

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE; 10,000 UNITS/ML; 0.5%	N050081 002	
----------	--------------------------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/GM;0.25%

A061039 002

EQ 3.5MG BASE/GM;0.5%

A061039 001

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/ML;0.25%

A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTRES A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1%

A062600 001 Jul 21, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1%

A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTRES A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1%

A062608 001 May 23, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1%

A062607 001 May 23, 1986

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS

NATRECOR

+ SCIOS LLC

1.5MG/VIAL

N020920 001 Aug 10, 2001

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

SCHERING EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

APOTEX INC 200MG

A203021 001 May 22, 2012

TECH ORGANIZED 200MG

A203176 001 May 22, 2012

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

APOTEX 400MG

A205258 001 Apr 03, 2014

CIPLA 400MG

A206448 001 Oct 15, 2015

MYLAN 100MG

A206271 001 Nov 09, 2015

TECH ORGANIZED 100MG

A207467 001 Jul 31, 2017

400MG

A207467 002 Jul 31, 2017

NIACIN

CAPSULE;ORAL

WAMPOCAP

MEDPOINTE PHARM HLC 500MG

N011073 003

TABLET;ORAL

NIACIN

EVERYLIFE 500MG

A083203 001

HALSEY 500MG

A083453 001

HIKMA PHARMS 500MG

A083718 001

IMPAX LABS 500MG

A083115 001

IVAX SUB TEVA PHARMS 500MG

A083180 001

MK LABS 500MG

A083525 001

PUREPAC PHARM 500MG

A083271 001

SANDOZ 500MG

A083306 001

TABLICAPS 500MG

A084237 001

WATSON LABS 500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIACIN

TABLET; ORAL

NICOLAR

SANOFI AVENTIS US 500MG A083823 001

TABLET, EXTENDED RELEASE; ORAL

NIACIN

YICHANG HUMANWELL 500MG A212017 001 Jun 10, 2019

750MG A212017 002 Jun 10, 2019

1GM A212017 003 Jun 10, 2019

NIASPAN

ABBVIE 375MG N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE 375MG; 500MG; 750MG N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS 15MG/5ML; 3.75MG/5ML; 600MG/5ML N008378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

CHIESI USA INC 20MG ** N019488 001 Dec 21, 1988

30MG ** N019488 002 Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

ANI PHARMS INC 20MG A074439 001 Dec 10, 1996

20MG A074540 001 Oct 28, 1996

20MG A074670 001 Oct 28, 1996

30MG A074439 002 Dec 10, 1996

30MG A074540 002 Oct 28, 1996

30MG A074670 002 Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

+ CHIESI USA INC 30MG ** N020005 001 Feb 21, 1992

+ 45MG ** N020005 002 Feb 21, 1992

+ 60MG ** N020005 003 Feb 21, 1992

INJECTABLE; INJECTION

CARDENE

+ CHIESI USA INC 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

LUITPOLD 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009

MYLAN INSTITUTIONAL 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009

NAVINTA LLC 25MG/10ML (2.5MG/ML) A090125 001 Nov 17, 2009

SUN PHARMA GLOBAL 25MG/10ML (2.5MG/ML) N078405 001 Nov 17, 2009

WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML) A078714 001 Dec 28, 2009

WOCKHARDT 25MG/10ML (2.5MG/ML) A090671 001 Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC 40MG/200ML (0.2MG/ML) N019734 005 Nov 07, 2008

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML) N022276 002 Apr 07, 2016

40MG/200ML (0.2MG/ML) N022276 003 Apr 07, 2016

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS 500MG N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS 15MG/16HR N020536 001 Jul 03, 1996

PROSTEP

AVEVA 11MG/24HR N019983 003 Dec 23, 1998

22MG/24HR N019983 004 Dec 23, 1998

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS EQ 2MG BASE
EQ 4MG BASEA076880 001 Feb 18, 2009
A077850 001 Feb 18, 2009

THRIVE

GLAXOSMITHKLINE CONS EQ 2MG BASE
EQ 4MG BASEA077658 001 Jun 19, 2007
A077656 001 Jun 19, 2007NIFEDIPINE

CAPSULE;ORAL

ADALAT

BAYER PHARMS 10MG
20MGN019478 001 Nov 27, 1985
N019478 002 Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ 10MG
20MGA072409 001 Jul 04, 1990
A073421 001 Jun 19, 1991

TEVA 10MG

A072651 001 Feb 19, 1992

PROCARDIA

+ PFIZER 20MG **

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL

AFEDITAB CR

WATSON LABS 60MG
WATSON LABS TEVA 30MGA075659 001 Oct 26, 2001
A075128 001 Mar 10, 2000

NIFEDIPINE

MARTEC USA LLC 90MG
MYLAN 30MGA075414 003 Mar 23, 2004
A075108 001 Dec 17, 1999

30MG

A090649 001 Jun 21, 2010

60MG

A090649 002 Jun 21, 2010

90MG

A090649 003 Jun 21, 2010

MYLAN LABS LTD 30MG

A090602 001 Sep 13, 2010

60MG

A090602 002 Sep 13, 2010

90MG

A090602 003 Sep 13, 2010

NILUTAMIDE

TABLET;ORAL

NILANDRON

CONCORDIA 50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

SUN PHARM INDS INC 30MG

A077067 001 Apr 17, 2007

NIMOTOP

+ BAYER PHARMS 30MG **

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

+ COVIS PHARMA BV 10MG **

N020356 001 Feb 02, 1995

+ 20MG **

N020356 002 Feb 02, 1995

+ 25.5MG **

N020356 006 Jan 02, 2008

+ 30MG **

N020356 003 Feb 02, 1995

+ 40MG **

N020356 004 Feb 02, 1995

NITRIC OXIDE

GAS; INHALATION

INOMAX

+ MALLINCKRODT HOSP 100PPM **

N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS 50MG
100MGA084326 001
A084326 002

TABLET;ORAL

FURADANTIN

PROCTER AND GAMBLE 50MG
100MGN008693 001
N008693 002

FURALAN

LANNETT 50MG
100MGA080017 001
A080017 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

ELKINS SINN	50MG	A080003	001
	100MG	A080003	002
IVAX SUB TEVA PHARMS	50MG	A080078	002
	100MG	A080078	001
SANDOZ	50MG	A080043	001
	100MG	A080043	002
WATSON LABS	50MG	A080447	001
	50MG	A085797	001
	100MG	A080447	002
	100MG	A085796	001
WHITEWORTH TOWN PLSN	100MG	A084085	002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001
--------------------	--------------------	---------	-----

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

INVATECH	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
MYLAN	50MG	A074967	001	Jul 09, 1997
	100MG	A074967	002	Jul 09, 1997
	100MG	A077025	001	Aug 18, 2004
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005
------------------	-----------	---------	-----	--------------

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE	0.2%	A083789	001
-------	------	---------	-----

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL	0.2%	N017343	001
----------------	------	---------	-----

OINTMENT; TOPICAL

FURACIN

SHIRE	0.2%	N005795	001
-------	------	---------	-----

NITROFURAZONE

AMBIX	0.2%	A086077	001
LANNETT	0.2%	A084393	001
PERRIGO NEW YORK	0.2%	A084968	001
TARO	0.2%	A086156	001
WENDT	0.2%	A086766	001

POWDER; TOPICAL

FURACIN

SHIRE	0.2%	A083791	001
-------	------	---------	-----

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001
WENDT	0.2%	A087081	001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
--------------	-------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996
VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996
	0.6MG/HR	A089774	001	Aug 30, 1996
VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996

NITROGLYCERIN

LANNETT CO INC	0.2MG/HR	A075115	001	Aug 10, 2004
	0.4MG/HR	A075115	002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
	0.2MG/HR	A074992	003	Nov 12, 1999
	0.4MG/HR	A074992	002	Nov 12, 1999
	0.6MG/HR	A074992	001	Nov 12, 1999

TRANSDERM-NITRO

+ NOVARTIS	0.1MG/HR **	N020144	001	Feb 27, 1996
+	0.2MG/HR **	N020144	002	Feb 27, 1996
+	0.4MG/HR **	N020144	003	Feb 27, 1996
+	0.6MG/HR **	N020144	004	Feb 27, 1996
+	0.8MG/HR **	N020144	005	Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
--------------	--------	---------	-----	--------------

NITRO-BID

SANOVI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
	10MG/ML	A071159	001	Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
+ HOSPIRA	5MG/ML **	N018531	001	
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
	10MG/100ML	A071846	001	Aug 31, 1990
	20MG/100ML	A071847	001	Aug 31, 1990
	40MG/100ML	A071848	001	Aug 31, 1990

NITROL

RORER	0.8MG/ML	N018774	001	Jan 19, 1983
-------	----------	---------	-----	--------------

NITRONAL

POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
--------------	--------	---------	-----	--------------

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987

TRIDIL

HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988

NIZATIDINE

ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002
	150MG	A075668	001	Sep 12, 2002
	300MG	A075461	002	Jul 08, 2002
	300MG	A075668	002	Sep 12, 2002
APOTEX INC	150MG	A076383	001	Jan 23, 2003
	300MG	A076383	002	Jan 23, 2003
MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
	300MG	A075934	002	Jul 09, 2002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NIZATIDINESOLUTION; ORAL
AXID

+ BRAINTREE 15MG/ML ** N021494 001 May 25, 2004

NONOXYNOL-9AEROSOL; VAGINAL
DELFIN

PERSONAL PRODS 12.5% N014349 002

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM EQ 1MG BASE/ML A040522 001 Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK EQ 0.033MG BASE/ML; 2%; 0.4% N008592 003

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS 5MG N010895 002

TABLET; ORAL-28

MICRONOR

+ JANSSEN PHARMS 0.35MG N016954 001

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

+ DURAMED RES 5MG ** N018405 001 Apr 21, 1982

NORETHINDRONE ACETATE

AUROBINDO PHARMA LTD 5MG A204236 001 Jan 08, 2016

NORLUTATE

PARKE DAVIS 5MG N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK 0.3% N019757 001 Jun 17, 1991

TABLET; ORAL

NOROXIN

+ MERCK 400MG ** N019384 002 Oct 31, 1986

NORGESTREL

TABLET; ORAL

OPILL

+ LABORATOIRE HRA 0.075MG N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY EQ 10MG BASE N014684 001

EQ 25MG BASE N014684 002

NORTRIPTYLINE HYDROCHLORIDE

ANI PHARMS INC EQ 10MG BASE A074054 001 Dec 31, 1992

EQ 25MG BASE A074054 002 Dec 31, 1992

EQ 50MG BASE A074054 003 Dec 31, 1992

EQ 75MG BASE A074054 004 Dec 31, 1992

AUROLIFE PHARMA LLC EQ 10MG BASE A074835 001 Jun 30, 1997

EQ 25MG BASE A074835 002 Jun 30, 1997

EQ 50MG BASE A074835 003 Jun 30, 1997

EQ 75MG BASE A074835 004 Jun 30, 1997

MYLAN EQ 10MG BASE A074234 001 Jul 26, 1993

EQ 25MG BASE A074234 002 Jul 26, 1993

EQ 50MG BASE A074234 003 Jul 26, 1993

EQ 75MG BASE A074234 004 Jul 26, 1993

TEVA EQ 10MG BASE A073667 001 Apr 11, 1996

EQ 25MG BASE A073667 002 Apr 11, 1996

EQ 50MG BASE A073667 003 Apr 11, 1996

EQ 75MG BASE A073667 004 Apr 11, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

AVENTYL

+ RANBAXY

EQ 10MG BASE/5ML **

N014685 001

PAMELOR

SPECGX LLC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

NYSTATIN

TARO

100,000 UNITS/GM

A062457 001 Jul 28, 1983

LOTION; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/ML

N050233 001

OINTMENT; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060571 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062731 001 Sep 22, 1986

NILSTAT

LEDERLE

100,000 UNITS/GM

A061444 001

PASTILLE; ORAL

MYCOSTATIN

DELCOR ASSET CORP

200,000 UNITS

N050619 001 Apr 09, 1987

POWDER; ORAL

BARSTATIN 100

BARLAN

100%

A062489 001 Apr 27, 1988

NILSTAT

+ DAVA PHARMS INC

100% **

N050576 001 Dec 22, 1983

NYSTATIN

PADDOCK LLC

100%

A062613 001 Nov 26, 1985

POWDER; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **

A060578 001

NYSTATIN

NESHER PHARMS

100,000 UNITS/GM

A065321 001 Aug 18, 2006

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT

100,000 UNITS

N050478 001

SUSPENSION; ORAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/ML

A061533 001

NILSTAT

+ GLENMARK GENERICS

100,000 UNITS/ML **

N050299 001

NYSTATIN

ACP NIMBLE

100,000 UNITS/ML

A062776 001 Dec 17, 1987

ALPHARMA US PHARMS

100,000 UNITS/ML

A062571 001 Oct 29, 1985

G AND W LABS INC

100,000 UNITS/ML

A062349 001 Jul 14, 1982

MORTON GROVE

100,000 UNITS/ML

A062835 001 Nov 19, 1987

PHARMADERM

100,000 UNITS/ML

A062518 001 Jul 06, 1984

PHARMAFAIR

100,000 UNITS/ML

A062541 001 Jan 16, 1985

SOCORRO

100,000 UNITS/ML

A062832 001 Dec 27, 1991

TEVA

100,000 UNITS/ML

A062670 001 Jun 18, 1987

NYSTEX

SAVAGE LABS

100,000 UNITS/ML

A062519 001 Jul 06, 1984

TABLET; ORAL

MYCOSTATIN

DELCOR ASSET CORP

500,000 UNITS

A060574 001

NILSTAT

LEDERLE

500,000 UNITS

A061151 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

NYSTATIN

TABLET; ORAL

NYSTATIN

QUANTUM PHARMICS	500,000 UNITS	A062525 001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065 001	
UPSHER SMITH LABS	500,000 UNITS	A062524 001	Nov 26, 1985
WATSON LABS	500,000 UNITS	A062402 001	Dec 16, 1982

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718 001	
----------------	---------------	-------------	--

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS	A060577 001	
-------------------	---------------	-------------	--

NILSTAT

LEDERLE	100,000 UNITS	A061325 001	
---------	---------------	-------------	--

NYSTATIN

FOUGERA	100,000 UNITS	A062459 001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS	A062615 001	Oct 17, 1985
PHARMADERM	100,000 UNITS	A062460 001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509 001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965 001	
TEVA	100,000 UNITS	A062502 001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176 001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCO-TRIA CET II

TEVA	100,000 UNITS/GM;0.1%	A061954 002	Sep 20, 1985
------	-----------------------	-------------	--------------

MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576 002	May 01, 1985
MYLAN	100,000 UNITS/GM;0.1% **	A062606 001	May 15, 1985

MYTrex F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597 001	Oct 08, 1985
-------------	-----------------------	-------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010 001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186 002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657 001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347 001	Mar 30, 1987

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596 001	Oct 08, 1985
------------	-----------------------	-------------	--------------

OINTMENT; TOPICAL

MYCO-TRIA CET II

TEVA	100,000 UNITS/GM;0.1%	A062045 002	Nov 26, 1985
------	-----------------------	-------------	--------------

MYCOLOG-II

MYLAN	100,000 UNITS/GM;0.1% **	A060572 001	Jun 28, 1985
-------	--------------------------	-------------	--------------

MYTrex F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601 001	Oct 09, 1985
-------------	-----------------------	-------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731 001	Dec 26, 2017
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280 002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656 001	Jul 30, 1986
ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764 001	Nov 08, 2018

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603 001	Oct 09, 1985
------------	-----------------------	-------------	--------------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

HERITAGE PHARMS INC	EQ 0.2MG BASE/ML	A203765 001	Sep 07, 2018
	EQ 1MG BASE/ML	A203765 002	Sep 07, 2018
SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329 001	Mar 04, 2008
	EQ 0.05MG BASE/ML	A077372 001	Aug 14, 2007
	EQ 0.1MG BASE/ML	A077329 002	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077372 002	Aug 14, 2007
	EQ 0.2MG BASE/ML	A077330 001	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077373 001	Aug 14, 2007
	EQ 0.5MG BASE/ML	A077329 003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372 003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331 001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373 002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	EQ 1MG BASE/ML	A090986 002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE			
WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985 002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985 003	May 11, 2011

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087 002	Mar 31, 1992
	40MG/ML	N020087 003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%			
ORTHO MCNEIL PHARM	400MG/100ML	N020087 001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
ORTHO MCNEIL PHARM	4MG/ML	N020087 004	Mar 31, 1992
	400MG/100ML	N020087 005	Mar 31, 1992

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

SANDOZ	0.3%	A076848 001	Nov 25, 2008
SANDOZ INC	0.3%	A076231 001	May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTIC

+ DAIICHI	0.3% **	N020799 001	Dec 16, 1997
OFLOXACIN			
ALVOGEN	0.3%	A090395 001	Aug 11, 2009
SANDOZ INC	0.3%	A078222 001	Mar 17, 2008

TABLET; ORAL

FLOXIN

JANSSEN PHARMS	200MG **	N019735 001	Dec 28, 1990
	300MG **	N019735 002	Dec 28, 1990
	400MG **	N019735 003	Dec 28, 1990
OFLOXACIN			
LARKEN LABS	200MG	A076093 001	Sep 02, 2003
	300MG	A076093 002	Sep 02, 2003
	400MG	A076093 003	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003
	300MG	A076220 002	Sep 02, 2003
	400MG	A076220 003	Sep 02, 2003

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AJANTA PHARMA LTD	2.5MG	A206711 001	Aug 30, 2016
	5MG	A206711 002	Aug 30, 2016
	7.5MG	A206711 003	Aug 30, 2016
	10MG	A206711 004	Aug 30, 2016
	15MG	A206711 005	Aug 30, 2016
	20MG	A206711 006	Aug 30, 2016
MYLAN	2.5MG	A076866 001	Apr 23, 2012
	5MG	A076866 002	Apr 23, 2012
	7.5MG	A076866 003	Apr 23, 2012
	10MG	A076866 004	Apr 23, 2012
	15MG	A076866 005	Apr 23, 2012
	20MG	A076866 006	Apr 23, 2012
SUNSHINE LAKE	2.5MG	A206238 001	Nov 19, 2018
	5MG	A206238 002	Nov 19, 2018
	7.5MG	A206238 003	Nov 19, 2018
	10MG	A206238 004	Nov 19, 2018
	15MG	A206238 005	Nov 19, 2018
	20MG	A206238 006	Nov 19, 2018

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AJANTA PHARMA LTD	5MG	A204320 001	May 30, 2017
	10MG	A204320 002	May 30, 2017
	15MG	A204320 003	May 30, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OLANZAPINETABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

	20MG	A204320 004	May 30, 2017
HEC PHARM	5MG	A208146 001	Jul 02, 2018
	10MG	A208146 002	Jul 02, 2018
	15MG	A208146 003	Jul 02, 2018
	20MG	A208146 004	Jul 02, 2018

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

TEVA PHARMS USA	5MG	A091079 001	Apr 24, 2017
	20MG	A091079 002	Apr 24, 2017
	40MG	A091079 003	Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

ZAMBON SPA	EQ 0.1% BASE	A204706 001	Dec 07, 2015
------------	--------------	-------------	--------------

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

+ ABBVIE INC	12.5MG;75MG;50MG	N207931 001	Jul 24, 2015
--------------	------------------	-------------	--------------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018 001	Jun 24, 2014
SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355 001	Jul 10, 2019
ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107 001	Jun 14, 2019

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

+ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977 001	Apr 23, 2014
------------	--	-------------	--------------

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+ ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060 001	May 05, 2014
----------------------	--	-------------	--------------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

LUPIN LTD	40MG	A202384 001	Aug 25, 2015
MYLAN	10MG	A075876 001	May 29, 2003
	40MG	A075876 003	Jan 21, 2009

PRILOSEC

+ ASTRAZENECA PHARMS	10MG **	N019810 003	Oct 05, 1995
	20MG **	N019810 001	Sep 14, 1989
	40MG **	N019810 002	Jan 15, 1998

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX	20MG	A210070 001	Feb 11, 2019
--------	------	-------------	--------------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM	20MG;1.1GM	A078966 001	May 25, 2010
	40MG;1.1GM	A078966 002	May 25, 2010

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

CHARTWELL MOLECULES	4MG	A077406 003	Dec 26, 2006
	8MG	A077406 004	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

NESHER PHARMS

4MG

A077717 001 Jun 25, 2007

8MG

A077717 002 Jun 25, 2007

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077368 001 Dec 26, 2006

HOSPIRA

EQ 2MG BASE/ML

A076695 001 Dec 26, 2006

LANNETT CO INC

EQ 2MG BASE/ML

A090116 001 Apr 14, 2010

EQ 2MG BASE/ML

A090883 001 Aug 05, 2010

LUITPOLD

EQ 2MG BASE/ML

A077582 001 Dec 26, 2006

EQ 2MG BASE/ML

A079039 001 Nov 18, 2008

MYLAN LABS LTD

EQ 2MG BASE/ML

A078257 001 Apr 23, 2008

PLIVA HRVATSKA DOO

EQ 2MG BASE/ML

A077544 001 Dec 26, 2006

SAGENT PHARMS

EQ 2MG BASE/ML

A078180 001 Mar 26, 2007

SUN PHARM INDS (IN)

EQ 2MG BASE/ML

A077172 001 Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.64MG BASE/ML

A076978 001 Feb 26, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC

EQ 2MG BASE/ML

A077343 001 Dec 26, 2006

HIKMA FARMACEUTICA

EQ 2MG BASE/ML

A076780 001 Dec 26, 2006

HOSPIRA

EQ 2MG BASE/ML

A076696 001 Dec 26, 2006

LUITPOLD

EQ 2MG BASE/ML

A077387 001 Dec 26, 2006

EQ 2MG BASE/ML

A079032 001 Nov 18, 2008

MYLAN LABS LTD

EQ 2MG BASE/ML

A078244 001 Apr 23, 2008

SUN PHARM INDS LTD

EQ 2MG BASE/ML

A077173 001 Dec 26, 2006

TARO PHARMS IRELAND

EQ 2MG BASE/ML

A078014 001 Mar 21, 2008

TEVA

EQ 2MG BASE/ML

A076759 001 Nov 22, 2006

ZOFRAN

+ NOVARTIS

EQ 2MG BASE/ML **

N020007 001 Jan 04, 1991

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE

EQ 0.64MG BASE/ML **

N020403 001 Jan 31, 1995

ZOFRAN PRESERVATIVE FREE

+ NOVARTIS

EQ 2MG BASE/ML **

N020007 003 Dec 10, 1993

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

CHARTWELL MOLECULES

EQ 4MG BASE

A077303 001 Jun 25, 2007

EQ 8MG BASE

A077303 002 Jun 25, 2007

EQ 24MG BASE

A077303 004 Jun 25, 2007

HIKMA INTL PHARMS

EQ 4MG BASE

A077545 001 Sep 06, 2007

EQ 8MG BASE

A077545 002 Sep 06, 2007

EQ 24MG BASE

A077545 003 Sep 06, 2007

MYLAN

EQ 24MG BASE

A076930 004 Jun 25, 2007

TARO

EQ 4MG BASE

A077729 001 Mar 28, 2011

EQ 8MG BASE

A077729 002 Mar 28, 2011

EQ 24MG BASE

A077729 003 Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ TELIGENT

30MG/ML

N013055 001

ORPHENADRINE CITRATE

WATSON LABS

30MG/ML

A087062 001

TABLET, EXTENDED RELEASE;ORAL

NORFLEX

+ MEDICIS

100MG

N012157 001

ORPHENADRINE CITRATE

ASCOT

100MG

A088067 001 Apr 06, 1983

SANDOZ

100MG

A085046 001

WATSON LABS

100MG

A084303 001

ORPHENADRINE HYDROCHLORIDE

TABLET;ORAL

DISIPAL

3M

50MG

N010653 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION;ORAL

TAMIFLU

ROCHE

EQ 12MG BASE/ML

N021246 001 Dec 14, 2000

OXACILLIN SODIUM

CAPSULE;ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A061336 001

EQ 250MG BASE

A062241 001

EQ 500MG BASE

A061336 002

EQ 500MG BASE

A062241 002

OXACILLIN SODIUM

ANI PHARMS INC

EQ 250MG BASE

A062222 001

EQ 500MG BASE

A062222 002

APOTHECON

EQ 250MG BASE

A061450 002

EQ 500MG BASE

A061450 001

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION;ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL **

A061334 009 Mar 26, 1982

EQ 1GM BASE/VIAL **

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL **

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL **

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL **

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL **

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL **

A061334 010

OXACILLIN SODIUM

+ APOTHECON

EQ 250MG BASE/VIAL **

N050195 001

+ APOTHECON

EQ 500MG BASE/VIAL **

N050195 002

+ APOTHECON

EQ 1GM BASE/VIAL **

N050195 003

+ APOTHECON

EQ 2GM BASE/VIAL **

N050195 004

+ APOTHECON

EQ 4GM BASE/VIAL **

N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

HOSPIRA INC

EQ 1GM BASE/VIAL

A203950 001 Dec 11, 2015

EQ 2GM BASE/VIAL

A203950 002 Dec 11, 2015

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

MYLAN LABS LTD

EQ 1GM BASE/VIAL

A091486 001 Aug 25, 2014

EQ 2GM BASE/VIAL

A091486 002 Aug 25, 2014

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

EQ 1GM BASE/VIAL

A061490 003

EQ 2GM BASE/VIAL

A061490 004

EQ 10GM BASE/VIAL

A061490 006 May 09, 1991

WATSON LABS INC

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXACILLIN SODIUM

POWDER; INTRAVENOUS

OXACILLIN SODIUM

SANDOZ

EQ 1GM BASE/VIAL

A062737 001 Dec 23, 1986

EQ 2GM BASE/VIAL

A062737 002 Dec 23, 1986

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ SANOFI AVENTIS US

50MG/VIAL **

N021492 001 Aug 09, 2002

+

100MG/VIAL **

N021492 002 Aug 09, 2002

+

200MG/40ML (5MG/ML) **

N021759 003 Nov 17, 2006

OXALIPLATIN

AM REGENT

50MG/10ML (5MG/ML)

A204378 001 May 12, 2017

100MG/20ML (5MG/ML)

A204378 002 May 12, 2017

FRESENIUS KABI ONCOL

50MG/VIAL

A078810 001 Aug 07, 2009

100MG/VIAL

A078810 002 Aug 07, 2009

HOSPIRA INC

50MG/VIAL

A078815 001 Sep 30, 2009

100MG/VIAL

A078815 002 Sep 30, 2009

MYLAN LABS LTD

50MG/VIAL

A200979 001 Aug 08, 2012

100MG/VIAL

A200979 002 Aug 08, 2012

200MG/40ML (5MG/ML)

A091358 003 Nov 14, 2017

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

SANDOZ INC

50MG/10ML (5MG/ML)

A078812 001 Aug 07, 2009

100MG/20ML (5MG/ML)

A078812 002 Aug 07, 2009

SUN PHARM

50MG/VIAL

A078818 001 Aug 07, 2009

50MG/10ML (5MG/ML)

A202922 001 Apr 08, 2014

100MG/VIAL

A078818 002 Aug 07, 2009

100MG/20ML (5MG/ML)

A202922 002 Apr 08, 2014

200MG/40ML (5MG/ML)

A202922 003 Feb 15, 2019

OXAMNIOUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDRIN

+ GEMINI LABS LLC

2.5MG

N013718 001

+

10MG

N013718 002 Nov 05, 2001

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH

600MG

A075843 001 Oct 03, 2001

BEXIMCO PHARMS USA

600MG

A075842 001 Apr 12, 2001

MYLAN

600MG

A075851 001 Aug 17, 2001

MYLAN PHARMS INC

600MG

A075847 001 Feb 28, 2001

SANDOZ

600MG

A075850 001 Apr 27, 2001

SUN PHARM INDS INC

600MG

A075844 001 Jan 03, 2002

WATSON LABS

600MG

A075848 001 Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE

600MG

N020776 001 Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP

10MG

A071955 001 Mar 03, 1988

15MG

A071956 001 Mar 03, 1988

30MG

A071957 001 Mar 03, 1988

FRONTIDA BIOPHARM

10MG

A071026 002 Aug 10, 1987

15MG

A071026 003 Aug 10, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

	30MG	A071026 001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943 001	Aug 03, 1987
	15MG	A070944 001	Aug 03, 1987
	30MG	A070945 001	Aug 03, 1987
MYLAN	10MG	A071713 001	Oct 20, 1987
	15MG	A071714 001	Oct 20, 1987
	30MG	A071715 001	Oct 20, 1987
WATSON LABS	15MG	A072953 001	Sep 28, 1990
	30MG	A072954 001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952 001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG **	N015539 002	
	15MG **	N015539 004	
	30MG **	N015539 006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650 001	Mar 01, 1988
	15MG	A070640 001	Mar 01, 1988
	30MG	A070641 001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

PARKE DAVIS	15MG	A071508 001	Feb 02, 1987
SUN PHARM INDUSTRIES	15MG	A070683 001	Jan 16, 1987
WATSON LABS	15MG	A071494 001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG **	N015539 008	
--------------------	---------	-------------	--

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS INC	150MG	A078005 001	Dec 11, 2007
	300MG	A078005 002	Dec 11, 2007
	600MG	A078005 003	Dec 11, 2007
JUBILANT CADISTA	150MG	A090239 001	Jan 25, 2010
	300MG	A090239 002	Jan 25, 2010
	600MG	A090239 003	Jan 25, 2010

OPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166 001	Dec 28, 1983
	40MG	N018166 002	Dec 28, 1983
	80MG	N018166 003	Dec 28, 1983
	160MG	N018166 004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268 012	Nov 27, 1984
-------------	-----------	-------------	--------------

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243 001	Dec 05, 1983
--------------	-----------	-------------	--------------

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268 011	
-------------	----------	-------------	--

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE	50MG/5ML	A088242 001	Dec 05, 1983
--------------	----------	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS	100MG	N009268 003	
	200MG	N009268 007	

OXTRIPHYLLINE

WATSON LABS	100MG	A087866 001	Aug 25, 1983
	200MG	A087835 001	Aug 25, 1983

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983
	600MG	A086742 001	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

BARR LABS DIV TEVA 3.9MG/24HR

A090526 001 Mar 04, 2014

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+ ALLERGAN 3%

N202513 001 Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

OXYBUTYNIN CHLORIDE

PAR PHARM INC 10% (100MG/PACKET)

A207329 001 May 31, 2018

SYRUP;ORAL

DITROPAN

+ ORTHO MCNEIL JANSSEN 5MG/5ML **

N018211 001

OXYBUTYNIN CHLORIDE

ANDA REPOSITORY 5MG/5ML

A075039 001 Jan 29, 1999

LANNETT CO INC 5MG/5ML

A076682 001 Dec 28, 2004

PHARM ASSOC 5MG/5ML

A074997 001 Oct 15, 1997

TABLET;ORAL

DITROPAN

+ JANSSEN PHARMS 5MG **

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS 5MG

A072296 001 Dec 08, 1988

USL PHARMA 5MG

A070746 001 Mar 10, 1988

WATSON LABS 5MG

A072485 001 Apr 19, 1989

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

+ JANSSEN PHARMS 15MG **

N020897 003 Jun 22, 1999

OXYBUTYNIN CHLORIDE

MYLAN 5MG

A076702 001 Nov 09, 2006

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

LANNETT CO INC 100MG/5ML

A204085 001 Sep 09, 2014

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

VINTAGE PHARMS 5MG

A077712 003 Mar 02, 2009

10MG

A077712 004 Apr 13, 2015

15MG

A077712 001 Jan 31, 2007

20MG

A077712 005 Apr 13, 2015

30MG

A077712 002 Jan 31, 2007

ROXYBOND

INSPIRION DELIVERY 5MG

N209777 001 Apr 20, 2017

15MG

N209777 002 Apr 20, 2017

30MG

N209777 003 Apr 20, 2017

TABLET, EXTENDED RELEASE;ORAL

ROXICODONE

ROXANE 10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC 0.025%

N018471 001 May 30, 1986

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

OPANA

+ ENDO PHARMS 1MG/ML

N011707 002

1.5MG/ML

N011707 001

SUPPOSITORY;RECTAL

NUMORPHAN

ENDO PHARMS 5MG

N011738 004

TABLET;ORAL

OPANA

+ ENDO PHARMS 5MG

N021611 001 Jun 22, 2006

+ 10MG

N021611 002 Jun 22, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

	ENDO PHARMS	5MG **	N021610 001	Jun 22, 2006
+		5MG	N201655 001	Dec 09, 2011
		7.5MG **	N021610 005	Feb 29, 2008
+		7.5MG	N201655 002	Dec 09, 2011
		10MG **	N021610 002	Jun 22, 2006
+		10MG	N201655 003	Dec 09, 2011
		15MG **	N021610 006	Feb 29, 2008
+		15MG	N201655 004	Dec 09, 2011
		20MG **	N021610 003	Jun 22, 2006
+		20MG	N201655 005	Dec 09, 2011
		30MG **	N021610 007	Feb 29, 2008
+		30MG	N201655 006	Dec 09, 2011
		40MG **	N021610 004	Jun 22, 2006
+		40MG	N201655 007	Dec 09, 2011

OXYMORPHONE HYDROCHLORIDE

PAR PHARM

		5MG	A200792 001	Oct 24, 2014
		7.5MG	A200792 002	Oct 24, 2014
		10MG	A200792 003	Oct 24, 2014
		15MG	A200792 004	Oct 24, 2014
		20MG	A200792 005	Oct 24, 2014
		30MG	A200792 006	Oct 24, 2014
		40MG	A200792 007	Oct 24, 2014
	SUN PHARM INDS LTD	5MG	A203506 001	Apr 24, 2015
		7.5MG	A203506 002	Apr 24, 2015
		10MG	A203506 003	Apr 24, 2015
		15MG	A203506 004	Apr 24, 2015
		20MG	A203506 005	Apr 24, 2015
		30MG	A203506 006	Apr 24, 2015
		40MG	A203506 007	Apr 24, 2015

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER	EQ 250MG BASE/VIAL	A060586 001
	EQ 500MG BASE/VIAL	A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015 001
-------------------	--------------------------------	-------------

OINTMENT; OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841 001
--------	--------------------------------	-------------

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001
--------	-----------------------------	-------------

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008
	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

+ ABBOTT	1USP UNITS/100ML **	N019185 004	Mar 29, 1985
----------	---------------------	-------------	--------------

+ ABBOTT	2USP UNITS/100ML **	N019185 003	Mar 29, 1985
----------	---------------------	-------------	--------------

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

+ ABBOTT	2USP UNITS/100ML **	N019185 002	Mar 29, 1985
----------	---------------------	-------------	--------------

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

+ ABBOTT	1USP UNITS/100ML **	N019185 001	Mar 29, 1985
----------	---------------------	-------------	--------------

SYNTOCINON

NOVARTIS	10USP UNITS/ML	N018245 001
----------	----------------	-------------

SOLUTION; NASAL

SYNTOCINON

RTRX	40USP UNITS/ML	N012285 001
------	----------------	-------------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
	6MG/ML	A205720 001	Aug 17, 2018
HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
MYLAN	6MG/ML	A075278 001	Jan 25, 2002
PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
SANDOZ INC	6MG/ML	A078167 001	Dec 26, 2007
TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002

TAXOL

+ HQ SPCLT PHARMA	6MG/ML	N020262 001	Dec 29, 1992
-------------------	--------	-------------	--------------

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

+ JANSSEN PHARMS	12MG **	N021999 004	Dec 19, 2006
------------------	---------	-------------	--------------

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

+ HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233 001	Aug 22, 2008
--------------------	------------------	-------------	--------------

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533 001	Apr 21, 2016
--------------------	---	-------------	--------------

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050 001	Mar 01, 2016
	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050 002	Mar 01, 2016

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

+	NOVARTIS	30MG/VIAL **	N020036 001	Oct 31, 1991
		60MG/VIAL	N020036 003	May 06, 1993
		90MG/VIAL	N020036 004	May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

		30MG/VIAL	A075594 001	May 06, 2002
		90MG/VIAL	A075594 002	May 06, 2002

LUITPOLD

		30MG/10ML (3MG/ML)	A078942 001	Jul 25, 2008
--	--	--------------------	-------------	--------------

		90MG/10ML (9MG/ML)	A078942 002	Jul 25, 2008
--	--	--------------------	-------------	--------------

MN PHARMS

		30MG/VIAL	A078300 001	Mar 10, 2009
--	--	-----------	-------------	--------------

		90MG/VIAL	A078300 002	Mar 10, 2009
--	--	-----------	-------------	--------------

SUN PHARMA GLOBAL

		30MG/VIAL	A077703 001	Dec 24, 2008
--	--	-----------	-------------	--------------

		90MG/VIAL	A077703 002	Dec 24, 2008
--	--	-----------	-------------	--------------

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

	ORGANON USA INC	30,000USP UNITS; 8,000USP UNITS; 30,000USP UNITS	N020580 001	Dec 09, 1996
--	-----------------	--	-------------	--------------

CAPSULE, DELAYED RELEASE; ORAL

ULTRESA

+	FOREST LABS INC	27,600USP UNITS; 13,800USP UNITS; 27,600USP UNITS	N022222 001	Mar 01, 2012
---	-----------------	---	-------------	--------------

+		41,400USP UNITS; 20,700USP UNITS; 41,400USP UNITS	N022222 002	Mar 01, 2012
---	--	---	-------------	--------------

+		46,000USP UNITS; 23,000USP UNITS; 46,000USP UNITS	N022222 003	Mar 01, 2012
---	--	---	-------------	--------------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN

		1MG/ML	A072058 001	Mar 23, 1988
--	--	--------	-------------	--------------

		2MG/ML	A072059 001	Mar 23, 1988
--	--	--------	-------------	--------------

		2MG/ML	A072060 001	Mar 23, 1988
--	--	--------	-------------	--------------

HOSPIRA

		2MG/ML	A072321 001	Jan 19, 1989
--	--	--------	-------------	--------------

IGI LABS INC

		1MG/ML	A072210 001	Mar 31, 1988
--	--	--------	-------------	--------------

		2MG/ML	A072211 001	Mar 31, 1988
--	--	--------	-------------	--------------

		2MG/ML	A072212 001	Mar 31, 1988
--	--	--------	-------------	--------------

		2MG/ML	A072213 001	Mar 31, 1988
--	--	--------	-------------	--------------

PAVULON

+	ORGANON USA INC	1MG/ML	N017015 002	
---	-----------------	--------	-------------	--

+		2MG/ML	N017015 001	
---	--	--------	-------------	--

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

MYLAN LABS LTD

		EQ 40MG BASE/VIAL	A208580 001	May 04, 2018
--	--	-------------------	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

SUN PHARM

		EQ 20MG BASE	A077058 001	Sep 10, 2007
--	--	--------------	-------------	--------------

		EQ 40MG BASE	A077058 002	Sep 10, 2007
--	--	--------------	-------------	--------------

SUN PHARM INDS LTD

		EQ 20MG BASE	A200794 001	May 02, 2012
--	--	--------------	-------------	--------------

		EQ 40MG BASE	A200794 002	May 02, 2012
--	--	--------------	-------------	--------------

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

		150MG	N006800 003	
--	--	-------	-------------	--

		300MG	N006800 001	
--	--	-------	-------------	--

SOLUTION; ORAL

PARADIONE

ABBVIE

		300MG/ML	N006800 002	
--	--	----------	-------------	--

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

		1MG	N012772 005	
--	--	-----	-------------	--

		2MG	N012772 006	
--	--	-----	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT	10MG	N013448 002
	25MG	N013448 003
	50MG	N013448 004

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

LOTUS PHARM CO LTD	1MCG	A206710 001	Feb 24, 2016
	2MCG	A206710 002	Feb 24, 2016
	4MCG	A206710 003	Feb 24, 2016

ZEMPLAR

+ ABBVIE	4MCG **	N021606 003	May 26, 2005
----------	---------	-------------	--------------

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER	EQ 250MG BASE	A062310 001
PARKE DALE	EQ 250MG BASE	A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522 001
-------------	-------------------	-------------

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

+ APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885 001	Oct 09, 1998
+	EQ 20MG BASE **	N020885 002	Oct 09, 1998
+	EQ 30MG BASE **	N020885 003	Oct 09, 1998
+	EQ 40MG BASE **	N020885 004	Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006
------------	------------------	-------------	--------------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004
	EQ 20MG BASE	A075716 002	Mar 08, 2004
	EQ 30MG BASE	A075716 003	Mar 08, 2004
	EQ 40MG BASE	A075716 004	Mar 08, 2004
ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007
	EQ 20MG BASE	A078026 002	Jun 29, 2007
	EQ 30MG BASE	A078026 003	Jun 29, 2007
	EQ 40MG BASE	A078026 004	Jun 29, 2007
SUN PHARM INDS INC	EQ 10MG BASE	A078194 001	Jun 29, 2007
	EQ 20MG BASE	A078194 002	Jun 29, 2007
	EQ 30MG BASE	A078194 003	Jun 29, 2007
	EQ 40MG BASE	A078194 004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007
	EQ 20MG BASE	A077082 002	Jun 29, 2007
	EQ 30MG BASE	A077082 003	Jun 29, 2007
	EQ 40MG BASE	A077082 004	Jun 29, 2007
UPSHER SMITH LABS	EQ 10MG BASE	A075566 001	Mar 08, 2004
	EQ 20MG BASE	A075566 002	Mar 08, 2004
	EQ 30MG BASE	A075566 003	Mar 08, 2004
	EQ 40MG BASE	A075566 004	Mar 08, 2004

PAXIL

APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031 004	Dec 29, 1992
---------------------	--------------	-------------	--------------

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

NOVARTIS	EQ 400MG BASE	N022465 002	Oct 19, 2009
----------	---------------	-------------	--------------

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ LEADIANT BIOSCI INC	250 UNITS/ML	N019818 001	Mar 21, 1990
-----------------------	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN	0.1%	N021079 001	Sep 24, 1999
--------	------	-------------	--------------

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT	18.75MG	N016832 001	
	37.5MG	N016832 002	
	75MG	N016832 003	

PEMOLINE

ACTAVIS ELIZABETH	18.75MG	A075595 001	Feb 28, 2000
	37.5MG	A075595 002	Feb 28, 2000
	75MG	A075595 003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286 001	Dec 27, 1999
	37.5MG	A075286 002	Jun 30, 1999
	75MG	A075286 003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726 003	Mar 30, 2001
	37.5MG	A075726 002	Mar 30, 2001
	75MG	A075726 001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030 003	Feb 22, 2000
	37.5MG	A075030 001	Jan 29, 1999
	75MG	A075030 002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328 001	Apr 19, 2000
	37.5MG	A075328 002	Apr 19, 2000
	75MG	A075328 003	Apr 19, 2000
WATSON LABS	18.75MG	A075287 001	Jun 13, 2001
	37.5MG	A075287 002	Sep 18, 2000
	75MG	A075287 003	Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT	37.5MG	N017703 001	
--------	--------	-------------	--

PEMOLINE

ACTAVIS ELIZABETH	37.5MG	A075678 001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555 001	Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

+ AUXILIUM PHARMS LLC	10MG **	N018976 001	Dec 30, 1987
+	20MG **	N018976 004	Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

VALEANT PHARMS INTL	125MG	N019853 002	
---------------------	-------	-------------	--

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

+ KING PHARMS LLC	300,000 UNITS/ML	N050141 003	
WYETH AYERST	300,000 UNITS/ML	N050131 001	

PERMAPEN

CASPER PHARMA LLC	600,000 UNITS/ML	N060014 001	
-------------------	------------------	-------------	--

SUSPENSION;ORAL

BICILLIN

WYETH AYERST	300,000 UNITS/5ML	N050126 002	
--------------	-------------------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G BENZATHINE

TABLET; ORAL

BICILLIN

WYETH AYERST 200,000 UNITS N050128 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS LLC 150,000 UNITS/ML; 150,000 UNITS/ML N050138 002

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN

TEVA 200,000 UNITS/5ML A060307 002

400,000 UNITS/5ML A060307 004

PENICILLIN G POTASSIUM

MYLAN 200,000 UNITS/5ML A060752 003

250,000 UNITS/5ML A060752 002

400,000 UNITS/5ML A060752 001

PUREPAC PHARM 250,000 UNITS/5ML A061740 001

400,000 UNITS/5ML A061740 002

PENICILLIN-2

TEVA 250,000 UNITS/5ML A060307 003

PENTIDS '200'

APOTHECON 200,000 UNITS/5ML A062149 001

PENTIDS '400'

APOTHECON 400,000 UNITS/5ML A062149 002

PFIZERPEN G

PFIZER 400,000 UNITS/5ML A060587 001

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON 1,000,000 UNITS/VIAL A060362 001

5,000,000 UNITS/VIAL A060362 003

10,000,000 UNITS/VIAL A060362 004

20,000,000 UNITS/VIAL A060362 002

CONSOLIDATED PHARM 500,000 UNITS/VIAL A060806 001

1,000,000 UNITS/VIAL A060806 002

5,000,000 UNITS/VIAL A060806 003

10,000,000 UNITS/VIAL A060806 004

LILLY 200,000 UNITS/VIAL A060384 004

500,000 UNITS/VIAL A060384 003

1,000,000 UNITS/VIAL A060384 002

5,000,000 UNITS/VIAL A060384 001

20,000,000 UNITS/VIAL A060384 005

20,000,000 UNITS/VIAL A060601 001

PARKE DAVIS 1,000,000 UNITS/VIAL A062003 001

5,000,000 UNITS/VIAL A062003 002

PFIZER 20,000,000 UNITS/VIAL A060074 003

SANDOZ 1,000,000 UNITS/VIAL ** A065079 001 Aug 30, 2002

WATSON LABS INC 1,000,000 UNITS/VIAL A062991 001 Sep 13, 1988

5,000,000 UNITS/VIAL A062991 002 Sep 13, 1988

10,000,000 UNITS/VIAL A062991 003 Sep 13, 1988

20,000,000 UNITS/VIAL A062991 004 Sep 13, 1988

PFIZERPEN

PFIZER 1,000,000 UNITS/VIAL ** A060657 001

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON 250,000 UNITS A060392 003

IVAX SUB TEVA PHARMS 400,000 UNITS A060073 004

LILLY 250,000 UNITS A060403 001

MYLAN 200,000 UNITS A060781 001

250,000 UNITS A060781 002

400,000 UNITS A060781 003

500,000 UNITS A060781 005

800,000 UNITS A060781 004

PUREPAC PHARM 200,000 UNITS A061588 001

250,000 UNITS A061588 002

400,000 UNITS A061588 003

TEVA 200,000 UNITS A060306 001

250,000 UNITS A060306 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN G POTASSIUM

TABLET;ORAL

PENICILLIN G POTASSIUM

	400,000 UNITS	A060306 003
	500,000 UNITS	A060306 004
WYETH AYERST	200,000 UNITS	A060413 001
	250,000 UNITS	A060413 002
	400,000 UNITS	A060413 003
PENTIDS '200'		
APOTHECON	200,000 UNITS	A062155 001
PENTIDS '250'		
APOTHECON	250,000 UNITS	A062155 002
PENTIDS '400'		
APOTHECON	400,000 UNITS	A060392 004
	400,000 UNITS	A062155 003
PENTIDS '800'		
APOTHECON	800,000 UNITS	A060392 005
	800,000 UNITS	A062155 004
PFIZERPEN G		
PFIZER	50,000 UNITS	A060075 001
	100,000 UNITS	A060075 002
	200,000 UNITS	A060075 003
	250,000 UNITS	A060075 004
	400,000 UNITS	A060075 005
	800,000 UNITS	A060075 006

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001
PENICILLIN G PROCAINE		
CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
	600,000 UNITS/1.2ML	A060800 002
PARKE DAVIS	300,000 UNITS/ML	A062029 001
PFIZER	300,000 UNITS/VIAL	A060099 001
	1,500,000 UNITS/VIAL	A060099 002
PFIZERPEN-AS		
PFIZER	300,000 UNITS/ML	A060286 001
	600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM

INJECTABLE;INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
COPANOS	5,000,000 UNITS/VIAL	A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001	Sep 13, 1988
-----------------	----------------------	-------------	--------------

PENICILLIN V

FOR SUSPENSION;ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002 001
-------	-------------	-------------

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001
	EQ 250MG BASE/5ML	A062270 002

BETAPEN-VK

APOTHECON	EQ 125MG BASE/5ML	A061149 001
	EQ 250MG BASE/5ML	A061149 002

LEDERCILLIN VK

LEDERLE	EQ 125MG BASE/5ML	A060136 001
	EQ 250MG BASE/5ML	A060136 002

PEN-VEE K

WYETH AYERST	EQ 125MG BASE/5ML	A060007 001
	EQ 250MG BASE/5ML	A060007 002

PENAPAR-VK

PARKE DAVIS	EQ 125MG BASE/5ML	A062002 001
-------------	-------------------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENAPAR-VK	EQ 250MG BASE/5ML	A062002 002
PENICILLIN V POTASSIUM		
AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061529 001
	EQ 250MG BASE/5ML	A061529 002
MYLAN	EQ 125MG BASE/5ML	A061624 002
	EQ 250MG BASE/5ML	A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061758 001
	EQ 250MG BASE/5ML	A061758 002
PFIZERPEN VK		
PFIZER	EQ 125MG BASE/5ML	A061815 001
	EQ 250MG BASE/5ML	A061815 002
V-CILLIN K		
LILLY	EQ 125MG BASE/5ML	A060004 001
	EQ 250MG BASE/5ML	A060004 002
VEETIDS		
APOTHECON	EQ 125MG BASE/5ML	A061410 001
	EQ 250MG BASE/5ML	A061410 002
VEETIDS '125'		
APOTHECON	EQ 125MG BASE/5ML	A061206 001
	EQ 125MG BASE/5ML	A062153 001
VEETIDS '250'		
APOTHECON	EQ 250MG BASE/5ML	A061206 002
	EQ 250MG BASE/5ML	A062153 002
TABLET;ORAL		
BEEPEN-VK		
GLAXOSMITHKLINE	EQ 250MG BASE	A062273 001
	EQ 500MG BASE	A062273 002
BETAPEN-VK		
BRISTOL	EQ 250MG BASE	A061150 001
	EQ 500MG BASE	A061150 002
LEDERCILLIN VK		
LEDERLE	EQ 250MG BASE	A060134 001
	EQ 500MG BASE	A060134 002
PEN-VEE K		
WYETH AYERST	EQ 125MG BASE	A060006 001
	EQ 250MG BASE	A060006 002
	EQ 500MG BASE	A060006 003
PENAPAR-VK		
PARKE DAVIS	EQ 250MG BASE	A062001 001
	EQ 500MG BASE	A062001 002
PENICILLIN V POTASSIUM		
AM ANTIBIOTICS	EQ 250MG BASE	A061528 001
	EQ 500MG BASE	A061528 002
IVAX SUB TEVA PHARMS	EQ 125MG BASE	A060518 001
	EQ 250MG BASE	A060518 002
	EQ 500MG BASE	A060518 003
MYLAN	EQ 250MG BASE	A061530 001
	EQ 500MG BASE	A061530 002
PUREPAC PHARM	EQ 125MG BASE	A061571 001
	EQ 250MG BASE	A061571 002
	EQ 500MG BASE	A061571 003
PFIZERPEN VK		
PFIZER	EQ 250MG BASE	A061836 001
	EQ 500MG BASE	A061836 002
UTICILLIN VK		
PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001
	EQ 500MG BASE	A061651 002
V-CILLIN K		
LILLY	EQ 125MG BASE **	A060003 001
	EQ 250MG BASE **	A060003 002
	EQ 500MG BASE **	A060003 003
VEETIDS		
APOTHECON	EQ 250MG BASE	A061411 001
	EQ 500MG BASE	A061411 002
VEETIDS '250'		
APOTHECON	EQ 250MG BASE	A061164 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENICILLIN V POTASSIUM

TABLET; ORAL

VEETIDS '250'

EQ 250MG BASE

A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE

A061164 002

EQ 500MG BASE

A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

+ WYETH AYERST

0.25MG/ML **

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA

600MG/VIAL

N019887 002 Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001 Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001 Jun 30, 1992

WATSON LABS

300MG/VIAL

A074303 001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N016194 001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

PENTOBARBITAL SODIUM

LANNETT

50MG

A085937 001

100MG

A085915 001

VITARINE

100MG

A083284 001

WHITEWORTH TOWN PLSN

100MG

A083338 001

SODIUM PENTOBARBITAL

ANABOLIC

100MG

A084590 001

ELKINS SINN

100MG

A083368 001

EVERYLIFE

100MG

A083259 001

HALSEY

100MG

A084677 001

IVAX SUB TEVA PHARMS

50MG

A083461 001

100MG

A083461 002

PARKE DAVIS

100MG

A084156 001

PERRIGO

100MG

A084560 001

PUREPAC PHARM

100MG

A083301 001

VALEANT PHARM INTL

100MG

A083264 001

WATSON LABS

100MG

A085791 001

WYETH AYERST

100MG

A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN

50MG/ML

A083270 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

SODIUM PENTOBARBITAL

WYETH AYERST

50MG/ML

A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS

30MG

A083247 001 Jan 25, 1982

60MG

A083247 002 Jan 25, 1982

120MG

A083247 003 Jan 25, 1982

200MG

A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE

100MG

A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC

100MG

A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST

10MG/ML

N009372 001

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

MYLAN INSTITUTIONAL

10MG/VIAL

A203554 001 Sep 19, 2014

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ANI PHARMS INC

400MG

A074878 001 Jul 09, 1997

400MG

A075107 001 Sep 04, 1998

400MG

A075199 001 Sep 03, 1999

HERITAGE PHARMS INC

400MG

A074877 001 Jul 08, 1997

IMPAX LABS

400MG

A075093 001 Aug 10, 1999

MYLAN

400MG

A074425 001 Jul 08, 1997

PLIVA

400MG

A074874 001 May 25, 1999

TRENTAL

+ US PHARM HOLDINGS

400MG **

N018631 001 Aug 30, 1984

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM

100%

N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY

50%; 50%

N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS

EQ 0.05MG BASE

A076094 001 Sep 04, 2003

EQ 0.25MG BASE

A076094 002 Sep 04, 2003

EQ 1MG BASE

A076094 003 Sep 04, 2003

PAR PHARM

EQ 0.05MG BASE

A076061 001 Nov 27, 2002

EQ 0.25MG BASE

A076061 002 Nov 27, 2002

EQ 1MG BASE

A076061 003 Nov 27, 2002

PERMAX

VALEANT PHARM INTL

EQ 0.05MG BASE

N019385 001 Dec 30, 1988

EQ 0.25MG BASE

N019385 002 Dec 30, 1988

EQ 1MG BASE

N019385 003 Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

+ SYMPLMED PHARMS LLC

2MG

N020184 001 Dec 30, 1993

+

4MG

N020184 002 Dec 30, 1993

+

8MG

N020184 003 Dec 30, 1993

PERINDOPRIL ERBUMINE

ANI PHARMS INC

2MG

A078138 001 Nov 10, 2009

4MG

A078138 002 Nov 10, 2009

8MG

A078138 003 Nov 10, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

APOTEX	2MG	A090463 001	Aug 30, 2010
	4MG	A090463 002	Aug 30, 2010
	8MG	A090463 003	Aug 30, 2010
LUPIN LTD	2MG	A078263 001	Jan 27, 2010
	4MG	A078263 002	Jan 27, 2010
	8MG	A078263 003	Jan 27, 2010

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435 001	Mar 31, 1986
-----------------	----	-------------	--------------

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360 001	May 25, 2001
-------------	----------	-------------	--------------

TRILAFON

SCHERING	16MG/5ML	N011557 001	
----------	----------	-------------	--

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213 002	
----------	--------	-------------	--

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294 002	
----------	---------	-------------	--

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC	2MG	A089707 001	Sep 10, 1987
	4MG	A089708 001	Sep 10, 1987
	8MG	A089456 001	Sep 10, 1987
	16MG	A089457 001	Sep 10, 1987

TRILAFON

+ SCHERING	2MG **	N010775 001	
------------	--------	-------------	--

+	4MG **	N010775 002	
---	--------	-------------	--

+	8MG **	N010775 003	
---	--------	-------------	--

+	16MG **	N010775 004	
---	---------	-------------	--

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361 002	
----------	-----	-------------	--

PHENACEMIDE

TABLET; ORAL

PHENURONE

+ ABBVIE	500MG **	N007707 001	
----------	----------	-------------	--

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

+ ROCHE	100MG; 500MG **	N013294 001	Sep 10, 1987
---------	-----------------	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG	N021105 001	Jun 26, 2001
------	------------------------------------	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

+ ROCHE	50MG; 500MG **	N019358 001	Aug 31, 1990
---------	----------------	-------------	--------------

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM	35MG	A086523 001	
---------	------	-------------	--

	35MG	A086524 001	
--	------	-------------	--

	35MG	A086525 001	
--	------	-------------	--

PHENDIMETRAZINE TARTRATE

SANDOZ	35MG	A085633 001	
--------	------	-------------	--

	35MG	A085694 001	
--	------	-------------	--

	35MG	A085702 001	
--	------	-------------	--

VIRTUS PHARMS	35MG	A085695 001	
---------------	------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

VALEANT

105MG

A088021 001 Sep 21, 1982

MELFIAT-105

NUMARK

105MG

A087487 001 Oct 13, 1982

PHENDIMETRAZINE TARTRATE

GRAHAM DM

105MG

A087214 001 May 26, 1982

105MG

A088020 001 Aug 16, 1982

105MG

A088028 001 Aug 16, 1982

105MG

A088062 001 Sep 13, 1982

105MG

A088063 001 Sep 10, 1982

105MG

A088111 001 Oct 18, 1982

VIRTUS PHARMS

105MG

A087378 001

SPRX-105

NUMARK

105MG

A088024 001 Dec 22, 1982

X-TROZINE L.A.

SHIRE RICHWOOD

105MG

A087371 001 Aug 24, 1982

TABLET; ORAL

ADPHEN

FERNDALE LABS

35MG

A083655 001

ALPHAZINE

SANDOZ

35MG

A085034 001

CAM-METRAZINE

ABC HOLDING

35MG

A085511 001

CAMALL

35MG

A085756 001

CHARTWELL RX

35MG

A083922 001

35MG

A085318 001

35MG

A085320 001

35MG

A085321 001

DI-METREX

PVT FORM

35MG

A085698 001

MELFIAT

NUMARK

35MG

A083790 002

METRA

FOREST PHARMS

35MG

A083754 001

PHENAZINE

MAST MM

35MG

A087305 001

PHENAZINE-35

ABC HOLDING

35MG

A085512 001

PHENDIMETRAZINE TARTRATE

BARR

35MG

A083644 001

35MG

A083684 001

35MG

A083686 001

35MG

A083687 001

35MG

A084831 001

35MG

A084834 001

35MG

A084835 001

CHARTWELL RX

35MG

A085761 001

35MG

A085941 001 Jun 27, 1983

FERNDALE LABS

35MG

A086834 001 Sep 15, 1983

INWOOD LABS

35MG

A084740 001

35MG

A084741 001

35MG

A084742 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A084743 001
IVAX PHARMS	35MG	A085611 001
	35MG	A085612 001
IVAX SUB TEVA PHARMS	35MG	A083682 001
KV PHARM	35MG	A084138 001
	35MG	A084141 001
	35MG	A085525 001
MFG CHEMISTS	35MG	A085914 001
NEXGEN PHARMA INC	35MG	A086020 001
NUMARK	35MG	A083790 001
PVT FORM	35MG	A085199 001
	35MG	A085697 001
SANDOZ	35MG	A085402 001
	35MG	A085830 001
	35MG	A086370 001
SOLVAY	35MG	A083993 001
UPSHER SMITH LABS	35MG	A084399 001
USL PHARMA	35MG	A083805 001
	35MG	A084398 001
VIRTUS PHARMS	35MG	A085497 001
	35MG	A086365 001
VITARINE	35MG	A085519 001
	35MG	A086005 001
	35MG	A086106 001
WATSON LABS	35MG	A085767 001
	35MG	A085768 001
	35MG	A085770 001
	35MG	A085773 001
PLEGINE		
WYETH AYERST	35MG **	N012248 001
STATOBEX		
TEVA	35MG	A086013 001
STATOBEX-G		
TEVA	35MG	A085095 001
X-TROZINE		
SHIRE RICHWOOD	35MG	A086550 001
	35MG	A086551 001
	35MG	A086552 001
	35MG	A086553 001
	35MG	A086554 001

PHENINDIONE

TABLET;ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767 002
-------------------	------	-------------

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460 005
----------------------	------	-------------

TABLET, EXTENDED RELEASE;ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752 004
	75MG	N011752 003

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

+ CONCORDIA	10MG	N008708 001
-------------	------	-------------

PHENPROCOUMON

TABLET;ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228 001
-----------------	-----	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS 500MG N008855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE 30MG ** N017352 001

OBESTIN-30

FERNDALE LABS 30MG A087144 001

OBY-TRIM

SHIRE RICHWOOD 30MG A087764 001 Mar 18, 1982

ONA-MAST

MAST MM 30MG A086511 001

30MG A086516 001

PHENTERMINE HYDROCHLORIDE

ABC HOLDING 30MG A085411 001

ABLE 15MG A040497 001 Mar 13, 2003

30MG A040403 001 Aug 30, 2001

30MG A040427 001 Aug 30, 2001

CAMALL 15MG A086735 001

30MG A087226 001

CHARTWELL RX 18.75MG A088576 001 May 23, 1984

30MG A085417 001

30MG A086732 002

30MG A087215 001

37.5MG A087915 001 Dec 22, 1983

37.5MG A087918 001 Dec 22, 1983

37.5MG A087930 001 Oct 14, 1983

37.5MG A088610 001 Jun 04, 1984

37.5MG A088611 001 Jun 04, 1984

37.5MG A088625 001 Aug 23, 1984

DURAMED PHARMS BARR 30MG A088948 001 Apr 25, 1986

ELITE LABS INC 15MG A040460 001 Jan 14, 2003

30MG A040227 001 Jun 18, 1997

30MG A040448 001 Jan 22, 2003

IVAX PHARMS 30MG A086329 001

LANNETT CO INC 30MG A091359 001 Jul 16, 2010

SANDOZ 30MG A087208 001

30MG A087223 001

37.5MG A088414 001 Oct 19, 1983

SUN PHARM INDUSTRIES 37.5MG A040527 001 Oct 23, 2003

TEVA 30MG A086911 001

30MG A087126 001

30MG A087777 001 Nov 01, 1985

30MG A088612 001 Apr 04, 1984

30MG A088613 001 Apr 09, 1984

30MG A088614 001 Apr 09, 1984

TG UNITED INC 30MG A040083 001 Mar 07, 1997

UPSHER SMITH LABS 30MG A084487 001 Apr 09, 1982

30MG A088430 001 Mar 27, 1984

USL PHARMA 30MG A088797 001 Dec 10, 1984

VITARINE 30MG A087202 001

30MG A087235 001

WATSON LABS 30MG A086740 001 Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM 8MG A086260 001

PHENTERMINE HYDROCHLORIDE

ABLE 37.5MG A040402 001 Aug 30, 2001

ACTAVIS ELIZABETH 37.5MG A040276 001 Nov 25, 1998

CHARTWELL RX 8MG A083923 001

8MG A085319 001

37.5MG A087805 001 Dec 06, 1982

37.5MG A088596 001 Apr 04, 1984

IVAX PHARMS 8MG A085553 001

NOVAST LABS 37.5MG A091451 001 Sep 21, 2012

SANDOZ 8MG A085671 001

8MG A085689 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE			
SANDOZ INC	30MG	A088605 001	Sep 28, 1987
SUN PHARM INDS INC	37.5MG	A040790 001	Aug 21, 2007
USL PHARMA	8MG	A083804 001	
	37.5MG	A088910 001	Jul 17, 1985
	37.5MG	A088917 001	Jul 17, 1985
VITARINE	8MG	A086453 001	
	8MG	A086456 001	
WATSON LABS	8MG	A085739 001	
TORA			
SOLVAY	8MG	A084035 001	
WILPO			
+ SANDOZ	8MG **	N012737 001	
TABLET, ORALLY DISINTEGRATING; ORAL			
SUPRENZA			
CITIUS PHARMS	15MG **	N202088 001	Jun 13, 2011
	30MG **	N202088 002	Jun 13, 2011
	37.5MG **	N202088 003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN			
UCB INC	EQ 15MG BASE **	N011613 004	
	EQ 30MG BASE **	N011613 002	
PHENTERMINE RESIN 30			
QUANTUM PHARMICS	EQ 30MG BASE	A089120 001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX			
LANNETT CO INC	EQ 15MG BASE	A040872 001	Jul 28, 2011
	EQ 30MG BASE	A040872 002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

REGITINE			
+ NOVARTIS	5MG/VIAL **	N008278 003	

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN			
PHARM RES ASSOC	50%	N011695 002	
TABLET; ORAL			
PHENY-PAS-TEBAMIN			
PHARM RES ASSOC	500MG	N011695 003	

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID			
SANOFI AVENTIS US	100MG	A087260 001	
BUTAZOLIDIN			
NOVARTIS	100MG	N008319 009	
PHENYLBUTAZONE			
FOSUN PHARMA	100MG	A087774 001	Jun 16, 1982
IVAX PHARMS	100MG	A088218 001	Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994 001	Dec 04, 1985
WATSON LABS	100MG	A087756 001	Dec 17, 1982
TABLET; ORAL			
AZOLID			
SANOFI AVENTIS US	100MG	A087091 001	
BUTAZOLIDIN			
NOVARTIS	100MG	N008319 008	
PHENYLBUTAZONE			
FOSUN PHARMA	100MG	A084339 001	
SUN PHARM INDUSTRIES	100MG	A088863 001	Dec 04, 1985
WATSON LABS	100MG	A086151 001	
	100MG	A087674 001	Apr 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC

+ ANI PHARMS

5MG/5ML;6.25MG/5ML **

N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY

5MG/5ML;6.25MG/5ML

A088868 001 Mar 02, 1987

PROMETH VC PLAIN

G AND W LABS INC

5MG/5ML;6.25MG/5ML

A088761 001 Nov 08, 1984

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML;6.25MG/5ML

A088815 001 Nov 22, 1985

WOCKHARDT

5MG/5ML;6.25MG/5ML

A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%;0.1%

N007953 001

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001 Sep 25, 1992

PHENYTOIN SODIUM

CAPSULE;ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC

100MG EXTENDED

A040435 001 Jun 20, 2003

100MG EXTENDED

A089441 001 Dec 18, 1986

SUN PHARM INDS (IN)

100MG EXTENDED

A040621 001 Dec 11, 2006

WOCKHARDT

30MG EXTENDED

A040759 001 Dec 18, 2007

WOCKHARDT USA

100MG EXTENDED

A040732 001 Jan 30, 2008

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

ANI PHARMS INC

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE;INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

PHENYTOIN SODIUM

FRESENIUS KABI USA

50MG/ML

A089003 001 May 31, 1985

HOSPIRA

50MG/ML

A089521 001 Mar 17, 1987

50MG/ML

A089744 001 Dec 18, 1987

LUITPOLD

50MG/ML

A040781 001 Dec 04, 2007

MARSAM PHARMS LLC

50MG/ML

A089501 001 Oct 13, 1987

50MG/ML

A089779 001 Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001 Dec 19, 1984

50MG/ML

A088521 001 Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001 Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001 Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

+ TELIGENT

1MG/0.5ML **

N012223 002

+

10MG/ML **

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

AKORN

5MG

N017431 001

OCUSERT PILO-40

AKORN

11MG

N017548 001

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

ALCON

4%

N018796 001 Oct 01, 1984

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ ACADIA PHARMS INC

EQ 17MG BASE

N207318 001 Apr 29, 2016

PIMOZIDE

TABLET; ORAL

ORAP

+ TEVA

1MG

N017473 003 Aug 27, 1997

+

2MG

N017473 001 Jul 31, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM

12.5MG

N019456 001 Dec 28, 1989

25MG

N019456 002 Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

ACP NIMBLE

5MG

A073661 001 Oct 31, 1993

5MG

A073687 001 Feb 26, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

10MG

A073687 002 Feb 26, 1993

10MG

A074123 002 Apr 17, 1997

MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992

10MG

A074018 001 Sep 24, 1992

NOSTRUM LABS

5MG

A074474 001 Oct 28, 1996

10MG

A074474 002 Oct 28, 1996

PUREPAC PHARM

5MG

A074125 001 Apr 28, 1993

10MG

A074125 002 Apr 28, 1993

WATSON LABS

5MG

A074437 001 Feb 27, 1995

10MG

A074437 002 Feb 27, 1995

ZYDUS PHARMS

5MG

A209866 001 Aug 18, 2017

10MG

A209866 002 Aug 18, 2017

VISKEN

+ NOVARTIS

5MG **

N018285 001 Sep 03, 1982

+

10MG **

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
+	EQ 2GM BASE/VIAL **	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
+	EQ 3GM BASE/VIAL **	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
+	EQ 4GM BASE/VIAL **	N050545 004	
+	EQ 40GM BASE/VIAL **	N050545 006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287 001	Jul 29, 2019
	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287 002	Jul 29, 2019
	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287 003	Jul 29, 2019
HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009
	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009
	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009
	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL			
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE			
BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE			
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
LANNETT	EQ 500MG BASE/5ML	A080963 001	
LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL			
SOLVAY	EQ 500MG BASE/5ML	A080992 001	
TABLET; ORAL			
ANTEPAR			
GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE			
IMPAX LABS	EQ 250MG BASE	A080874 001	

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000
----------------------	------------------	-------------	--------------

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT	10MG	N016245 001	
	25MG	N016245 002	

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

BAUSCH	EQ 0.2MG BASE/INH	N019009 001	Dec 30, 1986
MEDICIS	EQ 0.2MG BASE/INH	N020014 001	Nov 30, 1992

PIRFENIDONE

TABLET; ORAL

ESBRIET

+	GENENTECH INC	534MG **	N208780 002	Jan 11, 2017
---	---------------	----------	-------------	--------------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

BRECKENRIDGE	10MG	A208991 001	Feb 21, 2018
	20MG	A208991 002	Feb 21, 2018
CYCLE PHARMS LTD	10MG	A073651 001	Feb 26, 1993
	20MG	A073651 002	Feb 26, 1993
EGIS	10MG	A074808 001	Jul 08, 1997
	20MG	A074808 002	Jul 08, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PIROXICAM

CAPSULE; ORAL

PIROXICAM

IVAX SUB TEVA PHARMS	10MG	A074148 001	Jun 03, 1996
	20MG	A074148 002	Jun 03, 1996
MYLAN	10MG	A074043 001	Sep 22, 1992
	10MG	A074102 001	Jul 31, 1992
	20MG	A074043 002	Sep 22, 1992
	20MG	A074102 002	Jul 31, 1992
SCS	10MG	A074036 001	May 29, 1992
	20MG	A074036 002	May 29, 1992
SUN PHARM INDUSTRIES	10MG	A073536 002	Jan 23, 2008
	20MG	A073536 001	Mar 12, 1993
TEVA	10MG	A073637 001	Jan 28, 1994
	20MG	A073638 001	Jan 28, 1994
TEVA PHARMS	10MG	A074103 001	Aug 28, 1992
	20MG	A074103 002	Aug 28, 1992
WATSON LABS	10MG	A074287 001	May 16, 1996
	10MG	A074460 001	Sep 29, 1995
	20MG	A074287 002	May 16, 1996
	20MG	A074460 002	Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

MYLAN

EQ 1MG BASE	A206070 001	Apr 04, 2019
EQ 2MG BASE	A206070 002	Apr 04, 2019
EQ 4MG BASE	A206070 003	Apr 04, 2019

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

+ MEDICURE

EQ 1MG BASE	N208379 001	Jul 14, 2017
-------------	-------------	--------------

PITAVASTATIN SODIUM

TABLET; ORAL

NIKITA

+ LUPIN LTD

+

+

EQ 1MG BASE	N209875 001	Aug 04, 2017
EQ 2MG BASE	N209875 002	Aug 04, 2017
EQ 4MG BASE	N209875 003	Aug 04, 2017

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL	N050109 001	
------------	-------------	--

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

BAUSCH AND LOMB INC 0.5%

A090184 001	Jul 21, 2010
-------------	--------------

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP	N010753 001	
----------	-------------	--

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

LANNETT CO INC

17GM/SCOOPFUL

A076652 001	Jul 02, 2004
-------------	--------------

17GM/PACKET

A090600 001	Oct 06, 2009
-------------	--------------

17GM/SCOOPFUL

A090600 002	Oct 06, 2009
-------------	--------------

POLYETHYLENE GLYCOL 3350

BRECKENRIDGE PHARM

17GM/SCOOPFUL

A077736 001	May 26, 2006
-------------	--------------

NEXGEN PHARMA INC

17GM/SCOOPFUL

A077706 001	Sep 27, 2006
-------------	--------------

PADDOCK LLC

17GM/SCOOPFUL

A077893 001	May 26, 2006
-------------	--------------

TEVA PHARMS

17GM/SCOOPFUL

A090567 001	Oct 15, 2009
-------------	--------------

A077445 001	May 04, 2006
-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409 001	Apr 02, 2010
-------	--	-------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769 001	Jun 07, 2010
-------------	--	-------------	--------------

SOLUTION;ORAL

OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284 001	Apr 30, 1986
---------	---	-------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983 005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983 004	Oct 26, 1984
	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 010	Jan 31, 1989
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 007	Jun 12, 1987
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983 006	Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 008	Nov 14, 1991
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 009	Nov 14, 1991

GOLYTELY

+ BRAINTREE

	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011 002	Jun 02, 1992
--	--	-------------	--------------

PEG 3350 AND ELECTROLYTES

MYLAN

	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928 001	Jan 28, 2010
--	--	-------------	--------------

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712 001	Feb 25, 2010
--	--	-------------	--------------

FOR SUSPENSION;ORAL

CO-LAV

VINTAGE PHARMS

	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428 001	Jan 28, 1992
--	--	-------------	--------------

COLOVAGE

DYNAPHARM

	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320 001	Apr 20, 1988
--	--	-------------	--------------

E-Z-EM PREP LYTE

E Z EM

	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278 001	Nov 21, 1988
--	--	-------------	--------------

GLYCOPREP

GOLDLINE

	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319 001	Dec 23, 1988
--	--	-------------	--------------

GO-EVAC

VINTAGE PHARMS

	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433 001	Apr 28, 1992
--	--	-------------	--------------

PEG-LYTE

SANDOZ

	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098 001	Aug 31, 1993
--	--	-------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

	EQ 500,000 U BASE/VIAL	A062036 001	
--	------------------------	-------------	--

POLYMYXIN B SULFATE

WEST-WARD PHARMS INT

	EQ 500,000 UNITS BASE/VIAL	A060716 001	
--	----------------------------	-------------	--

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

	100,000,000 UNITS/BOT	A061578 001	
--	-----------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POLYMYXIN B SULFATE

POWDER;FOR RX COMPOUNDING

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET;ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIZIDE

PFIZER

0.5MG;EQ 1MG BASE

N017986 001

0.5MG;EQ 2MG BASE

N017986 002

0.5MG;EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET;ORAL

RENESE-R

PFIZER

2MG;0.25MG

N013636 001

POTASSIUM AMINOSALICYLATE

CAPSULE;ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER;ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET;ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

K-LEASE

SAVAGE LABS

8MEQ

A073398 001 Jan 28, 1992

10MEQ

A072427 001 Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS

10MEQ

A070980 001 Feb 17, 1987

TEVA

8MEQ

A073531 001 Apr 26, 1996

10MEQ

A073532 001 Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MICRO-K LS

KV PHARM

20MEQ/PACKET

N019561 003 Aug 26, 1988

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM

2MEQ/ML

A080204 001

2MEQ/ML

A084290 001

2MEQ/ML

A086713 001

2MEQ/ML

A086714 001

2MEQ/ML

A087787 001 Apr 20, 1982

2MEQ/ML

A087885 001 Feb 03, 1983

AKORN

2MEQ/ML

A088286 001 Sep 05, 1985

BAXTER HLTHCARE

2MEQ/ML

A080203 001

2MEQ/ML

A085499 001

FRESENIUS KABI USA

2MEQ/ML

A087817 001 Oct 20, 1982

GD SEARLE LLC

1MEQ/ML

A086219 001

2MEQ/ML

A086219 002

2MEQ/ML

A086220 002

3MEQ/ML

A086219 003

3MEQ/ML

A086220 001

4MEQ/ML

A086219 004

HOSPIRA

1MEQ/ML

A080205 003

1MEQ/ML

A083345 003

1.5MEQ/ML

A083345 001

2MEQ/ML

A083345 002

2.4MEQ/ML

A080205 004

3.2MEQ/ML

A080205 005

INTL MEDICATION

2MEQ/ML

A083163 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	
POTASSIUM CHLORIDE 30MEQ IN	PLASTIC CONTAINER			
+ ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998
TABLET, EXTENDED RELEASE; ORAL				
K+10				
FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10				
SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX				
APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE				
COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
PII	8MEQ	A206881	001	Jan 22, 2019
	10MEQ	A206630	001	Mar 29, 2019
	10MEQ	A206881	002	Jan 22, 2019
	10MEQ	A210097	001	Jun 17, 2019
	15MEQ	A206630	002	Mar 29, 2019
	20MEQ	A206630	003	Mar 29, 2019
	20MEQ	A210098	001	Apr 26, 2019
+ SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+	20MEQ **	N019439	001	Jun 13, 1986
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML; 900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML; 900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
+ BAXTER HLTHCARE	224MG/100ML; 900MG/100ML	N017648	003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML; 900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N018722	003	Nov 09, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN

300MG/100ML; 900MG/100ML

N018722 004 Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA

370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL

N013025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

+ UT SW MEDCTR

10MEQ/PACKET **

N019647 002 Oct 13, 1988

+

20MEQ/PACKET **

N019647 001 Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML **

N018551 001 Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDA PHARMS

130MG

N018307 001

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG

N017551 001

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

HERITAGE PHARMA

0.125MG

A078551 001 Oct 08, 2010

0.125MG

A090241 001 Oct 08, 2010

0.125MG

A091254 001 Nov 30, 2010

0.25MG

A078551 002 Oct 08, 2010

0.25MG

A090241 002 Oct 08, 2010

0.25MG

A091254 002 Nov 30, 2010

0.5MG

A078551 003 Oct 08, 2010

0.5MG

A090241 003 Oct 08, 2010

0.5MG

A091254 003 Nov 30, 2010

0.75MG

A090241 004 Oct 08, 2010

0.75MG

A091254 004 Nov 30, 2010

1MG

A078551 004 Oct 08, 2010

1MG

A090241 005 Oct 08, 2010

1MG

A091254 005 Nov 30, 2010

1.5MG

A078551 005 Oct 08, 2010

1.5MG

A090241 006 Oct 08, 2010

1.5MG

A091254 006 Nov 30, 2010

SANDOZ

0.125MG

A090190 001 Jul 06, 2010

0.25MG

A090190 002 Jul 06, 2010

0.5MG

A090190 003 Jul 06, 2010

0.75MG

A090190 006 Oct 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	1MG	A090190 004	Jul 06, 2010
	1.5MG	A090190 005	Jul 06, 2010
SUN PHARM INDS INC	0.125MG	A091683 001	Mar 27, 2013
	0.25MG	A091683 002	Mar 27, 2013
	0.5MG	A091683 003	Mar 27, 2013
	0.75MG	A091683 004	Mar 27, 2013
	1MG	A091683 005	Mar 27, 2013
	1.5MG	A091683 006	Mar 27, 2013

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMMLIN

ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005
----------------	-------------------------------------	-------------	--------------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

+ BRISTOL MYERS SQUIBB 10MG **

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

MYLAN

	10MG	A077013 001	Oct 23, 2006
	20MG	A077013 002	Oct 23, 2006
	40MG	A077013 003	Oct 23, 2006
	80MG	A077013 004	Dec 28, 2007
PLIVA HRVATSKA DOO	10MG	A077730 001	Nov 21, 2006
	20MG	A077730 002	Nov 21, 2006
	30MG	A077730 003	Nov 21, 2006
	40MG	A077730 005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007
	20MG	A076445 002	Apr 23, 2007
	40MG	A076445 003	Apr 23, 2007
	80MG	A076445 004	Apr 23, 2007

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001 May 16, 1989

EQ 2MG BASE

A072783 001 May 16, 1989

EQ 5MG BASE

A072784 001 May 16, 1989

ANI PHARMS INC

EQ 1MG BASE

A072577 002 May 16, 1989

EQ 2MG BASE

A072577 001 May 16, 1989

EQ 5MG BASE

A072577 003 May 16, 1989

DAVA PHARMS INC

EQ 1MG BASE

A072705 001 May 16, 1989

EQ 2MG BASE

A072706 001 May 16, 1989

EQ 5MG BASE

A072707 001 May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001 May 16, 1989

EQ 2MG BASE

A072921 001 May 16, 1989

EQ 5MG BASE

A072992 001 May 16, 1989

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE

CREAM;TOPICAL

METI-DERM

SCHERING 0.5% N010209 002

SYRUP;ORAL

PREDNISOLONE

IVAX SUB TEVA PHARMS 15MG/5ML A040287 001 May 28, 1999

NESHER PHARMS 5MG/5ML A040423 001 Oct 22, 2001

15MG/5ML A040364 001 Apr 10, 2002

PHARM ASSOC 5MG/5ML A040570 001 Aug 25, 2005

15MG/5ML A040571 001 Aug 25, 2005

TEVA PHARMS 15MG/5ML A040322 001 Jan 19, 2000

WE PHARMS 15MG/5ML A040192 001 May 28, 1998

PRELONE

MURO 5MG/5ML A089654 001 Jan 17, 1989

TABLET;ORAL

CORTALONE

HALSEY 1MG A080304 003

2.5MG A080304 002

5MG A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN 5MG N009987 004

FERNISOLONE-P

FERNDALE LABS 5MG A083941 001

PREDNISOLONE

AUROLIFE PHARMA LLC 5MG A084773 001

BARR 5MG A084426 002

BUNDY 5MG A083675 001

CHARTWELL RX 5MG A084542 001

ELKINS SINN 5MG A080625 001

EVERYLIFE 1MG A084439 001

2.5MG A084439 002

5MG A084439 003

FERRANTE 2.5MG A080562 001

5MG A080562 002

FOSUN PHARMA 5MG A080339 001

HEATHER 5MG A080326 001

IMPAX LABS 5MG A080780 001

INWOOD LABS 5MG A080748 001

IVAX SUB TEVA PHARMS 5MG A080378 001

LANNETT 5MG A080531 002

MARSHALL PHARMA 5MG A080307 001

PANRAY 1MG A080351 001

5MG A080351 002

PHOENIX LABS NY 5MG A080322 001

PUREPAC PHARM 5MG A080325 001

PVT FORM 5MG A080211 001

ROXANE 5MG A080327 002

SPERTI 1MG A080358 001

2.5MG A080358 002

5MG A080358 003

SUPERPHARM 5MG A088892 001 Feb 26, 1985

TABLICAPS 5MG A085170 001

TEVA 5MG A080398 001

UDL 5MG A087987 001 Jan 18, 1983

VALEANT PHARM INTL 5MG A080236 001

VITARINE 5MG A080534 001

WATSON LABS 5MG A085085 002

5MG A085415 001

5MG A085416 001

WEST WARD 5MG A080324 001

WHITEWORTH TOWN PLSN 5MG A080342 001

STERANE

PFIZER 5MG N009996 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING 25MG/ML N010255 002

PREDNISOLONE ACETATE

AKORN 25MG/ML A083032 001

50MG/ML A084492 001

BEL MAR 25MG/ML A083738 001

50MG/ML A083738 002

CENT PHARMS 25MG/ML A084717 001

50MG/ML A084717 002

WATSON LABS 25MG/ML A083398 001

25MG/ML A083654 001

40MG/ML A083767 001

50MG/ML A083764 001

50MG/ML A085781 001

STERANE

PFIZER 25MG/ML N011446 001

SUSPENSION; ORAL

FLO-PRED

TARO EQ 5MG BASE/5ML N022067 001 Jan 17, 2008

EQ 15MG BASE/5ML N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

EYEVANCE 0.125% N017468 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON 0.25%;10% A087771 001 Aug 06, 1993

METIMYD

SCHERING 0.5%;10% N010210 002 Sep 09, 1984

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088032 001 Apr 15, 1983

VASOCIDIN

NOVARTIS 0.5%;10% A088791 001 Oct 05, 1984

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON 0.25%;10% A087547 001

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING 0.5%;10% N010210 001

PREDAMIDE

AKORN 0.5%;10% A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR 0.5%;10% A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR 0.2%;10% A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB 0.5%;10% A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK EQ 20MG PHOSPHATE/ML N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS EQ 20MG PHOSPHATE/ML A080517 001

OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCK EQ 0.25% PHOSPHATE N011028 001

SOLUTION; ORAL

ORAPRED

CONCORDIA PHARMS INC EQ 15MG BASE/5ML ** A075117 001 Dec 14, 2000

PREDNISOLONE SODIUM PHOSPHATE

AMNEAL PHARMS EQ 15MG BASE/5ML A078345 001 Mar 10, 2009

MEDICIS PHARMS EQ 15MG BASE/5ML A075250 001 Jul 12, 2002

NESHER PHARMS EQ 5MG BASE/5ML A076982 001 May 24, 2005

EQ 15MG BASE/5ML A076988 001 May 24, 2005

PHARM ASSOC EQ 5MG BASE/5ML A076123 001 Dec 23, 2002

VINTAGE PHARMS EQ 5MG BASE/5ML A078416 001 Oct 31, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

WE PHARMS

EQ 5MG BASE/5ML

A075181 001 Dec 23, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

NOVARTIS

EQ 0.9% PHOSPHATE

A080751 002

INFLAMASE MILD

NOVARTIS

EQ 0.11% PHOSPHATE

A080751 001

METRETON

SCHERING

EQ 0.5% PHOSPHATE

A083834 001

PREDAIR

PHARMAFAIR

EQ 0.11% PHOSPHATE

A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR

EQ 0.9% PHOSPHATE

A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN

EQ 0.11% PHOSPHATE

A083358 001

EQ 0.9% PHOSPHATE

A083358 002

ALCON PHARMS LTD

EQ 0.11% PHOSPHATE

A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE

A081044 001 Oct 24, 1991

BAUSCH AND LOMB

EQ 0.11% PHOSPHATE

A040065 001 Jul 29, 1994

SOLA BARNES HIND

EQ 0.11% PHOSPHATE

A084171 001

EQ 0.9% PHOSPHATE

A084168 001

EQ 0.9% PHOSPHATE

A084169 001

EQ 0.9% PHOSPHATE

A084172 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

SANDOZ INC

EQ 0.23% PHOSPHATE;10%

A073630 001 May 27, 1993

SULSTER

AKORN

EQ 0.23% PHOSPHATE;10%

A074511 001 Jul 30, 1996

VASOCIDIN

+ NOVARTIS

EQ 0.23% PHOSPHATE;10% **

N018988 001 Aug 26, 1988

PREDNISOLONE TEBUTATE

INJECTABLE;INJECTION

HYDELTRA-TBA

MERCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISON

SOLUTION;ORAL

PREDNISON

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP;ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET;ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

+ PHARMACIA AND UPJOHN

2.5MG **

N009986 005

+

5MG **

N009986 002

+

10MG **

N009986 006

+

20MG **

N009986 007

+

50MG **

N009986 008

FERNISON

FERNDAL LABS

5MG

A083364 001

METICORTEN

+ SCHERING

1MG **

N009766 002

+

5MG **

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISON

TABLET;ORAL

PARACORT

PARKE DAVIS 5MG N010962 002

PREDNICEN-M

SCHWARZ PHARMA 5MG A084655 001

PREDNISON

AM THERAP 5MG A089387 001 Nov 06, 1986

10MG A089388 001 Nov 06, 1986

20MG A089389 001 Nov 06, 1986

AMNEAL PHARMS NY 5MG A089597 001 Oct 05, 1987

10MG A089598 001 Oct 05, 1987

20MG A089599 001 Oct 05, 1987

AUROLIFE PHARMA LLC 5MG A084774 001

10MG A089983 001 Jan 12, 1989

20MG A085813 001

50MG A089984 001 Jan 12, 1989

BUNDY 5MG A083676 001

CHARTWELL RX 5MG A083059 001

CONTRACT PHARMACAL 5MG A080209 001

DURAMED PHARMS BARR 5MG A088394 001 Oct 04, 1983

10MG A088395 001 Oct 04, 1983

20MG A088396 001 Oct 04, 1983

ELKINS SINN 5MG A080491 001

20MG A085811 001

EVERYLIFE 1MG A084440 001

2.5MG A084440 002

5MG A084440 003

FERRANTE 2.5MG A080563 001

5MG A080563 002

HALSEY 5MG A080300 001

HEATHER 5MG A080320 001

10MG A084341 001

20MG A084417 001

20MG A085543 001

50MG A086946 001

HIKMA PHARMS 1MG A040890 001 Nov 01, 2010

2.5MG A040538 001 Jan 08, 2004

IMPAX LABS 5MG A080782 001

INWOOD LABS 1MG A080328 001

2.5MG A080306 001

5MG A080279 001

IVAX SUB TEVA PHARMS 5MG A080283 001

10MG A084133 001

20MG A084134 001

KV PHARM 5MG A084236 001

LANNETT 5MG A080514 001

20MG A084275 001

LEDERLE 5MG A086968 001

MARSHALL PHARMA 5MG A080301 001

MUTUAL PHARM 5MG A080701 001

10MG A086595 001

20MG A084634 001

NYLOS 5MG A085115 001

PANRAY 1MG A080350 001

2.5MG A080350 002

5MG A080350 003

PHARMAVITE 5MG A084662 002

PHOENIX LABS NY 5MG A080321 001

20MG A083807 001

PUREPAC PHARM 5MG A080353 001

10MG A086062 001

20MG A086061 001

PVT FORM 20MG A085151 001

REXALL 5MG A080232 001

ROXANE 20MG N017109 001

25MG A087833 001 May 04, 1982

SANDOZ 5MG A080336 002

SCHERER LABS 5MG A080371 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PREDNISON

TABLET; ORAL

PREDNISON

SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUN PHARM INDUSTRIES	50MG	A086596	001	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	

SERVISONE

LEDERLE

5MG A080223 001

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

+ ASTRAZENECA	1% **	N014763	004	
+	2% **	N014763	005	
+	3% **	N014763	003	
CITANEST PLAIN				
+ ASTRAZENECA	4% **	N014763	007	
CITANEST PLAIN DENTAL				
+ DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA 250MG/5ML N010401 001

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	

PROBENECID

TABLET; ORAL

BENEMID

+ MERCK 500MG ** N007898 004

PROBENECID

IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535 001	
	500MG	N017535 002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG	A089219 001	Jul 01, 1986
	375MG	A089219 002	Jul 01, 1986
	500MG	A089219 003	Jul 01, 1986
ASCOT	250MG	A087542 001	Jan 08, 1982
	375MG	A087697 001	Mar 01, 1983
	500MG	A087543 001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604 001	
	375MG	A084595 001	
	500MG	A084606 001	
LANNETT	250MG	A083693 001	
	500MG	A084696 001	
LEDERLE	250MG	A086942 001	
	375MG	A086952 001	
	500MG	A086943 001	
ROXANE	250MG	A088989 001	Apr 26, 1985
	500MG	A088990 001	Apr 26, 1985
VANGARD	250MG	A087643 001	Jun 01, 1982
	500MG	A087875 001	Jun 01, 1982
WATSON LABS	250MG	A083287 001	
	250MG	A083795 001	
	250MG	A085167 001	
	375MG	A084403 001	
	375MG	A087020 001	
	500MG	A084280 001	
	500MG	A084357 001	
	500MG	A087021 001	

PROCAN

PARKE DAVIS	250MG	A085804 001	
	375MG	A087502 001	
	500MG	A085079 001	

PROCAPAN

PANRAY	250MG	A083553 002	
--------	-------	-------------	--

PRONESTYL

+ APOTHECON	250MG **	N007335 001	
+	375MG **	N007335 004	
+	500MG **	N007335 003	

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415 001	Nov 17, 1986
	500MG/ML	A089416 001	Nov 17, 1986
HOSPIRA	500MG/ML	A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML	A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824 001	Nov 20, 1985
	500MG/ML	A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530 001	Mar 04, 1985
	500MG/ML	A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528 001	May 03, 1988
	500MG/ML	A089529 001	May 03, 1988
WATSON LABS	100MG/ML	A087079 001	
	500MG/ML	A087080 001	
WEST-WARD PHARMS INT	100MG/ML	A089029 001	Apr 17, 1986
	500MG/ML	A089030 001	Apr 17, 1986

PRONESTYL

+ APOTHECON	100MG/ML **	N007335 002	
+	500MG/ML **	N007335 005	

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371 001	
	375MG	N017371 002	
	500MG	N017371 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG	A088958 001	Dec 02, 1985
	250MG	A089369 001	Aug 14, 1987
	500MG	A088959 001	Dec 02, 1985
	500MG	A088974 001	Jul 22, 1985
	500MG	A089369 002	Jan 09, 1987
	750MG	A089369 003	Aug 14, 1987
	750MG	A089438 001	Mar 23, 1987
	1GM	A040111 001	Dec 13, 1996
INWOOD LABS	500MG	A089840 001	Mar 06, 1989
SANDOZ	500MG	A089284 001	Jun 23, 1986
WATSON LABS	250MG	A088533 001	Dec 03, 1984
	250MG	A089026 001	Oct 22, 1985
	500MG	A088534 001	Dec 03, 1984
	500MG	A089027 001	Oct 22, 1985
	750MG	A088535 001	Nov 03, 1984
	750MG	A089042 001	Oct 22, 1985
	1GM	A089520 001	Jan 15, 1987
PROCAN SR			
PARKE DAVIS	250MG	A086468 001	
PARKE DALE	500MG	A086065 001	
	750MG	A087510 001	Apr 01, 1982
	1GM	A088489 001	Jan 16, 1985
PROCANBID			
KING PHARMS	500MG	N020545 001	Jan 31, 1996
	1GM	N020545 002	Jan 31, 1996
PRONESTYL-SR			
APOTHECON	500MG	A087361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362 003	
	2%	A085362 004	
	10%	A086797 001	
PROCAINE HYDROCHLORIDE			
ABRAXIS PHARM	1%	A080384 002	
	1%	A080421 001	
	2%	A080384 003	
	2%	A080421 002	
BEL MAR	1%	A080711 001	
	2%	A080756 001	
ELKINS SINN	1%	A083315 001	
	2%	A083315 002	
GD SEARLE LLC	1%	A086202 001	
	2%	A086202 002	
HOSPIRA	1%	A080416 001	
	2%	A080416 002	
MILES	1%	A080415 001	
	2%	A080415 002	
WATSON LABS	1%	A080658 001	
	1%	A083535 001	
	2%	A080658 002	
	2%	A083535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
	40MG/VIAL;250MG/VIAL	N050276 003	

TETRACYN

PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
	40MG/VIAL;250MG/VIAL	A060285 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG **

N011127 003

5MG **

N011127 001

25MG **

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001 Jul 11, 2001

5MG

A040407 002 Jul 11, 2001

25MG

A040407 003 Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001 Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001 Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

+

GLAXOSMITHKLINE

EQ 5MG BASE/ML **

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001 Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HOSPIRA

EQ 5MG BASE/ML

A089703 001 Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001 Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001 Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001 May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001 Jul 08, 1987

EQ 5MG BASE/ML

A089605 001 Jul 08, 1987

EQ 5MG BASE/ML

A089606 001 Jul 08, 1987

WEST-WARD PHARMS INT

EQ 5MG BASE/ML

A089523 001 May 03, 1988

WYETH AYERST

EQ 5MG BASE/ML

A086348 001

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001 Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002 Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE **

N010571 001

EQ 10MG BASE **

N010571 002

EQ 25MG BASE **

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001 May 01, 1997

EQ 5MG BASE

A089484 001 Jan 20, 1987

EQ 10MG BASE

A040207 002 May 01, 1997

EQ 10MG BASE

A089485 001 Jan 20, 1987

EQ 25MG BASE

A089486 001 Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE

A040162 001 Jan 20, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

	EQ 10MG BASE	A040162 002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101 003	Jul 19, 1996
TEVA PHARMS	EQ 5MG BASE	A040120 001	Jul 11, 1996
	EQ 10MG BASE	A040120 002	Jul 11, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS	2MG	N009818 005	
	5MG	N009818 003	

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

TEVA PHARMS	100MG	A202121 001	Feb 29, 2012
	200MG	A202121 002	Feb 29, 2012

PROMETRIUM

VIRTUS PHARMS	300MG	N019781 003	Oct 15, 1999
---------------	-------	-------------	--------------

INJECTABLE; INJECTION

PROGESTERONE

LILLY	25MG/ML	N009238 002	
	50MG/ML	N009238 001	
LUITPOLD	50MG/ML	A090845 001	Jun 22, 2009

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA	38MG	N017553 001	
------	------	-------------	--

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST	30MG/ML	N010942 001	
	100MG/ML	N010942 004	

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS	25MG/ML	A084510 001	
	50MG/ML	A084517 001	

SPARINE

BAXTER HLTHCARE CORP	25MG/ML	N010349 008	
	50MG/ML	N010349 006	

SYRUP; ORAL

SPARINE

WYETH AYERST	10MG/5ML	N010942 003	
--------------	----------	-------------	--

TABLET; ORAL

SPARINE

WYETH AYERST	10MG	N010348 006	
	25MG	N010348 001	
	50MG	N010348 002	
	100MG	N010348 003	
	200MG	N010348 004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST	25MG/ML	N008857 002	
	50MG/ML	N008857 003	

PROMETHAZINE HYDROCHLORIDE

ABBOTT	25MG/ML	A084223 001	
	50MG/ML	A084222 001	
AKORN	25MG/ML	A083955 002	
	50MG/ML	A083955 001	
AM REGENT	25MG/ML	A040515 001	Mar 19, 2003
BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
	50MG/ML	A040524 002	Mar 17, 2004
HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000
	50MG/ML	A040372 002	Jun 08, 2000
	50MG/ML	A083838 002	
MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988
	50MG/ML	A089477 001	May 02, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

MYLAN INSTITUTIONAL	25MG/ML	A040471	001	Nov 21, 2002
SANDOZ	25MG/ML	A040593	001	Nov 08, 2006
	50MG/ML	A040593	002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML **	A040454	001	Aug 22, 2002
	50MG/ML **	A040454	002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532	001	
	25MG/ML	A084591	001	
	50MG/ML	A080629	002	
	50MG/ML	A083532	002	
WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008
	50MG/ML	A040785	002	Sep 26, 2008

ZIPAN-25

ALTANA	25MG/ML	A083997	001	
--------	---------	---------	-----	--

ZIPAN-50

ALTANA	50MG/ML	A083997	002	
--------	---------	---------	-----	--

SUPPOSITORY; RECTAL

PHENERGAN

+ MYLAN	12.5MG **	N010926	002	
+	25MG **	N010926	001	
+	50MG **	N011689	001	

PROMETHACON

POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	

PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
------------	----------	---------	-----	--------------

PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772	001	
--------------------	----------	---------	-----	--

PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
----------------------	------------	---------	-----	--

PROMETHAZINE

CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
-------	------------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	

PROMETHAZINE HYDROCHLORIDE PLAIN

+ ANI PHARMS	6.25MG/5ML **	N008381	004	Apr 18, 1984
+	25MG/5ML **	N008381	003	

TABLET; ORAL

PHENERGAN

+ DELCOR ASSET CORP	12.5MG **	N007935	002	
+	25MG **	N007935	003	
+	50MG **	N007935	004	

PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
	25MG	A040791	003	Feb 12, 2008
	25MG	A084214	002	Jul 07, 1982
	50MG	A040791	001	May 20, 2008
INVATECH	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

LANNETT	12.5MG	A080949 001	
	25MG	A080949 002	
	50MG	A080949 003	
MYLAN	12.5MG	A091054 001	Aug 30, 2011
	25MG	A091054 002	Aug 30, 2011
	50MG	A091054 003	Aug 30, 2011
PVT FORM	12.5MG	A083214 001	
	25MG	A083658 001	
SANDOZ	12.5MG	A084176 002	May 22, 2009
SUN PHARM INDUSTRIES	12.5MG	A084555 001	
	25MG	A084554 001	
	50MG	A084557 001	
TABLICAPS	12.5MG	A084080 001	
	25MG	A084027 001	
TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	
REMSSED			
BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002
RYTHMOL			
+ GLAXOSMITHKLINE LLC	150MG	N019151 001	Nov 27, 1989
+	225MG	N019151 003	Nov 20, 1992
+	300MG	N019151 002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843 001	
---------------	-----------	-------------	--

TABLET; ORAL

PRO-BANTHINE

+ SHIRE	7.5MG **	N008732 003	
+	15MG **	N008732 002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
HIKMA	7.5MG	A080927 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
------------	------	-------------	--------------

OPHTHAINE

+ APOTHECON	0.5% **	N008883 001	
-------------	---------	-------------	--

OPHTHETIC

+ ALLERGAN	0.5% **	N012583 001	
------------	---------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PARACAINE

OPTOPICS 0.5%

A087681 001 Aug 05, 1982

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND 0.5%

A084144 001

0.5%

A084151 001

PROPIOLACTONE

SOLUTION;IRRIGATION

BETAPRONE

FOREST LABS N/A

N011657 001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

LARGON

WEST-WARD PHARMS INT 20MG/ML

N012382 002

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

FRESENIUS KABI USA 10MG/ML

N019627 001 Oct 02, 1989

PROPOFOL

TEVA PARENTERAL 10MG/ML

A075392 001 Sep 19, 2000

WEST-WARD PHARMS INT 10MG/ML

A074848 001 Apr 19, 2005

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

DARVON

XANODYNE PHARM 32MG

N010997 001

65MG

N010997 003

DOLENE

HERITAGE PHARMS INC 65MG

A080530 001

KESSO-GESIC

MK LABS 65MG

A083544 001

PROPHENE 65

HALSEY 65MG

A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG

A083184 001

IMPAX LABS 65MG

A083317 001

IVAX SUB TEVA PHARMS 32MG

A083597 001

MUTUAL PHARM 65MG

A083186 001

MYLAN 32MG

A083528 001

65MG

A040569 001 Dec 16, 2004

65MG

A083299 001

NEXGEN PHARMA INC 65MG

A083185 001

PAR PHARM 65MG

A080269 001

PUREPAC PHARM 65MG

A083278 001

PVT FORM 32MG

A083464 001

65MG

A083113 001

ROXANE 32MG

A083089 001

65MG

A083089 002

SANDOZ 32MG

A084014 001

65MG

A083125 002

65MG

A083688 001

65MG

A083870 002

65MG

A086495 001

TEVA 65MG

A088615 001 Oct 22, 1984

VALEANT PHARM INTL 65MG

A080783 001

VINTAGE PHARMS 65MG

A040908 001 Jul 17, 2009

WATSON LABS 65MG

A080908 002

65MG

A085190 001

WEST WARD 65MG

A083501 001

WHITEWORTH TOWN PLSN 65MG

A084551 001

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG

A083786 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET;ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

MYLAN 60MG A078022 001 Feb 15, 2007

80MG A078022 002 Feb 15, 2007

120MG A078022 003 Feb 15, 2007

160MG A078022 004 Feb 15, 2007

UPSHER SMITH LABS 60MG A078311 001 Mar 06, 2009

80MG A078311 002 Mar 06, 2009

120MG A078311 003 Mar 06, 2009

160MG A078311 004 Mar 06, 2009

CONCENTRATE;ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

+ BAXTER HLTHCARE CORP 1MG/ML N016419 001

FOSUN PHARMA 1MG/ML A076400 001 Feb 26, 2003

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE 20MG/5ML A071984 001 Mar 03, 1989

40MG/5ML A071985 001 Mar 03, 1989

SUSPENSION;ORAL

INDERAL

WYETH AYERST 10MG/ML N019536 001 Dec 12, 1986

TABLET;ORAL

INDERAL

+ WYETH PHARMS 10MG ** N016418 001

+ 20MG ** N016418 003

+ 40MG ** N016418 002

+ 60MG ** N016418 009 Oct 18, 1982

+ 80MG ** N016418 004

+ 90MG ** N016418 010 Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC 60MG A071791 001 Jul 15, 1987

90MG A071977 001 Apr 06, 1988

DAVA PHARMS INC 10MG A070125 001 Jul 30, 1985

20MG A070126 001 Jul 30, 1985

40MG A070127 001 Jul 30, 1985

60MG A071495 001 Dec 31, 1987

80MG A070128 001 Jul 30, 1985

90MG A071496 001 Dec 31, 1987

DURAMED PHARMS BARR 10MG A070306 001 Sep 09, 1985

20MG A070307 001 Sep 09, 1985

40MG A070308 001 Sep 09, 1985

60MG A070309 001 Oct 01, 1986

80MG A070310 001 Sep 09, 1985

90MG A071327 001 Oct 01, 1986

INTERPHARM 10MG A071368 001 May 05, 1987

20MG A071369 001 May 05, 1987

40MG A071370 001 May 05, 1987

80MG A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS 10MG A072063 001 Jul 29, 1988

20MG A072066 001 Jul 29, 1988

40MG A072067 001 Jul 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A071687	001	Jul 05, 1988
	40MG	A071688	001	Jul 05, 1988
	60MG	A072197	001	Jul 05, 1988
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986
YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986
	20MG	A070664	001	Jun 13, 1986
	40MG	A070665	001	Jun 13, 1986
	60MG	A070666	001	Oct 10, 1986
	80MG	A070667	001	Jun 13, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE 50% N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE 60% N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT 50MG A084075 001

ANABOLIC 50MG A080285 001

ANI PHARMS INC 50MG A080215 001

CHARTWELL RX 50MG A084543 001

HALSEY 50MG A080015 001

IMPAX LABS 50MG A080159 001

LANNETT 50MG A080016 001

LILLY 50MG N006213 001

QUAGEN 50MG A080154 001

SUN PHARM INDUSTRIES 50MG A083982 001

TABLICAPS 50MG A080840 001

WATSON LABS 50MG A080932 001

50MG A085201 001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+ LILLY 10MG/ML ** N006460 002

PHARMACIA AND UPJOHN 50MG/VIAL N007413 001

250MG/VIAL N007413 002 Aug 02, 1984

WEST-WARD PHARMS INT 10MG/ML A089474 001 Nov 05, 1986

10MG/ML A089475 001 Nov 05, 1986

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE 5% N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN 5% N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT 0.5MG/ML N017638 001

THYREL TRH

FERRING 0.5MG/ML N018087 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US 2MG A083459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS 5MG ** N016012 001

10MG ** N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US 120MG N017603 001

SUDAFED 12 HOUR

+ GLAXOSMITHKLINE 120MG ** N017941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE 120MG; 5MG N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG; 5MG A071798 001 Mar 16, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTAHIST

CENCI 30MG/5ML;1.25MG/5ML A088344 001 Feb 09, 1984

HISTAFED

CENCI 30MG/5ML;1.25MG/5ML A088283 001 Apr 20, 1984

MYFED

USL PHARMA 30MG/5ML;1.25MG/5ML A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS 30MG/5ML;1.25MG/5ML A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM 60MG;2.5MG A088860 001 Jan 31, 1985

CORPHED

FOSUN PHARMA 60MG;2.5MG A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ 60MG;2.5MG A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS 60MG;2.5MG A088515 001 Jan 09, 1985

TRIPHED

TEVA 60MG;2.5MG A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS 60MG;2.5MG A088318 002 Jan 13, 1984

WEST WARD 60MG;2.5MG A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 60MG;2.5MG A085273 001 Dec 12, 1984

SUPERPHARM 60MG;2.5MG A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12

UCB INC EQ 60MG HYDROCHLORIDE/5ML N019401 001 Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC 30MG A040512 002 Jul 20, 2005

60MG A040512 001 Oct 08, 2003

IMPAX LABS INC 60MG A040457 001 Dec 26, 2002

SOLVAY 30MG A089572 001 Nov 27, 1990

US ARMY 30MG N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEXA-BETALIN

LILLY 100MG/ML A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN 100MG/ML A087967 001 Oct 01, 1982

BEL MAR 100MG/ML A080761 001

DELL LABS 50MG/ML A083771 001

100MG/ML A083772 001

DR REDDYS 100MG/ML A080572 001

ELKINS SINN 100MG/ML A080581 001

LUITPOLD 100MG/ML A080669 001

MYLAN INSTITUTIONAL 100MG/ML A204879 001 Jul 14, 2016

WATSON LABS 100MG/ML A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS 25MG A080808 001

WATSON LABS 25MG A085231 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE

25MG; 500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET; ORAL

DORAL

GALT PHARMS

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013

EQ 50MG BASE

A201762 002 Feb 27, 2013

EQ 100MG BASE

A201762 003 Feb 27, 2013

EQ 150MG BASE

A201762 004 Feb 27, 2013

EQ 200MG BASE

A201762 005 Feb 27, 2013

EQ 300MG BASE

A201762 006 Feb 27, 2013

EQ 400MG BASE

A201762 007 Feb 27, 2013

MYLAN PHARMS INC

EQ 25MG BASE

A090323 001 Mar 27, 2012

SEROQUEL

+ ASTRAZENECA PHARMS

EQ 150MG BASE **

N020639 004 Dec 20, 1998

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AMNEAL PHARMS

EQ 400MG BASE

A211405 001 Oct 26, 2018

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

ACTAVIS LABS FL INC

EQ 5MG BASE

A076049 001 Jan 14, 2005

EQ 10MG BASE

A076049 002 Jan 14, 2005

EQ 20MG BASE

A076049 003 Jan 14, 2005

EQ 40MG BASE

A076049 004 Jan 14, 2005

ANI PHARMS INC

EQ 5MG BASE

A075504 001 Aug 24, 2007

EQ 10MG BASE

A075504 002 Aug 24, 2007

EQ 20MG BASE

A075504 003 Aug 24, 2007

EQ 40MG BASE

A075504 004 Aug 24, 2007

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

EQ 40MG BASE

A076240 004 Jan 26, 2006

MYLAN

EQ 5MG BASE

A076036 001 Jan 28, 2005

EQ 10MG BASE

A076036 002 Jan 28, 2005

EQ 20MG BASE

A076036 003 Jan 28, 2005

EQ 40MG BASE

A076036 004 Jan 28, 2005

SUN PHARM INDS LTD

EQ 5MG BASE

A076607 001 Dec 15, 2004

EQ 5MG BASE

A090800 001 Jun 18, 2009

EQ 10MG BASE

A076607 002 Dec 15, 2004

EQ 10MG BASE

A090800 002 Jun 18, 2009

EQ 20MG BASE

A076607 003 Dec 15, 2004

EQ 20MG BASE

A090800 003 Jun 18, 2009

EQ 40MG BASE

A076607 004 Dec 15, 2004

EQ 40MG BASE

A090800 004 Jun 18, 2009

YAOPHARMA CO LTD

EQ 5MG BASE

A076803 001 Mar 02, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

EQ 10MG BASE	A076803 002	Mar 02, 2005
EQ 20MG BASE	A076803 003	Mar 02, 2005
EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS

0.1MG	N016768 002	
0.2MG	N016768 003	

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE

50MG	N013264 001	
------	-------------	--

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE

50MG; 0.125MG	N013927 001	
---------------	-------------	--

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML	N007529 002	Feb 10, 1989
---------	-------------	--------------

TABLET; ORAL

QUINACT

BAYER HLTHCARE

266MG	A085978 001	
400MG	A086099 001	

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT

330MG	N017917 001	
-------	-------------	--

QUINAGLUTE

+ BAYER HLTHCARE

324MG	N016647 001	
-------	-------------	--

QUINALAN

LANNETT

324MG	A088081 001	Feb 10, 1986
-------	-------------	--------------

QUINATIME

WATSON LABS

324MG	A087448 001	
-------	-------------	--

QUINIDINE GLUCONATE

ANI PHARMS INC

324MG	A087810 001	Sep 29, 1982
-------	-------------	--------------

ASCOT

324MG	A088582 001	Jun 17, 1985
-------	-------------	--------------

AUROLIFE PHARMA LLC

324MG	A089894 001	Dec 15, 1988
-------	-------------	--------------

CYCLE PHARMS LTD

324MG	A088431 001	Jan 06, 1984
-------	-------------	--------------

HALSEY

324MG	A089476 001	Apr 10, 1987
-------	-------------	--------------

SUPERPHARM

324MG	A089164 001	Nov 21, 1985
-------	-------------	--------------

WATSON LABS

324MG	A087785 001	Jan 24, 1983
-------	-------------	--------------

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC

275MG	N011642 002	
-------	-------------	--

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG	A085296 001	
-------	-------------	--

300MG	A085297 001	
-------	-------------	--

QUINIDINE SULFATE

LILLY

200MG	A085103 001	
-------	-------------	--

TABLET; ORAL

CIN-QUIN

SOLVAY

100MG	A085299 001	
-------	-------------	--

200MG	A084932 001	
-------	-------------	--

300MG	A085298 001	
-------	-------------	--

QUINIDINE SULFATE

BARR

200MG	A084177 001	
-------	-------------	--

CONTRACT PHARMACAL

200MG	A083808 001	
-------	-------------	--

CYCLE PHARMS LTD

200MG	A083640 001	
-------	-------------	--

300MG	A085632 001	
-------	-------------	--

DAVA PHARMS INC

200MG	A087011 001	
-------	-------------	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA PHARMS	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUN PHARM INDUSTRIES	100MG	A081029	001	Apr 14, 1989
	200MG	A081030	001	Apr 14, 1989
	300MG	A081031	001	Apr 14, 1989
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

QUINIDINE SULFATE

ACP NIMBLE	300MG	A040045	001	Jun 30, 1994
------------	-------	---------	-----	--------------

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012
------------------	-------	---------	-----	--------------

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

+ EISAI INC	10MG **	N020973	001	May 29, 2002
-------------	---------	---------	-----	--------------

RABEPRAZOLE SODIUM

MYLAN	20MG	A076885	001	Nov 08, 2013
-------	------	---------	-----	--------------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009
WATSON LABS	5MG	A076549	003	Oct 24, 2005
YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008
	2.5MG	A077514	002	Jun 18, 2008
	5MG	A077514	003	Jun 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

10MG

A077514 004 Jun 18, 2008

TABLET; ORAL

ALTACE

+ KING PFIZER

1.25MG **

N022021 001 Feb 27, 2007

+

2.5MG **

N022021 002 Feb 27, 2007

+

5MG **

N022021 003 Feb 27, 2007

+

10MG **

N022021 004 Feb 27, 2007

RAMIPRIL

APOTEX

1.25MG

A091069 001 Dec 02, 2015

2.5MG

A091069 002 Dec 02, 2015

5MG

A091069 003 Dec 02, 2015

10MG

A091069 004 Dec 02, 2015

MYLAN PHARMS INC

1.25MG

A090650 001 Jun 30, 2011

2.5MG

A090650 002 Jun 30, 2011

5MG

A090650 003 Jun 30, 2011

10MG

A090650 004 Jun 30, 2011

ZYDUS PHARMS USA INC

1.25MG

A090697 001 Sep 24, 2009

2.5MG

A090697 002 Sep 24, 2009

5MG

A090697 003 Sep 24, 2009

10MG

A090697 004 Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET; ORAL

TRITEC

GLAXOSMITHKLINE

400MG

N020559 001 Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

+ GLAXOSMITHKLINE

EQ 150MG BASE **

N020095 001 Mar 08, 1994

ZANTAC 300

+ GLAXOSMITHKLINE

EQ 300MG BASE **

N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

TELIGENT

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 15MG BASE/ML

A076124 001 Feb 21, 2007

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

TORRENT

EQ 15MG BASE/ML

A090102 001 May 26, 2009

WOCKHARDT

EQ 15MG BASE/ML

A079211 001 May 26, 2009

EQ 15MG BASE/ML

A079212 001 Feb 23, 2009

ZANTAC

+ GLAXO GRP LTD

EQ 15MG BASE/ML

N019675 001 Dec 30, 1988

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

ANI PHARMS INC

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 75MG BASE

A075296 001 Jan 14, 2000

EQ 150MG BASE

A074488 001 Jul 31, 1997

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A074488 002 Jul 31, 1997

EQ 300MG BASE

A077426 002 Dec 19, 2005

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

CONTRACT PHARMACAL

EQ 75MG BASE

A075094 001 Jun 21, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000
	EQ 150MG BASE	A074023 001	Aug 22, 1997
	EQ 150MG BASE	A074552 001	Jul 30, 1998
	EQ 300MG BASE	A074023 002	Aug 22, 1997
	EQ 300MG BASE	A074552 002	Jul 30, 1998
RANBAXY	EQ 75MG BASE	A075254 001	Jan 14, 2000
	EQ 150MG BASE	A075000 001	Jan 30, 1998
	EQ 300MG BASE	A075000 002	Jan 30, 1998
SANDOZ	EQ 75MG BASE	A075519 001	Sep 26, 2002
SUN PHARM INDS LTD	EQ 75MG BASE	A075132 001	Jan 14, 2000
	EQ 150MG BASE	A075439 001	Apr 19, 2000
	EQ 300MG BASE	A075439 002	Apr 19, 2000
WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997
	EQ 300MG BASE	A074864 002	Oct 20, 1997
WOCKHARDT	EQ 75MG BASE	A078884 001	Jul 31, 2008
	EQ 150MG BASE	A078653 001	Nov 26, 2007
	EQ 150MG BASE	A078701 001	Nov 12, 2009
	EQ 300MG BASE	A078701 002	Dec 11, 2009
ZANTAC 150			
+ GLAXO GRP LTD	EQ 150MG BASE **	N018703 001	Jun 09, 1983
ZANTAC 300			
+ GLAXO GRP LTD	EQ 300MG BASE **	N018703 002	Dec 09, 1985
TABLET, EFFERVESCENT;ORAL			
ZANTAC 150			
GLAXO GRP LTD	EQ 150MG BASE	N020251 001	Mar 31, 1994
ZANTAC 25			
GLAXO GRP LTD	EQ 25MG BASE	N020251 003	Apr 01, 2004
ZANTAC 75			
+ SANOFI US	EQ 75MG BASE **	N020745 001	Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION

RAPLON

ORGANON USA INC	100MG/VIAL	N020984 001	Aug 18, 1999
	200MG/VIAL	N020984 002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

APOTEX INC	EQ 0.5MG BASE	A201950 001	Sep 12, 2013
	EQ 1MG BASE	A201950 002	Sep 12, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276 003	
	50MG	N009276 005	
	100MG	N009276 004	

HYSERPIN

PHYS PRODS VA	50MG	N010581 001	
---------------	------	-------------	--

KONGLUCOID

PANRAY	50MG	N009278 001	
	100MG	N009278 002	

RAUDIXIN

APOTHECON	50MG	N008842 001	
	100MG	N008842 002	

RAUSERPIN

FERNDALE LABS	50MG	N009926 002	
	100MG	N009926 004	

RAUVAL

PAL PAK	50MG	N009108 002	
	100MG	N009108 004	

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477 001	
	100MG	N009477 002	
HALSEY	50MG	A080498 001	
	100MG	A080498 002	
IMPAX LABS	50MG	N009273 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

RAUWOLFIA SERPENTINA

	100MG	N009273 002
IVAX SUB TEVA PHARMS	50MG	N011521 001
	100MG	N011521 002
PUREPAC PHARM	50MG	A080842 001
	100MG	A080842 002
PVT FORM	50MG	A080583 001
	100MG	A080583 002
SOLVAY	50MG	A080500 001
	100MG	A080500 002
TABLICAPS	50MG	A083867 001
	100MG	A083444 001
VALEANT PHARM INTL	50MG	N009668 001
	100MG	N009668 002
WATSON LABS	50MG	A080907 001
	100MG	A080914 001
WOLFINA		
FOREST PHARMS	50MG	N009255 008
	100MG	N009255 006

REPAGLINIDE

TABLET; ORAL

PRANDIN

+	GEMINI LABS LLC	0.5MG	N020741 001	Dec 22, 1997
+		1MG	N020741 002	Dec 22, 1997
+		2MG	N020741 003	Dec 22, 1997

REPAGLINIDE

MYLAN	0.5MG	A090252 001	Aug 23, 2013
	1MG	A090252 002	Jan 22, 2014
	2MG	A090252 003	Jan 22, 2014

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY	0.5MG	A084736 001
--------	-------	-------------

TABLET; ORAL

MODERIL

PFIZER	0.25MG	N010686 003
	0.5MG	N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS	0.2MG/4ML	N009115 005
----------	-----------	-------------

INJECTABLE; INJECTION

SANDRIL

LILLY	2.5MG/ML	N010012 001
-------	----------	-------------

SERPASIL

NOVARTIS	2.5MG/ML	N009434 002
----------	----------	-------------

TABLET; ORAL

HISERPIA

BOWMAN PHARMS	0.1MG	N009631 002
	0.25MG	N009631 004

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357 001
	0.25MG	N009357 004
	0.5MG	N009357 006
	1MG	N009357 008

RESERPINE

BARR	0.25MG	A080721 002
BELL PHARMA	0.1MG	A083058 001
	0.25MG	A083058 002
BUNDY	0.1MG	N009663 001
	0.25MG	N009663 003
CYCLE PHARMS LTD	0.1MG	N009859 001
	0.25MG	N009859 002
ELKINS SINN	0.1MG	A083145 001
	0.25MG	A083145 002
EVERYLIFE	0.1MG	N010441 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINETABLET; ORAL
RESERPINE

	0.25MG	N010441 002	
	0.5MG	N010441 003	
	1MG	N010441 004	
HALSEY	0.1MG	A080457 002	
	0.25MG	A080457 001	
	1MG	A080457 003	
HIKMA INTL PHARMS	0.1MG	A080975 001	
	0.25MG	A080975 002	
	1MG	A080975 003	
IMPAX LABS	0.1MG	N009627 001	
	0.25MG	N009627 002	
IVAX SUB TEVA PHARMS	0.1MG	N011185 001	
	0.25MG	N011185 002	
MARSHALL PHARMA	0.1MG	A080492 001	
	0.25MG	A080492 002	
MK LABS	0.1MG	A080525 002	
	0.25MG	A080525 001	
MYLAN	1MG	A084974 001	
PHARMAVITE	0.25MG	A084663 001	
PUREPAC PHARM	0.1MG	A080753 002	
	0.25MG	A080753 001	
PVT FORM	0.1MG	A086117 001	
	0.25MG	A080582 001	
	0.25MG	A085775 001	
	1MG	A080582 002	
REXALL	0.25MG	A080637 001	
+ SANDOZ	0.1MG	N009838 001	
+	0.25MG	N009838 002	
SOLVAY	0.25MG	A080446 001	
TABLICAPS	0.25MG	A085207 001	
TEVA	0.1MG	A089020 001	Mar 07, 1985
	0.25MG	A089019 001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667 001	
	0.25MG	N009667 002	
WATSON LABS	0.1MG	A080679 001	
	0.25MG	A080393 001	
	0.25MG	A085401 001	
	1MG	A080749 001	
WHITEWORTH TOWN PLSN	0.1MG	A080723 001	
	0.25MG	A080723 002	
	1MG	A080723 003	
SANDRIL			
LILLY	0.1MG	N009376 004	
	0.25MG	N009376 001	
SERPALAN			
LANNETT	0.1MG	N010124 001	
	0.25MG	N010124 002	
SERPANRAY			
PANRAY	0.1MG	N009391 001	
	0.25MG	N009391 002	
	1MG	N009391 004	
SERPASIL			
NOVARTIS	0.1MG	N009115 001	
	0.25MG	N009115 003	
	1MG	N009115 004	
SERPATE			
VALE	0.1MG	N009453 001	
	0.25MG	N009453 002	
SERPIVITE			
VITARINE	0.25MG	N009645 002	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US 0.1MG;2MG N012972 001

METATENSIN #4

SANOFI AVENTIS US 0.1MG;4MG N012972 002

NAQUIVAL

SCHERING 0.1MG;4MG N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS 0.1MG;4MG A085248 001

RIBAVIRIN

CAPSULE; ORAL

REBETOL

MERCK SHARP DOHME 200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy** N020903 001 Jun 03, 1998

RIBAVIRIN

CASI PHARMS INC 200MG A076192 001 Apr 06, 2004

SOLUTION; ORAL

REBETOL

+ SCHERING 40MG/ML N021546 001 Jul 29, 2003

TABLET; ORAL

COPEGUS

ROCHE 200MG ** N021511 001 Dec 03, 2002

400MG ** N021511 002 Jun 21, 2005

RIBAVIRIN

HERITAGE PHARMA 200MG A077053 001 Dec 05, 2005

RILUZOLE

TABLET; ORAL

RILUZOLE

DAITO PHARMS CO LTD 50MG A204430 001 Oct 16, 2018

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS 50MG/5ML N019650 001 Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

HERITAGE PHARMA 100MG A076375 001 Jan 14, 2003

IMPAX LABS INC 100MG A075916 001 Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

EYEVANCE 1% N020474 001 Dec 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

+ APIL 75MG ** N020835 004 Apr 16, 2007

RISEDRONATE SODIUM

HANGZHOU BINJIANG 35MG A207516 001 Feb 15, 2019

MYLAN 5MG A200477 001 Nov 30, 2015

30MG A200477 002 Nov 30, 2015

35MG A200477 003 Nov 30, 2015

75MG A200477 004 Jun 10, 2014

150MG A200477 005 Jun 10, 2014

TABLET, DELAYED RELEASE; ORAL

RISEDRONATE SODIUM

IMPAX LABS INC 35MG A205066 001 Jun 29, 2018

ZYDUS PHARMS 35MG A203822 001 Sep 11, 2018

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

ANI PHARMS INC 1MG/ML A076440 001 Jan 30, 2009

LANNETT CO INC 1MG/ML A202386 001 Jan 12, 2015

PRECISION DOSE 1MG/ML A076797 001 Jun 28, 2010

TORRENT 1MG/ML A078909 001 Jul 29, 2009

WOCKHARDT 1MG/ML A078744 001 Oct 08, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS 5MG N020272 005 Dec 29, 1993

RISPERIDONE

HERITAGE PHARMA 0.25MG A076228 001 Jun 30, 2008

0.25MG A077769 001 Oct 16, 2008

0.5MG A076228 002 Jun 30, 2008

0.5MG A077769 002 Oct 16, 2008

1MG A076228 003 Jun 30, 2008

1MG A077769 003 Oct 16, 2008

2MG A076228 004 Jun 30, 2008

2MG A077769 004 Oct 16, 2008

3MG A076228 005 Jun 30, 2008

3MG A077769 005 Oct 16, 2008

4MG A076228 006 Jun 30, 2008

4MG A077769 006 Oct 16, 2008

JUBILANT CADISTA 0.25MG A078828 001 Mar 23, 2009

0.5MG A078828 002 Mar 23, 2009

1MG A078828 003 Mar 23, 2009

2MG A078828 004 Mar 23, 2009

3MG A078828 005 Mar 23, 2009

4MG A078828 006 Mar 23, 2009

RATIOPHARM 0.25MG A077784 001 Jun 08, 2010

0.5MG A077784 002 Jun 08, 2010

1MG A077784 003 Jun 08, 2010

2MG A077784 004 Jun 08, 2010

3MG A077784 005 Jun 08, 2010

4MG A077784 006 Jun 08, 2010

SUN PHARM INDS INC 0.25MG A078036 001 Mar 10, 2014

0.5MG A078036 002 Mar 10, 2014

1MG A078036 003 Mar 10, 2014

2MG A078036 004 Mar 10, 2014

3MG A078036 005 Mar 10, 2014

4MG A078036 006 Mar 10, 2014

SYNTHON PHARMS 0.25MG A078187 001 Oct 22, 2009

0.5MG A078187 002 Oct 22, 2009

1MG A078187 003 Oct 22, 2009

2MG A078187 004 Oct 22, 2009

3MG A078187 005 Oct 22, 2009

4MG A078187 006 Oct 22, 2009

WATSON LABS 0.25MG A077860 001 Dec 05, 2008

0.5MG A077860 002 Dec 05, 2008

1MG A077860 003 Dec 05, 2008

2MG A077860 004 Dec 05, 2008

3MG A077860 005 Dec 05, 2008

4MG A077860 006 Dec 05, 2008

WEST WARD PHARMS 0.25MG A078740 001 May 29, 2009

0.5MG A078740 002 May 29, 2009

1MG A078740 003 May 29, 2009

2MG A078740 004 May 29, 2009

3MG A078740 005 May 29, 2009

4MG A078740 006 May 29, 2009

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

MYLAN PHARMS INC 0.25MG A091537 006 Feb 12, 2013

0.5MG A091537 001 Mar 30, 2011

1MG A091537 002 Mar 30, 2011

2MG A091537 003 Mar 30, 2011

3MG A091537 004 Mar 30, 2011

4MG A091537 005 Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM 10MG/ML A071188 001 Jul 23, 1987

15MG/ML A071189 001 Jul 23, 1987

HOSPIRA 10MG/ML A071618 001 Feb 28, 1991

15MG/ML A071619 001 Feb 28, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001 Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002 Sep 27, 1984

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001 Mar 01, 1996

+ ABBVIE

100MG **

N020945 001 Jun 29, 1999

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

+ NOVARTIS

EQ 1.5MG BASE

N020823 003 Apr 21, 2000

+

EQ 3MG BASE

N020823 004 Apr 21, 2000

+

EQ 4.5MG BASE

N020823 005 Apr 21, 2000

+

EQ 6MG BASE

N020823 006 Apr 21, 2000

SOLUTION; ORAL

EXELON

NOVARTIS

EQ 2MG BASE/ML

N021025 001 Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

+ MERCK

EQ 5MG BASE **

N020864 001 Jun 29, 1998

RIZATRIPTAN BENZOATE

APOTEX INC

EQ 5MG BASE

A202244 001 Dec 31, 2012

EQ 10MG BASE

A202244 002 Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

+ MERCK

EQ 5MG BASE **

N020865 001 Jun 29, 1998

RIZATRIPTAN BENZOATE

APOTEX INC

EQ 5MG BASE

A202477 001 Jul 01, 2013

EQ 10MG BASE

A202477 002 Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

+ ORGANON USA INC

50MG/5ML (10MG/ML) **

N020214 001 Mar 17, 1994

+

10MG/ML (10MG/ML) **

N020214 002 Mar 17, 1994

+

100MG/10ML (10MG/ML) **

N020214 003 Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001 May 20, 1999

25MG/5ML

N021052 002 May 20, 1999

TABLET; ORAL

VIOXX

MERCK

12.5MG

N021042 001 May 20, 1999

25MG

N021042 002 May 20, 1999

50MG

N021042 003 Feb 25, 2000

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

MYLAN

500MCG

A208257 001 Jul 13, 2018

ROLAPITANT HYDROCHLORIDE

EMULSION; INTRAVENOUS

VARUBI

+ TERSERA THERAPS LLC

EQ 166.5MG BASE/92.5ML (EQ 1.8MG
BASE/ML)

N208399 001 Oct 25, 2017

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

ACP NIMBLE

EQ 0.25MG BASE

A077460 001 May 05, 2008

EQ 0.5MG BASE

A077460 002 May 05, 2008

EQ 1MG BASE

A077460 003 May 05, 2008

EQ 2MG BASE

A077460 004 May 05, 2008

EQ 3MG BASE

A077460 005 May 05, 2008

EQ 4MG BASE

A077460 006 May 05, 2008

EQ 5MG BASE

A077460 007 May 19, 2008

EPIC PHARMA LLC

EQ 0.25MG BASE

A078230 001 May 20, 2008

EQ 0.5MG BASE

A078230 002 May 20, 2008

EQ 1MG BASE

A078230 003 May 20, 2008

EQ 2MG BASE

A078230 004 May 20, 2008

EQ 3MG BASE

A078230 005 May 20, 2008

EQ 4MG BASE

A078230 006 May 20, 2008

EQ 5MG BASE

A078230 007 May 20, 2008

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

+ GLAXOSMITHKLINE LLC

EQ 3MG BASE **

N022008 002 Jun 13, 2008

+

EQ 4MG BASE

N022008 003 Jun 13, 2008

ROPINIROLE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 2MG BASE

A200462 001 Oct 15, 2012

EQ 3MG BASE

A200462 002 Oct 15, 2012

EQ 4MG BASE

A200462 003 Oct 15, 2012

EQ 6MG BASE

A200462 004 Oct 15, 2012

EQ 8MG BASE

A200462 005 Oct 15, 2012

EQ 12MG BASE

A200462 006 Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

FRESENIUS KABI USA

50MG/10ML (5MG/ML)

N020533 013 May 01, 1998

75MG/10ML (7.5MG/ML)

N020533 012 Sep 24, 1996

ROSE BENGAL SODIUM I-131

INJECTABLE;INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL

N016224 001

1mCi/VIAL

N016224 002

2mCi/VIAL

N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML

N017318 001

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

+ SB PHARMCO

EQ 8MG BASE

N021071 004 May 25, 1999

ROSIGLITAZONE MALEATE

ANI PHARMS INC

EQ 2MG BASE

A076747 001 Jan 25, 2013

EQ 4MG BASE

A076747 002 Jan 25, 2013

EQ 8MG BASE

A076747 003 Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AMNEAL PHARMS CO

5MG

A208850 001 Oct 16, 2018

10MG

A208850 002 Oct 16, 2018

20MG

A208850 003 Oct 16, 2018

40MG

A208850 004 Oct 16, 2018

MYLAN

5MG

A079161 001 Jul 19, 2016

10MG

A079161 002 Jul 19, 2016

20MG

A079161 003 Jul 19, 2016

40MG

A079161 004 Jul 19, 2016

SCIEGEN PHARMS INC

5MG

A206381 001 Apr 24, 2019

10MG

A206381 002 Apr 24, 2019

20MG

A206381 003 Apr 24, 2019

40MG

A206381 004 Apr 24, 2019

TEVA PHARMS USA

5MG

A079166 001 Jul 19, 2016

10MG

A079166 002 Jul 19, 2016

20MG

A079166 003 Jul 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

	40MG	A079166 004	Jul 19, 2016
UMEDICA LABS PVT LTD	5MG	A207626 001	Apr 09, 2019
	10MG	A207626 002	Apr 09, 2019
	20MG	A207626 003	Apr 09, 2019
	40MG	A207626 004	Apr 09, 2019
ZYDUS PHARMS	5MG	A206513 001	Mar 01, 2019
	10MG	A206513 002	Mar 01, 2019
	20MG	A206513 003	Mar 01, 2019
	40MG	A206513 004	Mar 01, 2019

RUFINAMIDE

TABLET; ORAL

BANZEL

+ EISAI INC

100MG **

N021911 001 Nov 14, 2008

RUFINAMIDE

MYLAN

200MG

A205095 001 May 16, 2016

400MG

A205095 002 May 16, 2016

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

SAPROPTERIN DIHYDROCHLORIDE

PAR PHARM INC

500MG/PACKET

A210027 001 Aug 20, 2019

TABLET; ORAL

SAPROPTERIN DIHYDROCHLORIDE

PAR PHARM INC

100MG

A207200 001 May 10, 2019

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

+ HOFFMANN LA ROCHE

200MG **

N020828 001 Nov 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HOFFMANN LA ROCHE

EQ 200MG BASE

N020628 001 Dec 06, 1995

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

LANNETT

100MG

A085903 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

PARKE DAVIS	100MG	A084762	001
PERRIGO	100MG	A084561	001
PUREPAC PHARM	100MG	A085867	001
VALEANT PHARM INTL	100MG	A085477	001
VITARINE	100MG	A085898	001
	100MG	A086273	001
WATSON LABS	100MG	A085792	001
WEST WARD	100MG	A084926	001
WHITEWORTH TOWN PLSN	100MG	A085798	001
WYETH AYERST	100MG	A086390	001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN	100MG/VIAL	A083281	001
WYETH AYERST	50MG/ML	A083262	001

SECONAL SODIUM

LILLY	50MG/ML	N007392	002
-------	---------	---------	-----

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY	30MG	A086530	001
	60MG	A086530	002
	120MG	A086530	003
	200MG	A086530	004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING	75CU/VIAL	N018290	001
---------	-----------	---------	-----

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECFEFO

CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002
------------	------------	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

+ SOMERSET	5MG	N020647	001	May 15, 1996
------------	-----	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

LANNETT CO INC	5MG	A075145	001	Sep 15, 2003
----------------	-----	---------	-----	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

ACP NIMBLE	5MG	A074744	001	Jan 27, 1997
	5MG	A074756	001	Nov 25, 1998
ALLIED	5MG	A074672	001	Apr 01, 1997
CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996
	5MG	A074641	001	Aug 02, 1996
G AND W LABS INC	5MG	A074537	001	Aug 02, 1996
MYLAN	5MG	A074866	001	Nov 26, 1997
+ SOMERSET	5MG **	N019334	001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT	2.5%	A083892	001
------------------	------	---------	-----

SELENIUM SULFIDE

ACP NIMBLE	2.5%	A086209	001
ACTAVIS MID ATLANTIC	2.5%	A084394	001
IVAX PHARMS	2.5%	A085777	001

SELSUN

+ CHATTEM	2.5%	N007936	001
-----------	------	---------	-----

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001
MALLINCKRODT	100uCi/ML	N017098	001
PHARMALUCENCE	500uCi/ML	N017322	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SETHOTOPE

BRACCO

85-550uCi/ML

N017047 001

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+ EMD SERONO

EQ 0.05MG BASE/AMP **

N019863 001 Dec 28, 1990

+ EMD SERONO INC

EQ 0.5MG BASE/VIAL **

N020443 001 Sep 26, 1997

+

EQ 1MG BASE/VIAL **

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

ACI HEALTHCARE LTD

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006

RANBAXY LABS LTD

EQ 20MG BASE/ML

A078053 001 Feb 05, 2007

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACI HEALTHCARE LTD

EQ 25MG BASE

A076881 001 Feb 06, 2007

EQ 50MG BASE

A076881 002 Feb 06, 2007

EQ 100MG BASE

A076881 003 Feb 06, 2007

ANDA REPOSITORY

EQ 25MG BASE

A077818 001 Feb 06, 2007

EQ 50MG BASE

A077818 002 Feb 06, 2007

EQ 100MG BASE

A077818 003 Feb 06, 2007

CADILA

EQ 25MG BASE

A077106 001 Feb 06, 2007

EQ 50MG BASE

A077106 002 Feb 06, 2007

EQ 100MG BASE

A077106 003 Feb 06, 2007

CHARTWELL MOLECULAR

EQ 25MG BASE

A077162 001 Feb 06, 2007

EQ 50MG BASE

A077162 002 Feb 06, 2007

EQ 100MG BASE

A077162 003 Feb 06, 2007

FOSUN PHARMA

EQ 25MG BASE

A077713 001 Feb 06, 2007

EQ 50MG BASE

A077713 002 Feb 06, 2007

EQ 100MG BASE

A077713 003 Feb 06, 2007

HERITAGE PHARMA

EQ 25MG BASE

A076465 001 Aug 11, 2006

EQ 25MG BASE

A077299 001 Feb 06, 2007

EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 25MG BASE

A077663 001 Feb 06, 2007

EQ 50MG BASE

A076465 002 Aug 11, 2006

EQ 50MG BASE

A077299 002 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 50MG BASE

A077663 002 Feb 06, 2007

EQ 100MG BASE

A076465 003 Aug 11, 2006

EQ 100MG BASE

A077299 003 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

EQ 100MG BASE

A077663 003 Feb 06, 2007

HIKMA PHARMS

EQ 25MG BASE

A077864 001 Aug 10, 2009

EQ 50MG BASE

A077864 002 Aug 10, 2009

EQ 100MG BASE

A077864 003 Aug 10, 2009

IVAX SUB TEVA PHARMS

EQ 25MG BASE

A075719 003 Jun 30, 2006

EQ 50MG BASE

A075719 001 Jun 30, 2006

EQ 100MG BASE

A075719 002 Jun 30, 2006

MYLAN

EQ 25MG BASE

A076671 001 Feb 06, 2007

EQ 50MG BASE

A076671 002 Feb 06, 2007

EQ 100MG BASE

A076671 003 Feb 06, 2007

MYLAN PHARMS INC

EQ 25MG BASE

A076540 001 Mar 20, 2007

EQ 25MG BASE

A078626 001 Jan 31, 2008

EQ 50MG BASE

A076540 002 Mar 20, 2007

EQ 50MG BASE

A078626 002 Jan 31, 2008

EQ 100MG BASE

A076540 003 Mar 20, 2007

EQ 100MG BASE

A078626 003 Jan 31, 2008

SCIEGEN PHARMS INC

EQ 25MG BASE

A076442 001 Apr 30, 2007

EQ 50MG BASE

A076442 002 Apr 30, 2007

EQ 100MG BASE

A076442 003 Apr 30, 2007

SUN PHARM INDS (IN)

EQ 25MG BASE

A078108 001 Feb 06, 2007

EQ 50MG BASE

A078108 002 Feb 06, 2007

EQ 100MG BASE

A078108 003 Feb 06, 2007

ZOLOFT

+ PFIZER

EQ 150MG BASE **

N019839 003 Dec 30, 1991

+

EQ 200MG BASE **

N019839 004 Dec 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL

RENAGEL

GENZYME

403MG

N020926 001 Oct 30, 1998

SIBUTRAMINE HYDROCHLORIDE

CAPSULE;ORAL

MERIDIA

ABBOTT

5MG

N020632 001 Nov 22, 1997

10MG

N020632 002 Nov 22, 1997

15MG

N020632 003 Nov 22, 1997

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

ACTAVIS GRP PTC

EQ 20MG BASE

A200149 001 Feb 25, 2013

APOTEX CORP

EQ 20MG BASE

A091379 001 Nov 06, 2012

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD AF

DR REDDYS LA

1%

N018578 003 Jul 11, 1990

DRESSING;TOPICAL

SILDAFLO

FRANKLIN PHARMS

1%

N019608 001 Nov 30, 1989

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+ JANSSEN PRODS

EQ 150MG BASE

N205123 001 Nov 22, 2013

SIMETHICONE-CELLULOSE

SUSPENSION;ORAL

SONORX

BRACCO

7.5MG/ML

N020773 001 Oct 29, 1998

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

HISUN PHARM HANGZHOU

10MG

A206557 001 Nov 13, 2017

20MG

A206557 002 Nov 13, 2017

40MG

A206557 003 Nov 13, 2017

80MG

A206557 004 Nov 13, 2017

IVAX SUB TEVA PHARMS

5MG

A076052 001 Jun 23, 2006

10MG

A076052 002 Jun 23, 2006

20MG

A076052 003 Jun 23, 2006

40MG

A076052 004 Jun 23, 2006

80MG

A076052 005 Dec 20, 2006

MYLAN PHARMS INC

5MG

A090868 001 Jun 08, 2010

10MG

A090868 002 Jun 08, 2010

20MG

A090868 003 Jun 08, 2010

40MG

A090868 004 Jun 08, 2010

80MG

A090868 005 Jun 08, 2010

SUN PHARM INDS LTD

5MG

A076285 001 Dec 20, 2006

10MG

A076285 002 Dec 20, 2006

20MG

A076285 003 Dec 20, 2006

40MG

A076285 004 Dec 20, 2006

80MG

A076285 005 Jun 23, 2006

YAOPHARMA CO LTD

5MG

A077766 001 Dec 20, 2006

10MG

A077766 002 Dec 20, 2006

20MG

A077766 003 Dec 20, 2006

40MG

A077766 004 Dec 20, 2006

80MG

A077766 005 Dec 20, 2006

TABLET, ORALLY DISINTEGRATING;ORAL

SIMVASTATIN

SYNTHON PHARMS

10MG

N021961 001 Oct 09, 2007

20MG

N021961 002 Oct 09, 2007

40MG

N021961 003 Oct 09, 2007

80MG

N021961 004 Oct 09, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343	004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343	001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343	005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343	002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343	006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343	003	Oct 07, 2011

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+	PF PRISM CV	5MG **	N021110	003	Feb 23, 2004
---	-------------	--------	---------	-----	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

	B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987
--	---------	-------------------	---------	-----	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017
--	-------------	-----------	---------	-----	--------------

SODIUM BICARBONATE IN PLASTIC CONTAINER

+	ABBOTT	0.9MEQ/ML **	N019443	001	Jun 03, 1986
---	--------	--------------	---------	-----	--------------

+		1MEQ/ML **	N019443	002	Jun 03, 1986
---	--	------------	---------	-----	--------------

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985
--	------------------	-------------------	---------	-----	--------------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985
--	---------------	--------	---------	-----	--------------

SODIUM CHLORIDE

	ABBOTT	20GM/100ML	N017013	001	
--	--------	------------	---------	-----	--

	B BRAUN	20GM/100ML	N017038	001	
--	---------	------------	---------	-----	--

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	450MG/100ML	N018184	001	
--	---------	-------------	---------	-----	--

	MILES	450MG/100ML	N018503	001	
--	-------	-------------	---------	-----	--

SODIUM CHLORIDE 0.9%

+	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012
---	-------------	-------------------	---------	-----	--------------

+		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012
---	--	-----------------------	---------	-----	--------------

+		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012
---	--	-------------------	---------	-----	--------------

+		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012
---	--	-------------------	---------	-----	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	9MG/ML	N019218	001	Jul 13, 1984
--	--------	--------	---------	-----	--------------

+	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984
---	-----------------	--------	---------	-----	--------------

+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
---	------------------	---------------------	---------	-----	--------------

+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012
---	-------------	-----------------	---------	-----	--------------

	MILES	900MG/100ML	N018502	001	
--	-------	-------------	---------	-----	--

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

+	ABRAXIS PHARM	234MG/ML **	N019329	001	Apr 22, 1987
---	---------------	-------------	---------	-----	--------------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	450MG/100ML	N017864	001	
--	-----------------	-------------	---------	-----	--

		450MG/100ML	N018497	001	Feb 19, 1982
--	--	-------------	---------	-----	--------------

	HOSPIRA	450MG/100ML	N017670	001	
--	---------	-------------	---------	-----	--

		450MG/100ML	N018380	001	
--	--	-------------	---------	-----	--

SODIUM CHLORIDE IN PLASTIC CONTAINER

	MILES	900MG/100ML	N018247	001	
--	-------	-------------	---------	-----	--

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

	BRACCO	2mCi/VIAL	N013993	002	
--	--------	-----------	---------	-----	--

		200uCi/ML	N013993	001	
--	--	-----------	---------	-----	--

SODIUM CHROMATE CR 51

	CURIUM	100uCi/ML	N016708	001	
--	--------	-----------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

+ GE HEALTHCARE

2mCi/ML **

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML **

N022494 001 Jan 26, 2011

SODIUM FLUORIDE F-18

UIHC PET IMAGING

10-200mCi/ML

A204462 001 Nov 17, 2015

UNIV TX MD ANDERSON

10-200mCi/ML

A203247 001 Dec 23, 2013

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE

0.24%; 0.3%

N020231 001 Jul 11, 1997

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML **

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

CURIUM

0.8-100mCi

N016515 002

+

0.8-100mCi

N016517 001

15-100uCi

N016517 002

JUBILANT DRAXIMAGE

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

+

CURIUM

3.5-150mCi/VIAL

N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

BAXTER HLTHCARE

1.87GM/100ML

N016692 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N020004 001 Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

+

ABBVIE

50MG/VIAL **

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985
+ BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018
TEVA PARENTERAL	25MG/ML	A073465	001	Mar 30, 1992
VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+ EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017
------------------------	----------------------	---------	-----	--------------

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N010927	001	
SODIUM PHOSPHATE P 32				
MALLINCKRODT	0.67mCi/ML	N011777	001	
	1.5mCi/VIAL	N011777	002	

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000
--------------	-----------------	---------	-----	--------------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011
----------------	-----------------	---------	-----	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

+ CONCORDIA	453.6GM/BOT **	N011287	001	
-------------	----------------	---------	-----	--

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA	454GM/BOT	A040909	001	Dec 03, 2008
WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	15GM/60ML	A088717	001	Sep 11, 1984
ROXANE	15GM/60ML	A088453	001	Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN	30%	A080516	001	
-------------	-----	---------	-----	--

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

+ ELKINS SINN	1% **	N005970	004	
+ ELKINS SINN	3% **	N005970	005	

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY	250MG/ML	N020166	001	Feb 14, 1992
---------	----------	---------	-----	--------------

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH	5MG/VIAL	N019107	001	Oct 17, 1985
	10MG/VIAL	N019107	002	Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO	10 IU/VIAL	N017726	001	
--------	------------	---------	-----	--

ASELLACRIN 2

SERONO	2 IU/VIAL	N017726	002	Jul 21, 1983
--------	-----------	---------	-----	--------------

BIO-TROPIN

FERRING	4.8MG/VIAL	N019774	001	May 25, 1995
---------	------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOMATROPIN

INJECTABLE; INJECTION

CRESCORMON					
GENENTECH	4 IU/VIAL		N017992	001	
GENOTROPIN PRESERVATIVE FREE					
+ PHARMACIA	1.5MG/VIAL		N020280	004	Aug 24, 1995
NORDITROPIN					
NOVO NORDISK INC	5MG/1.5ML		N021148	001	Jun 20, 2000
	10MG/1.5ML		N021148	002	Jun 20, 2000
	15MG/1.5ML		N021148	003	Jun 20, 2000
NORDITROPIN NORDIFLEX					
NOVO NORDISK INC	5MG/1.5ML		N021148	004	Oct 01, 2004
	10MG/1.5ML		N021148	005	Oct 01, 2004
	15MG/1.5ML		N021148	006	Oct 01, 2004
	30MG/3ML		N021148	007	Mar 10, 2009
NUTROPIN					
GENENTECH	5MG/VIAL		N020168	001	Nov 17, 1993
	10MG/VIAL		N020168	002	Nov 17, 1993
NUTROPIN AQ					
GENENTECH	10MG/2ML (5MG/ML)		N020522	001	Dec 29, 1995
NUTROPIN AQ PEN					
+ GENENTECH	10MG/2ML (5MG/ML)		N020522	002	Apr 22, 2002
+ SAIZEN	20MG/2ML (10MG/ML)		N020522	006	Jan 03, 2008
SEROSTIM					
EMD SERONO	4MG/VIAL		N019764	005	Jan 16, 2007
	6MG/VIAL		N019764	001	Oct 08, 1996
SEROSTIM					
EMD SERONO	8.8MG/VIAL		N020604	004	Sep 06, 2001
INJECTABLE; SUBCUTANEOUS					
SEROSTIM LQ					
EMD SERONO	6MG/0.5ML (6MG/0.5ML)		N020604	005	Feb 11, 2005

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN					
EMERGENT	5MG/ML (5MG/ML)		N021538	001	Jan 23, 2008
HUMATROPE					
LILLY	2MG/VIAL		N019640	001	Jun 23, 1987
NORDITROPIN					
NOVO NORDISK INC	4MG/VIAL		N019721	001	May 08, 1995
	8MG/VIAL		N019721	002	May 08, 1995
NUTROPIN DEPOT					
GENENTECH	13.5MG/VIAL		N021075	001	Dec 22, 1999
	18MG/VIAL		N021075	002	Dec 22, 1999
	22.5MG/VIAL		N021075	003	Dec 22, 1999
VALTROPIN					
LG CHEM LTD	5MG/VIAL		N021905	001	Apr 19, 2007
ZORBTIVE					
EMD SERONO	4MG/VIAL		N021597	001	Dec 01, 2003
	5MG/VIAL		N021597	002	Dec 01, 2003
	6MG/VIAL		N021597	003	Dec 01, 2003

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	3GM/100ML		N018512	001	May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE					
COVIS PHARMA BV	320MG		N019865	004	Oct 30, 1992
BETAPACE AF					
COVIS PHARMA BV	40MG		N021151	006	Apr 02, 2003
	60MG		N021151	007	Apr 02, 2003
	100MG		N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE					
IMPAX PHARMS	80MG		A075663	001	Nov 07, 2000
	120MG		A075663	002	Nov 07, 2000
	160MG		A075663	003	Nov 07, 2000
	240MG		A075663	004	Nov 07, 2000
MYLAN	80MG		A075237	001	May 01, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

80MG	A075725 001	Dec 19, 2000
120MG	A075237 002	May 01, 2000
120MG	A075725 002	Dec 19, 2000
160MG	A075237 003	May 01, 2000
160MG	A075725 003	Dec 19, 2000
240MG	A075237 004	May 01, 2000
240MG	A075725 004	Dec 19, 2000
SUN PHARM INDUSTRIES 80MG	A075515 001	Oct 15, 2001
80MG	A076576 001	Apr 08, 2004
120MG	A075515 004	Oct 15, 2001
120MG	A076576 002	Apr 08, 2004
160MG	A075515 002	Oct 15, 2001
160MG	A076576 003	Apr 08, 2004
240MG	A075515 003	Oct 15, 2001
TEVA 80MG	A076883 001	Jul 26, 2004
120MG	A076883 002	Jul 26, 2004
160MG	A076883 003	Jul 26, 2004
UPSHER SMITH LABS 80MG	A075366 001	May 01, 2000
120MG	A075366 002	May 01, 2000
160MG	A075366 003	May 01, 2000
240MG	A075366 004	May 01, 2000
WATSON LABS 80MG	A075238 001	Jul 13, 2000
120MG	A075238 002	Jul 13, 2000
160MG	A075238 003	Jul 13, 2000
240MG	A075238 004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

HOSPIRA 10% N018969 001 Sep 24, 1984

LIPOSYN III 20%

HOSPIRA 20% N018970 001 Sep 25, 1984

LIPOSYN III 30%

HOSPIRA 30% N020181 001 Jan 13, 1998

SOYACAL 10%

ALPHA THERA 10% N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA 20% N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE 10% N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE 20% N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN 200MG N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER EQ 2GM BASE/VIAL N050347 001

EQ 4GM BASE/VIAL N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING 3MG N020240 001 Dec 29, 1994

6MG N020240 002 Dec 29, 1994

12MG N020240 003 Dec 29, 1994

24MG N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ACTAVIS ELIZABETH 25MG A040353 003 Mar 15, 2006

50MG A040353 001 Jul 29, 1999

100MG A040353 002 Jul 29, 1999

ASCOT 25MG A087687 001 Oct 20, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AUROBINDO PHARMA LTD	25MG	A202187 001	Mar 06, 2014
	50MG	A202187 002	Mar 06, 2014
	100MG	A202187 003	Mar 06, 2014
CASI PHARMS INC	25MG	A086809 001	
IVAX PHARMS	25MG	A087108 001	
LEDERLE	25MG	A087634 001	
MUTUAL PHARM	25MG	A087265 001	
MYLAN	25MG	A087086 001	
PUREPAC PHARM	25MG	A087998 001	Oct 14, 1983
	25MG	A088053 001	Aug 25, 1983
SUPERPHARM	25MG	A089364 001	Nov 07, 1986
UPSHER SMITH	25MG	A087554 001	
VANGARD	25MG	A087648 001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952 001	Nov 18, 1982
WATSON LABS	25MG	A086898 002	Mar 02, 1982
	25MG	A087078 001	

STANOZOLOL

TABLET;ORAL

WINSTROL

+ LUNDBECK INC	2MG	N012885 001	May 14, 1984
----------------	-----	-------------	--------------

STAVUDINE

CAPSULE;ORAL

STAVUDINE

HETERO LABS LTD III	15MG	A078957 001	Dec 29, 2008
	20MG	A078957 002	Dec 29, 2008
	30MG	A078957 003	Dec 29, 2008
	40MG	A078957 004	Dec 29, 2008
MYLAN	15MG	A079069 001	Dec 29, 2008
	20MG	A079069 002	Dec 29, 2008
	30MG	A079069 003	Dec 29, 2008
	40MG	A079069 004	Dec 29, 2008
MYLAN LABS LTD	30MG	A078775 001	Jan 05, 2009
	40MG	A078775 002	Jan 05, 2009

ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412 001	Jun 24, 1994
----------------------	-----	-------------	--------------

CAPSULE, EXTENDED RELEASE;ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002
	50MG	N021453 002	Dec 31, 2002
	75MG	N021453 003	Dec 31, 2002
	100MG	N021453 004	Dec 31, 2002

FOR SOLUTION;ORAL

STAVUDINE

AUROBINDO PHARMA	1MG/ML	A077774 001	Dec 29, 2008
CIPLA LTD	1MG/ML	A078030 001	Mar 20, 2009

ZERIT

+ BRISTOL-MYERS SQUIBB	1MG/ML	N020413 001	Sep 06, 1996
------------------------	--------	-------------	--------------

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099 001	Dec 29, 1987
	100%	A089100 001	Dec 29, 1987

STERILE WATER FOR INJECTION

+ HOSPIRA	100% (1ML)	N018801 001	Oct 27, 1982
WEST-WARD PHARMS INT	100% (20ML)	A206369 002	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077 001	Mar 02, 1984
---------	------	-------------	--------------

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246 001	
-------	------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684 001
LILLY	EQ 1GM BASE/VIAL	A060107 001
	EQ 1GM BASE/2ML	A060404 001
	EQ 5GM BASE/VIAL	A060107 002
PFIZER	EQ 1GM BASE/VIAL **	A060076 001
	EQ 1GM BASE/2.5ML	A060111 001
	EQ 5GM BASE/VIAL **	A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ INC	50MG/ML	N008453 003
	500MG/VIAL	N008453 001
	1GM/VIAL	N008453 004

QUELICIN PRESERVATIVE FREE

+ HOSPIRA	20MG/ML	N008845 001
	50MG/ML	N008845 002
	100MG/ML	N008845 004

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997 001	

SUCOSTRIN

APOTHECON	20MG/ML	N008847 001
	100MG/ML	N008847 003

SUCRALFATE

TABLET; ORAL

SUCRALFATE

NOSTRUM LABS INC	1GM	A074415 001	Jun 08, 1998
------------------	-----	-------------	--------------

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS	EQ 0.05MG BASE/ML	A074406 001	Dec 15, 1995
-------------	-------------------	-------------	--------------

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN	10%	A084015 001
----------	-----	-------------

CETAMIDE

ALCON	10%	A080021 001
-------	-----	-------------

SODIUM SULAMYD

+ SCHERING	10% **	N005963 002
------------	--------	-------------

SULFAIR 10

PHARMAFAIR	10%	A088000 001	Dec 22, 1982
------------	-----	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN	30%	A080028 002
----------	-----	-------------

ISOPTO CETAMIDE

ALCON	15%	A080020 002
-------	-----	-------------

OCUSULF-10

MIZA PHARMS USA	10%	A080660 001
-----------------	-----	-------------

OCUSULF-30

MIZA PHARMS USA	30%	A080660 002
-----------------	-----	-------------

SODIUM SULAMYD

+ SCHERING	10% **	N005963 001
------------	--------	-------------

+	30% **	N005963 003
---	--------	-------------

SODIUM SULFACETAMIDE

AKORN	10%	A083021 001
-------	-----	-------------

	15%	A083021 002
--	-----	-------------

	30%	A083021 003
--	-----	-------------

SOLA BARNES HIND	10%	A084143 001
------------------	-----	-------------

	10%	A084145 001
--	-----	-------------

	30%	A084146 001
--	-----	-------------

	30%	A084147 001
--	-----	-------------

SULF-10

NOVARTIS	10%	A080025 001
----------	-----	-------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULF-15

NOVARTIS 15% A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS 15% A080024 001

SULFACETAMIDE SODIUM

AKORN 30% A040216 001 May 25, 1999

ALCON PHARMS LTD 30% A089068 001 May 05, 1987

PHARMAFAIR 10% A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR 10% A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR 30% A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR 15% A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB 10% A087818 001 Feb 03, 1983

SULFACYTINE

TABLET;ORAL

RENOQUID

GLENWOOD 250MG N017569 001

SULFADIAZINE

TABLET;ORAL

SULFADIAZINE

ABBVIE 300MG N004125 005

EVERYLIFE 500MG A080088 001

IMPAX LABS 500MG A080081 001

LANNETT 500MG A080084 001

LEDERLE 500MG N004054 001

+ LILLY 500MG N004122 002

SULFADIAZINE SODIUM

INJECTABLE;INJECTION

SULFADIAZINE SODIUM

LEDERLE 250MG/ML N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION;ORAL

SULFONAMIDES DUPLEX

LILLY 250MG/5ML;250MG/5ML N006317 007

SULFAMETER

TABLET;ORAL

SULLA

BAYER HLTHCARE 500MG N016000 002

SULFAMETHIZOLE

TABLET;ORAL

MICROSUL

FOREST PHARMS 1GM A086012 001

PROKLAR

FOREST PHARMS 500MG A080273 001

THIOSULFIL

WYETH AYERST 250MG N008565 001

500MG N008565 004

SULFAMETHOXAZOLE

SUSPENSION;ORAL

GANTANOL

ROCHE 500MG/5ML N013664 002

TABLET;ORAL

GANTANOL

ROCHE 500MG N012715 002

GANTANOL-DS

ROCHE 1GM N012715 003

SULFAMETHOXAZOLE

ASCOT 500MG A087662 001 Oct 20, 1982

AUROLIFE PHARMA LLC 500MG A085844 001

BARR 500MG A087189 001 Jul 25, 1983

HEATHER 500MG A086163 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

WATSON LABS	500MG	A085053	001
	1GM	A086000	001

UROBAK

SHIONOGI	500MG	A087307	001
----------	-------	---------	-----

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

+ SUN PHARM INDS INC	80MG/ML; 16MG/ML **	N018374	001
----------------------	---------------------	---------	-----

SEPTRA

MONARCH PHARMS	80MG/ML; 16MG/ML **	N018452	001
----------------	---------------------	---------	-----

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM	80MG/ML; 16MG/ML	A070223	001	Dec 29, 1987
BEDFORD	80MG/ML; 16MG/ML	A072383	001	Apr 29, 1992
HOSPIRA	80MG/ML; 16MG/ML	A073199	001	Sep 11, 1992
TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991
WATSON LABS	80MG/ML; 16MG/ML	A071556	001	Dec 29, 1987
WEST-WARD PHARMS INT	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987
	80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

+ SUN PHARM INDUSTRIES	200MG/5ML; 40MG/5ML **	N017560	001
------------------------	------------------------	---------	-----

BACTRIM PEDIATRIC

SUN PHARM INDUSTRIES	200MG/5ML; 40MG/5ML **	N017560	002
----------------------	------------------------	---------	-----

SEPTRA

MONARCH PHARMS	200MG/5ML; 40MG/5ML **	N017598	001
----------------	------------------------	---------	-----

SEPTRA GRAPE

MONARCH PHARMS	200MG/5ML; 40MG/5ML **	N017598	002	Feb 12, 1986
----------------	------------------------	---------	-----	--------------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS INC	200MG/5ML; 40MG/5ML	A070028	001	Jun 02, 1987
TEVA	200MG/5ML; 40MG/5ML	N018812	001	Jan 28, 1983
	200MG/5ML; 40MG/5ML	N018812	002	Jun 10, 1983

SULFATRIM

PHARM ASSOC	200MG/5ML; 40MG/5ML	N018615	002	Jan 07, 1983
-------------	---------------------	---------	-----	--------------

SULMEPRIM

USL PHARMA	200MG/5ML; 40MG/5ML	A070063	001	Aug 01, 1986
------------	---------------------	---------	-----	--------------

SULMEPRIM PEDIATRIC

USL PHARMA	200MG/5ML; 40MG/5ML	A070064	001	Aug 01, 1986
------------	---------------------	---------	-----	--------------

TRIMETH/SULFA

ALPHARMA US PHARMS	200MG/5ML; 40MG/5ML	A072289	001	May 23, 1988
	200MG/5ML; 40MG/5ML	A072398	001	May 23, 1988
NASKA	200MG/5ML; 40MG/5ML	A072399	001	May 23, 1988

TABLET; ORAL

COTRIM

TEVA	400MG; 80MG	A070034	001	May 16, 1985
------	-------------	---------	-----	--------------

COTRIM D.S.

TEVA	800MG; 160MG	A070048	001	Mar 18, 1985
------	--------------	---------	-----	--------------

SULFAMETHOPRIM

NOVEL LABS INC	400MG; 80MG	A070022	001	Feb 15, 1985
----------------	-------------	---------	-----	--------------

SULFAMETHOPRIM-DS

NOVEL LABS INC	800MG; 160MG	A070032	001	Feb 15, 1985
----------------	--------------	---------	-----	--------------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

FOSUN PHARMA	400MG; 80MG	A070889	001	Nov 13, 1986
	400MG; 80MG	N018598	003	May 19, 1982
	800MG; 160MG	A070890	001	Nov 13, 1986
HEATHER	400MG; 80MG	N018946	001	Aug 10, 1984
	800MG; 160MG	N018946	002	Aug 10, 1984
INTERPHARM	400MG; 80MG	A071299	001	Oct 27, 1987
	800MG; 160MG	A071300	001	Oct 27, 1987
MARTEC USA LLC	400MG; 80MG	A072408	001	Dec 07, 1988
MUTUAL PHARM	400MG; 80MG	A070006	001	Nov 14, 1984
PLIVA	400MG; 80MG	A070215	001	Sep 10, 1985
	800MG; 160MG	A070216	001	Sep 10, 1985
ROXANE	400MG; 80MG	A072768	001	Aug 30, 1991
TEVA	400MG; 80MG	N018242	001	
	800MG; 160MG	N018242	002	
USL PHARMA	400MG; 80MG	A070203	001	Nov 08, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	800MG;160MG	A070204	001	Nov 08, 1985
WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
	400MG;80MG	N018852	001	May 09, 1983
	800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH				
HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

ACP NIMBLE	15%	A088718	001	Sep 19, 1985
------------	-----	---------	-----	--------------

SUPPOSITORY; VAGINAL

AVC

MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987
---------------------	--------	---------	-----	--------------

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC	500MG/5ML	N013093	001	
-----------------	-----------	---------	-----	--

TABLET; ORAL

SULFABID

PURDUE FREDERICK	500MG	N013092	002	
------------------	-------	---------	-----	--

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY	500MG	N000159	001	
-------	-------	---------	-----	--

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
----------------------	-----------	---------	-----	--

TABLET; ORAL

S.A.S.-500

SOLVAY	500MG	A083450	001	
--------	-------	---------	-----	--

SULFASALAZINE

HERITAGE PHARMS INC	500MG	A080197	001	
SANDOZ	500MG	A086184	001	
SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS	500MG	A088052	001	May 24, 1983
-------------	-------	---------	-----	--------------

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

+ NOVARTIS	200MG **	N011556	004	
------------	----------	---------	-----	--

SULFINPYRAZONE

BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFINPYRAZONE

CAPSULE; ORAL

SULFINPYRAZONE

VANGARD

200MG

A088666 001 Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS

100MG **

N011556 003

SULFINPYRAZONE

BARR

100MG

A087665 001 Sep 17, 1982

IVAX PHARMS

100MG

A087769 001 Jun 01, 1982

PAR PHARM

100MG

A088933 001 Sep 06, 1985

WATSON LABS

100MG

A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE

500MG

N006525 001

SOSOL

MK LABS

500MG

A080036 001

SOXAZOLE

ALRA

500MG

A080366 001

SULFALAR

PARKE DAVIS

500MG

A084955 001

SULFISOXAZOLE

ANI PHARMS INC

500MG

A080142 001

AUROLIFE PHARMA LLC

500MG

A085628 001

BARR

500MG

A084031 001

HEATHER

500MG

A080189 001

IMPAX LABS

500MG

A080109 001

LANNETT

500MG

A080085 001

LEDERLE

500MG

A087649 001

PHARMERAL

500MG

A084385 001

PUREPAC PHARM

500MG

A080087 001

ROXANE

500MG

A080082 001

VALEANT PHARM INTL

500MG

A080268 002

VITARINE

500MG

A087332 001

WATSON LABS

500MG

A085534 001

WEST WARD

500MG

A080379 001

SULSOXIN

SOLVAY

500MG

A080040 001

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE

EQ 1GM BASE/5ML

N009182 009

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE

EQ 500MG BASE/5ML

N009182 004

SYRUP; ORAL

GANTRISIN

ROCHE

EQ 500MG BASE/5ML

N009182 002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE

EQ 400MG BASE/ML

N006917 001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N008414 002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND

EQ 4% BASE

A084148 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SULFOXONE SODIUM

TABLET, DELAYED RELEASE;ORAL

DIASONE SODIUM

ABBVIE

165MG

N006044 003

SULFUR

POWDER;TOPICAL

BENSULFOID

POYTHRESS

33.32%

N002918 001

SULINDAC

TABLET;ORAL

CLINORIL

+ MERCK

150MG **

N017911 001

+

200MG **

N017911 002

SULINDAC

ANI PHARMS INC

150MG

A072972 001 Feb 28, 1992

200MG

A072973 001 Feb 28, 1992

EPIC PHARMA LLC

150MG

A073262 002 Sep 06, 1991

200MG

A073262 001 Sep 06, 1991

FOSUN PHARMA

150MG

A072712 001 Aug 30, 1991

200MG

A072713 001 Aug 30, 1991

SUMATRIPTAN

SPRAY;NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

ALSUMA

MERIDIAN MEDCL

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022377 001 Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

MYLAN LABS LTD

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A203322 001 Apr 14, 2014

PAR STERILE PRODUCTS

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A077871 001 Jul 09, 2009

SANDOZ INC

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

TEVA PHARMS USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A077907 001 Feb 06, 2009

ZYDUS

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090310 001 Aug 11, 2010

SUMAVEL DOSEPRO

+ ENDO VENTURES LTD

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

N022239 002 Nov 26, 2013

+

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022239 001 Jul 15, 2009

SYSTEM;IONTOPHORESIS

ZECURITY

+ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR

N202278 001 Jan 17, 2013

TABLET;ORAL

SUMATRIPTAN SUCCINATE

FOSUN PHARMA

EQ 25MG BASE

A076976 001 Aug 10, 2009

EQ 50MG BASE

A076976 002 Aug 10, 2009

EQ 100MG BASE

A076976 003 Aug 10, 2009

HIKMA PHARMS

EQ 25MG BASE

A078298 001 May 21, 2013

EQ 50MG BASE

A078298 002 May 21, 2013

EQ 100MG BASE

A078298 003 May 21, 2013

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT;TOPICAL

TRAVASE

+ ABBOTT

82,000 UNITS/GM **

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE;ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

HERITAGE PHARMA

EQ 5MG BASE

A090402 001 Jul 01, 2010

TADALAFIL

TABLET;ORAL

TADALAFIL

WATSON LABS INC

2.5MG

A205885 001 Mar 29, 2019

5MG

A205885 002 Mar 29, 2019

10MG

A205885 003 Mar 29, 2019

20MG

A205885 004 Mar 29, 2019

TALBUTAL

TABLET;ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET;ORAL

NOLVADEX

+ ASTRAZENECA

EQ 10MG BASE **

N017970 001

+

EQ 20MG BASE **

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC

EQ 10MG BASE

A076179 001 Feb 20, 2003

EQ 20MG BASE

A076179 002 Feb 20, 2003

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

MYLAN

0.4MG

A090408 001 Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+ ASSERTIO

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

FOUGERA PHARMS INC

0.1%

A211175 001 Jan 28, 2019

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION			
TC 99M-LUNGAGGREGATE			
GE HEALTHCARE	5mCi/ML		N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION			
A-N STANNOUS AGGREGATED ALBUMIN			
SYNCOR PHARMS	N/A		N017916 001
AN-MAA			
PHARMALUCENCE	N/A		N017792 001
LUNGAGGREGATE REAGENT			
GE HEALTHCARE	N/A		N017838 001
MACROTEC			
BRACCO	N/A		N017833 001
PULMOLITE			
+ JUBILANT DRAXIMAGE	N/A		N017776 001
TECHNESCAN MAA			
MALLINCKRODT	N/A		N017842 001
TECHNETIUM TC 99M MAA			
GE HEALTHCARE	N/A		N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION			
MICROLITE			
PHARMALUCENCE	N/A		N018263 001 Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION			
TECHNETIUM TC 99M HSA			
GE HEALTHCARE	N/A		N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION			
INSTANT MICROSPHERES			
3M	N/A		N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION			
ACUTECT			
CIS BIO INTL SA	N/A		N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION			
NEO TECT KIT			
CIS BIO INTL SA	N/A		N021012 001 Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION			
HEPATOLITE			
PHARMALUCENCE	N/A		N018467 001 Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION			
CINTICHEM TECHNETIUM 99M HEDSPA			
GE HEALTHCARE	N/A		N017653 001
MPI STANNOUS DIPHOSPHONATE			
GE HEALTHCARE	N/A		N017667 001
OSTEOSCAN			
MALLINCKRODT	N/A		N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT			
GE HEALTHCARE	N/A		N017562 001

TECHNETIUM TC-99M FERMENTETATE KIT

INJECTABLE; INJECTION			
RENOTEC			
BRACCO	N/A		N017045 001

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFEININ KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

MDP-BRACCO

CARDINAL HEALTH 414 N/A

N018107 001

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

JUBILANT DRAXIMAGE N/A

N017714 001

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

+ GE HEALTHCARE 2-100mCi/ML **

N017471 001

+ MALLINCKRODT 10-60mCi/ML **

N017725 001

PHARMALUCENCE 12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL

MINITEC

BRACCO 0.22-2.22 CI/GENERATOR N017339 001

SOLUTION;INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR N017771 001

ULTRA-TECHNEKOW FM

CURIUM 0.25-3 CI/GENERATOR N017243 002

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+ GE HEALTHCARE 68-2703mCi/GENERATOR N017693 002 Dec 13, 2013

830-16600mCi/GENERATOR N017693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE N/A N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION;INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML N017456 001

SOLUTION;ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A N017784 001

TESULOID

BRACCO N/A N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE;INJECTION

CARDIOTEC

BRACCO N/A N019928 001 Dec 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVUE

+ GE HEALTHCARE N/A N020372 001 Feb 09, 1996

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+ ALFASIGMA EQ 2MG BASE N021200 001 Jul 24, 2002

TELAPREVIR

TABLET;ORAL

INCIVEK

VERTEX PHARMS 375MG N201917 001 May 23, 2011

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+ CUMBERLAND PHARMS EQ 250MG BASE/VIAL N022110 001 Sep 11, 2009

TELBIVUDINE

SOLUTION;ORAL

TYZEKA

NOVARTIS 100MG/5ML N022154 001 Apr 28, 2009

TABLET;ORAL

TYZEKA

+ NOVARTIS 600MG N022011 001 Oct 25, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US	300MG	N021144 002	Feb 09, 2005
	400MG	N021144 001	Apr 01, 2004

TELMISARTAN

TABLET; ORAL

TELMISARTAN

CIPLA	20MG	A078710 001	Jan 08, 2014
	40MG	A078710 002	Jan 08, 2014
	80MG	A078710 003	Jan 08, 2014
HISUN PHARM HANGZHOU	20MG	A207843 001	Feb 19, 2019
	40MG	A207843 002	Feb 19, 2019
	80MG	A207843 003	Feb 19, 2019
MICRO LABS	20MG	A207016 001	Oct 03, 2017
	40MG	A207016 002	Oct 03, 2017
	80MG	A207016 003	Oct 03, 2017

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS	15MG	A070564 001	Oct 15, 1985
	30MG	A070547 001	Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR	15MG	A071708 001	Sep 29, 1988
	30MG	A071709 001	Sep 29, 1988
SUN PHARM INDUSTRIES	15MG	A071174 001	Jul 10, 1986
	30MG	A071175 001	Jul 10, 1986
USL PHARMA	15MG	A070489 001	Jul 07, 1986
	30MG	A070490 001	Jul 07, 1986
WATSON LABS	15MG	A070383 001	Mar 23, 1987
	15MG	A071446 001	May 21, 1993
	30MG	A070384 001	Mar 23, 1987
	30MG	A071447 001	May 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

APOTEX INC	5MG	A204159 001	Jul 05, 2018
	20MG	A204159 002	Jul 05, 2018
	100MG	A204159 003	Jul 05, 2018
	140MG	A204159 004	Jul 05, 2018
	180MG	A204159 005	Jul 05, 2018
	250MG	A204159 006	Jul 05, 2018
LANNETT CO INC	5MG	A203898 001	Feb 10, 2016
	20MG	A203898 002	Feb 10, 2016
	100MG	A203898 003	Feb 10, 2016
	140MG	A203898 004	Feb 10, 2016
	180MG	A203898 005	Feb 10, 2016
	250MG	A203898 006	Feb 10, 2016
MYLAN	5MG	A205227 001	Jun 29, 2016
	20MG	A205227 002	Jun 29, 2016
	100MG	A205227 003	Jun 29, 2016
	140MG	A205227 004	Jun 29, 2016
	180MG	A205227 005	Jun 29, 2016
	250MG	A205227 006	Jun 29, 2016

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA	10MG/ML	N020119 001	Jul 14, 1992
--------------------	---------	-------------	--------------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFVIR DISOPROXIL FUMARATE

CHARTWELL	300MG	A206481 001	Jul 26, 2018
-----------	-------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

HYTRIN

+	ABBOTT	EQ 1MG BASE **	N020347 001	Dec 14, 1994
+		EQ 2MG BASE **	N020347 002	Dec 14, 1994
+		EQ 5MG BASE **	N020347 003	Dec 14, 1994
+		EQ 10MG BASE **	N020347 004	Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

BEXIMCO PHARMS USA

EQ 1MG BASE	A075667 001	Jul 28, 2000
EQ 2MG BASE	A075667 002	Jul 28, 2000
EQ 5MG BASE	A075667 003	Jul 28, 2000
EQ 10MG BASE	A075667 004	Jul 28, 2000

MYLAN TECHNOLOGIES

EQ 1MG BASE	A075384 001	Dec 01, 2000
EQ 2MG BASE	A075384 002	Dec 01, 2000
EQ 5MG BASE	A075384 003	Dec 01, 2000
EQ 10MG BASE	A075384 004	Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE	A076021 001	Aug 22, 2002
EQ 2MG BASE	A076021 002	Aug 22, 2002
EQ 5MG BASE	A076021 003	Aug 22, 2002
EQ 10MG BASE	A076021 004	Aug 22, 2002

TABLET;ORAL

HYTRIN

ABBOTT	EQ 1MG BASE	N019057 001	Aug 07, 1987
	EQ 2MG BASE	N019057 002	Aug 07, 1987
	EQ 5MG BASE	N019057 003	Aug 07, 1987
	EQ 10MG BASE	N019057 004	Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE	A074530 001	Apr 21, 2000
EQ 2MG BASE	A074530 002	Apr 21, 2000
EQ 5MG BASE	A074530 003	Apr 21, 2000
EQ 10MG BASE	A074530 004	Apr 21, 2000

SANDOZ

EQ 1MG BASE	A074315 001	Dec 31, 1998
EQ 1MG BASE	A074657 001	Apr 28, 2000
EQ 2MG BASE	A074315 002	Dec 31, 1998
EQ 2MG BASE	A074657 002	Apr 28, 2000
EQ 5MG BASE	A074315 003	Dec 31, 1998
EQ 5MG BASE	A074657 003	Apr 28, 2000
EQ 10MG BASE	A074315 004	Dec 31, 1998
EQ 10MG BASE	A074657 004	Apr 28, 2000

TEVA

EQ 1MG BASE	A074446 001	May 18, 2000
EQ 2MG BASE	A074446 002	May 18, 2000
EQ 5MG BASE	A074446 003	May 18, 2000
EQ 10MG BASE	A074446 004	May 18, 2000

TERBINAFINE

GEL;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS	1%	N020846 001	Apr 29, 1998
----------------------	----	-------------	--------------

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

NOVARTIS	1%	N020192 001	Dec 30, 1992
----------	----	-------------	--------------

GRANULE;ORAL

LAMISIL

+	NOVARTIS	EQ 125MG BASE/PACKET	N022071 001	Sep 28, 2007
+		EQ 187.5MG BASE/PACKET	N022071 002	Sep 28, 2007

SOLUTION;TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS	1%	N020749 001	Oct 17, 1997
----------------------	----	-------------	--------------

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

CHARTWELL	EQ 250MG BASE	A078199 001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065 001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007
	EQ 250MG BASE	A077195 001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229 001	Jul 02, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS 0.2MG/INH N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US 0.2MG/INH N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

+ PHARMACARE 1MG/ML ** N018571 001

BRICANYL

SANOFI AVENTIS US 1MG/ML N017466 001

TERBUTALINE SULFATE

DR REDDYS 1MG/ML A076853 001 Jul 20, 2004

TABLET; ORAL

BRICANYL

SANOFI AVENTIS US 2.5MG N017618 001

5MG N017618 002

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS 0.8% N019964 001 Feb 21, 1991

TERAZOL 7

+ JANSSEN PHARMS 0.4% N019579 001 Dec 31, 1987

SUPPOSITORY; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS 80MG N019641 001 May 24, 1988

TERCONAZOLE

FOUGERA PHARMS 80MG A076850 001 Jul 12, 2006

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AMNEAL PHARMS CO 7MG A209613 001 Sep 28, 2018

14MG A209613 002 Sep 28, 2018

APOTEX 7MG A209601 001 Nov 02, 2018

14MG A209601 002 Nov 02, 2018

AUROBINDO PHARMA LTD 7MG A209638 001 Oct 26, 2018

14MG A209638 002 Oct 26, 2018

MSN 7MG A209623 001 Apr 24, 2019

14MG A209623 002 Apr 24, 2019

TEVA PHARMS USA 7MG A209700 001 Sep 04, 2018

14MG A209700 002 Sep 04, 2018

WATSON LABS TEVA 7MG A209549 001 Jul 27, 2018

14MG A209549 002 Jul 27, 2018

ZYDUS PHARMS 7MG A209668 001 Nov 30, 2018

14MG A209668 002 Nov 30, 2018

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US 200 UNITS/VIAL N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB 100MG/ML N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB 50MG N016118 001

250MG N016118 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

ALLERGAN	2.5MG/24HR	N020489 001	Sep 29, 1995
	5MG/24HR	N020489 002	May 02, 1997

TESTODERM

ALZA	4MG/24HR	N019762 001	Oct 12, 1993
	6MG/24HR	N019762 002	Oct 12, 1993

TESTODERM TTS

ALZA	5MG/24HR	N020791 001	Dec 18, 1997
------	----------	-------------	--------------

GEL;TRANSDERMAL

TESTOSTERONE

ANI PHARMS INC	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012
	50MG/5GM PACKET	N202763 002	Feb 14, 2012
PAR PHARM	25MG/2.5GM PACKET	A076744 001	May 23, 2007
PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013
	50MG/5GM PACKET	N203098 003	Jan 31, 2013

GEL, METERED;TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013
----------------	-------------------------	-------------	--------------

INJECTABLE;INJECTION

TESTOSTERONE

DR REDDYS	100MG/ML	A086417 001	Jul 07, 1983
WATSON LABS	25MG/ML	A086420 001	May 10, 1983
	50MG/ML	A086419 001	Aug 23, 1983

SOLUTION, METERED;TRANSDERMAL

AXIRON

+ ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504 001	Nov 23, 2010
--------------------	-------------------------	-------------	--------------

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+ AUXILIUM PHARMS LLC	30MG	N021543 001	Jun 19, 2003
-----------------------	------	-------------	--------------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN	50MG/ML	A085635 001	
----------------------	---------	-------------	--

TESTOSTERONE CYPIONATE

MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006
WATSON LABS	100MG/ML	A084401 001	
	100MG/ML	A086029 001	
	200MG/ML	A084401 002	

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYL

ENDO PHARMS	200MG/ML	N009165 001	
+	200MG/ML	N009165 003	

TESTOSTERONE ENANTHATE

MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009
WATSON LABS	100MG/ML	A083667 001	
	100MG/ML	A085599 001	
	200MG/ML	A083667 002	

TESTOSTERONE PROPIONATE

INJECTABLE;INJECTION

TESTOSTERONE PROPIONATE

BEL MAR	25MG/ML	A080741 001	
	50MG/ML	A080742 001	
	100MG/ML	A080743 001	
ELKINS SINN	25MG/ML	A080276 001	
LILLY	50MG/ML	A080254 002	
WATSON LABS	25MG/ML	A080188 001	
	25MG/ML	A085490 001	
	50MG/ML	A080188 002	
	50MG/ML	A085490 002	
	100MG/ML	A080188 003	
	100MG/ML	A083595 003	

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL	250MG	A061658	001
	250MG	A061888	001
	500MG	A061658	002
	500MG	A061888	002

CYCLOPAR

WARNER CHILCOTT	250MG	A061725	001
	250MG	A062175	001
	250MG	A062332	001
	500MG	A061725	002
	500MG	A062332	002

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A060347	001
----------------------	-------	---------	-----

RETET

SOLVAY	250MG	A061443	001
	500MG	A061443	002

ROBITET

WYETH AYERST	250MG	A061734	001
	500MG	A061734	002

SUMYCIN

APOTHECON	100MG	A060429	002
	125MG	A060429	004
	250MG	A060429	001
	500MG	A060429	003

TETRACHEL

ANGUS	250MG	A060343	001
	500MG	A060343	003

TETRACYCLINE HYDROCHLORIDE

ABBOTT	250MG	A061802	001
	500MG	A061802	002

ANI PHARMS INC	250MG	A061471	001
----------------	-------	---------	-----

ELKINS SINN	250MG	A060059	001
-------------	-------	---------	-----

FERRANTE	125MG	A060173	001
----------	-------	---------	-----

	250MG	A060173	002
--	-------	---------	-----

HEATHER	250MG	A061148	001
---------	-------	---------	-----

	500MG	A061148	002
--	-------	---------	-----

HIKMA PHARMS	250MG	A060768	001
--------------	-------	---------	-----

	500MG	A060768	002
--	-------	---------	-----

IMPAX LABS	100MG	A060469	002
------------	-------	---------	-----

	250MG	A060469	001
--	-------	---------	-----

	500MG	A060469	003
--	-------	---------	-----

IVAX SUB TEVA PHARMS	250MG	A060704	001
----------------------	-------	---------	-----

	500MG	A060704	002
--	-------	---------	-----

MAST MM	250MG	A062085	001
---------	-------	---------	-----

MYLAN	250MG	A060783	001
-------	-------	---------	-----

	500MG	A060783	002
--	-------	---------	-----

PUREPAC PHARM	250MG	A060290	001
---------------	-------	---------	-----

	500MG	A060290	002
--	-------	---------	-----

PVT FORM	250MG	A062686	001	Jul 24, 1986
----------	-------	---------	-----	--------------

	500MG	A062686	002	Jul 24, 1986
--	-------	---------	-----	--------------

ROXANE	500MG	A061214	002
--------	-------	---------	-----

SUN PHARM INDUSTRIES	250MG	A060736	001
----------------------	-------	---------	-----

	500MG	A060736	002
--	-------	---------	-----

SUPERPHARM	250MG	A062540	001	Mar 21, 1985
------------	-------	---------	-----	--------------

	500MG	A062540	002	Mar 21, 1985
--	-------	---------	-----	--------------

VALEANT PHARM INTL	250MG	A060471	001
--------------------	-------	---------	-----

	500MG	A060471	002
--	-------	---------	-----

WARNER CHILCOTT	250MG	A062300	001
-----------------	-------	---------	-----

	500MG	A062300	002
--	-------	---------	-----

WATSON LABS	250MG	A062103	001
-------------	-------	---------	-----

	250MG	A062343	001
--	-------	---------	-----

	500MG	A062103	002
--	-------	---------	-----

	500MG	A062343	002
--	-------	---------	-----

WYETH AYERST	250MG	A061685	001
--------------	-------	---------	-----

	500MG	A061685	002
--	-------	---------	-----

TETRACYN

PFIPHARMECS	250MG	A060082	003
-------------	-------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYN

500MG

A060082 004

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO

12.7MG/FIBER

N050653 001 Mar 25, 1994

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE

2.2MG/ML

N050493 001

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE

250MG/VIAL

N050273 002

500MG/VIAL

N050273 003

TETRACYN

PFIZER

250MG/VIAL

A060096 001

500MG/VIAL

A060096 002

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ

10MG/GM

N050266 001

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE

125MG/5ML

N050263 002

SUMYCIN

PAR PHARM

125MG/5ML

A060400 001

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS

125MG/5ML

A060633 001

FERRANTE

125MG/5ML

A060174 001

PROTER

125MG/5ML

A060446 001

PUREPAC PHARM

125MG/5ML

A060291 001

TETRACYN

PFIPHARMECS

125MG/5ML

A060095 001

TETRAMED

IVAX SUB TEVA PHARMS

125MG/5ML

A061468 001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ

1%

N050268 001

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A061705 001

500MG

A061705 002

SUMYCIN

PAR PHARM

50MG

A061147 003

100MG

A061147 002

250MG

A061147 001

500MG

A061147 004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL

EQ 100MG HYDROCHLORIDE

A061653 001

EQ 250MG HYDROCHLORIDE

A061653 002

EQ 250MG HYDROCHLORIDE

A061889 002

EQ 250MG HYDROCHLORIDE

N050212 002

EQ 500MG HYDROCHLORIDE

A061653 003

EQ 500MG HYDROCHLORIDE

A061889 001

EQ 500MG HYDROCHLORIDE

N050212 003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO

1mCi/ML

N018548 001 Dec 30, 1982

TRACE LIFE

1mCi/ML

A075569 001 Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

+

LANTHEUS MEDCL

2mCi/ML

N017806 002 Oct 09, 1998

MALLINKRODT NUCLEAR

2mCi/ML

A077698 001 Nov 09, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	

ELIXOPHYLLIN

FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984

SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985

THEOPHYLLINE

KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
----------------	------	---------	-----	--------------

AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
----------------	-------	---------	-----	--------------

AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
----------------	-------	---------	-----	--------------

ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985

SLO-BID

SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985

THEO-DUR

SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985

THEOBID

WHITBY	260MG	A085983	001	Mar 20, 1985
--------	-------	---------	-----	--------------

THEOBID JR.

WHITBY	130MG	A087854	001	Mar 20, 1985
--------	-------	---------	-----	--------------

THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
----------------	-------	---------	-----	--------------

THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982
----------------	-------	---------	-----	--------------

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
	100MG	A040052	001	Feb 14, 1994
INWOOD LABS	125MG	A040052	002	Feb 14, 1994

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEOPHYLLINE

	200MG	A040052 003	Feb 14, 1994
	300MG	A040052 004	Feb 14, 1994
SANDOZ	260MG	A087462 001	May 11, 1982
THEOPHYLLINE-SR			
SCHERER RP	300MG	A088255 001	Jun 12, 1986
THEOVENT			
SCHERING	125MG	A087010 001	Jan 31, 1985
	250MG	A087910 001	Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303 001	Jan 25, 1984
-------	-----------	-------------	--------------

LANOPHYLLIN

LANNETT	80MG/15ML	A084578 001	
---------	-----------	-------------	--

THEOLIXIR

PANRAY	80MG/15ML	A084559 001	
--------	-----------	-------------	--

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485 001	
--------------------	--------------	-------------	--

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223 001	May 27, 1988
CENCI	80MG/15ML	A087679 001	Apr 15, 1982
CHARTWELL RX	80MG/15ML	A085952 001	
HALSEY	80MG/15ML	A085169 001	
PHARM ASSOC	80MG/15ML	A086720 001	
PRECISION DOSE	80MG/15ML	A085863 001	
ROXANE	80MG/15ML	A084739 001	
TARO	80MG/15ML	A089626 001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748 001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	40MG/100ML	N019083 001	Nov 07, 1984
---------	------------	-------------	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	80MG/100ML	N019083 002	Nov 07, 1984
---------	------------	-------------	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	160MG/100ML	N019083 003	Nov 07, 1984
---------	-------------	-------------	--------------

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	200MG/100ML	N019212 001	Nov 07, 1984
---------	-------------	-------------	--------------

	200MG/100ML	N019826 004	Aug 14, 1992
--	-------------	-------------	--------------

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	4MG/ML	N019212 003	Nov 07, 1984
---------	--------	-------------	--------------

	400MG/100ML	N019212 002	Nov 07, 1984
--	-------------	-------------	--------------

	400MG/100ML	N019826 005	Aug 14, 1992
--	-------------	-------------	--------------

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982
-----------------	--------	-------------	--------------

	40MG/100ML	N018649 001	Jul 26, 1982
--	------------	-------------	--------------

	80MG/100ML	N018649 002	Jul 26, 1982
--	------------	-------------	--------------

	160MG/100ML	N018649 003	Jul 26, 1982
--	-------------	-------------	--------------

	200MG/100ML	N018649 004	Jul 26, 1982
--	-------------	-------------	--------------

	320MG/100ML	N018649 006	Nov 13, 1985
--	-------------	-------------	--------------

	400MG/100ML	N018649 005	Jul 26, 1982
--	-------------	-------------	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA INC	4MG/ML	N019211 007	Dec 14, 1984
---------------	--------	-------------	--------------

+	40MG/100ML	N019211 001	Dec 14, 1984
---	------------	-------------	--------------

	80MG/100ML	N019211 002	Dec 14, 1984
--	------------	-------------	--------------

+	160MG/100ML	N019211 003	Dec 14, 1984
---	-------------	-------------	--------------

	200MG/100ML	N019211 004	Dec 14, 1984
--	-------------	-------------	--------------

+	320MG/100ML	N019211 006	Jan 20, 1988
---	-------------	-------------	--------------

	400MG/100ML	N019211 005	Dec 14, 1984
--	-------------	-------------	--------------

SOLUTION;ORAL

AEROLATE

FLEMING PHARMS	150MG/15ML	A089141 001	Dec 03, 1986
----------------	------------	-------------	--------------

THEOLAIR

3M	80MG/15ML	A086107 001	
----	-----------	-------------	--

THEOPHYLLINE

ROXANE	80MG/15ML	A087449 001	Sep 15, 1983
--------	-----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINE

SUSPENSION;ORAL			
ELIXICON			
FOREST LABS	100MG/5ML	A085502	001
SYRUP;ORAL			
ACCURBRON			
SANOFI AVENTIS US	150MG/15ML	A088746	001 Nov 22, 1985
AQUAPHYLLIN			
FERNDALE LABS	80MG/15ML	A087917	001 Jan 18, 1983
SLO-PHYLLIN			
SANOFI AVENTIS US	80MG/15ML	A085187	001
THEOCLEAR-80			
CENT PHARMS	80MG/15ML	A087095	001 Mar 01, 1982
THEOPHYLLINE			
ALPHARMA US PHARMS	80MG/15ML	A086001	001
	150MG/15ML	A086545	001
TABLET;ORAL			
QUIBRON-T			
MONARCH PHARMS	300MG	A088656	001 Aug 22, 1985
SLO-PHYLLIN			
SANOFI AVENTIS US	100MG	A085202	001
	200MG	A085204	001
THEOCLEAR-100			
CENT PHARMS	100MG	A085353	002
THEOCLEAR-200			
CENT PHARMS	200MG	A085353	001
THEOLAIR			
MEDICIS	125MG	A086399	001
	250MG	A086399	002
THEOPHYL-225			
ORTHO MCNEIL PHARM	225MG	A084726	001
TABLET, CHEWABLE;ORAL			
THEOPHYL			
ORTHO MCNEIL PHARM	100MG	A086506	001 Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL			
DURAPHYL			
FOREST LABS	100MG	A088503	001 Apr 03, 1985
	200MG	A088504	001 Apr 03, 1985
	300MG	A088505	001 Apr 03, 1985
LABID			
WARNER CHILCOTT	250MG	A087225	001
QUIBRON-T/SR			
MONARCH PHARMS	300MG	A087563	001 Jun 21, 1983
SUSTAIRE			
ROERIG	100MG	A085665	001
	300MG	A085665	002
T-PHYL			
PHARM RES ASSOC	200MG	A088253	001 Aug 17, 1983
THEO-DUR			
SCHERING	100MG	A085328	001
	200MG	A086998	001
	300MG	A085328	002
	450MG	A089131	001 Jun 25, 1986
THEOCHRON			
NOSTRUM PHARMS LLC	300MG	A087400	002 Jan 11, 1983
THEOLAIR-SR			
3M	200MG	A088369	001 Jul 16, 1987
	250MG	A086363	002 Jul 16, 1987
	300MG	A088364	001 Jul 16, 1987
	500MG	A089132	001 Jul 16, 1987
THEOPHYLLINE			
ABLE	300MG	A040548	001 Apr 30, 2004
	400MG	A040543	001 Apr 27, 2004
	450MG	A040546	001 Apr 30, 2004
	600MG	A040539	001 Apr 27, 2004
HERITAGE PHARMA	450MG	A081236	001 Nov 09, 1992
INWOOD LABS	450MG	A040034	001 Apr 28, 1995
UNI-DUR			
SCHERING	400MG	A089822	001 Jan 04, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL
UNI-DUR

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATEELIXIR;ORAL
SYNOPHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL
ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLESUSPENSION;ORAL
MINTEZOL

MERCCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL
MINTEZOL

MERCCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDEINJECTABLE;INJECTION
BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

DR REDDYS

100MG/ML

A080571 001

200MG/ML

A080571 002

HOSPIRA

100MG/ML

A040079 001

May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WEST-WARD PHARMS INT

100MG/ML

A080575 001

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUMINJECTABLE;INJECTION
SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATEINJECTABLE;INJECTION
TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATESUPPOSITORY;RECTAL
TORECAN

NOVARTIS

10MG

N013247 001

TABLET;ORAL
TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUMSUSPENSION;RECTAL
PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINESUSPENSION;ORAL
MELLARIL-S

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML **

N017923 001

EQ 100MG HYDROCHLORIDE/5ML **

N017923 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS	30MG/ML **	N011808 012
	100MG/ML **	N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A088229 001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766 001	Apr 26, 1983
ANI PHARMS INC	30MG/ML	A089602 001	Nov 09, 1987
	100MG/ML	A089603 001	Nov 09, 1987
HI TECH PHARMA	30MG/ML	A040125 001	Aug 16, 1996
	100MG/ML	A040126 001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187 001	Aug 28, 1997
	100MG/ML	A040213 001	May 29, 1998
SANDOZ	30MG/ML	A088307 001	Nov 23, 1983
	100MG/ML	A088308 001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258 001	Jul 25, 1983
	100MG/ML	A088227 001	Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088941 001	Dec 16, 1985
	100MG/ML	A088942 001	Dec 16, 1985

TABLET; ORAL

MELLARIL

+	NOVARTIS	10MG **	N011808 003
+		15MG **	N011808 016
+		25MG **	N011808 006
+		50MG **	N011808 011
+		100MG **	N011808 009
+		150MG **	N011808 017
+		200MG **	N011808 015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC	10MG	A088270 001	Apr 14, 1983
	10MG	A088493 001	May 17, 1985
	15MG	A088271 001	Apr 14, 1983
	25MG	A088272 001	Apr 14, 1983
	50MG	A088194 001	Apr 14, 1983
	100MG	A088273 001	Oct 03, 1983
	100MG	A088456 001	May 17, 1985
FOSUN PHARMA	10MG	A088131 001	Aug 30, 1983
	15MG	A088132 001	Aug 30, 1983
	25MG	A088133 001	Aug 30, 1983
	50MG	A088134 001	Aug 30, 1983
	100MG	A088135 001	Nov 20, 1984
	150MG	A088136 001	Sep 17, 1986
	200MG	A088137 001	Sep 17, 1986
HERITAGE PHARMA	10MG	A088476 001	Nov 08, 1983
	25MG	A088478 001	Nov 08, 1983
	50MG	A088479 001	Nov 08, 1983
	100MG	A088736 001	Jul 24, 1984
MUTUAL PHARM	10MG	A088375 001	Nov 18, 1983
	25MG	A087264 001	Nov 18, 1983
	50MG	A088370 001	Nov 18, 1983
	100MG	A088379 001	Nov 16, 1983
MYLAN	10MG	A088332 001	Jun 27, 1983
	25MG	A088333 001	Jun 27, 1983
	50MG	A088334 001	Jun 27, 1983
	100MG	A088335 001	Nov 18, 1983
PAR PHARM	10MG	A088351 001	Dec 05, 1983
	15MG	A088352 001	Dec 05, 1983
	25MG	A088336 001	Dec 05, 1983
	50MG	A088322 001	Dec 05, 1983
	100MG	A088480 001	Dec 29, 1983
	150MG	A089764 001	Feb 09, 1988
	200MG	A089765 001	Feb 09, 1988
ROXANE	10MG	A088663 001	Mar 15, 1984
	25MG	A088664 001	Mar 15, 1984
	50MG	A088665 001	Mar 15, 1984
	100MG	A089048 001	Feb 26, 1985
SUN PHARM INDUSTRIES	10MG	A089953 004	Aug 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	15MG	A088461	001	Nov 18, 1983
	25MG	A089953	003	Aug 01, 1986
	50MG	A089953	002	Aug 01, 1986
	100MG	A089953	001	Oct 07, 1988
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

+ IMMUNEX

15MG/VIAL **

N020058 001 Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL

A075698 001 Sep 20, 2001

IMMUNEX

15MG/VIAL

N011683 001

TEVA PARENTERAL

15MG/VIAL **

A075730 001 Apr 20, 2001

30MG/VIAL **

A075730 002 Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

+ PFIZER

1MG **

N016584 001

+

2MG **

N016584 002

+

5MG **

N016584 003

+

10MG **

N016584 004

+

20MG **

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001 Aug 12, 1987

2MG

A071885 001 Aug 12, 1987

5MG

A071886 001 Aug 12, 1987

10MG

A071887 001 Aug 12, 1987

20MG

A072200 001 Dec 17, 1987

HERITAGE PHARMA

1MG

A070600 001 Jun 05, 1987

2MG

A070601 001 Jun 05, 1987

5MG

A070602 001 Jun 05, 1987

10MG

A070603 001 Jun 05, 1987

SANDOZ

1MG

A071529 002 Jun 24, 1987

2MG

A071529 003 Jun 24, 1987

5MG

A071529 001 Jun 24, 1987

10MG

A071529 004 Jun 24, 1987

WATSON LABS

2MG

A071626 001 Jun 25, 1987

5MG

A071627 001 Jun 25, 1987

10MG

A071628 001 Jun 25, 1987

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
HIKMA	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER	EQ 2MG BASE/ML	N016904	001	
	EQ 10MG BASE/VIAL	N016904	002	

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245	009	
	32MG	N002245	005	
	65MG	N002245	002	
	100MG	N002245	008	
	130MG	N002245	010	
	200MG	N002245	007	
	325MG	N002245	004	

THYROGLOBULIN

IMPAX LABS	64.8MG	A080151	001	
------------	--------	---------	-----	--

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US	10 IU/VIAL	N008682	001	
-------------------	------------	---------	-----	--

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646	006	Nov 29, 2005
	8MG	N020646	007	Nov 29, 2005
	10MG	N020646	008	Nov 29, 2005
	20MG	N020646	004	Sep 30, 1997

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019
WATSON LABS INC	60MG	A208390	001	Sep 04, 2018
	90MG	A208390	002	Sep 04, 2018

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001	
	EQ 3GM BASE/VIAL	A062690	001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002	
	EQ 6GM BASE/VIAL	N050497	003	
	EQ 20GM BASE/VIAL	N050497	004	
	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
MYLAN	250MG	A075161	001	Sep 13, 1999
	250MG	A075316	001	Nov 02, 1999
SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002
WATSON LABS	250MG	A075309	001	Apr 26, 2000
YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

250MG

A075326 001 Aug 20, 1999

TILUDRONATE DISODIUM

TABLET;ORAL

SKELID

+ SANOFI AVENTIS US

EQ 200MG BASE **

N020707 001 Mar 07, 1997

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AKORN

EQ 0.25% BASE

A074465 001 Mar 25, 1997

EQ 0.25% BASE

A074515 001 Mar 25, 1997

APOTEX INC

EQ 0.25% BASE

A075411 001 Sep 08, 2000

EQ 0.5% BASE

A075412 001 Sep 08, 2000

FOUGERA

EQ 0.25% BASE

A074667 001 Mar 25, 1997

EQ 0.5% BASE

A074668 001 Mar 25, 1997

TABLET;ORAL

BLOCADREN

+ MERCK

5MG **

N018017 001

+

10MG **

N018017 002

+

20MG **

N018017 004

TIMOLOL MALEATE

ANI PHARMS INC

5MG

A072917 001 Jul 31, 1991

10MG

A072918 001 Jul 31, 1991

20MG

A072919 001 Jul 31, 1991

QUANTUM PHARMICS

5MG

A072466 001 May 19, 1989

10MG

A072467 001 May 19, 1989

20MG

A072468 001 May 19, 1989

TEVA

5MG

A072648 001 Jun 16, 1993

10MG

A072649 001 Jun 16, 1993

20MG

A072650 001 Jun 16, 1993

USL PHARMA

5MG

A072001 001 Apr 11, 1989

10MG

A072002 001 Apr 11, 1989

20MG

A072003 001 Apr 11, 1989

WATSON LABS

5MG

A072269 001 Apr 11, 1989

10MG

A072270 001 Apr 11, 1989

20MG

A072271 001 Apr 11, 1989

YAOPHARMA CO LTD

5MG

A072550 001 Apr 13, 1989

10MG

A072551 001 Apr 13, 1989

20MG

A072552 001 Apr 13, 1989

TINZAPARIN SODIUM

INJECTABLE;INJECTION

INNOHEP

LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000

TIOCONAZOLE

CREAM;TOPICAL

TZ-3

PFIZER

1%

N018682 001 Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)

N020912 001 May 14, 1998

EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)

N020913 001 May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

ANI PHARMS INC

EQ 2MG BASE

A076283 001 Jul 12, 2002

EQ 2MG BASE

A076284 001 Jul 03, 2002

EQ 2MG BASE

A076321 001 Sep 30, 2004

EQ 2MG BASE

A076371 001 Apr 09, 2003

EQ 4MG BASE

A076283 002 Jul 12, 2002

EQ 4MG BASE

A076284 002 Jul 03, 2002

EQ 4MG BASE

A076321 002 Sep 30, 2004

EQ 4MG BASE

A076371 002 Apr 09, 2003

MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

	EQ 4MG BASE	A076282 002	Dec 16, 2003
PAR PHARM INC	EQ 2MG BASE	A207170 001	Jan 26, 2017
	EQ 4MG BASE	A207170 002	Jan 26, 2017
ZANAFLEX			
+ COVIS PHARMA BV	EQ 2MG BASE **	N020397 002	Feb 04, 2000

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

TEVA PHARMS USA	300MG/4ML	A210915 001	Jun 26, 2019
SOLUTION/DROPS; OPHTHALMIC			
TOBRAMYCIN			
ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
APOTEX INC	0.3%	A065087 001	Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008 004	
	EQ 10MG BASE/ML	A062707 001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477 005	
	EQ 40MG BASE/ML	A062008 001	
+	EQ 1.2GM BASE/VIAL **	N050519 001	
TOBRAMYCIN SULFATE			
APOTHECON			
	EQ 10MG BASE/ML	A064021 001	May 31, 1994
	EQ 40MG BASE/ML	A064021 002	May 31, 1994
	EQ 40MG BASE/ML	A064026 001	May 31, 1994
HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161 001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122 001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945 002	Aug 09, 1989
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991
TOBRAMYCIN SULFATE (PHARMACY BULK)			
HOSPIRA	EQ 40MG BASE/ML **	A063116 001	May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257 001	Nov 09, 1984
	600MG	N018257 002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162 001	Jan 14, 1986
	250MG	A070163 001	Jan 14, 1986
	500MG	A070164 001	Jan 14, 1986
COSETTE	100MG	N018894 001	Nov 02, 1984
	250MG	N018894 002	Nov 02, 1984
	500MG	N018894 003	Nov 02, 1984
DURAMED PHARMS BARR	100MG	A070165 001	Jan 10, 1986
	250MG	A070166 001	Jan 10, 1986
	500MG	A070167 001	Jan 10, 1986
INTERPHARM	250MG	A071270 001	Sep 23, 1986
	500MG	A071271 001	Sep 23, 1986
PAR PHARM	100MG	A070159 001	Jan 06, 1986
	250MG	A070160 001	Jan 06, 1986
	500MG	A070161 001	Jan 06, 1986
SUN PHARM INDUSTRIES	100MG	A071357 001	Jul 16, 1987
	250MG	A071358 001	Jul 16, 1987
	500MG	A071359 001	Jul 16, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

SUPERPHARM	250MG	A070763 001	Jun 16, 1986
	500MG	A070764 001	Jun 16, 1986
USL PHARMA	100MG	A071355 001	Jan 11, 1988
	250MG	A070168 001	Apr 02, 1986
	500MG	A070169 001	Apr 02, 1986
WATSON LABS	100MG	A070242 001	Aug 01, 1986
	100MG	A070513 001	Jan 09, 1986
	250MG	A070243 001	Aug 01, 1986
	250MG	A070514 001	Jan 09, 1986
	500MG	A070244 001	Aug 01, 1986
	500MG	A070515 001	Jan 09, 1986
YAOPHARMA CO LTD	100MG	A071633 001	Dec 09, 1987
	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986

TOLINASE

+ PHARMACIA AND UPJOHN	100MG **	N015500 002	
+	250MG **	N015500 004	
+	500MG **	N015500 005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS	25MG/ML	N006403 005	Feb 22, 1985
----------	---------	-------------	--------------

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN	250MG **	N010670 002	
	500MG **	N010670 001	

TOLBUTAMIDE

ALRA	500MG	A086141 001	
ANI PHARMS INC	500MG	A087093 001	
ASCOT	500MG	A087541 001	Mar 01, 1983
BARR	500MG	A087121 001	
DAVA PHARMS INC	500MG	A086926 001	
PARKE DAVIS	500MG	A086047 001	
PUREPAC PHARM	500MG	A088950 001	Jun 17, 1985
SANDOZ	500MG	N012678 001	
SUPERPHARM	500MG	A088893 001	Nov 19, 1984
VANGARD	500MG	A087876 001	Apr 20, 1982
WATSON LABS	250MG	A089110 001	May 29, 1987
	500MG	A086109 001	
	500MG	A087318 001	
	500MG	A089111 001	May 29, 1987
YAOPHARMA CO LTD	500MG	A086574 001	

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095 001	
----------------------	------------------	-------------	--

TOLCAPONE

TABLET; ORAL

TASMAR

BAUSCH	200MG	N020697 002	Jan 29, 1998
--------	-------	-------------	--------------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084 001	
------------------------	---------------	-------------	--

TOLMETIN SODIUM

ANI PHARMS INC	EQ 400MG BASE	A073308 001	Jan 24, 1992
	EQ 400MG BASE	A073392 001	Jan 24, 1992
	EQ 400MG BASE	A073519 001	May 29, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462 001	Apr 30, 1992
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311 001	Nov 27, 1991

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOLMETIN SODIUM

TABLET;ORAL

TOLECTIN

+ ORTHO MCNEIL JANSSEN EQ 200MG BASE

N017628 001

TOLECTIN 600

+ ORTHO MCNEIL JANSSEN EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACP NIMBLE EQ 600MG BASE

A074399 001 Mar 28, 1996

EQ 600MG BASE

A074729 001 Feb 27, 1997

ANI PHARMS INC EQ 600MG BASE

A073527 001 Jun 30, 1992

FOSUN PHARMA EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

SUN PHARM INDUSTRIES EQ 200MG BASE

A073310 001 Nov 27, 1991

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

APOTEX CORP 1MG

A200164 001 Sep 25, 2012

2MG

A200164 002 Sep 25, 2012

TOLVAPTAN

TABLET;ORAL

SAMSCA

+ OTSUKA AMERICA PHARM 60MG **

N022275 003 May 19, 2009

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG

N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

FOSUN PHARMA 15MG

A079206 001 Oct 14, 2009

25MG

A079206 002 Oct 14, 2009

MYLAN 15MG

A078418 001 Oct 14, 2009

25MG

A078418 002 Oct 14, 2009

TABLET;ORAL

TOPAMAX

JANSSEN PHARMS 300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA 25MG

A078637 001 Feb 27, 2013

50MG

A078637 002 Feb 27, 2013

100MG

A078637 003 Feb 27, 2013

200MG

A078637 004 Feb 27, 2013

BARR 25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

HIKMA PHARMS 25MG

A091185 001 Nov 25, 2013

50MG

A091185 002 Nov 25, 2013

100MG

A091185 003 Nov 25, 2013

200MG

A091185 004 Nov 25, 2013

LUPIN 25MG

A078410 001 Sep 11, 2013

50MG

A078410 002 Sep 11, 2013

100MG

A078410 003 Sep 11, 2013

200MG

A078410 004 Sep 11, 2013

MYLAN 25MG

A076314 001 Mar 27, 2009

50MG

A076314 002 Mar 27, 2009

100MG

A076314 003 Mar 27, 2009

200MG

A076314 004 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE 25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

WATSON LABS 25MG

A077643 001 Mar 27, 2009

50MG

A077643 002 Mar 27, 2009

100MG

A077643 003 Mar 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TOPIRAMATETABLET; ORAL
TOPIRAMATE

	200MG	A077643 004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353 001	Sep 01, 2010
	50MG	A090353 002	Sep 01, 2010
	100MG	A090353 003	Sep 01, 2010
	200MG	A090353 004	Sep 01, 2010

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376 001	Nov 29, 2010
MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203 001	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199 001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199 002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199 003	Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

+	ROCHE	50MG/5ML (10MG/ML) **	N020137 002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137 001	Aug 23, 1993

TORSEMIDE

AM REGENT	20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008

TABLET; ORAL

TORSEMIDE

SUN PHARM INDS	5MG	A078478 001	Feb 26, 2008
	10MG	A078478 002	Feb 26, 2008
	20MG	A078478 003	Feb 26, 2008
	100MG	A078478 004	Feb 26, 2008

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACCORD HLTHCARE	50MG	A202390 001	May 16, 2013
ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002
ASTA	50MG	A075974 001	Jul 12, 2002
FOSUN PHARMA	50MG	A075968 001	Jun 25, 2002
IVAX SUB TEVA PHARMS	50MG	A075963 001	Jul 03, 2002
MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002
NORTHSTAR HLTHCARE	50MG	A078935 001	May 26, 2010
POLYGEN PHARMS	50MG	A206706 001	Jul 02, 2019
SPECGX LLC	50MG	A075983 001	Jun 25, 2002
SUN PHARM INDUSTRIES	50MG	A076100 001	Jun 20, 2002
WATSON LABS	50MG	A075962 001	Jun 24, 2002

ULTRAM

JANSSEN PHARMS	100MG	N020281 001	Mar 03, 1995
----------------	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

+	PURDUE PHARMA	100MG **	N021745 001	Dec 30, 2008
+		200MG **	N021745 002	Dec 30, 2008
+		300MG **	N021745 003	Dec 30, 2008

TRAMADOL HYDROCHLORIDE

AUROBINDO PHARMA LTD	100MG	A204421 001	Oct 20, 2015
	200MG	A204421 002	Oct 20, 2015
	300MG	A204421 003	Oct 20, 2015
PAR PHARM INC	100MG	A078783 001	Nov 13, 2009
	200MG	A078783 002	Nov 13, 2009
	300MG	A078783 003	Sep 20, 2011

ULTRAM ER

+	VALEANT PHARMS	100MG	N021692 001	Sep 08, 2005
+		200MG	N021692 002	Sep 08, 2005
+		300MG	N021692 003	Sep 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

RYBIX ODT

SHIONOGI INC

50MG

N021693 001 May 05, 2005

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+ NOVARTIS

EQ 1MG

N204114 002 May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

MAVIK

+ ABBVIE

1MG **

N020528 001 Apr 26, 1996

+

2MG **

N020528 002 Apr 26, 1996

+

4MG **

N020528 003 Apr 26, 1996

TRANDOLAPRIL

CIPLA

1MG

A077307 002 Jun 12, 2007

2MG

A077307 001 Jun 12, 2007

4MG

A077307 003 Jun 12, 2007

DR REDDYS LABS LTD

1MG

A078493 001 Aug 25, 2008

2MG

A078493 002 Aug 25, 2008

4MG

A078493 003 Aug 25, 2008

EPIC PHARMA LLC

1MG

A077256 001 Jun 12, 2007

2MG

A077256 002 Jun 12, 2007

4MG

A077256 003 Jun 12, 2007

INVAGEN PHARMS

1MG

A078320 001 Jun 12, 2007

2MG

A078320 002 Jun 12, 2007

4MG

A078320 003 Jun 12, 2007

MYLAN

1MG

A078346 001 Apr 28, 2008

2MG

A078346 002 Apr 28, 2008

4MG

A078346 003 Apr 28, 2008

WATSON LABS

1MG

A077805 001 Jun 12, 2007

2MG

A077805 002 Jun 12, 2007

4MG

A077805 003 Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

+ ABBVIE

1MG;240MG

N020591 003 Oct 22, 1996

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

VIRTUS PHARMS

100MG/ML

A202755 001 Feb 25, 2016

TABLET;ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN

500MG

N019280 001 Dec 30, 1986

TRANEXAMIC ACID

AMERIGEN PHARMS LTD

650MG

A203256 001 Jul 25, 2016

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ NOVARTIS

0.003% **

N204822 001 May 15, 2014

TRAVATAN

+ ALCON PHARMS LTD

0.004% **

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

+ PRAGMA

50MG **

N018207 001

+

100MG **

N018207 002

+

150MG **

N018207 003 Mar 25, 1985

+

300MG **

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

AUROLIFE PHARMA LLC

100MG

A071140 001 Oct 29, 1986

FOSUN PHARMA

50MG

A072484 001 Apr 30, 1990

MYLAN

100MG

A072483 001 Apr 30, 1990

MYLAN

50MG

A071405 001 Feb 27, 1991

MYLAN

100MG

A071406 001 Feb 27, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

MYLAN PHARMS INC

50MG

A090514 001 Jun 02, 2009

100MG

A090514 002 Jun 02, 2009

150MG

A090514 003 Jun 02, 2009

300MG

A090514 004 Jun 02, 2009

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A070857 001 Oct 10, 1986

50MG

A071112 001 Nov 17, 1986

100MG

A070858 001 Oct 10, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+ ANGELINI PHARMA

150MG **

N022411 001 Feb 02, 2010

+

300MG **

N022411 002 Feb 02, 2010

TRETINOIN

CAPSULE; ORAL

VESANOID

+ CHEPLAPHARM

10MG **

N020438 001 Nov 22, 1995

CREAM; TOPICAL

TRETINOIN

ALLERGAN

0.0375%

A090098 001 Mar 22, 2010

0.075%

A202209 001 Oct 11, 2012

SOLUTION; TOPICAL

RETIN-A

+ VALEANT INTL

0.05%

N016921 001

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

WOCKHARDT

0.05%

A075260 001 Jan 25, 1999

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

DELCOR ASSET CORP

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

8MG

A084268 001

8MG

A084320 001

IMPAX LABS

4MG

A084340 001

IVAX SUB TEVA PHARMS

4MG

A083750 001

MYLAN

2MG

A084406 001

PUREPAC PHARM

2MG

A084020 002

4MG

A084020 003

ROXANE

2MG

A084708 001

4MG

A084709 001

8MG

A084707 001

SANDOZ

4MG

A085601 001

TEVA

4MG

A084775 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

WATSON LABS

4MG

A084270 001

4MG

A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE

0.1MG/INH

N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US

0.055MG/INH

N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS

0.025%

A083017 003

0.1%

A083016 004

0.5%

A083015 002

ARISTOCORT A

ASTELLAS

0.025%

A083017 004

0.025%

A088818 001 Oct 16, 1984

0.1%

A083016 005

0.1%

A088819 001 Oct 16, 1984

0.5%

A083015 003

0.5%

A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS

0.025%

A085539 001

0.1%

A085539 002

0.5%

A085539 003

KENALOG

DELCOR ASSET CORP

0.5%

A083943 001

KENALOG-H

DELCOR ASSET CORP

0.1%

A086240 001

TRIA CET

TEVA

0.025%

A084908 001

0.1%

A084908 002

0.5%

A084908 003

TRIA CORT

SOLVAY

0.1%

A087113 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC

0.1%

A087798 001 Jun 04, 1982

ALPHARMA US PHARMS

0.025%

A087797 001 Jun 07, 1982

AMBIX

0.025%

A087932 001 May 09, 1983

MORTON GROVE

0.025%

A088094 001 Sep 01, 1983

0.1%

A088095 001 Sep 01, 1983

0.5%

A088096 001 Sep 01, 1983

PHARMADERM

0.025%

A087990 001 Jul 07, 1983

0.1%

A087991 001 Jul 07, 1983

0.5%

A087992 001 Jul 07, 1983

PHARMAFAIR

0.025%

A087921 001 Aug 10, 1982

0.1%

A087912 001 Aug 10, 1982

0.5%

A087922 001 Aug 10, 1982

TARO

0.025%

A040038 001 Oct 26, 1994

0.025%

A086277 001

0.1%

A086276 001

0.5%

A086275 001

TOPIDERM

0.025%

A089274 001 Feb 21, 1989

0.1%

A089275 001 Feb 21, 1989

0.5%

A089276 001 Feb 21, 1989

TRIA TEX

IVAX PHARMS

0.025%

A087430 001 Nov 01, 1988

0.1%

A087429 001 Nov 01, 1988

0.5%

A087428 001 Nov 01, 1988

TRYMEX

SAVAGE LABS

0.025%

A088196 001 Mar 25, 1983

0.1%

A088197 001 Mar 25, 1983

0.5%

A088198 001 Mar 25, 1983

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE ACETONIDE

GEL; TOPICAL

ARISTOGEL

ASTELLAS	0.1%	A083380	001
----------	------	---------	-----

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL	3MG/ML	N019503	001	Oct 16, 1987
---------	--------	---------	-----	--------------

SANDOZ INC	10MG/ML	A090166	001	May 27, 2009
------------	---------	---------	-----	--------------

	40MG/ML	A090164	001	Jun 01, 2009
--	---------	---------	-----	--------------

WATSON LABS	40MG/ML	A085825	001
-------------	---------	---------	-----

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

+ ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008
------------	--------------------------	---------	-----	--------------

LOTION; TOPICAL

KENALOG

DELCOR ASSET CORP	0.025% **	A084343	001
-------------------	-----------	---------	-----

+	0.025% **	N011602	003
---	-----------	---------	-----

	0.1% **	A084343	002
--	---------	---------	-----

+	0.1% **	N011602	001
---	---------	---------	-----

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
--------------------	--------	---------	-----	--------------

	0.1%	A087192	001	Sep 08, 1982
--	------	---------	-----	--------------

OINTMENT; TOPICAL

ARISTOCORT

ASTELLAS	0.1%	A080750	004
----------	------	---------	-----

	0.5% **	A080745	002
--	---------	---------	-----

ARISTOCORT A

ASTELLAS	0.1%	A080750	003
----------	------	---------	-----

	0.1%	A088780	001	Oct 01, 1984
--	------	---------	-----	--------------

	0.5% **	A080745	003
--	---------	---------	-----

	0.5%	A088781	001	Oct 05, 1984
--	------	---------	-----	--------------

FLUTEX

IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
-------------	--------	---------	-----	--------------

	0.1%	A087377	001	Nov 01, 1988
--	------	---------	-----	--------------

	0.5%	A087376	001	Nov 01, 1988
--	------	---------	-----	--------------

KENALOG

DELCOR ASSET CORP	0.5% **	A083944	001
-------------------	---------	---------	-----

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
----------------------	------	---------	-----	--------------

ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
--------------------	------	---------	-----	--------------

MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
--------------	--------	---------	-----	--------------

	0.1%	A088091	001	Sep 01, 1983
--	------	---------	-----	--------------

	0.5%	A088092	001	Sep 01, 1983
--	------	---------	-----	--------------

+ MYLAN	0.025% **	N011600	003
---------	-----------	---------	-----

+	0.1% **	N011600	001
---	---------	---------	-----

PHARMADERM	0.025%	A088692	001	Aug 02, 1984
------------	--------	---------	-----	--------------

	0.1%	A088690	001	Aug 02, 1984
--	------	---------	-----	--------------

TARO	0.025%	A040040	001	Sep 30, 1994
------	--------	---------	-----	--------------

	0.025%	A040374	001	Jun 05, 2001
--	--------	---------	-----	--------------

	0.1%	A087902	001	Dec 27, 1982
--	------	---------	-----	--------------

	0.5%	A040386	001	Jun 05, 2001
--	------	---------	-----	--------------

TRYMEX

SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
-------------	--------	---------	-----	--------------

	0.1%	A088691	001	Aug 02, 1984
--	------	---------	-----	--------------

PASTE; DENTAL

KENALOG IN ORABASE

+ DELCOR ASSET CORP	0.1% **	N012097	001
---------------------	---------	---------	-----

ORALONE

TARO	0.1%	A071383	001	Jul 06, 1987
------	------	---------	-----	--------------

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
----------------	--------------	---------	-----	--------------

NASACORT HFA

SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
-------------------	---------------	---------	-----	--------------

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009
----------------	---------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

FOSUN PHARMA	25MG/ML	N011685	003
+	40MG/ML **	N012802	001

TRIAMCINOLONE DIACETATE

AKORN	25MG/ML	A085122	001
	40MG/ML	A086394	001
WATSON LABS	40MG/ML	A084072	001
	40MG/ML	A085529	001

SYRUP; ORAL

ARISTOCORT

ASTELLAS	2MG/5ML	N011960	004
----------	---------	---------	-----

KENACORT

DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001
-------------------	-----------------	---------	-----

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN	0.5MG	N017892	002	Nov 15, 1982
----------------------	-------	---------	-----	--------------

TRIAZOLAM

WATSON LABS	0.125MG	A074445	001	Oct 20, 1995
	0.25MG	A074445	002	Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988

NAQUA

SCHERING	2MG	N012265	001
	4MG	N012265	002

TRICHLOREX

LANNETT	4MG	A083436	001
	4MG	A085630	001

TRICHLORMAS

MAST MM	4MG	A086259	001
---------	-----	---------	-----

TRICHLORMETHIAZIDE

CHARTWELL RX	4MG	A085568	001
IMPAX LABS	4MG	A083967	001
PAR PHARM	2MG	A087007	001
	4MG	A087005	001
SANDOZ	4MG	A086171	001
WATSON LABS	2MG	A083847	001
	2MG	A086458	001
	4MG	A083462	001
	4MG	A083855	001
	4MG	A085962	001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US	1.5GM/15ML	N016830	001
-------------------	------------	---------	-----

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US	750MG	N016809	002
-------------------	-------	---------	-----

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE	10MG/ML	N009729	001
---------	---------	---------	-----

TABLET; ORAL

PATHILON

LEDERLE	25MG	N009489	005
---------	------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552	006
---	-----------------	--------------------	---------	-----

TRIFLUOPERAZINE HYDROCHLORIDE

FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982
WOCKHARDT	EQ 10MG BASE/ML	A088143	001	Jul 26, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

STELAZINE

+ GLAXOSMITHKLINE EQ 2MG BASE/ML ** N011552 005

TABLET; ORAL

STELAZINE

+ GLAXOSMITHKLINE EQ 1MG BASE ** N011552 001

+ EQ 2MG BASE ** N011552 002

+ EQ 5MG BASE ** N011552 003

+ EQ 10MG BASE ** N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR EQ 1MG BASE A088967 001 Apr 23, 1985

EQ 2MG BASE A088968 001 Apr 23, 1985

EQ 5MG BASE A088969 001 Apr 23, 1985

EQ 10MG BASE A088970 001 Apr 23, 1985

INVATECH EQ 1MG BASE A040153 001 Oct 25, 1996

EQ 2MG BASE A040153 002 Oct 25, 1996

EQ 5MG BASE A040153 003 Oct 25, 1996

EQ 10MG BASE A040153 004 Oct 25, 1996

IVAX PHARMS EQ 1MG BASE A087612 001 Nov 19, 1982

EQ 2MG BASE A087613 001 Nov 19, 1982

EQ 5MG BASE A087328 001 Nov 19, 1982

EQ 10MG BASE A087614 001 Nov 19, 1982

WATSON LABS EQ 1MG BASE A085975 001 Jun 23, 1988

EQ 2MG BASE A085976 001 Jun 23, 1988

EQ 5MG BASE A085973 001 Jun 23, 1988

EQ 10MG BASE A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON EQ 50MG HYDROCHLORIDE/5ML N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON 3MG/ML N011325 005

10MG/ML N011325 004

20MG/ML N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB 10MG N011123 001

25MG N011123 002

50MG N011123 003

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE 5MG N006773 010

5MG N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE 2MG/5ML N006773 009

TRIHENXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES 2MG/5ML A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

+ LEDERLE 2MG ** N006773 005

+ 5MG ** N006773 003

TREMIM

SCHERING 2MG A080381 001

5MG A080381 003

TRIHENXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS 2MG A040337 002 Feb 16, 2000

5MG A040337 001 Feb 16, 2000

NYLOS 5MG A085622 001

VANGARD 2MG A088035 001 Jul 30, 1982

WATSON LABS 2MG A040184 001 Feb 06, 1998

2MG A085117 001

5MG A040184 002 Feb 06, 1998

5MG A085105 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719 002	Dec 31, 1984
	60MG	N018719 001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316 004	
------------------	-------------	-------------	--

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316 003	
------------------	-------------------	-------------	--

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015 001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285 001	Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE	N011316 001	
------------------	---------------	-------------	--

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE	300MG	N005856 005	
--------	-------	-------------	--

SOLUTION; ORAL

TRIDIONE

ABBVIE	200MG/5ML	N005856 002	
--------	-----------	-------------	--

TABLET; ORAL

TRIDIONE

+ ABBVIE	150MG	N005856 009	
----------	-------	-------------	--

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE	50MG/ML	N008983 001	
-------	---------	-------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AM REGENT	100MG/ML	A091330 001	Mar 08, 2011
HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960 001	Apr 04, 1986
	100MG/ML	A089043 001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094 001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577 001	Oct 19, 1982
	100MG/ML	A087939 001	Dec 28, 1982

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT	100MG/ML	A091329 001	Mar 08, 2011
-----------	----------	-------------	--------------

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS	100MG	N017943 001	
	200MG	N017943 003	Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES	100MG	A070494 001	Jan 22, 1986
	200MG	A070495 001	Sep 24, 1986
TEVA	200MG **	A071259 001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952 001	
-------	-------	-------------	--

TRIMPEX 200

ROCHE	200MG	N017952 002	Nov 09, 1982
-------	-------	-------------	--------------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

ALLEGIS	EQ 25MG BASE/5ML	N074374 001	Jun 23, 1995
---------	------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL
EQ 200MG BASE/VIALN020326 001 Dec 17, 1993
N020326 002 Jul 31, 1998TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

+ ODYSSEY PHARMS

EQ 25MG BASE

N016792 001

+

EQ 50MG BASE

N016792 002

+

EQ 100MG BASE

N016792 003 Sep 15, 1982

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

ACP NIMBLE

3.7%; 2.86%; 3.42%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

3.7%; 2.86%; 3.42%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

3.7%; 2.86%; 3.42%

A087864 001 Sep 01, 1982

FOUGERA

3.7%; 2.86%; 3.42%

A086424 001

PERRIGO NEW YORK

3.7%; 2.86%; 3.42%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

3.7%; 2.86%; 3.42%

A087887 001 Jul 23, 1982

VAGILIA

ACP NIMBLE

3.7%; 2.86%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

184MG; 143.75MG; 172.5MG

N005794 002

TRIPLE SULFA

FOUGERA

184MG; 143.75MG; 172.5MG

A088463 001 Jan 03, 1985

PHARMADERM

184MG; 143.75MG; 172.5MG

A088462 001 Jan 03, 1985

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA 1.25MG/5ML A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML A085940 001

HALSEY 1.25MG/5ML A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML A087514 001 Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG A085610 001

WATSON LABS 2.5MG A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT 167MG/5ML; 167MG/5ML; 167MG/5ML A080123 002

NEOTRIZINE

LILLY 167MG/5ML; 167MG/5ML; 167MG/5ML N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML; 167MG/5ML; 167MG/5ML A080100 001

SULFOSE

WYETH AYERST 167MG/5ML; 167MG/5ML; 167MG/5ML A080013 002

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML; 167MG/5ML; 167MG/5ML N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/5ML; 167MG/5ML; 167MG/5ML A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML; 167MG/5ML; 167MG/5ML N006920 003

TABLET; ORAL

NEOTRIZINE

LILLY 167MG; 167MG; 167MG N006317 011

SULFA-TRIPLE #2

IMPAX LABS 167MG; 167MG; 167MG A080079 001

SULFALOID

FOREST PHARMS 167MG; 167MG; 167MG A080099 001

SULFOSE

WYETH AYERST 167MG; 167MG; 167MG A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG; 167MG; 167MG N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG; 167MG; 167MG A080086 001

TRIPLE SULFAS

LEDERLE 167MG; 167MG; 167MG N006920 002

TRIPLE SULFOID

PAL PAK 167MG; 167MG; 167MG A080094 001

TROGLITAZONE

TABLET; ORAL

PRELAY

SANKYO 200MG N020719 001 Jan 29, 1997

300MG N020719 003 Aug 04, 1997

400MG N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG N020720 001 Jan 29, 1997

300MG N020720 003 Aug 04, 1997

400MG N020720 002 Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

PHARM RES ASSOC 10% N011340 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

TROLEANDOMYCIN

CAPSULE; ORAL

TAO

PFIZER

EQ 250MG BASE

N050336 002

SUSPENSION; ORAL

TAO

PFIZER

EQ 125MG BASE/5ML

N050332 001

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+

HOSPIRA

3.6GM/100ML **

N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

ALCON

0.5% **

N012111 002

1% **

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001 Sep 16, 1983

1%

A088230 001 Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001 Aug 28, 1985

ALCON PHARMS LTD

1%

A089172 001 Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001 Jul 30, 1982

1%

A087637 001 Aug 09, 1982

WATSON LABS

0.5%

A089171 001 Dec 28, 1990

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

+

ALLERGAN

60MG **

N022103 001 Aug 03, 2007

TROSPIMUM CHLORIDE

UPSHER SMITH LABS

60MG

A091635 001 Apr 29, 2015

TABLET; ORAL

SANCTURA

+

ALLERGAN

20MG **

N021595 001 May 28, 2004

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001 Dec 18, 1997

EQ 200MG BASE

N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE; ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+

SUCAMPO PHARMA LLC

0.15% **

N021214 001 Aug 03, 2000

URACIL MUSTARD

CAPSULE; ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

UREA_C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA EQ 75MG/POUCH

N020586 002 May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS 125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA 125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES 100MG/VIAL

N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE;INTRAMUSCULAR

METRODIN

SERONO 75 IU/AMP

N019415 002 Sep 18, 1986

150 IU/AMP

N019415 003 Sep 18, 1986

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+ FERRING 75 IU/VIAL

N021289 001 May 06, 2002

INJECTABLE;SUBCUTANEOUS

FERTINEX

SERONO 75 IU/AMP

N019415 005 Aug 23, 1996

150 IU/AMP

N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE;INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS 5,000 IU/VIAL

N021846 003

9,000 IU/VIAL

N021846 002

250,000 IU/VIAL

N021846 001

URSODIOL

CAPSULE;ORAL

ACTIGALL

ALLERGAN 150MG

N019594 001 Dec 31, 1987

URSODIOL

IMPAX LABS INC 300MG

A077895 001 Jul 27, 2006

TABLET;ORAL

URSODIOL

TEVA PHARMS USA 250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

MYLAN EQ 500MG BASE

A078070 001 May 24, 2010

EQ 1GM BASE

A078070 002 May 24, 2010

WATSON LABS INC EQ 500MG BASE

A090370 001 Mar 16, 2011

EQ 1GM BASE

A090370 002 Mar 16, 2011

VALDECOXIB

TABLET;ORAL

BEXTRA

GD SEARLE 10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

+ ABBVIE EQ 100MG BASE/ML

N020593 001 Dec 30, 1996

VALPROIC ACID

CAPSULE;ORAL

DEPAKENE

+ ABBVIE 250MG

N018081 001

VALPROIC ACID

PAR PHARM 250MG

A070431 001 Feb 28, 1986

SCHERER RP 250MG

A070195 001 Jul 02, 1987

UPSHER SMITH LABS 250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

+ BIONPHARMA INC 125MG **

N022152 001 Jul 29, 2008

+ 250MG **

N022152 002 Jul 29, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VALPROIC ACID

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

+

500MG **

N022152 003 Jul 29, 2008

SYRUP;ORAL

DEPAKENE

+

ABBVIE

250MG/5ML

N018082 001

VALPROIC ACID

ANI PHARMS INC

250MG/5ML

A073178 001 Aug 25, 1992

APOTEX

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE;ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

SOLUTION;ORAL

PREXXARTAN

+

CARMEL BIOSCIENCES

20MG/5ML

N209139 001 Dec 19, 2017

+

80MG/20ML

N209139 002 Dec 19, 2017

TABLET;ORAL

VALSARTAN

TORRENT

40MG

A202728 001 Jan 05, 2015

80MG

A202728 002 Jan 05, 2015

160MG

A202728 003 Jan 05, 2015

320MG

A202728 004 Jan 05, 2015

WATSON LABS INC

40MG

A090642 001 Jan 05, 2015

80MG

A090642 002 Jan 05, 2015

160MG

A090642 003 Jan 05, 2015

320MG

A090642 004 Jan 05, 2015

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

FRESENIUS KABI USA

EQ 125MG BASE

A065453 001 Jun 18, 2012

EQ 250MG BASE

A065453 002 Jun 18, 2012

FOR SOLUTION;ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/VIAL **

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL **

A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL **

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL **

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL **

A062812 003 Nov 17, 1987

VANCOLED

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL **

A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL **

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL **

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL **

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL **

A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

EMCURE PHARMS LTD

EQ 500MG BASE/VIAL

A202275 001 Oct 31, 2013

EQ 1GM BASE/VIAL

A202275 002 Oct 31, 2013

EQ 10GM BASE/VIAL

A202464 001 Oct 09, 2013

EQ 5GM BASE/VIAL

A202274 001 Oct 31, 2013

HAINAN POLY PHARM

EQ 500MG BASE/VIAL

A212332 001 Jun 12, 2019

EQ 1GM BASE/VIAL

A212332 002 Jun 12, 2019

MYLAN LABS LTD

EQ 10GM BASE/VIAL

A091469 001 Jul 01, 2011

TEVA PHARMS USA

EQ 500MG BASE/VIAL

A201251 001 Dec 23, 2015

EQ 1GM BASE/VIAL

A201251 002 Dec 23, 2015

EQ 5GM BASE/VIAL

A201250 001 Dec 23, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
	EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
	EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR				
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

+	BAYER HLTHCARE	2.5MG **	N021400	003	Aug 19, 2003
	VARDENAFIL HYDROCHLORIDE				
	AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018
		10MG	A210738	002	Oct 31, 2018
		20MG	A210738	003	Oct 31, 2018

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

+	PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
---	-------------	----------------------	---------	-----	--

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

+	ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+		20MG/VIAL **	N018776	003	Jan 03, 1992

VECURONIUM BROMIDE

	HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
	WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
		20MG/VIAL	A074334	002	Aug 31, 1995
	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999
		20MG/VIAL	A075218	002	Aug 23, 1999

VELAGLUCERASE ALFA

POWDER; INTRAVENOUS

VPRIV

	SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010
--	---------------------	----------------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

	WYETH PHARMS	EQ 100MG BASE	N020699	003	Oct 20, 1997
	VENLAFAXINE HYDROCHLORIDE				
	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
		EQ 75MG BASE	A078087	002	Mar 16, 2012
		EQ 150MG BASE	A078087	003	Mar 16, 2012
	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
		EQ 75MG BASE	A078789	002	Jun 01, 2011
		EQ 150MG BASE	A078789	003	Jun 01, 2011

TABLET; ORAL

EFFEXOR

+	WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+		EQ 25MG BASE **	N020151	002	Dec 28, 1993
+		EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+		EQ 50MG BASE **	N020151	003	Dec 28, 1993
+		EQ 75MG BASE **	N020151	004	Dec 28, 1993
+		EQ 100MG BASE **	N020151	005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008
		EQ 37.5MG BASE	A077515	002	Jun 13, 2008
		EQ 50MG BASE	A077515	003	Jun 13, 2008
		EQ 75MG BASE	A077515	004	Jun 13, 2008
		EQ 100MG BASE	A077515	005	Jun 13, 2008
	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
		EQ 37.5MG BASE	A078517	002	Jun 13, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	EQ 50MG BASE	A078517 003	Jun 13, 2008
	EQ 75MG BASE	A078517 004	Jun 13, 2008
	EQ 100MG BASE	A078517 005	Jun 13, 2008
PRINSTON INC	EQ 25MG BASE	A090027 001	Aug 04, 2010
	EQ 37.5MG BASE	A090027 002	Aug 04, 2010
	EQ 50MG BASE	A090027 003	Aug 04, 2010
	EQ 75MG BASE	A090027 004	Aug 04, 2010
	EQ 100MG BASE	A090027 005	Aug 04, 2010

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

MYLAN	100MG	A078306 001	Aug 09, 2007
	200MG	A078306 002	Aug 09, 2007
	300MG	A078306 003	Aug 09, 2007

INJECTABLE;INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML	N019038 001	Mar 30, 1984
---------------	----------	-------------	--------------

ISOPTIN

+ MT ADAMS

2.5MG/ML **

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348 001	May 01, 1986
BEDFORD	2.5MG/ML	A072888 001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987
	2.5MG/ML	A070739 001	May 06, 1987
	2.5MG/ML	A070740 001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225 001	Nov 12, 1985
	2.5MG/ML	A070617 001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993
	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET;ORAL

CALAN

GD SEARLE LLC	40MG	N018817 003	Feb 23, 1988
+	80MG	N018817 001	Sep 10, 1984
+	120MG	N018817 002	Sep 10, 1984
	160MG	N018817 004	Feb 23, 1988

ISOPTIN

+ MT ADAMS

40MG

N018593 003

+ MT ADAMS

80MG

N018593 001

+ MT ADAMS

120MG

N018593 002

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	120MG	A070483 001	Sep 24, 1986
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SUN PHARM INDUSTRIES	80MG	A071489 002	Jan 13, 1988
	120MG	A071489 001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989
	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986
YAOPHARMA CO LTD	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+ PFIZER

180MG **

N019152 002 Dec 15, 1989

COVERA-HS

GD SEARLE LLC

180MG

N020552 001 Feb 26, 1996

240MG

N020552 002 Feb 26, 1996

VERAPAMIL HYDROCHLORIDE

APOTEX CORP

120MG

A200878 001 Apr 20, 2012

180MG

A200878 002 Apr 20, 2012

240MG

A200878 003 Apr 20, 2012

PLIVA

240MG

A072922 001 Mar 01, 1996

VERATRUM VIRIDE ROOT

TABLET;ORAL

VERTAVIS

MEDPOINTE PHARM HLC

130CSR UNIT

N005691 002

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE

EQ 187.4MG BASE/ML

N050523 001

OINTMENT;OPHTHALMIC

VIRA-A

PARKEDALE

3%

N050486 001

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

+ LILLY

10MG/VIAL

N012665 001

VINBLASTINE SULFATE

ABRAXIS PHARM

10MG/VIAL

A089011 001 Nov 18, 1985

HOSPIRA

10MG/VIAL

A089565 001 Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY

1MG/VIAL

N014103 001

1MG/ML

N014103 003 Mar 07, 1984

5MG/VIAL

N014103 002

VINCASAR PFS

TEVA PARENTERAL

1MG/ML

A071426 001 Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB

5MG/VIAL

A070867 001 Jul 12, 1988

VINCRISTINE SULFATE

ABIC

1MG/ML

A070873 001 Feb 19, 1987

ABRAXIS PHARM

1MG/ML

A070411 001 Sep 10, 1986

FRESENIUS KABI USA

1MG/ML

A076296 001 Dec 20, 2002

1MG/ML

A076401 001 Oct 28, 2003

HOSPIRA

1MG/VIAL

A071559 001 Apr 11, 1988

2MG/VIAL

A071560 001 Apr 11, 1988

5MG/VIAL

A071561 001 Apr 11, 1988

VINCRISTINE SULFATE PFS

TEVA PHARMS USA

1MG/ML

A075493 001 Sep 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

+ PIERRE FABRE

EQ 10MG BASE/ML

N020388 001 Dec 23, 1994

VINORELBINE TARTRATE

EBEWE PHARMA

EQ 10MG BASE/ML

A078408 001 Feb 13, 2008

HOSPIRA

EQ 10MG BASE/ML

A076827 001 Jun 02, 2005

MYLAN LABS LTD

EQ 10MG BASE/ML

A200148 001 Aug 31, 2012

NOVAST LABS

EQ 10MG BASE/ML

A208997 001 Aug 05, 2019

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER

EQ 1GM BASE/VIAL

A061086 001

EQ 5GM BASE/VIAL

A061086 002

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

VITAMIN A

CAPSULE;ORAL

AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002
	50,000USP UNITS	A083080 001

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001
CHASE CHEM	50,000 IU	A083351 001
EVERYLIFE	50,000 IU	A083134 001
IMPAX LABS	50,000USP UNITS	A080952 001
WEST WARD	50,000USP UNITS	A080985 001

VITAMIN A PALMITATE

CAPSULE;ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001
-------------------	----------------------	-------------

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883 001
-------	----------------------	-------------

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001
--------------	----------------------	-------------

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001
--------------	----------------------	-------------

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001
CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001
	EQ 50,000 UNITS BASE	A083207 001
ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001
EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001
	EQ 50,000 UNITS BASE	A083114 001
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001
	EQ 50,000 UNITS BASE	A080955 001
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001
	EQ 50,000 UNITS BASE	A083190 001
MK LABS	EQ 25,000 UNITS BASE	A083457 002
	EQ 50,000 UNITS BASE	A083457 001
WEST WARD	EQ 50,000 UNITS BASE	A080967 001
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311 001
	EQ 50,000 UNITS BASE	A083321 001
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001
	EQ 50,000 UNITS BASE	A083981 001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921 001
------	----------------------	-------------

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001
---------	-------------------------	-------------

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013
------------------	-----------	-------------	--------------

TABLET;ORAL

VORICONAZOLE

TEVA PHARMS	50MG	A091658 001	Apr 06, 2012
	200MG	A091658 002	Apr 06, 2012

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013
---------------------	-----------------	-------------	--------------

WARFARIN POTASSIUM

TABLET;ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771 007
	5MG	N011771 004
	10MG	N011771 005
	25MG	N011771 006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995
	50MG/VIAL	N009218	020	
	75MG/VIAL	N009218	012	

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771	003	
	10MG	N011771	002	
	25MG	N011771	001	

PANWARFIN

ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	

WARFARIN SODIUM

MYLAN

	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004

USL PHARMA

	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985

WATSON LABS

	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982

YAOPHARMA CO LTD

	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	

XENON XE 133-V.S.S.

GE HEALTHCARE	10mCi/VIAL	N017687	001	
---------------	------------	---------	-----	--

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT	18-25mCi/AMP	N017262	002	
--------------	--------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT

N017605 001

XYLOSE

LYNE

25GM/BOT

N018856 001 Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

MYLAN

5MG

A077238 001 Jun 06, 2008

10MG

A077238 002 Jun 06, 2008

UPSHER SMITH LABS

5MG

A078095 001 Jun 06, 2008

5MG

A078706 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

10MG

A078706 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

TERSERA THERAPS LLC

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

LUITPOLD

10MG/ML

A091457 001 May 06, 2010

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

+

300MG **

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

HEC PHARM

300MG

A202058 001 Oct 07, 2011

MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI USA INC

300MG

N020471 001 Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

CADILA

EQ 20MG BASE

A208988 001 Aug 22, 2017

EQ 40MG BASE

A208988 002 Aug 22, 2017

EQ 60MG BASE

A208988 003 Aug 22, 2017

EQ 80MG BASE

A208988 004 Aug 22, 2017

MYLAN

EQ 20MG BASE

A202395 001 Oct 10, 2013

EQ 40MG BASE

A202395 002 Oct 10, 2013

EQ 60MG BASE

A202395 003 Oct 10, 2013

EQ 80MG BASE

A202395 004 Oct 10, 2013

SUSPENSION; ORAL

GEODON

PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013
DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018
SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019
SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013
	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013

ZOMETA

+ NOVARTIS	EQ 4MG BASE/VIAL **	N021223	001	Aug 20, 2001
------------	---------------------	---------	-----	--------------

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

ANI PHARMS INC	2.5MG	A090861	001	Mar 04, 2014
	5MG	A090861	002	Mar 04, 2014
APOTEX INC	2.5MG	A202078	001	May 14, 2013
	5MG	A202078	002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015
	5MG	A203772	002	Sep 30, 2015
MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013
	5MG	A203186	002	May 14, 2013
SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
	5MG	A203476	002	Nov 13, 2014

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

APOTEX INC	2.5MG	A202476	001	May 14, 2013
	5MG	A202476	002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
	5MG	A204336	002	Oct 22, 2015

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
	10MG	A077985	002	Apr 23, 2007
HIKMA	5MG	A078129	001	Apr 30, 2008
	10MG	A078129	002	Apr 30, 2008
MYLAN	5MG	A076578	001	Apr 23, 2007
	10MG	A076578	002	Apr 23, 2007
MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
	10MG	A078016	002	Apr 23, 2007
STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007
	10MG	A076062	002	Apr 23, 2007
SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
	10MG	A077359	002	Apr 23, 2007
SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
	10MG	A078055	002	Apr 23, 2007
SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
	10MG	A077288	002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
	10MG	A077540	002	Apr 23, 2007
WATSON LABS	5MG	A077773	001	Apr 23, 2007
	10MG	A077773	002	Apr 23, 2007
WOCKHARDT	5MG	A078426	001	May 15, 2007
	10MG	A078426	002	May 15, 2007

TABLET;SUBLINGUAL

INTERMEZZO

+ PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+	3.5MG	N022328	002	Nov 23, 2011

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
	12.5MG	A078483	002	Jun 06, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
	10MG	N021412	002	Apr 25, 2007

DISCONTINUED DRUG PRODUCT LIST

** See List Footnote

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

+ SUNOVION PHARMS INC 50MG **

N020789 002 Aug 22, 2003

ZONISAMIDE

ANI PHARMS INC

25MG

A077639 001 Dec 22, 2005

25MG

A077641 003 Dec 22, 2005

50MG

A077639 002 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077639 003 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

AUROBINDO PHARMA LTD

25MG

A077645 002 Sep 29, 2006

50MG

A077645 003 Sep 29, 2006

100MG

A077645 001 Dec 22, 2005

EPIC PHARMA LLC

25MG

A077876 001 Feb 21, 2007

50MG

A077876 002 Feb 21, 2007

100MG

A077876 003 Feb 21, 2007

HERITAGE PHARMA

25MG

A077650 001 Apr 20, 2006

50MG

A077650 002 Apr 20, 2006

100MG

A077650 003 Apr 20, 2006

MYLAN

25MG

A077637 001 Dec 22, 2005

50MG

A077637 002 Dec 22, 2005

100MG

A077637 003 Dec 22, 2005

MYLAN PHARMS INC

25MG

A077647 001 Dec 22, 2005

50MG

A077647 002 Dec 22, 2005

100MG

A077647 003 Dec 22, 2005

ROXANE

25MG

A077648 001 Dec 22, 2005

50MG

A077648 002 Dec 22, 2005

100MG

A077648 003 Dec 22, 2005

SUN PHARM INDUSTRIES

25MG

A077635 001 Dec 22, 2005

50MG

A077635 002 Dec 22, 2005

100MG

A077635 003 Dec 22, 2005

UPSHER SMITH LABS

25MG

A077644 001 Dec 22, 2005

50MG

A077644 002 Dec 22, 2005

100MG

A077644 003 Dec 22, 2005

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPIRAZOLE
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
ABILIFY MYCITE KIT, ARIPIPIRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCRUFER, FERRIC MALTOL
ACCUNEB, ALBUTEROL SULFATE
ACUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN

APPENDIX A - PRODUCT NAME INDEX**** A ****

ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOSINE, ADENOSINE
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADMELOG, INSULIN LISPRO
ADMELOG SOLOSTAR, INSULIN LISPRO
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMP TOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENEX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKLIEF, TRIFAROTENE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** A **

ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
 ALFENTA, ALFENTANIL HYDROCHLORIDE
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALIMTA, PEMETREXED DISODIUM
 ALINIA, NITAZOXANIDE
 ALIQOPA, COPANLISIB DIHYDROCHLORIDE
 ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
 ALKERAN, MELPHALAN
 ALKERAN, MELPHALAN HYDROCHLORIDE
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLI, ORLISTAT (OTC)
 ALLOPURINOL, ALLOPURINOL
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALLZITAL, ACETAMINOPHEN
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALOCRI, NEDOCROMIL SODIUM
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ALOPRIM, ALLOPURINOL SODIUM
 ALORA, ESTRADIOL
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALOXI, PALONOSETRON HYDROCHLORIDE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 ALREX, LOTEHPREDNOL ETABONATE
 ALTABAX, RETAPAMULIN
 ALTACE, RAMIPRIL
 ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
 ALTAVERA, ETHINYL ESTRADIOL
 ALTOPREV, LOVASTATIN
 ALTRENO, TRETINOIN
 ALUNBRIG, BRIGATINIB
 ALVESCO, CICLESONIDE
 ALVIMOPAN, ALVIMOPAN
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ALYQ, TADALAFIL
 AMABELZ, ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMARYL, GLIMEPIRIDE
 AMBIEN, ZOLPIDEM TARTRATE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBISOME, AMPHOTERICIN B
 AMBRISENTAN, AMBRISENTAN
 AMCINONIDE, AMCINONIDE
 AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 AMICAR, AMINOCAPROIC ACID
 AMIDATE, ETOMIDATE
 AMIFOSTINE, AMIFOSTINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMINO ACIDS, AMINO ACIDS
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX**** A ****

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
APADAZ, ACETAMINOPHEN
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE

APPENDIX A - PRODUCT NAME INDEX**** A ****

APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ARISTADA, ARIPIPIRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPIRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARNUITY ELLIPTA, FLUTICASON FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABOJECT SYRINGE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX**** A ****

AUROVELA 1.5/30, ETHINYL ESTRADIOL
 AUROVELA 1/20, ETHINYL ESTRADIOL
 AUROVELA 24 FE, ETHINYL ESTRADIOL
 AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
 AUROVELA FE 1/20, ETHINYL ESTRADIOL
 AURYXIA, FERRIC CITRATE
 AUSTEDO, DEUTETRABENAZINE
 AUVI-Q, EPINEPHRINE
 AVAGARD, ALCOHOL (OTC)
 AVAGE, TAZAROTENE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVANDIA, ROSIGLITAZONE MALEATE
 AVAPRO, IRBESARTAN
 AVC, SULFANILAMIDE
 AVEED, TESTOSTERONE UNDECANOATE
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 AVIANE-28, ETHINYL ESTRADIOL
 AVITA, TRETINOIN
 AVODART, DUTASTERIDE
 AVYCAZ, AVIBACTAM SODIUM
 AXID AR, NIZATIDINE (OTC)
 AXUMIN, FLUCICLOVINE F-18
 AYUNA, ETHINYL ESTRADIOL
 AZACITIDINE, AZACITIDINE
 AZACTAM, AZTREONAM
 AZASAN, AZATHIOPRINE
 AZASITE, AZITHROMYCIN
 AZATHIOPRINE, AZATHIOPRINE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZEDRA, IOBENGUANE I-131
 AZELAIC ACID, AZELAIC ACID
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 AZELEX, AZELAIC ACID
 AZILECT, RASAGILINE MESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 AZOPT, BRINZOLAMIDE
 AZOR, AMLODIPINE BESYLATE
 AZTREONAM, AZTREONAM
 AZULFIDINE, SULFASALAZINE
 AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
 BACITRACIN, BACITRACIN
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
 BACLOFEN, BACLOFEN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BACTRIM, SULFAMETHOXAZOLE
 BACTRIM DS, SULFAMETHOXAZOLE
 BAL, DIMERCAPROL
 BALANCED SALT, CALCIUM CHLORIDE
 BALCOLTRA, ETHINYL ESTRADIOL
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BALVERSA, ERDAFITINIB
 BALZIVA-28, ETHINYL ESTRADIOL
 BANZEL, RUFINAMIDE
 BAQSIMI, GLUCAGON
 BARACLUDE, ENTECAVIR
 BASAGLAR, INSULIN GLARGINE
 BAXDELA, DELAFLOXACIN MEGLUMINE
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE

APPENDIX A - PRODUCT NAME INDEX**** B ****

BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAFLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEVYXXA, BETRIXABAN
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** B ****

BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE RECOMBINANT HUMAN
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREGO ELLIPTA, FLUTICASON FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETILUM TOSYLATE, BRETILUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BRUKINSA, ZANUBRUTINIB
BRYHALI, HALOBETASOL PROPIONATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC

APPENDIX A - PRODUCT NAME INDEX**** B ****

BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFECIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB

APPENDIX A - PRODUCT NAME INDEX**** C ****

CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACTOR, CEFACTOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFTRIAZONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERINTA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** C **

CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOAZONE, CHLORZOAZONE
CHOLAC, LACTULOSE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE

APPENDIX A - PRODUCT NAME INDEX

** C **

CIMETIDINE, CIMETIDINE (OTC)
 CIMETIDINE, CIMETIDINE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CINVANTI, APREPITANT
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
 CLADRIBINE, CLADRIBINE
 CLARAVIS, ISOTRETINOIN
 CLARINEX, DESLORATADINE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 CLARISCAN, GADOTERATE MEGLUMINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLARITIN, LORATADINE (OTC)
 CLARITIN HIVES RELIEF, LORATADINE (OTC)
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 CLARITIN REDITABS, LORATADINE (OTC)
 CLARITIN-D, LORATADINE (OTC)
 CLARITIN-D 24 HOUR, LORATADINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLENPIQ, CITRIC ACID
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLEOCIN, CLINDAMYCIN PHOSPHATE
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLEOCIN T, CLINDAMYCIN PHOSPHATE
 CLEVIPREX, CLEVIDIPINE
 CLIMARA, ESTRADIOL
 CLIMARA PRO, ESTRADIOL
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

** C **

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOVIQUE, TRIENTINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUPRI, LEVAMLODIPINE MALEATE

APPENDIX A - PRODUCT NAME INDEX

** C **

CONRAY, IOTHALAMATE MEGLUMINE
CONSENSI, AMLODIPINE BESYLATE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COUMADIN, WARFARIN SODIUM
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CYONANZ, ETHINYL ESTRADIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 CYSTADANE, BETAINE
 CYSTAGON, CYSTEAMINE BITARTRATE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
 CYTARABINE, CYTARABINE
 CYTOMEL, LIOTHYRONINE SODIUM
 CYTOTEC, MISOPROSTOL
 CYTOVENE, GANCICLOVIR SODIUM

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 DACARBAZINE, DACARBAZINE
 DACOGEN, DECITABINE
 DACTINOMYCIN, DACTINOMYCIN
 DALFAMPRIDINE, DALFAMPRIDINE
 DALIRESP, ROFLUMILAST
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DANTRIUM, DANTROLENE SODIUM
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DAPSONE, DAPSONE
 DAPTOMYCIN, DAPTOMYCIN
 DARAPRIM, PYRIMETHAMINE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DARUNAVIR, DARUNAVIR
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DATSCAN, IOFLUPANE I-123
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DAURISMO, GLASDEGIB MALEATE
 DAYPRO, OXAPROZIN
 DAYSEE, ETHINYL ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 DDAVP, DESMOPRESSIN ACETATE
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEFINITY, PERFLUTREN
 DEFITELIO, DEFIBROTIDE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELSTRIGO, DORAVIRINE
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 DELZICOL, MESALAMINE
 DEMADAX, TORSEMIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEMSER, METYROSINE
 DENAVIR, PENCICLOVIR
 DEPAKOTE, DIVALPROEX SODIUM

APPENDIX A - PRODUCT NAME INDEX

** D **

DEPAKOTE ER, DIVALPROEX SODIUM
 DEPEN, PENICILLAMINE
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMABET, BETAMETHASONE VALERATE
 DERMATOP, PREDNICARBATE
 DERMATOP E EMOLLIENT, PREDNICARBATE
 DERMOTIC, FLUOCINOLONE ACETONIDE
 DESCOVY, EMTRICITABINE
 DESFERAL, DEFEROXAMINE MESYLATE
 DESFLURANE, DESFLURANE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DESONATE, DESONIDE
 DESONIDE, DESONIDE
 DESOWEN, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 DESVENLAFAXINE, DESVENLAFAXINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DETROL, TOLTERODINE TARTRATE
 DETROL LA, TOLTERODINE TARTRATE
 DEXAMETHASONE, DEXAMETHASONE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXILANT, DEXLANSOPRAZOLE
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DEXTENZA, DEXAMETHASONE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

** D **

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
 DEXTROSE 50%, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DEXYCU KIT, DEXAMETHASONE
 DIABETA, GLYBURIDE
 DIACOMIT, STIRIPENTOL
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIASTAT, DIAZEPAM
 DIASTAT ACUDIAL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZOXIDE, DIAZOXIDE
 DICLEGIS, DOXYLAMINE SUCCINATE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 DIFFERIN, ADAPALENE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** D **

DIFFERIN, ADAPALENE
 DIFICID, FIDAXOMICIN
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 DIFLUCAN, FLUCONAZOLE
 DIFLUNISAL, DIFLUNISAL
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILANTIN, PHENYTOIN
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 DILATRATE-SR, ISOSORBIDE DINITRATE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DILTZAC, DILTIAZEM HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIOVAN, VALSARTAN
 DIOVAN HCT, HYDROCHLOROTHIAZIDE
 DIPENTUM, OLSALAZINE SODIUM
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIPRIVAN, PROPOFOL
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DISULFIRAM, DISULFIRAM
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DIURIL, CHLOROTHIAZIDE
 DIURIL, CHLOROTHIAZIDE SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DIVIGEL, ESTRADIOL
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOCETAXEL, DOCETAXEL
 DOCOSANOL, DOCOSANOL (OTC)
 DOFETILDE, DOFETILIDE
 DOFETILIDE, DOFETILIDE
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DOTOLET, AVATROMBOPAG MALEATE
 DORAL, QUAZEPAM
 DORYX, DOXYCYCLINE HYCLATE
 DORYX MPC, DOXYCYCLINE HYCLATE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOTAREM, GADOTERATE MEGLUMINE
 DOVATO, DOLUTEGRAVIR SODIUM
 DOVONEX, CALCIPOTRIENE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE

APPENDIX A - PRODUCT NAME INDEX

** D **

DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
 DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
 DRISDOL, ERGOCALCIFEROL
 DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
 DRONABINOL, DRONABINOL
 DROPERIDOL, DROPERIDOL
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 DROXIA, HYDROXYUREA
 DSUVIA, SUFENTANIL CITRATE
 DUAC, BENZOYL PEROXIDE
 DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
 DUAVEE, BAZEDOXIFENE ACETATE
 DUETACT, GLIMEPIRIDE
 DUEXIS, FAMOTIDINE
 DULERA, FORMOTEROL FUMARATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUOBRII, HALOBETASOL PROPIONATE
 DUODOTE, ATROPINE
 DUOPA, CARBIDOPA
 DURACLON, CLONIDINE HYDROCHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-37, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 DURAMORPH PF, MORPHINE SULFATE
 DURAPREP, IODINE POVACRYLEX (OTC)
 DUREZOL, DIFLUPREDNATE
 DURLAZA, ASPIRIN
 DUTASTERIDE, DUTASTERIDE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 DUTOPROL, HYDROCHLOROTHIAZIDE
 DUVOID, BETHANECHOL CHLORIDE
 DYANAVEL XR, AMPHETAMINE
 DYAZIDE, HYDROCHLOROTHIAZIDE
 DYCLOPRO, DYCLONINE HYDROCHLORIDE
 DYMISTA, AZELASTINE HYDROCHLORIDE
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 DYRENIUM, TRIAMTERENE

** E **

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)
 E-Z-HD, BARIUM SULFATE
 E-Z-PAQUE, BARIUM SULFATE
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 EC-NAPROSYN, NAPROXEN
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ECOZA, ECONAZOLE NITRATE
 EDARBI, AZILSARTAN KAMEDOXOMIL
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
 EDECRIN, ETHACRYNATE SODIUM
 EDECRIN, ETHACRYNIC ACID
 EDEX, ALPROSTADIL
 EDLUAR, ZOLPIDEM TARTRATE
 EDURANT, RILPIVIRINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ

APPENDIX A - PRODUCT NAME INDEX

** E **

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
EGRIFTA, TESAMORELIN ACETATE
ELCYS, CYSTEINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELEPSIA XR, LEVETIRACETAM
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCEN, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
ELURYNG, ETHINYL ESTRADIOL
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENULOSE, LACTULOSE
ENVARUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE

APPENDIX A - PRODUCT NAME INDEX

** E **

EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPINEPHRINE (COPACKAGED), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

APPENDIX A - PRODUCT NAME INDEX

** E **

ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
 ETOPOSIDE, ETOPOSIDE
 EUCRISA, CRISABOROLE
 EURAX, CROTAMITON
 EUTHYROX, LEVOTHYROXINE SODIUM **
 EVAMIST, ESTRADIOL
 EVEKEO, AMPHETAMINE SULFATE
 EVEKEO ODT, AMPHETAMINE SULFATE
 EVEROLIMUS, EVEROLIMUS
 EVISTA, RALOXIFENE HYDROCHLORIDE
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EVOMELA, MELPHALAN HYDROCHLORIDE
 EVOTAZ, ATAZANAVIR SULFATE
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 EVZIO (AUTOINJECTOR), NALOXONE HYDROCHLORIDE
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 EXELDERM, SULCONAZOLE NITRATE
 EXELON, RIVASTIGMINE
 EXEM FOAM KIT, AIR POLYMER-TYPE A
 EXEMESTANE, EXEMESTANE
 EXFORGE, AMLODIPINE BESYLATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
 EXJADE, DEFERASIROX
 EXONDYS 51, ETEPLIRSEN
 EXPAREL, BUPIVACAINE
 EXSERVAN, RILUZOLE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 EXTRANEAL, ICODEXTRIN
 EZALLOR, ROSUVASTATIN CALCIUM
 EZETIMIBE, EZETIMIBE
 EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE

** F **

FABIOR, TAZAROTENE
 FACTIVE, GEMIFLOXACIN MESYLATE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FALMINA, ETHINYL ESTRADIOL
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FANAPT, ILOPERIDONE
 FARESTON, TOREMIFENE CITRATE
 FARXIGA, DAPAGLIFLOZIN
 FARYDAK, PANOBINOSTAT LACTATE
 FASLODEX, FULVESTRANT
 FAYOSIM, ETHINYL ESTRADIOL
 FEBUXOSTAT, FEBUXOSTAT
 FELBAMATE, FELBAMATE
 FELBATOL, FELBAMATE
 FELDENE, PIROXICAM
 FELODIPINE, FELODIPINE
 FEMARA, LETROZOLE
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOGLIDE, FENOFIBRATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE

APPENDIX A - PRODUCT NAME INDEX

** F **

FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FENTANYL CITRATE, FENTANYL CITRATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 FENTORA, FENTANYL CITRATE
 FERAHEME, FERUMOXYTOL
 FERRIPROX, DEFERIPRONE
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FETROJA, CEFIDEROCOL SULFATE TOSYLATE
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FIASP, INSULIN ASPART
 FIASP FLEXTOUCH, INSULIN ASPART
 FIASP PENFILL, INSULIN ASPART
 FIBRICOR, FENOFIBRIC ACID
 FINACEA, AZELAIC ACID
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FIORINAL, ASPIRIN
 FIORINAL W/CODEINE, ASPIRIN
 FIRAZYR, ICATIBANT ACETATE
 FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
 FIRMAGON, DEGARELIX ACETATE
 FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
 FLAC, FLUOCINOLONE ACETONIDE
 FLAGYL, METRONIDAZOLE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLAREX, FLUOROMETHOLONE ACETATE
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLECTOR, DICLOFENAC EPOLAMINE
 FLOLAN, EPOPROSTENOL SODIUM
 FLOLIPID, SIMVASTATIN
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
 FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 FLOVENT HFA, FLUTICASONE PROPIONATE
 FLOXURIDINE, FLOXURIDINE
 FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUMADINE, RIMANTADINE HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL

APPENDIX A - PRODUCT NAME INDEX

** F **

FLUNISOLIDE, FLUNISOLIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUORESCITE, FLUORESCIEIN SODIUM
 FLUORODOPA F18, FLUORODOPA F-18
 FLUOROPLEX, FLUOROURACIL
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUOXYMESTERONE, FLUOXYMESTERONE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURANDRENOLIDE, FLURANDRENOLIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 FLUTAMIDE, FLUTAMIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FML, FLUROMETHOLONE
 FML FORTE, FLUROMETHOLONE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 FOLOTYN, PRALATREXATE
 FOMEPIZOLE, FOMEPIZOLE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FORANE, ISOFLURANE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN
 FORTESTA, TESTOSTERONE
 FOSAMAX, ALENDRONATE SODIUM
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSCAVIR, FOSCARNET SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FOSRENOL, LANTHANUM CARBONATE
 FRAGMIN, DALTEPARIN SODIUM
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FULVESTRANT, FULVESTRANT
 FURADANTIN, NITROFURANTOIN
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVIRTIDE
 FYAVOLV, ETHINYL ESTRADIOL
 FYCOMPA, PERAMPANEL

** G **

GABAPENTIN, GABAPENTIN
 GABITRIL, TIAGABINE HYDROCHLORIDE
 GABLOFEN, BACLOFEN

APPENDIX A - PRODUCT NAME INDEX

** G **

GADAVIST, GADOBUTROL
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GANZYK-RTU, GANCICLOVIR
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOSYL, NITRIC OXIDE
GENOTROPIN, SOMATROPIN
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** G **

GLYNASE, GLYBURIDE
 GLYRX-PF, GLYCOPYRROLATE
 GLYSET, MIGLITOL
 GLYXAMBI, EMPAGLIFLOZIN
 GOCOVRI, AMANTADINE HYDROCHLORIDE
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONAL-F, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONITRO, NITROGLYCERIN
 GOPRELTO, COCAINE HYDROCHLORIDE
 GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GVOKE HYPOPEN, GLUCAGON
 GVOKE PFS, GLUCAGON
 GYNAZOLE-1, BUTOCONAZOLE NITRATE

** H **

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HAILEY 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HALAVEN, ERIBULIN MESYLATE
 HALCINONIDE, HALCINONIDE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HARVONI, LEDIPASVIR
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HEMABATE, CARBOPROST TROMETHAMINE
 HEMADY, DEXAMETHASONE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPSERA, ADEFOVIR DIPIVOXIL
 HER STYLE, LEVONORGESTREL (OTC)

APPENDIX A - PRODUCT NAME INDEX

** H **

HETLIOZ, TASIMELTEON
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG TEMPO PEN, INSULIN LISPRO RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 Hycamtin, Topotecan Hydrochloride
 Hycodan, Homatropine Methylbromide
 HYDRA-ZIDE, Hydralazine Hydrochloride
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYPROGESTERON CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
 HYSINGLA ER, HYDROCODONE BITARTRATE
 HYZAAR, HYDROCHLOROTHIAZIDE

** I **

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBRANCE, PALBOCICLIB
 IBSRELA, TENAPANOR HYDROCHLORIDE
 IBU-TAB, IBUPROFEN
 IBU-TAB 200, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

** I **

IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICATIBANT ACETATE, ICATIBANT ACETATE
ICLEVIA, ETHINYL ESTRADIOL
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INAPSINE, DROPERIDOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGENOL MEBUTATE, INGENOL MEBUTATE
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSIDE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPIRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL

APPENDIX A - PRODUCT NAME INDEX

** I **

INTRALIPID 30%, SOYBEAN OIL
 INTRAROSA, PRASTERONE
 INTROVALE, ETHINYL ESTRADIOL
 INTUNIV, GUANFACINE HYDROCHLORIDE
 INVANZ, ERTAPENEM SODIUM
 INVEGA, PALIPERIDONE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVELTYS, LOTEPREDNOL ETABONATE
 INVIRASE, SAQUINAVIR MESYLATE
 INVOKAMET, CANAGLIFLOZIN
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE
 IOSAT, POTASSIUM IODIDE (OTC)
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN, IRBESARTAN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRESSA, GEFITINIB
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISENTRESS, RALTEGRAVIR POTASSIUM
 ISENTRESS HD, RALTEGRAVIR POTASSIUM
 ISIBLOOM, DESOGESTREL
 ISOFLURANE, ISOFLURANE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISONIAZID, ISONIAZID
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 ISOPTO ATROPINE, ATROPINE SULFATE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 ISORDIL, ISOSORBIDE DINITRATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 ISOTRETINOIN, ISOTRETINOIN
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 ISRADIPINE, ISRADIPINE
 ISTALOL, TIMOLOL MALEATE
 ISTODAX, ROMIDEPSIN
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 IVERMECTIN, IVERMECTIN
 IVY BLOCK, BENTOQUATAM (OTC)
 IXEMPRA KIT, IXABEPILONE

** J **

JADENU, DEFERASIROX
 JADENU SPRINKLE, DEFERASIROX
 JAIMIESS, ETHINYL ESTRADIOL
 JAKAFI, RUXOLITINIB PHOSPHATE
 JALYN, DUTASTERIDE
 JANTOVEN, WARFARIN SODIUM
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 JARDIANCE, EMPAGLIFLOZIN
 JATENZO, TESTOSTERONE UNDECANOATE
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM

APPENDIX A - PRODUCT NAME INDEX

** J **

JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYNARQUE, TOLVAPTAN

** K **

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KELNOR, ETHINYL ESTRADIOL
KEMEYA, DROSPIRENONE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** K ****

KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 KORLYM, MIFEPRISTONE
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
 KRINTAFEL, TAFENOQUINE SUCCINATE
 KURVELO, ETHINYL ESTRADIOL
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE
 KYBELLA, DEOXYCHOLIC ACID
 KYLEENA, LEVONORGESTREL
 KYPROLIS, CARFILZOMIB
 KYRA, DROSPIRENONE

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACRISERT, HYDROXYPROPYL CELLULOSE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTULOSE, LACTULOSE
 LAMICTAL, LAMOTRIGINE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL ODT, LAMOTRIGINE
 LAMICTAL XR, LAMOTRIGINE
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LAMISIL AT, TERBINAFINE (OTC)
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMIVUDINE, LAMIVUDINE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LANORINAL, ASPIRIN
 LANOXIN, DIGOXIN
 LANOXIN PEDIATRIC, DIGOXIN
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LANTHANUM CARBONATE, LANTHANUM CARBONATE
 LANTUS, INSULIN GLARGINE RECOMBINANT
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LAROTID, AMOXICILLIN
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 LASIX, FUROSEMIDE
 LASTACAPT, ALCAFTADINE
 LATANOPROST, LATANOPROST
 LATISSE, BIMATOPROST
 LATUDA, LURASIDONE HYDROCHLORIDE
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 LAZANDA, FENTANYL CITRATE
 LEFLUNOMIDE, LEFLUNOMIDE
 LENVIMA, LENVATINIB MESYLATE
 LERIBANE, ETHINYL ESTRADIOL
 LESCOL XL, FLUVASTATIN SODIUM
 LESSINA-28, ETHINYL ESTRADIOL
 LETAIRIS, AMBRISENTAN
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUKERAN, CHLORAMBUCIL
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX

** L **

LEVETIRACETAM, LEVETIRACETAM
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 LEVO-T, LEVOTHYROXINE SODIUM **
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOCARNITINE SF, LEVOCARNITINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LEVONEST, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LEVOXYL, LEVOTHYROXINE SODIUM **
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 LEXETTE, HALOBETASOL PROPIONATE
 LEXISCAN, REGADENOSON
 LEXIVA, FOSAMPRENAVIR CALCIUM
 LIALDA, MESALAMINE
 LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIDEX, FLUOCINONIDE
 LIDEX-E, FLUOCINONIDE
 LIDOCAINE, LIDOCAINE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDODERM, LIDOCAINE
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 LILETTA, LEVONORGESTREL
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 LINDANE, LINDANE
 LINEZOLID, LINEZOLID
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINZESS, LINACLOTIDE
 LIORESAL, BACLOFEN
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LIPIODOL, ETHIODIZED OIL
 LIPITOR, ATORVASTATIN CALCIUM
 LIPOFEN, FENOFIBRATE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LISINOPRIL, LISINOPRIL
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

** L **

LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LITHOBID, LITHIUM CARBONATE
 LITHOSTAT, ACETOHYDROXAMIC ACID
 LIVALO, PITAVASTATIN CALCIUM
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LO SIMPESE, ETHINYL ESTRADIOL
 LO-MALMOREDE, ETHINYL ESTRADIOL
 LO-ZUMANDIMINE, DROSPIRENONE
 LOCID, HYDROCORTISONE BUTYRATE
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LODOSYN, CARBIDOPA
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 LOGILIA, ULIPRISTAL ACETATE
 LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LONHALA MAGNAIR KIT, GLYCOPYRROLATE
 LONSURF, TIPIRACIL HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPID, GEMFIBROZIL
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LOPRESSOR, METOPROLOL TARTRATE
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 LOPROX, CICLOPIROX
 LOPURIN, ALLOPURINOL
 LORATADINE, LORATADINE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LORAZEPAM INTENSOL, LORAZEPAM
 LORBRENA, LORLATINIB
 LORYNA, DROSPIRENONE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 LOTEMAX, LOTEPRDNOL ETABONATE
 LOTEMAX SM, LOTEPRDNOL ETABONATE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTEPRDNOL ETABONATE, LOTEPRDNOL ETABONATE
 LOTREL, AMLODIPINE BESYLATE
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LOVENOX, ENOXAPARIN SODIUM
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 LUMIFY, BRIMONIDINE TARTRATE (OTC)
 LUMIGAN, BIMATOPROST
 LUNESTA, ESZOPICLONE
 LUPANETA PACK, LEUPROLIDE ACETATE
 LUPRON DEPOT, LEUPROLIDE ACETATE
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE

APPENDIX A - PRODUCT NAME INDEX**** L ****

LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 LUTATHERA, LUTETIUM DOTATATE LU-177
 LUVOX, FLUVOXAMINE MALEATE
 LUXIQ, BETAMETHASONE VALERATE
 LUZU, LULICONAZOLE
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 LYNPARZA, OLAPARIB
 LYRICA, PREGABALIN
 LYRICA CR, PREGABALIN
 LYSODREN, MITOTANE
 LYSTEDA, TRANEXAMIC ACID

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MACRILEN, MACIMORELIN ACETATE
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 MACUGEN, PEGAPTANIB SODIUM
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MALARONE, ATOVAQUONE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALATHION, MALATHION
 MALMOREDE, ETHINYL ESTRADIOL
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 25%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARINOL, DRONABINOL
 MARLISSA, ETHINYL ESTRADIOL
 MARPLAN, ISOCARBOXAZID
 MARQIBO KIT, VINCRISTINE SULFATE
 MATULANE, PROCARBAZINE HYDROCHLORIDE
 MAVENCLAD, CLADRIBINE
 MAVYRET, GLECAPREVIR
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 MAXIDEX, DEXAMETHASONE
 MAXIPIPE, CEFEPIME HYDROCHLORIDE
 MAXITROL, DEXAMETHASONE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 MAYZENT, SIPONIMOD FUMARIC ACID
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MEDROL, METHYLPREDNISOLONE

APPENDIX A - PRODUCT NAME INDEX

** M **

MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH)
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** M **

METOLAZONE, METOLAZONE
 METOPIRONE, METYRAPONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 METRONIDAZOLE, METRONIDAZOLE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIACALCIN, CALCITONIN SALMON
 MIBELAS 24 FE, ETHINYL ESTRADIOL
 MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
 MICARDIS, TELMISARTAN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICORT-HC, HYDROCORTISONE ACETATE
 MICRO-K, POTASSIUM CHLORIDE
 MICRO-K 10, POTASSIUM CHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 MIFEPREX, MIFEPRISTONE
 MIFEPRISTONE, MIFEPRISTONE
 MIGERGOT, CAFFEINE
 MIGLITOL, MIGLITOL
 MIGLUSTAT, MIGLUSTAT
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 MILI, ETHINYL ESTRADIOL
 MILRINONE LACTATE, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 MINIPRESS, PRAZOSIN HYDROCHLORIDE
 MINIRIN, DESMOPRESSIN ACETATE
 MINIVELLE, ESTRADIOL
 MINOCIN, MINOCYCLINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOLIRA, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL (OTC)
 MINOXIDIL, MINOXIDIL
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 MIOSTAT, CARBACHOL
 MIRABEGRON, MIRABEGRON
 MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** M **

MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHABOND ER, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON

APPENDIX A - PRODUCT NAME INDEX

** M **

MYSOLINE, PRIMIDONE
 MYTESI, CROFELEMER
 MYXREDLIN, INSULIN HUMAN
 MYZILRA, ETHINYL ESTRADIOL

** N **

NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NAFACILLIN SODIUM, NAFACILLIN SODIUM
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFACILLIN SODIUM
 NALOXONE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN, NAPROXEN
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARCAN, NALOXONE HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATESTO, TESTOSTERONE
 NATROBA, SPINOSAD
 NAYZILAM, MIDAZOLAM
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NEOPAP, ACETAMINOPHEN (OTC)
 NEOPROFEN, IBUPROFEN LYSINE
 NEORAL, CYCLOSPORINE
 NEOSPORIN, BACITRACIN ZINC
 NEOSPORIN, GRAMICIDIN
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NERLYNX, NERATINIB MALEATE

APPENDIX A - PRODUCT NAME INDEX

** N **

NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETNOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCDURNA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPOR, SOMATROPIN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** N **

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORITATE, METRONIDAZOLE
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
 NORTHERA, DROXIDOPA
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NORVASC, AMLODIPINE BESYLATE
 NORVIR, RITONAVIR
 NOURESS, CYSTEINE HYDROCHLORIDE
 NOURIANZ, ISTRADefylline
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOXAFIL, POSACONAZOLE
 NOXIVENT, NITRIC OXIDE
 NUBEQA, DAROLUTAMIDE
 NUCYNТА, TAPENTADOL HYDROCHLORIDE
 NUCYNТА ER, TAPENTADOL HYDROCHLORIDE
 NUEDEXТА, DEXTROMETHORPHAN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUPLAZID, PIMAVANSERIN TARTRATE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUTROPIN AQ NUSPIN, SOMATROPIN
 NUVARING, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 NUVIGIL, ARMODAFINIL
 NUZYRA, OMADACYCLINE TOSYLATE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

** O **

OCALIVA, OBETICHOIC ACID
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUFEN, FLURBIPROFEN SODIUM
 OCUFLOX, OFLOXACIN
 ODEFSEY, EMTRICITABINE
 ODOMZO, SONIDEGIB PHOSPHATE
 OFEV, NINTEDANIB ESYLATE

APPENDIX A - PRODUCT NAME INDEX

** O **

OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUMIANT, BARICITINIB
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONPATTRO, PATISIRAN SODIUM
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAIN HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORSYTHIA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** O **

ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 ORTIKOS, BUDESONIDE
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OSENI, ALOGLIPTIN BENZOATE
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMOLEX ER, AMANTADINE HYDROCHLORIDE
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 OSPHENA, OSPEMIFENE
 OTEZLA, APREMILAST
 OTICAIR, HYDROCORTISONE
 OTIPRIO, CIPROFLOXACIN
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
 OTREXUP, METHOTREXATE
 OVIDREL, CHORIOGONADOTROPIN ALFA
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXANDROLONE, OXANDROLONE
 OXAPROZIN, OXAPROZIN
 OXAYDO, OXYCODONE HYDROCHLORIDE
 OXAZEPAM, OXAZEPAM
 OXBRYTA, VOXELOTOR
 OXCARBAZEPINE, OXCARBAZEPINE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 OXISTAT, OXICONAZOLE NITRATE
 OXSORALEN-ULTRA, METHOXSALEN
 OXTELLAR XR, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OZEMPIC, SEMAGLUTIDE
 OZOBAX, BACLOFEN
 OZURDEX, DEXAMETHASONE

** P **

PACERONE, AMIODARONE HYDROCHLORIDE
 PACITAXEL, PACLITAXEL
 PACLITAXEL, PACLITAXEL
 PALIPERIDONE, PALIPERIDONE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCREAZE, PANCRELIPASE (AMYLASE)
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAGARD T 380A, COPPER

APPENDIX A - PRODUCT NAME INDEX**** P ****

PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PARLODEL, BROMOCRIPTINE MESYLATE
 PARNATE, TRANYLCPROMINE SULFATE
 PAROEX, CHLORHEXIDINE GLUCONATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PARSABIV, ETELICALCETIDE
 PASER, AMINOSALICYLIC ACID
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAZEO, OLOPATADINE HYDROCHLORIDE
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
 PEGANONE, ETHOTOIN
 PENICILLAMINE, PENICILLAMINE
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PENLAC, CICLOPIROX
 PENNSAID, DICLOFENAC SODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
 PENTASA, MESALAMINE
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PENTOSTATIN, PENTOSTATIN
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PENTOXIL, PENTOXIFYLLINE
 PEPCID, FAMOTIDINE
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 PERCOCET, ACETAMINOPHEN
 PERCODAN, ASPIRIN
 PERFOROMIST, FORMOTEROL FUMARATE
 PERIDEX, CHLORHEXIDINE GLUCONATE
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PERIOCHIP, CHLORHEXIDINE GLUCONATE
 PERIOGARD, CHLORHEXIDINE GLUCONATE
 PERMETHRIN, PERMETHRIN (OTC)
 PERMETHRIN, PERMETHRIN
 PERPHENAZINE, PERPHENAZINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PERSANTINE, DIPYRIDAMOLE
 PERSERIS KIT, RISPERIDONE
 PERTZYE, PANCRELIPASE (AMYLASE)
 PEXEVA, PAROXETINE MESYLATE
 PFIZERPEN, PENICILLIN G POTASSIUM
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENELZINE SULFATE, PHENELZINE SULFATE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** P **

PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PHENYTOIN, PHENYTOIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHILITH, ETHINYL ESTRADIOL
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PHOTOFRIN, PORFIMER SODIUM
 PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PICATO, INGENOL MEBUTATE
 PIFELTRO, DORAVIRINE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIMECROLIMUS, PIMECROLIMUS
 PIMOZIDE, PIMOZIDE
 PIMTREA, DESOGESTREL
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIPERACILLIN, PIPERACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIQRAY, ALPELISIB
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PIROXICAM, PIROXICAM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 PITOCIN, OXYTOCIN
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLENVU, ASCORBIC ACID
 PLIAGLIS, LIDOCAINE
 PODOFILOX, PODOFILOX
 POLMON, DEXCHLORPHENIRAMINE MALEATE
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PORTIA-28, ETHINYL ESTRADIOL
 POSACONAZOLE, POSACONAZOLE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

** P **

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
 POVIDONE IODINE, POVIDONE-IODINE (OTC)
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAMOSONE, HYDROCORTISONE ACETATE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVACHOL, PRAVASTATIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZIQUANTEL, PRAZIQUANTEL
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PRE-OP, HEXACHLOROPHENE
 PRE-OP II, HEXACHLOROPHENE
 PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PREDNICARBATE, PREDNICARBATE
 PREDNISOLONE, PREDNISOLONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISONE, PREDNISONE
 PREDNISONE INTENSOL, PREDNISONE
 PREGABALIN, PREGABALIN
 PREGNYL, GONADOTROPIN, CHORIONIC
 PRELONE, PREDNISOLONE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PREPIDIL, DINOPROSTONE
 PRESTALIA, AMLODIPINE BESYLATE
 PRETOMANID, PRETOMANID
 PREVACID, LANSOPRAZOLE
 PREVACID 24 HR, LANSOPRAZOLE (OTC)
 PREVALITE, CHOLESTYRAMINE
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVIFEM, ETHINYL ESTRADIOL
 PREVYMIS, LETERMIVIR
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR
 PRIALT, ZICONOTIDE ACETATE
 PRIFTIN, RIFAPENTINE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PRIMAQUINE, PRIMAQUINE PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX

** P **

PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PRIMATENE MIST, EPINEPHRINE (OTC)
 PRIMAXIN, CILASTATIN SODIUM
 PRIMIDONE, PRIMIDONE
 PRIMISOL, TRIMETHOPRIM HYDROCHLORIDE
 PRINIVIL, LISINAPRIL
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 PROAIR DIGIHALER, ALBUTEROL SULFATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROBALAN, PROBENECID
 PROBENECID, PROBENECID
 PROBENECID AND COLCHICINE, COLCHICINE
 PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROCALAMINE, AMINO ACIDS
 PROCARDIA, NIFEDIPINE
 PROCARDIA XL, NIFEDIPINE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROCOMP, PROCHLORPERAZINE MALEATE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 PROCYSBI, CYSTEAMINE BITARTRATE
 PROGESTERONE, PROGESTERONE
 PROGLYCEM, DIAZOXIDE
 PROGRAF, TACROLIMUS
 PROHANCE, GADOTERIDOL
 PROHANCE MULTIPACK, GADOTERIDOL
 PROLENSA, BROMFENAC SODIUM
 PROMACTA, ELTROMBOPAG OLAMINE
 PROMACTA KIT, ELTROMBOPAG OLAMINE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 PROMETRIUM, PROGESTERONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 PROPECIA, FINASTERIDE
 PROPOFOL, PROPOFOL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PROSCAR, FINASTERIDE
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROTAMINE SULFATE, PROTAMINE SULFATE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PROTONIX, PANTOPRAZOLE SODIUM
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
 PROTOPIC, TACROLIMUS
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 PROVAYBLUE, METHYLENE BLUE
 PROVENTIL-HFA, ALBUTEROL SULFATE
 PROVERA, MEDROXYPROGESTERONE ACETATE
 PROVIGIL, MODAFINIL
 PROVOCHOLINE, METHACHOLINE CHLORIDE
 PROZAC, FLUOXETINE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 PULMICORT FLEXHALER, BUDESONIDE
 PULMICORT RESPULES, BUDESONIDE
 PUR-WASH, PURIFIED WATER (OTC)
 PURINETHOL, MERCAPTOPURINE
 PURIXAN, MERCAPTOPURINE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 PYTEST, UREA, C-14
 PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINAPRIL
 QBREXZA, GLYCOPYRRONIUM TOSYLATE
 QMIIZ ODT, MELOXICAM
 QNASL, BECLOMETHASONE DIPROPIONATE
 QOLIANA, BRIMONIDINE TARTRATE
 QSYMIA, PHENTERMINE HYDROCHLORIDE
 QTERN, DAPAGLIFLOZIN
 QTERNMET XR, DAPAGLIFLOZIN
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
 QUALAQUIN, QUININE SULFATE
 QUARTETTE, ETHINYL ESTRADIOL
 QUASENSE, ETHINYL ESTRADIOL
 QUDEXY XR, TOPIRAMATE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINARETIC, HYDROCHLOROTHIAZIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 QUININE SULFATE, QUININE SULFATE
 QUTENZA, CAPSAICIN
 QUZYTIR, CETIRIZINE HYDROCHLORIDE
 QVAR REDHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RADICAVA, EDARAVONE
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
 RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMELTEON, RAMELTEON
 RAMIPRIL, RAMIPRIL
 RANEXA, RANOLAZINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE

APPENDIX A - PRODUCT NAME INDEX

** R **

RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYL BUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
REBETOL, RIBAVIRIN
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REDITREX, METHOTREXATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAK, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
REVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPIRAZOLE
REYATAZ, ATAZANAVIR SULFATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFAD, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL DIMESYLATE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** R **

RIMSO-50, DIMETHYL SULFOXIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 RINVOQ, UPADACITINIB
 RIOMET, METFORMIN HYDROCHLORIDE
 RIOMET ER, METFORMIN HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERDAL, RISPERIDONE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERIDONE, RISPERIDONE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITONAVIR, RITONAVIR
 RIVASTIGMINE, RIVASTIGMINE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROBAXIN, METHOCARBAMOL
 ROBAXIN-750, METHOCARBAMOL
 ROCALTROL, CALCITRIOL
 ROCKLATAN, LATANOPROST
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROFLUMILAST, ROFLUMILAST
 ROGAINE (FOR MEN), MINOXIDIL (OTC)
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 ROWASA, MESALAMINE
 ROXICET, ACETAMINOPHEN
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 ROZEREM, RAMELTEON
 ROZLYTREK, ENTRECTINIB
 RUBRACA, RUCAPARIB CAMSYLATE
 RUBY-FILL, RUBIDIUM CHLORIDE RB-82
 RUFINAMIDE, RUFINAMIDE
 RUZURGI, AMIFAMPRIDINE
 RYANODEX, DANTROLENE SODIUM
 RYBELSUS, SEMAGLUTIDE
 RYDAPT, MIDOSTAURIN
 RYTARY, CARBIDOPA
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

** S **

SABRIL, VIGABATRIN
 SAFYRAL, DROSPIRENONE
 SAIZEN, SOMATROPIN
 SALAGEN, PILOCARPINE HYDROCHLORIDE
 SALONPAS, MENTHOL (OTC)
 SAMSCA, TOLVAPTAN
 SANCUSO, GRANISETRON
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SAPHRIS, ASENAPINE MALEATE
 SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
 SARAFEM, FLUOXETINE HYDROCHLORIDE
 SAVAYSA, EDOXABAN TOSYLATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 SCANDONEST L, LEVONORDEFIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL
 SCENESSE, AFAMELANOTIDE
 SCLEROSOL, TALC

APPENDIX A - PRODUCT NAME INDEX

** S **

SCOPOLAMINE, SCOPOLAMINE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 SECONAL SODIUM, SECOBARBITAL SODIUM
 SECUADO, ASENAPINE
 SEEBRI, GLYCOPYRROLATE
 SEGLUROMET, ERTUGLIFLOZIN
 SEIZALAM, MIDAZOLAM HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SELENIOS ACID, SELENIOS ACID
 SELENIUM SULFIDE, SELENIUM SULFIDE
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 SELZENTRY, MARAVIROC
 SEMPRES-D, ACRIVASTINE
 SENSIPAR, CINACALCET HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE
 SEPTRA, SULFAMETHOXAZOLE
 SEPTRA DS, SULFAMETHOXAZOLE
 SEREVENT, SALMETEROL XINAFOATE
 SERNIVO, BETAMETHASONE DIPROPIONATE
 SEROMYCIN, CYCLOSERINE
 SEROQUEL, QUETIAPINE FUMARATE
 SEROQUEL XR, QUETIAPINE FUMARATE
 SEROSTIM, SOMATROPIN
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SETLAKIN, ETHINYL ESTRADIOL
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SEYSARA, SARECYCLINE HYDROCHLORIDE
 SFROWASA, MESALAMINE
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
 SIKLOS, HYDROXYUREA
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 SILODOSIN, SILODOSIN
 SILVADENE, SILVER SULFADIAZINE
 SIMBRINZA, BRIMONIDINE TARTRATE
 SIMPESE, ETHINYL ESTRADIOL
 SIMVASTATIN, SIMVASTATIN
 SINE-AID IB, IBUPROFEN (OTC)
 SINEMET, CARBIDOPA
 SINEMET CR, CARBIDOPA
 SINGULAIR, MONTELUKAST SODIUM
 SINUVA, MOMETASONE FUROATE
 SIROLIMUS, SIROLIMUS
 SIRTURO, BEDAQUILINE FUMARATE
 SITAVIG, ACYCLOVIR
 SIVEXTRO, TEDIZOLID PHOSPHATE
 SKELAXIN, METAXALONE
 SKLICE, IVERMECTIN
 SKYLA, LEVONORGESTREL
 SLYND, DROSPIRENONE
 SMOFLIPID 20%, FISH OIL
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN

APPENDIX A - PRODUCT NAME INDEX

** S **

STENDRA, AVANAFIL
 STERILE WATER, STERILE WATER FOR IRRIGATION
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERITALC, TALC
 STIE-CORT, HYDROCORTISONE
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 STRIBILD, COBICISTAT
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 STROMEKTOL, IVERMECTIN
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUBLOCADE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
 SUBSYS, FENTANYL
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUCRAID, SACROSIDASE
 SUCRALFATE, SUCRALFATE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SULAR, NISOLDIPINE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFADIAZINE, SULFADIAZINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULFAMYLON, MAFENIDE ACETATE
 SULFASALAZINE, SULFASALAZINE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SUMATRIPTAN, SUMATRIPTAN
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUNOSI, SOLRIAMFETOL
 SUPPRELIN LA, HISTRELIN ACETATE
 SUPRANE, DESFLURANE
 SUPRAX, CEFIXIME
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
 SURVANTA, BERACTANT
 SUSTIVA, EFAVIRENZ
 SUSTOL, GRANISETRON
 SUTENT, SUNITINIB MALATE
 SYEDA, DROSPIRENONE
 SYLEVIA, ETHINYL ESTRADIOL
 SYMBICORT, BUDESONIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 SYMDEKO (COPACKAGED), IVACAFTOR
 SYMFI, EFAVIRENZ
 SYMFI LO, EFAVIRENZ
 SYMJEPI, EPINEPHRINE
 SYMLIN, PRAMLINTIDE ACETATE
 SYMPAZAN, CLOBAZAM
 SYMPROIC, NALDEMEDINE TOSYLATE
 SYMTUZA, COBICISTAT
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNAREL, NAFARELIN ACETATE
 SYNDROS, DRONABINOL
 SYNERA, LIDOCAINE
 SYNERCID, DALFOPRISTIN

APPENDIX A - PRODUCT NAME INDEX

** S **

SYNJARDY, EMPAGLIFLOZIN
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNRIPO, OMACETAXINE MEPESUCCINATE
 SYNTHROID, LEVOTHYROXINE SODIUM **
 SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

TAB-PROFEN, IBUPROFEN (OTC)
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TAFINLAR, DABRAFENIB MESYLATE
 TAFLUPROST, TAFLUPROST
 TAGAMET HB, CIMETIDINE (OTC)
 TAGITOL V, BARIUM SULFATE
 TAGRISSO, OSIMERTINIB MESYLATE
 TALC, TALC
 TALICIA, AMOXICILLIN
 TALZENNA, TALAZOPARIB TOSYLATE
 TAMBOCOR, FLECAINIDE ACETATE
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TAPAZOLE, METHIMAZOLE
 TARCEVA, ERLOTINIB HYDROCHLORIDE
 TARGRETIN, BEXAROTENE
 TARKA, TRANDOLAPRIL
 TASIGNA, NILOTINIB HYDROCHLORIDE
 TASMAR, TOLCAPONE
 TAVALISSE, FOSTAMATINIB DISODIUM
 TAXOTERE, DOCETAXEL
 TAYTULLA, ETHINYL ESTRADIOL
 TAZAROTENE, TAZAROTENE
 TAZICEF, CEFTAZIDIME
 TAZORAC, TAZAROTENE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TECFIDERA, DIMETHYL FUMARATE
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
 TEFLARO, CEFTAROLINE FOSAMIL
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TEGSEDI, INOTERSEN SODIUM
 TEKTURNA, ALISKIREN HEMIFUMARATE
 TEKTURNA HCT, ALISKIREN HEMIFUMARATE
 TELMISARTAN, TELMISARTAN
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TEMAZEPAM, TEMAZEPAM
 TEMIXYS, LAMIVUDINE
 TEMODAR, TEMOZOLOMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 TEPADINA, THIOTEPA
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** T **

TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TERCONAZOLE, TERCONAZOLE
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TERIL, CARBAMAZEPINE
 TESSALON, BENZONATATE
 TESTIM, TESTOSTERONE
 TESTOPEL, TESTOSTERONE
 TESTOSTERONE, TESTOSTERONE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TESTRED, METHYLTESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TEXACORT, HYDROCORTISONE
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 THALOMID, THALIDOMIDE
 THEO-24, THEOPHYLLINE
 THEOCHRON, THEOPHYLLINE
 THEOPHYLLINE, THEOPHYLLINE
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THERMAZENE, SILVER SULFADIAZINE
 THEROXIDIL, MINOXIDIL (OTC)
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOGUANINE, THIOGUANINE
 THIOLA, TIOPRONIN
 THIOLA EC, TIOPRONIN
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 THIOTHIXENE, THIOTHIXENE
 THYRO-TABS, LEVOTHYROXINE SODIUM **
 THYROGEN, THYROTROPIN ALFA
 THYROSAFE, POTASSIUM IODIDE (OTC)
 THYROSHIELD, POTASSIUM IODIDE (OTC)
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TIAZAC, DILTIAZEM HYDROCHLORIDE
 TIBSOVO, IVOSIDENIB
 TICAGRELOR, TICAGRELOR
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIGLUTIK KIT, RILUZOLE
 TIKOSYN, DOFETILIDE
 TIMOLOL, TIMOLOL
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOPTIC, TIMOLOL MALEATE
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 TIMOPTIC-XE, TIMOLOL MALEATE
 TINDAMAX, TINIDAZOLE
 TINIDAZOLE, TINIDAZOLE
 TIOCONAZOLE, TIOCONAZOLE (OTC)
 TIROSINT, LEVOTHYROXINE SODIUM
 TIROSINT-SOL, LEVOTHYROXINE SODIUM
 TIS-U-SOL, MAGNESIUM SULFATE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TISSUEBLUE, BRILLIANT BLUE G
 TIVICAY, DOLUTEGRAVIR SODIUM
 TIVORBEX, INDOMETHACIN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBI, TOBRAMYCIN

APPENDIX A - PRODUCT NAME INDEX

** T **

TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBEX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREATANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELLEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRESIBA, INSULIN DEGLUDEC
TRETINOIN, TRETINOIN
Trexall, METHOTREXATE SODIUM
Treximet, NAPROXEN SODIUM
Trezix, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** T **

TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 TRI-MILI, ETHINYL ESTRADIOL
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRI-PREVI-FEM, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 TRIACIN-C, CODEINE PHOSPHATE
 TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
 TRIAMTERENE, TRIAMTERENE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIBENZOR, AMLODIPINE BESYLATE
 TRICOR, FENOFIBRATE
 TRIDERM, TRIAMCINOLONE ACETONIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 TRISENCE, TRIAMCINOLONE ACETONIDE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRIFLURIDINE, TRIFLURIDINE
 TRIGLIDE, FENOFIBRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR
 TRILEPTAL, OXCARBAZEPINE
 TRILIPIX, CHOLINE FENOFIBRATE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 TRIOSTAT, LIOTHYRONINE SODIUM
 TRIPTODUR KIT, TRIPTORELIN PAMOATE
 TRISENOX, ARSENIC TRIOXIDE
 TRIUMEQ, ABACAVIR SULFATE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 TRIVORA-28, ETHINYL ESTRADIOL
 TRIZIVIR, ABACAVIR SULFATE
 TROKENDI XR, TOPIRAMATE
 TROPHAMINE, AMINO ACIDS
 TROPHAMINE 10%, AMINO ACIDS
 TROPICACYL, TROPICAMIDE
 TROPICAMIDE, TROPICAMIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 TRULANCE, PLECANATIDE
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
 TRUVADA, EMTRICITABINE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 TURALIO, PEXIDARTINIB HYDROCHLORIDE
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
 TUSSIGON, HOMATROPINE METHYLBROMIDE
 TUXARIN ER, CHLORPHENIRAMINE MALEATE
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
 TWYNSTA, AMLODIPINE BESYLATE
 TYBOST, COBICISTAT
 TYDEMY, DROSPIRENONE
 TYGACIL, TIGECYCLINE
 TYKERB, LAPATINIB DITOSYLATE
 TYLENOL, ACETAMINOPHEN (OTC)
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 TYMLOS, ABALOPARATIDE

APPENDIX A - PRODUCT NAME INDEX

** T **

TYVASO, TREPROSTINIL
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

** U **

U-CORT, HYDROCORTISONE ACETATE
 UBRELVY, UBROGEPANT
 UCERIS, BUDESONIDE
 ULORIC, FEBUXOSTAT
 ULTACAN, ARTICAINE HYDROCHLORIDE
 ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
 ULTANE, SEVOFLURANE
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 ULTRAVATE, HALOBETASOL PROPIONATE
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 UNASYN, AMPICILLIN SODIUM
 UNISOM, DOXYLAMINE SUCCINATE (OTC)
 UNITHROID, LEVOTHYROXINE SODIUM **
 UPTRAVI, SELEXIPAG
 URECHOLINE, BETHANECHOL CHLORIDE
 UREX, METHENAMINE HIPPURATE
 UROCIT-K, POTASSIUM CITRATE
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 URSODIOL, URSODIOL
 UTIBRON, GLYCOPYRROLATE
 UVADEX, METHOXSALLEN

** V **

VABOMERE, MEROPENEM
 VAGIFEM, ESTRADIOL
 VAGISTAT-1, TIOCONAZOLE (OTC)
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALIUM, DIAZEPAM
 VALNAC, BETAMETHASONE VALERATE
 VALPROATE SODIUM, VALPROATE SODIUM
 VALPROIC ACID, VALPROIC ACID
 VALRUBICIN, VALRUBICIN
 VALSARTAN, VALSARTAN
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VALTRES, VALACYCLOVIR HYDROCHLORIDE
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
 VANDAZOLE, METRONIDAZOLE
 VANIQA, EFLORNITHINE HYDROCHLORIDE
 VANOS, FLUOCINONIDE
 VANTAS, HISTRELIN ACETATE
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VARIBAR HONEY, BARIUM SULFATE
 VARIBAR NECTAR, BARIUM SULFATE
 VARIBAR PUDDING, BARIUM SULFATE
 VARIBAR THIN HONEY, BARIUM SULFATE

APPENDIX A - PRODUCT NAME INDEX

** v **

VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITE X CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE)
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

** V **

VISIONBLUE, TRYPAN BLUE
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VISTOGARD, URIDINE TRIACETATE
 VISUDYNE, VERTEPORFIN
 VITAMIN D, ERGOCALCIFEROL
 VITAMIN K1, PHYTONADIONE
 VITRAKVI, LAROTRECTINIB SULFATE
 VITRASE, HYALURONIDASE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
 VIVELLE-DOT, ESTRADIOL
 VIVITROL, NALTREXONE
 VIVLODEX, MELOXICAM
 VIZAMYL, FLUTEMETAMOL F-18
 VIZIMPRO, DACOMITINIB
 VOGELXO, TESTOSTERONE
 VOLNEA, DESOGESTREL
 VOLTAREN, DICLOFENAC SODIUM
 VORICONAZOLE, VORICONAZOLE
 VOSEVI, SOFOSBUVIR
 VOSOL, ACETIC ACID, GLACIAL
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VPRIV, VELAGLUCERASE ALFA
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE
 VUMERITY, DIROXIMEL FUMARATE
 VUSION, MICONAZOLE NITRATE
 VYFEMLA, ETHINYL ESTRADIOL
 VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
 VYNDAMAX, TAFAMIDIS
 VYNDAQEL, TAFAMIDIS MEGLUMINE
 VYONDYS 53, GOLODIRSEN
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE
 VYXEOS, CYTARABINE
 VYZULTA, LATANOPROSTENE BUNOD

** W **

WAKIX, PITOLISANT HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WERA, ETHINYL ESTRADIOL
 WIXELA INHUB, FLUTICASONE PROPIONATE
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

** X **

XADAGO, SAFINAMIDE MESYLATE
 XALATAN, LATANOPROST
 XALKORI, CRIZOTINIB
 XANAX, ALPRAZOLAM
 XANAX XR, ALPRAZOLAM
 XARELTO, RIVAROXABAN
 XATMEP, METHOTREXATE SODIUM
 XELJANZ, TOFACITINIB CITRATE
 XELJANZ XR, TOFACITINIB CITRATE
 XELODA, CAPECITABINE
 XELPROS, LATANOPROST
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENLETA, LEFAMULIN ACETATE
 XENON XE 133, XENON XE-133
 XEPI, OZENOXACIN

APPENDIX A - PRODUCT NAME INDEX**** X ****

XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
 XERESE, ACYCLOVIR
 XERMELO, TELOTTRISTAT ETIPRATE
 XHANCE, FLUTICASONE PROPIONATE
 XIFAXAN, RIFAXIMIN
 XIGDUO XR, DAPAGLIFLOZIN
 XIIDRA, LIFITEGRAST
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 XOFLUZA, BALOXAVIR MARBOXIL
 XOLEGEL, KETOCONAZOLE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOSPATA, GILTERITINIB FUMARATE
 XPOVIO, SELINEXOR
 XTAMPZA ER, OXYCODONE
 XTANDI, ENZALUTAMIDE
 XULANE, ETHINYL ESTRADIOL
 XULTOPHY 100/3.6, INSULIN DEGLUDEC
 XURIDEN, URIDINE TRIACETATE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
 XYREM, SODIUM OXYBATE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

**** Y ****

YAELA, DROSPIRENONE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE
 YONDELIS, TRABECTEDIN
 YONSA, ABIRATERONE ACETATE
 YOSPRALA, ASPIRIN
 YUPELRI, REVEFENACIN
 YUTIQ, FLUOCINOLONE ACETONIDE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
 ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
 ZARONTIN, ETHOSUXIMIDE
 ZAROXOLYN, METOLAZONE
 ZAVESCA, MIGLUSTAT
 ZEGERID, OMEPRAZOLE
 ZEGERID OTC, OMEPRAZOLE (OTC)
 ZEJULA, NIRAPARIB TOSYLATE
 ZELAPAR, SELEGILINE HYDROCHLORIDE
 ZELBORAF, VEMURAFENIB
 ZELNORM, TEGASEROD MALEATE
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZEMDRI, PLAZOMICIN SULFATE
 ZEMPLAR, PARICALCITOL
 ZENATANE, ISOTRETINOIN
 ZENPEP, PANCRELIPASE (AMYLASE)
 ZEPATIER, ELBASVIR
 ZERBAXA, CEFTOLOZANE SULFATE
 ZERIT, STAVUDINE
 ZERVIAE, CETIRIZINE HYDROCHLORIDE
 ZESTORETIC, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

** Z **

ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE
ZUMANDIMINE, DROSPIRENONE
ZUPLENZ, ONDANSETRON
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEHPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3D IMAGING DRUG**

- * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M DRUG DELIVERY

- * 3M DRUG DELIVERY SYSTEMS
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

3M HEALTH CARE

- * 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ******60 DEGREES PHARMS**

- * 60 DEGREES PHARMACEUTICALS LLC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ******AAA USA INC**

- * ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM DOTATATE LU-177
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ANDROGEL, TESTOSTERONE
CREON, PANCRELIPASE (AMYLASE)
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ABBVIE ENDOCRINE INC
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC

* ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
ORILISSA, ELAGOLIX SODIUM
RINVOQ, UPADACITINIB
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

ABHAI INC

* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC

* ABHAI LLC
ATOVAQUONE, ATOVAQUONE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEFLUNOMIDE, LEFLUNOMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC

* ABON PHARMACEUTICALS LLC
CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ENTECAVIR, ENTECAVIR
 EPLERENONE, EPLERENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOPOSIDE, ETOPOSIDE
 EZETIMIBE, EZETIMIBE
 FINASTERIDE, FINASTERIDE
 FLUOROURACIL, FLUOROURACIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LISINAPRIL, LISINAPRIL
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLDOPA, METHYLDOPA
 MITOMYCIN, MITOMYCIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 SPIRONOLACTONE, SPIRONOLACTONE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC USA
 BUSULFAN, BUSULFAN
 TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CICLOPIROX, CICLOPIROX
 PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
 GABAPENTIN, GABAPENTIN

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
 DSUVIA, SUFENTANIL CITRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
 NATESTO, TESTOSTERONE

ACI HEALTHCARE LTD

* ACI HEALTHCARE LTD
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 LEVETIRACETAM, LEVETIRACETAM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
 LEVETIRACETAM, LEVETIRACETAM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA

* ACORDA THERAPEUTICS INC
 AMPYRA, DALFAMPRIDINE
 INBRIJA, LEVODOPA

ACP NIMBLE

* ACP NIMBLE BUYER INC
 ACEPHEN, ACETAMINOPHEN (OTC)
 ACYCLOVIR, ACYCLOVIR
 BETA-VAL, BETAMETHASONE VALERATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 INDOMETHACIN, INDOMETHACIN
 LIDOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MYKACET, NYSTATIN
 NYSTATIN, NYSTATIN
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 TAZAROTENE, TAZAROTENE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ACROTECH**

* ACROTECH BIOPHARMA LLC
 BELEODAQ, BELINOSTAT
 EVOMELA, MELPHALAN HYDROCHLORIDE
 FOLOTYN, PRALATREXATE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 KHAPZORY, LEVOLEUCOVORIN
 MARQIBO KIT, VINCRISTINE SULFATE

ACS DOBFAR

* ACS DOBFAR SPA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 ERTAPENEM SODIUM, ERTAPENEM SODIUM
 MEROPENEM, MEROPENEM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
 ALBENDAZOLE, ALBENDAZOLE
 ALPRAZOLAM, ALPRAZOLAM
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DEFERASIROX, DEFERASIROX
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GABAPENTIN, GABAPENTIN
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDAPAMIDE, INDAPAMIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOVASTATIN, LOVASTATIN
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXAZEPAM, OXAZEPAM
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS ELIZABETH LLC
 - PROPYLTHIOURACIL, PROPYLTHIOURACIL
 - RANOLAZINE, RANOLAZINE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - TEMAZEPAM, TEMAZEPAM
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - ALPRAZOLAM, ALPRAZOLAM
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - LAMOTRIGINE, LAMOTRIGINE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

- * ACTAVIS INC
 - DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 - METHOXSALLEN, METHOXSALLEN

ACTAVIS LABS

- * ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

- * ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 - GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 - GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 - GUAIFENESIN, GUAIFENESIN (OTC)
 - MESALAMINE, MESALAMINE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC

- * ACTAVIS LABORATORIES FL INC
 - BUDESONIDE, BUDESONIDE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CARTIA XT, DILTIAZEM HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DALFAMPRIDINE, DALFAMPRIDINE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 - DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 - DUTASTERIDE, DUTASTERIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 - LEVETIRACETAM, LEVETIRACETAM
 - LORATADINE, LORATADINE (OTC)
 - METAXALONE, METAXALONE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - NAPROXEN SODIUM, NAPROXEN SODIUM
 - NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 - NITROGLYCERIN, NITROGLYCERIN
 - OMEPRAZOLE, OMEPRAZOLE
 - OXYCODONE AND ASPIRIN, ASPIRIN
 - PALIPERIDONE, PALIPERIDONE
 - PAROXETINE MESYLATE, PAROXETINE MESYLATE
 - POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 - PREDNISONE, PREDNISONE
 - RAMELTEON, RAMELTEON
 - RISPERIDONE, RISPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS LABORATORIES FL INC
 - TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 - TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 - TETRABENAZINE, TETRABENAZINE
 - TRANEXAMIC ACID, TRANEXAMIC ACID
 - TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 - VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- ACTAVIS LABS UT INC**
- * ACTAVIS LABORATORIES UT INC
 - AZELAIC ACID, AZELAIC ACID
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 - CLONIDINE, CLONIDINE
 - FIORICET W/ CODEINE, ACETAMINOPHEN
 - LIDOCAINE, LIDOCAINE
 - PROGESTERONE, PROGESTERONE
 - TESTOSTERONE, TESTOSTERONE
- * ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - PIMECROLIMUS, PIMECROLIMUS
 - TESTOSTERONE, TESTOSTERONE
- ACTAVIS LLC**
- * ACTAVIS LLC
 - AZACITIDINE, AZACITIDINE
 - DAPSONE, DAPSONE
 - FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 - LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 - MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
- * ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - BUSULFAN, BUSULFAN
 - DOCETAXEL, DOCETAXEL
 - HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 - OXALIPLATIN, OXALIPLATIN
- ACTAVIS MID ATLANTIC**
- * ACTAVIS MID ATLANTIC LLC
 - ACYCLOVIR, ACYCLOVIR
 - ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 - ADAPALENE, ADAPALENE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - DESOXIMETASONE, DESOXIMETASONE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - ENULOSE, LACTULOSE
 - GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 - HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 - HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 - HYDROCORTISONE, HYDROCORTISONE
 - LEVETIRACETAM, LEVETIRACETAM
 - NITROFURANTOIN, NITROFURANTOIN
 - NYSTATIN, NYSTATIN
 - PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 - VALNAC, BETAMETHASONE VALERATE
- * ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - IBUPROFEN, IBUPROFEN
 - PERMETHRIN, PERMETHRIN (OTC)
- ACTAVIS PHARMA**
- * ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE
- ACTAVIS TOTOWA**
- * ACTAVIS TOTOWA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
- ACTAVIS TOTOWA TEVA**
- * ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FINASTERIDE, FINASTERIDE
- ACTELION PHARMS**
- * ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN
- ACTELION PHARMS LTD**
- * ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT
- ACTIENT PHARMS**
- * ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE
- ADAMAS PHARMA**
- * ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE
- ADAMIS PHARMS CORP**
- * ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE
- ADAPT**
- * ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE
- ADARE PHARMS INC**
- * ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
- ADDMEDICA SAS**
- * ADDMEDICA SAS
SIKLOS, HYDROXYUREA
- ADHERA**
- * ADHERA THERAPEUTICS INC
PRESTALIA, AMLODIPINE BESYLATE
- ADIENNE SA**
- * ADIENNE SA
TEPADINA, THIOTEPA
- AEGERION**
- * AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE
- AERIE PHARMS INC**
- * AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL DIMESYLATE
ROCKLATAN, LATANOPROST
- AGIOS PHARMS INC**
- * AGIOS PHARMACEUTICALS INC
TIBSOVO, IVOSIDENIB
- AGNITIO**
- * AGNITIO INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AGNITIO INC**ETHACRYNIC ACID, ETHACRYNIC ACID
TRIAMTERENE, TRIAMTERENE**AGOURON PHARMS***** AGOURON PHARMACEUTICALS LLC**

VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC*** AILEX PHARMACEUTICALS LLC**BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE**AJANTA PHARMA LTD***** AJANTA PHARMA LTD**ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
CAPTOPRIL, CAPTOPRIL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN**AKARX INC***** AKARX INC**

DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS*** AKCEA THERAPEUTICS INC**

TEGSEDI, INOTERSEN SODIUM

AKORN*** AKORN INC**ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESC EIN SODIUM
AK-FLUOR 25%, FLUORESC EIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IC-GREEN, INDOCYANINE GREEN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LATANOPROST, LATANOPROST
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PYRAZINAMIDE, PYRAZINAMIDE
 RIFAMPIN, RIFAMPIN
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOLOL, TIMOLOL
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TROPICACYL, TROPICAMIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC*** AKORN INC**

ACETYLCYSTEINE, ACETYLCYSTEINE
 APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DRONABINOL, DRONABINOL
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INAPSINE, DROPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALAN LABS INC

*** ALAN LABORATORIES INC**
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE

ALCON

*** ALCON LABORATORIES INC**
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 MIOSTAT, CARBACHOL
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON LABS

*** ALCON LABORATORIES LTD**
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC

*** ALCON LABORATORIES INC**
 ALCAINE, PROPARACAINE HYDROCHLORIDE
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 FLUORESCITE, FLUORESCEIN SODIUM
 ISOPTO ATROPINE, ATROPINE SULFATE

ALCON PHARMS LTD

*** ALCON PHARMACEUTICALS LTD**
 BETADINE, POVIDONE-IODINE
 ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC LTD

*** ALEMBIC LTD**
 LITHIUM CARBONATE, LITHIUM CARBONATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

*** ALEMBIC PHARMACEUTICALS LTD**
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BIMATOPROST, BIMATOPROST
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALEMBIC PHARMACEUTICALS LTD
 CELECOXIB, CELECOXIB
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DEFERASIROX, DEFERASIROX
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DESVENLAFAXINE, DESVENLAFAXINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TERIFLUNOMIDE, TERIFLUNOMIDE
 THEOPHYLLINE, THEOPHYLLINE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRAVOPROST, TRAVOPROST
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALEOR DERMACEUTICALS LTD
 DESONIDE, DESONIDE
 LIDOCAINE, LIDOCAINE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
 ADASUVE, LOXAPINE

ALFASIGMA

* ALFASIGMA USA INC
 ZELNORM, TEGASEROD MALEATE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
 ILUVIEN, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 CAPECITABINE, CAPECITABINE
 CEFIXIME, CEFIXIME
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DEFERASIROX, DEFERASIROX
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALKEM LABORATORIES LTD
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN, VALSARTAN

ALKERMES

* ALKERMES INC
 VIVITROL, NALTREXONE

ALKERMES INC

* ALKERMES INC
 ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
 ARISTADA, ARIPIPRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLEGIS

* ALLEGIS HOLDINGS LLC
 PRIMOSOL, TRIMETHOPRIM HYDROCHLORIDE

ALLERGAN

* ALLERGAN
 ACULAR LS, KETOROLAC TROMETHAMINE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 BLEPH-10, SULFACETAMIDE SODIUM
 GENOPTIC, GENTAMICIN SULFATE
 ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
 ACULAR, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACZONE, DAPSONE
 ALOCRIAL, NEDOCROMIL SODIUM
 ALPHAGAN P, BRIMONIDINE TARTRATE
 AVAGE, TAZAROTENE
 COMBIGAN, BRIMONIDINE TARTRATE
 ELESTAT, EPINASTINE HYDROCHLORIDE
 LASTACAFT, ALCAFTADINE
 LATISSE, BIMATOPROST
 LUMIGAN, BIMATOPROST
 OCUFLOX, OFLOXACIN
 OZURDEX, DEXAMETHASONE
 POLYTRIM, POLYMYXIN B SULFATE
 RESTASIS MULTIDOSE, CYCLOSPORINE
 RESTASIS, CYCLOSPORINE
 TAZORAC, TAZAROTENE
 ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
 BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLEPHAMIDE, PREDNISOLONE ACETATE
 FML FORTE, FLUOROMETHOLONE
 FML, FLUOROMETHOLONE
 OCUFEN, FLURBIPROFEN SODIUM
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE

* ALLERGAN SALES LLC
 ACTIGALL, URSODIOL
 ALORA, ESTRADIOL
 ANDRODERM, TESTOSTERONE
 AVYCAZ, AVIBACTAM SODIUM
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALLERGAN SALES LLC
 BREVICON 28-DAY, ETHINYL ESTRADIOL
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CANASA, MESALAMINE
 CARAFATE, SUCRALFATE
 CELEXA, CITALOPRAM HYDROBROMIDE
 CONDYLOX, PODOFILOX
 CRINONE, PROGESTERONE
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 ESTRACE, ESTRADIOL
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 FIORINAL W/CODEINE, ASPIRIN
 FIORINAL, ASPIRIN
 GELNIQUE, OXYBUTYNIN CHLORIDE
 INFED, IRON DEXTRAN
 KADIAN, MORPHINE SULFATE
 LEXAPRO, ESCITALOPRAM OXALATE
 LINZESS, LINACLOTIDE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OXYTROL, OXYBUTYNIN
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 RAPAFLO, SILODOSIN
 RECTIV, NITROGLYCERIN
 SAPHRIS, ASENAPINE MALEATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 TEFLARO, CEFTAROLINE FOSAMIL
 TRELSTAR, TRIPTORELIN PAMOATE
 UBRELVY, UBROGEPANT
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 VIIBRYD, VILAZODONE HYDROCHLORIDE
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
 VIBERZI, ELUXADOLINE

ALLERQUEST

* ALLERQUEST LLC
 PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLIED

* ALLIED PHARMA INC
 CARISOPRODOL, CARISOPRODOL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ALMIRALL

* ALMIRALL LLC
 ACTICLATE, DOXYCYCLINE HYCLATE
 ACZONE, DAPSONE
 ALTABAX, RETAPAMULIN
 AZELEX, AZELAIC ACID
 CORDRAN SP, FLURANDRENOLIDE
 CORDRAN, FLURANDRENOLIDE
 FLUOROPLEX, FLUOROURACIL
 SEYSARA, SARECYCLINE HYDROCHLORIDE
 VELTIN, CLINDAMYCIN PHOSPHATE
 VERDESO, DESONIDE
 XOLEGEL, KETOCONAZOLE

ALNYLAM PHARMS INC

* ALNYLAM PHARMACEUTICALS INC
 GIVLAARI, GIVOSIRAN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALNYLAM PHARMACEUTICALS INC
ONPATTRO, PATISIRAN SODIUM

ALRA

* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
ETHACRYNIC ACID, ETHACRYNIC ACID
OFLOXACIN, OFLOXACIN

* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

* ALVOGEN GROUP HOLDINGS 4 LLC
THYRO-TABS, LEVOTHYROXINE SODIUM **

* ALVOGEN GROUP HOLDINGS LLC
ADALAT CC, NIFEDIPINE

* ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

* ALVOGEN MALTA OPERATIONS LTD
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BONSITY, TERIPARATIDE RECOMBINANT HUMAN
BUDESONIDE, BUDESONIDE
CARBIDOPA, CARBIDOPA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MELPHALAN, MELPHALAN
NAPRELAN, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
NITROGLYCERIN, NITROGLYCERIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SPECTAZOLE, ECONAZOLE NITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
VORICONAZOLE, VORICONAZOLE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

ALVOGEN INC

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALVOGEN INC**

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

ALVOGEN PINE BROOK*** ALVOGEN PINE BROOK LLC**

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 ESTRADIOL, ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

AM ANTIBIOTICS*** AMERICAN ANTIBIOTICS INC**

AMOXICILLIN, AMOXICILLIN

AM REGENT*** AMERICAN REGENT INC**

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOSPORINE, CYCLOSPORINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 FOMEPIZOLE, FOMEPIZOLE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROXYPROGESTERON CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 INJECTAFER, FERRIC CARBOXYMALTOSIDE
 METHOCARBAMOL, METHOCARBAMOL
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 OLANZAPINE, OLANZAPINE
 SELENIOUS ACID, SELENIOUS ACID
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 VENOFER, IRON SUCROSE
 ZINC SULFATE, ZINC SULFATE

AMAG PHARMA USA*** AMAG PHARMA USA INC**

MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC*** AMAG PHARMACEUTICALS INC**

FERAHEME, FERUMOXYTOL
 INTRAROSA, PRASTERONE
 VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

AMARIN PHARMS*** AMARIN PHARMACEUTICALS IRELAND LTD**

VASCEPA, ICOSAPENT ETHYL

AMERIGEN PHARMS LTD*** AMERIGEN PHARMACEUTICALS LTD**

BEXAROTENE, BEXAROTENE
 CARBIDOPA, CARBIDOPA
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 INDAPAMIDE, INDAPAMIDE
 MIGLUSTAT, MIGLUSTAT
 PENICILLAMINE, PENICILLAMINE
 RANOLAZINE, RANOLAZINE
 TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN*** AMGEN INC**

SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC*** AMGEN INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMGEN INC
 CORLANOR, IVABRADINE
 CORLANOR, IVABRADINE HYDROCHLORIDE
 OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

AMICUS THERAPS US

* AMICUS THERAPEUTICS US INC
 GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMNEAL

* AMNEAL EU LTD
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 BUSULFAN, BUSULFAN
 CARMUSTINE, CARMUSTINE
 CLOFARABINE, CLOFARABINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DOCETAXEL, DOCETAXEL
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FULVESTRANT, FULVESTRANT
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OFLOXACIN, OFLOXACIN
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATOVAQUONE, ATOVAQUONE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ENTECAVIR, ENTECAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * AMNEAL PHARMACEUTICALS
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 LORAZEPAM, LORAZEPAM
 MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 WARFARIN SODIUM, WARFARIN SODIUM
- * AMNEAL PHARMACEUTICALS HOLDINGS GMBH
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
- * AMNEAL PHARMACEUTICALS OF NEW YORK LLC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 DUTASTERIDE, DUTASTERIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PALIPERIDONE, PALIPERIDONE
 PARICALCITOL, PARICALCITOL
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 RIVASTIGMINE, RIVASTIGMINE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE
 TOBRAMYCIN, TOBRAMYCIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARGATROBAN, ARGATROBAN
 BOSENTAN, BOSENTAN
 BUMETANIDE, BUMETANIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOBAZAM, CLOBAZAM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DEFERASIROX, DEFERASIROX
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FUROSEMIDE, FUROSEMIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 NADOLOL, NADOLOL
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PARICALCITOL, PARICALCITOL
 PHYTONADIONE, PHYTONADIONE
 PREGABALIN, PREGABALIN
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 URSODIOL, URSODIOL

AMNEAL PHARMS LLC

* AMNEAL PHARMACEUTICALS LLC
 ACTIVELLA, ESTRADIOL
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AZATHIOPRINE, AZATHIOPRINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS LLC
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 ELURYNG, ETHINYL ESTRADIOL
 ESTRADIOL, ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FLUOCINONIDE, FLUOCINONIDE
 MESALAMINE, MESALAMINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RITONAVIR, RITONAVIR
 SIROLIMUS, SIROLIMUS
 SUCRALFATE, SUCRALFATE
 TESTOSTERONE, TESTOSTERONE
 TIGECYCLINE, TIGECYCLINE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REPRESXAIN, HYDROCODONE BITARTRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
 BEXAROTENE, BEXAROTENE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOTRETINOIN, ISOTRETINOIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PROGESTERONE, PROGESTERONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
 AMPHADASE, HYALURONIDASE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
 CORTROSYN, COSYNTROPIN
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AMRING PHARMS**

- * AMRING PHARMACEUTICALS INC
 - ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 - LATANOPROST, LATANOPROST
 - MESALAMINE, MESALAMINE
 - NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 - NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 - NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 - SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

AMTA

- * AMTA LABS LTD
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ANACOR PHARMS INC

- * ANACOR PHARMACEUTICALS INC
 - EUCRISA, CRISABOROLE
 - KERYDIN, TAVABOROLE

ANBEX

- * ANBEX INC
 - IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB

- * ANBISON LABORATORY CO LTD
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

ANCHEN PHARMS

- * ANCHEN PHARMACEUTICALS INC
 - ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 - DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 - DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 - FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 - FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 - LAMOTRIGINE, LAMOTRIGINE
 - LEVETIRACETAM, LEVETIRACETAM
 - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 - POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - TRETINOIN, TRETINOIN
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * ANCHEN PHARMACEUTICALS TAIWAN INC
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
- * ANCHEN PHARMACEUTICALS, INC
 - ALPRAZOLAM, ALPRAZOLAM
 - CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY

- * ANDA REPOSITORY LLC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CICLOPIROX, CICLOPIROX
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 - DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 - FLAC, FLUOCINOLONE ACETONIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - IMIQUIMOD, IMIQUIMOD
 - ISONIAZID, ISONIAZID
 - LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANDA REPOSITORY LLC
 LEVETIRACETAM, LEVETIRACETAM
 MOMETASONE FUROATE, MOMETASONE FUROATE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PRIMIDONE, PRIMIDONE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

ANDOR PHARMS

* ANDOR PHARMACEUTICALS LLC
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
 CORTENEMA, HYDROCORTISONE
 LUVOX, FLUVOXAMINE MALEATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC

* ANI PHARMACEUTICALS INC
 ARIMIDEX, ANASTROZOLE
 ATACAND HCT, CANDESARTAN CILEXETIL
 ATACAND, CANDESARTAN CILEXETIL
 BRETHINE, TERBUTALINE SULFATE
 CASODEX, BICALUTAMIDE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ETODOLAC, ETODOLAC
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FELBAMATE, FELBAMATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 INDAPAMIDE, INDAPAMIDE
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE
 INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 LITHOBID, LITHIUM CARBONATE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NILUTAMIDE, NILUTAMIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANIMA

* ANIMA PHARMACEUTICALS PVT LTD
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 DEXAMETHASONE, DEXAMETHASONE

ANNORA

* ANNORA PHARMA PRIVATE LTD
 LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA

* ANNORA PHARMA PRIVATE LTD
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANTARES PHARMA INC

* ANTARES PHARMA INC
 OTREXUP, METHOTREXATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE

* ANTIBIOTICE SA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ANTIBIOTICE SA**

AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

APEX PHARMS INC*** APEX PHARMACEUTICALS INC**

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI*** ASTELLAS PHARMA GLOBAL DEVELOPMENT INC**

MYRBETRIQ, MIRABEGRON

APIL*** ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD**

ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
LO LOESTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP*** APNAR PHARMA LP**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOLLO*** APOLLO PHARMACEUTICALS INC**

DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID

APOPHARMA INC*** APOPHARMA INC**

FERRIPROX, DEFERIPRONE

APOTEX*** APOTEX INC**

ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
BUSULFAN, BUSULFAN
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX INC
 CIMETIDINE, CIMETIDINE (OTC)
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOSPORINE, CYCLOSPORINE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPLERENONE, EPLERENONE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ETODOLAC, ETODOLAC
 EZETIMIBE, EZETIMIBE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 ITRACONAZOLE, ITRACONAZOLE
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******APOTEX CORP**

* APOTEX CORP

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE

APOTEX INC

* APOTEX INC

ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DUTASTERIDE, DUTASTERIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE

ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC ETOBICOKE SITE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DILTZAC, DILTIAZEM HYDROCHLORIDE
 - ETODOLAC, ETODOLAC
 - FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 - GABAPENTIN, GABAPENTIN
 - LEFLUNOMIDE, LEFLUNOMIDE
 - LISINOPRIL, LISINOPRIL
 - LORATADINE, LORATADINE (OTC)
 - MELOXICAM, MELOXICAM
 - MIRTAZAPINE, MIRTAZAPINE
 - OXAPROZIN, OXAPROZIN
 - SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - TORSEMIDE, TORSEMIDE
 - ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - BUDESONIDE, BUDESONIDE (OTC)
 - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
- * APOTEX INC.
 - DILTZAC, DILTIAZEM HYDROCHLORIDE
 - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

- * APOTEX TECHNOLOGIES INC
 - PAXIL CR, PAROXETINE HYDROCHLORIDE
 - PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
 - KENALOG-10, TRIAMCINOLONE ACETONIDE
 - KENALOG-40, TRIAMCINOLONE ACETONIDE
 - KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

- * APPCO PHARMA LLC
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - BUDESONIDE, BUDESONIDE
 - HALOPERIDOL, HALOPERIDOL
 - METAXALONE, METAXALONE
 - MODAFINIL, MODAFINIL
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - VORICONAZOLE, VORICONAZOLE

APRECIA PHARMS

- * APRECIA PHARMACEUTICALS LLC
 - SPRITAM, LEVETIRACETAM

APTAPHARMA INC

- * APTAPHARMA INC
 - IBUPROFEN, IBUPROFEN (OTC)

AQUESTIVE THERAP

- * AQUESTIVE THERAPEUTICS
 - EXSERVAN, RILUZOLE
 - SYMPAZAN, CLOBAZAM

ARBOR PHARMS LLC

- * ARBOR PHARMACEUTICALS LLC
 - BIDIL, HYDRALAZINE HYDROCHLORIDE
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 - E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 - EDARBI, AZILSARTAN KAMEDOXOMIL
 - EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
 - ERY-TAB, ERYTHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ARBOR PHARMACEUTICALS LLC
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROMYCIN, ERYTHROMYCIN
 EVEKEO ODT, AMPHETAMINE SULFATE
 EVEKEO, AMPHETAMINE SULFATE
 GLIADEL, CARMUSTINE
 HORIZANT, GABAPENTIN ENACARBIL
 NYMALIZE, NIMODIPINE
 SKLICE, IVERMECTIN
 SOTYLIZE, SOTALOL HYDROCHLORIDE
 TRIPTODUR KIT, TRIPTORELIN PAMOATE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
 THYROSHIELD, POTASSIUM IODIDE (OTC)

ARDELYX INC

* ARDELYX INC
 IBSRELA, TENAPANOR HYDROCHLORIDE

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
 ALUNBRIG, BRIGATINIB
 ICLUSIG, PONATINIB HYDROCHLORIDE

ARISE

* ARISE PHARMACEUTICALS LLC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 CHLORTHALIDONE, CHLORTHALIDONE
 IBUPROFEN, IBUPROFEN (OTC)
 LAMIVUDINE, LAMIVUDINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

ARMSTRONG PHARMS

* ARMSTRONG PHARMACEUTICALS INC
 PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC

* ARRAY BIOPHARMA INC
 BRAFTOVI, ENCORAFENIB
 MEKTOVI, BINIMETINIB

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
 BINOSTO, ALENDRONATE SODIUM
 ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
 BENZONATATE, BENZONATATE
 DUTASTERIDE, DUTASTERIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN (OTC)
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

ASPEN

* ASPEN PHARMA USA INC
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPEN GLOBAL

* ASPEN GLOBAL INC
 MYLERAN, BUSULFAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ASPEN GLOBAL INC**

- * ASPEN GLOBAL INC
 - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 - CYCLESSA, DESOGESTREL
 - HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 - LEUKERAN, CHLORAMBUCIL
 - THIOGUANINE, THIOGUANINE

ASSERTIO

- * ASSERTIO THERAPEUTICS INC
 - CAMBIA, DICLOFENAC POTASSIUM
 - GRALISE, GABAPENTIN
 - ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS

- * ASTELLAS PHARMA US INC
 - AMBISOME, AMPHOTERICIN B
 - ASTAGRAF XL, TACROLIMUS
 - CRESEMBA, ISAVUCONAZONIUM SULFATE
 - LEXISCAN, REGADENOSON
 - MYCAMINE, MICAFUNGIN SODIUM
 - PROGRAF, TACROLIMUS
 - VESICARE, SOLIFENACIN SUCCINATE
 - XOSPATA, GILTERITINIB FUMARATE
 - XTANDI, ENZALUTAMIDE

ASTRAL

- * ASTRAL STERITECH PVT LTD
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM

ASTRAZENECA

- * ASTRAZENECA LP
 - PULMICORT FLEXHALER, BUDESONIDE
 - SYMBICORT, BUDESONIDE
- * ASTRAZENECA PHARMACEUTICALS LP
 - FASLODEX, FULVESTRANT
 - ZOMIG, ZOLMITRIPTAN
 - ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
 - CALQUENCE, ACALABRUTINIB
 - SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

- * ASTRAZENECA AB
 - BYDUREON BCISE, EXENATIDE
 - BYDUREON PEN, EXENATIDE SYNTHETIC
 - BYDUREON, EXENATIDE SYNTHETIC
 - BYETTA, EXENATIDE SYNTHETIC
 - FARXIGA, DAPAGLIFLOZIN
 - KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 - ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 - QTERN, DAPAGLIFLOZIN
 - QTERNMET XR, DAPAGLIFLOZIN
 - SYMLIN, PRAMLINTIDE ACETATE
 - XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

- * ASTRAZENECA LP
 - NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

- * ASTRAZENECA PHARMACEUTICALS LP
 - BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
 - BRILINTA, TICAGRELOR
 - DALIRESP, ROFLUMILAST
 - IRESSA, GEFITINIB
 - LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 - LYNPARZA, OLAPARIB
 - MOVANTIK, NALOXEGOL OXALATE
 - NEXIUM IV, ESOMEPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ASTRAZENECA PHARMACEUTICALS LP
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PULMICORT RESPULES, BUDESONIDE
 RHINOCORT ALLERGY, BUDESONIDE (OTC)
 SEROQUEL, QUETIAPINE FUMARATE
 TAGRISSO, OSIMERTINIB MESYLATE

ATHEM

* ATHEM HOLDINGS LLC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORTHALIDONE, CHLORTHALIDONE
 FOLIC ACID, FOLIC ACID
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

ATHENA

* ATHENA BIOSCIENCES LLC
 FIBRICOR, FENOFIBRIC ACID

ATHENEX

* ATHENEX PHARMACEUTICAL DIV
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

ATHENEX INC

* ATHENEX INC
 BUSULFAN, BUSULFAN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 VALPROATE SODIUM, VALPROATE SODIUM

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
 ANAPROX DS, NAPROXEN SODIUM
 EC-NAPROSYN, NAPROXEN
 NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
 LODOSYN, CARBIDOPA

AUCTA

* AUCTA PHARMACEUTICALS INC
 VIGADRONE, VIGABATRIN

AUREX

* AUREX LABORATORIES LTD LIABILITY CO
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

AUROBINDO

* AUROBINDO PHARMA LTD
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NEVIRAPINE, NEVIRAPINE
 ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AUROBINDO PHARMA**

* AUROBINDO PHARMA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ATENOLOL, ATENOLOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVIRIN, RIBAVIRIN
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AFIRMELLE, ETHINYL ESTRADIOL
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ARMODAFINIL, ARMODAFINIL
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATHENTIA NEXT, LEVONORGESTREL (OTC)
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AUROVELA 1.5/30, ETHINYL ESTRADIOL
 AUROVELA 1/20, ETHINYL ESTRADIOL
 AUROVELA 24 FE, ETHINYL ESTRADIOL
 AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
 AUROVELA FE 1/20, ETHINYL ESTRADIOL
 AYUNA, ETHINYL ESTRADIOL
 AZITHROMYCIN, AZITHROMYCIN
 BIVALIRUDIN, BIVALIRUDIN
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBIDOPA, CARBIDOPA
 CEFIXIME, CEFIXIME
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYONANZ, ETHINYL ESTRADIOL
 DALFAMPRIDINE, DALFAMPRIDINE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOFETILDE, DOFETILIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ENTACAPONE, ENTACAPONE
 ENTECAVIR, ENTECAVIR
 EPTIFIBATIDE, EPTIFIBATIDE
 ERTAPENEM SODIUM, ERTAPENEM SODIUM
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 ETOMIDATE, ETOMIDATE
 EZETIMIBE, EZETIMIBE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ICLEVIA, ETHINYL ESTRADIOL
 INCASSIA, NORETHINDRONE
 INDOMETHACIN, INDOMETHACIN
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KALLIGA, DESOGESTREL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LATANOPROST, LATANOPROST
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LO SIMPESSE, ETHINYL ESTRADIOL
 LO-ZUMANDIMINE, DROSPIRENONE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEVIRAPINE, NEVIRAPINE
NEXESTA FE, ETHINYL ESTRADIOL
NIACIN, NIACIN
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD

ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SIMPESE, ETHINYL ESTRADIOL
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TADALAFIL, TADALAFIL
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TIGECYCLINE, TIGECYCLINE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-MILI, ETHINYL ESTRADIOL
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZUMANDIMINE, DROSPIRENONE

* AUROBINDO PHARMA LTD INC

ZIDOVUDINE, ZIDOVUDINE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DUTASTERIDE, DUTASTERIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA

* AUSTARPHARMA LLC

FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC

METHOCARBAMOL, METHOCARBAMOL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS INC

* AUXILIUM PHARMACEUTICALS INC

TESTOPEL, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUXILIUM PHARMACEUTICALS INC
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
DILATRATE-SR, ISOSORBIDE DINITRATE
EDEX, ALPROSTADIL
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVACOR PRODS

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVADEL LEGACY

* AVADEL LEGACY PHARMACEUTICALS LLC
AKOVAZ, EPHEDRINE SULFATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
NOURESS, CYSTEINE HYDROCHLORIDE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

AVANIR PHARMS

* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVERITAS

* AVERITAS PHARMA INC
QUTENZA, CAPSAICIN

AVET

* AVET PHARMACEUTICALS INC
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AVION PHARMS

* AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL
GLOPERBA, COLCHICINE

AVONDALE PHARMS

* AVONDALE PHARMACEUTICALS LLC
NIACOR, NIACIN

AYTU

* AYTU BIOSCIENCE INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
KARBINAL ER, CARBINOXAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
ZOLPIMIST, ZOLPIDEM TARTRATE

**** B ******B BRAUN**

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC

LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC*** B BRAUN MEDICAL INC**

BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ*** BAJAJ MEDICAL LLC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BARR*** BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 DANAZOL, DANAZOL
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BARR LABORATORIES INC
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 ONDANSETRON, ONDANSETRON
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PORTIA-28, ETHINYL ESTRADIOL
 SPRIINTEC, ETHINYL ESTRADIOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRIINTEC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM
- * BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
- BARR LABS DIV TEVA**
- * BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
 BUDESONIDE, BUDESONIDE
- BARR LABS INC**
- * BARR LABORATORIES INC
 ACITRETIN, ACITRETIN
 CLOZAPINE, CLOZAPINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 ESTRADIOL, ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 TRETINOIN, TRETINOIN
 TRI LO SPRIINTEC, ETHINYL ESTRADIOL
- BAUSCH**
- * BAUSCH HEALTH AMERICAS INC
 ACANYA, BENZOYL PEROXIDE
 ARAZLO, TAZAROTENE
 BENZACLIN, BENZOYL PEROXIDE
 BRYHALI, HALOBETASOL PROPIONATE
 DUOBRII, HALOBETASOL PROPIONATE
 EDECRIN, ETHACRYNATE SODIUM
 EDECRIN, ETHACRYNIC ACID
 EFUDEX, FLUOROURACIL
 JUBLIA, EFINACONAZOLE
 LOCOID, HYDROCORTISONE BUTYRATE
 MEPHYTON, PHYTONADIONE
 ONEXTON, BENZOYL PEROXIDE
 OXSORALEN-ULTRA, METHOXSALEN
 SYPRINE, TRIENTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAUSCH HEALTH IRELAND LTD
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

* BAUSCH HEALTH US LLC
ALDARA, IMIQUIMOD
ANCOBON, FLUCYTOSINE
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DEMSER, METYROSINE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
ELIDEL, PIMECROLIMUS
ISORDIL, ISOSORBIDE DINITRATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
LOCOID, HYDROCORTISONE BUTYRATE
LOPROX, CICLOPIROX
MESTINON, PYRIDOSTIGMINE BROMIDE
METROGEL-VAGINAL, METRONIDAZOLE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
TASMAR, TOLCAPONE
TIAZAC, DILTIAZEM HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
XERESE, ACYCLOVIR
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPRDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPRDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VITRASE, HYALURONIDASE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPRDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
 DEXASPORIN, DEXAMETHASONE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUNISOLIDE, FLUNISOLIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 OFLOXACIN, OFLOXACIN
 OTICAIR, HYDROCORTISONE
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
 BEPREVE, BEPOTASTINE BESILATE
 LOTE MAX SM, LOTE PREDNOL ETABONATE
 LOTE MAX, LOTE PREDNOL ETABONATE
 LUMIFY, BRIMONIDINE TARTRATE (OTC)

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAXTER HEALTHCARE CORP

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODEXTRIN
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 IFEX, IFOSFAMIDE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP
 BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLINOLIPID 20%, OLIVE OIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MYXREDLIN, INSULIN HUMAN
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
 ALEVE, NAPROXEN SODIUM (OTC)
 ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

- * BAYER HEALTHCARE PHARMACEUTICALS INC
 ALIQOPA, COPANLISIB DIHYDROCHLORIDE
 NUBEQA, DAROLUTAMIDE
 VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 CLARITIN HIVES RELIEF, LORATADINE (OTC)
 CLARITIN REDITABS, LORATADINE (OTC)
 CLARITIN, LORATADINE (OTC)
 CLARITIN-D 24 HOUR, LORATADINE (OTC)
 CLARITIN-D, LORATADINE (OTC)
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
 ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC
 ADEMPAS, RIOCIQUAT
 ANGELIQ, DROSPIRENONE
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 BEYAZ, DROSPIRENONE
 BILTRICIDE, PRAZIQUANTEL
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CLIMARA PRO, ESTRADIOL
 CLIMARA, ESTRADIOL
 EOVIIST, GADOXETATE DISODIUM
 GADAVIST, GADOBUTROL
 KYLEENA, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAYER HEALTHCARE PHARMACEUTICALS INC**

LEVITRA, VARDENAFIL HYDROCHLORIDE
 MENOSTAR, ESTRADIOL
 MIRENA, LEVONORGESTREL
 NATAZIA, DIENOGEST
 NEXAVAR, SORAFENIB TOSYLATE
 SAFYRAL, DROSPIRENONE
 SKYLA, LEVONORGESTREL
 STAXYN, VARDENAFIL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 VITRAKVI, LAROTRECTINIB SULFATE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC*** BAYSHORE PHARMACEUTICALS LLC**

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 PINDOLOL, PINDOLOL
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI*** BIODELIVERY SCIENCES INTERNATIONAL INC**

BELBUCA, BUPRENORPHINE HYDROCHLORIDE
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
 SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS*** BE PHARMACEUTICALS AG**

DAPTOMYCIN, DAPTOMYCIN
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

BECTON DICKINSON*** BECTON DICKINSON AND CO**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO*** BECTON DICKINSON AND CO**

CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE*** BEIGENE USA INC**

BRUKINSA, ZANUBRUTINIB

BEIJING YILING*** BEIJING YILING BIO-ENGINEERING AND TECHNOLOGY CO LTD**

ANASTROZOLE, ANASTROZOLE
 LETROZOLE, LETROZOLE

BELCHER PHARMS*** BELCHER PHARMACEUTICALS LLC**

CEPHALEXIN, CEPHALEXIN
 DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC*** BELCHER PHARMACEUTICALS LLC**

ABLYSINOL, ALCOHOL
 CEFIXIME, CEFIXIME
 EPINEPHRINE, EPINEPHRINE
 MEFENAMIC ACID, MEFENAMIC ACID
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BELCHER PHARMACEUTICALS LLC
TACROLIMUS, TACROLIMUS

BELOTECA INC

* BELOTECA INC
DIAZEPAM, DIAZEPAM

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NADOLOL, NADOLOL
RIBAVIRIN, RIBAVIRIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA

* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON LIMITED

* BIOCON LIMITED
SIMVASTATIN, SIMVASTATIN

BIOCON LTD

* BIOCON LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC
RAPIVAB, PERAMIVIR

BIOFRONTERA

* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN

* BIOGEN
VUMERITY, DIROXIMEL FUMARATE

BIOGEN IDEC

* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC

* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BIONPHARMA INC
 DOFETILIDE, DOFETILIDE
 DUTASTERIDE, DUTASTERIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NIMODIPINE, NIMODIPINE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PARICALCITOL, PARICALCITOL
 PROGESTERONE, PROGESTERONE
 RUFINAMIDE, RUFINAMIDE
 TETRABENAZINE, TETRABENAZINE
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL
 ZONISAMIDE, ZONISAMIDE

BLAIREX

* BLAIREX LABORATORIES INC
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE EARTH

* BLUE EARTH DIAGNOSTICS LTD
 AXUMIN, FLUCICLOVINE F-18

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
 CATAPRES, CLONIDINE HYDROCHLORIDE
 CATAPRES-TTS-1, CLONIDINE
 CATAPRES-TTS-2, CLONIDINE
 CATAPRES-TTS-3, CLONIDINE
 GILOTRIF, AFATINIB DIMALEATE
 GLYXAMBI, EMPAGLIFLOZIN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICARDIS, TELMISARTAN
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
 * BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 AGGRENOX, ASPIRIN
 APTIVUS, TIPRANAVIR
 ATROVENT HFA, IPRATROPIUM BROMIDE
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 JARDIANCE, EMPAGLIFLOZIN
 JENTADUETO XR, LINAGLIPTIN
 JENTADUETO, LINAGLIPTIN
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MOBIC, MELOXICAM
 OFEV, NINTEDANIB ESYLATE
 PERSANTINE, DIPYRIDAMOLE
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
 SPIRIVA, TIOTROPIUM BROMIDE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNJARDY, EMPAGLIFLOZIN
 TRADJENTA, LINAGLIPTIN
 TWYNSTA, AMLODIPINE BESYLATE
 VIRAMUNE XR, NEVIRAPINE
 VIRAMUNE, NEVIRAPINE

BOSCOGEN

* BOSCOGEN INC
 ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BOSCOGEN INC
 CAPTOPRIL, CAPTOPRIL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 E-Z-HD, BARIUM SULFATE
 E-Z-PAQUE, BARIUM SULFATE
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 READI-CAT 2 SMOOTHIE, BARIUM SULFATE
 READI-CAT 2, BARIUM SULFATE
 TAGITOL V, BARIUM SULFATE
 VARIBAR HONEY, BARIUM SULFATE
 VARIBAR NECTAR, BARIUM SULFATE
 VARIBAR PUDDING, BARIUM SULFATE
 VARIBAR THIN HONEY, BARIUM SULFATE
 VARIBAR THIN LIQUID, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
 ALPRAZOLAM, ALPRAZOLAM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BRETILUM TOSYLATE, BRETILUM TOSYLATE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPLERENONE, EPLERENONE
 EXEMESTANE, EXEMESTANE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LEVETIRACETAM, LEVETIRACETAM
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 OMEPRAZOLE, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRECKENRIDGE PHARMACEUTICAL INC
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE, RIVASTIGMINE
 ROFLUMILAST, ROFLUMILAST
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 CILOSTAZOL, CILOSTAZOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 LEVETIRACETAM, LEVETIRACETAM
 MELOXICAM, MELOXICAM
 OXCARBAZEPINE, OXCARBAZEPINE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
 AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
 ENTECAVIR, ENTECAVIR

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
 AZACTAM, AZTREONAM
 BARACLUDE, ENTECAVIR
 PRAVACHOL, PRAVASTATIN SODIUM

* BRISTOL MYERS SQUIBB CO
 DROXIA, HYDROXYUREA
 HYDREA, HYDROXYUREA
 REYATAZ, ATAZANAVIR SULFATE
 SPRYCEL, DASATINIB
 SUSTIVA, EFAVIRENZ
 VIDEX EC, DIDANOSINE

* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
 ELIQUIS, APIXABAN
 ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB PHARMA CO
 COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
 EVOTAZ, ATAZANAVIR SULFATE
 VIDEX, DIDANOSINE

BTCP PHARMA

* BTCP PHARMA LLC
 LAZANDA, FENTANYL CITRATE
 SUBSYS, FENTANYL

BWXT ITG

* BWXT ITG CANADA INC
 INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ******CADILA**

* CADILA HEALTHCARE LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CADILA HEALTHCARE LTD
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DUTASTERIDE, DUTASTERIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELBAMATE, FELBAMATE
 INDOMETHACIN, INDOMETHACIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 NYSTATIN, NYSTATIN
 PIROXICAM, PIROXICAM
 RANOLAZINE, RANOLAZINE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 CELECOXIB, CELECOXIB
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 GEMFIBROZIL, GEMFIBROZIL
 GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 NATEGLINIDE, NATEGLINIDE
 OFLOXACIN, OFLOXACIN
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TELMISARTAN, TELMISARTAN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
 ADAPALENE, ADAPALENE

CAPELLON PHARMS LLC

* CAPELLON PHARMACEUTICALS LLC
 POLMON, DEXCHLORPHENIRAMINE MALEATE

CAPLIN

* CAPLIN STERILES LTD
 GLYCOPYRROLATE, GLYCOPYRROLATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
 SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
GEMFIBROZIL, GEMFIBROZIL

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CASI PHARMS INC

* CASI PHARMACEUTICALS INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CEFPROZIL, CEFPROZIL
CILOSTAZOL, CILOSTAZOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
ENTECAVIR, ENTECAVIR
HEPARIN SODIUM, HEPARIN SODIUM
LISINOPRIL, LISINOPRIL
METHIMAZOLE, METHIMAZOLE
NABUMETONE, NABUMETONE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
TENOFIVIR DISOPROXIL FUMARATE, TENOFIVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

CASPER PHARMA LLC

* CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
NEOSPORIN, BACITRACIN ZINC
ZYLOPRIM, ALLOPURINOL

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS

* CATALYST PHARMACEUTICALS INC
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CE DIPROF INC

* CE DIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS

* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELGENE

* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CELGENE CORP

* CELGENE CORP
IDHIFA, ENASIDENIB MESYLATE

CELLTRION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CELLTRION INC**

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FAMOTIDINE, FAMOTIDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TEMIXYS, LAMIVUDINE
 ZONISAMIDE, ZONISAMIDE

CEPHALON*** CEPHALON INC**

ACTIQ, FENTANYL CITRATE
 FENTORA, FENTANYL CITRATE
 GABITRIL, TIAGABINE HYDROCHLORIDE
 NUVIGIL, ARMODAFINIL
 PROVIGIL, MODAFINIL
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRISENOX, ARSENIC TRIOXIDE

CEYONE*** CEYONE PHARMA LLC**

BUMETANIDE, BUMETANIDE

CHANGZHOU PHARM*** CHANGZHOU PHARMACEUTICAL FACTORY**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL*** CHARTWELL LIFE MOLECULES LLC**

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 FLUCONAZOLE, FLUCONAZOLE

CHARTWELL LIFE SCI*** CHARTWELL LIFE SCIENCE LLC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULAR*** CHARTWELL MOLECULAR HOLDINGS LLC**

CALCIUM ACETATE, CALCIUM ACETATE
 CARVEDILOL, CARVEDILOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FOLIC ACID, FOLIC ACID
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE

CHARTWELL MOLECULES*** CHARTWELL MOLECULES LLC**

DISULFIRAM, DISULFIRAM
 GEMFIBROZIL, GEMFIBROZIL
 NABUMETONE, NABUMETONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX*** CHARTWELL RX SCIENCES LLC**

CALCIUM ACETATE, CALCIUM ACETATE
 CILOSTAZOL, CILOSTAZOL
 DUVOID, BETHANECHOL CHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 INDOMETHACIN, INDOMETHACIN
 LEVETIRACETAM, LEVETIRACETAM
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CHARTWELL RX SCIENCES LLC
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

CHARTWELL TETRA

* CHARTWELL TETRA LLC
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM

* CHATTEM INC
 UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMI SPA

* CHEMI SPA
 DECITABINE, DECITABINE
 TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
 ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL

* CHEMO RESEARCH SL
 BENZNIDAZOLE, BENZNIDAZOLE
 NUVESSA, METRONIDAZOLE

CHEPLAPHARM

* CHEPLAPHARM ARZNEIMITTEL GMBH
 CYTOVENE, GANCICLOVIR SODIUM
 ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
 XENICAL, ORLISTAT

CHIESI USA INC

* CHIESI USA INC
 BETHKIS, TOBRAMYCIN
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CLEVIPREX, CLEVIDIPINE
 CUROSURF, PORACTANT ALFA
 KENGREAL, CANGRELOR
 ZYFLO CR, ZILEUTON
 ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS

* CINTEX SERVICES LLC
 FLURANDRENOLIDE, FLURANDRENOLIDE

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
 CONZIP, TRAMADOL HYDROCHLORIDE
 LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMBRISENTAN, AMBRISENTAN
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

AZACITIDINE, AZACITIDINE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BOSENTAN, BOSENTAN
 BUDESONIDE, BUDESONIDE
 CELECOXIB, CELECOXIB
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DECITABINE, DECITABINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 EFAVIRENZ, EFAVIRENZ
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EMTRICITABINE, EMTRICITABINE
 ENTECAVIR, ENTECAVIR
 EXEMESTANE, EXEMESTANE
 FAMCICLOVIR, FAMCICLOVIR
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FLUTAMIDE, FLUTAMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 MELOXICAM, MELOXICAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREGABALIN, PREGABALIN
 RANOLAZINE, RANOLAZINE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE, TESTOSTERONE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZIDOVUDINE, ZIDOVUDINE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

CIPLA LTD*** CIPLA LTD**

ALBENDAZOLE, ALBENDAZOLE
 CARBOPLATIN, CARBOPLATIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 TOPIRAMATE, TOPIRAMATE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CIPLA USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CIPLA USA INC
ZEMDRI, PLAZOMICIN SULFATE

CIRCASSIA

* CIRCASSIA LTD
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

CLARUS

* CLARUS THERAPEUTICS INC
JATENZO, TESTOSTERONE UNDECANOATE

CLINIGEN

* CLINIGEN INC
ETHYOL, AMIFOSTINE
TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC

* CLINUVEL INC
SCENESSE, AFAMELANOTIDE

CLOVER PHARMS

* CLOVER PHARMACEUTICALS CORP
AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC

* CLOVIS ONCOLOGY INC
RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC

* CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC

CMP PHARMA INC

* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CNTY LINE PHARMS

* COUNTY LINE PHARMACEUTICALS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CICLOPIROX, CICLOPIROX
DYNACIN, MINOCYCLINE HYDROCHLORIDE
FLUOCINONIDE, FLUOCINONIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TAMBOCOR, FLECAINIDE ACETATE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
UREX, METHENAMINE HIPPURATE

COEPTIS

* COEPTIS PHARMACEUTICALS INC
CONSENSI, AMLODIPINE BESYLATE

COLGATE PALMOLIVE CO

* COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE

COMBE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COMBE INC

VAGISTAT-1, TIOCONAZOLE (OTC)

CONCORD BIOTECH LTD

* CONCORD BIOTECH LTD

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID**CONCORDIA**

* CONCORDIA PHARMACEUTICALS INC

DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANILCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE**CONCORDIA PHARMS INC**

* CONCORDIA PHARMACEUTICALS INC

KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE**CONTRACT PHARMACAL**

* CONTRACT PHARMACAL CORP

CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)**COOPERSURGICAL**

* COOPERSURGICAL INC

PARAGARD T 380A, COPPER

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC

KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA

GLEOSTINE, LOMUSTINE

COSETTE

* COSETTE PHARMACEUTICALS INC

ALBUTEROL SULFATE, ALBUTEROL SULFATE
MIGERGOT, CAFFEINE**COVIS PHARMA BV**

* COVIS PHARMA BV

ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
OMNARIS, CICLESONIDE
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZETONNA, CICLESONIDE**CPDC**

* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV

SUTENT, SUNITINIB MALATE

CROSSMEDIKA SA

* CROSSMEDIKA SA

MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CROSSMEDIKA SA
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
 ALA-CORT, HYDROCORTISONE
 TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 BENZONATATE, BENZONATATE
 CELECOXIB, CELECOXIB
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CONJUPRI, LEVAMLODIPINE MALEATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
 ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

* CUBIST PHARMACEUTICALS LLC
 CUBICIN RF, DAPTOMYCIN
 CUBICIN, DAPTOMYCIN
 DIFICID, FIDAXOMICIN
 SIVEXTRO, TEDIZOLID PHOSPHATE
 ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC
 ACETADOTE, ACETYLCYSTEINE
 CALDOLOR, IBUPROFEN
 LACTULOSE, LACTULOSE
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
 REDITREX, METHOTREXATE
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
 VIBATIV, TELAVANCIN HYDROCHLORIDE

CURIUM

* CURIUM US LLC
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 XENON XE 133, XENON XE-133

CURRAX

* CURRAX PHARMACEUTICALS LLC
 ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 TREXIMET, NAPROXEN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CUSTOPHARM INC**

* CUSTOPHARM INC
 ACETAMINOPHEN, ACETAMINOPHEN
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
 VALRUBICIN, VALRUBICIN

CYCLE PHARMS LTD

* CYCLE PHARMACEUTICALS LTD
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 NITYR, NITISINONE

**** D ******DAEWOONG PHARM CO**

* DAEWOONG PHARMACEUTICAL CO LTD
 MEROPENEM, MEROPENEM

DAIICHI SANKYO

* DAIICHI SANKYO INC
 AZOR, AMLODIPINE BESYLATE
 BENICAR HCT, HYDROCHLOROTHIAZIDE
 BENICAR, OLMESARTAN MEDOXOMIL
 TRIBENZOR, AMLODIPINE BESYLATE
 WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 MORPHABOND ER, MORPHINE SULFATE
 SAVAYSA, EDOXABAN TOSYLATE
 TURALIO, PEXIDARTINIB HYDROCHLORIDE
 WELCHOL, COLESEVELAM HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
 MIFEPREX, MIFEPRISTONE

DAVA INTL INC

* DAVA INTERNATIONAL INC
 ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 ATENOLOL, ATENOLOL
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PYRAZINAMIDE, PYRAZINAMIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
 PRE-OP II, HEXACHLOROPHENE
 PRE-OP, HEXACHLOROPHENE

DBL PHARMS

* DBL PHARMACEUTICALS INC
 METHOCARBAMOL, METHOCARBAMOL

DECATUR

* DECATUR MEMORIAL HOSP
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DECATUR MEMORIAL HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
 ORAQIX, LIDOCAINE

DEPO NF

* DEPO NF SUB LLC A SUB OF ASSERTIO THERAPEUTICS INC
 NUCYNТА ER, TAPENTADOL HYDROCHLORIDE
 NUCYNТА, TAPENTADOL HYDROCHLORIDE

DEPROCO

* DEPROCO INC
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 SCANDONEST L, LEVONORDEFIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIRA INC

* DERMIRA INC
 QBREXZA, GLYCOPYRRONIUM TOSYLATE

DEVA HOLDING AS

* DEVA HOLDING AS
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD

* DEXCEL LTD
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 HEMADY, DEXAMETHASONE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 PERIOCHIP, CHLORHEXIDINE GLUCONATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

DFB ONCOLOGY LTD

* DFB ONCOLOGY LTD
 DOCETAXEL, DOCETAXEL

DIAGNOSTIC GREEN

* DIAGNOSTIC GREEN GMBH
 INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC

* DIGESTIVE CARE INC
 PERTZYE, PANCRELIPASE (AMYLASE)

DORC

* DORC INTERNATIONAL BV
 MEMBRANEBLUE, TRYPAN BLUE
 VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
 MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
 ALTRENO, TRETINOIN
 ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

- * DR REDDYS LABORATORIES INC
 NITROGLYCERIN, NITROGLYCERIN
 PROGESTERONE, PROGESTERONE
 PROPOFOL, PROPOFOL
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE, TESTOSTERONE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * DR REDDYS LABORATORIES LTD
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 AZACITIDINE, AZACITIDINE
 CARFILZOMIB, CARFILZOMIB
 COLCHICINE, COLCHICINE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TETRABENAZINE, TETRABENAZINE
 THIOTEPA, THIOTEPA
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
- DR REDDYS LA**
- * DR REDDYS LABORATORIES LOUISIANA LLC
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LOPURIN, ALLOPURINOL
 SSD, SILVER SULFADIAZINE
- DR REDDYS LABS INC**
- * DR REDDYS LABORATORIES INC
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
- DR REDDYS LABS LTD**
- * DR REDDYS LABORATORIES LIMITED
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- * DR REDDYS LABORATORIES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BIVALIRUDIN, BIVALIRUDIN
 BORTEZOMIB, BORTEZOMIB
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOFARABINE, CLOFARABINE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOCETAXEL, DOCETAXEL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESZOPICLONE, ESZOPICLONE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

- * DR REDDYS LABORATORIES LTD
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHYTONADIONE, PHYTONADIONE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SIROLIMUS, SIROLIMUS
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZAFIRLUKAST, ZAFIRLUKAST
 ZENATANE, ISOTRETINOIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
- DR REDDYS LABS SA**
- * DR REDDYS LABORATORIES SA
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 HABITROL, NICOTINE (OTC)
 MERCAPTOPYRINE, MERCAPTOPYRINE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 RAMELTEON, RAMELTEON
 TOBRAMYCIN, TOBRAMYCIN
- DRAxIMAGE**
- * DRAxIMAGE INC
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
- DUCHESNAY**
- * DUCHESNAY INC
 BONJESTA, DOXYLAMINE SUCCINATE
 DICLEGIS, DOXYLAMINE SUCCINATE
 OSPHENA, OSPHEMIFENE
- DURAMED PHARMS BARR**
- * DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
 AVIANE-28, ETHINYL ESTRADIOL
 CRYSELLE, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ENPRESSE-28, ETHINYL ESTRADIOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VELIVET, DESOGESTREL
- DUSA**
- * DUSA PHARMACEUTICALS INC
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
- DUTCH OPHTHALMIC**
- * DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
 TISSUEBLUE, BRILLIANT BLUE G
- REDDYS**
- * DOCTOR REDDYS LABORATORIES LTD
 DESLORATADINE, DESLORATADINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DOCTOR REDDYS LABORATORIES LTD
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******E5 PHARMA INC**

* E5 PHARMA INC
 DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE
 RYANODEX, DANTROLENE SODIUM

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 METHIMAZOLE, METHIMAZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 VALPROIC ACID, VALPROIC ACID

ECOLAB

* ECOLAB INC
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
 DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

* ECR PHARMA
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
 ALBENDAZOLE, ALBENDAZOLE
 CARBIDOPA, CARBIDOPA
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 IVERMECTIN, IVERMECTIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
 METHERGINE, METHYLERGONOVINE MALEATE

EGALET

* EGALET US INC
 INDOCIN, INDOMETHACIN

EI INC

* EI INC
 THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
 ACIPHEX, RABEPRAZOLE SODIUM
 ARICEPT, DONEPEZIL HYDROCHLORIDE
 BANZEL, RUFINAMIDE
 BELVIQ XR, LORCASERIN HYDROCHLORIDE
 BELVIQ, LORCASERIN HYDROCHLORIDE
 FYCOMPA, PERAMPANEL
 HALAVEN, ERIBULIN MESYLATE
 LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELI LILLY AND CO
 BAQSIMI, GLUCAGON
 BASAGLAR, INSULIN GLARGINE
 EFFIENT, PRASUGREL HYDROCHLORIDE
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 OLUMIANT, BARICITINIB
 PROZAC, FLUOXETINE HYDROCHLORIDE
 VERZENIO, ABEMACICLIB

ELI LILLY CO

* ELI LILLY CO
 ADCIRCA, TADALAFIL
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 DANTROLENE SODIUM, DANTROLENE SODIUM
 ISRADIPINE, ISRADIPINE
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELYSIUM

* ELYSIUM PHARMACEUTICALS LTD
 CALCITRIOL, CALCITRIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
 ACARBOSE, ACARBOSE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BICNU, CARMUSTINE
 CIDOFOVIR, CIDOFOVIR
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ETOMIDATE, ETOMIDATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RIFAMPIN, RIFAMPIN
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO

* EMD SERONO INC
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 OVIDREL, CHORIOGONADOTROPIN ALFA
 SAIZEN, SOMATROPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EMD SERONO INC
 SEROSTIM, SOMATROPIN
 ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC

* EMD SERONO INC
 CETROTIDE, CETRORELIX
 MAVENCLAD, CLADRIBINE

EMERALD INTL LTD

* EMERALD INTERNATIONAL LTD
 BACLOFEN, BACLOFEN

EMMAUS MEDCL

* EMMAUS MEDICAL INC
 ENDARI, L-GLUTAMINE

ENCORE DERMAT

* ENCORE DERMATOLOGY INC
 IMPOYZ, CLOBETASOL PROPIONATE
 SERNIVO, BETAMETHASONE DIPROPIONATE

ENCUBE

* ENCUBE ETHICALS PRIVATE LTD
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESONIDE, DESONIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 PERMETHRIN, PERMETHRIN

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
 SUPPRELIN LA, HISTRELIN ACETATE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
 FORTESTA, TESTOSTERONE
 FROVA, FROVATRIPTAN SUCCINATE
 PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
 AVEED, TESTOSTERONE UNDECANOATE
 COLY-MYCIN S, COLISTIN SULFATE
 MEGACE ES, MEGESTROL ACETATE
 NASCOBAL, CYANOCOBALAMIN
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

EPI HLTH

* EPI HEALTH LLC
 CLODERM, CLOCORTOLONE PIVALATE
 MINOLIRA, MINOCYCLINE HYDROCHLORIDE
 RHOFAD, OXYMETAZOLINE HYDROCHLORIDE
 SITAVIG, ACYCLOVIR

EPIC PHARMA

* EPIC PHARMA INC
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 SULINDAC, SULINDAC
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EPIC PHARMA INC
 ESTRADIOL, ESTRADIOL
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 GABAPENTIN, GABAPENTIN
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE, GLYBURIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

ESPERO

* ESPERO BIOPHARMA INC
 DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON PHARMS

* ETON PHARMACEUTICALS
 BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE

EUGIA PHARMA

* EUGIA PHARMA SPECIALITIES LTD
 CAPECITABINE, CAPECITABINE
 CARBOPLATIN, CARBOPLATIN
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN
 PROGESTERONE, PROGESTERONE

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
 DROPERIDOL, DROPERIDOL
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EVUS

* EVUS HEALTH SOLUTIONS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EVUS HEALTH SOLUTIONS LLC
NITROMIST, NITROGLYCERIN

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
CAFFEINE CITRATE, CAFFEINE CITRATE
ELCYS, CYSTEINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GANZYK-RTU, GANCICLOVIR
GLYRX-PF, GLYCOPYRROLATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

* EXELTIS USA INC
SLYND, DROSPIRENONE

EYEPOINT PHARMS

* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE
YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE

* EYEVANCE PHARMACEUTICALS LLC
FLAREX, FLUOROMETHOLONE ACETATE
ZERVIAE, CETIRIZINE HYDROCHLORIDE

EYWA

* EYWA PHARMA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

EYWA PHARMA

* EYWA PHARMA PTE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
BACLOFEN, BACLOFEN
URSODIOL, URSODIOL

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG TEMPO PEN, INSULIN LISPRO RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELI LILLY AND CO
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 ZYPREXA ZYDIS, OLANZAPINE
 ZYPREXA, OLANZAPINE

**** F ******FDC LTD**

* FDC LTD
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 LATANOPROST, LATANOPROST
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

* FOUNDATION CONSUMER HEALTHCARE LLC
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 FLUORODOPA F18, FLUORODOPA F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
 TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
 DEXAMETHASONE, DEXAMETHASONE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE

FERRER INTERNACIONAL

* FERRER INTERNACIONAL SA
 XEPI, OZENOXACIN

FERRING

* FERRING PHARMACEUTICALS INC
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 ENDOMETRIN, PROGESTERONE
 FIRMAGON, DEGARELIX ACETATE
 MENOPUR, MENOTROPINS (FSH)
 MINIRIN, DESMOPRESSIN ACETATE
 ZOMACTON, SOMATROPIN

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
 CERVIDIL, DINOPROSTONE
 CLENPIQ, CITRIC ACID
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DDAVP, DESMOPRESSIN ACETATE
 LYSTEDA, TRANEXAMIC ACID
 NOCDURNA, DESMOPRESSIN ACETATE
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

FLAMINGO PHARMS

* FLAMINGO PHARMACEUTICALS LTD
 METRONIDAZOLE, METRONIDAZOLE
 PIROXICAM, PIROXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******FLEXION THERAPS INC**

* FLEXION THERAPEUTICS INC
ZILRETTA, TRIAMCINOLONE ACETONIDE

FOAMIX

* FOAMIX PHARMACEUTICALS INC
AMZEEQ, MINOCYCLINE HYDROCHLORIDE

FOLDRX PHARMS

* FOLDRX PHARMACEUTICALS INC SUB PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FOREST LABS LLC

* FOREST LABORATORIES LLC
NAMENDA XR, MEMANTINE HYDROCHLORIDE

FORTOVIA

* FORTOVIA THERAPEUTICS INC
ORAVIG, MICONAZOLE
SOLTAMOX, TAMOXIFEN CITRATE

FOSUN PHARMA

* FOSUN PHARMA USA INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PANDEL, HYDROCORTISONE PROBUTATE
PREDNICARBATE, PREDNICARBATE
SOLARAZE, DICLOFENAC SODIUM
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FOUGERA PHARMACEUTICALS INC
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 TACROLIMUS, TACROLIMUS
 TERCONAZOLE, TERCONAZOLE
 VEREGEN, SINECATECHINS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

* FRESENIUS KABI IPSUM SRL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 ARGATROBAN, ARGATROBAN
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACITRACIN, BACITRACIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BORTEZOMIB, BORTEZOMIB
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM GLUCONATE, CALCIUM GLUCONATE
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CEFOTETAN, CEFOTETAN DISODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAPTOMYCIN, DAPTOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FULVESTRANT, FULVESTRANT
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

**** G ******G AND W LABS INC**

* G AND W LABORATORIES INC
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
 CLOBEX, CLOBETASOL PROPIONATE
 EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
 CLOBEX, CLOBETASOL PROPIONATE
 * GALDERMA LABORATORIES LP
 CAPEX, FLUOCINOLONE ACETONIDE
 CLOBEX, CLOBETASOL PROPIONATE
 DESOWEN, DESONIDE
 DIFFERIN, ADAPALENE
 DIFFERIN, ADAPALENE (OTC)
 EPIDUO, ADAPALENE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 MIRVASO, BRIMONIDINE TARTRATE
 ORACEA, DOXYCYCLINE
 SOOLANTRA, IVERMECTIN
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 VECTICAL, CALCITRIOL

GALDERMA R AND D

* GALDERMA RESEARCH AND DEVELOPMENT INC
 AKLIEF, TRIFAROTENE

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
 SYNERA, LIDOCAINE

GALT PHARMS

* GALT PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM

GATE PHARMS

* GATE PHARMACEUTICALS
LINEZOLID, LINEZOLID

GD SEARLE

* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CYTOTEC, MISOPROSTOL
FLAGYL, METRONIDAZOLE
INSPIRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GENBIOPRO

* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENENTECH

* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ NUSPIN, SOMATROPIN

GENENTECH INC

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENERICS

* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS

* GENEYORK PHARMACEUTICALS GROUP LLC
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******GENUS**

* GENUS LIFESCIENCES INC
 HYCODAN, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 TIVORBEX, INDOMETHACIN

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
 GOPRELTO, COCAINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 YOSPRALA, ASPIRIN

GENZYME

* GENZYME CORP
 CEREZYME, IMIGLUCERASE
 CLOLAR, CLOFARABINE
 MOZOBIL, PLERIXAFOR
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENVELA, SEVELAMER CARBONATE
 THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORP
 CAPRELSA, VANDETANIB
 CERDELGA, ELIGLUSTAT TARTRATE

GILEAD

* GILEAD SCIENCES INC
 CAYSTON, AZTREONAM
 EMTRIVA, EMTRICITABINE
 HEPSERA, ADEFOVIR DIPIVOXIL
 LETAIRIS, AMBRISENTAN
 RANEXA, RANOLAZINE
 TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
 ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
 BIKTARVY, BICTEGRAVIR SODIUM
 COMPLERA, EMTRICITABINE
 DESCOVY, EMTRICITABINE
 EPCLUSA, SOFOSBUVIR
 GENVOYA, COBICISTAT
 HARVONI, LEDIPASVIR
 ODEFSEY, EMTRICITABINE
 SOVALDI, SOFOSBUVIR
 STRIBILD, COBICISTAT
 TYBOST, COBICISTAT
 VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VOSEVI, SOFOSBUVIR
 ZYDELIG, IDELALISIB

GISKIT

* GISKIT BV
 EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND PHARMA LTD

* GLAND PHARMA LTD
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 AZITHROMYCIN, AZITHROMYCIN
 BIMATOPROST, BIMATOPROST
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CISPLATIN, CISPLATIN
 CLOFARABINE, CLOFARABINE
 CYTARABINE, CYTARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLAND PHARMA LTD**

DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 FLUOROURACIL, FLUOROURACIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACITAXEL, PACITAXEL
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS*** GLASSHOUSE PHARMACEUTICALS LTD CANADA**

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE

GLAXO GRP ENGLAND*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**

INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD*** GLAXO GROUP LTD DBA GLAXOSMITHKLINE**

FLOVENT HFA, FLUTICASONE PROPIONATE

*** GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE**

ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 BREO ELLIPTA, FLUTICASONE FUROATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE*** GLAXOSMITHKLINE**

ABREVA, DOCOSANOL (OTC)
 AVODART, DUTASTERIDE
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 EPIVIR-HBV, LAMIVUDINE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLAXOSMITHKLINE
 - IMITREX, SUMATRIPTAN
 - IMITREX, SUMATRIPTAN SUCCINATE
 - JALYN, DUTASTERIDE
 - MALARONE PEDIATRIC, ATOVAQUONE
 - MALARONE, ATOVAQUONE
 - NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)
 - RELENZA, ZANAMIVIR
 - VALTREX, VALACYCLOVIR HYDROCHLORIDE
 - WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
- * GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
 - ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 - ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 - ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 - ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 - ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 - ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 - ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
 - ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 - ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 - ADVIL, IBUPROFEN (OTC)
 - ADVIL, IBUPROFEN SODIUM (OTC)
 - ALAVERT, LORATADINE (OTC)
 - AXID AR, NIZATIDINE (OTC)
 - CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 - CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 - CHILDREN'S ADVIL, IBUPROFEN (OTC)
 - CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 - INFANT'S ADVIL, IBUPROFEN (OTC)
 - JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
 - LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
 - LORATADINE, LORATADINE (OTC)
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
 - ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 - ARNUITY ELLIPTA, FLUTICASONE FUROATE
 - KRINTAFEL, TAFENOQUINE SUCCINATE
 - TRELEGY ELLIPTA, FLUTICASONE FUROATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
 - SEREVENT, SALMETEROL XINAFOATE
 - VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

- * GLAXOSMITHKLINE CONSUMER HEALTH
 - TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE
 - ALLI, ORLISTAT (OTC)
 - EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 - FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
 - FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
 - LAMISIL AT, TERBINAFINE (OTC)
 - LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)
 - VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

- * GLAXOSMITHKLINE LLC
 - AMERGE, NARATRIPTAN HYDROCHLORIDE
 - DYAZIDE, HYDROCHLOROTHIAZIDE
 - FLOLAN, EPOPROSTENOL SODIUM
 - LAMICTAL CD, LAMOTRIGINE
 - LAMICTAL ODT, LAMOTRIGINE
 - LAMICTAL XR, LAMOTRIGINE
 - LAMICTAL, LAMOTRIGINE
 - MEPRON, ATOVAQUONE
 - REQUIP XL, ROPINIROLE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLAXOSMITHKLINE LLC
 REQUIP, ROPINIROLE HYDROCHLORIDE
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK

* GLENMARK THERAPEUTICS INC USA
 ECOZA, ECONAZOLE NITRATE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
 ADAPALENE, ADAPALENE
 ADAPALENE, ADAPALENE (OTC)
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 IMIQUIMOD, IMIQUIMOD
 MOMETASONE FUROATE, MOMETASONE FUROATE
 NIZATIDINE, NIZATIDINE
 ZONISAMIDE, ZONISAMIDE

* GLENMARK GENERICS LIMITED
 BRIELLYN, ETHINYL ESTRADIOL
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* GLENMARK GENERICS LTD
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ASHLYNA, ETHINYL ESTRADIOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 CARVEDILOL, CARVEDILOL
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESOXIMETASONE, DESOXIMETASONE
 ESZOPICLONE, ESZOPICLONE
 FELODIPINE, FELODIPINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCINONIDE, FLUCINONIDE
 HEATHER, NORETHINDRONE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MARLISSA, ETHINYL ESTRADIOL
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN, NAPROXEN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VIORELE, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK GENERICS LTD
ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

- * GLENMARK PHARMACEUTICALS INC
TERIFLUNOMIDE, TERIFLUNOMIDE
- * GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- * GLENMARK PHARMACEUTICALS SA
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATOVAQUONE, ATOVAQUONE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC

- * GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
FULVESTRANT, FULVESTRANT
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GLENMARK PHARMS LTD

- * GLENMARK PHARMACEUTICALS LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUCINOLONE ACETONIDE, FLUCINOLONE ACETONIDE
FLUCINONIDE ACETONIDE, FLUCINOLONE ACETONIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS LTD
 LIDOCAINE, LIDOCAINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXCARBAZEPINE, OXCARBAZEPINE
 PIMECROLIMUS, PIMECROLIMUS
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 RUFINAMIDE, RUFINAMIDE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 TACROLIMUS, TACROLIMUS
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA

* GLENMARK PHARMACEUTICALS SA SWITZERLAND
 ACYCLOVIR, ACYCLOVIR
 APREPITANT, APREPITANT
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 NITROGLYCERIN, NITROGLYCERIN

GLOBAL BLOOD THERAPYS

* GLOBAL BLOOD THERAPEUTICS INC
 OXBRYTA, VOXELOTOR

GRANULES INDIA

* GRANULES INDIA LTD
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD

* GRANULES INDIA LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

GRANULES PHARMS

* GRANULES PHARMACEUTICALS INC
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS PRIVATE LTD
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE

GUARDIAN DRUG

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GUARDIAN DRUG CO
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)

GUERBET

* GUERBET LLC
 DOTAREM, GADOTERATE MEGLUMINE
 LIPIODOL, ETHIODIZED OIL

GW RES LTD

* GW RESEARCH LTD
 EPIDIOLEX, CANNABIDIOL

HANFORD GC

* GC HANFORD MANUFACTURING CO
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP

* G POHL BOSKAMP GMBH AND CO KG
 GONITRO, NITROGLYCERIN

**** H ******HAEMONETICS**

* HAEMONETICS CORP
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY PHARM

* HAINAN POLY PHARMACEUTICAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 EPTIFIBATIDE, EPTIFIBATIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
 ISOFLURANE, ISOFLURANE
 SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

* HALOZYME THERAPEUTICS INC
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS

* HAMELN PHARMA PLUS GMBH
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

HANGZHOU BINJIANG

* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANSAMED INC

* HANSAMED INC
 ULTACAN FORTE, ARTICAINA HYDROCHLORIDE
 ULTACAN, ARTICAINA HYDROCHLORIDE

HARMONY

* HARMONY BIOSCIENCES LLC
 WAKIX, PITOLISANT HYDROCHLORIDE

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
 FLUCONAZOLE, FLUCONAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HBT LABS INC

* HBT LABS INC
 FULVESTRANT, FULVESTRANT

HEBEI CHANGSHAN

* HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

HEC PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HEC PHARM USA INC
 CLARITHROMYCIN, CLARITHROMYCIN
 LEVOFLOXACIN, LEVOFLOXACIN
 PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD

* HEC PHARM CO LTD
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN

* HELSINN BIREX PHARMACEUTICALS LTD
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
 AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
 AKYNZEO, NETUPITANT
 ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
 NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
 CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIFLUNISAL, DIFLUNISAL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 INDOMETHACIN, INDOMETHACIN
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLDOPA, METHYLDOPA
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 NADOLOL, NADOLOL
 NIFEDIPINE, NIFEDIPINE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 CALCIUM ACETATE, CALCIUM ACETATE
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DUTASTERIDE, DUTASTERIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HERITAGE PHARMACEUTICALS INC
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FELODIPINE, FELODIPINE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE, GLYBURIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDOMETHACIN, INDOMETHACIN
 KETOPROFEN, KETOPROFEN
 LEFLUNOMIDE, LEFLUNOMIDE
 METRONIDAZOLE, METRONIDAZOLE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 NYSTATIN, NYSTATIN
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
 CINVANTI, APREPITANT
 SUSTOL, GRANISETRON

HETERO LABS LTD

* HETERO LABS LTD
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ATOVAQUONE, ATOVAQUONE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 OMEPRAZOLE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PREGABALIN, PREGABALIN
 RITONAVIR, RITONAVIR
 ROFLUMILAST, ROFLUMILAST
 SIMVASTATIN, SIMVASTATIN
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
 ACYCLOVIR, ACYCLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HETERO LABS LTD UNIT V
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 FAMCICLOVIR, FAMCICLOVIR
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TETRABENAZINE, TETRABENAZINE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE (II)

HI TECH

* HI-TECH PHARMACAL CO INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BIMATOPROST, BIMATOPROST
 BROMFENAC SODIUM, BROMFENAC SODIUM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 IBUPROFEN, IBUPROFEN
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 TRIFLURIDINE, TRIFLURIDINE

* HI-TECH PHARMACAL CO INC AN AKORN CO
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CICLOPIROX, CICLOPIROX
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CORMAX, CLOBETASOL PROPIONATE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 EMBELINE E, CLOBETASOL PROPIONATE
 EMBELINE, CLOBETASOL PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HI TECH PHARMACAL CO INC
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
 FLUNISOLIDE, FLUNISOLIDE
 PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
 FAMOTIDINE, FAMOTIDINE
 GATIFLOXACIN, GATIFLOXACIN
 LORAZEPAM, LORAZEPAM
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
 LEVETIRACETAM, LEVETIRACETAM

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
 VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
 CEFOTAXIME, CEFOTAXIME SODIUM

* HIKMA FARMACEUTICA PORTUGAL SA
 CEFOTETAN, CEFOTETAN DISODIUM
 CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
 ETOMIDATE, ETOMIDATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE

* HIKMA PHARMACEUTICALS
 AMOXICILLIN, AMOXICILLIN
 CEFACLOR, CEFACLOR
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE

* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
 ATIVAN, LORAZEPAM
 CAFKIT, CAFFEINE CITRATE
 CIMETIDINE, CIMETIDINE
 CODEINE SULFATE, CODEINE SULFATE
 DIGOXIN, DIGOXIN
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 FUROSEMIDE, FUROSEMIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 MORPHINE SULFATE, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
 ROBAXIN, METHOCARBAMOL
 RUFINAMIDE, RUFINAMIDE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

* HIKMA PHARMACEUTICALS LLC
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

* HIKMA PHARMACEUTICALS USA INC
 ACARBOSE, ACARBOSE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BOSENTAN, BOSENTAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOBAZAM, CLOBAZAM
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DALFAMPRIDINE, DALFAMPRIDINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DISULFIRAM, DISULFIRAM
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DUTASTERIDE, DUTASTERIDE
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 EVEROLIMUS, EVEROLIMUS
 EXEMESTANE, EXEMESTANE
 FAMCICLOVIR, FAMCICLOVIR
 FEBUXOSTAT, FEBUXOSTAT
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LACTULOSE, LACTULOSE
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS USA INC
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LORAZEPAM INTENSOL, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROXICET, ACETAMINOPHEN
 RUFINAMIDE, RUFINAMIDE
 SODIUM OXYBATE, SODIUM OXYBATE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TETRABENAZINE, TETRABENAZINE
 TINIDAZOLE, TINIDAZOLE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HIKMA FARMACEUTICA (PORTUGAL) SA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- * HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

- * HIKMA INTERNATIONAL PHARMACEUTICALS LLC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HCLATE, DOXYCYCLINE HCLATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

- * HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

- * HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DICYCLIMINE HYDROCHLORIDE, DICYCLIMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GEMFIBROZIL, GEMFIBROZIL
LETROZOLE, LETROZOLE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
- * HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL
- * HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS LLC
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DOXERCALCIFEROL, DOXERCALCIFEROL
 FOLIC ACID, FOLIC ACID
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 OLANZAPINE, OLANZAPINE
 PIROXICAM, PIROXICAM
 PREDNISONONE, PREDNISONONE
 ZALEPLON, ZALEPLON

HILL DERMAC

* HILL DERMACEUTICALS INC
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
 TOLAK, FLUOROURACIL

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
 SECUADO, ASENAPINE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
 SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
 CLADRIBINE, CLADRIBINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM

* HISUN PHARMACEUTICAL HANGZHOU CO LTD
 CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
 DACTINOMYCIN, DACTINOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 TICAGRELOR, TICAGRELOR

HLTHCARE

* HEALTHCARE PHARMACEUTICALS LTD
 ATENOLOL, ATENOLOL

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 XELODA, CAPECITABINE
 ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
 ALECENSA, ALECTINIB HYDROCHLORIDE
 INVIRASE, SAQUINAVIR MESYLATE

HOPE PHARMS

* HOPE PHARMACEUTICALS
 NITHIODOTE, SODIUM NITRITE
 SODIUM NITRITE, SODIUM NITRITE
 SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON MEDICINES LLC
 DUEXIS, FAMOTIDINE
 VIMOVO, ESOMEPRAZOLE MAGNESIUM

* HORIZON THERAPEUTICS IRELAND DAC
 PENNSAID, DICLOFENAC SODIUM

HORIZON PHARMA USA

* HORIZON PHARMA USA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HORIZON PHARMA USA INC
 PROCYSBI, CYSTEAMINE BITARTRATE
 RAYOS, PREDNISONE

HORIZON THERAP

* HORIZON THERAPEUTICS LLC
 BUPHENYL, SODIUM PHENYLBUTYRATE
 RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 AMIDATE, ETOMIDATE
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
 ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CORLOPAM, FENOLDOPAM MESYLATE
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50%, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA INC

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 25%, MANNITOL
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HOSPIRA INC
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TAZICEF, CEFTAZIDIME
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VITAMIN K1, PHYTONADIONE
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
- * HOSPIRA WORLDWIDE, INC
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NITROPRESS, SODIUM NITROPRUSSIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

- * HOSPIRA INC
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BUSULFAN, BUSULFAN
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 DAPTOMYCIN, DAPTOMYCIN
 DOCETAXEL, DOCETAXEL
 DOXERCALCIFEROL, DOXERCALCIFEROL
 EPINEPHRINE (COPACKAGED), EPINEPHRINE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAXIPIME, CEFEPIME HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIPENT, PENTOSTATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PARICALCITOL, PARICALCITOL
 SODIUM BICARBONATE, SODIUM BICARBONATE
 TACROLIMUS, TACROLIMUS
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

- * HOSPIRA WORLDWIDE PTY
 OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

- * HOT SHOTS NUCLEAR MEDICINE LLC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

- * HQ SPECIALTY PHARMA CORP
 CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
 CISPLATIN, CISPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HQ SPECIALTY PHARMA CORP
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEROPENEM, MEROPENEM

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HRA PHARMA

* HRA PHARMA RARE DISEASES
 LYSODREN, MITOTANE
 METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
 DUTASTERIDE, DUTASTERIDE
 IBUPROFEN, IBUPROFEN (OTC)

HUONS

* HUONS CO LTD
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE

ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 FUZEON, ENFUVIRTIDE
 KLONOPIN, CLONAZEPAM
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 VALIUM, DIAZEPAM

SHUANGCHENG

* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
 BIVALIRUDIN, BIVALIRUDIN
 PREGABALIN, PREGABALIN

**** I ******ICHNOS**

* ICHNOS SCIENCES SA
 DEFERASIROX, DEFERASIROX

ICU MEDICAL INC

* ICU MEDICAL INC
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MORPHINE SULFATE, MORPHINE SULFATE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* ICU MEDICAL INC**

NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDENTI PHARMS INC*** IDENTI PHARMACEUTICALS INC**

FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IDT AUSTRALIA LTD*** IDT AUSTRALIA LTD**

TEMOZOLOMIDE, TEMOZOLOMIDE

IMPACT*** IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP**

INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX*** IMPAX LABORATORIES LLC**

ADRENACLICK, EPINEPHRINE

IMPAX LABS*** IMPAX LABORATORIES INC**

ACARBOSE, ACARBOSE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX LABORATORIES INC
 ACITRETIN, ACITRETIN
 ALBENZA, ALBENDAZOLE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EMVERM, MEBENDAZOLE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RYTARY, CARBIDOPA
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP

* INCYTE CORP
 JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 PERSERIS KIT, RISPERIDONE
 SUBLOCADE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
 ALLOPURINOL, ALLOPURINOL
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 FEBUXOSTAT, FEBUXOSTAT
 GLIMEPIRIDE, GLIMEPIRIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE

INFORLIFE

* INFORLIFE SA
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* INFORLIFE SA**

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC

* INGENUS PHARMACEUTICALS LLC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 CABERGOLINE, CABERGOLINE
 CARBOPLATIN, CARBOPLATIN
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOFARABINE, CLOFARABINE
 DECITABINE, DECITABINE
 DOCETAXEL, DOCETAXEL
 FLUOROURACIL, FLUOROURACIL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 OXALIPLATIN, OXALIPLATIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

INGENUS PHARMS NJ

* INGENUS PHARMACEUTICALS NJ LLC
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

INNOGENIX

* INNOGENIX LLC
 HALOPERIDOL, HALOPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INSMED INC

* INSMED INC
 ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
 FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA (IBSA)
 TIROSINT, LEVOTHYROXINE SODIUM
 TIROSINT-SOL, LEVOTHYROXINE SODIUM

INSYS DEV CO INC

* INSYS DEVELOPMENT CO INC
 SYNDROS, DRONABINOL

INTAS PHARMS USA

* INTAS PHARMACEUTICALS USA
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC

* INTERCEPT PHARMACEUTICALS INC
 OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
 NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC

* INTERGEL PHARMACEUTICALS INC
 DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS

* INTERPHARMA PRAHA AS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTERSECT ENT INC

* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INVAGEN PHARMACEUTICALS INC
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VIGABATRIN, VIGABATRIN
 WARFARIN SODIUM, WARFARIN SODIUM
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

INVATECH

* INVATECH PHARMA SOLUTIONS LLC
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

INVENTIA

* INVENTIA HEALTHCARE LTD
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PALIPERIDONE, PALIPERIDONE
 TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

IONETIX

* IONETIX CORP
 AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD

* IPCA LABORATORIES LTD
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 INCRELEX, MECASERMIN RECOMBINANT
 ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS

* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
 JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISO TEX

* ISO TEX DIAGNOSTICS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

- * ISO TEX DIAGNOSTICS INC
 - JEANATOPE, ALBUMIN IODINATED I-125 SERUM
 - MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

- * ISOTEX DIAGNOSTICS
 - GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

- * ISTITUTO BIOCHIMICO ITALIANO SPA
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - AMPICILLIN SODIUM, AMPICILLIN SODIUM
 - NAFCILLIN SODIUM, NAFCILLIN SODIUM
 - PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 - PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 - PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SPA

- * ITALFARMACO SPA
 - TIGLUTIK KIT, RILUZOLE

IVAX PHARMS

- * IVAX PHARMACEUTICALS INC
 - VALSARTAN, VALSARTAN

IVAX PHARMS INC

- * IVAX PHARMACEUTICALS INC
 - OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS

- * IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 - ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 - BACLOFEN, BACLOFEN
 - CABERGOLINE, CABERGOLINE
 - CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 - CIMETIDINE, CIMETIDINE (OTC)
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CLOZAPINE, CLOZAPINE
 - CYCLOSPORINE, CYCLOSPORINE
 - DIAZEPAM, DIAZEPAM
 - ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 - FAMOTIDINE, FAMOTIDINE
 - FLUCONAZOLE, FLUCONAZOLE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - GABAPENTIN, GABAPENTIN
 - HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - OXAPROZIN, OXAPROZIN
 - TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******J AND J CONSUMER INC**

- * JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
 - CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 - CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 - CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 - IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 - JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 - MOTRIN IB, IBUPROFEN (OTC)
 - PEPCID AC, FAMOTIDINE (OTC)
 - PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 - SINE-AID IB, IBUPROFEN (OTC)
 - SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - TYLENOL, ACETAMINOPHEN (OTC)
 - ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

- * JACOBUS PHARMACEUTICAL CO
 - DAPSONE, DAPSONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JACOBUS PHARMACEUTICAL CO
PASER, AMINOSALICYLIC ACID

JACOBUS PHARM CO INC

* JACOBUS PHARMACEUTICAL CO INC
RUZURGI, AMIFAMPRIDINE

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
BALVERSA, ERDAFITINIB
ERLEADA, APALUTAMIDE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
NIZORAL, KETOCONAZOLE
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ

* JAZZ PHARMACEUTICALS IRELAND LTD
SUNOSI, SOLRIAMFETOL

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JDP

* JDP THERAPEUTICS LLC
QUZYTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GABAPENTIN, GABAPENTIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
THIOTEPA, THIOTEPA

JIANGXI BOYA SEEHOT

* JIANGXI BOYA SEEHOT PHARMACEUTICAL CO LTD
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
EXELDERM, SULCONAZOLE NITRATE

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JUBILANT DRAXIMAGE INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131
- * JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

- * JUBILANT GENERICS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

- * JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

- * KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

- * KADMON PHARMACEUTICALS LLC
CLOVIQUE, TRIENTINE HYDROCHLORIDE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

KAI PHARMS INC

- * KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALA PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KALA PHARMACEUTICALS INC
INVELTYS, LOTEPREDNOL ETABONATE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE
EVZIO (AUTOINJECTOR), NALOXONE HYDROCHLORIDE

KARYOPHARM THERAPS

* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KING PHARMS

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
TUSSIGON, HOMATROPINE METHYLBROMIDE
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
TAPAZOLE, METHIMAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KRAMER

* KRAMER LABORATORIES INC
NIZORAL A-D, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KVK TECH INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
APADAZ, ACETAMINOPHEN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
NOURIANZ, ISTRADefylline
SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ******L PERRIGO CO**

* L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMAStINE FUMARATE, CLEMAStINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA

* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC

* LANNETT CO INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT CO INC
 BACLOFEN, BACLOFEN
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CODEINE SULFATE, CODEINE SULFATE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DANAZOL, DANAZOL
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HCLATE, DOXYCYCLINE HCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DRONABINOL, DRONABINOL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE
 LAMIVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METAXALONE, METAXALONE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONOKET, ISOSORBIDE MONONITRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NYSTATIN, NYSTATIN
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE, PREDNISOLONE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT CO INC
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN, SUMATRIPTAN
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THEOPHYLLINE, THEOPHYLLINE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 URSODIOL, URSODIOL
 VALPROIC ACID, VALPROIC ACID
 ZAROXOLYN, METOLAZONE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
 DEFINITY, PERFLUTREN
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LARKEN LABS INC

* LARKEN LABORATORIES INC
 ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
 ALLZITAL, ACETAMINOPHEN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 DEXAMETHASONE, DEXAMETHASONE

LAURUS LABS LTD

* LAURUS LABS LTD
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
 ABELCET, AMPHOTERICIN B
 CARNITOR SF, LEVOCARNITINE
 CARNITOR, LEVOCARNITINE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC

* LEADING PHARMA LLC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 NIFEDIPINE, NIFEDIPINE

LEO LABS

* LEO LABORATORIES LTD
 PICATO, INGENOL MEBUTATE

LEO PHARMA AS

* LEO PHARMA AS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LEO PHARMA AS**

DESONATE, DESONIDE
 DOVONEX, CALCIPOTRIENE
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 FINACEA, AZELAIC ACID
 PROTOPIC, TACROLIMUS
 TACLONEX, BETAMETHASONE DIPROPIONATE

LEXICON PHARMS INC

* LEXICON PHARMACEUTICALS INC
 XERMELO, TELOTTRISTAT ETIPRATE

LG CHEM LTD

* LG CHEM LTD
 FACTIVE, GEMIFLOXACIN MESYLATE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
 CONRAY, IOTHALAMATE MEGLUMINE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 OPTIRAY 240, IOVERSOL
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR

* LIFE MOLECULAR IMAGING SA
 NEURACEQ, FLORBETABEN F-18

LIFEPHARMA

* LIFEPHARMA FZE
 LACTULOSE, LACTULOSE

LNK

* LNK INTERNATIONAL INC
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC

* LNK INTERNATIONAL INC
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
 ANTHELIOS 20, AVOBENZONE (OTC)
 ANTHELIOS 40, AVOBENZONE (OTC)
 ANTHELIOS SX, AVOBENZONE (OTC)
 CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
 LEVETIRACETAM, LEVETIRACETAM
 * LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
 CALCIUM ACETATE, CALCIUM ACETATE
 LEVETIRACETAM, LEVETIRACETAM

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BUSULFAN, BUSULFAN
 CAFFEINE CITRATE, CAFFEINE CITRATE
 DROPERIDOL, DROPERIDOL
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 NITROGLYCERIN, NITROGLYCERIN
 TRANEXAMIC ACID, TRANEXAMIC ACID

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUPIN

* LUPIN INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
SOLOSEC, SECNIDAZOLE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFdinIR
CEFPROZIL, CEFPROZIL
CEFTRIAZONE, CEFTRIAZONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINAPRIL, LISINAPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUPIN LTD
 BIMATOPROST, BIMATOPROST
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CELECOXIB, CELECOXIB
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DAYSEE, ETHINYL ESTRADIOL
 DECITABINE, DECITABINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAYOSIM, ETHINYL ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FYAVOLV, ETHINYL ESTRADIOL
 GATIFLOXACIN, GATIFLOXACIN
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KAITLIB FE, ETHINYL ESTRADIOL
 KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NIACIN, NIACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

NIKKI, DROSPIRENONE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RIFABUTIN, RIFABUTIN
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SUPRAX, CEFIXIME
 TADALAFIL, TADALAFIL
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TESTOSTERONE, TESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TYDEMY, DROSPIRENONE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZILEUTON, ZILEUTON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS*** LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL*** LYMOL MEDICAL CORP**

SCLEROSOL, TALC
 TALC, TALC

LYNE*** LYNE LABORATORIES INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LEVOCARNITINE, LEVOCARNITINE
 NYSTATIN, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO*** L PERRIGO CO**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* L PERRIGO CO**

DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TAB-PROFEN, IBUPROFEN (OTC)
 TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP**

* MASSACHUSETTS GENERAL HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CELECOXIB, CELECOXIB
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FAMCICLOVIR, FAMCICLOVIR
 FLUOCINONIDE, FLUOCINONIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MACLEODS PHARMACEUTICALS LTD**

TADALAFIL, TADALAFIL
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC*** MAIA PHARMACEUTICALS INC**

ANGIOMAX RTU, BIVALIRUDIN
 BACLOFEN, BACLOFEN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE*** MAINPOINTE PHARMACEUTICALS LLC**

TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD*** MALLINCKRODT ARD INC**

H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP*** MALLINCKRODT HOSP PRODUCTS IP LTD**

INOMAX, NITRIC OXIDE
 OFIRMEV, ACETAMINOPHEN
 UVADEX, METHOXSALEN

MALLINCKRODT NUCLEAR*** MALLINCKRODT NUCLEAR MEDICINE LLC**

SODIUM IODIDE I 123, SODIUM IODIDE I-123
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

MANKIND*** MANKIND CORP**

AFREZZA, INSULIN RECOMBINANT HUMAN

MARKSANS PHARMA*** MARKSANS PHARMA LTD**

CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 PARICALCITOL, PARICALCITOL

MARNEL PHARMS*** MARNEL PHARMACEUTICALS LLC**

ALA-SCALP, HYDROCORTISONE
 CROTAN, CROTAMITON

MAYER LABS INC*** MAYER LABORATORIES INC**

TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA*** MAYNE PHARMA INTERNATIONAL PTY LTD**

DORYX MPC, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MAYNE PHARMA INTERNATIONAL PTY LTD
 DORYX, DOXYCYCLINE HYCLATE
 ERYC, ERYTHROMYCIN

* MAYNE PHARMA LLC
 BUDESONIDE, BUDESONIDE
 CAMILA, NORETHINDRONE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLARITHROMYCIN, CLARITHROMYCIN
 CLONIDINE, CLONIDINE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ERRIN, NORETHINDRONE
 ESTAZOLAM, ESTAZOLAM
 ESTRADIOL, ESTRADIOL
 FABIOR, TAZAROTENE
 FLUOROURACIL, FLUOROURACIL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEXETTE, HALOBETASOL PROPIONATE
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 SORILUX, CALCIPOTRIENE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TOLCAPONE, TOLCAPONE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIVORA-28, ETHINYL ESTRADIOL
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DOFETILIDE, DOFETILIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 EXEMESTANE, EXEMESTANE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MAYNE PHARMA INTL

* MAYNE PHARMA INTERNATIONAL PTY LTD
 TOLSURA, ITRACONAZOLE

MCGUFF

* MCGUFF PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDGH

* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC

* MEDEFIL INC
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS

* MEDEXUS PHARMA INC
RASUVO, METHOTREXATE

MEDICINES360

* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
AMMONUL, SODIUM BENZOATE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
LUZU, LULICONAZOLE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE

MEDICURE

* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES

* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEITHEAL

* MEITHEAL PHARMACEUTICALS INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEITHEAL PHARMACEUTICALS INC
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CARBOPLATIN, CARBOPLATIN
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CYTARABINE, CYTARABINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

MELINTA

* MELINTA SUBSIDIARY CORP
 BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP

* MELINTA THERAPEUTICS INC
 ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
 CANCIDAS, CASPOFUNGIN ACETATE
 EMEND, APREPITANT
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 PRIMAXIN, CILASTATIN SODIUM
 PROSCAR, FINASTERIDE
 ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
 PRINIVIL, LISINAPRIL
 PROPECIA, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC

* MERCK AND CO INC
 EMEND, FOSAPREPITANT DIMEGLUMINE
 FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
 ASMANEX HFA, MOMETASONE FUROATE
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 BELSOMRA, SUVOREXANT
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 COZAAR, LOSARTAN POTASSIUM
 CRIXIVAN, INDINAVIR SULFATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS HD, RALTEGRAVIR POTASSIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NASONEX, MOMETASONE FUROATE
 NOXAFIL, POSACONAZOLE
 PREVMIS, LETERMOVIR
 REBETOL, RIBAVIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP
 SEGLUROMET, ERTUGLIFLOZIN
 SINEMET CR, CARBIDOPA
 SINEMET, CARBIDOPA
 STEGLATRO, ERTUGLIFLOZIN
 STEGLUJAN, ERTUGLIFLOZIN
 STROMEKTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 ZEPATIER, ELBASVIR

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
 SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MERRO PHARM

* MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC

* METACEL PHARMACEUTICALS LLC
 OZOBAX, BACLOFEN

METHAPHARM

* METHAPHARM INC
 PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
 STENDRA, AVANAFIL

MICRO LABS

* MICRO LABS LTD
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 APIXABAN, APIXABAN
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CELECOXIB, CELECOXIB
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DALFAMPRIDINE, DALFAMPRIDINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PIROXICAM, PIROXICAM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROFLUMILAST, ROFLUMILAST
 SIMVASTATIN, SIMVASTATIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TAFLUPROST, TAFLUPROST
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
 NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MICRO LABS LTD INDIA**

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US

* MIDATECH PHARMA US INC
 ZUPLENZ, ONDANSETRON

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
 AMMONIA N 13, AMMONIA N-13
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

* MIKART LLC
 BENZONATATE, BENZONATATE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTAPAP, ACETAMINOPHEN
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 CHLORZOXAZONE, CHLORZOXAZONE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 METHAZOLAMIDE, METHAZOLAMIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
 NINLARO, IXAZOMIB CITRATE
 VELCADE, BORTEZOMIB

MILLICENT

* MILLICENT HOLDINGS LTD
 FEMRING, ESTRADIOL ACETATE

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA

* MISSION PHARMACAL CO
 LITHOSTAT, ACETOHYDROXAMIC ACID
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TEXACORT, HYDROCORTISONE
 THIOLA, TIOPRONIN
 TINDAMAX, TINIDAZOLE
 UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 THIOLA EC, TIOPRONIN

mitsubishi tanabe

* MITSUBISHI TANABE PHARMA CORP
 RADICAVA, EDARAVONE

MLV

* MLV PHARMA LLC
 ACETIC ACID, ACETIC ACID, GLACIAL
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MOBIUS THERAP**

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM
SINGULAIR, MONTELUKAST SODIUM
ZOCOR, SIMVASTATIN

MSN

* MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CAPECITABINE, CAPECITABINE
CLOFARABINE, CLOFARABINE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
FEBUXOSTAT, FEBUXOSTAT
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC

* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MYLAN**

* MYLAN PHARMACEUTICALS
 FENOFIBRATE, FENOFIBRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

* MYLAN PHARMACEUTICALS INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACITRETIN, ACITRETIN
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPRAZOLAM, ALPRAZOLAM
 AMBRISENTAN, AMBRISENTAN
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 APIXABAN, APIXABAN
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 AVITA, TRETINOIN
 AZATHIOPRINE, AZATHIOPRINE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
 BICALUTAMIDE, BICALUTAMIDE
 BOSENTAN, BOSENTAN
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CABERGOLINE, CABERGOLINE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CAPECITABINE, CAPECITABINE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CIMETIDINE, CIMETIDINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOZAPINE, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
COLCHICINE, COLCHICINE
CYSTAGON, CYSTEAMINE BITARTRATE
DENA VIR, PENCICLOVIR
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
EFAVIRENZ, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIMITE, PERMETHRIN
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETOPOSIDE, ETOPOSIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXEMESTANE, EXEMESTANE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LUXIQ, BETAMETHASONE VALERATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NEVIRAPINE, NEVIRAPINE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLUX E, CLOBETASOL PROPIONATE
 OLUX, CLOBETASOL PROPIONATE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PALIPERIDONE, PALIPERIDONE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENYTEK, PHENYTOIN SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 PREDNISONE, PREDNISONE
 PREGABALIN, PREGABALIN
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULINDAC, SULINDAC
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYMFI LO, EFAVIRENZ
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TETRABENAZINE, TETRABENAZINE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAVOPROST, TRAVOPROST
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 URSODIOL, URSODIOL
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VUSION, MICONAZOLE NITRATE
 WIXELA INHUB, FLUTICASONE PROPIONATE
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONALON, DOXEPIN HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR

MYLAN ASI

* MYLAN ASI LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 AZITHROMYCIN, AZITHROMYCIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN ASI LLC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
MYLERAN, BUSULFAN
SULFAMYLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
FULVESTRANT, FULVESTRANT
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
MIACALCIN, CALCITONIN SALMON
PRETOMANID, PRETOMANID
YUPELRI, REVEFENACIN

MYLAN LABS

* MYLAN LABORATORIES LTD
NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMIFOSTINE, AMIFOSTINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BUSULFAN, BUSULFAN
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CIMDUO, LAMIVUDINE
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN LABORATORIES LTD
 CYTARABINE, CYTARABINE
 DACTINOMYCIN, DACTINOMYCIN
 DAPTOMYCIN, DAPTOMYCIN
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DOCETAXEL, DOCETAXEL
 DOCETAXEL, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LAMIVUDINE, LAMIVUDINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MITOMYCIN, MITOMYCIN
 MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PARICALCITOL, PARICALCITOL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN LABORATORIES LTD

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SYMFI, EFAVIRENZ
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 AMNESTEEM, ISOTRETINOIN
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AVITA, TRETINOIN
 BACLOFEN, BACLOFEN
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 ESZOPICLONE, ESZOPICLONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ITRACONAZOLE, ITRACONAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 NABUMETONE, NABUMETONE
 NEVIRAPINE, NEVIRAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYTOIN, PHENYTOIN
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLAZAMIDE, TOLAZAMIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VORICONAZOLE, VORICONAZOLE
 ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC.
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 NIZATIDINE, NIZATIDINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
 ACCUNEB, ALBUTEROL SULFATE
 ANADROL-50, OXYMETHOLONE
 ASTELIN, AZELASTINE HYDROCHLORIDE
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 AVC, SULFANILAMIDE
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 CESAMET, NABILONE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 CORTIFOAM, HYDROCORTISONE ACETATE
 DEMADEX, TORSEMIDE
 DEPEN, PENICILLAMINE
 DIPENTUM, OLSALAZINE SODIUM
 DYMISTA, AZELASTINE HYDROCHLORIDE
 EDLUAR, ZOLPIDEM TARTRATE
 ELESTRIN, ESTRADIOL
 EPIFOAM, HYDROCORTISONE ACETATE
 EPIPEN JR., EPINEPHRINE
 EPIPEN, EPINEPHRINE
 FELBATOL, FELBAMATE
 GASTROCROM, CROMOLYN SODIUM
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 MUSE, ALPROSTADIL
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 ROWASA, MESALAMINE
 SFROWASA, MESALAMINE
 SOMA, CARISOPRODOL
 TOBI PODHALER, TOBRAMYCIN
 TOBI, TOBRAMYCIN

MYLAN SPECTL

* MYLAN SPECIALTY LP
 PERFORMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CLONIDINE, CLONIDINE
 ESTRADIOL, ESTRADIOL
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 RIVASTIGMINE, RIVASTIGMINE
 SCOPOLAMINE, SCOPOLAMINE
 XULANE, ETHINYL ESTRADIOL

**** N ******NAARI PTE LTD**

* NAARI PTE LTD
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

* NABRIVA THERAPEUTICS IRELAND DAC
 XENLETA, LEFAMULIN ACETATE

NALPROPION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NALPROPION PHARMACEUTICALS INC
CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
LINEZOLID, LINEZOLID

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO PHARMA

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
BOSENTAN, BOSENTAN
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOPHARMA

* NEOPHARMA INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMOXIL, AMOXICILLIN
ANASTROZOLE, ANASTROZOLE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
IRBESARTAN, IRBESARTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NEOPHARMA INC**

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAROTID, AMOXICILLIN
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

NEOS THERAP INC

* NEOS THERAPEUTICS INC
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS

* NEOS THERAPEUTICS
 ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC

* NEOS THERAPEUTICS INC
 ADZENYS ER, AMPHETAMINE
 COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON

* NEPHRON CORP
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

* NEPHRON PHARMACEUTICALS CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BUDESONIDE, BUDESONIDE

NESHER PHARMS

* NESHER PHARMACEUTICALS USA LLC
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 MICRO-K 10, POTASSIUM CHLORIDE
 MICRO-K, POTASSIUM CHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEUROCRINE

* NEUROCRINE BIOSCIENCES INC
 INGREZZA, VALBENZAZINE TOSYLATE

NEXGEN PHARMA

* NEXGEN PHARMA INC
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHENODIOL, CHENODIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

* NEXGEN PHARMA INC
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 NABUMETONE, NABUMETONE

NEXTWAVE

* NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS

* NEXTWAVE PHARMACEUTICALS INC
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS

* NEXUS PHARMACEUTICALS INC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 BUSULFAN, BUSULFAN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NEXUS PHARMACEUTICALS INC
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
 PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA

* NODEN PHARMA DAC
 TEKTRUNA HCT, ALISKIREN HEMIFUMARATE
 TEKTRUNA, ALISKIREN HEMIFUMARATE

NORATECH

* NORATECH PHARMACEUTICALS INC
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

* NORTHLAND NUCLEAR MEDICINE LLC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
 ALLOPURINOL, ALLOPURINOL
 BACLOFEN, BACLOFEN
 GEMFIBROZIL, GEMFIBROZIL
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

* NORTHSTAR MEDICAL RADIOISOTOPES LLC
 RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

* NORTON WATERFORD LTD
 QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

* NOSTRUM LABORATORIES INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CARISOPRODOL, CARISOPRODOL
 CLARITHROMYCIN, CLARITHROMYCIN
 DAPSONE, DAPSONE
 ELIXOPHYLLIN, THEOPHYLLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NITROFURANTOIN, NITROFURANTOIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 THEOCHRON, THEOPHYLLINE

NOVA LABS LTD

* NOVA LABORATORIES LTD
 PURIXAN, MERCAPTOPYRINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******NOVADAQ TECH**

* NOVADAQ TECHNOLOGIES ULC
 SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
 AFINITOR, EVEROLIMUS
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ARGATROBAN, ARGATROBAN
 ARRANON, NELARABINE
 AZOPT, BRINZOLAMIDE
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 COARTEM, ARTEMETHER
 DESFERAL, DEFEROXAMINE MESYLATE
 DIOVAN HCT, HYDROCHLOROTHIAZIDE
 DIOVAN, VALSARTAN
 DUREZOL, DIFLUPREDNATE
 EGATEN, TRICLABENDAZOLE
 EXELON, RIVASTIGMINE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXFORGE, AMLODIPINE BESYLATE
 EXJADE, DEFERASIROX
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 GILENYA, FINGOLIMOD HYDROCHLORIDE
 GLEEVEC, IMATINIB MESYLATE
 HYCANTIN, TOPOTECAN HYDROCHLORIDE
 ILEVRO, NEPAFENAC
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 JADENU SPRINKLE, DEFERASIROX
 KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
 KISQALI, RIBOCICLIB SUCCINATE
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LESCOL XL, FLUVASTATIN SODIUM
 LOTREL, AMLODIPINE BESYLATE
 MAXIDEX, DEXAMETHASONE
 MAXITROL, DEXAMETHASONE
 MAYZENT, SIPONIMOD FUMARIC ACID
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
 MYDRIACYL, TROPICAMIDE
 MYFORTIC, MYCOPHENOLIC ACID
 NATACYN, NATAMYCIN
 NEORAL, CYCLOSPORINE
 NEVANAC, NEPAFENAC
 OMNIPRED, PREDNISOLONE ACETATE
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAZEO, OLOPATADINE HYDROCHLORIDE
 PIQRAY, ALPELISIB
 PROMACTA KIT, ELTROMBOPAG OLAMINE
 PROMACTA, ELTROMBOPAG OLAMINE
 RECLAST, ZOLEDRONIC ACID
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RYDAPT, MIDOSTAURIN
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
 SIGNIFOR, PASIREOTIDE DIASPARTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 SIMBRINZA, BRIMONIDINE TARTRATE
 TAFINLAR, DABRAFENIB MESYLATE
 TASIGNA, NILOTINIB HYDROCHLORIDE
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TOBRADEX ST, DEXAMETHASONE
 TOBRADEX, DEXAMETHASONE
 TOBREX, TOBRAMYCIN
 TRAVATAN Z, TRAVOPROST
 TRIESENCE, TRIAMCINOLONE ACETONIDE
 TRILEPTAL, OXCARBAZEPINE
 TYKERB, LAPATINIB DITOSYLATE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIVELLE-DOT, ESTRADIOL
 VOLTAREN, DICLOFENAC SODIUM
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 XIIDRA, LIFITEGRAST
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS
 ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
 AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
 ENTRESTO, SACUBITRIL
 JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
 NORETHINDRONE, NORETHINDRONE

* NOVAST LABORATORIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, CARISOPRODOL
 CICLOPIROX, CICLOPIROX
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 HER STYLE, LEVONORGESTREL (OTC)
 INDOMETHACIN, INDOMETHACIN
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LERIBANE, ETHINYL ESTRADIOL
 LIDOCAINE, LIDOCAINE
 LO-MALMOREDE, ETHINYL ESTRADIOL
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MALMOREDE, ETHINYL ESTRADIOL
 MELAMISA, DROSPIRENONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NADOLOL, NADOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVAST LABORATORIES LTD
 NIFEDIPINE, NIFEDIPINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE, NORETHINDRONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PIMTREA, DESOGESTREL
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PROBENECID AND COLCHICINE, COLCHICINE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 SETLAKIN, ETHINYL ESTRADIOL
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 ELINEST, ETHINYL ESTRADIOL
 FALMINA, ETHINYL ESTRADIOL
 LEVONEST, ETHINYL ESTRADIOL
 MONO-LINYAH, ETHINYL ESTRADIOL
 PHILITH, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA
 STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CARBIDOPA, CARBIDOPA
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FAMOTIDINE, FAMOTIDINE
 FLUCYTOSINE, FLUCYTOSINE
 FLUOCINONIDE, FLUOCINONIDE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MISOPROSTOL, MISOPROSTOL
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN, NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
 PHENELZINE SULFATE, PHENELZINE SULFATE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVEL LABORATORIES INC**

POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
 TEMAZEPAM, TEMAZEPAM
 TINIDAZOLE, TINIDAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VORICONAZOLE, VORICONAZOLE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS*** NOVELGENIX THERAPEUTICS PVT LTD**

METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 VALPROIC ACID, VALPROIC ACID

NOVEN*** NOVEN PHARMACEUTICALS INC**

MINIVELLE, ESTRADIOL

NOVEN PHARMS INC*** NOVEN PHARMACEUTICALS INC**

COMBIPATCH, ESTRADIOL
 DAYTRANA, METHYLPHENIDATE

NOVITIUM PHARMA*** NOVITIUM PHARMA LLC**

ACETAZOLAMIDE, ACETAZOLAMIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DAPSONE, DAPSONE
 LEVOCARNITINE SF, LEVOCARNITINE
 LEVOCARNITINE, LEVOCARNITINE
 NITISINONE, NITISINONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 THIOTHIXENE, THIOTHIXENE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NOVO*** NOVO NORDISK INC**

FIASP FLEXTOUCH, INSULIN ASPART
 FIASP PENFILL, INSULIN ASPART
 FIASP, INSULIN ASPART
 MACRILEN, MACIMORELIN ACETATE
 OZEMPIC, SEMAGLUTIDE
 RYBELSUS, SEMAGLUTIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 TRESIBA, INSULIN DEGLUDEC
 XULTOPHY 100/3.6, INSULIN DEGLUDEC

NOVO NORDISK*** NOVO NORDISK PHARMACEUTICALS INC**

GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC*** NOVO NORDISK INC**

LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 NORDITROPIN FLEXPEN, SOMATROPIN
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVO NORDISK INC
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOVOLOG, INSULIN ASPART RECOMBINANT
 VAGIFEM, ESTRADIOL
 VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC

* NOVOCOL INC
 DYCLOPRO, DYCLONINE HYDROCHLORIDE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
 GATEX KIT, TEDUGLUTIDE RECOMBINANT

NUVO PHARM

* NUVO PHARMACEUTICAL INC
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 FENOFIBRATE, FENOFIBRATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC

* NUVO PHARMACEUTICALS INC
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 FOLIC ACID, FOLIC ACID
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NXDC

* NX DEVELOPMENT CORP
 GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ******OAK PHARMS**

* OAK PHARMACEUTICALS INC
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN

* OAK PHARMACEUTICALS INC SUB AKORN INC
 COGENTIN, BENZTROPINE MESYLATE
 DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC

* OAK PHARMACEUTICALS INC
 ZIOPTAN, TAFLUPROST
 * OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
 AZASITE, AZITHROMYCIN
 BETIMOL, TIMOLOL
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
 COSOPT, DORZOLAMIDE HYDROCHLORIDE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OCULAR THERAPEUTIX

* OCULAR THERAPEUTIX INC
 DEXTENZA, DEXAMETHASONE

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
 ANTABUSE, DISULFIRAM
 URECHOLINE, BETHANECHOL CHLORIDE

OHM

* OHM CORP
 IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
VALSARTAN, VALSARTAN

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMEROS

* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONY

* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL

* OPKO IRELAND GLOBAL HOLDINGS LTD
RAYALDEE, CALCIFEDIOL

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

OREXO US INC

* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
NEXPLANON, ETNOGESTREL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
MIGLITOL, MIGLITOL
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FENOFIBRATE, FENOFIBRATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

ORPHAN EUROPE

* ORPHAN EUROPE SARL
CYSTADANE, BETAINE

OSI PHARMS

* OSI PHARMACEUTICALS LLC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
ABILIFY MYCITE KIT, ARIPIPIRAZOLE
DACOGEN, DECITABINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPIRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

* OXFORD PHARMACEUTICALS LLC
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**** P ******P AND L**

* P AND L DEVELOPMENT LLC
ADAPALENE, ADAPALENE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

P AND L DEV LLC

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PACIRA PHARMS INC**

* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE

PADDOCK LLC

* PADDOCK LABORATORIES LLC
ATOVAQUONE, ATOVAQUONE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PANACEA BIOTEC LTD

* PANACEA BIOTEC LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
EVEROLIMUS, EVEROLIMUS
PROPAPENONE HYDROCHLORIDE, PROPAPENONE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE

* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 DOXEPIH HYDROCHLORIDE, DOXEPIH HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 ESTAZOLAM, ESTAZOLAM
 FLUTAMIDE, FLUTAMIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYUREA, HYDROXYUREA
 IBUPROFEN, IBUPROFEN (OTC)
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LAMOTRIGINE, LAMOTRIGINE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXANDROLONE, OXANDROLONE
 PIMOZIDE, PIMOZIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM PHENYL BUTYRATE, SODIUM PHENYL BUTYRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRANYLCPROMINE SULFATE, TRANYLCPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 ACCOLATE, ZAFIRLUKAST
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 AMBRISENTAN, AMBRISENTAN
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BOSENTAN, BOSENTAN
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOFETILIDE, DOFETILIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 PENICILLAMINE, PENICILLAMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PRAZIQUANTEL, PRAZIQUANTEL
 SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZILEUTON, ZILEUTON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
 ADRENALIN, EPINEPHRINE
 ARGATROBAN, ARGATROBAN
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 CORPHEDRA, EPHEDRINE SULFATE
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 KETALAR, KETAMINE HYDROCHLORIDE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PITOCIN, OXYTOCIN
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TREPROSTINIL, TREPROSTINIL
 TRIOSTAT, LIOTHYRONINE SODIUM
 VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARATEK PHARMS INC

* PARATEK PHARMACEUTICALS INC
 NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 CEREBYX, FOSPHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 NARDIL, PHENELZINE SULFATE
 NEURONTIN, GABAPENTIN
 ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS

* PARKE-DAVIS DIVISION OF PFIZER INC
 DILANTIN, PHENYTOIN SODIUM
 ZARONTIN, ETHOSUXIMIDE

PERRIGO

* PERRIGO CO
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 * PERRIGO LLC
 DESLORATADINE, DESLORATADINE

PERRIGO CO

* PERRIGO CO OF TENNESSEE INC
 CICLOPIROX, CICLOPIROX
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 ERYTHROMYCIN, ERYTHROMYCIN
 STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO CO TENNESSEE INC
 BACITRACIN, BACITRACIN
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
 ERYTHROMYCIN, ERYTHROMYCIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS LTD
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GYNAZOLE-1, BUTOCONAZOLE NITRATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 MESALAMINE, MESALAMINE
 MINOXIDIL, MINOXIDIL (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NITROGLYCERIN, NITROGLYCERIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PERMETHRIN, PERMETHRIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 TERCONAZOLE, TERCONAZOLE
 TESTOSTERONE, TESTOSTERONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CENTANY, MUPIROCIN
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN (OTC)
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 ENTOCORT EC, BUDESONIDE
 EVAMIST, ESTRADIOL
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 TRETINOIN, TRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
 LORATADINE, LORATADINE (OTC)
 PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 NAPROXEN, NAPROXEN
 SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ESTRADIOL, ESTRADIOL
 FLURANDRENOLIDE, FLURANDRENOLIDE
 INGENOL MEBUTATE, INGENOL MEBUTATE
 METRONIDAZOLE, METRONIDAZOLE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TESTOSTERONE, TESTOSTERONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERSION

* PERSION PHARMACEUTICALS LLC
 ZOHYDRO ER, HYDROCODONE BITARTRATE

PETNET

* PETNET SOLUTIONS INC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
 BOSULIF, BOSUTINIB MONOHYDRATE
 CHANTIX, VARENICLINE TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PF PRISM CV
 - INLYTA, AXITINIB
 - LYRICA CR, PREGABALIN
 - LYRICA, PREGABALIN
 - PRISTIQ, DESVENLAFAXINE SUCCINATE
 - RAPAMUNE, SIROLIMUS
 - TORISEL, TEMSIROLIMUS
 - TYGACIL, TIGECYCLINE
 - VFEND, VORICONAZOLE
 - XALKORI, CRIZOTINIB
 - XELJANZ, TOFACITINIB CITRATE
- PFIZER**
- * PFIZER CENTRAL RESEARCH
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER CHEMICALS DIV PFIZER INC
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER INC
 - CADUET, AMLODIPINE BESYLATE
 - CALAN SR, VERAPAMIL HYDROCHLORIDE
 - CARDURA XL, DOXAZOSIN MESYLATE
 - ELELYSO, TALIGLUCERASE ALFA
 - GEODON, ZIPRASIDONE HYDROCHLORIDE
 - GEODON, ZIPRASIDONE MESYLATE
 - GLUCOTROL XL, GLIPIZIDE
 - GLUCOTROL, GLIPIZIDE
 - HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 - HEPARIN SODIUM, HEPARIN SODIUM
 - LIPITOR, ATORVASTATIN CALCIUM
 - MERREM, MEROPENEM
 - NORVASC, AMLODIPINE BESYLATE
 - PROCARDIA, NIFEDIPINE
 - REVATIO, SILDENAFIL CITRATE
 - SONATA, ZALEPLON
 - TESSALON, BENZONATATE
 - TOVIAZ, FESOTERODINE FUMARATE
 - UNASYN, AMPICILLIN SODIUM
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER LABORATORIES DIV PFIZER INC
 - CARDURA, DOXAZOSIN MESYLATE
 - FELDENE, PIROXICAM
 - MINIPRESS, PRAZOSIN HYDROCHLORIDE
 - PFIZERPEN, PENICILLIN G POTASSIUM
 - PROCARDIA XL, NIFEDIPINE
 - UNASYN, AMPICILLIN SODIUM
 - VIBRAMYCIN, DOXYCYCLINE
 - VIBRAMYCIN, DOXYCYCLINE CALCIUM
 - VIBRAMYCIN, DOXYCYCLINE HYCLATE
- * PFIZER PHARMACEUTICALS INC
 - DILANTIN, PHENYTOIN
 - ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
 - TIKOSYN, DOFETILIDE
- PFIZER INC**
- * PFIZER INC
 - CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 - DAURISMO, GLASDEGIB MALEATE
 - ELLENCEN, EPIRUBICIN HYDROCHLORIDE
 - FRAGMIN, DALTEPARIN SODIUM
 - IBRANCE, PALBOCICLIB
 - LORBRENA, LORLATINIB
 - NICOTROL, NICOTINE
 - TALZENNA, TALAZOPARIB TOSYLATE
 - VIAGRA, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PFIZER INC
 VIZIMPRO, DACOMITINIB
 XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
 RELPAX, ELETRIPTAN HYDROBROMIDE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
 ACCUPRIL, QUINAPRIL HYDROCHLORIDE
 ACCURETIC, HYDROCHLOROTHIAZIDE
 LOPID, GEMFIBROZIL
 NEURONTIN, GABAPENTIN
 NITROSTAT, NITROGLYCERIN

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LORAZEPAM, LORAZEPAM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

* PHARMACEUTICAL ASSOCIATES INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE, PREDNISOLONE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 THEOPHYLLINE, THEOPHYLLINE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
 MESALAMINE, MESALAMINE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
 CARBOPLATIN, CARBOPLATIN
 CISPLATIN, CISPLATIN
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN
 GENOTROPIN, SOMATROPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PHARMACIA AND UPJOHN**

- * PHARMACIA AND UPJOHN
 - XANAX XR, ALPRAZOLAM
- * PHARMACIA AND UPJOHN CO
 - AROMASIN, EXEMESTANE
 - AZULFIDINE EN-TABS, SULFASALAZINE
 - AZULFIDINE, SULFASALAZINE
 - BACITRACIN, BACITRACIN
 - CAVERJECT IMPULSE, ALPROSTADIL
 - CAVERJECT, ALPROSTADIL
 - CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 - CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 - CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - CLEOCIN T, CLINDAMYCIN PHOSPHATE
 - CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 - CLEOCIN, CLINDAMYCIN PHOSPHATE
 - CORTEF, HYDROCORTISONE
 - CORVERT, IBUTILIDE FUMARATE
 - CYKLOKAPRON, TRANEXAMIC ACID
 - DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 - DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 - DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 - DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 - DETROL LA, TOLTERODINE TARTRATE
 - DETROL, TOLTERODINE TARTRATE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 - EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 - ESTRING, ESTRADIOL
 - GLYNASE, GLYBURIDE
 - GLYSET, MIGLITOL
 - HALCION, TRIAZOLAM
 - HEMABATE, CARBOPROST TROMETHAMINE
 - IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 - LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 - MEDROL, METHYLPREDNISOLONE
 - MYCOBUTIN, RIFABUTIN
 - NICOTROL, NICOTINE
 - OGEN 5, ESTROPIPATE
 - PREPIDIL, DINOPROSTONE
 - PROSTIN E2, DINOPROSTONE
 - PROSTIN VR PEDIATRIC, ALPROSTADIL
 - PROVERA, MEDROXYPROGESTERONE ACETATE
 - R-GENE 10, ARGININE HYDROCHLORIDE
 - SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 - SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
 - SOMAVERT, PEGVISOMANT
 - XALATAN, LATANOPROST
 - XANAX, ALPRAZOLAM
 - ZINECARD, DEXRAZOXANE HYDROCHLORIDE
 - ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
 - DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACIA UPJOHN

- * PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC
 - COLESTID, COLESTIPOL HYDROCHLORIDE
 - FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

PHARMACYCLICS INC

- * PHARMACYCLICS INC
 - IMBRUVICA, IBRUTINIB

PHARMADAX INC

- * PHARMADAX INC
 - GLYBURIDE, GLYBURIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMALUCENCE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PHARMALUCENCE INC**

AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

PHARMASCIENCE INC*** PHARMASCIENCE INC**

BUSULFAN, BUSULFAN
 DECITABINE, DECITABINE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS LTD*** PHARMAXIS LTD**

ARIDOL KIT, MANNITOL

PHOTOCURE ASA*** PHOTOCURE ASA**

CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA*** PIERRE FABRE DERMATOLOGIE**

HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL*** PIERREL S.P.A.**

ORABLOC, ARTICAINA HYDROCHLORIDE

PII*** PHARMACEUTICS INTERNATIONAL INC**

BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 ITRACONAZOLE, ITRACONAZOLE
 PIROXICAM, PIROXICAM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PINNACLE BIOLGS*** PINNACLE BIOLOGICS INC**

PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL*** PIRAMAL CRITICAL CARE INC**

GABLOFEN, BACLOFEN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ISOFLURANE, ISOFLURANE
 MITIGO, MORPHINE SULFATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 SOJOURN, SEVOFLURANE

*** PIRAMAL CRITICAL CARE LTD**

LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL ENT*** PIRAMAL ENTERPRISES LTD**

ISOFLURANE, ISOFLURANE

PIRAMAL HLTHCARE UK*** PIRAMAL HEALTHCARE UK LTD**

CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DEFERASIROX, DEFERASIROX

PLD ACQUISITIONS*** PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS**

CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC*** PLD ACQUISITIONS LLC**

LORATADINE, LORATADINE (OTC)
 ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA*** PLIVA INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PLIVA INC
 AZITHROMYCIN, AZITHROMYCIN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CIMETIDINE, CIMETIDINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 METRONIDAZOLE, METRONIDAZOLE
 NAPROXEN, NAPROXEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

PLIVA LACHEMA

* PLIVA LACHEMA AS
 CARBOPLATIN, CARBOPLATIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
 TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
 VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

* POLYGEN PHARMACEUTICALS INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
 NEOPAP, ACETAMINOPHEN (OTC)

PORTOLA PHARMS INC

* PORTOLA PHARMACEUTICALS INC
 BEVYXXA, BETRIXABAN

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
 ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA

* PRAGMA PHARMACEUTICALS LLC
 KEFLEX, CEPHALEXIN

PRAXAIR DISTRIBUTION

* PRAXAIR DISTRIBUTION INC
 NOXIVENT, NITRIC OXIDE

PRECISION DERMAT

* PRECISION DERMATOLOGY INC
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC

* PRECISION DOSE INC
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PRINSTON INC**

* PRINSTON PHARMACEUTICAL INC
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPTOPRIL, CAPTOPRIL
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOFETILIDE, DOFETILIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FENOFIBRATE, FENOFIBRATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
 AZEDRA, IOBENGUANE I-131

PROVELL

* PROVELL PHARMACEUTICALS LLC
 EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

* PROVENSIS LTD
 VARITHENA, POLIDOCANOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PROVEPHARM SAS**

* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PTC THERAP

* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC

* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH

* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM

* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC

* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE

* PURDUE GMP CENTER LLC
SEROMYCIN, CYCLOSERINE

PURDUE PHARMA LP

* PURDUE PHARMA LP
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ******Q BIOMED**

* Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU

* QILU PHARMACEUTICAL CO LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAZONE, CEFTRIAZONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TENOFVIR DISOPROXIL FUMARATE, TENOFVIR DISOPROXIL FUMARATE

QINGDAO BAHEAL PHARM

* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Q ****

* QOL MEDICAL LLC
SUCRAID, SACROSIDASE

QUAGEN

* QUAGEN PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ******R-PHARM US LLC**

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

RADIUS HEALTH INC

* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

RB HLTH

* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECIP

* RECIP AB
THYROSAFE, POTASSIUM IODIDE (OTC)

RECIPHARM

* RECIPHARM PHARMASERVICES PRIVATE LTD
FLUCYTOSINE, FLUCYTOSINE

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
INDOCIN, INDOMETHACIN SODIUM
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

REDHILL

* REDHILL BIOPHARMA INC
AEMCOLO, RIFAMYCIN SODIUM
* REDHILL BIOPHARMA LTD
TALICIA, AMOXICILLIN

RELYPSA INC

* RELYPSA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS

* REMPEX PHARMACEUTICALS
MINOCIN, MINOCYCLINE HYDROCHLORIDE
* REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS INC
VABOMERE, MEROPENEM

RENATA

* RENATA LTD
RISPERIDONE, RISPERIDONE

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RHODES PHARMACEUTICALS LP
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DOFETILIDE, DOFETILIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

RIGEL PHARMS INC

* RIGEL PHARMACEUTICALS INC
 TAVALISSE, FOSTAMATINIB DISODIUM

RISING

* RISING PHARMA HOLDINGS INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACETIC ACID, ACETIC ACID, GLACIAL
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCORTISONE, HYDROCORTISONE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 METHIMAZOLE, METHIMAZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 PARICALCITOL, PARICALCITOL
 PERPHENAZINE, PERPHENAZINE
 PREGABALIN, PREGABALIN
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RISPERIDONE, RISPERIDONE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TOREMIFENE CITRATE, TOREMIFENE CITRATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 ZILEUTON, ZILEUTON

ROCHE PALO

* ROCHE PALO ALTO LLC
 CELLCEPT, MYCOPHENOLATE MOFETIL
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROCKWELL MEDICAL INC

* ROCKWELL MEDICAL INC
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

* ROMARK LABORATORIES
 ALINIA, NITAZOXANIDE

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
 LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******RTRX**

* RETROPHIN INC
CHOLBAM, CHOLIC ACID

RUBICON

* RUBICON RESEARCH PRIVATE LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACLOFEN, BACLOFEN
CARVEDILOL, CARVEDILOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LAMOTRIGINE, LAMOTRIGINE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

RXMTM THERAPS LLC

* RXMTM THERAPEUTICS LLC A WHOLLY OWNED SUB OF CUTISPHARMA INC
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE

**** S ******SAGE PRODS**

* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP

* SAGE THERAPEUTICS INC
ZULRESSO, BREXANOLONE

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
CAFFEINE CITRATE, CAFFEINE CITRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SAGENT PHARMACEUTICALS INC**

KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OXYTOCIN, OXYTOCIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PROPOFOL, PROPOFOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAI LIFE SCIENCES

*** SAI LIFE SCIENCES LTD**
 DAPSONE, DAPSONE

SALIX

*** SALIX PHARMACEUTICALS INC**
 FENOGLIDE, FENOFIBRATE
 PLENVU, ASCORBIC ACID
 RELISTOR, METHYLNALTREXONE BROMIDE
 TRULANCE, PLECANATIDE
 UCERIS, BUDESONIDE
 ZEGERID, OMEPRAZOLE

SALIX PHARMS

*** SALIX PHARMACEUTICALS INC**
 ANUSOL HC, HYDROCORTISONE
 DIURIL, CHLOROTHIAZIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SAMSON MEDCL

*** SAMSON MEDICAL TECHNOLOGIES LLC**
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ*** SANDOZ**

DOCETAXEL, DOCETAXEL

*** SANDOZ INC**

ALPRAZOLAM, ALPRAZOLAM
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 APREPITANT, APREPITANT
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFERGOT, CAFFEINE
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARVEDILOL, CARVEDILOL
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COSYNTROPIN, COSYNTROPIN
 CYCLOSPORINE, CYCLOSPORINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPLERENONE, EPLERENONE
 ETODOLAC, ETODOLAC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 HALOPERIDOL, HALOPERIDOL
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOLAZONE, METOLAZONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 OMNITROPE, SOMATROPIN
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SULFADIAZINE, SULFADIAZINE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC

* SANDOZ INC
 ACETAMINOPHEN, ACETAMINOPHEN
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ANGIOMAX, BIVALIRUDIN
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BIMATOPROST, BIMATOPROST
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 CEFTRIAZONE, CEFTRIAZONE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DECITABINE, DECITABINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EZETIMIBE, EZETIMIBE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 FULVESTRANT, FULVESTRANT
 GATIFLOXACIN, GATIFLOXACIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLATOPA, GLATIRAMER ACETATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LATANOPROST, LATANOPROST
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MAXITROL, DEXAMETHASONE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYDRIACYL, TROPICAMIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEVIRAPINE, NEVIRAPINE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QOLIANA, BRIMONIDINE TARTRATE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILODOSIN, SILODOSIN
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TELMISARTAN, TELMISARTAN
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 TOBEX, TOBRAMYCIN
 TREPROSTINIL, TREPROSTINIL
 TRIFLURIDINE, TRIFLURIDINE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL

SANOFI

* SANOFI GENZYME
 HECTOROL, DOXERCALCIFEROL
 RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
 JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 AMARYL, GLIMEPIRIDE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBIEN, ZOLPIDEM TARTRATE
 APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
 APIDRA, INSULIN GLULISINE RECOMBINANT
 ARAVA, LEFLUNOMIDE
 AUBAGIO, TERIFLUNOMIDE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVAPRO, IRBESARTAN
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DIABETA, GLYBURIDE
 ELOXATIN, OXALIPLATIN
 FERLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 LANTUS, INSULIN GLARGINE RECOMBINANT
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOVENOX, ENOXAPARIN SODIUM
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NICODERM CQ, NICOTINE (OTC)
 PLAVIX, CLOPIDOGREL BISULFATE
 PRIFTIN, RIFAPENTINE
 PRIMAQUINE, PRIMAQUINE PHOSPHATE
 RIFADIN, RIFAMPIN
 RIFAMATE, ISONIAZID
 RIFATER, ISONIAZID
 TAXOTERE, DOCETAXEL
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

SANOFI US

* SANOFI US
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

SANOFI US SERVICES

* SANOFI US SERVICES INC
 TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US

* SANOFI-AVENTIS US LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANOFI-AVENTIS US LLC
ADLYXIN, LIXISENATIDE
ADMELOG SOLOSTAR, INSULIN LISPRO
ADMELOG, INSULIN LISPRO
SOLIQUA 100/33, INSULIN GLARGINE

SANOVEL ILAC

* SANOVEL ILAC SAN VE TIC AS
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

SANTARUS INC

* SANTARUS INC
GLUMETZA, METFORMIN HYDROCHLORIDE

SAOL THERAPS RES LTD

* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN

SAPTALIS PHARMS

* SAPTALIS PHARMACEUTICALS LLC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
EXONDYS 51, ETEPLIRSEN
VYONDYS 53, GOLODIRSEN

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA

* SAWAI USA INC
MIRABEGRON, MIRABEGRON
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

SCHERING

* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
BUDESONIDE, BUDESONIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SCIEGEN PHARMACEUTICALS INC
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
- SCILEX PHARMS INC**
- * SCILEX PHARMACEUTICALS
 ZTLIDO, LIDOCAINE
- SCINOPHARM TAIWAN**
- * SCINOPHARM TAIWAN LTD
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
- SEBELA IRELAND LTD**
- * SEBELA IRELAND LTD
 BRISDELLE, PAROXETINE MESYLATE
 IMURAN, AZATHIOPRINE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 MICORT-HC, HYDROCORTISONE ACETATE
 MOTOFEN, ATROPINE SULFATE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 ONMEL, ITRACONAZOLE
 PEXEVA, PAROXETINE MESYLATE
 PRAMOSONE, HYDROCORTISONE ACETATE
 RIDAURA, AURANOFIN
- SECAN PHARMS**
- * SECAN PHARMACEUTICALS INC
 LEVETIRACETAM, LEVETIRACETAM
- SECURA**
- * SECURA BIO INC
 FARYDAK, PANOBINOSTAT LACTATE
- SENTYNL THERAPS INC**
- * SENTYNL THERAPEUTICS INC
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
- SEPTODONT**
- * SEPTODONT INC
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
- SEPTODONT HOLDING**
- * SEPTODONT HOLDING SAS
 ORAVERSE, PHENTOLAMINE MESYLATE
- SEPTODONT INC**
- * SEPTODONT INC
 LIDOCAINE, LIDOCAINE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
- SERB SA**
- * SERB SA
 CYANOKIT, HYDROXOCOBALAMIN
- SETON PHARM**
- * SETON PHARMACEUTICAL LLC
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
- SETON PHARMS**
- * SETON PHARMACEUTICALS LLC
 CAPTOPRIL, CAPTOPRIL
 PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
- SHANDONG**
- * SHANDONG NEW TIME PHARMACEUTICAL CO LTD
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
- SHANDONG XINHUA**
- * SHANDONG XINHUA PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
- SHANGHAI HENGRUI**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
 DESFLURANE, DESFLURANE
 SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHIELD TX

* SHIELD TX UK LTD
 ACCRUFER, FERRIC MALTOL

SHILPA MEDICARE

* SHILPA MEDICARE LTD
 AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
 BUSULFAN, BUSULFAN
 CAPECITABINE, CAPECITABINE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHIONOGI INC

* SHIONOGI INC
 FETROJA, CEFIDEROCOL SULFATE TOSYLATE
 MULPLETA, LUSUTROMBOPAG
 PONSTEL, MEFENAMIC ACID

SHIRE

* SHIRE DEVELOPMENT INC
 ADDERALL XR 10, AMPHETAMINE ASPARTATE
 ADDERALL XR 15, AMPHETAMINE ASPARTATE
 ADDERALL XR 20, AMPHETAMINE ASPARTATE
 ADDERALL XR 25, AMPHETAMINE ASPARTATE
 ADDERALL XR 30, AMPHETAMINE ASPARTATE
 ADDERALL XR 5, AMPHETAMINE ASPARTATE
 INTUNIV, GUANFACINE HYDROCHLORIDE
 LIALDA, MESALAMINE
 PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC
 CARBATROL, CARBAMAZEPINE
 FOSRENOL, LANTHANUM CARBONATE
 MOTEGRITY, PRUCALOPRIDE SUCCINATE
 MYDAYIS, AMPHETAMINE ASPARTATE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
 VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
 AGRYLIN, ANAGRELIDE HYDROCHLORIDE
 FOSRENOL, LANTHANUM CARBONATE

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES LLC
 FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOthyRONINE SODIUM, LIOthyRONINE SODIUM
NITROGLYCERIN, NITROGLYCERIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILVERGATE PHARMS

* SILVERGATE PHARMACEUTICALS INC
EPANED, ENALAPRIL MALEATE
KATERZIA, AMLODIPINE BENZOATE
QBRELIS, LISINOPRIL
XATMEP, METHOTREXATE SODIUM

SINOTHERAPEUTICS INC

* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROPAPENONE HYDROCHLORIDE, PROPAPENONE HYDROCHLORIDE

SKINMEDICA

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE

* SLATE RUN PHARMACEUTICALS LLC
CILOSTAZOL, CILOSTAZOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL

SLAYBACK PHARMA LLC

* SLAYBACK PHARMA LLC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
PROGESTERONE, PROGESTERONE

SOFIE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOMERSET

- * SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE
- * SOMERSET THERAPEUTICS LLC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC

- * SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SPARC

- * SUN PHARMA ADVANCED RESEARCH CO LTD
ELEPSIA XR, LEVETIRACETAM

SPECGX LLC

- * SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SPECGX LLC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES

* SPECTRA MEDICAL DEVICES INC
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPECTRON MRC LLC

* SPECTRON MRC LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPIL

* SUN PHARMA INDUSTRIES LTD
 KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
 ADDYI, FLIBANSERIN

SQUARE PHARMS LTD

* SQUARE PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 VALSARTAN, VALSARTAN

ST RENATUS

* ST RENATUS LLC
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
 IVY BLOCK, BENTOQUATAM (OTC)

STANDARD CHEM PHARM

* STANDARD CHEM AND PHARM CO LTD
 RILUZOLE, RILUZOLE

STASON PHARMS

* STASON PHARMACEUTICALS INC
 PURINETHOL, MERCAPTOPURINE

STI PHARMA LLC

* STI PHARMA LLC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 CARMUSTINE, CARMUSTINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
 DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
 SORIATANE, ACITRETIN

STRIDES PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACARBOSE, ACARBOSE
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALBENDAZOLE, ALBENDAZOLE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 BENZONATATE, BENZONATATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 ERGOCALCIFEROL, ERGOCALCIFEROL
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 KETOCONAZOLE, KETOCONAZOLE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOXSALLEN, METHOXSALLEN
 METRONIDAZOLE, METRONIDAZOLE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NEVIRAPINE, NEVIRAPINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US

* STRONGBRIDGE US INC
 KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
 AMITIZA, LUBIPROSTONE

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
 ABSORICA LD, ISOTRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMBRISENTAN, AMBRISENTAN
 AMIFOSTINE, AMIFOSTINE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BOSENTAN, BOSENTAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CARBOPLATIN, CARBOPLATIN
 CERINTA, ETHINYL ESTRADIOL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DALFAMPRIDINE, DALFAMPRIDINE
 DEFERASIROX, DEFERASIROX
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOFETILIDE, DOFETILIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESZOPICLONE, ESZOPICLONE
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GANIRELIX ACETATE, GANIRELIX ACETATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 INFUGEM, GEMCITABINE HYDROCHLORIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 KEMEYA, DROSPIRENONE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KYRA, DROSPIRENONE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 PALIPERIDONE, PALIPERIDONE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANOLAZINE, RANOLAZINE
 RIOMET ER, METFORMIN HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SYLEVIA, ETHINYL ESTRADIOL
 TADALAFIL, TADALAFIL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TETRABENAZINE, TETRABENAZINE
 TOBRAMYCIN, TOBRAMYCIN
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
 ABSORICA, ISOTRETINOIN
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOZAPINE, CLOZAPINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 EURAX, CROTAMITON
 FLUMADINE, RIMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
 GLIPIZIDE, GLIPIZIDE
 HALOG, HALCINONIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 KENALOG, TRIAMCINOLONE ACETONIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 XIMINO, MINOCYCLINE HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DOXYCYCLINE, DOXYCYCLINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 RILUZOLE, RILUZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
 RIOMET, METFORMIN HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOPIRAMATE, TOPIRAMATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUALAQUIN, QUININE SULFATE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 TEMAZEPAM, TEMAZEPAM
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
 BROMSITE, BROMFENAC SODIUM
 CEQUA, CYCLOSPORINE
 DECITABINE, DECITABINE
 DOCETAXEL, DOCETAXEL
 DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 EZALLOR, ROSUVASTATIN CALCIUM
 ODOMZO, SONIDEGIB PHOSPHATE
 ORTIKOS, BUDESONIDE
 XELPROS, LATANOPROST
 YONSA, ABIRATERONE ACETATE

SUNGEN PHARMA

* SUNGEN PHARMA LLC
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 LIDOCAINE, LIDOCAINE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE

SUNNY PHARMTECH INC

* SUNNY PHARMTECH INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUNNY PHARMTECH INC
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
 BROVANA, ARFORMOTEROL TARTRATE
 XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
 APTIOM, ESLICARBAZEPINE ACETATE
 ARCAPTA NEOHALER, INDACATEROL MALEATE
 LATUDA, LURASIDONE HYDROCHLORIDE
 LUNESTA, ESZOPICLONE
 SEEBRI, GLYCOPYRROLATE
 UTIBRON, GLYCOPYRROLATE
 ZONEGRAN, ZONISAMIDE

SUNOVION RESP

* SUNOVION RESPIRATORY DEVELOPMENT INC
 LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNRISE PHARM INC

* SUNRISE PHARMACEUTICAL INC
 NAPROXEN, NAPROXEN

SUNSHINE LAKE

* SUNSHINE LAKE PHARMA CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 CLARITHROMYCIN, CLARITHROMYCIN
 ENTACAPONE, ENTACAPONE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 TADALAFIL, TADALAFIL

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
 PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
 OXTELLAR XR, OXCARBAZEPINE
 TROKENDI XR, TOPIRAMATE

SUVEN LIFE

* SUVEN LIFE SCIENCES LTD
 MALATHION, MALATHION

SVC PHARMA

* SVC PHARMA LP
 DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
 ORFADIN, NITISINONE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ******ACME LABS**

* THE ACME LABORATORIES LTD
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP

* THE GENERAL HOSPITAL CORP
 AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES

* THE METHODIST HOSP RESEARCH INSTITUTE
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

REDITOSE CORP

* THE RITEDOSE CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* THE RITEDOSE CORP
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC
 LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
 ACTOPLUS MET, METFORMIN HYDROCHLORIDE
 ACTOS, PIOGLITAZONE HYDROCHLORIDE
 COLCRYS, COLCHICINE
 DEXILANT, DEXLANSOPRAZOLE
 DUETACT, GLIMEPIRIDE
 KAZANO, ALOGLIPTIN BENZOATE
 NESINA, ALOGLIPTIN BENZOATE
 OSENI, ALOGLIPTIN BENZOATE
 PREVACID, LANSOPRAZOLE
 ROZEREM, RAMELTEON
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 ULORIC, FEBUXOSTAT

TAMARANG

* TAMARANG SA
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CARBAMAZEPINE, CARBAMAZEPINE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 DESLORATADINE, DESLORATADINE
 DESONIDE, DESONIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FELBAMATE, FELBAMATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 PHENYTOIN, PHENYTOIN
 TERIL, CARBAMAZEPINE
 WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AZELAIC ACID, AZELAIC ACID
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DAPSONE, DAPSONE
 DERMABET, BETAMETHASONE VALERATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 KETOZOLE, KETOCONAZOLE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 PHENYTOIN, PHENYTOIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 AMCINONIDE, AMCINONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 DESLORATADINE, DESLORATADINE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE, HYDROCORTISONE
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 PLIAGLIS, LIDOCAINE
 TAZAROTENE, TAZAROTENE
 TOPICORT, DESOXIMETASONE
 TRETINOIN, TRETINOIN

TASMAN PHARMA

* TASMAN PHARMA INC
 CLOTRIMAZOLE, CLOTRIMAZOLE
 VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
 FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA

* TEIKOKU PHARMA USA INC
 DOCETAXEL, DOCETAXEL

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
 LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
 CEFOTAN, CEFOTETAN DISODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZINACEF, CEFUROXIME SODIUM

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE, FLUOCINONIDE
 FLURANDRENOLIDE, FLURANDRENOLIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TELIGENT PHARMA INC**

LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE, LIDOCAINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TERSERA THERAPS LLC*** TERSERA THERAPEUTICS LLC**

ERGOMAR, ERGOTAMINE TARTRATE
 PRIALT, ZICONOTIDE ACETATE
 QMIIZ ODT, MELOXICAM
 VARUBI, ROLAPITANT HYDROCHLORIDE
 ZOLADEX, GOSERELIN ACETATE

TESARO INC*** TESARO INC**

ZEJULA, NIRAPARIB TOSYLATE

TETRAPHASE PHARMS*** TETRAPHASE PHARMACEUTICALS INC**

XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA*** TEVA NEUROSCIENCE INC**

AZILECT, RASAGILINE MESYLATE

*** TEVA PHARMACEUTICALS USA INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL, CAPTOPRIL
 CARVEDILOL, CARVEDILOL
 CEFACLOR, CEFACLOR
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPITOL, CARBAMAZEPINE
 ESZOPICLONE, ESZOPICLONE
 ETODOLAC, ETODOLAC
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALZIN, ZINC ACETATE
 GEMFIBROZIL, GEMFIBROZIL
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE, GLYBURIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MUPIROCIN, MUPIROCIN
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 RIBAVIRIN, RIBAVIRIN
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 AUSTEDO, DEUTETRABENAZINE
 EMLA, LIDOCAINE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 PROAIR DIGIHALER, ALBUTEROL SULFATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
 AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
 AIRDUO RESPICLICK, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 AZITHROMYCIN, AZITHROMYCIN
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUDESONIDE, BUDESONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPROZIL, CEFPROZIL
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FAMCICLOVIR, FAMCICLOVIR
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GABAPENTIN, GABAPENTIN
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IRBESARTAN, IRBESARTAN
 LANSOPRAZOLE, LANSOPRAZOLE
 LEFLUNOMIDE, LEFLUNOMIDE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 ZALEPLON, ZALEPLON

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 SYNRIPO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ACITRETIN, ACITRETIN
 ADENOSINE, ADENOSINE
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPROSTADIL, ALPROSTADIL
 ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUDESONIDE, BUDESONIDE
 CARBOPLATIN, CARBOPLATIN
 CLARAVIS, ISOTRETINOIN
 CLOZAPINE, CLOZAPINE
 COPAXONE, GLATIRAMER ACETATE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPTIFIBATIDE, EPTIFIBATIDE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 ETOPOSIDE, ETOPOSIDE
 EZETIMIBE, EZETIMIBE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 GABAPENTIN, GABAPENTIN
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOGILIA, ULIPRISTAL ACETATE
 MESNA, MESNA
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TREPROSTINIL, TREPROSTINIL
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VIGABATRIN, VIGABATRIN
 VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN

* TEVA PHARMACEUTICALS USA INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ALYQ, TADALAFIL
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CAPECITABINE, CAPECITABINE
 DAPTOMYCIN, DAPTOMYCIN
 DARUNAVIR, DARUNAVIR
 DEFERASIROX, DEFERASIROX
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL, ESTRADIOL
 EVEROLIMUS, EVEROLIMUS
 ICATIBANT ACETATE, ICATIBANT ACETATE
 IVERMECTIN, IVERMECTIN
 LIDOCAINE, LIDOCAINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESALAMINE, MESALAMINE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METRONIDAZOLE, METRONIDAZOLE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
 FULVESTRANT, FULVESTRANT
 POTASSIUM CITRATE, POTASSIUM CITRATE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BENZONATATE, BENZONATATE
 ISONIAZID, ISONIAZID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* THEPHARMANETWORK LLC
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 THERMAZENE, SILVER SULFADIAZINE

THERAPEUTICSMD INC

* THERAPEUTICSMD INC
 ANNOVERA, ETHINYL ESTRADIOL
 BIJUVA, ESTRADIOL
 IMVEXXY, ESTRADIOL

THERATECHNOLOGIES

* THERATECHNOLOGIES INC
 EGRIFTA, TESAMORELIN ACETATE

TIANJIN TIANYAO

* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
 METHYLPREDNISOLONE, METHYLPREDNISOLONE

TIME-CAP LABS INC

* TIME-CAP LABORATORIES INC
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TITAN PHARMS

* TITAN PHARMACEUTICALS INC
 PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

TOLMAR

* TOLMAR INC
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 ATRIDOX, DOXYCYCLINE HYCLATE
 AZELAIC ACID, AZELAIC ACID
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
 ELIGARD, LEUPROLIDE ACETATE

TOPROL

* TOPROL ACQUISITION LLC
 TOPROL-XL, METOPROLOL SUCCINATE
 ZONTIVITY, VORAPAXAR SULFATE

TORPHARM

* TORPHARM INC
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT

* TORRENT PHARMA INC
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

* TORRENT PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARIPIRAZOLE, ARIPIRAZOLE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TORRENT PHARMACEUTICALS LTD
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 ITRACONAZOLE, ITRACONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 ROFLUMILAST, ROFLUMILAST
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TADALAFIL, TADALAFIL
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
 LEVOFLOXACIN, LEVOFLOXACIN

* TORRENT PHARMACEUTICALS LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* TORRENT PHARMACEUTICALS LTD.
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 OLANZAPINE, OLANZAPINE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 LEVETIRACETAM, LEVETIRACETAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OLANZAPINE, OLANZAPINE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRIS PHARMA INC

* TRIS PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TRIS PHARMA INC**

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DYANAVAL XR, AMPHETAMINE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA*** TRUSTEES OF THE UNIV OF PENNSYLVANIA**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC*** TULEX PHARMACEUTICALS INC**

OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS*** TWI PHARMACEUTICALS INC**

BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 TESTOSTERONE, TESTOSTERONE
 ZOLMITRIPTAN, ZOLMITRIPTAN

TWI PHARMS INC*** TWI PHARMACEUTICALS INC**

CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ******UCB INC***** UCB INC**

BRIVIACT, BRIVARACETAM
 KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 NAYZILAM, MIDAZOLAM
 NEUPRO, ROTIGOTINE
 VIMPAT, LACOSAMIDE

UCLA BIOMEDICAL*** UCLA BIOMEDICAL CYCLOTRON**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RADIOPHARM*** UCSF RADIOPHARMACEUTICAL FACILITY**

AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******UIHC PET IMAGING**

- * UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68

ULTRATAB LABS INC

- * ULTRATAB LABORATORIES INC
IBUPROFEN, IBUPROFEN (OTC)

UMEDICA LABS PVT LTD

- * UMEDICA LABORATORIES PRIVATE LTD
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

UNICHEM

- * UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
ZALEPLON, ZALEPLON

UNICHEM LABS LTD

- * UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
- * UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN

UNICHEM PHARMS (USA)

- * UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

- * UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS

- * UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
 FLUCONAZOLE, FLUCONAZOLE
 GLIPIZIDE, GLIPIZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
 RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
 ORENITRAM, TREPROSTINIL DIOLAMINE
 REMODULIN, TREPROSTINIL
 TYVASO, TREPROSTINIL

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
 AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES INC
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE

* UPSHER SMITH LABORATORIES LLC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BEXAROTENE, BEXAROTENE
 BUMETANIDE, BUMETANIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 EXEMESTANE, EXEMESTANE
 FLUOXYMESTERONE, FLUOXYMESTERONE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 JANTOVEN, WARFARIN SODIUM
 Klor-CON M10, POTASSIUM CHLORIDE
 Klor-CON M15, POTASSIUM CHLORIDE
 Klor-CON M20, POTASSIUM CHLORIDE
 Klor-CON, POTASSIUM CHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UPSHER SMITH LABORATORIES LLC
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OXANDROLONE, OXANDROLONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PACERONE, AMIODARONE HYDROCHLORIDE
 PENTOXIL, PENTOXIFYLLINE
 PREVALITE, CHOLESTYRAMINE
 QUDEXY XR, TOPIRAMATE
 SORINE, SOTALOL HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TOSYMRA, SUMATRIPTAN
 VOGELXO, TESTOSTERONE
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
 DRISDOL, ERGOCALCIFEROL
 HIPREX, METHENAMINE HIPPURATE
 LASIX, FUROSEMIDE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 LOPRESSOR, METOPROLOL TARTRATE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
 APOKYN, APOMORPHINE HYDROCHLORIDE
 REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC

* US WORLDMEDS LLC
 CORGARD, NADOLOL
 LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
 XADAGO, SAFINAMIDE MESYLATE

USPHARMA

* USPHARMA LTD
 NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS

* USPHARMA WINDLAS LLC
 PRASUGREL, PRASUGREL HYDROCHLORIDE

USV

* USV PRIVATE LTD
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ******VALEANT**

* VALEANT PHARMACEUTICALS INTERNATIONAL
 BONTRIL PDM, PHENDIMETRAZINE TARTRATE
 MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
 DERMATOP E EMOLLIENT, PREDNICARBATE
 PENLAC, CICLOPIROX
 RETIN-A, TRETINOIN

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
 RETIN-A MICRO, TRETINOIN
 RETIN-A, TRETINOIN
 RETIN-A-MICRO, TRETINOIN
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 * VALEANT INTERNATIONAL SRL
 BENZAMYCIN, BENZOYL PEROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******VALEANT LUXEMBOURG**

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC

- * VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

VALEANT PHARMS INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
CUPRIMINE, PENICILLAMINE
LACRISERT, HYDROXYPROPYL CELLULOSE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
UCERIS, BUDESONIDE

VALEANT PHARMS LLC

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
MACUGEN, PEGAPTANIB SODIUM
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
KLARON, SULFACETAMIDE SODIUM
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
SECONAL SODIUM, SECOBARBITAL SODIUM
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE

VALIDUS PHARMS

- * VALIDUS PHARMACEUTICALS LLC
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

- * VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

- * VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

- * VELOXIS PHARMACEUTICALS INC
ENVARUS XR, TACROLIMUS

VERASTEM INC

- * VERASTEM INC
COPIKTRA, DUVELISIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******VERO BIOTECH**

* VERO BIOTECH
GENOSYL, NITRIC OXIDE

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VGYAAN

* VGYAAN PHARMACEUTICALS LLC
NADOLOL, NADOLOL

VICURON

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE

* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

- * VINTAGE PHARMACEUTICALS
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 KIMIDESS, DESOGESTREL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
- * VINTAGE PHARMACEUTICALS INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 DIAZEPAM, DIAZEPAM
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LEVETIRACETAM, LEVETIRACETAM
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PERPHENAZINE, PERPHENAZINE
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SULFASALAZINE, SULFASALAZINE
 TORSEMIDE, TORSEMIDE

VINTAGE PHARMS LLC

- * VINTAGE PHARMACEUTICALS LLC
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 DUTASTERIDE, DUTASTERIDE
 EMOQUETTE, DESOGESTREL
 FELODIPINE, FELODIPINE
 GILDESS 1.5/30, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 LETROZOLE, LETROZOLE
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYZILRA, ETHINYL ESTRADIOL
 ORSYTHIA, ETHINYL ESTRADIOL
 PERCOCET, ACETAMINOPHEN
 PREVIFEM, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL

VIOKACE

- * VIOKACE LLC
 VIOKACE, PANCRELIPASE (AMYLASE)

VIRTUS PHARM

- * VIRTUS PHARMACEUTICAL INC
 ACARBOSE, ACARBOSE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS

- * VIRTUS PHARMACEUTICALS LLC
 DAPSONE, DAPSONE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PROMETRIUM, PROGESTERONE

VISTA PHARMS

- * VISTA PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
CLOBAZAM, CLOBAZAM
DIGOXIN, DIGOXIN
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIVUS INC

* VIVUS INC
PANCREAZE, PANCRELIPASE (AMYLASE)

VKT PHARMA PVT LTD

* VKT PHARMA PRIVATE LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WATSON LABORATORIES INC
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COL-PROBENECID, COLCHICINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESTAZOLAM, ESTAZOLAM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEPROBAMATE, MEPROBAMATE
 METHYLDOPA, METHYLDOPA
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NABUMETONE, NABUMETONE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- * WATSON LABS INC
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

- * WATSON LABORATORIES INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMBRISENTAN, AMBRISENTAN
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BOSENTAN, BOSENTAN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WATSON LABORATORIES INC
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 PENICILLAMINE, PENICILLAMINE
 PERPHENAZINE, PERPHENAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALVIMOPAN, ALVIMOPAN
 BICALUTAMIDE, BICALUTAMIDE
 BUPRENORPHINE, BUPRENORPHINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 GLIPIZIDE, GLIPIZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ISRADIPINE, ISRADIPINE
 LEVOFLOXACIN, LEVOFLOXACIN
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PROBENECID, PROBENECID
 SIMVASTATIN, SIMVASTATIN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WATSON PHARMS TEVA

* WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 RIFAMPIN, RIFAMPIN

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
 VISTOGARD, URIDINE TRIACETATE
 XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMRINONE LACTATE, INAMRINONE LACTATE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUMETANIDE, BUMETANIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CARBOPLATIN, CARBOPLATIN
 CEFOXITIN, CEFOXITIN SODIUM
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYCLOSPORINE, CYCLOSPORINE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DURAMORPH PF, MORPHINE SULFATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 INFUMORPH, MORPHINE SULFATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NALOXONE, NALOXONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOSTATIN, PENTOSTATIN
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 THIOTEPA, THIOTEPA
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
 CARISOPRODOL, CARISOPRODOL
 NATEGLINIDE, NATEGLINIDE
 PERPHENAZINE, PERPHENAZINE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

WINDLAS HLTHCARE

* WINDLAS HEALTHCARE PVT LTD
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE

WOCKHARDT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT LTD**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FAMOTIDINE, FAMOTIDINE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM
 LISINAPRIL, LISINAPRIL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIACIN, NIACIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

WOCKHARDT BIO AG*** WOCKHARDT BIO AG**

ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DECITABINE, DECITABINE
 DEXAMETHASONE, DEXAMETHASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 GENERLAC, LACTULOSE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT BIO AG**

MEGESTROL ACETATE, MEGESTROL ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID

WOCKHARDT LTD*** WOCKHARDT LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENTACAPONE, ENTACAPONE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA*** WOCKHARDT USA INC**

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

*** WOCKHARDT USA LLC**

LANSOPRAZOLE, LANSOPRAZOLE

WOODWARD*** WOODWARD PHARMA SERVICES LLC**

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE

WRASER PHARMS*** WRASER PHARMACEUTICALS LLC**

CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC*** WRASER PHARMACEUTICALS LLC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON*** WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS*** WYETH PHARMACEUTICALS LLC**

DUAVEE, BAZEDOXIFENE ACETATE
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTONIX, PANTOPRAZOLE SODIUM
 TRECATOR, ETHIONAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WYETH PHARMACEUTICALS LLC
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 ZOSYN, PIPERACILLIN SODIUM

**** X ******X GEN PHARMS**

* X GEN PHARMACEUTICALS INC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 AMPHOTERICIN B, AMPHOTERICIN B
 BACIIM, BACITRACIN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NYSTATIN, NYSTATIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC

* X-GEN PHARMACEUTICALS INC
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DACTINOMYCIN, DACTINOMYCIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
 BACITRACIN, BACITRACIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TIGECYCLINE, TIGECYCLINE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

XERIS

* XERIS PHARMACEUTICALS INC
 GVOKE HYPOPEN, GLUCAGON
 GVOKE PFS, GLUCAGON

XIAMEN LP PHARM CO

* XIAMEN LP PHARMACEUTICAL CO LTD
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

XIROMED

* XIROMED PHARMA ESPANA SL
 ALTAVERA, ETHINYL ESTRADIOL
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 ELIFEMME, ETHINYL ESTRADIOL
 ESTARYLLA, ETHINYL ESTRADIOL
 FLUOCINONIDE, FLUOCINONIDE
 INTROVALE, ETHINYL ESTRADIOL
 ISIBLOOM, DESOGESTREL
 JAIMIESS, ETHINYL ESTRADIOL
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORYNA, DROSPIRENONE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROGESTERONE, PROGESTERONE
 SYEDA, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ****

- * XIROMED PHARMA ESPANA SL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

XSPIRE PHARMA

- * XSPIRE PHARMA
NALFON, FENOPROFEN CALCIUM
- * XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

- * XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

XTTRIUM LABS INC

- * XTTRIUM LABORATORIES INC
LACTULOSE, LACTULOSE

**** Y ******YABAO PHARM**

- * YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YAOPHARMA CO LTD

- * YAOPHARMA CO LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL

- * YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

YILING PHARM LTD

- * YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE

YUNG SHIN PHARM

- * YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** Z ******ZAMBON SPA**

- * ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZENNOVA

- * ZENNOVA LLC
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

ZENPEP

- * ZENPEP LLC
ZENPEP, PANCRELIPASE (AMYLASE)

ZHEJIANG HISUN PHARM

- * ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JUTAI PHARM

- * ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******ZHEJIANG YONGTAI**

* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZO SKIN HEALTH

* ZO SKIN HEALTH
 TRETINOIN, TRETINOIN

ZYDUS

* ZYDUS WORLDWIDE DMCC
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LEFLUNOMIDE, LEFLUNOMIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 PHYTONADIONE, PHYTONADIONE
 URSODIOL, URSODIOL

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS NOVELTECH INC

* ZYDUS NOVELTECH INC
 RIVASTIGMINE, RIVASTIGMINE

ZYDUS PHARMS

* ZYDUS PHARMACEUTICALS USA INC
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ACYCLOVIR, ACYCLOVIR
 ALBENDAZOLE, ALBENDAZOLE
 ALLOPURINOL, ALLOPURINOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMBRISENTAN, AMBRISENTAN
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BOSENTAN, BOSENTAN
 BUDESONIDE, BUDESONIDE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA, CARBIDOPA
 CHLORTHALIDONE, CHLORTHALIDONE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEFERASIROX, DEFERASIROX
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 DESOXIMETASONE, DESOXIMETASONE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ENTECAVIR, ENTECAVIR
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETODOLAC, ETODOLAC
 ETOMIDATE, ETOMIDATE
 EXEMESTANE, EXEMESTANE
 EZETIMIBE, EZETIMIBE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE, FLUOCINONIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LINEZOLID, LINEZOLID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NADOLOL, NADOLOL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RAMELTEON, RAMELTEON
 SIROLIMUS, SIROLIMUS
 SPIRONOLACTONE, SPIRONOLACTONE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TADALAFIL, TADALAFIL
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMOZOLOMIDE, TEMOZOLOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 AZATHIOPRINE, AZATHIOPRINE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 LAMOTRIGINE, LAMOTRIGINE
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SIMVASTATIN, SIMVASTATIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 CARVEDILOL, CARVEDILOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 OMEPRAZOLE, OMEPRAZOLE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

40TH EDITION - 2020 - APPROVED DRUG PRODUCT LIST

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL, FOAM	OINTMENT
AEROSOL, METERED	OINTMENT, AUGMENTED
BAR, CHEWABLE	PASTE
CAPSULE	PATCH
CAPSULE, DELAYED REL PELLETS	PELLET
CAPSULE, DELAYED RELEASE	PELLETS
CAPSULE, EXTENDED RELEASE	POWDER
CLOTH	POWDER, EXTENDED RELEASE
CONCENTRATE	POWDER, METERED
CREAM	RING
CREAM, AUGMENTED	SHAMPOO
ELIXIR	SOLUTION
EMULSION	SOLUTION FOR SLUSH
ENEMA	SOLUTION, EXTENDED RELEASE
FILM	SOLUTION, GEL FORMING/DROPS
FILM, EXTENDED RELEASE	SOLUTION, METERED
FOAM	SOLUTION/DROPS
FOR SOLUTION	SPONGE
FOR SUSPENSION	SPRAY
FOR SUSPENSION, DELAYED RELEASE	SPRAY, METERED
FOR SUSPENSION, EXTENDED RELEASE	SUPPOSITORY
GAS	SUSPENSION
GEL	SUSPENSION, EXTENDED RELEASE
GEL, AUGMENTED	SUSPENSION, LIPOSOMAL
GEL, METERED	SUSPENSION/DROPS
GRANULE	SWAB
GRANULE, DELAYED RELEASE	SYRUP
GUM, CHEWING	SYSTEM
IMPLANT	SYSTEM, EXTENDED RELEASE
INHALANT	TABLET
INJECTABLE	TABLET, CHEWABLE
INJECTABLE, LIPID COMPLEX	TABLET, DELAYED RELEASE
INJECTABLE, LIPOSOMAL	TABLET, EFFERVESCENT
INJECTION, EXTENDED RELEASE	TABLET, EXTENDED RELEASE
INSERT	TABLET, EXTENDED RELEASE, CHEWABLE
INSERT, EXTENDED RELEASE	TABLET, FOR SUSPENSION
INTRAUTERINE DEVICE	TABLET, ORALLY DISINTEGRATING
JELLY	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
LIQUID	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
LOTION	TAPE
LOTION, AUGMENTED	TROCHE/LOZENGE
LOTION/SHAMPOO	
OIL	
OIL/DROPS	

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL	INTRAVESICAL
DENTAL	INTRAVITREAL
ENDOCERVICAL	IRRIGATION
ENDOTRACHEAL	IV (INFUSION)
ENTERAL	N/A
IMPLANTATION	NASAL
INHALATION	OPHTHALMIC
INJECTION	ORAL
INTERSTITIAL	ORAL-21
INTRA-ANAL	ORAL-28
INTRA-ARTERIAL	OTIC
INTRA-ARTICULAR	PERFUSION, CARDIAC
INTRACRANIAL	PERIODONTAL
INTRADERMAL	RECTAL
INTRAMUSCULAR	SPINAL
INTRAOCULAR	SUBCUTANEOUS
INTRAOSSEOUS	SUBLINGUAL
INTRAPERITONEAL	TOPICAL
INTRAPLEURAL	TRANSDERMAL
INTRATHECAL	TRANSMUCOSAL
INTRATRACHEAL	URETHRAL
INTRAUTERINE	VAGINAL
INTRAVENOUS	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS****ABBREVIATIONS**

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
SC	SUBCUTANEOUS
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c) (3) (E) and Section 505(j) (5) (F) of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j) (5) (B) (iv) of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j) (5) (B) (v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.¹ FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the NDA or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b) (2) application or ANDA.²

The patents that FDA regards as covered by the statutory provisions for submission of patent information are:

- Patents that claim the drug substance (i.e., active ingredient(s))
- Drug product patents, which include formulation/composition patents
- Method-of-use patents that claim one or more approved methods of using the approved drug product

This information, as provided by the sponsor on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the [Orange Book](#), updated daily, should be consulted for the most recent patent and exclusivity information.

¹ Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x) (1) and (2) of the FD&C Act).

² See 21 CFR 314.50(i) (4) and 314.94(a) (12) (vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d) (5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001					I-765	Feb 07, 2021
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579	Y	I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580	Y		
	8822438	Aug 24, 2027	U-2235	Y		
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
	9889144	Mar 17, 2034	DP			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-817	Nov 21, 2022
	10167291	Jul 01, 2036	DP U-2666		NCE	Oct 31, 2022
	10167291	Jul 01, 2036	DP U-2667		ODE-175	Oct 31, 2024
	10167291	Jul 01, 2036	DP U-2668		ODE-274	Nov 21, 2026
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028		U-2262	M-196	Jan 27, 2020
	10383834	Nov 13, 2028		U-2621	PED	Jul 27, 2020
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031		U-2261		
	9399012	Sep 11, 2031		U-2262		
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028		U-2263		
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028		U-2261		
	9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767 001	8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP	U-2249		
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP	U-2249		
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP	U-2249		
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP			
	7976870	Jun 01, 2027		U-1498		
	8372432	Mar 11, 2029	DP	U-1499		
	8377453	Nov 19, 2029	DP	U-1499		
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029		U-1499		
	8741885	May 16, 2032	DP	U-1499		
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032		U-1499		
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025		U-1373		
	8653061	Aug 24, 2025		U-1373		
	8722738	Apr 06, 2032		U-1373		
	9327028	Jul 21, 2031		U-1839		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP	U-1373		
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032		U-1373		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP	U-1373		
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032		U-1373		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10034867	Jul 07, 2020	DP U-2513		
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP U-2513		
		8051851	Apr 22, 2027	DP		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10034867	Jul 07, 2020	DP U-2513	NC	Mar 29, 2022
		10034867	Jul 07, 2020	DP U-2514		
		10085974	Mar 13, 2029	DP U-2513		
		6681768	Aug 07, 2022	DP		
		7078412	Jul 07, 2020	DS DP U-2513		
		7750023	Jul 07, 2020	DP U-2513		
		8051851	Apr 22, 2027	DP		
		8129405	Jul 07, 2020	DP U-2513		
		9056100	Jul 07, 2020	DP U-2513		
		9333195	Jul 07, 2020	DP U-2513		
		RE46417	Feb 10, 2025	DS DP U-2513		
<u>ACYCLOVIR - AVACLYR</u>						
N 202408	001				ODE-235	Mar 29, 2026
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	8592434	Jun 16, 2030	DP U-1460		
		8747896	Jun 03, 2027	DP U-1460		
		8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	7223387	Nov 13, 2022	DP U-1006		
		7223387	Nov 13, 2022	DP U-1484		
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	7579377	Feb 23, 2025	U-818		
		7737181	Aug 29, 2024	DP		
		7834060	Mar 12, 2023	U-1078		
		7838558	Mar 12, 2023	DP		
		7868044	Mar 12, 2023	U-1078		
		8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	7998467	May 31, 2028	DP U-1078		
		8435502	Sep 15, 2026	DP U-1078		
		8709392	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	7820186	Nov 23, 2025	DP		
		7964202	Sep 01, 2024	DP U-1078		
		8071644	Jul 18, 2027	DP U-1078		
		8080537	Jul 18, 2027	U-1078		
		8105618	Dec 23, 2022	U-1078		
		8129362	Jul 18, 2027	U-1078		
		8241649	Dec 23, 2022	DP		
		8445543	Jul 12, 2027	U-1078		
		8809305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001	8445543	Dec 23, 2022	U-1078		
		8703820	Mar 12, 2023	U-1078		
		8729127	Mar 12, 2023	U-1078		
		8785420	Dec 23, 2022	U-1078		
		8809305	Dec 23, 2022	U-1078		
		8936800	Dec 23, 2022	DP U-1078		
		9381179	Mar 12, 2023	U-1078		
		9387187	Mar 12, 2023	U-1078		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917	001 9814690	Dec 23, 2022	DP U-1078			
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797	001 10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003 10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
	8426586	Oct 10, 2029	DS		ODE-115	Apr 15, 2023
	8545884	Dec 19, 2029	DP		ODE-230	Jan 12, 2025
	9539258	Nov 09, 2026	U-1950		ODE-50	Jul 12, 2020
	RE43431	Jan 22, 2022	DS			
<u>AIR POLYMER-TYPE A - EXEM FOAM KIT</u>						
N 212279	001 9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899	001 6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949	001 6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949	002 6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983	001 7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001 10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	7105152	Sep 12, 2023	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001 10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001 9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002 10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950	001 6632842	Dec 28, 2021		U-532		
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001 6988496	Feb 23, 2020	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134	001 8664215	Dec 23, 2027		U-1493		
<u>ALCOHOL - ABLYSINOL</u>						
N 207987	001				ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u>						
N 207987	002				ODE-192	Jun 21, 2025
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001 9126931	May 29, 2031	DS		I-756	Nov 06, 2020
	9365514	Mar 04, 2032	DP		NCE	Dec 11, 2020
	9440922	Jun 09, 2030	DP		ODE-105	Dec 11, 2022
					ODE-159	Nov 06, 2024
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344	001 7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985	001 8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985	002 8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 210709	001				NP	Nov 14, 2020
					PED	May 14, 2021
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001 8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002 8613949	Dec 21, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004	8613949	Dec 21, 2029	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	004	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	005	8183295	May 16, 2023	DP		
		8618174	Nov 15, 2021	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	001	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	002	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	003	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107	004	8618172	Jul 13, 2028	DP		
		9023893	Mar 03, 2022	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	001	8168616	Jul 03, 2026	DP		
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217	002	8168616	Jul 03, 2026	DP		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	10183012	Nov 26, 2028			U-2104
		8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029			U-2104
		8283369	Nov 26, 2028			U-2104
		8357713	Nov 26, 2028	DP		U-2104
		8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029			U-2104
		9216179	Aug 01, 2031			U-2104
		9956205	Dec 28, 2031			U-2104
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002	10183012	Nov 26, 2028			U-2104
		8003681	Aug 25, 2025	DS		
		8084483	Aug 17, 2029			U-2104
		8283369	Nov 26, 2028			U-2104
		8357713	Nov 26, 2028	DP		U-2104
		8546436	Feb 29, 2032	DS		
		8546437	Apr 29, 2029			U-2104
		9216179	Aug 01, 2031			U-2104
		9956205	Dec 28, 2031			U-2104

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	002	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	003	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Dec 02, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8697125	Jun 16, 2029	DP		
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029	DP		
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002	7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Jun 24, 2025	DS		
		8900638	May 24, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	005	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		
		8637079	Jun 04, 2029	DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006	6329404	Jun 19, 2021		DP U-1334	
		7807689	Jun 27, 2028	DS DP	U-1337	
		8173663	Mar 15, 2025		U-1338	
		8288539	Mar 15, 2025	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	006 8637079	Jun 04, 2029	DP			
<u>ALPELISIB - PIORAY</u>						
N 212526	001 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526	002 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526	003 8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775	001 6469030	Nov 29, 2020	U-879			
	8112290	Jul 31, 2030	U-1443	Y		
	8645160	Jun 18, 2029	U-1485	Y		
	8946262	Feb 12, 2030	U-1655			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	001 10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
	8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	002 10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
	8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001 10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002 10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002	8252331				
		Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	003	10213393				
		Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	001	8377933				
		Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081	002	8377933				
		Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321	001				ODE-244	May 06, 2026
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPOSE</u>						
N 208078	001				NCE ODE-223	Nov 28, 2023 Nov 28, 2025
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356	001	10251900				
		May 15, 2035	U-2414		ODE-214	Sep 28, 2025
	7718189	Jun 06, 2025	DP U-2415		GAIN	Sep 28, 2030
	8226975	Aug 15, 2028	DP			
	8632804	Dec 05, 2026	U-2416			
	8642075	Dec 05, 2026	DP			
	8679532	Dec 05, 2026	U-2415			
	8802137	Apr 08, 2024	DP U-2414			
	9566234	Jan 18, 2034	DP U-2415			
	9827317	Apr 08, 2024	DP U-2415			
	9895385	May 15, 2035	U-2417			
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212492	001				CGT	May 30, 2020
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780	001				CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965	001	10357567				
		Jan 12, 2038	U-804		I-766	Mar 09, 2021
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630	001				ODE-146	Jun 06, 2024
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	001	6869939				
		May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	002	6869939				
		May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	003	6869939				
		May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	001	6828339				
		Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	002	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	003	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	001	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	002	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	003	10350171	Jun 14, 2038	DP	NC	May 31, 2021
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	6544555	Oct 13, 2020	DS DP U-897		
		6669948	Oct 13, 2020	DS DP U-897		
		6723341	Oct 13, 2020	DS DP U-897		
		8299052	May 07, 2027		U-1304	
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020		U-926	
		7217430	Apr 04, 2020	DP	U-926	
		7250176	Apr 04, 2020		U-926	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004	001	10238606	Feb 12, 2034	DP		
		9050263	Feb 12, 2034	DP	U-2660	
		9498445	Feb 12, 2034	DP	U-2660	
		9603806	Feb 12, 2034	DP	U-2660	
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325	001	8709491	Jun 28, 2032	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147	001	10086087	Mar 15, 2027	DP		
		8062667	Mar 29, 2029	DP		
		8597684	Mar 15, 2027	DP		
		8747902	Mar 15, 2027	DP		
		8883217	Mar 15, 2027	DP		
		9675703	Mar 15, 2027	DP		
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522	007	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522	008	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522	009	6384020	Jul 06, 2020			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522	010	6384020	Jul 06, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522	011	6384020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522	012	6384020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522	013	6384020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	001	6913768	May 24, 2023	DP U-2025	M-248	Sep 13, 2022
		8846100	Aug 24, 2029	DP	NP	Jun 20, 2020
		9173857	May 12, 2026	U-2025	PED	Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	002	6913768	May 24, 2023	DP U-2025	M-248	Sep 13, 2022
		8846100	Aug 24, 2029	DP	NP	Jun 20, 2020
		9173857	May 12, 2026	U-2025	PED	Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	003	6913768	May 24, 2023	DP U-2025	M-248	Sep 13, 2022
		8846100	Aug 24, 2029	DP	NP	Jun 20, 2020
		9173857	May 12, 2026	U-2025	PED	Mar 13, 2023
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063	004	6913768	May 24, 2023	DP U-2025	M-248	Sep 13, 2022
		8846100	Aug 24, 2029	DP	NP	Jun 20, 2020
		9173857	May 12, 2026	U-2025	PED	Mar 13, 2023
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	001	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	002	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	003	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	004	10130580	Apr 19, 2024	DP		
		10441554	Mar 10, 2037	DP		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		10335451	Dec 16, 2029	U-2581		
		10493124	Dec 18, 2034	U-2679		
		10500247	Dec 16, 2029	U-2680		
		10500247	Dec 16, 2029	U-2681		
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Nov 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		10335451	Dec 16, 2029	U-2581		
		10493124	Dec 18, 2034	U-2679		
		10500247	Dec 16, 2029	U-2680		
		10500247	Dec 16, 2029	U-2681		
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Nov 20, 2030	U-2221		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	9867863	Dec 16, 2029	U-2231		
<u>ANIDULAFUNGIN - ERAxis</u>						
N 021632	001	5965525	Feb 17, 2020	DS DP	U-540	
		6960564	Apr 12, 2021	DP	U-540	
		7709444	Apr 12, 2021	DP	U-540	
<u>ANIDULAFUNGIN - ERAxis</u>						
N 021632	002	5965525	Feb 17, 2020	DS DP	U-540	
		6960564	Apr 12, 2021	DP	U-540	
		7709444	Apr 12, 2021	DP	U-540	
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	10052314	Sep 23, 2033	U-2381	I-808	Sep 17, 2022
		10052314	Sep 23, 2033	U-2382	NCE	Feb 14, 2023
		8445507	Sep 15, 2030	DS DP	U-2237	
		8445507	Sep 15, 2030	DS DP	U-2624	
		8802689	Mar 27, 2027	U-2237		
		8802689	Mar 27, 2027	U-2624		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP	U-2237	
		9481663	Jun 04, 2033	DS DP	U-2624	
		9884054	Sep 23, 2033	U-2237		
		9987261	Mar 27, 2027	DP		
<u>APIXABAN - ELIQUIS</u>						
N 202155	001	6967208	Nov 21, 2026	DS DP	U-1167	
		6967208	Nov 21, 2026	DS DP	U-1200	
		6967208	Nov 21, 2026	DS DP	U-1301	
		6967208	Nov 21, 2026	DS DP	U-1302	
		6967208	Nov 21, 2026	DS DP	U-1323	
		6967208	Nov 21, 2026	DS DP	U-1501	
		6967208	Nov 21, 2026	DS DP	U-1502	
		6967208	Nov 21, 2026	DS DP	U-1729	
		6967208	Nov 21, 2026	DS DP	U-1730	
		9326945	Feb 24, 2031	DP		
<u>APIXABAN - ELIQUIS</u>						
N 202155	002	6967208	Nov 21, 2026	DS DP	U-1200	
		6967208	Nov 21, 2026	DS DP	U-1301	
		6967208	Nov 21, 2026	DS DP	U-1302	
		6967208	Nov 21, 2026	DS DP	U-1323	
		9326945	Feb 24, 2031	DP		
<u>APREMILAST - OTEZLA</u>						
N 205437	001	10092541	May 29, 2034	U-2403	I-803	Jul 19, 2022
		10092541	May 29, 2034	U-2659	ODE-248	Jul 19, 2026
		6962940	Mar 19, 2023	U-1504		
		6962940	Mar 19, 2023	U-2656		
		6962940	Mar 19, 2023	U-2657		
		6962940	Mar 19, 2023	U-2658		
		7208516	Mar 19, 2023	U-1505		
		7427638	Feb 16, 2028	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7659302	Mar 19, 2023	U-2657		
		7659302	Mar 19, 2023	U-2658		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8455536	Mar 19, 2023	U-2657		
		8455536	Mar 19, 2023	U-2658		
		8802717	Mar 19, 2023	U-1561		
		9018243	Mar 19, 2023	U-1505		
		9018243	Mar 19, 2023	U-1595		
		9018243	Mar 19, 2023	U-2656		
		9018243	Mar 19, 2023	U-2657		
		9018243	Mar 19, 2023	U-2658		
		9724330	Mar 19, 2023	U-1561		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-1504			
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-1504			
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437	003	9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREPITANT - EMEND</u>						
N 021549	001	8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 021549	002	8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 021549	003	8258132	Sep 26, 2027	DP U-1743		
		8258132	Sep 26, 2027	DP U-901		
<u>APREPITANT - EMEND</u>						
N 207865	001	8258132	Sep 26, 2027	DP U-1916		
<u>APREPITANT - CINVANTI</u>						
N 209296	001	10500208	Sep 18, 2035	DP		
		9561229	Sep 18, 2035	DP U-2161		
		9808465	Sep 18, 2035	U-2161		
		9974742	Sep 18, 2035	DP		
		9974793	Sep 18, 2035	DP		
		9974794	Sep 18, 2035	DP U-2161		
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912	001	6472563	Nov 09, 2021	DS		
		6667344	Jun 22, 2021	DP		
		6720453	Nov 09, 2021	DS		
		6814953	Jun 22, 2021	U-793		
		7145036	Nov 09, 2021	DS		
		7348362	Jun 22, 2021	DP U-793		
		7462645	Jun 22, 2021	U-793		
		7465756	Jun 22, 2021	DP		
		7473710	Jun 22, 2021	U-793		
		7541385	Jun 22, 2021	U-793		
		8110706	Nov 09, 2021	DP		
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434	001	7589106	Sep 26, 2027	DP U-1163		
		7687516	Sep 26, 2027	DP U-1164		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436	001	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			
		8759350	Mar 02, 2027	U-1529		
		9089567	Jan 28, 2022	U-543		
		9125939	Jul 28, 2026	U-1749		
		9359302	Sep 25, 2022	DS DP U-1859		
		9387182	Dec 25, 2023	U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436	002	7053092	Jan 28, 2022	U-839	ODE-80	Dec 12, 2021
		8017615	Jun 16, 2024	DP		
		8017615*PED	Dec 16, 2024			
		8580796	Sep 25, 2022	DS		
		8580796*PED	Mar 25, 2023			
		8642600	Jan 28, 2022	U-1492		
		8642600*PED	Jul 28, 2022			
		8642760	Sep 25, 2022	DS		
		8642760*PED	Mar 25, 2023			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	6977257	Apr 24, 2022	DP		ODE-80	Dec 12, 2021
	6977257*PED	Oct 24, 2022				
	7053092	Jan 28, 2022		U-839		
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027		U-1529		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020		DP		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005	7053092	Jan 28, 2022		U-839	ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020		DP		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866 001	7115587	Jul 21, 2024	DP	U-764	ODE-80	Dec 12, 2021
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024		U-1632		
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338427	Mar 15, 2025	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024		U-1632		
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338427	Mar 15, 2025	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024		U-1632		
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338427	Mar 15, 2025	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8399469	Jun 29, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	8759350	Mar 02, 2027				
	8847766	Mar 29, 2030	DP			
	8945005	Aug 19, 2029	DP			
	8956288	Jul 06, 2029	DP			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9577864	Oct 03, 2033	DP		U-2169	
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	May 12, 2029				
	7053092	Jan 28, 2022				
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9577864	Oct 03, 2033	DP		U-2169	
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	May 12, 2029				
	7053092	Jan 28, 2022				
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	May 12, 2029	DP		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10016415	Sep 08, 2035	DP		NCE	Oct 05, 2020
	10112903	Jun 24, 2030	DS	U-543		
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030		U-543		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001					ODE-167	Jan 12, 2025
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002					ODE-167	Jan 12, 2025
<u>ASCORBIC ACID - ASCOR</u>						
N 209112 001					ODE-160	Oct 02, 2024
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	10016504	Sep 10, 2033	DP		NP	May 04, 2021
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033		U-2310		
	9592252	Aug 11, 2032	DP	U-2310		
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP	U-1960	D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP	U-1961	I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP	U-1962		
	5763476	Jun 09, 2020	DP	U-1963		
	5763476	Jun 09, 2020	DP	U-326		
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP	U-1064		
	7741358	Apr 06, 2026	DS DP	U-1960		
	7741358	Apr 06, 2026	DS DP	U-1961		
	7741358	Apr 06, 2026	DS DP	U-1962		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-1960		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476	Jun 09, 2020	DP U-326			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	8865187	Mar 23, 2022	DP			
	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	10039718	Oct 04, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					M-204	Jun 23, 2020
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
	7501409	May 05, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
	7501409	May 05, 2023	DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	May 05, 2025	DS DP		I-802	Jun 26, 2022
	8338429	Jun 30, 2023	U-2577		NCE	May 21, 2023
	8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
	8765764	Jan 15, 2023	U-2578			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
	7141581	Jun 30, 2020	U-1220			
	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
	7141581	Jun 30, 2020	U-1220			
	8791140	Dec 14, 2030	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	10117812	Oct 18, 2027	DP U-1796			
	10322085	Oct 24, 2023	DP			
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
	9211259	Feb 28, 2029	U-1796			
	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-1667			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-81			
	8163723*PED	Feb 29, 2024				
	8168620	Feb 24, 2026	DP			
	9259428	Jun 13, 2023	U-644			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	9259428*PED 9901585	Dec 13, 2023 Jun 13, 2023	DP		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	001	7157584 7572920 9066936	May 22, 2025 Jan 07, 2025 Mar 26, 2028	DS DP U-3 DP		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	002	7157584 7572920 9066936	May 22, 2025 Jan 07, 2025 Mar 26, 2028	DS DP U-3 DP		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001	7157584 7572920 9066936 9169238 9387249	May 22, 2025 Jan 07, 2025 Mar 26, 2028 Feb 04, 2030 Jul 01, 2031	DS DP U-3 DP DP U-3		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002	7157584 7572920 9066936 9169238 9387249	May 22, 2025 Jan 07, 2025 Mar 26, 2028 Feb 04, 2030 Jul 01, 2031	DS DP U-3 DP DP U-3		
<u>AZITHROMYCIN - ZMAX</u>						
N 050797	001	6984403 7887844	Feb 14, 2024 Feb 14, 2024	DP U-282 DP		
<u>AZTREONAM - CAYSTON</u>						
N 050814	001	7208141 7214364 7427633 8399496	Dec 20, 2021 Dec 20, 2021 Dec 20, 2021 Dec 20, 2021	DP U-1031 DP DP U-1031 DP U-1377		
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	001	10392406 8927710 8987441 9815835	Apr 27, 2036 May 05, 2031 Sep 21, 2031 Jun 14, 2030	DS DP DS DP DP	I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854	002	10392406 8927710 8987441 9815835	Apr 27, 2036 May 05, 2031 Sep 21, 2031 Jun 14, 2030	DS DP DS DP DP	I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610	001	7452872 7625884	Aug 24, 2026 Aug 24, 2026	U-141 U-141		
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205	001	7452872 7625884 8497256 9192616	Aug 24, 2026 Aug 24, 2026 Jun 23, 2031 Aug 02, 2026	U-1229 U-1229 U-1229 U-1229		
<u>BARICITINIB - OLUMIANT</u>						
N 207924	001	8158616 8420629	Jun 08, 2030 Mar 10, 2029	DS DP U-247	NCE	May 31, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	6479535 6479535 7683051 7683051	May 06, 2024 May 06, 2024 Mar 10, 2027 Mar 10, 2027	DP U-594 DP U-904 DS DP U-594 DS DP U-904		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIIHALER</u>						
N 207921 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIIHALER</u>						
N 207921 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321		NPP	Aug 09, 2022
	8546428	Mar 19, 2029	DS DP U-1321		ODE-251	Aug 09, 2026
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		ODE-68	Jul 03, 2021
	8835501	Oct 27, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	002	8609863*PED	Jul 12, 2026			
		8669279	Mar 26, 2029	DP U-1402		
		8669279*PED	Sep 26, 2029			
		8791270	Jan 12, 2026	DP U-1542		
		8791270*PED	Jul 12, 2026			
		8883836	Mar 26, 2029	DP U-1402		
		8883836*PED	Sep 26, 2029			
		8895756	Jan 12, 2026	DP		
		8895756*PED	Jul 12, 2026			
		9533955	Mar 26, 2029	DP U-1949		
		9533955	Mar 26, 2029	DP U-1952		
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	003	8344006	Sep 23, 2029	DP U-1402		
		8344006*PED	Mar 23, 2030			
		8445524	Mar 26, 2029	DS		
		8445524*PED	Sep 26, 2029			
		8791270	Jan 12, 2026	DP U-1542		
		8791270*PED	Jul 12, 2026			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	004	8344006	Sep 23, 2029	DP U-1402		
		8344006*PED	Mar 23, 2030			
		8445524	Mar 26, 2029	DS		
		8445524*PED	Sep 26, 2029			
		8791270	Jan 12, 2026	DP U-1542		
		8791270*PED	Jul 12, 2026			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580	001	10010533	Jan 28, 2031	DP		
		8609707	Aug 11, 2031	DP U-1971		
		8609707	Aug 11, 2031	DP U-1972		
		8791270	Jan 12, 2026	DP U-1971		
		8791270	Jan 12, 2026	DP U-1972		
		9265831	Jan 28, 2031	DP		
		9572796	Jan 28, 2031	DP U-1971		
		9572796	Jan 28, 2031	DP U-1972		
		9572797	Jan 28, 2031	U-1971		
		9572797	Jan 28, 2031	U-1972		
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194	001	10010533	Jan 28, 2031	DP	ODE-179	Dec 07, 2022
		10052385	Mar 15, 2033	U-1971		
		10052385	Mar 15, 2033	U-1972		
		8609707	Aug 11, 2031	DP U-1542		
		8791270	Jan 12, 2026	DP U-1790		
		9000021	Mar 15, 2033	U-1542		
		9034908	Mar 15, 2033	U-1542		
		9144568	Mar 15, 2033	U-1542		
		9265831	Jan 28, 2031	DP		
		9572796	Jan 28, 2031	DP U-1971		
		9572796	Jan 28, 2031	DP U-1972		
		9572797	Jan 28, 2031	U-1971		
		9572797	Jan 28, 2031	U-1972		
		9572887	Mar 15, 2033	U-1971		
		9572887	Mar 15, 2033	U-1972		
		9579384	Mar 15, 2033	U-1971		
		9579384	Mar 15, 2033	U-1972		
		9597397	Mar 15, 2033	U-1971		
		9597397	Mar 15, 2033	U-1972		
		9597398	Mar 15, 2033	U-1971		
		9597399	Mar 15, 2033	U-1971		
		9597399	Mar 15, 2033	U-1972		
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570	001				NCE	Aug 29, 2022
					ODE-154	Aug 29, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570	002				NCE ODE-154	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	10220049	Jun 03, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-124		
		8663699	Jun 03, 2029	U-124		
		8895070	Jun 03, 2029	U-124		
		9078870	Jun 03, 2029	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	10137142	Jun 03, 2029	DP U-916		
		10220049	Jun 03, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-1033		
		8288434	Aug 05, 2029	DP U-124		
		8288434	Aug 05, 2029	DP U-134		
		8288434	Aug 05, 2029	DP U-818		
		8288434	Aug 05, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-921		
		9504704	Jun 03, 2029	DP U-124		
		9504704	Jun 03, 2029	DP U-134		
		9504704	Jun 03, 2029	DP U-818		
		9504704	Jun 03, 2029	DP U-916		
		9561208	Jun 03, 2029	DP U-916		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129	001	6793931	Jul 11, 2022	DP U-970		
		7294342	May 19, 2024	U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288	001	8784789	Sep 05, 2024	DP		
		8877168	Jul 30, 2023	DP		
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308	001	6685958	Jun 29, 2021	DP U-80		
		8415342	Nov 07, 2030	U-80		
		8481526	Jan 09, 2031	DS		
		8604020	Mar 12, 2030	DP		
		8937062	Nov 13, 2029	U-80		
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	10179137	Aug 31, 2030	DP U-1858		
		9364485	Aug 31, 2030	DP U-1858		
		9433630	Aug 31, 2030	DP U-1858		
		9439911	Aug 31, 2030	DP U-1858		
		9655907	Aug 31, 2030	DP U-1858		
		9775851	Aug 31, 2030	DP U-1858		
		9877974	Aug 31, 2030	DP U-1858		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 021852	001	6753013	Jan 27, 2020	DP U-193		
		6753013	Jan 27, 2020	DP U-88		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185	001	6753013	Jan 27, 2020	DP U-1761	NPP	Jul 25, 2022
		6753013	Jan 27, 2020	DP U-193	PED	Jan 25, 2023
		6753013	Jan 27, 2020	DP U-88		
		6787529	Jan 27, 2020	DP U-1761		
		6787529	Jan 27, 2020	DP U-193		
		6787529	Jan 27, 2020	DP U-88		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589	001	10130640	Jun 10, 2031	DP	NPP	Jul 30, 2022
		10130640*PED	Dec 10, 2031		PED	Jan 30, 2023
		6753013	Jan 27, 2020	DP U-1761		
		6753013	Jan 27, 2020	DP U-2627		
		9119781	Jun 10, 2031	DP U-1761		
		9119781	Jun 10, 2031	DP U-2627		
		9119781*PED	Dec 10, 2031			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589	001	9566286	Jun 10, 2031	DP		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BETRIXABAN - BEVYXXA</u>						
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167	NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502		
		6376515	Sep 15, 2020	DS DP U-2029		
		6376515	Sep 15, 2020	DS DP U-2030		
		6835739	Sep 15, 2020	DS DP		
		7598276	Nov 08, 2026	DS		
		8404724	Mar 29, 2031	DP U-2034		
		8518977	Sep 15, 2020	DS		
		8557852	Sep 08, 2028	U-1167		
		8557852	Sep 08, 2028	U-2030		
		8691847	Sep 15, 2020	DS DP U-2029		
		8691847	Sep 15, 2020	DS DP U-2035		
		8987463	Dec 28, 2030	DP		
		9555023	Nov 07, 2026	U-1502		
		9629831	Sep 15, 2020	U-1167		
		9629831	Sep 15, 2020	U-1502		
		9629831	Sep 15, 2020	U-2030		
		9629831	Sep 15, 2020	U-2035		
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	001	10385067	Jun 19, 2035	U-257	NCE	Feb 07, 2023
		6642245	Nov 04, 2020	U-257	NPP	Jun 18, 2022
		6703396	Mar 09, 2021	DS DP	ODE-256	Jun 18, 2026
		7390791	May 07, 2022	DS DP		
		7803788	Feb 02, 2022	U-257		
		8754065	Aug 15, 2032	DS DP U-257		
		9216996	Dec 19, 2033	DS DP		
		9296769	Aug 15, 2032	DS DP U-257		
		9708342	Jun 19, 2035	DS DP		
		9732092	Dec 19, 2033	DS DP		
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	7851504	Jun 13, 2027	DS DP		
		8278353	Mar 16, 2025	DP		
		8299118	Mar 16, 2025	U-1295		
		8309605	Mar 16, 2025	U-1293		
		8309605	Mar 16, 2025	U-1294		
		8338479	Mar 16, 2025	DP U-1295		
		8524777	Mar 16, 2025	U-1235		
		8586630	Mar 16, 2025	U-1458		
		8772338	Mar 16, 2025	DP U-1528		
		8933120	Mar 16, 2025	DP		
		8933127	Mar 16, 2025	DP		
		9155716	Mar 16, 2025	DP U-1528		
		9241918	Mar 16, 2025	DP U-1814		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	8038988	Aug 25, 2023	DS DP U-1208		
		8101161	May 25, 2024	U-1217		
		8101161	May 25, 2024	U-1218		
		8263054	Jan 15, 2023	U-1277		
		8541466	Jan 31, 2021	U-1217		
		8632760	Jan 15, 2023	U-1487		
		8758733	Jan 15, 2023	U-1487		
		8906962	Jan 31, 2021	U-1217		
		8986715	Jan 15, 2023	U-1217		
		9216183	Jan 15, 2023	U-1487		
		9226931	Jan 15, 2023	U-1799		
		9579270	Jan 31, 2021	U-1975		
<u>BINIMETINIB - MEKTOVI</u>						
N 210498	001	10005761	Aug 27, 2030	U-2331	NCE	Jun 27, 2023
		7777050	Mar 13, 2023	DS DP	ODE-194	Jun 27, 2025
		8178693	Mar 13, 2023	DS DP		
		8193229	Mar 13, 2023	U-2330		
		8513293	Mar 13, 2023	U-2331		
		9314464	Jul 04, 2031	U-2332		
		9562016	Oct 18, 2033	DS DP		
		9593100	Aug 27, 2030	DP		
		9598376	Oct 18, 2033	U-2330		
		9850229	Aug 27, 2030	U-2333		
		9980944	Oct 18, 2033	U-2334		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551	003	7291324	Oct 22, 2022	U-837		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873	001	7582727	Jul 27, 2028	DP		
		7598343	Jul 27, 2028	DP		
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258	001	7772178	Nov 11, 2027	DP U-1128		
		8119602	Mar 17, 2027	U-1233		
		RE43298	Dec 22, 2024	DS DP U-1128		
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001	6713446	Jan 25, 2022	DS DP	ODE-76	Oct 08, 2021
		6713446*PED	Jul 25, 2022		PED	Apr 08, 2022
		6958319	Jan 25, 2022	DS DP		
		6958319*PED	Jul 25, 2022			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004	001	8962572	Nov 03, 2032	DP		
<u>BOSENTAN - TRACLEER</u>						
N 021290	001				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290	002				NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279	001	7959945	Dec 28, 2027	DP	NP	Sep 05, 2020
		8309126	May 15, 2026	DP	ODE-161	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001	7417148	Dec 11, 2025	U-1283	I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP	ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP		
		RE42376	Apr 13, 2024	DS		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	002	7417148	Dec 11, 2025	U-1283	I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP	ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP		
		RE42376	Apr 13, 2024	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	003	7417148				
		Dec 11, 2025		U-1283	I-759	Dec 19, 2020
		7767678	DS DP		ODE-163	Dec 19, 2024
		Nov 23, 2026				
		7919625		DP		
		Dec 11, 2025				
		RE42376	DS			
		Apr 13, 2024				
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557	001	10286034				
		Nov 05, 2033		U-2568	NCE	Jun 21, 2024
		6579968	DS DP			
		Jun 28, 2020				
		6794489	DS DP			
		Jun 28, 2020				
		9352013		U-2568		
		Nov 05, 2033				
		9700592		U-2568		
		Nov 05, 2033				
<u>BREXANOLONE - ZULRESSO</u>						
N 211371	001	10117951				
		Mar 13, 2029	DP		NCE	Jun 17, 2024
		10251894		U-2552		
		Nov 27, 2033				
		10322139		DP		
		Jan 23, 2033				
		7635773		DP		
		Mar 13, 2029				
		8410077		DP		
		Mar 13, 2029				
		9200088		DP		
		Mar 13, 2029				
		9750822		DP		
		Mar 13, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	001	10307419				
		Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	DS			
		Apr 12, 2026				
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	002	10307419				
		Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	DS			
		Apr 12, 2026				
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	003	10307419				
		Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	DS			
		Apr 12, 2026				
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	004	10307419				
		Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	DS			
		Apr 12, 2026				
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	005	10307419				
		Oct 12, 2032	DP		NCE	Jul 10, 2020
		7888362	DS			
		Apr 12, 2026				
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	006	7888362				
		Apr 12, 2026	DS		NCE	Jul 10, 2020
		8349840		DP U-1529		
		Apr 12, 2026				
		8618109		U-543		
		Apr 12, 2026				
		9839637		DP U-1529		
		Apr 12, 2026				
		9839637		DP U-543		
		Apr 12, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	001	10385078	Nov 10, 2035	DS DP U-1927	NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS	ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927		
		9611283	Apr 10, 2034	U-1927		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	002	10385078	Nov 10, 2035	DS DP U-1927	NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS	ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927		
		9611283	Apr 10, 2034	U-1927		
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772	003	10385078	Nov 10, 2035	DS DP U-1927	NCE	Apr 28, 2022
		9012462	Jul 31, 2030	DS	ODE-142	Apr 28, 2024
		9273077	May 21, 2029	U-1927		
		9611283	Apr 10, 2034	U-1927		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262	001	6562873	Jul 10, 2021			
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
<u>BRIMONIDINE TARTRATE - QOLIANA</u>						
N 021764	001	7265117	Aug 19, 2025	DP		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001	10307368	Jul 10, 2021	DP		
		6562873	Jul 10, 2021	DP		
		6627210	Jul 18, 2021	DP		
		6641834	Jul 28, 2021	DP		
		6673337	Jul 26, 2021	DP		
		8858961	Sep 02, 2023	DP		
		8858961*PED	Mar 02, 2024			
		9295641	Jul 10, 2021	U-1833		
		9295641*PED	Jan 10, 2022			
		9687443	Jul 10, 2021	DP		
		9687443*PED	Jan 10, 2022			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	10201517	Jun 13, 2031	DP		
		7439241	Aug 25, 2025	U-1428		
		8053427	Jun 13, 2031	DP U-1428		
		8163725	Jun 13, 2031	DP		
		8231885	May 24, 2025	DP		
		8410102	May 24, 2025	U-1428		
		8426410	May 24, 2025	U-1428		
		8513247	Mar 25, 2031	DP U-1428		
		8513249	Mar 25, 2031	DP U-1428		
		8859551	May 25, 2024	U-1428		
		9861631	Mar 25, 2031	U-1428		
		9861632	Mar 25, 2031	U-1428		
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144	001	8293742	Jul 14, 2030	U-2222	NP	Dec 22, 2020
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251	001	9044484	Oct 30, 2030	DP		
		9421265	Jun 17, 2030	DP		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	7030149	Apr 19, 2022	U-849		
		7320976	Apr 19, 2022	U-849		
		7323463	Jan 19, 2023	DP	Y	
		7642258	Apr 19, 2022	DS DP U-1024		
		8133890	Apr 19, 2022	U-1235		
		8354409	Apr 19, 2022	DP U-1371		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
	9474751	Apr 19, 2022	DP U-1524			
	9770453	Apr 19, 2022	DP U-2131			
	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Aug 07, 2029	DP U-1834			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9352025	Jun 07, 2030				U-2111
	9352025	Jun 07, 2030				U-2112
	9352025	Jun 07, 2030				U-2113
	9352025	Jun 07, 2030				U-2114
	9352025	Jun 07, 2030				U-2115
	9352025	Jun 07, 2030				U-2116
	9352025	Jun 07, 2030				U-2117
	9352025	Jun 07, 2030				U-2118
	9352025	Jun 07, 2030				U-2119
	9522117	Apr 30, 2032	DP			U-1939
	9522117	Apr 30, 2032	DP			U-976
	9700555	Apr 30, 2032	DP			U-2183
	9700555	Apr 30, 2032	DP			U-2184
	9700555	Apr 30, 2032	DP			U-2185
	9700555	Apr 30, 2032	DP			U-2186
	9700555	Apr 30, 2032	DP			U-2187
	9700555	Apr 30, 2032	DP			U-2188
	9700555	Apr 30, 2032	DP			U-2189
	9700555	Apr 30, 2032	DP			U-2190
	9700555	Apr 30, 2032	DP			U-2191
	9700555	Apr 30, 2032	DP			U-2192
	9700555	Apr 30, 2032	DP			U-2193
	9700555	Apr 30, 2032	DP			U-2194
	9700555	Apr 30, 2032	DP			U-2195
	9700555	Apr 30, 2032	DP			U-2196
	9700555	Apr 30, 2032	DP			U-2197
	9700555	Apr 30, 2032	DP			U-2198
	9895422	Jun 07, 2030				U-2114
	9895422	Jun 07, 2030				U-2116
	9895422	Jun 07, 2030				U-2281
	9895422	Jun 07, 2030				U-2282
	9895422	Jun 07, 2030				U-2283
	9895422	Jun 07, 2030				U-2284
	9895422	Jun 07, 2030				U-2285
	9895422	Jun 07, 2030				U-2286
	9895422	Jun 07, 2030				U-2287
	9993474	Apr 30, 2032				U-2384
	9993474	Apr 30, 2032				U-2385
	9993474	Apr 30, 2032				U-2386
	9993474	Apr 30, 2032				U-2387
	9993474	Apr 30, 2032				U-2388
	9993474	Apr 30, 2032				U-2389
	9993474	Apr 30, 2032				U-2390
	9993474	Apr 30, 2032				U-2391
	9993474	Apr 30, 2032				U-2392
	9993474	Apr 30, 2032				U-2393
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10064878	Jun 09, 2020	DP			U-1325
	10105374	Jun 09, 2020	DP			U-1325
	10143698	Jun 09, 2020	DP			U-1325
	10307375	Sep 07, 2031	DP			
	7410651	Jun 09, 2020	DP			U-1325
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP			U-1325
	9320716	Jun 09, 2020	DP			U-1325
	9532954	Jun 09, 2020	DP			U-1325
	RE43799	Jun 09, 2020	DP			U-1325
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036				U-2554
	9707182	Sep 09, 2036	DP			U-2554

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
	10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
	10166247	Jan 29, 2023	DP U-2122		NPP	Jan 27, 2020
	10166247*PED	Jul 29, 2023			PED	Jul 27, 2020
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
	10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001					M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002					M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003					M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004					M-250	Oct 13, 2020
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005					M-250	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031		U-2489	NP	Nov 30, 2020
	8921387	Jan 06, 2032	DP	U-2173		
	8921387	Jan 06, 2032	DP	U-2174		
	8975270	Sep 05, 2031	DP	U-2175		
	8975270	Sep 05, 2031	DP	U-2206		
	9272044	Jun 06, 2031		U-2176		
	9272044	Jun 06, 2031		U-2177		
	9272044	Jun 06, 2031		U-2178		
	9272044	Jun 06, 2031		U-2209		
	9498432	Jun 06, 2031	DP	U-2179		
	9782402	Jun 06, 2031	DP	U-2176		
	9782402	Jun 06, 2031	DP	U-2180		
	9782402	Jun 06, 2031	DP	U-2207		
	9782402	Jun 06, 2031	DP	U-2208		
	9827241	Jun 06, 2031	DP	U-2174		
	9827241	Jun 06, 2031	DP	U-2181		
	9827241	Jun 06, 2031	DP	U-2206		
	9827241	Jun 06, 2031	DP	U-2210		
	9827241	Jun 06, 2031	DP	U-2211		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031		U-2489	NP	Nov 30, 2020
	8921387	Jan 06, 2032	DP	U-2173		
	8921387	Jan 06, 2032	DP	U-2174		
	8975270	Sep 05, 2031	DP	U-2175		
	8975270	Sep 05, 2031	DP	U-2206		
	9272044	Jun 06, 2031		U-2176		
	9272044	Jun 06, 2031		U-2177		
	9272044	Jun 06, 2031		U-2178		
	9272044	Jun 06, 2031		U-2209		
	9498432	Jun 06, 2031	DP	U-2179		
	9782402	Jun 06, 2031	DP	U-2176		
	9782402	Jun 06, 2031	DP	U-2180		
	9782402	Jun 06, 2031	DP	U-2207		
	9782402	Jun 06, 2031	DP	U-2208		
	9827241	Jun 06, 2031	DP	U-2174		
	9827241	Jun 06, 2031	DP	U-2181		
	9827241	Jun 06, 2031	DP	U-2206		
	9827241	Jun 06, 2031	DP	U-2210		
	9827241	Jun 06, 2031	DP	U-2211		
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024		U-1878		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	7579019	Jan 22, 2020		U-1769		
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	7579019	Jan 22, 2020				
	8147866	Jul 23, 2027	DP	U-1769		
	9655843	Jul 23, 2027	DP	U-1556		
	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP	U-1411		
	8603514	Apr 03, 2024	DP	U-1464		
	9687454	Aug 07, 2029	DP	U-1464		
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP	U-1411		
	8603514	Apr 03, 2024	DP	U-1464		
	9687454	Aug 07, 2029	DP	U-1464		
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP	U-1411		
	8603514	Apr 03, 2024	DP	U-1464		
	9687454	Aug 07, 2029	DP	U-1464		
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP	U-1411		
	8603514	Apr 03, 2024	DP	U-1464		
	9687454	Aug 07, 2029	DP	U-1464		
	9855221	Feb 14, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410	004	9931305	Feb 14, 2022	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	001	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	002	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	003	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	004	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	005	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	006	8470361	May 22, 2030	DP	U-1425	
		8658198	Dec 03, 2027	DP	U-1494	
		8940330	Sep 18, 2032	DP		
		9259421	Sep 18, 2032	DP		
		9439900	Sep 18, 2032	DP		
						Y
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	001	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	002	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637	003	7579019	Jan 22, 2020		U-1521	
		8147866	Jul 23, 2027	DP	U-1521	
		8703177	Aug 20, 2032	DP		
		9522188	Apr 24, 2035	DP		
		9655843	Jul 23, 2027	DP	U-2017	
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108	001	7241805	Jun 27, 2026	DP		
		7569610	Jun 27, 2026		U-997	
		7572935	Jun 27, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497 001	7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034		U-1583		
	10307376	Nov 08, 2027		U-1585		
	7375111	Mar 26, 2025	DP			
	7462626	Jul 20, 2024		U-1583		
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027		U-1584		
	8722085	Nov 08, 2027		U-1585		
	8815889	Jul 20, 2024		U-1586		
	8916195	Feb 02, 2030		U-1639		
	9107837	Jun 04, 2027		U-1639		
	9125868	Nov 08, 2027		U-1585		
	9248123	Jan 13, 2032		U-1808		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030		U-1630		
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP	U-1617		
	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP	U-1617		
	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031		U-2488	I-760	Dec 19, 2020
	10039757	Jul 18, 2031		U-1480	I-792	Jan 14, 2022
	7579473	Aug 14, 2026	DS DP		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024		U-1220		
	8497284	Sep 24, 2024		U-1480		
	8497284	Sep 24, 2024		U-2488		
	8877776	Oct 08, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001	9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002	10034873	Jul 18, 2031		U-2488	I-760 Dec 19, 2020
		10039757	Jul 18, 2031		U-1480	I-792 Jan 14, 2022
		7579473	Aug 14, 2026	DS DP		ODE-227 Jan 14, 2026
		8497284	Sep 24, 2024		U-1220	
		8497284	Sep 24, 2024		U-1480	
		8497284	Sep 24, 2024		U-2488	
		8877776	Oct 08, 2030	DS DP		
		9724342	Jul 09, 2033	DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003	10034873	Jul 18, 2031		U-2488	I-760 Dec 19, 2020
		10039757	Jul 18, 2031		U-1480	I-792 Jan 14, 2022
		7579473	Aug 14, 2026	DS DP		ODE-227 Jan 14, 2026
		8497284	Sep 24, 2024		U-1220	
		8497284	Sep 24, 2024		U-1480	
		8497284	Sep 24, 2024		U-2488	
		8877776	Oct 08, 2030	DS DP		
		9724342	Jul 09, 2033	DP		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	10213442	Feb 02, 2027	DP		
		10300078	Mar 14, 2034	DP		
		10357502	Mar 14, 2034	DP		
		6582727	Aug 22, 2020	DP		
		8207149	Apr 25, 2028		U-1871	
		8361488	Jul 19, 2028	DP		
		8426391	Aug 27, 2028		U-1872	
		8778373	Apr 25, 2028		U-1873	
		8906410	Feb 02, 2027	DP		
		9408858	Apr 25, 2028		U-1888	
		9498486	Apr 25, 2028		U-1920	
		9861644	Mar 14, 2034	DP		
		9925147	Apr 25, 2028	DP	U-2255	
		9925147	Apr 25, 2028	DP	U-2256	
		9925147	Apr 25, 2028	DP	U-2257	
		9925147	Apr 25, 2028	DP	U-2258	
		9925147	Apr 25, 2028	DP	U-2259	
		9943530	Feb 02, 2027		U-2274	
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001	8263580	May 07, 2028	DP	U-1280	
		8263580	May 07, 2028	DP	U-2662	
		8629128	May 26, 2026	DP	U-1280	
		8629128	May 26, 2026	DP	U-1767	
		8629128	May 26, 2026	DP	U-2662	
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001	6440392	Feb 02, 2021	DP	U-227	
		RE40812	Feb 02, 2021	DP		
		RE43580	Feb 02, 2021	DP	U-227	
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160	002	6576665	Apr 03, 2021			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003	6576665	Apr 03, 2021			
		6875445	Jul 30, 2021	DP		
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581	001	8591938	Feb 23, 2030	DP	U-1469	
		8592480	Jul 20, 2027		U-1469	
		9089528	Jul 20, 2027		U-1469	
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958	001	6814978	Aug 26, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXPIRATION DATE
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193	001 7084130	Nov 29, 2021	DP U-891			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026	001				ODE-85	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026	002				ODE-85	Jan 13, 2022
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906	001 10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906	002 10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001 7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
	7943582	Feb 26, 2029	DS DP U-2632		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002 7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
	7943582	Feb 26, 2029	DS DP U-2632		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001 7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
	7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002 7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
	7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003 7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
	7943582	Feb 26, 2029	DS DP U-493		M-197	Feb 01, 2020
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003	8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004	7943582	Feb 26, 2029	DS DP U-2441	I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493	M-197	Feb 01, 2020
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	6723340	Oct 25, 2021	DP	I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2441		
		7943582	Feb 26, 2029	DS DP U-493		
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002	7943582	Feb 26, 2029	DS DP U-2441	I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003	6723340	Oct 25, 2021	DP	I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-2441		
		7943582	Feb 26, 2029	DS DP U-493		
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004	7943582	Feb 26, 2029	DS DP U-2441	I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493		
		7943788	Jul 14, 2027	DS DP		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	10039780	Jul 10, 2035	U-2260	NCE	Jun 22, 2020
		6130208	Jun 29, 2023	DP U-1715		
		8680052	Mar 09, 2033	U-1715		
		9295687	Jul 10, 2035	DP		
		9427448	Nov 10, 2030	U-1926		
		9439921	Jul 10, 2035	DP		
		9700575	Jul 10, 2035	DP		
		9925265	May 13, 2029	U-2260		
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	10092525	Jun 17, 2035	U-2427	NCE	Sep 28, 2023
		10111840	Jun 17, 2035	U-2442	ODE-216	Sep 28, 2025
		10111840	Jun 17, 2035	U-2443		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	10137095	Jun 17, 2035	U-2454		
		10137095	Jun 17, 2035	U-2455		
		10195159	May 07, 2022	DS		
		9949937	Jun 17, 2035	U-2421		
		9956183	Jun 17, 2035	U-2422		
		9956183	Jun 17, 2035	U-2423		
		9956184	Jun 17, 2035	U-2424		
		9956185	Jun 17, 2035	U-2425		
		9956186	Jun 17, 2035	U-2426		
<u>CAPSAICIN - OUTENZA</u>						
N 022395	001	10034841	Sep 06, 2025	DP		
		10463598	Sep 05, 2023	DP		
		6239180	Jun 04, 2021	DP		
		8263059	Sep 05, 2023	U-2705		
		8821920	Mar 26, 2030	DP		
		8889113	Sep 05, 2023	U-2705		
		9226903	Dec 15, 2028	DP		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	001	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	002	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	003	6977253	May 19, 2024	U-693		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	7635773	Mar 13, 2029	DP	ODE-124	Oct 07, 2023
		8410077	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		
		9750822	Mar 13, 2029	DP		
		9770407	Nov 10, 2028	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485	001	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485	002	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485	003	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485	004	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485	005	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485	006	6500867	Jun 29, 2020	DP U-219		
		6797732	Jun 29, 2020	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	7094427	May 29, 2022	DP U-1645	Y	
		8377474	Dec 26, 2028	DP U-1645		
		8377474	Dec 26, 2028	DP U-219		
		8454998	Dec 26, 2028	DP U-1645		
		8454998	Dec 26, 2028	DP U-1646		
		8454998	Dec 26, 2028	DP U-1647		
		8454998	Dec 26, 2028	DP U-1649		
		8454998	Dec 26, 2028	DP U-219		
		8557283	Dec 26, 2028	DP U-1645		
		8557283	Dec 26, 2028	DP U-219		
		9089607	Dec 26, 2028	DP U-1645		
		9089607	Dec 26, 2028	DP U-1720		
		9089608	Dec 26, 2028	DP		
		9463246	Dec 26, 2028	DP U-219		
		9533046	Dec 26, 2028	DP U-219		
		9901640	Dec 26, 2028	DP U-219		

CARBIDOPA; LEVODOPA - DUOPA

N 203952 001

ODE-84

Jan 09, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025		U-1260		
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025		U-1260		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029		U-1924		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025		U-1260		
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025		U-1260		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029		U-1924		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025		U-2319		
	7491704	Apr 14, 2025		U-2320		
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025		U-2319		
	8129346	Apr 14, 2025		U-2320		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-2319		
	8207127	Apr 14, 2025		U-2320		
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029		U-1924		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP	U-1750	I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP	U-2543	M-213	Nov 09, 2020
	7737142	Sep 17, 2029	DS DP	U-2544	NCE	Sep 17, 2020
	7737142	Sep 17, 2029	DS DP	U-2545		
	7943621	Dec 16, 2028	DS DP			
	RE47350	Jul 16, 2029		U-1750		
	RE47350	Jul 16, 2029		U-2543		
	RE47350	Jul 16, 2029		U-2544		
	RE47350	Jul 16, 2029		U-2545		
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP	U-1750	I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP	U-2543	M-213	Nov 09, 2020
	7737142	Sep 17, 2029	DS DP	U-2544	NCE	Sep 17, 2020
	7737142	Sep 17, 2029	DS DP	U-2545		
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP	U-1750	I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP	U-2543	M-213	Nov 09, 2020
	7737142	Sep 17, 2029	DS DP	U-2544	NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370	004	7737142	Sep 17, 2029	DS DP U-1750	I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543	M-213	Nov 09, 2020
		7737142	Sep 17, 2029	DS DP U-2544	NCE	Sep 17, 2020
		7943621	Dec 16, 2028	DS DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	001	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	002	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	003	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012	004	7268156	Jun 27, 2023	DS DP U-3		
		7268156	Jun 27, 2023	DS DP U-313		
		8101209	Sep 11, 2025	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	001	9636407	Dec 21, 2032	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	002	9636407	Dec 21, 2032	DP		
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445	001	10004750	Sep 03, 2035	DS DP	NCE	Nov 14, 2024
		9238657	Nov 19, 2031	DS DP U-282	GAIN	Nov 14, 2029
		9949982	Sep 03, 2035	DP		
<u>CEFIXIME - SUPRAX</u>						
N 202091	001	9233112	Dec 14, 2028	DP U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676		
		6906055	Dec 15, 2021	DS DP		
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676		
		6906055	Dec 15, 2021	DS DP		
		7419973	Dec 15, 2021	DP		
		8247400	Feb 10, 2031	DP U-282		
		9629861	Sep 21, 2030	DP		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	10028963	Sep 07, 2032	U-2565	NCE	Dec 19, 2019
		10028963	Sep 07, 2032	U-2566	GAIN	Dec 19, 2024
		10125149	Aug 14, 2035	DP		
		10376496	Sep 09, 2034	U-2610		
		10376496	Sep 09, 2034	U-2611		
		10420841	Mar 14, 2034	U-1672		
		10420841	Mar 14, 2034	U-2631		
		7129232	May 15, 2028	DS DP U-1676		
		7129232	May 15, 2028	DS DP U-36		
		8476425	Sep 27, 2032	DS		
		8685957	Sep 27, 2032	DS U-36		
		8906898	May 28, 2034	DS DP		
		8968753	Mar 14, 2034	U-1672		
		8968753	Mar 14, 2034	U-1673		
		9320740	Mar 14, 2034	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	9724353	Sep 07, 2032	U-2565		
		9724353	Sep 07, 2032	U-2566		
		9872906	Mar 14, 2034	DP		
<u>CERITINIB - ZYKADIA</u>						
N 205755	001	7153964	Feb 26, 2021	DS DP	M-199	May 26, 2020
		7893074	Apr 25, 2026	DS DP	ODE-145	May 26, 2024
		7964592	Jan 13, 2027	DS DP	ODE-66	Apr 29, 2021
		8039479	Jun 29, 2030	DS DP		
		8188276	Jan 31, 2023	DS DP		
		8377921	Nov 20, 2027		U-1179	
		8399450	Nov 20, 2027	DS DP		
		8703787	Feb 02, 2032		U-1179	
		8835430	Jan 31, 2023	DS DP		
		9018204	Jan 31, 2023	DS DP		
		9309229	Jan 18, 2032	DS DP		
		9416112	Jan 31, 2023	DS DP		
<u>CERITINIB - ZYKADIA</u>						
N 211225	001	7153964	Feb 26, 2021	DS DP		
		7893074	Apr 25, 2026	DS DP		
		7964592	Jan 13, 2027	DS DP		
		8039479	Jun 29, 2030	DS DP		
		8188276	Jan 31, 2023	DS DP		
		8377921	Nov 20, 2027		U-1179	
		8399450	Nov 20, 2027	DS DP		
		8703787	Feb 02, 2032		U-1179	
		8835430	Jan 31, 2023	DS DP		
		9018204	Jan 31, 2023	DS DP		
		9309229	Jan 18, 2032	DS DP		
		9416112	Jan 31, 2023	DS DP		
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694	001	8829005	Mar 15, 2030		U-1680	NDF
		8829005*PED	Sep 15, 2030			PED
		9254286	Jul 09, 2032	DP		
		9254286*PED	Jan 09, 2033			
		9750684	Mar 15, 2030	DP		
		9993471	Mar 15, 2030		U-1680	
<u>CETIRIZINE HYDROCHLORIDE - OUZYTIR</u>						
N 211415	001	8263581	Feb 28, 2030		U-2635	NP
		8314083	Feb 28, 2030		U-2634	
		8513259	Feb 11, 2030		U-2636	
		9119771	Feb 11, 2030		U-2635	
		9180090	Feb 11, 2030		U-2635	
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150	002	7014867	Jun 10, 2022	DP		
		7226614	Jun 10, 2022		U-295	
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669	001	7066916	Feb 17, 2024		U-737	
		7427574	Apr 25, 2026	DP		
		7595021	May 12, 2023	DP	U-1022	
		7717889	Feb 27, 2025	DP	U-1022	
		7935093	Oct 02, 2027	DP	U-1022	
<u>CHLORHEXIDINE GLUCONATE - READYPREP CHG</u>						
N 207964	001					NP
						Nov 20, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	001	6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	002	6729786	Mar 14, 2023	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
		7241065	Mar 14, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	002	7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	004	6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	005	6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	006	6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	007	6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524	001				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524	002				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524	003				M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP</u>						
N 208288	001	8623935	Jul 26, 2029	DP U-1022	NP	Aug 08, 2021
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791	001	8969412	Sep 05, 2026	DP U-2609	NP	Sep 26, 2020
		9504666	Dec 11, 2033	DP		
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER</u>						
N 206323	001	9066942	Jan 03, 2032	U-1716		
		9107921	Jan 03, 2032	DP		
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441	001	7863287	Feb 28, 2027	DP		
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587	001	10238640	May 25, 2024	DP		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253	001				CGT	May 25, 2020
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253	002				CGT	May 25, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				NCE ODE-91	Mar 17, 2020 Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				NCE ODE-91	Mar 17, 2020 Mar 17, 2022
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	001	7259186	Jan 07, 2025	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	002 7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149	002 6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002 8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003 8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001 6767901	Oct 21, 2020	DP			
	8371292	Feb 01, 2028	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001 8371292	Feb 01, 2028	U-1357			
<u>CILASTATIN SODIUM; IMPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819	001 8487093	Nov 19, 2029	DS DP	U-2586		
	8487093	Nov 19, 2029	DS DP	U-2587		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	001 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	002 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688	003 7829595	Sep 22, 2026	DP	U-1098	M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001 8318817	Apr 27, 2030		U-1792	I-770	Mar 02, 2021
	9205048	Apr 21, 2029		U-1793		
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
	9603796	Apr 21, 2029	DS DP	U-2252		
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744	001 6488962	Jun 20, 2020	DP			
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251	001 8932610	Mar 24, 2030	DP	U-1578		
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	001 7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473	002 7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001 6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP	U-1578		
	9149486	Sep 13, 2022	DP	U-1578		
	9345714	Sep 13, 2022	DP	U-1578		
	9402805	Sep 13, 2022	DP	U-1578		
	9402805	Sep 13, 2022	DP	U-1679		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535	001 8450338	Oct 10, 2028	DP		NPP	Aug 15, 2021
	8481083	Oct 10, 2028	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001 9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561	001 7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001 10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002 10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003 10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767	001 6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782	001 6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793	001 6899890	Apr 27, 2023	DP U-137			
	9789057	Dec 02, 2026	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801	001 7141237	Feb 03, 2024	DP			
	7374747	Jan 23, 2024	DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802	001 6387383	Aug 03, 2020	DP U-916			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	001 8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	002 8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	003 8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644	001 7700081	Jan 03, 2022	U-1044			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001 8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483	001 10064875	Aug 31, 2030	DP U-1408		NP	Nov 28, 2020
	10064875	Aug 31, 2030	DP U-1858			
	10064875	Aug 31, 2030	DP U-193			
	10064875	Aug 31, 2030	DP U-742			
	10064875	Aug 31, 2030	DP U-88			
	9855334	Mar 11, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483	001	9956231	Aug 31, 2030	DP	U-1408	
		9956231	Aug 31, 2030	DP	U-1761	
		9956231	Aug 31, 2030	DP	U-1858	
		9956231	Aug 31, 2030	DP	U-193	
		9956231	Aug 31, 2030	DP	U-742	
		9956231	Aug 31, 2030	DP	U-88	
<u>CLOZAPINE - VERSACLOZ</u>						
N 203479	001	8057811	May 01, 2028	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	10039718	Oct 04, 2032	DP		NPP Aug 22, 2022
		8148374	Sep 03, 2029	DS DP	U-1279	ODE-260 Aug 22, 2026
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395	001	10039718	Oct 04, 2032	DP		
		7700645	Dec 26, 2026	DS DP		
		7700645*PED	Jun 26, 2027			
		8148374	Sep 03, 2029	DS DP	U-1279	
		8518987	Feb 16, 2024	DS DP		
		8518987*PED	Aug 16, 2024			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10039718	Oct 04, 2032	DP		NC Jul 17, 2020
		6642245	Nov 04, 2020		U-2352	NCE Nov 05, 2020
		6703396	Mar 09, 2021	DS DP		
		7390791	May 07, 2022	DS DP		
		7700645	Dec 26, 2026	DS DP		
		7803788	Feb 02, 2022		U-2352	
		8148374	Sep 03, 2029	DS DP	U-2353	
		8148374	Sep 03, 2029	DS DP	U-2364	
		8148374	Sep 03, 2029	DS DP	U-2365	
		8518987	Feb 16, 2024	DS DP		
		8754065	Aug 15, 2032	DS DP	U-2352	
		9296769	Aug 15, 2032	DS DP	U-2352	
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	10039718	Oct 04, 2032	DP		D-173 Dec 10, 2021
		6642245	Nov 04, 2020		U-257	NCE Nov 05, 2020
		6642245*PED	May 04, 2021			NPP Sep 25, 2020
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		7176220	Aug 27, 2026	DS DP	U-257	
		7390791	May 07, 2022	DS DP		
		7635704	Oct 26, 2026	DS DP	U-257	
		7803788	Feb 02, 2022		U-257	
		8148374	Sep 03, 2029	DS DP	U-1279	
		8633219	Apr 24, 2030		U-257	
		8754065	Aug 15, 2032	DS DP	U-257	
		8981103	Oct 26, 2026	DS DP		
		9296769	Aug 15, 2032	DS DP	U-257	
		9891239	Sep 03, 2029	DP	U-257	
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	10039718	Oct 04, 2032	DP		NPP Jan 27, 2020
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
		7176220	Aug 27, 2026	DS DP	U-257	
		7635704	Oct 26, 2026	DS DP	U-257	
		8148374	Sep 03, 2029	DS DP	U-1279	
		8592397	Jan 13, 2024		U-257	
		8633219	Apr 24, 2030		U-257	
		8716264	Jan 13, 2024		U-257	
		8981103	Oct 26, 2026	DS DP		
		9457036	Jan 13, 2024		U-257	
		9744181	Jan 13, 2024		U-257	
		9891239	Sep 03, 2029	DP	U-257	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		NCE	Nov 10, 2020
	7803839	Feb 01, 2027	DS DP		ODE-101	Nov 10, 2022
	8362002	Oct 05, 2026	U-1776			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029	U-1007			
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
	9399036	Aug 22, 2033	U-1020			
	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176 001	7229613	Apr 17, 2022	U-851			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001	7229613	Apr 17, 2022	U-493			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002	7229613	Apr 17, 2022	U-493			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>COPANLISIB DIHYDROCHLORIDE - ALIOOPA</u>						
N 209936 001	10383876	Mar 29, 2032	DS DP		NCE	Sep 14, 2022
	7511041	May 13, 2024	DS DP		ODE-155	Sep 14, 2024
	9636344	Mar 29, 2032	U-2124			
	RE46856	Oct 22, 2029	DS DP U-2124			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	9682092	Feb 16, 2027	U-1932			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
	7825137	May 12, 2027		U-1179		
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
	7825137	May 12, 2027		U-1179		
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP	U-1319		
	8962680	Oct 31, 2031		U-1319		
	9585868	Oct 31, 2031		U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
	7879349	Aug 01, 2024	DP	U-1152		
	8003353	Aug 01, 2024		U-817		
	8940714	Feb 26, 2024		U-1152		
	9415007	Jul 28, 2024		U-1896		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
	8877245	Nov 14, 2023		U-979		
	9375410	Nov 14, 2023		U-1088		
	9399025	Nov 14, 2023	DP	U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
	8877245	Nov 14, 2023		U-979		
	9375410	Nov 14, 2023		U-1088		
	9399025	Nov 14, 2023	DP	U-979		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024		U-1479		
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024		U-1483		
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024		U-1479		
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024		U-1479		
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024		U-1483		
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024		U-1479		
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10441630	Aug 23, 2033	DP			
	8980839	Aug 23, 2033	DP	U-1483		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - CEQUA</u>						
N 210913	001	9937225	Aug 23, 2033	DP U-1483		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	001	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	ODE-162	Dec 22, 2024
		8026284	Sep 22, 2027	U-1399	ODE-45	Apr 30, 2020
		8026284*PED	Mar 22, 2028		ODE-97	Aug 14, 2022
		9173851	Jun 17, 2034	DP	PED	Oct 30, 2020
		9173851*PED	Dec 17, 2034		PED	Jun 22, 2021
		9192590	Jan 26, 2027	U-1399	PED	Feb 14, 2023
		9192590*PED	Jul 26, 2027			
		9198882	Jan 26, 2027	U-1399		
		9198882*PED	Jul 26, 2027			
		9233077	Jun 17, 2034	DP		
		9233077*PED	Dec 17, 2034			
		9925156	Jan 26, 2027	DS DP U-1399		
		9925157	Jan 26, 2027	DS DP U-1399		
		9925158	Jan 26, 2027	DS DP U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002	10143665	Aug 16, 2036	U-1399	M-216	Dec 22, 2020
		10328037	Aug 16, 2036	U-1399	ODE-162	Dec 22, 2024
		8026284	Sep 22, 2027	U-1399	ODE-45	Apr 30, 2020
		8026284*PED	Mar 22, 2028		ODE-97	Aug 14, 2022
		9173851	Jun 17, 2034	DP	PED	Oct 30, 2020
		9173851*PED	Dec 17, 2034		PED	Jun 22, 2021
		9192590	Jan 26, 2027	U-1399	PED	Feb 14, 2023
		9192590*PED	Jul 26, 2027			
		9198882	Jan 26, 2027	U-1399		
		9198882*PED	Jul 26, 2027			
		9233077	Jun 17, 2034	DP		
		9233077*PED	Dec 17, 2034			
		9925156	Jan 26, 2027	DS DP U-1399		
		9925157	Jan 26, 2027	DS DP U-1399		
		9925158	Jan 26, 2027	DS DP U-1399		
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660	001	10478453	Jan 15, 2039	DP		
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401	001	10028912	Sep 29, 2034	DP U-2341	NP	Aug 03, 2020
		10028912	Sep 29, 2034	DP U-2342		
		10166184	Oct 15, 2032	DP U-2341		
		7850990	Jan 23, 2027	DP U-2090		
		8022279	Sep 14, 2027	DP U-2090		
		8092828	Apr 01, 2029	U-2090		
		8431806	Apr 22, 2025	DP U-2090		
		8518437	Jun 07, 2026	DP		
		9271931	Jan 23, 2027	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	001	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	002	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		
		9925174	Jun 14, 2023	DP		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	003	6087380	Dec 28, 2021	DS DP U-1931		
		7866474	Aug 31, 2027	DP	Y	
		7932273	Sep 07, 2025	DS DP		
		9034822	Jan 20, 2031	U-1759		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512	003	9925174	Jun 14, 2023	DP		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	001	7994185	Jan 20, 2030	DS DP U-1406	I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031	I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032	I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296	M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406	ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031	ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032	ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296	ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713	ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032		
		8703781	Oct 15, 2030	DS DP U-2296		
		8703781	Oct 15, 2030	DS DP U-2297		
		8703781	Oct 15, 2030	DS DP U-2298		
		8835443	Jun 10, 2025	U-2026		
		8835443	Jun 10, 2025	U-2027		
		8835443	Jun 10, 2025	U-2296		
		8835443	Jun 10, 2025	U-2298		
		8952018	Oct 15, 2030	U-2027		
		9233956	May 04, 2029	U-1811		
		9233956	May 04, 2029	U-2031		
		9233956	May 04, 2029	U-2032		
		9233956	May 04, 2029	U-2296		
		9233956	May 04, 2029	U-2297		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002	7994185	Jan 20, 2030	DS DP U-1406	I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031	I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032	I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296	M-246	Oct 06, 2022
		8415345	Jan 20, 2030	DS DP U-1406	ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-2031	ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2032	ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2296	ODE-47	May 29, 2020
		8703781	Oct 15, 2030	DS DP U-1713	ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-2032		
		8703781	Oct 15, 2030	DS DP U-2296		
		8703781	Oct 15, 2030	DS DP U-2297		
		8703781	Oct 15, 2030	DS DP U-2298		
		8835443	Jun 10, 2025	U-2026		
		8835443	Jun 10, 2025	U-2027		
		8835443	Jun 10, 2025	U-2296		
		8835443	Jun 10, 2025	U-2298		
		8952018	Oct 15, 2030	U-2027		
		9233956	May 04, 2029	U-1811		
		9233956	May 04, 2029	U-2031		
		9233956	May 04, 2029	U-2032		
		9233956	May 04, 2029	U-2296		
		9233956	May 04, 2029	U-2297		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001	8329159	Apr 13, 2028	DS	NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1725		
		8900566	Aug 08, 2027	U-1724		
		8900566	Aug 08, 2027	U-1725		
		9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002	8329159	Apr 13, 2028	DS	NCE	Jul 24, 2020
		8629171	Jun 13, 2031	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1724		
		8642025	Aug 11, 2027	DS DP U-1725		
		8900566	Aug 08, 2027	U-1724		
		8900566	Aug 08, 2027	U-1725		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002	9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	003	9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	001	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206 ODE-213	Sep 27, 2025 Sep 27, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	002	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206 ODE-213	Sep 27, 2025 Sep 27, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288	003	7772243	Aug 26, 2028	DS DP	NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403	ODE-206 ODE-213	Sep 27, 2025 Sep 27, 2025
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001	6900175	Dec 25, 2023	U-1517	NCE	May 23, 2019
		7115564	Nov 14, 2023	DP	GAIN	May 23, 2024
		7119061	Nov 14, 2023	DP		
		8143212	Nov 14, 2023	U-1517		
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250	001	8007826	May 26, 2027	U-1030	Y	
		8354437	Dec 22, 2026	U-1030	Y	
		8440703	Apr 08, 2025	U-1030	Y	
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	001				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	002				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	003				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	004				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	007				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	008				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	009				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	010				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	011				NPP	May 16, 2022
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001	7758890	Jul 01, 2025	DP	ODE-69	Jul 22, 2021
		8110225	Dec 24, 2022	DP		
		8604072	Dec 24, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001 8685460	Feb 15, 2023	U-1546			
	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001 6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-493		M-238	Feb 22, 2022
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002 6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-493		M-238	Feb 22, 2022
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	001 6414126	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	002 6414126	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP	U-493		
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP	U-493		
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP	U-493		
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8685934	May 26, 2030		U-1522		
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - OTERNET XR</u>						
N 210874 001	6414126	Oct 04, 2020	DS DP	U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP	U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - OTERNET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP	U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020		U-493		
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP	U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - OTERNET XR</u>						
N 210874 003	6414126	Oct 04, 2020	DS DP	U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP	U-493		
	6936590	Oct 04, 2020		U-493		
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP	U-493		
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020		U-493		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNET XR</u>						
N 210874	003	9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNET XR</u>						
N 210874	004	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091	001	6414126	Oct 04, 2020	DS DP U-493	I-804	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493	NC	Feb 27, 2020
		6936590	Oct 04, 2020	U-1976		
		6936590	Oct 04, 2020	U-1977		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-1976		
		8361972	Mar 21, 2028	U-1977		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-1976		
		8501698	Jun 20, 2027	DP U-1977		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-1976		
		9198925	Oct 04, 2020	U-1977		
		9198925	Oct 04, 2020	U-493		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091	002	6414126	Oct 04, 2020	DS DP U-493	NS	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPSONE - ACZONE</u>						
N 207154	001	9161926	Nov 18, 2033	DP	NPP	Sep 10, 2022
		9517219	Nov 18, 2033	U-1033		
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667	001				CGT	Jan 12, 2020
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572	002	8003673	Sep 04, 2028	U-1180	M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572	003	9138456	Nov 23, 2030	DP	M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099	001	10010530	Jan 28, 2036	DS	NCE	Jul 30, 2024
		10383853	Jan 28, 2036	DS		
		8975254	Oct 27, 2030	DS DP U-2605		
		9657003	Oct 27, 2030	DS DP U-2605		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	8975254	Oct 27, 2030	DS DP	U-2605		
	9657003	Oct 27, 2030	DS DP	U-2605		
<u>DARUNAVIR - PREZISTA</u>						
N 021976 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 003	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP	U-1753		
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP	U-1636		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032		U-1637		
	8492386	Sep 04, 2032		U-1840		
	8501238	Sep 17, 2028	DS DP	U-1636		
	8642538	Sep 10, 2029	DS DP	U-1638		
	8680106	Sep 04, 2032		U-1637		
	8685984	Sep 04, 2032		U-1840		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
	9139536	Nov 09, 2028		U-1753		
	9629841	Oct 18, 2033	DP	U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10105365	Jan 02, 2035	DP	U-1889		
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032		U-1889		
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP	U-1636		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020	U-780		PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020	U-780		PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020		U-779	ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020		U-780	PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020		U-780	PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025		DP		
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020		U-779	ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020		U-780	PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020		U-780	PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025		DP		
	8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020		U-779	ODE-225	Dec 21, 2025
	7125875	Apr 13, 2020		U-780	PED	May 09, 2021
	7125875*PED	Oct 13, 2020			PED	Jun 21, 2022
	7153856	Apr 28, 2020		U-780	PED	May 09, 2025
	7153856*PED	Oct 28, 2020			PED	Jun 21, 2026
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025		DP		
	8680103*PED	Aug 04, 2025				
<u>DEFERASIROX - DEFERASIROX</u>						
A 208697 002					PC	Jun 14, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		M-239	Dec 12, 2021
					M-241	Jul 24, 2022
					ODE-39	Jan 23, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910	003 9283209	Nov 21, 2034	DS DP		M-239 M-241 ODE-39	Dec 12, 2021 Jul 24, 2022 Jan 23, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001 7049328	Jun 28, 2021		U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001 7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002 7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735		
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001				NCE ODE-112	Mar 30, 2021 Mar 30, 2023
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	003				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	004				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				NCE ODE-130 ODE-252	Feb 09, 2022 Feb 09, 2024 Jun 07, 2026
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001 5925730 9415085 9579359	May 18, 2021 Apr 27, 2032 Feb 10, 2029	DS DP	U-943 U-1895 U-1978		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	002 5925730 9415085 9579359	May 18, 2021 Apr 27, 2032 Feb 10, 2029	DS DP	U-943 U-1895 U-1978		
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610	001 7728143 8252813 8273892	Nov 20, 2027 Oct 02, 2026 Aug 06, 2026	DS DP DS	U-2028	I-815 NCE GAIN	Oct 24, 2022 Jun 19, 2022 Jun 19, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208610	001	8648093	Oct 07, 2025	DP U-2028		
		8871938	Sep 23, 2029	DS		
		8969569	Oct 07, 2025	DP U-2028		
		9539250	Oct 07, 2025	DS DP U-2028		
		RE46617	Dec 28, 2029	DS		
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611	001	7635773	Mar 13, 2029	DP	I-815	Oct 24, 2022
		7728143	Nov 20, 2027	DS	NCE	Jun 19, 2022
		8252813	Oct 02, 2026	DP U-2028	GAIN	Jun 19, 2027
		8273892	Aug 06, 2026	DS		
		8410077	Mar 13, 2029	DP		
		8648093	Oct 07, 2025	DP U-2028		
		8871938	Sep 23, 2029	DS		
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
		9539250	Oct 07, 2025	DS DP U-2028		
		9750822	Mar 13, 2029	DP		
		RE46617	Dec 28, 2029	DS		
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001	7622130	Dec 10, 2027	U-1690		
		7754230	Dec 10, 2027	U-1690		
		8101593	Mar 02, 2030	DP		
		8242294	May 16, 2028	DS		
		8298556	Aug 03, 2025	U-1690		
		8367649	Mar 02, 2030	DP		
		8461140	Feb 21, 2028	DP		
		8546367	Feb 21, 2028	DP U-1690		
		8653058	Mar 02, 2030	DP		
		8846066	Feb 08, 2025	U-1690		
		8883770	Feb 21, 2028	DP		
		9522155	Feb 21, 2028	DP U-1940		
		9636349	Feb 21, 2028	U-1940		
		9949986	Feb 21, 2028	U-1940		
<u>DESLORATADINE - CLARINEX</u>						
N 021312	001	7618649	Dec 19, 2020	DP U-1017		
<u>DESLORATADINE - CLARINEX</u>						
N 021312	002	7618649	Dec 19, 2020	DP U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313	001	6709676	Feb 18, 2021	DP U-707		
		7618649	Dec 19, 2020	DP U-1017		
		8187630	Dec 19, 2020	DP U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605	001	6979463	Mar 28, 2022	DP		
		7618649	Dec 19, 2020	DP U-1017		
		7820199	Mar 28, 2022	DP		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	001	10307459	May 07, 2023	DP	NP	Jun 21, 2021
		7560429	Feb 02, 2024	DP U-2326		
		7947654	Dec 29, 2023	DP		
		8802624	Dec 29, 2023	U-2326		
		9220747	May 07, 2023	U-2326		
		9504647	May 07, 2023	DP U-2326		
		9919025	May 07, 2023	U-2326		
		9974826	Apr 13, 2030	U-2326		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	002	10137167	May 21, 2029	U-2327	NP	Jun 21, 2021
		10307459	May 07, 2023	DP		
		7560429	Feb 02, 2024	DP U-2326		
		7947654	Dec 29, 2023	DP		
		8802624	Dec 29, 2023	U-2326		
		9220747	May 07, 2023	U-2326		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2327			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
<u>DESONIDE - DESONATE</u>						
N 021844 001	6387383	Aug 03, 2020	DS DP U-783			
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
	8962000	Aug 31, 2025	DP U-1412			
	9492384	Aug 31, 2025	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	10076526	Jan 09, 2023	DP			
	6726918	Oct 20, 2020	DP U-1204			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	6726918	Oct 20, 2020	DP U-1205			
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9012437	Oct 20, 2020	U-1205			
	9192511	Jan 09, 2023	DP			
	9283178	Oct 20, 2020	U-1205			
	9592242	Oct 20, 2020	U-1989			
	9592242	Oct 20, 2020	U-1990			
	9775849	Oct 20, 2020	U-1989			
	9775849	Oct 20, 2020	U-1990			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10022502	Sep 12, 2020	U-2340		NP	Feb 09, 2021
	10028965	May 23, 2034	U-2340			
	10159683	May 23, 2034	DP			
	6960346	Jul 03, 2023	DP			
	7560120	Sep 05, 2022	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001					ODE-271	Oct 03, 2026
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032			U-1805	
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP		U-949	
	6462058	Jun 15, 2020	DS DP		U-950	
	6462058	Jun 15, 2020	DS DP		U-951	
	6664276	Jan 30, 2023	DS DP		U-1507	
	6664276	Jan 30, 2023	DS DP		U-949	
	6664276	Jan 30, 2023	DS DP		U-950	
	6664276	Jan 30, 2023	DS DP		U-951	
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020			U-949	
	6939971	Jun 15, 2020			U-950	
	6939971	Jun 15, 2020			U-951	
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026		DP		
	8105626	Sep 27, 2026		DP		
	8173158	Mar 17, 2030			U-949	
	8173158	Mar 17, 2030			U-950	
	8173158	Mar 17, 2030			U-951	
	8461187	Jan 17, 2026		DP		
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023		DP		
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023		DP	U-1552	
	8784885	Oct 15, 2023		DP	U-1553	
	8784885	Oct 15, 2023		DP	U-1554	
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028		DP		
	9011926	Feb 24, 2026		DP		
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032			U-1805	
	9238029	Jan 17, 2026		DP		
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6462058	Jun 15, 2020	DS DP		U-950	
	6462058	Jun 15, 2020	DS DP		U-951	
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP		U-950	
	6664276	Jan 30, 2023	DS DP		U-951	
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020			U-950	
	6939971	Jun 15, 2020			U-951	
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	8461187	Jan 17, 2026		DP		
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023		DP		
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028		DP		
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026		DP		
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026		DP		
	9241910	Mar 10, 2029		DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	10016396	Jan 04, 2032		DP		
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	10016396	Jan 04, 2032	DP		
		8242158	Jan 04, 2032	DP		
		8242158*PED	Jul 04, 2032			
		8338470	Jan 04, 2032	DP		
		8338470*PED	Jul 04, 2032			
		8455527	Jan 04, 2032		U-421	
		8455527*PED	Jul 04, 2032			
		8648106	Jan 04, 2032	DP		
		8648106*PED	Jul 04, 2032			
		9320712	Jan 04, 2032	DP		
		9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	8242158	Jan 04, 2032	DP		
		8242158*PED	Jul 04, 2032			
		8338470	Jan 04, 2032	DP		
		8338470*PED	Jul 04, 2032			
		8455527	Jan 04, 2032		U-421	
		8455527*PED	Jul 04, 2032			
		8648106	Jan 04, 2032	DP		
		8648106*PED	Jul 04, 2032			
		9320712	Jan 04, 2032	DP		
		9320712*PED	Jul 04, 2032			
		9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628	003	9649296	Apr 20, 2036	DP		
		9717796	Apr 20, 2036	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628	004	9649296	Apr 20, 2036	DP		
		9717796	Apr 20, 2036	DP		
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025	001	6727253	Mar 13, 2020		U-829	
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620	001	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-685	
		7838032	Apr 28, 2020	DP		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP	U-685	
		7838032	Apr 28, 2020	DP		
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879	001	7659282	Aug 13, 2026		U-1093	
		8227484	Jul 17, 2023		U-1093	
<u>DIAZOXIDE - DIAZOXIDE</u>						
A 211050	001				CGT	Jun 17, 2020
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366	002				ODE-96	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001	8679544	Apr 23, 2030	DP		
		8999387	Apr 23, 2030		U-55	
		9017721	Apr 23, 2030	DP		
		9173854	Apr 23, 2030	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001	9180095	Apr 23, 2030		U-55	
		9180096	Apr 23, 2030	DP		
		9186328	Apr 23, 2030		U-55	
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	002	8679544	Apr 23, 2030	DP		
		8999387	Apr 23, 2030		U-55	
		9017721	Apr 23, 2030	DP		
		9173854	Apr 23, 2030	DP		
		9180095	Apr 23, 2030		U-55	
		9180096	Apr 23, 2030	DP		
		9186328	Apr 23, 2030		U-55	
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976	001					NP Dec 19, 2021
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 222165	001	7759394	Jun 16, 2026	DS DP	U-436	
		8097651	Jun 16, 2026	DS DP	U-436	
		8927604	Jun 16, 2026		U-436	
		9827197	Jun 16, 2026	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 222202	001	7662858	Feb 24, 2029		U-1035	
		7884095	Feb 24, 2029		U-1111	
		7939518	Feb 24, 2029		U-980	
		8110606	Feb 24, 2029		U-980	
		8623920	Feb 24, 2029		U-1482	
		9561200	Feb 24, 2029		U-1482	
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 202947	001	8217078	Jul 10, 2029		U-1248	
		8546450	Aug 09, 2030		U-1435	
		8546450	Aug 09, 2030		U-1436	
		8618164	Jul 10, 2029		U-1477	
		8741956	Jul 10, 2029		U-1435	
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 222396	001	8946292	Mar 22, 2027		U-1659	
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	8217078	Jul 10, 2029		U-1477	
		8252838	Apr 21, 2028	DP	U-1489	
		8546450	Aug 09, 2030		U-1435	
		8546450	Aug 09, 2030		U-1436	
		8563613	Oct 17, 2027	DP	U-1488	
		8618164	Jul 10, 2029		U-1477	
		8741956	Jul 10, 2029		U-1435	
		8871809	Oct 17, 2027		U-1614	
		9066913	Oct 17, 2027	DP	U-1488	
		9101591	Oct 17, 2027	DP	U-1488	
		9132110	Oct 17, 2027		U-1488	
		9168304	Oct 17, 2027	DP		
		9168305	Oct 17, 2027		U-1488	
		9220784	Oct 17, 2027		U-1488	
		9339551	Oct 17, 2027		U-1488	
		9339552	Oct 17, 2027	DP	U-1488	
		9370501	Jul 10, 2029		U-1614	
		9375412	Jul 10, 2029		U-1614	
		9415029	Jul 10, 2029		U-1614	
		9539335	Oct 17, 2027		U-1614	
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 222252	001	8071577	May 13, 2026	DP	U-1	
		8153616	Jan 30, 2028		U-1240	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIGOXIN - DIGOXIN</u>						
A 213000	001				CGT	Apr 01, 2020
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001	6923984	Feb 25, 2021	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002	6923984	Feb 25, 2021	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003	6923984	Feb 25, 2021	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	004	6923984	Feb 25, 2021	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	005	6923984	Feb 25, 2021	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	006	6923984	Feb 25, 2021	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	7619001	Jun 20, 2020	U-1384		
		8399514	Feb 07, 2028	U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	7619001	Jun 20, 2020	U-1384		
		8399514	Feb 07, 2028	U-1384		
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394	001	8263647	May 30, 2022	DP		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393	001	8883849	Jan 17, 2022	U-1618		
		9155718	Jan 17, 2022	DP		
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855	001	10080733	Sep 20, 2033	DS DP	U-1384	
		8669281	Sep 20, 2033	DS DP		
		9090558	Sep 20, 2033		U-1384	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	
		9763880	Sep 30, 2033		U-2563	
		9763880	Sep 30, 2033		U-2564	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	
		9763880	Sep 30, 2033		U-2563	
		9763880	Sep 30, 2033		U-2564	
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	8940786	Sep 30, 2033	DP	U-1789	
		9308195	Sep 30, 2033	DP		
		9763880	Sep 30, 2033		U-2558	
		9763880	Sep 30, 2033		U-2559	
		9763880	Sep 30, 2033		U-2560	
		9763880	Sep 30, 2033		U-2561	
		9763880	Sep 30, 2033		U-2562	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	9763880	Sep 30, 2033	U-2563		
		9763880	Sep 30, 2033	U-2564		
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003	8129385	Oct 05, 2027	DS DP	I-758	Nov 21, 2020
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994	001	8129385	Oct 05, 2027	DS DP	NC	Apr 08, 2022
		9242986	Dec 08, 2029	DS DP		
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192	001	10426780	Jan 24, 2031	DS DP	U-257	NC
		6838464	Feb 26, 2021	DS DP		Nov 21, 2020
		7125879	Apr 21, 2025	DS DP	U-257	
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8129385	Oct 05, 2027	DS DP		
		9242986	Dec 08, 2029	DS DP		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001	8481565	Oct 04, 2026	DP		
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025	U-1641		
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	8039009	Mar 24, 2029	U-1641		
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029	U-1641		
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-1641		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-1641		
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025	U-1641		
		8362085	Nov 22, 2025	U-1641		
		8362085*PED	May 22, 2026			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	003	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	004	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806	001	8486975	Oct 07, 2031	DS DP	U-2394	NCE Aug 30, 2023
		8486975	Oct 07, 2031	DS DP	U-2630	
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807	001	8486975	Oct 07, 2031	DS DP	U-2395	I-806 Sep 19, 2022
		8486975	Oct 07, 2031	DS DP	U-2629	NCE Aug 30, 2023
<u>DORIPENEM - DORIBAX</u>						
N 022106	001	8247402	Mar 30, 2021	DS DP		
<u>DORIPENEM - DORIBAX</u>						
N 022106	002	8247402	Mar 30, 2021	DS DP		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	10238620	May 18, 2027		U-620	
		6211229	Feb 17, 2020		U-620	
		7915307	Aug 24, 2027		U-620	
		8513299	Sep 07, 2030		U-620	
		9107898	May 01, 2028		U-620	
		9486437	May 18, 2027		U-620	
		9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027		U-620	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
	6211229	Feb 17, 2020	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8603506	Apr 05, 2022	U-1063			
	8709478	Apr 07, 2024	U-1063			
	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661	001	9089489	Feb 18, 2033	DP U-1382		
		9375404	Feb 18, 2033	DP U-1382		
		9526703	Feb 18, 2033	DP U-1382		
		9937132	Feb 18, 2033	DP U-1382		
<u>DRONABINOL - SYNDROS</u>						
N 205525	001	10265293	Aug 06, 2028	DS DP		
		8222292	Aug 06, 2028	DS DP		
		9345771	Aug 06, 2028	DS DP		
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001	8410167	Apr 16, 2029	U-1387		
		8410167	Apr 16, 2029	U-1388		
		8602215	Jun 30, 2031	U-1473		
		9107900	Apr 16, 2029	U-1726		
		9107900	Apr 16, 2029	U-1728		
<u>DROSPIRENONE - SLYND</u>						
N 211367	001	10179140	Jun 28, 2031	U-2553	NP	May 23, 2022
		9603860	Jun 28, 2031	U-2553		
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	001	8906890	Oct 22, 2031	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098	001	6787531	Aug 31, 2020	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676	001	6787531	Aug 31, 2020	DP		
		6958326	Dec 20, 2021	DP		
		7163931	Dec 20, 2021	U-1		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	6441168	Jul 30, 2022	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022	U-1		
		8617597	Feb 08, 2030	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	6441168	Apr 17, 2020	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022	U-1		
		8617597	Feb 08, 2030	DP		
<u>DROXIDOPA - NORTHERA</u>						
N 203202	001				ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	002				ODE-61	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	003				ODE-61	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	001	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	002	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	003	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	004	10413525	Apr 13, 2037	DP		
		9839626	Apr 13, 2037	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DUVELISIB - COPIKTRA</u>						
N 211155	001	8193182	Feb 13, 2030	DS	NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412	ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413	ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412		
		9840505	Jan 10, 2032	U-2413		
		RE46621	May 17, 2032	DS DP		
<u>DUVELISIB - COPIKTRA</u>						
N 211155	002	8193182	Feb 13, 2030	DS	NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412	ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413	ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412		
		9840505	Jan 10, 2032	U-2413		
		RE46621	May 17, 2032	DS DP		
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175	001	10071054	Aug 08, 2031	DP		
<u>EDARAVONE - RADICAVA</u>						
N 209176	001	6933310	Nov 13, 2020	U-2013	NCE ODE-144	May 05, 2022 May 05, 2024
<u>EDARAVONE - RADICAVA</u>						
N 209176	002	6933310	Nov 13, 2020	U-2013	NCE	May 05, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Jun 12, 2023	DS	M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP	NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	6642245	Nov 04, 2020	U-1170		
		6642245	Nov 04, 2020	U-750		
		6703396	Mar 09, 2021	DS DP		
		8592397	Jan 13, 2024	DP U-1170		
		8592397	Jan 13, 2024	DP U-750		
		8598185	Apr 28, 2029	DP		
		8716264	Jan 13, 2024	DP U-257		
		9018192	Jun 13, 2026	U-1170		
		9018192	Jun 13, 2026	U-750		
		9457036	Jan 13, 2024	DP U-257		
		9545414	Jun 13, 2026	DP U-1170		
		9545414	Jun 13, 2026	DP U-750		
		9744181	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	10105444	Jul 08, 2030	DP		
		10512640	Jan 03, 2028	U-1969		
		7214506	Oct 05, 2021	U-281		
		8039494	Jul 08, 2030	U-281		
		8486978	Oct 24, 2030	DP		
		9302009	Oct 24, 2030	DP		
		9566272	Jan 03, 2028	U-1969		
		9662394	Oct 02, 2034	DP		
		9861698	Jul 08, 2030	DP		
		9877955	Jan 03, 2028	U-1969		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	001	6872728	Jan 25, 2021	DS DP	NCE	Jul 23, 2023
		7056927	Sep 10, 2024	DS DP		
		7176211	Jul 06, 2024	U-2360		
		7179815	Mar 07, 2021	U-2360		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2024	DS DP U-2360			
	7462625	Jan 25, 2021	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7179815	Mar 07, 2021	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
	7462625	Jan 25, 2021	DS DP U-2360			
<u>ELBASVIR; GRAZOPREXIN - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-2652		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-2653		ODE-275	Oct 21, 2026
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8354427	Jul 06, 2026	U-2646			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8598181	May 01, 2027	U-2645			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9670163	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-2650			
	9974781	Apr 09, 2027	DP U-2645			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS U-1571		ODE-73	Aug 19, 2021
	7196205	Jun 26, 2026	DS			
	7253185	Apr 29, 2022	DP			
	7615573	Apr 29, 2022	U-1571			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451		ODE-75	Aug 26, 2021
	7160870*PED	May 20, 2023			PED	Feb 26, 2022
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1575		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1714		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306		ODE-74	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1736		PED	Feb 26, 2022
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP		NCE	May 27, 2020
	10213415	Mar 14, 2025	DS U-2152			
	7741356	Mar 25, 2028	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025		U-1709		
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS	U-1709		
	8772325	Mar 14, 2025		U-1709		
	9115091	Jul 07, 2028	DS DP	U-1738		
	9205076	Mar 14, 2025		U-1709		
	9364489	Jul 07, 2028		U-1709		
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP	U-1709		
	9789125	Jul 07, 2028	DP	U-2152		
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP		NCE	May 27, 2020
	10213415	Mar 14, 2025	DS U-2152			
	7741356	Mar 25, 2028	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025		U-1709		
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS	U-1709		
	8772325	Mar 14, 2025		U-1709		
	9115091	Jul 07, 2028	DS DP	U-1738		
	9205076	Mar 14, 2025		U-1709		
	9364489	Jul 07, 2028		U-1709		
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP	U-1709		
	9789125	Jul 07, 2028	DP	U-2152		
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP	U-257		
	7635704	Oct 26, 2026	DS DP	U-257		
	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP	U-257		
	7635704	Oct 26, 2026	DS DP	U-257		
	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034		U-2290		
	10406172	Jun 15, 2030		U-1652		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029		U-1651		
	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034		U-2290		
	10406172	Jun 15, 2030		U-1652		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029		U-1651		
	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034		U-2290		
	10406172	Jun 15, 2030		U-1652		
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8178541	Aug 12, 2023	DP		U-1654	
	8551957	Oct 14, 2029	DP		U-1651	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP		U-1772	
	9949998	Jun 11, 2034			U-2290	
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034			U-2290	
	10406172	Jun 15, 2030			U-1652	
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1651	
	8178541	Aug 12, 2023	DP		U-1653	
	8178541	Aug 12, 2023	DP		U-1654	
	8551957	Oct 14, 2029	DP		U-1651	
	8673927	May 04, 2027			U-1652	
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP		U-1772	
	9949998	Jun 11, 2034			U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034			U-2290	
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034			U-2290	
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034			U-2290	
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034			U-2290	
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034			U-2290	
	6488962	Jun 20, 2020	DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034			U-2290	
	6488962	Jun 20, 2020	DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034			U-2290	
	6488962	Jun 20, 2020	DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034			U-2290	
	6488962	Jun 20, 2020	DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034		U-2290		
	6488962	Jun 20, 2020	DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034		U-2290		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500 001	6642245	Nov 04, 2020		U-257		
	6642245	Nov 04, 2020		U-541		
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896 001	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	6642245	Nov 04, 2020		U-257	M-206	Aug 21, 2020
	6642245*PED	May 04, 2021			M-207	Aug 21, 2020
	6703396	Mar 09, 2021	DS DP		NCE	Nov 05, 2020
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP	U-257		
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP	U-257		
	9296769	Aug 15, 2032	DS DP	U-257		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	6642245	Nov 04, 2020		U-257		
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP	U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP	U-257		
	8716264	Jan 13, 2024	DP	U-257		
	8841310	Dec 09, 2025	DP	U-257		
	9457036	Jan 13, 2024	DP	U-257		
	9744181	Jan 13, 2024	DP	U-257		
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	6642245	Nov 04, 2020		U-1663	I-812	Oct 03, 2022
	6642245*PED	May 04, 2021			NCE	Nov 05, 2020
	6703396	Mar 09, 2021	DS DP		NPP	Sep 25, 2020
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-1663		
	8754065	Aug 15, 2032	DS DP	U-1259		
	8754065	Aug 15, 2032	DS DP	U-1663		
	8754065	Aug 15, 2032	DS DP	U-257		
	9296769	Aug 15, 2032	DS DP	U-1259		
	9296769	Aug 15, 2032	DS DP	U-1663		
	9296769	Aug 15, 2032	DS DP	U-257		
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	6642245	Nov 04, 2020		U-1170		
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP	U-1170		
	8592397	Jan 13, 2024	DP	U-248		
	8592397	Jan 13, 2024	DP	U-541		
	8716264	Jan 13, 2024	DP	U-257		
	9457036	Jan 13, 2024	DP	U-257		
	9744181	Jan 13, 2024	DP	U-257		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1892			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	9855214	Nov 06, 2032	DP			
	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	10039745	Mar 25, 2036	DP			
	10154987	Mar 25, 2036	U-1723			
	10154987	Mar 25, 2036	U-185			
	10154987	Mar 25, 2036	U-1892			
	10154987	Mar 25, 2036	U-3			
	10154987	Mar 25, 2036	U-71			
	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1892			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
	10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
	10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP U-2335			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031		U-2336		
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032		U-2335		
	9850229	Aug 27, 2030		U-2337		
	9850230	Aug 27, 2030		U-2334		
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030		U-2335	NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP	U-2335		
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031		U-2336		
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032		U-2335		
	9850229	Aug 27, 2030		U-2337		
	9850230	Aug 27, 2030		U-2334		
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035		U-2617	NCE	Aug 15, 2024
	10231965	Feb 17, 2035		U-2618	ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028		U-2617		
	8673893	Jul 08, 2028		U-2618		
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028		U-2617		
	9255087	Jul 08, 2028		U-2618		
	9616059	Jul 08, 2028		U-2618		
	9649306	May 22, 2033		U-2617		
	9649306	May 22, 2033		U-2618		
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035		U-2617	NCE	Aug 15, 2024
	10231965	Feb 17, 2035		U-2618	ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028		U-2617		
	8673893	Jul 08, 2028		U-2618		
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028		U-2617		
	9255087	Jul 08, 2028		U-2618		
	9616059	Jul 08, 2028		U-2618		
	9649306	May 22, 2033		U-2617		
	9649306	May 22, 2033		U-2618		
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
	8183274	Aug 24, 2026		U-1281	I-808	Dec 16, 2022
	8183274	Aug 24, 2026		U-1588		
	8183274	Aug 24, 2026		U-2345		
	9126941	May 15, 2026		U-1588		
	9126941	May 15, 2026		U-2345		
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430	002	7449012	Sep 11, 2025	DP		
		7794432	Sep 11, 2025	DP		
		8048035	Sep 11, 2025	DP		
		8870827	Sep 11, 2025	DP		
		9586010	Sep 11, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800	001	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800	002	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800	003	10166344	Jan 21, 2025	DP		
		7905352	Apr 12, 2027	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800	004	10166344	Jan 21, 2025	DP		
		7905352	Apr 12, 2027	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	001	10314977	Nov 23, 2024	DP		
		10335549	Apr 30, 2025	DP		
		7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025	DP	U-1758	
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	10314977	Nov 23, 2024	DP		
		10335549	Apr 30, 2025	DP		
		7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	9149579	Jul 19, 2025	U-1758		
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	003	10314977	Nov 23, 2024	DP		
		10335549	Apr 30, 2025	DP		
		7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025	U-1758		
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
		9724471	May 23, 2027	DP	U-2092	
		9737669	Nov 23, 2024	DP		
		9833573	Nov 23, 2024	U-2172		
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200	001	9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035	U-1829		
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640	001	10130592	Mar 13, 2035	DP		
		9119876	Mar 13, 2035	DP		
		9295657	Mar 13, 2035	U-1829		
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029	001	10004700	Aug 14, 2034	DP	U-2325	
		10039728	Aug 14, 2034	U-1828		
		9283197	Aug 15, 2034	DP	U-1828	
		9283197	Aug 15, 2034	DP	U-1829	
		9283197	Aug 15, 2034	DP	U-1830	
<u>EPINEPHRINE - PRIMATENE MIST</u>						
N 205920	001	8367734	Jan 26, 2026	DP	NP	Nov 07, 2021
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504	001	6629968	Jun 30, 2020	DS DP		
		6635045	Jun 29, 2021	DS DP		
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	001	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	002	8318802	Mar 15, 2027	DP		
		8598227	Feb 02, 2027			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109	001	8796245	Aug 07, 2029	U-2380	NCE	Aug 27, 2023
		8906887	Dec 28, 2030	DP	GAIN	Aug 27, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109	001	8796245				
		Aug 07, 2029		U-2380	NCE	Aug 27, 2023
		8906887		DP	GAIN	Aug 27, 2028
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	001	8895601				
		May 22, 2031	DS DP		NCE	Apr 12, 2024
		9464071		U-2518		
		Apr 28, 2031				
		9902714		DP		
		Mar 26, 2035				
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	002	8895601				
		May 22, 2031	DS DP		NCE	Apr 12, 2024
		9464071		U-2518		
		Apr 28, 2031				
		9902714		DP		
		Mar 26, 2035				
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	003	8895601				
		May 22, 2031	DS DP		NCE	Apr 12, 2024
		9464071		U-2518		
		Apr 28, 2031				
		9902714		DP		
		Mar 26, 2035				
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532	001	6214865				
		Jul 20, 2023	DS		ODE-107	Jan 28, 2023
		8097648		U-1096		
		Jan 22, 2021				
		RE46965		DP		
		Jan 08, 2027				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	001	6900221				
		Nov 09, 2020	DS DP	U-1046		
		6900221		U-1403		
		Nov 09, 2020				
		6900221		U-659		
		Nov 09, 2020				
		6900221		U-875		
		Nov 09, 2020				
		6900221*PED				
		May 09, 2021				
		7087613		U-1045		
		Nov 09, 2020				
		7087613		U-1403		
		Nov 09, 2020				
		7087613		U-659		
		Nov 09, 2020				
		7087613*PED				
		May 09, 2021				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	002	6900221				
		Nov 09, 2020	DS DP	U-1046		
		6900221		U-1403		
		Nov 09, 2020				
		6900221		U-659		
		Nov 09, 2020				
		6900221		U-875		
		Nov 09, 2020				
		6900221*PED				
		May 09, 2021				
		7087613		U-1045		
		Nov 09, 2020				
		7087613		U-1403		
		Nov 09, 2020				
		7087613		U-659		
		Nov 09, 2020				
		7087613*PED				
		May 09, 2021				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	003	6900221				
		Nov 09, 2020	DS DP	U-1046		
		6900221		U-1403		
		Nov 09, 2020				
		6900221		U-659		
		Nov 09, 2020				
		6900221		U-875		
		Nov 09, 2020				
		6900221*PED				
		May 09, 2021				
		7087613		U-1045		
		Nov 09, 2020				
		7087613		U-1403		
		Nov 09, 2020				
		7087613		U-659		
		Nov 09, 2020				
		7087613*PED				
		May 09, 2021				
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803	001	8080580				
		Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803	002	8080580				
		Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806	001	8080580				
		Jul 13, 2030	DS DP	U-2214	NCE	Dec 19, 2022
		9308204		DP		
		Oct 21, 2030				
		9439902		U-2214		
		Oct 21, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
	7326708	Nov 24, 2026	DS DP U-2214			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
	7326708	Nov 24, 2026	DS DP U-2214			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 001					CGT	May 09, 2020
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 002					CGT	May 09, 2020
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031		U-2502	NCE*	Mar 05, 2024
	9592207	Mar 20, 2027		U-2502		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032		U-2041		
	9750747	Aug 24, 2032		U-2121		
	9763954	Sep 13, 2028		U-2123		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032		U-2041		
	9750747	Aug 24, 2032		U-2121		
	9763954	Sep 13, 2028		U-2123		
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	6926907	Feb 28, 2023	DP U-1052		NPP	Jul 06, 2020
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
	8945621	Oct 17, 2031		U-1661		
	9161920	May 31, 2022		U-1760		
	9198888	May 31, 2022		U-1781		
	9220698	Mar 10, 2031		U-1781		
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029		U-1781		
	9707181	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	6926907	Feb 28, 2023	DP U-1052		NPP	Jul 06, 2020
	8557285	May 31, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	002	8852636	May 31, 2022	DP	U-1052	
		8858996	May 31, 2022	DP	U-1052	
		8945621	Oct 17, 2031		U-1661	
		9161920	May 31, 2022		U-1760	
		9198888	May 31, 2022		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
		9707181	May 31, 2022	DP		
<u>ESTRADIOL - VAGIFEM</u>						
N 020908	002	7018992	Sep 17, 2022		U-1023	
<u>ESTRADIOL - ELESTRIN</u>						
N 021813	001	7198801	Jun 25, 2022	DP		
		7470433	Aug 03, 2021	DP		
<u>ESTRADIOL - EVAMIST</u>						
N 022014	001	6978945	Jul 31, 2022	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	001	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	002	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	003	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	004	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9730900	Jul 10, 2028		U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	005	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
		9724310	Jul 10, 2028	DS DP		
		9730900	Jul 10, 2028	DP	U-2086	
		9833419	Jul 10, 2028	DP		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	001	10258630	Dec 20, 2033		U-2316	NP May 29, 2021
		10258630	Dec 20, 2033		U-2317	
		10398708	Dec 20, 2033		U-2317	
		10398708	Dec 20, 2033		U-2614	
		10471072	Jun 18, 2033		U-2316	
		10471072	Jun 18, 2033		U-2317	
		9180091	Dec 20, 2033	DP	U-2316	
		9180091	Dec 20, 2033	DP	U-2317	
		9289382	Nov 21, 2032	DP		
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	002	10258630	Dec 20, 2033		U-2316	NP May 29, 2021
		10258630	Dec 20, 2033		U-2317	
		10398708	Dec 20, 2033		U-2317	
		10398708	Dec 20, 2033		U-2614	
		10471072	Jun 18, 2033		U-2316	
		10471072	Jun 18, 2033		U-2317	
		9180091	Dec 20, 2033	DP	U-2316	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	002	9180091	Dec 20, 2033	DP U-2317		
		9289382	Nov 21, 2032	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	001	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	002	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	003	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040	001	6747019	Mar 20, 2020	U-311		
		7320970	Mar 30, 2020	DP U-844		
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132	001	10052386	Nov 21, 2032	DP	NP	Oct 28, 2021
		10206932	Nov 21, 2032	U-2439		
		8633178	Nov 21, 2032	DP		
		8846648	Nov 21, 2032	U-2439		
		8846649	Nov 21, 2032	DP U-2439		
		8987237	Nov 21, 2032	DP		
		8993548	Nov 21, 2032	DP		
		8993549	Nov 21, 2032	DP		
		9006222	Nov 21, 2032	DP U-2439		
		9114145	Nov 21, 2032	U-2439		
		9114146	Nov 21, 2032	DP U-2439		
		9301920	Nov 21, 2032	DP U-2439		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	001	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	002	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	003	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	004	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVA</u>						
N 021443	005	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>Etelcalcetide - PARSABIV</u>						
N 208325	001	10344765	Jun 27, 2034	DP	NCE	Feb 07, 2022
		8377880	Jul 29, 2030	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
	8377880	Jul 29, 2030	DS DP			
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
	8377880	Jul 29, 2030	DS DP			
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918		NCE	Sep 19, 2021
	10364431	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
	10364431	Mar 14, 2034	U-1919			
	8486907	Jun 28, 2025	U-1904	Y		
	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
	RE47751	Jun 28, 2025	U-1918			
	RE47751	Jun 28, 2025	U-2664			
	RE47751	Jun 28, 2025	U-2673			
	RE47751	Jun 28, 2025	U-2674			
	RE47769	Jun 28, 2025	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918		NCE	Sep 19, 2021
	10364431	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
	10364431	Mar 14, 2034	U-1919			
	8486907	Jun 28, 2025	U-1904	Y		
	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
	RE47751	Jun 28, 2025	U-1918			
	RE47751	Jun 28, 2025	U-2664			
	RE47751	Jun 28, 2025	U-2673			
	RE47751	Jun 28, 2025	U-2674			
	RE47769	Jun 28, 2025	DP			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024	U-828			
	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946 001	6156742	Dec 05, 2020	U-374			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061	001	8415332	Mar 11, 2029	DP		
		8450299	Oct 07, 2025	U-1		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612	001	6716814	Aug 16, 2021	DS DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501	001	7704984	Feb 02, 2029	U-1090		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA</u>						
N 204426	001	6652880	Mar 29, 2020	DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654	001	7704984	Feb 02, 2029	U-1		
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627	001				NCE	Aug 10, 2023
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE-64	Apr 04, 2021
<u>ETONOGESTREL - IMPLANON</u>						
N 021529	001	9757552	Jul 28, 2030	DP U-1		
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	8722037	Sep 28, 2027	DP		
		8888745	Aug 28, 2026	DP		
		9757552	Jul 28, 2030	DP U-1		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	001	6878717*PED	May 05, 2020		NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1016	PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-1237		
		7037917	Dec 13, 2020	DS DP U-2354		
		7037917	Dec 13, 2020	DS DP U-256		
		7037917*PED	Jun 13, 2021			
		8003789*PED	May 01, 2020			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002	6878717*PED	May 05, 2020		NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1016	PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-1237		
		7037917	Dec 13, 2020	DS DP U-2354		
		7037917	Dec 13, 2020	DS DP U-256		
		7037917*PED	Jun 13, 2021			
		8003789*PED	May 01, 2020			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	003	6878717*PED	May 05, 2020		NPP	Jul 16, 2021
		7037917	Dec 13, 2020	DS DP U-1237	PED	Jan 16, 2022
		7037917	Dec 13, 2020	DS DP U-2354		
		7037917*PED	Jun 13, 2021			
		8003789*PED	May 01, 2020			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001	5665772*PED	Mar 09, 2020			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002	5665772*PED	Mar 09, 2020			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003	5665772*PED	Mar 09, 2020			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001	8410131	Nov 01, 2025	U-1368	ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026			
		8436010	Feb 22, 2022	U-1396		
		8436010*PED	Aug 22, 2022			
		8778962	Feb 18, 2022	U-1541		
		8778962*PED	Aug 18, 2022			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001	9006224				
		Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002	8410131			ODE-108	Feb 26, 2023
		8410131*PED				
		8436010				
		8436010*PED				
		8778962				
		8778962*PED				
		9006224				
		Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003	8410131			ODE-108	Feb 26, 2023
		8410131*PED				
		8436010				
		8436010*PED				
		8778962				
		8778962*PED				
		9006224				
		Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004	8410131			ODE-108	Feb 26, 2023
		8410131*PED				
		8436010				
		8436010*PED				
		8778962				
		8778962*PED				
		9006224				
		Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	8617598			I-773	Apr 10, 2021
		8617598*PED			ODE-169	Apr 10, 2025
		8778962				
		8778962				
		8778962*PED				
		Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	8617598			I-773	Apr 10, 2021
		8617598*PED			ODE-169	Apr 10, 2025
		8778962				
		8778962				
		8778962*PED				
		Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	8617598			I-773	Apr 10, 2021
		8617598*PED			ODE-169	Apr 10, 2025
		8778962				
		8778962				
		8778962*PED				
		Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210	001	6414126			NP	Oct 20, 2020
		6479065				
		6515117				
		6667061				
		6824822				
		6872700				
		6872700				
		6872700				
		6936590				
		7223440				
		7456254				
		7456254				
		7456254				
		7456254				
		7563871				
		7612176				
		7612176				
		7612176				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8329648	Aug 18, 2026				
	8361972	Mar 21, 2028				
	8431685	Apr 13, 2025	DP			
	8431685	Apr 13, 2025	DP			
	8431685	Apr 13, 2025	DP			
	8431685	Apr 13, 2025	DP			
	8461105	Apr 13, 2025	DP			
	8461105	Apr 13, 2025	DP			
	8461105	Apr 13, 2025	DP			
	8461105	Apr 13, 2025	DP			
	8501698	Jun 20, 2027				
	8895033	Oct 04, 2030	DP			
	8895033	Oct 04, 2030	DP			
	8895033	Oct 04, 2030	DP			
	8895033	Oct 04, 2030	DP			
	8895033	Oct 04, 2030	DP			
	8895033	Oct 04, 2030	DP			
	8906851	Aug 18, 2026				
	8906851	Aug 18, 2026				
	8906851	Aug 18, 2026				
	8906851	Aug 18, 2026				
	9198925	Oct 04, 2020				
	9238076	Apr 15, 2024	DP			
	9238076	Apr 15, 2024	DP			
	9238076	Apr 15, 2024	DP			
	9238076	Apr 15, 2024	DP			
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
	9884092	Aug 18, 2026				
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001	6872700	Jan 14, 2020				
	6902744	Jan 14, 2020	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002	6872700	Jan 14, 2020				
	6902744	Jan 14, 2020	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP		M-224	Apr 02, 2021
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP			
	6515117	Oct 04, 2020	DS DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020				
	6872700	Jan 14, 2020				
	6936590	Oct 04, 2020				
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026				
	8361972	Mar 21, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8906851	Aug 18, 2026	U-1313			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-412			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2139		M-224	Apr 02, 2021
	6414126	Oct 04, 2020	DS DP U-493			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-2288			
	6872700	Jan 14, 2020	U-654			
	6936590	Oct 04, 2020	U-493			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8216180	Jan 12, 2028	DP			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8690837	May 19, 2029	DP			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8906851	Aug 18, 2026	U-1313			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-412			
	9320853	Mar 25, 2028	DP			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7030106	Jan 25, 2022	DP			
	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 002	6814978	Aug 26, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519	001	8067033	Jul 18, 2026	DP		
		8067451	Jul 18, 2026	DP	U-1196	
		8309127	Jul 18, 2026	DP		
		8318202	Jul 18, 2026	DP		
		8449910	Jul 18, 2026	DP		
		8501228	Jul 18, 2026		U-1196	
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001	7361676	Mar 08, 2024	DP	M-205	Aug 15, 2020
		8372872	Sep 08, 2031	U-1346		
		9107912	Sep 08, 2031	U-1346		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002	7361676	Mar 08, 2024	DP	M-205	Aug 15, 2020
		8372872	Sep 08, 2031	U-1346		
		9107912	Sep 08, 2031	U-1346		
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327	001	10391094	Jun 04, 2032	DP	U-2607	
		7528143	Dec 16, 2026	DS		NCE
		7825246	Dec 16, 2026	DS		ODE-259
		8138199	Jun 30, 2028		U-2607	Aug 16, 2024
						Aug 16, 2026
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	001	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	002	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001	6375986	Sep 21, 2020	DP	U-615	
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	002	6375986	Sep 21, 2020	DP	U-615	
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	001	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	003	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	004	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	005	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
		9314447	May 31, 2033	DP	U-1447	
		9314447	May 31, 2033	DP	U-1448	
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	001	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002	7658944				
		8124125				
		8481078				
		9173847				
		Dec 09, 2024	DP			
		Oct 01, 2024	DP	U-1234		
		Oct 01, 2024	DP	U-1416		
		Oct 01, 2024	DP			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	001	7569612				
		7741373				
		7741374				
		7741374				
		7915247				
		7915247				
		7915247				
		Aug 20, 2027		U-1000		
		Aug 20, 2027		U-1059		
		Aug 20, 2027		U-1060		
		Aug 20, 2027		U-1061		
		Aug 20, 2027		U-1000		
		Aug 20, 2027		U-1059		
		Aug 20, 2027		U-1061		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002	7569612				
		7741373				
		7741374				
		7741374				
		7915247				
		7915247				
		7915247				
		Aug 20, 2027		U-1000		
		Aug 20, 2027		U-1059		
		Aug 20, 2027		U-1060		
		Aug 20, 2027		U-1061		
		Aug 20, 2027		U-1000		
		Aug 20, 2027		U-1059		
		Aug 20, 2027		U-1061		
<u>FENTANYL - SUBSYS</u>						
N 202788	001	10016403				
		8486972				
		8486973				
		8835459				
		8835460				
		9241935				
		9289387				
		9642797				
		9642844				
		Jan 25, 2027	DP			
		Apr 27, 2030	DP			
		Apr 27, 2030		U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	002	10016403				
		8486972				
		8486973				
		8835460				
		9241935				
		9289387				
		9642797				
		9642844				
		Jan 25, 2027	DP			
		Apr 27, 2030	DP			
		Apr 27, 2030		U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	003	10016403				
		8486972				
		8486973				
		8835459				
		8835460				
		9241935				
		9289387				
		9642797				
		9642844				
		Jan 25, 2027	DP			
		Apr 27, 2030	DP			
		Apr 27, 2030		U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	004	10016403				
		8486972				
		8486973				
		8835459				
		8835460				
		9241935				
		9289387				
		9642797				
		9642844				
		Jan 25, 2027	DP			
		Apr 27, 2030	DP			
		Apr 27, 2030		U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP	U-55		
		Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	005	10016403				
		8486972				
		Jan 25, 2027	DP			
		Apr 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486973				
		Apr 27, 2030			U-55	
		8835460				
		Jan 25, 2027			DP U-55	
		9241935				
		Jan 25, 2027			DP	
		9289387				
		Jan 25, 2027			DP U-55	
		9642797				
		Jan 25, 2027			DP U-55	
		9642844				
		Jan 25, 2027			DP	
<u>FENTANYL - SUBSYS</u>						
N 202788	006	10016403				
		Jan 25, 2027			DP	
		8486972				
		Apr 27, 2030			DP	
		8486973				
		Apr 27, 2030			U-55	
		8835459				
		Jan 25, 2027			DP	
		8835460				
		Jan 25, 2027			DP U-55	
		9241935				
		Jan 25, 2027			DP	
		9289387				
		Jan 25, 2027			DP U-55	
		9642797				
		Jan 25, 2027			DP U-55	
		9642844				
		Jan 25, 2027			DP	
<u>FENTANYL - SUBSYS</u>						
N 202788	007	10016403				
		Jan 25, 2027			DP	
		8486972				
		Apr 27, 2030			DP	
		8486973				
		Apr 27, 2030			U-55	
		8835459				
		Jan 25, 2027			DP	
		8835460				
		Jan 25, 2027			DP U-55	
		9241935				
		Jan 25, 2027			DP	
		9289387				
		Jan 25, 2027			DP U-55	
		9642797				
		Jan 25, 2027			DP U-55	
		9642844				
		Jan 25, 2027			DP	
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	001	7862832				
		Jun 15, 2028			DP	
		7862833				
		Jun 15, 2028			DP	
		8092832				
		Dec 30, 2024			DP	
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	002	7862832				
		Jun 15, 2028			DP	
		7862833				
		Jun 15, 2028			DP	
		8092832				
		Dec 30, 2024			DP	
		8119158				
		Dec 30, 2024			DP	
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	003	7862832				
		Jun 15, 2028			DP	
		7862833				
		Jun 15, 2028			DP	
		8092832				
		Dec 30, 2024			DP	
		8119158				
		Dec 30, 2024			DP	
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	004	7862832				
		Jun 15, 2028			DP	
		7862833				
		Jun 15, 2028			DP	
		8092832				
		Dec 30, 2024			DP	
		8119158				
		Dec 30, 2024			DP	
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	005	7862832				
		Jun 15, 2028			DP	
		7862833				
		Jun 15, 2028			DP	
		8092832				
		Dec 30, 2024			DP	
		8119158				
		Dec 30, 2024			DP	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	001	7579019				
		Jan 22, 2020			U-767	
		9597288				
		Jul 23, 2027			DP U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	002	7579019				
		Jan 22, 2020			U-767	
		9597288				
		Jul 23, 2027			DP U-767	
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266	003	7579019				
		Jan 22, 2020			U-767	
		9597288				
		Jul 23, 2027			DP U-767	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
	9731121	Oct 17, 2031	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			
	7754702	Feb 15, 2028	DP U-2557			
	8895612	Jan 08, 2027	DP U-1620			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
	9757416	Feb 18, 2024	DS DP U-1577			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC MALTO - ACCRUFER</u>						
N 212320	001	9802973	Oct 23, 2035	DS DP U-2603		
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317	001	7816404	Apr 17, 2029	DP U-1656		
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551	001	7816404	Apr 17, 2029	U-1656		
		7857977	Sep 08, 2027	U-1656		
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180	001	6599498	Jun 30, 2023	DS DP	I-767	Feb 02, 2021
		7553479	Mar 08, 2020	DS DP		
		7871597	Mar 08, 2020	DS DP		
		8501158	Mar 08, 2020	U-1422		
		8591864	Mar 08, 2020	DP		
		8926947	Mar 08, 2020	DS DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	001	6858650	Jul 03, 2022	DS U-913		
		7807715	Jun 07, 2027	DP U-913		
		8088398	Jun 07, 2027	DP U-913		
		8501723	Jun 07, 2027	DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	002	6858650	Jul 03, 2022	DS U-913		
		7807715	Jun 07, 2027	DP U-913		
		8088398	Jun 07, 2027	DP U-913		
		8501723	Jun 07, 2027	DP		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909	002	6723348	Nov 26, 2021	DP U-1466		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909	003	6723348	Nov 26, 2021	DP		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373	001	8933097	Aug 02, 2030	DP		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373	002	8933097	Aug 02, 2030	DP		
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704	002	6613357	Dec 25, 2020	DP U-1159		
<u>FIDAXOMICIN - DIFICID</u>						
N 201699	001	7378508	Jul 31, 2027	DS DP		
		7863249	Jul 31, 2027	DS DP		
		7906489	Mar 04, 2027	U-319		
		8586551	Jul 15, 2023	DS DP		
		8586551*PED	Jan 15, 2024			
		8859510	Jul 31, 2027	U-319		
		8859510*PED	Jan 31, 2028			
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001	8536167	Aug 08, 2031	U-1679		
		9119859	Jul 02, 2030	U-1679		
		9504691	Nov 21, 2033	DP U-1679		
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527	001	8324283	Mar 29, 2026	DP	NPP	May 11, 2021
		8324283*PED	Sep 29, 2026		PED	Nov 11, 2021
		9187405	Jun 25, 2027	U-2613		
		9187405*PED	Dec 25, 2027			
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527	002	9592208	Mar 30, 2032	DP U-2315	NS	May 11, 2021
		9592208*PED	Sep 30, 2032		PED	Nov 11, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	001	10350186	Nov 05, 2024	U-2585	NCE	Jul 27, 2023
		9566260	Jul 11, 2025	DP U-2366	ODE-202	Jul 27, 2025
		9629821	Jul 11, 2025	DP U-2367		
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	002	10350186	Nov 05, 2024	U-2585	NCE	Jul 27, 2023
		9566260	Jul 11, 2025	DP U-2366	ODE-202	Jul 27, 2025
		9629821	Jul 11, 2025	DP U-2367		
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	001				NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	002				NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	003				NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	004				NCE	Jul 13, 2021
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001	7151103	May 09, 2023	U-1734	NCE	Aug 18, 2020
		7420057	Aug 01, 2022	DS DP		
		8227471	May 09, 2023	U-1734		
		9468639	Oct 16, 2022	U-1734		
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677	001	7807135	Mar 18, 2029	DS DP U-1497		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	001	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	002	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	003	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001	10010632	Nov 28, 2026	DP	NCE	May 27, 2021
		10124079	Dec 30, 2035	U-2450		
		5808146	Nov 09, 2020	DS		
		9387266	Nov 28, 2026	U-1879		
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273	001	7148207	Dec 20, 2022	DP U-944		
<u>FLUOCINOLONE ACETONIDE - ILLUVIEN</u>						
N 201923	001	6375972	Apr 26, 2020	DP U-1597		
		8871241	Aug 12, 2027	DP		
<u>FLUOCINOLONE ACETONIDE - YUTIQ</u>						
N 210331	001	6375972	Apr 26, 2020	DP U-708	NP	Nov 12, 2021
		8574613	Apr 26, 2020	DP		
		8574659	Apr 26, 2020	DP		
		8871241	Aug 12, 2027	DP		
		9192579	Apr 26, 2020	DP		
		9849085	Apr 26, 2020	U-708		
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	7915243	Sep 08, 2023	DP		
		7939516	Sep 08, 2023	DP		
		8247395	Oct 25, 2022	DP		
		8653053	Oct 25, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001 6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023		U-861		
	7794738	Sep 11, 2022		U-1084		
	8232264	Mar 09, 2023	DP			
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655	001				NCE	Oct 10, 2024
					W	Oct 10, 2024
<u>FLUOROURACIL - CARAC</u>						
N 020985	001 6670335	Jun 02, 2021	DP	U-68		
<u>FLUOROURACIL - TOLAK</u>						
N 022259	001 7169401	Jul 18, 2023	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	001 7270800	Sep 03, 2025	DS DP	U-336		
	7351401	Jan 24, 2023	DS DP	U-336		
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023		U-336		
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	002 7270800	Sep 03, 2025	DS DP	U-336		
	7351401	Jan 24, 2023	DS DP	U-336		
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023		U-336		
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051	002 6858596	Aug 03, 2021	DP	U-1890		
	7101866	Aug 03, 2021	DS DP	U-1890		
	7541350	Aug 03, 2021	DP	U-1890		
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001 7101866	Aug 03, 2021	DS DP	U-1559	NPP	May 17, 2021
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	002 7101866	Aug 03, 2021	DS DP	U-1559		
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	003 7101866	Aug 03, 2021	DS DP	U-2349	NS	May 17, 2021
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	6537983	Aug 03, 2021	DP U-2125		I-775	Apr 24, 2021
	6759398	Aug 03, 2021	DP U-2125			
	6878698	Aug 03, 2021	U-2134			
	7101866	Aug 03, 2021	DS DP U-2126			
	7439393	May 21, 2025	DS DP U-2127			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		M-202	May 15, 2020
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	6537983	Aug 03, 2021	DP U-1691		M-202	May 15, 2020
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	6743413		U-581	Y	
		7500444		DP		
		7500444*PED				
		7832351		DP		
		9861771		DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	7500444		DP		
		7500444*PED				
		7832351		DP		
		9861771		DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	10022510		DP	NP	Jan 27, 2020
		10124131		DP		
		10195375		DP		
		6701917		DP		
		6718972		DP		
		6748947		DP		
		6871646		DP		
		7540282		DP		
		8006690		DP		
		8651103		DP		
		8714149		DP		
		8978966		DP		
		9216260		DP		
		9463288		DP		
		9616024		DP		
		9731087		DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	10022510		DP	NP	Jan 27, 2020
		10124131		DP		
		10195375		DP		
		6701917		DP		
		6718972		DP		
		6748947		DP		
		6871646		DP		
		7540282		DP		
		8006690		DP		
		8651103		DP		
		8714149		DP		
		8978966		DP		
		9216260		DP		
		9463288		DP		
		9616024		DP		
		9731087		DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	003	10022510		DP	NP	Jan 27, 2020
		10124131		DP		
		10195375		DP		
		6701917		DP		
		6718972		DP		
		6748947		DP		
		6871646		DP		
		7540282		DP		
		8006690		DP		
		8651103		DP		
		8714149		DP		
		8978966		DP		
		9216260		DP		
		9463288		DP		
		9616024		DP		
		9731087		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10076614	Oct 20, 2034	DP		NP	Sep 18, 2020
	10076615	Jul 30, 2029	U-2133			
	10124132	Mar 06, 2027	DP U-2133			
	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
	10478574	Nov 04, 2033	U-2133			
	6715485	Mar 03, 2020	DP			
	7975690	Dec 29, 2025	U-2133			
	8327844	Oct 08, 2023	U-2133			
	8522778	May 11, 2022	DP			
	8550073	Oct 22, 2029	DP			
	8555878	Mar 20, 2020	DP			
	8978647	Aug 06, 2030	DP			
	9072857	Apr 10, 2021	DP			
	9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001					M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002					M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003					M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP		NP	Jan 27, 2020
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP		NP	Jan 27, 2020
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP		NP	Jan 27, 2020
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP	U-645		
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192 001	6242003	Apr 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 001	7465462	May 10, 2020	DP	U-929		
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 002	7465462	May 10, 2020	DP	U-929		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 001	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 002	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 003	7741268	Apr 02, 2024	DP			
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS DP			
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831 001	6887459	Nov 28, 2020		U-762		
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP	U-813		
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP	U-813		
	8623922	Jun 22, 2021	DP			
	9730890	Jun 22, 2021	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030		U-2546		
	8703806	May 28, 2030		U-2546		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294	001	8808713	May 28, 2030	DP U-2546		
		8815258	Mar 17, 2031	U-2546		
		9415009	May 28, 2030	U-2546		
		9463161	May 28, 2030	DP U-2546		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	001	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020		PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068		
		7566705*PED	Nov 21, 2020			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	002	7067502	May 21, 2020	DP U-1068	M-214	Dec 20, 2020
		7067502*PED	Nov 21, 2020		PED	Jun 20, 2021
		7566705	May 21, 2020	DP U-1068		
		7566705*PED	Nov 21, 2020			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	001				NPP	Apr 03, 2021
					PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	002				NPP	Apr 03, 2021
					PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493	001	10208073	May 23, 2032	U-2301	NCE	Apr 19, 2023
		8426450	May 23, 2032	DS DP		
		8895586	May 23, 2032	U-2301		
		9186357	Nov 18, 2030	U-2301		
		9403772	May 23, 2032	DS U-2301		
		9908907	May 23, 2032	DS DP		
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244	001	6204257	Jul 01, 2022	DS DP U-945		
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299	001	7449458	Sep 04, 2026	DS	NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294	ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294		
		8163902	Jun 17, 2026	DS U-2294		
		8211889	Jan 19, 2026	DS		
		8263122	Nov 24, 2030	DP		
		8445485	Jun 17, 2026	DP		
		8652492	Nov 06, 2028	DP		
		8771648	Jul 27, 2032	DP		
		8912170	Jun 17, 2026	U-2294		
		8951504	Jul 27, 2032	U-2294		
		9266912	Jan 19, 2026	U-2294		
		9283238	Jun 17, 2026	U-2294		
		9737554	Jan 19, 2026	DP		
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299	002	7449458	Sep 04, 2026	DS	NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294	ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294		
		8163902	Jun 17, 2026	DS U-2294		
		8211889	Jan 19, 2026	DS		
		8263122	Nov 24, 2030	DP		
		8445485	Jun 17, 2026	DP		
		8652492	Nov 06, 2028	DP		
		8771648	Jul 27, 2032	DP		
		8912170	Jun 17, 2026	U-2294		
		8951504	Jul 27, 2032	U-2294		
		9266912	Jan 19, 2026	U-2294		
		9283238	Jun 17, 2026	U-2294		
		9737554	Jan 19, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826		I-749	Aug 25, 2020
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN - NEURONTIN</u>						
N 021129 001	7256216	May 28, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	6488962	Jun 20, 2020	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	6488962	Jun 20, 2020	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	002 8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277	001				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	002				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	003				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	004				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	005				I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277	006 5980864	Nov 09, 2021	DS DP U-1119		I-801	Jul 12, 2022
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	001 6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711	002 6676929	May 04, 2020	DP			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	001				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	002				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	003				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	004				NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	005				NPP	Aug 25, 2020
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	001 6039931	Nov 13, 2021	U-1239			
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	002 6039931	Nov 13, 2021	U-1239			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547	001 9375498	Aug 10, 2032	DP		NCE ODE-120	Jun 01, 2021 Jun 01, 2023
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828	001				NCE W	Aug 21, 2024 Aug 21, 2024
<u>GANCICLOVIR - GANZYK-RTU</u>						
N 209347	001 9486530	Sep 02, 2034	DP			
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493	001 6333045*PED	Feb 20, 2020				
<u>GEFITINIB - IRESSA</u>						
N 206995	001				ODE-95	Jul 13, 2022
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	001 9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313	002 9241948	Jul 01, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 003	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 004	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 005	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 006	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 007	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 008	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 009	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 010	9241948	Jul 01, 2033	DP			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	8969336	Jan 27, 2031	DS DP		NCE	Nov 28, 2023
	9487491	Jul 28, 2030		U-2456	ODE-222	Nov 28, 2025
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	10119143	Oct 03, 2034	DS DP	U-2672	NCE	Nov 20, 2024
	10125364	Mar 15, 2033	DS DP	U-2672	ODE-273	Nov 20, 2026
	10131907	Aug 24, 2028	DS DP	U-2672		
	10273477	Mar 08, 2024	DS			
	8106022	Dec 12, 2029	DS DP	U-2672		
	8546143	Jan 09, 2022	DS	U-2672		
	8828956	Dec 04, 2028	DS DP	U-2672		
	9133461	May 14, 2033	DS DP	U-2672		
	9150605	Aug 28, 2025	DS DP			
	9631193	Mar 15, 2033		U-2672		
	9708610	Jan 01, 2024	DS DP	U-2672		
	9708615	Mar 08, 2024	DS			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	8148401	Jan 30, 2031	DS DP		ODE-224	Nov 21, 2025
	8431597	Jun 29, 2028	DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	8148401	Jan 30, 2031	DS DP		ODE-224	Nov 21, 2025
	8431597	Jun 29, 2028	DP			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8232250	Aug 19, 2030		U-441		
	8399413	Aug 19, 2030		U-441		
	8969302	Aug 19, 2030		U-441		
	9155776	Aug 19, 2030		U-441		
	9402874	Aug 19, 2030		U-441		
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030		U-2141	D-175	Sep 26, 2022
	10028937	Jun 10, 2030		U-2532	M-230	Aug 06, 2021
	10039754	Jun 10, 2030		U-2141	NCE	Aug 03, 2022
	10039754	Jun 10, 2030		U-2532	NPP	Apr 30, 2022
	10286029	Mar 14, 2034		U-2532	ODE-232	Apr 30, 2026
	8648037	Jan 19, 2032	DS DP	U-2141	ODE-233	Apr 30, 2026
	8648037	Jan 19, 2032	DS DP	U-2532		
	8937150	May 18, 2032	DS DP			
	9321807	Jun 05, 2035	DS			
	9586978	Jun 10, 2030		U-2141		
	9586978	Jun 10, 2030		U-2532		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030		U-2141	D-175	Sep 26, 2022
	10028937	Jun 10, 2030		U-2532	M-230	Aug 06, 2021
	10039754	Jun 10, 2030		U-2141	NCE	Aug 03, 2022
	10039754	Jun 10, 2030		U-2532	NPP	Apr 30, 2022
	10286029	Mar 14, 2034		U-2532	ODE-232	Apr 30, 2026
	8648037	Jan 19, 2032	DS DP	U-2141	ODE-233	Apr 30, 2026
	8648037	Jan 19, 2032	DS DP	U-2532		
	8937150	May 18, 2032	DS DP			
	9321807	Jun 05, 2035	DS			
	9586978	Jun 10, 2030		U-2141		
	9586978	Jun 10, 2030		U-2532		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 001	7700128	Jan 30, 2027		DP		
	8071130	Jun 08, 2028		DP		
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 002	7700128	Jan 30, 2027		DP		
	8071130	Jun 08, 2028		DP		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10213487	Feb 16, 2036		DP U-2604	NP	Jul 24, 2022
	6938798	Jan 03, 2022		DP		
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004					NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10045958	Sep 22, 2030		U-1816	NPP	Apr 28, 2020
	10045959	Sep 22, 2030		U-1816	ODE-157	Apr 28, 2024
	10183002	Sep 22, 2030		U-1816	ODE-42	Feb 01, 2020
	10183003	Sep 22, 2030		U-1816		
	10183004	Sep 22, 2030		U-1816		
	10183005	Sep 22, 2030		U-1816		
	10183006	Sep 22, 2030		U-1816		
	8404215	Mar 09, 2032		U-1383		
	8642012	Sep 22, 2030		U-1383		
	9095559	Mar 09, 2032		U-1383		
	9254278	Mar 09, 2032		U-1816		
	9326966	Mar 09, 2032		U-1816		
	9561197	Sep 22, 2030		U-1383		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	9962359	Sep 22, 2030	U-1816		
		9999608	Sep 22, 2030	U-1816		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571	001	7638552	Aug 20, 2023	U-1076		
		7816396	Aug 20, 2023	U-1076		
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923	001	7229607	Apr 09, 2021	U-1773		
		7736670	Jun 27, 2021	DP		
		8029768	Apr 09, 2021	U-1773		
		8048451	Jun 27, 2021	DP		
		8182838	Oct 20, 2028	DP		
		8303991	Jun 27, 2021	DP		
		8435567	Jun 27, 2021	DP		
		8479730	Oct 11, 2028	DP		
		8580306	Jun 27, 2021	DP		
		8956661	Jun 27, 2021	DP		
		9931304	Jun 27, 2021	DP		
		9962338	Jun 27, 2021	DP		
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437	001	10376661	Sep 14, 2035	DP	NP	Dec 05, 2020
		6962151	Oct 27, 2020	DP		
		7316067	Sep 06, 2022	DP		
		7458372	Nov 18, 2024	DP		
		7931212	Nov 25, 2025	DP		
		8511581	Nov 08, 2023	DP		
		9168556	Sep 01, 2032	DP		
		9265900	Dec 07, 2028	DP		
		9604018	May 16, 2033	DP		
		9789270	Oct 30, 2030	DP		
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930	001	6878721	Feb 25, 2025	DS DP U-1773		
		7229607	Apr 09, 2021	U-1773		
		7736670	Jun 27, 2021	DP		
		7820694	Jun 02, 2020	DP U-1773		
		8029768	Apr 09, 2021	U-1773		
		8048451	Jun 27, 2021	DP		
		8067437	Jun 02, 2020	U-1773		
		8182838	Oct 20, 2028	DP		
		8283362	Jun 02, 2020	DP U-1773		
		8303991	Jun 27, 2021	DP		
		8435567	Jun 27, 2021	DP		
		8479730	Oct 11, 2028	DP		
		8580306	Jun 27, 2021	DP		
		8658673	Jun 02, 2020	DP U-1773		
		8796307	Jun 02, 2020	DP		
		8956661	Jun 27, 2021	DP		
		9931304	Jun 27, 2021	DP		
		9962338	Jun 27, 2021	DP		
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361	001	10004717	Feb 28, 2033	DP U-2398		
		10052267	Oct 17, 2028	DP U-2398		
		6433003	Apr 10, 2020	U-2398		
		8618160	Dec 10, 2029	DP U-2398		
		8859610	Feb 28, 2033	DP U-2398		
		9259414	Feb 28, 2033	U-2398		
		9744105	Jul 18, 2030	DP U-2398		
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970	001	10227590	Jun 28, 2025	DS DP	NCE	Dec 12, 2024
		10266827	Jun 28, 2025	U-2675		
		10421966	Jun 28, 2025	DS DP		
		9024007	Jun 28, 2025	DS DP		
		9416361	May 04, 2021	DS		
		9994851	Jun 28, 2025	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970	001 RE47691	Jun 28, 2025	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726	001 7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578	001 7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N 022198	001 7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445	001 10357570	Sep 28, 2024		U-2253		
	6613355	Jun 28, 2021	DP			
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024		U-1891		
	8715710	Sep 28, 2024	DP			
	9913910	Sep 28, 2024		U-2253		
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	001 6372252	Apr 28, 2020		U-489		
	6955821	Apr 28, 2020	DP	U-489		
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	002 6372252	Apr 28, 2020		U-489		
	6955821	Apr 28, 2020	DP	U-489		
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474	001 10105324	Nov 13, 2035	DS DP	U-2023		
	9549907	Nov 13, 2035	DS DP	U-2023		
	9808431	Nov 13, 2035	DS DP	U-2023		
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	001 6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-686		
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	002 6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP	U-686		
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001 6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP	U-494		
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002 6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP	U-494		
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003 6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP	U-494		
	6811794*PED	Jan 04, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001	8962028	Jun 19, 2033	DP U-1775			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	10478502	Nov 02, 2031	DP U-2625		NP	Nov 06, 2021
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NDF	May 24, 2021
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	10426787	Jun 06, 2036		U-2625		
	10478502	Nov 02, 2031	DP U-2625			
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
	7348361	Nov 06, 2020	DP U-2250			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058 001	8062652	Jun 16, 2026	U-1197			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727 001	6465463	Sep 08, 2020	U-71			
	6784177	Sep 08, 2020	U-71			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 001	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 002	6358986	Jan 10, 2020				
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9339499	Jul 25, 2033				
	9421200	Jul 25, 2033				
	9433619	Jul 25, 2033				
	9452163	Sep 12, 2034				
	9486451	Sep 12, 2034				
	9610286	Jul 25, 2033				
	9713611	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10028946	Jul 25, 2033				
	10092559	Sep 12, 2034				
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033				
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033				
	9326982	Jul 25, 2033				
	9333201	Jul 25, 2033				
	9339499	Jul 25, 2033				
	9421200	Jul 25, 2033				
	9433619	Jul 25, 2033				
	9452163	Sep 12, 2034				
	9486451	Sep 12, 2034				
	9610286	Jul 25, 2033				
	9713611	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10028946	Jul 25, 2033				
	10092559	Sep 12, 2034				
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033				
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033				
	9326982	Jul 25, 2033				
	9333201	Jul 25, 2033				
	9339499	Jul 25, 2033				
	9421200	Jul 25, 2033				
	9433619	Jul 25, 2033				
	9452163	Sep 12, 2034				
	9486451	Sep 12, 2034				
	9610286	Jul 25, 2033				
	9713611	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10028946	Jul 25, 2033				
	10092559	Sep 12, 2034				
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033				
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033				
	9326982	Jul 25, 2033				
	9333201	Jul 25, 2033				
	9339499	Jul 25, 2033				
	9421200	Jul 25, 2033				
	9433619	Jul 25, 2033				
	9452163	Sep 12, 2034				
	9486451	Sep 12, 2034				
	9610286	Jul 25, 2033				
	9713611	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10028946	Jul 25, 2033				
	10092559	Sep 12, 2034				
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033				
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033				
	9326982	Jul 25, 2033				
	9333201	Jul 25, 2033				
	9339499	Jul 25, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9421200	Jul 25, 2033		U-1810		
	9433619	Jul 25, 2033		U-1810		
	9452163	Sep 12, 2034		U-55		
	9486451	Sep 12, 2034		U-55		
	9610286	Jul 25, 2033		U-1810		
	9713611	Sep 12, 2034	DP	U-55		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	005	9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	006	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		
		9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	007	10130591	Nov 20, 2023	DP	U-1819	
		10369109	Jun 16, 2023	DP		
		6733783	Oct 30, 2021	DP	U-1556	
		8309060	Nov 20, 2023	DP	U-1556	
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP	U-1556	
		9056052	Oct 30, 2020	DP		
		9060940	Oct 30, 2020		U-1556	
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027		U-1556	
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2020	DP		
		9205056	Oct 30, 2020	DP		
		9289391	Oct 30, 2020	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027		U-1556	
		9492391	Aug 24, 2027		U-1556	
		9517236	Oct 30, 2020	DP		
		9545380	Aug 24, 2027		U-1556	
		9572779	Dec 21, 2031	DP		
		9572804	Oct 30, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	007	9669023	Oct 30, 2020	DP		
		9669024	Oct 30, 2020	DP		
		9675610	Jun 16, 2023	DP		
		9675611	Oct 30, 2020		U-1556	
		9682077	Oct 30, 2020		U-1556	
		9750703	Dec 21, 2031	DP		
		9763933	Aug 24, 2027	DP		
		9770416	Aug 24, 2027	DP		
		9775809	Aug 24, 2027	DP		
		9861584	Dec 21, 2031	DP		
		9872837	Dec 21, 2031	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	001	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	002	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	003	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	004	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975	005	8445018	Jul 31, 2029	DP		
		9216176	Sep 13, 2027	DP		
		9572803	Sep 13, 2027	DP		
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N 022076	001	7378405	Dec 19, 2026	DP		
		7981877	Jan 23, 2025	DP		
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305	001	10098910	Apr 21, 2035	DP	U-2205	NP Dec 14, 2020
		7381427	Jun 08, 2022		U-2205	
		9675639	Jul 04, 2035	DP	U-2205	
		9980983	Apr 21, 2035		U-2205	
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	001	6589960	Nov 09, 2020	DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034	002	6589960	Nov 09, 2020	DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	003	6589960	Nov 09, 2020	DS DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034	004	6589960	Nov 09, 2020	DS DP		
		9248229	Mar 12, 2034	DP		
		9731082	Apr 23, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	6589960	Nov 09, 2020	DS DP			
	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 003	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 004	6589960	Nov 09, 2020	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	10471075	May 02, 2036		U-2236		
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036		U-2236		
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					NP ODE-177	Dec 21, 2020 Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					NP ODE-177	Dec 21, 2020 Dec 21, 2024
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 002	7192938	May 06, 2023		U-798		
	7410957	May 06, 2023		U-887		
	7718634	May 06, 2023		U-642		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10004746	Jun 03, 2031		U-1684	D-176	Aug 24, 2021
	10004746	Jun 03, 2031		U-1946	I-741	Jan 18, 2020
	10004746	Jun 03, 2031		U-2241	I-753	Aug 02, 2020
	10004746	Jun 03, 2031		U-2242	M-236	Jan 25, 2022
	10016435	Jun 03, 2031		U-1650	ODE-109	Mar 04, 2023
	10106548	Jun 03, 2033	DS DP		ODE-117	May 06, 2023
	10125140	Jun 03, 2033	DS DP		ODE-128	Jan 18, 2024
	10294231	Jun 03, 2033	DP		ODE-152	Aug 02, 2024
	10294232	Jun 03, 2033	DP		ODE-55	Nov 13, 2020
	10463668	Oct 24, 2034		U-2654	ODE-60	Feb 12, 2021
	10478439	Jun 03, 2031		U-1456	ODE-72	Jul 28, 2021
	10478439	Jun 03, 2031		U-1650	ODE-86	Jan 29, 2022
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1650		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2219		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		
	8952015	Dec 28, 2026		U-1946		
	8952015	Dec 28, 2026		U-1947		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1683		
	8999999	Jun 03, 2031		U-1684		
	9125889	Jun 03, 2031		U-1745		
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
	9540382	Aug 18, 2033		U-1456		
	9540382	Aug 18, 2033		U-1650		
	9540382	Aug 18, 2033		U-1684		
	9540382	Aug 18, 2033		U-1946		
	9540382	Aug 18, 2033		U-1947		
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-2150		
	9801881	Jun 03, 2031		U-1491		
	9801883	Jun 03, 2031		U-2159		
	9814721	Jun 03, 2031		U-1947		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031		U-1684	D-176	Aug 24, 2021
	10004746	Jun 03, 2031		U-1946	M-236	Jan 25, 2022
	10004746	Jun 03, 2031		U-2241		
	10004746	Jun 03, 2031		U-2242		
	10016435	Jun 03, 2031		U-1650		
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10294231	Jun 03, 2033	DP			
	10294232	Jun 03, 2033	DP			
	10463668	Oct 24, 2034		U-2654		
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001	8497277	Dec 28, 2026	U-1947		
		8497277	Dec 28, 2026	U-2241		
		8497277	Dec 28, 2026	U-2242		
		8563563	Apr 26, 2027	U-1491		
		8563563	Apr 26, 2027	U-1650		
		8563563	Apr 26, 2027	U-1946		
		8563563	Apr 26, 2027	U-2241		
		8563563	Apr 26, 2027	U-2242		
		8697711	Dec 28, 2026	DS DP		
		8703780	Dec 28, 2026	U-1491		
		8703780	Dec 28, 2026	U-2242		
		8735403	Dec 28, 2026	DS DP		
		8754090	Jun 03, 2031	U-1456		
		8754091	Dec 28, 2026	DP		
		8952015	Dec 28, 2026	U-1456		
		8952015	Dec 28, 2026	U-1491		
		8952015	Dec 28, 2026	U-1650		
		8952015	Dec 28, 2026	U-1946		
		8952015	Dec 28, 2026	U-1947		
		8952015	Dec 28, 2026	U-2241		
		8952015	Dec 28, 2026	U-2242		
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031	U-1491		
		8999999	Jun 03, 2031	U-1946		
		8999999	Jun 03, 2031	U-2241		
		8999999	Jun 03, 2031	U-2242		
		9125889	Jun 03, 2031	U-1650		
		9181257	Dec 28, 2026	DS		
		9296753	Oct 30, 2033	DS		
		9655857	Mar 03, 2036	DP		
		9725455	Jun 03, 2033	DS		
		9795604	Oct 24, 2034	U-2150		
		9801881	Jun 03, 2031	U-1491		
		9801881	Jun 03, 2031	U-2242		
		9801883	Jun 03, 2031	U-2159		
		9801883	Jun 03, 2031	U-2243		
		9814721	Jun 03, 2031	U-1947		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002	10004746	Jun 03, 2031	U-1684	D-176	Aug 24, 2021
		10004746	Jun 03, 2031	U-1946	M-236	Jan 25, 2022
		10004746	Jun 03, 2031	U-2241		
		10004746	Jun 03, 2031	U-2242		
		10010507	Mar 03, 2036	DP		
		10016435	Jun 03, 2031	U-1650		
		10106548	Jun 03, 2033	DS DP		
		10125140	Jun 03, 2033	DS DP		
		10213386	Mar 03, 2036	DP		
		10463668	Oct 24, 2034	U-2654		
		10478439	Jun 03, 2031	U-1456		
		10478439	Jun 03, 2031	U-1650		
		10478439	Jun 03, 2031	U-1684		
		10478439	Jun 03, 2031	U-1946		
		10478439	Jun 03, 2031	U-1947		
		10478439	Jun 03, 2031	U-2241		
		10478439	Jun 03, 2031	U-2242		
		10478439	Jun 03, 2031	U-2665		
		7514444	Dec 28, 2026	DS DP		
		8008309	Dec 28, 2026	DS DP		
		8476284	Dec 28, 2026	U-1456		
		8476284	Dec 28, 2026	U-1650		
		8476284	Dec 28, 2026	U-1946		
		8476284	Dec 28, 2026	U-1947		
		8476284	Dec 28, 2026	U-2241		
		8497277	Dec 28, 2026	U-1456		
		8497277	Dec 28, 2026	U-1491		
		8497277	Dec 28, 2026	U-1650		
		8497277	Dec 28, 2026	U-1946		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10004746	Jun 03, 2031	U-1684		D-176	Aug 24, 2021
	10004746	Jun 03, 2031	U-1946		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004	8497277	Dec 28, 2026	U-1947		
		8497277	Dec 28, 2026	U-2241		
		8497277	Dec 28, 2026	U-2242		
		8563563	Apr 26, 2027	U-1491		
		8563563	Apr 26, 2027	U-1650		
		8563563	Apr 26, 2027	U-1946		
		8563563	Apr 26, 2027	U-2241		
		8563563	Apr 26, 2027	U-2242		
		8697711	Dec 28, 2026	DS DP		
		8703780	Dec 28, 2026	U-1491		
		8703780	Dec 28, 2026	U-2242		
		8735403	Dec 28, 2026	DS DP		
		8754090	Jun 03, 2031	U-1456		
		8754091	Dec 28, 2026	DP		
		8952015	Dec 28, 2026	U-1456		
		8952015	Dec 28, 2026	U-1491		
		8952015	Dec 28, 2026	U-1650		
		8952015	Dec 28, 2026	U-1946		
		8952015	Dec 28, 2026	U-1947		
		8952015	Dec 28, 2026	U-2241		
		8952015	Dec 28, 2026	U-2242		
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031	U-1491		
		8999999	Jun 03, 2031	U-1946		
		8999999	Jun 03, 2031	U-2241		
		8999999	Jun 03, 2031	U-2242		
		9125889	Jun 03, 2031	U-1650		
		9181257	Dec 28, 2026	DS		
		9296753	Oct 30, 2033	DS		
		9655857	Mar 03, 2036	DP		
		9725455	Jun 03, 2033	DS		
		9795604	Oct 24, 2034	U-2150		
		9801881	Jun 03, 2031	U-1491		
		9801881	Jun 03, 2031	U-2242		
		9801883	Jun 03, 2031	U-2159		
		9801883	Jun 03, 2031	U-2243		
		9814721	Jun 03, 2031	U-1947		
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589	002	10238640	May 25, 2024	DP		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001	6727286	Nov 27, 2021	DP	U-981	
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	6727286	Nov 27, 2021	DP	U-981	
		8735452	Sep 30, 2029	U-981		
		8871810	Sep 30, 2029	U-981		
		9012508	Sep 14, 2030	U-981		
		9114068	Sep 30, 2029	U-1735		
		9138404	Sep 30, 2029	U-1756		
		9295639	Sep 30, 2029	U-1756		
		9649284	Sep 30, 2029	U-2018		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	003	8735452	Sep 30, 2029	U-981		
		8871810	Sep 30, 2029	U-981		
		9012508	Sep 14, 2030	U-981		
		9072661	Mar 16, 2032	U-2264		
		9072710	Mar 16, 2032	U-2266		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903	001	6342530	Nov 14, 2020	DP	U-1127	
		6342530	Nov 14, 2020	DP	U-794	
		6344479	Mar 20, 2021	DS DP	U-794	Y
		8415337	Mar 02, 2032	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
	6949535	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
	6949535	Apr 24, 2021	DS U-1560		ODE-71	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007	9072742				
		9074254				
		9074255				
		9074256				
		9138432				
		9157121				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	6958335				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	6958335				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	001	6958335				
		6958335				
		6958335*PED				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588	002	6958335				
		6958335				
		6958335*PED				
<u>IMIQUIMOD - ALDARA</u>						
N 020723	001	7696159				
		7696159				
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001	10238644				
		10238645				
		10238645				
		8236816				
		8299109				
		8598196				
		8598196				
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	002	8222270				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383	001	6878721				
		8067437				
		8479730				
		8658673				
		8796307				
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	001	6689761				
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	003	6689761				
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	005	6689761				
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	006	6689761				
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580	001	6915154				
		7881777				
		8185176				
		8406860				
		8647605				
		8647605				
		8892190				
		9421280				
		9421280				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001	8734847	Apr 23, 2030	DP		
		8992982	Apr 23, 2030	DP		
		9089471	Apr 23, 2030	U-55		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002	8734847	Apr 23, 2030	DP		
		8992982	Apr 23, 2030	DP		
		9089471	Apr 23, 2030	U-55		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	001	7410656	Oct 10, 2020		U-1222	
		8278292	Jul 06, 2027	DP		
		8372827	Dec 18, 2026	DP		
		8372828	Dec 18, 2026	DP		
		8377919	Dec 18, 2026	DP		
		8536163	Dec 18, 2026		U-1440	
		8716271	Dec 18, 2026		U-1440	
		8735375	Dec 18, 2026		U-1440	
		9789078	May 15, 2033		U-2138	
		9820959	Dec 18, 2026	DP	U-1440	
		9833428	Dec 18, 2026	DP		
		9833429	Dec 18, 2026	DP		
		9861603	Dec 18, 2026		U-1440	
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	002	7410656	Oct 10, 2020		U-1222	
		8278292	Jul 06, 2027	DP		
		8372827	Dec 18, 2026	DP		
		8372828	Dec 18, 2026	DP		
		8377919	Dec 18, 2026	DP		
		8536163	Dec 18, 2026		U-1440	
		8716271	Dec 18, 2026		U-1440	
		8735375	Dec 18, 2026		U-1440	
		9820959	Dec 18, 2026	DP	U-1440	
		9833428	Dec 18, 2026	DP		
		9833429	Dec 18, 2026	DP		
		9861603	Dec 18, 2026		U-1440	
<u>INOTERSEN SODIUM - TEGSEDI</u>						
N 211172	001	7015315	Mar 21, 2023	DS		NCE Oct 05, 2023
		7101993	Sep 05, 2023	DS		ODE-212 Oct 05, 2025
		8101743	Apr 01, 2025	DS DP		
		8697860	Apr 29, 2031	DP		
		9061044	Apr 29, 2031	DS		
		9399774	Apr 29, 2031		U-2430	
<u>INSULIN ASPART - FIASP</u>						
N 208751	001	8324157	Jun 25, 2030	DP	M-247	Oct 21, 2022
					NP	Sep 29, 2020
					NPP	Dec 19, 2022
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751	002	10220155	Jul 17, 2026	DP	NP	Sep 29, 2020
		10357616	Jan 20, 2026	DP	NPP	Dec 19, 2022
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8324157	Jun 25, 2030	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Jan 20, 2026	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART - FIASP PENFILL</u>						
N 208751 003					NPP	Dec 19, 2022
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986 004	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP		NCE	Sep 25, 2020
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	9884094	May 01, 2033		U-2238		
	RE46363	Aug 03, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP		NCE	Sep 25, 2020
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP		NCE	Sep 25, 2020
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP		NCE	Sep 25, 2020
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583	001	9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536	002	9265893	Sep 23, 2032	DP		
		RE41956	Jan 21, 2021	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	10220155	Jul 17, 2026	DP		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081	001	7476652	Jul 23, 2023	DP		
		7713930	Jun 13, 2023	DP		
		7918833	Sep 23, 2027	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024		U-1832	
		9233211	Mar 02, 2024	DP		
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		
		9561331	Aug 28, 2024	DP		
		9604008	Mar 02, 2024	DP		
		9604009	Aug 16, 2024	DP		
		9610409	Mar 02, 2024	DP		
		9623189	Aug 19, 2024	DP		
		9717852	Apr 08, 2033	DP		
		9775954	Mar 02, 2024	DP		
		9827379	Mar 02, 2024	DP	U-2146	
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538	001	10369291	Sep 16, 2035	DP	NPP	Nov 26, 2022
		7918833	Sep 23, 2027	DP		
		7918833*PED	Mar 23, 2028			
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024		U-1832	
		9233211	Mar 02, 2024	DP		
		9345750	May 18, 2031	DP	U-1855	
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	10369291	Sep 16, 2035	DP		NPP	Nov 26, 2022
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP	U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Nov 11, 2030	DP		NCE	Jul 27, 2021
	10117909	Oct 09, 2029	DP			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526764	Oct 09, 2029	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9821032	May 09, 2032		U-2182		
	9827379	Mar 02, 2024	DP	U-2146		
	9950039	Dec 10, 2035		U-2277		
	9950039	Dec 10, 2035		U-2278		
	9950039	Dec 10, 2035		U-2279		
	RE45313	Jul 12, 2020	DS DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629	002	6960561	Jan 25, 2023	DP U-471		
		7452860	Mar 22, 2022	DP		
		7696162	Mar 22, 2022	DP U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	6960561	Jan 25, 2023	DP U-471		
		7452860	Mar 22, 2022	DP		
		7696162	Mar 22, 2022	DP U-471		
		7918833	Sep 23, 2027	DP		
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	U-1832		
		9233211	Mar 02, 2024	DP		
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		
		9561331	Aug 28, 2024	DP		
		9604008	Mar 02, 2024	DP		
		9604009	Aug 16, 2024	DP		
		9610409	Mar 02, 2024	DP		
		9623189	Aug 19, 2024	DP		
		9717852	Apr 08, 2033	DP		
		9775954	Mar 02, 2024	DP		
		9827379	Mar 02, 2024	DP U-2146		
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780	004	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO - ADMELOG</u>						
N 209196	001				NP	Dec 11, 2020
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196	002	7918833	Sep 23, 2027	DP	NP	Dec 11, 2020
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	DP U-1832		
		9233211	Mar 02, 2024	DP		
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		
		9561331	Aug 28, 2024	DP		
		9604008	Mar 02, 2024	DP		
		9604009	Aug 16, 2024	DP		
		9610409	Mar 02, 2024	DP		
		9623189	Aug 19, 2024	DP		
		9717852	Apr 08, 2033	DP		
		9775954	Mar 02, 2024	DP		
		9827379	Mar 04, 2024	DP U-2146		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563	003	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747	001	7291132	Aug 09, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	001	6582728	Jun 24, 2020	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	002	6582728	Jun 24, 2020	DP		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472	001	10046031	Aug 11, 2029		U-2383	
		10201672	Aug 02, 2030	DP		
		10342938	Jun 12, 2029	DP		
		10500159	Nov 02, 2030	DP		
		6444226	Jun 29, 2020	DP	U-1534	
		6652885	Jun 29, 2020		U-1535	
		7305986	Jan 16, 2023	DP		
		7464706	Mar 02, 2023	DP		
		7648960	Jun 29, 2020		U-1535	
		7943178	Jun 29, 2020	DP	U-1535	
		7943572	Aug 10, 2026		U-1539	
		8119593	Aug 11, 2029		U-1537	
		8146588	Apr 24, 2023	DP		
		8156936	Jan 16, 2023	DP		
		8215300	Nov 24, 2022	DP		
		8258095	Aug 11, 2029		U-1537	
		8389470	Jun 29, 2020	DP	U-1621	
		8424518	Oct 17, 2031	DP		
		8485180	Mar 25, 2030	DP		
		8499757	Feb 19, 2032	DP		
		8551528	Jun 11, 2030	DP		
		8623817	Sep 18, 2029		U-1537	
		8636001	Jul 12, 2032	DP		
		8729019	Dec 26, 2028	DP		
		8734845	Jun 11, 2030	DP		
		8778403	Jun 11, 2030	DP	U-1538	
		8889099	Jun 29, 2020	DP	U-1621	
		8912193	Jun 12, 2029	DP	U-1538	
		8950397	Jul 20, 2021	DP		
		9192675	Jun 12, 2029	DP	U-1788	
		9283193	Sep 14, 2026	DP		
		9339615	Oct 20, 2029	DP		
		9358352	Feb 15, 2031	DP	U-1861	
		9393372	Jul 04, 2029	DP		
		9446133	Jun 12, 2029	DP	U-1861	
		9511198	Feb 16, 2030		U-1929	
		9511198	Feb 16, 2030		U-1930	
		9597374	Oct 08, 2031		U-1987	
		9662461	Jun 12, 2029	DP	U-2019	
		9717689	Sep 14, 2026	DP		
		9943571	Aug 11, 2029		U-1537	
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472	002	10046031	Aug 11, 2029		U-2383	
		10201672	Aug 02, 2030	DP		
		10342938	Jun 12, 2029	DP		
		10500159	Nov 02, 2030	DP		
		6444226	Jun 29, 2020	DP	U-1534	
		6652885	Jun 29, 2020		U-1535	
		7305986	Jan 16, 2023	DP		
		7464706	Mar 02, 2023	DP		
		7648960	Jun 29, 2020		U-1535	
		7943178	Jun 29, 2020	DP	U-1535	
		7943572	Aug 10, 2026		U-1539	
		8119593	Aug 11, 2029		U-1537	
		8146588	Apr 24, 2023	DP		
		8156936	Jan 16, 2023	DP		
		8215300	Nov 24, 2022	DP		
		8258095	Aug 11, 2029		U-1537	
		8389470	Jun 29, 2020	DP	U-1621	
		8424518	Oct 17, 2031	DP		
		8485180	Mar 25, 2030	DP		
		8499757	Feb 19, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	DP	U-1537		
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP	U-1788		
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP	U-1861		
	9511198	Feb 16, 2030		U-1929		
	9511198	Feb 16, 2030		U-1930		
	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029		U-1537		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10046031	Aug 11, 2029		U-2383		
	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
	10500159	Nov 02, 2030	DP			
	6444226	Jun 29, 2020	DP	U-1534		
	6652885	Jun 29, 2020		U-1535		
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020		U-1535		
	7943178	Jun 29, 2020	DP	U-1535		
	7943572	Aug 10, 2026		U-1539		
	8119593	Aug 11, 2029		U-1537		
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029		U-1537		
	8389470	Jun 29, 2020	DP	U-1621		
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029		U-1537		
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP	U-1538		
	8889099	Jun 29, 2020	DP	U-1621		
	8912193	Jun 12, 2029	DP	U-1538		
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP	U-1788		
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP	U-1861		
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP	U-1861		
	9511198	Feb 16, 2030		U-1929		
	9511198	Feb 16, 2030		U-1930		
	9597374	Oct 08, 2031		U-1987		
	9662461	Jun 12, 2029	DP	U-2019		
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029		U-1537		
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717	002	7291132	Aug 09, 2024	DP		
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781	001	7291132	Aug 09, 2024	DP		
<u>ILOBENGUANE I-131 - AZEDRA</u>						
N 209607	001				NP ODE-204	Jul 30, 2021 Jul 30, 2025
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351	002				I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808	002				I-752	Apr 05, 2020
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	6739333	May 26, 2020	DP		
		6983743	May 26, 2020	DP		
		8474447	Jan 17, 2030	DP		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	001	6403569	Apr 28, 2020		U-449	
		6794370	May 01, 2020		U-606	
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	002	6403569	Apr 28, 2020		U-449	
		6794370	May 01, 2020		U-606	
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	10456360	Oct 15, 2036	DP	ODE-99	Oct 22, 2022
		8147867	Aug 29, 2028	DS DP		
		8329213	May 02, 2025	DS DP		
		8703181	May 02, 2025		U-1434	
		8992970	May 02, 2025	DS DP		
		9339497	Jun 12, 2033		U-1848	
		9364473	Jun 12, 2033		U-1856	
		9452162	Jun 12, 2033		U-1899	
		9492442	Jun 12, 2033		U-1848	
		9492442	Jun 12, 2033		U-1899	
		9492442	Jun 12, 2033		U-1917	
		9717724	Jun 12, 2033		U-1848	
		9717724	Jun 12, 2033		U-2091	
		9724303	May 02, 2025	DS DP		
		9730891	May 02, 2025		U-1848	
		9782349	May 02, 2025	DS DP		
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001	6812238	Oct 31, 2020	DS	NCE	Mar 06, 2020
		7459561	Oct 31, 2020	DS	ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001	6812238	Oct 31, 2020	DS	NCE	Mar 06, 2020
		7459561	Oct 31, 2020	DS	ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872	001				NP	Apr 26, 2022
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	001	7435427	Sep 21, 2021	DP		
		8367102	Sep 21, 2021		U-1347	
		8952064	Sep 21, 2021	DP		
		9078925	Sep 21, 2021	DP		
		9089534	Sep 21, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	DP	U-2623		
	7727994	Jan 18, 2023	DP	U-2623		
	8318201	Sep 05, 2027	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	DP	U-2623		
	7727994	Jan 18, 2023	DP	U-2623		
	8318201	Sep 05, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ITRACONAZOLE - ONMEL</u>						
N 022484	001	8486456	Oct 03, 2028	DP U-1054		
<u>ITRACONAZOLE - TOLSURA</u>						
N 208901	001	10463740	Jun 21, 2033	DP U-2453		
		8771739	Jul 25, 2023	DP		
		8921374	Jun 21, 2033	DP		
		9272046	Jun 21, 2033	DP		
		9713642	Jun 21, 2033	U-2453		
<u>IVABRADINE - CORLANOR</u>						
N 209964	001	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694	NP	Apr 22, 2022
		7867996	Feb 22, 2026	DS DP U-1694	ODE-234	Apr 22, 2026
		7879842	Feb 22, 2026	DS DP U-1694	PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	001	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361649*PED	Aug 22, 2026		PED	Oct 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694		
		7361650*PED	Aug 22, 2026			
		7867996	Feb 22, 2026	DS DP U-1694		
		7867996*PED	Aug 22, 2026			
		7879842	Feb 22, 2026	DS DP U-1694		
		7879842*PED	Aug 22, 2026			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	002	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361649*PED	Aug 22, 2026		PED	Oct 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694		
		7361650*PED	Aug 22, 2026			
		7867996	Feb 22, 2026	DS DP U-1694		
		7867996*PED	Aug 22, 2026			
		7879842	Feb 22, 2026	DS DP U-1694		
		7879842*PED	Aug 22, 2026			
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	7495103	May 20, 2027	DS DP	NPP	Jul 31, 2020
		8324242	Aug 05, 2027	U-1311	ODE-186	Feb 21, 2021
		8324242	Aug 05, 2027	U-1906	ODE-187	Dec 29, 2021
		8354427	Jul 06, 2026	U-1311	ODE-189	Jul 31, 2024
		8354427	Jul 06, 2026	U-1905	ODE-190	May 17, 2024
		8410274	Dec 28, 2026	DP	ODE-199	Aug 15, 2025
		8629162	Jun 24, 2025	U-2234		
		8754224	Dec 28, 2026	DS DP		
		9670163	Dec 28, 2026	DP U-1311		
<u>IVACAFTOR - KALYDECO</u>						
N 203188	002				NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	10272046	Feb 27, 2033	DP U-2531	NPP	Jul 31, 2020
		7495103	May 20, 2027	DS DP	NPP	Apr 29, 2022
		8324242	Aug 05, 2027	U-1311	ODE-188	Mar 17, 2022
		8324242	Aug 05, 2027	U-1906	ODE-189	Jul 31, 2024
		8324242	Aug 05, 2027	U-2527	ODE-190	May 17, 2024
		8354427	Jul 06, 2026	U-1311	ODE-199	Aug 15, 2025
		8354427	Jul 06, 2026	U-1905	ODE-236	Apr 29, 2026
		8354427	Jul 06, 2026	U-2528		
		8410274	Dec 28, 2026	DP		
		8629162	Jun 24, 2025	U-2234		
		8629162	Jun 24, 2025	U-2529		
		8754224	Dec 28, 2026	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411		M-218	Jan 25, 2021
	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	7973038	Nov 08, 2026	U-1973		ODE-123	Sep 28, 2023
	8324242	Aug 05, 2027	U-1311		ODE-93	Jul 02, 2022
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7495103	May 20, 2027	DS DP		M-218	Jan 25, 2021
	7973038	Nov 08, 2026	U-1973		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1911		ODE-123	Sep 28, 2023
	8410274	Dec 28, 2026	DP		ODE-93	Jul 02, 2022
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	7973038	Nov 08, 2026		U-2374	NP	Aug 07, 2021
	8324242	Aug 05, 2027		U-2374	ODE-195	Aug 07, 2025
	8410274	Dec 28, 2026		DP		
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028		DP		
	8716338	Sep 20, 2030		DP U-2396		
	8741933	Nov 08, 2026		U-2374		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-2375		
	8993600	Dec 11, 2030		DP		
	9150552	Dec 04, 2028		U-2375		
	9192606	Sep 29, 2029		DP U-2397		
	9216969	Nov 08, 2026		DP		
	9670163	Dec 28, 2026		DP U-2376		
	9931334	Dec 28, 2026		DP U-2376		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	7973038	Nov 08, 2026		U-2374	NP	Aug 07, 2021
	8324242	Aug 05, 2027		U-2374	ODE-195	Aug 07, 2025
	8410274	Dec 28, 2026		DP		
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028		DP		
	8716338	Sep 20, 2030		DP U-2396		
	8741933	Nov 08, 2026		U-2374		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-2375		
	8993600	Dec 11, 2030		DP		
	9150552	Dec 04, 2028		U-2375		
	9192606	Sep 29, 2029		DP U-2397		
	9216969	Nov 08, 2026		DP		
	9670163	Dec 28, 2026		DP U-2376		
	9931334	Dec 28, 2026		DP U-2376		
<u>IVERMECTIN - IVERMECTIN</u>						
A 210019 001					PC	Apr 11, 2020
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	8791153	Oct 12, 2027		DP		
	8927595	Oct 12, 2027		U-1782		
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034		U-1631		
	7550440	Apr 22, 2024		DP U-1631		
	8080530	Apr 22, 2024		DP U-1631		
	8093219	Apr 22, 2024		DP U-1631		
	8415311	Apr 22, 2024		DP U-1631		
	8470788	Apr 22, 2024		DP U-1631		
	8815816	Apr 22, 2024		DP U-1631		
	9089587	Mar 13, 2034		U-1631		
	9233117	Mar 13, 2034		U-1631		
	9233118	Mar 13, 2034		U-1631		
	9782425	Mar 13, 2034		U-1631		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10449184	Mar 13, 2035		DP	I-816	May 02, 2022
	9474779	Aug 19, 2033	DS DP	U-2350	NCE	Jul 20, 2023
	9474779	Aug 19, 2033	DS DP	U-2533	ODE-203	Jul 20, 2025
	9474779	Aug 19, 2033	DS DP	U-2534	ODE-242	May 02, 2026
	9850277	Jan 18, 2033	DS DP	U-2350		
	9850277	Jan 18, 2033	DS DP	U-2533		
	9850277	Jan 18, 2033	DS DP	U-2534		
	9968595	Mar 13, 2035		DP U-2351		
	9968595	Mar 13, 2035		DP U-2533		
	9968595	Mar 13, 2035		DP U-2534		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	001	6670384	Jan 23, 2022	DP U-959		
		6670384	Jan 23, 2022	DP U-960		
		7022330	Jan 23, 2022	DP U-958		
		7312237	Aug 21, 2024	U-965		
		RE41393	Feb 08, 2022	U-961		
		RE41911	Sep 28, 2020	DS DP U-961		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002	6670384	Jan 23, 2022	DP U-959		
		6670384	Jan 23, 2022	DP U-960		
		7022330	Jan 23, 2022	DP U-958		
		7312237	Aug 21, 2024	U-965		
		RE41393	Feb 08, 2022	U-961		
		RE41911	Sep 28, 2020	DS DP U-961		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001	7442830	Nov 20, 2029	DS DP U-2434	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434		
		8530694	Aug 06, 2027	DS DP U-2434		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-2434		
		9175017	Jun 16, 2029	U-2434		
		9233115	Aug 12, 2024	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	002	7442830	Nov 20, 2029	DS DP U-2434	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434		
		8530694	Aug 06, 2027	DS DP U-2434		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-2434		
		9175017	Jun 16, 2029	U-2434		
		9233115	Aug 12, 2024	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	003	7442830	Nov 20, 2029	DS DP U-2434	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434		
		8530694	Aug 06, 2027	DS DP U-2434		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-2434		
		9175017	Jun 16, 2029	U-2434		
		9233115	Aug 12, 2024	U-2434		
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946	001	8232276	Nov 24, 2020	DP		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001	8008338	May 24, 2027	DS DP U-1181		
		8207215	May 28, 2024	U-1251		
		8377982	May 28, 2024	U-1363		
		8377982*PED	Nov 28, 2024			
		8541463	May 28, 2024	U-1441		
		8541463*PED	Nov 28, 2024			
		8648107	May 28, 2024	DP		
		8906950	May 28, 2024	U-1626		
		8946281	May 28, 2024	U-1662		
		9216167	May 28, 2024	U-1800		
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427	001	7842714	Aug 15, 2029	DS DP		
		8512717	Mar 07, 2028	DP		
		8992952	Aug 05, 2024	DP		
		9192571	Mar 07, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388	001	8173707	Jul 30, 2023	U-1518	NPP	Dec 08, 2020
		8173707*PED	Jan 30, 2024		PED	Jun 08, 2021
		8586633	Jul 30, 2023	DP		
		8586633*PED	Jan 30, 2024			
		9066856	Oct 23, 2023	DP		
		9066856*PED	Apr 23, 2024			
		9278101	Jul 30, 2023	U-1518		
		9278101*PED	Jan 30, 2024			
		9399040	Jul 30, 2023	DP		
		9399040*PED	Jan 30, 2024			
		9486406	Oct 23, 2023	DP		
		9486406*PED	Apr 23, 2024			
		9855246	Oct 23, 2023	DP		
<u>L-GLUTAMINE - ENDARI</u>						
N 208587	001				I-748 ODE-150	Jul 07, 2020 Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
<u>LACOSAMIDE - VIMPAT</u>						
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565	M-217	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-1568		
<u>LACOSAMIDE - VIMPAT</u>						
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1567	NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140		
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713	Oct 21, 2022	U-1663		
		7217713*PED	Apr 21, 2023			
		7435734	Oct 21, 2022	U-1663		
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-1663		
		7754731*PED	Sep 11, 2029			
		7820660	Apr 25, 2023	DS		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512	Jun 14, 2028	DP		
		9144547	Sep 22, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512				
		9144547				
		Jun 14, 2028	DP			
		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512				
		9144547				
		Jun 14, 2028	DP			
		Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001	7919115				
		8840925				
		9339504				
		Jan 04, 2029	DS DP			
		Jul 02, 2028	DP U-1596			
		Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	004	7919115				
		8840925				
		9339504				
		Jan 04, 2029	DS DP			
		Jul 02, 2028	DP U-1596			
		Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	001	5595760				
		Mar 08, 2020	DP U-831			
					I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	002	5595760				
		Mar 08, 2020	DP U-831			
					I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	003	5595760				
		Mar 08, 2020	DP U-831			
					I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566	001	7396841				
		Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	001	7381428				
		7465465				
		Aug 26, 2024			U-890	
		Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	002	7381428				
		7465465				
		Aug 26, 2024			U-890	
		Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	003	7381428				
		7465465				
		Aug 26, 2024			U-890	
		Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468	004	7381428				
		7465465				
		Aug 26, 2024			U-890	
		Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	001	7465465				
		8980327				
		9023397				
		Aug 26, 2024	DP			
		Dec 01, 2030	DP			
		Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	002	7465465				
		8980327				
		9023397				
		Aug 26, 2024	DP			
		Dec 01, 2030	DP			
		Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059	001	6713485				
		6713485				
		7157466				
		8821927				
		Sep 29, 2020	DS DP U-1429		M-235	Dec 06, 2021
		Sep 29, 2020	DS DP U-800			
		Nov 19, 2021	DS DP			
		Sep 18, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10005783	Oct 21, 2029		U-2472	NCE	Nov 26, 2023
	10047097	Oct 21, 2029		U-2474	ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035		U-2470	ODE-221	Nov 26, 2025
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029		U-2469		
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029		U-2470		
	9676783	Oct 21, 2029		U-2469		
	9782414	Nov 16, 2035		U-2475		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10005783	Oct 21, 2029		U-2472	NCE	Nov 26, 2023
	10047097	Oct 21, 2029		U-2474	ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035		U-2470	ODE-221	Nov 26, 2025
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029		U-2469		
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029		U-2470		
	9676783	Oct 21, 2029		U-2469		
	9782414	Nov 16, 2035		U-2475		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10005783	Oct 21, 2029		U-2472	NCE	Nov 26, 2023
	10045991	Apr 04, 2037		U-2473	ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029		U-2474	ODE-220	Nov 26, 2025
	10137127	Apr 04, 2037		DP	ODE-221	Nov 26, 2025
	10172861	Nov 16, 2035	DS			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029		U-2469		
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029		U-2470		
	9676783	Oct 21, 2029		U-2469		
	9782414	Nov 16, 2035		U-2471		
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028		U-2400		
	9629852	Sep 12, 2029		DP		
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP	U-1524	NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP	U-1524	NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP	U-1524		
	9096569	Jul 11, 2026	DS DP	U-1524		
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP	U-1524		
	9993470	Mar 14, 2034	DS DP	U-1524		
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	7273946	Oct 03, 2025	DS DP	U-2144		
	7629345	Jan 05, 2025		DP U-2144		
	7910767	Jan 05, 2025	DS DP	U-2144		
	8058467	Jan 05, 2025	DS	U-2144		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP	U-2369	D-177	Nov 15, 2022
	10039779	Jan 30, 2034	DS DP	U-2370	NPP	Apr 07, 2020
	10039779*PED	Jul 30, 2034			ODE-136	Apr 07, 2024
	10456414	Sep 14, 2032		DP	PED	Oct 07, 2024
	7964580	Mar 26, 2029	DS DP	U-1470		
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP	U-1470		
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-1470		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834	001	8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8735372*PED	Sep 21, 2028			
		8822430	May 12, 2030	DS DP U-1470		
		8822430*PED	Nov 12, 2030			
		8841278	May 12, 2030	DP U-1470		
		8841278*PED	Nov 12, 2030			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
		9393256	Sep 14, 2032	U-1470		
		9393256*PED	Mar 14, 2033			
		9511056	May 12, 2030	DP U-1470		
		9511056*PED	Nov 12, 2030			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834	002	10039779	Jan 30, 2034	DS DP U-1470	D-177	Nov 15, 2022
		10039779*PED	Jul 30, 2034			
		10456414	Sep 14, 2032	DP		
		7964580	Mar 26, 2029	DS DP U-1470		
		7964580*PED	Sep 26, 2029			
		8088368	May 12, 2030	DS DP		
		8088368*PED	Nov 12, 2030			
		8273341	May 12, 2030	U-1470		
		8273341*PED	Nov 12, 2030			
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8735372*PED	Sep 21, 2028			
		8822430	May 12, 2030	DS DP U-1470		
		8822430*PED	Nov 12, 2030			
		8841278	May 12, 2030	DP U-1470		
		8841278*PED	Nov 12, 2030			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
		9393256	Sep 14, 2032	U-1470		
		9393256*PED	Mar 14, 2033			
		9511056	May 12, 2030	U-1470		
		9511056*PED	Nov 12, 2030			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477	001	10456414	Sep 14, 2032	DP	D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470	ODE-262	Aug 28, 2026
		7964580*PED	Sep 26, 2029		ODE-263	Aug 28, 2026
		8088368	May 12, 2030	DS DP	ODE-264	Aug 28, 2026
		8088368*PED	Nov 12, 2030			
		8273341	May 12, 2030	U-1470		
		8273341*PED	Nov 12, 2030			
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP U-1470		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032		U-1470		
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	10456414	Sep 14, 2032		DP	D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032		U-1470		
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	6315720	Oct 23, 2020	U-1210		I-796	May 28, 2022
	6561977	Oct 23, 2020	U-1210		I-797	May 28, 2022
	6755784	Oct 23, 2020	U-1210		ODE-131	Feb 22, 2024
	7189740	Apr 11, 2023	U-1982		ODE-241	May 28, 2026
	7465800	Apr 27, 2027	DS DP		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-49	Jun 05, 2020
	7468363	Oct 07, 2023	U-2550		ODE-88	Feb 17, 2022
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-787	Aug 15, 2021
	10407393	Aug 26, 2035	DS		I-807	Sep 17, 2022
	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE-196	Aug 15, 2025
	9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-787	Aug 15, 2021
	10407393	Aug 26, 2035	DS		I-807	Sep 17, 2022
	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE-196	Aug 15, 2025
	9006256	Jul 27, 2027	U-1695		ODE-87	Feb 13, 2022
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311		NCE	Dec 22, 2020
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-2505			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	6626870	Mar 27, 2020	DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	6626870	Mar 27, 2020	DP			
	8470359	Oct 15, 2023	DS DP U-621			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379	001 8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488	001 6626870	Mar 27, 2020	DP			
	8470359	Oct 15, 2023	DS DP U-621			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731	001 6626870	Mar 27, 2020	DP			
	8470359	Oct 15, 2023	DS DP U-621			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEUPROLIDE ACETATE - LUTRATE DEPOT KIT</u>						
N 205054	001 9789064	Dec 15, 2020	DP			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001 6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002 6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003 6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004 6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001 7256310	Oct 08, 2024	DS DP U-636			
	8765153	Dec 08, 2023	DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	001 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	002 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	003 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	004 8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	001 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	002 7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	001 8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	002 8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417	002	8163306	Sep 03, 2027	DP		
		8425938	Feb 22, 2026	DP		
		8431156	Oct 31, 2027	DP		
		8470367	Oct 31, 2027	DP		
		8535717	Feb 22, 2026	DP		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	001	9339489	Mar 14, 2034	DP U-1850		
		9669009	Mar 14, 2034	U-1850		
		9669009	Mar 14, 2034	U-2021		
		9669009	Mar 14, 2034	U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	002	9339489	Mar 14, 2034	DP U-1850		
		9669009	Mar 14, 2034	U-1850		
		9669009	Mar 14, 2034	U-2021		
		9669009	Mar 14, 2034	U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	003	9339489	Mar 14, 2034	DP U-1850		
		9669009	Mar 14, 2034	U-1850		
		9669009	Mar 14, 2034	U-2021		
		9669009	Mar 14, 2034	U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	004	9339489	Mar 14, 2034	DP U-1850		
		9669009	Mar 14, 2034	U-1850		
		9669009	Mar 14, 2034	U-2021		
		9669009	Mar 14, 2034	U-2022		
<u>LEVOCARNITINE - LEVOCARNITINE</u>						
A 211676	001				CGT	Apr 13, 2020
<u>LEVOCARNITINE - LEVOCARNITINE SF</u>						
A 211676	002				CGT	Apr 13, 2020
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182	001	6335369	Jan 18, 2021	U-433		
		6429230	Jan 18, 2021	U-433		
		6696493	Jan 18, 2021	U-433		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090	001	8633194	Oct 16, 2027	DP		
<u>LEVODOPA - INBRIJA</u>						
N 209184	001	6514482	Sep 19, 2020	DP U-2484	NP	Dec 21, 2021
		6613308	Sep 19, 2020	U-2484		
		6858199	Nov 04, 2021	U-2485		
		6921528	Jun 19, 2020	U-2485		
		6979437	Sep 19, 2020	U-2484		
		7146978	Apr 16, 2021	U-2486		
		7182961	Feb 22, 2024	DP		
		7384649	Nov 20, 2022	DP		
		7556798	Nov 04, 2021	U-2485		
		8404276	Mar 19, 2023	U-2484		
		8545878	Nov 16, 2032	DP		
		8586093	Mar 19, 2023	U-2484		
		8628754	Jun 19, 2020	U-2485		
		8685442	Nov 16, 2032	DP		
		8945612	Nov 16, 2032	DP		
		9155699	Mar 19, 2023	DP		
		9393210	Nov 16, 2032	DP		
		RE43711	Feb 03, 2029	U-2484		
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721	001	6806256	Feb 26, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031		U-839	M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031		U-839	M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031		U-839	M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031		U-839	M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029		DP U-2003		
	9668912	Apr 01, 2031		DP		
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	7252839	Nov 13, 2023		DP		
	9615965	Sep 16, 2029		DP U-2003		
	9668912	Apr 01, 2031		DP		
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	10028858	Mar 22, 2034		DP U-2348		
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023		DP		
	9615965	Sep 16, 2029		DP U-2003		
	9668912	Apr 01, 2031		DP		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022		DP		
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022		DP		
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022		DP		
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022		DP		
	7101569	Oct 02, 2023			U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022		DP		
	7101569	Oct 02, 2023			U-759	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632	003	10398669	Dec 01, 2036	DP		
		9782376	Dec 01, 2036	DP		
<u>LIDOCAINE - ZTLIDO</u>						
N 207962	001	9283174	May 10, 2031	DP	NP	Feb 28, 2021
		9925264	May 10, 2031	DP U-2267		
		9931403	May 10, 2031	DP		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114	001	8540665	Oct 22, 2029	U-1438		
		9358338	Apr 27, 2035	U-1870		
		9370622	Sep 28, 2035	U-1870		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221	001	8759401	Jul 24, 2026	DP U-1523		
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623	001	6465709	Jul 07, 2020	DP		
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717	001	10350180	Jan 14, 2031	DP		
<u>LIFITEGRAST - XIIDRA</u>						
N 208073	001	10124000	Nov 05, 2024	U-1900	NCE	Jul 11, 2021
		7314938	Mar 10, 2025	DS DP		
		7745460	Nov 05, 2024	DS DP	U-1880	
		7790743	Nov 05, 2024		U-1880	
		7928122	Nov 05, 2024	DS DP		
		8084047	May 17, 2026	DS DP		
		8168655	May 09, 2029		U-1880	
		8367701	Apr 15, 2029	DP	U-1880	
		8592450	May 17, 2026		U-1880	
		8927574	Nov 12, 2030	DP		
		9085553	Jul 25, 2033	DP		
		9216174	Nov 05, 2024	DP		
		9353088	Oct 21, 2030	DP		
		9447077	Apr 15, 2029		U-1900	
		9890141	Oct 21, 2030	DS		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001	7304036	Aug 30, 2026	DS DP	U-1278	
		7304036	Aug 30, 2026	DS DP	U-1516	
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Oct 30, 2031		U-1515	
		8748573	Oct 30, 2031		U-1516	
		8802628	Oct 30, 2031	DP		
		8933030	Feb 17, 2031	DP		
		9708371	Aug 16, 2033	DP	U-1515	
		9708371	Aug 16, 2033	DP	U-1516	
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002	7304036	Aug 30, 2026	DS DP	U-1278	
		7304036	Aug 30, 2026	DS DP	U-1516	
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Oct 30, 2031		U-1515	
		8748573	Oct 30, 2031		U-1516	
		8802628	Oct 30, 2031	DP		
		8933030	Feb 17, 2031	DP		
		9708371	Aug 16, 2033	DP	U-1515	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NS	Jan 25, 2020
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1516		
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029		U-2347		
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-1270		
	8119648	Aug 12, 2023		U-774		
	8178541	Aug 12, 2023		U-1244		
	8178541	Aug 12, 2023		U-1245		
	8178541	Aug 12, 2023		U-1270		
	8178541	Aug 12, 2023		U-775		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503	Y	
	8853156	Mar 05, 2031		U-1642		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1503			
	9173859	May 04, 2027	DP U-1768			
	9486526	Aug 05, 2029	U-1915			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379	Apr 02, 2029		U-2339		
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379	Apr 02, 2029		U-2339		
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029		U-2339		
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503	Y	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029		U-2339		
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027		U-1503		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP	U-1503		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP	U-1967		
	9555001	Mar 06, 2033	DP	U-1968		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029		U-2339		
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-1853		
	8673927	May 04, 2027		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP	U-1503		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP	U-1967		
	9555001	Mar 06, 2033	DP	U-1968		
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP	U-968	I-750	Aug 25, 2020
	6268343*PED	Feb 22, 2023			NPP	Jun 17, 2022
	7762994	May 23, 2024	DP		PED	Dec 17, 2022
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037		U-2313		
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP	U-1255		
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037		U-2438		
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023		U-727		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023		U-727		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023		U-727		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023		U-727		
	7105486	Feb 24, 2023		U-842		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023		U-842		
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10039800	Nov 06, 2035	U-1723			
	10039800	Nov 06, 2035	U-185			
	10039800	Nov 06, 2035	U-1864			
	10039800	Nov 06, 2035	U-1991			
	10039800	Nov 06, 2035	U-3			
	10039800	Nov 06, 2035	U-71			
	10039800	Nov 06, 2035	U-8			
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
	10201663	Mar 10, 2034	DP			
	8475414	Dec 28, 2030	DP U-1881			
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9440029	Jan 30, 2032	DP			
	9511193	Jan 19, 2032	DP			
	9707176	Nov 11, 2030	DP			
	9821032	May 09, 2032	U-2200			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
	10201663	Mar 10, 2034	DP			
	8475414	Dec 28, 2030	DP U-1881			
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9440029	Jan 30, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471	002	9511193				
		9707176				
		9821032			U-2200	
		9855388			DP U-1881	
		9981013			U-2297	
		RE45313	DS DP			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229	001				NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	001	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	002	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	003	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	004	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	005	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	10016404			U-1316	
		5712279		DS DP	U-1317	
		7932268			U-1316	
		8618135			U-1316	
		9265758			U-1316	
		9364470			U-1851	
		9433617			U-1316	
		9861622			U-1316	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	10016404				
		Mar 07, 2025			U-1316	
		5712279		DS DP	U-1317	
		Feb 21, 2020				
		7932268			U-1316	
		Aug 19, 2027				
		8618135			U-1316	
		Mar 07, 2025				
		9265758			U-1316	
		Mar 07, 2025				
		9364470			U-1851	
		Mar 07, 2025				
		9433617			U-1316	
		Mar 07, 2025				
		9861622			U-1316	
		Mar 07, 2025				
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448	001	6814978				
		Aug 26, 2021		DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226	001	7141593				
		May 22, 2020		DP		
		7432294				
		May 22, 2020		DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251	001	6911214				
		Nov 28, 2021		DP	U-895	
		8501219				
		Nov 28, 2021		DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	001	7364752				
		Nov 10, 2020		DP	U-688	
		8025899				
		Dec 14, 2027		DP		
		8025899*PED				
		Jun 14, 2028				
		8268349				
		Aug 25, 2024		DP		
		8309613				
		Dec 24, 2024			U-688	
		8377952				
		Oct 22, 2027			U-1372	
		8377952*PED				
		Apr 22, 2028				
		8399015				
		Aug 25, 2024		DP		
		8399015*PED				
		Feb 25, 2025				
		8470347				
		Sep 17, 2026		DP		
		8470347*PED				
		Mar 17, 2027				
		8691878				
		Aug 25, 2024			U-1513	
		8691878*PED				
		Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	002	7364752				
		Nov 10, 2020		DP	U-688	
		8025899				
		Dec 14, 2027		DP		
		8025899*PED				
		Jun 14, 2028				
		8268349				
		Aug 25, 2024		DP		
		8309613				
		Dec 24, 2024			U-688	
		8377952				
		Oct 22, 2027			U-1372	
		8377952*PED				
		Apr 22, 2028				
		8399015				
		Aug 25, 2024		DP		
		8399015*PED				
		Feb 25, 2025				
		8470347				
		Sep 17, 2026		DP		
		8470347*PED				
		Mar 17, 2027				
		8691878				
		Aug 25, 2024			U-1513	
		8691878*PED				
		Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529	001	6953787				
		Apr 10, 2023		DS DP	U-1252	
		6953787				
		Apr 10, 2023		DS DP	U-1253	
		6953787				
		Apr 10, 2023		DS DP	U-1254	
		6953787				
		Apr 10, 2023		DS DP	U-1255	
		7514422				
		Apr 10, 2023			U-1252	
		7514422				
		Apr 10, 2023			U-1253	
		7514422				
		Apr 10, 2023			U-1254	
		7514422				
		Apr 10, 2023			U-1255	
		7977329				
		Apr 10, 2023		DS DP	U-1252	
		7977329				
		Apr 10, 2023		DS DP	U-1253	
		7977329				
		Apr 10, 2023		DS DP	U-1254	
		7977329				
		Apr 10, 2023		DS DP	U-1255	
		8168624				
		Apr 18, 2029		DS DP		
		8207158				
		Apr 10, 2023			U-1252	
		8207158				
		Apr 10, 2023			U-1253	
		8207158				
		Apr 10, 2023			U-1254	
		8207158				
		Apr 10, 2023			U-1255	
		8273734				
		Apr 10, 2023			U-1254	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8273734	Apr 10, 2023			U-1255	
	8367657	Apr 10, 2023	DS DP		U-1252	
	8367657	Apr 10, 2023	DS DP		U-1253	
	8367657	Apr 10, 2023	DS DP		U-1254	
	8367657	Apr 10, 2023	DS DP		U-1255	
	8546379	Apr 10, 2023	DS DP		U-1252	
	8546379	Apr 10, 2023	DS DP		U-1253	
	8546379	Apr 10, 2023	DS DP		U-1254	
	8546379	Apr 10, 2023	DS DP		U-1255	
	8575149	Apr 10, 2023			U-1452	
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025			U-1252	
	8980881	Dec 20, 2025			U-1253	
	8980881	Dec 20, 2025			U-1254	
	8980881	Dec 20, 2025			U-1255	
	8999970	Feb 07, 2033			U-1688	
	8999970	Feb 07, 2033			U-1689	
	8999970	Feb 07, 2033			U-1692	
	9169213	Dec 06, 2032			U-1762	
	9169213	Dec 06, 2032			U-1763	
	9169213	Dec 06, 2032			U-1764	
	9169213	Dec 06, 2032			U-1765	
	9770455	Aug 31, 2031			U-2110	
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031		DP		
	10463676	Aug 31, 2031			U-2661	
	6953787	Apr 10, 2023	DS DP		U-1252	
	6953787	Apr 10, 2023	DS DP		U-1253	
	6953787	Apr 10, 2023	DS DP		U-1254	
	6953787	Apr 10, 2023	DS DP		U-1255	
	7514422	Apr 10, 2023			U-1252	
	7514422	Apr 10, 2023			U-1253	
	7514422	Apr 10, 2023			U-1254	
	7514422	Apr 10, 2023			U-1255	
	7977329	Apr 10, 2023	DS DP		U-1252	
	7977329	Apr 10, 2023	DS DP		U-1253	
	7977329	Apr 10, 2023	DS DP		U-1254	
	7977329	Apr 10, 2023	DS DP		U-1255	
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023			U-1252	
	8207158	Apr 10, 2023			U-1253	
	8207158	Apr 10, 2023			U-1254	
	8207158	Apr 10, 2023			U-1255	
	8273734	Apr 10, 2023			U-1254	
	8273734	Apr 10, 2023			U-1255	
	8367657	Apr 10, 2023	DS DP		U-1252	
	8367657	Apr 10, 2023	DS DP		U-1253	
	8367657	Apr 10, 2023	DS DP		U-1254	
	8367657	Apr 10, 2023	DS DP		U-1255	
	8546379	Apr 10, 2023	DS DP		U-1252	
	8546379	Apr 10, 2023	DS DP		U-1253	
	8546379	Apr 10, 2023	DS DP		U-1254	
	8546379	Apr 10, 2023	DS DP		U-1255	
	8575149	Apr 10, 2023			U-1452	
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025			U-1252	
	8980881	Dec 20, 2025			U-1253	
	8980881	Dec 20, 2025			U-1254	
	8980881	Dec 20, 2025			U-1255	
	8999970	Feb 07, 2033			U-1688	
	8999970	Feb 07, 2033			U-1689	
	8999970	Feb 07, 2033			U-1692	
	9169213	Dec 06, 2032			U-1884	
	9169213	Dec 06, 2032			U-1885	
	9169213	Dec 06, 2032			U-1886	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524	001	9169213	Dec 06, 2032	U-1887		
		9770455	Aug 31, 2031	U-2110		
<u>LORLATINIB - LORBRENA</u>						
N 210868	001	10420749	Jul 27, 2036	DS DP U-2633	NCE	Nov 02, 2023
		8680111	Mar 05, 2033	DS DP	ODE-217	Nov 02, 2025
					ODE-218	Nov 02, 2025
					ODE-219	Nov 02, 2025
<u>LORLATINIB - LORBRENA</u>						
N 210868	002	10420749	Jul 27, 2036	DS DP U-2633	NCE	Nov 02, 2023
		8680111	Mar 05, 2033	DS DP	ODE-217	Nov 02, 2025
					ODE-218	Nov 02, 2025
					ODE-219	Nov 02, 2025
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872	001				M-229	Jul 20, 2021
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219	001				NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565	001	10058511	May 03, 2033	DP U-2492	NP	Aug 22, 2021
		9056057	May 03, 2033	DP U-2491		
		9393213	May 03, 2033	DP		
		9532955	May 03, 2033	U-2491		
		9737491	May 03, 2033	U-2492		
		9827191	May 03, 2033	DP U-2493		
<u>LOXAPINE - ADASUVE</u>						
N 022549	001	6716416	May 20, 2022	DP		
		7052679	Oct 26, 2021	DP		
		7078020	Oct 26, 2021	DP U-1375		
		7090830	Oct 26, 2021	DP		
		7458374	Aug 18, 2024	DP		
		7537009	Oct 28, 2024	DP		
		7585493	Oct 26, 2021	DP		
		7601337	Oct 26, 2021	DP		
		8074644	Jul 25, 2022	DP		
		8173107	Oct 26, 2021	DP		
		8235037	Oct 26, 2021	DP		
		8387612	Oct 23, 2026	DP		
		8955512	Oct 26, 2021	DP		
		8991387	May 21, 2024	DP		
		9370629	May 20, 2024	DP		
		9439907	Oct 26, 2021	DP		
		9440034	Oct 26, 2021	DP		
		9687487	Oct 26, 2021	DS DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	6414016	Sep 05, 2020	U-1392	M-225	Apr 26, 2021
		6414016	Sep 05, 2020	U-717		
		6583174	Oct 16, 2020	DP		
		6982283	Dec 04, 2022	U-1391		
		7064148	Aug 30, 2022	U-1404		
		7064148	Aug 30, 2022	U-739		
		7417067	Oct 16, 2020	DP		
		8026393	Oct 25, 2027	DP		
		8071613	Sep 05, 2020	U-1203		
		8071613	Sep 05, 2020	U-1393		
		8088934	May 18, 2021	DS		
		8097649	Oct 16, 2020	DP		
		8097653	Nov 14, 2022	U-1214		
		8097653	Nov 14, 2022	U-1394		
		8114890	Sep 05, 2020	DP		
		8338639	Jan 23, 2027	DP		
		8389542	Nov 14, 2022	DP U-1345		
		8389542	Nov 14, 2022	DP U-1395		
		8748481	Sep 01, 2025	U-1520		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	001	8779187	Jan 23, 2027	DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908	002	6414016	Sep 05, 2020	U-874	M-225	Apr 26, 2021
		6583174	Oct 16, 2020	DP		
		7064148	Aug 30, 2022	U-739		
		7064148	Aug 30, 2022	U-873		
		7417067	Oct 16, 2020	DP		
		7795312	Sep 17, 2024	U-1085		
		8026393	Oct 25, 2027	DP		
		8071613	Sep 05, 2020	U-1202		
		8088934	May 18, 2021	DS		
		8097649	Oct 16, 2020	DP		
		8114890	Sep 05, 2020	DP		
		8338639	Jan 23, 2027	DP		
		8748481	Sep 01, 2025	U-1519		
		8779187	Jan 23, 2027	DP		
<u>LULICONAZOLE - LUZU</u>						
N 204153	001	5900488	Jan 18, 2020	DS DP	NPP	Feb 20, 2021
		8980931	Apr 28, 2034	DP		
		9012484	Sep 06, 2033	DS DP	U-540	
		9199977	Sep 06, 2033	DS DP		
		9453006	Sep 06, 2033	DS		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	001	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP	U-543	
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	002	8729085	May 26, 2026	DP	NPP	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Mar 05, 2021
		8883794	May 26, 2026	DP	PED	Jul 27, 2020
		8883794*PED	Nov 26, 2026			
		9174975	Feb 20, 2024	U-1770		
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		
		9259423*PED	Nov 23, 2031			
		9555027	May 26, 2026	DP	U-543	
		9815827	Feb 20, 2024	U-2166		
		9815827	Feb 20, 2024	U-543		
		9827242	May 23, 2031	U-2199		
		9827242	May 23, 2031	U-2201		
		9907794	May 26, 2026	DP		
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	003	8729085	May 26, 2026	DP	M-195	Jan 27, 2020
		8729085*PED	Nov 26, 2026		NPP	Jan 27, 2020
		8883794	May 26, 2026	DP	NPP	Mar 05, 2021
		8883794*PED	Nov 26, 2026		PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770	PED	Jul 27, 2020
		9174975*PED	Aug 20, 2024			
		9259423	May 23, 2031	U-1822		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP	U-543		
	9815827	Feb 20, 2024		U-2166		
	9815827	Feb 20, 2024		U-543		
	9827242	May 23, 2031		U-2199		
	9827242	May 23, 2031		U-2201		
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024		U-1770		
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031		U-1822		
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP	U-543		
	9815827	Feb 20, 2024		U-2166		
	9815827	Feb 20, 2024		U-543		
	9827242	May 23, 2031		U-2199		
	9827242	May 23, 2031		U-2201		
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	8729085	May 26, 2026	DP		M-195	Jan 27, 2020
	8729085*PED	Nov 26, 2026			NPP	Jan 27, 2020
	8883794	May 26, 2026	DP		NPP	Mar 05, 2021
	8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
	9174975	Feb 20, 2024		U-1770	PED	Jul 27, 2020
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031		U-1822		
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP	U-543		
	9815827	Feb 20, 2024		U-2166		
	9815827	Feb 20, 2024		U-543		
	9827242	May 23, 2031		U-2199		
	9827242	May 23, 2031		U-2201		
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923 001	7601746	Sep 05, 2024	DS DP	U-2344	NCE	Jul 31, 2023
	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE	Jan 26, 2023
					ODE-166	Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP	U-2220	NCE	Dec 20, 2022
	8192719	Oct 12, 2027		U-2220	ODE-170	Dec 20, 2024
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP		ODE-54	Oct 18, 2020
	8268847	Apr 18, 2029		U-1446		
	8367685	Oct 04, 2028	DP	U-1445		
	9265762	May 29, 2027	DP	U-1820		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910 001	7300674	Mar 04, 2023	DP	U-785		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001 6946149	Mar 07, 2023	DP U-837			
<u>MALATHION - OVIDE</u>						
N 018613	001 7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001 6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002 6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	003 6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	004 6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984	001 6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001 7838564	Mar 07, 2026	DP		ODE-51	Aug 23, 2020
	7872050	Jul 08, 2029	U-1427			
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
	9382191	Mar 07, 2026	DP			
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBO PROVERA 104</u>						
N 021583	001 6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001 6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
<u>MELOXICAM - VIVLODEX</u>						
N 207233	001 9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
<u>MELOXICAM - VIVLODEX</u>						
N 207233	002 9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210	001 8545879	Aug 31, 2030	DP			
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210	002 8545879	Aug 31, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	10040872	Jan 30, 2034	DP	ODE-110	Mar 10, 2023
		8410077	Mar 13, 2029	DP		
		9200088	Mar 13, 2029	DP		
		9493582	Feb 27, 2033	DP		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001	8039009	Mar 24, 2029	U-539		
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8039009	Mar 24, 2029	U-539		
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8039009	Mar 24, 2029	U-539		
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8039009	Mar 24, 2029	U-539		
		8039009*PED	Sep 24, 2029			
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002 8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001 6353029	Aug 24, 2020				
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919	001				ODE-65	Apr 28, 2021
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776	001 10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031		U-2490		
	8680136	Aug 17, 2031	DS DP			
	9694025	Aug 08, 2031		U-2120		
<u>MESALAMINE - SFROWASA</u>						
N 019618	002 7645801	Jul 24, 2027	DS DP			
<u>MESALAMINE - CANASA</u>						
N 021252	002 8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001 6893662	Nov 15, 2021	DP	U-141		
	8580302	Nov 15, 2021	DP			
	9089492	Nov 15, 2021	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000	001 6773720	Jun 08, 2020	DP			
<u>MESALAMINE - APRISO</u>						
N 022301	001 8865688	May 01, 2030			U-1310	
<u>MESALAMINE - DELZICOL</u>						
N 204412	001 6649180	Apr 13, 2020	DP			
<u>METAXALONE - SKELAXIN</u>						
N 013217	003 7122566	Feb 06, 2026		U-915		
	7714006	Dec 03, 2021		U-1050		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001 6790459	Mar 17, 2021		U-604		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002 6790459	Mar 17, 2021		U-604		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001 6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	001 6488962	Jun 20, 2020	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002 7780987	Mar 23, 2025	DS DP			
	8323692	Mar 30, 2023	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595	001 9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	6790459	Mar 17, 2021	U-974		
		6866866	Mar 17, 2021	DP		
		7785627	Jul 31, 2026	DP		
		7959946	Jul 31, 2026	DP		
		8470368	Sep 19, 2023	DP		
		8668931	Sep 19, 2023	DP		
		9060941	Sep 19, 2023	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	002	6790459	Mar 17, 2021	U-974		
		6866866	Mar 17, 2021	DP		
		7785627	Jul 31, 2026	DP		
		7959946	Jul 31, 2026	DP		
		8470368	Sep 19, 2023	DP		
		8668931	Sep 19, 2023	DP		
		9060941	Sep 19, 2023	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	001	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	002	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	003	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	004	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410	005	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	001	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003	8628799	Jul 13, 2025	DP	M-198	Feb 27, 2020
		9339472	Jul 13, 2025	DP		
		RE44186	Jul 31, 2023	DS DP U-1097		
		RE44186	Jul 31, 2023	DS DP U-1838		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001	6699871	Jul 26, 2022	DS DP U-802		
		7125873	Jul 26, 2022	DP U-1036		
		7125873	Jul 26, 2022	DP U-1038		
		7125873	Jul 26, 2022	DP U-803		
		7326708	Nov 24, 2026	DS DP U-802		
		8414921	Jul 21, 2028	DP U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002	6699871	Jul 26, 2022	DS DP U-802		
		7125873	Jul 26, 2022	DP U-1036		
		7125873	Jul 26, 2022	DP U-1038		
		7125873	Jul 26, 2022	DP U-803		
		7326708	Nov 24, 2026	DS DP U-802		
		8414921	Jul 21, 2028	DP U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001	6699871	Jul 26, 2022	DS DP U-1227		
		7125873	Jul 26, 2022	DP U-1227		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001	7326708	Nov 24, 2026	DS DP	U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	002	6699871	Jul 26, 2022	DS DP	U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Nov 24, 2026	DS DP	U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	003	6699871	Jul 26, 2022	DS DP	U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Nov 24, 2026	DS DP	U-1227	
<u>METHOTREXATE - OTREXUP</u>						
N 204824	001	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	002	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	003	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	004	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	005	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824	006	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	007	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - OTREXUP</u>						
N 204824	008	6746429	Apr 12, 2020	DP		
		8021335	Oct 04, 2026	DP		
		8480631	Mar 19, 2030	DP	U-1442	
		8562564	Jan 24, 2026	DP		
		8579865	Mar 19, 2030	DP	U-1442	
		8945063	Mar 19, 2030	DP	U-1442	
		9421333	Mar 19, 2030	DP	U-1442	
		9533102	Jan 24, 2026	DP		
		9629959	Jan 24, 2026	DP		
<u>METHOTREXATE - RASUVO</u>						
N 205776	001	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	002	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	003	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	004	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	005	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	006	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	007	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	008	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	009	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE - RASUVO</u>						
N 205776	010	8664231	Jun 01, 2029		U-1442	
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400	001	10231927	Jan 02, 2033		ODE-137	Apr 25, 2024
		10231927	Jan 02, 2033		ODE-138	Apr 25, 2024
		9259427	Jan 02, 2033	DP		
		9855215	Jan 02, 2033	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630	001				ODE-113	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	001	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	002	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	003	10376584	Apr 08, 2024	DP U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
		9492445	Sep 30, 2029	DP U-1185		
		9669096	Apr 08, 2024	DP		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271	001	10307417	Mar 10, 2031	DP		
		10376505	Mar 10, 2031	DP		
		8420663	Sep 30, 2029	U-1185		
		8524276	Mar 10, 2031	DP		
		8956651	Mar 10, 2031	DP		
		9180125	Sep 30, 2029	DP U-1185		
		9314461	Mar 10, 2031	DP		
		9492445	Sep 30, 2029	DP U-1185		
		9724343	Sep 30, 2029	DP U-1185		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	001	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025	U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	002	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025	U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	003	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025	U-2024		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	004	8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
		9668981	Oct 07, 2025	U-2024		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489	001	8840924	Jun 05, 2026	DP	NP	Jun 19, 2020
		9072680	Jun 28, 2032	DP		
		9089496	Jun 28, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 004	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP	U-1415		
	8563033	Feb 15, 2031	DP	U-1415		
	8778390	Feb 15, 2031	DP	U-1543		
	8956649	Feb 15, 2031	DP	U-1665		
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719*PED	Jun 16, 2020				
	6419960*PED	Jun 16, 2020				
	7083808*PED	Jun 16, 2020				
	7247318*PED	Jun 16, 2020				
	7438930*PED	Jun 16, 2020				
	8580310*PED	Jun 16, 2020				
	9066869*PED	Jun 16, 2020				
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 001	8202537	Mar 15, 2027		DP		
	8287903	Feb 15, 2031		DP		
	8999386	Aug 14, 2033		DP		
	9295642	Aug 14, 2033		DP U-1827		
	9545399	Aug 14, 2033		DP U-1827		
	9844544	Aug 14, 2033		DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 002	8202537	Mar 15, 2027		DP		
	8287903	Feb 15, 2031		DP		
	8999386	Aug 14, 2033		DP		
	9295642	Aug 14, 2033		DP U-1827		
	9545399	Aug 14, 2033		DP U-1827		
	9844544	Aug 14, 2033		DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960 003	8202537	Mar 15, 2027		DP		
	8287903	Feb 15, 2031		DP		
	8999386	Aug 14, 2033		DP		
	9295642	Aug 14, 2033		DP U-1827		
	9545399	Aug 14, 2033		DP U-1827		
	9844544	Aug 14, 2033		DP U-2203		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032		DP	NP	Aug 08, 2021
	10292937	Mar 23, 2032		U-2357		
	8916588	Mar 23, 2032		U-2357		
	8927010	Mar 23, 2032		DP		
	9023389	Mar 23, 2032		DP		
	9028868	Mar 23, 2032		U-2357		
	9034902	Mar 23, 2032		U-2357		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
	10292937	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
	10292937	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
	10292937	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP		NP	Aug 08, 2021
	10292937	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035		U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035		U-2357		
	10500162	Oct 30, 2035		U-2357		
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035		U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035		U-2357		
	10500162	Oct 30, 2035		U-2357		
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035		U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035		U-2357		
	10500162	Oct 30, 2035		U-2357		
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035		U-2357		
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035		U-2357	NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035		U-2357		
	10500162	Oct 30, 2035		U-2357		
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035		U-2357		
	9974752	Oct 30, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METRONIDAZOLE - METROGEL</u>						
N 021789 001	6881726	Feb 21, 2022	DP	U-743		
	7348317	Feb 21, 2022	DP	U-743		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806	001 7456207	Sep 22, 2024	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001 10238634	Jun 28, 2032	DP			
	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	002 6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	003 6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MICONAZOLE - ORAVIG</u>						
N 022404	001 6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308	001 6153635	Nov 28, 2020				Y
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026	001 8147852	Mar 30, 2028	U-1426			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321	001 8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIDAZOLAM HYDROCHLORIDE - SEIZALAM</u>						
N 209566	001				ODE-207	Sep 14, 2025
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997	001 7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE-140	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001 10006924	Aug 12, 2036	U-1643			
	10151763	Jan 18, 2037	U-1643			
	10166242	Apr 20, 2036	U-1643			
	10166243	Apr 20, 2036	U-1643			
	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
	10495650	Aug 12, 2036	U-1643			
	10500216	Mar 05, 2033	U-1643			
	8921348	Aug 27, 2028	U-1643			
	9829495	Aug 15, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001 10076514	Mar 15, 2037	U-2371		NCE	Aug 10, 2023
	10251873	May 30, 2038	U-2371		ODE-205	Aug 10, 2025
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	10471053	May 30, 2038	U-2371			
	8592362	Feb 12, 2029	U-2371			
	9000011	May 16, 2027	U-2371			
	9095584	Feb 12, 2029	U-2371			
	9480682	May 16, 2027	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001	9987263	May 16, 2027	U-2371		
		9999618	Apr 28, 2028	U-2372		
		9999618	Apr 28, 2028	U-2373		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	001	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	002	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	003	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	004	6602911	Jan 14, 2023	U-882		
		6992110	Nov 05, 2021	U-882		
		7888342	Nov 05, 2021	U-882		
		7994220	Sep 19, 2029	U-819		
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684	001				ODE-63	Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444	001	9084802	May 12, 2031	U-282		
		9278105	May 12, 2031	U-282		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781	001	6682348	Mar 29, 2022	DP		
		7699609	Mar 29, 2022	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	001	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	002	7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	003	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	004	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	006	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	007	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	008	7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	001	7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		
		7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	003	7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		
		7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	005	7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		
		7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379	001	10086080	Oct 01, 2030	U-2647		
		10137200	Oct 01, 2030	U-2647		
		10213512	Oct 01, 2030	DP U-2647		
		10265404	Oct 01, 2030	DP		
		10398641	Sep 08, 2037	U-2647		
		8865139	Oct 01, 2030	DP U-2647		
		8945516	Oct 01, 2030	DP		
		8992896	Oct 01, 2030	DP U-2647		
		9675700	Oct 01, 2030	DP U-2647		
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568	001	7015315	Mar 21, 2023	DS	ODE-41	Jan 29, 2020
		7101993	Sep 05, 2023	DS		
		7407943	Aug 01, 2021	U-1353		
		7511131	Jan 29, 2027	DS		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	6346532	Mar 27, 2022	DS DP	I-777	Apr 27, 2021
		6562375	Aug 01, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023	DP		
		8772315	Oct 30, 2028	U-2300		
		8835474	Nov 04, 2023	U-1527		
		RE44872	Nov 04, 2023	U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	6346532	Mar 27, 2022	DS DP	I-777	Apr 27, 2021
		6562375	Aug 01, 2020	DP		
		7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023	DP		
		8772315	Oct 30, 2028	U-2300		
		8835474	Nov 04, 2023	U-1527		
		RE44872	Nov 04, 2023	U-1527		
<u>MITOMYCIN - MITOSOL</u>						
N 022572	001	7806265	Feb 01, 2029	DP		
		8186511	Jul 19, 2026	DP		
		9205075	Jul 19, 2026	DP		
		9539241	Jan 02, 2028	DS DP	U-2095	
		9649428	May 21, 2029	U-2095		
<u>MODAFINIL - PROVIGIL</u>						
N 020717	001	7297346	Nov 29, 2023	DP		
<u>MODAFINIL - PROVIGIL</u>						
N 020717	002	7297346	Nov 29, 2023	DP		
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310	001	10232152	Nov 24, 2034	DP	U-2272	NP Dec 08, 2020
		10357640	Oct 03, 2031	U-2272		
		10406332	Mar 13, 2034	DP		
		7544192	Nov 29, 2026	U-2272		
		7662141	Mar 12, 2024	U-2272		
		7713255	Mar 12, 2024	U-2272		
		7951130	Mar 12, 2024	U-2272		
		7951131	Mar 12, 2024	U-2272		
		7951133	Mar 12, 2024	U-2272		
		8025635	Jun 12, 2027	DP	U-2272	
		8109918	Mar 12, 2024	U-2272		
		8763222	Feb 08, 2032	DP		
		9585681	Apr 04, 2026	U-2272		
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409	001	8007830	Oct 24, 2022	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	001	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034	U-43		
		9192608	Mar 12, 2034	U-55		
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	002	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034	U-43		
		9192608	Mar 12, 2034	U-55		
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	003	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034	U-43		
		9192608	Mar 12, 2034	U-55		
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	004	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034	U-43		
		9192608	Mar 12, 2034	U-55		
		9248229	Mar 12, 2034	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP	U-1556		
	9549899	Jul 01, 2033	DP	U-1556		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NCE ODE-193	Jun 13, 2023 Jun 13, 2025
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	6548079	Jul 25, 2020	DP	U-298		
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033		U-540		
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP	U-1185		
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024		DP	U-1185	
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024			U-1185	
	8617530	Oct 18, 2022			U-1185	
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024		DP	U-1185	
	7662365	Oct 18, 2022	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10143972	May 24, 2031		U-2476		
	10220158	Mar 20, 2035	DP	U-2500		
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031		U-1907		
	10335549	Apr 30, 2025	DP			
	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP	U-1907		
	9517307	Jul 18, 2034	DP	U-1925		
	9724471	May 23, 2027	DP	U-2092		
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	10085937	Mar 16, 2035		U-1903		
	9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP	U-1903		
	9561177	Mar 16, 2035	DP	U-1903		
	9629965	Mar 16, 2035	DP	U-1903		
	9775838	Mar 16, 2035		U-1903		
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP	U-1903		
	9707226	Mar 16, 2035	DP	U-1903		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031		U-2476		
	10220158	Mar 20, 2035	DP	U-2500		
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031		U-1907		
	10335549	Apr 30, 2025	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
	9555000	Apr 04, 2023	DP U-1556			
	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
	9555000	Apr 04, 2023	DP U-1556			
	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
<u>NALTREXONE - VIVITROL</u>						
N 021897 001	6264987	May 19, 2020	DP			
	6379704	May 19, 2020	DP			
	6495164	May 25, 2020	DP			
	6534092	May 19, 2020	DP			
	6667061	May 25, 2020	DP			
	7799345	May 25, 2020	DP			
	7919499	Oct 15, 2029	U-1123			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>						
N 021897	001 7919499	Oct 15, 2029	U-1124			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	001 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	002 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	003 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	004 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	005 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	006 7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920	001 10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			
	10028925	Mar 03, 2026	DP U-1732			
	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001 7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	002 7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	002 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	003 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	004 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	005 6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302	001 7803838	Aug 29, 2026	DP			
	7838552	Oct 04, 2027	U-185			
<u>NEPAFENAC - NEVANAC</u>						
N 021862	001 7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491	001 7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
	9662398	Dec 01, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051	001	10035788				
		7399865				
		7982043				
		8518446				
		8790708				
		9139558				
		9211291				
		9630946				
			Oct 15, 2028	U-2043	NCE	Jul 17, 2022
			Dec 29, 2025	DS DP		
			Oct 08, 2025	U-2043		
			Nov 20, 2030	DP U-2043		
			Nov 05, 2030	DP U-2043		
			Oct 15, 2028	U-2043		
			Mar 24, 2030	U-2043		
			Oct 15, 2028	U-2043		
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254	001	10174017				
		8394826				
		8450344				
		9096569				
		9415043				
		9931336				
			Jan 27, 2030	DS DP U-1524	NCE	Dec 18, 2022
			Nov 10, 2030	DS DP U-1524		
			Jul 11, 2026	DS DP U-1524		
			Jul 11, 2026	DS DP U-1524		
			Mar 14, 2034	DS		
			Mar 14, 2034	DS DP U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	10233154				
		6297375				
		8623826				
		8951969				
		9186357				
		9271975				
		9943515				
		9951016				
			Sep 25, 2035	DS		
			Feb 22, 2020	DS		
			Nov 18, 2030	U-2293		
			Nov 18, 2030	DP		
			Nov 18, 2030	U-2293		
			Sep 09, 2031	U-2293		
			Nov 18, 2030	U-2293		
			Sep 25, 2035	DS DP		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152	001	8460704				
			Mar 12, 2029	U-1409		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	7612102				
		7659291				
		8455524				
		9364564				
			Dec 26, 2027	DP		
			Apr 18, 2027	U-1029		
			Apr 18, 2027	U-1029		
			Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	7612102				
		7659291				
		8455524				
		9364564				
			Dec 26, 2027	DP		
			Apr 18, 2027	U-1029		
			Apr 18, 2027	U-1029		
			Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	7612102				
		7659291				
		8455524				
		9364564				
			Dec 26, 2027	DP		
			Apr 18, 2027	U-1029		
			Apr 18, 2027	U-1029		
			Dec 26, 2027	DP		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	005	7612102				
		7659291				
		8455524				
		9364564				
			Dec 26, 2027	DP		
			Apr 18, 2027	U-1029		
			Apr 18, 2027	U-1029		
			Dec 26, 2027	DP		
<u>NICOTINE - NICODERM CO</u>						
N 020165	004	8075911				
		8663680				
		8999379				
			May 22, 2021	DP		
			Feb 13, 2020	DP		
			Feb 13, 2020	U-1686		
<u>NICOTINE - NICODERM CO</u>						
N 020165	005	8075911				
		8663680				
		8999379				
			May 22, 2021	DP		
			Feb 13, 2020	DP		
			Feb 13, 2020	U-1686		
<u>NICOTINE - NICODERM CO</u>						
N 020165	006	8075911				
		8663680				
		8999379				
			May 22, 2021	DP		
			Feb 13, 2020	DP		
			Feb 13, 2020	U-1686		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002 8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002 8323683	Apr 30, 2028	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001 8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002 8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	001 7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	002 7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	003 7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	DS DP U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE-46	May 10, 2020
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001 10105323	Jun 04, 2029	DP		I-805	Sep 06, 2022
	10154990	Dec 20, 2025	U-2620		ODE-261	Sep 06, 2026
	6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
	7119093	Feb 21, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024		U-1677		
	9907756	Jun 07, 2029		DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10105323	Jun 04, 2029		DP	I-805	Sep 06, 2022
	10154990	Dec 20, 2025		U-2620	ODE-261	Sep 06, 2026
	6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
	7119093	Feb 21, 2024	DS DP			
	7989474	Apr 06, 2024		U-1677		
	9907756	Jun 07, 2029		DP		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071579	Aug 12, 2027		U-2655	I-813	Oct 23, 2022
	8071623	Mar 22, 2030	DS DP		I-814	Oct 23, 2022
	8143241	Aug 12, 2027		U-2655	NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE-133	Mar 27, 2024
	8859562	Aug 04, 2031		U-2655	ODE-277	Oct 23, 2026
					ODE-278	Oct 23, 2026
<u>NITISINONE - ORFADIN</u>						
N 021232 001					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 002					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 003					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 004					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033		DP U-1836	D-169	Sep 01, 2020
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035		DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035		DP U-1836		
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035		DP U-1836		
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8282966	Jun 30, 2029		U-1286		
	8291904	Jan 06, 2031		DP U-1226		
	8293284	Jun 30, 2029		U-1286		
	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031		DP		
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031		DP U-1453		
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031		DP U-1226		
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031		DP U-1226		
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029		U-1286		
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029		U-1286		
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8282966	Jun 30, 2029		U-1286		
	8291904	Jan 06, 2031		DP U-1226		
	8293284	Jun 30, 2029		U-1286		
	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
	9770570	May 03, 2036	U-2148			
	9770570*PED	Nov 03, 2036				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 12, 2029	DP U-2223			
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>NIZATIDINE - AXID</u>						
N 021494 001	6930119	Jul 17, 2022	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942		M-226	May 14, 2021
	10266822	Dec 05, 2025	DP U-1943		NCE	Dec 23, 2021
	10266822	Dec 05, 2025	DP U-1944		ODE-127	Dec 23, 2023
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
	9926559	Jan 09, 2034	U-1943			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
	10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
	10174073	Jun 17, 2033	DS			
	7138390	Nov 16, 2022	DS DP			
	8058267	Feb 21, 2022	U-1854			
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
	10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
	10174073	Jun 17, 2033	DS			
	7138390	Nov 16, 2022	DS DP			
	8058267	Feb 21, 2022	U-1854			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	002	8377916				
		9238673		U-1854		
			DP			
<u>OLAPARIB - LYNPARZA</u>						
N 206162	001	7151102				
		7449464		DS DP	ODE-83	Dec 19, 2021
		7981889		DS DP		
		8143241		DS DP		
		8247416			U-1634	
		8859562		DS		
		8912187			U-1634	
					U-1634	
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	7151102				
		7449464		DS DP	I-762	Jan 12, 2021
		7981889		DS DP	I-776	Dec 19, 2021
		8143241		DS DP	I-818	Dec 27, 2022
		8143241			NP	Aug 17, 2020
		8143241			ODE-180	Aug 17, 2024
		8143241			ODE-181	Aug 17, 2024
		8143241			ODE-226	Dec 19, 2025
		8143241			ODE-83	Dec 19, 2021
		8143241			U-2482	
		8475842		DP	U-2483	
		8859562			U-2101	
		8859562			U-2480	
		8859562			U-2481	
		8859562			U-2482	
		8859562			U-2483	
		8912187			U-2101	
		8912187			U-2480	
		8912187			U-2481	
		8912187			U-2482	
		8912187			U-2483	
<u>OLAPARIB - LYNPARZA</u>						
N 208558	002	7151102				
		7449464		DS DP	I-762	Jan 12, 2021
		7981889		DS DP	I-776	Dec 19, 2021
		8143241		DS DP	I-818	Dec 27, 2022
		8143241			NP	Aug 17, 2020
		8143241			ODE-180	Aug 17, 2024
		8143241			ODE-181	Aug 17, 2024
		8143241			ODE-226	Dec 19, 2025
		8143241			ODE-83	Dec 19, 2021
		8143241			U-2482	
		8475842		DP	U-2483	
		8859562			U-2101	
		8859562			U-2480	
		8859562			U-2481	
		8859562			U-2482	
		8859562			U-2483	
		8912187			U-2101	
		8912187			U-2480	
		8912187			U-2481	
		8912187			U-2482	
		8912187			U-2483	
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001	6988496				
		7056916		DP	U-1547	
		7220742		DS DP		
		7284474		DS DP	U-1547	
		7396341		DP		
		7491719		DP	U-1547	
		7727984		DS DP		
		7786111		DS		
		7837235			DP	
		7896264			DP	
		7988001			DP	
		8034809			U-1547	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001 8044046	Nov 10, 2023				
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001 6988496	Feb 23, 2020				
	6988496*PED	Aug 23, 2020				
	7056916	Dec 07, 2023	DS DP			
	7220742	May 12, 2025	DS DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7491719	Nov 10, 2023	DS DP			
	7727984	Jan 19, 2027	DS			
	7786111	Nov 10, 2023	DP			
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025				
	8044046	Nov 10, 2023				
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545	001 6995186	Nov 12, 2023	DP			
	7402609	Jun 19, 2022	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861	001 7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022				
	8399508*PED	Mar 17, 2023				
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276	001 8791154	May 19, 2032	DP			
	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585	001 6987103	Oct 26, 2026				
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816	001 10111890	Aug 03, 2037				
	10124014	Mar 05, 2029				
	10383884	Oct 31, 2037				
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029				
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021				
	9365500	Jun 29, 2021				
	9724358	Mar 05, 2029				
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817	001 10124014	Mar 05, 2029				
	10383884	Oct 31, 2037				
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021				
	9365500	Jun 29, 2021				
	9724358	Mar 05, 2029				
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931	001 7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIQUE</u>						
N 207931	001	8268349*PED	Feb 25, 2025			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8420596	Apr 10, 2031	DS DP		
		8420596*PED	Oct 10, 2031			
		8642538	Sep 10, 2029	DS DP	U-1638	
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030		U-1687	
		9044480	Apr 10, 2031		U-1638	
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060	001	10117844	Jan 04, 2033		U-2447	
		5792795	May 13, 2020	DP		
		5948818	May 13, 2020	DP		
		7960370	Dec 20, 2026	DP		
		8383678	Feb 07, 2025	DP	U-1511	
		9012501	Feb 07, 2025	DP	U-1511	
		9050308	Jan 04, 2033		U-1511	
		9050309	Jan 04, 2033	DS		
		9132112	Feb 07, 2025	DP	U-1511	
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032	001	9023391	Aug 16, 2025	DP		
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 209400	001	10076494	Dec 08, 2036	DP		
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	001	8580830	Nov 23, 2029	DP		
		9095577	Jul 13, 2030	DP		
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	002	8580830	Nov 23, 2029	DP		
		9095577	Jul 13, 2030	DP		
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334	001	5840684	Nov 24, 2020	DS DP	U-1569	NCE Aug 06, 2019
		8420592	Aug 29, 2029		U-1570	GAIN Aug 06, 2024
		9649352	Jul 16, 2035	DP		
		9682061	Apr 26, 2030		U-1569	
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	001	10183020	Jan 02, 2035	DP	U-1777	I-774 Apr 18, 2021
		10183020	Jan 02, 2035	DP	U-2289	NCE Nov 13, 2020
		8946235	Aug 08, 2032	DS DP	U-1777	ODE-102 Nov 13, 2022
		8946235	Aug 08, 2032	DS DP	U-2289	ODE-176 Apr 18, 2025
		9732058	Jul 25, 2032	DS DP	U-1777	
		9732058	Jul 25, 2032	DS DP	U-2289	
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	002	10183020	Jan 02, 2035	DP	U-1777	I-774 Apr 18, 2021
		10183020	Jan 02, 2035	DP	U-2289	NCE Nov 13, 2020
		8946235	Aug 08, 2032	DS DP	U-1777	ODE-102 Nov 13, 2022
		8946235	Aug 08, 2032	DS DP	U-2289	ODE-176 Apr 18, 2025
		9732058	Jul 25, 2032	DS DP	U-1777	
		9732058	Jul 25, 2032	DS DP	U-2289	
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505	001	6245819	Jul 21, 2025		U-1370	I-793 Jan 25, 2022
		6245819	Jul 21, 2025		U-905	
		8236861	Aug 11, 2026		U-1369	
		8236861	Aug 11, 2026		U-1370	
		8236861	Aug 11, 2026		U-905	
		8470890	Feb 13, 2024		U-1369	
		8470890	Feb 13, 2024		U-1370	
		8470890	Feb 13, 2024		U-905	
		8642079	Jul 09, 2028	DP		
		8772353	Feb 13, 2024		U-1369	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPEMIFENE - OSPHENA</u>						
N 203505	001	8772353	Feb 13, 2024		U-1370	
		8772353	Feb 13, 2024		U-905	
		9241915	Feb 13, 2024		U-1369	
		9241915	Feb 13, 2024		U-1370	
		9241915	Feb 13, 2024		U-905	
		9566252	Jul 21, 2020		U-1370	
		9855224	Feb 13, 2024		U-1369	
		9855224	Feb 13, 2024		U-1370	
		9855224	Feb 13, 2024		U-905	
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285	001	8119148	Dec 19, 2020	DP	U-724	
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001	10220042	Apr 13, 2027		U-2501	
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027		U-2041	
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027		U-2041	
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002	10220042	Apr 13, 2027		U-2501	
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027		U-2041	
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027		U-2041	
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003	10220042	Apr 13, 2027		U-2501	
		7722898	Apr 13, 2027	DP		
		7910131	Apr 13, 2027		U-2041	
		8617600	Apr 13, 2027	DP		
		8821930	Apr 13, 2027	DP		
		9119791	Apr 13, 2027		U-2041	
		9351975	Apr 13, 2027	DP		
		9370525	Apr 13, 2027	DP		
		9855278	Apr 13, 2027	DP		
<u>OXYBUTYRNIN - OXYTROL</u>						
N 021351	002	6743441	Apr 26, 2020	DP	U-318	
		7081249	Apr 26, 2020	DP	U-318	
		7081250	Apr 26, 2020	DP	U-318	
		7081251	Apr 26, 2020	DP	U-318	
		7081252	Apr 26, 2020	DP	U-318	
		7179483	Apr 26, 2020	DS DP	U-318	
<u>OXYBUTYRNIN - OXYTROL FOR WOMEN</u>						
N 202211	001	6743441	Apr 26, 2020	DP	U-1329	
		7081249	Apr 26, 2020	DP	U-1329	
		7081250	Apr 26, 2020	DP	U-1329	
		7081251	Apr 26, 2020	DP	U-1329	
		7081252	Apr 26, 2020	DP	U-1329	
		7179483	Apr 26, 2020		U-1329	
<u>OXYBUTYRNIN - GELNIQUE 3%</u>						
N 202513	001	7029694	Apr 26, 2020	DP	U-318	
		7179483	Apr 26, 2020		U-318	
		7198801	Jun 25, 2022	DP		
		8241662	Apr 26, 2020		U-318	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN CHLORIDE - GELNIOUE</u>						
N 022204	001	10272061				
		Apr 26, 2020			U-2525	
		10449173				
		Nov 06, 2029	DP		U-2637	
		7029694				
		Apr 26, 2020	DP		U-318	
		7179483				
		Apr 26, 2020			U-318	
		8241662				
		Apr 26, 2020			U-318	
		8920392				
		Mar 26, 2031			U-1644	
		9259388				
		Nov 06, 2029			U-1644	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001	10004729				
		Dec 10, 2030	DP		U-1556	
		10188644				
		Sep 02, 2036	DP		U-1556	
		10525052				
		Jul 07, 2023	DP		U-1556	
		10525053				
		Jul 07, 2023	DP			
		7399488				
		Mar 24, 2025	DP			
		7771707				
		Mar 24, 2025	DP			
		8449909				
		Mar 24, 2025	DP			
		8557291				
		Mar 21, 2025	DP			
		8758813				
		Jun 10, 2025			U-1556	
		8840928				
		Jul 07, 2023	DP		U-1556	
		9044398				
		Jul 07, 2023	DP			
		9248195				
		Jul 07, 2023			U-1556	
		9592200				
		Jul 07, 2023	DP			
		9682075				
		Dec 10, 2030	DP		U-1556	
		9737530				
		Sep 02, 2036	DP		U-1556	
		9763883				
		Jul 07, 2023	DP			
		9968598				
		Sep 02, 2036	DP		U-1556	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	002	10004729				
		Dec 10, 2030	DP		U-1556	
		10188644				
		Sep 02, 2036	DP		U-1556	
		10525052				
		Jul 07, 2023	DP		U-1556	
		10525053				
		Jul 07, 2023	DP			
		7399488				
		Mar 24, 2025	DP			
		7771707				
		Mar 24, 2025	DP			
		8449909				
		Mar 24, 2025	DP			
		8557291				
		Mar 21, 2025	DP			
		8758813				
		Jun 10, 2025			U-1556	
		8840928				
		Jul 07, 2023	DP		U-1556	
		9044398				
		Jul 07, 2023	DP			
		9248195				
		Jul 07, 2023			U-1556	
		9592200				
		Jul 07, 2023	DP			
		9682075				
		Dec 10, 2030	DP		U-1556	
		9737530				
		Sep 02, 2036	DP		U-1556	
		9763883				
		Jul 07, 2023	DP			
		9968598				
		Sep 02, 2036	DP		U-1556	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	10004729				
		Dec 10, 2030	DP		U-1556	
		10188644				
		Sep 02, 2036	DP		U-1556	
		10525052				
		Jul 07, 2023	DP		U-1556	
		10525053				
		Jul 07, 2023	DP			
		7399488				
		Mar 24, 2025	DP			
		7771707				
		Mar 24, 2025	DP			
		8449909				
		Mar 24, 2025	DP			
		8557291				
		Mar 21, 2025	DP			
		8758813				
		Jun 10, 2025			U-1556	
		8840928				
		Jul 07, 2023	DP		U-1556	
		9044398				
		Jul 07, 2023	DP			
		9248195				
		Jul 07, 2023			U-1556	
		9592200				
		Jul 07, 2023	DP			
		9682075				
		Dec 10, 2030	DP		U-1556	
		9737530				
		Sep 02, 2036	DP		U-1556	
		9763883				
		Jul 07, 2023	DP			
		9968598				
		Sep 02, 2036	DP		U-1556	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	10004729				
		Dec 10, 2030	DP		U-1556	
		10188644				
		Sep 02, 2036	DP		U-1556	
		10525052				
		Jul 07, 2023	DP		U-1556	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10525053	Jul 07, 2023	DP			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025		U-1556		
	8840928	Jul 07, 2023	DP	U-1556		
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023		U-1556		
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP	U-1556		
	9737530	Sep 02, 2036	DP	U-1556		
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10004729	Dec 10, 2030	DP	U-1556		
	10188644	Sep 02, 2036	DP	U-1556		
	10525052	Jul 07, 2023	DP	U-1556		
	10525053	Jul 07, 2023	DP			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025		U-1556		
	8840928	Jul 07, 2023	DP	U-1556		
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023		U-1556		
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP	U-1556		
	9737530	Sep 02, 2036	DP	U-1556		
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	7674799	Mar 30, 2025	DP		Y	
	7674800	Mar 30, 2025	DS		Y	
	7683072	Mar 30, 2025	DS		Y	
	7776314	Apr 19, 2025	DP		Y	
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP		Y	
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027		U-1556		
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027		U-1556		
	9522919	Mar 30, 2025	DS	DP		
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	7674799	Mar 30, 2025	DP		Y	
	7674800	Mar 30, 2025	DS		Y	
	7683072	Mar 30, 2025	DS		Y	
	7776314	Apr 19, 2025	DP		Y	
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	7674799	Mar 30, 2025	DP		Y	
	7674800	Mar 30, 2025	DS		Y	
	7683072	Mar 30, 2025	DS		Y	
	7776314	Apr 19, 2025	DP		Y	
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP		NP	Apr 20, 2020
	7955619	Aug 12, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567		NP	Jan 18, 2020
	7812049	May 02, 2028	U-1959			
	8420688	Aug 02, 2024	U-1959			
	8815929	Jan 22, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
	9974773	Jun 11, 2035	U-2306			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876			
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS		NCE	Dec 11, 2022
	9180200	Jan 29, 2032	DP	U-805		
	9399014	Dec 15, 2029		U-805		
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026		U-1434	ODE-52	Sep 06, 2020
	7758891*PED	Aug 21, 2026			PED	Mar 06, 2021
	7820788	Oct 27, 2024	DP	U-1092		
	7820788	Oct 27, 2024	DP	U-1290		
	7820788	Oct 27, 2024	DP	U-1434		
	7820788*PED	Apr 27, 2025				
	7923536	Dec 09, 2023		U-1117		
	7923536	Dec 09, 2023		U-1290		
	7923536	Dec 09, 2023		U-1434		
	7923536*PED	Jun 09, 2024				
	8034375	Aug 13, 2026		U-1290		
	8138229	Dec 09, 2023	DP	U-1092		
	8138229	Dec 09, 2023	DP	U-1290		
	8138229	Dec 09, 2023	DP	U-1434		
	8138229*PED	Jun 09, 2024				
	8268348	Feb 21, 2026		U-1290		
	8314156	Dec 09, 2023		U-1290		
	8314156	Dec 09, 2023		U-1434		
	8314156*PED	Jun 09, 2024				
	8853260	Oct 10, 2020	DP	U-1092		
	8853260	Oct 10, 2020	DP	U-1290		
	8853260	Oct 10, 2020	DP	U-1434		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	8853260*PED	Apr 10, 2021			
		9101543	Feb 21, 2026	U-1434		
		9101543*PED	Aug 21, 2026			
		9393318	Mar 04, 2032	U-1290		
		9393318*PED	Sep 04, 2032			
		9511046	Jan 12, 2034	U-1434		
		9511046*PED	Jul 12, 2034			
		9597409	Mar 04, 2032	U-1290		
		9597409*PED	Sep 04, 2032			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	001	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	002	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	003	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP		
		7456168	Jan 16, 2023	U-1998		
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	001	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	002	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436	003	6936612	Jan 22, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-2515		
		RE47739	Jan 16, 2023	DS DP		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	001	9439906	Jan 26, 2031	U-1901	M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	002	9439906	Jan 26, 2031	U-1901	M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	003	9439906	Jan 26, 2031	U-1901	M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	004	9439906	Jan 26, 2031	U-1901	M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	005	9439906	Jan 26, 2031	U-1901	M-215	Dec 20, 2020
		9439906	Jan 26, 2031	U-543		
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	001	10143693	Apr 05, 2036	U-2457		
		10143693	Apr 05, 2036	U-2458		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	10143693	Apr 05, 2036		U-2457		
	10143693	Apr 05, 2036		U-2458		
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	10143693	Apr 05, 2036		U-2457		
	10143693	Apr 05, 2036		U-2458		
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	10143693	Apr 05, 2036		U-2457		
	10143693	Apr 05, 2036		U-2458		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	7947724	Jan 30, 2024		DP		
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024		DP		
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024		DP		
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024		DP		
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024		DP		
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024		DP		
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024		DP U-528		
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024		DP U-528		
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024		DP		
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024		DP		
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024		DP		
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024		DP		
	9457020*PED	Jul 30, 2024				
	9457021	Jan 30, 2024		DP		
	9457021*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	7947724	Jan 30, 2024		DP		
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024		DP		
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024		DP		
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024		DP		
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024		DP		
	8598218*PED	Jul 30, 2024				
	9173942	Jan 30, 2024		DP		
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024		DP		
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024		DP		
	9457020*PED	Jul 30, 2024				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	7658918	Feb 20, 2028		DP		
	8221747	Feb 20, 2028		DP		
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028		DP		
	8562979	Feb 20, 2028		DP U-1274		
	8562980	Feb 20, 2028		DP U-1274		
	8562981	Feb 20, 2028		U-1274		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028	DP	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 001	9198871	Feb 07, 2030	DP	U-1787		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 002	9198871	Feb 07, 2030	DP	U-1787		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 003	9198871	Feb 07, 2030	DP	U-1787		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 004	9198871	Feb 07, 2030	DP	U-1787		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	005 9198871	Feb 07, 2030	DP U-1787			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	001 6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	002 6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	003 6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001 6780881	Nov 17, 2021	DP			
	7351723	Nov 17, 2021	DP			
	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001 7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024	U-859			
	7553498	Sep 30, 2024	U-859			
	7838027	Sep 30, 2024	DP U-859			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001				ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002				ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003				ODE-125	Oct 18, 2023
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004 7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001 7598271	May 04, 2025	DS			
	8658663	Apr 06, 2029	DS DP U-904			
	8946251	Aug 04, 2026	DS DP U-904			
	9393237	Aug 04, 2026	U-904			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001 7473761	Dec 14, 2026	DS DP			
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002 7473761	Dec 14, 2026	DS DP			
	8299209	Dec 27, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	001	7473761	Dec 14, 2026	DS DP	I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP	ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629	ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	002	7473761	Dec 14, 2026	DS DP	I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP	ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629	ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	003	7473761	Dec 14, 2026	DS DP	I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP	ODE-268	Jun 29, 2025
		8822637	Aug 06, 2023	U-1629	ODE-81	Dec 15, 2021
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	004	7473761	Dec 14, 2026	DS DP	I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP	ODE-268	Jun 29, 2025
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	005	7473761	Dec 14, 2026	DS DP	I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP	ODE-268	Jun 29, 2025
		9351923	May 23, 2028	DP		
<u>PATIREOMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	001	10485821	Mar 30, 2024	U-1766	NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766		
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	May 29, 2027	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS	U-1766	
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
		9925212	Oct 08, 2033	U-1766		
<u>PATIREOMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	002	10485821	Mar 30, 2024	U-1766	NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766		
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	May 29, 2027	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS	U-1766	
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
		9925212	Oct 08, 2033	U-1766		
<u>PATIREOMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	003	10485821	Mar 30, 2024	U-1766	NCE	Oct 21, 2020
		7556799	Feb 27, 2025	U-1766		
		8147873	Jun 20, 2028	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	May 29, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	003	8287847				
		Mar 30, 2024			U-1766	
		8337824		DS	U-1766	
		May 29, 2030				
		8475780			U-1766	
		Mar 30, 2024				
		8778324			U-1766	
		Mar 30, 2024				
		8889115			U-1766	
		Mar 30, 2024				
		9492476			U-1766	
		Oct 08, 2033				
		9925212			U-1766	
		Oct 08, 2033				
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922	001	8058069				
		Apr 15, 2029		DP		
		8158601				
		Nov 10, 2030		DP	U-2378	NCE
		8168775		DS	DP	U-2378
		Oct 20, 2029				
		8334373		DS	DP	
		May 27, 2025				
		8362231		DS	DP	
		Mar 30, 2021				
		8372968		DS	DP	
		Mar 30, 2021				
		8492359			DP	
		Apr 15, 2029				
		8552171		DS	DP	
		Mar 30, 2021				
		8642076			DP	
		Oct 03, 2027				
		8741866			U-2378	
		Oct 20, 2029				
		8778902			U-2378	
		Mar 30, 2021				
		8802644			DP	U-2378
		Oct 21, 2030				
		8822668			DP	U-2378
		Apr 15, 2029				
		8895718		DS	DP	
		Mar 30, 2021				
		8895721		DS	DP	
		Mar 30, 2021				
		9193753			U-2378	
		Mar 30, 2021				
		9234196			DP	U-2378
		Oct 20, 2029				
		9364435			DP	U-2378
		Apr 15, 2029				
		9567582		DS	DP	
		Mar 30, 2021				
		9943538			DP	
		Nov 04, 2023				
		9943539			DP	
		Nov 04, 2023				
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	001	7105530				
		Oct 19, 2023		DS	DP	
		7262203			DS	DP
		Dec 19, 2021				
		8114885			DS	DP
		Dec 19, 2021				
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530				
		Oct 19, 2023		DS	DP	
		7262203			DS	DP
		Dec 19, 2021				
		8114885			DS	DP
		Dec 19, 2021				
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	001	7084245				
		May 12, 2024		DS	DP	U-1238
		7414105			DS	DP
		May 12, 2024				
		7528104			DS	DP
		May 12, 2024				
		7550433				U-1238
		Jun 02, 2026				
		7919118		DS	DP	
		May 12, 2024				
		7919461				U-1238
		Jun 02, 2026				
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	002	7084245				
		May 12, 2024		DS	DP	U-1238
		7414105			DS	DP
		May 12, 2024				
		7528104			DS	DP
		May 12, 2024				
		7550433				U-1238
		Jun 02, 2026				
		7919118		DS	DP	
		May 12, 2024				
		7919461				U-1238
		Jun 02, 2026				
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	003	7084245				
		May 12, 2024		DS	DP	U-1238
		7414105			DS	DP
		May 12, 2024				
		7528104			DS	DP
		May 12, 2024				
		7550433				U-1238
		Jun 02, 2026				
		7919118		DS	DP	
		May 12, 2024				
		7919461				U-1238
		Jun 02, 2026				
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	004	7084245				
		May 12, 2024		DS	DP	U-1238
		7414105			DS	DP
		May 12, 2024				
		7528104			DS	DP
		May 12, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7550433	Jun 02, 2026				
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026				
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	7772209	Nov 24, 2021				U-1296
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	7772209	Nov 24, 2021				U-1296
<u>PENCICLOVIR - DENAVIR</u>						
N 020629 001	6579981	Jun 17, 2020				U-501
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027			U-2622	
	6562861	Dec 16, 2023	DS			
	8778997	May 07, 2027			U-1627	
	8778997	May 07, 2027			U-2622	
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP		U-106	
	6949571	Jun 08, 2021	DS DP		U-2088	
	6949571	Jun 08, 2021	DS DP		U-2089	
	6949571	Jun 08, 2021	DS DP		U-2428	
	6949571	Jun 08, 2021	DS DP		U-2429	
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP		U-106	
	6949571	Jun 08, 2021	DS DP		U-2088	
	6949571	Jun 08, 2021	DS DP		U-2089	
	6949571	Jun 08, 2021	DS DP		U-2428	
	6949571	Jun 08, 2021	DS DP		U-2429	
	8772497	Jul 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003	6949571	Jun 08, 2021	DS DP U-106		
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		6949571	Jun 08, 2021	DS DP U-2428		
		6949571	Jun 08, 2021	DS DP U-2429		
		8772497	Jul 01, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004	6949571	Jun 08, 2021	DS DP U-106		
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		6949571	Jun 08, 2021	DS DP U-2428		
		6949571	Jun 08, 2021	DS DP U-2429		
		8772497	Jul 01, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005	6949571	Jun 08, 2021	DS DP U-106		
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		6949571	Jun 08, 2021	DS DP U-2428		
		6949571	Jun 08, 2021	DS DP U-2429		
		8772497	Jul 01, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	006	6949571	Jun 08, 2021	DS DP U-106		
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		6949571	Jun 08, 2021	DS DP U-2428		
		6949571	Jun 08, 2021	DS DP U-2429		
		8772497	Jul 01, 2026	DS		
<u>PERAMPANEL - FYCOMPA</u>						
N 208277	001	6949571	Jun 08, 2021	DS DP U-106		
		6949571	Jun 08, 2021	DS DP U-2088		
		6949571	Jun 08, 2021	DS DP U-2089		
		6949571	Jun 08, 2021	DS DP U-2428		
		6949571	Jun 08, 2021	DS DP U-2429		
		8772497	Jul 01, 2026	DS		
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	9789210	Mar 16, 2037	U-665		
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810	001	10189833	May 05, 2036	U-2606	NCE	Aug 02, 2024
		10435404	Jul 24, 2038	DP	ODE-250	Aug 02, 2026
		7893075	Oct 13, 2028	DS		
		8404700	Nov 21, 2027	DS		
		8461169	Apr 19, 2028	U-2606		
		8722702	Nov 21, 2027	DS		
		9169250	Nov 21, 2027	DS		
		9358235	Jun 08, 2033	U-2606		
		9802932	May 05, 2036	DS		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	001	7056890	Jun 14, 2020	DP U-1262		
		7553818	Jun 14, 2020	U-1262		
		7659256	Jun 14, 2020	DP U-1262		
		7674776	Jun 14, 2020	DP U-1262		
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029	U-1262		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 001	8895057	Jun 09, 2028			U-1262	
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 002	7056890	Jun 14, 2020	DP		U-1262	
	7553818	Jun 14, 2020			U-1262	
	7659256	Jun 14, 2020	DP		U-1262	
	7674776	Jun 14, 2020	DP		U-1262	
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
	8895057	Jun 09, 2028			U-1262	
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 003	7056890	Jun 14, 2020	DP		U-1262	
	7553818	Jun 14, 2020			U-1262	
	7659256	Jun 14, 2020	DP		U-1262	
	7674776	Jun 14, 2020	DP		U-1262	
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
	8895057	Jun 09, 2028			U-1262	
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 004	7056890	Jun 14, 2020	DP		U-1262	
	7553818	Jun 14, 2020			U-1262	
	7659256	Jun 14, 2020	DP		U-1262	
	7674776	Jun 14, 2020	DP		U-1262	
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
	8895057	Jun 09, 2028			U-1262	
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028			U-1262	
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	6764678	May 11, 2021			U-967	
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023			U-967	
	7575757	Apr 21, 2025	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033			U-1594	
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033			U-1594	
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	10028944	Jan 15, 2024			U-1974	
	6756393	Mar 06, 2021	DS DP			
	6815458	Mar 06, 2021	DS DP		U-1843	
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026			U-1844	
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024			U-1845	
	8921393	Jan 15, 2024			U-1846	
	9296694	Mar 06, 2021	DS DP			
	9566271	Jan 15, 2024			U-1974	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	001	9765053	Jul 27, 2022	U-1974		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	002	10028944	Jan 15, 2024	U-1974	NCE	Apr 29, 2021
		10517860	Mar 23, 2037	U-1974		
		6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		
		7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026	U-1844		
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024	U-1845		
		8921393	Jan 15, 2024	U-1846		
		9296694	Mar 06, 2021	DS DP		
		9566271	Jan 15, 2024	U-1974		
		9765053	Jul 27, 2022	U-1974		
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793	001	10028944	Jan 15, 2024	U-1974	NCE	Apr 29, 2021
		10449185	Aug 27, 2038	DP		
		6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		
		7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026	U-1844		
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024	U-1845		
		8921393	Jan 15, 2024	U-1846		
		9296694	Mar 06, 2021	DS DP		
		9566271	Jan 15, 2024	U-1974		
		9765053	Jul 27, 2022	U-1974		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	001	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	002	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	003	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684	004	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	001	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750	002	6900184	Apr 14, 2023	DP	U-282	
		7915229	Apr 14, 2023	DP		
		8133883	Apr 14, 2023	DP	U-282	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029			ODE-77	Oct 15, 2021
	7635707	Apr 22, 2029	U-1600			
	7696236	Dec 18, 2027	U-1609			
	7767225	Sep 22, 2026	DP U-1601			
	7767700	Dec 18, 2027	U-1602			
	7816383	Jan 08, 2030	U-1601			
	7910610	Jan 08, 2030	U-1603			
	7988994	Sep 22, 2026	DP U-1604			
	8013002	Jan 08, 2030	U-1602			
	8084475	Jan 08, 2030	U-1603			
	8318780	Jan 08, 2030	U-1605			
	8383150	Sep 22, 2026	U-1606			
	8420674	Dec 18, 2027	DP U-2361			
	8592462	Apr 22, 2029	DP U-1608			
	8609701	Apr 22, 2029	U-1609			
	8648098	Jan 08, 2030	U-1610			
	8753679	Sep 22, 2026	U-1611			
	8754109	Jan 08, 2030	DP U-1602			
	8778947	Aug 30, 2033	U-1612			
			U-1613			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP		ODE-77	Oct 15, 2021
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	001	8778947				
		9561217		U-2045		
			DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	002	10188637				
		7566729		DP	ODE-77	Oct 15, 2021
		7566729		U-2269		
		7566729		U-2270		
		7635707		U-2072		
		7635707		U-2073		
		7635707		U-2074		
		7635707		U-2075		
		7635707		U-2076		
		7635707		U-2083		
		7767700		U-2080		
		7816383		U-2042		
		7816383		U-2050		
		7910610		U-2048		
		7910610		U-2049		
		8013002		U-2047		
		8013002		U-2082		
		8084475		U-2054		
		8084475		U-2268		
		8318780		U-2046		
		8318780		U-2081		
		8383150		DP U-2361		
		8420674		U-2079		
		8592462		U-2055		
		8592462		U-2056		
		8592462		U-2057		
		8592462		U-2058		
		8592462		U-2059		
		8592462		U-2060		
		8592462		U-2061		
		8592462		U-2062		
		8592462		U-2063		
		8609701		U-2064		
		8609701		U-2065		
		8609701		U-2066		
		8609701		U-2067		
		8609701		U-2068		
		8609701		U-2069		
		8609701		U-2070		
		8648098		U-2051		
		8648098		U-2052		
		8754109		U-2053		
		8778947		U-2044		
		8778947		U-2045		
		9561217		DP		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780	003	10188637				
		7566729		DP	ODE-77	Oct 15, 2021
		7566729		U-2077		
		7566729		U-2078		
		7635707		U-2072		
		7635707		U-2073		
		7635707		U-2074		
		7635707		U-2075		
		7635707		U-2076		
		7635707		U-2083		
		7767700		U-2080		
		7816383		U-2042		
		7816383		U-2050		
		7910610		U-2048		
		7910610		U-2049		
		8013002		U-2047		
		8013002		U-2082		
		8084475		U-2052		
		8084475		U-2054		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRIFENIDONE - ESBRIET</u>						
N 208780 003	8318780	Jan 08, 2030		U-2046		
	8318780	Jan 08, 2030		U-2081		
	8383150	Sep 22, 2026	DP	U-2361		
	8420674	Dec 18, 2027		U-2079		
	8592462	Apr 22, 2029		U-2055		
	8592462	Apr 22, 2029		U-2056		
	8592462	Apr 22, 2029		U-2057		
	8592462	Apr 22, 2029		U-2058		
	8592462	Apr 22, 2029		U-2059		
	8592462	Apr 22, 2029		U-2060		
	8592462	Apr 22, 2029		U-2061		
	8592462	Apr 22, 2029		U-2062		
	8592462	Apr 22, 2029		U-2063		
	8609701	Apr 22, 2029		U-2064		
	8609701	Apr 22, 2029		U-2065		
	8609701	Apr 22, 2029		U-2066		
	8609701	Apr 22, 2029		U-2067		
	8609701	Apr 22, 2029		U-2068		
	8609701	Apr 22, 2029		U-2069		
	8609701	Apr 22, 2029		U-2070		
	8648098	Jan 08, 2030		U-2051		
	8648098	Jan 08, 2030		U-2052		
	8754109	Jan 08, 2030		U-2053		
	8778947	Aug 30, 2033		U-2044		
	8778947	Aug 30, 2033		U-2045		
	9561217	Jan 25, 2022	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 001	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 002	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 003	8829186	Jan 19, 2031	DS DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1101	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026		U-1101		
	8486947	Sep 26, 2029		U-1101		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1101	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026		U-1101		
	8486947	Sep 26, 2029		U-1101		
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	8383596	Jun 02, 2031	DS	U-2328	NCE	Jun 25, 2023
	8822424	Nov 21, 2028		DP	GAIN	Jun 25, 2028
	9266919	Nov 21, 2028		U-2328		
	9688711	Nov 21, 2028	DS	U-2328		
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022		U-1964		
	9610321	Sep 15, 2031		U-1999		
	9610321	Sep 15, 2031		U-2230		
	9616097	Jul 02, 2032		DP		
	9919024	Sep 15, 2031		U-1999		
	9919024	Sep 15, 2031		U-2230		
	9925231	Sep 15, 2031		DP		
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023		U-936		
	7897590	Jul 22, 2023		U-936		
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	6572873	May 26, 2020		U-1461		
	6846412	Jul 19, 2022		DP		
	6942165	May 26, 2020		DP		
	7025290	May 26, 2020		DP U-1461		
	7357336	May 26, 2020		U-1461		
	7604185	May 26, 2020	DS DP	U-1462		
	7731986	Nov 17, 2024	DS DP	U-1463		
	7814943	Nov 19, 2027		DP U-1461		
	7842282	May 26, 2020		U-1461		
	7842283	May 26, 2020		DP		
	8122917	Sep 09, 2024		DP		
	8323677	May 26, 2020		DS		
	8734833	May 26, 2020	DS DP			
	9480652	May 12, 2032		DP		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	6315720	Oct 23, 2020		U-1361	ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	8198262	Jun 17, 2025		U-1360		
	8198262	Jun 17, 2025		U-2254		
	8315886	Oct 23, 2020		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8673939	May 15, 2023		U-2254		
	8735428	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-2254		
	8828427	Jun 21, 2031	DS DP			
	9993467	May 19, 2030		DP		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	6315720	Oct 23, 2020		U-1361	ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	8198262	Jun 17, 2025		U-1360		
	8198262	Jun 17, 2025		U-2254		
	8315886	Oct 23, 2020		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8673939	May 15, 2023		U-2254		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8735428	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-2254		
	8828427	Jun 21, 2031	DS DP			
	9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	6315720	Oct 23, 2020		U-1361	ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	8198262	Jun 17, 2025		U-1360		
	8198262	Jun 17, 2025		U-2254		
	8315886	Oct 23, 2020		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8673939	May 15, 2023		U-2254		
	8735428	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-2254		
	8828427	Jun 21, 2031	DS DP			
	9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	6315720	Oct 23, 2020		U-1361	ODE-43	Feb 08, 2020
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	8198262	Jun 17, 2025		U-1360		
	8198262	Jun 17, 2025		U-2254		
	8315886	Oct 23, 2020		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8673939	May 15, 2023		U-2254		
	8735428	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-2254		
	8828427	Jun 21, 2031	DS DP			
	9993467	May 19, 2030	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003 001	8263600	Apr 01, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596	001	10117951	Mar 13, 2029	DP		
		8410077	Mar 13, 2029	DP		
		9023790	Jul 04, 2031	DP	U-1698	
		9358297	Jun 24, 2031	DP	U-1454	
		9493582	Feb 27, 2033	DP		
		9750822	Mar 13, 2029	DP		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	001	6028071	Jul 16, 2022	DS DP	U-1004	
		7622470	May 31, 2025		U-1015	
		8299078	May 31, 2025		U-1004	
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	002	6028071	Jul 16, 2022	DS DP	U-1004	
		7622470	May 31, 2025		U-1015	
		8299078	May 31, 2025		U-1004	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	001	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	002	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	003	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	004	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	005	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	006	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	007	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP	U-219	
<u>PRASTERONE - INTRAROSA</u>						
N 208470	001	8268806	Mar 19, 2031	DP		
		8629129	Aug 07, 2028	DP		
		8957054	Aug 07, 2028		U-1922	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	001	7799331	Oct 11, 2028	DP	U-1068	
		7799331	Oct 11, 2028	DP	U-139	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	002	7799331	Oct 11, 2028	DP	U-1068	
		7799331	Oct 11, 2028	DP	U-139	
<u>PREDNISONE - RAYOS</u>						
N 202020	001	6488960	Mar 14, 2020	DP	U-1267	
		6677326	Mar 14, 2020	DP	U-1268	
		8309124	Apr 23, 2024		U-1292	
		8394407	Apr 23, 2024	DP	U-1362	
		9040085	Apr 23, 2024		U-1362	
		9186332	Apr 23, 2024		U-1362	
		9504699	Aug 03, 2027		U-1362	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020	002	6488960	Mar 14, 2020	DP U-1267		
		6677326	Mar 14, 2020	DP U-1268		
		8309124	Apr 23, 2024			
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020	003	8168218	Jan 07, 2028	DP U-1269		
		8309124	Apr 23, 2024	U-1292		
		8394407	Apr 23, 2024	DP U-1362		
		9040085	Apr 23, 2024	U-1362		
		9186332	Apr 23, 2024	U-1362		
		9504699	Aug 03, 2027	U-1362		
<u>PREGABALIN - LYRICA</u>						
N 021446	001				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	002				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	003				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	004				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	005				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	006				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	007				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446	008				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488	001				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 022488	001				NPP	May 03, 2021
					NPP	May 23, 2022
					PED	Nov 03, 2021
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA CR</u>						
N 209501	001	10022447		Nov 02, 2026	U-2136	NP
		10022447		Nov 02, 2026	U-2137	PED
		10022447*PED		May 02, 2027		
		8945620		Nov 02, 2026	DP U-2136	
		8945620		Nov 02, 2026	DP U-2137	
		8945620*PED		May 02, 2027		
		9144559		Nov 02, 2026	DP	
		9144559*PED		May 02, 2027		
<u>PREGABALIN - LYRICA CR</u>						
N 209501	002	10022447		Nov 02, 2026	U-2136	NP
		10022447		Nov 02, 2026	U-2137	PED
		10022447*PED		May 02, 2027		
		8945620		Nov 02, 2026	DP U-2136	
		8945620		Nov 02, 2026	DP U-2137	
		8945620*PED		May 02, 2027		
		9144559		Nov 02, 2026	DP	
		9144559*PED		May 02, 2027		
<u>PREGABALIN - LYRICA CR</u>						
N 209501	003	10022447		Nov 02, 2026	U-2136	NP
		10022447		Nov 02, 2026	U-2137	PED
		10022447*PED		May 02, 2027		
		8945620		Nov 02, 2026	DP U-2136	
		8945620		Nov 02, 2026	DP U-2137	
		8945620*PED		May 02, 2027		
		9144559		Nov 02, 2026	DP	
		9144559*PED		May 02, 2027		
<u>PRETOMANID - PRETOMANID</u>						
N 212862	001				NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
<u>PROPOFOL - DIPRIVAN</u>						
N 019627	002	8476010		Dec 01, 2024	DS DP	
		8476010*PED		Jun 01, 2025		
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	001	6500454		Oct 04, 2021	DP	
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	002	6500454		Oct 04, 2021	DP	
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410	001	8338489		Oct 16, 2028	U-1496	ODE-62
		8987262		Oct 16, 2028	U-1988	Mar 14, 2021
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	001				NCE	Dec 14, 2023
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	002				NCE	Dec 14, 2023
<u>QUAZEPAM - DORAL</u>						
N 018708	001	7608616		Jun 03, 2028	U-1012	
<u>QUAZEPAM - DORAL</u>						
N 018708	003	7608616		Jun 03, 2028	U-1012	
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971	001	6635234		Nov 17, 2022	U-2271	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
	7217713	Oct 21, 2022		U-257	PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-900		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			NS	May 26, 2020
	7217713	Oct 21, 2022		U-257	PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-900		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030		DP		
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RAMELTEON - ROZEREM</u>						
N 021782 001	10098866	Nov 16, 2021	DP	U-2433		
<u>RAMIPRIL - ALTACE</u>						
N 019901 001	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 002	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 003	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 004	7368469	Aug 30, 2020		U-871		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RAMIPRIL - ALTACE</u>						
N 022021	001 7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021	002 7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021	003 7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021	004 7368469	Aug 30, 2020	U-871			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001 7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	002 7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001 6403567	Apr 10, 2022	DS DP U-869		M-194	Jan 17, 2020
	8106183	Feb 02, 2027	DS			
	RE47301	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001 7351834	Jun 28, 2022	DS		I-744	Apr 27, 2020
	8637553	Feb 16, 2031	DS DP		ODE-139	Apr 27, 2024
	8680124	Jun 02, 2030	U-1506		ODE-44	Feb 25, 2020
	9458107	Apr 08, 2031	DP			
	9957232	Jul 09, 2032	DS			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055	001 7875630	Feb 14, 2027	DS			
	8207191	Aug 30, 2024	U-805			
	RE43390	Apr 12, 2021	DS DP U-805			
<u>REVEFFENACIN - YUPELRI</u>						
N 210598	001 10106503	Mar 10, 2025	U-2440		NCE	Nov 09, 2023
	10343995	Mar 10, 2025	U-2440			
	7288657	Dec 23, 2025	DS			
	7491736	Mar 10, 2025	U-2440			
	7521041	Mar 10, 2025	U-2440			
	7550595	Mar 10, 2025	DP			
	7585879	Mar 10, 2025	DS DP U-2440			
	7910608	Mar 10, 2025	DS DP			
	8034946	Mar 10, 2025	DP			
	8053448	Mar 10, 2025	U-2440			
	8273894	Mar 10, 2025	DP			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001 6790837	Apr 05, 2023	DP			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092	001 8324225	Jun 17, 2028	DS DP		I-783	Jul 18, 2021
	8415355	Feb 19, 2031	DS DP		I-784	Jul 18, 2021
	8685980	May 25, 2030	DS DP		NCE	Mar 13, 2022
	8962630	Dec 09, 2029	U-1981			
	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIFAMYCIN SODIUM - AEMCOLO</u>						
N 210910	001	8263120	May 03, 2025	DP		
		8486446	May 03, 2025	DP		
		8529945	May 03, 2025	DP		
		8741948	May 03, 2025	DP U-2448		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001	7045620	Jun 19, 2024	DS DP		
		7612199	Jun 19, 2024	DS DP		
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7928115	Jul 24, 2029		U-1121	
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP		
		8518949	Feb 27, 2026	DP		
		8741904	Feb 27, 2026	DS	U-1526	
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
		9271968	Feb 27, 2026	DP		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001	10314828	Oct 02, 2029		U-1481	
		10335397	Oct 02, 2029		U-2579	
		10456384	Feb 26, 2029		U-2643	
		10456384	Feb 26, 2029		U-2644	
		7045620	Jun 19, 2024	DS		
		7612199	Jun 19, 2024	DS DP		
		7902206	Jun 19, 2024	DS DP		
		7906542	Jun 01, 2025	DS DP		
		7915275	Feb 23, 2025		U-1707	
		7915275	Feb 23, 2025		U-1708	
		8158644	Jun 19, 2024	DP		
		8158781	Jun 19, 2024	DS		
		8193196	Sep 02, 2027	DS DP	U-1707	
		8193196	Sep 02, 2027	DS DP	U-1708	
		8309569	Jul 18, 2029		U-1707	
		8309569	Jul 18, 2029		U-1708	
		8518949	Feb 27, 2026	DP		
		8642573	Oct 02, 2029		U-1481	
		8741904	Feb 27, 2026	DS	U-1526	
		8741904	Feb 27, 2026	DS	U-1707	
		8741904	Feb 27, 2026	DS	U-1708	
		8829017	Jul 24, 2029		U-1562	
		8835452	Jun 19, 2024	DS DP		
		8853231	Jun 19, 2024	DP		
		8946252	Jul 24, 2029		U-1481	
		8969398	Oct 02, 2029		U-1481	
		9271968	Feb 27, 2026	DP		
		9421195	Mar 10, 2030		U-1481	
		9629828	Jul 24, 2029		U-1994	
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001	6838464	Feb 26, 2021	DS DP	M-223	Feb 01, 2021
		7125879	Apr 21, 2025	DS DP	U-1153	
		7125879	Apr 21, 2025	DS DP	U-1307	
		7125879	Apr 21, 2025	DS DP	U-1740	
		7638522	Apr 14, 2023	DP		
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RILUZOLE - TIGLUTIK KIT</u>						
N 209080	001 8765150	Mar 12, 2029	DP U-2401			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	001 7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	002 7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	003 7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	004 7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819	005 7173037	Dec 04, 2026	DS DP		ODE-53	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835	005 7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560	001 7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346	001 6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346	002 6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346	003 6667061	May 25, 2020	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655	001 10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026		U-2363		
	10376590	Feb 13, 2028		U-2608		
	10406160	Jun 26, 2026	DP U-2608			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028		U-543		
	9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655	002 10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026		U-2363		
	10376590	Feb 13, 2028		U-2608		
	10406160	Jun 26, 2026	DP U-2608			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028		U-543		
	9597402	Sep 26, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N 020945	001 7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417	001 7364752	Nov 10, 2020	DP U-688			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024		U-688		
	8691878*PED	Feb 25, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N 209512	001				ODE-184	Jun 07, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406	001	7157456	Aug 28, 2024	DS DP U-1301	D-168	Oct 27, 2020
		7157456	Aug 28, 2024	DS DP U-1302	I-810	Oct 11, 2022
		7585860	Dec 11, 2020	DS		
		7592339	Dec 11, 2020		U-1167	
		7592339	Dec 11, 2020		U-1200	
		7592339	Dec 11, 2020		U-1301	
		7592339	Dec 11, 2020		U-1302	
		7592339	Dec 11, 2020		U-1303	
		7592339	Dec 11, 2020		U-2142	
		7592339	Dec 11, 2020		U-2640	
		9415053	Nov 13, 2024	DP	U-1167	
		9415053	Nov 13, 2024	DP	U-1200	
		9415053	Nov 13, 2024	DP	U-1301	
		9415053	Nov 13, 2024	DP	U-1302	
		9415053	Nov 13, 2024	DP	U-2142	
		9415053	Nov 13, 2024	DP	U-2640	
		9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1957	
		9539218	Feb 17, 2034		U-2143	
		9539218	Feb 17, 2034		U-2641	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	002	7157456	Aug 28, 2024	DS DP U-1301	I-810	Oct 11, 2022
		7157456	Aug 28, 2024	DS DP U-1302		
		7585860	Dec 11, 2020	DS		
		7592339	Dec 11, 2020		U-1167	
		7592339	Dec 11, 2020		U-1200	
		7592339	Dec 11, 2020		U-1301	
		7592339	Dec 11, 2020		U-1302	
		7592339	Dec 11, 2020		U-1303	
		9415053	Nov 13, 2024	DP	U-1167	
		9415053	Nov 13, 2024	DP	U-1200	
		9415053	Nov 13, 2024	DP	U-1301	
		9415053	Nov 13, 2024	DP	U-1302	
		9415053	Nov 13, 2024	DP	U-1303	
		9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1956	
		9539218	Feb 17, 2034		U-1957	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7157456	Aug 28, 2024	DS DP U-1301	I-810	Oct 11, 2022
		7157456	Aug 28, 2024	DS DP U-1302		
		7585860	Dec 11, 2020	DS		
		7592339	Dec 11, 2020		U-1167	
		7592339	Dec 11, 2020		U-1200	
		7592339	Dec 11, 2020		U-1301	
		7592339	Dec 11, 2020		U-1302	
		7592339	Dec 11, 2020		U-1303	
		9415053	Nov 13, 2024	DP	U-1167	
		9415053	Nov 13, 2024	DP	U-1200	
		9415053	Nov 13, 2024	DP	U-1301	
		9415053	Nov 13, 2024	DP	U-1302	
		9539218	Feb 17, 2034		U-1953	
		9539218	Feb 17, 2034		U-1954	
		9539218	Feb 17, 2034		U-1955	
		9539218	Feb 17, 2034		U-1957	
<u>RIVAROXABAN - XARELTO</u>						
N 022406	004	7157456	Aug 28, 2024	DS DP	I-810	Oct 11, 2022
		7585860	Dec 11, 2020	DS		
		7592339	Dec 11, 2020		U-2435	
		9415053	Nov 13, 2024	DP	U-2435	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	7157456	Aug 28, 2024	DS DP		I-810	Oct 11, 2022
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-2435		
	9415053	Nov 13, 2024	DP	U-2435		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP	U-1115	D-171	Jan 23, 2021
	8431154	Feb 19, 2023	DP		M-208	Aug 31, 2020
	8536206	Mar 08, 2024		U-1115		
	8604064	Mar 08, 2024		U-1115		
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP	U-1115	NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024		U-1115		
	8604064	Mar 08, 2024		U-1115		
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Dec 08, 2023	DS DP	U-1741	NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027		U-1741		
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Apr 04, 2027		U-1741		
	8470842	Jan 18, 2029		U-1741		
	8796299	Dec 17, 2022		U-1741		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Dec 08, 2023	DS DP	U-1741	NCE	Sep 01, 2020
	7981905	Apr 04, 2027		U-1741		
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027		U-1741		
	8470842	Jan 18, 2029		U-1741		
	8796299	Dec 17, 2022		U-1741		
	9101615	Jul 14, 2032		U-1741		
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393 001	7608280	Aug 22, 2021	DS			
	7611724	Aug 22, 2021	DS			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006	7927624	Dec 02, 2021	DP	U-20	M-203	Mar 23, 2020
	8303986	Apr 12, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	006	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	007	7828787	Oct 18, 2025	DP		
		7857802	Nov 28, 2026	DP		
		8118802	May 18, 2023	DP		
		8162915	May 23, 2024	DP		
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	002	7358366	Apr 19, 2020	DS		
		7358366*PED	Oct 19, 2020		Y	
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	003	7358366	Apr 19, 2020	DS		
		7358366*PED	Oct 19, 2020		Y	
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071	004	7358366	Apr 19, 2020	DS		
		7358366*PED	Oct 19, 2020		Y	
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	002	6316460	Aug 04, 2020	DP		ODE-118 May 27, 2023
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618	Dec 17, 2021	U-618		
		6858618*PED	Jun 17, 2022			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	003	6316460	Aug 04, 2020	DP		ODE-118 May 27, 2023
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618	Dec 17, 2021	U-618		
		6858618*PED	Jun 17, 2022			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	004	6316460	Aug 04, 2020	DP		ODE-118 May 27, 2023
		6858618	Dec 17, 2021	U-1032		
		6858618	Dec 17, 2021	U-1807		
		6858618	Dec 17, 2021	U-618		
		6858618*PED	Jun 17, 2022			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366	005	6316460	Aug 04, 2020	DP		ODE-118 May 27, 2023
		6858618	Dec 17, 2021	U-618		
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647	001	10413543	Feb 12, 2036	DP		
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647	002	10413543	Feb 12, 2036	DP		
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647	003	10413543	Feb 12, 2036	DP		
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647	004	10413543	Feb 12, 2036	DP		
<u>ROTIGOTINE - NEUPRO</u>						
N 021829	001	10130589	Dec 22, 2030	DP		
		10350174	Dec 22, 2030	DP		
		6699498	Nov 27, 2020	DP		
		6884434	Mar 30, 2021	DP		
		8246979	Sep 01, 2027	DP	U-1272	
		8246979	Sep 01, 2027	DP	U-1273	
		8246980	Nov 27, 2025	DP		
		8617591	Jul 22, 2023	DP	U-1474	
		9925150	Mar 01, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	8246979	Sep 01, 2027	DP	U-1272		
	8246979	Sep 01, 2027	DP	U-1273		
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP	U-1474		
	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024		U-2012		
	7351701	Jul 23, 2024		U-2101		
	7351701	Jul 23, 2024		U-2273		
	7531530	Jul 23, 2024		U-2012		
	7531530	Jul 23, 2024		U-2101		
	7531530	Jul 23, 2024		U-2273		
	8071579	Aug 12, 2027		U-2012		
	8071579	Aug 12, 2027		U-2101		
	8071579	Aug 12, 2027		U-2273		
	8143241	Aug 12, 2027		U-2012		
	8143241	Aug 12, 2027		U-2101		
	8143241	Aug 12, 2027		U-2273		
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031		U-2012		
	8859562	Aug 04, 2031		U-2101		
	8859562	Aug 04, 2031		U-2273		
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031		U-2012		
	9861638	Feb 10, 2031		U-2101		
	9861638	Feb 10, 2031		U-2273		
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10130636	Aug 17, 2035		U-2012	I-772	Apr 06, 2021
	10130636	Aug 17, 2035		U-2101	NCE	Dec 19, 2021
	10130636	Aug 17, 2035		U-2273	ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024		U-2012		
	7351701	Jul 23, 2024		U-2101		
	7351701	Jul 23, 2024		U-2273		
	7531530	Jul 23, 2024		U-2012		
	7531530	Jul 23, 2024		U-2101		
	7531530	Jul 23, 2024		U-2273		
	8071579	Aug 12, 2027		U-2012		
	8071579	Aug 12, 2027		U-2101		
	8071579	Aug 12, 2027		U-2273		
	8143241	Aug 12, 2027		U-2012		
	8143241	Aug 12, 2027		U-2101		
	8143241	Aug 12, 2027		U-2273		
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031		U-2012		
	8859562	Aug 04, 2031		U-2101		
	8859562	Aug 04, 2031		U-2273		
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031		U-2012		
	9861638	Feb 10, 2031		U-2101		
	9861638	Feb 10, 2031		U-2273		
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10130636	Aug 17, 2035		U-2012	I-772	Apr 06, 2021
	10130636	Aug 17, 2035		U-2101	NCE	Dec 19, 2021
	10130636	Aug 17, 2035		U-2273	ODE-126	Dec 19, 2023
	10278974	Feb 10, 2031	DP		ODE-168	Apr 06, 2025
	6495541	Jan 10, 2021	DS DP			
	7351701	Jul 23, 2024		U-2012		
	7351701	Jul 23, 2024		U-2101		
	7351701	Jul 23, 2024		U-2273		
	7531530	Jul 23, 2024		U-2012		
	7531530	Jul 23, 2024		U-2101		
	7531530	Jul 23, 2024		U-2273		
	8071579	Aug 12, 2027		U-2012		
	8071579	Aug 12, 2027		U-2101		
	8071579	Aug 12, 2027		U-2273		
	8143241	Aug 12, 2027		U-2012		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003	8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2273		
		8754072	Feb 10, 2031	DS DP		
		8859562	Aug 04, 2031	U-2012		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2273		
		9045487	Feb 10, 2031	DS DP		
		9861638	Feb 10, 2031	U-2012		
		9861638	Feb 10, 2031	U-2101		
		9861638	Feb 10, 2031	U-2273		
		9987285	Aug 17, 2035	DP		
<u>RUFINAMIDE - BANZEL</u>						
N 021911	001	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 021911	002	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 021911	003	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUFINAMIDE - BANZEL</u>						
N 201367	001	6740669	Nov 14, 2022	DS DP		
		6740669*PED	May 14, 2023			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	10016429	Jun 12, 2028	U-2536	I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201	ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622	ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP		
		8722693	Jun 12, 2028	DS DP		
		8822481	Jun 12, 2028	U-1573		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
		9814722	Dec 12, 2026	U-2536		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	10016429	Jun 12, 2028	U-2536	I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201	ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622	ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP		
		8722693	Jun 12, 2028	DS DP		
		8822481	Jun 12, 2028	U-1573		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
		9814722	Dec 12, 2026	U-2536		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	10016429	Jun 12, 2028	U-2536	I-799	May 24, 2022
		7598257	Dec 24, 2027	DS DP U-1201	ODE-238	May 24, 2026
		7598257	Dec 24, 2027	DS DP U-1622	ODE-79	Dec 04, 2021
		8415362	Dec 24, 2027	DS DP		
		8722693	Jun 12, 2028	DS DP		
		8822481	Jun 12, 2028	U-1573		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		9079912	Dec 12, 2026	U-1573		
		9079912	Dec 12, 2026	U-1721		
		9814722	Dec 12, 2026	U-2536		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028		U-2536	I-799	May 24, 2022
	7598257	Dec 24, 2027	DS DP	U-1201	ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP	U-1622	ODE-79	Dec 04, 2021
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9814722	Dec 12, 2026		U-2536		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028		U-2536	I-799	May 24, 2022
	7598257	Dec 24, 2027	DS DP	U-1201	ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP	U-1622	ODE-79	Dec 04, 2021
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
	9814722	Dec 12, 2026		U-2536		
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9255261	Feb 07, 2034	DS DP			
	9469847	Feb 07, 2034	DS DP			
	9849161	Feb 07, 2034	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023		DP	NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023		DP	PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023		DP		
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026		U-1723		
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023		DP	NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023		DP	PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023		DP		
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026		U-1723		
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023		DP	NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023		DP	PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023		DP		
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023		U-1723		
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	003	9388134	Nov 08, 2026	U-1723		
		9388134*PED	May 08, 2027			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145	001	8076515	Dec 10, 2028	DS DP U-1993	NCE	Mar 21, 2022
		8278485	Jun 08, 2027	DS U-1993		
		8283380	Sep 01, 2027	U-1993		
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145	002	8076515	Dec 10, 2028	DS DP U-1993	NCE	Mar 21, 2022
		8278485	Jun 08, 2027	DS U-1993		
		8283380	Sep 01, 2027	U-1993		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001	7566462	Nov 16, 2025	DP		
		7566462*PED	May 16, 2026			
		7566714	Nov 17, 2024	U-989		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		7727987	Nov 17, 2024	DP		
		7727987*PED	May 17, 2025			
		7947681	Nov 17, 2024	U-1156	Y	
		7947681*PED	May 17, 2025			
		8003126	Nov 16, 2025			
		8003126*PED	May 16, 2026			
		8067416	Nov 17, 2024	U-989		
		8067416*PED	May 17, 2025			
		8318745	Nov 17, 2024	DP		
		8318745*PED	May 17, 2025			
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1156		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521	001	8318706	May 01, 2031	DS DP U-2405	NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406		
		9255068	Feb 09, 2033	DS DP U-2407		
		9255068	Feb 09, 2033	DS DP U-2408		
		9481639	Aug 10, 2028	U-2409		
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521	002	8318706	May 01, 2031	DS DP U-2405	NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406		
		9255068	Feb 09, 2033	DS DP U-2407		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 002	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 003	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	7951400	Nov 30, 2028	DP		M-198	Feb 27, 2020
	RE44186	Jul 31, 2023	DS DP U-1837			
	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	7951400	Nov 30, 2028	DP		M-198	Feb 27, 2020
	RE44186	Jul 31, 2023	DS DP U-1837			
	RE44186	Jul 31, 2023	DS DP U-995			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583		NCE GAIN	Sep 15, 2022 Sep 15, 2027
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	008	7205302	Apr 04, 2023	DS DP U-1797	NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP	ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798		
		9284280	Jun 25, 2030	U-1831		
<u>SELINEXOR - XPOVIO</u>						
N 212306	001	8999996	Sep 15, 2032	DS DP	NCE	Jul 03, 2024
		9079865	Jul 26, 2032	U-2584	ODE-257	Jul 03, 2026
		9714226	Jul 26, 2032	DS DP		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	10220155	Jul 17, 2026	DP	NCE	Dec 05, 2022
		10335462	Jun 21, 2033	U-2580		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8114833	Aug 13, 2025	DP		
		8129343	Jan 29, 2029	DS DP U-2202		
		8536122	Mar 20, 2026	DS DP U-2202		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	001	10086047	Dec 16, 2031	DP	NCE	Dec 05, 2022
		10278923	May 02, 2034	U-2628	NP	Sep 20, 2022
		8129343	Jan 29, 2029	DS DP U-2628		
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	002	10086047	Dec 16, 2031	DP	NCE	Dec 05, 2022
		10278923	May 02, 2034	U-2628	NP	Sep 20, 2022
		8129343	Jan 29, 2029	DS DP U-2628		
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003	10086047	Dec 16, 2031	DP	NCE	Dec 05, 2022
		10278923	May 02, 2034	U-2628	NP	Sep 20, 2022
		8129343	Jan 29, 2029	DS DP U-2628		
		8536122	Mar 20, 2026	DS DP U-2628		
		9278123	Dec 16, 2031	DP U-2628		
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990	001	7067555*PED	Apr 11, 2020			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127	001	7985418	Oct 27, 2025	DP		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	001	9095509	Dec 06, 2030	DP		
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318	002	9095509	Dec 06, 2030	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	001 6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179	002 6733780	Oct 18, 2020	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001 7671032	May 19, 2025	DS DP			
	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			
	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
	9040562	Jul 28, 2026	DS DP U-1467			
	9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
	9856265	Jul 28, 2026	DS DP U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	001 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	002 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	001 6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	002 6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	003 6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	004 6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	005 6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6699871	Jul 26, 2022	DS DP U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
	5795911	Oct 31, 2020	U-172			
	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE-92	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE-92	May 28, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOLE</u>						
N 201444	001	8496973	Mar 29, 2031	DS DP U-1419		
		8568793	Dec 24, 2031	DS DP		
		9345724	Mar 29, 2031	DS DP U-2015		
		9585912	Mar 29, 2031	DS DP		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196	001	10213400	Mar 15, 2033	U-2499	NPP	Oct 26, 2021
		6780889	Jul 04, 2020	DP	ODE-231	Oct 26, 2025
		6780889*PED	Jan 04, 2021		PED	Apr 26, 2022
		7262219	Jul 04, 2020	DP		
		7262219*PED	Jan 04, 2021			
		7668730	Jun 16, 2024	U-1110	Y	
		7668730*PED	Dec 16, 2024			
		7851506*PED	Jun 22, 2020			
		8263650*PED	Jun 22, 2020			
		8324275*PED	Jun 22, 2020			
		8731963	Dec 17, 2022	U-1110		
		8731963*PED	Jun 17, 2023			
		8772306	Mar 15, 2033	U-1532		
		8772306*PED	Sep 15, 2033			
		8859619*PED	Jun 22, 2020			
		8952062*PED	Jun 22, 2020			
		9050302	Mar 15, 2033	U-1532		
		9050302*PED	Sep 15, 2033			
		9486426	Mar 15, 2033	U-1532		
		9486426*PED	Sep 15, 2033			
		9539330*PED	Jun 22, 2020			
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892	001	7687075	Jun 22, 2028	DS DP		
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923	001	8496973	Mar 29, 2031	DS DP U-1419		
		9345724	Mar 29, 2031	DS DP U-2015		
		9585912	Mar 29, 2031	DS DP		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	001	10300087	Oct 14, 2035	DS	U-2312	NCE May 18, 2023
		10335432	Feb 10, 2032		U-2312	
		10398730	Feb 10, 2032		U-2312	
		10413569	Feb 10, 2032	DS		
		8802152	Apr 19, 2032	DS		
		8808750	Feb 10, 2032		U-2312	
		8877255	Oct 22, 2033	DS		
		9592253	Oct 14, 2035	DS	U-2312	
		9844567	Feb 10, 2032		U-2312	
		9861658	Feb 10, 2032		U-2312	
		9913860	Oct 22, 2033	DS	U-2312	
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	002	10300087	Oct 14, 2035	DS	U-2312	NCE May 18, 2023
		10398730	Feb 10, 2032		U-2312	
		10413569	Feb 10, 2032	DS		
		8802152	Apr 19, 2032	DS		
		8808750	Feb 10, 2032		U-2312	
		8877255	Oct 22, 2033	DS		
		9592253	Oct 14, 2035	DS	U-2312	
		9844567	Feb 10, 2032		U-2312	
		9861658	Feb 10, 2032		U-2312	
		9913860	Oct 22, 2033	DS	U-2312	
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	7964580	Mar 26, 2029	DS DP U-1470	NPP	Apr 07, 2020
		7964580*PED	Sep 26, 2029		ODE-135	Apr 07, 2024
		8334270	Mar 21, 2028	DS DP U-1470	PED	Oct 07, 2024
		8334270*PED	Sep 21, 2028			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSEBUVIR; VELPATASVIR - EPCUSA</u>						
N 208341 001	10086011	Jan 30, 2034		U-1470	D-177	Nov 15, 2022
	7964580	Mar 26, 2029	DS DP	U-1470	NCE	Jun 28, 2021
	7964580*PED	Sep 26, 2029			NPP	Aug 01, 2020
	8334270	Mar 21, 2028	DS DP	U-1470		
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP	U-1470		
	8580765	Mar 21, 2028	DS DP	U-1470		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-1470		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-1470		
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP	U-1470		
	8940718	Nov 16, 2032	DS DP	U-1470		
	9085573	Mar 21, 2028	DS DP	U-1470		
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP	U-1470		
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034		DP		
<u>SOFOSEBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP	U-2039	NCE	Jul 18, 2022
	7964580	Mar 26, 2029	DS DP	U-2040		
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP	U-2039		
	8334270	Mar 21, 2028	DS DP	U-2040		
	8334270*PED	Sep 21, 2028				
	8575135	Nov 05, 2033	DS DP	U-2039		
	8575135	Nov 05, 2033	DS DP	U-2040		
	8580765	Mar 21, 2028	DS DP	U-2039		
	8580765	Mar 21, 2028	DS DP	U-2040		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-2039		
	8618076	Dec 11, 2030	DS DP	U-2040		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-2039		
	8633309	Mar 26, 2029	DS DP	U-2040		
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP	U-2039		
	8735372	Mar 21, 2028	DS DP	U-2040		
	8889159	Mar 26, 2029	DS DP	U-2039		
	8889159	Mar 26, 2029	DS DP	U-2040		
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP	U-2039		
	8921341	Nov 16, 2032	DS DP	U-2040		
	8940718	Nov 16, 2032	DS DP	U-2039		
	8940718	Nov 16, 2032	DS DP	U-2040		
	9085573	Mar 21, 2028	DS DP	U-2039		
	9085573	Mar 21, 2028	DS DP	U-2040		
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP	U-2039		
	9284342	Sep 13, 2030	DS DP	U-2040		
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP	U-2039		
	9585906	Mar 21, 2028	DS DP	U-2040		
	9868745	Nov 16, 2032	DS DP			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037		DP	NCE	Jun 17, 2024
	10351517	Jun 07, 2026		U-2548	ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027		U-2548		
	8877806	Jun 07, 2026		U-2548		
	9604917	Jun 07, 2026		U-2548		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230	002	10195151	Sep 05, 2037	DP	NCE	Jun 17, 2024
		10351517	Jun 07, 2026	U-2548	ODE-254	Jun 17, 2026
		8440715	Aug 25, 2027	U-2548		
		8877806	Jun 07, 2026	U-2548		
		9604917	Jun 07, 2026	U-2548		
<u>SOMATROPIN - NORDITROPIN NORDIFLEX</u>						
N 021148	004	RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN - NORDITROPIN NORDIFLEX</u>						
N 021148	005	RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN - NORDITROPIN NORDIFLEX</u>						
N 021148	006	RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN - NORDITROPIN NORDIFLEX</u>						
N 021148	007	RE41956	Jan 21, 2021	DP		
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148	008	10220155	Jul 17, 2026	DP		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148	009	10220155	Jul 17, 2026	DP		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148	010	10220155	Jul 17, 2026	DP		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148	010	9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148	011	10220155	Jul 17, 2026	DP		
		10357616	Jan 20, 2026	DP		
		10376652	Jan 20, 2026	DP		
		6899699	Jan 02, 2022	DP		
		7762994	May 23, 2024	DP		
		8579869	Jun 30, 2023	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
		9616180	Jan 20, 2026	DP		
		9687611	Feb 27, 2027	DP		
		9775953	Jul 17, 2026	DP		
		9861757	Jan 20, 2026	DP		
		RE46363	Aug 03, 2026	DP		
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266	001	8063043	Sep 15, 2029	DS DP	NCE	Jul 24, 2020
		8178563	Feb 06, 2029	DS	U-1722	
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	7235576	Jan 12, 2020	DS DP	ODE-56	Nov 22, 2020
		7351834	Jan 12, 2020	DS		
		7897623	Jan 12, 2020	DP		
		8124630	Jan 12, 2020		U-1459	
		8618141	Feb 11, 2023		U-1480	
		8841330	Jan 12, 2020		U-1696	
		8877933	Dec 24, 2027	DS DP	U-1624	
		9737488	Sep 10, 2028	DP	U-1480	
		9737488	Sep 10, 2028	DP	U-1696	
		9737488	Sep 10, 2028	DP	U-2107	
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108	001	10206895	Apr 01, 2034	DP	U-2096	
		10206895	Apr 01, 2034	DP	U-2494	
		9724297	Aug 31, 2035	DP	U-2096	
<u>SPINOSAD - NATROBA</u>						
N 022408	001	6063771	Jul 25, 2023	DP	U-1670	
		7030095	Jul 02, 2021	DP	U-1105	
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478	001	10493083	Oct 28, 2036	DP		
		9757394	Oct 28, 2036	DP	U-2109	
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001	7135465	Feb 18, 2023	DP	U-167	
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002	7135465	Feb 18, 2023	DP	U-167	
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003	7135465	Feb 18, 2023	DP	U-167	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	001				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	002				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	001				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	002				NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001 6174442	Jun 12, 2020	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128	001 10245228	Jan 05, 2027	DP U-1351		NP	Nov 02, 2021
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001 10232061	Jul 06, 2038	DP		NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884	001 8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001 7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001	8267903	Mar 18, 2023	DP		
		8287489	Dec 06, 2024	DP		
		8343130	Oct 18, 2022	DP		
		8491524	Nov 21, 2022	DP		
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377	001	7811254	Aug 26, 2027	DP	U-1083	
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278	001	6745071	Feb 21, 2023	DP		
		7973058	Apr 12, 2027		U-1328	
		8155737	Apr 12, 2027		U-1328	
		8366600	Apr 21, 2029		U-1327	
		8470853	Apr 12, 2027		U-1328	
		8597272	Apr 12, 2027	DP		
		8983594	Nov 19, 2030	DP	U-1328	
		9272137	Sep 07, 2027	DP		
		9327114	Oct 08, 2032	DP	U-1328	
		9427578	Apr 12, 2027	DP	U-1328	
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001	10076614	Oct 20, 2034	DP		
		10076615	Jul 30, 2029		U-2010	
		10076615	Jul 30, 2029		U-2011	
		10076615	Jul 30, 2029		U-2404	
		10124132	Mar 06, 2027	DP	U-1719	
		10124132	Mar 06, 2027	DP	U-2010	
		10124132	Mar 06, 2027	DP	U-2011	
		10398859	Dec 19, 2027	DP		
		10478574	Nov 04, 2033		U-2404	
		6715485	Mar 03, 2020	DP		
		7975690	Aug 18, 2025	DP	U-1809	
		8047202	Jul 02, 2023	DP		
		8327844	Oct 03, 2023		U-1809	
		8550073	Oct 22, 2029	DP		
		8555877	Mar 03, 2020	DP		
		8590530	Sep 15, 2025	DP	U-1809	
		8875704	Apr 07, 2028	DP	U-1809	
		8899229	Aug 18, 2030	DP		
		8978647	Dec 06, 2030	DP		
		9108015	Sep 15, 2025	DP		
		9119932	Apr 23, 2024	DP		
		9649456	Oct 21, 2030	DP	U-1719	
		9649456	Oct 21, 2030	DP	U-2010	
		9649456	Oct 21, 2030	DP	U-2011	
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	001	6573293	Feb 15, 2021	DS DP	U-1154	I-755
		6573293	Feb 15, 2021	DS DP	U-2171	PED
		6573293*PED	Aug 15, 2021			Nov 16, 2020
		7125905	Feb 15, 2021	DS DP		May 16, 2021
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020		U-883	
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	002	6573293	Feb 15, 2021	DS DP	U-1154	I-755
		6573293	Feb 15, 2021	DS DP	U-2171	PED
		6573293*PED	Aug 15, 2021			Nov 16, 2020
		7125905	Feb 15, 2021	DS DP		May 16, 2021
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020		U-883	
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003	6573293	Feb 15, 2021	DS DP	U-1154	I-755
		6573293	Feb 15, 2021	DS DP	U-2171	PED
		6573293*PED	Aug 15, 2021			Nov 16, 2020
		7125905	Feb 15, 2021	DS DP		May 16, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003	7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	004	6573293	Feb 15, 2021	DS DP U-1154	I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171	PED	May 16, 2021
		6573293*PED	Aug 15, 2021			
		7125905	Feb 15, 2021	DS DP		
		7125905*PED	Aug 15, 2021			
		7211600	Dec 22, 2020	U-883		
		7211600*PED	Jun 22, 2021			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001	10098892	May 29, 2033	DP		
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002	10098892	May 29, 2033	DP		
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003	10098892	May 29, 2033	DP		
		7951797	Nov 20, 2029	DS DP U-620		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004	10098892	May 29, 2033	DP		
		7951797	Nov 20, 2029	DS DP U-620		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	001	10166190	May 30, 2028	DP	ODE-94	Jul 10, 2022
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8644239	Aug 30, 2028	DP U-2677		
		8644239	Aug 30, 2028	DP U-2678		
		8664239	May 30, 2028	U-1752		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
		9549918	May 30, 2028	DP		
		9757362	Aug 30, 2024	DP		
		9763920	Aug 30, 2024	DP		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	002	10166190	May 30, 2028	DP	ODE-94	Jul 10, 2022
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8644239	Aug 30, 2028	DP U-2677		
		8644239	Aug 30, 2028	DP U-2678		
		8664239	May 30, 2028	U-1752		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP	U-1752		
	8586084	Aug 30, 2024		U-1752		
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024		U-1752		
	8644239	Aug 30, 2028	DP	U-2677		
	8644239	Aug 30, 2028	DP	U-2678		
	8664239	May 30, 2028		U-1752		
	8685998	Aug 30, 2028	DP	U-1752		
	8685998	Aug 30, 2028	DP	U-2677		
	8685998	Aug 30, 2028	DP	U-2678		
	8889185	Aug 30, 2024		U-1752		
	8889186	Aug 30, 2024		U-1752		
	9161907	Aug 30, 2024	DP	U-1752		
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-269	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-269	May 24, 2025
<u>TADALAFIL - CIALIS</u>						
N 021368 001	6943166	Apr 26, 2020		U-1184	M-219	Feb 15, 2021
	6943166	Apr 26, 2020		U-155	PED	Aug 15, 2021
	6943166	Apr 26, 2020		U-614		
	6943166*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	6943166	Apr 26, 2020		U-155	M-219	Feb 15, 2021
	6943166	Apr 26, 2020		U-614	PED	Aug 15, 2021
	6943166*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	6943166	Apr 26, 2020		U-614	M-219	Feb 15, 2021
	6943166*PED	Oct 26, 2020			PED	Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 004	6943166	Apr 26, 2020		U-155	M-219	Feb 15, 2021
	6943166*PED	Oct 26, 2020			PED	Aug 15, 2021
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023		U-2524	ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP	U-2524		
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023		U-2524	ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024		U-2524		
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035		U-2582	NCE NP	Jul 20, 2023 Aug 08, 2021
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795 001					NCE ODE-201	Jul 20, 2023 Jul 20, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>T AFLUPROST - ZIOPTAN</u>						
N 202514	001	5886035	Dec 18, 2022	DS DP U-778		
		9999593	May 28, 2029	DP		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651	001	10189837	Oct 20, 2031	DS DP	NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP		
		8420650	Jul 27, 2029	DS DP		
		8735392	Oct 20, 2031	DS DP		
		9820985	Jul 27, 2029	U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651	002	10189837	Oct 20, 2031	DS DP	NCE	Oct 16, 2023
		8012976	Oct 19, 2029	DS DP		
		8420650	Jul 27, 2029	DS DP		
		8735392	Oct 20, 2031	DS DP		
		9820985	Jul 27, 2029	U-2437		
<u>TALC - STERITALC</u>						
N 205555	001				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	002				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	003				ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458	001	8227230	Feb 24, 2024	DS DP		
		8741620	Feb 24, 2024	DS DP		
		8790641	Oct 18, 2025	U-1564		
		8790641	Oct 18, 2025	U-1574		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	001	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	002	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	003	7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	001	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	002	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	002	RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	003	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	004	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	005	7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 203794	001	7994364	Jun 27, 2025	DS DP U-1289		
		RE39593	Aug 05, 2022	DS DP U-1289		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	10071977	Feb 12, 2035	DS DP	ODE-59	Jan 31, 2021
		10149829	Jan 25, 2033	U-2477		
		10376487	Jul 27, 2035	U-2615		
		10449176	Jan 25, 2033	U-2149		
		5856529	Dec 09, 2022	DS DP U-2149		
		9060995	Jan 25, 2033	U-1710		
		9539234	Jan 25, 2033	U-1934		
		9549913	Jan 25, 2033	U-1486		
		9730910	May 17, 2034	U-2085		
		9855241	Jan 25, 2033	U-2149		
		RE46604	Jan 25, 2033	U-2147		
<u>TAVABOROLE - KERIDIN</u>						
N 204427	001	7582621	May 26, 2027	U-2016	Y	
		7582621*PED	Nov 26, 2027			
		9549938	Feb 16, 2026	U-1951		
		9549938*PED	Aug 16, 2026			
		9566289	Feb 16, 2026	DP		
		9566289*PED	Aug 16, 2026			
		9566290	Feb 16, 2026	U-1970		
		9566290*PED	Aug 16, 2026			
		9572823	Feb 16, 2026	U-1970		
		9572823*PED	Aug 16, 2026			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZAROTENE - FABIOR</u>						
N 202428	001 8808716	Feb 24, 2030	DP			
<u>TAZAROTENE - ARAZLO</u>						
N 211882	001 6517847	Aug 03, 2020	DP U-2368		NP	Dec 18, 2022
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVUE 30ML</u>						
N 020372	002 9549999	Mar 10, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001 6409990	May 12, 2020	DS		ODE-67	Jun 13, 2021
	9439985	Sep 27, 2033	DS DP			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627	001 7737168	May 03, 2027		U-2346	NCE	Jul 13, 2023
	8039504	Jul 23, 2027		DP	ODE-200	Jul 13, 2025
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024		DP		
	8802714	Jun 18, 2024		U-2346		
	9339466	Mar 23, 2031	DS DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001 10065947	Feb 03, 2030		DP	NCE	Jun 20, 2019
	10442829	Feb 03, 2030		DS	GAIN	Jun 20, 2024
	7816379	Feb 23, 2028	DS DP	U-282		
	8420676	Feb 23, 2028	DS DP	U-282		
	8426389	Dec 31, 2030	DS DP	U-282		
	9624250	Feb 03, 2030	DS DP	U-2507		
	9988406	Feb 03, 2030		DP		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001 10065947	Feb 03, 2030		DP	NCE	Jun 20, 2019
	10442829	Feb 03, 2030		DS	GAIN	Jun 20, 2024
	7816379	Feb 23, 2028	DS DP	U-282		
	8420676	Feb 23, 2028	DS DP	U-282		
	8426389	Dec 31, 2030	DS DP	U-282		
	9624250	Feb 03, 2030	DS DP	U-2507		
	9988406	Feb 03, 2030		DP		
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001 5789379	Apr 14, 2020	DS DP	U-1320	ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020				
	7056886	Sep 18, 2022		DP U-1320		
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025		U-1320		
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025		U-1320		
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025		U-1320		
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025		U-1320		
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025		U-1320		
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025		U-1320		
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025		U-1320		
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025		U-1320		
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025		U-1320		
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025		U-2308		
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025		U-2308		
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025		U-1320		
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025		U-1320		
	9974835*PED	May 01, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001	9974837	Nov 01, 2025	U-1320		
		9974837*PED	May 01, 2026			
		9981014	Nov 01, 2025	U-1320		
		9981014*PED	May 01, 2026			
		9981016	Nov 01, 2025	U-1320		
		9981016*PED	May 01, 2026			
		9987334	Nov 01, 2025	U-1320		
		9987334*PED	May 01, 2026			
		9987335	Nov 01, 2025	U-1320		
		9987335*PED	May 01, 2026			
		9993528	Nov 01, 2025	U-1320		
		9993528*PED	May 01, 2026			
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001	7820671	Feb 25, 2025	DS DP		
		8431615	May 30, 2028	U-1398		
		8529882	Aug 31, 2021	U-1398		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001	6635618	Sep 11, 2023	DS DP	U-728	
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021		U-1005	
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP	U-728	
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021		U-282	
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002	6635618	Sep 11, 2023	DS DP	U-728	
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021		U-1005	
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP	U-728	
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021		U-282	
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELBIVUDINE - TYZKA</u>						
N 022011	001	6569837	Oct 25, 2020		U-782	
		6569837	Oct 25, 2020		U-999	
		7589079	Sep 11, 2023	DS DP	U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELBIVUDINE - TYZKA</u>						
N 022154	001	6569837	Oct 25, 2020		U-999	
		7858594	Sep 11, 2023	DS DP	U-999	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	001	6358986	Jan 10, 2020			
<u>TELMISARTAN - MICARDIS</u>						
N 020850	002	6358986	Jan 10, 2020			
		7998953	Jun 06, 2020		U-1177	
		8003679	Oct 06, 2022		U-1176	
<u>TELMISARTAN - MICARDIS</u>						
N 020850	003	6358986	Jan 10, 2020			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794	001	7553840	Dec 11, 2027	DS	NCE	Feb 28, 2022
		7709493	Dec 11, 2027	DS	U-1979	Feb 28, 2024
		7968559	Dec 11, 2027		ODE-132	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794	001	8193204	Feb 27, 2031	DS		
		8653094	Dec 19, 2028		U-1979	
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	6987108	Sep 08, 2023	DP		
		7786118	Feb 21, 2023	DP		
		8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	8026276	Jan 20, 2026	DP		
		8299116	Jul 25, 2023	DP		
		8455539	Jul 25, 2023	DP		
		8455539*PED	Jan 25, 2024			
		8722700	Jul 25, 2023	DP		
		8722700*PED	Jan 25, 2024			
		8791097	May 10, 2032		U-1550	
		8791097	May 10, 2032		U-1551	
		8791097*PED	Nov 10, 2032			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801	001	8541448	Dec 30, 2029	DS DP		NCE Sep 12, 2024
		8969377	Dec 30, 2029	DS DP		
		9006281	May 02, 2030		U-2626	
		9408840	Dec 30, 2029		U-2626	
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464	001	7390791	May 07, 2022	DS DP		NCE Nov 05, 2020
		7803788	Feb 02, 2022		U-999	
		8754065	Aug 15, 2032	DS DP	U-999	
		9296769	Aug 15, 2032	DS DP	U-999	
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	001					NPP Dec 11, 2021
						PED Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	002					NPP Dec 11, 2021
						PED Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	003					NPP Dec 11, 2021
						PED Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	004					NPP Dec 11, 2021
						PED Jun 11, 2022
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577	001					NPP Dec 11, 2021
						PED Jun 11, 2022
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992	001	6794410	Sep 12, 2026		U-1285	
		8802735	Sep 14, 2030	DP		
		9186346	Feb 04, 2034		U-1786	
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992	002	6794410	Sep 12, 2026		U-1285	
		8802735	Sep 14, 2030	DP		
		9186346	Feb 04, 2034		U-1786	
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318	001	7517334	Mar 25, 2025	DP		
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318	002	7517334	Mar 25, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
	8314066	Aug 14, 2023	U-1100			
	8435945	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 002	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
	8314066	Aug 14, 2023	U-1100			
	8435945	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP			
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	Feb 27, 2026	U-1500			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	6315720	Oct 23, 2020		U-442		
	6315720	Oct 23, 2020		U-731		
	6561977	Oct 23, 2020		U-371		
	6561977	Oct 23, 2020		U-731		
	6755784	Oct 23, 2020		U-371		
	6755784	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-732		
	6869399	Oct 23, 2020		U-733		
	7141018	Oct 23, 2020		U-371		
	7141018	Oct 23, 2020		U-731		
	7141018	Oct 23, 2020		U-732		
	7141018	Oct 23, 2020		U-733		
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020		U-1155		
	8315886	Oct 23, 2020		U-1249		
	8626531	Oct 23, 2020		U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6315720	Oct 23, 2020		U-442		
	6315720	Oct 23, 2020		U-731		
	6561977	Oct 23, 2020		U-371		
	6561977	Oct 23, 2020		U-731		
	6755784	Oct 23, 2020		U-371		
	6755784	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-732		
	6869399	Oct 23, 2020		U-733		
	7141018	Oct 23, 2020		U-371		
	7141018	Oct 23, 2020		U-731		
	7141018	Oct 23, 2020		U-732		
	7141018	Oct 23, 2020		U-733		
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020		U-1155		
	8315886	Oct 23, 2020		U-1249		
	8626531	Oct 23, 2020		U-1465		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	6315720	Oct 23, 2020		U-442		
	6315720	Oct 23, 2020		U-731		
	6561977	Oct 23, 2020		U-371		
	6561977	Oct 23, 2020		U-731		
	6755784	Oct 23, 2020		U-371		
	6755784	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-732		
	6869399	Oct 23, 2020		U-733		
	7141018	Oct 23, 2020		U-371		
	7141018	Oct 23, 2020		U-731		
	7141018	Oct 23, 2020		U-732		
	7141018	Oct 23, 2020		U-733		
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020		U-1155		
	8315886	Oct 23, 2020		U-1249		
	8626531	Oct 23, 2020		U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	6315720	Oct 23, 2020		U-731		
	6561977	Oct 23, 2020		U-731		
	6755784	Oct 23, 2020		U-731		
	6869399	Oct 23, 2020		U-731		
	7141018	Oct 23, 2020		U-731		
	7959566	Oct 23, 2020		U-1155		
	8315886	Oct 23, 2020		U-1249		
	8626531	Oct 23, 2020		U-1465		
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE-129	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE-129	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036		U-2541		
	10300065	Jan 27, 2036		U-2542		
	7265124	Jul 09, 2021	DS DP	U-1171		
	7265124	Jul 09, 2021	DS DP	U-1860		
	7265124	Jul 09, 2021	DS DP	U-1868		
	7265124	Jul 09, 2021	DS DP	U-1869		
	8425934	Apr 17, 2030		DP		
	RE46276	Oct 30, 2024	DS DP	U-1935		
	RE46276	Oct 30, 2024	DS DP	U-1936		
	RE46276	Oct 30, 2024	DS DP	U-1937		
	RE46276	Oct 30, 2024	DS DP	U-1938		
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036		U-2541		
	10300065	Jan 27, 2036		U-2542		
	7265124	Jul 09, 2021	DS DP	U-1171		
	7265124	Jul 09, 2021	DS DP	U-1860		
	7265124	Jul 09, 2021	DS DP	U-1868		
	7265124	Jul 09, 2021	DS DP	U-1869		
	8425934	Apr 17, 2030		DP		
	RE46276	Oct 30, 2024	DS DP	U-1935		
	RE46276	Oct 30, 2024	DS DP	U-1936		
	RE46276	Oct 30, 2024	DS DP	U-1937		
	RE46276	Oct 30, 2024	DS DP	U-1938		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	7879828	Feb 05, 2029		DP		
	8372995	Oct 08, 2030		DP		
	8975242	Oct 24, 2028		DP		
	9254328	Mar 13, 2026		DP		
	9694078	Mar 13, 2026		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	8975242	Oct 24, 2028	DP			
	9254328	Mar 13, 2026	DP			
	9694078	Mar 13, 2026	DP			
<u>TIGECYCLINE - TIGECYCLINE</u>						
N 211158 001	9855335	Apr 07, 2033	DP			
<u>TIOPRONIN - THIOLA</u>						
N 019569 001					ODE-267	Jun 28, 2026
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	6988496	Feb 23, 2020	DP		NPP	Feb 15, 2020
	6988496*PED	Aug 23, 2020			PED	Aug 15, 2020
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	6988496	Feb 23, 2020	DP		NPP	Feb 15, 2020
	6988496*PED	Aug 23, 2020			PED	Aug 15, 2020
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	001	10456399				
		Feb 03, 2037		U-2642	I-794	Feb 22, 2022
		10457666			NCE	Sep 22, 2020
		6479500		DS DP	ODE-229	Feb 22, 2026
		9527833		U-1751		
		Jun 17, 2034		DS DP		
		RE46284		U-1751		
		Dec 16, 2026		U-2503		
		RE46284		U-2503		
		Dec 16, 2026				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	002	10456399				
		Feb 03, 2037		U-2642	I-794	Feb 22, 2022
		10457666			NCE	Sep 22, 2020
		6479500		DS DP	ODE-229	Feb 22, 2026
		9527833		U-1751		
		Jun 17, 2034		DS DP		
		RE46284		U-1751		
		Dec 16, 2026		U-2503		
		RE46284		U-2503		
		Dec 16, 2026				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	001	6770660				
		May 01, 2023		U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	002	6770660				
		May 01, 2023		U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	001	6770660				
		May 01, 2023		U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	002	6770660				
		May 01, 2023		U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	003	6770660				
		May 01, 2023		U-1444		
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688	001	10207066				
		Nov 04, 2030		DP U-909		
		7368102		DP U-909		
		Dec 19, 2022		DP		
		7442388		DP		
		May 10, 2020		DP		
		7516741		DP		
		Jan 11, 2024		DP		
		7559325		DP		
		Oct 27, 2025		DP		
		8069851		DP		
		Sep 24, 2024		DP		
		8349294		DP		
		May 10, 2020		U-909		
		8664187		DP U-909		
		Jun 20, 2025		DP U-909		
		8715623		DP U-909		
		Dec 19, 2022		DP U-909		
		8869794		DP U-909		
		Sep 12, 2028		DP U-909		
		9421166		DP U-909		
		Dec 19, 2022				
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820	001	6987094				
		Sep 22, 2022		DP		
		7696178		DP		
		Sep 22, 2022		U-1324		
		7939502				
		Jun 14, 2022				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001	6956041				
		Dec 08, 2020		DP	I-761	Dec 14, 2020
		6965027		DS	I-780	May 30, 2021
		Mar 25, 2023		U-247		
		7091208		DS		
		Dec 08, 2020		DS		
		7265221		DS		
		Dec 08, 2020		U-2322		
		7301023		DS		
		May 23, 2022		DS		
		7842699		U-2322		
		Dec 08, 2020		DS		
		RE41783		DS		
		Dec 08, 2025				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	002	6956041				
		Dec 08, 2020		DP	I-780	May 30, 2021
		6965027		DS		
		Mar 25, 2023		DS		
		7265221		DS		
		Dec 08, 2020		U-2322		
		7301023		DS		
		May 23, 2022		DS		
		7842699		U-2322		
		Dec 08, 2020		DS		
		RE41783		DS		
		Dec 08, 2025				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	6956041				
		Dec 08, 2020		DP	I-761	Dec 14, 2020
		6965027		DS		
		Mar 25, 2023		U-247		
		7091208		DS		
		Dec 08, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	7842699	Dec 08, 2020		U-2322		
	9937181	Mar 14, 2034	DP			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	6956041	Dec 08, 2020	DP			
	6965027	Mar 25, 2023	DS			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	7842699	Dec 08, 2020		U-2322		
	RE41783	Dec 08, 2025	DS			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	5753677	May 19, 2020		U-2307	I-779	Apr 23, 2021
	8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP	U-1675		
	10314790	Nov 16, 2027	DP	U-1992		
	8298576	Apr 04, 2028	DP	U-106		
	8298576	Apr 04, 2028	DP	U-1992		
	8298580	Nov 16, 2027	DP	U-106		
	8298580	Nov 16, 2027	DP	U-1992		
	8663683	Nov 16, 2027	DP	U-106		
	8663683	Nov 16, 2027	DP	U-1992		
	8877248	Nov 16, 2027	DP	U-106		
	8877248	Nov 16, 2027	DP	U-1992		
	8889191	Nov 16, 2027		U-106		
	8889191	Nov 16, 2027		U-1992		
	8992989	Nov 16, 2027	DP	U-1675		
	8992989	Nov 16, 2027	DP	U-1992		
	9549940	Nov 16, 2027	DP	U-1675		
	9549940	Nov 16, 2027	DP	U-1992		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
		8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
		8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		
		9622983	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
		8298576	Apr 04, 2028	DP U-106		
		8298576	Apr 04, 2028	DP U-1992		
		8298580	Nov 16, 2027	DP U-106		
		8298580	Nov 16, 2027	DP U-1992		
		8663683	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-1992		
		8877248	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-1992		
		8889191	Nov 16, 2027	U-106		
		8889191	Nov 16, 2027	U-1992		
		8992989	Nov 16, 2027	DP U-1675		
		8992989	Nov 16, 2027	DP U-1992		
		9549940	Nov 16, 2027	DP U-1675		
		9549940	Nov 16, 2027	DP U-1992		
		9555004	Nov 16, 2027	DP U-1675		
		9555004	Nov 16, 2027	DP U-1992		
		9622983	Nov 16, 2027	DP U-1675		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004 9622983	Nov 16, 2027	DP	U-1992		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001 10363224	Mar 19, 2033		U-766		
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002 10363224	Mar 19, 2033		U-766		
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003 10363224	Mar 19, 2033		U-766		
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004 10363224	Mar 19, 2033		U-766		
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005 10363224	Mar 19, 2033		U-766		
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	001 8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	002 8158645	Dec 10, 2024	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953	001 8895557	Jan 07, 2028	DP		M-232	Jun 29, 2021
	8895557*PED	Jul 07, 2028			NCE	Oct 23, 2020
					ODE-100	Oct 23, 2022
					PED	Apr 23, 2021
					PED	Dec 29, 2021
					PED	Apr 23, 2023
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	001 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	002 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	003 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	001 7858118	Apr 11, 2022	DP	U-1104		
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	002 7858118	Apr 11, 2022	DP	U-1104		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	003 7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001 7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
	8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
	8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
	8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
	8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
	8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
	8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002 7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
	8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
	8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
	8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
	8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
	8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
	8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003 7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
	8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
	8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
	8703781	Oct 15, 2030	DS DP U-2020		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2037		ODE-148	Jun 22, 2024
	8703781	Oct 15, 2030	DS DP U-2302		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-2305		ODE-183	May 04, 2025
	8835443	Jun 10, 2025	U-1581		ODE-48	May 29, 2020
	8835443	Jun 10, 2025	U-1582		ODE-57	Jan 08, 2021
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430	001 7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994	001	8268299				
		Oct 13, 2029	DP			
		8323630				
		Sep 20, 2027	DP			
		8388941				
		Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822	001	8178582				
		Oct 10, 2029	DP			
		8722735				
		Oct 10, 2029	DP			
		8754123				
		May 19, 2029	DP			
		9144561				
		Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	001	8133893				
		Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	002	8133893				
		Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	003	8133893				
		Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207	004	8133893				
		Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	001	6607748				
		Jun 29, 2020	DP			
		7829120				
		Mar 27, 2027	DP U-796			
		8133893				
		Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411	002	6607748				
		Jun 29, 2020	DP			
		7829120				
		Mar 27, 2027	DP U-796			
		8133893				
		Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	001	10076505				
		Dec 16, 2024	DP			
		7999007				
		Mar 29, 2029	DP U-1437			
		8653137				
		Sep 05, 2028	U-1437			
		8658694				
		Sep 05, 2028	U-1437			
		9199908				
		May 24, 2024	U-1771			
		9593066				
		Dec 15, 2028	DS			
		9604901				
		Dec 15, 2028	DS			
		9713599				
		Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	002	10076505				
		Dec 16, 2024	DP			
		7999007				
		Mar 29, 2029	DP U-1437			
		8653137				
		Sep 05, 2028	U-1437			
		8658694				
		Sep 05, 2028	U-1437			
		9199908				
		May 24, 2024	U-1771			
		9593066				
		Dec 15, 2028	DS			
		9604901				
		Dec 15, 2028	DS			
		9713599				
		Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	003	10076505				
		Dec 16, 2024	DP			
		7999007				
		Mar 29, 2029	DP U-1437			
		8653137				
		Sep 05, 2028	U-1437			
		8658694				
		Sep 05, 2028	U-1437			
		9199908				
		May 24, 2024	U-1771			
		9593066				
		Dec 15, 2028	DS			
		9604901				
		Dec 15, 2028	DS			
		9713599				
		Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272	004	10076505				
		Dec 16, 2024	DP			
		7999007				
		Mar 29, 2029	DP U-1437			
		8653137				
		Sep 05, 2028	U-1437			
		8658694				
		Sep 05, 2028	U-1437			
		9199908				
		May 24, 2024	U-1771			
		9593066				
		Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS	Y		
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028		U-1849		
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 001	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 002	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 003	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 004	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024		U-1475	ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024		U-1475	ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024		U-1475	ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8497393	Dec 15, 2028	DS	Y		
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024		U-1475	ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024		U-1475	ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP	U-2368	NDF	Aug 23, 2021
<u>TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE</u>						
A 212384 001					CGT	May 30, 2020
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		
	8211880	Mar 10, 2029		U-1258		
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	8828440	Aug 04, 2031	DP		NP	Oct 06, 2020
	9555048	Aug 04, 2031		U-2151		
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE	Feb 13, 2024
					ODE-228	Feb 13, 2026
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
	8227507	Dec 21, 2025		U-818		
	8470871	Dec 21, 2025		U-2639		
	9084778	May 30, 2033	DP	U-134		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437	001 10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956	001 10166181	Feb 10, 2029	DP		NP ODE-149	Jun 29, 2020 Jun 29, 2024
<u>UBROGEPANT - UBRELVY</u>						
N 211765	001				NCE	Dec 23, 2024
<u>UBROGEPANT - UBRELVY</u>						
N 211765	002				NCE	Dec 23, 2024
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001 10159681	Apr 13, 2030		U-2510		
	8426392	Jun 12, 2030		U-1389		
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030		U-1657		
	9283233	Apr 13, 2030		U-1821		
	9844510	Dec 08, 2028	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001 7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025		U-1476		
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025		U-1476		
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001 7439393	May 21, 2025	DS DP	U-1476	M-245	Jun 09, 2022
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025		U-1476		
	8309572	Apr 27, 2025		U-1476		
	8511304	Jun 14, 2027	DP	U-1476		
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP	U-1476		
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214	001 6458836	Jul 09, 2021		U-1315		
	6458836	Jul 09, 2021		U-333		
<u>UPADACITINIB - RINVOO</u>						
N 211675	001 8962629	Jan 15, 2031	DS	U-2616	NCE	Aug 16, 2024
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159	001 6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
	7776838	Aug 17, 2027		U-1791	ODE-104	Dec 11, 2022
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169	001 6258795	Jul 10, 2023	DP		NCE	Sep 04, 2020
					ODE-98	Sep 04, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241	001	10065952	Oct 28, 2036	DS DP U-1995	NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP		
		8357697	Nov 08, 2027	U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241	002	10065952	Oct 28, 2036	DS DP U-1995	NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP		
		8357697	Nov 08, 2027	U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257	001	8889109	Dec 11, 2027	DP		
		9642911	Dec 11, 2027	DP		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910	001	10493028	Mar 13, 2035	DP		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910	002	10493028	Mar 13, 2035	DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	001	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	002	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	003	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	004	10039804	Nov 06, 2035	DP U-282		
		10188697	Nov 06, 2035	DP U-282		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	001	7173038	Aug 14, 2021	DS DP		
		8067427	Aug 08, 2028	DP		
		8642608	Feb 06, 2022	U-1490		
		RE42353	Jun 27, 2022	DS DP		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	002	7173038	Aug 14, 2021	DS DP		
		8067427	Aug 08, 2028	DP		
		8642608	Feb 06, 2022	U-1490		
		RE42353	Jun 27, 2022	DS DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	001	8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	002	8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	003	8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400	004	8273876	Jul 23, 2027	U-1288		
		8841446	Jul 03, 2023	DP		
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179	001	8613950	Dec 23, 2028	DP		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6410550	May 10, 2020	DS DP U-56	M-237	Feb 22, 2022
		6410550*PED	Nov 10, 2020		PED	Aug 22, 2022
		6890927	May 06, 2022	DS DP U-56		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6890927*PED	Nov 06, 2022			
		7265119	Aug 03, 2022	DS DP	U-56	
		7265119*PED	Feb 03, 2023			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002	6410550	May 10, 2020	DS DP	U-56	
		6410550*PED	Nov 10, 2020			M-237 PED Feb 22, 2022 Aug 22, 2022
		6890927	May 06, 2022	DS DP	U-56	
		6890927*PED	Nov 06, 2022			
		7265119	Aug 03, 2022	DS DP	U-56	
		7265119*PED	Feb 03, 2023			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	001	9375478	Jan 30, 2035		U-1857	
		9687526	Jan 30, 2035		U-1857	
		9744209	Jan 30, 2035		U-1857	
		9744239	Jan 30, 2035		U-1857	
		9750785	Jan 30, 2035	DP		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	002	9375478	Jan 30, 2035		U-1857	
		9687526	Jan 30, 2035		U-1857	
		9744209	Jan 30, 2035		U-1857	
		9744239	Jan 30, 2035		U-1857	
		9750785	Jan 30, 2035	DP		
		9937223	Jan 30, 2035		U-1857	
<u>VENURAFENIB - ZELBORAF</u>						
N 202429	001	7504509	Oct 22, 2026	DS DP		I-757 Nov 06, 2020
		7863288	Jun 20, 2029	DS DP		ODE-158 Nov 06, 2024
		8143271	Jun 21, 2026	DS DP		
		8470818	Aug 02, 2026		U-1418	
		8470818	Aug 02, 2026		U-2164	
		8741920	Jul 27, 2030	DS DP		
		9447089	Jun 06, 2032	DP		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	001	8546399	Jun 27, 2031	DS DP		I-782 Jun 08, 2021
		9174982	May 26, 2030		U-2323	I-789 Nov 21, 2021
		9174982	May 26, 2030		U-2445	I-795 May 15, 2022
		9174982	May 26, 2030		U-2446	M-228 Jun 08, 2021
		9174982	May 26, 2030		U-2537	NCE Apr 11, 2021
		9539251	Sep 06, 2033		U-2538	ODE-114 Apr 11, 2023
						ODE-185 Jun 08, 2025
						ODE-211 Nov 21, 2025
						ODE-239 May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	002	8546399	Jun 27, 2031	DS DP		I-782 Jun 08, 2021
		9174982	May 26, 2030		U-2323	I-789 Nov 21, 2021
		9174982	May 26, 2030		U-2445	I-795 May 15, 2022
		9174982	May 26, 2030		U-2446	M-228 Jun 08, 2021
		9174982	May 26, 2030		U-2537	NCE Apr 11, 2021
		9539251	Sep 06, 2033		U-2538	ODE-114 Apr 11, 2023
						ODE-185 Jun 08, 2025
						ODE-211 Nov 21, 2025
						ODE-239 May 15, 2026
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003	8546399	Jun 27, 2031	DS DP		I-782 Jun 08, 2021
		9174982	May 26, 2030		U-2323	I-789 Nov 21, 2021
		9174982	May 26, 2030		U-2445	I-795 May 15, 2022
		9174982	May 26, 2030		U-2446	M-228 Jun 08, 2021
		9174982	May 26, 2030		U-2537	NCE Apr 11, 2021
		9539251	Sep 06, 2033		U-2538	ODE-114 Apr 11, 2023
						ODE-185 Jun 08, 2025
						ODE-211 Nov 21, 2025
						ODE-239 May 15, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	7834020	Jun 05, 2022	DS DP	U-839	
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	7834020	Jun 05, 2022	DS DP	U-839	
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	7834020	Jun 05, 2022	DS DP	U-839	
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VINCRISTINE SULFATE - MARQIBO KIT</u>						
N 202497	001	6723338	Mar 31, 2020		U-1271	
		7247316	Sep 25, 2020	DP		
		7887836	Mar 31, 2020		U-1271	
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388	001	7888364	Nov 11, 2028	DS DP		
		9278961	Dec 15, 2028		U-1825	
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	7235567	Jun 13, 2021	DS DP		
		7304078	Apr 06, 2024	DS DP	U-1512	
		7713999	May 30, 2024	DS DP	U-2291	
<u>VORICONAZOLE - VFEND</u>						
N 021266	001					NPP Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266	002					NPP Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267	001					NPP Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630	001					NPP Jan 29, 2022
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025		U-892	
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023		DP	
		7732490	Mar 04, 2023		U-892	
		7851509	Feb 21, 2024	DP	U-892	
		8067472	Mar 04, 2023		U-892	
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023		U-892	
		8450372	Mar 18, 2028		U-892	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	001	7144884	Jun 17, 2026	DS DP	U-1439	M-227 May 02, 2021
		8476279	Oct 02, 2022		DP U-1439	M-234 Oct 19, 2021
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027		U-1668	
		9125908	Jun 15, 2027		U-2309	
		9125909	Jun 15, 2027		U-2309	
		9125910	Jun 15, 2027		U-2309	
		9227946	Jun 15, 2027		U-1668	
		9278096	Mar 21, 2032		U-2436	
		9861630	Jun 15, 2027		U-1668	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	002	7144884	Jun 17, 2026	DS DP	U-1439	M-227 May 02, 2021
		8476279	Oct 02, 2022		DP U-1439	M-234 Oct 19, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
	9125908	Jun 15, 2027		U-2309		
	9125909	Jun 15, 2027		U-2309		
	9125910	Jun 15, 2027		U-2309		
	9227946	Jun 15, 2027		U-1668		
	9278096	Mar 21, 2032		U-2436		
	9861630	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	7144884	Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
	8476279	Oct 02, 2022		DP U-1439	M-234	Oct 19, 2021
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
	9125908	Jun 15, 2027		U-2309		
	9125909	Jun 15, 2027		U-2309		
	9125910	Jun 15, 2027		U-2309		
	9227946	Jun 15, 2027		U-1668		
	9278096	Mar 21, 2032		U-2436		
	9861630	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	7144884	Jun 17, 2026	DS DP	U-1439	M-227	May 02, 2021
	8476279	Oct 02, 2022		DP U-1439	M-234	Oct 19, 2021
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027		U-1668		
	9125908	Jun 15, 2027		U-2309		
	9125909	Jun 15, 2027		U-2309		
	9125910	Jun 15, 2027		U-2309		
	9227946	Jun 15, 2027		U-1668		
	9278096	Mar 21, 2032		U-2436		
	9861630	Jun 15, 2027		U-1668		
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					NCE	Nov 25, 2024
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	9447106	Apr 22, 2034	DS DP	U-2145	NCE ODE-276	Nov 14, 2024 Nov 14, 2026
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
	9707270	Oct 01, 2024		U-2084		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
	9707270	Oct 01, 2024		U-2084		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483	001	7175855	May 18, 2020	DP		
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	002	8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
		8324189	May 29, 2025	U-53		
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003	7932241	Feb 05, 2028	DP		
		8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
		8324189	May 29, 2025	U-53		
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001	7932241	Feb 05, 2028	DP		
		8052987	Oct 27, 2023	U-1199		
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003	6750237	Nov 28, 2020	DP		
		6750237*PED	May 28, 2021			
		7220767	Nov 28, 2020	DP		
		7220767*PED	May 28, 2021			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004	6750237	Nov 28, 2020	DP		
		7220767	Nov 28, 2020	DP		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001	9265720	Feb 25, 2031	U-674		
		9597281	Apr 06, 2027	U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	002	9265720	Feb 25, 2031	U-674		
		9597281	Apr 06, 2027	U-674		
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196	001	8236285	Aug 07, 2032	DS DP	U-70	
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	001	7658945	Apr 15, 2027	DP	U-1194	
		7682628	Feb 16, 2025		U-1194	
		8242131	Aug 20, 2029		U-1266	
		8252809	Feb 16, 2025	DP		
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	002	7658945	Apr 15, 2027	DP	U-1194	
		7682628	Feb 16, 2025		U-1194	
		8242131	Aug 20, 2029		U-1266	
		8252809	Feb 16, 2025	DP		

PATENT AND EXCLUSIVITY TERMS**PATENT & EXCLUSIVITY ABBREVIATIONS**

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M ² OR 175MG/M ² INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM ".1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPIENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
- D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
- D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
- D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
- D-154 ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
- D-155 SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- D-156 DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
- D-157 UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
- D-158 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
- D-159 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
- D-160 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
- D-161 DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
- D-162 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
- D-163 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
- D-164 UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
- D-165 DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- D-166 BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
- D-167 ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
- D-168 NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- D-169 ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE
- D-170 TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
- D-171 REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
- D-172 ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- RECEIVED ONE TO THREE LINES OF THERAPY
- D-173 DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
- D-174 MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
- D-175 EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
- D-176 IBRUTINIB IN COMBINATION WITH RITUXIMAB
- D-177 INFORMATION ADDED TO THE DOSIG SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
- D-178 INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS

EXCLUSIVITY INDICATION

- I-1 DYSMENORRHEA
- I-2 CHOLANGIOPANCREATOGRAPHY
- I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
- I-5 HYSTEROSALPINGOGRAPHY
- I-6 TREATMENT OF JUVENILE ARTHRITIS
- I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
- I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
- I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-10 PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
- I-11 RELIEF OF MILD TO MODERATE PAIN
- I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
- I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
- I-14 SEBORRHEIC DERMATITIS
- I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
- I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
- I-17 MANAGEMENT OF CONGESTIVE HEART FAILURE
- I-18 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
- I-19 HERNIOGRAPHY
- I-20 KNEE ARTHROGRAPHY
- I-21 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
- I-22 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
- I-23 SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- I-24 TREATMENT OF RHEUMATOID ARTHRITIS
- I-25 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-26 TREATMENT OF LIVER FLUKES

I-27 ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE

I-28 SELECTIVE ADULT VISCERAL ARTERIOGRAPHY

I-29 METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION

I-30 TREATMENT OF TINEA PEDIS

I-31 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES

I-32 PEDIATRIC MYELOGRAPHY

I-33 ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN

I-34 ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT

I-35 PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING

I-36 ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS

I-37 RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS

I-38 CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)

I-39 TREATMENT OF ACUTE MYOCARDIAL INFARCTION

I-40 PRIMARY NOCTURNAL ENURESIS

I-41 MIGRAINE HEADACHE PROPHYLAXIS

I-42 HERPES ZOSTER

I-43 HERPES SIMPLEX ENCEPHALITIS

I-44 MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY

I-45 ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS

I-46 USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING

I-47 TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

I-48 PEDIATRIC ANGIOCARDIOGRAPHY

I-49 TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI

I-50 FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER

I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

I-52 PEDIATRIC EXCRETORY UROGRAPHY

I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

I-54 RENAL CONCENTRATION CAPACITY TEST

I-55 HYPERTENSION

I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE

I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER

I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS

I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE

I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE

I-61 FEMALE ANDROGENETIC ALOPECIA

I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION

I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

I-66 UNCOMPLICATED GONORRHEA

I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER

I-68 CENTRAL PRECOCIOUS PUBERTY

I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY

I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

I-71 VARICELLA INFECTIONS (CHICKENPOX)

I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE

I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES

I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS

I-76 PREVENTION OF OSTEOPOROSIS

I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM

I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY

I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM

I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE

I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS

I-82 TREATMENT OF TRAVELERS' DIARRHEA

I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN

I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION

I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY

I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN

I-88 MANAGEMENT OF ENDOMETRIOSIS

I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE

I-90 INTENSIVE CARE UNIT SEDATION

I-91 MONOTHERAPY USE FOR HYPERTENSION

I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE

I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS

I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]

I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT

I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY

I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER

I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY

I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY

I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN

I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL

I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION

I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS

I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS

I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN

I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS

I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS

I-148 TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO₂) IS LESS THAN OR EQUAL TO 55 TORR

I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER

I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA

I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS

I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]

I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE

I-155 TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT

I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE

I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES

I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER

I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS

I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY

I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE

I-163 TREATMENT OF PHOTOPHOBIA

I-164 CHRONIC BACTERIAL PROSTATITIS

I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

I-166 TREATMENT OF BULIMIA

I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS

I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)

I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER

I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS

I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD

I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER

I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS

I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

I-321 JUVENILE RHEUMATOID ARTHRITIS

I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

I-323 COLORECTAL CANCER

I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS

I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

I-326 GENERALIZED ANXIETY DISORDER

I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

	PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOISIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

PLATINUM-BASED THERAPY

- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY

I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)

I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING

I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS

I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY

I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE

I-603 GOUT FLARES

I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK

I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER

I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY

I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS

I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY

I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION

I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY

I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS

I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE

I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER

I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE

I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)

I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY

I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED

I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)

I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE

I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY

I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.

I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS

I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.

I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION

I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER

I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.

I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE

I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.

I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)

I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)

I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY

I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY

I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA

I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS

I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-680	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-681	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
I-682	TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
I-683	TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
I-684	PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
I-685	EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
I-686	INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
I-687	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
I-688	GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
I-689	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
I-690	INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
I-691	INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
I-692	INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
I-693	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
I-694	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
I-695	REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
I-696	USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
I-697	FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
I-698	SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
I-699	FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
I-700	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
I-701	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL
I-702	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
I-703	MODERATE TO SEVERE BINGE EATING DISORDER (BED)
I-704	EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
I-705	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
I-706	EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-707	POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
I-708	DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
- I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
- I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
- I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION
- I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
- I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
- I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
- I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
- I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
- I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
- I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
- I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
- I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
- I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
- I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
- I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
- I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
- I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
- I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
- I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

THERAPY.

- I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
- I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
- I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
- I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
- I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
- I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
- I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
- I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
- I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
- I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
- I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
- I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-751 TREATMENT OF TARDIVE DYSKINESIA
- I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
- I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
- I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
- I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
- I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
- I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-760 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
- I-761 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
- I-762 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
- I-763 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-764 TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
- I-765 ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
- I-766 TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
- I-767 TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
- I-768 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- I-769 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- I-770 TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
- I-771 REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
- I-772 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- I-773 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
- I-774 TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST
- I-775 REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS
- I-776 FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY
- I-777 CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- I-778 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- I-779 USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
- I-780 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
- I-781 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 147

EXCLUSIVITY INDICATION

- I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
- I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
- I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
- I-789 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- I-790 USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS
- I-791 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-792 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- I-793 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
- I-794 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- I-795 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
- I-796 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
- I-797 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
- I-798 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
- I-799 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
- I-800 TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY
- I-801 USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)
- I-802 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- I-803 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
- I-804 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-805 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
- I-806 EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

DISOPROXIL FUMARATE

- I-807 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
- I-808 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
- I-809 TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
- I-810 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
- I-811 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
- I-812 FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
- I-813 TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- I-814 TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
- I-815 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
- I-816 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- I-817 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- I-818 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
- I-819 ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE
- I-820 INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

INFORMATION

- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

SUBSECTIONS

- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY

M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS

M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)

M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER

M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL

M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY

M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY

M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS

M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS

M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)

M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA

M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS

M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY

M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE

M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)

M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES

M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL

M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY

M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD

M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION

M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION

M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE

M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

CHILDREN AGES 1-12

- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- M-104 INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-105 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)

M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES

M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008

M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL

M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

M-119 LABELING CHANGES REGARDING MISSED DOSES

M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS

M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43

M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL

M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS

M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE

M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086

M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004

M-128 CLINICAL TRIAL STUDY RESULTS

M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE

M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT

M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
- M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
- M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
- M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
- M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
- M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
- M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
- M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
- M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
- M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
- M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
- M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
- M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
- M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
- M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
- M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
- M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
- M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
- M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
- M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
- M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL) "
- M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
- M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
- M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
- M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
- M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
- M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
- M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
- M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
- M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
- M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
- M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
- M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
- M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
- M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
- M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
- M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
- M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
- M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
- M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
- M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
- M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
- M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
- M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
- M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
- M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
- M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE
- M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17
- M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
- M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
- M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
- M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
- M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
- M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
- M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.
- M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569
- M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT
- M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY
- M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY
- M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
- M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
- M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE
- M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

	CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
M-213	INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
M-214	INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
M-215	INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED
M-216	UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
M-217	INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING
M-218	ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)
M-219	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY
M-220	ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY
M-221	DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING
M-222	ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1
M-223	INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)
M-224	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN
M-225	REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES \geq 6 YEARS TO $<$ 18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION
M-226	CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
M-227	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
M-228	INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
M-229	REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
M-230	REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596
M-231	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3
M-232	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
M-233	INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS
M-234	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
M-235	INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1

- M-236 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
- M-237 INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS
- M-238 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M² OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
- M-239 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
- M-240 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
- M-241 INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD
- M-242 INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES
- M-243 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
- M-244 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- M-245 ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL
- M-246 ADDITION OF STUDY BRf117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN
- M-247 REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART
- M-248 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
- M-249 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4
- M-250 REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1

ORPHAN DRUG EXCLUSIVITY

- ODE-1 TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
- ODE-2 FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- ODE-3 TO TREAT INFANTILE SPASMS
- ODE-4 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
- ODE-5 FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
- ODE-6 FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-7 TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
- ODE-8 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- ODE-9 TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-10 FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- ODE-11 TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-12 TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-13 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-14 TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
- ODE-15 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
- ODE-16 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
- ODE-17 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
- ODE-18 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
- ODE-19 TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
- ODE-20 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
- ODE-21 AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
- ODE-22 FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
- ODE-23 ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- ODE-24 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
- ODE-25 MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
- ODE-26 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- ODE-27 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- ODE-28 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- ODE-29 LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
- ODE-30 TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
- ODE-31 TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
- ODE-32 TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
- ODE-33 TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
- ODE-34 TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

NOT AN OPTION OR HAS NOT BEEN CURATIVE

- ODE-35 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
- ODE-36 ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- ODE-37 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-38 PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
- ODE-39 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
- ODE-40 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
- ODE-41 ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- ODE-42 USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-43 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
- ODE-44 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
- ODE-45 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
- ODE-46 IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
- ODE-47 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
- ODE-48 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
- ODE-49 TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- ODE-50 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
- ODE-51 TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
- ODE-52 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
- ODE-53 TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
- ODE-54 TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENERD PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
- ODE-55 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-56 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

TREATMENT.

- ODE-57 TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
- ODE-58 DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
- ODE-59 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- ODE-60 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-61 TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
- ODE-62 TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
- ODE-63 TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
- ODE-64 SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
- ODE-65 TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
- ODE-66 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
- ODE-67 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- ODE-68 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
- ODE-69 TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
- ODE-70 RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
- ODE-71 RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-72 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-73 LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
- ODE-74 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
- ODE-75 TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
- ODE-76 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
- ODE-77 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- ODE-78 TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
- ODE-79 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- ODE-80 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
- ODE-81 TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-82 TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
- ODE-83 USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- ODE-84 TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
- ODE-85 AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
- ODE-86 TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
- ODE-87 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
- ODE-88 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
- ODE-89 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
- ODE-90 TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
- ODE-91 TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
- ODE-92 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
- ODE-93 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
- ODE-94 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-95 FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-96 TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIODIC PARALYSIS, AND RELATED VARIANTS
- ODE-97 TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
- ODE-98 TREATMENT OF HEREDITARY OROTIC ACIDURIA
- ODE-99 FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
- ODE-100 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
- ODE-101 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
- ODE-102 FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
- ODE-103 USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-104 EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
- ODE-105 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-106 FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
- ODE-107 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN

- ODE-108 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- ODE-109 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
- ODE-110 FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
- ODE-111 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
- ODE-112 FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
- ODE-113 FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
- ODE-114 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-115 TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- ODE-116 TREATMENT OF PROGRESSIVE KERATOCONUS
- ODE-117 FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-118 AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
- ODE-119 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
- ODE-120 FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
- ODE-121 TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
- ODE-122 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- ODE-123 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
- ODE-124 REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
- ODE-125 INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
- ODE-126 AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
- ODE-127 TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
- ODE-128 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
- ODE-129 INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
- ODE-130 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
- ODE-131 TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
- ODE-132 TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

(SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY

- ODE-133 INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- ODE-134 TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
- ODE-135 TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-136 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
- ODE-137 TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
- ODE-138 TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
- ODE-139 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
- ODE-140 TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
- ODE-141 TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
- ODE-142 TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-143 TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
- ODE-144 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- ODE-145 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
- ODE-146 OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
- ODE-147 DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-148 TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-149 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
- ODE-150 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
- ODE-151 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-152 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
- ODE-153 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- ODE-154 FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
- ODE-155 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-156 TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-157 FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS \geq 2 MONTHS AND $<$ 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-158 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
- ODE-159 FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
- ODE-160 FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
- ODE-161 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
- ODE-162 TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
- ODE-163 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
- ODE-164 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
- ODE-165 PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
- ODE-166 TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
- ODE-167 ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- ODE-168 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- ODE-169 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
- ODE-170 FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
- ODE-171 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
- ODE-172 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
- ODE-173 TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- ODE-174 FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- ODE-175 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-176 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
- ODE-177 TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
- ODE-178 INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-179 TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
- ODE-180 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- ODE-181 TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
- ODE-182 TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- ODE-183 TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- ODE-184 INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
- ODE-185 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-186 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
- ODE-187 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
- ODE-188 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
- ODE-189 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
- ODE-190 TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
- ODE-191 TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
- ODE-192 INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
- ODE-193 INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
- ODE-194 ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
- ODE-195 FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
- ODE-196 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
- ODE-197 INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
- ODE-198 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
- ODE-199 THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- ODE-200 INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- ODE-201 INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
- ODE-202 INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
- ODE-203 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-204 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
- ODE-205 INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
- ODE-206 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-207 TREATMENT OF STATUS EPILEPTICUS IN ADULTS
- ODE-208 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
- ODE-209 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- ODE-210 INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
- ODE-211 INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-212 INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
- ODE-213 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-214 TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
- ODE-215 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
- ODE-216 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
- ODE-217 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE
- ODE-218 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
- ODE-219 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
- ODE-220 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
- ODE-221 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

FOLLOWING TREATMENT

- ODE-222 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- ODE-223 INDICATED FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN ADULTS
- ODE-224 INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE ≥ 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-225 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
- ODE-226 MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
- ODE-227 INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- ODE-228 INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
- ODE-229 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- ODE-230 FIRST-LINE TREATMENT OF METASTATIC NONSMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- ODE-231 INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
- ODE-232 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
- ODE-233 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
- ODE-234 INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
- ODE-235 INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
- ODE-236 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- ODE-237 TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
- ODE-238 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
- ODE-239 TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-240 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-241 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
- ODE-242 TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE ≥ 75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
- ODE-243 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

AND OLDER

- ODE-244 TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
- ODE-245 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
- ODE-246 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- ODE-247 TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- ODE-248 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
- ODE-249 TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- ODE-250 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
- ODE-251 INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- ODE-252 TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
- ODE-253 INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
- ODE-254 INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- ODE-255 INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
- ODE-256 FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
- ODE-257 IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
- ODE-258 FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-259 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
- ODE-260 INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
- ODE-261 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
- ODE-262 TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
- ODE-263 TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-264 TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS

PATENT AND EXCLUSIVITY TERMS**ORPHAN DRUG EXCLUSIVITY**

- OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-265 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
- ODE-266 ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
- ODE-267 INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
- ODE-268 INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-269 PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
- ODE-270 INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
- ODE-271 INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
- ODE-272 INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
- ODE-273 INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
- ODE-274 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- ODE-275 INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
- ODE-276 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- ODE-277 TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
- ODE-278 TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY

PATENT USE

- U-1 PREVENTION OF PREGNANCY
- U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
- U-3 TREATMENT OF HYPERTENSION
- U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
- U-5 METHOD OF PRODUCING BRONCHODILATION
- U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
- U-7 INCREASING CARDIAC CONTRACTILITY
- U-8 ACUTE MYOCARDIAL INFARCTION
- U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
- U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
- U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
- U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
- U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
- U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES

U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE

U-16 USE IN LUNG SCANNING PROCEDURES

U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS

U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS

U-19 TREATMENT OF INFLAMMATION

U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT

U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS

U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS

U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE

U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST

U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS

U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF

U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF

U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY

U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY

U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY

U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY

U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN

U-33 TREATING VIRAL INFECTIONS IN A MAMMAL

U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL

U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION

U-36 METHODS OF TREATING BACTERIAL ILLNESSES

U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE

U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

U-39 ANGINA PECTORIS

U-40 METHOD OF TREATMENT OF BURNS

U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS

U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER

U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

U-44 RELIEF OF NAUSEA AND VOMITING

U-45 TREATMENT OF INFLAMMATION AND ANALGESIA

U-46 TREATMENT OF PANIC DISORDER

U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE

U-48 ANALGESIA

U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA

U-50 USE IN TREATING INFLAMMATORY DERMATOSES

U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING

U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-53 HYPERCALCEMIA OF MALIGNANCY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS

U-55 TREATMENT OF PAIN

U-56 AID TO SMOKING CESSATION

U-57 OPHTHALMIC USE OF NORFLOXACIN

U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES

U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA

U-60 NASAL ADMINISTRATION OF BUTORPHANOL

U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD

U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY

U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE

U-64 TREATMENT OF VIRAL INFECTIONS

U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV

U-66 TRIPHASIC REGIMEN

U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL

U-68 TREATMENT OF ACTINIC KERATOSIS

U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS

U-70 TREATMENT OF TRANSIENT INSOMNIA

U-71 METHOD OF TREATMENT OF HEART FAILURE

U-72 TREATMENT OF MIGRAINE

U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT

U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS

U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM

U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-78 ULCERATIVE COLITIS

U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD

U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS

U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS

U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE

U-83 TREATMENT OF SEIZURES

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS

U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY

U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS

U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS

U-89 TREATMENT OR PROPHYLAXIS OF EMESIS

U-90 TREATMENT OF PSYCHOTIC DISORDERS

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PESSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

U-131 PHOTODAMAGED SKIN

U-132 INHIBITING HIV PROTEASE

U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H. PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS

U-185 METHOD OF TREATING HYPERTENSION

U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT

U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER

U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE

U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR

U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

U-192 USE IN TREATING ALLERGIC REACTIONS

U-193 PSORIASIS

U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE

U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON

U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS

U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA

U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT

U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-205 METHOD FOR TREATING HEARTBURN

U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

FERTILIZATION

- U-207 USE AS NASAL SPRAY
- U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
- U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
- U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
- U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
- U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
- U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
- U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
- U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
- U-217 METHOD OF PRODUCING ANESTHESIA
- U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
- U-219 TREATMENT OF PARKINSON'S DISEASE
- U-220 METHOD OF DIAGNOSIS
- U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
- U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
- U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
- U-224 CONTROLLING INTRAOCULAR PRESSURE
- U-225 METHOD FOR DELIVERY
- U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
- U-227 NASAL ADMINISTRATION
- U-228 ASTHMA
- U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
- U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
- U-231 USE IN PARKINSON'S DISEASE
- U-232 METHOD OF TREATING MIGRAINE
- U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
- U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
- U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
- U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
- U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
- U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
- U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
- U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION

U-243 TOPICAL ADMINISTRATION

U-244 PLATELET AGGREGATION INHIBITORS

U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-246 PHOSPHATE BINDING

U-247 TREATMENT OF RHEUMATOID ARTHRITIS

U-248 TREATMENT OF HIV

U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE

U-250 TREATMENT OF HEPATITIS B INFECTION

U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES

U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE

U-253 ORAL TRANSMUCOSAL USE

U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN

U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS

U-257 TREATMENT OF HIV INFECTION

U-258 TREATMENT OF NEURODEGENERATIVE DISEASES

U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE

U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION

U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE

U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE

U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN

U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN

U-265 USE AS LAXATIVE

U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS

U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

U-268 ACROMEGALY

U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS

U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT

U-271 METHOD OF TREATING TUMORS

U-272 METHOD OF TREATING CARCINOMA

U-273 CUTANEOUS T-CELL LYMPHOMA

U-274 ZANAMIVIR FOR INHALATION

U-275 METHOD OF USE OF THE DRUG SUBSTANCE

U-276 METHOD OF USE OF LEVOBUPIVACAINE

U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT

U-279 METHOD OF USE OF THE APPROVED PRODUCT

U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE

U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS

U-282 METHOD OF TREATING BACTERIAL INFECTIONS

U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE

U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS

U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA

U-286 DEPRESSION

U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS

U-288 THERAPY OF INFLUENZA

U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP

U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)

U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN

U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE

U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID

U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS

U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY

U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS

U-298 METHOD OF COMBATING BACTERIA IN A PATIENT

U-299 TREATMENT OF ADENOMATOUS POLYPS

U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA

U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS

U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS

U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION

U-305 METHODS FOR USING THE DRUG PRODUCT

U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY

U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA

U-309 TREATING SJOEGREN SYNDROME

U-310 TREATMENT OF XEROSTOMIA

U-311 HORMONE REPLACEMENT

U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER

U-313 TREATMENT OF CONGESTIVE HEART FAILURE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT

U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER

U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

U-319 TREATMENT OF MICROBIAL INFECTIONS

U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

U-322 TREATMENT OF ALZHEIMER'S DEMENTIA

U-323 USE AS A BILE ACID SEQUESTRANT

U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE

U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-330 TREATMENT OF NAUSEA AND VOMITING

U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM

U-333 METHOD OF TREATING OCULAR HYPERTENSION

U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR

U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS

U-336 DIAGNOSTIC RADIOIMAGING

U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI

U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME

U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER

U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR

U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS

U-348 METHOD OF USE FOR INHIBITING HIV INFECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION

U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR

U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS

U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING

U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.

U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE

U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER

U-359 METHOD OF USE OF VISICOL

U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY

U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS

U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011

U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION

U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION

U-367 TREATMENT OF CARDIOVASCULAR DISORDERS

U-368 HEARTBURN

U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE

U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS

U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHOMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABILIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPTHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
- U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
- U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
- U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-540 TREATMENT OF FUNGAL INFECTIONS

U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1

U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION

U-543 TREATMENT OF SCHIZOPHRENIA

U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.

U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT

U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER

U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER

U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID

U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS

U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING

U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-572 INTENSIVE CARE UNIT SEDATION

U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.

U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.

U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN

U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.

U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.

U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS

U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413

U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762

U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928

U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY

U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS

U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH

U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION

U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966

U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955

U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG

U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-598 PROPHYLACTIC TREATMENT OF MIGRAINE

U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS

U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN

U-601 TREATMENT OF BIPOLAR DISORDER

U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS

U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION

U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS

U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER

U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.

U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA

U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA

U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.

U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER

U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-613 REDUCTION OF SERUM PHOSPHATE

U-614 TREATMENT OF SEXUAL DYSFUNCTION

U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER

U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.

U-619 TREATMENT OF MALIGNANT NEOPLASM

U-620 TREATMENT OF INSOMNIA

U-621 METHOD OF TREATING CANCER

U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.

U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

U-625 ALLERGIC RHINITIS OR NASAL POLYPS

U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS

U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE

U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE

U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN

U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-685 EXPECTORANT AND COUGH SUPPRESSANT

U-686 EXPECTORANT AND NASAL DECONGESTANT

U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

OPTIMAL CLINICAL RESPONSE.

- U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
- U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
- U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
- U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
- U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
- U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
- U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
- U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
- U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
- U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- U-707 ALLERGIC RHINITIS
- U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
- U-709 METHOD OF COMBATING BACTERIA IN A PATIENT
- U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
- U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
- U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
- U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
- U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-718 TREATMENT OF FUNGAL INFECTIONS
- U-719 TREATMENT OF PSYCHOSIS
- U-720 TREATMENT OF NEUROLEPTIC DISEASES
- U-721 TREATMENT OF INFLUENZA
- U-722 PROPHYLAXIS OF INFLUENZA
- U-723 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-724 METHOD OF TREATING SEIZURES
- U-725 ALLERGIC RHINITIS AND URTICARIA
- U-726 ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS

U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID

U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT

U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY

U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE

U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER

U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS

U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA

U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS

U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)

U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE

U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
- U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
- U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
- U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
- U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
- U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
- U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
- U-867 TREATMENT OF MIGRAINE
- U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
- U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
- U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
- U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
- U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
- U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
- U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
- U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
- U-879 A METHOD OF TREATING OR PREVENTING ILEUS
- U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
- U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER
- U-882 MANAGEMENT OF FIBROMYALGIA (FM)
- U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
- U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS
- U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
- U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
- U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS

U-952 USE AS AN ANALGESIC

U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

U-955 PROPHYLACTIC TREATMENT OF MIGRAINE

U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT (DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS
- U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
- U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
- U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
- U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
- U-975 TREATMENT OF PULMONARY HYPERTENSION
- U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
- U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
- U-978 METHOD OF TREATING HYPONATREMIA
- U-979 RELIEF OF MUSCLE SPASM
- U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-982 A METHOD OF TREATING OSTEOPOROSIS
- U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
- U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
- U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
- U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL

U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS

U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1131 TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C

U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
- U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1176 TREATMENT OR PREVENTION OF STROKE
- U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
- U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
- U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
- U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
- U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
- U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
- U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION
- U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
- U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
- U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
- U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
- U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
- U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
- U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
- U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
- U-1194 METHOD FOR TREATING INSOMNIA
- U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
- U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
- U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
- U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
- U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
- U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
- U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
- U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
- U-1204 TREATMENT OF UVEITIS
- U-1205 TREATMENT OF MACULAR EDEMA
- U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
- U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS
- U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA

U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS

U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER

U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS

U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER

U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA

U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE

U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA

U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS

U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE

U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG

U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT

U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE

U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY

U-1254 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN

U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY

U-1256 TREATMENT OF SEBORRHEIC DERMATITIS

U-1257 TREATMENT OF OPHTHALMIC DISORDERS

U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES

U-1259 PROPHYLAXIS OF HIV-1 INFECTION

U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION

U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT

U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS

U-1264 TREATMENT OF A RESPIRATORY DISEASE

U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA

U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE

U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE

U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET

U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)

U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES

U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM

U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS

U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN

U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS

U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS

U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL

U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING

U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA

U-1284 A METHOD OF TREATING A NEOPLASM

U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE

U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET

U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN

U-1290 TREATMENT OF LUNG CANCER

U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT

U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION

U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS

U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES

U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)

U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM

U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES

U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS

U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
- U-1308 MULTIPLE MYELOMA
- U-1309 BONE METASTASES
- U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- U-1311 METHOD OF TREATING CYSTIC FIBROSIS
- U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA
- U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
- U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- U-1322 METHOD OF REDUCING OCULAR HYPERTENSION
- U-1323 REDUCING THE RISK OF STROKE
- U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
- U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
- U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
- U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
- U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
- U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
- U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
- U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
- U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

INHIBITOR AND METFORMIN

- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
- U-1347 TREATMENT OF A SKIN DISORDER
- U-1348 TREATMENT OF OSTEOARTHRITIS
- U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
- U-1351 TREATMENT OF ACUTE PAIN
- U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
- U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
- U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
- U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
- U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
- U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY

U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN

U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN

U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB

U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

U-1370 TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE

U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA

U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION

U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS

U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)

U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER

U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE

U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT

U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS

U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF

U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1389 ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD

U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF

U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION

U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
- U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
- U-1398 METHOD OF TREATING CHRONIC HEPATITIS C
- U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
- U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
- U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
- U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
- U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES
- U-1406 TREATMENT OF MELANOMA
- U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
- U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
- U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
- U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
- U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1412 TREATMENT OF ATOPIC DERMATITIS
- U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
- U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
- U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
- U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
- U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS
- U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
- U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
- U-1420 METHOD OF ONCE A DAY ADMINISTRATION
- U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
- U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
- U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
- U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
- U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
- U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
- U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
- U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
- U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
- U-1434 TREATMENT OF PANCREATIC CANCER
- U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
- U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY

U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT

U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT

U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1455 TREATMENT OF PERIANAL WARTS

U-1456 TREATMENT OF MANTLE CELL LYMPHOMA

U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM

U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1459 TREATMENT OF CARCINOMA OF THE THYROID

U-1460 TREATMENT OF HERPES LABIALIS

U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE

U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1467 METHOD OF TREATING HEPATITIS C

U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

U-1469 USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

U-1470 FOR THE TREATMENT OF HEPATITIS C

U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.

U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA

U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)

U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER

U-1487 METHOD OF INCREASING EYELASH GROWTH

U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN

U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS

U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.

U-1496 METHOD TO TREAT HEMANGIOMA.

U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM

U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM

U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4

U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR

U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED

U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER

U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.

U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA

U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL

U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.

U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
- U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
- U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
- U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
- U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
- U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
- U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
- U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
- U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
- U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
- U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
- U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
- U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
- U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
- U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
- U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
- U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
- U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
- U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
- U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
- U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
- U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.

U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

U-1552 FOR HEALING OF ALL GRADES OF EROSION ESOPHAGITIS (EE)

U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)

U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER

U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE

U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.

U-1564 A METHOD OF TREATING GAUCHER'S DISEASE

U-1565 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-1567 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1

U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.

U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

U-1576 TREATMENT OF LEUKEMIA

U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS

U-1578 TREATMENT OF ACUTE OTITIS MEDIA

U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

CHEMOTHERAPY

- U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
- U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
- U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
- U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
- U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
- U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
- U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
- U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
- U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
- U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
- U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
- U-1594 DILATION OF THE PUPIL
- U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
- U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- U-1597 TREATMENT OF DIABETIC MACULAR EDEMA
- U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
- U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
- U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
- U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
- U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
- U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
- U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
- U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
- U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER

U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN

U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN

U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER

U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT

U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.

U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.

U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREXIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREXIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREXIR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN

U-1643 TREATING CUSHING'S SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN

U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)

U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)

U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN

U-1659 MANAGEMENT OF PAIN

U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

U-1662 A METHOD OF TREATING OCULAR PAIN

U-1663 TREATMENT OF HIV-1 INFECTION

U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1

U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER

U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE

U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS

U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION

U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS

U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS

U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1681 TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC

U-1682 TREATMENT OF BACTERIAL VAGINOSIS

U-1683 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR

U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT

U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

U-1697 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.

U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN

U-1702 TREATMENT OF COPD

U-1703 TREATMENT OF RESPIRATORY COMPLAINTS

U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES

U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE

U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.

U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE

U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1712 MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
- U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
- U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
- U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
- U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
- U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
- U-1719 ACUTE TREATMENT OF MIGRAINE
- U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
- U-1721 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
- U-1722 TREATMENT OF BASAL CELL CARCINOMA
- U-1723 TREATMENT OF HEART FAILURE
- U-1724 METHOD OF INHIBITING HEPATITIS C VIRUS
- U-1725 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
- U-1726 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1727 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
- U-1728 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
- U-1729 REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
- U-1730 REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
- U-1731 TEMPORARY RELIEF OF MINOR ACHES AND PAINS
- U-1732 TEMPORARY REDUCTION OF FEVER
- U-1733 TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
- U-1734 USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
- U-1735 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
- U-1736 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1737 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
- U-1738 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
- U-1739 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1740 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1741 PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1742 ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1743 FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

U-1745 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA

U-1746 MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY

U-1747 FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD

U-1748 FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1749 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-1750 TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

U-1752 PROPHYLAXIS OF ORGAN REJECTION

U-1753 TREATMENT OF HCV INFECTION USING DASABUVIR

U-1754 FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

U-1755 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

U-1756 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

U-1757 INHIBITION ON PI3K KINASE

U-1758 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION

U-1759 METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB

U-1760 RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

U-1761 PLAQUE PSORIASIS

U-1762 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1763 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1764 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1765 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1766 TREATMENT OF HYPERKALEMIA

U-1767 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN

U-1769 TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE

U-1770 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA

U-1771 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION

U-1772 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1773 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-1774 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

U-1775 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS

U-1776 METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA

U-1777 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

U-1778 METHOD FOR TREATING MULTIPLE MYELOMA

U-1779 METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS

U-1780 METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA

U-1781 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

U-1782 FOR HEAD LICE INFESTATIONS

U-1783 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium AS CLAIMED

U-1784 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium trihydrate AS CLAIMED

U-1785 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN Eesomeprazole magnesium FORMULATION AS CLAIMED

U-1786 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

U-1787 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

U-1788 TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN

U-1789 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

U-1790 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA

U-1791 EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

U-1792 TREATMENT OF OTIC INFECTION OR INFLAMMATION

U-1793 TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1794 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK

U-1795 REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

U-1796 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1797 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG

U-1798 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN

U-1799 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES

U-1800 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT

U-1801 REDUCTION OF SERUM URIC ACID LEVELS

U-1802 TREATMENT OF GOUT

U-1803 TREATMENT OF HYPERURICEMIA

U-1804 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1805 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
- U-1806 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
- U-1807 TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- U-1808 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- U-1809 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
- U-1810 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-1811 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
- U-1812 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
- U-1813 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
- U-1814 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
- U-1815 TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-1816 TREATMENT OF A UREA CYCLE DISORDER
- U-1817 PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-1818 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1819 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
- U-1820 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1821 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-1822 TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
- U-1823 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
- U-1824 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1825 METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
- U-1826 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1827 A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
- U-1828 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
- U-1829 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
- U-1830 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
- U-1831 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
- U-1832 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1833 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

OR OCULAR HYPERTENSION

- U-1834 TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
- U-1835 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- U-1836 TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
- U-1837 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
- U-1838 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1839 COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
- U-1840 TREATMENT OF HCV INFECTION USING PARITAPREVR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
- U-1841 USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-1842 METHOD OF TREATING EPILEPSY
- U-1843 TREATMENT OF PSYCHOSIS
- U-1844 TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
- U-1845 TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
- U-1846 TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
- U-1847 METHOD OF TREATING A BACTERIAL INFECTION
- U-1848 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
- U-1849 METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
- U-1850 METHOD OF ADMINISTERING LEVETIRACETAM
- U-1851 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1852 METHOD OF TREATING TYPE 2 DIABETES
- U-1853 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
- U-1854 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
- U-1855 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
- U-1856 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-1857 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
- U-1858 TREATMENT OF PLAQUE PSORIASIS
- U-1859 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1860 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
- U-1861 USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
- U-1862 TREATMENT OF POST-MYOCARDIAL INFARCTION
- U-1863 TREATMENT OF STROKE
- U-1864 TREATMENT OF MYOCARDIAL INFARCTION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1865 TREATMENT OF THROMBOTIC STROKE

U-1866 TREATMENT OF STABLE AND UNSTABLE ANGINA

U-1867 METHOD OF INHIBITING PLATELET AGGREGATION

U-1868 TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION

U-1869 TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE

U-1870 ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1871 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D

U-1872 USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY

U-1873 ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE

U-1874 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8

U-1875 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3

U-1876 METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH

U-1877 METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL

U-1878 FOR OPIOID DEPENDENCE

U-1879 METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY

U-1880 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

U-1881 IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR

U-1882 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY

U-1883 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)

U-1884 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1885 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1886 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1887 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1888 USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE

U-1889 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

U-1890 OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))

U-1891 TREATMENT OR PREVENTION OF NAUSEA AND VOMITING

U-1892 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION

U-1893 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS

U-1894 COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1895 METHOD OF TREATING PROSTATE CANCER

U-1896 SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES

U-1897 METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1898 METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1899 TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1900 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

U-1901 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

U-1902 TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS

U-1903 USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

U-1904 (I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1905 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1906 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1907 USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE

U-1908 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR

U-1909 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR

U-1910 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338

U-1911 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR

U-1912 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606

U-1913 TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1914 IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-1915 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN

U-1916 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)

U-1917 TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1918 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1919 RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1920 USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4

U-1921 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1950 TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
- U-1951 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
- U-1952 FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
- U-1953 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1954 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1955 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1956 FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1957 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
- U-1958 FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
- U-1959 TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
- U-1960 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
- U-1961 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
- U-1962 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
- U-1963 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
- U-1964 ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
- U-1965 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
- U-1966 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
- U-1967 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1968 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
- U-1969 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
- U-1970 TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
- U-1971 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1972 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
- U-1973 METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
- U-1974 TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
- U-1975 METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2032 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
- U-2033 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
- U-2034 INHIBITING COAGULATION
- U-2035 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
- U-2036 A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
- U-2037 MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
- U-2038 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
- U-2039 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
- U-2040 TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
- U-2041 TREATMENT OF PARTIAL-ONSET SEIZURES
- U-2042 DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2043 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
- U-2044 DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2045 ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
- U-2046 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
- U-2047 ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2048 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2049 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
- U-2050 ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
- U-2051 DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2052 DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2053 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2054 ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
- U-2055 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2056 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2057 DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2058 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
- U-2059 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
- U-2060 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
- U-2061 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2062 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
- U-2063 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
- U-2064 DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2065 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
- U-2066 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
- U-2067 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2068 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
- U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
- U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
- U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
- U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
- U-2078 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2079 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2080 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2081 DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
- U-2082 MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2083 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
- U-2084 TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
- U-2085 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
- U-2086 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
- U-2087 TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
- U-2088 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
- U-2089 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
- U-2090 FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2091 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-2092 METHOD FOR CONFIRMING DOSE DELIVERY
- U-2093 TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
- U-2094 TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
- U-2095 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
- U-2096 SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
- U-2097 TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2098 INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2099 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
- U-2100 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2101 MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
- U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
- U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
- U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
- U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
- U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
- U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
- U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
- U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
- U-2116 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
- U-2117 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
- U-2118 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
- U-2119 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
- U-2120 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
- U-2121 TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
- U-2122 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2123 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
- U-2124 TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
- U-2125 THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
- U-2126 USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- U-2127 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2128 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
- U-2129 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
- U-2130 TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-2131 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
- U-2132 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
- U-2133 METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
- U-2134 THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
- U-2135 AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
- U-2136 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-2137 TREATMENT OF POSTHERPETIC NEURALGIA
- U-2138 TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
- U-2139 TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
- U-2140 METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2141 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
- U-2142 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
- U-2143 AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
- U-2144 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-2145 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2146 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE

U-2147 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME

U-2148 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE

U-2149 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON

U-2150 TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

U-2151 METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE

U-2152 TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-2153 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2154 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2155 REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2156 REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2157 TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE

U-2158 DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION

U-2159 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

U-2160 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM

U-2161 TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

U-2162 FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY

U-2163 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

U-2164 ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

U-2165 MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM

U-2166 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-2167 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2168 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER

U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2170 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

U-2171 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY

U-2172 METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)

U-2173 TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE

U-2174 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH

U-2175 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY

U-2176 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE

U-2177 TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2178 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION

U-2179 IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION

U-2180 TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

U-2181 TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE

U-2182 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2183 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13

U-2184 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14

U-2185 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27

U-2186 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28

U-2187 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39

U-2188 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

U-2189 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52

U-2190 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53

U-2191 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64

U-2192 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65

U-2193 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75

U-2194 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76

U-2195 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

BIPOLAR DISORDER

- U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2203 A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
- U-2204 TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
- U-2205 TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
- U-2206 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
- U-2207 TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
- U-2208 TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
- U-2209 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
- U-2210 TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
- U-2211 TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
- U-2212 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2213 REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
- U-2214 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
- U-2215 ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2216 ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2217 TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2218 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
- U-2219 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
- U-2220 A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
- U-2221 TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
- U-2222 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
- U-2223 METHOD OF TREATING ANGINA PECTORIS
- U-2224 TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2225 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-2226 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
- U-2227 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
- U-2228 TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
- U-2229 IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
- U-2230 IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
- U-2231 TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR

- U-2232 TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
- U-2233 TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
- U-2234 USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2235 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
- U-2236 REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
- U-2237 TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
- U-2238 METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
- U-2239 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
- U-2240 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
- U-2241 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
- U-2242 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
- U-2243 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
- U-2244 A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2245 A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2246 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- U-2247 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- U-2248 TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- U-2249 MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
- U-2250 DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
- U-2251 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-2252 THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
- U-2253 PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
- U-2254 USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
- U-2255 TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS

- U-2256 TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2257 TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2258 TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2259 TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
- U-2260 METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
- U-2261 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
- U-2262 MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
- U-2263 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
- U-2264 METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
- U-2265 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
- U-2266 METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
- U-2267 METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
- U-2268 DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
- U-2269 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2270 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2271 THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
- U-2272 TREATMENT OF NASAL POLYPS IN PATIENTS ≥ 18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
- U-2273 A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
- U-2274 MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
- U-2275 TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
- U-2276 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2277 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
- U-2278 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2279 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
- U-2280 ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
- U-2281 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
- U-2282 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
- U-2283 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
- U-2284 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
- U-2285 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
- U-2286 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
- U-2287 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
- U-2288 TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
- U-2289 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
- U-2290 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M² ≤ EGFR < 60 ML/MIN/1.73 M²) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
- U-2291 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
- U-2292 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
- U-2293 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
- U-2294 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- U-2295 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
- U-2296 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2297 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
- U-2298 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC)

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- U-2299 TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION
- U-2300 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-2301 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
- U-2302 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2303 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
- U-2304 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
- U-2305 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
- U-2306 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
- U-2307 TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
- U-2308 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-2309 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
- U-2310 FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
- U-2311 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
- U-2312 TREATMENT OF HYPERKALEMIA IN ADULTS
- U-2313 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
- U-2314 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
- U-2315 TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
- U-2316 TREATMENT OF DYSPAREUNIA
- U-2317 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
- U-2318 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2319 KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-2320 KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- U-2321 A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
- U-2322 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
- U-2323 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2324 FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
- U-2325 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
- U-2326 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
- U-2327 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
- U-2328 METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
- U-2329 METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
- U-2330 METHOD OF TREATING MELANOMA
- U-2331 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
- U-2332 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
- U-2333 INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2334 TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2335 TREATMENT OF MELANOMA
- U-2336 TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
- U-2337 INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
- U-2338 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
- U-2339 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
- U-2340 TREATMENT OF POSTOPERATIVE INFLAMMATION
- U-2341 METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2342 METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2343 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2344 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
- U-2345 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
- U-2346 TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
- U-2347 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
- U-2348 A METHOD FOR PREVENTION OF PREGNANCY
- U-2349 FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
- U-2350 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
- U-2351 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2352 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2353 TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2354 COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
- U-2355 IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
- U-2356 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- U-2357 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- U-2358 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
- U-2359 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
- U-2360 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
- U-2361 METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
- U-2362 TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
- U-2363 ADMINISTRATION OF RISPERIDONE
- U-2364 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
- U-2365 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
- U-2366 TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
- U-2367 USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
- U-2368 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
- U-2369 FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
- U-2370 FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS
- U-2371 THE TREATMENT OF FABRY PATIENTS
- U-2372 A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
- U-2373 A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYL CERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
- U-2374 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
- U-2375 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
- U-2376 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
- U-2377 USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY

PATENT AND EXCLUSIVITY TERMS

ADB 134 of 147

PATENT USE

U-2378 TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

U-2379 USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY

U-2380 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER

U-2381 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

U-2382 TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

U-2383 METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL

U-2384 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10

U-2385 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11

U-2386 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19

U-2387 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20

U-2388 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28

U-2389 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29

U-2390 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41

U-2391 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42

U-2392 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50

U-2393 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51

U-2394 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2395 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2396 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFOR

U-2397 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFOR AND IVACAFOR AS RECITED IN CLAIM 1 OF US PATENT 9192606

U-2398 TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER

U-2399 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2400 REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-2401 A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1

U-2402 TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION

U-2403 TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE

U-2404 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

U-2405 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE

U-2406 A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE

U-2407 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT

U-2408 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT

U-2409 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES

U-2410 TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE

U-2411 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR

U-2412 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)

U-2413 FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)

U-2414 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN

U-2415 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN

U-2416 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN

U-2417 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN

U-2418 METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY

U-2419 METHOD OF OPERATING AN INJECTION DEVICE

U-2420 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621

U-2421 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2422 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM

U-2423 USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM

U-2424 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

U-2425 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2426 USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2427 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2428 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER

U-2429 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

U-2430 TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS

U-2431 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS

U-2432 LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2433 METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA

U-2434 USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-2435 REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD

U-2436 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT

U-2437 TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

U-2438 CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

U-2439 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS

U-2440 FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2441 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

U-2442 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME

U-2443 USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2444 TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION

U-2445 TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

U-2446 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-2447 TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET

U-2448 TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS

U-2449 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION

U-2450 POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT

U-2451 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-2452 COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA

U-2453 TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS

U-2454 USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME

U-2455 USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-2456 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

U-2457 REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO

U-2458 REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO

U-2459 TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2460 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2461 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2462 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2463 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2464 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2465 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2466 VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

U-2467 VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER

U-2468 VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER

U-2469 METHOD OF TREATING CANCEROUS SOLID TUMORS

U-2470 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

U-2471 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT

U-2472 METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

U-2473 METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION

U-2474 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION

U-2475 METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT

U-2476 USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE

U-2477 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS

U-2478 METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES

U-2479 METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES

U-2480 MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

U-2481 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 138 of 147

PATENT USE

- U-2482 TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
- U-2483 TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
- U-2484 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
- U-2485 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
- U-2486 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
- U-2487 DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
- U-2488 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
- U-2489 TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
- U-2490 TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
- U-2491 A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
- U-2492 A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
- U-2493 A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
- U-2494 INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
- U-2495 VENTRICULAR FIBRILLATION
- U-2496 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-2497 TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
- U-2498 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
- U-2499 METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
- U-2500 USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
- U-2501 TREATMENT OF PARTIAL-ONSET SEIZURES
- U-2502 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
- U-2503 TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
- U-2504 TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- U-2505 TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-2506 METHOD OF TREATING TESTOSTERONE DEFICIENCY
- U-2507 METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA

PATENT AND EXCLUSIVITY TERMS

ADB 139 of 147

PATENT USE

- U-2508 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2509 A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2510 A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-2511 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
- U-2512 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
- U-2513 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2514 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2515 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-2516 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2517 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2518 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
- U-2519 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2520 TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2521 TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
- U-2522 TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2523 TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA
- U-2524 TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
- U-2525 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
- U-2526 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
- U-2527 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2528 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
- U-2529 TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2530 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2531 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
- U-2532 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
- U-2533 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
- U-2534 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
- U-2535 USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
- U-2536 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
- U-2537 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- U-2538 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
- U-2539 IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
- U-2540 TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
- U-2541 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2542 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2543 TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
- U-2544 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
- U-2545 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
- U-2546 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2547 METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE
- U-2548 TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
- U-2549 CONTROL OF SERUM PHOSPHORUS LEVELS
- U-2550 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
- U-2551 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
- U-2552 METHOD OF TREATING POSTPARTUM DEPRESSION
- U-2553 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
- U-2554 TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2555 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
- U-2556 METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
- U-2557 A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
- U-2558 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- U-2559 USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- U-2560 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- U-2561 USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
- U-2562 TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
- U-2563 TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
- U-2564 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
- U-2565 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
- U-2566 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
- U-2567 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
- U-2568 TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
- U-2569 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
- U-2570 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
- U-2571 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
- U-2572 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
- U-2573 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2574 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2575 TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
- U-2576 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2577 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- U-2578 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
- U-2579 REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
- U-2580 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
- U-2581 TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
- U-2582 FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
- U-2583 TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
- U-2584 XPROVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
- U-2585 TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
- U-2586 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
- U-2587 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
- U-2588 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
- U-2589 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
- U-2590 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
- U-2591 LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
- U-2592 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
- U-2593 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2594 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2595 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2596 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2597 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
- U-2598 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
- U-2599 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS

PATENT AND EXCLUSIVITY TERMS

ADB 143 of 147

PATENT USE

U-2600 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2601 STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2602 DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2603 METHOD OF TREATING IRON DEFICIENCY

U-2604 TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES

U-2605 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

U-2606 TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY

U-2607 TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS

U-2608 METHOD OF TREATING SCHIZOPHRENIA

U-2609 A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL

U-2610 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-2611 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-2612 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER

U-2613 TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)

U-2614 TREATMENT OF MODERATE TO SEVERE DYSpareunia

U-2615 TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD

U-2616 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE

U-2617 TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

U-2618 TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION

U-2619 TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS

U-2620 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

U-2621 MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN

U-2622 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

U-2623 A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY

U-2624 TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

U-2625 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

U-2626 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR

U-2627 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER

U-2628 METHOD OF TREATING TYPE 2 DIABETES MELLITUS

U-2629 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2630 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
- U-2631 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
- U-2632 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
- U-2633 TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
- U-2634 METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
- U-2635 TREATMENT OF ACUTE URTICARIA
- U-2636 METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
- U-2637 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
- U-2638 INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
- U-2639 METHOD OF ACTIVATING RARGAMMA RECEPTOR
- U-2640 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
- U-2641 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
- U-2642 METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
- U-2643 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
- U-2644 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
- U-2645 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2646 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2647 TREATMENT OF NON-NODULAR ACNE VULGARIS
- U-2648 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2649 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
- U-2650 TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
- U-2651 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
- U-2652 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
- U-2653 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

- U-2654 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
- U-2655 A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
- U-2656 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
- U-2657 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- U-2658 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
- U-2659 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
- U-2660 TREATMENT OF H. PYLORI INFECTION IN ADULTS
- U-2661 CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
- U-2662 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
- U-2663 USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
- U-2664 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
- U-2665 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-2666 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- U-2667 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
- U-2668 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2669 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2670 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
- U-2671 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2672 TREATMENT OF ACUTE HEPATIC PORPHYRIA
- U-2673 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
- U-2674 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
- U-2675 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
- U-2676 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
- U-2677 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
- U-2678 PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
- U-2679 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
- U-2680 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
- U-2681 TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
- U-2682 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- 100MG OF ACALABRUTINIB TWICE DAILY
- U-2683 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
- U-2684 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
- U-2685 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
- U-2686 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2687 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2688 USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2689 USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2690 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2691 USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2692 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2693 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2694 USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
- U-2695 USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (\geq 150 MG/DL) AND ON STATIN THERAPY
- U-2696 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2697 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2698 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2699 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
- U-2700 USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
- U-2701 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG \geq 150 MG/DL TO ABOUT 500 MG/DL)
- U-2702 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
- U-2703 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-2704 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
- U-2705 METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
- U-2706 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
- U-2707 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
- U-2708 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER